<SEC-DOCUMENT>0001193125-15-063338.txt : 20150226
<SEC-HEADER>0001193125-15-063338.hdr.sgml : 20150226
<ACCEPTANCE-DATETIME>20150225210305
ACCESSION NUMBER:		0001193125-15-063338
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150226
DATE AS OF CHANGE:		20150225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		15649781

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d842626d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 10-K
</B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>For the fiscal year ended December&nbsp;31, 2014 </B></FONT></P>
 <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>or </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Commission File Number: 0-24006 </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>NEKTAR THERAPEUTICS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3134940</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>455 Mission Bay Boulevard South </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Francisco, California 94158 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices and zip code) </B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>415-482-5300
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:156pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Each Exchange on Which Registered</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock, $0.0001 par value</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Select Market</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>None </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is not required to file reports pursuant
to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K (&#167; 229.405) is not contained
herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check
one): </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule
12b-2)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the
registrant&#146;s common stock on the last business day of the registrant&#146;s most recently completed second fiscal quarter, June&nbsp;30, 2014, as reported on the NASDAQ Global Select Market, was approximately $1,625,943,780. This calculation
excludes approximately 457,759 shares held by directors and executive officers of the registrant. Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;20, 2015, the number of outstanding shares of the registrant&#146;s common stock was 131,381,612. </FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Portions of registrant&#146;s definitive Proxy Statement to be filed for its 2015 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with
the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEKTAR THERAPEUTICS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2014 ANNUAL REPORT ON FORM 10-K </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART I</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_1">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_3">Unresolved Staff Comments</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_4">Properties</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_5">Legal Proceedings</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_6">Mine Safety Disclosures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_7">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_8">Selected Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;7A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_10">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_11">Financial Statements and Supplementary Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_12">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_13">Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;9B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_14">Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;III</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_15">Directors, Executive Officers and Corporate Governance</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_16">Executive Compensation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_17">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_18">Certain Relationships and Related Transactions and Director Independence</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_19">Principal Accountant Fees and Services</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;IV</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_20">Exhibits and Financial Statement Schedules </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_21">Signatures </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This report includes &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended. All statements other than statements of historical fact are &#147;forward-looking statements&#148; for purposes of this annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> including any projections of earnings,
revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any
statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start
or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the success of our collaboration arrangements or future payments that may come due
to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified
by the use of terminology such as &#147;may,&#148; &#147;will,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;potential&#148; or &#147;continue,&#148; or the negative thereof or other comparable
terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ
materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not
limited to, the risk factors set forth in Part I, Item&nbsp;1A &#147;Risk Factors&#148; below and for the reasons described elsewhere in this annual report on Form 10-K. All forward-looking statements and reasons why results may differ included in
this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this annual report on Form 10-K, the
&#147;Company,&#148; &#147;Nektar,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Trademarks </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nektar brand and product names,
including but not limited to Nektar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, contained in this document are trademarks and registered trademarks of
Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART I </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_1"></A>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Business</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of
new molecular entities that target known mechanisms of action. Our current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, and immunology. Our research and
development activities involve small molecule drugs, peptides and other biologic drug candidates. We create innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of
pharmacophores to create new molecular entities. Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures with drug molecules to alter the properties of a molecule. Additionally, we may utilize established
pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise. Our drug candidates are designed to improve the overall benefits
and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life, bioavailability and mechanism of action. Our objective is to apply our advanced polymer conjugate technology platform to create
new drug candidates in multiple therapeutic areas. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, we achieved the first approval of one of our
proprietary drug candidates, MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>&nbsp;(previously referred to as naloxegol and NKTR-118), under a global
license agreement with AstraZeneca AB (AstraZeneca). MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> is an oral peripherally-acting mu-opioid
antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines. MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the
completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. On September&nbsp;16, 2014, the United States Food and Drug Administration, or FDA, approved MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> as the first once-daily oral PAMORA medication for the treatment of OIC, in adult patients with chronic, non-cancer pain. On December&nbsp;9, 2014, the European
Commission, or EC, granted Marketing Authorisation to MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (the naloxegol brand name in the European Union,
or EU) as the first once-daily oral PAMORA to be approved in the European Union (EU) for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#146;s approval applies to all 28 European Union member
countries plus Iceland and Norway. On January&nbsp;23, 2015, the United States Drug Enforcement Agency published its final rule in the Federal Register, effective immediately on the date it was published, which removed naloxegol and its salts from
the schedules of the Controlled Substances Act. AstraZeneca is planning the commercial launch of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in
the United States late in the first quarter of 2015 and commercial launch of MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in Europe in the second
half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I (topo I) inhibitor currently
being evaluated in a Phase 3 open-label, randomized, multicenter clinical study as a single-agent therapy for women with metastatic breast cancer. This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102),
has completed enrollment of approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting. Patients in the BEACON
study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician&#146;s choice. The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free
survival and objective tumor response rate. In November 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with
an anthracycline, a taxane, and capecitabine. In January 2014, we announced that the Independent Data Monitoring Committee created to provide safety oversight for the BEACON study recommended continuation of the BEACON study following an interim
data analysis which was performed after reaching 50% of the events needed to achieve the primary endpoint of overall survival. We have now achieved the necessary number of events in the BEACON study to assess the overall survival primary endpoint
and other secondary endpoints. We are now conducting blinded data verification activities and currently plan to un-blind </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and announce the top-line data from the BEACON Study in March 2015. We have also studied etirinotecan pegol in colorectal cancer and ovarian cancer and, in addition, have provided or are
providing support for investigator initiated research with etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma, relapsed small cell lung cancer, metastatic and recurrent non-small cell lung cancer, and with
refractory brain metastases in patients with lung cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic
pain conditions. NKTR-181 has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such
as sedation and respiratory depression, which are associated with standard opioid therapies. NKTR-181&#146;s potential abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach, a common
method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid. In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. In June 2013, we
announced results from a human abuse liability study that demonstrated that NKTR-181 had highly statistically significant lower &#147;drug liking&#148; scores and reduced &#147;feeling high&#148; scores as compared to oxycodone at all doses tested.
In September 2013, we announced topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. In this study, NKTR-181 performed as expected as an opioid analgesic
throughout the study. However, patients who were randomized to the placebo arm following a drug titration phase did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies. This lack of a
placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint, which was the average change in a patient&#146;s pain score from baseline to the end of the double-blind, randomized treatment period.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of certain
considerations for the Phase 3 clinical study program. In this Phase 3 program for NKTR-181 we plan to include two separate efficacy studies in patients with chronic lower back pain, a long-term safety study, and a human abuse liability study. We
enrolled the first patient in this first Phase 3 study on February&nbsp;24, 2015. In this first efficacy study, we plan to randomize approximately 416 chronic low back pain patients in a clinical study that utilizes an enriched enrollment randomized
withdrawal design. The study includes a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, and then is followed by a 12 week double-blind randomized period where a total of approximately 416 patients
will be randomized on a 1:1 basis to continue receiving NKTR-181 or crossover to receive placebo. The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring
committee. The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders (&gt;30% reduction in pain score) and
patient impression of change. We plan to have further interactions with the FDA to finalize the study design for the other clinical studies planned for the Phase 3 program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also have additional proprietary preclinical and clinical drug candidates in research and development. We have an ongoing Phase 1 clinical development program for NKTR-171, a new sodium channel blocker
being developed as a potential oral therapy for the treatment of peripheral neuropathic pain. This year we plan to advance NKTR-214, an engineered immune-stimulatory cytokine being developed for the treatment of solid tumors, into a Phase 1 clinical
study. NKTR-214 is engineered to selectively activate interlerleukin-2 (IL-2) receptors present on the surface of cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors present on the regulatory T cells that would
otherwise dampen the immune response to tumors. We are also advancing numerous other drug candidates in preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a collaboration with Baxter Healthcare (Baxter), to identify and develop PEGylated drug candidates with the objective of
providing new long-acting therapies for hemophilia patients. Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxter is responsible for all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
clinical development. The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE
[Antihemophilic Factor (Recombinant)]. In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855. This regulatory submission was based on positive results from a prospective, global, multi-center,
open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients. Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for
patients who were 12 years or older. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also have a collaboration with Bayer Healthcare LLC (Bayer), to develop BAY41-6551
(Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. We originally developed the NKTR-061 drug candidate and the associated liquid aerosol inhalation platform and entered into a
collaboration agreement with Bayer to advance the drug candidate into further clinical development and potential commercialization. Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale. Bayer is conducting this study
under a Special Protocol Assessment process agreed to with the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also have a number of license, manufacturing and
supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Halozyme Therapeutics, Inc., Merck&nbsp;&amp; Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB
Pharma. A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or E.U. There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer
conjugate technologies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;31, 2008, we completed the sale and transfer of certain pulmonary technology rights,
certain pulmonary collaboration agreements and approximately 140 dedicated pulmonary personnel and operations to Novartis Pharma AG (Novartis). We retained all of our rights to Amikacin Inhale and our right to receive royalties on net sales of the
Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction. In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the
Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis. The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a
period of 48 weeks. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated in California in 1990 and reincorporated in Delaware in 1998. We maintain our executive offices at 455 Mission Bay Boulevard South, San Francisco, California 94158, and our main
telephone number is (415)&nbsp;482-5300. Our website is located at www.nektar.com. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Technology Platform </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a leader in the PEGylation field, we have advanced our technology platform to include new advanced polymer conjugate chemistries and polymer technologies that can be tailored in specific and customized
ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs targeting numerous disease areas. PEGylation has been a highly effective technology platform for the
development of therapeutics with significant commercial success, such as Amgen&#146;s Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (pegfilgrastim)
and Roche&#146;s PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (PEG-interferon alfa-2a). Nearly all of the PEGylated drugs approved over the last
fifteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of well-known biotechnology and pharmaceutical companies. PEGylation is a versatile technology as a result of polyethylene
glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body. Its primary use to date has been in currently approved biologic drugs to favorably alter their pharmacokinetic or
pharmacodynamic properties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
However, in spite of its widespread success in commercial drugs, there are some limitations with the first-generation PEGylation approaches that have been used with biologics. These techniques
cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology. Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and
bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With our expertise and proprietary technology in PEGylation, we have created the next generation of PEGylation technology. Our advanced polymer conjugate technology platform is designed to overcome the
limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas. We have also developed robust manufacturing processes for generating second
generation PEGylation reagents that allow us to utilize the full potential of these newer approaches. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both our PEGylation and
advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">improve efficacy or safety of a drug as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">improve targeting or binding affinity of a drug to its target receptors with the potential to improve efficacy and reduce toxicity or drug resistance;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">improve solubility of a drug; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enable oral administration of parenterally-administered drugs, or drugs that must be administered intravenously or subcutaneously, and increase oral
bioavailability of small molecules; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prevent drugs from crossing the blood-brain barrier, or reduce their rate of passage into the brain, thereby limiting undesirable central nervous
system effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce first-pass metabolism effects of certain drug classes with the potential to improve efficacy, which could reduce the need for other medicines
and reduce toxicity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the rates of drug absorption and of elimination or metabolism by improving stability of the drug in the body and providing it with more time to
act on its target; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differentially alter binding affinity of a drug for multiple receptors, improving its selectivity for one receptor over another; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a broad range of approaches that we may use when designing our own drug candidates, some of which are further described below.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Small Molecule Stable Polymer Conjugates </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our customized approach for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and
pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit. In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that have low
bioavailability when delivered orally. The benefits of this approach can also include: improved potency, modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the
blood-brain barrier. Two examples of reducing transport across the blood-brain barrier are MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>, an
orally-available peripherally-acting opioid antagonist that was recently approved in the United States and European Union, and NKTR-171, a novel peripherally-acting sodium channel blocker that is currently in a Phase 1 clinical study for the
treatment of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
neuropathic pain. An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid
analgesic molecule that is currently in Phase 3 development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Small Molecule Pro-Drug Releasable Polymer Conjugates
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small
molecule drug to substantially increase its efficacy and improve its side effect profile. We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy. With our
releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body. We are using
this approach with our lead oncolytic drug candidate, etirinotecan pegol, a next-generation topoisomerase I-inhibitor currently in the Phase 3 BEACON clinical study for treatment of metastatic breast cancer. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Large Molecule Polymer Conjugates (Proteins and Peptides) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today.
Based on our knowledge of the technology and biologics, our scientists have designed novel hydrolyzable linkers that in many cases can be used to optimize bioactivity. Through rational drug design, a protein or peptide&#146;s pharmacokinetics and
pharmacodynamics can be substantially improved and its half-life can be significantly extended. An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, for which Baxter filed a
biologic license application with the United States Food and Drug Administration on December&nbsp;1, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Antibody
Fragment Polymer Conjugates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This approach uses a large molecular weight PEG conjugated to
antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody. The specially designed PEG replaces the function of the fragment crystallizable (Fc) domain of full
length antibodies with a branched architecture PEG with either stable or degradable linkage. This approach can be used to reduce antigenicity, reduce glomerular filtration rate, enhance uptake by inflamed tissues, and retain antigen-binding affinity
and recognition. There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn&#146;s Disease, psoriatic arthritis and ankylosing
spondylitis in the U.S. and rheumatoid arthritis in the U.S. and E.U. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key elements of our business strategy are described below: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advance Our Proprietary Clinical Pipeline of Drug Candidates that Leverage Our PEGylation and Advanced Polymer Conjugate Platform </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our objective is to create value by advancing our lead drug candidates through various stages of clinical development. To support this
strategy, we have significantly expanded and added expertise to our internal preclinical, clinical development and regulatory departments. A key component of our development strategy is to potentially reduce the risks and time associated with drug
development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets. For many of our novel drug candidates, we may seek to study the drug candidates in
indications for which the parent drugs have not been studied or approved. We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies. In addition, in certain
instances we have the opportunity to develop new treatments for patients for which the parent drugs are not currently approved. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ensure Future Growth of our Proprietary Pipeline through Internal Research Efforts and
Advancement of our Preclinical Drug Candidates into Clinical Trials </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe it is important to maintain a diverse
pipeline of new drug candidates to continue to build on the value of our business. Our discovery research organization is continuing to identify new drug candidates by applying our technology platform to a wide range of molecule classes, including
small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early stage
research programs to human clinical studies over the next several years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Enter into Strategic and High-Value
Partnerships to Bring Certain of Our Drug Candidates to Market </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We decide on a drug candidate-by-drug candidate basis
how far to advance clinical development (e.g. Phase&nbsp;1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches. For example, in December 2010, we decided that we would move
etirinotecan pegol (also known as NKTR-102) into Phase 3 clinical development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate. When we determine to seek a partner, our strategy is to enter into
collaborations with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing process, and market and sell drugs in one or more geographies. The options for future collaboration
arrangements range from comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the structure of economic risk sharing, the cost
and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Continue to Build a Leading Intellectual Property Estate in the Field of PEGylation and Polymer Conjugate Chemistry across
Therapeutic Modalities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are committed to continuing to build on our intellectual property position in the field of
PEGylation and polymer conjugate chemistry. To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates,
formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nektar Proprietary Drugs and Drug Candidates
in Clinical Development </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our proprietary drugs and drug candidates that have either received
regulatory approval or are being developed by us or in collaboration with other pharmaceutical companies or independent investigators. The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of
the clinical development program. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug Candidate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Target Indication</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status(1)</B></FONT></TD></TR>


<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>
(naloxegol tablets)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opioid-induced constipation in adult patients with chronic non-cancer pain</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved in U.S. (Partnered<BR>with AstraZeneca AB)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(brand name for MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in Europe)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opioid-induced constipation in adult patients who have an inadequate response to laxatives</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved in E.U. (Partnered<BR>with AstraZeneca AB)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol (next-generation topoisomerase I inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Locally recurrent or metastatic breast cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAX 855 (PEGylated rFVIII)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hemophilia A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 ongoing and filed for<BR>approval in U.S. (partnered with<BR>Baxter Healthcare)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug Candidate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Target Indication</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status(1)</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAY41-6551 (Amikacin Inhale, formerly NKTR-061)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gram-negative pneumonias</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 (Partnered with Bayer<BR>Healthcare LLC)*</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-181 (orally-available mu-opioid analgesic molecule)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moderate to severe chronic pain</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Platinum-resistant/refractory ovarian cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed Phase 2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second-line metastatic colorectal cancer in patients with the KRAS gene mutation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed Phase 2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol (in combination with 5-Fluorouracil/leucovorin)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gastrointestinal-related solid tumors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed Phase 1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-171 (orally-available peripherally-acting sodium channel blocker)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neuropathic pain</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>
fixed-dose combinations (opioid/naloxegol combinations)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chronic pain without constipation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research/Preclinical (Partnered<BR>with AstraZeneca AB)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-214 (cytokine immunostimulatory therapy)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research/Preclinical</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Status definitions are: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Filed </I>&#151; an application for approval and marketing has been filed with the applicable government health authority. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 3 or Pivotal </I>&#151; product in large-scale clinical trials conducted to obtain regulatory approval to market and sell the
drug (these trials are typically initiated following encouraging Phase 2 trial results). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 2 </I>&#151; a drug
candidate in clinical trials to establish dosing and efficacy in patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 &#151; </I>a drug candidate in clinical
trials, typically in healthy subjects, to test safety. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research/Preclinical &#151; a drug candidate is being studied in
research by way of in vitro studies and/or animal studies </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>*</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This drug candidate uses, in part, a liquid aerosol technology platform that was transferred to Novartis by us in the pulmonary asset sale transaction that was
completed on December&nbsp;31, 2008. As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approved Drugs and Drug Candidates Enabled By Our Technology through Licensing Collaborations
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual
property and, in some cases, purchase our proprietary PEGylation materials for their drug products. A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or Europe. There are also a number of other
candidates that have been filed for approval or are in various stages of clinical development. These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply
agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Primary or Target</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Indications</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Marketer/Partner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status(1)</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(pegfilgrastim)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neutropenia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(peginterferon alfa-2a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hepatitis-C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">F. Hoffmann-La Roche&nbsp;Ltd</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Somavert<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(pegvisomant)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acromegaly</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEG-INTRON<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (peginterferon
 alfa-2b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hepatitis-C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merck (through its acquisition of Schering-Plough Corporation)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macugen<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(pegaptanib sodium injection)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Age-related macular degeneration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valeant Pharmaceuticals International, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(certolizumab pegol)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rheumatoid arthritis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">UCB Pharma</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved*</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(certolizumab pegol)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Crohn&#146;s disease</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">UCB Pharma</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved*</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(certoluzimab pegol)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Psoriasis/Ankylosing Spondylitis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">UCB Pharma</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved*</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(C.E.R.A.) (Continuous Erythropoietin Receptor Activator)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">F. Hoffmann-La Roche&nbsp;Ltd</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved**</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(peginesatide)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anemia associated with chronic kidney disease (CKD) in adult patients on dialysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Affymax, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved (currently withdrawn from market)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (naloxegol tablets)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opioid-induced constipation in adult patients with chronic non-cancer pain</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AstraZeneca AB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved in U.S.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(brand name for MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in Europe)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opioid-induced constipation in adult patients who have an inadequate response to laxatives</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AstraZeneca AB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved in E.U.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT>
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Migraine</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allergan, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed for approval in U.S.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAX 855 (PEGylated rFVIII)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hemophilia A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter Healthcare</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 ongoing and filed for approval in U.S.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Primary or Target</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Indications</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Marketer/Partner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status(1)</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FOVISTA&#153;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neovascular age-related macular degeneration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ophthotech Corporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cipro Dry Powder Inhaler (Cipro DPI)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cystic fibrosis lung infections</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bayer Schering Pharma AG</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3***</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEGPH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pancreatic and Non-Small Cell Lung Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Halozyme Therapeutics, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 1 and 2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Longer-acting blood clotting proteins</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hemophilia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter Healthcare</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research/Preclinical</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Status definitions are: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Approved </I>&#151; regulatory approval to market and sell product obtained in one or more of the U.S., E.U. or other countries.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Filed </I>&#151; an application for approval and marketing has been filed with the applicable government health authority.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 3 or Pivotal </I>&#151; product in large-scale clinical trials conducted to obtain regulatory approval to market and
sell the drug (these trials are typically initiated following encouraging Phase 2 trial results). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 2 </I>&#151; a drug
candidate in clinical trials to establish dosing and efficacy in patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research/Preclinical &#151; </I>a drug candidate
is being studied in research by way of in vitro studies and/or animal studies </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> effective as of January&nbsp;1, 2012. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La&nbsp;Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from
marketing MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the U.S. until July 2014. In February 2012, we sold our rights to receive royalties on
future worldwide net sales of MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> effective as of January&nbsp;1, 2012 until the agreement with Roche is
terminated or expires. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This drug candidate was developed using our proprietary pulmonary delivery technology that was transferred by us to Novartis in an asset sale transaction that closed on
December&nbsp;31, 2008. As part of the transaction, Novartis assumed our rights and obligations for Cipro DPI (formerly known as Cipro Inhale) under our agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive royalties
on commercial sales of Cipro DPI if the drug candidate is approved. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to all of our collaboration
and license agreements with third parties, please refer to Item&nbsp;1A, Risk Factors, including without limitation, &#147;We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms
that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Overview of Selected Nektar Proprietary Drug Development Programs and Significant Partnered Drug Development Programs </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT> and MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT> Fixed-Dose
Combination Products (previously referred to as naloxegol, NKTR-118 and NKTR-119), License Agreement with AstraZeneca AB </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In September 2009, we entered into a global license agreement with AstraZeneca AB pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and
other intellectual property to develop, market and sell MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> and
MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination products.
MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> was developed using our oral small molecule
polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced
constipation (OIC), which is a common side effect of prescription opioid </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
medications. Opioids attach to specific proteins called opioid receptors. When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur. OIC is a
result of decreased fluid absorption and lower gastrointestinal motility due to opioid receptor binding in the gastrointestinal tract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;16, 2014, the FDA approved MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain. On December&nbsp;9, 2014, the
European Commission, or EC, granted Marketing Authorisation to MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (the naloxegol brand name in the
European Union, or EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#146;s approval applies to all 28 European Union member
countries plus Iceland and Norway. On January&nbsp;23, 2015, the DEA published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled
Substances Act. AstraZeneca is planning the commercial launch of MOVANTIK&#153; in the United States late in the first quarter of 2015 and MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the second half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of our license agreement, AstraZeneca made an initial license payment to us of $125.0&nbsp;million and AstraZeneca has responsibility for all activities and bears all costs associated with
research, development and commercialization for MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
and MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination products. We
received $70.0 million and $25.0 million upon the acceptance for review of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> regulatory approval applications filed with the FDA and European Medicines Agency (EMA), respectively, in 2013. In 2014, we received an additional $35.0 million payment upon the FDA&#146;s approval of
MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">. The remaining $140.0 million of development
milestone payments are due upon the commercial launches of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> in the U.S. ($100 million) and in the E.U. ($40 million). We are also entitled to up to $375.0 million in sales milestones for MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> if the program achieves certain annual commercial sales levels. For the MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination products, we are also eligible to receive
significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels. For both MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at
20% of net sales in the U.S. and 18% of net sales in the E.U. and rest of world, varying by country of sale and level of annual net sales. Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the
later of (a)&nbsp;a specified period of time after the first commercial sale of the product in that country or (b)&nbsp;the expiration of patent rights in that particular country. AstraZeneca has agreed to use commercially reasonable efforts to
develop one MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination product and
has the right to develop multiple products which combine MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> with opioids. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Etirinotecan pegol (NKTR-102, next generation, long-acting
topoisomerase I inhibitor) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing etirinotecan pegol (also known as NKTR-102), a next generation
topoisomerase I (topo&nbsp;I) inhibitor which was designed using our PEGylation technology. Etirinotecan pegol is a novel macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its
toxicities. Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, etirinotecan pegol&#146;s pro-drug design results in a lower initial peak concentration of active topo I
inhibitor in the blood. The large etirinotecan pegol molecule is inactive when administered. Over time, the body&#146;s natural enzymatic processes slowly metabolize the linkers within the molecule, continuously freeing active drug that then can
work to stop tumor cell division through topo I inhibition. In preclinical models, etirinotecan pegol achieved a 300-fold increase in tumor concentration as compared to irinotecan. Because etirinotecan pegol is a large molecule, based on preclinical
studies we believe that it may penetrate the leaky vasculature within the tumor environment more readily than normal vasculature, concentrating and trapping etirinotecan pegol in tumor tissue. Clinical studies have shown that etirinotecan pegol has
an extended pharmacokinetic profile and remains in circulation throughout the entire chemotherapy cycle, providing sustained exposure to topo I inhibition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol is currently being evaluated as a single-agent therapy (145&nbsp;mg/m2 every 21&nbsp;days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic
breast cancer. This Phase&nbsp;3 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with
anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting. We completed enrollment in the BEACON study in late July 2013. This study randomized patients on a 1:1 basis to receive single-agent etirinotecan pegol or a single
agent chosen from a defined set of physician&#146;s choice alternatives. The physician&#146;s choice single agents include the following: ixabepilone, vinorelbine, gemcitabine, eribulin, or a taxane. Randomization was stratified by geographic
region, prior treatment with eribulin and whether or not the patient had triple negative breast cancer.&nbsp;The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor
response rate. Secondary endpoints and objectives also include clinical benefit rate, duration of response, pharmacokinetic data, safety profiles, quality-of-life measurements, and pharmacoeconomic implications. Exploratory objectives of the study
include collecting specific biomarker data to correlate with objective tumor response rate, progression-free survival, overall survival and selected toxicities. In November 2012, the FDA designated etirinotecan pegol as a Fast Track development
program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine. On January&nbsp;14, 2014, we announced that the Independent Data Monitoring
Committee, or the DMC, created to provide safety oversight for the BEACON study recommended continuation of the Phase 3 BEACON study following an interim data analysis which was performed after reaching 50% of the events needed to achieve the
primary endpoint of overall survival. We are now conducting blinded data verification activities and currently plan to unblind and announce the top-line data from the BEACON Study in March 2015. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">According to the American Cancer Society and World Health Organization, more than 1.4&nbsp;million women worldwide are diagnosed with
breast cancer globally every year. The chance of developing invasive breast cancer at some time in a woman&#146;s life is a little less than one in eight (12%). In 2015, the American Cancer Society estimates there will be 231,840 new cases of breast
cancer in the U.S. Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.&nbsp;Anthracyclines and taxanes are the among the most active and widely used chemotherapeutic agents for breast cancer, but
the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease.&nbsp;There are currently no
FDA-approved topoisomerase I inhibitors indicated to treat breast cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have also conducted clinical studies for
etirinotecan pegol in other solid tumor settings. In 2013, we completed a Phase 2 clinical study for etirinotecan pegol in approximately 170 patients with platinum-resistant/refractory ovarian cancer. We also initiated a Phase 2 clinical study of
etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene. The Phase 2 clinical study was designed to enroll 174 patients with metastatic colorectal cancer. In February 2014, we
decided to close&nbsp;enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line
metastatic&nbsp;colorectal therapy in the U.S. or E.U.&nbsp;We plan to submit a manuscript describing the results of this study in the first half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate etirinotecan pegol in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.
The chemotherapy agent 5-FU is currently used as a part of a combination treatment regimen for colorectal cancer in combination with irinotecan, which is also known as the FOLFIRI regimen. On January&nbsp;18, 2014, we presented data from this study
at the 2014 Gastrointestinal Cancers Symposium in San Francisco, California. In addition to the clinical study of etirinotecan pegol being conducted by us, we are also providing support for four investigator-initiated Phase 2 studies being conducted
for etirinotecan pegol. On August&nbsp;7, 2012, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at&nbsp;the Stanford Cancer
Institute. In May 2013, the study completed enrollment of 20 patients with high-grade glioma who had received a median of three prior lines of therapy before enrolling in the study. A separate investigator-initiated clinical study is also being
conducted at Stanford </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to evaluate etirinotecan pegol in patients with brain metastasis from primary lung cancer. On February&nbsp;5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan
pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the&nbsp;Abramson Cancer Center&nbsp;of the&nbsp;University of Pennsylvania. On October&nbsp;24, 2013, we announced a Phase 2 investigator-initiated
clinical study of etirinotecan pegol in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>BAY41-6551 (Amikacin Inhale, formerly NKTR-061), Agreement with Bayer Healthcare LLC </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2007, we entered into a co-development, license and co-promotion agreement with Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly
called NKTR-061) for the treatment of gram-negative pneumonias. Under the terms of the agreement, Bayer is responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings,
approvals and related activities, further development of formulated Amikacin and final product packaging for Amikacin Inhale. We are responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial
use. We have engaged third party contract manufacturers to perform our device manufacturing activities for this program. We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of
certain annual sales targets. We are also entitled to royalties based on annual worldwide net sales of Amikacin Inhale. Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial
sale of the product in that country or the expiration of certain patent rights in that particular country, subject to certain exceptions. We share a portion of these royalties with the Research Foundation of the State University of New York under a
license agreement. The agreement expires in relation to a particular country upon the expiration of all royalty and payment obligations between the parties related to such country. Subject to termination fee payment obligations in certain
circumstances, Bayer also has the right to terminate the agreement for convenience. In addition, the agreement may also be terminated by either party for certain product safety concerns, the product&#146;s failure to meet certain minimum commercial
profile requirements or uncured material breaches by the other party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gram-negative pneumonias are often the result of
complications of other patient conditions or surgeries. Gram-negative pneumonias carry a mortality risk that can exceed 50% in mechanically-ventilated patients and accounts for a substantial proportion of the pneumonias in intensive care units
today. Amikacin Inhale is designed to be an adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care. The aerosol generator within the nebulizer for Amikacin Inhale delivers a fine aerosol of the
antimicrobial agent directly to the site of infection in the lungs. This nebulizer device containing amikacin can be integrated with conventional mechanical ventilators or used as a hand-held &#145;off-vent&#146; device for patients no longer
requiring breathing assistance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2013, Bayer initiated enrollment in a global Phase 3 clinical study, which it calls
INHALE, to evaluate the efficacy and safety of Amikacin Inhale versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics. The global
INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Japan, Australia and Asia. The INHALE development
program is being conducted by Bayer under a Special Protocol Assessment agreement with the FDA that is intended to support the submission of an NDA if the INHALE clinical studies are successful. In November 2014, the FDA granted qualified infectious
disease product (QIDP) designation to Amikacin Inhale. Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track designation, priority review by FDA and a five-year extension of
market exclusivity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>NKTR-181 (mu-opioid analgesic molecule for chronic pain) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-181 is an orally-available novel mu-opioid analgesic molecule in development as a long-acting analgesic to treat chronic pain.
NKTR-181 is designed with the objective to address the abuse liability and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
serious central nervous system (CNS) side effects associated with current opioid therapies. NKTR-181 was created using Nektar&#146;s proprietary polymer conjugate technology, which provides it
with a long-acting profile and slows its entry into the CNS. NKTR-181&#146;s abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach to prevent its conversion into a more abusable form of an
opioid. In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2012, we initiated
a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. The Phase 2 clinical study utilized a double-blind, placebo-controlled,
randomized withdrawal, enriched enrollment study design. The study enrolled 213 opioid-na&iuml;ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication. Patients who
qualified during the baseline period entered a titration phase, during which they were titrated on NKTR-181 tablets administered orally twice-daily until a dose was reached that provided a reduction of at least 20% in the patient&#146;s pain score
as compared to the patient&#146;s own baseline. Patients that achieved this level of analgesia were then randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for up to 25 days. The primary
endpoint of the study was the average change in a patient&#146;s pain score from baseline to the end of the double-blind, randomized treatment period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2013, we announced results from this Phase 2 efficacy study. Of the 295 patients that entered the study, only 9 (3%)&nbsp;patients were unable to achieve meaningful pain relief with
NKTR-181. A total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study. NKTR-181 performed as expected as an opioid analgesic throughout the study with patients continuing to show a reduction in
pain scores throughout the randomized phase of the study. However, patients who were randomized to placebo did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies. This unusual lack of
a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2014, we had an end-of-Phase
2 meeting for NKTR-181 with the FDA, which included discussions of the design of the Phase 3 clinical study program. In this Phase 3 program for NKTR-181 we plan to include two separate efficacy studies in patients with chronic lower back pain, a
long-term safety study, and a human abuse liability study. We enrolled the first patient in this first Phase 3 study on February&nbsp;24, 2015. In this first efficacy study, we plan to enroll approximately 416 patients in an enriched enrollment
randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1
basis to receive either NKTR-181 or placebo. The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee. The primary endpoint will be change in weekly
pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders (&gt;30% reduction in pain score) and patient impression of change. We plan to have further
interactions with the FDA to finalize the study design for the other clinical studies planned for the Phase 3 program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181. In this study, NKTR-181 had highly statistically significant lower &#147;drug liking&#148; scores and reduced &#147;feeling high&#148; scores as compared to
oxycodone at all doses tested (p &lt; 0.0001). On June&nbsp;19, 2013, we presented data from the HAL study at the 2013 Annual Meeting of The College on Problems of Drug Dependence in San Diego, California. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">According to a 2011 report from the National Academy of Sciences, chronic pain conditions, such as osteoarthritis, back pain and cancer
pain, affect at least 100&nbsp;million adults in the U.S. annually and contribute to over $300 billion a year in lost productivity. Opioids are considered to be the most effective therapeutic option for pain. However, opioids cause significant
problems for physicians and patients because of their serious side effects such as respiratory depression and sedation, as well as the risks they pose for addiction, abuse, misuse, and diversion. The FDA has cited prescription opioid analgesics as
being at the center of a major public health </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
crisis of addiction, misuse, abuse, overdose and death. A 2010 report from the Center for Disease Control and Prevention notes that emergency room visits tied to the abuse of prescription
painkillers was at an all-time high at that point, having increased 111 percent over the preceding five-year period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>NKTR-171 (neuropathic pain) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain. NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by
blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system. Chronic neuropathic pain arises from nerves injured or damaged by systemic disease, infection, toxins, or physical trauma that are in a
continuous state of hyper-excitability, often due to aberrant sodium channel firing. This hyper-excitability results in transmission of abnormal pain signals from the periphery to the central nervous system (CNS). Existing therapies that block
sodium channels have been shown to provide effective pain relief but are typically associated with significant unwanted CNS side effects, including dizziness, ataxia and somnolence. NKTR-171 is designed to be a peripherally-restricted molecule which
selectively blocks hyper-excitable sodium channels without causing the CNS side effects that limit usage of existing therapies. In January 2014, a single-ascending dose Phase 1 clinical study of NKTR-171 was completed. This study assessed the
pharmacokinetics, tolerability, and safety of NKTR-171 in healthy subjects. In January 2015, a multiple-ascending dose Phase 1 clinical study was initiated to assess its pharmacokinetics, tolerability, and safety of NKTR-171. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>NKTR-214 (cytokine immunostimulatory therapy) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors.&nbsp;NKTR-214 is engineered to selectively activate IL-2 receptors on the surface of
cytotoxic T cells that kill tumor cells while imparting substantially reduced affinity for IL-2 receptors present on the regulatory T cells that would otherwise dampen the immune response to tumors. This receptor selectivity is intended to increase
efficacy and improve safety over existing immunostimulatory cytokine drugs.&nbsp;The product candidate is currently in Investigational New Drug application (IND)-enabling studies and we plan to start a Phase 1 clinical study in the second half of
2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;1, 2014, we announced positive preclinical data for NKTR-214 at the ASCO Annual Meeting in Chicago. Nektar
scientists conducted a series of studies using preclinical models of breast tumors (EMT6) and colon tumors (CT26) to assess the safety and efficacy of both single agent and combination dosing of NKTR-214 with checkpoint inhibitors, either an
anti-PD-1 therapy or an anti-CTLA-4 therapy. The studies also compared NKTR-214 single agent and combination dosing regimens with single agent and combination dosing regimens of anti-PD-1 and anti-CTLA-4 therapies. In both the breast and colon tumor
models, the combination dosing regimens of NKTR-214 therapy with anti-PD-1 therapy or anti-CTLA-4 therapy resulted in significant tumor growth inhibition. In the aggressive EMT6 breast tumor model where activity with single-agent anti-PD-1 therapy
or single-agent anti-CTLA-4 therapy was not observed, pre-dosing of NKTR-214 followed by anti-PD-1 demonstrated better efficacy (tumor growth inhibition of 74%) as compared to a concomitant dosing regimen of anti-CTLA-4 and anti-PD-1 therapies
(tumor growth inhibition of 23%).&nbsp;NKTR-214 was also very well-tolerated when co-dosed with either antibody in these preclinical studies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview of Select Technology Licensing Collaborations and Programs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have a number of product candidates in clinical development and approved products in collaboration with our partners that use our technology or involve rights over which we have patents or other
proprietary intellectual property. In a typical collaboration involving our PEGylation technology, we license our proprietary intellectual property related to our PEGylation technology or proprietary conjugated drug molecules in exchange for upfront
payments, development milestone payments and royalties from sales of the resulting commercial product as well as sales milestones. In certain cases, we also manufacture and supply our proprietary PEGylation materials to our partners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>BAX 855 and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of
Baxter International Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2005, we entered into an exclusive research, development, license,
manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter) to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation
technology. The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein. BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was
developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method). We are entitled to up to $65.0 million in total development and sales milestone payments, as well as royalties on net sales varying by
product and country of sale. The royalties start in the mid-single digits for net sales of BAX 855 up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion. Our right to receive these royalties in any particular country will
expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, Baxter completed a Phase 1 clinical study for BAX 855 that was a prospective, open-label study assessing the safety,
tolerability and pharmacokinetics of BAX 855 in 19 previously treated patients age 18 years or older with severe hemophilia A. In January 2013, Baxter announced the top level results from this Phase&nbsp;1 clinical study. This study demonstrated
that the half-life (measuring the duration of activity of the drug in the body) of BAX 855 was approximately 1.5-fold higher compared to ADVATE. A longer half-life was achieved in all patients in the study using BAX 855, no patients developed
inhibitors to either base molecule, BAX 855 or PEG, and no patients had allergic reactions. Eleven adverse events were reported in eight patients across both treatment arms, but none was serious, treatment-related or resulted in withdrawal from the
study. Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013. The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146
previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding. In August 2014, Baxter announced positive top-line results from
the PROLONG-ATE clinical study which met the primary endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. In December 2014, Baxter announced that it filed a
biologic license application with the FDA for BAX 855. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cipro DPI (formerly known as Cipro Inhale), Agreement with Bayer
Schering Pharma AG Assigned to Novartis as of December&nbsp;31, 2008 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were a party to a collaborative research,
development and commercialization agreement with Bayer Schering Pharma AG, (Bayer), related to the development of an inhaled powder formulation of ciprofloxacin delivered by way of a dry powder inhaler, Cipro DPI (formerly known as Cipro Inhale) for
the treatment of chronic lung infections caused by <I>Pseudomonas aeruginosa </I>in cystic fibrosis patients. On December&nbsp;31, 2008, we assigned the agreement to Novartis Pharma AG in connection with the completion of the pulmonary asset sale
transaction. However, we retained our economic interest in the future potential net sales royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer. Cipro DPI has completed Phase&nbsp;2 clinical development
for the treatment of chronic lung infections. In August 2012, Bayer initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis. In patients with bronchiectasis, the
bronchial tubes are enlarged, allowing mucus to pool and making the area prone to infection. In the two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, Bayer plans to enroll up to 600 patients and to evaluate Cipro DPI as a chronic, intermittent
therapy over a period of 48 weeks. In November 2014, the FDA granted qualified infectious disease product (QIDP) designation to Cipro DPI. Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are
eligible for fast-track designation, priority review by FDA and a five-year extension of market exclusivity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FOVISTA&#153; (Anti-PDGF Therapy), Agreement with Ophthotech Corporation
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2006, we entered into a license, manufacturing and supply agreement with (OSI)
Eyetech, Inc. (Eyetech) under which we granted Eyetech a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent
linked with the active ingredient in Fovista&#153;. In July 2007, as a result of a divestiture agreement between Eyetech and Ophthotech Corporation (Ophthotech), Ophthotech acquired from Eyetech certain technology rights and other assets owned or
controlled by Eyetech relating to particular anti-platelet-derived growth factor aptamers, or anti-PDGFs, including Fovista&#153;. As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech
and us. Fovista&#153; is an anti-PDGF agent administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (or wet AMD). On May&nbsp;19, 2014, Ophthotech
entered into a Licensing and Commercialization Agreement with Novartis Pharma AG to develop and commercialize
Fovista<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and related combination products in all countries outside of the U.S. Under our agreement with
Ophthotech, in June 2014 we received a $19.75 million payment in connection with this licensing agreement. We are entitled to up to $9.5 million in total development and sales milestone payments, low- to mid- single-digit royalties on net sales that
vary by sales levels and are subject to reduction in the absence of patent coverage, and additional consideration if Ophthotech grants certain third-party commercialization rights to Fovista&#153;. Our right to receive royalties in any particular
country will expire upon the later of ten years after first commercial sale of the product or expiration of patent rights in the particular country. We are the exclusive supplier for all of Ophthotech&#146;s clinical and future commercial
requirements of our proprietary PEGylation reagent used in the manufacture of Fovista&#153;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In June
2012, Ophthotech announced completion of a prospective, randomized, controlled Phase 2b clinical study of 449 patients with wet AMD comparing Fovista&#153;, administered in combination with Lucentis<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (ranibizumab injection) anti-VEGF therapy with Lucentis<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> monotherapy. Fovista&#153; met the pre-specified primary efficacy endpoint of mean vision gain. Patients receiving the combination of Fovista&#153; (1.5 mg) and
Lucentis<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> gained a mean of 10.6 letters of vision at 24 weeks on the Early Treatment Diabetic Retinopathy Study
standardized eye chart, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a statistically significant 62% additional benefit. In September 2013, Ophthotech announced the initiation of patient enrollment in
the first of three planned pivotal Phase 3 clinical studies of Fovista&#153; in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with wet AMD. These three studies plan to enroll a total of approximately 1,866 patients
to evaluate the efficacy and safety of Fovista&#153;. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PEGPH20, Agreement with Halozyme, Inc. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2006, we entered into a license agreement with Halozyme, Inc. (Halozyme) under which we granted Halozyme
a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked only with certain qualifying hyaluronidase
protein molecules including PEGPH20. According to Halozyme, certain cancers, including pancreatic, breast, colon and prostate, have been shown to accumulate high levels of hyaluronan (HA). Halozyme&#146;s FDA-approved,&nbsp;HYLENEX<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;recombinant human hyaluronidase, rHuPH20, is administered subcutaneously and temporarily and reversibly
degrades HA to facilitate the absorption and dispersion of other injected drugs or fluids and for subcutaneous fluid administration. However, rHuPH20 acts only locally at the injection site, is rapidly inactivated in the body, and does not survive
in the blood. PEGPH20 is an investigational PEGylated form of rHuPH20, under development by Halozyme to increase the half-life of the compound in the blood and allow for intravenous administration. Halozyme is currently evaluating PEGPH20 in a Phase
2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Halozyme is also evaluating PEGPH20&nbsp;in an on-going Phase 1b multi-center, randomized clinical trial
evaluating PEGPH20 as a second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer. On October&nbsp;2, 2014, the FDA granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer. We are
entitled to future development milestones and royalties on net sales subject to reduction in the absence of patent coverage. Our right to receive royalties in any particular </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
country will expire upon the later of twelve years after first commercial sale of the product or expiration of patent rights in the particular country. We also manufacture and supply Halozyme
with clinical and future commercial supply of our proprietary PEGylation reagent used in the manufacture of PEGPH20. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>SEMPRANA<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with MAP Pharmaceuticals, Inc. (a wholly-owned subsidiary of Allergan, Inc.) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2004, we entered into a license agreement with MAP Pharmaceuticals, Inc. (MAP), which includes a worldwide,
exclusive license, to certain of our patents and other intellectual property rights to develop and commercialize a formulation of dihydroergotamine (DHE) for administration to patients via the pulmonary or nasal delivery route, which resulted in the
development of SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, formerly known as LEVADEX<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. In 2006, we amended and restated this agreement. Under the terms of the agreement, we have the right to receive certain milestone payments based on development
criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Our right to
receive royalties for the net sales of SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> under the license agreement in any particular country will
expire upon the later of (i)&nbsp;10 years after first commercial sale in that country, (ii)&nbsp;the date upon which the licensed know-how becomes known to the general public, and (iii)&nbsp;expiration of certain patent claims, each on a
country-by-country basis. Either party may terminate the agreement upon a material, uncured default of the other party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a self-administered formulation of DHE using an
inhaler device that is currently under review by the FDA. On May&nbsp;26, 2011, MAP submitted an NDA to the FDA for
SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. In March of 2012, the FDA issued a complete response letter to MAP identifying issues relating to
chemistry, manufacturing and controls deficiencies of the product at a contracted third party manufacturer. On April&nbsp;17, 2013, the FDA issued a second complete response letter identifying issues related to a supplier that provided the canister
filling unit for SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. In June 2014, Allergan announced that it had received a third complete response
letter from the FDA related to specifications around content uniformity on the improved canister filling process and on standards for device actuation. Allergan has responded to the FDA&#146;s latest complete response letter and has stated that it
expects a response from the FDA on the NDA for SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the second half of 2015. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. pursuant to which Allergan
received a co-exclusive license to market and promote SEMPRANA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to neurologists and pain specialists in the U.S.
Under this arrangement, Allergan paid MAP an upfront payment of $60 million and MAP was also entitled to receive up to an additional $97 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the SEMPRANA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> NDA and first commercial sale associated with the initial acute migraine indication. On March&nbsp;1, 2013,
Allergan, Inc. completed a merger and acquisition transaction with MAP pursuant to which MAP become a wholly-owned subsidiary of Allergan. On January&nbsp;23, 2015, we filed a breach of contract action against Allergan and MAP in California Superior
Court in San Mateo County seeking monetary damages related to MAP&#146;s failure to pay us a certain specified percentage of $80 million in upfront and milestone payments received to date from Allergan under the 2011 Collaboration Agreement which we
believe we were entitled to receive under the terms of our license agreement with MAP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview of Select Licensing Partnerships for
Approved Products </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Neulasta<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with Amgen,
Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 1995, we entered into a non-exclusive supply and license agreement (the 1995
Agreement) with Amgen, Inc., pursuant to which we licensed our proprietary PEGylation technology to be used in the development and manufacture of Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> selectively
stimulates the production of neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia that makes it more difficult for the body to fight infections. On October&nbsp;29, 2010, we amended and restated the 1995 Agreement
by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and an amended and restated license agreement with Amgen Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of
the 2010 Agreement, we guarantee the manufacture and supply of our proprietary PEGylation materials (Polymer Materials) to Amgen in an existing manufacturing suite to be used exclusively for the manufacture of Polymer Materials for Amgen in our
manufacturing facility in Huntsville, Alabama. This supply </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other
third party and Amgen is free to procure the Polymer Materials from any other third party. Under the terms of the 2010 Agreement, we received a $50.0&nbsp;million upfront payment in return for guaranteeing supply of certain quantities of Polymer
Materials to Amgen and the Additional Rights described below, and Amgen will pay manufacturing fees calculated based on fixed and variable components applicable to the Polymer Materials ordered by Amgen and delivered by us. Amgen has no minimum
purchase commitments. If quantities of the Polymer Materials ordered by Amgen exceed specified quantities (with each specified quantity representing a small portion of the quantity that we historically supplied to Amgen), significant additional
payments become payable to us in return for guaranteeing supply of additional quantities of the Polymer Materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term
of the 2010 Agreement runs through October&nbsp;29, 2020. In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Alabama, we fail to manufacture and supply the
Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturing facility to operate the
manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights). Amgen may terminate the 2010 Agreement for convenience or due to an uncured material default by us. Either party may terminate the 2010 Agreement
in the event of insolvency or bankruptcy of the other party. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PEGASYS<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with F. Hoffmann-La&nbsp;Roche Ltd </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In February 1997, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La&nbsp;Roche Ltd and Hoffmann-La&nbsp;Roche Inc. (Roche), under which we granted Roche a worldwide,
exclusive license to use certain intellectual property related to our PEGylation materials to manufacture and commercialize a certain class of products, of which PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is the only product currently commercialized. PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient&#146;s immune system fight the Hepatitis C
virus. As a result of Roche exercising a license extension option in December 2009, beginning in 2010 Roche has the right to manufacture all of its requirements for our proprietary PEGylation materials for PEGASYS<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and we supply raw materials or perform additional manufacturing, if any, only on a back-up basis. In connection with
Roche&#146;s exercise of the license extension option in December 2009, we received a payment of $31.0&nbsp;million. The agreement expires on the later of December&nbsp;31, 2015 or the expiration of our last relevant patent containing a valid claim.
In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce
PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, all of which were delivered in the last quarter of 2013, for total consideration of approximately $18.6 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Somavert<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with
Pfizer, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2000, we entered into a license, manufacturing and supply agreement with
Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer, Inc. in 2003), for the PEGylation of Somavert<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly. We currently manufacture our proprietary PEGylation reagent for Pfizer,
Inc. on a price per gram basis. The agreement expires on the later of ten years from the grant of first marketing authorization in the designated territory, which occurred in March 2003, or the expiration of our last relevant patent containing a
valid claim. In addition, Pfizer, Inc. may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PEG-Intron<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>,
Agreement with Merck (through its acquisition of Schering-Plough Corporation) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2000, we entered into a
manufacturing and supply agreement with Schering-Plough Corporation (Schering) for the manufacture and supply of our proprietary PEGylation materials to be used by Schering in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
production of a PEGylated recombinant human interferon-alpha (PEG-Intron). PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary
of, Merck&nbsp;&amp; Co., Inc. We currently manufacture our proprietary PEGylation materials for Schering on a price per gram basis. In December 2010, the parties amended the manufacturing and supply agreement to provide for a transition plan to an
alternative manufacturer and extension of the term through the successful manufacturing transition or December&nbsp;31, 2018 at the latest. The amended agreement provided for a one-time payment and milestone payments as well as increased pricing for
any future manufacturing performed by us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Macugen<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with Valeant Pharmaceuticals International, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2002, we entered into a license, manufacturing and supply agreement with Eyetech, Inc. (subsequently acquired by Valeant Pharmaceuticals International, Inc. or Valeant), pursuant to which we license
certain intellectual property related to our proprietary PEGylation technology for the development and commercialization of
Macugen<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S.&nbsp;and
E.U. for age-related macular degeneration. We currently manufacture our proprietary PEGylation materials for Valeant on a price per gram basis. Under the terms of the agreement, we will receive royalties on net product sales in any particular
country for the longer of ten years from the date of the first commercial sale of the product in that country or the duration of patent coverage. We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc. The
agreement expires upon the expiration of our last relevant patent containing a valid claim. In addition, Valeant may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and
either party may terminate for cause if certain conditions are met. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>CIMZIA<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, Agreement with UCB Pharma </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2000, we entered into a license, manufacturing and supply agreement covering our proprietary PEGylation materials for use in CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (certolizumab pegol) with Celltech Chiroscience Ltd., which was acquired by UCB Pharma (UCB) in 2004. Under the terms of the agreement, UCB is responsible for all
clinical development, regulatory, and commercialization expenses. We also manufacture and supply UCB with our proprietary PEGylation reagent used in the manufacture of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> on a fixed price per gram. We were also entitled to receive royalties on net sales of the CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country. In
February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> effective as of
January&nbsp;1, 2012 until the agreement with UCB is terminated or expires. This sale is further discussed in Note&nbsp;7 of Item&nbsp;8, Financial Statements and Supplementary Data. We share a portion of the payments we receive from UCB with Enzon
Pharmaceuticals, Inc. The agreement expires upon the expiration of all of UCB&#146;s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties. In addition, UCB may
terminate the agreement should it cease the development and marketing of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and either party may terminate
for cause under certain conditions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MIRCERA<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator), Agreement with F.&nbsp;Hoffmann-La&nbsp;Roche Ltd </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La&nbsp;Roche Ltd
and Hoffmann-La&nbsp;Roche Inc. (Roche), which was amended and restated in its entirety in December 2005. Pursuant to the agreement, we license our intellectual property related to our proprietary PEGylation materials for the manufacture and
commercialization of Roche&#146;s MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product. MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and
patients not on dialysis. As of the end of 2006, we were no longer required to manufacture and supply our proprietary PEGylation materials for MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> under our original agreement. In February 2012, we entered into a toll-manufacturing agreement with Roche under which we manufactured our proprietary PEGylation
material for MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Roche entered into the <FONT STYLE="white-space:nowrap">toll-manufacturing</FONT>
agreement with the objective of establishing us as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
a secondary back-up source on a non-exclusive basis through December&nbsp;31, 2016. Under the terms of this agreement, Roche paid us an up-front payment of $5.0 million plus a total of $22.0
million in performance-based milestone payments upon our achievement of certain manufacturing readiness, validation and production milestones, including the delivery of specified quantities of PEGylation materials, all of which were successfully
completed by the end of January 2013. Roche would also pay us additional consideration for any future orders of the PEGylation materials for MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beyond the initial quantities ordered as part of the initial arrangement. In August 2013, we agreed to deliver additional quantities of PEGylation materials used by
Roche to produce PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, all of which were delivered by the fourth quarter of 2013, for total consideration of approximately $18.6 million. Roche may terminate the toll-manufacturing
agreement due to an uncured material default by us or for convenience under certain circumstances and subject to certain financial obligations. We were also entitled to receive royalties on net sales of the MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product. In February 2012, we sold all of our future rights to receive royalties on future worldwide net sales of
MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> effective as of January&nbsp;1, 2012. This sale is further discussed in Note&nbsp;7 of Item&nbsp;8,
Financial Statements and Supplementary Data. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>OMONTYS<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> (Peginesatide), Agreement with Affymax, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In April 2004, we entered into a license, manufacturing and supply agreement with Affymax, Inc. (Affymax), under which we granted Affymax a worldwide, non-exclusive license to certain of our proprietary
PEGylation technology to develop, manufacture and commercialize OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. OMONTYS<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a synthetic PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as
an erythropoietin stimulating agent (ESA). It is the only ESA that is peptide-based and its building blocks (amino acids) are arranged in a different order than erythropoietin (i.e., it has no sequence homology to endogenous erythropoietin). The
compound was discovered by Affymax and is being co-developed and marketed by Affymax and Takeda Pharmaceutical Company Limited (Takeda). In March 2012, the FDA approved OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the treatment of dialysis patients with anemia due to chronic kidney disease (CKD). OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is the first once-monthly ESA for anemia in CKD for dialysis patients available in the U.S. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;23, 2013, Affymax and Takeda announced a voluntary recall of all lots of OMONTYS<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;drug product to the user level as a result of new post-marketing reports regarding serious hypersensitivity
reactions, including anaphylaxis, which can be life-threatening or fatal.&nbsp;The FDA has been notified by Affymax of 19 reports of anaphylaxis with 3 of those cases resulting in death. The reported serious hypersensitivity reactions have occurred
within 30 minutes after such administration of OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. There have been no reports of such reactions following
subsequent dosing, or in patients who have completed their dialysis session. Since launch of the drug, more than 25,000 patients have received OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the post-marketing setting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective as of April&nbsp;1, 2013, Affymax announced that it had amended its collaboration agreement with Takeda to transfer regulatory, manufacturing, and development responsibilities for OMONTYS<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to Takeda. In July 2013, Affymax terminated the license, manufacturing and supply agreement with us. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by
the FDA and by comparable regulatory agencies in other countries. These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in&nbsp;vitro, in animals, and
in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S.&nbsp;depends on whether the chemical composition of the product has previously been
approved for use in other dosage forms. If the product is a new chemical entity that has not been previously approved, the process includes the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extensive preclinical laboratory and animal testing; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission of an Investigational New Drug application (IND) prior to commencing clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for the intended
indication;</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extensive pharmaceutical development for the characterization of the chemistry, manufacturing process and controls for the active ingredient and drug
product; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an NDA for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket
Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the
active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests relating to systemic toxicity normally required for the IND and NDA or BLA may not be necessary if the company
has a right of reference to such data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section&nbsp;505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of
the product and its chosen formulation. Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations. The results of the preclinical tests for drugs, biological products and combination
products subject to the primary jurisdiction of the FDA&#146;s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before
clinical trials can begin. Clinical trials may begin 30&nbsp;days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period. Clinical trials involve the administration of the drug to healthy
volunteers or patients under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review. Drug products to be used in clinical trials must be manufactured according to current good
manufacturing practices (cGMP). Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be
evaluated in the study. Each protocol is submitted to the FDA in the IND. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Apart from the IND process described above, each
clinical study must be reviewed by an independent Institutional Review Board (IRB) and the IRB must be kept current with respect to the status of the clinical study. The IRB considers, among other things, ethical factors, the potential risks to
subjects participating in the trial and the possible liability to the institution where the trial is conducted. The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the
clinical study. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials are typically conducted in three sequential phases. Phase 1 involves the initial introduction
of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion. Phase 2 involves studies in a limited patient population to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">determine the preliminary efficacy of the product for specific targeted indications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">determine dosage and regimen of administration;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identify possible adverse effects and safety risks. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are undertaken to evaluate the further clinical efficacy and safety of the
drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of efficacy and tolerability. The FDA, the clinical trial sponsor, the investigators
or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk. In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed
prior to entering Phase 3 trials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following a series of formal meetings and communications between the drug sponsor and the
regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product. The FDA may deny approval if
applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria
for approval. Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the
product. Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk evaluation and mitigation strategies. Product approvals, once obtained, may be withdrawn if compliance with regulatory standards
is not maintained or if safety concerns arise after the product reaches the market. The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized
and has the power to prevent or limit future marketing of the product based on the results of such programs. After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited
reports for serious and unexpected adverse events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each manufacturing establishment producing the active pharmaceutical
ingredient and finished drug product for the U.S.&nbsp;market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment. Such inspections are also held
periodically after the commercialization. Establishments handling controlled substances must also be licensed by the U.S.&nbsp;Drug Enforcement Administration. Manufacturing establishments of U.S.&nbsp;marketed products are subject to inspections by
the FDA for compliance with cGMP and other U.S.&nbsp;regulatory requirements. They are also subject to U.S.&nbsp;federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance
controls, among others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For product candidates currently under development utilizing pulmonary technology, the pulmonary
inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molecule. The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary
responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBER are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where
the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction. In the case of our product candidates, CDER in consultation with CDRH could be involved in the review. The assessment of jurisdiction within the FDA is
based upon the primary mode of action of the drug or the location of the specific expertise in one of the centers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where CDRH
is determined to have primary jurisdiction over a product, 510(k) clearance or PMA approval is required. Medical devices are classified into one of three classes&nbsp;&#151; Class&nbsp;I, Class&nbsp;II, or Class&nbsp;III&nbsp;&#151; depending on the
degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. Devices deemed to pose lower risks are placed in either Class&nbsp;I or II, which requires the manufacturer to submit to the FDA
a Premarket Notification requesting permission to commercially distribute the device. This process is known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as
life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device are placed in Class&nbsp;III, requiring PMA approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, our partners have generally been responsible for clinical and regulatory approval procedures, but we may participate in this
process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, PEGylation materials or drug. For our proprietary products, we prepare and submit
an IND and are responsible for additional clinical and regulatory procedures for product candidates being developed under an IND. The clinical and manufacturing, development and regulatory review and approval process generally takes a number of
years and requires the expenditure of substantial resources. Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and
success in obtaining marketing approvals from the FDA and equivalent foreign health authorities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of our products outside the U.S.&nbsp;are subject to local regulatory requirements
governing clinical trials and marketing approval for drugs. Such requirements vary widely from country to country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S.&nbsp;The company
that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. In addition, the Orphan Drug Act provides for protocol
assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication may be approved
during the exclusivity period only if the second product is shown to be &#147;clinically superior&#148; to the original orphan drug in that it is more effective, safer or otherwise makes a &#147;major contribution to patient care&#148; or the holder
of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similar incentives also are available for orphan drugs in
the E.U. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the U.S., the FDA may grant Fast Track or Breakthrough designation to a product candidate, which allows the FDA
to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Important features of Fast Track or Breakthrough designation include a potentially
reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Patents and Proprietary Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own more than 215 U.S. and 750 foreign
patents and a number of pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer
conjugate technologies and our proprietary product candidates. More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of
administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates. Our patent portfolio contains patents and patent applications that encompass our PEGylation and advanced polymer conjugate technology platforms, some of
which we acquired in our acquisition of Shearwater Corporation in June 2001. Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world.
Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or
jurisdiction that issued the patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2002, we entered into a Cross-License and Option Agreement with Enzon
Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party&#146;s PEGylation patent portfolio. In certain cases, we have the option to license certain of Enzon&#146;s PEGylation patents
for use in our proprietary products or for sublicenses to third parties in each case in exchange for payments to Enzon based on manufacturing profits, revenue share or royalties on net sales if a designated product candidate is approved in one or
more markets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;31, 2008, we completed the sale of certain assets related to our pulmonary business,
associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (Novartis Pulmonary Asset Sale). In connection with the
Novartis Pulmonary Asset Sale, as of December&nbsp;31, 2008, we entered into an exclusive license agreement with Novartis Pharma AG. Pursuant to the exclusive license agreement, Novartis Pharma AG grants back to us an exclusive, irrevocable,
perpetual, royalty-free and worldwide license under certain specific patent rights and other related intellectual property rights acquired by Novartis from us in the Novartis Pulmonary Asset Sale, as well as certain improvements or modifications
thereto that are made by </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novartis. Certain of such patent rights and other related intellectual property rights relate to our development
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
program for inhaled vancomycin or are necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and
commercialization activities related to BAY41-6551 partnered with Bayer Healthcare LLC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secret
protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information or
otherwise gain access to, or disclose, our trade secrets. Please refer to Item&nbsp;1A, Risk Factors, including but not limited to &#147;We rely on trade secret protection and other unpatented proprietary rights for important proprietary
technologies, and any loss of such rights could harm our business, results of operations and financial condition.&#148; In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our
technologies may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary drug, we cannot guarantee that we will not be accused of, or determined to be, infringing a third
party&#146;s rights and be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial
condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve
complex legal and factual issues. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a
judgment is time consuming and costly.&nbsp;Additionally, issued patents can be subject to opposition or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that
renders the patent without commercially relevant or broad coverage).&nbsp;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and
commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patent.&nbsp;We may
have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us. Please refer to Item&nbsp;1A, Risk Factors, including without limitation,
&#147;If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">U.S.&nbsp;and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, medical devices and equipment and methods for
preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights
exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against any such claims. Furthermore, parties
making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S.&nbsp;and abroad and could result in the award of substantial
damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable
terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition. Please refer to
Item&nbsp;1A, Risk Factors, including without limitation, &#147;We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who
receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the
individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can be no assurance, however, that these agreements will provide meaningful
protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Customer
Concentrations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue is derived from our collaboration agreements with partners, under which we may receive contract
research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties or product sales revenue. AstraZeneca, UCB and Roche represented 52%, 16%, and 11% of our revenue, respectively, for the year
ended December&nbsp;31, 2014. No other collaboration partner accounted for more than 10% of our total revenue during the year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Backlog </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our collaboration agreements, we manufacture and
supply our proprietary PEGylation materials. Inventory is produced and sales are made pursuant to customer purchase orders for delivery. The volume of our proprietary PEGylation materials actually ordered by our customers, as well as shipment
schedules, are subject to frequent revisions that reflect changes in both the customers&#146; needs and our manufacturing capacity. In our partnered programs where we provide contract research services, those services are typically provided under a
work plan that is subject to frequent revisions that change based on the development needs and status of the program. The backlog at a particular time is affected by a number of factors, including scheduled date of manufacture and delivery and
development program status. In light of industry practice and our own experience, we do not believe that backlog as of any particular date is indicative of future results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competition in the pharmaceutical and biotechnology industry
is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world. We frequently compete with pharmaceutical companies and other institutions with greater
financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that
might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical
companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Science and Technology Competition </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our proprietary and partnered products will compete with others in the market on the basis of one or more of the following
parameters: efficacy, safety, ease of use and cost. We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates. A
number of the drug candidates in our pipeline have direct and indirect competition from large pharmaceutical companies and biopharmaceutical companies. With our PEGylation and advanced polymer conjugate technologies, we believe we have competitive
advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules. We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing
opportunities where appropriate, and determine the best applications for our technology platforms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the fields of
PEGylation and advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr.&nbsp;Reddy&#146;s Laboratories, Ltd., Enzon Pharmaceuticals, Inc., Mountain View Pharmaceuticals, Inc., SunBio
Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.). Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technology, advanced polymer conjugate
technology or technologies intended to deliver similar scientific and medical benefits. Some of these companies license intellectual property or PEGylation materials to other companies, while others apply the technology to create their own drug
candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product and Program Specific Competition </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT> (previously referred to as naloxegol and NKTR-118) (orally-available peripheral opioid antagonist) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no other once-daily oral drugs that act specifically to block or reverse the action of opioids on receptors
in the gastrointestinal tract which are approved specifically for the treatment of opioid-induced constipation (OIC) or opioid bowel dysfunction (OBD) in patients with chronic, non-cancer pain. The only approved oral treatment or opioid-induced
constipation in adults with chronic, non-cancer pain is a twice daily oral therapy called AMITIZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(lubiprostone), which acts by specifically activating CIC-2 chloride channels in the gastrointestinal tract to increase secretions. AMITIZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is marketed by Sucampo Pharmaceuticals and Takeda. There is also a subcutaneous treatment known as RELISTOR<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Subjectaneous Injection (methylnaltrexone bromide) marketed by Salix Pharmaceuticals, Ltd under a license from Progenics Pharmaceuticals, Inc. In 2014, RELISTOR<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Subjectaneous Injection was approved by the FDA for adult patients with chronic non-cancer pain. Other therapies
used to treat OIC and OBD include over-the-counter laxatives and stool softeners, such as docusate sodium, senna, and milk of magnesia. These therapies do not address the underlying cause of constipation as a result of opioid use and are generally
viewed as ineffective or only partially effective to treat the symptoms of OIC and OBD. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of companies
developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations. Potential competitors include Cubist Pharmaceuticals, Inc., GlaxoSmithKline
plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc, Mundipharma Int. Limited, Theravance, Inc., Develco Pharma, Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Etirinotecan pegol (NKTR-102, next-generation, long acting topoisomerase I inhibitor) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical
development for breast and ovarian cancers including but not limited to: Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (paclitaxel protein-bound
particles for injectable suspension (albumin bound)), Afinitor<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (everolimus), Doxil<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (doxorubicin HCl), Ellence<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (epirubicin), Gemzar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(gemcitabine), Halaven<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (eribulin), Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (trastuzumab), Hycamtin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(topotecan), Ibrance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (palbociclib), Ixempra<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (ixabepilone), Navelbine<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(vinolrebine), Paraplatin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (carboplatin), Taxol<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (paclitaxel), Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(capecitabine) and Taxotere<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (docetaxel). These therapies are only partially effective in treating breast and
ovarian cancer. Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol-Meyers Squibb Company, Eisai, Inc., Roche Holding Group (including its Genentech subsidiary),
GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly&nbsp;&amp; Co., Johnson&nbsp;&amp; Johnson, Sanofi Aventis S.A., and many others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are also a number of chemotherapies and cancer therapies approved today and in clinical development for the treatment of colorectal cancer. Approved therapies for the treatment of colorectal cancer
include Eloxatin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (oxaliplatin), Camptosar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (irinotecan), Avastin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(bevacizumab), Zaltrap<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (Ziv-afilbercept), Stivarga<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (regorafenib), Erbitux<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(cetuximab), Vectibix<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (panitumumab), Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (capecitabine), Adrucil<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(fluorouracil), and Wellcovorin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (leucovorin). These therapies are only partially effective in treating the
disease. There are a number of drugs in various stages of preclinical and clinical development from companies exploring cancer therapies or improved chemotherapeutic agents to potentially treat colorectal cancer. If these drugs are approved, they
could be competitive with etirinotecan pegol if it is approved by government health authorities. These include products in development from Bristol-Myers Squibb Company, Pfizer, Inc., GlaxoSmithKline plc, Antigenics, Inc., F. Hoffman-La&nbsp;Roche
Ltd, Novartis AG, Cell Therapeutics, Inc., Neopharm Inc., Meditech Research Ltd, Alchemia Limited, Enzon Pharmaceuticals Inc. and many others. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>BAY41-6551 (Amikacin Inhale, formerly NKTR-061) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are currently
no approved drugs on the market for adjunctive treatment or prevention of gram-negative pneumonias in mechanically ventilated patients which are also administered via the pulmonary route. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The current standard of care includes approved intravenous antibiotics which are partially effective for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in
patients on mechanical ventilators. These drugs include drugs that fall into the categories of antipseudomonal cephalosporins, antipseudomonal carbepenems, beta-lactam/beta-lactamase inhibitors, antipseudomonal fluoroquinolones, such as
ciprofloxacin or levofloxacin, and aminoglycosides, such as amikacin, gentamycin or tobramycin. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>BAX 855 (PEGylated
rFVIII) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;6, 2014, the FDA approved Biogen Idec &#146;s ELOCTATE&#153; [Antihemophilic Factor
(Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A. ELOCTATE&#153; is intended to be an extended half-life
Factor VIII therapy with prolonged circulation in the body with the potential to extend the interval between prophylactic infusions. Prior to its 2014 approval, the fusion protein in ELOCTATE&#153; was not used outside of the clinical trial setting
for hemophilia A patients. There are other long-acting Factor VIII programs in late-stage development for hemophilia A patients. Bayer Healthcare and Novo Nordisk have ongoing Phase 3 clinical development programs for longer acting Factor VIII
proteins based on pegylation technology approaches. These programs, if developed successfully and approved by health authorities, would be competitors in the longer acting Factor VIII market. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>NKTR-181(mu-opioid analgesic molecule for chronic pain) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are numerous companies developing pain therapies designed to have less abuse potential primarily through formulation technologies
and techniques applied to existing pain therapies. Potential competitors include Acura Pharmaceuticals, Inc., Cara Therapeutics, Inc., Collegium Pharmaceutical, Inc., Egalet Ltd, Elite Pharmaceuticals, Inc., Endo Health Solutions Inc., KemPharm,
Inc., Pfizer, Inc., Purdue Pharma L.P., and Teva Pharmaceutical Industries Ltd. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our total research and development expenditures can be disaggregated into the following significant types of expenses (in millions):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third party and direct materials costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel, overhead and other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing and Supply </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have a manufacturing facility located in Huntsville, Alabama that is capable of manufacturing PEGylated derivatives and starting materials for active pharmaceutical ingredients (APIs). The facility is
also used to produce APIs and finished drug products to support the early phases of clinical development of our proprietary drug candidates. The facility and associated equipment are designed and operated to be consistent with all applicable laws
and regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we do not maintain the capability to manufacture finished drug products for all development products, we
primarily utilize contract manufacturers to manufacture the finished drug product for us. We source drug starting materials for our manufacturing activities from one or more suppliers. For the drug starting materials necessary for our proprietary
drug candidate development, we have agreements for the supply of such drug </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
components with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials and services from one or
a limited number of suppliers and there is a risk that if such supply or services were interrupted, it would materially harm our business. In addition, we typically order raw materials and services on a purchase order basis and do not enter into
long-term dedicated capacity or minimum supply arrangements. We also utilize the services of contract manufacturers to manufacture APIs required for later phases of clinical development and eventual commercialization for us under all applicable laws
and regulations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Environment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a manufacturer of PEG reagents for the U.S.&nbsp;market, we are subject to inspections by the FDA for compliance with cGMP and other U.S.&nbsp;regulatory requirements, including U.S.&nbsp;federal,
state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We
have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties for failure to comply with these laws and regulations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees and Consultants </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we had 438&nbsp;employees, of which 321&nbsp;employees were engaged in research and development, commercial
operations and quality activities and 117&nbsp;employees were engaged in general administration and business development. Of the 438&nbsp;employees, 357 were located in the U.S. and 81 were located in India. We have a number of employees who hold
advanced degrees, such as Ph.D.s. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages. We believe that we maintain good relations with our employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovigilance, process engineering,
manufacturing, quality assurance, clinical development and business development. These individuals include scientific advisors as well as independent consultants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Available Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our website address is <I>http://www.nektar.com</I>.
The information in, or that can be accessed through, our website is not part of this annual report on Form&nbsp;10-K. Our annual reports on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q and current reports on Form&nbsp;8-K and amendments to
those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC). The public may read and copy any
materials we file with the SEC at the SEC&#146;s Public Reference Room at 100&nbsp;F&nbsp;Street, NE, Washington,&nbsp;D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling 1-800-SEC-0330. The SEC maintains
an Internet site that contains reports, proxy and information statements and other information regarding our filings at <I>www.sec.gov</I>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTIVE OFFICERS OF THE REGISTRANT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the names, ages and positions of our executive officers as of February&nbsp;15, 2015: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Howard W. Robin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Nicholson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ivan P. Gergel, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Drug Development and Chief Medical Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen K. Doberstein,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gil M. Labrucherie,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, General Counsel and Secretary</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maninder Hora, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Pharmaceutical Development and Manufacturing Operations</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jillian B. Thomsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Finance and Chief Accounting Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Howard W. Robin </I>has served as our President and Chief Executive Officer since January 2007 and has
served as a member of our board of directors since February 2007. Mr.&nbsp;Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001
to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr.&nbsp;Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a
subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr.&nbsp;Robin was Director of Business Planning and Development at Berlex.
He was a Senior Associate with Arthur Andersen&nbsp;&amp; Co. prior to joining Berlex. Mr.&nbsp;Robin serves as a director of the Biotechnology Industry Organization, the world&#146;s largest biotechnology industry trade organization, and also
serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>John Nicholson </I>has served as our Senior Vice President and Chief Financial Officer since December 2007. Mr.&nbsp;Nicholson joined
the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007. Before joining Nektar, Mr.&nbsp;Nicholson spent 18&nbsp;years
in various executive roles at Schering Berlin, Inc., the U.S. management holding company of Bayer Schering Pharma AG, a pharmaceutical company. From 1997 to September 2007, Mr.&nbsp;Nicholson served as Schering Berlin Inc.&#146;s Vice President of
Corporate Development and Treasurer. From 2001 to September 2007, he concurrently served as President of Schering Berlin Insurance Co., and from February 2007 through September 2007, he also concurrently served as President of Bayer Pharma Chemicals
and Schering Berlin Capital Corp. Mr.&nbsp;Nicholson holds a B.B.A. from the University of Toledo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Ivan P. Gergel, M.D.
</I>has served as our Senior Vice President, Drug Development and Chief Medical Officer since May 2014. From April 2008 through March 2014, Dr.&nbsp;Gergel served as Executive Vice President, Research&nbsp;&amp; Development and Chief Scientific
Officer of Endo Pharmaceuticals, a pharmaceutical company. Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that,
Dr.&nbsp;Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline
Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr.&nbsp;Gergel is a member of the Board of Directors of Corium International, Inc., a commercial-stage biopharmaceutical company. He also serves as a member
of the Board of Directors of Pennsylvania BIO and the PhRMA Foundation and has served as a Member of PhRMA&#146;s Scientific and Regulatory Executive Committee. Dr.&nbsp;Gergel received his M.D. from the Royal Free Medical School of the University
of London and an MBA from the Wharton School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stephen K. Doberstein,&nbsp;Ph.D. </I>has served as our Senior Vice
President and Chief Scientific Officer since January 2010. From October 2008 through December 2009, Dr.&nbsp;Doberstein served as Vice President, Research at </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Xoma (US) LLC, a publicly traded clinical stage biotechnology company. From July 2004 until August 2008, he served as Vice President, Research at privately held Five Prime Therapeutics, Inc., a
clinical stage biotechnology company. From September 2001 until July 2004, Dr.&nbsp;Doberstein was Vice President, Research at privately held Xencor, Inc., a clinical stage biotechnology company. From 1997 to 2000, he held various pharmaceutical
research positions at Exelixis, Inc. (Exelixis), a publicly traded clinical stage biotechnology company. Prior to working at Exelixis, Dr.&nbsp;Doberstein was a Howard Hughes Postdoctoral Fellow and a Muscular Dystrophy Association Senior
Postdoctoral Fellow at the University of California, Berkeley. Dr.&nbsp;Doberstein received his Ph.D. Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine and received a B.S. in Chemical Engineering from the
University of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gil M. Labrucherie </I>has served as our Senior Vice President, General Counsel and Secretary
since April 2007, responsible for all aspects of our legal affairs. Mr.&nbsp;Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007. From October 2000 to September 2005, Mr.&nbsp;Labrucherie was Vice President
of Corporate Development at E2open. While at E2open, Mr.&nbsp;Labrucherie was responsible for global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an
Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr.&nbsp;Labrucherie serves on the General Counsel Committee of the Biotechnology Industry Organization, the world&#146;s largest
biotechnology industry trade organization. Mr.&nbsp;Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. Mr.&nbsp;Labrucherie received his J.D. from the Berkeley
Law School and a B.A. from the University of California Davis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Maninder Hora, Ph.D.</I> has served as our Senior Vice
President, Pharmaceutical Development and Manufacturing Operations since August 2010. From December 2008 to July 2010, he was Vice President, Product and Quality Operations at Facet Biotech Corporation, a clinical stage biotechnology company, which
was acquired by Abbott Laboratories in April 2010. From July 2006 to December 2008, Dr.&nbsp;Hora served in various management capacities at PDL Biopharma, Inc., a biopharmaceutical company, most recently as Vice President, Product Operations. From
1986 to 2006, Dr.&nbsp;Hora held positions of increasing responsibility with Chiron Corporation (Chiron and now Novartis), a pharmaceutical company, serving most recently at Chiron as Vice President of Process and Product Development. Dr.&nbsp;Hora
served as a key member of various teams that successfully registered eight drugs or vaccines in the U.S. and Europe during his 20-year tenure at Chiron. Dr.&nbsp;Hora has also held positions at Wyeth Pharmaceuticals and GlaxoSmithKline&nbsp;plc
prior to joining Chiron. Dr.&nbsp;Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, and received his B.S. in chemistry from the University
of Jabalpur. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Jillian B. Thomsen </I>has served as our Senior Vice President, Finance and Chief Accounting Officer since
February 2010. From March 2006 through March 2008, Ms.&nbsp;Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before
joining Nektar, Ms.&nbsp;Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms.&nbsp;Thomsen is a certified public accountant and previously was a senior manager at Arthur
Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms.&nbsp;Thomsen holds a Masters of Accountancy from the University of Denver and a
B.A. in Business Economics from Colorado College. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_2"></A>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Risk Factors</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate,
we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of
the Securities Act. You should understand that it is not possible to predict or identify all such factors. Consequently, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and
rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a number of proprietary drug candidates and partnered drug candidates in research and development ranging from the early discovery
research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive and highly uncertain processes. It will take us, or our collaborative partners, several years to complete clinical studies.
The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of
care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#146; financial constraints. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and clinical development. Typically, there is a high rate of
attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The risk of failure increases for our drug candidates that are based on new
technologies, such as the application of our advanced polymer conjugate technology to etirinotecan pegol, NKTR-181, NKTR-171, NKTR-214 and other drug candidates currently in discovery research or preclinical development. For example, while we
recently started a Phase 3 clinical program for NKTR-181 which we believe employs the most appropriate clinical trial design, we were unable to identify a single cause for the Phase 2 study for NKTR-181 not meeting its primary efficacy endpoint, and
therefore there is increased risk in effectively designing a Phase 3 clinical program for NKTR-181. The failure of one or more of our drug candidates could have a material adverse effect on our business, financial condition and results of
operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even with success in previously completed clinical trials, the risk of clinical failure for any drug
candidate remains high prior to regulatory approval. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of companies have suffered significant unforeseen
failures in late stage (i.e. Phase 3) clinical studies due to factors such as inconclusive efficacy or safety, even after achieving positive results in earlier clinical studies that were satisfactory both to them and to reviewing government health
authorities. While etirinotecan pegol and Amikacin Inhale have each demonstrated positive results from earlier clinical studies, there is a substantial risk that Phase 3 clinical study outcomes for these drug candidates from larger patient
populations will not demonstrate positive efficacy, safety or other clinical outcomes sufficient to support regulatory filings and achieve regulatory approval. Phase 3 clinical study outcomes remain very unpredictable and it is possible that one or
more of these Phase 3 clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. If one or more of these drug candidates fail in Phase&nbsp;3 clinical studies, it would have a
material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our results of operations and
financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When we sign a collaborative development agreement or license agreement to develop a drug candidate with a pharmaceutical or biotechnology company, the pharmaceutical or biotechnology company is generally
expected to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">design and conduct large scale clinical studies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prepare and file documents necessary to obtain government approvals to sell a given drug candidate; and/or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market and sell the drugs when and if they are approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the
amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising (where appropriate), product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and
supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their
own drugs or other drugs that they have in-licensed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to
litigation or arbitration proceedings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on
commercially reasonable terms or consistent with our current business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">partners may be unable to pay us as expected; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in
other cases with no termination fee penalty. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given these risks, the success of our current and future
collaboration partnerships is highly unpredictable and can have a substantial negative or positive impact on our business&#151;in particular, we expect the commercial outcomes of MOVANTIK&#153;, and if approved, BAX 855, to have a particularly
significant impact on our near to mid- term financial results and financial condition. If our collaboration arrangements underperform or fail, our drug development efforts for our proprietary drug candidate pipeline could be delayed or reduced
unless we can secure capital funding from other sources. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial
condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The commercial potential of a drug candidate in development is difficult to predict. If the market size for
a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">It is very difficult to estimate the commercial potential of product candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic
drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either
during the long drug development process or after commercial introduction, and the availability of generic versions of our successful product candidates following approval by government health authorities based on the expiration of regulatory
exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and
negatively impact the commercial terms of any collaboration partnership potential for such drug candidate or, if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be
significantly diminished and would negatively impact our business, financial condition and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are a party to numerous collaboration agreements and other significant agreements
which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently derive, and expect to derive in the foreseeable future, all of our revenue from collaboration agreements with biotechnology
and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be
difficult to enforce if disputes arise as to adequacy of our partner&#146;s performance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate
development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with
complicated cost allocation formulas and methodologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the
collaboration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent
life, generic competitors, bundled pricing and other factors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">indemnity obligations for intellectual property infringement, product liability and certain other claims. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a party to certain significant agreements, including an asset purchase agreement with Novartis pursuant to
which we sold a significant portion of our pulmonary business at the end of 2008, the worldwide exclusive license agreement with AstraZeneca related to the further development and commercialization of MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, and the purchase and sale agreement with RPI Finance Trust (RPI)
related to the sale of our royalty interests in UCB&#146;s CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Roche&#146;s MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> that we completed in February 2012. Each of these agreements contains complex representations and warranties,
covenants and indemnification obligations. If we breach any of our agreements with Novartis, AstraZeneca, RPI or any other third party agreements, it could subject us to substantial liabilities and harm our financial condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we have informal dispute resolution discussions with third parties regarding the appropriate interpretation of the
complex commercial terms contained in our agreements. For example, on January&nbsp;23, 2015, we filed a lawsuit against Allergan and MAP seeking economic damages related to a dispute over the economic sharing provisions of our license agreement with
MAP. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract
terms, which would have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we
or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial
condition will be negatively affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We or our partners may not obtain regulatory approval for drug candidates on a
timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive
review process for safety and efficacy by the FDA and equivalent foreign government health authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign health authorities
have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including
recalls. Further, health authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners which could lead such authorities to arrive at different conclusions regarding the safety or
efficacy of a drug candidate. In addition, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the
delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca will be conducting a post-marketing, observational epidemiological study comparing MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> to other treatments of OIC in patients with chronic, non-cancer pain and the results of this study could at some point
in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we or our partners receive regulatory approval of a product, the
approval may limit the indicated uses for which the drug may be marketed. Our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the
FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of
related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of
operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have substantial future capital requirements and there is a risk we may not have
access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to
raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we had cash and investments in marketable securities valued at approximately $262.8 million, of which $25.0 million was restricted in relation to our 12.0% senior secured
notes, and indebtedness of approximately $151.8 million. The indebtedness includes approximately $125.0 million in senior secured notes due July 2017, but excludes our long-term liability relating to the sale of future royalties as this royalty
obligation liability will not be settled in cash. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous
unpredictable factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost, timing and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates that we have licensed to our collaboration
partners &#151; important examples include Amikacin Inhale and CIPRO Inhale licensed to Bayer, and BAX 855 that is being developed by Baxter; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commercial launch and sales levels of products marketed by our collaboration partners for which we are entitled to royalties and sales milestones
&#151; importantly, AstraZeneca&#146;s level of success in marketing and selling MOVANTIK&#153;; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those
collaborations achieve clinical, regulatory or commercial success; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress, timing, cost and results of our clinical development programs &#151; in particular our Phase 3 BEACON study for etirinotecan pegol for
which we expect to have topline results in March 2015 and our Phase 3 clinical program for NKTR-181; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net
cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the government health
authorities in order to consider for approval our drug candidates and those of our collaboration partners; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our general and administrative expenses, capital expenditures and other uses of cash; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or
royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant multi-year capital commitment is required to advance our drug candidates
through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not
enter into any new collaboration partnerships with significant upfront payments and we choose to continue our later stage research and development programs, we may need to pursue financing alternatives, including dilutive equity-based financings,
such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us
or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially
impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>While we have conducted numerous experiments using laboratory and home-based chemistry techniques that have not been able to convert NKTR-181 into a rapid-acting and more abusable opioid, there is a
risk that a technique could be discovered in the future to convert NKTR-181 into a rapid-acting and more abusable opioid, which would significantly diminish the value of this drug candidate. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An important objective of our NKTR-181 drug development program is to create a unique opioid molecule that does not rapidly enter a
patient&#146;s central nervous system and therefore has the potential to be less susceptible to abuse than alternative opioid therapies. To date, we have conducted numerous experiments using laboratory and home-based chemistry techniques that have
been unable to convert NKTR-181 into a rapidly-acting, more abusable form of opioid. In the future, an alternative chemistry technique, process or method of administration, or combination thereof, may be discovered to enable the conversion of
NKTR-181 into a more abusable opioid, which could significantly and negatively impact the commercial potential or diminish the value of NKTR-181. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and
development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence
and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration
arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material
adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preliminary and interim data from our
clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation
and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our
business prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Delays in clinical studies are common and have many causes, and any significant delay
in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We or our partners may experience delays in clinical trials of drug candidates. We currently have ongoing Phase 3 studies for etirinotecan pegol in patients with metastatic breast cancer and NKTR-181 in
patients with chronic lower back pain. In addition, our collaboration partners have several ongoing Phase 3 clinical programs including Baxter for BAX 855, Bayer for Amikacin Inhale and CIPRO Inhale, and Ophthotech for Fovista&#153;. These and other
clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Our clinical trials for any of our product candidates could be delayed for a variety of reasons, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in obtaining regulatory approval to commence a clinical study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in reaching agreement with applicable health authorities on a clinical study design; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other health authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or termination of a clinical study by us, our partners, the FDA or foreign health authorities due to adverse side effects of a drug on
subjects in the trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in recruiting suitable patients to participate in a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in having patients complete participation in a trial or return for post-treatment follow-up; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical sites dropping out of a trial to the detriment of enrollment rates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in manufacturing and delivery of sufficient supply of clinical trial materials; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in health authorities policies or guidance applicable to our drug candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other
reasons, the regulatory approval process would be delayed and the ability to commercialize and commence sales of these drug candidates could be materially harmed, which could have a material adverse effect on our business, financial condition and
results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to obtain intellectual property licenses related to the development of our
drug candidates on a commercially reasonable basis, if at all. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerous pending and issued U.S. and foreign patent
rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent references
will be considered relevant to our or our collaboration partners&#146; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be
asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the scope and adequacy of these licenses is very uncertain and can change substantially during long development and
commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain
alternate technology. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all,
we may be prevented from developing and selling the drug, which could significantly harm our business, results of operations, and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If any of our pending patent applications do not issue, or are deemed invalid
following issuance, we may lose valuable intellectual property protection. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent positions of pharmaceutical and
biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 215 U.S. and 750 foreign patents and a number of pending patent applications that cover various aspects of our technologies. There
can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.
Additionally, issued patents can be subject to opposition or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially
relevant and/or broad coverage).&nbsp;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be
subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patents.&nbsp;We may have to participate in interference proceedings
declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and
advanced polymer conjugate technologies and our proprietary product candidates.&nbsp;There can be no assurance that the patent applications for which we apply would actually issue as patents, or do so with commercially relevant and/or broad
coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&nbsp;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our
right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions
covered by our patents or patent applications.&nbsp;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from
or to third parties or require us to cease using the technology in dispute.&nbsp;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all,
thereby raising concerns on our ability to freely commercialize our technologies or products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are involved in legal
proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our
obligations to them. The third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of
infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement,
product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief
against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial
damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third-party claims involving proprietary rights or other matters could also result in
substantial settlement payments or substantial damages to be paid by us. For instance, a settlement might require us to enter a license agreement under which we would pay substantial royalties or other compensation to a third party, diminishing our
future economic returns from the related drug. In December 2013, we entered into a litigation settlement with the Research Foundation of the State University of New York (SUNY) pursuant to which we agree to the payment of a total of $12.0 million in
future installments and certain other terms and conditions in exchange for the full release of certain breach of contract claims by SUNY. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, from time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have
already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies.&nbsp;For example, we are currently involved in a German litigation proceeding whereby Bayer is seeking co-ownership rights in
certain of our patent filings pending at the European Patent Office covering (among other things) PEGylated Factor VIII which we have exclusively licensed to Baxter.&nbsp;The subject matter of our patent filings in this proceeding relates to
Bayer&#146;s investigational PEGylated recombinant Factor VIII compound.&nbsp;We believe that Bayer&#146;s claim to an ownership interest in these patent filings is without merit and are vigorously defending sole and exclusive ownership rights to
this intellectual property. We are also regularly involved in opposition proceedings at the European Patent Office where third parties seek to invalidate or limit the scope of our allowed European patents applications covering (among other things)
our drugs and platform technologies.&nbsp;The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#146;s attention. Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or
royalties.</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our manufacturing operations and those of our contract manufacturers are subject to laws and other
governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We and our contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical
ingredients, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, the Drug Enforcement Administration or comparable agencies in other jurisdictions administering
such compliance. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and
document our or our contract manufacturers&#146; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing
obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for
our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products,
delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. The results of these inspections could result in costly
manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending
resolution of regulatory deficiencies or suspensions would have a material adverse effect on our business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we or our contract manufacturers are not able to manufacture drugs or drug
substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial
condition and results of operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we or our contract manufacturers are not able to manufacture and supply
sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#146; clinical studies or result in a breach
of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#146; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we
would otherwise be entitled to receive could be reduced, delayed or eliminated. In some cases, we rely on contract manufacturing organizations to manufacture and supply drug product for our clinical studies and those of our collaboration partners.
Pharmaceutical manufacturing of drugs and devices involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of
impurities, optimal formulations, process and analytical methods validations, device performance and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected
expenses as we validate third party contract manufacturers required for drug and device supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our contract manufacturers to supply
drug product or devices in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures
could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training
qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making
modifications to the drug formulation, which may cause significant delays in clinical development. We experienced repeated significant delays in starting the Phase 3 clinical development program for Amikacin Inhale as we sought to finalize and
validate the device design with a demonstrated capability to be manufactured at commercial scale. Drug/device combination products are particularly complex, expensive and time-consuming to develop due to the number of variables involved in the final
product design, including ease of patient and doctor use, maintenance of clinical efficacy, reliability and cost of manufacturing, regulatory approval requirements and standards and other important factors. There continues to be substantial and
unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not
necessarily indicative of our future revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue is exclusively derived from our collaboration agreements,
from which we receive contract research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties and manufacturing revenue. Significant variations in the timing of receipt of cash payments and
our recognition of revenue can result from significant milestone payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch and the achievement of certain annual sales
thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable collaboration partners, the timing of the
negotiation and conclusion of collaboration agreements with such partners, whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets,
reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any product
candidate under our collaboration agreement, our business, financial condition, results of operations and prospectus could be materially and adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable either to create sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our
products successfully. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no sales, marketing or distribution capabilities. To commercialize any of our
drugs that receive regulatory approval for commercialization, we must either develop internal sales, marketing and distribution capabilities, which would be expensive and time consuming, or enter into collaboration arrangements with third parties to
perform these services. If we decide to market our products directly, we must commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and
compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or indirectly with our partners include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to use or prescribe our products;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more
extensive product lines; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a
sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to
market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any
revenue we receive will depend upon the efforts of third parties, which may not be successful and are only partially in our control &#151; important examples of this risk include MOVANTIK&#153; partnered with AstraZeneca and BAX 855 partnered with
Baxter. In the event that we market our products without a partner, we would be required to build a sales and marketing organization and infrastructure, which would require a significant investment and we may not be successful in building this
organization and infrastructure in a timely or efficient manner. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We purchase some of the starting material for drugs
and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third
parties. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We often face very limited supply of a critical raw material that can only be obtained from a single, or a
limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunity or contract liability to third parties. For example, there are only a limited number of qualified suppliers, and in some
cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply or failure to procure such raw materials on commercially feasible terms could harm our
business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on trade secret protection and other unpatented proprietary rights for
important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and
proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be
difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations
and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to continue to incur substantial losses and negative cash flow from operations and
may not achieve or sustain profitability in the future. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended December&nbsp;31, 2014, we reported a net
loss of $53.9 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone payments and royalties received, the timing of revenue under our collaboration agreements, the amount of
investments we make in our proprietary product candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotech companies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effectively estimate and manage clinical development costs, particularly the cost of the BEACON study and the clinical studies for NKTR-181;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">receive necessary regulatory and marketing approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain or expand manufacturing at necessary levels; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achieve market acceptance of our partnered products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain sufficient funds to finance our activities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If government and private insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have
a negative impact on our business, results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In both domestic and foreign
markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of payment or
reimbursement from third-party payers, such as government health administration authorities, managed care providers, private health insurers and other organizations. Such third-party payers are increasingly challenging the price and cost
effectiveness of medical products and services. Therefore, significant uncertainty exists as to the pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Moreover, legislation and regulations
affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit pricing approvals for, and reimbursement of, our products from government authorities and third-party
payers. A government or third- party payer decision not to approve pricing for, or provide adequate coverage and reimbursements of, our products would limit market acceptance of such products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on third parties to conduct the clinical trials for our proprietary product
candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary product candidates. We rely heavily
on these parties for successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that
each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our
products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial
arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or our reliance on results of trials that we have not directly conducted or monitored could hinder or delay the development,
approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product
candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our PEGylation and advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete with various pharmaceutical and biotechnology companies.
Competitors of our PEGylation and polymer conjugate chemistry technologies include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr.&nbsp;Reddy&#146;s Laboratories Ltd., Enzon Pharmaceuticals, Inc., SunBio Corporation, Mountain View
Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technologies or technologies that
have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">There are several competitors for our proprietary product candidates currently in development. For Amikacin Inhale,
the current standard of care includes several approved intravenous antibiotics for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in patients on mechanical ventilators. For MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, there are currently several alternative therapies used to address
opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including Relistor<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(methylnaltrexone bromide) Subcutaneous Injection, oral Amitizia (lubiprostone), and oral and rectal over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of magnesia. In addition, there are a number of companies
developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations, including Cubist Pharmaceuticals, Inc., Progenics Pharmaceuticals, Inc. in
collaboration with Salix Pharmaceuticals, Ltd., Mundipharma Int. Limited, Sucampo Pharmaceuticals, Inc., Develco Pharma GmbH, Alkermes, Inc., GlaxoSmithKline plc, Theravance, Inc., and Takeda Pharmaceutical Company Limited. For etirinotecan pegol,
there are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast and ovarian cancers, including, but not limited to: Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (capecitabine), Afinitor<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(everolimus), Doxil<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (doxorubicin HCl), Ellence<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (epirubicin), Gemzar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(gemcitabine), Halaven<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (eribulin), Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (trastuzumab), Hycamtin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(topotecan), Ibrance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (palbociclib), Ixempra<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (ixabepilone), Navelbine<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(vinolrebine), Iniparib, Paraplatin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (carboplatin), Taxol<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (paclitaxel) and Taxotere<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(docetaxel). Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include, but are not limited to, Bristol-Meyers Squibb Company, Eli Lilly&nbsp;&amp; Co., Roche, GlaxoSmithKline plc, Johnson
and Johnson, Pfizer, Inc. Eisai, Inc., and Sanofi Aventis S.A. There are approved therapies for the treatment of colorectal cancer, including Eloxatin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (oxaliplatin), </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
Camptosar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (irinotecan), Avastin<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (bevacizumab), Zaltrap<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (Ziv-afilbercept), Stivarga<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(regorafenib), Erbitux<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (cetuximab), Vectibix<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (panitumumab), Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(capecitabine), Adrucil<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (fluorouracil) and Wellcovorin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (leucovorin). In addition, there are a number of drugs in various stages of preclinical and clinical development from companies exploring cancer therapies or improved
chemotherapeutic agents to potentially treat colorectal cancer, including, but not limited to, products in development from Bristol-Myers Squibb Company, Pfizer, Inc., GlaxoSmithKline plc, Antigenics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG,
Cell Therapeutics, Inc., Neopharm Inc. (acquired by Insys Therapeutics, Inc.), Meditech Research Ltd, Alchemia Limited, and Enzon Pharmaceuticals, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of
our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas
such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program
partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These
developments could make our products or technologies uncompetitive or obsolete. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If product liability lawsuits are
brought against us, we may incur substantial liabilities. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacture, clinical testing, marketing and sale of
medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage, we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether
or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business.
Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future depends on the proper management of our current and future business operations and their associated expenses.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business strategy requires us to manage our business to provide for the continued development and potential
commercialization of our proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties,
while simultaneously managing the capital necessary to support this strategy. Our decision to bear a majority or all of the clinical development costs of etirinotecan pegol substantially increases our future capital requirements. If we are unable to
manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to
reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to
obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other
financing arrangements on unfavorable terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are dependent on our management team and key technical personnel, and
the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm
our business, operating results and financial condition. The relationships that our key managers have cultivated </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly
technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without
penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we
need to support our operations and growth. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must attract and retain experts in the areas of clinical testing,
manufacturing, research, regulatory and finance, and may need to attract and retain marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies,
research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our
industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock options they are to receive
in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely
affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If earthquakes or other catastrophic events strike, our business may be harmed. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco
Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our PEGylation and advanced polymer conjugate technologies in Huntsville, Alabama and own and lease
offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these
locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and
financial condition would be harmed. Our collaborative partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes and tornadoes, any of which could harm our business, results of operations and financial condition.
We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist
activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may
be beneficial to our stockholders. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions of our certificate of incorporation and bylaws, as well as provisions of
Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of a classified board of directors such that not all members of the board may be elected at one time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect
director candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability of our board to authorize the issuance of &#147;blank check&#148; preferred stock to increase the number of outstanding shares and thwart a
takeover attempt; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by
stockholders at stockholder meetings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations on who may call a special meeting of stockholders. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a
third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for
their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are
terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of our common stock is expected to remain volatile. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
stock price is volatile. During the year ended December&nbsp;31, 2014, based on closing prices on The NASDAQ Global Select Market, our stock price ranged from $10.53 to $17.05 per share. We expect our stock price to remain volatile. A variety of
factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#147;Risk Factors&#148; and the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding
efficacy and safety, delays in clinical development, regulatory approval or commercial launch; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial
economic interest; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements regarding terminations or disputes under our collaboration agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in our results of operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license
agreements and the costs associated with those arrangements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of changes in governmental regulation affecting us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation brought against us or third parties to whom we have indemnification obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern as to the safety of drug formulations developed by us or others; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our financing needs and activities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to
dramatic price swings in recent years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The indenture governing the senior secured notes imposes significant operating and
financial restrictions on us and our subsidiaries that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The indenture governing the senior secured notes contains covenants that restrict our and our subsidiaries&#146; ability to take various actions, such as: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">incur or guarantee additional indebtedness or issue disqualified capital stock or cause certain of our subsidiaries to issue preferred stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pay dividends or distributions, redeem equity interests or subordinated indebtedness or make certain types of investments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">create or incur liens; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfer, sell, lease or otherwise dispose of assets and issue or sell equity interests in certain of our subsidiaries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">incur restrictions on certain of our subsidiaries&#146; ability to pay dividends or other distributions to the Company or to make intercompany loans or
asset transfers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into transactions with affiliates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">engage in any business other than businesses which are the same, similar, ancillary or reasonably related to our business as of July&nbsp;11, 2012; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">consummate a merger, consolidation, reorganization or business combination, or sell, assign, transfer, lease or otherwise dispose of all or
substantially all of our assets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the indenture governing the senior secured notes contains a
financial maintenance covenant requiring us to maintain a $25.0 million segregated cash reserve account until July&nbsp;1, 2015 to be applied to interest payments on the senior secured notes in the event of a default, subject to certain conditions.
This indenture also requires us not to permit, thereafter and through the quarter ending June&nbsp;30, 2017, the aggregate balance of our unrestricted cash and cash equivalents at the end of any two consecutive fiscal quarters to be less than $25.0
million, subject to certain conditions. Our ability to comply with these covenants will likely be affected by many factors, including events beyond our control, and we may not satisfy those requirements. Our failure to comply with our debt-related
obligations could result in an event of default under our other indebtedness and the acceleration of our other indebtedness, in whole or in part, could result in an event of default under the indenture governing the senior secured notes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The restrictions contained in the indenture governing the senior secured notes could also limit our ability to plan for or react to
market conditions, meet capital needs or otherwise restrict our activities or business plans and adversely affect our ability to finance our operations, enter into acquisitions or to engage in other business activities that would be in our interest.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_3"></A>Item&nbsp;1B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Unresolved Staff Comments</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_4"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Properties</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>California </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We lease a
126,285&nbsp;square foot facility in the Mission Bay Area of San&nbsp;Francisco, California (Mission Bay Facility), under an operating lease which expires in 2020. The Mission Bay Facility is our corporate headquarters and also includes our research
and development operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lease for approximately 100,000&nbsp;square feet of the San&nbsp;Carlos Facility is under a
capital lease which expires in 2016. We have subleased all of the San Carlos Facility. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alabama </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently own four facilities consisting of approximately 165,000 square feet in Huntsville, Alabama, which house laboratories as well as administrative, clinical and commercial manufacturing
facilities for our PEGylation and advanced polymer conjugate technology operations as well as manufacturing of APIs for early clinical studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In July 2012, we consolidated our U.S.-based research activities into our Mission Bay Facility and ceased use of one of our buildings located in Huntsville that was dedicated to research activities. We
are currently seeking a buyer for the land and building. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>India </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own a research and development facility consisting of approximately 88,000&nbsp;square feet, near Hyderabad, India. In addition, we
lease approximately 504&nbsp;square feet of office space in Hyderabad, India, under a one-year operating lease that will expire in 2015. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_5"></A>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Legal Proceedings</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From time to time, we are subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect
on our business, financial condition or results of operations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_6"></A>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Mine Safety Disclosures</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;II </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_7"></A>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock trades on The NASDAQ Global Select Market under the symbol &#147;NKTR.&#148; The table below sets forth the high and low
closing sales prices for our common stock as reported on The NASDAQ Global Select Market during the periods indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2013:</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th&nbsp;Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2014:</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th&nbsp;Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Holders of Record </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;20, 2015, there were approximately 212 holders of record of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividend Policy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the
foreseeable future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no sales of unregistered securities and there were no common stock repurchases made during the
year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities Authorized for Issuance Under Equity Compensation Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information regarding our equity compensation plans as of December&nbsp;31, 2014 is disclosed in Item&nbsp;12 &#147;Security Ownership of
Certain Beneficial Owners and Management and Related Stockholder Matters&#148; of this Annual Report on Form&nbsp;10-K and is incorporated herein by reference from our proxy statement for our 2015 annual meeting of stockholders to be filed with the
SEC pursuant to Regulation&nbsp;14A not later than 120&nbsp;days after the end of the fiscal year covered by this Annual Report on Form&nbsp;10-K. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Performance Measurement Comparison </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material in this section is being furnished and shall not be deemed &#147;filed&#148; with the SEC for purposes of Section&nbsp;18 of
the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or
the Exchange Act, except as otherwise expressly stated in such filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following graph compares, for the five year period
ended December&nbsp;31, 2014, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i)&nbsp;the NASDAQ Composite Index, (ii)&nbsp;the NASDAQ Pharmaceutical Index, (iii)&nbsp;the RGD
SmallCap Pharmaceutical Index, (iv)&nbsp;the NASDAQ Biotechnology Index and (v)&nbsp;the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December&nbsp;31, 2010, December&nbsp;31, 2011,
December&nbsp;31, 2012, December&nbsp;31, 2013 and December&nbsp;31, 2014. The graph assumes that $100 was invested on December&nbsp;31, 2009 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RGD
SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price
performance. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g842626g16f09.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_8"></A></B><B><I>Selected Financial Data</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SELECTED CONSOLIDATED FINANCIAL INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands, except per
share information) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The selected consolidated financial data set forth below should be read together with the consolidated
financial statements and related notes, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and the other information contained herein. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non cash royalty revenue related to sale of future royalties</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">222,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195,417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(120,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(141,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(123,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on liability related to<BR>sale of future royalties</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(133,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) )&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding used in computing basic and diluted net loss per share</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">302,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">414,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">315,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">224,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,661</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">236,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">434,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">497,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">606,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">521,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible subordinated notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">214,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">214,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior secured notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to the sale of future royalties</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,585</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,786,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,732,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,570,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,398,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,264,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we sold all of our rights to receive future royalty payments on net sales of UCB&#146;s CIMZIA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Roche&#146;s MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated
royalty payment </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
period. As a result of this liability accounting, even though the royalties from UCB and Roche are remitted directly to the purchaser of these royalty interests starting in the second quarter of
2012, we will continue to record revenue for these royalties. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per share is based upon the weighted average number of common shares outstanding. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ
materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in &#147;Part&nbsp;I, Item&nbsp;1A&nbsp;&#151; Risk
Factors.&#148; </I></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_9"></A>Item&nbsp;7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Strategic
Direction of Our Business </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our
PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our current proprietary pipeline is comprised of drug candidates across a
number of therapeutic areas including oncology, pain, anti-infectives, and immunology. Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates. We create innovative drug candidates by using
our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities. Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures
with drug molecules to alter the properties of a molecule. Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer
chemistry technology and expertise. Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life and/or bioavailability of
drugs. Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas that address large potential markets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca. MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation, or OIC, a side
effect caused by chronic administration of prescription opioid pain medicines. MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> was developed using
our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. On September&nbsp;16, 2014, the United States Food and Drug Administration, or
FDA, approved MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA)
medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. On December&nbsp;9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (the naloxegol brand name in the European Union, or EU) as the first once-daily oral PAMORA to be approved in the
European Union (EU) for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#146;s approval applies to all 28 European Union member countries plus Iceland and Norway. On January&nbsp;23, 2015, the DEA
published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act. AstraZeneca is planning the commercial launch of MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in the United States late in the first quarter of 2015 and
MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the second half of 2015. Given the significant milestones and royalty opportunity for us associated
with MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> under our AstraZeneca license agreement, the level of sales achieved by AstraZeneca for MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> will have a significant impact on our operating results and financial condition over the coming years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I (topo I)
inhibitor proprietary drug candidate, currently being evaluated in a Phase 3 open-label, randomized, multicenter clinical study as a single-agent therapy for women with metastatic breast cancer. This Phase 3 clinical study, which we call the BEACON
study (BrEAst Cancer Outcomes with NKTR-102), has completed enrollment of approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or
metastatic setting. Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician&#146;s choice. The primary endpoint of the BEACON study is overall survival, and
secondary endpoints include progression-free survival and objective tumor response rate. We have now achieved the necessary number of events in the BEACON study to assess the overall survival endpoint and certain other topline data. We are now
conducting blinded data verification activities and currently plan to unblind and announce the top-line data from the BEACON Study in March 2015. If the BEACON study is successful and etirinotecan pegol is ultimately approved by the FDA, our current
plan would be to market and sell etirinotecan pegol in the United States ourselves for the FDA approved metastatic breast cancer indication and license the commercial rights outside of the U.S. to one or more collaboration partners. As a result, the
outcome of the BEACON study will have a significant impact on whether or not we invest significant capital in building and maintaining a sales and market organization for the U.S. that we currently do not have in place. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions. NKTR-181 has been designed to have a slow rate of
entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are commonly
associated with standard opioid therapies. Its potential differentiating properties are inherent to its molecular design and, as a new molecular structure, NKTR-181&#146;s potential abuse deterrent properties do not rely on a formulation approach, a
common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid. In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. In June
2013, we announced results from a human abuse liability study that demonstrated that NKTR-181 had highly statistically significant lower &#147;drug liking&#148; scores and reduced &#147;feeling high&#148; scores as compared to oxycodone at all doses
tested (p&lt;0.0001). In September 2013, we announced topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. In this study, NKTR-181 performed as expected as an
opioid analgesic throughout the study. However, patients who were randomized to the placebo arm following a drug titration phase did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal
studies. This lack of a placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of certain considerations for the Phase 3 clinical study program. In this Phase 3 program for
NKTR-181 we plan to include two separate efficacy studies in patients with chronic lower back pain, a long-term safety study, and a human abuse liability study. We enrolled the first patient in this first Phase 3 study on February&nbsp;24, 2015. In
this first efficacy study, we plan to enroll approximately 416 patients in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients,
followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo. The study design also includes a single interim analysis for sample size reassessment which will be
conducted by an independent data monitoring committee. The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of
responders (&gt;30% reduction in pain score) and patient impression of change. We plan to have further interactions with the FDA to finalize the study design for the other clinical studies planned for the Phase 3 program. Over the next two to three
years, the NKTR-181 clinical development program will require a substantial investment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a collaboration with Baxter
Healthcare (Baxter), to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients. Under the terms of this collaboration, we are providing our PEGylation technology and expertise
and Baxter is responsible for all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
clinical development. The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE
[Antihemophilic Factor (Recombinant)]. In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855. This regulatory submission was based on positive results from a prospective, global, multi-center,
open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients. Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for
patients who were 12 years or older. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also have two significant drug development programs with Bayer. This first is a
collaboration to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. We originally developed the liquid aerosol inhalation platform and the NKTR-061 drug candidate
and entered into a collaboration agreement with Bayer to further advance the drug candidate&#146;s development and potential commercialization. Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale. Bayer is
conducting this study under a Special Protocol Assessment process agreed to with the FDA. The second is our significant royalty rights in Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer that we transferred to
Novartis as part of a 2008 asset divestiture transaction. In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis. These programs represent a
significant future economic opportunity for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While the approved drugs and clinical development programs described above
are key elements of the future success of our company, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical
development or being explored in research that we are preparing to advance into the clinic in future years. We also have additional proprietary preclinical and clinical drug candidates in research and development. We have an ongoing Phase 1 clinical
development program for NKTR-171, a new sodium channel blocker being developed as a potential oral therapy for the treatment of peripheral neuropathic pain. This year we plan to advance NKTR-214, an engineered immunostimulatory cytokine being
developed for the treatment of solid tumors, into a Phase 1 clinical study. NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T
cells that dampen the immune response to tumors. We are also advancing numerous other drug candidates in preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications. While we believe that our substantial
investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrate positive clinical results, receive regulatory approval in one or more major markets and achieve commercialization
success, drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval and the timing and outcome of clinical trial results are extremely difficult to predict. Clinical
development successes and failures can have a disproportionate positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operation and market value. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historically, we have entered into a number of license and supply contracts under which we manufactured and supplied our proprietary
PEGylation reagents on a cost-plus or fixed price basis. Our current strategy is to manufacture and supply PEGylation reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and
commercialization relationship or where we derive substantial economic benefit. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Key Developments and Trends in
Liquidity and Capital Resources </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we estimated that we had at least twelve months of
working capital to fund our current business plans. At December&nbsp;31, 2014, we had approximately $262.8 million in cash and investments in marketable securities, of which $25.0 million was restricted in relation to our 12.0% senior secured notes,
and $151.8 million in indebtedness. The indebtedness includes $125.0 million in aggregate principal amount of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
12.0% senior secured notes due July&nbsp;15, 2017, but excludes our long-term liability relating to the sale of future royalties under the Purchase and Sale Agreement with RPI Finance Trust. As
is further described in Note 7 to our Consolidated Financial Statements, this royalty obligation liability will not be settled in cash. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Years Ended December&nbsp;31, 2014, 2013, and 2012 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue (in thousands, except percentages) </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non cash royalty revenue related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&gt;100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&gt;100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue is derived from our collaboration agreements, under which we may receive product sales
revenue, royalties, license fees, milestone payments or contract research payments. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is
reasonably assured. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as manufacturing and supply commitments, are recognized ratably over our expected performance period
under the arrangement. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the period over which we expect to fulfill our performance obligations.
Given the uncertainties in research and development collaborations, significant judgment is required by us to determine the performance periods. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product sales </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales include fixed price and cost-plus
manufacturing and supply agreements with our collaboration partners and result from the receipt of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is
not ratable throughout the year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales decreased for the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 primarily as a result of decreased product demand from a number of our collaboration partners. Product sales increased for the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 primarily as a
result of a $9.0 million increase in product sales to one of our collaboration partners. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently expect product sales to
increase in 2015 as compared to 2014 due to increased product demand from a number of our collaboration partners. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Royalty revenue and non-cash royalty revenue related to sale of future royalties </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We receive royalty revenue from certain of our collaboration partners based on their net sales of commercial products. Royalty revenue
received in cash decreased during the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 due primarily to decreases in the underlying net sales of the applicable products
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
as well as the completion of the royalty term for one product. Royalty revenue decreased during the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 primarily
as a result of the sale of our rights to receive the royalties from product sales of UCB&#146;s CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and
Roche&#146;s MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> as is further described below. Royalties from CIMZIA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> recognized after the royalty sale transaction took effect are presented on a separate revenue line item entitled &#147;Non-cash royalty revenue related to sale of
future royalties.&#148; AstraZeneca is planning the commercial launch of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in the U.S. late in the
first quarter of 2015 and MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the EU in the second half of 2015. If sales of MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (and/or MOVENTIG<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) are initiated during 2015, we expect royalty revenue received in cash will increase in 2015 as compared to 2014 due to royalties we expect to receive from net sales
of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we sold all of our rights to receive future royalty payments on CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. As described in
Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period. As a result of this liability accounting, even though the royalties from UCB
and Roche are remitted directly to the purchaser of these royalty interests, we will continue to record revenue for these royalties. We expect non-cash royalties from net sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in 2015 to be
consistent with 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License, collaboration and other revenue </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue includes the recognition of upfront payments and milestone payments received in connection with
our license and collaboration agreements and reimbursed research and development expenses. The level of license, collaboration and other revenue depends in part upon the estimated amortization period of the upfront payments, the achievement of
milestones, the continuation of existing collaborations, the amount of reimbursed research and development work, and entering into new collaboration agreements, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue increased for the year ended December&nbsp;31, 2014 compared to the year
ended December&nbsp;31, 2013 primarily as a result of the recognition in 2014 of the $35.0 million and $70.0 million milestone payments received in October 2014 and November 2013, respectively, from AstraZeneca as a result of the FDA&#146;s approval
of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in September 2014. In addition, we recognized $8.0 million of milestones received in December 2014
related to positive results from Baxter&#146;s BAX 855 Phase 3 study. These increases in 2014 as compared to 2013 were partially offset by the recognition in 2013 of a $25.0 million payment from AstraZeneca achieved in September 2013 on the
acceptance for review by the EMA of the MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> regulatory approval application filed by AstraZeneca as well
as the recognition in July 2013 of the remaining $6.7 million deferred revenue balance related to our agreement with Affymax as a result of the termination of that agreement. In addition, in April 2013, we recognized a $10.0 million milestone
achieved upon the start of the Amikacin Inhale Phase 3 clinical trial by Bayer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue
increased for the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 primarily as a result of the recognition of a $25.0 million payment from AstraZeneca achieved in September 2013, the recognition of the $10.0
million milestone achieved upon the start of the Amikacin Inhale Phase 3 clinical trial by Bayer in April 2013, and the recognition of the remaining $6.7 million deferred revenue balance related to our agreement with Affymax as noted above. In
addition, we recognized $7.9 million related to the delivery of additional quantities of our proprietary PEGylation reagent to Roche in the fourth quarter of 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect license, collaboration and other revenue in 2015 will be significantly impacted by the outcome and timing
of AstraZeneca&#146;s launch of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> as we are entitled to $140.0 million of development milestone
payments due upon the commercial launches of MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> in the U.S. ($100.0 million) and in the E.U. ($40.0
million). If these activities occur in 2015, our license, collaboration and other revenue in 2015 will increase from 2014. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The timing and future success of our drug development programs and those of our
collaboration partners are subject to a number of risks and uncertainties. See &#147;Part&nbsp;I, Item&nbsp;1A&nbsp;&#151; Risk Factors&#148; for discussion of the risks associated with the complex nature of our collaboration agreements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue by geography </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue by geographic area is based on locations of our partners. The following table sets forth revenue by geographic area (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">United States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Europe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in revenue attributable to European countries for the year ended December&nbsp;31, 2014
compared to the year ended December&nbsp;31, 2013 is primarily attributable to increased milestone and royalty revenues from our existing European based collaboration partners, including the recognition of the $105.0 million milestone payments from
AstraZeneca described above. The increase in revenue attributable to European countries for the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 is primarily attributable to increased milestone and royalty revenues
from our existing European based collaboration partners, including the $25.0 million milestone payment from AstraZeneca described above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cost of goods sold (in thousands, except percentages) </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product gross profit (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&gt;100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product gross margin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold decreased during the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 primarily due to the decrease in product sales of $19.7 million in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013. During the year ended December 31, 2014, our gross profit was
negative. The manufacturing arrangement with one of our collaboration partners includes a fixed price for proprietary pegylation reagent sales, which is less than the fully burdened manufacturing cost for the reagent in 2014 and this situation is
expected to continue in future years. As a result of decreased overall manufacturing volume in 2014 as compared to 2013 and given the increase in the percentage of overall sales attributable to this partner, gross profit for the year was negative.
In addition to product sales from the reagent, we also receive royalty revenues from this collaboration. In 2014, the royalty revenue from the collaboration exceeded the related negative gross profit. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold and product gross profit increased during the year ended December&nbsp;31, 2013 compared to the year ended
December&nbsp;31, 2012 primarily due to the $9.4 million increase in product sales in the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012. Product gross margin in the year ended December&nbsp;31, 2013 was
consistent with the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect product gross margin to continue to fluctuate in future
periods depending on the level and mix of manufacturing orders from our customers due to the predominantly fixed cost base associated with our manufacturing activities. We currently expect product gross margin to increase in 2015 as compared to 2014
as a result of the anticipated increase in product sales, as well as based on the anticipated product mix. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development expense (in thousands, except percentages)
</I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense consists primarily of clinical study costs, direct costs of outside
research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and
facilities-related costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense decreased during the year ended December&nbsp;31, 2014 compared to
the year ended December&nbsp;31, 2013 primarily due to reduced activities on our ongoing Phase 3 BEACON study for etirinotecan pegol as the study progresses toward completion as well as the completion of our Phase 2 clinical study for NKTR-181 in
the third quarter of 2013. In addition, during the year ended December&nbsp;31, 2013, we recorded a charge of $11.3 million resulting from the settlement of a dispute with the Research Foundation of the State University of New York related to our
collaboration with Bayer to develop inhaled amikacin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense increased during the year ended
December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 primarily due to the Phase 3 BEACON clinical study initiated in December 2011, the NKTR-181 Phase 2 clinical study initiated in July 2012 and the $11.3 million settlement
charge recorded in 2013 noted above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We utilize our employee and infrastructure resources across multiple development and
research programs. The following table shows expenses incurred for clinical and regulatory services, clinical supplies, and preclinical study support provided by third parties as well as direct materials costs for each of our drug candidates. The
table also presents other costs and overhead consisting of personnel, facilities and other indirect costs (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Clinical<BR>Study<BR>Status<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Etirinotecan pegol (NKTR-102) (topoisomerase I inhibitor-polymer conjugate)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAY41-6551 (Amikacin Inhale)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase&nbsp;3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-181 (mu-opioid analgesic molecule for chronic pain)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-171 (neuropathic pain)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase&nbsp;1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,913</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKTR-214 (cytokine immunostimulatory therapy)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Various</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total third party and direct materials costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel, overhead and other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Study Status definitions are provided in the chart found in Part&nbsp;I, Item&nbsp;1. Business. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We partnered this program with Bayer Healthcare LLC in August 2007. As part of the Novartis Pulmonary Asset Sale in 2008, we retained an exclusive license to this
technology for the development and commercialization of this drug candidate. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect research and development expense to increase in 2015 as compared to 2014. In
particular, in 2015, we are commencing Phase 3 clinical studies for NKTR-181. Over the next two to three years, we expect that the NKTR-181 clinical development program will require a substantial investment. In addition, we plan to continue to
advance etirinotecan pegol in the Phase 3 BEACON study for metastatic breast cancer for which we expect the clinical study to continue through 2015. The clinical development costs for the BEACON clinical study will continue to be significant. We
estimate that the total third party and direct material costs over the life of the BEACON study will be approximately $85.0&nbsp;million, of which $72.7 million was incurred through the end of 2014. We have also studied or have ongoing studies being
conducted for etirinotecan pegol, including investigator-initiated clinical studies, in bevacizumab (Avastin)-resistant high-grade glioma, colorectal cancer, relapsed or refractory small-cell lung cancer, metastatic and recurrent non-small cell lung
cancer, and ovarian cancer. We are unable to estimate the timing or costs to complete the clinical development for etirinotecan pegol across all the potential oncology indications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our <FONT STYLE="white-space:nowrap">NKTR-181</FONT> and etirinotecan pegol development activities, in 2015, we plan to
continue to advance the development of <FONT STYLE="white-space:nowrap">NKTR-171</FONT> and <FONT STYLE="white-space:nowrap">NKTR-214.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, we plan to continue to make substantial investments to support the clinical and commercial manufacturing preparation and scale-up for the nebulizer devices to supply Bayer for the Amikacin
Inhale program. Under our collaboration agreement with Bayer, we are responsible for all clinical and commercial supply of the nebulizer devices for this drug candidate. We do not expect to have any significant future research and development costs
associated with MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> or the MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> fixed-dose combination products as AstraZeneca is responsible for all further development and commercialization costs for these drug candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our drug candidates that we plan to have in clinical development during 2015 and beyond, we believe it is vitally
important to continue our substantial investment in a diverse pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates by
applying our PEGylation technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We plan to continue to advance our most promising early
research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through
clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to
complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of patients required for a given clinical study design; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the length of time required to enroll clinical study participants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and location of sites included in the clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study needed to
demonstrate efficacy and safety outcomes); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential for changing standards of care for the target patient population; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of producing supplies of the product candidates needed for clinical trials and regulatory submissions; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the safety and efficacy profile of the drug candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the use of clinical research organizations to assist with the management of the trials;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs and timing of, and the ability to secure, approvals from government health authorities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate
in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and Amikacin Inhale. In these situations, the clinical development program and process for a drug candidate and the
estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements
would affect our development plans or capital requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The risks and uncertainties associated with our research and
development projects are discussed more fully in Item&nbsp;1A&nbsp;&#151; Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and
development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and administrative expense (in thousands, except percentages) </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General&nbsp;and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense includes the cost of administrative staffing, business development,
marketing, finance, and legal activities. General and administrative expense was consistent during the years ended December&nbsp;31, 2014, 2013 and 2012. In 2015, we expect general and administrative expenses to increase compared with 2014. In
particular, if the BEACON study is successful and etirinotecan pegol is ultimately approved by the FDA, our current plan would be to market and sell etirinotecan pegol in the United States. We would expect to incur significant costs related to these
activities in 2015 and future years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest expense (in thousands except percentages) </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2014 vs.<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)<BR>2013 vs.<BR>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on liability related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense for the year ended December&nbsp;31, 2014 decreased marginally as compared to the year
ended December&nbsp;31, 2013. The increase in interest expense for the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 is attributable to the interest expense recorded on the senior secured notes we issued in
2012. On July&nbsp;11, 2012, we issued $125.0 million of 12% senior secured notes maturing on July&nbsp;15, 2017. In connection with the issuance of senior secured notes in July 2012, we retired a principal amount of $42.5 million
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of our $215.0 million in aggregate principal amount of 3.25% convertible subordinated notes in exchange for $42.5 million in principal amount of 12% senior secured notes. We repaid the remaining
$172.4 million in principal amount of convertible subordinated notes in full at maturity on September&nbsp;28, 2012. We expect interest expense to increase slightly in 2015 compared to 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on the liability related to sale of future royalties for the year ended December&nbsp;31,
2014 decreased marginally as compared to the year ended December&nbsp;31, 2013 due to the decrease in 2014 of the average balance of the related liability. The increase in non-cash interest expense on liability related to sale of future royalties
for the year ended December&nbsp;31, 2013 compared to the year ended December&nbsp;31, 2012 is attributable to the timing of the royalty sale transaction that we completed in 2012. On February&nbsp;24, 2012, we sold all of our rights to receive
future royalty payments on CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in exchange for $124.0 million. As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that
amortizes over the estimated royalty payment period as CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> royalties are remitted directly to the purchaser. We impute interest on the transaction and record interest expense
at the effective interest rate, which we currently estimate to be approximately 17%. There are a number of factors that could materially affect the estimated interest rate, in particular, the amount and timing of royalty payments from future net
sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, and we will assess this estimate on a periodic basis. As a result, future interest rates could differ significantly and any such change in interest rate will be
adjusted prospectively. Unless we adjust our estimated interest rate, we expect non-cash interest expense on the liability related to sale of future royalties during the full year of 2015 to be consistent with 2014. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have financed our operations primarily through revenue from product sales, royalties and research and development contracts, as well as public offering and private placements of debt and equity
securities. At December&nbsp;31, 2014, we had approximately $262.8 million in cash and investments in marketable securities, of which $25.0 million was restricted as required by our 12% senior secured notes, and $151.8 million in indebtedness. The
indebtedness includes $125.0 million in aggregate principal amount of 12.0% senior secured notes due July&nbsp;15, 2017, but excludes our long-term liability related to the sale of future royalties. As is further described in Note 7 to our
Consolidated Financial Statements, this royalty obligation liability will not be settled in cash. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">As of
December&nbsp;31, 2014, we estimated that we had at least twelve months of working capital to fund our current business plans. We expect the clinical development of our proprietary drug candidates, including etirinotecan pegol, Amikacin Inhale,
NKTR-181, and NKTR-171, will require significant investment in order to continue to advance in clinical development with the objective of entering into a collaboration partnership or obtaining regulatory approval. However, we have no credit facility
or any other sources of committed capital. In the past we have received a number of significant payments from collaboration agreements and other significant transactions.&nbsp;In the future we expect to receive royalties from commercial sales of
products such as MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>&nbsp;and BAX 855 (if approved) and substantial payments from future collaboration
transactions if our later stage clinical development programs such as etirinotecan pegol and NKTR-181 have positive clinical outcomes.&nbsp;Our current business plan is also subject to significant uncertainties and risks as a result of, among other
factors, the sales levels of products for which we are entitled to royalties such as MOVANTIK<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT>, clinical
program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent
liabilities, including litigation matters and indemnification obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The availability and terms of various financing
alternatives substantially depend on many factors including the success or failure of drug development programs in our pipeline, including etirinotecan pegol, BAX 855, Amikacin Inhale, NKTR-181, NKTR-171, NKTR-214, as well as other early stage
development programs. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are successful in obtaining health authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions.&nbsp;We will pursue
various financing alternatives, including equity and debt, as needed to continue to fund our research and development activities and to fund the expansion of our business as appropriate.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the potential for adverse developments in the credit markets in 2015 and thereafter, we may experience reduced liquidity with
respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before
maturity, we may experience losses on liquidation. At December&nbsp;31, 2014, the average time to maturity of the investments held in our portfolio was approximately five months and the maturity of any single investment did not exceed one year. To
date we have not experienced any liquidity issues with respect to these securities, but if such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues
with respect to these securities, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash flows from operating activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cash flows used in operating activities for the year ended December&nbsp;31, 2014 totaled $142.0 million, which includes $199.0 million of net operating cash uses as well as $15.0 million for interest
payments on our senior secured notes, partially offset by the receipt of $72.0 million of milestones from collaboration agreements. During the year ended December&nbsp;31, 2014, we recognized as revenue a $70.0 million payment made to us from
AstraZeneca in November 2013, which was previously recorded in the line item &#147;Liability related to receipt of refundable milestone payment&#148; on our Consolidated Balance Sheet at December&nbsp;31, 2013. We expect that cash flows used in
operating activities, excluding upfront and milestone payments received, if any, will increase in 2015 as a result of increased spending on our proprietary research and development programs, including the initiation of the Phase 3 clinical program
for NKTR-181. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows used in operating activities for the year ended December&nbsp;31, 2013 totaled $38.5 million, which
includes $158.3 million of net operating cash uses as well as $15.2 million for interest payments on our senior secured notes, partially offset by the receipt of $135.0 million for milestones from collaboration agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows used in operating activities for the year ended December&nbsp;31, 2012 totaled $129.8 million, which includes $148.3 million
of net operating cash uses, partially offset by the receipt of $18.5 million from collaboration agreements. Net operating cash uses also include $6.7 million in interest payments on our convertible subordinated notes retired in full on
September&nbsp;28, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash flows from investing activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We paid $10.0&nbsp;million, $4.1&nbsp;million, and $10.6&nbsp;million to purchase property and equipment in the years ended
December&nbsp;31, 2014, 2013, and 2012, respectively. We expect our capital expenditures in 2015 to increase as compared to 2014 primarily as a result of our plan to continue to build commercial manufacturing capacity for Amikacin Inhale devices.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash flows used in financing activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;28, 2014, we completed the issuance and sale of 9,775,000 shares of our common stock in a public offering with total
proceeds of approximately $117.2 million after deducting the underwriting commissions and discounts of approximately $7.5 million. In addition, we incurred approximately $0.6 million in legal and accounting fees, filing fees, and other costs in
connection with this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;24, 2012, we sold all of our rights to receive future
royalty payments on CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in exchange for $124.0 million. As part of this sale, we incurred approximately $4.4 million in transaction costs. During the years ended December&nbsp;31, 2014 and
2013, we made payments of $7.0 million and $3.0 million, respectively, to the purchaser of these royalties because certain minimum MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> net sales thresholds were not met. The remaining $120.5 million royalty obligation liability at December&nbsp;31, 2014 will not be settled in cash. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;11, 2012, we issued $125.0 million of senior secured notes maturing on July&nbsp;15, 2017. As part of this transaction, we
incurred approximately $4.5 million in issuance costs. In connection with this transaction, we retired the principal amount of $42.5 million of our $215.0 million in aggregate principal amount of convertible subordinated notes in exchange for $42.5
million in principal amount of the senior secured notes. In addition, $25.0 million of the proceeds from the senior secured notes issuance is required to be maintained in a restricted account until July&nbsp;1, 2015. On September&nbsp;28, 2012, we
repaid the remaining $172.4 million in principal amount of the convertible subordinated notes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We received proceeds from
issuance of common stock related to our employee option and stock purchase plans of $47.0 million, $8.2&nbsp;million, and $4.1&nbsp;million in the years ended December&nbsp;31, 2014, 2013, and 2012, respectively. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Contractual Obligations (in thousands) </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&lt;=1 Yr<BR>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2-3 Yrs<BR>2016-2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>4-5 Yrs<BR>2018-2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020+</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Obligations<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12% Senior secured notes due July 2017, including interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating leases</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,929</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital leases and other financing, including interest</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase commitments</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation settlements, including interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above table does not include certain commitments and contingencies which are discussed in Note&nbsp;8 of Item&nbsp;8. Financial Statements and Supplementary Data.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2010, we moved into our Mission Bay Facility, which includes our corporate headquarters and a research and development center. Under the terms of the
sublease we entered into with Pfizer Inc. on September&nbsp;30, 2009 for the Mission Bay Facility, we began making non-cancelable lease payments in 2014. The sublease is discussed in Note&nbsp;6 of Item&nbsp;8. Financial Statements and Supplementary
Data. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These amounts primarily result from capital lease obligations arising from our office space lease at 201 Industrial Road in San&nbsp;Carlos, California. In November
2010, we ceased use of this space as a result of the relocation of all of our California functions to our Mission Bay Facility. We have subleased all of the San Carlos Facility. This is further discussed in Note&nbsp;6 of Item&nbsp;8. Financial
Statements and Supplementary Data. In addition, these amounts include our obligation to purchase manufacturing equipment supporting our Amikacin Inhale program, which is further discussed in Note 4 of Item&nbsp;8. Financial Statements and
Supplementary Data. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantially all of this amount was subject to open purchase orders as of December&nbsp;31, 2014 that were issued under existing contracts. This amount does not
represent any minimum contract termination liabilities for our existing contracts. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Off Balance Sheet Arrangements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation and presentation of financial statements in conformity with U.S.&nbsp;Generally Accepted Accounting Principles (GAAP) requires management to make judgments, estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances,
the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources, and evaluate our estimates on an ongoing basis. Actual results may differ materially from
those estimates under different assumptions or conditions. We have determined that for the periods in this report, the following accounting policies and estimates are critical in understanding our financial condition and results of our operations.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other research revenue is recognized based on the facts and circumstances of each contractual agreement and includes amortization of upfront fees. We defer income under
contractual agreements when we have further obligations that indicate that a separate earnings process has not been completed. The amount of upfront fees and other payments received under our license and collaboration agreements that are allocated
to our continuing obligations are recognized ratably over our expected performance period under each arrangement. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include
technology transfer assistance, research and development activities, or manufacturing activities through the completion of clinical development or the termination or expiration of the collaboration agreement. Given the complexities and uncertainties
of collaboration arrangements, significant judgment is required by management to determine the duration of the performance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we had $21.4&nbsp;million of deferred upfront fees related to two collaboration agreements that include research and development obligations that are being amortized over 11
to 20&nbsp;years, or an average of approximately 16&nbsp;years. For our collaboration agreements, our performance obligations may span the life of the agreement. For these, the shortest reasonable period is the end of the development period
(estimated to be 4 to 8&nbsp;years) and the longest period is the contractual life of the agreement, which is generally 10-12&nbsp;years from the first commercial sale. Given the statistical probability of drug development success in the
bio-pharmaceutical industry, drug development programs have only a 5% to 10% probability of reaching commercial success. If we had determined a longer or shorter amortization period was appropriate, our annual upfront fee amortization for these
agreements could be as low as $2.0&nbsp;million or as high as $11.0&nbsp;million as compared to the $2.1 million recognized in the year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we also had $78.4&nbsp;million of deferred upfront fees related to seven license, manufacturing and supply agreements that are being amortized over periods from 3 to
14&nbsp;years. Our performance obligations for these agreements may include technology transfer assistance and/or back-up manufacturing and supply services for a specified period of time; therefore, the time estimated to complete the performance
obligations related to licenses is either specified or is much shorter than the collaboration agreements. We may experience delays in the execution of technology transfer plans, which may result in a longer amortization period for applicable
agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our original estimates are periodically evaluated to determine if circumstances have caused
the estimates to change and if so, amortization of revenue is adjusted prospectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, at the inception of each
new multiple-element arrangement or the material modification of an existing multiple-element arrangement, we allocate arrangement consideration to all units of accounting based on the relative selling price method, generally based on our best
estimate of selling price (ESP). The objective of ESP is to determine the price at which we would transact a sale if the product or service was sold on a stand-alone basis. We determine ESP for the elements in our collaboration arrangements by
considering multiple factors including, but not limited to, technical complexity of the performance obligation and similarity of elements to those performed under previous arrangements. Since we apply significant judgment in arriving at the ESPs,
any material changes would significantly affect the allocation of the total consideration to the different elements of a multiple element arrangement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Trial Accruals </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We record accruals for the estimated costs
of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts
depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. We generally accrue costs associated with the start-up and reporting phases of
the clinical studies ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical studies based on the total estimated cost of the treatment phase on a per
patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the studies. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses
using a methodology that we consider to be more reflective of the timing of costs incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and
recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to
make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in
cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period first identified. During the year ended December&nbsp;31, 2014, we recorded a reduction related to prior periods of
approximately $4.7&nbsp;million to our research and development expenses primarily related to our Beacon Phase 3 clinical trial for etirinotecan pegol. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use the Black-Scholes option pricing
model for each respective grant to determine the estimated fair value of stock options on the date of grant (grant date fair value) and common stock purchased under our Employee Stock Purchase Plan (ESPP). We expense the estimated fair value of each
award, as adjusted by the estimated historical forfeiture rate, ratably over the expected service period of the award. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not
limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and
because changes in the subjective input assumptions can materially affect fair value estimates, in management&#146;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common
stock purchased under our ESPP. In addition, management continually assesses the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available
over time, which could result in changes to the assumptions and methodologies, and which could materially impact our fair value determination, as well as our stock-based compensation expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, for awards that vest upon the achievement of performance milestones, we
estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-cash Interest Expense on Liability Related to Sale of Future Royalties </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we sold all of our rights to receive future royalty payments from sales of the CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> drug products
marketed by UCB and Roche, respectively. Although we are required to make payments to the purchaser (RPI) only in certain situations, including the event of our breach of a representation, warranty or covenant in the Purchase and Sale Agreement that
gives rise to a liability in accordance with the terms and conditions of such agreement, this royalty sale transaction was recorded as a liability (Royalty Obligation) that we will amortize using the interest method over the estimated life of the
Purchase and Sale Agreement. As a result, we impute interest on the transaction and record interest expense at the estimated interest rate. Our estimate of the interest rate under the agreement is based on the amount of royalty payments to be
received by RPI over the life of the arrangement and payments we are required to make to RPI under the agreement. We will periodically assess the expected royalty payments to RPI from UCB and Roche using a combination of historical results and
forecasts from market data sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the
Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from
CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products,
manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties
remitted to RPI are made in U.S. dollars (USD) while significant portions of the underlying sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and
MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> are made in currencies other than USD, and other events or circumstances that result in reduced royalty
payments from CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, all of which would result in a reduction of non-cash royalty revenue and non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales of
CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> are higher than expected, non-cash royalty revenue and non-cash interest expense would also be greater over the term of the Royalty Obligation. If we had determined
that the interest rate used in 2014 should have been one percentage point higher than our current estimate of 17%, the non-cash interest expense recognized in the year ended December&nbsp;31, 2014 would have increased by $1.3 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in ASC 606, <I>Revenue Recognition &#151; Revenue from Contracts with Customers</I>, which amends the guidance in
former ASC 605, <I>Revenue Recognition, </I>and is effective for public companies for fiscal years beginning after December&nbsp;15, 2016. We are currently evaluating the impact of the provisions of ASC 606. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, Disclosure of Uncertainties about an Entity&#146;s Ability
to Continue as a Going Concern (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is
effective in 2016 with early adoption permitted. We do not believe the impact of adopting ASU 2014-15 on our consolidated financial statements will be significant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_10"></A>Item&nbsp;&nbsp;7A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Quantitative and Qualitative Disclosures About Market Risk</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Interest Rate and Market Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary objective of our investment
activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to
interest rate risk. To minimize the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exposure due to an adverse shift in interest rates, we invest in short-term securities and maintain a weighted average maturity of one year or less. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A hypothetical 50&nbsp;basis point increase in interest rates would result in an approximate $0.5 million decrease, less than 1%, in the
fair value of our available-for-sale securities at December&nbsp;31, 2014. This potential change is based on sensitivity analyses performed on our investment securities at December&nbsp;31, 2014. Actual results may differ materially. The same
hypothetical 50&nbsp;basis point increase in interest rates would have resulted in an approximate $0.5&nbsp;million decrease, less than 1%, in the fair value of our available-for-sale securities at December&nbsp;31, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we held $225.5&nbsp;million of available-for-sale investments, excluding money market funds, with an
average time to maturity of five months. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe
that, even allowing for potential liquidity issues with respect to these securities, our remaining cash, cash equivalents, and investments will be sufficient to meet our anticipated cash needs for at least the next twelve months. Based on our
available cash and our expected operating cash requirements, we currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized
cost basis. Accordingly, we believe there are no other-than-temporary impairments on these securities and have not recorded any provisions for impairment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Currency Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The majority of our revenue, expense, and capital
purchasing activities are transacted in U.S.&nbsp;dollars. However, since a portion of our operations consists of research and development activities outside the United States, we have entered into transactions in other currencies, primarily the
Indian Rupee, and we therefore are subject to foreign exchange risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our international operations are subject to risks
typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. We do not utilize
derivative financial instruments to manage our exchange rate risks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_11"></A>Item&nbsp;8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Financial Statements and Supplementary Data</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NEKTAR THERAPEUTICS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL
STATEMENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_22">Reports of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_23">Consolidated Balance Sheets at December&nbsp;31, 2014 and 2013</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_24">Consolidated Statements of Operations for each of the years in the three year period ended December&nbsp;
31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_25">Consolidated Statements of Comprehensive Loss for each of the years in the three year period ended December&nbsp;31,
 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_26">Consolidated Statements of Stockholders&#146; Equity (Deficit) for each of the years in the three year period
 ended December&nbsp;31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_27">Consolidated Statements of Cash Flows for each of the years in the three year period ended December&nbsp;
31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_28">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_1"></A><A NAME="tx842626_22"></A>Report of Independent Registered Public
Accounting Firm </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors and Stockholders of Nektar Therapeutics </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated balance sheets of Nektar Therapeutics as of December&nbsp;31, 2014 and 2013, and the related consolidated statements of operations, comprehensive loss,
stockholders&#146; equity (deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2014. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an
opinion on these financial statements based on our audits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the financial statements referred to
above present fairly, in all material respects, the consolidated financial position of Nektar Therapeutics at December&nbsp;31, 2014 and 2013, and the consolidated results of its operations and its cash flows for each of the three years in the
period ended December&nbsp;31, 2014, in conformity with U.S. generally accepted accounting principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also have audited, in accordance
with the standards of the Public Company Accounting Oversight Board (United States), Nektar Therapeutics&#146; internal control over financial reporting as of December&nbsp;31, 2014, based on criteria established in Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&nbsp;25, 2015 expressed an unqualified opinion thereon. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ E<SMALL>RNST</SMALL>&nbsp;&amp; Y<SMALL>OUNG</SMALL> LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Redwood City, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of Independent Registered Public Accounting Firm </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors and Shareholders of Nektar Therapeutics </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have audited Nektar Therapeutics internal control over financial reporting as of December&nbsp;31, 2014, based on criteria established in Internal Control - Integrated Framework issued by the Committee
of Sponsoring Organizations of the Treadway Commission (2013 framework), (&#147;the COSO criteria&#148;). Nektar Therapeutics&#146; management is responsible for maintaining effective internal control over financial reporting, and for its assessment
of the effectiveness of internal control over financial reporting included in the accompanying Management&#146;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company&#146;s internal
control over financial reporting based on our audit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audit in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included
obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing
such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A company&#146;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#146;s internal control over financial reporting includes those policies and procedures that
(1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors
of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#146;s assets that could have a material effect on the financial statements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, Nektar Therapeutics maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31,
2014, based on the COSO criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the balance sheets of Nektar Therapeutics as of December&nbsp;31, 2014 and 2013, and the related consolidated statements of operations, comprehensive loss, stockholders&#146; equity (deficit), and cash flows for each of the three
years in the period ended December&nbsp;31, 2014 of Nektar Therapeutics and our report dated February&nbsp;25, 2015 expressed an unqualified opinion thereon. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;E<SMALL>RNST</SMALL>&nbsp;&amp; Y<SMALL>OUNG</SMALL> LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Redwood City, California
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_23"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In&nbsp;thousands,&nbsp;except par&nbsp;value&nbsp;information) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable, net of allowance of nil at December&nbsp;31, 2014 and 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">257,882</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">434,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital lease obligations, current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,473</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to the sale of future royalties, current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior secured notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital lease obligations, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to receipt of refundable milestone payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to the sale of future royalties, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">405,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">524,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.0001 par value; 10,000 shares authorized, no shares designated, issued or outstanding at December&nbsp;31,
2014 and 2013, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.0001&nbsp;par value; 300,000 authorized; 131,216 shares and 116,494 shares issued and outstanding at
December&nbsp;31, 2014 and 2013, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital in excess of par value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,824,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,643,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,786,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,732,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">434,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_24"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;information) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash royalty revenue related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment of long-lived assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">222,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(120,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(141,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-operating income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on liability related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">814</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total non-operating expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(39,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before (benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(159,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding used in computing basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_25"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income (loss):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net unrealized (loss) gain on available-for-sale investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax provision (benefit) on unrealized gain on available-for-sale investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign currency translation (loss) gain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income (loss), net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_26"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Par<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Capital in<BR>Excess of<BR>Par Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated&nbsp;Other<BR>Comprehensive<BR>Income/(Loss)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>Stockholders&#146;<BR>Equity&nbsp;(Deficit)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,597,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,398,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued under equity compensation plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,617,744</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,570,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued under equity compensation plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,643,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,732,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sale of common stock, net of issuance costs of $617</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued under equity compensation plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,824,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,786,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_27"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash royalty revenue related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on liability related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other non-cash transactions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to receipt of refundable milestone payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(142,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(38,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(129,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maturities of investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">319,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">307,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(297,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(268,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(164,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,661</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock, net of issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Repayment of) proceeds from sale of future royalties, net of $4.4 million of transaction costs in 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of senior secured notes, net of $4.5 million of issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayment of convertible subordinated notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(172,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from shares issued under equity compensation plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of exchange rates on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of cash flow information:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental schedule of non-cash investing and financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment acquired through capital leases and other financing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 5,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retirement of convertible subordinated notes in exchange for senior secured notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_28"></A>NEKTAR THERAPEUTICS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES&nbsp;TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2014 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;1&nbsp;&#151; Organization and Summary of Significant Accounting Policies </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Organization </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer
conjugate technology platforms with the objective to improve the benefits of drugs for patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development
activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We
have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&nbsp;31, 2014, we had approximately $262.8 million in cash and investments in marketable
securities, of which $25.0 million was restricted in relation to our 12% senior secured notes, and $151.8 million in indebtedness. The indebtedness includes $125.0 million in aggregate principal amount of 12.0% senior secured notes due July&nbsp;15,
2017, but excludes our long-term liability relating to the sale of future royalties. As is further described in Note 7, this royalty obligation liability will not be settled in cash. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of Presentation, Principles of Consolidation and Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics (India) Private Limited and Nektar
Therapeutics UK, Ltd. (Nektar UK). All intercompany accounts and transactions have been eliminated in consolidation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
consolidated financial statements are denominated in U.S.&nbsp;dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S.&nbsp;dollar will affect the translation of each foreign subsidiary&#146;s financial
results into U.S.&nbsp;dollars for purposes of reporting our consolidated financial results. Translation gains and losses are included in accumulated other comprehensive income (loss) in the stockholders&#146; equity (deficit) section of the balance
sheet. To date, such cumulative translation adjustments have not been significant to our consolidated financial position. Aggregate gross foreign currency transaction gains (losses) recorded in operations for the years ended December&nbsp;31, 2014,
2013, and 2012 were not significant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of consolidated financial statements in conformity with U.S. generally
accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. On an ongoing basis,
we evaluate our estimates, including those related to estimated selling prices of deliverables in collaboration agreements, estimated periods of performance, the net realizable value of inventory, the impairment of investments, the impairment of
goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base
our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these
values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reclassifications </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously
reported total revenue, operating loss or net loss or total assets, liabilities or stockholders&#146; equity (deficit). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash, Cash
Equivalents, and Investments, and Fair Value of Financial Instruments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consider all investments in marketable
securities with an original maturity of three months or less when purchased to be cash equivalents. Investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations
or to make them available for current operations, are classified as short-term investments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments are designated as
available-for-sale and are carried at fair value, with unrealized gains and losses reported in stockholders&#146; equity (deficit) as accumulated other comprehensive income (loss). The disclosed fair value related to our cash equivalents and
investments is based primarily on the reported fair values in our period-end brokerage statements, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active
markets or have been derived from observable market data. We independently validate these fair values using available market quotes and other information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Interest and dividends on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, are included in interest income. Realized gains and
losses and declines in value of available-for-sale securities judged to be other-than-temporary, if any, are included in other income (expense). The cost of securities sold is based on the specific identification method. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our cash, cash equivalents, and short-term investments are exposed to credit risk in the event of default by the third parties that hold
or issue such assets. Our cash, cash equivalents, and short-term investments are held by financial institutions that management believes are of high credit quality and our investment policy limits investments to fixed income securities denominated
and payable in U.S. dollars such as U.S. government obligations, money market instruments and funds, and corporate bonds and places restrictions on maturities and concentrations by type and issuer.</FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounts Receivable and Significant Customer Concentrations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&nbsp;and Europe. Our accounts receivable balance contains billed and unbilled trade receivables from
product sales and royalties, as well as time and materials based billings from collaborative research and development agreements. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful
accounts. We generally do not require collateral from our customers. We perform a regular review of our customers&#146; payment histories and associated credit risk. We have not experienced significant credit losses from our accounts receivable. At
December&nbsp;31, 2014, three different customers represented 40%, 31%, and 15%, respectively, of our accounts receivable. At December&nbsp;31, 2013, three different customers represented 30%, 28%, and 28%, respectively, of our accounts receivable.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inventory and Significant Supplier Concentrations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventory is generally manufactured upon receipt of firm purchase orders from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead and cost is
determined on a first-in, first-out basis. Inventory is valued at the lower of cost or market and defective or excess inventory is written down to net realizable value based on historical experience or projected usage. Inventory related to our
research and development activities is expensed when purchased. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are dependent on our suppliers and contract manufacturers to provide raw materials, drugs
and devices of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are
delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial
condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long-Lived Assets </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment are stated at cost. Major improvements are capitalized, while maintenance and repairs are expensed when incurred. Manufacturing, laboratory and other equipment are
depreciated using the straight-line method generally over estimated useful lives of three to seven years. Leasehold improvements and buildings recorded under capital leases are depreciated using the straight-line method over the shorter of the
estimated useful life or the remaining term of the lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the excess of the price paid for another entity
over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized,
but instead tested for impairment annually in the fourth quarter of each year using an October&nbsp;1 measurement date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
assess the impairment of long-lived assets, primarily property, plant and equipment and goodwill included in other non-current assets, whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be
fully recoverable. When such events occur, we determine whether there has been an impairment in value by comparing the asset&#146;s carrying value with its fair value, as measured by the anticipated undiscounted net cash flows of the asset. In the
case of goodwill impairment, market capitalization is generally used as the measure of fair value. If an impairment in value exists, the asset is written down to its estimated fair value. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue is derived from our arrangements
with pharmaceutical and biotechnology collaboration partners and may result from one or more of the following: upfront and license fees, payments for contract research and development, milestone payments, manufacturing and supply payments, and
royalties. Our performance obligations under our collaborations may include licensing our intellectual property, manufacturing and supply obligations, and research and development obligations. In order to account for the multiple-element
arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each
deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. Revenue is recognized separately for each identified unit of accounting when the basic revenue recognition criteria are met:
there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At the inception of each new multiple-element arrangement or the material modification of an existing multiple-element arrangement, we allocate all consideration received under multiple-element
arrangements to all units of accounting based on the relative selling price method, generally based on our best estimate of selling price (ESP). The objective of ESP is to determine the price at which we would transact a sale if the product or
service was sold on a stand-alone basis. We determine ESP for the elements in our collaboration arrangements by considering multiple factors including, but not limited to, technical complexity of the performance obligation and similarity of elements
to those performed under previous arrangements. Since we apply significant judgment in arriving at the ESPs, any material change in our estimates would significantly affect the allocation of the total consideration to the different elements of a
multiple element arrangement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product sales </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Product sales are primarily derived from fixed price and cost-plus manufacturing and supply agreements with our collaboration partners. We have not experienced any significant returns from our customers.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Royalty revenues </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. We
recognize royalty revenue when the cash is received or when the royalty amount to be received is estimable and collection is reasonably assured. With respect to the non-cash royalties related to sale of future royalties described at Note&nbsp;7,
revenue is recognized when estimable, otherwise, revenue is recognized during the period in which the related royalty report is received, which generally occurs in the quarter after the applicable product sales are made. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License, collaboration and other </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amount of upfront fees and other payments received by us in license and collaboration arrangements that are allocated to continuing performance obligations, such as manufacturing and supply
obligations, are deferred and generally recognized ratably over our expected performance period under each respective arrangement. We make our best estimate of the period over which we expect to fulfill our performance obligations, which may include
technology transfer assistance, research activities, clinical development activities, and manufacturing activities from development through the commercialization of the product. Given the uncertainties of these collaboration arrangements,
significant judgment is required to determine the duration of the performance period and this estimate is periodically re-evaluated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved, which we believe is consistent with the
substance of our performance under our various license and collaboration agreements. A milestone is defined as an event (i)&nbsp;that can only be achieved based in whole or in part either on the entity&#146;s performance or on the occurrence of a
specific outcome resulting from the entity&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&nbsp;that would result in additional payments
being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the milestone or the increase in value to the collaboration resulting from
our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our license and collaboration agreements with our partners provide for payments to us upon the achievement of development milestones, such as the completion of clinical trials or regulatory submissions,
approvals by health authorities, and commercial launches of drugs. Given the challenges inherent in developing and obtaining regulatory approval for drug products and in achieving commercial launches, there was substantial uncertainty whether any
such milestones would be achieved at the time of execution of these licensing and collaboration agreements. In addition, we evaluated whether the development milestones meet the remaining criteria to be considered substantive. As a result of our
analysis, we consider our remaining development milestones under all of our license and collaboration agreements to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones only if and as each
milestone is achieved. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our license and collaboration agreements with certain partners also provide for contingent payments to
us based solely upon the performance of the respective partner. For such contingent amounts we expect to recognize the payments as revenue when earned under the applicable contract, which is generally upon completion of performance by the respective
partner, provided that collection is reasonably assured. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our license and collaboration agreements with our partners also provide for payments to us
upon the achievement of specified sales volumes of approved drugs. We consider these payments to be similar to royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is
reasonably assured. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shipping and Handling Costs </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recognize costs related to shipping and handling of product to customers in cost of goods sold. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and
development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds
without reimbursement from a third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We record accruals for the estimated costs of our clinical trial activities
performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the
achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over
the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per
patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to
be more reflective of the timing of costs incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related
goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future
periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be
changes in estimates and will be reflected in research and development expenses in the period first identified. During the year ended December 31, 2014, we recorded a reduction related to prior periods of approximately $4.7 million to our research
and development expenses primarily related to our Beacon Phase 3 clinical trial for etirinotecan pegol. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation arrangements include stock option grants and restricted stock unit (RSU) awards under our
equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of
grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, our
stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes
in the subjective input assumptions can materially affect the fair value estimate, in management&#146;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased
under the ESPP. Management will continue to assess the assumptions and methodologies used to calculate the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and
methodologies, and which could materially impact our fair value determination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expense the value of the portion of the
option or award that is ultimately expected to vest based on the historical forfeiture rate on a straight line basis over the requisite service periods in our Consolidated Statements of Operations. For awards that vest upon the achievement of
performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. Stock-based compensation expense for purchases under the
ESPP is recognized over the respective six-month purchase period. Expense amounts are recorded in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee.
Stock-based compensation charges are non-cash charges and as such have no impact on our reported cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Loss Per Share
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net loss per share is calculated based on the weighted-average number of common shares outstanding during the
periods presented. For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. Basic and diluted net loss per share are the same due to our historical net
losses and the requirement to exclude potentially dilutive securities which would have an anti-dilutive effect on net loss per share. During 2014, 2013 and 2012, potentially dilutive securities consisted of common shares underlying outstanding stock
options and there were weighted average outstanding stock options of 21.9 million, 20.7 million and 18.8 million during the years ended December 31, 2014, 2013 and 2012, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for income taxes under the liability
method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected
to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce
their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the
period such determination is made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We utilize a two-step approach to recognize and measure uncertain tax positions. The first
step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related
appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comprehensive loss </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss is the change in
stockholders&#146; equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) is comprised of net loss,
gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606, <I>Revenue Recognition &#151; Revenue from Contracts with
Customers</I>, which </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
amends the guidance in former ASC 605, <I>Revenue Recognition, </I>and is effective for public companies for fiscal years beginning after December&nbsp;15, 2016. We are currently evaluating the
impact of the provisions of ASC 606. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, Disclosure
of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide
related footnote disclosures. ASU 2014-15 is effective in 2016 with early adoption permitted. We do not believe the impact of adopting ASU 2014-15 on our consolidated financial statements will be significant. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;2&nbsp;&#151; Cash and Investments in Marketable Securities </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and investments in marketable securities, including cash equivalents and restricted cash, are as follows (in
thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated Fair Value at</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and investments in marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to
interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of December&nbsp;31, 2014 and 2013,
all of our investments had contractual maturities of one year or less and were classified as short-term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross unrealized
gains and losses were not significant at either December&nbsp;31, 2014 or 2013. During the years ended December&nbsp;31, 2014, 2013 and 2012, we sold available-for-sale securities totaling $21.7 million, $2.9&nbsp;million and $5.4 million
respectively, and realized gains and losses were not significant in any of those periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash of $25.0 million is
required to be maintained in a separate account until July&nbsp;1, 2015 under the terms of our 12% senior secured notes due July 2017. Upon release of this restriction on July&nbsp;1, 2015, a covenant of the senior secured notes requires that the
aggregate balance of our unrestricted cash and cash equivalents at the end of any two consecutive fiscal quarters may not be less than $25.0 million, subject to certain conditions (see Note 5). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our portfolio of cash and investments in marketable securities includes (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;
Value</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hierarchy</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated Fair Value at</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes and bonds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate commercial paper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Available-for-sale investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, including restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and investments in marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Level&nbsp;1&nbsp;&#151; </I>Quoted prices in active markets for identical assets or liabilities. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Level&nbsp;2&nbsp;&#151; </I>Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Level&nbsp;3&nbsp;&#151; </I>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our investments are categorized as Level 1 or Level 2, as explained in the table above. We use a market approach to value our
Level 2 investments. During the years ended December&nbsp;31, 2014, 2013 and 2012, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014 and 2013, we had letter of credit arrangements in favor of a landlord and certain vendors totaling $2.4&nbsp;million. These letters of credit are secured by investments of
similar amounts. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;3&nbsp;&#151; Inventory </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory consists of the following (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work-in-process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,565</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;4&nbsp;&#151; Property, Plant and Equipment </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment consists of the following (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building and leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture, fixtures and other equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciable property, plant and equipment at cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(93,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(84,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciable property, plant and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Construction-in-progress</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building and leasehold improvements include our manufacturing, research and development and
administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets
being built to enhance our manufacturing and research and development efforts, including manufacturing equipment supporting our Amikacin Inhale program at third-party contract manufacturing locations in the U.S. and Germany. Under the terms of our
arrangement with these contract manufacturers, during the period the equipment is being constructed, we are obligated to pay for their costs </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
incurred to date. As of December 31, 2014, we have recorded a total of $7.2 million in other current and other long-term liabilities related to our obligation to purchase this equipment, which is
recorded in property, plant and equipment. After the assets are placed into service, this liability will be paid over approximately three years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In July 2012, we consolidated our U.S.-based research activities into our existing San Francisco facility and ceased use of and plan to sell one of our buildings located in Huntsville, Alabama that was
dedicated to research activities. The announcement of this consolidation plan in March 2012 triggered the recognition of a $1.7&nbsp;million impairment charge relating to these assets in the year ended December&nbsp;31, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation expense, including depreciation of assets acquired through capital leases, for the years ended December&nbsp;31, 2014, 2013,
and 2012 was $11.7&nbsp;million, $13.0&nbsp;million, and $13.8&nbsp;million, respectively. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;5&nbsp;&#151; Senior Secured Notes </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;11, 2012, we issued $125.0 million in aggregate principal amount of senior secured notes (Senior Notes)
with the entire principal amount due on July&nbsp;15, 2017. The Senior Notes bear interest at 12.0%&nbsp;per annum payable in cash semi-annually in arrears on January&nbsp;15 and July&nbsp;15 of each year. The Senior Notes are secured by a
first-priority lien on substantially all of our assets. In connection with this transaction, we retired $42.5 million of principal amount of our convertible subordinated notes due September 2012 in exchange for the same principal amount of Senior
Notes and received the remaining proceeds in cash, less approximately $4.5 million in transaction costs. We used the proceeds from the issuance of the Senior Notes and our existing cash to repay the remaining $172.4 million in principal amount of
our convertible subordinated notes in full at maturity on September&nbsp;28, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Senior Notes contain customary
covenants, including covenants that limit or restrict our ability to incur liens, incur indebtedness, and make certain restricted payments, but do not contain covenants related to future financial performance. In particular, $25.0 million of the
proceeds is required to be maintained in a restricted account until July&nbsp;1, 2015 and is classified as restricted cash on our Consolidated Balance Sheets. From July&nbsp;1, 2015 through the quarter ending June&nbsp;30, 2017, the aggregate
balance of our unrestricted cash and cash equivalents at the end of any two consecutive fiscal quarters may not be less than $25.0 million, subject to certain conditions. The Senior Notes are callable by us at any time, subject to certain prepayment
premiums and conditions. If we experience certain change of control events, the holders of the Senior Notes will have the right to require us to purchase all or a portion of the Senior Notes at a purchase price in cash equal to 101% of the principal
amount thereof, plus accrued and unpaid interest to the date of purchase. In addition, upon certain asset sales, we may be required to offer to use the net proceeds thereof to purchase some of the Senior Notes at 100% of the principal amount
thereof, plus accrued and unpaid interest to the date of purchase. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, based on a discounted cash
flow analysis using Level 3 inputs including financial discount rates, we believe the $125.0 million carrying amount of our 12% Senior Secured Notes due July 2017 is consistent with its fair value. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;6&nbsp;&#151; Leases </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capital Leases </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We lease office space at 201 Industrial Road in San&nbsp;Carlos, California under a capital lease arrangement. Under the terms of the lease, rent increases up to 3% annually and the lease termination date
is October&nbsp;5, 2016. As of November&nbsp;29, 2010, we ceased use of this space as a result of the relocation of our San&nbsp;Carlos operations and corporate headquarters to San&nbsp;Francisco, California. As of April 2013, we have subleased all
of the San Carlos facility and our future minimum rental receipts under these subleases total $4.8 million as of December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014 and 2013, the gross amount of assets recorded under capital leases was $2.7 million and 2.3&nbsp;million, respectively, and the recorded value of these assets, net of
depreciation, was $1.2 million and $1.0 million, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future minimum payments for our capital leases at December&nbsp;31, 2014 are as follows (in
thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Years ending December&nbsp;31,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total minimum payments required</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: amount representing interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Present value of future minimum lease payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital lease obligation, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Lease </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2009, we entered into an operating sublease (Sublease) with Pfizer, Inc. for a 126,285&nbsp;square foot facility located in San&nbsp;Francisco, California (Mission Bay Facility).
Under the terms of the Sublease, we began making non-cancelable lease payments in 2014, after the expiration of our free rent period on August&nbsp;1, 2014. The Sublease term is 114 months, commencing in August 2010 and terminating on
January&nbsp;31, 2020. Monthly base rent will escalate over the term of the sublease at various intervals. In addition, throughout the term of the Sublease, we are responsible for paying certain costs and expenses specified in the Sublease,
including insurance costs and a pro rata share of operating expenses and applicable taxes for the Mission Bay Facility. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
future minimum lease payments for our operating leases at December&nbsp;31, 2014 are as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Years ending December&nbsp;31,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total future minimum lease payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize rent expense on a straight-line basis over the lease period. For the years ended
December&nbsp;31, 2014, 2013, and 2012, rent expense for all our operating leases, including our Mission Bay Facility, was approximately $3.2&nbsp;million, $2.9&nbsp;million, and $2.8&nbsp;million, respectively. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 7 &#151; Liability Related to Sale of Future Royalties </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale
Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after
January&nbsp;1, 2012, of (a)&nbsp;CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, under Nektar&#146;s license, manufacturing and supply agreement with
UCB Pharma (UCB), and (b)&nbsp;MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, under Nektar&#146;s license, manufacturing and supply agreement with F.
Hoffmann-La&nbsp;Roche Ltd and Hoffmann-La&nbsp;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&nbsp;As part of this sale, we incurred approximately $4.4 million in
transaction costs, which will be amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these royalties as revenue and recorded the
$124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that will be amortized using the interest method over the estimated life of the Purchase and Sale Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the activity within the liability account during the year ended December&nbsp;31, 2014 and for the period from
the inception of the royalty transaction on February&nbsp;24, 2012 (inception) to December&nbsp;31, 2014 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year ended<BR>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period from</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>inception to
<BR>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to sale of future royalties &#151; beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments from Nektar to RPI</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> royalty
revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability related to sale of future royalties &#151; ending balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Purchase and Sale Agreement, in March 2014 and March 2013, we were
required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
for the 12 month periods ended on December&nbsp;31, 2013 and 2012 not reaching certain minimum thresholds. As of December&nbsp;31, 2014, we do not expect to make any further payments related to the Purchase and Sale Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of this liability accounting, even though the royalties from UCB and Roche are remitted directly to RPI
starting with royalties arising from product sales in the first quarter of 2012, we will continue to recognize revenue for these royalties. During the years ended December&nbsp;31, 2014, 2013 and 2012, we recognized $21.9 million, $22.1 million and
$10.8 million, respectively, in non-cash royalties from net sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">As royalties are remitted to RPI from Roche and UCB, the balance of the Royalty Obligation will be effectively repaid over the life of the agreement. In order to determine the amortization of the Royalty
Obligation, we are required to estimate the total amount of future royalty payments to be received by RPI and payments we are required to make to RPI as noted above over the life of the agreement. The sum of these amounts less the $124.0 million
proceeds we received will be recorded as interest expense over the life of the Royalty Obligation. Since inception, our estimate of this total interest expense resulted in an effective annual interest rate of approximately 17%. We periodically
assess the estimated royalty payments to RPI from UCB and Roche and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will prospectively
adjust the amortization of the Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, most of which
are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that
result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI are made in U.S. dollars (USD) while significant portions of the underlying
sales of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from CIMZIA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales
of CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the Royalty Obligation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating
to the Royalty Entitlement and contains other representations and warranties, covenants and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement,
however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;8&nbsp;&#151; Commitments and Contingencies </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Royalty Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have third party licenses that require us to pay royalties based on our sales of certain products and/or on our recognition of royalty revenue under certain of our collaboration agreements. Royalty
expense, which is reflected in cost of goods sold in our Consolidated Statements of Operations, was approximately $3.4&nbsp;million, $4.1&nbsp;million, and $2.9&nbsp;million for the years ended December&nbsp;31, 2014, 2013, and 2012, respectively.
The overall maximum amount of these obligations is based upon sales of the applicable products by our collaboration partners and cannot be reasonably estimated. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchase Commitments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the normal course of business, we enter
into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&nbsp;31, 2014, these commitments were approximately $16.9&nbsp;million, all of which are expected to be paid in
2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal Matters </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the
ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to
reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to
occur in any specific period, there exists the possibility of a material adverse impact on the results of operations of that period or on our cash flows and liquidity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Operations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We operate in a number of foreign countries. As
a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnification Obligations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally
perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on
our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, the overall maximum
amount of any such obligations cannot be reasonably estimated. No liabilities have been recorded for these obligations on our Consolidated Balance Sheets as of December&nbsp;31, 2014 or 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnifications in Connection with Commercial Agreements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part
of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs based on our proprietary technologies and drug candidates, we generally agree to defend,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of
intellectual property to the extent the intellectual property is developed by us and licensed to our partners. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of the sale of our royalty interest in the CIMZIA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and
MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, we and RPI made representations and warranties and entered into certain covenants and
ancillary agreements which are supported by indemnity obligations. Additionally, as part of our pulmonary asset sale to Novartis in 2008, we and Novartis made representations and warranties and entered into certain covenants and ancillary agreements
which are supported by an indemnity obligation. In the event it is determined that we breached certain of the representations and warranties or covenants and agreements made by us in any such agreements, we could incur substantial indemnification
liabilities depending on the timing, nature, and amount of any such claims. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnification of Underwriters and Initial Purchasers of
our Securities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with our sale of equity and senior secured debt securities, we have agreed to defend,
indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director and Officer Indemnifications </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for
certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our
exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we
believe any obligations under this indemnification would not be material, other than an initial $1,500,000 per incident for merger and acquisition related claims, $1,000,000 per incident for securities related claims and $500,000 per incident for
non-securities related claims retention deductible per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation
against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;9&nbsp;&#151; Stockholders&#146; Equity </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have authorized 10,000,000&nbsp;shares of Preferred Stock with each share having a par value of $0.0001. In 2011, 3,100,000&nbsp;shares were previously designated Series&nbsp;A Junior Participating
Preferred Stock (Series&nbsp;A Preferred Stock) in connection with our Share Purchase Rights Plan (Rights Plan) that expired on June&nbsp;1, 2011. On March&nbsp;30, 2012, we filed a certificate of elimination of the Series A Preferred Stock. As of
December&nbsp;31, 2014 and 2013, no preferred shares are designated, issued or outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Common Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;28, 2014, we completed the issuance and sale of 9,775,000 shares of our common stock in a public offering with total
proceeds of approximately $117.2 million after deducting the underwriting commissions and discounts of approximately $7.5 million. In addition, we incurred approximately $0.6 million in legal and accounting fees, filing fees, and other costs in
connection with this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Equity Compensation Plans </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014, we had 24,806,565 reserved shares of common stock, all of which are reserved for issuance under our equity
compensation plans as summarized in the following table (share number in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities&nbsp;to&nbsp;be<BR>Issued Upon Exercise of<BR>Outstanding
Options<BR>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-Average<BR>Exercise Price of<BR>Outstanding&nbsp;Options<BR>(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities&nbsp;Remaining<BR>Available for Issuance Under<BR>Equity Compensation
Plans<BR>(Excluding Securities Reflected<BR>in Column(a))<BR>(c)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes shares of common stock available for future issuance under our ESPP as of December&nbsp;31, 2014. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2012 Performance Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2012 Performance Incentive Plan (2012 Plan) was adopted by the Board of Directors on April&nbsp;4, 2012 and was approved by our stockholders on June&nbsp;28, 2012. On the date of approval, any shares
of our common stock that were available for issuance under all other previously existing stock plans (the 2008 Equity Incentive Plan, the 2000 Equity Incentive Plan, and the 2000 Non-Officer Equity Incentive Plan) became available for issuance under
the 2012 Plan. In addition, 5,300,000 new shares were made available for award grants under the 2012 Plan. No new awards were granted under any of the previous stock plans after June&nbsp;28, 2012. Any shares of common stock subject to outstanding
awards under the previous stock plans that expire, are cancelled, or otherwise terminate at any time after December&nbsp;31, 2011 are also available for award grant purposes under the 2012 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the 2012 Plan and our other incentive plans is to attract, motivate, retain, and reward directors, officers, employees,
and other eligible persons through the grant of awards and incentives for high levels of individual performance and increasing the value of our business, as well as to further align the interests of award recipients and our stockholders. The 2012
Plan authorizes stock options, stock appreciation rights, restricted stock, performance stock, stock units, stock bonuses, dividend equivalents, other similar rights to purchase or acquire shares, and other forms of awards granted or denominated in
our common stock or units of the company&#146;s common stock, as well as cash bonus awards. Directors, officers, or employees, and certain consultants and advisors may receive awards under the 2012 Plan. Pursuant to the 2012 Plan, we granted or
issued incentive stock options to officers and non-qualified stock options to employees, officers, and non-employee directors. In 2013 and 2014, the requisite service period for stock options granted to our employees under the 2012 Plan as well as
all other previously existing stock plans was generally four years; the requisite service period for stock options granted to our directors was generally one year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The maximum number of shares of our common stock that may be issued or transferred pursuant to awards under the 2012 Plan is 10,347,140 shares, plus any shares subject to outstanding awards under the
previous stock plans that expire, are cancelled, or otherwise terminate for any reason. Generally, shares that are subject to or underlie awards which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any
other reason (except for shares exchanged by a participant or withheld to pay the exercise price of an award granted and related tax withholding obligations) are not paid or delivered under the 2012 Plan will again be available for subsequent awards
under the 2012 Plan. Shares issued in respect of any award, other than a stock option or stock appreciation right, granted under the 2012 Plan will be counted against the plan&#146;s share limit as 1.5&nbsp;shares for every one share actually issued
in connection with the award. We did not grant any RSU awards during the years ended December&nbsp;31, 2014, 2013 or 2012 and no RSUs are outstanding at December&nbsp;31, 2014. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2012 Plan will terminate on April&nbsp;3, 2022, unless earlier terminated by the Board
of Directors. The maximum term of a stock option or stock appreciation right under the 2012 Plan is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of the
company&#146;s common stock on the Nasdaq Global Select Market on the date of grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Equity Incentive Plans </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the 2012 Plan, we have other equity incentive plans under which options granted remain outstanding but no new options may
be granted either as a result of the approval of the 2012 Plan or plan expiration. These plans include: (i)&nbsp;the 2008 Equity Incentive Plan (2008 Plan) which was adopted by the Board of Directors on March&nbsp;20, 2008 and approved by our
stockholders on June&nbsp;6, 2008; (ii)&nbsp;the 2000 Equity Incentive Plan (2000 Plan) which was adopted by the Board of Directors on April&nbsp;19, 2000 by amending and restating our 1994 Equity Incentive Plan, and which expired on
February&nbsp;9, 2010; and (iii)&nbsp;the 1998 Non-Officer Equity Incentive Plan which was adopted by our Board of Directors on August&nbsp;18, 1998, and which was amended and restated in its entirety and renamed the 2000 Non-Officer Equity
Incentive Plan on June&nbsp;6, 2000 (2000 Non-Officer Plan). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the 2008 Plan and the 2000 Plan, we previously
granted or issued incentive stock options to employees and officers and non-qualified stock options, rights to acquire restricted stock, restricted stock units, and stock bonuses to employees, officers, non-employee directors, and consultants.
Pursuant to the 2000 Non-Officer Plan, we previously granted or issued non-qualified stock options, rights to acquire restricted stock and stock bonuses to employees and consultants who are neither officers nor directors of Nektar. The maximum term
of a stock option under all of these plans is eight years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee Stock Purchase Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 1994<B>, </B>our Board of Directors adopted the Employee Stock Purchase Plan (ESPP) pursuant to section&nbsp;423(b) of the
Internal Revenue Code of 1986. Under the ESPP, 2,500,000&nbsp;shares of our common stock have been authorized for issuance. The terms of the ESPP provide eligible employees with the opportunity to acquire an ownership interest in Nektar through
participation in a program of periodic payroll deductions for the purchase of our common stock. Employees may elect to enroll or re-enroll in the ESPP on a semi-annual basis. Stock is purchased at 85% of the lower of the closing price on the first
day of the enrollment period or the last day of the enrollment period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>401(k) Retirement Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual
compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $3,000 per participant. For the
years ended December&nbsp;31, 2014, 2013, and 2012, we recognized $0.9 million, $1.0&nbsp;million, and $0.9&nbsp;million, respectively, of compensation expense in connection with our 401(k) retirement plan. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in Control Severance Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;6, 2006, our Board of Directors approved a Change of Control Severance Benefit Plan (CIC Plan). This CIC Plan has subsequently been amended a number of times by our Board of Directors
with the most recent amendment occurring on April&nbsp;5, 2011. The CIC Plan is designed to make certain benefits available to our eligible employees in the event of a change of control of Nektar and, following such change of control, an
employee&#146;s employment with us or a successor company is terminated in certain specified circumstances. We adopted the CIC Plan to support the continuity of the business in the context of a change of control transaction. The CIC Plan was not
adopted in contemplation of any specific change of control transaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the CIC Plan, in the event of a change of control of Nektar and a subsequent
termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) or initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) in each case within twelve months following a
change of control transaction, (i)&nbsp;the Chief Executive Officer would be entitled to receive cash severance pay equal to 24&nbsp;months base salary plus annual target incentive pay, the extension of employee benefits over this severance period
and the full acceleration of unvested outstanding equity awards, and (ii)&nbsp;our Senior Vice Presidents and Vice Presidents (including Principal Fellows) would each be entitled to receive cash severance pay equal to twelve months base salary plus
annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards. In the event of a change of control of Nektar and a subsequent termination of employment
initiated by the Company or a successor company other than for Cause within twelve months following a change of control transaction, all other employees would each be entitled to receive cash severance pay equal to 6&nbsp;months base salary plus a
pro-rata portion of annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of each such employee&#146;s unvested outstanding equity awards. Under the CIC Plan, as amended, non-employee
directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;10&nbsp;&#151; License and Collaboration Agreements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into various collaboration agreements including license agreements and collaborative research,
development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone payments, royalties, sales milestones,
and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. All of our collaboration agreements are generally cancelable by our partners without significant
financial penalty. Our costs of performing these services are generally included in research and development expense, except that costs for product sales to our collaboration partners are included in cost of goods sold. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:26pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Partner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Agreement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AstraZeneca AB</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> (NKTR-118) and MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination program (NKTR-119)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roche</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter Healthcare</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAX 855 (Hemophilia)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bayer Healthcare LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">BAY41-6551 (Amikacin Inhale)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Affymax, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License, collaboration and other revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, our collaboration agreements with partners included
potential future payments for development milestones totaling approximately $130.3 million, including amounts from our agreements with Baxter and Bayer described below. In addition, we are entitled to receive the contingent payments described below
related to the MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (previously referred to as
naloxegol and NKTR-118) and MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose
combination (previously referred to as NKTR-119) drug development programs, respectively, based on development and regulatory events to be pursued and completed solely by AstraZeneca. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>AstraZeneca AB</I></B><I>: MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT> (naloxegol oxalate), previously referred to as naloxegol and NKTR-118, and MOVANTIK<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT> fixed-dose combination program, previously referred to as NKTR-119 </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2009, we entered into a license agreement with AstraZeneca AB (AstraZeneca), as amended by AstraZeneca
and us in August 2013, under which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing, and sublicensable license under our patents and other intellectual property to develop, market, and sell MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and
MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination program. AstraZeneca is
responsible for all costs associated with research, development and commercialization and is responsible for all drug development and commercialization decisions for MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">and the MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">fixed-dose combination program. AstraZeneca paid us an upfront payment of $125.0&nbsp;million, which we received in
the fourth quarter of 2009 and which was fully recognized as of December&nbsp;31, 2010. As of December&nbsp;31, 2014, we are entitled to receive up to an additional $140.0 million and $75.0 million of contingent payments related to MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and the MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> fixed-dose combination program, respectively, based on development
events to be pursued and completed solely by AstraZeneca, as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;16,
2014, the United States Food and Drug Administration (FDA) approved MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. On December&nbsp;9, 2014, AstraZeneca announced that MOVENTIG<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (the naloxegol brand name in the European Union) has been granted Marketing Authorisation by the European Commission
(EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). As a result of the FDA&#146;s approval, on September&nbsp;16, 2014, we were entitled to a $35.0 million non-refundable
payment from AstraZeneca, which was fully recognized as revenue in September 2014 and was received in October 2014. In addition, the FDA&#146;s approval of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> extinguished our contingent obligation to repay the $70.0 million payment made to us by AstraZeneca in November 2013
after the MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> New Drug Application was accepted for
review by the FDA. As a result, in September 2014, we fully recognized this $70.0 million payment, which was previously recorded in the line item &#147;Liability related to receipt of refundable milestone payment&#148; on our Consolidated Balance
Sheet at December 31, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of its approval of MOVANTIK</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, the FDA required AstraZeneca to perform a post-marketing,
observational epidemiological study comparing MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
to other treatments of OIC in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in the U.S. by AstraZeneca will be reduced by up to two percentage points to fund 33% of the external costs incurred
by AstraZeneca to fund such post approval study subject to a $35.0 million aggregate cap. Any costs incurred by AstraZeneca can only be recovered by the reduction of the royalty paid to us. In no case can amounts be recovered by the reduction of a
contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be
entitled to up to an additional $140.0 million of contingent payments upon the first commercial sale of
MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, $100.0 million of which will be payable upon
the first commercial sale in the U.S. and $40.0 million of which will be payable upon the first commercial sale in one major European Union country. We are also entitled to receive up to $75.0 million of commercial launch contingent payments related
to the MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">fixed-dose combination program, based on
development events to be pursued and completed solely by AstraZeneca. In addition, we are entitled to royalties and sales milestone payments based on annual worldwide net sales of MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">and MOVANTIK</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">fixed-dose combination products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Roche</I></B><I>: PEGASYS<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> and
MIRCERA<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In February
1997, we entered into a license, manufacturing and supply agreement with Roche, under which we granted Roche a worldwide, exclusive license to certain intellectual property related to our proprietary PEGylation materials used in the manufacture and
commercialization of PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. As a result of Roche exercising a license extension option in December 2009,
Roche has the right to manufacture all of its requirements for our proprietary PEGylation materials for PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
and we perform additional manufacturing, if any, only on an as-requested basis. In connection with Roche&#146;s exercise of the license </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
extension option in December 2009, we received a payment of $31.0&nbsp;million. As of December&nbsp;31, 2014, we have deferred revenue of approximately $5.1 million related to this agreement,
which we expect to recognize through December 2015, the period through which we are required to provide back-up manufacturing and supply services related to PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we
entered into a toll-manufacturing agreement with Roche under which we will manufacture the proprietary PEGylation material used by Roche to produce MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Roche entered into the toll-manufacturing agreement with the objective of establishing us as a secondary back-up supply source on a non-exclusive basis. Under the
terms of our toll-manufacturing agreement, Roche paid us an upfront payment of $5.0 million and an additional $22.0 million in performance-based milestone payments upon our achievement of certain manufacturing readiness, validation and production
milestones, including the delivery of specified quantities of PEGylation materials, all of which were completed as of January 2013. Roche will also pay us additional consideration for any future orders of the PEGylation materials for MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beyond the initial quantities manufactured through January 2013.&nbsp;Roche has the right to terminate the
toll-manufacturing agreement due to an uncured material default by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We analyzed the milestone payments under the agreement
and determined that they did not meet the criteria for revenue recognition under the milestone method as a result of our continuing manufacturing obligations. We have identified our back-up manufacturing obligation through December 2016 and the
delivery of PEGylation materials specified in the agreement in 2012 and early 2013 as the units of accounting in the arrangement. We made our best estimate of the selling prices for these deliverables and have allocated the total $27.0 million
consideration to these items based on the relative selling price method. As of December&nbsp;31, 2014, we have deferred revenue of approximately $10.7&nbsp;million, which we expect to recognize through December 2016, the estimated end of our
obligations under this agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2013, we agreed to deliver additional quantities of
PEGylation materials used by Roche to produce PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and MIRCERA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, all of which were delivered in the last quarter of 2013, for total consideration of $18.6 million. We determined
that these incremental activities should be considered a material modification of the existing PEGASYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and
MIRCERA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> -related arrangements described above. As a result, we allocated the $18.6 million consideration to
each of these arrangements and determined the amounts to be recognized or deferred based on the estimated selling prices of the undelivered obligations. As of December&nbsp;31, 2014, we have deferred revenue of approximately $4.6&nbsp;million
related to these activities, which we expect to recognize through December 2016, the estimated end of our obligations under the modified arrangements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Baxter Healthcare</I></B><I>: BAX 855/Hemophilia </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September
2005, we entered into an exclusive research, development, license and manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (together referred to as Baxter) to develop products designed to improve therapies
for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding and are responsible for supplying Baxter with its requirements for our proprietary materials. Baxter is
responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of this agreement, as of December&nbsp;31, 2014, we are entitled to up to $20.0 million of development milestones related to Hemophilia A upon achievement of certain development
objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on annual worldwide net sales of products resulting from this agreement. This Hemophilia A program includes BAX 855. In August 2014, Baxter
announced positive top-line results from its Phase 3 pivotal clinical trial of BAX 855 which met the primary endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or
older. As a result of this Phase 3 clinical trial meeting its primary endpoint, we achieved development milestones totaling $8.0 million. Given our significant efforts in the development of this
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
product, we consider these milestones to be substantive and we recognized the milestones in their entirety in the year ended December&nbsp;31, 2014. As of December&nbsp;31, 2014, we do not have
significant deferred revenue related to this agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amgen, Inc.</I></B><I>: Neulasta</I><B><I></I></B><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> <B><I> </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the amended and restated agreement) and
a license agreement with Amgen Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the amended and restated agreement, we guarantee the manufacture and supply of our proprietary PEGylation materials (Polymer
Materials) to Amgen in an existing manufacturing suite to be used exclusively for the manufacture of Polymer Materials for Amgen (the Manufacturing Suite) in our manufacturing facility in Huntsville, Alabama (the Facility). This supply arrangement
is on a non-exclusive basis (other than the use of the Manufacturing Suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from
any other third party. Under the terms of the amended and restated agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of Polymer Materials to Amgen including
without limitation the Additional Rights described below and manufacturing fees that are calculated based on fixed and variable components applicable to the Polymer Materials ordered by Amgen and delivered by us. Amgen has no minimum purchase
commitments. If quantities of the Polymer Materials ordered by Amgen exceed specified quantities, significant additional payments become payable to us in return for our guaranteeing the supply of additional quantities of the Polymer Materials.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of the amended and restated agreement ends on October&nbsp;29, 2020. In the event we become subject to a bankruptcy
or insolvency proceeding, we cease to own or control the Facility, we fail to manufacture and supply or certain other events, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the
dedicated equipment and access the Facility to operate the Manufacturing Suite solely for the purpose of manufacturing the Polymer Materials (the Additional Rights). Amgen may terminate the amended and restated agreement for convenience or due to an
uncured material default by us. Our research facility in Huntsville, Alabama that we propose to sell is a different building and location from that of the Facility described here. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we have deferred revenue of approximately $29.2&nbsp;million related to this agreement, which we expect to
recognize through October 2020, the estimated end of our obligations under this agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Bayer Healthcare LLC</I></B><I>:
BAY41-6551 (Amikacin Inhale) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2007, we entered into a co-development, license and co-promotion agreement with
Bayer Healthcare LLC (Bayer) to develop a specially-formulated inhaled Amikacin. We are responsible for development and manufacturing and supply of the nebulizer device included in the Amikacin product. Bayer is responsible for most future clinical
development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of Amikacin Inhale and final product packaging and distribution. In the years prior to 2014, we
received an upfront payment of $40.0&nbsp;million in 2007 and milestone payments of $30.0&nbsp;million, including a $10.0 million development milestone which was achieved in 2013 as a result of the start of the Phase 3 clinical trial by Bayer in the
treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia in April 2013. In addition, in June 2013, we paid $10.0 million to Bayer for the reimbursement of its costs of the Phase 3 clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we are entitled to receive a total of up to $50.0 million for development milestones upon achievement of certain development
objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on annual worldwide net sales of Amikacin Inhale. As of December&nbsp;31, 2014, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
have deferred revenue of approximately $20.8 million related to this agreement, which we expect to recognize through February 2028, the estimated end of our obligations under this agreement.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Ophthotech Corporation</I></B><I>: Fovista</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> <I> </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a party
to an agreement with Ophthotech Corporation (Ophthotech), dated September&nbsp;30, 2006, under which Ophthotech received a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and sell Fovista<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Under the terms of our agreement, we are the exclusive supplier of all of Ophthotech&#146;s clinical and commercial
requirements for our proprietary PEGylation reagent used in Fovista<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. On May&nbsp;19, 2014, Ophthotech entered
into a Licensing and Commercialization Agreement with Novartis Pharma AG for Fovista<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Under our agreement with
Ophthotech, we received a $19.75 million payment in connection with this licensing agreement in June 2014. As of December&nbsp;31, 2014, we have deferred revenue of approximately $18.9 million related to this agreement, which we expect to recognize
through March 2028, the estimated end of our obligations under our agreement with Ophthotech. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, we are entitled to up to $9.5 million in additional payments based upon Ophthotech&#146;s potential achievement of certain regulatory and sales milestones. We are also entitled to royalties on net sales of Fovista<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> that vary based on sales levels. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Affymax, Inc.</I></B><I>: OMONTYS<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2004, we entered into a license, manufacturing and supply agreement with Affymax, Inc. (Affymax) under which
we provided Affymax with a worldwide, non-exclusive license under certain of our proprietary PEGylation technology to develop, manufacture and commercialize OMONTYS<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (peginesatide). On February&nbsp;23, 2013, Affymax and Takeda Pharmaceutical Company Limited announced a voluntary recall of all lots of OMONTYS<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;drug product as a result of new post-marketing reports regarding serious hypersensitivity reactions, including
anaphylaxis, which can be life-threatening or fatal.&nbsp;In July 2013, Affymax terminated the license, manufacturing and supply agreement with Nektar. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have received milestone and related payments under our agreement with Affymax and, as a result of the termination of our agreement with Affymax and our related performance obligations, we recognized
the remaining $6.7 million of deferred revenue from this agreement in the year ended December&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended December&nbsp;31, 2014, two of our collaboration partners achieved the successful transfer of our commercial
manufacturing process in connection with the PEGylation materials used in their products. In connection with our assistance with these manufacturing technology transfers, we received a total of $9.0 million of milestone payments. We concluded that
these payments are substantive milestones and recognized them in their entirety in the year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, as of December&nbsp;31, 2014, we have a number of collaboration agreements, including our collaboration partner UCB, under which we are entitled to up to a total of $53.8 million of development milestones upon achievement of certain
development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these
collaboration agreements, we cannot estimate the probability or timing of achieving these milestones. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;11 &#151; Stock-Based Compensation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issue stock-based awards from our equity incentive plans, which are more fully described in Note&nbsp;9. Stock-based
compensation expense was recognized as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, total unrecognized compensation costs of $51.9 million related to unvested
stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of 2.1 years. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Black-Scholes Assumptions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following tables list the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average volatility factor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average weighted average expected life</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.0&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average risk-free interest rate is based on the U.S.&nbsp;treasury yield curve in effect at the time
of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of 0.0%. Our estimate of expected
volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended December&nbsp;31, 2014, 2013, and 2012, we estimated the weighted-average expected life based on the contractual and
vesting terms of the stock options, as well as historic cancellation and exercise data. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation resulting
from our ESPP was not material in the years ended December&nbsp;31, 2014, 2013, and 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Summary of Stock Option Activity </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and
contractual life information): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Price</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>per Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Contractual</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Life&nbsp;(in&nbsp;Years)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Intrinsic</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Value<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options forfeited&nbsp;&amp; canceled</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested&nbsp;and expected to vest at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&nbsp;31, 2014.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted-average grant-date fair value per share of options granted during the years ended
December&nbsp;31, 2014, 2013, and 2012 was $6.50, $4.95, and $3.92, respectively. The total intrinsic value of options exercised during the years ended December&nbsp;31, 2014, 2013, and 2012 was $25.9 million, $4.5&nbsp;million, and
$1.9&nbsp;million, respectively. The estimated fair value of options vested during the years ended December&nbsp;31, 2014, 2013, and 2012 was $15.2 million, $14.1&nbsp;million, and $15.7&nbsp;million, respectively. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;12&nbsp;&#151; Income Taxes </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before (benefit) provision for income taxes includes the following components (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Domestic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(174,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,809</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before (benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(159,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(171,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provision for Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The (benefit) provision for income taxes consists of the following (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(487</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foreign benefit provision in the year ended December&nbsp;31, 2014 is due to the
reduction in taxes related to a favorable determination received from India proceedings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax provision related to
continuing operations differs from the amount computed by applying the statutory income tax rate of 35% to pretax loss as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. federal provision (benefit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(60,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest expense on liability related to sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign tax inclusion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign tax differential</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,933</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(487</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Benefit) provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred Tax Assets and Liabilities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount
of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">423,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">391,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and other credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sale of future royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capitalized research expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves and accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,580</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets before valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">595,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">586,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance for deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(595,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(586,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount
of which are uncertain. Because of our lack of U.S.&nbsp;earnings history, the net U.S.&nbsp;deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $9.7&nbsp;million and $51.8&nbsp;million during
the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
years ended December&nbsp;31, 2014 and 2013, respectively. The valuation allowance includes approximately $35.6&nbsp;million of income tax benefit at both December&nbsp;31, 2014 and
December&nbsp;31, 2013 related to stock-based compensation and exercises prior to the implementation of the accounting guidance for stock-based compensation that will be credited to additional paid in capital when realized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Undistributed earnings of our foreign subsidiary in India are considered to be permanently reinvested and accordingly, no deferred
U.S.&nbsp;income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, we would be subject to U.S.&nbsp;income tax. As of December&nbsp;31, 2014, U.S. income taxes have not been provided on a
cumulative total of $3.9 million of such earnings. Any incremental tax liability would be insignificant due to foreign tax credits that would be realized upon distribution. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Operating Loss and Tax Credit Carryforwards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of
December&nbsp;31, 2014, we had a net operating loss carryforward for federal income tax purposes of approximately $1,131.8&nbsp;million, portions of which will begin to expire in 2018. As of December&nbsp;31, 2014, we had a total state net operating
loss carryforward of approximately $709.2&nbsp;million, of which approximately $124.6 million does not meet the more likely than not standard and has not been included in our deferred tax assets. Our state operating loss carryforwards will begin to
expire in 2015. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code of 1986 and similar state
provisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have federal research credits of approximately $40.0&nbsp;million, which will begin to expire in 2019 and
state research credits of approximately $22.6 million which have no expiration date. We have federal orphan drug credits of $17.7&nbsp;million which will begin to expire in 2026. These tax credits are subject to the same limitations discussed above.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unrecognized tax benefits </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have incurred net operating losses since inception. Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the
consolidated statements of operations. If we are eventually able to recognize our uncertain positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the
timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Any adjustments to our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry
forwards rather than resulting in a cash outlay. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file income tax returns in the U.S., California, Alabama, and India.
Because of net operating losses and research credit carryovers, substantially all of our domestic tax years remain open and subject to examination. We are currently under examination in India for the fiscal years ending 2009 through 2014.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have the following activity relating to unrecognized tax benefits (in thousands):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax positions related to current year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reductions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax positions related to prior year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reductions &#151; foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lapses in statute of limitations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ending balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within
the next twelve months, we do not anticipate any significant changes to unrecognized tax benefits over the next twelve&nbsp;months. During the years ended December&nbsp;31, 2014, 2013 and 2012, no significant interest or penalties were recognized
relating to unrecognized tax benefits. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;13&nbsp;&#151; Segment Reporting </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We operate in one business segment which focuses on applying our technology platforms to improve the performance of
established and novel medicines. We operate in one segment because our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and
regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer and his management team. Within our one business segment we have two components, PEGylation technology and pulmonary technology.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue is derived primarily from clients in the pharmaceutical and biotechnology industries. AstraZeneca, UCB and Roche
represented 52%, 16%, and 11% of our revenue, respectively, for the year ended December&nbsp;31, 2014. Revenue from Roche, UCB, AstraZeneca and Bayer represented 28%, 21%, 17% and 10% of our revenue, respectively, for the year ended
December&nbsp;31, 2013. Revenue from UCB, Roche and Affymax represented 30%, 23% and 11% of our revenue, respectively, for the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue by geographic area is based on the locations of our partners. The following table sets forth revenue by geographic area (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">United States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Europe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014, $63.7&nbsp;million, or approximately 90%, of the net book value of our
property and equipment was located in the United States and $6.7&nbsp;million, or approximately 10%, was located in India. At </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
December&nbsp;31, 2013, $57.3&nbsp;million, or approximately 88%, of the net book value of our property and equipment was located in the United States and $7.7&nbsp;million, or approximately 12%,
was located in India. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note&nbsp;14&nbsp;&#151; Selected Quarterly Financial Data (Unaudited) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information
set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these
fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and you should not rely on our results for any one quarter as an indication of
our future performance. Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications have not materially impacted previously reported total
revenues, operating loss or net loss. All data is in thousands except per share information. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year 2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q4</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Q4</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,661</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(45,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(32,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(46,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(32,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(45,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,543</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding. </FONT></TD></TR></TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_12"></A>Item&nbsp;9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_13"></A>Item&nbsp;9A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Controls and Procedures</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain disclosure controls and
procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules
and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our
management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule&nbsp;13a-15. Based upon, and as of the date
of, this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were effective. Accordingly, management believes that the financial statements included in this report fairly
present in all material respects our financial condition, results of operations and cash flows for the periods presented. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Management&#146;s Annual Report on Internal Control over Financial Reporting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Exchange Act Rule&nbsp;13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management has assessed the effectiveness of our internal control over financial
reporting as of December&nbsp;31, 2014. In making its assessment of internal control over financial reporting, management used the criteria described in <I>Internal Control&nbsp;&#151; Integrated Framework </I>issued by the Committee of Sponsoring
Organizations of the Treadway Commission (2013 Framework). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our evaluation under the framework described in
<I>Internal Control&nbsp;&#151; Integrated Framework</I>, our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effectiveness of our internal control over financial reporting as of December&nbsp;31, 2014 has been audited by Ernst&nbsp;&amp;
Young, LLP, an independent registered public accounting firm, as stated in their report, which is included herein. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Internal
Control Over Financial Reporting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continuously seek to improve the efficiency and effectiveness of our internal
controls. This results in refinements to processes throughout the Company. There was no change in our internal control over financial reporting during the quarter ended December&nbsp;31, 2014, which was identified in connection with our
management&#146;s evaluation required by Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Inherent Limitations on the Effectiveness of Controls </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent
all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or
mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in
conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_14"></A>Item&nbsp;9B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Other Information</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;III </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_15"></A>Item&nbsp;10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Directors, Executive Officers and Corporate Governance</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information relating to our executive officers required by this item is set forth in Part&nbsp;I&nbsp;&#151; Item&nbsp;1 of this report
under the caption &#147;Executive Officers of the Registrant&#148; and is incorporated herein by reference. The other information required by this Item is incorporated by reference from the definitive proxy statement for our 2015 Annual Meeting of
Stockholders to be filed with the SEC pursuant to Regulation&nbsp;14A (Proxy Statement) not later than 120&nbsp;days after the end of the fiscal year covered by this Form&nbsp;10-K under the captions &#147;Corporate Governance and Board of
Directors,&#148; &#147;Proposal&nbsp;1&nbsp;&#151;&nbsp;Election of Directors&#148; and &#147;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Information regarding our audit committee financial expert will be set forth in the Proxy Statement under the caption &#147;Audit Committee,&#148; which information is incorporated herein by reference.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer,
principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at <I>www.nektar.com</I>. Amendments to, and waivers from, the Code
of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item&nbsp;406(b) of Regulation&nbsp;S-K will be disclosed at
the website address provided above and, to the extent required by applicable regulations, on a current report on Form&nbsp;8-K. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As permitted by SEC Rule&nbsp;10b5-1, certain of our executive officers, directors and other employees have or may set up a predefined,
structured stock trading program with their broker to sell our stock. The stock trading program allows a broker acting on behalf of the executive officer, director or other employee to trade our stock during blackout periods or while such executive
officer, director or other employee may be aware of material, nonpublic information, if the trade is performed according to a pre-existing contract, instruction or plan that was established with the broker when such executive officer, director or
employee was not aware of any material, nonpublic information. Our executive officers, directors and other employees may also trade our stock outside of the stock trading programs set up under Rule&nbsp;10b5-1 subject to our securities trading
policy. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_16"></A>Item&nbsp;11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Executive Compensation</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is included in the Proxy Statement and incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_17"></A>Item&nbsp;12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is included in the Proxy Statement and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<A NAME="tx842626_18"></A>tem&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Certain Relationships and Related Transactions and Director Independence</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is included in the Proxy Statement and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<A NAME="tx842626_19"></A>tem&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Principal Accountant Fees and Services</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is included in the Proxy Statement and incorporated herein by reference. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;IV </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_20"></A>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Exhibits and Financial Statement Schedules</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following documents are filed as part of this report: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Consolidated Financial Statements:</I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following financial statements are filed as part of this Annual Report on Form&nbsp;10-K under Item&nbsp;8 &#147;Financial Statements and Supplementary Data.&#148; </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_22">Reports of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_23">Consolidated Balance Sheets at December&nbsp;31, 2014 and 2013</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_24">Consolidated Statements of Operations for each of the three years in the period ended December&nbsp;
31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_25">Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December&nbsp;31,
 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_26">Consolidated Statements of Stockholders&#146; Equity (Deficit) for each of the three years in the period ended
 December&nbsp;31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_27">Consolidated Statements of Cash Flows for each of the three years in the period ended December&nbsp;
31, 2014</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx842626_28">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Financial Statement Schedules:</I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item&nbsp;8
of this Annual Report on Form&nbsp;10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exhibits.</I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as so
indicated in Exhibit&nbsp;32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&nbsp;10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Purchase Agreement, dated October&nbsp;20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary
of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.5(6)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference is made to Exhibits&nbsp;3.1, 3.2, 3.3, 3.4, and 3.5.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock certificate.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due
2017.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1(9)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Stock Purchase Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2008 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5(11)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Compensation Plan for Non-Employee Directors.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8(12)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">401(k) Retirement Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discretionary Incentive Compensation Policy.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Change of Control Severance Benefit Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Severance Letter for executive officers of the company.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with Howard W. Robin.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with John Nicholson.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement, executed effective on December&nbsp;10, 2009, with Stephen K. Doberstein,&nbsp;Ph.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko Ghosh.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Built-to-Suite&nbsp;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&nbsp;17, 2004, as amended on January&nbsp;11, 2005 and
July&nbsp;19, 2007.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease, dated as of September&nbsp;30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19(15)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement Agreement and General Release, dated June&nbsp;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville,
Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development, License and Co-Promotion Agreement, dated August&nbsp;1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as
amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated
September&nbsp;26, 2005, as amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated December&nbsp;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&nbsp;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing,
Limited.+</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&nbsp;20, 2009.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25(7)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February&nbsp;28, 2013, by and between Nektar Therapeutics
and Wells Fargo Bank, National Association.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank,
National Association, as escrow agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.28(17)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.29(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.30(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (reference is made to the signature page).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1350 Certifications.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, formatted in XBRL (Extensible Business Reporting
Language): (i)&nbsp;Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders&#146; Equity, (v) Consolidated Statements of Cash Flows,
and (vi) Notes to Consolidated Financial Statements.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange
Act, except as otherwise stated in such filing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL information is filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 1998.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2000.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on January&nbsp;23, 2003.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on April&nbsp;11, 2011. </FONT></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;10, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;11, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-98321), filed on August&nbsp;19,
2002. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2011.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;3, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2004.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2007.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx842626_21"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City and County of San&nbsp;Francisco, State of California on February&nbsp;25, 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John Nicholson</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Vice President and Chief Financial Officer</I></B></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ILLIAN</SMALL> B. T<SMALL>HOMSEN</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jillian B. Thomsen</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Vice President, Finance and Chief Accounting Officer</I></B></FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Nicholson and Jillian B.
Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all
amendments to this Annual Report on Form&nbsp;10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of
them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all
that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;H<SMALL>OWARD</SMALL> W.
R<SMALL>OBIN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Howard W. Robin</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief&nbsp;Executive&nbsp;Officer,&nbsp;President and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL>
N<SMALL>ICHOLSON</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>John Nicholson</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Financial Officer (Principal Financial Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ILLIAN</SMALL> B.
T<SMALL>HOMSEN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jillian B. Thomsen</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>OBERT</SMALL> B.
C<SMALL>HESS</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Robert B. Chess</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;R. S<SMALL>COTT</SMALL>
G<SMALL>REER</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>R. Scott Greer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OSEPH</SMALL> J.
K<SMALL>RIVULKA</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Joseph J. Krivulka</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;C<SMALL>HRISTOPHER</SMALL> A.
K<SMALL>UEBLER</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Christopher A. Kuebler</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;L<SMALL>UTZ</SMALL>
L<SMALL>INGNAU</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Lutz Lingnau</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>USAN</SMALL>
W<SMALL>ANG</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Susan Wang</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>OY</SMALL> A.
W<SMALL>HITFIELD</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Roy A. Whitfield</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>ENNIS</SMALL> L.
W<SMALL>INGER</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dennis L. Winger</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;25, 2015</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as so indicated in Exhibit&nbsp;32.1, the following exhibits are filed as part of, or
incorporated by reference into, this Annual Report on Form&nbsp;10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Purchase Agreement, dated October&nbsp;20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary
of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.5(6)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference is made to Exhibits&nbsp;3.1, 3.2, 3.3, 3.4, and 3.5.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock certificate.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due
2017.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1(9)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Stock Purchase Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2008 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5(11)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Compensation Plan for Non-Employee Directors.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8(12)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">401(k) Retirement Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discretionary Incentive Compensation Policy.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Change of Control Severance Benefit Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Severance Letter for executive officers of the company.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with Howard W. Robin.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with John Nicholson.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement, executed effective on December&nbsp;10, 2009, with Stephen K. Doberstein,&nbsp;Ph.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko
Ghosh.++</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Built-to-Suite&nbsp;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&nbsp;17, 2004, as amended on January&nbsp;11, 2005 and
July&nbsp;19, 2007.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease, dated as of September&nbsp;30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19(15)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement Agreement and General Release, dated June&nbsp;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville,
Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development, License and Co-Promotion Agreement, dated August&nbsp;1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as
amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated
September&nbsp;26, 2005, as amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated December&nbsp;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&nbsp;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing,
Limited.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&nbsp;20, 2009.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25(7)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February&nbsp;28, 2013, by and between Nektar Therapeutics
and Wells Fargo Bank, National Association.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank,
National Association, as escrow agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.28(17)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.29(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.30(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (reference is made to the signature page).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule&nbsp;13a-14(a) or
Rule&nbsp;15d-14(a).</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1350 Certifications.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, formatted in XBRL (Extensible Business Reporting
Language): (i)&nbsp;Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders&#146; Equity, (v) Consolidated Statements of Cash Flows,
and (vi) Notes to Consolidated Financial Statements.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange
Act, except as otherwise stated in such filing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL information is filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 1998.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2000.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on January&nbsp;23, 2003.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on April&nbsp;11, 2011. </FONT></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;10, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;11, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-98321), filed on August&nbsp;19,
2002. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2011.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;3, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2004.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2007.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>d842626dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g842626st99.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Exhibit 10.16</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;14, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivan Gergel,
M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Address] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Address] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ivan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased present to you with this offer letter
agreement (the &#147;Letter Agreement&#148;) setting forth certain terms and conditions of your employment as Senior Vice President, Drug Development and Chief Medical Officer of Nektar Therapeutics (&#147;Nektar&#148; or the &#147;Company&#148;),
reporting to me. Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Company&#146;s Change of Control Severance Benefit Plan, as it may be amended from time to time (the &#147;COC Plan&#148; a copy of which
is enclosed herewith). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your annual cash compensation will consist of two components: base salary and an annual performance bonus. Your base salary will
be $600,000 on an annual basis and paid in accordance with Nektar&#146;s regular payroll schedule. Your annual performance bonus target each year will be at least 50% of your annual base salary (&#147;Target Annual Bonus&#148;) commencing in 2014
subject to proration for the portion of the 2014 annual period that you are employed at Nektar. Your base salary and Target Annual Bonus shall be subject to annual performance review by the Organization and Compensation Committee of the Board of
Directors (&#147;Compensation Committee&#148;) in consultation with me. The actual amount of your annual performance bonus will range from 0% to 200% of the Target Annual Bonus based on the Compensation Committee&#146;s assessment in consultation
with me of the achievement of a combination of annual corporate objectives and your achievement of personal objectives agreed upon by you and me at the beginning of each annual performance period commencing in 2014. Your annual performance bonus for
a particular year will be paid not later than March&nbsp;15 of the following year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of your first day of full-time employment with Nektar
(&#147;Start Date&#148;, which we currently anticipate will be May&nbsp;19, 2014), you will be granted a stock option to purchase 550,000 shares of Nektar common stock (the &#147;Stock Option&#148;) under Nektar&#146;s 2012 Performance Incentive
Plan (&#147;2012 Plan&#148;). The maximum number of shares subject to the Stock Option will be granted as an incentive stock option within the meaning of Section&nbsp;422 of the Internal Revenue Code to the extent permissible under the 2012 Plan.
The exercise price will be set at the closing price of Nektar&#146;s common stock on Nasdaq on your Start Date. The shares subject to the Stock Option will vest over 4 years with 25% of the shares vesting on the one year anniversary of your Start
Date and the remainder vesting monthly on a pro-rata basis over the following 3 years. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;Nektar&nbsp;Therapeutics&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;455&nbsp;Mission&nbsp;Bay&nbsp;Boulevard&nbsp;South&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;San&nbsp;Francisco,&nbsp;CA&nbsp;94158&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;P&nbsp;415.482.5300&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;www.nektar.com&nbsp;&nbsp;</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g842626st99.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Page 2</TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible for annual equity awards, in the sole discretion of the Compensation Committee, based on
the Compensation Committee&#146;s review, in consultation with me, of your individual performance and annual equity compensation levels of senior executive officers with similar roles at comparator companies as analyzed by a reputable,
nationally-recognized, independent compensation consultancy firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are also eligible to participate in Nektar&#146;s standard employee benefits
programs including Medical, Dental and Vision Insurance, Term Life Insurance, 401(k), ESPP, Flexible Health Spending Account, Short&nbsp;&amp; Long Term Disability, COC Plan and the terms specified in those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You agree to devote your full-time attention to your responsibilities to the Company. Subject to advance consent from me, which will not be unreasonably
withheld, you may serve on corporate or charitable boards, as long as your commitment to such boards does not create a conflict of interest and/or does not interfere with your responsibilities to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your employment is by continued mutual agreement and may be terminated at will with or without cause by either you or Nektar at any time with at least thirty
(30)&nbsp;days prior written notice. You will also be required to enter into Nektar&#146;s standard Employee Agreement and such agreement contains certain terms and conditions of your employment with Nektar other than those set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that your employment terminates due to your death or Disability (as defined in the stock option agreement under the 2012 Plan), (a)&nbsp;50% of
the then-unvested portion of any outstanding stock options granted to you by the Company will automatically vest in the event of your Disability (with the remainder of such unvested portion terminating immediately thereafter), and 100% of the
then-unvested portion of any outstanding stock options granted to you by the Company shall automatically vest in the event of your death, (b)&nbsp;Nektar will pay to you or your estate, as applicable, all unreimbursed expenses, all of your then
accrued but unpaid base salary, and your target bonus prorated for the portion of the last year in which you were employed by Nektar prior to death or Disability, and (c)&nbsp;you and your dependents shall be entitled to continued medical, dental,
and vision insurance, at your or their expense, at the same level of coverage as was provided to you and your dependents under Nektar&#146;s insurance and benefits plans immediately prior to the termination by electing COBRA continuation coverage in
accordance with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event your employment is terminated for reasons not related to a Change of Control (a)&nbsp;by the Company without
Cause, or (b)&nbsp;by you for a Good Reason Resignation, then you and the Company will meet in good faith to discuss the terms of an appropriate separation. In any event, at a minimum, the Company will enter into a severance arrangement with you
which will include the following: (i)&nbsp;a fully effective waiver and release in favor of the Company in such form as the Company may reasonably require, (ii)&nbsp;a cash severance payment equal to your total annual cash compensation target
(defined as your then current monthly base salary annualized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;Nektar&nbsp;Therapeutics&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;455&nbsp;Mission&nbsp;Bay&nbsp;Boulevard&nbsp;South&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;San&nbsp;Francisco,&nbsp;CA&nbsp;94158&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;P&nbsp;415.482.5300&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;www.nektar.com&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g842626st99.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page 3</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for twelve (12)&nbsp;months, plus your bonus target multiplied by the expected pay-out percentage used by the Company for its GAAP financial statements in the previous calendar quarter, but not
to exceed 100%), payable in accordance with the severance payment schedule described in Section&nbsp;4.2 of the COC Plan (including, without limitation and as applicable, the six-month delay for payments to &#147;specified employees&#148; as set
forth in such section), (iii)&nbsp;the exercise period for the portion of your outstanding stock options that are vested as of your termination date shall be twelve (12)&nbsp;months following the termination date (subject to earlier termination at
the end of the option term or in connection with a change in control of the Company in accordance with the applicable option plan and agreement), and (iv)&nbsp;the Company shall pay all applicable COBRA payments for you and your family for one year
after the termination date (such payments shall cease in the event that you become eligible for comparable benefits with another employer). In addition to the definition of Good Reason Resignation set forth in the COC Plan, in the event that your
work responsibilities are substantially changed from those set forth in the work responsibilities letter between you and the Company with the same date as this Letter Agreement, a voluntary resignation by you following such a substantial change in
work responsibilities would also constitute a Good Reason Resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reimbursements pursuant to the foregoing provisions of this Letter Agreement
shall be made in accordance with the Company&#146;s reimbursement policies, practices and procedures in effect from time to time and shall be paid as soon as reasonably practicable and in all events not later than the end of the calendar year
following the year in which the related expense was incurred.&nbsp;Your rights to reimbursement hereunder are not subject to liquidation or exchange for another benefit and the amount of expenses eligible for reimbursement in one calendar year shall
not affect the amount of expenses eligible for reimbursement in any other year.&nbsp;Any tax gross-up payments made pursuant to the foregoing provisions of this Letter Agreement shall be made as soon as practicable and in all events not later than
the end of the calendar year following the year in which you remit the related taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms, compensation and benefits set forth in this Letter
Agreement shall be governed by California law without reference to principles of conflicts of laws, may not be reduced without your prior written consent and shall be binding upon and inure to the benefit of (a)&nbsp;your heirs, executors, and legal
representatives upon your death and (b)&nbsp;any person or entity which at any time, whether by purchase, merger, or otherwise, directly or indirectly acquires all or a majority of the assets, business, capital stock, or voting stock of Nektar. Any
such person or entity shall be deemed substituted for Nektar under this Letter Agreement for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation and benefits payable
hereunder are intended to either be exempt from or comply with Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (&#147;Section 409A&#148;), so as not to subject you to payment of any additional tax, penalty or interest imposed
under Section&nbsp;409A. The provisions of this offer letter shall be construed and interpreted to avoid the imputation of any such additional tax, penalty or interest under Section&nbsp;409A yet preserve (to the nearest extent reasonably possible)
the intended benefit payable you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;Nektar&nbsp;Therapeutics&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;455&nbsp;Mission&nbsp;Bay&nbsp;Boulevard&nbsp;South&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;San&nbsp;Francisco,&nbsp;CA&nbsp;94158&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;P&nbsp;415.482.5300&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;www.nektar.com&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g842626st99.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Page 4</TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivan, we are delighted at the prospect of your leadership of the clinical and medical organization and as a key
member of Nektar&#146;s senior executive team. This offer set forth in this Letter Agreement will expire at the close of business on May&nbsp;16, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Howard W. Robin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Howard W. Robin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACCEPTED: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ivan Gergel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivan Gergel, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;Nektar&nbsp;Therapeutics&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;455&nbsp;Mission&nbsp;Bay&nbsp;Boulevard&nbsp;South&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;San&nbsp;Francisco,&nbsp;CA&nbsp;94158&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;P&nbsp;415.482.5300&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;www.nektar.com&nbsp;&nbsp;</TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d842626dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of Nektar Therapeutics* </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Jurisdiction&nbsp;of<BR>Incorporation&nbsp;or<BR>Organization</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nektar Therapeutics UK, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;Kingdom</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nektar Therapeutics (India) Pvt. Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">India</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Includes subsidiaries that do not fall under the definition of &#147;Significant Subsidiary&#148; as defined under Rule&nbsp;1-02(w) of Regulation S-X. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d842626dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Registration Statement (Form S-3 No.&nbsp;333-193454) of Nektar Therapeutics, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Registration Statements (Form S-8 Nos. 333-54078, 333-71936, 333-76638, 333-98321, 333-103040, 333-117975, 333-136498, 333-145259, 333-153106, 333-170371,
333-183193 and 333-197781) pertaining to the amended and restated 2000 Non-Officer Equity Incentive Plan, the 401(k) Retirement Plan, the Employee Stock Purchase Plan, the amended and restated 2000 Equity Incentive Plan, the amended and restated
2008 Equity Incentive Plan, and the 2012 Performance Incentive Plan of Nektar Therapeutics; of our reports dated February&nbsp;25, 2015, with respect to the consolidated financial statements of Nektar Therapeutics and the effectiveness of internal
control over financial reporting of Nektar Therapeutics included in this Annual Report (Form&nbsp;10-K) of Nektar Therapeutics for the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ E<SMALL>RNST</SMALL>&nbsp;&amp; Y<SMALL>OUNG</SMALL> LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;25, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d842626dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Howard W. Robin,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&nbsp;31, 2014; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;25, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Howard W. Robin</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Chief Executive Officer, President and Director</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d842626dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John Nicholson,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&nbsp;31, 2014; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;25, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>John Nicholson</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior Vice President and Chief Financial Officer</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d842626dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1350 CERTIFICATIONS<SUP STYLE="font-size:85%; vertical-align:top">&#042; </SUP></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and
Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#147;Company&#148;), and John Nicholson, Senior Vice
President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company&#146;s
Annual Report on Form 10-K, for the year ended December&nbsp;31, 2014, to which this Certification is attached as Exhibit 32.1 (the &#147;Annual Report&#148;), fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The information contained in the Annual Report fairly presents, in all material respects, the
financial condition and results of operations of the Company for the period covered by the Annual Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&nbsp;25, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; text-indent:0.00em; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Howard W. Robin</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="text-indent:0.00em; font-size:10pt; font-family:Times New Roman"><B>John Nicholson</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Chief&nbsp;Executive&nbsp;Officer,&nbsp;President&nbsp;and&nbsp;Director</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</B></P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#042;</TD>
<TD ALIGN="left" VALIGN="top">This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the
Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
</TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>nktr-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:nktr="http://www.nektar.com/20141231" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="nktr-20141231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20150220_0" unitRef="shares" decimals="INF" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_2_8">131381612</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_0_20120711_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_167BDD1E-1262-42A1-8576-E7A4E57A87B8_1_0">25000000</us-gaap:RestrictedCashAndCashEquivalents>
  <nktr:ConvertibleSubordinatedNotesRepaid contextRef="eol_PE10737---1410-K0010_STD_0_20120711_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_DA88A0AA-195D-4546-939E-356A3374AAA9_1_0">172400000</nktr:ConvertibleSubordinatedNotesRepaid>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE10737---1410-K0010_STD_0_20120711_0_1279211x1276340" unitRef="pure" decimals="INF" id="id_5242063_0F72FFB7-1B86-4863-984B-2C10B9D6964A_1001_3">0.120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1410-K0010_STD_0_20120711_0_1279211x1276340" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0F72FFB7-1B86-4863-984B-2C10B9D6964A_1001_0">125000000</us-gaap:SeniorLongTermNotes>
  <nktr:OperatingSublease contextRef="eol_PE10737---1410-K0010_STD_0_20090930_0_1281318x1560943" unitRef="sqft" decimals="0" id="id_5242063_65029C8C-EC12-4447-85AA-5275E903A25B_1001_0">126285</nktr:OperatingSublease>
  <dei:EntityPublicFloat contextRef="eol_PE10737---1410-K0010_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_3_9">1625943780</dei:EntityPublicFloat>
  <nktr:ContingentPaymentsReceivedBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20140916_0_1277733x1534371_1279908x1574670_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_CE0AB8FC-5542-4220-8280-5ADB4CA24318_2001_0">35000000</nktr:ContingentPaymentsReceivedBasedOnDevelopmentEvents>
  <nktr:PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies contextRef="eol_PE10737---1410-K0010_STD_0_20140916_0_1279908x1574670_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_7B9E6A34-34B4-4DA7-BA82-CC37A5D957C5_2001_2">35000000</nktr:PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1006_900001">197811000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_5001_0">13576000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2001_40">15312000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_5242063_6032059C-AA8D-4A19-B050-66CF246E8B58_1003_2">3100000</nktr:PreferredStockShareDesignated>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1004_700001">-1103000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1005_800001">-1398525000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1001_400002">114485000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1001_500001">11000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_1003_600001">1597428000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3006_900008">47018000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_4003_0">14067000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1003_40">25437000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3004_700008">-357000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3005_800008">-1570380000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3001_400009">115259000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3001_500008">11000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_3003_600008">1617744000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_45">116494000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_46">116494000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_44">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_41">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_43">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_38">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_37">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_40">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_27">125000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_25">10587000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_11">586040000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_31">82384000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2_5">84148000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PreferredStockValue contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_36" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_26">98221000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_28">8049000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_21">6917000</us-gaap:InterestPayableCurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_5242063_16E92588-B839-4777-9EBD-BBA2F3DDDE72_1002_0">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_42">11000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_34" />
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_48">-1181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_17">9115000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_49">-1732393000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_47">1643660000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_19">6243000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_50">-89903000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_32">19256000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_51">434527000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_5242063_16E92588-B839-4777-9EBD-BBA2F3DDDE72_1002_1">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_23">23664000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_4002_0">16363000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:Liabilities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_33">524430000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_18">14254000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_22">3536000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_13">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_6">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_2">39067000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConstructionInProgressGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2_7">6261000</us-gaap:ConstructionInProgressGross>
  <us-gaap:Goodwill contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_12">76501000</us-gaap:Goodwill>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_11">66974000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_2_2">197959000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_10">586190000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C1EB26C4-2C4E-4406-AF04-645D0B470E8D_2_2">25000000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_9">2539000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_3">35588000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_2">61707000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_4">25962000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_2_2">3359000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:CapitalLeasedAssetsGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_821E04AF-8B36-4975-A5BF-9ED1BD2C5689_2_0">2300000</us-gaap:CapitalLeasedAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_1">391385000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:Assets contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_14">434527000</us-gaap:Assets>
  <us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_821E04AF-8B36-4975-A5BF-9ED1BD2C5689_2_1">1000000</us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_14">150000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_12">150000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:InventoryNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_7">13452000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_2_0">3947000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_5">2229000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_4">197959000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_8">5175000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_13">8170000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_9">257882000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_7">14685000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_2_1">6146000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_10">25000000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2_4">144861000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:NumberOfCustomersAccountedForMajorAccountsReceivable contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="Customer" decimals="INF" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_4_0">3</nktr:NumberOfCustomersAccountedForMajorAccountsReceivable>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_24">7000000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent>
  <nktr:DeferredTaxAssetsCapitalizedResearchExpenses contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_6">17687000</nktr:DeferredTaxAssetsCapitalizedResearchExpenses>
  <nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_8">8580000</nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_3001_0">128520000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyalties>
  <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C1EB26C4-2C4E-4406-AF04-645D0B470E8D_2_3">262026000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
  <nktr:CashAndRestrictedCash contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_2_4">37614000</nktr:CashAndRestrictedCash>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_39">0</nktr:PreferredStockShareDesignated>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_30">121520000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
  <nktr:RefundableMilestonePaymentLiabilities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_29">70000000</nktr:RefundableMilestonePaymentLiabilities>
  <nktr:DepreciablePropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2_6">60713000</nktr:DepreciablePropertyPlantAndEquipmentNet>
  <nktr:LettersOfCreditOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0757E77B-9883-4519-A1DB-AA85F20B4344_1002_0">2400000</nktr:LettersOfCreditOutstanding>
  <nktr:DeferredTaxAssetsFromSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_2_5">28057000</nktr:DeferredTaxAssetsFromSaleOfFutureRoyalties>
  <nktr:AccruedClinicalTrialExpenses contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_2_20">16905000</nktr:AccruedClinicalTrialExpenses>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1269048_1274212x1268840" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_1002_0">138515000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1269048_1274212x1598263" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_2002_1">59444000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1272304_1274212x1277587" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_3002_3">26453000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_2001_0">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_2001_0">20655000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1271500" unitRef="iso4217_USD" decimals="-5" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_1002_0">57300000</us-gaap:PropertyPlantAndEquipmentNet>
  <nktr:PercentageOfPropertyPlantEquipmentNetInAssets contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1271500" unitRef="pure" decimals="2" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_1002_1">0.88</nktr:PercentageOfPropertyPlantEquipmentNetInAssets>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1274866" unitRef="iso4217_USD" decimals="-5" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_2002_2">7700000</us-gaap:PropertyPlantAndEquipmentNet>
  <nktr:PercentageOfPropertyPlantEquipmentNetInAssets contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1274866" unitRef="pure" decimals="2" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_2002_3">0.12</nktr:PercentageOfPropertyPlantEquipmentNetInAssets>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1269313" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1002_2">23699000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1274094" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2002_3">23235000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1457720" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_3002_1">26621000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1542878" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_4002_0">71306000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_5242063_6032059C-AA8D-4A19-B050-66CF246E8B58_1002_2">0</nktr:PreferredStockShareDesignated>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_5004_700015">-1181000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_5005_800015">-1732393000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_5001_400016">116494000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_5001_500015">11000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_5003_600015">1643660000</us-gaap:StockholdersEquity>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20131231_0_1277551x1274174" unitRef="iso4217_USD" decimals="INF" id="id_5242063_615DCA30-9E80-4570-9821-1A34321FFFD4_1002_0">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_45">131216000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_46">131216000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_371B9831-4CF8-4DED-A6AD-4112C475ABA8_3_1">10.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_44">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_41">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_43">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_38">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_37">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_40">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_27">125000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_25">5567000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_11">595690000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_31">76911000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_5">8651000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_2">175000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_1">4268000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1_5">93807000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PreferredStockValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_36" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_5">452000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_26">64047000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_28">4139000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_21">6917000</us-gaap:InterestPayableCurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_5242063_16E92588-B839-4777-9EBD-BBA2F3DDDE72_1001_0">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_42">13000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_34" />
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_48">-1567000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_17">2703000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_49">-1786309000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_7300D30C-2872-41A4-92D9-1E92E653891D_1_0">16900000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_3">5187000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_0">5572000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_47">1824195000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_19">6418000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_50">36332000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_32">14721000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_6">25662000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_4">5344000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_2">5037000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_51">441621000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_5242063_16E92588-B839-4777-9EBD-BBA2F3DDDE72_1001_1">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_3">10015000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0DA3EC88-CEF8-4183-AED5-3180E639BCAB_1001_0">3900000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_23">24473000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_4001_10">27522000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_1">4892000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:Liabilities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_33">405289000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_18">5749000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_22">4512000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:PurchaseObligation contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E5A14F23-DEEF-4544-847B-77BB4ED18D5F_1001_1">7200000</us-gaap:PurchaseObligation>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C9D149AD-5063-4B60-9325-7082A981C83B_1001_0">4750000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_13">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_6">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_224B436C-E884-4BD8-94F7-39C5B24DFF66_1_4">1364000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_2">12365000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConstructionInProgressGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1_7">16309000</us-gaap:ConstructionInProgressGross>
  <us-gaap:Goodwill contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_12">76501000</us-gaap:Goodwill>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_11">70368000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_3">25000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_1_2">225459000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_10">595866000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_C1EB26C4-2C4E-4406-AF04-645D0B470E8D_1_2">25000000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_9">2218000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_3">29758000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_2">66666000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_4">21948000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_1_2">5565000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:CapitalLeasedAssetsGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_821E04AF-8B36-4975-A5BF-9ED1BD2C5689_1_0">2700000</us-gaap:CapitalLeasedAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_1">423776000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:Assets contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_14">441621000</us-gaap:Assets>
  <us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_821E04AF-8B36-4975-A5BF-9ED1BD2C5689_1_1">1200000</us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_14">176000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_12">176000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_83596BE7-921D-4B35-8B35-2A9D73BE4090_1001_0">51900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:InventoryNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_7">12952000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_1_0">2200000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_5">3607000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_4">225459000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_8">8817000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_13">6552000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_9">288200000</us-gaap:AssetsCurrent>
  <us-gaap:CapitalLeasesFutureMinimumSubleaseRentals contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D470B5CD-08D1-4837-B686-9352E6FCE9CB_1_0">4800000</us-gaap:CapitalLeasesFutureMinimumSubleaseRentals>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_7">8288000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_CB76D908-5B2F-403F-B059-EB87D4FC1746_1_1">5187000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1_4">147866000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:NumberOfCustomersAccountedForMajorAccountsReceivable contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="Customer" decimals="INF" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_3_0">3</nktr:NumberOfCustomersAccountedForMajorAccountsReceivable>
  <nktr:RestrictedStockUnitsOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5242063_3C4A536B-3B85-4C97-95BF-496B1922193D_2001_2">0</nktr:RestrictedStockUnitsOutstanding>
  <nktr:DebtCapitalLeaseAndOtherLongTermLiabilities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_480CF8DE-58BA-49A8-88BD-7CC1795997E3_1_1">151800000</nktr:DebtCapitalLeaseAndOtherLongTermLiabilities>
  <nktr:DeferredTaxAssetsCapitalizedResearchExpenses contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_6">14795000</nktr:DeferredTaxAssetsCapitalizedResearchExpenses>
  <nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_8">8264000</nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_1001_5">120471000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyalties>
  <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_480CF8DE-58BA-49A8-88BD-7CC1795997E3_1_0">262824000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
  <nktr:CashAndRestrictedCash contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_1_4">26136000</nktr:CashAndRestrictedCash>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_39">0</nktr:PreferredStockShareDesignated>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_30">120471000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
  <nktr:DepreciablePropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1_6">54059000</nktr:DepreciablePropertyPlantAndEquipmentNet>
  <nktr:LettersOfCreditOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0757E77B-9883-4519-A1DB-AA85F20B4344_1001_0">2400000</nktr:LettersOfCreditOutstanding>
  <nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_207653D4-92CA-4A46-AC5F-EABFB19EB484_3_2">2812000</nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_207653D4-92CA-4A46-AC5F-EABFB19EB484_3_1">21995000</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding>
  <nktr:DeferredTaxAssetsFromSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_027A0E36-DB70-43C0-B6E8-33C4C0941560_1_5">20153000</nktr:DeferredTaxAssetsFromSaleOfFutureRoyalties>
  <nktr:AccruedClinicalTrialExpenses contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_59FD44D9-ED0D-4E49-8B0E-017161B542CD_1_20">7708000</nktr:AccruedClinicalTrialExpenses>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1269048_1274212x1268840" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_1001_0">182544000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1269048_1274212x1598263" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_2001_1">42915000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1272304_1274212x1277587" unitRef="iso4217_USD" decimals="-3" id="id_5242063_1EA333BF-D5F4-4790-8637-EAAABD91FD92_3001_3">11229000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1269523x1275948_1270313x1495054" unitRef="shares" decimals="INF" id="id_5242063_D1403907-907F-4300-ABB0-D5BA3D1A0AE8_1001_0">10347140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1001_5">21338000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1001_4">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1001_6">13007000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1001_6">8.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1001_5">10.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1001_4">21995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-3" id="id_5242063_520F10A5-FB52-4280-A7FA-4C3F03E56A52_1001_0">112549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-3" id="id_5242063_520F10A5-FB52-4280-A7FA-4C3F03E56A52_1001_1">111071000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-3" id="id_5242063_520F10A5-FB52-4280-A7FA-4C3F03E56A52_1001_2">85839000</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1277228" unitRef="shares" decimals="INF" id="id_5242063_97A846A7-477C-4A6C-B21E-0A65102A3437_2001_0">2500000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1348884" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_371B9831-4CF8-4DED-A6AD-4112C475ABA8_2_1">9.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1348884" unitRef="shares" decimals="-3" id="id_5242063_207653D4-92CA-4A46-AC5F-EABFB19EB484_2_1">3394000</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1411249" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_371B9831-4CF8-4DED-A6AD-4112C475ABA8_1_1">10.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1411249" unitRef="shares" decimals="-3" id="id_5242063_207653D4-92CA-4A46-AC5F-EABFB19EB484_1_2">2812000</nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1411249" unitRef="shares" decimals="-3" id="id_5242063_207653D4-92CA-4A46-AC5F-EABFB19EB484_1_1">18601000</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding>
  <nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1495054" unitRef="shares" decimals="INF" id="id_5242063_3C4A536B-3B85-4C97-95BF-496B1922193D_3001_0">1.5</nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1271500" unitRef="iso4217_USD" decimals="-5" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_1001_0">63700000</us-gaap:PropertyPlantAndEquipmentNet>
  <nktr:PercentageOfPropertyPlantEquipmentNetInAssets contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1271500" unitRef="pure" decimals="2" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_1001_1">0.90</nktr:PercentageOfPropertyPlantEquipmentNetInAssets>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1271500_1279908x1574670" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D99F4D10-1FDE-4438-B811-FC6B85E608B1_1001_1">100000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1272262_1279908x1574670" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D99F4D10-1FDE-4438-B811-FC6B85E608B1_2001_2">40000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1274866" unitRef="iso4217_USD" decimals="-5" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_2001_2">6700000</us-gaap:PropertyPlantAndEquipmentNet>
  <nktr:PercentageOfPropertyPlantEquipmentNetInAssets contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1274866" unitRef="pure" decimals="2" id="id_5242063_5153F98F-7BE2-4D5D-BA8A-BE52A159E05A_2001_3">0.10</nktr:PercentageOfPropertyPlantEquipmentNetInAssets>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1269313" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_1001_2">25212000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1274094" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_2001_3">23451000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1457720" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_3001_1">26975000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:DepreciablePropertyPlantAndEquipmentGross contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1542878" unitRef="iso4217_USD" decimals="-3" id="id_5242063_EDD961B4-1BCF-4128-9BB8-3C21FA278654_4001_0">72228000</nktr:DepreciablePropertyPlantAndEquipmentGross>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_5242063_6032059C-AA8D-4A19-B050-66CF246E8B58_1001_2">0</nktr:PreferredStockShareDesignated>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_7004_700025">-1567000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_7005_800025">-1786309000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_5242063_3C5F863D-DB84-453B-9660-B251C19D7E0D_1001_0">24806565</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:SharesOutstanding contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_7001_400026">131216000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_7001_500025">13000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_7003_600025">1824195000</us-gaap:StockholdersEquity>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1274174" unitRef="iso4217_USD" decimals="INF" id="id_5242063_615DCA30-9E80-4570-9821-1A34321FFFD4_1001_0">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1336336" unitRef="iso4217_USD" decimals="0" id="id_5242063_4F6FBBE7-E92D-41D5-A672-0AA5A335C2BF_1001_0">1000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
  <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1446321" unitRef="iso4217_USD" decimals="0" id="id_5242063_4F6FBBE7-E92D-41D5-A672-0AA5A335C2BF_2001_1">500000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
  <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1613541" unitRef="iso4217_USD" decimals="0" id="id_5242063_4F6FBBE7-E92D-41D5-A672-0AA5A335C2BF_3001_2">1500000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1277733x1431967_1279908x1574670" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D99F4D10-1FDE-4438-B811-FC6B85E608B1_3001_0">140000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279211x1276340" unitRef="pure" decimals="INF" id="id_5242063_480CF8DE-58BA-49A8-88BD-7CC1795997E3_1001_3">0.120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279211x1276340" unitRef="iso4217_USD" decimals="-5" id="id_5242063_480CF8DE-58BA-49A8-88BD-7CC1795997E3_1001_5">25000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1422248_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_4AF9149D-FF57-48D6-914E-5476D83CDCD8_2002_0">5100000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="INF" id="id_5242063_6301DF67-F49B-4A52-87F2-029C3778D110_1002_1">0</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1492025_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_C4652FE9-9847-4304-9012-97A703816B57_2001_1">4600000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1497306_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D85E0C23-00E3-4206-83EF-DBBC5BA30E04_2002_1">10700000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1572230_1281318x1572225" unitRef="iso4217_USD" decimals="-5" id="id_5242063_26B08853-E7FD-40A5-8E30-A16E40C2C31B_1002_1">18900000</us-gaap:DeferredRevenue>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1574669_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E1F649C9-A715-4039-BE0E-9E4C6E76B816_2002_2">75000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1574670_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E1F649C9-A715-4039-BE0E-9E4C6E76B816_3002_1">140000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280323x1400250" unitRef="pure" decimals="INF" id="id_5242063_12F159BC-1E9D-414B-B4FF-9E3785594449_1001_0">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:SeniorNotes contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280323x1400250" unitRef="iso4217_USD" decimals="-5" id="id_5242063_12F159BC-1E9D-414B-B4FF-9E3785594449_1001_2">125000000</us-gaap:SeniorNotes>
  <nktr:MinimumRequiredCashBalance contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280323x1466165" unitRef="iso4217_USD" decimals="-5" id="id_5242063_2AA5A40A-03CE-473A-B14E-CB0C25604BE2_1001_0">25000000</nktr:MinimumRequiredCashBalance>
  <nktr:CumulativeGrossIncomeTaxResearchCredits contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_5242063_56F04FDE-2E72-4FAA-8B91-854C3ECE447B_2001_2">22600000</nktr:CumulativeGrossIncomeTaxResearchCredits>
  <nktr:NetOperatingLossCarryforwardForIncomeTax contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F8D6AC6C-9E11-4EDC-8681-2C30828EAC10_3001_2">709200000</nktr:NetOperatingLossCarryforwardForIncomeTax>
  <nktr:NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F8D6AC6C-9E11-4EDC-8681-2C30828EAC10_3001_3">124600000</nktr:NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets>
  <nktr:NetOperatingLossCarryforwardForIncomeTax contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F8D6AC6C-9E11-4EDC-8681-2C30828EAC10_4001_0">1131800000</nktr:NetOperatingLossCarryforwardForIncomeTax>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1281318x1314996" unitRef="iso4217_USD" decimals="-5" id="id_5242063_CB4F6450-F77E-4622-A677-A554700A420B_1001_0">29200000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_0_20141231_0_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_4D091578-E176-4901-BDD5-74DF9CF57932_2001_1">20800000</us-gaap:DeferredRevenue>
  <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross contextRef="eol_PE10737---1410-K0010_STD_1_20120224_0_1279908x1457294" unitRef="iso4217_USD" decimals="-5" id="id_5242063_A23806BC-5957-4675-8366-91CC6DFE69D5_1001_0">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
  <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_1_20120224_0_1279908x1457294" unitRef="iso4217_USD" decimals="-5" id="id_5242063_A23806BC-5957-4675-8366-91CC6DFE69D5_1001_1">4400000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
  <nktr:PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired contextRef="eol_PE10737---1410-K0010_STD_1_20140916_0_1279908x1574670_1281318x1367107" unitRef="pure" decimals="2" id="id_5242063_7B9E6A34-34B4-4DA7-BA82-CC37A5D957C5_1001_0">0.02</nktr:PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_1_20140916_0_1279908x1574670_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_CE0AB8FC-5542-4220-8280-5ADB4CA24318_1002_1">70000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:PercentageOfPostApprovalStudyCostsToRepay contextRef="eol_PE10737---1410-K0010_STD_1_20140916_0_1279908x1574670_1281318x1367107" unitRef="pure" decimals="2" id="id_5242063_7B9E6A34-34B4-4DA7-BA82-CC37A5D957C5_1001_1">0.33</nktr:PercentageOfPostApprovalStudyCostsToRepay>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE10737---1410-K0010_STD_1_20140128_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_308CC111-4FED-46C9-812C-1E6ED37A23E7_1_1">117200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE10737---1410-K0010_STD_1_20140128_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_308CC111-4FED-46C9-812C-1E6ED37A23E7_1001_0">9775000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE10737---1410-K0010_STD_1_20140128_0_1276401x1270422" unitRef="iso4217_USD" decimals="-5" id="id_5242063_308CC111-4FED-46C9-812C-1E6ED37A23E7_1001_2">600000</us-gaap:PaymentsOfStockIssuanceCosts>
  <nktr:UnderwritersCommissionsAndDiscount contextRef="eol_PE10737---1410-K0010_STD_1_20140128_0_1276401x1270422" unitRef="iso4217_USD" decimals="-5" id="id_5242063_308CC111-4FED-46C9-812C-1E6ED37A23E7_1001_3">7500000</nktr:UnderwritersCommissionsAndDiscount>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE10737---1410-K0010_STD_1_20141231_0_1280323x1400250" id="id_5242063_12F159BC-1E9D-414B-B4FF-9E3785594449_1002_1">2017-07-15</us-gaap:DebtInstrumentMaturityDate>
  <nktr:PartialRepaymentOfRoyaltySaleProceeds contextRef="eol_PE10737---1410-K0010_STD_1041_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_2_2">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
  <nktr:ProceedsFromSaleOfPotentialFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_1041_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_2_1">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyalties>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_1041_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_2_3">54783000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1410-K0010_STD_1041_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_2_4">61254000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_29_20120229_0_1271118x1349198_1279908x1497306_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_B12E51AE-3184-494F-BB40-B3C5306FAADB_1001_1">22000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_29_20120229_0_1279908x1497306_1280342x1273416_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_B12E51AE-3184-494F-BB40-B3C5306FAADB_2001_0">5000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:AllocatedConsideration contextRef="eol_PE10737---1410-K0010_STD_29_20120229_0_1279908x1497306_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D85E0C23-00E3-4206-83EF-DBBC5BA30E04_1001_0">27000000</nktr:AllocatedConsideration>
  <nktr:PaymentForReimbursementOfCosts contextRef="eol_PE10737---1410-K0010_STD_30_20130630_0_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_21927EA5-9299-4E2F-83C1-956F253914D1_3002_3">10000000</nktr:PaymentForReimbursementOfCosts>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_30_20140630_0_1279908x1572230_1281318x1572225" unitRef="iso4217_USD" decimals="-4" id="id_5242063_26B08853-E7FD-40A5-8E30-A16E40C2C31B_1001_0">19750000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE10737---1410-K0010_STD_31_20120731_0_1279211x1276340" id="id_5242063_0F72FFB7-1B86-4863-984B-2C10B9D6964A_1003_1">2017-07-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtIssuanceCosts contextRef="eol_PE10737---1410-K0010_STD_31_20120731_0_1279211x1276340" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0F72FFB7-1B86-4863-984B-2C10B9D6964A_1003_4">4500000</us-gaap:DebtIssuanceCosts>
  <nktr:DebtInstrumentExchangedAmount contextRef="eol_PE10737---1410-K0010_STD_31_20120731_0_1279211x1277063" unitRef="iso4217_USD" decimals="-5" id="id_5242063_0F72FFB7-1B86-4863-984B-2C10B9D6964A_2003_2">42500000</nktr:DebtInstrumentExchangedAmount>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_31_20091231_0_1280342x1459186_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_4AF9149D-FF57-48D6-914E-5476D83CDCD8_1001_1">31000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_365_20071231_0_1280342x1273416_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_21927EA5-9299-4E2F-83C1-956F253914D1_2003_0">40000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_2_2">0.612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_20">-38527000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_2_1">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_2_3">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_2_0">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_22">115732000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_21">-1.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_23">268068000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_44">1014000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_2_1">1300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_2_2">-268000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_551DC194-04C2-4CC9-93DB-82D22D2C18D5_2_0">51800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6006_900010">8208000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_1">44846000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_29">2992000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6006_900013">-824000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_11">-6423000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_10">-4817000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_889BDEDA-6B0F-4AA9-9236-633C64D7E129_2_0">2900000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_12">-120130000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_8">6273000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_2_6">-162837000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_17">-39638000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_18">-159768000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_2">1148000</us-gaap:RoyaltyRevenue>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_16">1124000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_5">148921000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_26">4091000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_7">-664000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_20">-162013000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_43">17590000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_9">-3576000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6006_900012">17708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_2_0">-161068000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_5">17708000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_9">406000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_38">32000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_9">1286000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_17">-12399000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_13">5481000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_14">18453000</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_8">190010000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2_3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2_8">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_7">49000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_2_3">-470000</us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_39">13630000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_8">-65000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_7">-20000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_1">-55919000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_19">2245000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_7">38509000</us-gaap:CostOfGoodsSold>
  <us-gaap:Depreciation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E5A14F23-DEEF-4544-847B-77BB4ED18D5F_2_0">13000000</us-gaap:Depreciation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_6">14275000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_2A4FEDD4-3B17-4A83-97CB-B523C81B3B28_2_0">4100000</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_16">-166000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_37">2216000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_36">8208000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_3A04D355-5B32-4D2D-85A3-134942F6D202_2_2">1000000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_4">7808000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_5">271000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_14">-1915000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_27">49909000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_3">1838000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_4">1839000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_11">269051000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_2">50000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_8107F019-451C-4118-AA37-920815648F07_2_0">2900000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_2_4">1026000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_9">40532000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_12">6199000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_22">319181000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_24">2887000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_2_3">17708000</us-gaap:ShareBasedCompensation>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_2_6">422000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_2_3">55042000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_19">9164000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_31">-3000000</nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts>
  <nktr:IncreaseDecreaseInMilestonePaymentLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_18">70000000</nktr:IncreaseDecreaseInMilestonePaymentLiabilities>
  <nktr:PercentageOfAccountsReceivableCustomersTwo contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_2_2">0.28</nktr:PercentageOfAccountsReceivableCustomersTwo>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_4">80872000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:ValuationAllowanceRelatedToStockBasedCompensationAndExercises contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_551DC194-04C2-4CC9-93DB-82D22D2C18D5_2_1">35600000</nktr:ValuationAllowanceRelatedToStockBasedCompensationAndExercises>
  <nktr:PercentageOfAccountsReceivableCustomersThree contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_2_3">0.28</nktr:PercentageOfAccountsReceivableCustomersThree>
  <nktr:PercentageOfAccountsReceivableCustomersOne contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_2_1">0.30</nktr:PercentageOfAccountsReceivableCustomersOne>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_3">22055000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_15">-595000</nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_2_15">22309000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_2_46">2000000</nktr:PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1268687x1281225" unitRef="shares" decimals="-5" id="id_5242063_EA3D7819-BB85-4F9F-A608-B147069DB7A4_1002_0">20700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_5242063_3C4A536B-3B85-4C97-95BF-496B1922193D_1002_1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_2_0">4.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_2_2">14100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_2_1">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270436x1272891_1273333x1270636" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_1002_2">106386000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1270436x1272891_1273333x1271500" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_2002_1">42535000</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_1002_2">8501000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1270466" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_2002_0">1297000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1383680" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_3002_1">7910000</us-gaap:ShareBasedCompensation>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1354061_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_2002_1">0.21</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1385879_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_3002_0">0.17</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1404400_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_4002_3">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1465729_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_5002_2">0.28</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6004_700013">-824000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6005_800014">-162013000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6001_400011">1235000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6003_600010">8208000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_6003_600012">17708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1348036" unitRef="iso4217_USD" decimals="-5" id="id_5242063_69EC82E4-6A9E-4089-968E-89D7AFC0A09D_1002_0">22100000</nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1364415_1281318x1505467" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_1002_4">15293000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1425630_1281318x1313684" unitRef="iso4217_USD" decimals="-5" id="id_5242063_B8D639E6-FE59-4853-BA23-876B7C78C465_1001_0">6700000</us-gaap:DeferredRevenueRevenueRecognized>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1425630_1281318x1313684" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_2002_5">7149000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_3002_2">1702000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1492025_1281318x1465729" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_4002_1">18382000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1570062_1281318x1314996" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_5002_3">5035000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1591145_1281318x1367107" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_6002_0">25016000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1274075" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_1002_6">802000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2002_2">381000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3002_4">636000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3002_1">477000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20131231_0_1281318x1358779" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_7002_6">8295000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_10EDAD65-E0CD-43BD-8D8F-89772639B3D1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;10&amp;#xA0;&amp;#x2014; License and Collaboration
 Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have entered
 into various collaboration agreements including license agreements
 and collaborative research, development and commercialization
 agreements with various pharmaceutical and biotechnology companies.
 Under these collaboration arrangements, we are entitled to receive
 license fees, upfront payments, milestone payments, royalties,
 sales milestones, and payments for the manufacture and supply of
 our proprietary PEGylation materials and/or reimbursement for
 research and development activities. All of our collaboration
 agreements are generally cancelable by our partners without
 significant financial penalty. Our costs of performing these
 services are generally included in research and development
 expense, except that costs for product sales to our collaboration
 partners are included in cost of goods sold.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In accordance
 with our collaboration agreements, we recognized license,
 collaboration and other revenue as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="40%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="39%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 26pt"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Partner&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1px; MARGIN-TOP: 0px" align="center"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Agreement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;AstraZeneca AB&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(NKTR-118) and
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination program (NKTR-119)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;105,001&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Roche&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,845&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,382&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,146&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Baxter
 Healthcare&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;BAX 855 (Hemophilia)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,258&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,702&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amgen, Inc.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Neulasta&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,035&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Bayer Healthcare
 LLC&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;BAY41-6551 (Amikacin Inhale)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,717&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,293&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,971&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Affymax, Inc.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;OMONTYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,149&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,829&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,468&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,295&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,884&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;License, collaboration and
 other revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;153,289&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;80,872&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;30,127&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As of
 December&amp;#xA0;31, 2014, our collaboration agreements with partners
 included potential future payments for development milestones
 totaling approximately $130.3 million, including amounts from our
 agreements with Baxter and Bayer described below. In addition, we
 are entitled to receive the contingent payments described below
 related to the MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(previously
 referred to as naloxegol and NKTR-118) and
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination (previously referred to as NKTR-119) drug development
 programs, respectively, based on development and regulatory events
 to be pursued and completed solely by AstraZeneca.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;AstraZeneca AB&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: MOVANTIK&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 (naloxegol oxalate), previously referred to as naloxegol and
 NKTR-118, and MOVANTIK&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 fixed-dose combination program, previously referred to as
 NKTR-119&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In September
 2009, we entered into a license agreement with AstraZeneca AB
 (AstraZeneca), as amended by AstraZeneca and us in August 2013,
 under which we granted AstraZeneca a worldwide, exclusive,
 perpetual, royalty-bearing, and sublicensable license under our
 patents and other intellectual property to develop, market, and
 sell MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;and
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination program. AstraZeneca is responsible for all costs
 associated with research, development and commercialization and is
 responsible for all drug development and commercialization
 decisions for MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;and the
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination program. AstraZeneca paid us an upfront payment of
 $125.0&amp;#xA0;million, which we received in the fourth quarter of
 2009 and which was fully recognized as of December&amp;#xA0;31, 2010.
 As of December&amp;#xA0;31, 2014, we are entitled to receive up to an
 additional $140.0 million and $75.0 million of contingent payments
 related to MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;and the
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination program, respectively, based on development events to
 be pursued and completed solely by AstraZeneca, as described
 below.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 September&amp;#xA0;16, 2014, the United States Food and Drug
 Administration (FDA) approved MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;for the
 treatment of opioid-induced constipation (OIC) in adult patients
 with chronic, non-cancer pain. On December&amp;#xA0;9, 2014,
 AstraZeneca announced that MOVENTIG&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (the naloxegol brand name in the European Union) has been granted
 Marketing Authorisation by the European Commission (EC) for the
 treatment of opioid-induced constipation (OIC) in adult patients
 who have had an inadequate response to laxative(s). As a result of
 the FDA&amp;#x2019;s approval, on September&amp;#xA0;16, 2014, we were
 entitled to a $35.0 million non-refundable payment from
 AstraZeneca, which was fully recognized as revenue in September
 2014 and was received in October 2014. In addition, the FDA&amp;#x2019;s
 approval of MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;extinguished
 our contingent obligation to repay the $70.0 million payment made
 to us by AstraZeneca in November 2013 after the
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;New Drug
 Application was accepted for review by the FDA. As a result, in
 September 2014, we fully recognized this $70.0 million payment,
 which was previously recorded in the line item &amp;#x201C;Liability
 related to receipt of refundable milestone payment&amp;#x201D; on our
 Consolidated Balance Sheet at December 31, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As part of its
 approval of MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;, the FDA required AstraZeneca to perform a
 post-marketing, observational epidemiological study comparing
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;to other
 treatments of OIC in patients with chronic, non-cancer pain. As a
 result, the royalty rate payable to us from net sales of
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;in the U.S. by
 AstraZeneca will be reduced by up to two percentage points to fund
 33% of the external costs incurred by AstraZeneca to fund such post
 approval study subject to a $35.0 million aggregate cap. Any costs
 incurred by AstraZeneca can only be recovered by the reduction of
 the royalty paid to us. In no case can amounts be recovered by the
 reduction of a contingent payment due from AstraZeneca to us or
 through a payment from us to AstraZeneca.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We will be
 entitled to up to an additional $140.0 million of contingent
 payments upon the first commercial sale of
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;, $100.0 million of which will be payable upon the first
 commercial sale in the U.S. and $40.0 million of which will be
 payable upon the first commercial sale in one major European Union
 country. We are also entitled to receive up to $75.0 million of
 commercial launch contingent payments related to the
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination program, based on development events to be pursued and
 completed solely by AstraZeneca. In addition, we are entitled to
 royalties and sales milestone payments based on annual worldwide
 net sales of MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;and
 MOVANTIK&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;TM&lt;/sup&gt;&lt;/font&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;fixed-dose
 combination products.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Roche&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: PEGASYS&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;
 and MIRCERA&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In February
 1997, we entered into a license, manufacturing and supply agreement
 with Roche, under which we granted Roche a worldwide, exclusive
 license to certain intellectual property related to our proprietary
 PEGylation materials used in the manufacture and commercialization
 of PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.
 As a result of Roche exercising a license extension option in
 December 2009, Roche has the right to manufacture all of its
 requirements for our proprietary PEGylation materials for
 PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and we perform additional manufacturing, if any, only on an
 as-requested basis. In connection with Roche&amp;#x2019;s exercise of
 the license extension option in December 2009, we received a
 payment of $31.0&amp;#xA0;million. As of December&amp;#xA0;31, 2014, we
 have deferred revenue of approximately $5.1 million related to this
 agreement, which we expect to recognize through December 2015, the
 period through which we are required to provide back-up
 manufacturing and supply services related to PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In February
 2012, we entered into a toll-manufacturing agreement with Roche
 under which we will manufacture the proprietary PEGylation material
 used by Roche to produce MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.
 Roche entered into the toll-manufacturing agreement with the
 objective of establishing us as a secondary back-up supply source
 on a non-exclusive basis. Under the terms of our toll-manufacturing
 agreement, Roche paid us an upfront payment of $5.0 million and an
 additional $22.0 million in performance-based milestone payments
 upon our achievement of certain manufacturing readiness, validation
 and production milestones, including the delivery of specified
 quantities of PEGylation materials, all of which were completed as
 of January 2013. Roche will also pay us additional consideration
 for any future orders of the PEGylation materials for
 MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 beyond the initial quantities manufactured through January
 2013.&amp;#xA0;Roche has the right to terminate the toll-manufacturing
 agreement due to an uncured material default by us.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We analyzed the
 milestone payments under the agreement and determined that they did
 not meet the criteria for revenue recognition under the milestone
 method as a result of our continuing manufacturing obligations. We
 have identified our back-up manufacturing obligation through
 December 2016 and the delivery of PEGylation materials specified in
 the agreement in 2012 and early 2013 as the units of accounting in
 the arrangement. We made our best estimate of the selling prices
 for these deliverables and have allocated the total $27.0 million
 consideration to these items based on the relative selling price
 method. As of December&amp;#xA0;31, 2014, we have deferred revenue of
 approximately $10.7&amp;#xA0;million, which we expect to recognize
 through December 2016, the estimated end of our obligations under
 this agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2013,
 we agreed to deliver additional quantities of PEGylation materials
 used by Roche to produce PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
 all of which were delivered in the last quarter of 2013, for total
 consideration of $18.6 million. We determined that these
 incremental activities should be considered a material modification
 of the existing PEGASYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 -related arrangements described above. As a result, we allocated
 the $18.6 million consideration to each of these arrangements and
 determined the amounts to be recognized or deferred based on the
 estimated selling prices of the undelivered obligations. As of
 December&amp;#xA0;31, 2014, we have deferred revenue of approximately
 $4.6&amp;#xA0;million related to these activities, which we expect to
 recognize through December 2016, the estimated end of our
 obligations under the modified arrangements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Baxter
 Healthcare&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: BAX 855/Hemophilia&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In September
 2005, we entered into an exclusive research, development, license
 and manufacturing and supply agreement with Baxter Healthcare SA
 and Baxter Healthcare Corporation (together referred to as Baxter)
 to develop products designed to improve therapies for Hemophilia A
 patients using our PEGylation technology. Under the terms of the
 agreement, we are entitled to research and development funding and
 are responsible for supplying Baxter with its requirements for our
 proprietary materials. Baxter is responsible for all clinical
 development, regulatory, and commercialization expenses. The
 agreement is terminable by the parties under customary
 conditions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Under the terms
 of this agreement, as of December&amp;#xA0;31, 2014, we are entitled to
 up to $20.0 million of development milestones related to Hemophilia
 A upon achievement of certain development objectives, as well as
 sales milestones upon achievement of annual sales targets and
 royalties based on annual worldwide net sales of products resulting
 from this agreement. This Hemophilia A program includes BAX 855. In
 August 2014, Baxter announced positive top-line results from its
 Phase 3 pivotal clinical trial of BAX 855 which met the primary
 endpoint for the control and prevention of bleeding, routine
 prophylaxis and perioperative management for patients who were 12
 years or older. As a result of this Phase 3 clinical trial meeting
 its primary endpoint, we achieved development milestones totaling
 $8.0 million. Given our significant efforts in the development of
 this product, we consider these milestones to be substantive and we
 recognized the milestones in their entirety in the year ended
 December&amp;#xA0;31, 2014. As of December&amp;#xA0;31, 2014, we do not
 have significant deferred revenue related to this
 agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Amgen,
 Inc.&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: Neulasta&lt;/i&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 &lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October
 2010, we amended and restated an existing supply and license
 agreement by entering into a supply, dedicated suite and
 manufacturing guarantee agreement (the amended and restated
 agreement) and a license agreement with Amgen Inc. and Amgen
 Manufacturing, Limited (together referred to as Amgen). Under the
 terms of the amended and restated agreement, we guarantee the
 manufacture and supply of our proprietary PEGylation materials
 (Polymer Materials) to Amgen in an existing manufacturing suite to
 be used exclusively for the manufacture of Polymer Materials for
 Amgen (the Manufacturing Suite) in our manufacturing facility in
 Huntsville, Alabama (the Facility). This supply arrangement is on a
 non-exclusive basis (other than the use of the Manufacturing Suite
 and certain equipment) whereby we are free to manufacture and
 supply the Polymer Materials to any other third party and Amgen is
 free to procure the Polymer Materials from any other third party.
 Under the terms of the amended and restated agreement, we received
 a $50.0 million payment in the fourth quarter of 2010 in return for
 our guaranteeing the supply of certain quantities of Polymer
 Materials to Amgen including without limitation the Additional
 Rights described below and manufacturing fees that are calculated
 based on fixed and variable components applicable to the Polymer
 Materials ordered by Amgen and delivered by us. Amgen has no
 minimum purchase commitments. If quantities of the Polymer
 Materials ordered by Amgen exceed specified quantities, significant
 additional payments become payable to us in return for our
 guaranteeing the supply of additional quantities of the Polymer
 Materials.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The term of the
 amended and restated agreement ends on October&amp;#xA0;29, 2020. In
 the event we become subject to a bankruptcy or insolvency
 proceeding, we cease to own or control the Facility, we fail to
 manufacture and supply or certain other events, Amgen or its
 designated third party will have the right to elect, among certain
 other options, to take title to the dedicated equipment and access
 the Facility to operate the Manufacturing Suite solely for the
 purpose of manufacturing the Polymer Materials (the Additional
 Rights). Amgen may terminate the amended and restated agreement for
 convenience or due to an uncured material default by us. Our
 research facility in Huntsville, Alabama that we propose to sell is
 a different building and location from that of the Facility
 described here.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As of
 December&amp;#xA0;31, 2014, we have deferred revenue of approximately
 $29.2&amp;#xA0;million related to this agreement, which we expect to
 recognize through October 2020, the estimated end of our
 obligations under this agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Bayer Healthcare
 LLC&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: BAY41-6551 (Amikacin Inhale)&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2007,
 we entered into a co-development, license and co-promotion
 agreement with Bayer Healthcare LLC (Bayer) to develop a
 specially-formulated inhaled Amikacin. We are responsible for
 development and manufacturing and supply of the nebulizer device
 included in the Amikacin product. Bayer is responsible for most
 future clinical development and commercialization costs, all
 activities to support worldwide regulatory filings, approvals and
 related activities, further development of Amikacin Inhale and
 final product packaging and distribution. In the years prior to
 2014, we received an upfront payment of $40.0&amp;#xA0;million in 2007
 and milestone payments of $30.0&amp;#xA0;million, including a $10.0
 million development milestone which was achieved in 2013 as a
 result of the start of the Phase 3 clinical trial by Bayer in the
 treatment of intubated and mechanically ventilated patients with
 Gram-negative pneumonia in April 2013. In addition, in June 2013,
 we paid $10.0 million to Bayer for the reimbursement of its costs
 of the Phase 3 clinical trial.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In addition, we
 are entitled to receive a total of up to $50.0 million for
 development milestones upon achievement of certain development
 objectives, as well as sales milestones upon achievement of annual
 sales targets and royalties based on annual worldwide net sales of
 Amikacin Inhale. As of December&amp;#xA0;31, 2014, we have deferred
 revenue of approximately $20.8 million related to this agreement,
 which we expect to recognize through February 2028, the estimated
 end of our obligations under this agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Ophthotech Corporation&lt;/i&gt;&lt;/b&gt;&lt;i&gt;:
 Fovista&lt;/i&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 &lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are a party
 to an agreement with Ophthotech Corporation (Ophthotech), dated
 September&amp;#xA0;30, 2006, under which Ophthotech received a
 worldwide, exclusive license to certain of our proprietary
 PEGylation technology to develop, manufacture and sell
 Fovista&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.
 Under the terms of our agreement, we are the exclusive supplier of
 all of Ophthotech&amp;#x2019;s clinical and commercial requirements for
 our proprietary PEGylation reagent used in Fovista&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.
 On May&amp;#xA0;19, 2014, Ophthotech entered into a Licensing and
 Commercialization Agreement with Novartis Pharma AG for
 Fovista&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.
 Under our agreement with Ophthotech, we received a $19.75 million
 payment in connection with this licensing agreement in June 2014.
 As of December&amp;#xA0;31, 2014, we have deferred revenue of
 approximately $18.9 million related to this agreement, which we
 expect to recognize through March 2028, the estimated end of our
 obligations under our agreement with Ophthotech.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In addition, we
 are entitled to up to $9.5 million in additional payments based
 upon Ophthotech&amp;#x2019;s potential achievement of certain regulatory
 and sales milestones. We are also entitled to royalties on net
 sales of Fovista&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 that vary based on sales levels.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Affymax,
 Inc.&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: OMONTYS&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2004,
 we entered into a license, manufacturing and supply agreement with
 Affymax, Inc. (Affymax) under which we provided Affymax with a
 worldwide, non-exclusive license under certain of our proprietary
 PEGylation technology to develop, manufacture and commercialize
 OMONTYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (peginesatide). On February&amp;#xA0;23, 2013, Affymax and Takeda
 Pharmaceutical Company Limited announced a voluntary recall of all
 lots of OMONTYS&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;&amp;#xA0;drug
 product as a result of new post-marketing reports regarding serious
 hypersensitivity reactions, including anaphylaxis, which can be
 life-threatening or fatal.&amp;#xA0;In July 2013, Affymax terminated
 the license, manufacturing and supply agreement with
 Nektar.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
 received milestone and related payments under our agreement with
 Affymax and, as a result of the termination of our agreement with
 Affymax and our related performance obligations, we recognized the
 remaining $6.7 million of deferred revenue from this agreement in
 the year ended December&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Other&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the year
 ended December&amp;#xA0;31, 2014, two of our collaboration partners
 achieved the successful transfer of our commercial manufacturing
 process in connection with the PEGylation materials used in their
 products. In connection with our assistance with these
 manufacturing technology transfers, we received a total of $9.0
 million of milestone payments. We concluded that these payments are
 substantive milestones and recognized them in their entirety in the
 year ended December&amp;#xA0;31, 2014.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In addition, as
 of December&amp;#xA0;31, 2014, we have a number of collaboration
 agreements, including our collaboration partner UCB, under which we
 are entitled to up to a total of $53.8 million of development
 milestones upon achievement of certain development objectives, as
 well as sales milestones upon achievement of annual sales targets
 and royalties based on net sales of commercialized products, if
 any. However, given the current phase of development of the
 potential products under these collaboration agreements, we cannot
 estimate the probability or timing of achieving these
 milestones.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_C4CF293C-23C8-4BD2-8131-D7621AE80F3E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;8&amp;#xA0;&amp;#x2014;
 Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Royalty
 Expense&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have third
 party licenses that require us to pay royalties based on our sales
 of certain products and/or on our recognition of royalty revenue
 under certain of our collaboration agreements. Royalty expense,
 which is reflected in cost of goods sold in our Consolidated
 Statements of Operations, was approximately $3.4&amp;#xA0;million,
 $4.1&amp;#xA0;million, and $2.9&amp;#xA0;million for the years ended
 December&amp;#xA0;31, 2014, 2013, and 2012, respectively. The overall
 maximum amount of these obligations is based upon sales of the
 applicable products by our collaboration partners and cannot be
 reasonably estimated.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Purchase
 Commitments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In the normal
 course of business, we enter into various firm purchase commitments
 related to contract manufacturing, clinical development and certain
 other items. As of December&amp;#xA0;31, 2014, these commitments were
 approximately $16.9&amp;#xA0;million, all of which are expected to be
 paid in 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Legal
 Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to
 time, we are involved in lawsuits, arbitrations, claims,
 investigations and proceedings, consisting of intellectual
 property, commercial, employment and other matters, which arise in
 the ordinary course of business. We make provisions for liabilities
 when it is both probable that a liability has been incurred and the
 amount of the loss can be reasonably estimated. Such provisions are
 reviewed at least quarterly and adjusted to reflect the impact of
 settlement negotiations, judicial and administrative rulings,
 advice of legal counsel, and other information and events
 pertaining to a particular case. Litigation is inherently
 unpredictable. If any unfavorable ruling were to occur in any
 specific period, there exists the possibility of a material adverse
 impact on the results of operations of that period or on our cash
 flows and liquidity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Foreign
 Operations&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We operate in a
 number of foreign countries. As a result, we are subject to
 numerous local laws and regulations that can result in claims made
 by foreign government agencies or other third parties that are
 often difficult to predict even after the application of good faith
 compliance efforts.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Indemnification
 Obligations&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the
 course of our normal operating activities, we have agreed to
 certain contingent indemnification obligations as further described
 below. The term of our indemnification obligations is generally
 perpetual. There is generally no limitation on the potential amount
 of future payments we could be required to make under these
 indemnification obligations. To date, we have not incurred
 significant costs to defend lawsuits or settle claims based on our
 indemnification obligations. If any of our indemnification
 obligations is triggered, we may incur substantial liabilities.
 Because the aggregate amount of any potential indemnification
 obligation is not a stated amount, the overall maximum amount of
 any such obligations cannot be reasonably estimated. No liabilities
 have been recorded for these obligations on our Consolidated
 Balance Sheets as of December&amp;#xA0;31, 2014 or 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Indemnifications in
 Connection with Commercial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As part of our
 collaboration agreements with our partners related to the license,
 development, manufacture and supply of drugs based on our
 proprietary technologies and drug candidates, we generally agree to
 defend, indemnify and hold harmless our partners from and against
 third party liabilities arising out of the agreement, including
 product liability (with respect to our activities) and infringement
 of intellectual property to the extent the intellectual property is
 developed by us and licensed to our partners.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As part of the
 sale of our royalty interest in the CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 products, we and RPI made representations and warranties and
 entered into certain covenants and ancillary agreements which are
 supported by indemnity obligations. Additionally, as part of our
 pulmonary asset sale to Novartis in 2008, we and Novartis made
 representations and warranties and entered into certain covenants
 and ancillary agreements which are supported by an indemnity
 obligation. In the event it is determined that we breached certain
 of the representations and warranties or covenants and agreements
 made by us in any such agreements, we could incur substantial
 indemnification liabilities depending on the timing, nature, and
 amount of any such claims.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Indemnification of
 Underwriters and Initial Purchasers of our
 Securities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In connection
 with our sale of equity and senior secured debt securities, we have
 agreed to defend, indemnify and hold harmless our underwriters or
 initial purchasers, as applicable, as well as certain related
 parties from and against certain liabilities, including liabilities
 under the Securities Act of 1933, as amended.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Director and Officer
 Indemnifications&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As permitted
 under Delaware law, and as set forth in our Certificate of
 Incorporation and our Bylaws, we indemnify our directors, executive
 officers, other officers, employees, and other agents for certain
 events or occurrences that may arise while in such capacity. The
 maximum potential amount of future payments we could be required to
 make under this indemnification is unlimited; however, we have
 insurance policies that may limit our exposure and may enable us to
 recover a portion of any future amounts paid. Assuming the
 applicability of coverage, the willingness of the insurer to assume
 coverage, and subject to certain retention, loss limits and other
 policy provisions, we believe any obligations under this
 indemnification would not be material, other than an initial
 $1,500,000 per incident for merger and acquisition related claims,
 $1,000,000 per incident for securities related claims and $500,000
 per incident for non-securities related claims retention deductible
 per our insurance policy. However, no assurances can be given that
 the covering insurers will not attempt to dispute the validity,
 applicability, or amount of coverage without expensive litigation
 against these insurers, in which case we may incur substantial
 liabilities as a result of these indemnification
 obligations.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_0132BEC8-3288-472B-915B-06CB0C199F96_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per
 Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss
 per share is calculated based on the weighted-average number of
 common shares outstanding during the periods presented. For all
 periods presented in the Consolidated Statements of Operations, the
 net loss available to common stockholders is equal to the reported
 net loss. Basic and diluted net loss per share are the same due to
 our historical net losses and the requirement to exclude
 potentially dilutive securities which would have an anti-dilutive
 effect on net loss per share. During 2014, 2013 and 2012,
 potentially dilutive securities consisted of common shares
 underlying outstanding stock options and there were weighted
 average outstanding stock options of 21.9 million, 20.7 million and
 18.8 million during the years ended December 31, 2014, 2013 and
 2012, respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B291A71E-4646-469B-ACF1-6DB2EF0D94EF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In accordance with our collaboration agreements, we recognized
 license, collaboration and other revenue as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="39%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td width="37%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;Partner&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 AstraZeneca AB&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;MOVANTIK&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt; (NKTR-118) and
 MOVANTIK&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;
 fixed-dose combination program (NKTR-119)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;105,001&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;25,016&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;59&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Roche&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;PEGASYS&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; and
 MIRCERA&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Baxter Healthcare&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAX 855 (Hemophilia)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,258&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amgen, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Neulasta&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Bayer Healthcare LLC&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAY41-6551 (Amikacin Inhale)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,717&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Affymax, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;OMONTYS&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,829&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,884&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 License, collaboration and other revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,127&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_4D4F8B1C-F9EE-499D-B94A-7CC93B80BEE0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Income tax
 provision related to continuing operations differs from the amount
 computed by applying the statutory income tax rate of 35% to pretax
 loss as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;U.S. federal provision
 (benefit)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At statutory
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(55,919&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(60,007&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(48&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,831&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;55,042&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;47,349&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash interest expense
 on liability related to sale of future royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,311&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,808&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,320&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,832&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;271&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;236&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign tax
 inclusion&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,510&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign tax
 differential&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(17&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(20&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(227&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,933&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,273&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(591&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,286&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;864&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Benefit) provision for
 income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <dei:DocumentType contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_15A9270A-DFBF-4CA7-8B71-8ED538E1B5E7_1_0">10-K</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_1">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_4">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_0">NKTR</dei:TradingSymbol>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_310A5642-C21D-4DD2-94B8-5516CE8D4474_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our portfolio
 of cash and investments in marketable securities includes (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Hierarchy&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated Fair Value
 at&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Corporate notes and
 bonds&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;182,544&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;138,515&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Corporate commercial
 paper&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;42,915&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59,444&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Available-for-sale
 investments&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;225,459&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;197,959&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Money market
 funds&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,229&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,453&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash, including restricted
 cash&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;N/A&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,136&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37,614&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total cash and investments
 in marketable securities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,026&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_A6631B32-ED8A-405B-8068-920F7F8F0957_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We account for income taxes under the liability method. Under this
 method, deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax reporting bases
 of assets and liabilities and are measured using enacted tax rates
 and laws that are expected to be in effect when the differences are
 expected to reverse. Realization of deferred tax assets is
 dependent upon future earnings, the timing and amount of which are
 uncertain. We record a valuation allowance against deferred tax
 assets to reduce their carrying value to an amount that is more
 likely than not to be realized. When we establish or reduce the
 valuation allowance related to the deferred tax assets, our
 provision for income taxes will increase or decrease, respectively,
 in the period such determination is made.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We utilize a two-step approach to recognize and measure uncertain
 tax positions. The first step is to evaluate the tax position for
 recognition by determining if the weight of available evidence
 indicates that it is more likely than not that the position will be
 sustained upon tax authority examination, including resolution of
 related appeals or litigation processes, if any. The second step is
 to measure the tax benefit as the largest amount that is more than
 50% likely of being realized upon ultimate settlement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_7BF41C52-73AC-44ED-99A9-4AC59ECE1B05_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Inventory consists of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_91BE23D0-2F59-46AC-B131-42CE8D6FF4B7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The table below presents a summary of stock option activity under
 our equity incentive plans (in thousands, except for price per
 share and contractual life information):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;per Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Life&amp;#xA0;(in&amp;#xA0;Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value(1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,655&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,713&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options forfeited&amp;#xA0;&amp;amp; canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,521&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,549&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested&amp;#xA0;and expected to vest at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,338&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,007&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Aggregate intrinsic value represents
 the difference between the exercise price of the option and the
 closing market price of our common stock on December&amp;#xA0;31,
 2014.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B574AA00-184F-4244-A84C-E50936908431_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note&amp;#xA0;13&amp;#xA0;&amp;#x2014;&amp;#xA0;Segment Reporting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel medicines. We operate in one segment because our business
 offerings have similar economics and other characteristics,
 including the nature of products and manufacturing processes, types
 of customers, distribution methods and regulatory environment. We
 are comprehensively managed as one business segment by our Chief
 Executive Officer and his management team. Within our one business
 segment we have two components, PEGylation technology and pulmonary
 technology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our revenue is derived primarily from clients in the pharmaceutical
 and biotechnology industries. AstraZeneca, UCB and Roche
 represented 52%, 16%, and 11% of our revenue, respectively, for the
 year ended December&amp;#xA0;31, 2014. Revenue from Roche, UCB,
 AstraZeneca and Bayer represented 28%, 21%, 17% and 10% of our
 revenue, respectively, for the year ended December&amp;#xA0;31, 2013.
 Revenue from UCB, Roche and Affymax represented 30%, 23% and 11% of
 our revenue, respectively, for the year ended December&amp;#xA0;31,
 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue by geographic area is based on the locations of our
 partners. The following table sets forth revenue by geographic area
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,591&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Europe&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;106,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200,707&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,921&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014, $63.3&amp;#xA0;million, or approximately
 90%, of the net book value of our property and equipment was
 located in the United States and $7.1&amp;#xA0;million, or
 approximately 10%, was located in India. At December&amp;#xA0;31, 2013,
 $57.3&amp;#xA0;million, or approximately 88%, of the net book value of
 our property and equipment was located in the United States and
 $7.7&amp;#xA0;million, or approximately 12%, was located in India.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_1_2">0.516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <dei:EntityFilerCategory contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_7">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityVoluntaryFilers contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_6">No</dei:EntityVoluntaryFilers>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B6FC3C12-6FC3-4549-9476-851B2448C0A9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following tables list the Black-Scholes option-pricing model
 assumptions used to calculate the fair value of employee and
 director stock options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Average risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Average volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Average weighted average expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.2&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.2&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_83596BE7-921D-4B35-8B35-2A9D73BE4090_1_1">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_EA0031E7-8DB8-4CEE-99C6-90FECCD130BC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note&amp;#xA0;3&amp;#xA0;&amp;#x2014; Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Inventory consists of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_20">-142006000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_A0D2414A-4A81-4605-8D06-B6D878E4772C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense was recognized as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,297&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,496&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,328&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,621&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,017&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_7379D7CF-AE5E-4359-9C89-D85612D6C1BB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue
 Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our revenue is
 derived from our arrangements with pharmaceutical and biotechnology
 collaboration partners and may result from one or more of the
 following: upfront and license fees, payments for contract research
 and development, milestone payments, manufacturing and supply
 payments, and royalties. Our performance obligations under our
 collaborations may include licensing our intellectual property,
 manufacturing and supply obligations, and research and development
 obligations. In order to account for the multiple-element
 arrangements, the Company identifies the deliverables included
 within the arrangement and evaluates which deliverables represent
 separate units of accounting. Analyzing the arrangement to identify
 deliverables requires the use of judgment, and each deliverable may
 be an obligation to deliver services, a right or license to use an
 asset, or another performance obligation. Revenue is recognized
 separately for each identified unit of accounting when the basic
 revenue recognition criteria are met: there is persuasive evidence
 that an arrangement exists, delivery has occurred, the price is
 fixed or determinable, and collection is reasonably
 assured.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At the
 inception of each new multiple-element arrangement or the material
 modification of an existing multiple-element arrangement, we
 allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 sales&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product sales
 are primarily derived from fixed price and cost-plus manufacturing
 and supply agreements with our collaboration partners. We have not
 experienced any significant returns from our customers.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Royalty
 revenues&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Generally, we
 are entitled to royalties from our collaboration partners based on
 the net sales of their approved drugs that are marketed and sold in
 one or more countries where we hold royalty rights. We recognize
 royalty revenue when the cash is received or when the royalty
 amount to be received is estimable and collection is reasonably
 assured. With respect to the non-cash royalties related to sale of
 future royalties described at Note&amp;#xA0;7, revenue is recognized
 when estimable, otherwise, revenue is recognized during the period
 in which the related royalty report is received, which generally
 occurs in the quarter after the applicable product sales are
 made.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;License, collaboration
 and other&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The amount of
 upfront fees and other payments received by us in license and
 collaboration arrangements that are allocated to continuing
 performance obligations, such as manufacturing and supply
 obligations, are deferred and generally recognized ratably over our
 expected performance period under each respective arrangement. We
 make our best estimate of the period over which we expect to
 fulfill our performance obligations, which may include technology
 transfer assistance, research activities, clinical development
 activities, and manufacturing activities from development through
 the commercialization of the product. Given the uncertainties of
 these collaboration arrangements, significant judgment is required
 to determine the duration of the performance period and this
 estimate is periodically re-evaluated.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Contingent
 consideration received from the achievement of a substantive
 milestone is recognized in its entirety in the period in which the
 milestone is achieved, which we believe is consistent with the
 substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&amp;#xA0;that can only be achieved based in whole or in part either
 on the entity&amp;#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&amp;#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the
 arrangement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with our partners provide for payments to
 us upon the achievement of development milestones, such as the
 completion of clinical trials or regulatory submissions, approvals
 by health authorities, and commercial launches of drugs. Given the
 challenges inherent in developing and obtaining regulatory approval
 for drug products and in achieving commercial launches, there was
 substantial uncertainty whether any such milestones would be
 achieved at the time of execution of these licensing and
 collaboration agreements. In addition, we evaluated whether the
 development milestones meet the remaining criteria to be considered
 substantive. As a result of our analysis, we consider our remaining
 development milestones under all of our license and collaboration
 agreements to be substantive and, accordingly, we expect to
 recognize as revenue future payments received from such milestones
 only if and as each milestone is achieved.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with certain partners also provide for
 contingent payments to us based solely upon the performance of the
 respective partner. For such contingent amounts we expect to
 recognize the payments as revenue when earned under the applicable
 contract, which is generally upon completion of performance by the
 respective partner, provided that collection is reasonably
 assured.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with our partners also provide for
 payments to us upon the achievement of specified sales volumes of
 approved drugs. We consider these payments to be similar to royalty
 payments and we will recognize such sales-based payments upon
 achievement of such sales volumes, provided that collection is
 reasonably assured.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_3B4377FA-18F6-4F2F-ACDB-68D6A9AE6EA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue by geographic area is based on the locations of our
 partners. The following table sets forth revenue by geographic area
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,591&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Europe&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;106,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200,707&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,921&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_1_1">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_1_3">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_10A10351-119C-4221-8FFC-B7ADE61C1BD2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Estimated Fair Value at&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;225,459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash and investments in marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_056F87BB-8F21-44EF-BDCB-108A9E1C7028_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The (benefit) provision for income taxes consists of the following
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(482&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(481&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 (Benefit) provision for income taxes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_6A4599B0-A749-4175-8932-5A1D9DF8059A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future minimum payments for our capital leases at December&amp;#xA0;31,
 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;Years ending December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,572&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total minimum payments required&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,015&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: amount representing interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,364&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Present value of future minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capital lease obligation, less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_1_0">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_E1AC7CE5-CB29-4431-9879-505DCFBB42E8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Shipping and Handling Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We recognize costs related to shipping and handling of product to
 customers in cost of goods sold.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="shares" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_22">126873000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_15A9270A-DFBF-4CA7-8B71-8ED538E1B5E7_1_2">2014-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F33B5819-15A9-46BD-A3CA-2E541237AFC1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash
 Equivalents, and Investments, and Fair Value of Financial
 Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We consider all
 investments in marketable securities with an original maturity of
 three months or less when purchased to be cash equivalents.
 Investments in securities with remaining maturities of less than
 one year, or where our intent is to use the investments to fund
 current operations or to make them available for current
 operations, are classified as short-term investments.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Investments are
 designated as available-for-sale and are carried at fair value,
 with unrealized gains and losses reported in stockholders&amp;#x2019;
 equity (deficit) as accumulated other comprehensive income (loss).
 The disclosed fair value related to our cash equivalents and
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Interest and
 dividends on securities classified as available-for-sale, as well
 as amortization of premiums and accretion of discounts to maturity,
 are included in interest income. Realized gains and losses and
 declines in value of available-for-sale securities judged to be
 other-than-temporary, if any, are included in other income
 (expense). The cost of securities sold is based on the specific
 identification method.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our cash, cash
 equivalents, and short-term investments are exposed to credit risk
 in the event of default by the third parties that hold or issue
 such assets. Our cash, cash equivalents, and short-term investments
 are held by financial institutions that management believes are of
 high credit quality and our investment policy limits investments to
 fixed income securities denominated and payable in U.S. dollars
 such as U.S. government obligations, money market instruments and
 funds, and corporate bonds and places restrictions on maturities
 and concentrations by type and issuer.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_88875E8B-01C0-4B95-B90E-CA57E6612445_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Long-Lived
 Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant
 and equipment are stated at cost. Major improvements are
 capitalized, while maintenance and repairs are expensed when
 incurred. Manufacturing, laboratory and other equipment are
 depreciated using the straight-line method generally over estimated
 useful lives of three to seven years. Leasehold improvements and
 buildings recorded under capital leases are depreciated using the
 straight-line method over the shorter of the estimated useful life
 or the remaining term of the lease.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill
 represents the excess of the price paid for another entity over the
 fair value of the assets acquired and liabilities assumed in a
 business combination. We are organized in one reporting unit and
 evaluate the goodwill for the Company as a whole. Goodwill has an
 indefinite useful life and is not amortized, but instead tested for
 impairment annually in the fourth quarter of each year using an
 October&amp;#xA0;1 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We assess the
 impairment of long-lived assets, primarily property, plant and
 equipment and goodwill included in other non-current assets,
 whenever events or changes in business circumstances indicate that
 the carrying amounts of the assets may not be fully recoverable.
 When such events occur, we determine whether there has been an
 impairment in value by comparing the asset&amp;#x2019;s carrying value
 with its fair value, as measured by the anticipated undiscounted
 net cash flows of the asset. In the case of goodwill impairment,
 market capitalization is generally used as the measure of fair
 value. If an impairment in value exists, the asset is written down
 to its estimated fair value.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_DECDE375-9FE9-47D9-A73D-5AC112644723_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Note&amp;#xA0;14&amp;#xA0;&amp;#x2014; Selected Quarterly Financial Data
 (Unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth certain unaudited quarterly
 financial data. In our opinion, the unaudited information set forth
 below has been prepared on the same basis as the audited
 information and includes all adjustments necessary to present
 fairly the information set forth herein. We have experienced
 fluctuations in our quarterly results and expect these fluctuations
 to continue in the future. Due to these and other factors, we
 believe that quarter-to-quarter comparisons of our operating
 results will not be meaningful, and you should not rely on our
 results for any one quarter as an indication of our future
 performance. Certain items previously reported in specific
 financial statement captions have been reclassified to conform to
 the current period presentation. Such reclassifications have not
 materially impacted previously reported total revenues, operating
 loss or net loss. All data is in thousands except per share
 information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="44%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fiscal Year 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fiscal Year 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Product sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,795&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,802&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,096&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,324&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,672&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,004&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,862&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,877&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,960&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,338&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,494&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(22,916&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(37,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(35,894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46,201&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55,063&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(42,748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Quarterly loss per share amounts may
 not total to the year-to-date loss per share due to rounding.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_7F0E96C1-9DF5-4EC5-92E6-B90A9EB1312C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Research and
 Development Expense&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and
 development costs are expensed as incurred and include salaries,
 benefits and other operating costs such as outside services,
 supplies and allocated overhead costs. We perform research and
 development for our proprietary drug candidates and technology
 development and for certain third parties under collaboration
 agreements. For our proprietary drug candidates and our internal
 technology development programs, we invest our own funds without
 reimbursement from a third party.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We record
 accruals for the estimated costs of our clinical trial activities
 performed by third parties. The financial terms of these agreements
 are subject to negotiation, vary from contract to contract and may
 result in uneven payment flows to our vendors. Payments under the
 contracts depend on factors such as the achievement of certain
 events, successful enrollment of patients, and completion of
 portions of the clinical trial or similar conditions. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period first identified. During the year ended December 31, 2014,
 we recorded a reduction related to prior periods of approximately
 $4.7 million to our research and development expenses primarily
 related to our Beacon Phase 3 clinical trial for etirinotecan
 pegol.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_6FAD6A19-9F6F-450F-B514-F9326418E15D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note&amp;#xA0;9&amp;#xA0;&amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We have authorized 10,000,000&amp;#xA0;shares of Preferred Stock with
 each share having a par value of $0.0001. In 2011,
 3,100,000&amp;#xA0;shares were previously designated Series&amp;#xA0;A
 Junior Participating Preferred Stock (Series&amp;#xA0;A Preferred
 Stock) in connection with our Share Purchase Rights Plan (Rights
 Plan) that expired on June&amp;#xA0;1, 2011. On March&amp;#xA0;30, 2012, we
 filed a certificate of elimination of the Series A Preferred Stock.
 As of December&amp;#xA0;31, 2014 and 2013, no preferred shares are
 designated, issued or outstanding.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On January&amp;#xA0;28, 2014, we completed the issuance and sale of
 9,775,000 shares of our common stock in a public offering with
 total proceeds of approximately $117.2 million after deducting the
 underwriting commissions and discounts of approximately $7.5
 million. In addition, we incurred approximately $0.6 million in
 legal and accounting fees, filing fees, and other costs in
 connection with this offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Equity Compensation Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014, we had 24,806,565 reserved shares of
 common stock, all of which are reserved for issuance under our
 equity compensation plans as summarized in the following table
 (share number in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 49.1pt"&gt;
 &lt;b&gt;Plan Category&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Securities&amp;#xA0;to&amp;#xA0;be&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Issued Upon Exercise of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Outstanding Options&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise Price of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Outstanding&amp;#xA0;Options&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Securities&amp;#xA0;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Available for Issuance Under&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Equity Compensation Plans&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Excluding Securities Reflected&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Column(a))&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity compensation plans approved by security holders(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity compensation plans not approved by security holders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Includes shares of common stock
 available for future issuance under our ESPP as of
 December&amp;#xA0;31, 2014.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;2012 Performance Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Our 2012 Performance Incentive Plan (2012 Plan) was adopted by the
 Board of Directors on April&amp;#xA0;4, 2012 and was approved by our
 stockholders on June&amp;#xA0;28, 2012. On the date of approval, any
 shares of our common stock that were available for issuance under
 all other previously existing stock plans (the 2008 Equity
 Incentive Plan, the 2000 Equity Incentive Plan, and the 2000
 Non-Officer Equity Incentive Plan) became available for issuance
 under the 2012 Plan. In addition, 5,300,000 new shares were made
 available for award grants under the 2012 Plan. No new awards were
 granted under any of the previous stock plans after June&amp;#xA0;28,
 2012. Any shares of common stock subject to outstanding awards
 under the previous stock plans that expire, are cancelled, or
 otherwise terminate at any time after December&amp;#xA0;31, 2011 are
 also available for award grant purposes under the 2012 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The purpose of the 2012 Plan and our other incentive plans is to
 attract, motivate, retain, and reward directors, officers,
 employees, and other eligible persons through the grant of awards
 and incentives for high levels of individual performance and
 increasing the value of our business, as well as to further align
 the interests of award recipients and our stockholders. The 2012
 Plan authorizes stock options, stock appreciation rights,
 restricted stock, performance stock, stock units, stock bonuses,
 dividend equivalents, other similar rights to purchase or acquire
 shares, and other forms of awards granted or denominated in our
 common stock or units of the company&amp;#x2019;s common stock, as well
 as cash bonus awards. Directors, officers, or employees, and
 certain consultants and advisors may receive awards under the 2012
 Plan. Pursuant to the 2012 Plan, we granted or issued incentive
 stock options to officers and non-qualified stock options to
 employees, officers, and non-employee directors. In 2013 and 2014,
 the requisite service period for stock options granted to our
 employees under the 2012 Plan as well as all other previously
 existing stock plans was generally four years; the requisite
 service period for stock options granted to our directors was
 generally one year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The maximum number of shares of our common stock that may be issued
 or transferred pursuant to awards under the 2012 Plan is 10,347,140
 shares, plus any shares subject to outstanding awards under the
 previous stock plans that expire, are cancelled, or otherwise
 terminate for any reason. Generally, shares that are subject to or
 underlie awards which expire or for any reason are cancelled or
 terminated, are forfeited, fail to vest, or for any other reason
 (except for shares exchanged by a participant or withheld to pay
 the exercise price of an award granted and related tax withholding
 obligations) are not paid or delivered under the 2012 Plan will
 again be available for subsequent awards under the 2012 Plan.
 Shares issued in respect of any award, other than a stock option or
 stock appreciation right, granted under the 2012 Plan will be
 counted against the plan&amp;#x2019;s share limit as 1.5&amp;#xA0;shares for
 every one share actually issued in connection with the award. We
 did not grant any RSU awards during the years ended
 December&amp;#xA0;31, 2014, 2013 or 2012 and no RSUs are outstanding at
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The 2012 Plan will terminate on April&amp;#xA0;3, 2022, unless earlier
 terminated by the Board of Directors. The maximum term of a stock
 option or stock appreciation right under the 2012 Plan is eight
 years from the date of grant. The per share exercise price of an
 option generally may not be less than the fair market value of a
 share of the company&amp;#x2019;s common stock on the Nasdaq Global
 Select Market on the date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Other Equity Incentive Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In addition to the 2012 Plan, we have other equity incentive plans
 under which options granted remain outstanding but no new options
 may be granted either as a result of the approval of the 2012 Plan
 or plan expiration. These plans include: (i)&amp;#xA0;the 2008 Equity
 Incentive Plan (2008 Plan) which was adopted by the Board of
 Directors on March&amp;#xA0;20, 2008 and approved by our stockholders
 on June&amp;#xA0;6, 2008; (ii)&amp;#xA0;the 2000 Equity Incentive Plan
 (2000 Plan) which was adopted by the Board of Directors on
 April&amp;#xA0;19, 2000 by amending and restating our 1994 Equity
 Incentive Plan, and which expired on February&amp;#xA0;9, 2010; and
 (iii)&amp;#xA0;the 1998 Non-Officer Equity Incentive Plan which was
 adopted by our Board of Directors on August&amp;#xA0;18, 1998, and
 which was amended and restated in its entirety and renamed the 2000
 Non-Officer Equity Incentive Plan on June&amp;#xA0;6, 2000 (2000
 Non-Officer Plan).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Pursuant to the 2008 Plan and the 2000 Plan, we previously granted
 or issued incentive stock options to employees and officers and
 non-qualified stock options, rights to acquire restricted stock,
 restricted stock units, and stock bonuses to employees, officers,
 non-employee directors, and consultants. Pursuant to the 2000
 Non-Officer Plan, we previously granted or issued non-qualified
 stock options, rights to acquire restricted stock and stock bonuses
 to employees and consultants who are neither officers nor directors
 of Nektar. The maximum term of a stock option under all of these
 plans is eight years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 1994&lt;b&gt;,&lt;/b&gt; our Board of Directors adopted the
 Employee Stock Purchase Plan (ESPP) pursuant to section&amp;#xA0;423(b)
 of the Internal Revenue Code of 1986. Under the ESPP,
 2,500,000&amp;#xA0;shares of our common stock have been authorized for
 issuance. The terms of the ESPP provide eligible employees with the
 opportunity to acquire an ownership interest in Nektar through
 participation in a program of periodic payroll deductions for the
 purchase of our common stock. Employees may elect to enroll or
 re-enroll in the ESPP on a semi-annual basis. Stock is purchased at
 85% of the lower of the closing price on the first day of the
 enrollment period or the last day of the enrollment period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;401(k) Retirement Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We sponsor a 401(k) retirement plan whereby eligible employees may
 elect to contribute up to the lesser of 60% of their annual
 compensation or the statutorily prescribed annual limit allowable
 under Internal Revenue Service regulations. The 401(k) plan permits
 us to make matching contributions on behalf of all participants, up
 to a maximum of $3,000 per participant. For the years ended
 December&amp;#xA0;31, 2014, 2013, and 2012, we recognized $0.9 million,
 $1.0&amp;#xA0;million, and $0.9&amp;#xA0;million, respectively, of
 compensation expense in connection with our 401(k) retirement
 plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Change in Control Severance Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On December&amp;#xA0;6, 2006, our Board of Directors approved a Change
 of Control Severance Benefit Plan (CIC Plan). This CIC Plan has
 subsequently been amended a number of times by our Board of
 Directors with the most recent amendment occurring on April&amp;#xA0;5,
 2011. The CIC Plan is designed to make certain benefits available
 to our eligible employees in the event of a change of control of
 Nektar and, following such change of control, an employee&amp;#x2019;s
 employment with us or a successor company is terminated in certain
 specified circumstances. We adopted the CIC Plan to support the
 continuity of the business in the context of a change of control
 transaction. The CIC Plan was not adopted in contemplation of any
 specific change of control transaction.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Under the CIC Plan, in the event of a change of control of Nektar
 and a subsequent termination of employment initiated by us or a
 successor company other than for Cause (as defined in the CIC Plan)
 or initiated by the employee for a Good Reason Resignation (as
 defined in the CIC Plan) in each case within twelve months
 following a change of control transaction, (i)&amp;#xA0;the Chief
 Executive Officer would be entitled to receive cash severance pay
 equal to 24&amp;#xA0;months base salary plus annual target incentive
 pay, the extension of employee benefits over this severance period
 and the full acceleration of unvested outstanding equity awards,
 and (ii)&amp;#xA0;our Senior Vice Presidents and Vice Presidents
 (including Principal Fellows) would each be entitled to receive
 cash severance pay equal to twelve months base salary plus annual
 target incentive pay, the extension of employee benefits over this
 severance period and the full acceleration of unvested outstanding
 equity awards. In the event of a change of control of Nektar and a
 subsequent termination of employment initiated by the Company or a
 successor company other than for Cause within twelve months
 following a change of control transaction, all other employees
 would each be entitled to receive cash severance pay equal to
 6&amp;#xA0;months base salary plus a pro-rata portion of annual target
 incentive pay, the extension of employee benefits over this
 severance period and the full acceleration of each such
 employee&amp;#x2019;s unvested outstanding equity awards. Under the CIC
 Plan, as amended, non-employee directors would also be entitled to
 full acceleration of vesting of all outstanding stock awards in the
 event of a change of control transaction.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_15A9270A-DFBF-4CA7-8B71-8ED538E1B5E7_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_15A9270A-DFBF-4CA7-8B71-8ED538E1B5E7_1_3">2014</dei:DocumentFiscalYearFocus>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_9BF907B0-CCD7-4C0E-BC8E-7460EC662FAB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
 Presentation, Principles of Consolidation and Use of
 Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our
 consolidated financial statements include the financial position,
 results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited and
 Nektar Therapeutics UK, Ltd. (Nektar UK). All intercompany accounts
 and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our
 consolidated financial statements are denominated in
 U.S.&amp;#xA0;dollars. Accordingly, changes in exchange rates between
 the applicable foreign currency and the U.S.&amp;#xA0;dollar will
 affect the translation of each foreign subsidiary&amp;#x2019;s financial
 results into U.S.&amp;#xA0;dollars for purposes of reporting our
 consolidated financial results. Translation gains and losses are
 included in accumulated other comprehensive income (loss) in the
 stockholders&amp;#x2019; equity (deficit) section of the balance sheet.
 To date, such cumulative translation adjustments have not been
 significant to our consolidated financial position. Aggregate gross
 foreign currency transaction gains (losses) recorded in operations
 for the years ended December&amp;#xA0;31, 2014, 2013, and 2012 were not
 significant.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles (GAAP) requires management
 to make estimates and assumptions that affect the reported amounts
 of assets and liabilities and disclosure of contingent assets and
 liabilities at the date of the consolidated financial statements
 and the reported amounts of revenue and expenses during the
 reporting period. Accounting estimates and assumptions are
 inherently uncertain. Actual results could differ materially from
 those estimates and assumptions. On an ongoing basis, we evaluate
 our estimates, including those related to estimated selling prices
 of deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. Estimates are
 assessed each period and updated to reflect current information and
 any changes in estimates will generally be reflected in the period
 first identified.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_1D2DBD2F-FA53-4CF5-B6C0-F9023480FB07_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;12&amp;#xA0;&amp;#x2014; Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss before
 (benefit) provision for income taxes includes the following
 components (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Domestic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,414&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(161,068&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(174,258&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,986&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,300&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,809&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss before (benefit)
 provision for income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(54,428&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(159,768&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(171,449&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Provision for Income
 Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The (benefit)
 provision for income taxes consists of the following (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Current:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(482&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,838&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,029&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total Current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(481&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;893&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;422&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(422&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(49&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(31&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(65&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total Deferred&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(31&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Benefit) provision for
 income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The foreign
 benefit provision in the year ended December&amp;#xA0;31, 2014 is due
 to the reduction in taxes related to a favorable determination
 received from India proceedings.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Income tax
 provision related to continuing operations differs from the amount
 computed by applying the statutory income tax rate of 35% to pretax
 loss as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;U.S. federal provision
 (benefit)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At statutory
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(55,919&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(60,007&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(48&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,831&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;55,042&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;47,349&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash interest expense
 on liability related to sale of future royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,311&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,808&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,320&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,832&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;271&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;236&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign tax
 inclusion&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,510&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign tax
 differential&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(17&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(20&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(227&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,933&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,273&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(591&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,286&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;864&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Benefit) provision for
 income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Deferred Tax Assets
 and Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred income
 taxes reflect the net tax effects of loss and credit carryforwards
 and temporary differences between the carrying amount of assets and
 liabilities for financial reporting purposes and the amounts used
 for income tax purposes. Significant components of our deferred tax
 assets for federal and state income taxes are as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax
 assets:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net operating loss
 carryforwards&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;423,776&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;391,385&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and other
 credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,666&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;61,707&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;29,758&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;35,588&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,948&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,962&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Sale of future
 royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,153&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;28,057&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Capitalized research
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,795&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,687&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reserves and
 accruals&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,288&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,685&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,264&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,580&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,218&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,539&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets before
 valuation allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;595,866&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;586,190&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Valuation allowance for
 deferred tax assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(595,690&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(586,040&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;176&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;176&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Realization of
 our deferred tax assets is dependent upon future earnings, if any,
 the timing and amount of which are uncertain. Because of our lack
 of U.S.&amp;#xA0;earnings history, the net U.S.&amp;#xA0;deferred tax
 assets have been fully offset by a valuation allowance. The
 valuation allowance increased by $9.7&amp;#xA0;million and
 $51.8&amp;#xA0;million during the years ended December&amp;#xA0;31, 2014
 and 2013, respectively. The valuation allowance includes
 approximately $35.6&amp;#xA0;million of income tax benefit at both
 December&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013 related to
 stock-based compensation and exercises prior to the implementation
 of the accounting guidance for stock-based compensation that will
 be credited to additional paid in capital when realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Undistributed
 earnings of our foreign subsidiary in India are considered to be
 permanently reinvested and accordingly, no deferred
 U.S.&amp;#xA0;income taxes have been provided thereon. Upon
 distribution of those earnings in the form of dividends or
 otherwise, we would be subject to U.S.&amp;#xA0;income tax. As of
 December&amp;#xA0;31, 2014, U.S. income taxes have not been provided on
 a cumulative total of $3.9 million of such earnings. Any
 incremental tax liability would be insignificant due to foreign tax
 credits that would be realized upon distribution.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Net Operating Loss
 and Tax Credit Carryforwards&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As of
 December&amp;#xA0;31, 2014, we had a net operating loss carryforward
 for federal income tax purposes of approximately
 $1,131.8&amp;#xA0;million, portions of which will begin to expire in
 2018. As of December&amp;#xA0;31, 2014, we had a total state net
 operating loss carryforward of approximately $709.2&amp;#xA0;million,
 of which approximately $124.6 million does not meet the more likely
 than not standard and has not been included in our deferred tax
 assets. Our state operating loss carryforwards will begin to expire
 in 2015. Utilization of some of the federal and state net operating
 loss and credit carryforwards are subject to annual limitations due
 to the &amp;#x201C;change in ownership&amp;#x201D; provisions of the Internal
 Revenue Code of 1986 and similar state provisions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have federal
 research credits of approximately $40.0&amp;#xA0;million, which will
 begin to expire in 2019 and state research credits of approximately
 $22.6 million which have no expiration date. We have federal orphan
 drug credits of $17.7&amp;#xA0;million which will begin to expire in
 2026. These tax credits are subject to the same limitations
 discussed above.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Unrecognized tax
 benefits&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
 incurred net operating losses since inception. Our policy is to
 include interest and penalties related to unrecognized tax
 benefits, if any, within the provision for income taxes in the
 consolidated statements of operations. If we are eventually able to
 recognize our uncertain positions, our effective tax rate may be
 reduced. We currently have a full valuation allowance against our
 U.S. net deferred tax asset which would impact the timing of the
 effective tax rate benefit should any of these uncertain tax
 positions be favorably settled in the future. Any adjustments to
 our uncertain tax positions would result in an adjustment of our
 net operating loss or tax credit carry forwards rather than
 resulting in a cash outlay.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We file income
 tax returns in the U.S., California, Alabama, and India. Because of
 net operating losses and research credit carryovers, substantially
 all of our domestic tax years remain open and subject to
 examination. We are currently under examination in India for the
 fiscal years ending 2009 through 2014.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have the
 following activity relating to unrecognized tax benefits (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Beginning
 balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,363&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,576&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax positions related to
 current year&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Additions:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;502&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;477&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;289&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,141&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;381&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;302&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reductions&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax positions related to
 prior year&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Additions:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;636&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,258&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;802&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reductions &amp;#x2014;
 foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(742&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Settlements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Lapses in statute of
 limitations&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ending balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,522&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,363&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Although it is
 reasonably possible that certain unrecognized tax benefits may
 increase or decrease within the next twelve months, we do not
 anticipate any significant changes to unrecognized tax benefits
 over the next twelve&amp;#xA0;months. During the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012, no significant interest or
 penalties were recognized relating to unrecognized tax
 benefits.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_EB517723-94B7-4C59-A270-AFBC5114690E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note&amp;#xA0;5&amp;#xA0;&amp;#x2014; Senior Secured Notes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On July&amp;#xA0;11, 2012, we issued $125.0 million in aggregate
 principal amount of senior secured notes (Senior Notes) with the
 entire principal amount due on July&amp;#xA0;15, 2017. The Senior Notes
 bear interest at 12.0%&amp;#xA0;per annum payable in cash semi-annually
 in arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year. The
 Senior Notes are secured by a first-priority lien on substantially
 all of our assets. In connection with this transaction, we retired
 $42.5 million of principal amount of our convertible subordinated
 notes due September 2012 in exchange for the same principal amount
 of Senior Notes and received the remaining proceeds in cash, less
 approximately $4.5 million in transaction costs. We used the
 proceeds from the issuance of the Senior Notes and our existing
 cash to repay the remaining $172.4 million in principal amount of
 our convertible subordinated notes in full at maturity on
 September&amp;#xA0;28, 2012.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Senior Notes contain customary covenants, including covenants
 that limit or restrict our ability to incur liens, incur
 indebtedness, and make certain restricted payments, but do not
 contain covenants related to future financial performance. In
 particular, $25.0 million of the proceeds is required to be
 maintained in a restricted account until July&amp;#xA0;1, 2015 and is
 classified as restricted cash on our Consolidated Balance Sheets.
 From July&amp;#xA0;1, 2015 through the quarter ending June&amp;#xA0;30,
 2017, the aggregate balance of our unrestricted cash and cash
 equivalents at the end of any two consecutive fiscal quarters may
 not be less than $25.0 million, subject to certain conditions. The
 Senior Notes are callable by us at any time, subject to certain
 prepayment premiums and conditions. If we experience certain change
 of control events, the holders of the Senior Notes will have the
 right to require us to purchase all or a portion of the Senior
 Notes at a purchase price in cash equal to 101% of the principal
 amount thereof, plus accrued and unpaid interest to the date of
 purchase. In addition, upon certain asset sales, we may be required
 to offer to use the net proceeds thereof to purchase some of the
 Senior Notes at 100% of the principal amount thereof, plus accrued
 and unpaid interest to the date of purchase.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2014, based on a discounted cash flow
 analysis using Level 3 inputs including financial discount rates,
 we believe the $125.0 million carrying amount of our 12% Senior
 Secured Notes due July 2017 is consistent with its fair value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_FEAD425D-B705-4831-B286-EFCC6829C5BF_1_0">&lt;div&gt;
 &lt;font size="2"&gt;Significant components of our deferred tax assets
 for federal and state income taxes are as follows (in
 thousands):&lt;/font&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax
 assets:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net operating loss
 carryforwards&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;423,776&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;391,385&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and other
 credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,666&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;61,707&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;29,758&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;35,588&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,948&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,962&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Sale of future
 royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,153&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;28,057&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Capitalized research
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,795&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,687&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reserves and
 accruals&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,288&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,685&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,264&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,580&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,218&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,539&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets before
 valuation allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;595,866&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;586,190&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Valuation allowance for
 deferred tax assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(595,690&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(586,040&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;176&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;176&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_92B58C4D-3628-42AF-A4B9-FFEF371252C8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our future minimum lease payments for our operating leases at
 December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;Years ending December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total future minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B8EB4BB1-750F-4FCF-865D-C3D6B0B6FBA1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth certain unaudited quarterly
 financial data. In our opinion, the unaudited information set forth
 below has been prepared on the same basis as the audited
 information and includes all adjustments necessary to present
 fairly the information set forth herein. All data is in thousands
 except per share information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="44%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fiscal Year 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fiscal Year 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Product sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,795&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,802&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,096&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,324&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,672&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,004&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,862&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,877&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,960&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,338&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,494&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(22,916&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(37,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(35,894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46,201&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55,063&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(42,748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Quarterly loss per share amounts may
 not total to the year-to-date loss per share due to rounding.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_2">0000906709</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_52B1B30F-EF50-46DB-9989-7B76F85B1094_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;11 &amp;#x2014;
 Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We issue
 stock-based awards from our equity incentive plans, which are more
 fully described in Note&amp;#xA0;9. Stock-based compensation expense
 was recognized as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods
 sold&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,161&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,297&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,496&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and
 development&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,528&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,910&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,082&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;General and
 administrative&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,328&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,501&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,621&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total stock-based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,017&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,708&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,199&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As of
 December&amp;#xA0;31, 2014, total unrecognized compensation costs of
 $51.9 million related to unvested stock-based compensation
 arrangements are expected to be recognized as expense over a
 weighted-average period of 2.1 years.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Black-Scholes
 Assumptions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 tables list the Black-Scholes option-pricing model assumptions used
 to calculate the fair value of employee and director stock
 options.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="39%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year
 Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year
 Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year
 Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Average risk-free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Average volatility
 factor&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;51.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;61.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;62.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Average weighted average
 expected life&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.2&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.2&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.0&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The average
 risk-free interest rate is based on the U.S.&amp;#xA0;treasury yield
 curve in effect at the time of grant for periods commensurate with
 the expected life of the stock-based award. We have never paid
 dividends, nor do we expect to pay dividends in the foreseeable
 future; therefore, we used a dividend yield of 0.0%. Our estimate
 of expected volatility is based on the daily historical trading
 data of our common stock at the time of grant over a historical
 period commensurate with the expected life of the stock-based
 award.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the years
 ended December&amp;#xA0;31, 2014, 2013, and 2012, we estimated the
 weighted-average expected life based on the contractual and vesting
 terms of the stock options, as well as historic cancellation and
 exercise data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation resulting from our ESPP was not material in the years
 ended December&amp;#xA0;31, 2014, 2013, and 2012.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Summary of Stock
 Option Activity&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The table below
 presents a summary of stock option activity under our equity
 incentive plans (in thousands, except for price per share and
 contractual life information):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;per
 Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Life&amp;#xA0;(in&amp;#xA0;Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 December&amp;#xA0;31, 2013&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,655&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9.06&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,713&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13.96&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Options
 exercised&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,852&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9.43&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Options
 forfeited&amp;#xA0;&amp;amp; canceled&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,521&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11.89&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 December&amp;#xA0;31, 2014&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,995&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.96&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;112,549&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Vested&amp;#xA0;and expected to
 vest at December&amp;#xA0;31, 2014&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,338&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.89&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;111,071&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercisable at
 December&amp;#xA0;31, 2014&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,007&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8.90&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3.47&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2px; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; MARGIN-TOP: 0px; LINE-HEIGHT: 8px; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Aggregate intrinsic value
 represents the difference between the exercise price of the option
 and the closing market price of our common stock on
 December&amp;#xA0;31, 2014.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
 weighted-average grant-date fair value per share of options granted
 during the years ended December&amp;#xA0;31, 2014, 2013, and 2012 was
 $6.50, $4.95, and $3.92, respectively. The total intrinsic value of
 options exercised during the years ended December&amp;#xA0;31, 2014,
 2013, and 2012 was $25.9 million, $4.5&amp;#xA0;million, and
 $1.9&amp;#xA0;million, respectively. The estimated fair value of
 options vested during the years ended December&amp;#xA0;31, 2014, 2013,
 and 2012 was $15.2 million, $14.1&amp;#xA0;million, and
 $15.7&amp;#xA0;million, respectively.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_21">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_5242063_6619601B-22E3-4BB1-9D61-A4EABF98C969_1_0">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_EBF1FCBC-48C4-43B7-A2AE-8F8F60A1FC40_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;2&amp;#xA0;&amp;#x2014;
 Cash and Investments in Marketable Securities&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and
 investments in marketable securities, including cash equivalents
 and restricted cash, are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated Fair Value
 at&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash
 equivalents&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,365&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Short-term
 investments&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;225,459&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;197,959&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Restricted cash&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total cash and investments
 in marketable securities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,026&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We invest in
 liquid, high quality debt securities. Our investments in debt
 securities are subject to interest rate risk. To minimize the
 exposure due to an adverse shift in interest rates, we invest in
 securities with maturities of two years or less and maintain a
 weighted average maturity of one year or less. As of
 December&amp;#xA0;31, 2014 and 2013, all of our investments had
 contractual maturities of one year or less and were classified as
 short-term.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gross
 unrealized gains and losses were not significant at either
 December&amp;#xA0;31, 2014 or 2013. During the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012, we sold available-for-sale
 securities totaling $21.7 million, $2.9&amp;#xA0;million and $5.4
 million respectively, and realized gains and losses were not
 significant in any of those periods.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Restricted cash
 of $25.0 million is required to be maintained in a separate account
 until July&amp;#xA0;1, 2015 under the terms of our 12% senior secured
 notes due July 2017. Upon release of this restriction on
 July&amp;#xA0;1, 2015, a covenant of the senior secured notes requires
 that the aggregate balance of our unrestricted cash and cash
 equivalents at the end of any two consecutive fiscal quarters may
 not be less than $25.0 million, subject to certain conditions (see
 Note 5).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our portfolio
 of cash and investments in marketable securities includes (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Hierarchy&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated Fair Value
 at&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Corporate notes and
 bonds&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;182,544&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;138,515&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Corporate commercial
 paper&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;42,915&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59,444&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Available-for-sale
 investments&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;225,459&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;197,959&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Money market
 funds&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,229&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,453&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash, including restricted
 cash&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;N/A&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,136&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37,614&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total cash and investments
 in marketable securities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;262,026&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2px; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; MARGIN-TOP: 0px; LINE-HEIGHT: 8px; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Level&amp;#xA0;1&amp;#xA0;&amp;#x2014;&lt;/i&gt; Quoted prices in active
 markets for identical assets or liabilities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Level&amp;#xA0;2&amp;#xA0;&amp;#x2014;&lt;/i&gt; Inputs other than Level&amp;#xA0;1
 that are observable, either directly or indirectly, such as quoted
 prices for similar assets or liabilities; quoted prices in markets
 that are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Level&amp;#xA0;3&amp;#xA0;&amp;#x2014;&lt;/i&gt; Unobservable inputs that are
 supported by little or no market activity and that are significant
 to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All of our
 investments are categorized as Level 1 or Level 2, as explained in
 the table above. We use a market approach to value our Level 2
 investments. During the years ended December&amp;#xA0;31, 2014, 2013
 and 2012, there were no transfers between Level 1 and Level 2 of
 the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At
 December&amp;#xA0;31, 2014 and 2013, we had letter of credit
 arrangements in favor of a landlord and certain vendors totaling
 $2.4&amp;#xA0;million. These letters of credit are secured by
 investments of similar amounts.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_72DE111F-E22F-43E0-A577-372238AA4DCD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC) 606,
 &lt;i&gt;Revenue Recognition &amp;#x2014; Revenue from Contracts with
 Customers&lt;/i&gt;, which amends the guidance in former ASC 605,
 &lt;i&gt;Revenue Recognition,&lt;/i&gt; and is effective for public companies
 for fiscal years beginning after December&amp;#xA0;15, 2016. We are
 currently evaluating the impact of the provisions of ASC 606.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August 2014, the FASB issued Accounting Standards Update
 No.&amp;#xA0;2014-15, Disclosure of Uncertainties about an
 Entity&amp;#x2019;s Ability to Continue as a Going Concern (ASU
 2014-15). ASU 2014-15 requires management to evaluate whether there
 is substantial doubt about an entity&amp;#x2019;s ability to continue as
 a going concern and to provide related footnote disclosures. ASU
 2014-15 is effective in 2016 with early adoption permitted. We do
 not believe the impact of adopting ASU 2014-15 on our consolidated
 financial statements will be significant.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_AB4DD0CC-FE15-45E0-B18D-07E9F6268ED4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;1&amp;#xA0;&amp;#x2014;
 Organization and Summary of Significant Accounting
 Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are a
 biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our research
 and development activities have required significant ongoing
 investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At December&amp;#xA0;31, 2014,
 we had approximately $262.8 million in cash and investments in
 marketable securities, of which $25.0 million was restricted in
 relation to our 12% senior secured notes, and $151.8 million in
 indebtedness. The indebtedness includes $125.0 million in aggregate
 principal amount of 12.0% senior secured notes due July&amp;#xA0;15,
 2017, but excludes our long-term liability relating to the sale of
 future royalties. As is further described in Note 7, this royalty
 obligation liability will not be settled in cash.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
 Presentation, Principles of Consolidation and Use of
 Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our
 consolidated financial statements include the financial position,
 results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited and
 Nektar Therapeutics UK, Ltd. (Nektar UK). All intercompany accounts
 and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our
 consolidated financial statements are denominated in
 U.S.&amp;#xA0;dollars. Accordingly, changes in exchange rates between
 the applicable foreign currency and the U.S.&amp;#xA0;dollar will
 affect the translation of each foreign subsidiary&amp;#x2019;s financial
 results into U.S.&amp;#xA0;dollars for purposes of reporting our
 consolidated financial results. Translation gains and losses are
 included in accumulated other comprehensive income (loss) in the
 stockholders&amp;#x2019; equity (deficit) section of the balance sheet.
 To date, such cumulative translation adjustments have not been
 significant to our consolidated financial position. Aggregate gross
 foreign currency transaction gains (losses) recorded in operations
 for the years ended December&amp;#xA0;31, 2014, 2013, and 2012 were not
 significant.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles (GAAP) requires management
 to make estimates and assumptions that affect the reported amounts
 of assets and liabilities and disclosure of contingent assets and
 liabilities at the date of the consolidated financial statements
 and the reported amounts of revenue and expenses during the
 reporting period. Accounting estimates and assumptions are
 inherently uncertain. Actual results could differ materially from
 those estimates and assumptions. On an ongoing basis, we evaluate
 our estimates, including those related to estimated selling prices
 of deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. Estimates are
 assessed each period and updated to reflect current information and
 any changes in estimates will generally be reflected in the period
 first identified.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Certain items
 previously reported in specific financial statement captions have
 been reclassified to conform to the current period presentation.
 Such reclassifications do not materially impact previously reported
 total revenue, operating loss or net loss or total assets,
 liabilities or stockholders&amp;#x2019; equity (deficit).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash
 Equivalents, and Investments, and Fair Value of Financial
 Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We consider all
 investments in marketable securities with an original maturity of
 three months or less when purchased to be cash equivalents.
 Investments in securities with remaining maturities of less than
 one year, or where our intent is to use the investments to fund
 current operations or to make them available for current
 operations, are classified as short-term investments.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Investments are
 designated as available-for-sale and are carried at fair value,
 with unrealized gains and losses reported in stockholders&amp;#x2019;
 equity (deficit) as accumulated other comprehensive income (loss).
 The disclosed fair value related to our cash equivalents and
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Interest and
 dividends on securities classified as available-for-sale, as well
 as amortization of premiums and accretion of discounts to maturity,
 are included in interest income. Realized gains and losses and
 declines in value of available-for-sale securities judged to be
 other-than-temporary, if any, are included in other income
 (expense). The cost of securities sold is based on the specific
 identification method.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our cash, cash
 equivalents, and short-term investments are exposed to credit risk
 in the event of default by the third parties that hold or issue
 such assets. Our cash, cash equivalents, and short-term investments
 are held by financial institutions that management believes are of
 high credit quality and our investment policy limits investments to
 fixed income securities denominated and payable in U.S. dollars
 such as U.S. government obligations, money market instruments and
 funds, and corporate bonds and places restrictions on maturities
 and concentrations by type and issuer.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable
 and Significant Customer Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our customers
 are primarily pharmaceutical and biotechnology companies that are
 located in the U.S.&amp;#xA0;and Europe. Our accounts receivable
 balance contains billed and unbilled trade receivables from product
 sales and royalties, as well as time and materials based billings
 from collaborative research and development agreements. When
 appropriate, we provide for an allowance for doubtful accounts by
 reserving for specifically identified doubtful accounts. We
 generally do not require collateral from our customers. We perform
 a regular review of our customers&amp;#x2019; payment histories and
 associated credit risk. We have not experienced significant credit
 losses from our accounts receivable. At December&amp;#xA0;31, 2014,
 three different customers represented 40%, 31%, and 15%,
 respectively, of our accounts receivable. At December&amp;#xA0;31,
 2013, three different customers represented 30%, 28%, and 28%,
 respectively, of our accounts receivable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Inventory and
 Significant Supplier Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventory is
 generally manufactured upon receipt of firm purchase orders from
 our collaboration partners. Inventory includes direct materials,
 direct labor, and manufacturing overhead and cost is determined on
 a first-in, first-out basis. Inventory is valued at the lower of
 cost or market and defective or excess inventory is written down to
 net realizable value based on historical experience or projected
 usage. Inventory related to our research and development activities
 is expensed when purchased.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are
 dependent on our suppliers and contract manufacturers to provide
 raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Long-Lived
 Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant
 and equipment are stated at cost. Major improvements are
 capitalized, while maintenance and repairs are expensed when
 incurred. Manufacturing, laboratory and other equipment are
 depreciated using the straight-line method generally over estimated
 useful lives of three to seven years. Leasehold improvements and
 buildings recorded under capital leases are depreciated using the
 straight-line method over the shorter of the estimated useful life
 or the remaining term of the lease.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill
 represents the excess of the price paid for another entity over the
 fair value of the assets acquired and liabilities assumed in a
 business combination. We are organized in one reporting unit and
 evaluate the goodwill for the Company as a whole. Goodwill has an
 indefinite useful life and is not amortized, but instead tested for
 impairment annually in the fourth quarter of each year using an
 October&amp;#xA0;1 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We assess the
 impairment of long-lived assets, primarily property, plant and
 equipment and goodwill included in other non-current assets,
 whenever events or changes in business circumstances indicate that
 the carrying amounts of the assets may not be fully recoverable.
 When such events occur, we determine whether there has been an
 impairment in value by comparing the asset&amp;#x2019;s carrying value
 with its fair value, as measured by the anticipated undiscounted
 net cash flows of the asset. In the case of goodwill impairment,
 market capitalization is generally used as the measure of fair
 value. If an impairment in value exists, the asset is written down
 to its estimated fair value.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue
 Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our revenue is
 derived from our arrangements with pharmaceutical and biotechnology
 collaboration partners and may result from one or more of the
 following: upfront and license fees, payments for contract research
 and development, milestone payments, manufacturing and supply
 payments, and royalties. Our performance obligations under our
 collaborations may include licensing our intellectual property,
 manufacturing and supply obligations, and research and development
 obligations. In order to account for the multiple-element
 arrangements, the Company identifies the deliverables included
 within the arrangement and evaluates which deliverables represent
 separate units of accounting. Analyzing the arrangement to identify
 deliverables requires the use of judgment, and each deliverable may
 be an obligation to deliver services, a right or license to use an
 asset, or another performance obligation. Revenue is recognized
 separately for each identified unit of accounting when the basic
 revenue recognition criteria are met: there is persuasive evidence
 that an arrangement exists, delivery has occurred, the price is
 fixed or determinable, and collection is reasonably
 assured.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At the
 inception of each new multiple-element arrangement or the material
 modification of an existing multiple-element arrangement, we
 allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 sales&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product sales
 are primarily derived from fixed price and cost-plus manufacturing
 and supply agreements with our collaboration partners. We have not
 experienced any significant returns from our customers.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Royalty
 revenues&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Generally, we
 are entitled to royalties from our collaboration partners based on
 the net sales of their approved drugs that are marketed and sold in
 one or more countries where we hold royalty rights. We recognize
 royalty revenue when the cash is received or when the royalty
 amount to be received is estimable and collection is reasonably
 assured. With respect to the non-cash royalties related to sale of
 future royalties described at Note&amp;#xA0;7, revenue is recognized
 when estimable, otherwise, revenue is recognized during the period
 in which the related royalty report is received, which generally
 occurs in the quarter after the applicable product sales are
 made.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;License, collaboration
 and other&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The amount of
 upfront fees and other payments received by us in license and
 collaboration arrangements that are allocated to continuing
 performance obligations, such as manufacturing and supply
 obligations, are deferred and generally recognized ratably over our
 expected performance period under each respective arrangement. We
 make our best estimate of the period over which we expect to
 fulfill our performance obligations, which may include technology
 transfer assistance, research activities, clinical development
 activities, and manufacturing activities from development through
 the commercialization of the product. Given the uncertainties of
 these collaboration arrangements, significant judgment is required
 to determine the duration of the performance period and this
 estimate is periodically re-evaluated.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Contingent
 consideration received from the achievement of a substantive
 milestone is recognized in its entirety in the period in which the
 milestone is achieved, which we believe is consistent with the
 substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&amp;#xA0;that can only be achieved based in whole or in part either
 on the entity&amp;#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&amp;#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the
 arrangement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with our partners provide for payments to
 us upon the achievement of development milestones, such as the
 completion of clinical trials or regulatory submissions, approvals
 by health authorities, and commercial launches of drugs. Given the
 challenges inherent in developing and obtaining regulatory approval
 for drug products and in achieving commercial launches, there was
 substantial uncertainty whether any such milestones would be
 achieved at the time of execution of these licensing and
 collaboration agreements. In addition, we evaluated whether the
 development milestones meet the remaining criteria to be considered
 substantive. As a result of our analysis, we consider our remaining
 development milestones under all of our license and collaboration
 agreements to be substantive and, accordingly, we expect to
 recognize as revenue future payments received from such milestones
 only if and as each milestone is achieved.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with certain partners also provide for
 contingent payments to us based solely upon the performance of the
 respective partner. For such contingent amounts we expect to
 recognize the payments as revenue when earned under the applicable
 contract, which is generally upon completion of performance by the
 respective partner, provided that collection is reasonably
 assured.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our license and
 collaboration agreements with our partners also provide for
 payments to us upon the achievement of specified sales volumes of
 approved drugs. We consider these payments to be similar to royalty
 payments and we will recognize such sales-based payments upon
 achievement of such sales volumes, provided that collection is
 reasonably assured.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Shipping and Handling
 Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We recognize
 costs related to shipping and handling of product to customers in
 cost of goods sold.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Research and
 Development Expense&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and
 development costs are expensed as incurred and include salaries,
 benefits and other operating costs such as outside services,
 supplies and allocated overhead costs. We perform research and
 development for our proprietary drug candidates and technology
 development and for certain third parties under collaboration
 agreements. For our proprietary drug candidates and our internal
 technology development programs, we invest our own funds without
 reimbursement from a third party.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We record
 accruals for the estimated costs of our clinical trial activities
 performed by third parties. The financial terms of these agreements
 are subject to negotiation, vary from contract to contract and may
 result in uneven payment flows to our vendors. Payments under the
 contracts depend on factors such as the achievement of certain
 events, successful enrollment of patients, and completion of
 portions of the clinical trial or similar conditions. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period first identified. During the year ended December 31, 2014,
 we recorded a reduction related to prior periods of approximately
 $4.7 million to our research and development expenses primarily
 related to our Beacon Phase 3 clinical trial for etirinotecan
 pegol.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
 Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation arrangements include stock option grants and
 restricted stock unit (RSU) awards under our equity incentive
 plans, as well as shares issued under our Employee Stock Purchase
 Plan (ESPP), through which employees may purchase our common stock
 at a discount to the market price.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We use the
 Black-Scholes option pricing model for the respective grant to
 determine the estimated fair value of the option on the date of
 grant (grant date fair value) and the estimated fair value of
 common stock purchased under the ESPP. The Black-Scholes option
 pricing model requires the input of highly subjective assumptions.
 These variables include, but are not limited to, our stock price
 volatility over the term of the awards, and actual and projected
 employee stock option exercise behaviors. Because our employee
 stock options have characteristics significantly different from
 those of traded options, and because changes in the subjective
 input assumptions can materially affect the fair value estimate, in
 management&amp;#x2019;s opinion, the existing models may not provide a
 reliable single measure of the fair value of our employee stock
 options or common stock purchased under the ESPP. Management will
 continue to assess the assumptions and methodologies used to
 calculate the estimated fair value of stock-based compensation.
 Circumstances may change and additional data may become available
 over time, which could result in changes to these assumptions and
 methodologies, and which could materially impact our fair value
 determination.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We expense the
 value of the portion of the option or award that is ultimately
 expected to vest based on the historical forfeiture rate on a
 straight line basis over the requisite service periods in our
 Consolidated Statements of Operations. For awards that vest upon
 the achievement of performance milestones, we estimate the vesting
 period based on our evaluation of the probability of achievement of
 each respective milestone and the related estimated date of
 achievement. Stock-based compensation expense for purchases under
 the ESPP is recognized over the respective six-month purchase
 period. Expense amounts are recorded in cost of goods sold,
 research and development expense, and general and administrative
 expense based on the function of the applicable employee.
 Stock-based compensation charges are non-cash charges and as such
 have no impact on our reported cash flows.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per
 Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss
 per share is calculated based on the weighted-average number of
 common shares outstanding during the periods presented. For all
 periods presented in the Consolidated Statements of Operations, the
 net loss available to common stockholders is equal to the reported
 net loss. Basic and diluted net loss per share are the same due to
 our historical net losses and the requirement to exclude
 potentially dilutive securities which would have an anti-dilutive
 effect on net loss per share. During 2014, 2013 and 2012,
 potentially dilutive securities consisted of common shares
 underlying outstanding stock options and there were weighted
 average outstanding stock options of 21.9 million, 20.7 million and
 18.8 million during the years ended December 31, 2014, 2013 and
 2012, respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Income
 Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We account for
 income taxes under the liability method. Under this method,
 deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax reporting bases
 of assets and liabilities and are measured using enacted tax rates
 and laws that are expected to be in effect when the differences are
 expected to reverse. Realization of deferred tax assets is
 dependent upon future earnings, the timing and amount of which are
 uncertain. We record a valuation allowance against deferred tax
 assets to reduce their carrying value to an amount that is more
 likely than not to be realized. When we establish or reduce the
 valuation allowance related to the deferred tax assets, our
 provision for income taxes will increase or decrease, respectively,
 in the period such determination is made.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We utilize a
 two-step approach to recognize and measure uncertain tax positions.
 The first step is to evaluate the tax position for recognition by
 determining if the weight of available evidence indicates that it
 is more likely than not that the position will be sustained upon
 tax authority examination, including resolution of related appeals
 or litigation processes, if any. The second step is to measure the
 tax benefit as the largest amount that is more than 50% likely of
 being realized upon ultimate settlement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
 loss&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Comprehensive
 loss is the change in stockholders&amp;#x2019; equity (deficit) from
 transactions and other events and circumstances other than those
 resulting from investments by stockholders and distributions to
 stockholders. Our other comprehensive income (loss) is comprised of
 net loss, gains and losses from the foreign currency translation of
 the assets and liabilities of our India and UK subsidiaries, and
 unrealized gains and losses on investments in available-for-sale
 securities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting
 Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In May 2014,
 the Financial Accounting Standards Board (FASB) issued guidance
 codified in Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue
 Recognition &amp;#x2014; Revenue from Contracts with Customers&lt;/i&gt;,
 which amends the guidance in former ASC 605, &lt;i&gt;Revenue
 Recognition,&lt;/i&gt; and is effective for public companies for fiscal
 years beginning after December&amp;#xA0;15, 2016. We are currently
 evaluating the impact of the provisions of ASC 606.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2014,
 the FASB issued Accounting Standards Update No.&amp;#xA0;2014-15,
 Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to
 Continue as a Going Concern (ASU 2014-15). ASU 2014-15 requires
 management to evaluate whether there is substantial doubt about an
 entity&amp;#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective in
 2016 with early adoption permitted. We do not believe the impact of
 adopting ASU 2014-15 on our consolidated financial statements will
 be significant.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_9480A2BC-DD9A-410D-93CE-14D79256E890_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note&amp;#xA0;4&amp;#xA0;&amp;#x2014;
 Property, Plant and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant
 and equipment consists of the following (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Building and leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72,228&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;71,306&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Laboratory
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,975&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,621&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Manufacturing
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,212&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture, fixtures and
 other equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,451&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,235&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciable property, plant
 and equipment at cost&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;147,866&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;144,861&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Less: accumulated
 depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(93,807&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(84,148&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciable property, plant
 and equipment, net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;60,713&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Construction-in-progress&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,309&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,261&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment, net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;70,368&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,974&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Building and
 leasehold improvements include our manufacturing, research and
 development and administrative facilities and the related
 improvements to these facilities. Laboratory and manufacturing
 equipment include assets that support both our manufacturing and
 research and development efforts. Construction-in-progress includes
 assets being built to enhance our manufacturing and research and
 development efforts, including manufacturing equipment supporting
 our Amikacin Inhale program at third-party contract manufacturing
 locations in the U.S. and Germany. Under the terms of our
 arrangement with these contract manufacturers, during the period
 the equipment is being constructed, we are obligated to pay for
 their costs incurred to date. As of December 31, 2014, we have
 recorded a total of $7.2 million in other current and other
 long-term liabilities related to our obligation to purchase this
 equipment, which is recorded in property, plant and equipment.
 After the assets are placed into service, this liability will be
 paid over approximately three years.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In July 2012,
 we consolidated our U.S.-based research activities into our
 existing San Francisco facility and ceased use of and plan to sell
 one of our buildings located in Huntsville, Alabama that was
 dedicated to research activities. The announcement of this
 consolidation plan in March 2012 triggered the recognition of a
 $1.7&amp;#xA0;million impairment charge relating to these assets in the
 year ended December&amp;#xA0;31, 2012.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciation
 expense, including depreciation of assets acquired through capital
 leases, for the years ended December&amp;#xA0;31, 2014, 2013, and 2012
 was $11.7&amp;#xA0;million, $13.0&amp;#xA0;million, and $13.8&amp;#xA0;million,
 respectively.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_15A9270A-DFBF-4CA7-8B71-8ED538E1B5E7_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_E846957D-74B5-4599-90E3-58C603000DDC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported total revenue, operating loss or net loss or
 total assets, liabilities or stockholders&amp;#x2019; equity
 (deficit).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_1BBFA8A4-0A1B-4F5D-945B-30CBD824E13F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant
 and equipment consists of the following (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Building and leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72,228&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;71,306&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Laboratory
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,975&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,621&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Manufacturing
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,212&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture, fixtures and
 other equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,451&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,235&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciable property, plant
 and equipment at cost&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;147,866&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;144,861&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Less: accumulated
 depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(93,807&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(84,148&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciable property, plant
 and equipment, net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;60,713&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Construction-in-progress&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,309&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,261&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment, net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;70,368&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,974&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_FDE4B397-F891-45C1-8815-5CC32E3C5325_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have the
 following activity relating to unrecognized tax benefits (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Beginning
 balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,363&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,576&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax positions related to
 current year&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Additions:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;502&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;477&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;289&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,141&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;381&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;302&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reductions&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax positions related to
 prior year&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Additions:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;636&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,258&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;802&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Reductions &amp;#x2014;
 foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(742&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Settlements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Lapses in statute of
 limitations&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ending balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,522&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,363&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_78AC882D-9C51-4EF6-AB57-A8CE3F5152DC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
 Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based
 compensation arrangements include stock option grants and
 restricted stock unit (RSU) awards under our equity incentive
 plans, as well as shares issued under our Employee Stock Purchase
 Plan (ESPP), through which employees may purchase our common stock
 at a discount to the market price.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We use the
 Black-Scholes option pricing model for the respective grant to
 determine the estimated fair value of the option on the date of
 grant (grant date fair value) and the estimated fair value of
 common stock purchased under the ESPP. The Black-Scholes option
 pricing model requires the input of highly subjective assumptions.
 These variables include, but are not limited to, our stock price
 volatility over the term of the awards, and actual and projected
 employee stock option exercise behaviors. Because our employee
 stock options have characteristics significantly different from
 those of traded options, and because changes in the subjective
 input assumptions can materially affect the fair value estimate, in
 management&amp;#x2019;s opinion, the existing models may not provide a
 reliable single measure of the fair value of our employee stock
 options or common stock purchased under the ESPP. Management will
 continue to assess the assumptions and methodologies used to
 calculate the estimated fair value of stock-based compensation.
 Circumstances may change and additional data may become available
 over time, which could result in changes to these assumptions and
 methodologies, and which could materially impact our fair value
 determination.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We expense the
 value of the portion of the option or award that is ultimately
 expected to vest based on the historical forfeiture rate on a
 straight line basis over the requisite service periods in our
 Consolidated Statements of Operations. For awards that vest upon
 the achievement of performance milestones, we estimate the vesting
 period based on our evaluation of the probability of achievement of
 each respective milestone and the related estimated date of
 achievement. Stock-based compensation expense for purchases under
 the ESPP is recognized over the respective six-month purchase
 period. Expense amounts are recorded in cost of goods sold,
 research and development expense, and general and administrative
 expense based on the function of the applicable employee.
 Stock-based compensation charges are non-cash charges and as such
 have no impact on our reported cash flows.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_F3AF8B72-DD31-4AA1-965E-C03495BC7EA6_1_5">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9006_900017">116536000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_23">297251000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_44">964000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_1_1">1986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_1_2">-95000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_551DC194-04C2-4CC9-93DB-82D22D2C18D5_1_0">9700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9006_900020">46984000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_1">25152000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_29">3536000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9006_900023">-386000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_11">3294000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_10">-500000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_889BDEDA-6B0F-4AA9-9236-633C64D7E129_1_0">21700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_12">-16485000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_8">2933000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_1_6">-54302000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_17">-37943000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_18">-54428000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_2">329000</us-gaap:RoyaltyRevenue>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_16">814000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_5">200707000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_26">9976000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_7">560000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_20">-53916000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_43">17445000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_9">1378000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9006_900022">17017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_1_0">-56414000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_5">17017000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_1_9">-31000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_38">-109000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_9">-487000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_17">-4664000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_13">-8505000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_14">17869000</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_8">147734000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_1_3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_1_8">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_39">-26702000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_1_8">-31000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_7">-17000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_1">-19050000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_19">-512000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_7">28533000</us-gaap:CostOfGoodsSold>
  <us-gaap:Depreciation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E5A14F23-DEEF-4544-847B-77BB4ED18D5F_1_0">11700000</us-gaap:Depreciation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_6">12927000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_2A4FEDD4-3B17-4A83-97CB-B523C81B3B28_1_0">3400000</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_37">152984000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_36">46984000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9006_900018">617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_1_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_3A04D355-5B32-4D2D-85A3-134942F6D202_1_2">900000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_4">7311000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_5">2832000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_14">273000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_27">-37571000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_1_3">-482000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_1_4">-481000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_11">217192000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_2">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_8107F019-451C-4118-AA37-920815648F07_1_0">3200000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_1_4">291000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_9">40925000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_12">-6359000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_22">247995000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_24">21661000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_1_3">17017000</us-gaap:ShareBasedCompensation>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B22416C2-F47E-4BD4-8989-E29CBDDB4FEF_1_0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_1_3">11831000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_19">-13801000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <nktr:OrganizationPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_43364729-F93C-440C-B554-9FCA84332C47_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are a
 biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our research
 and development activities have required significant ongoing
 investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At December&amp;#xA0;31, 2014,
 we had approximately $262.8 million in cash and investments in
 marketable securities, of which $25.0 million was restricted in
 relation to our 12% senior secured notes, and $151.8 million in
 indebtedness. The indebtedness includes $125.0 million in aggregate
 principal amount of 12.0% senior secured notes due July&amp;#xA0;15,
 2017, but excludes our long-term liability relating to the sale of
 future royalties. As is further described in Note 7, this royalty
 obligation liability will not be settled in cash.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</nktr:OrganizationPolicyTextBlock>
  <nktr:PartialRepaymentOfRoyaltySaleProceeds contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_B11CFBBF-67AE-4ECF-A1ED-FFBA1BF0A113_1_2">7000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
  <nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_31">-7000000</nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts>
  <nktr:SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_BB9357F1-C04D-40D7-88D2-42310464EEC6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014, we had 24,806,565 reserved shares of
 common stock, all of which are reserved for issuance under our
 equity compensation plans as summarized in the following table
 (share number in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 49.1pt"&gt;
 &lt;b&gt;Plan Category&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Securities&amp;#xA0;to&amp;#xA0;be&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Issued Upon Exercise of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Outstanding Options&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise Price of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Outstanding&amp;#xA0;Options&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Securities&amp;#xA0;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Available for Issuance Under&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Equity Compensation Plans&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Excluding Securities Reflected&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Column(a))&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity compensation plans approved by security holders(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity compensation plans not approved by security holders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Includes shares of common stock
 available for future issuance under our ESPP as of
 December&amp;#xA0;31, 2014.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</nktr:SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_9BA3F568-7629-45C6-B329-05056C97ACFB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note 7 &amp;#x2014; Liability
 Related to Sale of Future Royalties&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 February&amp;#xA0;24, 2012, we entered into a Purchase and Sale
 Agreement (the Purchase and Sale Agreement) with RPI Finance Trust
 (RPI), an affiliate of Royalty Pharma, pursuant to which we sold,
 and RPI purchased, our right to receive royalty payments (the
 Royalty Entitlement) arising from the worldwide net sales, from and
 after January&amp;#xA0;1, 2012, of (a)&amp;#xA0;CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
 under Nektar&amp;#x2019;s license, manufacturing and supply agreement
 with UCB Pharma (UCB), and (b)&amp;#xA0;MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
 under Nektar&amp;#x2019;s license, manufacturing and supply agreement
 with F. Hoffmann-La&amp;#xA0;Roche Ltd and Hoffmann-La&amp;#xA0;Roche Inc.
 (together referred to as Roche). We received aggregate cash
 proceeds of $124.0 million for the Royalty Entitlement.&amp;#xA0;As
 part of this sale, we incurred approximately $4.4 million in
 transaction costs, which will be amortized to interest expense over
 the estimated life of the Purchase and Sale Agreement. Although we
 sold all of our rights to receive royalties from the
 CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 products, as a result of our ongoing manufacturing and supply
 obligations related to the generation of these royalties, we will
 continue to account for these royalties as revenue and recorded the
 $124.0 million in proceeds from this transaction as a liability
 (Royalty Obligation) that will be amortized using the interest
 method over the estimated life of the Purchase and Sale
 Agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 table shows the activity within the liability account during the
 year ended December&amp;#xA0;31, 2014 and for the period from the
 inception of the royalty transaction on February&amp;#xA0;24, 2012
 (inception) to December&amp;#xA0;31, 2014 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Period
 from&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;inception
 to&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Liability related to sale
 of future royalties &amp;#x2014; beginning balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;128,520&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Proceeds from sale of
 future royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;124,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Payments from Nektar to
 RPI&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 royalty revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,937&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(54,783&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash interest expense
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;61,254&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Liability related to sale
 of future royalties &amp;#x2014; ending balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;120,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;120,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to the
 Purchase and Sale Agreement, in March 2014 and March 2013, we were
 required to pay RPI $7.0 million and $3.0 million, respectively, as
 a result of worldwide net sales of MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 for the 12 month periods ended on December&amp;#xA0;31, 2013 and 2012
 not reaching certain minimum thresholds. As of December&amp;#xA0;31,
 2014, we do not expect to make any further payments related to the
 Purchase and Sale Agreement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As a result of
 this liability accounting, even though the royalties from UCB and
 Roche are remitted directly to RPI starting with royalties arising
 from product sales in the first quarter of 2012, we will continue
 to recognize revenue for these royalties. During the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012, we recognized $21.9 million,
 $22.1 million and $10.8 million, respectively, in non-cash
 royalties from net sales of CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As royalties
 are remitted to RPI from Roche and UCB, the balance of the Royalty
 Obligation will be effectively repaid over the life of the
 agreement. In order to determine the amortization of the Royalty
 Obligation, we are required to estimate the total amount of future
 royalty payments to be received by RPI and payments we are required
 to make to RPI as noted above over the life of the agreement. The
 sum of these amounts less the $124.0 million proceeds we received
 will be recorded as interest expense over the life of the Royalty
 Obligation. Since inception, our estimate of this total interest
 expense resulted in an effective annual interest rate of
 approximately 17%. We periodically assess the estimated royalty
 payments to RPI from UCB and Roche and to the extent such payments
 are greater or less than our initial estimates, or the timing of
 such payments is materially different than our original estimates,
 we will prospectively adjust the amortization of the Royalty
 Obligation. There are a number of factors that could materially
 affect the amount and timing of royalty payments from
 CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
 most of which are not within our control. Such factors include, but
 are not limited to, changing standards of care, the introduction of
 competing products, manufacturing or other delays, biosimilar
 competition, intellectual property matters, adverse events that
 result in governmental health authority imposed restrictions on the
 use of the drug products, significant changes in foreign exchange
 rates as the royalties remitted to RPI are made in U.S. dollars
 (USD) while significant portions of the underlying sales of
 CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 are made in currencies other than USD, and other events or
 circumstances that could result in reduced royalty payments from
 CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
 all of which would result in a reduction of non-cash royalty
 revenues and the non-cash interest expense over the life of the
 Royalty Obligation. Conversely, if sales of CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 are more than expected, the non-cash royalty revenues and the
 non-cash interest expense recorded by us would be greater over the
 term of the Royalty Obligation.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In addition,
 the Purchase and Sale Agreement grants RPI the right to receive
 certain reports and other information relating to the Royalty
 Entitlement and contains other representations and warranties,
 covenants and indemnification obligations that are customary for a
 transaction of this nature. To our knowledge, we are currently in
 compliance with these provisions of the Purchase and Sale
 Agreement, however, if we were to breach our obligations, we could
 be required to pay damages to RPI that are not limited to the
 purchase price we received in the sale transaction.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
  <nktr:NumberOfOperatingBusinessSegment contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="Segment" decimals="INF" id="id_5242063_9885C685-27C2-4BF4-8AB3-56F6BB47D791_1_0">1</nktr:NumberOfOperatingBusinessSegment>
  <nktr:LeasesDisclosureTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_7E868262-F6F7-4538-9707-34ADE66CDD06_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note&amp;#xA0;6&amp;#xA0;&amp;#x2014; Leases&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Capital Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We lease office space at 201 Industrial Road in San&amp;#xA0;Carlos,
 California under a capital lease arrangement. Under the terms of
 the lease, rent increases up to 3% annually and the lease
 termination date is October&amp;#xA0;5, 2016. As of November&amp;#xA0;29,
 2010, we ceased use of this space as a result of the relocation of
 our San&amp;#xA0;Carlos operations and corporate headquarters to
 San&amp;#xA0;Francisco, California. As of April 2013, we have subleased
 all of the San Carlos facility and our future minimum rental
 receipts under these subleases total $4.8 million as of
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2014 and 2013, the gross amount of assets
 recorded under capital leases was $2.7 million and
 2.3&amp;#xA0;million, respectively, and the recorded value of these
 assets, net of depreciation, was $1.2 million and $1.0 million,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future minimum payments for our capital leases at December&amp;#xA0;31,
 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;Years ending December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,572&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total minimum payments required&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,015&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: amount representing interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,364&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Present value of future minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capital lease obligation, less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;30, 2009, we entered into an operating sublease
 (Sublease) with Pfizer, Inc. for a 126,285&amp;#xA0;square foot
 facility located in San&amp;#xA0;Francisco, California (Mission Bay
 Facility). Under the terms of the Sublease, we began making
 non-cancelable lease payments in 2014, after the expiration of our
 free rent period on August&amp;#xA0;1, 2014. The Sublease term is 114
 months, commencing in August 2010 and terminating on
 January&amp;#xA0;31, 2020. Monthly base rent will escalate over the
 term of the sublease at various intervals. In addition, throughout
 the term of the Sublease, we are responsible for paying certain
 costs and expenses specified in the Sublease, including insurance
 costs and a pro rata share of operating expenses and applicable
 taxes for the Mission Bay Facility.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our future minimum lease payments for our operating leases at
 December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;Years ending December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total future minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We recognize rent expense on a straight-line basis over the lease
 period. For the years ended December&amp;#xA0;31, 2014, 2013, and 2012,
 rent expense for all our operating leases, including our Mission
 Bay Facility, was approximately $3.2&amp;#xA0;million,
 $2.9&amp;#xA0;million, and $2.8&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;/div&gt;</nktr:LeasesDisclosureTextBlock>
  <nktr:SubleaseTermCommencedEndDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_92DF90E8-E67D-4E50-9C68-8670E882C6AC_1_2">January 31, 2020</nktr:SubleaseTermCommencedEndDate>
  <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_199A4DEB-7C67-48B3-8F43-1889F9788D46_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 table shows the activity within the liability account during the
 year ended December&amp;#xA0;31, 2014 and for the period from the
 inception of the royalty transaction on February&amp;#xA0;24, 2012
 (inception) to December&amp;#xA0;31, 2014 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Period
 from&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;inception
 to&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Liability related to sale
 of future royalties &amp;#x2014; beginning balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;128,520&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Proceeds from sale of
 future royalties&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;124,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Payments from Nektar to
 RPI&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash CIMZIA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 and MIRCERA&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 royalty revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,937&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(54,783&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Non-cash interest expense
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;61,254&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Liability related to sale
 of future royalties &amp;#x2014; ending balance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;120,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;120,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
  <nktr:IncreaseDecreaseInMilestonePaymentLiabilities contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_18">-70000000</nktr:IncreaseDecreaseInMilestonePaymentLiabilities>
  <nktr:PercentageOfAccountsReceivableCustomersTwo contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_1_2">0.31</nktr:PercentageOfAccountsReceivableCustomersTwo>
  <nktr:PercentageCeilingOnRentIncrease contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_ABE47BA0-E1D0-4240-808A-D35D16A869A7_1_0">0.03</nktr:PercentageCeilingOnRentIncrease>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_4">153289000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PercentageOfAmountRealizedUponUltimateSettlement contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_41DC4979-1433-4ABD-B0BF-EB9A6B11D32F_1_0">0.50</nktr:PercentageOfAmountRealizedUponUltimateSettlement>
  <nktr:ValuationAllowanceRelatedToStockBasedCompensationAndExercises contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_551DC194-04C2-4CC9-93DB-82D22D2C18D5_1_1">35600000</nktr:ValuationAllowanceRelatedToStockBasedCompensationAndExercises>
  <nktr:FederalOrphanDrugCreditsExpirationYear contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_56F04FDE-2E72-4FAA-8B91-854C3ECE447B_1_4">2026</nktr:FederalOrphanDrugCreditsExpirationYear>
  <nktr:RoyaltyAgreementContingentPaymentDescription contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_58BED1FB-B316-43FC-ACA3-A3FD861FD2F4_1_2">As a  result of worldwide net sales of MIRCERA for the 12 month periods ended on  December 31, 2013 and 2012 not reaching certain minimum thresholds.</nktr:RoyaltyAgreementContingentPaymentDescription>
  <nktr:PercentageOfAccountsReceivableCustomersThree contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_1_3">0.15</nktr:PercentageOfAccountsReceivableCustomersThree>
  <nktr:NumberOfComponentsWithinBusinessSegment contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="Segment" decimals="INF" id="id_5242063_9885C685-27C2-4BF4-8AB3-56F6BB47D791_1_1">2</nktr:NumberOfComponentsWithinBusinessSegment>
  <nktr:FederalOrphanDrugCredits contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_56F04FDE-2E72-4FAA-8B91-854C3ECE447B_1_3">17700000</nktr:FederalOrphanDrugCredits>
  <nktr:MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_073B67A9-0F35-476B-BD08-5D43767B0980_1_0">Three months</nktr:MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents>
  <nktr:RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_3A642C20-43FD-4A47-96FD-6A02D172A47D_1_0">1.01</nktr:RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl>
  <nktr:CashSeverancePaymentForToChiefExecutiveOfficer contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_6080F13C-C0A6-4FE3-A790-0E4DA2363FC9_1_2">24 months base  salary plus annual target incentive pay</nktr:CashSeverancePaymentForToChiefExecutiveOfficer>
  <nktr:MaximumContributionPerEmployeeAnnualSalaryPercentage contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_5242063_3A04D355-5B32-4D2D-85A3-134942F6D202_1_0">0.60</nktr:MaximumContributionPerEmployeeAnnualSalaryPercentage>
  <nktr:MaturityTermOfInvestmentsConsideredAsShortTerm contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_073B67A9-0F35-476B-BD08-5D43767B0980_1_1">Less than one year</nktr:MaturityTermOfInvestmentsConsideredAsShortTerm>
  <nktr:RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_5242063_3A642C20-43FD-4A47-96FD-6A02D172A47D_1_1">1.00</nktr:RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets>
  <nktr:SignificantConcentrationsPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_DCCD6A6E-89F2-43AD-A8B1-CBEF0A85BEF6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable and Significant Customer
 Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&amp;#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as time and
 materials based billings from collaborative research and
 development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&amp;#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable. At December&amp;#xA0;31, 2014, three different customers
 represented 40%, 31%, and 15%, respectively, of our accounts
 receivable. At December&amp;#xA0;31, 2013, three different customers
 represented 30%, 28%, and 28%, respectively, of our accounts
 receivable.&lt;/p&gt;
 &lt;/div&gt;</nktr:SignificantConcentrationsPolicyTextBlock>
  <nktr:SeverancePaymentPeriodForEmployees contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_6080F13C-C0A6-4FE3-A790-0E4DA2363FC9_1_1">6 months</nktr:SeverancePaymentPeriodForEmployees>
  <nktr:EstimatedAnnualInterestRateOnRoyaltyLiability contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_580D20D0-1491-427F-AEB9-CE9207CE2A10_1_0">0.17</nktr:EstimatedAnnualInterestRateOnRoyaltyLiability>
  <nktr:DebtInstrumentMaximumMaturityPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B21730F0-9E8C-4B73-B8AE-4772081498E3_1_0">Two  years or less</nktr:DebtInstrumentMaximumMaturityPeriod>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_59E1FA07-D108-4667-935F-5DBAD6EA9401_1_0">130300000</nktr:PotentialDevelopmentMilestones>
  <nktr:IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_C0D2118C-30D9-40C5-BC3A-FC4193225466_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss before
 (benefit) provision for income taxes includes the following
 components (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Domestic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,414&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(161,068&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(174,258&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,986&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,300&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,809&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss before (benefit)
 provision for income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(54,428&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(159,768&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(171,449&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</nktr:IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock>
  <nktr:SubleaseTermCommencedPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_92DF90E8-E67D-4E50-9C68-8670E882C6AC_1_1">114 months</nktr:SubleaseTermCommencedPeriod>
  <nktr:SubleaseTermCommencedStartDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_92DF90E8-E67D-4E50-9C68-8670E882C6AC_1_0">August 2010</nktr:SubleaseTermCommencedStartDate>
  <nktr:ComprehensiveLossPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_D971637C-6DE2-4240-ABEA-644A2EFD98A0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss is the change in stockholders&amp;#x2019; equity
 (deficit) from transactions and other events and circumstances
 other than those resulting from investments by stockholders and
 distributions to stockholders. Our other comprehensive income
 (loss) is comprised of net loss, gains and losses from the foreign
 currency translation of the assets and liabilities of our India and
 UK subsidiaries, and unrealized gains and losses on investments in
 available-for-sale securities.&lt;/p&gt;
 &lt;/div&gt;</nktr:ComprehensiveLossPolicyTextBlock>
  <nktr:DebtInstrumentWeightedAverageMaturityPeriodOne contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_B21730F0-9E8C-4B73-B8AE-4772081498E3_1_1">One year or less</nktr:DebtInstrumentWeightedAverageMaturityPeriodOne>
  <nktr:CapitalLeasesTerminationDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_ABE47BA0-E1D0-4240-808A-D35D16A869A7_1_1">2016-10-05</nktr:CapitalLeasesTerminationDate>
  <nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_5C6E27D5-9A0C-42AB-9464-1A692A8F9598_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Inventory and Significant Supplier Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Inventory is generally manufactured upon receipt of firm purchase
 orders from our collaboration partners. Inventory includes direct
 materials, direct labor, and manufacturing overhead and cost is
 determined on a first-in, first-out basis. Inventory is valued at
 the lower of cost or market and defective or excess inventory is
 written down to net realizable value based on historical experience
 or projected usage. Inventory related to our research and
 development activities is expensed when purchased.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.&lt;/p&gt;
 &lt;/div&gt;</nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock>
  <nktr:SeverancePaymentPeriodForExecutives contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_6080F13C-C0A6-4FE3-A790-0E4DA2363FC9_1_0">12 months</nktr:SeverancePaymentPeriodForExecutives>
  <nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_7CABC204-3E4C-43FD-820B-4B321BF4E9EE_1_0">Next twelve months</nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange>
  <nktr:PercentageOfAccountsReceivableCustomersOne contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_5242063_6EB30D57-ED62-4647-B9DE-286496AD4DC3_1_1">0.40</nktr:PercentageOfAccountsReceivableCustomersOne>
  <nktr:ResearchAndDevelopmentExpenditureCredits contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_C2444380-7F26-4DF4-97CA-3FC4530A4A25_1_0">4700000</nktr:ResearchAndDevelopmentExpenditureCredits>
  <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_30">116536000</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_3">21937000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_15">-9197000</nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses>
  <nktr:ConvertibleSubordinatedNotesMaturityDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_DA88A0AA-195D-4546-939E-356A3374AAA9_2_1">2012-09-28</nktr:ConvertibleSubordinatedNotesMaturityDate>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_1_15">20888000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="Reporting_Unit" decimals="INF" id="id_5242063_893E01F7-F605-422C-A2C9-EB3E6D098CE9_1_0">1</nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment>
  <nktr:PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_1_46">5231000</nktr:PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing>
  <nktr:EquipmentPurchaseObligationPayableTerm contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0" id="id_5242063_E5A14F23-DEEF-4544-847B-77BB4ED18D5F_1_2">P3Y</nktr:EquipmentPurchaseObligationPayableTerm>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1268687x1281225" unitRef="shares" decimals="-5" id="id_5242063_EA3D7819-BB85-4F9F-A608-B147069DB7A4_1001_0">21900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1269523x1275948" id="id_5242063_68BF4A20-F552-447A-9B08-C9BA9CB37963_1001_1">7</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:DeferredCompensationArrangementWithIndividualEmployerContribution contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1269523x1275948" unitRef="iso4217_USD" decimals="0" id="id_5242063_3A04D355-5B32-4D2D-85A3-134942F6D202_1001_1">3000</us-gaap:DeferredCompensationArrangementWithIndividualEmployerContribution>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1269523x1277596" id="id_5242063_68BF4A20-F552-447A-9B08-C9BA9CB37963_2001_0">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_5242063_3C4A536B-3B85-4C97-95BF-496B1922193D_1001_1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1_1">7713000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" id="id_5242063_61F72913-FE0C-456D-A6A2-B9B859D74F21_1_1">P4Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1_2">9.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_1_0">6.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1_3">1521000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" id="id_5242063_61F72913-FE0C-456D-A6A2-B9B859D74F21_1_0">P4Y11M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1_3">11.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" id="id_5242063_61F72913-FE0C-456D-A6A2-B9B859D74F21_1_2">P3Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3510C937-E1A8-4F24-9230-6422DCA6F998_1_1">13.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="shares" decimals="-3" id="id_5242063_D8842E54-CF0E-4910-803D-2B41E550BDDB_1_2">4852000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_1_2">15200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_1_1">25900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <nktr:PercentageOfPurchasePriceOfStock contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1277228" unitRef="pure" decimals="2" id="id_5242063_97A846A7-477C-4A6C-B21E-0A65102A3437_1001_1">0.85</nktr:PercentageOfPurchasePriceOfStock>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1379513" id="id_5242063_AD69395A-FC58-4911-B267-2AE6E58C25B0_1001_0">P8Y</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054" unitRef="shares" decimals="INF" id="id_5242063_3F02B2A8-C2E0-4702-BE54-5C97B7F6B1A1_1001_0">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054" id="id_5242063_F0D51B6E-A485-485E-8DBF-6FC9664B7C9B_1001_0">P8Y</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054_1273383x1273921" id="id_5242063_A888C5D6-1F7C-47DE-9906-30BC77CD02CB_1001_1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054_1273383x1505004" id="id_5242063_A888C5D6-1F7C-47DE-9906-30BC77CD02CB_2001_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270436x1272891_1273333x1270636" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_1001_2">168193000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1270436x1272891_1273333x1271500" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_2001_1">32514000</us-gaap:Revenues>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1271118x1349198_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_21927EA5-9299-4E2F-83C1-956F253914D1_1001_1">30000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:DevelopmentMilestonePaymentReceived contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1271118x1349198_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_21927EA5-9299-4E2F-83C1-956F253914D1_1001_2">10000000</nktr:DevelopmentMilestonePaymentReceived>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_1001_2">8328000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1270466" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_2001_0">1161000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1383680" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_3001_1">7528000</us-gaap:ShareBasedCompensation>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1354061_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_2001_1">0.16</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1385879_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_3001_0">0.52</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1465729_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_5001_2">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9004_700023">-386000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9005_800024">-53916000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9001_400019">9775000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9001_400021">4947000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9001_500017">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9001_500020">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9003_600017">116535000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9003_600020">46983000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_9003_600022">17017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279211x1276340" id="id_5242063_480CF8DE-58BA-49A8-88BD-7CC1795997E3_1002_4">2017-07-15</us-gaap:DebtInstrumentMaturityDate>
  <nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1348036" unitRef="iso4217_USD" decimals="-5" id="id_5242063_69EC82E4-6A9E-4089-968E-89D7AFC0A09D_1001_0">21900000</nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1364415_1281318x1505467" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_1001_4">4717000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="-5" id="id_5242063_6301DF67-F49B-4A52-87F2-029C3778D110_1001_0">8000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_3001_2">10258000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="-5" id="id_5242063_2DBAB460-CDFA-47C2-A11B-47E89F95C22D_1001_0">20000000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1492025_1281318x1465729" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_4001_1">12845000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:ConsiderationReceivedForProductDelivered contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1497306_1281318x1465729" unitRef="iso4217_USD" decimals="-5" id="id_5242063_C4652FE9-9847-4304-9012-97A703816B57_1002_0">18600000</nktr:ConsiderationReceivedForProductDelivered>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1570062_1281318x1314996" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_5001_3">5000000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1572230_1281318x1572225" unitRef="iso4217_USD" decimals="-5" id="id_5242063_CAEE3F82-FE77-453C-8D9D-CD96BAD7B522_1001_0">9500000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1591145_1281318x1367107" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_6001_0">105001000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1274075" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_1001_7">742000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2001_5">5258000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2001_2">6141000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <nktr:NetOperatingLossCarryforwardExpirationYear contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1276398" id="id_5242063_F8D6AC6C-9E11-4EDC-8681-2C30828EAC10_1001_4">2015</nktr:NetOperatingLossCarryforwardExpirationYear>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_5242063_56F04FDE-2E72-4FAA-8B91-854C3ECE447B_1001_0">40000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3001_1">502000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <nktr:NetOperatingLossCarryforwardExpirationYear contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1280458" id="id_5242063_F8D6AC6C-9E11-4EDC-8681-2C30828EAC10_2001_1">2018</nktr:NetOperatingLossCarryforwardExpirationYear>
  <nktr:FederalResearchAndDevelopmentCreditsExpirationYear contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1280458" id="id_5242063_56F04FDE-2E72-4FAA-8B91-854C3ECE447B_1001_1">2019</nktr:FederalResearchAndDevelopmentCreditsExpirationYear>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1358779" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F408429D-7CA1-4EA0-A5CC-D788F9F1B57E_1001_0">9000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1358779" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_7001_6">15468000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1358779" unitRef="iso4217_USD" decimals="-5" id="id_5242063_DF0454DD-A88C-42F8-88DB-2AA17B78EE6F_1001_0">53800000</nktr:PotentialDevelopmentMilestones>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1505467" unitRef="iso4217_USD" decimals="-5" id="id_5242063_4D091578-E176-4901-BDD5-74DF9CF57932_1001_0">50000000</nktr:PotentialDevelopmentMilestones>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_3_2">0.622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_20">-129756000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_3_1">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_3_3">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="pure" decimals="3" id="id_5242063_34192D02-5DA9-4B8C-911B-0C0D55F58650_3_0">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="shares" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_22">114820000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_21">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_23">164662000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_25">25000000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_44">1021000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_3_1">2809000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_3_2">1206000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4006_900003">4117000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_1">35399000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_29">2437000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4006_900006">746000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_11">-6031000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_10">5613000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_889BDEDA-6B0F-4AA9-9236-633C64D7E129_3_0">5400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_12">-141201000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_8">591000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_3_6">-171109000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:RepaymentsOfSubordinatedDebt contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_35">172407000</us-gaap:RepaymentsOfSubordinatedDebt>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_17">-30248000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_18">-171449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_47">42548000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_2">4874000</us-gaap:RoyaltyRevenue>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_34">4500000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_16">3298000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_5">81191000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_26">10583000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_7">-2520000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_20">-171855000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_43">9620000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_9">867000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4006_900005">16199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_64D0ECCD-8F2B-4FA8-B2FE-B4BA00428572_3_0">-174258000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_5">16199000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_9">-487000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_38">60000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_9">864000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_17">-9384000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_13">-4034000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_14">15489000</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_8">148675000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3_3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3_8">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_7">-49000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_3_3">470000</us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_39">10125000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_8">-16000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_7">-227000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_1">-60007000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_19">406000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_1">-137000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_7">30428000</us-gaap:CostOfGoodsSold>
  <us-gaap:Depreciation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E5A14F23-DEEF-4544-847B-77BB4ED18D5F_3_0">13800000</us-gaap:Depreciation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_6">14508000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_2A4FEDD4-3B17-4A83-97CB-B523C81B3B28_3_0">2900000</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_16">5278000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_37">26801000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_36">4117000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_3A04D355-5B32-4D2D-85A3-134942F6D202_3_2">900000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_4">6320000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_5">236000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_14">1495000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_27">113020000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_3">1029000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_4">893000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_11">222392000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_2">-48000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxSettlementsForeign contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_6">6510000</us-gaap:IncomeTaxReconciliationTaxSettlementsForeign>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_8107F019-451C-4118-AA37-920815648F07_3_0">2800000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31E4CF89-D53E-4D2C-993F-866F2654C560_3_4">-10000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
  <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_33">77940000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_9">41614000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_12">-122000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_22">307887000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_24">5378000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_3_3">16199000</us-gaap:ShareBasedCompensation>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_AE52213E-C17F-4EA4-AEE8-8A3DACB1225A_3_6">-422000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_10">1675000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_31497301-166E-4E73-BB3A-EDC0104E55F1_3_3">47349000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_19">3275000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3_9">137000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_31">119588000</nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_4">30127000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PaymentForTransactionCosts contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_32">4400000</nktr:PaymentForTransactionCosts>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_3">10791000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_D9657A20-C78B-47FD-BB5E-289E113EF44B_3_15">5547000</nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_3E006206-B2CD-4726-A701-07C091BFA263_3_15">18057000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1268687x1281225" unitRef="shares" decimals="-5" id="id_5242063_EA3D7819-BB85-4F9F-A608-B147069DB7A4_1003_0">18800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_5242063_3C4A536B-3B85-4C97-95BF-496B1922193D_1003_1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1275629" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_3_0">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_5242063_B60ED574-031B-40A0-BDC4-FC1F970AD790_1001_0">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_3_2">15700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_5242063_F0BA1483-C24C-4F2D-B4DA-264CFE1A2C97_3_1">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270436x1272891_1273333x1270636" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_1003_2">46600000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1270436x1272891_1273333x1271500" unitRef="iso4217_USD" decimals="-3" id="id_5242063_E076A7F4-1970-4BE0-A3C7-07C6F36EFD84_2003_1">34591000</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_1003_2">7621000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1270466" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_2003_0">1496000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1383680" unitRef="iso4217_USD" decimals="-3" id="id_5242063_97EFBAE4-F4C3-42BB-AD5D-730585EA1A93_3003_1">7082000</us-gaap:ShareBasedCompensation>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1313684_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_1003_4">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1354061_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_2003_1">0.30</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1465729_1277042x1272910" unitRef="pure" decimals="2" id="id_5242063_F476DC99-FC29-4EA7-9C7A-78209462498E_5003_2">0.23</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276136x1269228" unitRef="iso4217_USD" decimals="-5" id="id_5242063_82B12B15-40FC-45B1-BB2B-1646BC195CD2_1001_0">1700000</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4004_700006">746000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4005_800007">-171855000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1270422" unitRef="shares" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4001_400004">774000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4003_600003">4117000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_5242063_195FA818-6F8F-4FCE-AC09-AB822BE773BA_4003_600005">16199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1348036" unitRef="iso4217_USD" decimals="-5" id="id_5242063_69EC82E4-6A9E-4089-968E-89D7AFC0A09D_1003_0">10800000</nktr:RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1364415_1281318x1505467" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_1003_4">2971000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1425630_1281318x1313684" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_2003_5">2829000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1454928_1281318x1533619" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_3003_2">6238000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1492025_1281318x1465729" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_4003_1">7146000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1570062_1281318x1314996" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_5003_3">5000000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1591145_1281318x1367107" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_6003_0">59000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_2003_2">302000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3003_4">37000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-3" id="id_5242063_7CEB4E04-620C-423D-9A85-3ED0B923A399_3003_1">289000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1410-K0010_STD_366_20121231_0_1281318x1358779" unitRef="iso4217_USD" decimals="-3" id="id_5242063_9FD4D1BA-C85B-41E7-9495-DEE6836FB991_7003_6">5884000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PaymentMadeForMilestoneNotAchievedYearOne contextRef="eol_PE10737---1410-K0010_STD_37_20130331_0_1268826x1359534" unitRef="iso4217_USD" decimals="-5" id="id_5242063_58BED1FB-B316-43FC-ACA3-A3FD861FD2F4_1003_0">3000000</nktr:PaymentMadeForMilestoneNotAchievedYearOne>
  <nktr:PaymentMadeForMilestoneNotAchievedYearTwo contextRef="eol_PE10737---1410-K0010_STD_39_20140331_0_1268826x1443598" unitRef="iso4217_USD" decimals="-5" id="id_5242063_58BED1FB-B316-43FC-ACA3-A3FD861FD2F4_2002_1">7000000</nktr:PaymentMadeForMilestoneNotAchievedYearTwo>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_8">-0.48</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_7">-0.48</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_0">11810000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_4">-45106000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_1">23004000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_5">-55063000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_3">45618000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_5_2">11661000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_8">-0.37</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_7">-0.37</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_0">5795000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_4">-36402000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_1">19771000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_5">-46201000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_3">38338000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_1_2">7907000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_8">-0.37</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_7">-0.37</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_0">10324000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_4">-32605000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_1">33862000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_5">-42748000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_3">52230000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_6_2">5011000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_8">-0.26</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_7">-0.26</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_0">5802000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_4">-22916000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_1">28513000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_5">-32637000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_3">36702000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_2_2">5108000</us-gaap:CostOfGoodsSold>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_92_20091231_0_1279908x1591145_1280342x1273416_1281318x1367107" unitRef="iso4217_USD" decimals="-5" id="id_5242063_E1F649C9-A715-4039-BE0E-9E4C6E76B816_1001_0">125000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1410-K0010_STD_92_20101231_0_1281318x1314996" unitRef="iso4217_USD" decimals="-5" id="id_5242063_981EC8A4-84BC-4D39-8B61-16480266C3CB_1001_0">50000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_8">-0.14</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_7">-0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_0">14672000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_4">-6525000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_1">60909000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_5">-16543000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_3">43914000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_7_2">12877000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_8">0.53</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_7">0.55</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_0">6096000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_4">80321000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_1">132871000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_5">70605000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_3">34200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_3_2">9220000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_8">-0.41</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_7">-0.41</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_0">8040000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_4">-35894000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_1">31146000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_5">-47659000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_3">48248000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_8_2">8960000</us-gaap:CostOfGoodsSold>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_8">-0.35</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_7">-0.35</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_0">7460000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_4">-37488000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_1">19551000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_5">-45683000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_3">38494000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1410-K0010_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5242063_4D2EF4A0-F554-41C8-9261-34AAF8254363_4_2">6298000</us-gaap:CostOfGoodsSold>
  <context id="eol_PE10737---1410-K0010_STD_92_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_92_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_92_20101231_0_1281318x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_92_20091231_0_1279908x1591145_1280342x1273416_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_39_20140331_0_1268826x1443598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nktr:MilestoneScenarioTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-21</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_37_20130331_0_1268826x1359534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nktr:MilestoneScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-02-23</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1281318x1358779">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1280651x1280458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1280651x1276398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1591145_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1570062_1281318x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1492025_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1454928_1281318x1533619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxterHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1425630_1281318x1313684">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AffymaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:OmontysMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1364415_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1279908x1348036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:CimziaAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1276136x1269228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1465729_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:RocheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1354061_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:UcbPharmaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1275930x1313684_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:AffymaxIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1383680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1270466">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1270436x1272891_1273333x1271500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1270436x1272891_1273333x1270636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1270313x1271212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1281318x1358779">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1280458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1276398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1280651x1274075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1591145_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1572230_1281318x1572225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1570062_1281318x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1497306_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1492025_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1454928_1281318x1533619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxterHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1364415_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279908x1348036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:CimziaAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1279211x1276340">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1465729_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:RocheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1385879_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1275930x1354061_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:UcbPharmaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1383680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1270466">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1271118x1349198_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis">nktr:PerformanceMilestonePaymentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270436x1272891_1273333x1271500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270436x1272891_1273333x1270636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054_1273383x1505004">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054_1273383x1273921">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1495054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1379513">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandNonOfficerEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1277228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1270313x1271212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1281318x1358779">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1280458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1276398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1280651x1274075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1591145_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1570062_1281318x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1492025_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1454928_1281318x1533619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxterHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1425630_1281318x1313684">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AffymaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:OmontysMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1364415_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1279908x1348036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:CimziaAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1465729_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:RocheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1404400_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:BayerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1385879_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1275930x1354061_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">nktr:UcbPharmaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1383680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1270466">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1270436x1272891_1273333x1271500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1270436x1272891_1273333x1270636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1270313x1271212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_365_20071231_0_1280342x1273416_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_31_20091231_0_1280342x1459186_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nktr:LicenseOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-12-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_31_20120731_0_1279211x1277063">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_31_20120731_0_1279211x1276340">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_30_20140630_0_1279908x1572230_1281318x1572225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_30_20130630_0_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_29_20120229_0_1279908x1497306_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_29_20120229_0_1279908x1497306_1280342x1273416_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_29_20120229_0_1271118x1349198_1279908x1497306_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis">nktr:PerformanceMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1041_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2012-02-25</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1_20141231_0_1280323x1400250">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-31</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1_20140128_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-28</startDate>
      <endDate>2014-01-28</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1_20140128_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-01-28</startDate>
      <endDate>2014-01-28</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1_20140916_0_1279908x1574670_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-09-16</startDate>
      <endDate>2014-09-16</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_1_20120224_0_1279908x1457294">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-24</startDate>
      <endDate>2012-02-24</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1281318x1505467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1281318x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1280458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1280651x1276398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1280323x1466165">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1280323x1400250">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1574670_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1574669_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1572230_1281318x1572225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1497306_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1492025_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1454928_1281318x1533619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxterHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279908x1422248_1281318x1465729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1279211x1276340">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1277733x1431967_1279908x1574670">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nktr:FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1613541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1446321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1336336">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1277551x1274174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1542878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1457720">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1274094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1276136x1269313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1274866">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1272262_1279908x1574670">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1271500_1279908x1574670">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1273333x1271500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1495054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1411249">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:EquityCompensationPlansApprovedByShareholdersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:EquityCompensationPlansUnapprovedBySecurityHoldersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1277228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1269523x1275948_1270313x1495054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1272304_1274212x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1269048_1274212x1598263">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nktr:CorporateCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0_1269038x1269048_1274212x1268840">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1277551x1274174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1542878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1457720">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1274094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1276136x1269313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1274866">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1273333x1271500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1272304_1274212x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1269048_1274212x1598263">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nktr:CorporateCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0_1269038x1269048_1274212x1268840">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20121231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0_1276401x1268669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20140916_0_1279908x1574670_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-16</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20140916_0_1277733x1534371_1279908x1574670_1281318x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nktr:CardiovascularSafetyStudyNotRequiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-16</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20090930_0_1281318x1560943">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:PfizerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-09-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20120711_0_1279211x1276340">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-11</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20120711_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2012-07-11</instant>
    </period>
  </context>
  <context id="eol_PE10737---1410-K0010_STD_0_20150220_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2015-02-20</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Customer">
    <measure>nktr:Customer</measure>
  </unit>
  <unit id="Segment">
    <measure>nktr:Segment</measure>
  </unit>
  <unit id="Reporting_Unit">
    <measure>nktr:Reporting_Unit</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nktr-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
  xmlns:us-types="http://fasb.org/us-types/2014-01-31"
  xmlns:nktr="http://www.nektar.com/20141231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.nektar.com/20141231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital" id="Role_StatementOfPartnersCapital">
        <link:definition>106 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>107 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>108 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>109 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical" id="Role_StatementOfCashFlowsIndirectParen">
        <link:definition>110 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>111 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>112 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>113 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>114 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock" id="Role_NotesToFinancialStatementsLongTermDebtTextBlock">
        <link:definition>115 - Disclosure - Senior Secured Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock" id="Role_NotesToFinancialStatementsLeasesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
        <link:definition>117 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>118 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>119 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>120 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>121 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>122 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" id="Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
        <link:definition>123 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>124 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>125 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>126 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>128 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsLeasesDisclosureTextBlockTables">
        <link:definition>129 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables" id="Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables">
        <link:definition>130 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>133 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>134 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables">
        <link:definition>135 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>136 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>137 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" id="DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
        <link:definition>138 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" id="DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
        <link:definition>139 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" id="DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
        <link:definition>140 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory" id="DisclosureInventoryInventory">
        <link:definition>141 - Disclosure - Inventory - Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>142 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation" id="DisclosurePropertyPlantAndEquipmentAdditionalInformation">
        <link:definition>143 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation" id="DisclosureSeniorSecuredNotesAdditionalInformation">
        <link:definition>144 - Disclosure - Senior Secured Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation" id="DisclosureLeasesAdditionalInformation">
        <link:definition>145 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases" id="DisclosureLeasesFutureMinimumPaymentsForCapitalLeases">
        <link:definition>146 - Disclosure - Leases - Future Minimum Payments for Capital Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases" id="DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases">
        <link:definition>147 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" id="DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
        <link:definition>148 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties" id="DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties">
        <link:definition>149 - Disclosure - Liability Related to Sale of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>150 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>151 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans" id="DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans">
        <link:definition>152 - Disclosure - Stockholders' Equity - Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" id="DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
        <link:definition>153 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" id="DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
        <link:definition>154 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense" id="DisclosureStockBasedCompensationStockBasedCompensationExpense">
        <link:definition>155 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>156 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions" id="DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions">
        <link:definition>157 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans" id="DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans">
        <link:definition>158 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes" id="DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes">
        <link:definition>159 - Disclosure - Income Taxes - Loss Before (Benefit) Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes" id="DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes">
        <link:definition>160 - Disclosure - Income Taxes - (Benefit) Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>161 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations" id="DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations">
        <link:definition>162 - Disclosure - Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities">
        <link:definition>163 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesUnrecognizedTaxBenefits">
        <link:definition>164 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation" id="DisclosureSegmentReportingAdditionalInformation">
        <link:definition>165 - Disclosure - Segment Reporting - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea" id="DisclosureSegmentReportingRevenueByGeographicArea">
        <link:definition>166 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData" id="DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData">
        <link:definition>167 - Disclosure - Selected Quarterly Financial Data - Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeasesAlternate1" id="DisclosureLeasesFutureMinimumPaymentsForCapitalLeasesAlt1">
        <link:definition>168 - Disclosure - Leases - Future Minimum Payments for Capital Leases (Detail) (Alternate 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="nktr-20141231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="nktr-20141231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="nktr-20141231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="nktr-20141231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedClinicalTrialExpenses" id="nktr_AccruedClinicalTrialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AffymaxIncMember" id="nktr_AffymaxIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllocatedConsideration" id="nktr_AllocatedConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmgenIncMember" id="nktr_AmgenIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AstraZenecaAbMember" id="nktr_AstraZenecaAbMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AstraZenecaMember" id="nktr_AstraZenecaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BaxterHealthcareMember" id="nktr_BaxterHealthcareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BayerHealthcareLlcMember" id="nktr_BayerHealthcareLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BayerMember" id="nktr_BayerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BayFourOneSixFiveFiveOneAmikacinInhaleMember" id="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BuildingAndLeaseholdImprovementsMember" id="nktr_BuildingAndLeaseholdImprovementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CapitalLeasesTerminationDate" id="nktr_CapitalLeasesTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CardiovascularSafetyStudyNotRequiredMember" id="nktr_CardiovascularSafetyStudyNotRequiredMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndInvestmentsInMarketableSecuritiesLineItems" id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndInvestmentsInMarketableSecuritiesTable" id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CashAndRestrictedCash" id="nktr_CashAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" id="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashSeverancePaymentForToChiefExecutiveOfficer" id="nktr_CashSeverancePaymentForToChiefExecutiveOfficer" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CimziaAndMirceraMember" id="nktr_CimziaAndMirceraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComprehensiveLossPolicyTextBlock" id="nktr_ComprehensiveLossPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsiderationReceivedForProductDelivered" id="nktr_ConsiderationReceivedForProductDelivered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentPaymentsReceivableBasedOnDevelopmentEvents" id="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentPaymentsReceivedBasedOnDevelopmentEvents" id="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleSubordinatedNotesMaturityDate" id="nktr_ConvertibleSubordinatedNotesMaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleSubordinatedNotesRepaid" id="nktr_ConvertibleSubordinatedNotesRepaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CorporateCommercialPaperMember" id="nktr_CorporateCommercialPaperMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CumulativeGrossIncomeTaxResearchCredits" id="nktr_CumulativeGrossIncomeTaxResearchCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtCapitalLeaseAndOtherLongTermLiabilities" id="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentExchangedAmount" id="nktr_DebtInstrumentExchangedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentMaximumMaturityPeriod" id="nktr_DebtInstrumentMaximumMaturityPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentWeightedAverageMaturityPeriodOne" id="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedResearchExpenses" id="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsDepreciationPropertyAndEquipment" id="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsFromSaleOfFutureRoyalties" id="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciablePropertyPlantAndEquipmentGross" id="nktr_DepreciablePropertyPlantAndEquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciablePropertyPlantAndEquipmentNet" id="nktr_DepreciablePropertyPlantAndEquipmentNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentMilestonePaymentReceived" id="nktr_DevelopmentMilestonePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="nktr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeMember" id="nktr_EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EntityWidePortfolioCarryingAmountMajorCustomerLineItems" id="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquipmentPurchaseObligationPayableTerm" id="nktr_EquipmentPurchaseObligationPayableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityCompensationPlansApprovedByShareholdersMember" id="nktr_EquityCompensationPlansApprovedByShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityCompensationPlansUnapprovedBySecurityHoldersMember" id="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedAnnualInterestRateOnRoyaltyLiability" id="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalOrphanDrugCredits" id="nktr_FederalOrphanDrugCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalOrphanDrugCreditsExpirationYear" id="nktr_FederalOrphanDrugCreditsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalResearchAndDevelopmentCreditsExpirationYear" id="nktr_FederalResearchAndDevelopmentCreditsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" id="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FovistaMember" id="nktr_FovistaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HemophiliaMember" id="nktr_HemophiliaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" id="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInAccruedClinicalTrialExpenses" id="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInMilestonePaymentLiabilities" id="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" id="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" id="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LaboratoryEquipmentMember" id="nktr_LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesDisclosureTextBlock" id="nktr_LeasesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesLineItems" id="nktr_LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LettersOfCreditOutstanding" id="nktr_LettersOfCreditOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyalties" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsAbstract" id="nktr_LicenseAndCollaborationAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="nktr_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="nktr_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LicenseCollaborationOtherRevenue" id="nktr_LicenseCollaborationOtherRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseOptionMember" id="nktr_LicenseOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaturityTermOfInvestmentsConsideredAsShortTerm" id="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" id="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumContributionPerEmployeeAnnualSalaryPercentage" id="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MergerAndAcquisitionRelatedClaimsMember" id="nktr_MergerAndAcquisitionRelatedClaimsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneScenarioOneMember" id="nktr_MilestoneScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneScenarioTwoMember" id="nktr_MilestoneScenarioTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumRequiredCashBalance" id="nktr_MinimumRequiredCashBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MirceraMember" id="nktr_MirceraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikAndMovantikFixedDoseCombinationProgramMember" id="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikFixedDoseCombinationProgramMember" id="nktr_MovantikFixedDoseCombinationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikMember" id="nktr_MovantikMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetOperatingLossCarryforwardExpirationYear" id="nktr_NetOperatingLossCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetOperatingLossCarryforwardForIncomeTax" id="nktr_NetOperatingLossCarryforwardForIncomeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" id="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NeulastaMember" id="nktr_NeulastaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashInterestExpenseRelatedToSaleOfRoyalties" id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonSecuritiesRelatedClaimsMember" id="nktr_NonSecuritiesRelatedClaimsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfComponentsWithinBusinessSegment" id="nktr_NumberOfComponentsWithinBusinessSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfCustomersAccountedForMajorAccountsReceivable" id="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfOperatingBusinessSegment" id="nktr_NumberOfOperatingBusinessSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfReportingUnitsToEvaluateGoodwillForImpairment" id="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" id="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" id="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OmontysMember" id="nktr_OmontysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingSublease" id="nktr_OperatingSublease" type="num:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OphthotechCorporationMember" id="nktr_OphthotechCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OrganizationPolicyTextBlock" id="nktr_OrganizationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherPartnerMember" id="nktr_OtherPartnerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PartialRepaymentOfRoyaltySaleProceeds" id="nktr_PartialRepaymentOfRoyaltySaleProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentForReimbursementOfCosts" id="nktr_PaymentForReimbursementOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentForTransactionCosts" id="nktr_PaymentForTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentMadeForMilestoneNotAchievedYearOne" id="nktr_PaymentMadeForMilestoneNotAchievedYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentMadeForMilestoneNotAchievedYearTwo" id="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PegasysAndMirceraMember" id="nktr_PegasysAndMirceraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PegasysMember" id="nktr_PegasysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageCeilingOnRentIncrease" id="nktr_PercentageCeilingOnRentIncrease" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAccountsReceivableCustomersOne" id="nktr_PercentageOfAccountsReceivableCustomersOne" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAccountsReceivableCustomersThree" id="nktr_PercentageOfAccountsReceivableCustomersThree" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAccountsReceivableCustomersTwo" id="nktr_PercentageOfAccountsReceivableCustomersTwo" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAmountRealizedUponUltimateSettlement" id="nktr_PercentageOfAmountRealizedUponUltimateSettlement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfPostApprovalStudyCostsToRepay" id="nktr_PercentageOfPostApprovalStudyCostsToRepay" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfPropertyPlantEquipmentNetInAssets" id="nktr_PercentageOfPropertyPlantEquipmentNetInAssets" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfPurchasePriceOfStock" id="nktr_PercentageOfPurchasePriceOfStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceMilestonePaymentsMember" id="nktr_PerformanceMilestonePaymentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PfizerMember" id="nktr_PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialDevelopmentMilestones" id="nktr_PotentialDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" id="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" id="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockShareDesignated" id="nktr_PreferredStockShareDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" id="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromSaleOfPotentialFutureRoyalties" id="nktr_ProceedsFromSaleOfPotentialFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" id="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" id="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseAndSaleAgreementMember" id="nktr_PurchaseAndSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" id="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" id="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" id="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RefundableMilestonePaymentLiabilities" id="nktr_RefundableMilestonePaymentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" id="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentExpenditureCredits" id="nktr_ResearchAndDevelopmentExpenditureCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentMember" id="nktr_ResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedStockUnitsOutstanding" id="nktr_RestrictedStockUnitsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RocheMember" id="nktr_RocheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementContingentPaymentDescription" id="nktr_RoyaltyAgreementContingentPaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" id="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesInformationLineItems" id="nktr_SalesInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfLeasesTable" id="nktr_ScheduleOfLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecuritiesRelatedClaimsMember" id="nktr_SecuritiesRelatedClaimsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorSecuredDebtAbstract" id="nktr_SeniorSecuredDebtAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeverancePaymentPeriodForEmployees" id="nktr_SeverancePaymentPeriodForEmployees" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeverancePaymentPeriodForExecutives" id="nktr_SeverancePaymentPeriodForExecutives" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationPlansShareLimitForEveryOneShare" id="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" id="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantConcentrationsPolicyTextBlock" id="nktr_SignificantConcentrationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseTermCommencedEndDate" id="nktr_SubleaseTermCommencedEndDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseTermCommencedPeriod" id="nktr_SubleaseTermCommencedPeriod" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseTermCommencedStartDate" id="nktr_SubleaseTermCommencedStartDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" id="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" id="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandNonOfficerEquityIncentivePlanMember" id="nktr_TwoThousandNonOfficerEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandTwelveEquityIncentivePlanMember" id="nktr_TwoThousandTwelveEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UcbPharmaMember" id="nktr_UcbPharmaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnderwritersCommissionsAndDiscount" id="nktr_UnderwritersCommissionsAndDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" id="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ValuationAllowanceRelatedToStockBasedCompensationAndExercises" id="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>nktr-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSeniorSecuredNotesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumPaymentsForCapitalLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumPaymentsForCapitalLeasesAlt1" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeasesAlternate1"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefits" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingRevenueByGeographicArea" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RefundableMilestonePaymentLiabilities" xlink:label="nktr_RefundableMilestonePaymentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SeniorLongTermNotes" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nktr_RefundableMilestonePaymentLiabilities" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.3400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nktr_AccruedClinicalTrialExpenses" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.3200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RoyaltyRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInMilestonePaymentLiabilities" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="us-gaap_RepaymentsOfSubordinatedDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.3200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfSubordinatedDebt" order="1.2900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.1700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="nktr_CashAndRestrictedCash" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_ConstructionInProgressGross" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeasesAlternate1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="1.0900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1100" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>nktr-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSeniorSecuredNotesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumPaymentsForCapitalLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefits" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingRevenueByGeographicArea" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersOne" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersThree" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersTwo" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAmountRealizedUponUltimateSettlement" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentExpenditureCredits" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersOne" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersTwo" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersThree" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_ResearchAndDevelopmentExpenditureCredits" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAmountRealizedUponUltimateSettlement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentMaximumMaturityPeriod" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LettersOfCreditOutstanding" xlink:label="nktr_LettersOfCreditOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInstrumentMaximumMaturityPeriod" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_LettersOfCreditOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashAndRestrictedCash" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="nktr_CorporateCommercialPaperMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BuildingAndLeaseholdImprovementsMember" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LaboratoryEquipmentMember" xlink:label="nktr_LaboratoryEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentGross" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentNet" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktr_BuildingAndLeaseholdImprovementsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktr_LaboratoryEquipmentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquipmentPurchaseObligationPayableTerm" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:label="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_EquipmentPurchaseObligationPayableTerm" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesMaturityDate" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesRepaid" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentExchangedAmount" xlink:label="nktr_DebtInstrumentExchangedAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="us-gaap_DebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MinimumRequiredCashBalance" xlink:label="nktr_MinimumRequiredCashBalance"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_DebtInstrumentExchangedAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtIssuanceCosts" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_ConvertibleSubordinatedNotesRepaid" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_ConvertibleSubordinatedNotesMaturityDate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_MinimumRequiredCashBalance" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SeniorNotes" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" xlink:label="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CapitalLeasesTerminationDate" xlink:label="nktr_CapitalLeasesTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LeasesLineItems" xlink:label="nktr_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OperatingSublease" xlink:label="nktr_OperatingSublease"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageCeilingOnRentIncrease" xlink:label="nktr_PercentageCeilingOnRentIncrease"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PfizerMember" xlink:label="nktr_PfizerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ScheduleOfLeasesTable" xlink:label="nktr_ScheduleOfLeasesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedEndDate" xlink:label="nktr_SubleaseTermCommencedEndDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedPeriod" xlink:label="nktr_SubleaseTermCommencedPeriod"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedStartDate" xlink:label="nktr_SubleaseTermCommencedStartDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_PfizerMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_ScheduleOfLeasesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_PercentageCeilingOnRentIncrease" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_CapitalLeasesTerminationDate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasedAssetsGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_OperatingSublease" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_SubleaseTermCommencedStartDate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_SubleaseTermCommencedEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_ScheduleOfLeasesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SubleaseTermCommencedEndDate" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SubleaseTermCommencedStartDate" xlink:to="nktr_SubleaseTermCommencedPeriod" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CimziaAndMirceraMember" xlink:label="nktr_CimziaAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PurchaseAndSaleAgreementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_CimziaAndMirceraMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioOneMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioTwoMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonSecuritiesRelatedClaimsMember" xlink:label="nktr_NonSecuritiesRelatedClaimsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SecuritiesRelatedClaimsMember" xlink:label="nktr_SecuritiesRelatedClaimsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DirectOperatingCostRoyaltyExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_SecuritiesRelatedClaimsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_NonSecuritiesRelatedClaimsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_MergerAndAcquisitionRelatedClaimsMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashSeverancePaymentForToChiefExecutiveOfficer" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EmployeeMember" xlink:label="nktr_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPurchasePriceOfStock" xlink:label="nktr_PercentageOfPurchasePriceOfStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RestrictedStockUnitsOutstanding" xlink:label="nktr_RestrictedStockUnitsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForEmployees" xlink:label="nktr_SeverancePaymentPeriodForEmployees"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForExecutives" xlink:label="nktr_SeverancePaymentPeriodForExecutives"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwoThousandNonOfficerEquityIncentivePlanMember" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UnderwritersCommissionsAndDiscount" xlink:label="nktr_UnderwritersCommissionsAndDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_PreferredStockShareDesignated" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_UnderwritersCommissionsAndDiscount" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_RestrictedStockUnitsOutstanding" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_PercentageOfPurchasePriceOfStock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_SeverancePaymentPeriodForExecutives" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_SeverancePaymentPeriodForEmployees" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_CashSeverancePaymentForToChiefExecutiveOfficer" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_TwoThousandTwelveEquityIncentivePlanMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_TwoThousandNonOfficerEquityIncentivePlanMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nktr_EmployeeMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="1.3200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansApprovedByShareholdersMember" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_EquityCompensationPlansApprovedByShareholdersMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BaxterHealthcareMember" xlink:label="nktr_BaxterHealthcareMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OmontysMember" xlink:label="nktr_OmontysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_NeulastaMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_OmontysMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxterHealthcareMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AffymaxIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AllocatedConsideration" xlink:label="nktr_AllocatedConsideration"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BaxterHealthcareMember" xlink:label="nktr_BaxterHealthcareMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CardiovascularSafetyStudyNotRequiredMember" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DevelopmentMilestonePaymentReceived" xlink:label="nktr_DevelopmentMilestonePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseOptionMember" xlink:label="nktr_LicenseOptionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OmontysMember" xlink:label="nktr_OmontysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MirceraMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_FovistaMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_OmontysMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementGeographicalAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ProductOrServiceAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialDevelopmentMilestones" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_AllocatedConsideration" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ConsiderationReceivedForProductDelivered" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_DevelopmentMilestonePaymentReceived" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PaymentForReimbursementOfCosts" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="nktr_LicenseOptionMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OphthotechCorporationMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxterHealthcareMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AffymaxIncMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="nktr_PerformanceMilestonePaymentsMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="nktr_CardiovascularSafetyStudyNotRequiredMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentMember" xlink:label="nktr_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="nktr_ResearchAndDevelopmentMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CumulativeGrossIncomeTaxResearchCredits" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCredits" xlink:label="nktr_FederalOrphanDrugCredits"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCreditsExpirationYear" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalResearchAndDevelopmentCreditsExpirationYear" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardExpirationYear" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_UndistributedEarningsOfForeignSubsidiaries" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryforwardForIncomeTax" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryforwardExpirationYear" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalResearchAndDevelopmentCreditsExpirationYear" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_CumulativeGrossIncomeTaxResearchCredits" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalOrphanDrugCredits" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalOrphanDrugCreditsExpirationYear" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" order="1.1400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaMember" xlink:label="nktr_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerMember" xlink:label="nktr_BayerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IN" xlink:label="country_IN"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfComponentsWithinBusinessSegment" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfOperatingBusinessSegment" xlink:label="nktr_NumberOfOperatingBusinessSegment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPropertyPlantEquipmentNetInAssets" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SalesInformationLineItems" xlink:label="nktr_SalesInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UcbPharmaMember" xlink:label="nktr_UcbPharmaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_AstraZenecaMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_UcbPharmaMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_RocheMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_BayerMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_AffymaxIncMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_SalesInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_NumberOfOperatingBusinessSegment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_NumberOfComponentsWithinBusinessSegment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SalesInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SalesInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_PercentageOfPropertyPlantEquipmentNetInAssets" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_MajorCustomersAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementGeographicalAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_IN" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:label="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReportableGeographicalComponentsMember" xlink:label="us-gaap_ReportableGeographicalComponentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_ReportableGeographicalComponentsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:to="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="us-gaap_Revenues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConsolidationItemsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_StatementGeographicalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>nktr-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1276885_1_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label id="id_5242063_1276885_2_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label id="id_5242063_1282972_1_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</label>
    <label id="id_5242063_1282972_2_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <label id="id_5242063_1288279_1_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label id="id_5242063_1288279_2_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance of nil at December 31, 2014 and 2013</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses" xlink:type="locator"/>
    <label id="id_5242063_1564243_3_1" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses.</label>
    <label id="id_5242063_1564243_1_1" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expenses</label>
    <label id="id_5242063_1564243_2_1" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AccruedClinicalTrialExpenses" xlink:to="nktr_AccruedClinicalTrialExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1283401_1_1" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label id="id_5242063_1283401_2_1" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <label id="id_5242063_1282041_1_1" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label id="id_5242063_1282041_14_1" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <label id="id_5242063_1282967_1_1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label id="id_5242063_1282967_2_1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <label id="id_5242063_1268669_1_1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <label id="id_5242063_1268669_2_1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label id="id_5242063_1283392_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label id="id_5242063_1283392_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital in excess of par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label id="id_5242063_1273630_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label id="id_5242063_1273630_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital in Excess of Par Value [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label id="id_5242063_1284706_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label id="id_5242063_1284706_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <label id="id_5242063_1287295_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label id="id_5242063_1287295_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1278564_1_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label id="id_5242063_1278564_2_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember" xlink:type="locator"/>
    <label id="id_5242063_1313684_3_1" xlink:label="nktr_AffymaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affymax Inc.</label>
    <label id="id_5242063_1313684_1_1" xlink:label="nktr_AffymaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affymax Inc [Member]</label>
    <label id="id_5242063_1313684_2_1" xlink:label="nktr_AffymaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affymax, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AffymaxIncMember" xlink:to="nktr_AffymaxIncMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AllocatedConsideration" xlink:label="nktr_AllocatedConsideration" xlink:type="locator"/>
    <label id="id_5242063_1613229_3_1" xlink:label="nktr_AllocatedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocated Consideration</label>
    <label id="id_5242063_1613229_1_1" xlink:label="nktr_AllocatedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Consideration</label>
    <label id="id_5242063_1613229_2_1" xlink:label="nktr_AllocatedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated consideration</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AllocatedConsideration" xlink:to="nktr_AllocatedConsideration_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label id="id_5242063_1285222_1_1" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label id="id_5242063_1285222_2_1" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <label id="id_5242063_1285183_1_1" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
    <label id="id_5242063_1285183_2_1" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <label id="id_5242063_1276506_1_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label id="id_5242063_1276506_2_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember" xlink:type="locator"/>
    <label id="id_5242063_1314996_3_1" xlink:label="nktr_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen Inc.</label>
    <label id="id_5242063_1314996_1_1" xlink:label="nktr_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen Inc [Member]</label>
    <label id="id_5242063_1314996_2_1" xlink:label="nktr_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AmgenIncMember" xlink:to="nktr_AmgenIncMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label id="id_5242063_1280165_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label id="id_5242063_1280165_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average diluted securities excluded from diluted net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <label id="id_5242063_1268687_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label id="id_5242063_1268687_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <label id="id_5242063_1268688_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label id="id_5242063_1268688_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <label id="id_5242063_1275318_1_1" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label id="id_5242063_1275318_2_1" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <label id="id_5242063_1287793_1_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label id="id_5242063_1287793_6_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1273668_1_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label id="id_5242063_1273668_2_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label id="id_5242063_1288812_1_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label id="id_5242063_1288812_6_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label id="id_5242063_1276921_1_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label id="id_5242063_1276921_2_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember" xlink:type="locator"/>
    <label id="id_5242063_1367107_3_1" xlink:label="nktr_AstraZenecaAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca AB.</label>
    <label id="id_5242063_1367107_1_1" xlink:label="nktr_AstraZenecaAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca Ab [Member]</label>
    <label id="id_5242063_1367107_2_1" xlink:label="nktr_AstraZenecaAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca AB [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AstraZenecaAbMember" xlink:to="nktr_AstraZenecaAbMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_AstraZenecaMember" xlink:label="nktr_AstraZenecaMember" xlink:type="locator"/>
    <label id="id_5242063_1385879_3_1" xlink:label="nktr_AstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astra Zeneca [Member]</label>
    <label id="id_5242063_1385879_1_1" xlink:label="nktr_AstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca [Member]</label>
    <label id="id_5242063_1385879_2_1" xlink:label="nktr_AstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AstraZenecaMember" xlink:to="nktr_AstraZenecaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <label id="id_5242063_1285760_1_1" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</label>
    <label id="id_5242063_1285760_2_1" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:type="locator"/>
    <label id="id_5242063_1282028_1_1" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss) before Taxes</label>
    <label id="id_5242063_1282028_2_1" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on available-for-sale investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1288320_1_1" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</label>
    <label id="id_5242063_1288320_2_1" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:type="locator"/>
    <label id="id_5242063_1282952_1_1" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds</label>
    <label id="id_5242063_1282952_2_1" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, sold</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" xlink:type="locator"/>
    <label id="id_5242063_1286260_1_1" xlink:label="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Income Tax Expense on Change in Unrealized Holding Gain (Loss)</label>
    <label id="id_5242063_1286260_14_1" xlink:label="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit) on unrealized gain on available-for-sale investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1270313_1_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label id="id_5242063_1270313_2_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_BaxterHealthcareMember" xlink:label="nktr_BaxterHealthcareMember" xlink:type="locator"/>
    <label id="id_5242063_1533619_3_1" xlink:label="nktr_BaxterHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baxter healthcare.</label>
    <label id="id_5242063_1533619_1_1" xlink:label="nktr_BaxterHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baxter Healthcare [Member]</label>
    <label id="id_5242063_1533619_2_1" xlink:label="nktr_BaxterHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baxter Healthcare [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BaxterHealthcareMember" xlink:to="nktr_BaxterHealthcareMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember" xlink:type="locator"/>
    <label id="id_5242063_1505467_3_1" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer Healthcare LLC.</label>
    <label id="id_5242063_1505467_1_1" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer Healthcare Llc [Member]</label>
    <label id="id_5242063_1505467_2_1" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer Healthcare LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BayerHealthcareLlcMember" xlink:to="nktr_BayerHealthcareLlcMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_BayerMember" xlink:label="nktr_BayerMember" xlink:type="locator"/>
    <label id="id_5242063_1404400_3_1" xlink:label="nktr_BayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer [Member]</label>
    <label id="id_5242063_1404400_1_1" xlink:label="nktr_BayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer [Member]</label>
    <label id="id_5242063_1404400_2_1" xlink:label="nktr_BayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BayerMember" xlink:to="nktr_BayerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:type="locator"/>
    <label id="id_5242063_1364415_3_1" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BAY41-6551 (Amikacin Inhale).</label>
    <label id="id_5242063_1364415_1_1" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bay Four One Six Five Five One Amikacin Inhale [Member]</label>
    <label id="id_5242063_1364415_2_1" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAY41-6551 (Amikacin Inhale) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_BuildingAndLeaseholdImprovementsMember" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="locator"/>
    <label id="id_5242063_1542878_3_1" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Building and Leasehold Improvements.</label>
    <label id="id_5242063_1542878_1_1" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building And Leasehold Improvements [Member]</label>
    <label id="id_5242063_1542878_2_1" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building and Leasehold Improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="nktr_BuildingAndLeaseholdImprovementsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross" xlink:type="locator"/>
    <label id="id_5242063_1287325_1_1" xlink:label="us-gaap_CapitalLeasedAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leased Assets, Gross</label>
    <label id="id_5242063_1287325_2_1" xlink:label="us-gaap_CapitalLeasedAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book value of assets, gross</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsGross" xlink:to="us-gaap_CapitalLeasedAssetsGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <label id="id_5242063_1284679_1_1" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <label id="id_5242063_1284679_2_1" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligations, current portion</label>
    <label id="id_5242063_1284679_14_1" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator"/>
    <label id="id_5242063_1282476_1_1" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>
    <label id="id_5242063_1282476_2_1" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligation, less current portion</label>
    <label id="id_5242063_1282476_12_1" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligations, less current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:type="locator"/>
    <label id="id_5242063_1287833_1_1" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Balance Sheet, Assets by Major Class, Net</label>
    <label id="id_5242063_1287833_2_1" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value of assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:to="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <label id="id_5242063_1283815_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</label>
    <label id="id_5242063_1283815_6_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum payments required</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <label id="id_5242063_1283365_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label id="id_5242063_1283365_2_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <label id="id_5242063_1282009_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</label>
    <label id="id_5242063_1282009_2_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <label id="id_5242063_1282010_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</label>
    <label id="id_5242063_1282010_2_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="locator"/>
    <label id="id_5242063_1285261_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</label>
    <label id="id_5242063_1285261_14_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: amount representing interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="locator"/>
    <label id="id_5242063_1282007_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</label>
    <label id="id_5242063_1282007_2_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</label>
    <label id="id_5242063_1282007_6_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" xlink:label="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" xlink:type="locator"/>
    <label id="id_5242063_1288854_1_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Sublease Rentals</label>
    <label id="id_5242063_1288854_2_1" xlink:label="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental receipts under the San Carlos facility subleases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" xlink:to="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CapitalLeasesTerminationDate" xlink:label="nktr_CapitalLeasesTerminationDate" xlink:type="locator"/>
    <label id="id_5242063_1513658_3_1" xlink:label="nktr_CapitalLeasesTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital leases termination date.</label>
    <label id="id_5242063_1513658_1_1" xlink:label="nktr_CapitalLeasesTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases Termination Date</label>
    <label id="id_5242063_1513658_2_1" xlink:label="nktr_CapitalLeasesTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Carlos facility capital leases, termination date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CapitalLeasesTerminationDate" xlink:to="nktr_CapitalLeasesTerminationDate_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CardiovascularSafetyStudyNotRequiredMember" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember" xlink:type="locator"/>
    <label id="id_5242063_1534371_3_1" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiovascular safety study is not required. [Member]</label>
    <label id="id_5242063_1534371_1_1" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular Safety Study Not Required [Member]</label>
    <label id="id_5242063_1534371_2_1" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-approval Cardiovascular Safety Study Not Required [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CardiovascularSafetyStudyNotRequiredMember" xlink:to="nktr_CardiovascularSafetyStudyNotRequiredMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272011_1_1" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label id="id_5242063_1272011_2_1" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_5242063_1285262_1_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label id="id_5242063_1285262_4_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <label id="id_5242063_1285262_5_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <label id="id_5242063_1285262_2_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <label id="id_5242063_1286290_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label id="id_5242063_1286290_6_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1275397_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label id="id_5242063_1275397_2_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments, and Fair Value of Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="locator"/>
    <label id="id_5242063_1295468_3_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</label>
    <label id="id_5242063_1295468_1_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</label>
    <label id="id_5242063_1295468_2_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="locator"/>
    <label id="id_5242063_1553219_3_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</label>
    <label id="id_5242063_1553219_1_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</label>
    <label id="id_5242063_1553219_2_1" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash" xlink:type="locator"/>
    <label id="id_5242063_1408021_3_1" xlink:label="nktr_CashAndRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash</label>
    <label id="id_5242063_1408021_1_1" xlink:label="nktr_CashAndRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash</label>
    <label id="id_5242063_1408021_2_1" xlink:label="nktr_CashAndRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, including restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndRestrictedCash" xlink:to="nktr_CashAndRestrictedCash_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" xlink:label="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1508196_3_1" xlink:label="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Available For Sale Investments [Abstract]</label>
    <label id="id_5242063_1508196_1_1" xlink:label="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Available For Sale Investments [Abstract]</label>
    <label id="id_5242063_1508196_2_1" xlink:label="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Available For Sale Investments [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" xlink:to="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1270378_1_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label id="id_5242063_1270378_2_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="locator"/>
    <label id="id_5242063_1397849_3_1" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</label>
    <label id="id_5242063_1397849_1_1" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</label>
    <label id="id_5242063_1397849_2_1" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and investments in marketable securities</label>
    <label id="id_5242063_1397849_6_1" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments in marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CashSeverancePaymentForToChiefExecutiveOfficer" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer" xlink:type="locator"/>
    <label id="id_5242063_1444405_3_1" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Severance Payment For To Chief Executive Officer</label>
    <label id="id_5242063_1444405_1_1" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Severance Payment For To Chief Executive Officer</label>
    <label id="id_5242063_1444405_2_1" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash severance payment for chief executive officer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashSeverancePaymentForToChiefExecutiveOfficer" xlink:to="nktr_CashSeverancePaymentForToChiefExecutiveOfficer_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CimziaAndMirceraMember" xlink:label="nktr_CimziaAndMirceraMember" xlink:type="locator"/>
    <label id="id_5242063_1348036_3_1" xlink:label="nktr_CimziaAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cimzia And Mircera.</label>
    <label id="id_5242063_1348036_1_1" xlink:label="nktr_CimziaAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cimzia And Mircera [Member]</label>
    <label id="id_5242063_1348036_2_1" xlink:label="nktr_CimziaAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CIMZIA and MIRCERA [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CimziaAndMirceraMember" xlink:to="nktr_CimziaAndMirceraMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label id="id_5242063_1277017_1_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <label id="id_5242063_1277017_2_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:type="locator"/>
    <label id="id_5242063_1268790_1_1" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label id="id_5242063_1268790_2_1" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1268796_1_1" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label id="id_5242063_1268796_2_1" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label id="id_5242063_1282923_1_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label id="id_5242063_1282923_2_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272029_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label id="id_5242063_1272029_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1268805_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label id="id_5242063_1268805_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <label id="id_5242063_1278673_1_1" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label id="id_5242063_1278673_2_1" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares reserved for issuance in equity compensation plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <label id="id_5242063_1270422_1_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label id="id_5242063_1270422_2_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label id="id_5242063_1278675_1_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label id="id_5242063_1278675_2_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label id="id_5242063_1270423_1_1" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label id="id_5242063_1270423_2_1" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label id="id_5242063_1268808_1_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label id="id_5242063_1268808_2_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1268809_1_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label id="id_5242063_1268809_2_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <label id="id_5242063_1282921_1_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label id="id_5242063_1282921_2_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 authorized; 131,216 shares and 116,494 shares issued and outstanding at December 31, 2014 and 2013, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <label id="id_5242063_1283349_1_1" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label id="id_5242063_1283349_6_1" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ComprehensiveLossPolicyTextBlock" xlink:label="nktr_ComprehensiveLossPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1502786_3_1" xlink:label="nktr_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive loss.</label>
    <label id="id_5242063_1502786_1_1" xlink:label="nktr_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Loss Policy [Text Block]</label>
    <label id="id_5242063_1502786_2_1" xlink:label="nktr_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ComprehensiveLossPolicyTextBlock" xlink:to="nktr_ComprehensiveLossPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <label id="id_5242063_1270409_1_1" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label id="id_5242063_1270409_2_1" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <label id="id_5242063_1277042_1_1" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label id="id_5242063_1277042_2_1" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <label id="id_5242063_1273765_1_1" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label id="id_5242063_1273765_2_1" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage revenue from clients</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered" xlink:type="locator"/>
    <label id="id_5242063_1446575_3_1" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration received for product delivered.</label>
    <label id="id_5242063_1446575_1_1" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Received for Product Delivered</label>
    <label id="id_5242063_1446575_2_1" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received for product delivered in 2013</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ConsiderationReceivedForProductDelivered" xlink:to="nktr_ConsiderationReceivedForProductDelivered_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis" xlink:type="locator"/>
    <label id="id_5242063_1270436_1_1" xlink:label="us-gaap_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</label>
    <label id="id_5242063_1270436_2_1" xlink:label="us-gaap_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain" xlink:type="locator"/>
    <label id="id_5242063_1278682_1_1" xlink:label="us-gaap_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</label>
    <label id="id_5242063_1278682_2_1" xlink:label="us-gaap_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_ConsolidationItemsDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277051_1_1" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label id="id_5242063_1277051_2_1" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation, Principles of Consolidation and Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" xlink:type="locator"/>
    <label id="id_5242063_1285294_1_1" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</label>
    <label id="id_5242063_1285294_2_1" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1268826_1_1" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
    <label id="id_5242063_1268826_2_1" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator"/>
    <label id="id_5242063_1273774_1_1" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
    <label id="id_5242063_1273774_2_1" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:type="locator"/>
    <label id="id_5242063_1513403_3_1" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments receivable based on development events.</label>
    <label id="id_5242063_1513403_1_1" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Payments Receivable Based On Development Events</label>
    <label id="id_5242063_1513403_2_1" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" xlink:type="locator"/>
    <label id="id_5242063_1613253_3_1" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments received based on development events.</label>
    <label id="id_5242063_1613253_1_1" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Payments Received Based On Development Events</label>
    <label id="id_5242063_1613253_2_1" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payments received based on development events</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" xlink:to="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember" xlink:type="locator"/>
    <label id="id_5242063_1277063_1_1" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Subordinated Debt [Member]</label>
    <label id="id_5242063_1277063_2_1" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Subordinated Notes [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtMember" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesMaturityDate" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate" xlink:type="locator"/>
    <label id="id_5242063_1569299_3_1" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible subordinated notes maturity date.</label>
    <label id="id_5242063_1569299_1_1" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Subordinated Notes Maturity Date</label>
    <label id="id_5242063_1569299_2_1" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity date of convertible subordinated notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ConvertibleSubordinatedNotesMaturityDate" xlink:to="nktr_ConvertibleSubordinatedNotesMaturityDate_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesRepaid" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid" xlink:type="locator"/>
    <label id="id_5242063_1613233_3_1" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible subordinated notes repaid.</label>
    <label id="id_5242063_1613233_1_1" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Subordinated Notes Repaid</label>
    <label id="id_5242063_1613233_2_1" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible subordinated notes remaining</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ConvertibleSubordinatedNotesRepaid" xlink:to="nktr_ConvertibleSubordinatedNotesRepaid_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember" xlink:type="locator"/>
    <label id="id_5242063_1598263_3_1" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Commercial Paper [Member]</label>
    <label id="id_5242063_1598263_1_1" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Commercial Paper [Member]</label>
    <label id="id_5242063_1598263_2_1" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Commercial Paper [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CorporateCommercialPaperMember" xlink:to="nktr_CorporateCommercialPaperMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <label id="id_5242063_1268840_1_1" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label id="id_5242063_1268840_2_1" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Notes and Bonds [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <label id="id_5242063_1286843_1_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</label>
    <label id="id_5242063_1286843_2_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <label id="id_5242063_1270466_1_1" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</label>
    <label id="id_5242063_1270466_2_1" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <label id="id_5242063_1287875_1_1" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</label>
    <label id="id_5242063_1287875_6_1" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1275457_1_1" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <label id="id_5242063_1275457_2_1" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating costs and expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_CumulativeGrossIncomeTaxResearchCredits" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits" xlink:type="locator"/>
    <label id="id_5242063_1396218_3_1" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative gross income tax research credits.</label>
    <label id="id_5242063_1396218_1_1" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Gross Income Tax Research Credits</label>
    <label id="id_5242063_1396218_2_1" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax research credits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CumulativeGrossIncomeTaxResearchCredits" xlink:to="nktr_CumulativeGrossIncomeTaxResearchCredits_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1286842_1_1" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <label id="id_5242063_1286842_2_1" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label id="id_5242063_1276508_1_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label id="id_5242063_1276508_2_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1287873_1_1" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <label id="id_5242063_1287873_2_1" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1287874_1_1" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1287874_6_1" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272082_1_1" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label id="id_5242063_1272082_2_1" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1287373_1_1" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <label id="id_5242063_1287373_2_1" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1320376_3_1" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Capital Lease And Other Long Term Liabilities</label>
    <label id="id_5242063_1320376_1_1" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Capital Lease And Other Long Term Liabilities</label>
    <label id="id_5242063_1320376_2_1" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" xlink:to="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <label id="id_5242063_1283792_1_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <label id="id_5242063_1283792_2_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of convertible subordinated notes in exchange for senior secured notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1278728_1_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label id="id_5242063_1278728_2_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <label id="id_5242063_1280323_1_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label id="id_5242063_1280323_2_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentExchangedAmount" xlink:label="nktr_DebtInstrumentExchangedAmount" xlink:type="locator"/>
    <label id="id_5242063_1484223_3_1" xlink:label="nktr_DebtInstrumentExchangedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Exchanged Amount</label>
    <label id="id_5242063_1484223_1_1" xlink:label="nktr_DebtInstrumentExchangedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Exchanged Amount</label>
    <label id="id_5242063_1484223_2_1" xlink:label="nktr_DebtInstrumentExchangedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of convertible subordinated notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtInstrumentExchangedAmount" xlink:to="nktr_DebtInstrumentExchangedAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <label id="id_5242063_1270470_1_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label id="id_5242063_1270470_2_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</label>
    <label id="id_5242063_1270470_12_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <label id="id_5242063_1280316_1_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label id="id_5242063_1280316_2_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity date of senior secured notes</label>
    <label id="id_5242063_1280316_12_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, maturity date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentMaximumMaturityPeriod" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod" xlink:type="locator"/>
    <label id="id_5242063_1488478_3_1" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument maximum maturity period.</label>
    <label id="id_5242063_1488478_1_1" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Maximum Maturity Period</label>
    <label id="id_5242063_1488478_2_1" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum maturity term for debt securities investment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtInstrumentMaximumMaturityPeriod" xlink:to="nktr_DebtInstrumentMaximumMaturityPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <label id="id_5242063_1268871_1_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label id="id_5242063_1268871_2_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" xlink:type="locator"/>
    <label id="id_5242063_1506074_3_1" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Weighted Average Maturity Period One</label>
    <label id="id_5242063_1506074_1_1" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Weighted Average Maturity Period One</label>
    <label id="id_5242063_1506074_2_1" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average maturity term for debt securities investment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" xlink:to="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="us-gaap_DebtIssuanceCosts" xlink:type="locator"/>
    <label id="id_5242063_1288906_1_1" xlink:label="us-gaap_DebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</label>
    <label id="id_5242063_1288906_2_1" xlink:label="us-gaap_DebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCosts" xlink:to="us-gaap_DebtIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" xlink:type="locator"/>
    <label id="id_5242063_1286869_1_1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Employer Contribution</label>
    <label id="id_5242063_1286869_2_1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matching 401(k) employer contribution, maximum amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1288921_1_1" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1288921_2_1" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred U.S. income taxes</label>
    <label id="id_5242063_1288921_12_1" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1286331_1_1" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1286331_2_1" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1285325_1_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1285325_6_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1277108_1_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label id="id_5242063_1277108_2_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <label id="id_5242063_1284641_1_1" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</label>
    <label id="id_5242063_1284641_2_1" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="locator"/>
    <label id="id_5242063_1280340_1_1" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</label>
    <label id="id_5242063_1280340_2_1" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" xlink:type="locator"/>
    <label id="id_5242063_1280341_1_1" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</label>
    <label id="id_5242063_1280341_2_1" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1280342_1_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <label id="id_5242063_1280342_2_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <label id="id_5242063_1275514_1_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <label id="id_5242063_1275514_2_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <label id="id_5242063_1284239_1_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</label>
    <label id="id_5242063_1284239_2_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <label id="id_5242063_1281965_1_1" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label id="id_5242063_1281965_2_1" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, less current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized" xlink:type="locator"/>
    <label id="id_5242063_1285327_1_1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <label id="id_5242063_1285327_2_1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue recognized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized" xlink:to="us-gaap_DeferredRevenueRevenueRecognized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1285842_1_1" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1285842_2_1" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:type="locator"/>
    <label id="id_5242063_1337423_3_1" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets, capitalized research expenses.</label>
    <label id="id_5242063_1337423_1_1" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Capitalized Research Expenses</label>
    <label id="id_5242063_1337423_2_1" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:to="nktr_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <label id="id_5242063_1286875_1_1" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
    <label id="id_5242063_1286875_2_1" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:type="locator"/>
    <label id="id_5242063_1378212_3_1" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets depreciation property and equipment.</label>
    <label id="id_5242063_1378212_1_1" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Depreciation Property And Equipment</label>
    <label id="id_5242063_1378212_2_1" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:to="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1543861_3_1" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets From Sale Of Future Royalties</label>
    <label id="id_5242063_1543861_1_1" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets From Sale Of Future Royalties</label>
    <label id="id_5242063_1543861_2_1" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" xlink:to="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <label id="id_5242063_1285845_1_1" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label id="id_5242063_1285845_6_1" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets before valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <label id="id_5242063_1287893_1_1" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label id="id_5242063_1287893_6_1" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <label id="id_5242063_1287895_1_1" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label id="id_5242063_1287895_6_1" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator"/>
    <label id="id_5242063_1277112_1_1" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label id="id_5242063_1277112_2_1" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <label id="id_5242063_1287389_1_1" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label id="id_5242063_1287389_2_1" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <label id="id_5242063_1286340_1_1" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label id="id_5242063_1286340_2_1" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <label id="id_5242063_1286884_1_1" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label id="id_5242063_1286884_2_1" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and other credits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <label id="id_5242063_1286888_1_1" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label id="id_5242063_1286888_2_1" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <label id="id_5242063_1288929_1_1" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label id="id_5242063_1288929_2_1" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves and accruals</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label id="id_5242063_1281963_1_1" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label id="id_5242063_1281963_14_1" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1285105_1_1" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label id="id_5242063_1285105_14_1" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <label id="id_5242063_1287407_1_1" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</label>
    <label id="id_5242063_1287407_2_1" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense in connection with 401(k) retirement plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <label id="id_5242063_1295162_3_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciable Property, plant and equipment, Gross.</label>
    <label id="id_5242063_1295162_1_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciable Property Plant And Equipment Gross</label>
    <label id="id_5242063_1295162_2_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciable property and equipment at cost</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentGross_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label id="id_5242063_1494928_3_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciable Property, plant and equipment, Net.</label>
    <label id="id_5242063_1494928_1_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciable Property Plant And Equipment Net</label>
    <label id="id_5242063_1494928_6_1" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Depreciable property, plant and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <label id="id_5242063_1286908_1_1" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <label id="id_5242063_1286908_2_1" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <label id="id_5242063_1286909_1_1" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label id="id_5242063_1286909_2_1" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DevelopmentMilestonePaymentReceived" xlink:label="nktr_DevelopmentMilestonePaymentReceived" xlink:type="locator"/>
    <label id="id_5242063_1619014_3_1" xlink:label="nktr_DevelopmentMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development milestone payment received.</label>
    <label id="id_5242063_1619014_1_1" xlink:label="nktr_DevelopmentMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payment Received</label>
    <label id="id_5242063_1619014_2_1" xlink:label="nktr_DevelopmentMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone achieved in 2013</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DevelopmentMilestonePaymentReceived" xlink:to="nktr_DevelopmentMilestonePaymentReceived_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense" xlink:type="locator"/>
    <label id="id_5242063_1286919_1_1" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Operating Cost, Royalty Expense</label>
    <label id="id_5242063_1286919_2_1" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCostRoyaltyExpense" xlink:to="us-gaap_DirectOperatingCostRoyaltyExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" xlink:type="locator"/>
    <label id="id_5242063_1273921_1_1" xlink:label="us-gaap_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</label>
    <label id="id_5242063_1273921_2_1" xlink:label="us-gaap_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1273909_1_1" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label id="id_5242063_1273909_2_1" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1278832_1_1" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label id="id_5242063_1278832_2_1" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1272203_1_1" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label id="id_5242063_1272203_2_1" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_DocumentAndEntityInformationAbstract" xlink:label="nktr_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
    <label id="id_5242063_1430739_3_1" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</label>
    <label id="id_5242063_1430739_1_1" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label id="id_5242063_1430739_2_1" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="nktr_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label id="id_5242063_1279677_1_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label id="id_5242063_1279677_2_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label id="id_5242063_1276510_1_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label id="id_5242063_1276510_2_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label id="id_5242063_1274889_1_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label id="id_5242063_1274889_2_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <label id="id_5242063_1269867_1_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label id="id_5242063_1269867_2_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <label id="id_5242063_1280458_1_1" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label id="id_5242063_1280458_2_1" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label id="id_5242063_1275595_1_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label id="id_5242063_1275595_2_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <label id="id_5242063_1277213_1_1" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label id="id_5242063_1277213_2_1" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label id="id_5242063_1278860_1_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label id="id_5242063_1278860_2_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <label id="id_5242063_1268986_1_1" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label id="id_5242063_1268986_2_1" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1268988_1_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label id="id_5242063_1268988_2_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator"/>
    <label id="id_5242063_1270592_1_1" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label id="id_5242063_1270592_2_1" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal provision (benefit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <label id="id_5242063_1278867_1_1" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label id="id_5242063_1278867_2_1" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <label id="id_5242063_1285368_1_1" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label id="id_5242063_1285368_2_1" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EmployeeMember" xlink:label="nktr_EmployeeMember" xlink:type="locator"/>
    <label id="id_5242063_1505004_3_1" xlink:label="nktr_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee [Member]</label>
    <label id="id_5242063_1505004_1_1" xlink:label="nktr_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [Member]</label>
    <label id="id_5242063_1505004_2_1" xlink:label="nktr_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EmployeeMember" xlink:to="nktr_EmployeeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1284606_1_1" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label id="id_5242063_1284606_2_1" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label id="id_5242063_1270610_1_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label id="id_5242063_1270610_2_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <label id="id_5242063_1287944_1_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label id="id_5242063_1287944_2_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <label id="id_5242063_1272251_1_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label id="id_5242063_1272251_2_1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized over a weighted-average period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:type="locator"/>
    <label id="id_5242063_1277228_1_1" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</label>
    <label id="id_5242063_1277228_2_1" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label id="id_5242063_1275629_1_1" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label id="id_5242063_1275629_2_1" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label id="id_5242063_1278115_1_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label id="id_5242063_1278115_2_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1276513_1_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label id="id_5242063_1276513_2_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label id="id_5242063_1281311_1_1" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <label id="id_5242063_1281311_2_1" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <label id="id_5242063_1273139_1_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <label id="id_5242063_1273139_2_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <label id="id_5242063_1271511_1_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label id="id_5242063_1271511_2_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <label id="id_5242063_1284726_1_1" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <label id="id_5242063_1284726_2_1" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <label id="id_5242063_1269875_1_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label id="id_5242063_1269875_2_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <label id="id_5242063_1271521_1_1" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <label id="id_5242063_1271521_2_1" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <label id="id_5242063_1269876_1_1" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label id="id_5242063_1269876_2_1" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:type="locator"/>
    <label id="id_5242063_1406745_3_1" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]</label>
    <label id="id_5242063_1406745_1_1" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]</label>
    <label id="id_5242063_1406745_2_1" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:to="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EquipmentPurchaseObligationPayableTerm" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm" xlink:type="locator"/>
    <label id="id_5242063_1615234_3_1" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Purchase Obligation Payable Term</label>
    <label id="id_5242063_1615234_1_1" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Purchase Obligation Payable Term</label>
    <label id="id_5242063_1615234_2_1" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation related to purchase of equipment liability payable term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EquipmentPurchaseObligationPayableTerm" xlink:to="nktr_EquipmentPurchaseObligationPayableTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <label id="id_5242063_1269012_1_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <label id="id_5242063_1269012_2_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansApprovedByShareholdersMember" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember" xlink:type="locator"/>
    <label id="id_5242063_1411249_3_1" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity compensation plans approved by security holders.</label>
    <label id="id_5242063_1411249_1_1" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Compensation Plans Approved By Shareholders [Member]</label>
    <label id="id_5242063_1411249_2_1" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Compensation Plans Approved by Security Holders [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EquityCompensationPlansApprovedByShareholdersMember" xlink:to="nktr_EquityCompensationPlansApprovedByShareholdersMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" xlink:type="locator"/>
    <label id="id_5242063_1348884_3_1" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity compensation plans approved by security holders.</label>
    <label id="id_5242063_1348884_1_1" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Compensation Plans Unapproved By Security Holders [Member]</label>
    <label id="id_5242063_1348884_2_1" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Compensation Plans Not Approved by Security Holders [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" xlink:to="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label id="id_5242063_1272258_1_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <label id="id_5242063_1272258_2_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:type="locator"/>
    <label id="id_5242063_1484773_3_1" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Annual Interest Rate On Royalty Liability</label>
    <label id="id_5242063_1484773_1_1" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annual Interest Rate On Royalty Liability</label>
    <label id="id_5242063_1484773_2_1" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember" xlink:type="locator"/>
    <label id="id_5242063_1272262_1_1" xlink:label="us-gaap_EuropeanUnionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</label>
    <label id="id_5242063_1272262_2_1" xlink:label="us-gaap_EuropeanUnionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeanUnionMember" xlink:to="us-gaap_EuropeanUnionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember" xlink:type="locator"/>
    <label id="id_5242063_1270636_1_1" xlink:label="us-gaap_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</label>
    <label id="id_5242063_1270636_2_1" xlink:label="us-gaap_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeMember" xlink:to="us-gaap_EuropeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator"/>
    <label id="id_5242063_1280493_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label id="id_5242063_1280493_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <label id="id_5242063_1277254_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label id="id_5242063_1277254_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator"/>
    <label id="id_5242063_1282855_1_1" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label id="id_5242063_1282855_2_1" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 to level 2 transfers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator"/>
    <label id="id_5242063_1283736_1_1" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label id="id_5242063_1283736_2_1" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 to level 1 transfers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1270656_1_1" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label id="id_5242063_1270656_2_1" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <label id="id_5242063_1269038_1_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <label id="id_5242063_1269038_2_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <label id="id_5242063_1274013_1_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label id="id_5242063_1274013_2_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1278936_1_1" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label id="id_5242063_1278936_2_1" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <label id="id_5242063_1272304_1_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label id="id_5242063_1272304_2_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy Level 1 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <label id="id_5242063_1269048_1_1" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <label id="id_5242063_1269048_2_1" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy Level 2 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <label id="id_5242063_1270691_1_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <label id="id_5242063_1270691_2_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCredits" xlink:label="nktr_FederalOrphanDrugCredits" xlink:type="locator"/>
    <label id="id_5242063_1424943_3_1" xlink:label="nktr_FederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal orphan drug credits.</label>
    <label id="id_5242063_1424943_1_1" xlink:label="nktr_FederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Orphan Drug Credits</label>
    <label id="id_5242063_1424943_2_1" xlink:label="nktr_FederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal orphan drug credits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FederalOrphanDrugCredits" xlink:to="nktr_FederalOrphanDrugCredits_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCreditsExpirationYear" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear" xlink:type="locator"/>
    <label id="id_5242063_1411523_3_1" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal Orphan Drug Credits Expiration Year</label>
    <label id="id_5242063_1411523_1_1" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Orphan Drug Credits Expiration Year</label>
    <label id="id_5242063_1411523_2_1" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal orphan drug credits, expiration year</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FederalOrphanDrugCreditsExpirationYear" xlink:to="nktr_FederalOrphanDrugCreditsExpirationYear_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_FederalResearchAndDevelopmentCreditsExpirationYear" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear" xlink:type="locator"/>
    <label id="id_5242063_1452359_3_1" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal Research And Development Credits Expiration Year</label>
    <label id="id_5242063_1452359_1_1" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Research And Development Credits Expiration Year</label>
    <label id="id_5242063_1452359_2_1" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax research credits, expiration year</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FederalResearchAndDevelopmentCreditsExpirationYear" xlink:to="nktr_FederalResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1278976_1_1" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label id="id_5242063_1278976_2_1" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" xlink:type="locator"/>
    <label id="id_5242063_1431967_3_1" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Food and Drug Administration "FDA" and European Medicines Agency "EMA" Approval [Member]</label>
    <label id="id_5242063_1431967_1_1" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Food and Drug Administration and European Medicines Agency Approval [Member]</label>
    <label id="id_5242063_1431967_2_1" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US and EU Commercial Launch [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" xlink:to="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <label id="id_5242063_1274075_1_1" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label id="id_5242063_1274075_2_1" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember" xlink:type="locator"/>
    <label id="id_5242063_1572230_3_1" xlink:label="nktr_FovistaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fovista.</label>
    <label id="id_5242063_1572230_1_1" xlink:label="nktr_FovistaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fovista [Member]</label>
    <label id="id_5242063_1572230_2_1" xlink:label="nktr_FovistaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fovista [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FovistaMember" xlink:to="nktr_FovistaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <label id="id_5242063_1274094_1_1" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <label id="id_5242063_1274094_2_1" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures and Other Equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label id="id_5242063_1288487_1_1" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</label>
    <label id="id_5242063_1288487_2_1" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <label id="id_5242063_1269133_1_1" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label id="id_5242063_1269133_2_1" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:label="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="locator"/>
    <label id="id_5242063_1279026_1_1" xlink:label="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</label>
    <label id="id_5242063_1279026_2_1" xlink:label="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue by geographic area</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <label id="id_5242063_1285421_1_1" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</label>
    <label id="id_5242063_1285421_2_1" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember" xlink:type="locator"/>
    <label id="id_5242063_1454928_3_1" xlink:label="nktr_HemophiliaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia.</label>
    <label id="id_5242063_1454928_1_1" xlink:label="nktr_HemophiliaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia [Member]</label>
    <label id="id_5242063_1454928_2_1" xlink:label="nktr_HemophiliaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAX 855 (Hemophilia) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_HemophiliaMember" xlink:to="nktr_HemophiliaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:label="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:type="locator"/>
    <label id="id_5242063_1286468_1_1" xlink:label="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss</label>
    <label id="id_5242063_1286468_2_1" xlink:label="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:to="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <label id="id_5242063_1289029_1_1" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
    <label id="id_5242063_1289029_2_1" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IN" xlink:label="country_IN" xlink:type="locator"/>
    <label id="id_5242063_1274866_1_1" xlink:label="country_IN_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INDIA</label>
    <label id="id_5242063_1274866_2_1" xlink:label="country_IN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">India [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IN" xlink:to="country_IN_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" xlink:label="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1493448_3_1" xlink:label="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income loss before provision for income taxes.</label>
    <label id="id_5242063_1493448_1_1" xlink:label="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss Before Provision For Income Taxes Table [Text Block]</label>
    <label id="id_5242063_1493448_2_1" xlink:label="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Before (Benefit) Provision for Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" xlink:to="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <label id="id_5242063_1284997_1_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label id="id_5242063_1284997_2_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <label id="id_5242063_1281842_1_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label id="id_5242063_1281842_2_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <label id="id_5242063_1283677_1_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label id="id_5242063_1283677_6_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before (benefit) provision for income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272476_1_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <label id="id_5242063_1272476_2_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label id="id_5242063_1274159_1_1" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label id="id_5242063_1274159_2_1" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label id="id_5242063_1270824_1_1" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label id="id_5242063_1270824_2_1" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <label id="id_5242063_1280651_1_1" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label id="id_5242063_1280651_2_1" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <label id="id_5242063_1279066_1_1" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label id="id_5242063_1279066_2_1" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator"/>
    <label id="id_5242063_1275793_1_1" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
    <label id="id_5242063_1275793_2_1" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:type="locator"/>
    <label id="id_5242063_1279067_1_1" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</label>
    <label id="id_5242063_1279067_2_1" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272478_1_1" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label id="id_5242063_1272478_2_1" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277417_1_1" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label id="id_5242063_1277417_2_1" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <label id="id_5242063_1281841_1_1" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label id="id_5242063_1281841_2_1" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_5242063_1286481_1_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label id="id_5242063_1286481_2_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Benefit) provision for income taxes</label>
    <label id="id_5242063_1286481_6_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Benefit) provision for income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1270827_1_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label id="id_5242063_1270827_2_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label id="id_5242063_1289034_1_1" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label id="id_5242063_1289034_2_1" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <label id="id_5242063_1286479_1_1" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label id="id_5242063_1286479_2_1" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax differential</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <label id="id_5242063_1286480_1_1" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label id="id_5242063_1286480_2_1" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At statutory rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <label id="id_5242063_1287510_1_1" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <label id="id_5242063_1287510_2_1" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <label id="id_5242063_1287511_1_1" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>
    <label id="id_5242063_1287511_2_1" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <label id="id_5242063_1285437_1_1" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label id="id_5242063_1285437_2_1" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <label id="id_5242063_1288018_1_1" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label id="id_5242063_1288018_2_1" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <label id="id_5242063_1283210_1_1" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label id="id_5242063_1283210_2_1" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax research credits</label>
    <label id="id_5242063_1283210_14_1" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research credits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:type="locator"/>
    <label id="id_5242063_1288019_1_1" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Amount</label>
    <label id="id_5242063_1288019_2_1" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax inclusion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <label id="id_5242063_1288515_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label id="id_5242063_1288515_2_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <label id="id_5242063_1284543_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label id="id_5242063_1284543_14_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:type="locator"/>
    <label id="id_5242063_1561127_3_1" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses.</label>
    <label id="id_5242063_1561127_1_1" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accrued Clinical Trial Expenses</label>
    <label id="id_5242063_1561127_2_1" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1287513_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label id="id_5242063_1287513_2_1" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <label id="id_5242063_1285447_1_1" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label id="id_5242063_1285447_2_1" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1285448_1_1" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label id="id_5242063_1285448_2_1" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <label id="id_5242063_1287018_1_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>
    <label id="id_5242063_1287018_2_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <label id="id_5242063_1282774_1_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label id="id_5242063_1282774_14_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInMilestonePaymentLiabilities" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1363099_3_1" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase(Decrease) in Milestone Payment Liabilities</label>
    <label id="id_5242063_1363099_1_1" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase(Decrease) in Milestone Payment Liabilities</label>
    <label id="id_5242063_1363099_2_1" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to receipt of refundable milestone payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" xlink:to="nktr_IncreaseDecreaseInMilestonePaymentLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label id="id_5242063_1279090_1_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label id="id_5242063_1279090_2_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <label id="id_5242063_1282772_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label id="id_5242063_1282772_14_1" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1289051_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <label id="id_5242063_1289051_2_1" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <label id="id_5242063_1281825_1_1" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label id="id_5242063_1281825_14_1" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember" xlink:type="locator"/>
    <label id="id_5242063_1274174_1_1" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</label>
    <label id="id_5242063_1274174_2_1" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification Obligation [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <label id="id_5242063_1285466_1_1" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</label>
    <label id="id_5242063_1285466_14_1" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <label id="id_5242063_1284523_1_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</label>
    <label id="id_5242063_1284523_2_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <label id="id_5242063_1282754_1_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</label>
    <label id="id_5242063_1282754_2_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:label="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1517191_3_1" xlink:label="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory and significant supplier concentrations.</label>
    <label id="id_5242063_1517191_1_1" xlink:label="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory And Significant Supplier Concentrations Policy [Text Block]</label>
    <label id="id_5242063_1517191_2_1" xlink:label="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory and Significant Supplier Concentrations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:to="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1270865_1_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <label id="id_5242063_1270865_2_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1272541_1_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label id="id_5242063_1272541_2_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <label id="id_5242063_1287054_1_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label id="id_5242063_1287054_2_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <label id="id_5242063_1288055_1_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</label>
    <label id="id_5242063_1288055_2_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <label id="id_5242063_1288055_6_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <label id="id_5242063_1288057_1_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label id="id_5242063_1288057_2_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <label id="id_5242063_1289073_1_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label id="id_5242063_1289073_2_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>
    <label id="id_5242063_1287048_1_1" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <label id="id_5242063_1287048_2_1" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1274212_1_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <label id="id_5242063_1274212_2_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <label id="id_5242063_1270878_1_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</label>
    <label id="id_5242063_1270878_2_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" xlink:type="locator"/>
    <label id="id_5242063_1466165_3_1" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">From Jul 1, 2015 through June 30, 2017 [Member].</label>
    <label id="id_5242063_1466165_1_1" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July First Two Thousand Fifteen Through June Thirty Two Thousand Seventeen [Member]</label>
    <label id="id_5242063_1466165_2_1" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 1, 2015 through June 30, 2017 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" xlink:to="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LaboratoryEquipmentMember" xlink:label="nktr_LaboratoryEquipmentMember" xlink:type="locator"/>
    <label id="id_5242063_1457720_3_1" xlink:label="nktr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory equipment.</label>
    <label id="id_5242063_1457720_1_1" xlink:label="nktr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label id="id_5242063_1457720_2_1" xlink:label="nktr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LaboratoryEquipmentMember" xlink:to="nktr_LaboratoryEquipmentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" xlink:type="locator"/>
    <label id="id_5242063_1269228_1_1" xlink:label="us-gaap_LandAndBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Building [Member]</label>
    <label id="id_5242063_1269228_2_1" xlink:label="us-gaap_LandAndBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and Building [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <label id="id_5242063_1288064_1_1" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label id="id_5242063_1288064_2_1" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense for operating leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272548_1_1" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</label>
    <label id="id_5242063_1272548_2_1" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LeasesDisclosureTextBlock" xlink:label="nktr_LeasesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1327228_3_1" xlink:label="nktr_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Disclosure.</label>
    <label id="id_5242063_1327228_1_1" xlink:label="nktr_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Text Block]</label>
    <label id="id_5242063_1327228_2_1" xlink:label="nktr_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LeasesDisclosureTextBlock" xlink:to="nktr_LeasesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LeasesLineItems" xlink:label="nktr_LeasesLineItems" xlink:type="locator"/>
    <label id="id_5242063_1490793_3_1" xlink:label="nktr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</label>
    <label id="id_5242063_1490793_1_1" xlink:label="nktr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</label>
    <label id="id_5242063_1490793_2_1" xlink:label="nktr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_LeasesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <label id="id_5242063_1281318_1_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <label id="id_5242063_1281318_2_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LettersOfCreditOutstanding" xlink:label="nktr_LettersOfCreditOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1525559_3_1" xlink:label="nktr_LettersOfCreditOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Letters Of Credit Outstanding</label>
    <label id="id_5242063_1525559_1_1" xlink:label="nktr_LettersOfCreditOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters Of Credit Outstanding</label>
    <label id="id_5242063_1525559_2_1" xlink:label="nktr_LettersOfCreditOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LettersOfCreditOutstanding" xlink:to="nktr_LettersOfCreditOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <label id="id_5242063_1284515_1_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label id="id_5242063_1284515_6_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label id="id_5242063_1283630_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label id="id_5242063_1283630_6_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_5242063_1275871_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label id="id_5242063_1275871_2_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1282281_1_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label id="id_5242063_1282281_6_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label id="id_5242063_1272565_1_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label id="id_5242063_1272565_2_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="locator"/>
    <label id="id_5242063_1295401_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</label>
    <label id="id_5242063_1295401_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</label>
    <label id="id_5242063_1295401_2_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="locator"/>
    <label id="id_5242063_1350142_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Table]</label>
    <label id="id_5242063_1350142_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Table]</label>
    <label id="id_5242063_1350142_2_1" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1382984_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of potential future royalties.</label>
    <label id="id_5242063_1382984_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties</label>
    <label id="id_5242063_1382984_4_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties - ending balance</label>
    <label id="id_5242063_1382984_5_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties-beginning balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1316283_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Current</label>
    <label id="id_5242063_1316283_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Current</label>
    <label id="id_5242063_1316283_2_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="locator"/>
    <label id="id_5242063_1427390_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</label>
    <label id="id_5242063_1427390_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</label>
    <label id="id_5242063_1427390_2_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, less current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1313594_3_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of potential future royalties.</label>
    <label id="id_5242063_1313594_1_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</label>
    <label id="id_5242063_1313594_2_1" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1359660_3_1" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</label>
    <label id="id_5242063_1359660_1_1" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Abstract]</label>
    <label id="id_5242063_1359660_2_1" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="locator"/>
    <label id="id_5242063_1534348_3_1" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</label>
    <label id="id_5242063_1534348_1_1" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</label>
    <label id="id_5242063_1534348_2_1" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable" xlink:type="locator"/>
    <label id="id_5242063_1345378_3_1" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</label>
    <label id="id_5242063_1345378_1_1" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</label>
    <label id="id_5242063_1345378_2_1" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="nktr_LicenseAndCollaborationAgreementsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue" xlink:type="locator"/>
    <label id="id_5242063_1395416_3_1" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</label>
    <label id="id_5242063_1395416_1_1" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Collaboration Other Revenue</label>
    <label id="id_5242063_1395416_2_1" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, collaboration and other revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseCollaborationOtherRevenue" xlink:to="nktr_LicenseCollaborationOtherRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_LicenseOptionMember" xlink:label="nktr_LicenseOptionMember" xlink:type="locator"/>
    <label id="id_5242063_1459186_3_1" xlink:label="nktr_LicenseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Option.</label>
    <label id="id_5242063_1459186_1_1" xlink:label="nktr_LicenseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Option [Member]</label>
    <label id="id_5242063_1459186_2_1" xlink:label="nktr_LicenseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Extension Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseOptionMember" xlink:to="nktr_LicenseOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator"/>
    <label id="id_5242063_1269270_1_1" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <label id="id_5242063_1269270_2_1" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:type="locator"/>
    <label id="id_5242063_1272587_1_1" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <label id="id_5242063_1272587_2_1" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277547_1_1" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</label>
    <label id="id_5242063_1277547_2_1" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1279211_1_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <label id="id_5242063_1279211_2_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <label id="id_5242063_1270935_1_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <label id="id_5242063_1270935_2_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="locator"/>
    <label id="id_5242063_1277551_1_1" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
    <label id="id_5242063_1277551_2_1" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xlink:type="locator"/>
    <label id="id_5242063_1280798_1_1" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <label id="id_5242063_1280798_2_1" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <label id="id_5242063_1279197_1_1" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</label>
    <label id="id_5242063_1279197_2_1" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator"/>
    <label id="id_5242063_1283601_1_1" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</label>
    <label id="id_5242063_1283601_2_1" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification Obligations, liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:type="locator"/>
    <label id="id_5242063_1279202_1_1" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
    <label id="id_5242063_1279202_2_1" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <label id="id_5242063_1275930_1_1" xlink:label="us-gaap_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</label>
    <label id="id_5242063_1275930_2_1" xlink:label="us-gaap_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:type="locator"/>
    <label id="id_5242063_1269313_1_1" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Facility [Member]</label>
    <label id="id_5242063_1269313_2_1" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" xlink:type="locator"/>
    <label id="id_5242063_1456887_3_1" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity term of investments considered as short term.</label>
    <label id="id_5242063_1456887_1_1" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Term Of Investments Considered As Short Term</label>
    <label id="id_5242063_1456887_2_1" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity term of investments considered as short-term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" xlink:to="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" xlink:type="locator"/>
    <label id="id_5242063_1427439_3_1" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity term of investments in marketable securities to be considered as cash equivalents.</label>
    <label id="id_5242063_1427439_1_1" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Term Of Investments In Marketable Securities To Be Considered As Cash Equivalents</label>
    <label id="id_5242063_1427439_2_1" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum maturity term of investments in marketable securities to be considered as cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" xlink:to="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" xlink:type="locator"/>
    <label id="id_5242063_1445106_3_1" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum contribution per employee annual salary percentage.</label>
    <label id="id_5242063_1445106_1_1" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Contribution Per Employee Annual Salary Percentage</label>
    <label id="id_5242063_1445106_2_1" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum 401(k) per employee, percentage of annual salary</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" xlink:to="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <label id="id_5242063_1275948_1_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label id="id_5242063_1275948_2_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:type="locator"/>
    <label id="id_5242063_1613541_3_1" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger And Acquisition Related Claims [Member]</label>
    <label id="id_5242063_1613541_1_1" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger And Acquisition Related Claims [Member]</label>
    <label id="id_5242063_1613541_2_1" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger and Acquisition Related Claims [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:to="nktr_MergerAndAcquisitionRelatedClaimsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember" xlink:type="locator"/>
    <label id="id_5242063_1359534_3_1" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Scenario One.</label>
    <label id="id_5242063_1359534_1_1" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Scenario One [Member]</label>
    <label id="id_5242063_1359534_2_1" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Scenario One [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MilestoneScenarioOneMember" xlink:to="nktr_MilestoneScenarioOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember" xlink:type="locator"/>
    <label id="id_5242063_1443598_3_1" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Scenario Two.</label>
    <label id="id_5242063_1443598_1_1" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Scenario Two [Member]</label>
    <label id="id_5242063_1443598_2_1" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Scenario Two [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MilestoneScenarioTwoMember" xlink:to="nktr_MilestoneScenarioTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <label id="id_5242063_1277596_1_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <label id="id_5242063_1277596_2_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MinimumRequiredCashBalance" xlink:label="nktr_MinimumRequiredCashBalance" xlink:type="locator"/>
    <label id="id_5242063_1440733_3_1" xlink:label="nktr_MinimumRequiredCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum Required Cash Balance</label>
    <label id="id_5242063_1440733_1_1" xlink:label="nktr_MinimumRequiredCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Required Cash Balance</label>
    <label id="id_5242063_1440733_2_1" xlink:label="nktr_MinimumRequiredCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Cash Requirement (Jul 1, 2015 through June 30, 2017)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MinimumRequiredCashBalance" xlink:to="nktr_MinimumRequiredCashBalance_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember" xlink:type="locator"/>
    <label id="id_5242063_1497306_3_1" xlink:label="nktr_MirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mircera.</label>
    <label id="id_5242063_1497306_1_1" xlink:label="nktr_MirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mircera [Member]</label>
    <label id="id_5242063_1497306_2_1" xlink:label="nktr_MirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MIRCERA [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MirceraMember" xlink:to="nktr_MirceraMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <label id="id_5242063_1277587_1_1" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</label>
    <label id="id_5242063_1277587_2_1" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:type="locator"/>
    <label id="id_5242063_1591145_3_1" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Movantik And Movantik Fixed Dose Combination Program.</label>
    <label id="id_5242063_1591145_1_1" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movantik And Movantik Fixed Dose Combination Program [Member]</label>
    <label id="id_5242063_1591145_2_1" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember" xlink:type="locator"/>
    <label id="id_5242063_1574669_3_1" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Movantik Fixed Dose Combination Program.</label>
    <label id="id_5242063_1574669_1_1" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movantik Fixed Dose Combination Program [Member]</label>
    <label id="id_5242063_1574669_2_1" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movantik Fixed-dose Combination Program [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikFixedDoseCombinationProgramMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember" xlink:type="locator"/>
    <label id="id_5242063_1574670_3_1" xlink:label="nktr_MovantikMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Movantik.</label>
    <label id="id_5242063_1574670_1_1" xlink:label="nktr_MovantikMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movantik [Member]</label>
    <label id="id_5242063_1574670_2_1" xlink:label="nktr_MovantikMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MOVANTIK [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikMember" xlink:to="nktr_MovantikMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <label id="id_5242063_1280859_1_1" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</label>
    <label id="id_5242063_1280859_2_1" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain" xlink:type="locator"/>
    <label id="id_5242063_1275977_1_1" xlink:label="us-gaap_NameOfReportingCategoryDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Reporting Category [Domain]</label>
    <label id="id_5242063_1275977_2_1" xlink:label="us-gaap_NameOfReportingCategoryDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Reporting Category [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="us-gaap_NameOfReportingCategoryDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_5242063_1287111_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label id="id_5242063_1287111_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1269355_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label id="id_5242063_1269355_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_5242063_1287595_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label id="id_5242063_1287595_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1277599_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label id="id_5242063_1277599_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1274345_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label id="id_5242063_1274345_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_5242063_1272684_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label id="id_5242063_1272684_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label id="id_5242063_1284477_1_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label id="id_5242063_1284477_2_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</label>
    <label id="id_5242063_1284477_6_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label id="id_5242063_1284477_12_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardExpirationYear" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear" xlink:type="locator"/>
    <label id="id_5242063_1361184_3_1" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carryforward Expiration Year</label>
    <label id="id_5242063_1361184_1_1" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carryforward Expiration Year</label>
    <label id="id_5242063_1361184_2_1" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward, expiration year</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NetOperatingLossCarryforwardExpirationYear" xlink:to="nktr_NetOperatingLossCarryforwardExpirationYear_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:type="locator"/>
    <label id="id_5242063_1497792_3_1" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward for income tax.</label>
    <label id="id_5242063_1497792_1_1" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carryforward for Income Tax</label>
    <label id="id_5242063_1497792_2_1" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward for income tax</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:to="nktr_NetOperatingLossCarryforwardForIncomeTax_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" xlink:type="locator"/>
    <label id="id_5242063_1613543_3_1" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts included in state net operating losses not MLTN.</label>
    <label id="id_5242063_1613543_1_1" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carry forwards Not Included In Deferred Tax Assets</label>
    <label id="id_5242063_1613543_2_1" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts included in state net operating losses not MLTN</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" xlink:to="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember" xlink:type="locator"/>
    <label id="id_5242063_1570062_3_1" xlink:label="nktr_NeulastaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neulasta.</label>
    <label id="id_5242063_1570062_1_1" xlink:label="nktr_NeulastaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neulasta [Member]</label>
    <label id="id_5242063_1570062_2_1" xlink:label="nktr_NeulastaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neulasta [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NeulastaMember" xlink:to="nktr_NeulastaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1279254_1_1" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label id="id_5242063_1279254_2_1" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1575191_3_1" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</label>
    <label id="id_5242063_1575191_1_1" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Interest Expense Related to Sale of Royalties</label>
    <label id="id_5242063_1575191_2_1" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</label>
    <label id="id_5242063_1575191_12_1" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</label>
    <label id="id_5242063_1575191_14_1" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1541554_3_1" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non cash royalty revenue related to sale future royalties</label>
    <label id="id_5242063_1541554_1_1" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</label>
    <label id="id_5242063_1541554_2_1" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</label>
    <label id="id_5242063_1541554_14_1" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash CIMZIA&#xAe; and MIRCERA&#xAe;royalty revenue</label>
    <label id="id_5242063_1541554_18_1" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <label id="id_5242063_1283571_1_1" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label id="id_5242063_1283571_6_1" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating expense, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <label id="id_5242063_1274361_1_1" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label id="id_5242063_1274361_2_1" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NonSecuritiesRelatedClaimsMember" xlink:label="nktr_NonSecuritiesRelatedClaimsMember" xlink:type="locator"/>
    <label id="id_5242063_1446321_3_1" xlink:label="nktr_NonSecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Securities related claims.</label>
    <label id="id_5242063_1446321_1_1" xlink:label="nktr_NonSecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Securities Related Claims [Member]</label>
    <label id="id_5242063_1446321_2_1" xlink:label="nktr_NonSecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Securities Related Claims [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NonSecuritiesRelatedClaimsMember" xlink:to="nktr_NonSecuritiesRelatedClaimsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NumberOfComponentsWithinBusinessSegment" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment" xlink:type="locator"/>
    <label id="id_5242063_1421782_3_1" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of components within business segment.</label>
    <label id="id_5242063_1421782_1_1" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Components Within Business Segment</label>
    <label id="id_5242063_1421782_2_1" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of components within business segment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NumberOfComponentsWithinBusinessSegment" xlink:to="nktr_NumberOfComponentsWithinBusinessSegment_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" xlink:type="locator"/>
    <label id="id_5242063_1304260_3_1" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of customers accounted for major accounts receivable.</label>
    <label id="id_5242063_1304260_1_1" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Customers Accounted For Major Accounts Receivable</label>
    <label id="id_5242063_1304260_2_1" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of customers accounted for major accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" xlink:to="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NumberOfOperatingBusinessSegment" xlink:label="nktr_NumberOfOperatingBusinessSegment" xlink:type="locator"/>
    <label id="id_5242063_1326212_3_1" xlink:label="nktr_NumberOfOperatingBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating business segment.</label>
    <label id="id_5242063_1326212_1_1" xlink:label="nktr_NumberOfOperatingBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Business Segment</label>
    <label id="id_5242063_1326212_2_1" xlink:label="nktr_NumberOfOperatingBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating business segment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NumberOfOperatingBusinessSegment" xlink:to="nktr_NumberOfOperatingBusinessSegment_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:type="locator"/>
    <label id="id_5242063_1605066_3_1" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of reporting units to evaluate goodwill for impairment</label>
    <label id="id_5242063_1605066_1_1" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Reporting Units To Evaluate Goodwill For Impairment</label>
    <label id="id_5242063_1605066_2_1" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting unit evaluated for goodwill</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:to="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:type="locator"/>
    <label id="id_5242063_1527850_3_1" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of securities remaining available for issuance under equity compensation plans.</label>
    <label id="id_5242063_1527850_1_1" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Securities Available For Issuance Under Equity Compensation Plans</label>
    <label id="id_5242063_1527850_2_1" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:to="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:type="locator"/>
    <label id="id_5242063_1519826_3_1" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Obligations under Director and Officer Indemnifications per incident.</label>
    <label id="id_5242063_1519826_1_1" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligations Under Director And Officer Indemnifications Per Incident</label>
    <label id="id_5242063_1519826_2_1" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligations under Director and Officer Indemnifications per incident</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:to="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OmontysMember" xlink:label="nktr_OmontysMember" xlink:type="locator"/>
    <label id="id_5242063_1425630_3_1" xlink:label="nktr_OmontysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omontys.</label>
    <label id="id_5242063_1425630_1_1" xlink:label="nktr_OmontysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omontys [Member]</label>
    <label id="id_5242063_1425630_2_1" xlink:label="nktr_OmontysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OMONTYS [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OmontysMember" xlink:to="nktr_OmontysMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label id="id_5242063_1283121_1_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label id="id_5242063_1283121_2_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</label>
    <label id="id_5242063_1283121_6_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <label id="id_5242063_1283561_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <label id="id_5242063_1283561_6_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <label id="id_5242063_1284896_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label id="id_5242063_1284896_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <label id="id_5242063_1283562_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label id="id_5242063_1283562_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <label id="id_5242063_1283125_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label id="id_5242063_1283125_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <label id="id_5242063_1283564_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label id="id_5242063_1283564_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <label id="id_5242063_1284469_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label id="id_5242063_1284469_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <label id="id_5242063_1282235_1_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label id="id_5242063_1282235_2_1" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OperatingSublease" xlink:label="nktr_OperatingSublease" xlink:type="locator"/>
    <label id="id_5242063_1341746_3_1" xlink:label="nktr_OperatingSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating sublease.</label>
    <label id="id_5242063_1341746_1_1" xlink:label="nktr_OperatingSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Sublease</label>
    <label id="id_5242063_1341746_2_1" xlink:label="nktr_OperatingSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating sublease</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OperatingSublease" xlink:to="nktr_OperatingSublease_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember" xlink:type="locator"/>
    <label id="id_5242063_1572225_3_1" xlink:label="nktr_OphthotechCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ophthotech Corporation.</label>
    <label id="id_5242063_1572225_1_1" xlink:label="nktr_OphthotechCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthotech Corporation [Member]</label>
    <label id="id_5242063_1572225_2_1" xlink:label="nktr_OphthotechCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ophthotech Corporation [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OphthotechCorporationMember" xlink:to="nktr_OphthotechCorporationMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator"/>
    <label id="id_5242063_1299311_3_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</label>
    <label id="id_5242063_1299311_1_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label id="id_5242063_1299311_2_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator"/>
    <label id="id_5242063_1405018_3_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</label>
    <label id="id_5242063_1405018_1_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <label id="id_5242063_1405018_2_1" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1276020_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label id="id_5242063_1276020_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1279280_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label id="id_5242063_1279280_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="nktr_OrganizationPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1294443_3_1" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization.</label>
    <label id="id_5242063_1294443_1_1" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Policy [Text Block]</label>
    <label id="id_5242063_1294443_2_1" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OrganizationPolicyTextBlock" xlink:to="nktr_OrganizationPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <label id="id_5242063_1288617_1_1" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</label>
    <label id="id_5242063_1288617_2_1" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <label id="id_5242063_1288618_1_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label id="id_5242063_1288618_2_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <label id="id_5242063_1288131_1_1" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</label>
    <label id="id_5242063_1288131_14_1" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net foreign currency translation (loss) gain</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <label id="id_5242063_1282225_1_1" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <label id="id_5242063_1282225_2_1" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss)</label>
    <label id="id_5242063_1282225_6_1" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <label id="id_5242063_1279287_1_1" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label id="id_5242063_1279287_2_1" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_5242063_1281714_1_1" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</label>
    <label id="id_5242063_1281714_2_1" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1274403_1_1" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</label>
    <label id="id_5242063_1274403_2_1" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_5242063_1283538_1_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label id="id_5242063_1283538_2_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <label id="id_5242063_1284439_1_1" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <label id="id_5242063_1284439_14_1" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash transactions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label id="id_5242063_1284001_1_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label id="id_5242063_1284001_2_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income (expense), net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember" xlink:type="locator"/>
    <label id="id_5242063_1358779_3_1" xlink:label="nktr_OtherPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other.</label>
    <label id="id_5242063_1358779_1_1" xlink:label="nktr_OtherPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Partner [Member]</label>
    <label id="id_5242063_1358779_2_1" xlink:label="nktr_OtherPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OtherPartnerMember" xlink:to="nktr_OtherPartnerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:label="nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="locator"/>
    <label id="id_5242063_1299106_3_1" xlink:label="nktr_PartialRepaymentOfRoyaltySaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partial Repayment of Royalty Sale Proceeds</label>
    <label id="id_5242063_1299106_1_1" xlink:label="nktr_PartialRepaymentOfRoyaltySaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partial Repayment of Royalty Sale Proceeds</label>
    <label id="id_5242063_1299106_14_1" xlink:label="nktr_PartialRepaymentOfRoyaltySaleProceeds_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments from Nektar to RPI</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="nktr_PartialRepaymentOfRoyaltySaleProceeds_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts" xlink:type="locator"/>
    <label id="id_5242063_1307077_3_1" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment made to Bayer for cost of Phase 3 clinical trial.</label>
    <label id="id_5242063_1307077_1_1" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Reimbursement Of Costs</label>
    <label id="id_5242063_1307077_2_1" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Bayer for cost of Phase 3 clinical trial</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentForReimbursementOfCosts" xlink:to="nktr_PaymentForReimbursementOfCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PaymentForTransactionCosts" xlink:label="nktr_PaymentForTransactionCosts" xlink:type="locator"/>
    <label id="id_5242063_1536727_3_1" xlink:label="nktr_PaymentForTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Transaction Costs</label>
    <label id="id_5242063_1536727_1_1" xlink:label="nktr_PaymentForTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Transaction Costs</label>
    <label id="id_5242063_1536727_2_1" xlink:label="nktr_PaymentForTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalties transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentForTransactionCosts" xlink:to="nktr_PaymentForTransactionCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:type="locator"/>
    <label id="id_5242063_1361628_3_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Made For Milestone Not Achieved Year One</label>
    <label id="id_5242063_1361628_1_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Made For Milestone Not Achieved Year One</label>
    <label id="id_5242063_1361628_2_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made for milestone not achieved year one</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:type="locator"/>
    <label id="id_5242063_1544601_3_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Made For Milestone Not Achieved Year Two</label>
    <label id="id_5242063_1544601_1_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Made For Milestone Not Achieved Year Two</label>
    <label id="id_5242063_1544601_2_1" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made for milestone not achieved year two</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <label id="id_5242063_1283983_1_1" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label id="id_5242063_1283983_2_1" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <label id="id_5242063_1281683_1_1" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label id="id_5242063_1281683_2_1" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal, accounting fees, filing fees and other offering expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator"/>
    <label id="id_5242063_1281685_1_1" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label id="id_5242063_1281685_14_1" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label id="id_5242063_1284434_1_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label id="id_5242063_1284434_14_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember" xlink:type="locator"/>
    <label id="id_5242063_1492025_3_1" xlink:label="nktr_PegasysAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pegasys And Mircera.</label>
    <label id="id_5242063_1492025_1_1" xlink:label="nktr_PegasysAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pegasys And Mircera [Member]</label>
    <label id="id_5242063_1492025_2_1" xlink:label="nktr_PegasysAndMirceraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEGASYS and MIRCERA [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PegasysAndMirceraMember" xlink:to="nktr_PegasysAndMirceraMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember" xlink:type="locator"/>
    <label id="id_5242063_1422248_3_1" xlink:label="nktr_PegasysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pegasys.</label>
    <label id="id_5242063_1422248_1_1" xlink:label="nktr_PegasysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pegasys [Member]</label>
    <label id="id_5242063_1422248_2_1" xlink:label="nktr_PegasysMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEGASYS [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PegasysMember" xlink:to="nktr_PegasysMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageCeilingOnRentIncrease" xlink:label="nktr_PercentageCeilingOnRentIncrease" xlink:type="locator"/>
    <label id="id_5242063_1382008_3_1" xlink:label="nktr_PercentageCeilingOnRentIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage ceiling on rent increase.</label>
    <label id="id_5242063_1382008_1_1" xlink:label="nktr_PercentageCeilingOnRentIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Ceiling On Rent Increase</label>
    <label id="id_5242063_1382008_2_1" xlink:label="nktr_PercentageCeilingOnRentIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage ceiling on rent increases, annually, capital lease</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageCeilingOnRentIncrease" xlink:to="nktr_PercentageCeilingOnRentIncrease_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersOne" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne" xlink:type="locator"/>
    <label id="id_5242063_1519925_3_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers one.</label>
    <label id="id_5242063_1519925_1_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Accounts Receivable Customers One</label>
    <label id="id_5242063_1519925_2_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers one</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfAccountsReceivableCustomersOne" xlink:to="nktr_PercentageOfAccountsReceivableCustomersOne_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersThree" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree" xlink:type="locator"/>
    <label id="id_5242063_1418112_3_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers three.</label>
    <label id="id_5242063_1418112_1_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Accounts Receivable Customers Three</label>
    <label id="id_5242063_1418112_2_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers three</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfAccountsReceivableCustomersThree" xlink:to="nktr_PercentageOfAccountsReceivableCustomersThree_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersTwo" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo" xlink:type="locator"/>
    <label id="id_5242063_1378119_3_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers two.</label>
    <label id="id_5242063_1378119_1_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Accounts Receivable Customers Two</label>
    <label id="id_5242063_1378119_2_1" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of accounts receivable customers two</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfAccountsReceivableCustomersTwo" xlink:to="nktr_PercentageOfAccountsReceivableCustomersTwo_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfAmountRealizedUponUltimateSettlement" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement" xlink:type="locator"/>
    <label id="id_5242063_1399442_3_1" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of amount realized upon ultimate settlement.</label>
    <label id="id_5242063_1399442_1_1" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Amount Realized Upon Ultimate Settlement</label>
    <label id="id_5242063_1399442_2_1" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum percentage of amount realized upon ultimate settlement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfAmountRealizedUponUltimateSettlement" xlink:to="nktr_PercentageOfAmountRealizedUponUltimateSettlement_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:type="locator"/>
    <label id="id_5242063_1575317_3_1" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of post approval study costs to repay.</label>
    <label id="id_5242063_1575317_1_1" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Post Approval Study Costs to Repay</label>
    <label id="id_5242063_1575317_2_1" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of post approval study costs to repay</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfPropertyPlantEquipmentNetInAssets" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets" xlink:type="locator"/>
    <label id="id_5242063_1335112_3_1" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Property Plant Equipment Net In Assets</label>
    <label id="id_5242063_1335112_1_1" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Property Plant Equipment Net In Assets</label>
    <label id="id_5242063_1335112_2_1" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net book value of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfPropertyPlantEquipmentNetInAssets" xlink:to="nktr_PercentageOfPropertyPlantEquipmentNetInAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PercentageOfPurchasePriceOfStock" xlink:label="nktr_PercentageOfPurchasePriceOfStock" xlink:type="locator"/>
    <label id="id_5242063_1320605_3_1" xlink:label="nktr_PercentageOfPurchasePriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of stock.</label>
    <label id="id_5242063_1320605_1_1" xlink:label="nktr_PercentageOfPurchasePriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Purchase Price Of Stock</label>
    <label id="id_5242063_1320605_2_1" xlink:label="nktr_PercentageOfPurchasePriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfPurchasePriceOfStock" xlink:to="nktr_PercentageOfPurchasePriceOfStock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember" xlink:type="locator"/>
    <label id="id_5242063_1349198_3_1" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Milestone Payments.</label>
    <label id="id_5242063_1349198_1_1" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Milestone Payments [Member]</label>
    <label id="id_5242063_1349198_2_1" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-based Milestone Payments [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PerformanceMilestonePaymentsMember" xlink:to="nktr_PerformanceMilestonePaymentsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PfizerMember" xlink:label="nktr_PfizerMember" xlink:type="locator"/>
    <label id="id_5242063_1560943_3_1" xlink:label="nktr_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</label>
    <label id="id_5242063_1560943_1_1" xlink:label="nktr_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</label>
    <label id="id_5242063_1560943_2_1" xlink:label="nktr_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PfizerMember" xlink:to="nktr_PfizerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones" xlink:type="locator"/>
    <label id="id_5242063_1491199_3_1" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development milestones.</label>
    <label id="id_5242063_1491199_1_1" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development Milestones</label>
    <label id="id_5242063_1491199_2_1" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future additional payments for development milestones</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialDevelopmentMilestones" xlink:to="nktr_PotentialDevelopmentMilestones_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:type="locator"/>
    <label id="id_5242063_1330198_3_1" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</label>
    <label id="id_5242063_1330198_1_1" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</label>
    <label id="id_5242063_1330198_2_1" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential reduction in royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" xlink:type="locator"/>
    <label id="id_5242063_1477035_3_1" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential royalty reduction on US sales to repay post-approval study if required</label>
    <label id="id_5242063_1477035_1_1" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Royalty Reduction on US Sales to Repay Post Approval Study if Required</label>
    <label id="id_5242063_1477035_2_1" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential reduction in U.S. royalty rate for repayment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" xlink:to="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label id="id_5242063_1280976_1_1" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label id="id_5242063_1280976_2_1" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated" xlink:type="locator"/>
    <label id="id_5242063_1414054_3_1" xlink:label="nktr_PreferredStockShareDesignated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock, shares designated.</label>
    <label id="id_5242063_1414054_1_1" xlink:label="nktr_PreferredStockShareDesignated_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Share Designated</label>
    <label id="id_5242063_1414054_2_1" xlink:label="nktr_PreferredStockShareDesignated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PreferredStockShareDesignated" xlink:to="nktr_PreferredStockShareDesignated_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <label id="id_5242063_1279344_1_1" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label id="id_5242063_1279344_2_1" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <label id="id_5242063_1280980_1_1" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label id="id_5242063_1280980_2_1" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1276106_1_1" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label id="id_5242063_1276106_2_1" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <label id="id_5242063_1282154_1_1" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label id="id_5242063_1282154_2_1" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized, no shares designated, issued or outstanding at December 31, 2014 and 2013, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:type="locator"/>
    <label id="id_5242063_1271118_1_1" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Transaction Revenue, Description of Reporting Category [Axis]</label>
    <label id="id_5242063_1271118_2_1" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Transaction Revenue, Description of Reporting Category [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <label id="id_5242063_1280991_1_1" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
    <label id="id_5242063_1280991_2_1" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label id="id_5242063_1287188_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label id="id_5242063_1287188_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="locator"/>
    <label id="id_5242063_1526169_3_1" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</label>
    <label id="id_5242063_1526169_1_1" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</label>
    <label id="id_5242063_1526169_2_1" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <label id="id_5242063_1288185_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</label>
    <label id="id_5242063_1288185_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of senior secured notes, net of $4.5 million of issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="locator"/>
    <label id="id_5242063_1287190_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</label>
    <label id="id_5242063_1287190_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <label id="id_5242063_1288690_1_1" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</label>
    <label id="id_5242063_1288690_2_1" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator"/>
    <label id="id_5242063_1288697_1_1" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</label>
    <label id="id_5242063_1288697_2_1" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyalties" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1370071_3_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of potential future royalties.</label>
    <label id="id_5242063_1370071_1_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties</label>
    <label id="id_5242063_1370071_2_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProceedsFromSaleOfPotentialFutureRoyalties" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="locator"/>
    <label id="id_5242063_1360615_3_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</label>
    <label id="id_5242063_1360615_1_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</label>
    <label id="id_5242063_1360615_2_1" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of royalty rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <label id="id_5242063_1277733_1_1" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</label>
    <label id="id_5242063_1277733_2_1" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <label id="id_5242063_1281004_1_1" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</label>
    <label id="id_5242063_1281004_2_1" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" xlink:label="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" xlink:type="locator"/>
    <label id="id_5242063_1615227_3_1" xlink:label="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property And Equipment Acquired Through Capital Leases And Other Financing</label>
    <label id="id_5242063_1615227_1_1" xlink:label="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property And Equipment Acquired Through Capital Leases And Other Financing</label>
    <label id="id_5242063_1615227_2_1" xlink:label="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment acquired through capital leases and other financing</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" xlink:to="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
    <label id="id_5242063_1277741_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label id="id_5242063_1277741_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label id="id_5242063_1276136_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label id="id_5242063_1276136_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1279373_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label id="id_5242063_1279373_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator"/>
    <label id="id_5242063_1279374_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label id="id_5242063_1279374_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment estimated useful lives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
    <label id="id_5242063_1269502_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label id="id_5242063_1269502_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label id="id_5242063_1285626_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label id="id_5242063_1285626_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <label id="id_5242063_1285626_6_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment, net</label>
    <label id="id_5242063_1285626_12_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1276143_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label id="id_5242063_1276143_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1281009_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label id="id_5242063_1281009_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <label id="id_5242063_1274491_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <label id="id_5242063_1274491_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:type="locator"/>
    <label id="id_5242063_1468839_3_1" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Useful Life and Values [Abstract]</label>
    <label id="id_5242063_1468839_1_1" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Useful Life and Values [Abstract]</label>
    <label id="id_5242063_1468839_2_1" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Useful Life and Values [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember" xlink:type="locator"/>
    <label id="id_5242063_1457294_3_1" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase and sale agreement.</label>
    <label id="id_5242063_1457294_1_1" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase And Sale Agreement [Member]</label>
    <label id="id_5242063_1457294_2_1" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase and Sale Agreement with RPI [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PurchaseAndSaleAgreementMember" xlink:to="nktr_PurchaseAndSaleAgreementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <label id="id_5242063_1283047_1_1" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</label>
    <label id="id_5242063_1283047_2_1" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments related to contract manufacturing, clinical development and certain other items</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <label id="id_5242063_1284808_1_1" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</label>
    <label id="id_5242063_1284808_2_1" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation related to purchase of equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator"/>
    <label id="id_5242063_1277772_1_1" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
    <label id="id_5242063_1277772_2_1" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1276165_1_1" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
    <label id="id_5242063_1276165_2_1" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <label id="id_5242063_1269523_1_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <label id="id_5242063_1269523_2_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <label id="id_5242063_1279402_1_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <label id="id_5242063_1279402_2_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:type="locator"/>
    <label id="id_5242063_1346401_3_1" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</label>
    <label id="id_5242063_1346401_1_1" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</label>
    <label id="id_5242063_1346401_2_1" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" xlink:type="locator"/>
    <label id="id_5242063_1437356_3_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control</label>
    <label id="id_5242063_1437356_1_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control</label>
    <label id="id_5242063_1437356_2_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of repurchase of notes on principal amount of notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" xlink:type="locator"/>
    <label id="id_5242063_1464864_3_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets</label>
    <label id="id_5242063_1464864_1_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets</label>
    <label id="id_5242063_1464864_2_1" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of repurchase of notes on principal amount of notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RefundableMilestonePaymentLiabilities" xlink:label="nktr_RefundableMilestonePaymentLiabilities" xlink:type="locator"/>
    <label id="id_5242063_1438430_3_1" xlink:label="nktr_RefundableMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refundable Milestone Payment Liabilities</label>
    <label id="id_5242063_1438430_1_1" xlink:label="nktr_RefundableMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refundable Milestone Payment Liabilities</label>
    <label id="id_5242063_1438430_2_1" xlink:label="nktr_RefundableMilestonePaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to receipt of refundable milestone payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RefundableMilestonePaymentLiabilities" xlink:to="nktr_RefundableMilestonePaymentLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:type="locator"/>
    <label id="id_5242063_1300789_3_1" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</label>
    <label id="id_5242063_1300789_1_1" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</label>
    <label id="id_5242063_1300789_2_1" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Repayment of) proceeds from sale of future royalties, net of $4.4 million of transaction costs in 2012</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator"/>
    <label id="id_5242063_1282129_1_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label id="id_5242063_1282129_14_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of capital lease obligations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="us-gaap_RepaymentsOfSubordinatedDebt" xlink:type="locator"/>
    <label id="id_5242063_1283462_1_1" xlink:label="us-gaap_RepaymentsOfSubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Subordinated Debt</label>
    <label id="id_5242063_1283462_14_1" xlink:label="us-gaap_RepaymentsOfSubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible subordinated notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSubordinatedDebt" xlink:to="us-gaap_RepaymentsOfSubordinatedDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReportableGeographicalComponentsMember" xlink:label="us-gaap_ReportableGeographicalComponentsMember" xlink:type="locator"/>
    <label id="id_5242063_1272891_1_1" xlink:label="us-gaap_ReportableGeographicalComponentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Geographical Components [Member]</label>
    <label id="id_5242063_1272891_2_1" xlink:label="us-gaap_ReportableGeographicalComponentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Geographical Components [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportableGeographicalComponentsMember" xlink:to="us-gaap_ReportableGeographicalComponentsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentExpenditureCredits" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits" xlink:type="locator"/>
    <label id="id_5242063_1526153_3_1" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expenditure Credits</label>
    <label id="id_5242063_1526153_1_1" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expenditure Credits</label>
    <label id="id_5242063_1526153_2_1" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of prior periods research and development expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ResearchAndDevelopmentExpenditureCredits" xlink:to="nktr_ResearchAndDevelopmentExpenditureCredits_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label id="id_5242063_1285664_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label id="id_5242063_1285664_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <label id="id_5242063_1285664_12_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label id="id_5242063_1276218_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label id="id_5242063_1276218_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentMember" xlink:label="nktr_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <label id="id_5242063_1383680_3_1" xlink:label="nktr_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development.</label>
    <label id="id_5242063_1383680_1_1" xlink:label="nktr_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</label>
    <label id="id_5242063_1383680_2_1" xlink:label="nktr_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ResearchAndDevelopmentMember" xlink:to="nktr_ResearchAndDevelopmentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <label id="id_5242063_1286186_1_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label id="id_5242063_1286186_2_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_5242063_1285658_1_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label id="id_5242063_1285658_2_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="locator"/>
    <label id="id_5242063_1289248_1_1" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</label>
    <label id="id_5242063_1289248_2_1" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RestrictedStockUnitsOutstanding" xlink:label="nktr_RestrictedStockUnitsOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1318492_3_1" xlink:label="nktr_RestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding</label>
    <label id="id_5242063_1318492_1_1" xlink:label="nktr_RestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding</label>
    <label id="id_5242063_1318492_2_1" xlink:label="nktr_RestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RestrictedStockUnitsOutstanding" xlink:to="nktr_RestrictedStockUnitsOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <label id="id_5242063_1271212_1_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label id="id_5242063_1271212_2_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label id="id_5242063_1283021_1_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label id="id_5242063_1283021_2_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label id="id_5242063_1269588_1_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label id="id_5242063_1269588_2_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator"/>
    <label id="id_5242063_1282115_1_1" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label id="id_5242063_1282115_2_1" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestones achieved</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1272964_1_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label id="id_5242063_1272964_2_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <label id="id_5242063_1284373_1_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label id="id_5242063_1284373_2_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</label>
    <label id="id_5242063_1284373_6_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember" xlink:type="locator"/>
    <label id="id_5242063_1465729_3_1" xlink:label="nktr_RocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche.</label>
    <label id="id_5242063_1465729_1_1" xlink:label="nktr_RocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche [Member]</label>
    <label id="id_5242063_1465729_2_1" xlink:label="nktr_RocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RocheMember" xlink:to="nktr_RocheMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription" xlink:type="locator"/>
    <label id="id_5242063_1416159_3_1" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty agreement contingent payment description.</label>
    <label id="id_5242063_1416159_1_1" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreement Contingent Payment Description</label>
    <label id="id_5242063_1416159_2_1" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty agreement contingent payment description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RoyaltyAgreementContingentPaymentDescription" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <label id="id_5242063_1283914_1_1" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</label>
    <label id="id_5242063_1283914_2_1" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" xlink:type="locator"/>
    <label id="id_5242063_1536891_3_1" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Revenue And Non-cash Royalty Revenue From Cimzia And Mircera</label>
    <label id="id_5242063_1536891_1_1" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue And Non-cash Royalty Revenue From Cimzia And Mircera</label>
    <label id="id_5242063_1536891_2_1" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalties from net sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" xlink:to="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SalesInformationLineItems" xlink:label="nktr_SalesInformationLineItems" xlink:type="locator"/>
    <label id="id_5242063_1484884_3_1" xlink:label="nktr_SalesInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Information [Line Items]</label>
    <label id="id_5242063_1484884_1_1" xlink:label="nktr_SalesInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Information [Line Items]</label>
    <label id="id_5242063_1484884_2_1" xlink:label="nktr_SalesInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Information [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_SalesInformationLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <label id="id_5242063_1282106_1_1" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</label>
    <label id="id_5242063_1282106_2_1" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xlink:type="locator"/>
    <label id="id_5242063_1281141_1_1" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net [Abstract]</label>
    <label id="id_5242063_1281141_2_1" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <label id="id_5242063_1272910_1_1" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</label>
    <label id="id_5242063_1272910_2_1" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1274594_1_1" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label id="id_5242063_1274594_2_1" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1269615_1_1" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</label>
    <label id="id_5242063_1269615_2_1" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, Collaboration and Other Revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1274600_1_1" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label id="id_5242063_1274600_2_1" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Benefit) Provision for Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277849_1_1" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label id="id_5242063_1277849_2_1" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Components of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1269624_1_1" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label id="id_5242063_1269624_2_1" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Provision Related to Continuing Operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label id="id_5242063_1276285_1_1" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label id="id_5242063_1276285_2_1" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1272939_1_1" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label id="id_5242063_1272939_2_1" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator"/>
    <label id="id_5242063_1277858_1_1" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <label id="id_5242063_1277858_2_1" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1274615_1_1" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <label id="id_5242063_1274615_2_1" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Payments for Capital Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277866_1_1" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label id="id_5242063_1277866_2_1" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments for Operating Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1271258_1_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label id="id_5242063_1271258_2_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ScheduleOfLeasesTable" xlink:label="nktr_ScheduleOfLeasesTable" xlink:type="locator"/>
    <label id="id_5242063_1508044_3_1" xlink:label="nktr_ScheduleOfLeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Leases [Table]</label>
    <label id="id_5242063_1508044_1_1" xlink:label="nktr_ScheduleOfLeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Leases [Table]</label>
    <label id="id_5242063_1508044_2_1" xlink:label="nktr_ScheduleOfLeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Leases [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ScheduleOfLeasesTable" xlink:to="nktr_ScheduleOfLeasesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:label="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1341123_3_1" xlink:label="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of potential future royalties.</label>
    <label id="id_5242063_1341123_1_1" xlink:label="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties Table [Text Block]</label>
    <label id="id_5242063_1341123_2_1" xlink:label="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Liability Related to Potential Future Royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <label id="id_5242063_1272974_1_1" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label id="id_5242063_1272974_2_1" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1277899_1_1" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label id="id_5242063_1277899_2_1" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1272984_1_1" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</label>
    <label id="id_5242063_1272984_2_1" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue by Geographic Area</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <label id="id_5242063_1274651_1_1" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <label id="id_5242063_1274651_2_1" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <label id="id_5242063_1271276_1_1" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label id="id_5242063_1271276_2_1" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1271278_1_1" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label id="id_5242063_1271278_2_1" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity Under Equity Incentive Plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <label id="id_5242063_1281133_1_1" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <label id="id_5242063_1281133_2_1" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1281136_1_1" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</label>
    <label id="id_5242063_1281136_2_1" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SecuritiesRelatedClaimsMember" xlink:label="nktr_SecuritiesRelatedClaimsMember" xlink:type="locator"/>
    <label id="id_5242063_1336336_3_1" xlink:label="nktr_SecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities related claims.</label>
    <label id="id_5242063_1336336_1_1" xlink:label="nktr_SecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Related Claims [Member]</label>
    <label id="id_5242063_1336336_2_1" xlink:label="nktr_SecuritiesRelatedClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Related Claims [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SecuritiesRelatedClaimsMember" xlink:to="nktr_SecuritiesRelatedClaimsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <label id="id_5242063_1276336_1_1" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</label>
    <label id="id_5242063_1276336_2_1" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xlink:type="locator"/>
    <label id="id_5242063_1279548_1_1" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label id="id_5242063_1279548_2_1" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1271302_1_1" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <label id="id_5242063_1271302_2_1" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes" xlink:type="locator"/>
    <label id="id_5242063_1281607_1_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent</label>
    <label id="id_5242063_1281607_2_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes</label>
    <label id="id_5242063_1281607_12_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes" xlink:type="locator"/>
    <label id="id_5242063_1282104_1_1" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</label>
    <label id="id_5242063_1282104_2_1" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Notes carrying amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <label id="id_5242063_1276340_1_1" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</label>
    <label id="id_5242063_1276340_2_1" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12% Senior Secured Notes Due July 2017 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SeniorSecuredDebtAbstract" xlink:label="nktr_SeniorSecuredDebtAbstract" xlink:type="locator"/>
    <label id="id_5242063_1448135_3_1" xlink:label="nktr_SeniorSecuredDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Debt [Abstract]</label>
    <label id="id_5242063_1448135_1_1" xlink:label="nktr_SeniorSecuredDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Debt [Abstract]</label>
    <label id="id_5242063_1448135_2_1" xlink:label="nktr_SeniorSecuredDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Debt [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SeniorSecuredDebtAbstract" xlink:to="nktr_SeniorSecuredDebtAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <label id="id_5242063_1269676_1_1" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label id="id_5242063_1269676_2_1" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForEmployees" xlink:label="nktr_SeverancePaymentPeriodForEmployees" xlink:type="locator"/>
    <label id="id_5242063_1470849_3_1" xlink:label="nktr_SeverancePaymentPeriodForEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance payment period for employees.</label>
    <label id="id_5242063_1470849_1_1" xlink:label="nktr_SeverancePaymentPeriodForEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payment Period For Employees</label>
    <label id="id_5242063_1470849_2_1" xlink:label="nktr_SeverancePaymentPeriodForEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance payment period for employees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SeverancePaymentPeriodForEmployees" xlink:to="nktr_SeverancePaymentPeriodForEmployees_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForExecutives" xlink:label="nktr_SeverancePaymentPeriodForExecutives" xlink:type="locator"/>
    <label id="id_5242063_1518424_3_1" xlink:label="nktr_SeverancePaymentPeriodForExecutives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance payment period for executives.</label>
    <label id="id_5242063_1518424_1_1" xlink:label="nktr_SeverancePaymentPeriodForExecutives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payment Period For Executives</label>
    <label id="id_5242063_1518424_2_1" xlink:label="nktr_SeverancePaymentPeriodForExecutives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance payment period for executives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SeverancePaymentPeriodForExecutives" xlink:to="nktr_SeverancePaymentPeriodForExecutives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label id="id_5242063_1288753_1_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</label>
    <label id="id_5242063_1288753_2_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" xlink:type="locator"/>
    <label id="id_5242063_1613230_3_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award award exercise period maximum years.</label>
    <label id="id_5242063_1613230_1_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Exercise Period Maximum Years</label>
    <label id="id_5242063_1613230_2_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum term of stock options under equity incentive plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <label id="id_5242063_1277942_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label id="id_5242063_1277942_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period for stock options granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" xlink:type="locator"/>
    <label id="id_5242063_1559830_3_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Maximum Years</label>
    <label id="id_5242063_1559830_1_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Maximum Years</label>
    <label id="id_5242063_1559830_2_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum term of stock options under equity incentive plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <label id="id_5242063_1274705_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label id="id_5242063_1274705_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <label id="id_5242063_1285692_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label id="id_5242063_1285692_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of options vested</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <label id="id_5242063_1273029_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label id="id_5242063_1273029_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <label id="id_5242063_1273030_1_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label id="id_5242063_1273030_2_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average weighted average expected life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label id="id_5242063_1274709_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label id="id_5242063_1274709_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average risk-free interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <label id="id_5242063_1271322_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <label id="id_5242063_1271322_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average volatility factor</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator"/>
    <label id="id_5242063_1269692_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label id="id_5242063_1269692_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <label id="id_5242063_1274711_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label id="id_5242063_1274711_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional new shares available for award grants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <label id="id_5242063_1281179_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label id="id_5242063_1281179_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares available for stock options grants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1530107_3_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options and restricted stock units outstanding.</label>
    <label id="id_5242063_1530107_1_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding</label>
    <label id="id_5242063_1530107_2_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Securities to be Issued Upon Exercise of Outstanding Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <label id="id_5242063_1273034_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label id="id_5242063_1273034_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1273035_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label id="id_5242063_1273035_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label id="id_5242063_1277951_1_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label id="id_5242063_1277951_2_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <label id="id_5242063_1288760_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label id="id_5242063_1288760_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <label id="id_5242063_1273037_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label id="id_5242063_1273037_14_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Options forfeited and canceled</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <label id="id_5242063_1269694_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label id="id_5242063_1269694_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Options granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label id="id_5242063_1271328_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label id="id_5242063_1271328_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <label id="id_5242063_1285691_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label id="id_5242063_1285691_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label id="id_5242063_1281183_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label id="id_5242063_1281183_4_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Outstanding, Ending balance</label>
    <label id="id_5242063_1281183_5_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Outstanding, Beginning balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1271330_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label id="id_5242063_1271330_4_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Outstanding, Ending balance</label>
    <label id="id_5242063_1271330_5_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Outstanding, Beginning balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label id="id_5242063_1276363_1_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label id="id_5242063_1276363_2_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life, Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <label id="id_5242063_1286208_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label id="id_5242063_1286208_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to Vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <label id="id_5242063_1269697_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label id="id_5242063_1269697_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Vested and Expected to Vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1277958_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label id="id_5242063_1277958_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Vested and expected to vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label id="id_5242063_1269698_1_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label id="id_5242063_1269698_2_1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life, Vested and expected to Vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" xlink:type="locator"/>
    <label id="id_5242063_1507235_3_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercisable Intrinsic Value</label>
    <label id="id_5242063_1507235_1_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercisable Intrinsic Value</label>
    <label id="id_5242063_1507235_2_1" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label id="id_5242063_1274697_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <label id="id_5242063_1274697_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1269701_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label id="id_5242063_1269701_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Options exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1276367_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label id="id_5242063_1276367_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Options forfeited and Canceled</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label id="id_5242063_1277960_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label id="id_5242063_1277960_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share, Options granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <label id="id_5242063_1281187_1_1" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label id="id_5242063_1281187_2_1" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:type="locator"/>
    <label id="id_5242063_1422560_3_1" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation plan's share limit for every one share.</label>
    <label id="id_5242063_1422560_1_1" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plans Share Limit For Every One Share</label>
    <label id="id_5242063_1422560_2_1" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:to="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <label id="id_5242063_1269703_1_1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label id="id_5242063_1269703_2_1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price of Outstanding Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" xlink:label="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1308202_3_1" xlink:label="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular Disclosure of shares of common stock for issuance under existing equity compensation plans.</label>
    <label id="id_5242063_1308202_1_1" xlink:label="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Of Common Stock For Issuance Under Existing Equity Compensation Plans Table [Text Block]</label>
    <label id="id_5242063_1308202_2_1" xlink:label="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" xlink:to="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label id="id_5242063_1279581_1_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</label>
    <label id="id_5242063_1279581_4_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Shares</label>
    <label id="id_5242063_1279581_5_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1274716_1_1" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <label id="id_5242063_1274716_2_1" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SignificantConcentrationsPolicyTextBlock" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1470046_3_1" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant concentrations.</label>
    <label id="id_5242063_1470046_1_1" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Concentrations Policy [Text Block]</label>
    <label id="id_5242063_1470046_2_1" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Significant Customer Concentrations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SignificantConcentrationsPolicyTextBlock" xlink:to="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <label id="id_5242063_1276398_1_1" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <label id="id_5242063_1276398_2_1" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label id="id_5242063_1276400_1_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <label id="id_5242063_1276400_2_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label id="id_5242063_1276401_1_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <label id="id_5242063_1276401_2_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <label id="id_5242063_1273333_1_1" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</label>
    <label id="id_5242063_1273333_2_1" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <label id="id_5242063_1279599_1_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <label id="id_5242063_1279599_2_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label id="id_5242063_1281214_1_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label id="id_5242063_1281214_2_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label id="id_5242063_1271363_1_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label id="id_5242063_1271363_2_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator"/>
    <label id="id_5242063_1271364_1_1" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <label id="id_5242063_1271364_2_1" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_5242063_1281215_1_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label id="id_5242063_1281215_2_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <label id="id_5242063_1274733_1_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <label id="id_5242063_1274733_2_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label id="id_5242063_1283431_1_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label id="id_5242063_1283431_4_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <label id="id_5242063_1283431_5_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label id="id_5242063_1283431_6_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity (deficit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_5242063_1276413_1_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label id="id_5242063_1276413_2_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_5242063_1276414_1_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label id="id_5242063_1276414_2_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label id="id_5242063_1274739_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label id="id_5242063_1274739_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</label>
    <label id="id_5242063_1274739_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <label id="id_5242063_1274741_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label id="id_5242063_1274741_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under equity compensation plans, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label id="id_5242063_1281224_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label id="id_5242063_1281224_14_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of Shares, Options exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label id="id_5242063_1281592_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label id="id_5242063_1281592_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock, net of issuance costs of $617</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <label id="id_5242063_1282086_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label id="id_5242063_1282086_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under equity compensation plans</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <label id="id_5242063_1281225_1_1" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</label>
    <label id="id_5242063_1281225_2_1" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedEndDate" xlink:label="nktr_SubleaseTermCommencedEndDate" xlink:type="locator"/>
    <label id="id_5242063_1339671_3_1" xlink:label="nktr_SubleaseTermCommencedEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease term commenced end date.</label>
    <label id="id_5242063_1339671_1_1" xlink:label="nktr_SubleaseTermCommencedEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Term Commenced End Date</label>
    <label id="id_5242063_1339671_2_1" xlink:label="nktr_SubleaseTermCommencedEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Sublease term commenced end date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SubleaseTermCommencedEndDate" xlink:to="nktr_SubleaseTermCommencedEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedPeriod" xlink:label="nktr_SubleaseTermCommencedPeriod" xlink:type="locator"/>
    <label id="id_5242063_1498043_3_1" xlink:label="nktr_SubleaseTermCommencedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease term commenced Period.</label>
    <label id="id_5242063_1498043_1_1" xlink:label="nktr_SubleaseTermCommencedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Term Commenced Period</label>
    <label id="id_5242063_1498043_2_1" xlink:label="nktr_SubleaseTermCommencedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Sublease term commenced period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SubleaseTermCommencedPeriod" xlink:to="nktr_SubleaseTermCommencedPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedStartDate" xlink:label="nktr_SubleaseTermCommencedStartDate" xlink:type="locator"/>
    <label id="id_5242063_1501697_3_1" xlink:label="nktr_SubleaseTermCommencedStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease term commenced start date.</label>
    <label id="id_5242063_1501697_1_1" xlink:label="nktr_SubleaseTermCommencedStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Term Commenced Start Date</label>
    <label id="id_5242063_1501697_2_1" xlink:label="nktr_SubleaseTermCommencedStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Sublease term commenced start date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SubleaseTermCommencedStartDate" xlink:to="nktr_SubleaseTermCommencedStartDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <label id="id_5242063_1271385_1_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label id="id_5242063_1271385_2_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract" xlink:type="locator"/>
    <label id="id_5242063_1276429_1_1" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</label>
    <label id="id_5242063_1276429_2_1" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <label id="id_5242063_1273383_1_1" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <label id="id_5242063_1273383_2_1" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <label id="id_5242063_1276433_1_1" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <label id="id_5242063_1276433_2_1" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <label id="id_5242063_1269880_1_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label id="id_5242063_1269880_2_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:type="locator"/>
    <label id="id_5242063_1452842_3_1" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction costs related to sale of potential future royalties.</label>
    <label id="id_5242063_1452842_1_1" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs Related To Sale Of Potential Future Royalties</label>
    <label id="id_5242063_1452842_2_1" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to sale of potential future royalties</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:to="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" xlink:type="locator"/>
    <label id="id_5242063_1400250_3_1" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twelve Percent Senior Secured Notes Due July Two Thousand Seventeen [Member]</label>
    <label id="id_5242063_1400250_1_1" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twelve Percent Senior Secured Notes Due July Two Thousand Seventeen [Member]</label>
    <label id="id_5242063_1400250_2_1" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12% Senior Secured Notes Due July 2017 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" xlink:to="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_TwoThousandNonOfficerEquityIncentivePlanMember" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember" xlink:type="locator"/>
    <label id="id_5242063_1379513_3_1" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2000 Non-Officer Equity Incentive Plan.</label>
    <label id="id_5242063_1379513_1_1" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Non Officer Equity Incentive Plan [Member]</label>
    <label id="id_5242063_1379513_2_1" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2000 Non-Officer Equity Incentive Plan [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_TwoThousandNonOfficerEquityIncentivePlanMember" xlink:to="nktr_TwoThousandNonOfficerEquityIncentivePlanMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember" xlink:type="locator"/>
    <label id="id_5242063_1495054_3_1" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twelve Equity Incentive Plan [Member]</label>
    <label id="id_5242063_1495054_1_1" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twelve Equity Incentive Plan [Member]</label>
    <label id="id_5242063_1495054_2_1" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2012 Performance Incentive Plan [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="nktr_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <label id="id_5242063_1279908_1_1" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label id="id_5242063_1279908_2_1" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_UcbPharmaMember" xlink:label="nktr_UcbPharmaMember" xlink:type="locator"/>
    <label id="id_5242063_1354061_3_1" xlink:label="nktr_UcbPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma.</label>
    <label id="id_5242063_1354061_1_1" xlink:label="nktr_UcbPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ucb Pharma [Member]</label>
    <label id="id_5242063_1354061_2_1" xlink:label="nktr_UcbPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_UcbPharmaMember" xlink:to="nktr_UcbPharmaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_UnderwritersCommissionsAndDiscount" xlink:label="nktr_UnderwritersCommissionsAndDiscount" xlink:type="locator"/>
    <label id="id_5242063_1396031_3_1" xlink:label="nktr_UnderwritersCommissionsAndDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriters Commissions And Discount</label>
    <label id="id_5242063_1396031_1_1" xlink:label="nktr_UnderwritersCommissionsAndDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters Commissions And Discount</label>
    <label id="id_5242063_1396031_2_1" xlink:label="nktr_UnderwritersCommissionsAndDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting commission and discounts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_UnderwritersCommissionsAndDiscount" xlink:to="nktr_UnderwritersCommissionsAndDiscount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="locator"/>
    <label id="id_5242063_1283874_1_1" xlink:label="us-gaap_UndistributedEarningsOfForeignSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</label>
    <label id="id_5242063_1283874_2_1" xlink:label="us-gaap_UndistributedEarningsOfForeignSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes have not been provided on a cumulative total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="us-gaap_UndistributedEarningsOfForeignSubsidiaries_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <label id="id_5242063_1284319_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label id="id_5242063_1284319_4_1" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <label id="id_5242063_1284319_5_1" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <label id="id_5242063_1285716_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label id="id_5242063_1285716_14_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <label id="id_5242063_1289283_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label id="id_5242063_1289283_14_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="locator"/>
    <label id="id_5242063_1285717_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</label>
    <label id="id_5242063_1285717_14_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <label id="id_5242063_1283872_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label id="id_5242063_1283872_2_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax positions related to current year, Additions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <label id="id_5242063_1281565_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label id="id_5242063_1281565_2_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax positions related to prior year, Additions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:type="locator"/>
    <label id="id_5242063_1518818_3_1" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease) reasonable period of change</label>
    <label id="id_5242063_1518818_1_1" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change</label>
    <label id="id_5242063_1518818_2_1" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, period may increase or decrease due to tax examination</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:to="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator"/>
    <label id="id_5242063_1289286_1_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <label id="id_5242063_1289286_14_1" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lapses in statute of limitations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="locator"/>
    <label id="id_5242063_1568043_3_1" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and Milestone Payments Received Under License Agreement</label>
    <label id="id_5242063_1568043_1_1" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront and Milestone Payments Received Under License Agreement</label>
    <label id="id_5242063_1568043_2_1" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Received upfront and milestone payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <label id="id_5242063_1273416_1_1" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Up-front Payment Arrangement [Member]</label>
    <label id="id_5242063_1273416_2_1" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment Arrangement in 2007 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <label id="id_5242063_1271500_1_1" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</label>
    <label id="id_5242063_1271500_2_1" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <label id="id_5242063_1282061_1_1" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label id="id_5242063_1282061_2_1" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="nktr-20141231.xsd#nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" xlink:type="locator"/>
    <label id="id_5242063_1400072_3_1" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation allowance related to stock-based compensation and exercises.</label>
    <label id="id_5242063_1400072_1_1" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance Related To Stock Based Compensation And Exercises</label>
    <label id="id_5242063_1400072_2_1" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance related to stock-based compensation and exercises prior to the implementation of ASC 515 and 718</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" xlink:to="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label id="id_5242063_1274823_1_1" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label id="id_5242063_1274823_2_1" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding used in computing basic and diluted net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>nktr-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-02-25T00:24:34Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosurePropertyPlantAndEquipmentAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSeniorSecuredNotesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumPaymentsForCapitalLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefits" roleURI="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSegmentReportingRevenueByGeographicArea" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData" roleURI="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLeasesDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DocumentAndEntityInformationAbstract" xlink:label="nktr_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RefundableMilestonePaymentLiabilities" xlink:label="nktr_RefundableMilestonePaymentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nktr_RefundableMilestonePaymentLiabilities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nktr_AccruedClinicalTrialExpenses" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="nktr_PreferredStockShareDesignated" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_Revenues" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital" xlink:title="152000 - Statement - Statement of Partners' Capital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_IncreaseDecreaseInMilestonePaymentLiabilities" xlink:label="nktr_IncreaseDecreaseInMilestonePaymentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" xlink:label="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="us-gaap_RepaymentsOfSubordinatedDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0100" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfSubordinatedDebt" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="1.2700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentForTransactionCosts" xlink:label="nktr_PaymentForTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nktr_PaymentForTransactionCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" xlink:label="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" xlink:label="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" xlink:label="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" xlink:label="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:label="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersOne" xlink:label="nktr_PercentageOfAccountsReceivableCustomersOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersThree" xlink:label="nktr_PercentageOfAccountsReceivableCustomersThree"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAccountsReceivableCustomersTwo" xlink:label="nktr_PercentageOfAccountsReceivableCustomersTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfAmountRealizedUponUltimateSettlement" xlink:label="nktr_PercentageOfAmountRealizedUponUltimateSettlement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentExpenditureCredits" xlink:label="nktr_ResearchAndDevelopmentExpenditureCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_MaturityTermOfInvestmentsConsideredAsShortTerm" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersOne" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersTwo" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAccountsReceivableCustomersThree" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_ResearchAndDevelopmentExpenditureCredits" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="nktr_PercentageOfAmountRealizedUponUltimateSettlement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentMaximumMaturityPeriod" xlink:label="nktr_DebtInstrumentMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" xlink:label="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LettersOfCreditOutstanding" xlink:label="nktr_LettersOfCreditOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInstrumentMaximumMaturityPeriod" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInstrumentWeightedAverageMaturityPeriodOne" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_LettersOfCreditOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" xlink:label="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashCashEquivalentsAndAvailableForSaleInvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashAndRestrictedCash" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="nktr_CorporateCommercialPaperMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BuildingAndLeaseholdImprovementsMember" xlink:label="nktr_BuildingAndLeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:label="nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LaboratoryEquipmentMember" xlink:label="nktr_LaboratoryEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentGross" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_DepreciablePropertyPlantAndEquipmentNet" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktr_BuildingAndLeaseholdImprovementsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktr_LaboratoryEquipmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquipmentPurchaseObligationPayableTerm" xlink:label="nktr_EquipmentPurchaseObligationPayableTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:label="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="nktr_EquipmentPurchaseObligationPayableTerm" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesMaturityDate" xlink:label="nktr_ConvertibleSubordinatedNotesMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConvertibleSubordinatedNotesRepaid" xlink:label="nktr_ConvertibleSubordinatedNotesRepaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DebtInstrumentExchangedAmount" xlink:label="nktr_DebtInstrumentExchangedAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="us-gaap_DebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" xlink:label="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MinimumRequiredCashBalance" xlink:label="nktr_MinimumRequiredCashBalance"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" xlink:label="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SeniorSecuredDebtAbstract" xlink:label="nktr_SeniorSecuredDebtAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" xlink:label="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_DebtInstrumentExchangedAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtIssuanceCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_ConvertibleSubordinatedNotesRepaid" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_ConvertibleSubordinatedNotesMaturityDate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_MinimumRequiredCashBalance" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SeniorNotes" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SeniorSecuredDebtAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" xlink:label="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CapitalLeasesTerminationDate" xlink:label="nktr_CapitalLeasesTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LeasesLineItems" xlink:label="nktr_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OperatingSublease" xlink:label="nktr_OperatingSublease"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageCeilingOnRentIncrease" xlink:label="nktr_PercentageCeilingOnRentIncrease"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PfizerMember" xlink:label="nktr_PfizerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ScheduleOfLeasesTable" xlink:label="nktr_ScheduleOfLeasesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedEndDate" xlink:label="nktr_SubleaseTermCommencedEndDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedPeriod" xlink:label="nktr_SubleaseTermCommencedPeriod"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SubleaseTermCommencedStartDate" xlink:label="nktr_SubleaseTermCommencedStartDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_PfizerMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nktr_ScheduleOfLeasesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_PercentageCeilingOnRentIncrease" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_CapitalLeasesTerminationDate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasedAssetsGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_OperatingSublease" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_SubleaseTermCommencedStartDate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LeasesLineItems" xlink:to="nktr_SubleaseTermCommencedEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_ScheduleOfLeasesTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_ScheduleOfLeasesTable" xlink:to="nktr_LeasesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SubleaseTermCommencedEndDate" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SubleaseTermCommencedStartDate" xlink:to="nktr_SubleaseTermCommencedPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CimziaAndMirceraMember" xlink:label="nktr_CimziaAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" xlink:label="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PurchaseAndSaleAgreementMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_CimziaAndMirceraMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioOneMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioTwoMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:label="nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyalties" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyalties" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_PartialRepaymentOfRoyaltySaleProceeds" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:label="nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NonSecuritiesRelatedClaimsMember" xlink:label="nktr_NonSecuritiesRelatedClaimsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:label="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SecuritiesRelatedClaimsMember" xlink:label="nktr_SecuritiesRelatedClaimsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DirectOperatingCostRoyaltyExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_SecuritiesRelatedClaimsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_NonSecuritiesRelatedClaimsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="nktr_MergerAndAcquisitionRelatedClaimsMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CashSeverancePaymentForToChiefExecutiveOfficer" xlink:label="nktr_CashSeverancePaymentForToChiefExecutiveOfficer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EmployeeMember" xlink:label="nktr_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" xlink:label="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPurchasePriceOfStock" xlink:label="nktr_PercentageOfPurchasePriceOfStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RestrictedStockUnitsOutstanding" xlink:label="nktr_RestrictedStockUnitsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForEmployees" xlink:label="nktr_SeverancePaymentPeriodForEmployees"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SeverancePaymentPeriodForExecutives" xlink:label="nktr_SeverancePaymentPeriodForExecutives"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:label="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwoThousandNonOfficerEquityIncentivePlanMember" xlink:label="nktr_TwoThousandNonOfficerEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="nktr_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UnderwritersCommissionsAndDiscount" xlink:label="nktr_UnderwritersCommissionsAndDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_PreferredStockShareDesignated" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_UnderwritersCommissionsAndDiscount" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_RestrictedStockUnitsOutstanding" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_PercentageOfPurchasePriceOfStock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_SeverancePaymentPeriodForExecutives" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_SeverancePaymentPeriodForEmployees" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nktr_CashSeverancePaymentForToChiefExecutiveOfficer" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_TwoThousandTwelveEquityIncentivePlanMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_TwoThousandNonOfficerEquityIncentivePlanMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nktr_EmployeeMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansApprovedByShareholdersMember" xlink:label="nktr_EquityCompensationPlansApprovedByShareholdersMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" xlink:label="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:label="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_EquityCompensationPlansApprovedByShareholdersMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BaxterHealthcareMember" xlink:label="nktr_BaxterHealthcareMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OmontysMember" xlink:label="nktr_OmontysMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_NeulastaMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_OmontysMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxterHealthcareMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AffymaxIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="nktr_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AllocatedConsideration" xlink:label="nktr_AllocatedConsideration"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BaxterHealthcareMember" xlink:label="nktr_BaxterHealthcareMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CardiovascularSafetyStudyNotRequiredMember" xlink:label="nktr_CardiovascularSafetyStudyNotRequiredMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DevelopmentMilestonePaymentReceived" xlink:label="nktr_DevelopmentMilestonePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" xlink:label="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LicenseOptionMember" xlink:label="nktr_LicenseOptionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OmontysMember" xlink:label="nktr_OmontysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MirceraMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_FovistaMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_OmontysMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementGeographicalAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ProductOrServiceAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialDevelopmentMilestones" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_AllocatedConsideration" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ConsiderationReceivedForProductDelivered" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_DevelopmentMilestonePaymentReceived" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PaymentForReimbursementOfCosts" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="nktr_LicenseOptionMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OphthotechCorporationMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxterHealthcareMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AffymaxIncMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="nktr_PerformanceMilestonePaymentsMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="nktr_CardiovascularSafetyStudyNotRequiredMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ResearchAndDevelopmentMember" xlink:label="nktr_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="nktr_ResearchAndDevelopmentMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" xlink:label="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_CumulativeGrossIncomeTaxResearchCredits" xlink:label="nktr_CumulativeGrossIncomeTaxResearchCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCredits" xlink:label="nktr_FederalOrphanDrugCredits"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalOrphanDrugCreditsExpirationYear" xlink:label="nktr_FederalOrphanDrugCreditsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_FederalResearchAndDevelopmentCreditsExpirationYear" xlink:label="nktr_FederalResearchAndDevelopmentCreditsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardExpirationYear" xlink:label="nktr_NetOperatingLossCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:label="nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" xlink:label="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:label="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:label="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" xlink:label="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_UndistributedEarningsOfForeignSubsidiaries" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryforwardForIncomeTax" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryforwardExpirationYear" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalResearchAndDevelopmentCreditsExpirationYear" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_CumulativeGrossIncomeTaxResearchCredits" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalOrphanDrugCredits" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_FederalOrphanDrugCreditsExpirationYear" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems" xlink:to="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="nktr_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:label="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" xlink:label="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AffymaxIncMember" xlink:label="nktr_AffymaxIncMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_AstraZenecaMember" xlink:label="nktr_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_BayerMember" xlink:label="nktr_BayerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IN" xlink:label="country_IN"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfComponentsWithinBusinessSegment" xlink:label="nktr_NumberOfComponentsWithinBusinessSegment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_NumberOfOperatingBusinessSegment" xlink:label="nktr_NumberOfOperatingBusinessSegment"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_PercentageOfPropertyPlantEquipmentNetInAssets" xlink:label="nktr_PercentageOfPropertyPlantEquipmentNetInAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SalesInformationLineItems" xlink:label="nktr_SalesInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_UcbPharmaMember" xlink:label="nktr_UcbPharmaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_AstraZenecaMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_UcbPharmaMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_RocheMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_BayerMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="nktr_AffymaxIncMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_NumberOfOperatingBusinessSegment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_NumberOfComponentsWithinBusinessSegment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SalesInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SalesInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_SalesInformationLineItems" xlink:to="nktr_PercentageOfPropertyPlantEquipmentNetInAssets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_MajorCustomersAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementGeographicalAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="nktr_SalesInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_IN" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:label="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:label="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReportableGeographicalComponentsMember" xlink:label="us-gaap_ReportableGeographicalComponentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_ReportableGeographicalComponentsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" xlink:to="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="us-gaap_Revenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConsolidationItemsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_StatementGeographicalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="nktr_EntityWidePortfolioCarryingAmountMajorCustomerLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ComprehensiveLossPolicyTextBlock" xlink:label="nktr_ComprehensiveLossPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:label="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="nktr_OrganizationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SignificantConcentrationsPolicyTextBlock" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktr_OrganizationPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktr_SignificantConcentrationsPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktr_ComprehensiveLossPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LeasesDisclosureTextBlock" xlink:label="nktr_LeasesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="nktr_LeasesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:label="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" xlink:label="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="nktr-20141231.xsd#nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" xlink:label="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g842626g16f09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g842626g16f09.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Y^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!Q@```C,````&`&<`,0`V
M`&8`,``Y`````0`````````````````````````!``````````````(S```!
MQ@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"^$````!````<````%H`
M``%0``!V(```"\4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!:`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U0S!C4]@=%4%_4B/=B,!AT1=.H;NK_P`$/IO]G\A6,B\45>HYKWB6
MMVUM+W>YPK^@SW;6[O?^XQ-CWMOJ;:UKV!WYMC2QPUV^YCX<WA)3C9/3G6-N
MMS:WT5@.=NKRWL!-CO<UWV>NM[6_UM__`*,5=U>.7GVECGAKFAF=:6R0WZ&Y
MFUE7]3]'^B]1=,DDIYJRG#=6]A>_;94'N#LNQNH]1FRO<S]$Q[;W_IZO3?\`
MS:/8^BQ^]SF,]^X.&20&N!J;[:WU;/3_`$#&^]G[_I?SRU[L5MSBYUEK9`;M
M8]S!I.OLCW>Y,,.O>U_J6DM,P;'$&#/N9NVI*<4UUM<:ZR=S#ZFN8]UFZH>E
M_A*[7;JZJ??LWO\`]+_/6^L.O&Q:=K-]@KL#A9&;<\[7F+?3W,W?G?X.QEE?
MI?HO26V>GL(CU[Q[=H(M=I_*Y^FI.P6.<7>K<-QD@6.`XC03[4E.,UN.V\7E
MH:[?8^/M5AK.X65NEKJQ2VMWJO\`^N;/13&G#:X;'!C06AM@S'->UK`WW-9L
M_2/9[_T=N_U_\-_@UM?8@'[A?=&LMWD@R-GYWN;M^DW9^>B4T"G=#WOW&?>X
MNC^KN24X%M6,9O>0VRXAMH.8\-98VUUOJ5O]+8W;_P`'Z?\`W%])6L7`R<>\
M9#<5S["27;\Q[VR3:3:*G,]+U'>K^Y_A-G^"K6TDDIJB[/\`48#C,%9#2]PM
MDM)'O`9Z8W['?RE:2224_P#_T/4;W7MKFAC;+)'M>[:(GW>X->E2ZYS`;V-K
ML[M8XO')CWEM?YO\A*]EEE9;58:7D@AX`<0`0YPVOEOO;[$J66,8&V6&UXF7
MD`$R2?HL#6^U)21))))2DE&RQE;"^QP8QO+B8""<FPA[JZ'N#`2"89N(_,8U
MYW_]N-K24V$D#%RAD5M+V.HN+0Y]%D![9\=NYKOZS$=)2DDDDE*2252_J%;-
MK*/TUUHW4L;KN'M'J"/\"SU6>K=_-5_U_324MU;JV%T?!?G9KBVEA`AH+GN<
MXPUE=;?=8[^JKBIX^"UESLW*=ZN49VN))94W7]'C,=[:O:[]-<W]+E?X7_`U
M57$E/__1]-SCB_9S]K=MI+ZQ,EON+V"D;F0[W7>FFP'8CL9APG!^/'L<"7#E
MT^YTN^DC6O>QFYE9M=+1L:0#!(:YWO+6_HV_I%0MZAU0W-HQ^FOW.K:]UUUE
M;:F%QL::W.K==;9:ST]^RJO9^D_GJTE.B2`"28`U)*IV]1G9]CK^TAUFQ]FX
M,K:`)>_U7#]+M_X#U54?B=1M<UV87W;=0VIE;6`^UTAF1=8SVN;^C]2I]G]O
MWH>?@_:;,)UG2[<LTY5=H-N0UHIVBV,O8VU_K^CZKF>AM_PO_!I*;?K8YL:Z
MV\9%PUVUM=9`(]2MU5=>]K/:[^?<W_KJG9E9'IN%>-DOAKO>/2:9$M]@LL;[
M_P`^O]'Z:EZG46B*L6D-\#<6_P#44/3NLZKZ;]N/1ZFT[`;GD;H]F[]6;[=R
M2FK59=9CXOK`X^0ZMI;Z[AZC7EONK=8RL4ONW[?58QVRW](K-65FN)K?CL%K
M?IM;82!_HW^ZICG5V>_W,:HU_M>S'K]9F-7:YC?69+[&A\?I&L/Z/V;_`**K
MOZ7U0P:,RG%<TES/3H+HGZ3/TV0]OHO_`#ZZV4_YZ2FW1F76W7U.H-8H>&->
M22'@@/W-VL]OM/YR61EMII-U]S,6D:.>\$02"WVNMV-W;]OI^Q9F*SJ[;\T=
M0==:PW,^S!KR&BL5MW;7X6+5;[KM_M?_`"/^$5VFMP:+,?#K%I=J^PN!G\ZQ
M]EE?KO\`\SWI*:MS^HYN51]BJ>S&=59ZF?D>T,)]-U/I=/+J_M%CMN_U,BG9
M1_X`K6*W&QFNMQ0;S:=V1FW.C=MGW.N</<SW.]&O'9]EJ_P?HL2/2KK\NG+S
M,IUCJ!8&45M#*?T@8W<YCO5MLLK]/]&_U?SU;KQ,>LR&;G'E[R7NT_EV;GI*
M:&78VS"LL=7;U0MXQ\?V-?)`BMUCZJ;-GTOTN1_TUJI))*?_TO4W[RQP80'P
M=I<)`/;<T%N[_.4:1<&`7N:^V/<YC2UIU_-8YUCO^FB*ECU95#J\8,-F.R0<
MFR]SK3RX%S2SW^[V_P`XDINI*.P>)^\H&2[+9'V:EMVA)WVFO4?1;I7;]))3
M9240W369^)4;0]M;C4W>\#VL+BT$_P!;W)*2)(5(M<R;F>F^2-K7EXC\T[HK
M^DI[!XG[RDIDDJ])RG.BZIM;8F6VEYW?N[=C/:C;!XG[RDIDDJ[SDBYK65!U
M)C=8;"")/NBO8[=M;_+1M@\3]Y24R20K?5;M]%@LD^[<\M@>/T7[E*HV.K:;
M6AEA'N8#N`/D^&;O\U)3_]/U+U:MYKWMWANXMD3MF-^W]U-Z].PO]1NP"2Z1
M`![RJ('3OM)`Z>0_TP?6^SP"-Q_0^IMW;F_SFU"KLZ<WW,Z58S<TM)&,`8</
M=6Z/=M=L_P"+24ZQ<T`DD`#4F>R4SPLLMZ6'.:>F&07,G[,""&./YVW^;=_.
M5JSC96.US,>G&MH:\N('HN8P'^<>YS@W8S>[]_Z;TE-M1]6O:7;V[0=I,B)G
M9M_SO:E=L],^HW>W26[=TZ_NK.JOP;<>YW[-MK:+GM?4_'@O+;?Z0UFOJ5V7
M.^ULL^G_`(=)3?&5C$2+6$'N'#MKXJ9>QH+G.``Y).BRZ[,`06=*L8X"0/L[
M01]'VS]'Z2?;TDR#TPZM@SB\@!WL^A_924ZJ9SFL:7.(:UHDDZ``<E`Q\IEI
M#&TVU@`QO86"&G9^=^]^8FSKJJ*'V64/R=M;W>G57ZCG`"75-;^_;]!C/STE
M)79%#"T/L8TOU:"X"?ZJ?UJM/>WW&&ZC4^`5"VS"=Z)=T^RSVC:?0!],>T[#
MO^A_84''IOJ&>FO+B'ASOLP.D'U/=M]_J_R?YU)3I"VLN<T/:7,(#A(D$B6[
MDY>T<D#D\^'*S7'IKG`.Z<YT;`UQQI$;&.9^;[=C=M7_``?II`=*<YM9Z<0+
M'!FN-[9/=_L]K/\`A'^Q)3__U/54*S)IK?L>2'?U71_G1M15FY/]*?\`SW(_
MF^.&_224V1U'#+MHL]Q[;7>&[]U3.7C@3N,1/T7<'^RLP_S3?Z5]+_"?UJ?Y
MW_7_`$B1^DS^D?1;]+X'^D?RDE.@[J&&P`NLVSQ(=Y']W^4G/4,,6BDV#U''
M:T0=3+F\QM_,<J_3.&_SO\W_`(7GZ16@DIJ_M/!D`V@$Z:@C^";]J8,QZNO$
M0[M'\G^4K:22FLWJ&&Y@L%DL(D.@Q'W*5&=BY#]E-FYQ;N`@C0';^</WD=))
M2DDDDE*22224_P#_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@!Q@(S`P$1``(1`0,1`?_=``0`1__$`)D``0`"
M`@,!`0$````````````'"`4&!`D*`P(!`0$!`0$``````````````````0(#
M$```!@,```4"!`0$`P8$!P`"`P0%!@<``0@1$A,4"146(5:6%R(CUQ@Q-7:W
M0249,B34UEB844(S)F)D-B=W60H1`0$!``("`P`#``(#`0$````!$2$Q41)!
M80)Q@2*1L:$R4O!"_]H`#`,!``(1`Q$`/P#W\8#`8#`8#`8#`8#`ZW/D4Z(M
MRJ2N7Z0H*1L\#MWKWH9@I9IM!\CJ.7)ZMB!#.YR:=3AIB[J6<PR.5(FYN)3-
MR)P`)$88K$,W6]%:ULLG=K2%YW87!T(ZPN>XNC$'6?.%8<ZRBTZV36)%8]%+
M_:[8B#:Y.BN&N[E6<)BD(>JWD*=*#TUYP=N:92H"5HHM.0(T^+Q<R<J56%9W
MR$<Y<-0CY.Y9UXHM-V#&Z<N>WN5%E3U6P4@NJZV'F)@<:YKIZ:8Z39,8D\,9
M)FG]L^*7MP$L4(3-GE&A/\FW/:_YM]<8!7\G-[5U\R%Y558MEEF\#15AKA@;
MV%3#8,WZ@LOL3C(WIB-/?W8GBZ&?.*B0+*NDB<M*O=CB`FN>@^F$LDOT&\GK
M/6>5`J^^5CY$W3D+J*U+/Z')@4QC?07#J:'2A/5-**"*KIGIQD?IZ[I"FQ96
M7TJ0@(A#DV&:4NR58M+]MX@-#L9FQM7UFR8[8N`NR+4L[M.PZC8^R"N^^5&3
MG#=DR&^U5)0:HTM.6^CFS8TI*Z,EU>Q2%0V4E/T-5GNAI)B<U42$(1`,+`E5
M:-,V<=94=\$?);T9<_;1::Z'5'_9YVZ3?BKX^@#C+`S*&\SFJ=KHZ\M:AZ0Q
MUH?G55.(6A/>%`7=:O,)5%DE)=%%F:T8U;^9)QW%093\D]Y:DWR`()%\GDQI
MNWJ=["ZKIOE?F!@X_J6T4EE,5;N^B*<AI,C246\2!P=)5(#QQX7K._U$)9`%
M1QGB/9PG]KDX_P`NR.-]:=P.'5?/%1R!M;&&9SKXEG_HR9<^+F..-K29UJB>
MT+6C2.$A7-FYI&48'@[;>>V:=M(T81B";HTTKU]F<F7^50.$.Z[YL+HFB:[M
M[MJ:17HR0/;NU],<3]=<Z,%-LBP'M737M.7Y7"ZX;U1$ABZI('Z>C>7S1SZ3
M_$<4(W0P:+9QUPL33LV[M[IIB\NSZQ[%<^?VAFG]UM',-$QJIZKD=<J8G3CZ
M\Q]M-N]TF\7>IS)7FPUK`:4N$B7MQ;2`?N$A>MBT0`<3)BI]F_-#TBRR+XU>
M@XVS#5<_6IS=)KE[$J",Q1B>3$[+$YSJL[-GT3=7%J/L!*FK=P&>\(D:5R+(
M-2)-:6>H3HX[3>B?F?ZGR[9?CVZEG_2=T_($B?;$0V#5M6WY$&*@E#6T19$V
MMU92>MVJ6-_TYWCS,V+I,A==N`51*MQ.6J!%F:T$W0/`.$LS$.166]9=Y=&]
MFLU9=92;DRF>3+8!SY`&BL:SJ^8R:<6DP1EM>9I.+-=+3C,HVNC+8].84Z)F
M;0MQ"Q)O^:=HTOUCAQ)-G;KRG_RD],NL#XG:IETJGY8?%73G7W+G75P5S3<(
MLQO>7KG1M8=Q^7QF$S>O[#-;RG\YT2"/(;4X0!/7'[UH))999+5]9MX=]/",
MS'8-)*Y<'K&3=D-[K.7[33:LJJ&*TJX-J)`WL;:="B8C$H'7210B:71&I5A7
M*&\2DX;@,O9PRBB@@K-_AU$0+M7IE][VEC/='2W07.G/RGNJ1<Z4;`WWB6NE
ME`6\U18UI;8U!=]//4:03AFE5S.R%VTW:+T>(H@`#`+=;,`67&LF<3G'9+\D
M5D=0<]5]!>IZ`>UD@@-!2]-*>HJ!)C4.=#+:Y\/\A$[>(Y('9C42N.S6M6[0
MG9'[!R1)3DX#Q*@*-$@3G*GYR\5U=7IW5W&N^/;N_P"2VN[2<:DJMSD]3L/!
M%>K:TJUQ<F>K4U]5K6<GO.7?>,$>WQR>+G1.+AM`U.AAZ1I1'C.(+,V8A5%/
MM9)LB[/"=W+;6NM8TIOD@Z"Z<2,,%?Y,[UC:7!:'FF,C;B5[&R!D`;%5\UU(
M<<XLSF^IMEMR9U$<I`8,S9!A))HRR6<=*M\>?)IT/:W?@!V8]-QG!W84QZ)J
MSAG9$<CR(I)*>8EL=;S9`HER*/(7]8DM]O1/)Y"5W<%@OJN])T>BBRM%":M_
M,S[0+;/R(V@R]+=\06Q/E`E7*A-,7`K@_.U5L7)M2V^EEA!D)*>6MG$\'TC)
MY(YN*J0Z]L4E.=`KE(1[T6/7AH07]F<3_+O(YSOFXR/C\A'1_5\)41.WV"@'
MBT;;AY38;'G'W,287A\/,4,)Q&S8V]R-B:25BAOV2';>K5#3^D#TO3U6;WD4
M7YO9_DVZ)I/GGM6*]E1-#*;B616S9%S!+JNAJ3FULHR4N0G/<`89`Q0MTN<B
M<MT6,3C`]'NQQIZWU"!B+(WY\G*WUFS$I4'U#>DUE/R]-TFG/U-%R[9DBC]%
M$_;,/1_8S0AIP^5)4GJ-\?2&R;TGX&C_`%'@3@:+P\FQ;+_@QY+)_EU!W/\`
M*EW56E,_$Q<;9;'U9%9U03"].MV<-;588=;$+K*PH$*:E$>C`1G0X9,`7N>Q
M"C_TH02M",!_.`7O3>FO6?Z6'0?)#U=.?E"Z:K2'VFB3\E0VL^IF6J8FDAM;
MN'GLOF:HH;]U2\,P/B*F5/",FUG9:(DH;B:WB]$2<90P%"T)O*>L]9Y2]*^X
MNHVSXA>*>H45G^A>EN69SA'["G/V57AGW`T3VRU,?EB3[9.B1D/:OJK07HGU
M$+>F-(\/,2(L?\6/@R>UGPO'PWT#;MQ=&?)%`[&EOW%%*#Z79:^J9J^@QAH^
MU(@K@J)Y4-'OF)E;')]]1R.$9[AR.6*M>/ET9H/@'"6<13?Y;^[>KZ2M2$53
MQ*M;CY32E,R[MGJIL4QZ/2(+ESO!)5'HV7"S3'V.R`;)J4:,=U"H]`)$[)TR
M,HPD\H!FS,5?S)>TR_(?<EZJ.&'/O7CSKB25%$HYS^VVY'X<UU/2<]9+((E(
M65X85[ZZV;"):^1]0E:7?1(TZ$PH`1AWHP'J:WO1))N6(CFUM=G\^L/QHJY%
MV#)[B5=>]=T'%;!/D-+\_1,2"LYW7#L^R.OFL$-KEM)`D6.P2CM.0`%.Q7I:
M"6H``0@[>#B^W"&%OR-=65WQ;UA4DIGB>5_(M4?:+=Q)4DI41.O6U9.7Z[9@
MC6T/89D-:8HWP(O3A7)CN>B)^BB(5_0@B4$C$8:/;_M<FR__`,M4L'LZ^XIW
M5U_SA;7R1W71$0Y\CG)+;7HZLX7@O0JB=/T[YYC\GMN1R=1$.9K(5Q,Y?--:
M<DY"H:-,,3J>0A+"G1^B0_LR9+COHA;1/+!Y7B:.*]'3)7.)O6C"\1SIAQJ6
M%QR<*?N5&E?V>:KZ:DD*:(>Q/)S0M+`:T+V%+[46]@/2EGA$'59^>G5AP[*N
MV9]TCV&TW'WU.IE67%5[(X(LB)G/G,S&3:L5U"`RA<.1O$2JUHDS`H"8=O6O
MI*DHS>B]:T+\=ZW%N9..T:UW9WR%=&<,37Y.HMU\=5SR*,W#<]1\K(:FJQ\H
MY'6%3O$K+05U8;N\1]394DDTT988H]R]IGQ"-$H7E[(++"1Y<<]K_F7UQQ>H
M.CNS7ZM_CPZHHCLV94W!/D*Z+XNI8ZD$]'\Z3)GI5KZ!KU0?-7*.3&=5B]S.
M4NS5)HVI4E:<E(TXQJQ@+\B<!(`B2<RSI:KN^XNJ^8.:.?\`G2G+W.M7N[IR
M[F6F:ONF9P&KF)>6B52=PFLTL-\KYCANZP)8*[@!:=D5"+:!["0I*6"*.5><
M6R22VW.%<I9\DUY2WXK>;.E8/+/L+H-7T51W/'0@3(E$U:UNG*"R"Z]N5B7Q
M>21]U98\=*])?J!91"8L]`F<2M$C*$'\&\+D]K/AZ'<K#S']%=^3J'?(/W?2
MUJ_)O).(JBI#7,I=(,#%S!5%S)WQ39E%-4QL`M>\.]*3J3[-;Y.,A002J7:,
M4;=!DI_Y9(0%3^VY.)_G:T:?_(#W0R5W\20+ZO.=<=NW33=V@;T-,X9RY&[0
ML!^9:D21=PH>7@HUVJ:SY'&G&6H'!*:M1-#<6640\&K#BR4Y0`)'A<G^LCL<
MJ4Z];]YKG<TI?Y0+XDJ^)SAX,,LR7\1T_4\A)!&($6[+ZZ*KVT^?(02N8%YT
MA;W#;V4U&F>N6),2JWH"DD+^V>-_]77)OJSY"8C\)<T^21U[;DTMM65P:!&Q
M&+KJ%YI:H[6SVX]:0FL7=\:C6>JTHI&<Y0@*Y%LAU(5)BOJ`SBP!/)(-`^%R
M>V8[>NH.@;=KOY%_BWHB'2WZ/5/1G][?[RQ7Z#&'#[Q_:&BX_,:[_P">.C*N
MDD>^WI(N-4_\J6(?=^;TU/K%:T#3PDG'ZKSZP;Y0>J97S^OF3+\D\RDW:RR?
MS1CK#B%MXOJN6MMFFQVS5;`RQ5+)8?1[:]G$.T.3^[5*DKR4<BUH6QF!$'>L
M:UZSQP["'/Y/NA:5^6.44I?6R4G'ZZ+<T5_("$[+%A-W.M[WY6Z"11-T=9NW
M-".3N<0DLW9G5G5J716>WHO<DGA&G"6$HYO*>N_G9V^5%=-_*3T%P_SO;]*+
M8W;=DKN@[R1W`XOD'@[*<97]46P\#C36GTR36J8_M.ZQ6+*8]MJ(:MJWQ4X)
MQC>F49`U:AR6?F7EZ(6,#P6R,Y<B4H5D@+:V\#ZK;$1K:VJG@*0D+FI;VX]>
MZGH$)ZW0Q%$C5*1E%[T'9IF]>?=893`8#`8#`8#`8#`8#`__T/?Q@,!@,!@,
M!@,!@,"G/:')!76,*@"=AL5VINX*3M*-771EMM#,DD^X38T7*7(DYC[$5ZQM
M13&)O+0ZJ4CBUFJ4P5)9@=^IK8-:V67$,5=PS:SY).@YMVITLX]$K.A:2'SL
MZ57`XN\4Y0D.JI62ZD/9+1`13F:#>YT_#=U1VY"K/`O0`7*DR?RD&9%WK(KK
M_P!+'H675)!^.[F[=#8_#,"<841^W2>C6R-798=;UN[-+Q!*=L&WD\X6M8XJ
MR&L2$E0N;F)(XKTZ,(-B)\_B6P]IW)RQ_77PL,O5\A[DD:^_S84M[`FG(DWC
M6TM5Z>ATPX\N5?)ZC<"@FZLAD^^RK*B$S<R!>`6736!3L&PK0^.A,)^LSADY
MI\-++(!]`)(W>NHC';HO;CZX&!B#56G8->LO(\:31AK@@50;':]234M0I"_!
MPT4WZ;?#P]JJ_P`<8>W7#L[ZAJ267WSS<-)PBR-5#(K5@KW`B+(^UC)F;%6V
M3D?29`M1QTJ30XQ8XJ(\I5)TI@7)-M(H.`H_C]+TAU)Q==8;[\&7,4;BG/ZK
MFA<IY^OGG>?U98$5O$P$WLL3ZNK\PDR1-DEKYXL]C8!MECF`$:X@0GHM@.WK
MR^8G0R3)B^UYU)P?B;K:0<^]Q<_V?.ASAJ["Z]NWL&.RE%#2XT_T1.;1U&U$
M3U&#12A]&^/E;.<=T8%T"8UA=DZ@Y*:D)(,-"8P]N96=8?CHFKE;E:7)<?4#
MY8$QB/"<RXEF4AAT"657,9M]VR$YR%=35+4=E2E7!)XE:Q%A$%,2J\SL$2\D
M],'8$A8WOA%,=^,KHF323DQIZ8[/;+OJ'BBU8I;M1ITE%$Q.\YE)*_2*$L`(
MM6YEMCRD]Q;V,`B`N@4;<4.3:(T8O%Z^BS2F'M.<G-<]1\;725<I+OJCECM1
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M54;DZUJ)#M<@5>];W%3X&'>`2R2BQLR2Q@*\^*&)5<[<).L5N!^5*>/;*O>W
MYNZ2F*D/DEZ%L3H)@-;9E(WIY2R1G2PE06ZGB4%!+1NH?:EE)M_Q`$H,8>W;
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M:R)IHW.:+I!Q/4KHZF5G&IT_\D(U.RQB,\I>P#&SPK$^?`YR^Q5!2[%SZZ*Z
M/Z.HF0U%-H7TJ(B;3X]3.:U=6AW?9"]U6Y6DR1@15@KD*A0K2H%3>%*J4!$4
M+91>R#6'M=N]+(I_C!K21-7R"12XI.59T&[VL1)8+K'RX@7&UM6KVV-(V9F/
M8'D^120+S(8\]-Y#LWN.TR'2=42`(B#`Z%YF'MUGPM%SO0TMK+F*'\ZWE:0.
MC%D<@ZNM'RPET14P1=-X5[54QM:.1M`9C,5)SRGB9I2!:X:<=G.!A6U(]`-,
M'E2WG8Z\X9\8?2D3C%3\ZD=]RQ#QM25D,4VA,-B5;#A?1;A$(F_'/\2IN2="
M1^P$GC$&-2866)>@8TCBI3D`)UHD`2_2F+[3O.6TV9\=70J*VNK9KRUUG%J<
M@O;)+<9=L$G]"I[55QF2%Q`4$>YO5<C26%"3$+F^,!PC1H7-.L3`6ZV9H>P"
M``D2SC9TQ\I^'NOG]EY6A26TW!+7O-')'0O**A@=82E>'>P4'0%8ZKQTG2E^
M32=E21MV959AKII,4WJ@J#S-``<F\FC,8>W?\M>Y;^&B*\VO7-S@JNHVP4%)
M49T93LY1*:W%'UMQ+^C)B[R=_F2UWU83X9%C6A`Z!;0)-E.8U!"<L>U)8O'6
M,+^MWAK$5^)&]$E>49RS/.RF::\7\]6W$K3AL'*H!N9+ID;=`):IET-K:96<
M5/UD<-8&Q8MV6H<$C`2L5E$A#H!.AZT4P]IS<Y3$U?'[UG6%[=06_P`Z]T0:
MKF7J"TB+3D<)EG'Z*TU#$Z)&-*PI4224JK_B@EA):1-O8A:0)M#$+_L:\/Q&
MS)L?)+\/M&V5=-^7_P!ENB?J>Q[H<8HD9SP-LXIQAKB`1")(HLA@S4R1&UW,
MMY*=!)-K%ZDXPHI0>+7D3%;T,1C#VZD9B*?&0ZQKXV+/^.%1T*I?(O)TT^C-
M:V6XUJ(3Q7%>2V6:EK'%'A@W89@9VLB:M2J("N"X,X%"<PH`4Q&B=:&S@]N=
MQ,ET\-_N^V<'MW[H?;W]DUR53;?K?9/U;]S/VQB"J*_;_I_=K9]F?7/<^O[O
MS.WMO+Y/1-\?/JIO?VB:??%?`9W\E,#^0P^P5:$B,L\:7RNC?M8:MCL"W(%%
M)G!ZXMITE6Y6F+1.D%C,I3DH4OT=0(!K<$85(`G&E[F<K[<8XC]P+T_&^NNJ
M^J>;^U8;37]V/[&_><$EW*"2X?I/[$UD37,=^GRA5>L)]3W_`*ZY8;Y6XCP]
MT`K?G]'1I@V9)8[)ZT9IY'H'&&2SIPV65/VYL`GE,[9H:77S7)W0)A@C'-%"
MR7Z4%QTD98@ATGTX*M!V'Q\^_'PU65;>:>1@\\6WV':(Y\&9@ZRN-OMD4?%$
M],`8(%#&$T;%'1.6Y(^:E83]$>MM5M,W>'F\GH[\/-LMNXHF5\6/0L-J>?<?
M4QVZ&N^&K"735-^W"VC6R4736]<60ZNSK/:BKBW%4X1M148?=OJXA.N<F)8O
M;B%@M`V:,.QF3%]IWG*W%^<#12V*ZX;JJ"2_]J83P[TOS3?,0:OMHR9;DD9Y
MK97J/L59"4'2:.G,@WIL="@">1[<!I]I]B$D/V9ORU)>_MJW1WQJ5GUYU5";
MXZ0D`[&JNKZ>>J_K7GXI!)HFCCL^E$G0O,FMM78D8L!M=W-S<V1M(:M-I:!(
MG`2048,TT9>M;$N3(J)*_A#;D4*Z#J:A.B0TO3=N7Y1/2%=UXYU.YV<12]D5
M&E(!)CTCR\7(QKILW66N1)#CP*])3D($9)7JJ-!%L4Q?;K9R[.>>ZSZS@CS(
M5?175$&Z"95[8E3QQGB?-2*C%$>="U6S53FK=DMM6,)])5)/`H*?9";18OX_
M.+_LY4N?$0NE^.VOGFZOD5L6U7U'9U>?(;'.?8O*JF71+Z27!6VBJN=:W]5/
M+=21S-D+F_*'$MU1JBF]I/9%:8O90CC`@/"-Z^E42/BBZ'8&WA-7#^\T*>Q?
MC_%T8PU'8<WYB(G:Q\K>]8S&(2R1&8LH[V84"]UK6&LRIM(<RQ%`7ISDN]I$
MYB09BJ8OM.>.W9%3U6]%LD%G\6Z*Z*B=[O4J(5((Y(XG0R6DT\5:US.H;E25
M6Q);+L`,C.,5GZ/"=M4CV$(?3\N_'SZJ;/B*H,_Q>Q,?Q;$_&/-K1<Y+'RX2
MIC([89XDFC3AMX36<=;$8D1,-5R&3)R@,4G*1^JD$YF>[*3"UHXG9NMES.,7
MV_U[/G5_"O1CITW0'2_7O5,3O5[Y4B%GQ>DV.OJ*(J(I2[V[&D4,G%@6"X*)
M]-QNC^\QEO+*VB0%(D1!P=&%;"'U`&C9EDB-4_P[1`?!S!Q\Z7*N%8M<6U+K
MSI'IJ/P($>EU1V<^V.[6"S/S%&?O5S,5)VP+J)M7)_K)`7)-K9@1)3PD&)V'
MMSJ0E_Q=L-DS#LF4=%6:W6XE[4H:AZAL!E:*R!`T\>E5*Q(QG_=&,'GSJ9!3
M.+E+-E/S8AV5K3(I3E%^X6:#ZFV'MUB>?CMXV,X)Y7A?-!UF#MXV)/DX>S9X
M9$10<QV,FDN=I4,LR/"E4S$F&A$Z[)V9MP.V?L'J>`/-Y=6);MU>#"&`P&`P
M&`P&`P&`P&!__]'W\8#`8#`K;UU>!//'/E@V64[QMED1*1LB<`6R]<E;HN"R
M[`>6^$5Z9)%:L],0FC"*6/Z54['B&$"5J(4J!B"64,02SFJFU]W^YR2J*M^U
M8Y$[WMMZ?+[KB6N,5G['%*U'+>94:IPETKU(F]%./:1^SHNC3/<=);TKGOR/
MC>4>(E.,]8FBYRR<+^0MYG3W`8`U4.-%:USQ.E+,I^+.UG(2HXMJV]8)?M@1
MF36;,6Z'.AL#>6!HYMD1+PV-3;*/15GMH$BA8%2>-)4S_@7_`"-IP-4E?FJD
MWQ0U557KO8=Z?5YLR-3E`R(/?-K\ZVC$XPC;VQ_3S^7Q*?4T]F(P^X:VIU;T
MVS/?)C1D$'C$K5]V`XSRS:QB^JD5ME<7<KN5-5EDZFS8M<5H*25*$+ZIF4#$
MSHE<6*EAJ4:EBTE7NPS$`-B<=-BKRHQ#/OE4VT^ZKGJX7=220$Q9"U0233:,
M<JS4#0(:?[WKVDJYLR35?/4IRC:1>^.#7)U3\P'!\OU!$WNQ!NBQ($_NHN3A
MNMT?),W1TSH2*P*-)S'*N6?H&&1:8Z>BGQV27!3%03.P%KI*:T+90@:ZF(D$
M14L1;N8[F*U#X4`DQM)0J"7`8SY<R"=]3*UG_FMXKBNT+M35I.-\-K_+'5\;
MVB:2+]BX6G&^ND=B*H9)<12&SLMR3$H7PY&Y*"D!1AP&\H[7G&=N/'/DRW+W
M`N&0ZH8S/;-=I'2K/&V2OKXC,K@*A'>L=Z`?HV-\M<B*)&%(^1,SF]_3R%*T
M)WY"F&)/MO7N?J""%IZI_P"O9!<D+;:LDE;VNH@()3<U$5"^L)4.ALK0#36I
M:C##'R0)5\D9CG(MT;6M]%[4.MA3;,)`(PG?B,.ZDSG8B!+UK:M67/;,#LMB
M;YU4-?71SK2@K?&],T5E+8^735]:KTRT^`LT9.0R)$7-I6)0Z*/>M($"-<2%
M(2L](\)`SAK49^4=AE\%/F,:I]QD"N1!H=?5,?99VUJ3)*U]"WM6]"PILL)Z
M6,+>R578"!]M1H<7!HV<\)2VXX>R'!0<G5E)IJ^K8)]\D+?5,R<H=8-;QM*[
M-318A"Z-1*ZHW-K!;IK6'-<WZ8D")_A[5'"4D6@3S&ZW>6YD=W)R2/+@K)3G
MF,29$I`H",<F7?(F"O#FN$6%537"KKE`JH=(G#'NU$GV)]FW'&+DEL:DDRLI
M#"UB^-*&1%0$I0/"-''WC13RE3)T1S@G5A6%M/7QTVQK^06%.\.GLP3UY,4Q
M%?4S0]O.S:XGMR-<>&[[DO&DPQM)OQ-(.-BTDHEP4;7@$-&Y(5B<Y,(0!>;=
M3$&5[\@UC;;(0KL^ODWWU/E-TQJ'5Y#G=LU&Y')V?M"#\O5N2OESFE&YQH")
M9,P`<U'I*B=H$:IP"28<).BR+B;95W!*:[LBKZPL^C4E=/T[>(XQ*G"66\Q,
MD5?7236<\5PE04=,GF,MD0M1Z;D363(E+*\+X;(CF-R1!0-RYS.VVEU,3AV)
M;<\HSG:P+0K1B8Y%,8[]LDM;=(U9R-I\K]+V&.+%9QA&MC,.1(W89I(-_P`&
MS@@V/0@:$`0G-5`BGR!3"")["D'1M>(6>LV"UNSXVSV!%I0D=7HAHY:;[*L1
MV;5L#*8$!0FY!7==+T9#J)VTK<75"/U$*<@XE0;%SK%I.7NITW1ALV:5$13Q
M210=N@S\X`895J?1(]FL0B1#8T),R*C\92CF["LB3@E?VDM.:6W&@3FD*UJ1
M8E5&U+,4?YE[UMV?03X^VVYAPZ,6O=[Q!Y/;BA"W@;HM-:*L[A/I?I:#V/"Q
M+E0],!22:56E9W[6QZVA=V)Q!HL#>L0''Q;)SX?2D.^[*OR#],-U6R&GY[<8
MJ_'?G+\:8WR,"-35;-Y5)XA"8!.T"J4MR)/<$0(8&I<ZHGE:R$_49:WH5!J8
MK1B@`LDQDM].VP%F?84QVS8[;-S+LY&@PFWH*A6"O[^KM@O2VE%?S%T5MC;$
M8U2]EPAQ3(1ZC+_'TBY(4N3KTBM0I.2A%L9&\VKU587.2;HVM[$LJ$/<JBD>
MYH54O;<G8V6`M29XZPG-HU+'FZRR=.^HHX&U-)*H<)2\+$I+4FU$SB_5("-.
M>J.&;F/U4?5<XZ<9N8X!!K(C,6E,]B'0SC>EK5ZW1J6%)9'RG+ZPJ2=L51EO
MX)=!V\^Q9Y:*-^9%SFD?4FX@F,&20>)20L)%F:E)%T18%85!W$\V"`%K2+BO
M[W7('YF9`QQ7:K$S<ZPOH>/-SNTM0#VELGY**9A9W`#:6!(JV2G<"4R0*X*%
M/4SI]I)-+>YCB;A<%OW0WW5%TM6O[Y*:Y01.%Q9]76D2HC&HJU\\*&I-'Q:@
MSPL<E;<H2RU>\K"1*6Y4-W)**5A/';#N_:<Z:+(;Z`,H-(HZ&=94A84,7(MI
M'JL1LCW5-@VS'YD=9A\')?RFA<WU:^,YR?47$O3O:30=$&H#"W`0SY^$<1+Y
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M*/DB60>Q3+8?Y8VJVW:5\=(M"N9[0N-H0H?J`2CV%T.=HDDT9Z@-##KS%C#K
MQWX5).T6LO><E?93$*N2T-HBXK/8:5G-:117:2$,6/KV[X5T'.V1]L*;)8:J
M.A[W&6GF23)W9N;&N1EA7&MQ:14K*5FGI1GVA"(_*&?'H8Q!L^$$N<_;F:S[
M+M9D0R%O:7Z-UTU=)W53L+8*YC;0U2(JV[+TW4^[;&W$J6M,LTS#V4M&K6(T
MI\U?5>6JNH4%J7I<-`HX%(V.64",(+7<'1<U&,C/]UJBG"F!L:A*:8=)`6M`
M`J'[6RP%?10)]HUGE5"T#*EF257CY!>JKNYQ1.Q=4QZ)J497'G;]YFR=^4"/
M<&29<]5M'9#"!)F498D;HS%O,C+$N2F;T-8$8-`-)"2:%1%DE<B8?(*IK<]T
MA5CU2PPRY2[*A5>LT4<;<)/KX9<XJE_N1*_RBSDD!-6,"=@BT3<T;D2B8'@0
M7HHA.C&L3*0+=#&9NCJN1./*-67E5!4KA*ZS+@I.`JTNX8CFDT8F^97*SUM-
MTC#&327!MDKPG"-8!L/*+4)ENO24$Z,*,!O8DYLJ!H_TKT/,G-IBD<L5S0Q-
M^[`B7/#=9<SJ>(Q&XF]4FI*UK`M:+26K%PE"!B&QR"*L8FA<YLK0L<&YQ--*
M2J$0D+HN&1)RB^[Y16:+E-3-6-5.G/HJ.5JV7VD@2)`<WU<\\WS#H]QVHB:A
MP=(<NNM$GK]<R$"T24S^U<$CN-L-TG4(#JF3M8;FVR')_D%RU[(+5>K-7UJ]
MQQ8A63VGY/3%GL\4E+:X$H`3AK=*^K6'RM.LD,5=QM;]'6Q*W+4(-%B*T81L
M]0*I#&.S[:IIEEDVZC7V*URN'\[W3<T_I"351&FF`RE\J:$G62O1<87[!$!L
M*F\90,#(X@$VRJ0.DF6MIZ5R&6VZ3+DVXN;TL(T]MSA+9:V`V)SZ"')(_<D&
MI"5OK1;+7,#T$MM:K4MJUX)E9P0]B`]HBVQ>G;Y$,U6A"U.*@'L!/"4)RHJI
MGVB9O^1I;8BICCD/986Q20=F\<B7J8K8K!=<<,K7HF[E%:2"+N\GCC6VQAJM
M:+EL"Y.Z)&E6_-2(U0G&D=5F_4T5%SY<+EJ[NG^OZ)(M%MN)AIV3P:DN<%FD
MIL!B[A"+"N*R^2J6Z7E\OLT+\VKGM+3(U=S(V@A!%U[`Y)1-CD9MR&+9):<6
M25.%C=YL-7W,U52_QN)KR%[_`!N(#4L-M1]VL`]XEE;?N`R2I!5C:T+U:*IU
M2O?T;3P].C,XGN`#3$C6J1@TJ'4DU(G-G4[A>A[`VRNL%%6/<VH^O.BX0V"F
M""9A<JRL8U:D1)GQ4C:&33%/8TL2DZ=VXD"]N*+<$@DKDK$)26E%F*&03K?I
ME_KV,6-'W^=3IP7%7\OM!ADG+\LA-35Y$(#![G71J61"[%</C$1D:Y#/8G&D
M.DA;I(!.Y+@I+`27Y1K4<7(GB%]YS)%6ZE1;=80N&V0R5%RG:2D]^NZ+QJLU
M$;ZB<K&C$<D$WGCO&V]/!%;3(:B>_J;4U(90HULQ(0V;=#5`0!&<\->(^3\E
MTA\BG4:H9YDT;KBI+)M6U7!NL1@2ELX*RN*\:%<8]!"WAG;%4Z4R2QJ+7_25
M*HMB3C:E92I9[(S6TNVGK]I+:.X9BEL9U@MA4"",)8S>)G.<F?8W:[5,!EVB
MX<WINJHL1'FQQB,,`[19RJYT;TRYP6*6L;?(%H4I:=6C*/<2ZF?;4X-\D;7/
M53I#V"OXG(K45.=$ML$88+=+1.:[?SN@-7(?'DDCMMGAX&AB<X*W4%*54G"T
M(9*B3%HB@MBMV./"7J+C,2+Y#DD-L5!6<QJ%='I2Q%0(%M,1LY:G22QE=8TW
M>X8Q:K=C9&5RU:K6A0LP)*X*#5$?.)C#@E-(3J7,2AJ35,X:Q=?R%O;)2\2E
MU25L!9.+*J>W+2BZ:7O"<ID8VRG.@.?:+DJ1VVA!ZRQS=!WT2O;]E_R2]H!!
M.T/0M`%%QN<6[,G4@=9%"(/4+I;%C1E^Z+>I3&S);&X1MFA=+V^IK`F/1%R$
MTK6Z9321.X34L?3K?HZ-:6WG&N;DW"$5ZPR>>$4]!_)"M@Q5X0B+,$0:9Y%(
M5?:R"KT=BQNQY"RRJCCB0J@VW7\>;S66`(Y>V"&YLB8;^XNQJ$(/J*!M--T5
MII/S\K'=7=0N?-$K87]8A&\UQ'^9>QK\GL?;DR3<C?-<Z1RL)2TMS"XK3B4Z
M%4J0O[D3X&;T48::5L>PZ!XY4DU@4_9LZ4VBIY[*H5)OH).Z"6&1/]V4?V$F
MKPJ#LDY42M;8GV1[\M^2ER!*SC:"&)23M[-"$*X3=YG(`SYWA7FG?D^"XPRB
MD<^B1+W-7^JJ(F5SJFQZ1-+ZRO5XN2EK;$$!KYL:WP$Y/B9*;ZK(0!<6PI&T
M'%C;QNBK8T9<U;^>UW*&ZA07Q.[=K]M@4CB[O0SX;"+44/BYJ-1-%BB='(3=
M%60:$TTV0IG."IV^3%N`0DD`;'YO*$'2W:U*AJ9F+3X0P&`P&`P/_]+W\8#`
M8#`TV55]$)NY05VE+1]665K+_OV&^JO<TZ1LEH8S)(B0\*FU&M3MKX-$R2U=
MI,4X%*DZ96,I84`"Q,F/)".U7-%)K+)>K<40O>[`D2AP6/3T7)9<G3+U[K7K
M35+FY&Q]._E1L#HOKM@0-1JH",*@:9`F\1^<@H0"[6FN/%W/"S<74H8B]QM\
M@L.J"!0:5Q:P+`8I9#8Q0[9:S'5R*//Z.3A7(E#"PWC+$"E3L0U+R@?#TSD-
M83HH!8VN6BXVYQ01.0PDBO!BCTMK`NGI20?,)VH7R*":E4PG*M(\/1TG&\K7
M]XF<_>71Q?!*/K;DN<3352LT6P["-J'*SXC40KI%OO-UFK6K9H>KO1P@T,CZ
M2R6Y`G<KXD+>^OCDH8)%;,LK.'J&\DI64N!%8\R%21Q6;=%N@'@T3L;QB?)S
MRIS_`&7"K1KN=UPWR6'7-.4-E6,S.#O)/*^3IL1Q%`W25(N(>27.-."%+!&K
M1/THY$66)+YPAT,TX1@VL-*./*#F;]+GR21J1.)$Z'+UDFBH;(L=!`EC[/J\
M<:HF4J2P5ME:.+-,LD%>NZIN.<4:4A2':HY46("T\Y2,;7%?.+N=']X5/:N$
M+2%3FX.:]]2(9A,TS'(=/U7)*8DJ)YCFG\;`H12NN&Q$W.V@)BS'/2%.:I&8
M<4$S!M?*&\6<_0F3,DV1L$Q?IM'C:\-:Y9-K9M::O!&JG9+,C=<I]_<LS<4`
MD,49+BDI)"?T-$&C=C3SP&J/(<$;4[SN!PRP&UG1SAL`YML6E\1L5JT8Y.36
M6W2JO7]#+(J]&'MJY`,X#,^-9*C9)PAI3M%^0\LPO8@;(BA-6G-]B2&4N+9N
M,2R12*8TET+*=,,]<7%4?(XB@9"J-L$]`SR49;>R*&^M4VV[11932\@;31#+
M5?\`>-B+RP+!Q9SQ'4A#:DBDC6M#8X56LBS(]V99CVRP1)2=H1^YZNCL`:G.
M7*44,B<2LN*MSB6UMX"$2@A$F;U!9S6F3(B1M0=;'*G(5D16]7E/8#9&W`F0
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MR*4_MU30Y(]#;S2`^8&QM<PCG+BU9#%UB:EI3M7#`K<U%ES(_HB8.%?S)RKF
MS9--WQ3=[P*?&1:7JX5;"MU4+]/`QZ0GZ4-QX0H0C0Z&U(\3:J"Z*I:<50UV
MD3=\.<':2)YDL;K(<GV4QY;*)6Y3QK:3WHE]62V,?;1BXC[?*4'A,3M:1'HG
M8TX0;$.9RT",LWQ_S!TU6T?L"E+"D<1EEZ3ETAI=XMTVD)$KL)LF42Z!=99'
M/O=R6K@+T4S>DCRD<$XT+:-49H)*899?ICE.]&U)4]=LQDEJMU?)4V3YCB"A
M'-'^TIE;YCY"F5K/_;Y&PR^92B5GGQ!M9G@TU![53LE3M8:K,&>H4G*#1;J-
ME7''(UF5O0+$7`6>2P"DJI=Z]Y\>X].YGI3&JEL*EU=)NC;&+#CDN(DCVR2B
MGWG:/2PYR5F';]NX%G>^(3JRQMY;C=E&<W3IJC*FZH_&4K-'VPZHXFK72ES@
M#>W)+CD$#BC?!VA4QOT;(`X2N<,<8(8DX!;5E2)&UF-GIN)*081M8%7QA1;N
MW/:.3IK*E[E('*MG1PF,BN^Y5%@DGT])%\OK`ECGR*=()9%D,-DSJJ7)T[6K
M1DG*U)QR@)QIQHQC:R[-S-SY6RU-8)C*X:=H?*5UK'SZQK1L></"21(J\?JZ
M%*9/,+*FLB<75-&:X?W)O0Z=%)Z-F1JSQ)`)]C&/8VOD]\Q\_P!D:>YBE:58
M5MBRI%;(YS`[`F#&L6R=;6S+6899&WB-21.C1(916C,A;W).BT%J?T9)>UY"
MO>_-L;7.HWE>G>>*_DE55RT/(J[E2Q4N=HM,Y,]V`F.,<F!NC3PG$Y3)8]/R
MIL=6MK)*$C4JSTB8@(4R4M.D+*3@%MO*/''D3E:(,*TJ?EO#I%7B'`YZ9B;D
MNVR)4QQF)VR_QF((:VKTZ?3E>5$7B>2H3*UHCVPPA^7+0-R,A2+9*$DL;4@P
MWE*EX5*&J=I6>32&P6>4J)DFG\XL&>328'/IT"=JO(&X/$BD2\QR;&R`OBMN
M2(#PC0I?<&J2R=+335(QJ#)3Q)SG/V^MX76#T*#G<Q.G.]9+BH1/9JXRF*P7
MGAE.F]84VXNK=82*0PR0I8W9Z-U+<E1IKTJ;7),<J]XF4D[V-J07?A7FUY:4
M;$IBTG3M>XP[PF5)FVS+(;=VC#Y%,7ZPI-'+A/12HE3:C=)YQ+'=S<OK@UIR
MU0\N031B)<5Q2@;7]EG(/,"QU6/4]:7%:GDS\_DL[)*[8L`,39Y7:,O;I9*`
MU]'EDQ(:8N_3V7MB<XPIK+),,'LTE,`LI6L*4#:QZ#D?F"PHV)]BZJ0N\6F[
MQ<<S22.N[LL!M;'UGZ2E!,^N-@:I)!)D@TOKBQYH6)Y.;2E!B`EQ.,4(]$#'
MXX-J8;<K:CWB,(Y+<"1A:X94$>G;P%_?)0NA<8@L5=JUDT$GCN\.J9Z8VIN8
M4]:O[F2H4K3/0;TXQ*0"),*`<6.4:O7.?+DDD423%^BT6&MK2!%5JZ1*UY7'
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M$I]I32U(0[V.9_+B7W"N1XTYG3*YY6S5;+IQ*8[+&B:&6O(*ZF`Y=6<2>(DV
M/\)7H).V+FTZ.P67."%T^G``D/9W%06Y@-2G&Z$)OPVIQC'+<:H.`JGV0PMK
MY[KIQK:RX9.9':BP$02N+!*V>55W-7"U'J6B,E`G*8'(U>EKFZ+0/:M3K:@2
MK:@6C!RBYPA7!G0TH56$TV'`I5+)+8%>I3953O2TBBSDXVO!(18".!%(U]/V
M>P;U8Z>M9,^$?R-A='%A(`6I]=(VI`I1S$M_VD4/J%KX/J+/PD;C8*6V3Y4I
ML>RW&TPVB@0HVANL(BXW27K;6)ES<PMY+60LT\^J6S%_3M;]AL2;8VMOK*B*
M_JE7,G=@+D[W);#$S_?$MG\VEMAR:2)X\E7(F!L4NDR>7D:!A9$KFITE;404
MK>2-4>:$GUE!YAA$.E\&\U;BKA`7*,3&05XHKR=U,S5](K;M=XAL'KFRXPMA
M4SBM>,BN9C(@Z1=#W$]I1GMVR%C(U&B1-9R))OT<+M2?*.9Z/FJZ4N,I@B=Z
M4S6=1>RI3I6]R;VKS,X;"T=>1UT4H"GHI`%.BAR`I$-$64!`I"'9AY)AHA&;
M&U'T4X>YSB2AF7IXU+WYVCR:IV]F=YC;5LR]>W--%2PR;T^RI!/\U7)D[-`I
M&:-0E2@+"2>(T[:H*C:A1LT;6E3'DSC2"0I)'9(M4U+6D<I%IK^0Q\'05C5M
M#9+0M#1$#82AL\`;#:$\RBT#@@0IGAV=S#U!K)O:9T5G(!C)$-K=Y5Q10TH?
M9!)QLDA;79[E378I#:W3VP6Z!M5HL4/;8(RV&GK=FE;3#3WY)%F1"B-"8EV0
MH3)O(,'B<>(T;7RYMYWJ3DY@KVOTDP4OUE+ZM@=6)I!.)Q(G62S1AI6.'ZTV
MP2.3682E;'8FSJGIP==LK2:8D;-.(M"WLH!.P"W4JPZ`TPDKV54-"BV95!XO
M]<KR:0MKE2]X71E5-F1+-7>+2-;MZ6R9A>7B,V$E=0$J%!*P#>[)5!/E(.3C
MV.>T8V%S'S(`EFDDM2?8BUM)YUK6+3@BSI9"7=F/JV5S>-\]1J-R+[I1;12,
M^3W^]L:3T1?49$9)?IR@2SU$Q(!M<AEXEYF8(M-H8W5XN%'[&B3_``:;D.5A
MV>^+Y%&I58T_MN1I5KZ]S-P?@KGJQ[2?W50O+4@7F*'(>MG>F`H!8VMJEG+-
M"3HR7F2ZODS[J?61NW)@0M?93M&^S\5&MW-ICTK0E/A:(*8ZE&DAD,;RRP-I
M@`;5"3[6C&I$-K16WASGQL1O(0-=@KW]Z:ZL:#9R]W);3[/&Q/2#C)W6HSHU
M*7>9K'"*JX(MFCKM,8W;2[4@<51:SW):D\)@VN<DXJY\0*6-4@CLL0[:OH0W
M4A':-G)4=@*HU8#[:[,Y6LD(EP"+0=D]E2AR>CE;X%<H6JW!2%4,X@\TD0VL
M.?P;S2I*D1)\5E9I3[%;!@Z%,=:5FJ&V$1*T)U$[/F3%7#&HEIK#!$CA8D&:
M78H3<E(-2FH"$Y`RT1)24`VLJ^<3<\2!MVV+(S)DI:PZS]R%8SV38K*ZS-MN
MM_2RFW(W,W5KE"5?)(G8,B1%*US6H,$B`8#P3ED`V(.QM819P%RXZ:<$SO"9
M(Z,ZPVTQ(8NIM2UB8A&4]V*7)?:B"(Q1OFB)@C2&9.CPJ5'@2)R]DGF!V1LK
M1)`2AM3-;7/U17HE6([3B7W2F7UI:]/*R_KTG9/5KF\&AH8;1COGCCTT&%_<
M[2PI"O=AV%<B]+S)#B!B&(0W&NS;EFF9Y*7:>N3-)F2P'EP:7)5/818EA028
M$*&>+.$)3%MC[$9.SJV=$HBKH>D4ITNR2%7B6>:$2DA.>4-:HU<1<XQ]+!6R
M.Q*21YCKZ,5Q"VJ.LMGVBA87R+5"_*I/6+-/6PN8[(L1/#']:<H3#>_?G&Z.
M,(4#.3&&$B&UEVGDFG(@:4X5NVR.N9`-;#C7J2Q>>V"E?9@WQ6[PWVL;YXXB
MEFU<\.E4T7/`'-:\C7K5B"1.R0XTQ&Y+DZ@;5F\(8#`8#`8'_]/W\8#`8#`8
M#`8#`8#`8#`8&EV1'C)=7<]BA(5PS9/"Y3'B@M;NNC[D(QZ8US:`+<_MBYK<
MF1=L2G7HK$ZE.>F,\#"S2Q!T/0G<=&--\QVTR0B/6%$HOT%&9]#*)^+>(0TM
MQF=PQ1Q)?:XMR1%=,,C[$)'(VL4H0L48<EB-6G?4:UNU'%'MF\'TQ1Z9L;U9
MKBV'=1L=XJ'"XY38BQ29$;D#=3<\UU9K97CI/55H1@^M7"-V!/N@IU"Y#HB,
M?5!1P,"B[8V)8R:)$^>Q6I6Q``EQ"%N<LWVTQOJ>=51`'5V>KPZ<=V>RZYT>
MC0FSVK-V!!GRN[NC):A24C/E5;*DRU.>$0R3'6++U83-GJ&MH3Z&SC4I1ZI.
MJ&3H%G[1.BS(L4S2_)O$9-613:\)+/:.8K%'#*7@R)X<1NK@QIVB'CJB'V.[
MI4Z$U4W#/?`$[.$:/U1QF*W3&FKL<><+)I2HJZO!Y8?['NJ:F34/T!5$76N_
M+;\^T`_12$5?S7T\CB,./MUKE$P3MC$622Z3$A<S@"J.<D7MB4QA=F[]KK7"
M_P!US^R]W+S_`$O8\>D=?<U795<?DMAQ!-$!R>UKMF]((ZJ:S8P\+")<[P*L
M%T8<)-(7`]*0A0HR_31C4G*%8$Y..K5?8_RM?M"M:^H`0]%:U/,,LY0Z/:VB
MO6X].A?W+GYRK^N[6@BE/.Y"NVKGD@C4#C4^;"!JBR'^2MSIYMDJ5(SS!LJV
M=,3MRN+L^:6"GIRZ*DCD7HA57!4CL^K97!&Z\=AM$IZ8GQC/?&)`N2)JV0A5
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M2UK-B.H!)HEU@[VVX]"50Z7U*OON>1^J3H@Q_)5SG8+)(ZY4F2`AE(61VAXZ
MXNL:7P$Y,JA["@6)G429T,3$X3_]_P"&2D5"=,*U=\QA&?T83"815G<2[G9(
MVW3:K=H-C'R:L7GG`:5T0SQ,\R5<UC4OOVT4[*%:=O(#LDD!11"8!0V<>7PF
ML-Z?DFIBS',71+A?\@L:V3Y*['.<SUSXX<N/M+S%NC$90(1NP*3VN4J%;2W$
MLK>EU*TTVT<Y&$%(!J%HQQ_36BHAUA%(9]+CW[X0GI:/2>$JH;.I"]2Q/RY"
M.;6/GF(-+T3*"W%Z+H=.W,*]&Y)5K,M(W)QS0&G<*<2$!;@`<?TU%%8TU@\@
MM>TJX<.FFU@YRYOXZZ5FU?36Z9)/FRS7(^Q;X0WBCCZ-UM&7,,E6V[4K0Y%M
M2K1H6J0O[<V.2(*G1"92(KL5L"J+A7<@TC#9`)]L&X4W0_#=GV>;MQ5O)R=S
M9NX:(NNYE#8H<URHY-"J^;$+P-O2!-$2W,+84F3AT4267JL\;?"GLAI[KMMC
M\-?H\KZ,/?IB[]*_W#`)M>>N;\XU0U=H56^Q"/09$[SD+;"IHX<LH9.AA1[#
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M5\_E1V/Q./1&WK7MJVTK2\VD:\&M9<I<T3B04O`E)0HVTA"#9.-C0[(I;J>H
M+M*BU!0]P=:YC')_3E7\P6.E&G4HJ7D/4-Y\4M$<KR2MH5J9<&)\XZ@3W*&L
M\K1)6H,B(:DX1J6D1BH<6<N"W<W691D6F=#/]>320TLW33GN[JBGO*_N&J1T
M"\1A&FK^:GPJ*2U-/%$T>X@Z5^R2Y0R#0NH7XJ6/FR49PTI2$\;&;@::ZXS;
M=7VM.(#9%DPB,W)>!R*UFSG8NNKLLZ-RSGJJHPRV%=-2Q%BCJPB3`E+.LC*=
MS/8F%2K:6%'L;8E3EIS5(XQQ7WG&\[T0'UD?6C?7E,VY?W0O2DXA-M-@%\?3
M0T^.,M9U[6$E:(#)BP(I':DYDKI:XTR=4(UN7MY87`8%AAZ<T;)\\MLJU\OZ
MB70FYK]IJV+?F33S%'>:QN-;0U3-I*[6)SI;5QZ>)@WLK*!Q?D#-V5&)1&I`
MA7>D!G0J&$*=X4H!!3"$+EXC[I:XLB<?'Y)HS#8+,X1-)9U2NLB-UK*X8K9Y
M)5D>>N_4=O)&IRBSD!F3*B8;"E/U)46A4J&<P(#0-BY4@TE4F#Y;/=?&,FEU
MC5).YC+II:\FEU_TN1:CQ#0'5"T1*G:9J[J;<82MB>#/262MZ17,;J7$O*TU
MW5JW,IV+1BV!$46G`)50;5BW:2&N6J+QZ/=#[G\#@=D+ZFDVWRZ)^<ZO+#TQ
M;PHHQ^6*3Z)1UHF3!3#'%%>W^R721`D+(O+;FQJ<%6W=,M+QRG1)S==<A=$"
MV6.72AP)[>GR+.]F(]7[<S<U"A+?;5U$<=HD+8V6&D0Q*+$05<R'L*5H`A+V
M6!)ZH=Z(*`63C_I'!5==/P&*1EC<F3HA_BTWIG@IZMAU=)Y>EBGL-ZKF;K7^
MY2326/0:3K[MFC<8],M:M[]%HHYLJ+8UJ%0>,IH(=@&C8S-6Q;I).SUX7T.P
M=:ORU#7:>+TNWUI(YM'G:/6S'>J+J)>W"T7-%.)BS-J=QHP5>[;':>.SZRGL
M3>[IC'->H7G:7CCX:4Q0;NII*ECNLE-X+ITV%+9'=3/'H+;C"T2%RCW5M/2T
MD,`GLJZ*F,=FJA;2K3*"8ZUUU&&Y$JBJHQF>2TRX#6UX.&.Z!K[IFPI'=-P1
M6-]5-\E<(!\B$>Y>5MK[<,:?(RZSSE?G4-!A;XTP2!-^V:.23^+210W:>4S6
M!"_%%!6A2NH4I02S.E@K*:KM:W;HA>3!NNYO>:B0WTKC2^M[)EL"J<_GUUKY
MW;JH;(N\&F/-?)7IHV<WDIVZ.(0V&EF!"IW++"0<,U:2?'A@.8:XZ%UTG#I!
M+F">JZDBMH6F_0)ZDD;L^+-++#YQS16+,=IHC]W3^P;8CC4XVDTO!0DCRH0*
M37'2A=IK0%K@!,%S$G.%%VK(^F[&)<VJS6BF;&[J7SF9'Q";2V`MLQJ]N^+Z
M@Z]8E[ZYP>1Q]Y<(H"]X*)N]N,WTC7)O\AA8BO'S#>/M4YIJWI-_AU0-%]1;
MJ";7:7?WQI2B"+BGJQ'6N(S3%061S');P.MTUODPZ\.E[',8-,7IY-D11KX\
M&GLBQ.%8)`)2D+Q\-ABD#[81H;3"[R*_'.U7BN+<:Y$@BD9M*!Q\Z_W>YH1_
M;_)V&XIY?UA5^KBL>T-4N)%#X@1&D]>Z6M\I2!$0A91DX=E/*<EG+)#XG55V
MI9X=?9J.T)18K_(%BY_BL@?X]8"%LDDD@CRH-TF9*TERV7)7"&L9)*<#3'3`
M(!%%*&]26&I?_"X&$,!@,!@,!@,!@,!@,!@,!@?_U/?Q@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@8E_?&R,,3U)'M0-(S1YI<7QW5%I5:XQ,V-*,Y>O4%HF\A
M4O6#)2IQBT4048<9O7E`$0MZUL*H:[@J`K?TUQ8+:9YL=,85!VZLG*M'X%A.
MCQ9<4ELSKP].Q)0JB431+&."/`@JUJA(2W&-QX'+:+90_*7$:63\C551^NW.
M8UO')U8[DT-4+<G]"1"I8WLT"/FMFN54M[%9+X%G5!C,A+ED9>4AZ4LM6-`8
MW;-6[2HSTRHT8S/6/<!7,L@E<8!64AEJJ-\M6KTKI\)*>`1P1=:R&,,>HDK6
M-C"[;)4.8'PTP9P-C-(-]H2$@P:TO>A)K=R.V*J4@5-A$7M\RQ$<U/@BBFP5
MJ\CM<IT2U^QVJI<S(R`8DY493UW)$#B-Q&J"F"<K*;O-]7,`WB&,7?W7K!6]
M54':\">JO<(;?U@0Z+L%@6C,5==UPS1B9UU-K":I>\OBAJ4*T12M/%"4I2=0
M2G,]=:$(_(,.P;$G*((]V_9,Z3UXTP&#T_*76QNJ%_.T2LQALZ0R"@YTP-O)
MEB=1+K)@4Q;H,6ZR!(@45^IBJ@E,F4H`.I1PBW`[TC22HN>6Y(NM[->IIOGQ
M%6T%:>E4EFR*"OJ13.WA]JMEA4:JN#VRKN9&Z)XDQRM_:U;19C`W%1\2)O6`
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MUW?.EQ</(E[0XHXG!K"*99S$7F&O3A7-G`?Q5Y/$#<[D%'"C\M'$W0L@!OI+
MDQZ`XI6G3F:"$0LQ06I/DXW/8^W/SN5SZH^M\[W'?2UGKVYG::RRGRJ@969Y
M6L]TP]N@YSNSH7$#X$@9Z/9KB0J3B*);E>AF&)HMBR3YWS3C-'7][3-TY?BF
MI%938Q/3="921!I_:%1P^2S&>U+#)<L:`@7RQD00UV"+8TP$IIK6N((,/5(5
M:<FIE9:ONWJLF:6O@N#1.8XME[?4221N"N'OXH775AW:T-#I7=8R^7'H$:9N
MEDL^O-X4)8B=!WIW:O<;3#=FT"D8T&:_(?7C4T5\^P6"6?-VFP[%KN,Q5<77
M\M0)+#A,_>G:.HY[4ZL34:DEZ/;PWE:(*/&@V:B5D.(M@;#R%I@QMHOD$Y[`
MC&NWNQ_;M+(YR2>F:K:3B)JIBCEMSBBI@X60KTDVA8A0RTZX>FMQ3%&JEFM(
M#E1!)R,HU0`96!NKY!*NK2M+QFD<:9-(G&LH!TP]018]QR11FMK<L?ER&3N3
MV15\6GYS6I3&/+&IKQU(.,]#TU138X'-VUP&]9LD2=)$5]O<_-3@^A?GV21R
M*LRNW&I-9;Y"I,BK>32"A$\E5W)&HG)OIQ@7Q^@B:%O(S"`%!TY@9UXFP2X*
M%7LD97(A_9E/2NP4U4KDEBP&Q5+XQ1S45LBNY+$5);O*H+8]F19,)R5I#6$X
M$@@E3OR\@TE6:46-`8C/$4X!&D",9.2]+L1<#YVLJ!M_W7#^A[(JV)QMS6C6
M,0M1.T42]R:)DF2*$1BHX!S8F*4)R#0$[.)/#O8@?X8,[1\T_(+SV\M#:\I/
MW*`1*V&-2*L42NL)<D>+?;I7-V:M6H5;,QZ`#D[B#.Y&WH%`U12(E.2M*<!C
MTU"VNT,K6(?\A5=NK?,UDJA=C,BZ*3^YF19'&B#2E^D\;KFD%49036SK!9"F
MI.JB[2SN$G)(&27[PY>+0A-87`L!@P#%A8_T]34IM/=+1^3*'6RP!5+SXPD9
M7<P]/%$\4CLO(L0U7I']/W6KJBES8C0OH31-RQW6:;RC1+25))`R]K`80P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__U??Q@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@:;8T,)L:O9W7JA_DT53SR&RB&'RB%NHF&8QLF4,BYD-?XF^`*.&S2
M9G`NVH0*]`'M.J+`9H._+X8%'JF^.>N:LF;7/D<G$4]H9O5=@J6>$U[7=8P=
M1(JJA5VP1`<1%HDQ%#+U)&R[EBIT.4JUBY0X)"S-*`E"V0$NN&M^.:-$L$PA
M\1N2?P^)VB\HWJV6Q(R0=T6S!6TW1.+K:34#JYL!QL;5#<9P-D7F@+4;5,*!
M(45I,K`-88-^DT=#\EL?0K\<[.LT?(PD>*.M2@Y2WM#<V+#76(V<[0F0"7MJ
MYP"9IE?&!\@J8PLS9*HD\DTPH9>M^4>A+B/+B^/FK+?L&06JZ+4*B;O,Z*FJ
M74XKRO;5AK:`ZHH?3SRP;A4Y87!N5(7)J@K6Z%J?4*7I7=$4(!^T8E")0-^$
MW$<TPY)#N:82D=WLAKYADD3D\1.*3Q]&HD*Z)UM+JT(#(TK4RMK*04Y-\R4K
M%`&U(@*"K"'T0%$_RL&]HP?.*6;[@;Y!7EHS2L?M[HQTZ=AC&RM,.>XU#+$E
MM*6;2=D)F%FDC$XD$1NPT5K.K\N1[WL!4D4'+2-E[4G@&-<@GC1`VGE3AEN"
MQ2;]!9#]:BJ[W5'"W%R?'R35_&ZN>(E((0@C3)"5=6FP:%LJ$EG2I4:I/MG2
M+`+M.035QPW_`(2%2W.3;4J.VSULO>93*;PDI<IG;XWMK)7:%"K20IAKYK;H
M$S01(TG1%L:8U&TNB31K%SMM9LQ0-<,8@>F+=0-*N!BK.9"6*Y+XL"R]1^GY
MW2D)DR^.P9JGB.-6&DCS>_/\WEZ-D,6SV:>PC1(`G[`WMAQIQRE0@/5[)/(&
M^(D6;<8PJ;N\^>E$YL./+[`Z#3]%*U\4=&YE>&"6I>36#D4A'%W@ML-6M*=+
M#8\2[IU.MC6$/6_4"9Z(0DZ&](*KOXOZQ@<@(E89HN"]^-5F.*>&P"N*XCCF
MJJ.'=$PMC=EC+&8^%0OD,A2=*/:U\<ERM:N<'$E.+1I*<O2;4Q?:I#9>&C(5
M#W"M:RZ!M.O*]F4+K^'6:V,B.)CE#^97]40RE"Y9"IN<SA=JRELKKJOVE`Z*
M4(#RB]I`JFTIN<!FK#*FH]LCXWHY*)Y,+@;YNN<[`$\7%,X.;((W#SY']=M6
MA;&H\<)F5NJV-SL=[JR,-=CK1L#04J2IF?6R]#`L]`C9<Q?;X6$Y@YP>Z;0-
M\FL6?.-DVHHIRG:=<'I4VL+2VLD0J5O?E#8Q-*9A:VLA>K52B9NZQ>YC**,<
M-F)PZ(3E)BB@U+4,D_'4Q+:UA-12^]+1E4`JV#6/":S8]LM8,FXX&RJ=GU%N
M+ZY.[5!RI!(W-F@%DNI2(DY66@VJ.">J3J3"4^R1OTS*7X_XP6E1PU=:LY7T
MTQ36X[3BM8[:XDF$RV=>K#8[-.7Y1,"&?3R[L9#A<$G>&QL-`'25W=?5./4D
M)DB8@;]<L!$_C;KB.V#"[)7/[,]R9C6TO()4]*J?JTZ5267T)%HO#((\L$[>
MF)_FM?-B^.01B(>&YO7C*4B:2S$8V\Q2O$L&MXB'$**,(JEC"NY[%>:XY]>:
M[/H^N]I(PU,4/C58J7`46C[V-O:@GS!:WLRA*SDN9_HJ2FAM(+UKW)JU6K&N
M$+X_:U$Q7RP_>DX]M?\`%K5BDD.\S!Z[,CMKI&^>F'I2Q_\`)_3TI;99T`Y(
M$ON-'`^G(DWJ:&=ZII@UK<]^.B*V/$Y;5TDMR>BIUQWU$[02!H6F')5=>3#K
M6%V[!+#D::5B93G*0IXLQ7Q+28RA5%A);RG@0%8G#2=)LB+OUR^=A?'ZSRF)
M2F(*)J^3>O&Q3TQ/*BI5_.9X<R1^T^DHI:[!(E3K:<>C#Q-"&-E+NJ3)8^:0
MC-51].]#-%IR.1(/0&H!?^+.BK:B][G63()2&:WO,^6V!AE;E-*Q0V!4$*H]
MS?G.6V$6X5I7D?A@'-V;Y6]-J-I;4BLYQ*7?]Z4(B5B@IO&R8[.YU2D4F[55
M+'H:F-L]/V%!;!BK;'RD29&$^OTRQ(QL!I!R8\LECTE5^F(!.BS`@+#H`@^&
M5G59!?'W`$[+1:1GGLU:Y!SE6[5`JNE(DT9<%C>L8[%KJQV^4.B!6S"0.*U0
MJKHML6IP!()4-#DM*!Z)PRE!)=1K(?BYKN6#6R"53XV761(72WELLG<UJ.F)
MMM0GNAUCKV]AB,9E<,=V*$O$)<HZ$477D@4F(BU)P'`+IH6MA&K*17DB*P^\
M">@&F9S34["W"@RDDU2@^VE5(HXRW-,6I74>)1DMZ2,0V4-89,W+2@A=BGM:
MX^*C:-P4)-C>,6RPA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__UO?Q@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_U_?Q@,!@5:[3Z+<N
M3N9[-OUH@*ZRW"!I&$1$82*%Z%&'[@E+)%S)%)7)J9I$Z-4+AY3UMV>U:9`L
M.3-2,\P)6_+XZ+)MD5C1?(5,C&KC>5'T5$':!=5/D"A9\X@_1$3FZ%HFT\ES
MM%@(:V;HY%7(=F,$3;VK3Z_.+BHBI;<U*0$%A5.Q9[85%SOEHL?^4AUDQD_1
M-5/5WN1E7LDH:DX$X7;8#'/9^XOW1$GH.(V+8C6_\R-3!7=4OP(HI?!N\;=+
M`$E(\$.R#%_\C&GKT[".:[O0]&TC`[D0L"N*;EJ1W)=8NM7$NAT=DL7D3O#Y
M:Q@=TY"0AY2-4HCZPA.M`20%80`!VBR_/Y`UF\)SP&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&!_]#W\8#`8$+=#4?'^C:?F=/2603&)MTN0DD`D\!D;E%9
M6Q+T2LAP;W%M=6M0G-,*+5I@A5(SO41N*,1J546:G.,+$67+JL,8^-:@XK'J
MSB*&1W&9$(`]L,N?82=9+F9![:G<<N%=T"VSBS8H<G.:ULD#<S@-\-.:PM6E
M>R4J%3HYM1)$9##VK)O?QW4M)7:1R:1S6]I%,UJYC6P"=2*UG:13*D`QJT0W
M,Q(:J?GQ(XJ24*"Q2BE>POWUX9Z1.2W'B-;"@(]#5G:JI6OJ=J>*TM$FDU3!
M8FU[;4R23*C9*O=C3UQ[NZO$B7NOKF/+V^OJP]>L/,U_-5GC'H(=;T'0W;K/
M5VF3HXV>D2$$I4B666"F2I4Q0"$Z9.1/Y,400004$)9)))8=!"$.M!"'6M:U
MX8*WG"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]'W\8#`8#`8#`8&F0/_
M`"1=_K.QO]PI1A:W/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]+W\8#`
M8#`8#`8&F0/_`"1=_K.QO]PI1A:W/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P/_]/W\8#`8'6O\EW6]T\@5Q6TYJF%19R8GVRXW';+LN?,5@R2OJLC;C(8
MZUD*IFCJ]N=Y:PM,F,=C4_UP"1<2W#)T6%(J5JDA(I6OS)47]!_(;;7-\PGC
MO+*\JR64R9RU=/15./$+DLRV*7EU5!(9*(ZV"M!^C[7`9@Z6,Z.KUHQACZ-2
M[1V/M9+VH$J2+`A+:2:C*QODQZ&KALLV(+*VI1YM[G?^[N77`M2NT\;Z[EU>
M\ATOSI>D@;:W2G$K)$P3*<QSIME;DA[F<M0MZQL5G&%J"S2BBVKZSR[J$LC9
MU$=0RDY82VLJ]L0.P%CJ<0@*3I'(@@]-M8:<;I.G'O2@`=ZV/>O/OPUO>5A@
M:Y5I5\:/6H5*=8C52ZPSTRM(<6H3*"3+!DXBSB#R1#*.*&'?CH0=[UO7^&%K
M>\(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]3W\8#`8%8^F^/J#Z]9(FQ7
MG$5<A)@\D0R6,N3-(Y#$7YM,)=&=Q>64#Y&')K<C(W+B&0A(ZHA&;*4D!`,/
MIJ24R@@LMG3"`X2Y,!))3)]4PQB.F43D\)?(X:\2PZN=1^;PMHKB:ELE4'2`
M=815VF4`843*[.;6T(G-R;$I292H-*!H.AM\L&X?'ER`[P9DKIWJ=2[QECD<
MIE.MNUE6RYR60N<Z0H&J<)9].ET[43BS(Y-&9I1('=GD3BZ-#FWH$B52F-3I
M4Y18V]KIX1ID#_R1=_K.QO\`<*486MSPA@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>:CY%
M/GQ/X1Z]FO.*"NV*TD$-5TJND7D0/K"_Q9MD$?23*Q(V-<J>0,<D=)%#9.S*
MH\[I]ED-:O:M,O;U6@%'#FMS\;-=QWQ]],K.Q>/:4Z2<C&`3I9[3)5KNGBS,
M^L4>:WA@G,HB+LPM2.2KW)[4I8ZXQ\U![X\9?U,2;:P!*8L\*<JLV9;%R<(8
M#`8#`__5]_&`P&`P&`P&!ID#_P`D7?ZSL;_<*486MSPA@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,"E/=G>=$_'[2[A;=S/0#G!7Z[;7=;M:U$7,[-E.B]"(9(^E5&:"F;TPC
M`&.3F=KV;8FWYS-B,&22<62WIX(.RN:_D9[>Z8LOJJ8<A7NU*KK!#I8S!B7.
M'0,@B_VDFA3#%X>B:5T5KB5'&_2HM'$9!ASEIN<%NPZ5&HTHC]D%9=99)FO:
MY\(M96#3GQ@<QUS:<+E5>SN/!N83W$)O&GV(2AI`]=!6O(&G;I&Y,W-+ZUB<
M61U3*B0J4Q0QD'@'K7E%K>[.G/\`7_M7:SE9,!@,!@?_UO?Q@,!@,!@,!@:9
M`_\`)%W^L[&_W"E&%K<\(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_(A!`$0QB"```[$(0MZ"$
M(0Z\1"$+?AH(0ZUX[WO_``P.D3K[YV>7><Y<15%41J==5VV]J'R*1=LII"F=
MH.MM1)Y6YFKG[T]P(,C>SY(L2)'$J.)GLUJ]P$!X-*A%)3)K4_-J+N'_`(N+
M8M.VT?R!?*T]$V_TTX^DXU713EM,Y5ESFR"/4.+,V"8B1GQQ=(V(:X6TJ`D)
MS>U*?,K,-7.AGNTS/*W]?'YZ>@[*P8#`8#`8#`__U_?Q@,!@0#U+/+)K+G^S
MYS3[-'Y!9C`P%G0UFDQZ(EI7O"MS;VXLK:=QDL-1O#F$E8,2!L&[MGU9>$E$
M%40(_1H2SFNHZO?D&Z:FW*_*%HPZPJ`GUM6))$58R*J%E.6BQVI<-RGR*('*
M*_:8C]X,J&I6>%U`\N$EE,R,"ZL90"D3FE2DM"D))L7)M;18W??3%83>]&67
M-37$E+Q.GJ"\D,DGJMG=(5,8XGZJH+FA;;RRP(A?2V3OY=?&72D>'...4?B9
MJU&M*VD7#TG4[`,EQV+\EWC);6I5YEEL*8LAE5?W+T%24LDK&B41:%R5;1%Y
MSRG"IJRMKT^ORAC;Y:GB!*P:0UP5:2*SS2`'&!`$0JEB=:Y5I5\:/6H5*=8C
M52ZPSTRM(<6H3*"3+!DXBSB#R1#*.*&'?CH0=[UO7^&"M[PA@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@5SZ*ZDJOF5HC9\Z')Y%,9^XK6*K*CK:,N$ZMNV)$WIBU:UE@4+:M>Y7B
M0$'E"6KU1B-H;`'%C7*TQ9@1[+)KJFZ?[<M9VKZ6\IV1S3!K*ZNZE1'L](<,
MUS8CU+)7`ZR6-Q.ELZ[/LJ+N\8885&0J->]5$LR@E(<DWM`6O4$A6.2>-2?.
M\)G^.OXJ8CRBZ"Z!O!;&+=["DK62D62]FCC<PUK1["-$>C!5O.T.2(&]NA<.
M9F]6-O\`=D)4AZQ,'82R49!IB83$OZWB=.W[*R8#`8#`8#`8'__0]_&`P&!J
M<Z@D,L^'R&O[$B['-81+&P]GDL6DK<F=F1Z;%.M>JD7H%99A!P/.$(P;WKS%
MF!",&PC"'>@JLT?';QDQ,-61ULHJ-HT-+LCBPUT>C<9(W.3&D?%R1UDBHQR:
MWI$L='B5NJ`E4[+50SE3D>4`2@9GD#X%V^4C*./^75CK:#VKH>LE+K=*%U;;
M07*(NWG'2Y$_.B-_?BEWJ%B"FV^R-N3.BT:;1(U;LF*7&[&K+`<$;>.4NU]7
MD'JB',E?5O%F:%PN.$J"&6.,",M"VH=+5JIS<#@E`_B.6N;JN/5JU!FQGJE9
MYAQHQFF#&(G;^0/_`"1=_K.QO]PI1A:W/"&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P(RMZY:OH.#+[+N&:,\!@K6N9FQ;(WL2C2,IQD3LC8F-"`M(0J5*%;H[K
MR2"2RRQB$,S7X>'CO0[0C5G>O(-V3QGK&KKUB4NGTA3NJICBZ0A^1.3L0QMY
MSL[B0!=6=`2I$WMJ<P\P(1[$$H&Q>'AK>%RK=X0P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&!Q%B]"W@(,7K4B$"E6E0)AK%)*8"A<N.`F1(B!'#!HU
M6L4#"646'Q&8/>@AUO>_#`HW<$D[6M*R)'3%`1-IYVKIA`W)97UU9Q,=G#R[
MF.;>@=3T'.%.-KLN2/CFWI%P2#GV8&(6M$N"<6!L<!$"#LO'=5HLWI^\TE@L
M_P`?O#+`X7W>U<UU'F>Y.R+K?F1]@G.7U,A.V)'VTSHXU$?N#>CRTMY[EJ,@
M*:3#SQ)E)I)Z3:D!47)W5JN+.#J?XJC,@^UCWFQ+DLAP,D-W]$6&=IYMFX)4
MJ.$K6.$A?5`U"E"QE+3!C1-)!OM$OF$8+UE1AZDZI;O\+N80P&`P&`P&`P&!
M_]'W\8#`8#`8#`8&F0/_`"1=_K.QO]PI1A:W/"&`P&`P&`P&`P&`P&`P&`P&
M`P(^L^V*QI.&NEAV_8$.K*#,P0_4Y9.9$UQEB2F&:'LA+MQ=U*5.:N5[+V$A
M.#8CU!G\!8!"WK6QVI$#M6Y+PULGBGE.96-'E!P4Z6_>C%SIS-0QQ!P`[*?(
MLBD$8?KRLMI+V+S:.;(D2W*0AWZ2_>_#"YG=<Y-SCW%96]*[R[N45RWKBQ;7
M5[QK2\%KM`A_A\@$1=J7F1?5@.0?$.A&*T9+`</SBT6`GP"+0V>&4_Z><%5_
MSGWI;OQ]<!?_`%7'^^7HN)^K_P`=_P#)JZF\+BZ?Q,V(7\E`5X>;RZ\`!``(
MWZBBGR%\A-%+TG`['C74W:+"TP[J7D5Z?7*;7S-^@XY!61-TC69CK:2J.72D
MM+WBNMB`[>DON-'(2U",`3TYR<1B<R-2[;Q.E?#>HKOD?7G'FZQMVN_DT(K-
MWO.2%LU<5[_;A>#4R/%-N\<>5,M=I&[E4-(!%I5/G;?2!$PK7+P2BV4$\L90
MR9?AWH4!US2O1Q[\P0QW>8U9T,],%A4?9T?<*[NNO33=Z"6*4UY(0)W?32H,
M\0IG9#[UD7""+VJP_01;U6;+%FL(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8'Q4J4Z-.>K5GDI4B4DU2J5*30$)TR<@`C3SSSS1!+)))+#L0A"WH(0ZWO>
M_#`K36?5%5=$K[4C/.<N3S]RKE")O,L=-%98ZT6;-E6G5*1'6JS425!#[`71
MQ>A*&](V%U4&I"3P`$:6:(6BRYF:A>ON*T*>7,W0_9-KJ^F+JA"@,LC+E)TA
M,+Y[H9>VD&*!.=-4N4XK(S&US*6#1FI,_*'J2A&G"H"O3_\`8"-^(H2XW[;W
MS.L<SI/FAAL7G+C!'/U\5M[L9<]A:Y;<D2C"\M.[0#FUHCB\:-<EFZU&J1.S
MRM6*VU$T&!]5.>H/$@R=M9Z\WMW,T10E4\U5HQU+3431Q&&L?K*-DE#-6.S\
M]K?(-XE<L?5@SG:4R^0*0>NX.:XTY6K.WYC![\-:U6+=[3#@,!@,!@,!@,!@
M,#__TO?Q@,!@,!@,!@:9`_\`)%W^L[&_W"E&%K<\(8#`8#`8#`8#`8#`8#`8
M#`X3BXM[.WKW=W7HFIJ:D2IQ<W-Q5$(6]N;T)`U*U>O6J1E)D:)&F*$8::8(
M("P!V(6]:UO>!UMKNS+4Z96+8G\=T'C\[C9#@I99#V9;('=LYCC)Z0U0G<OV
MM;6[:*7],R!"<D,*+^@C118*G8/6>]!\Q>XUF=I"JK@6MH],FJY[^D\FZXZ+
M;#C5K;;5W!2.+3`U9Y^E(R*0J)+XUG2;8G-U_)$S(=.VP^/N%ZD6]BW4WXG2
M]^$,!@,!@5EZ*Y,J3I1.PN<K2O,2M&"C/657>U;N@X?<]5.IP#0B5PV;H"]J
M]-BD1N_>LZX"UC=`?P+4:@'AK19;%=H'TY:?.D[C=`=VG-`@2UT2QBC.QX\U
M!CM2W4\'A-^FP:TV<!IZ*C;V<""-B(1F'CCDB,`9IL4E*/(W;&;S'9'A#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`I#<O99T6L-[H:@*0LKICH!A*:MR.,1I&
M.$536OU]H0O[(IMZ^)>C(@T3*<6)P*6%(&WZX_G$"#LMN'H8=[+GS;PW&5<\
M)>GJ>KN(=F1F,OSLU/**83ZN:SFEA$4O)WQ`6[DMT:DB%4?&UMGP-O\`?)U8
MVY^1B0*W)$4<8E\@-%8-R\-1[(ZMI3XV>5WBXY%$2D\&@NF*)0FL*^3QB-&N
MSP\*@-T?BT5:5*EG:D*%/L0CU.DA1HT3<G/4!3F!)$'8DVXZI8_S??'S(6[$
M^G>H&JVN8N"&&-Z::DY(4S=^8IST4T*URAT.L>ZFAC<$;;$HW,B5!!.D00FK
ME;8D*`F/"F,+<ED[:V?GB=O0M%(I&(+&F&&0N/LT3B,6:4+#&XS'6U(SL3"R
MMB<M(W-30U("B$3>WHDQ02RBB@!``(=:UK*PS^`P&`P(WD=R5!#W8]AEMJUO
M%GQ*`@Q2S2.<QAD=DY:DD"A,8>W.;HE6%`4$&!&#8@:T,`M;UXZWXX,;?'Y'
M'I:T))!%7YFDS"X>X]@]Q]T0O+0M]JJ.1*O:.3<>I1*?;+4QA)GD&+R&EB!O
MP$'>M!F<!@,!@,#_T_?Q@,!@43^2NT++ISB^XI]3\^BU9V$UDQ%*QRZ6.C`R
M)TJ=VG$<:W]LCSS+6YVB39/Y!'%:M!&S'1,>AV_J48#`[\^O!5_/<=?$$[$N
M:R6'A8RL.H)7(;,L]Z;HS+*8EE*4RRG/T?J?H)?">I+;ON>-:B2,S1%8Y"FP
M^.QD<(6LI;_,PIE"0U:0L-;T$:R<\(NB'?O4,C*:FA?=R%&5=[CS8LE$P11:
MHP+>,CKB[,M6@9+!HX%5$5<>4FE1*$ID#6.?)7]:1(BE2@[:HD8&Y.,GAW#\
M47/+;AY)JFV[(6`?I.\-DA2NTACS&(9<R(C,WD4.:9PWL492J4^@3AH9$SQZ
M;>3M&#2W>TX0I]`\*S9EQ8*N5):R-'JR0J`%*)=89Q8%:14@4A`.P9.(.CT2
MXE.L2FZUO\0&E@&'?X;UK>"M[PA@,!@,!@,!@,!@,!@,!@58Z)Z[J_G=5'H@
MN3R.S+NGH%`:NYYJMN+E5OV$<GT+1RU"P!4IDD;B#>(.]N$B>E#<PMI81"4*
MP;UH(BR;_"MK?R/;76BUKG/R&.;..$IU:![BO"=;O:ASHJ/'IA[6(#N@):)*
MVN/2LP0*-$C&C.)0PQ(H)V$IO7:WI6.+N=.RQN;F]G;T#0T($34U-2)*W-C8
MW)2$+>W-Z$@"9$@0(DP"DR-$C3%!+**+"$!8`Z"'6M:UK*RYN`P&`P&!CVYV
M:G<L\YI<V]T*2JC42DUN6)EI:=82$`CDAXTQAH2E1030[$6+>AAT+7CK\=8&
M0P-*L>MX';\%E%96?$F.=0":-*ACE,3DB`ER9GIL4^40TZI*=K>M#*-``TDT
M&PG)SRP&E"`8`(M!UQQJ?S7XZ'UJK/H>;OE@<829\0QVD.E9:<L=Y1SVZ.ZP
MANC=)]+2,SW*ES@BM2>6EC%@K1:T0/RM[Z:`6TJTV-=]=NT\(@C"$8!!&`8=
M""(.]""((M>(1!%KQT((M;\=;U_CE9?K`8#`8#`8#`8#`8#`8#`8#`8#`U">
MV!!ZMB3W/+'EC!"(9'$1K@^2:3NB1G9VU(4'8A&*%JTTHK0Q[UY2R];V8:/>
M@`"(6]:V'3[\:/R'VIV6S=--RW<><+$V%QO#EI#*HY*JZABFGI^G<44!KI\?
M@PE,NENZAES4G;9;)&9,\E[&\$Z)&><#9(9*U^OSF+<0;E>\YA.(M:_6W34I
MF[U$)`CE<3HNA-O%(<WQ9Z;E85K48^HVQU4VC=IS4H(*&'4I>S&4X81;$SAT
M+8<J;/B+XJU:5`F/6KE*=$C2E#/4JU9Q:=,G)+UYC#CSSA`*)*`'7CL0MZUK
M6$=*'=OS)(>4^D&SD"H><Y=TW?TGA!+I'&""RYA/]&=OYXRXI$GB.,!,FE"`
MHMO3G.3L-<4UGID(DQJ<I20I,4I9K4_.S=X0I\>?PSO[#)F[JKY()@\=!=#J
MI0[6/#*BETP?K%JZBY-)3DBE8ZF[DKN^)IS8B<EM1%:5#$8W-XD1.RO>'I4B
MXIBW]?$Z>B+*P8#`8#`A&\^DJ'YIC1,LO:U(A6K2N.VD927]RUM_E+EH180L
ML*B2`"V5SA_-$<'1;>T(EJTSS:\I6\+);TZ6ZJO-JNCLKIAZ6410T#JYYMFG
MW663SO+316MRZA+;1=5LAC%5]#2=G-G)2B2H$`W1`XR%4R(4Q"PK9B,Y1ZR<
MN-9Q.79?\=_V]_;B]?:/T;[4_NP^03[8^W/8_;WV]_?STO\`1?H/TS_EOT;Z
M;Z7M?;_R/0\OI_P^&5F]KQX0P&`P&!__U/?Q@,!@:Y+HA%Y]&'V%3:/M,JB4
MG;%3-(8Z^HB'%H>&M:7LI2B7(E(!DGDF@W_AO7CK>M;UO6]:WH(V.YIYT5+8
M>Y*Z$IE<Z5ZUL;'`W5?6,*7.L,9XPJ,71QLBSFK9#ES"A85QPST924PH"<\8
MC"]!&+8MAM1E1U2:@G#4;6->F-=FK3W&R6TR%QL:"PG!46$I2OG",3;M/+%J
M@H`0C-7A4#&'6M;WO6L#=6YN;V=O0-#0@1-34U(DK<V-C<E(0M[<WH2`)D2!
M`B3`*3(T2-,4$LHHL(0%@#H(=:UK6L#68'_DB[_6=C?[A2C"UN>$,!@,!@,!
M@,!@,!@,#A.+BWL[>O=W=>B:FIJ1*G%S<W%40A;VYO0D#4K5Z]:I&4F1HD:8
MH1AII@@@+`'8A;UK6]X'6HY]0W1U\I<(5P&F;V"L-'&MDH[SL%@-<ZS2!`>:
MA<TG,<"6[0J+^EB$TLW1;ZH$E@Z,\CQ]PZ^/M]ER3M9[G/DVI^:4D@7Q0E\E
M]G3P\E?:MZV4ZBF%S6L[$!UHI7,IJL*+4B;$/AY4#.A`C9&LO^!&D(#L6MBW
M5DAJTI:DA$8I3EK%12@],D&<6%2I)2;("J.(($+1IQ282HO1@@ZWH&S`^/AY
MM>)$-0[HVE;&<;?9*XGS18;_`$*ZKF"V(]"`K),^Q&2-YKZF51A2V-290I62
M0"^,KTGL4VCE/O$IA'D]77DPN5KK;?,KF-'.MMUUSM=+K*"59J&/TI8C9'J1
MLF0F$OB-H.7&D66_-#1'6<M(H-<-&KU!)YR-,/T2#3QDDF#.>V1FLLZ/%`ZY
M=ZLIJNED_DHXX?8</MJY'"&-=8H5K2!RDB4J1P"L[9+G3XRN6MMA9:0E*C/,
M%[D*G90/(8.&PR8=\ZM&#EPU-40J5&D5[LI7)ELR+M%.O"4X[0EP=O:D!D35
MI#SO:!-&O5$#*#ZP@A,WY`X3_M_&8J^]7'+#9`OJ$SGT3`F#!D#,TS,FXR)3
MZ$:]V;+'=:]'PE4P;4A>-EEHT)*G18T>A#WL!^QC_M0'O5UZMC_&?2"V8.M6
M)F@=@5@D*?*G769"W1BY:=;@AK==BN>O9J:8O;,Z-]/J7/ZL[L"8TQ&V"6*D
MB;W!!(!QJ9L51J4ANHF]*14\=4'S<LN&14=9*_HKG?B*ZF0="2NHFN0U\GI&
MS)!-I+!()'"[,+4OJH;,Z.;6V.;\F,=TVEJQ,2$\!>Y=O#N,F-Z+JZBU6/LQ
MIBZ%CM81S`V2&-U?"U%Q+*J>W=N2*5Q$Y/@1KEO;&Q.*@:0]U;REB/8BA&ZW
MHG>AY6<;,Z7O3#'<$<Y^>[1@S-=TQC)\QB%6.TC;&Z;RV-)=OWO':+L"Q02N
MD)*$J+N1IX483C"$Z$\XP(2BACT,N;\-WEL2B\]B\@A,VC[/*XA*V=PC\EC4
M@;TSJR/K(ZIC$;DU.K:L+-2K4*U*:(!A8P["(._#>$=:<#F<N^/VQXKSW;KJ
MYR/C*?NR")<O7W)G@US=Z.DZX.B6+F6\7]RV%0HBRXT'M(!)UAIAH]:)97`X
MQ3[0\R-=\_+M-RLF`P&`P&`P&`P&`P&`P&!&MJ7-45&1D4TNBT*_J:)!4:1Z
MDEC3!@AC*:N$2<H+;TSC(5[>F5.)Q*<8BTY0AG&:#ORAWX8,WI$5&]D4ETG*
M72/4H;8LU9FAB5/:FT/V?M*-4TL-2N+6W_0H[:LOB4?ALQD"D#L!440S*EX!
MI"C3?/K18M86RSM$CZQ?)#;CL[(4TXY[XZ@!3XXIVMTB#([].WB\Q]&K/3-[
MGI?-T%<T_`G!Z2!"I]N:R2X*38@`$,>PC"(<,_V'P)2O;=3--=7*%2XRF,LW
MTJ'6^8Q0QZG$34KW")K)4]M#7(HVZP$#M,DT2*2+1B9]A*2J5`$FDWJ>.A+9
M6(KGBF=1B^*SOJR.PKINMYJB(V!!XM&I)7G,\"8!1FQTK`4_,KJ?3M)5Z_.3
M.6XQ-I<$Z0Q7L@E<V$&!#K6C`F#9F2)LL?JVA*Z1W$G<KAJ%-+J0A),SGL7D
M=F1V,?::=W*<01,F;N)XUXX<3)W-O]N0,],8?_,`(!!OG*"8,KS$V)U/VM\X
MD89^4N?Z$@L1@L4L3<BO+JQX,L,JGXFXM+P^:BT?A3)*TD?7S-T8H>Z)]FIW
MQG/7.CL(MS)96`*=&N(G;>3\\VN^G@;XQN>N!6!<OAY#A95ZR\D9MI]&6#KZ
ME9$[<UIWO7;290J4N&XI'%CB+9NF]*<,9OE`-:H6J`>XW<8OZM_AV-X0P&`P
M*L7UV;S[SHY((G.)>I?;4?DWN(C1=9,3O9UY339@RR4H(Y5T,2.TH,3+%)H"
MPKE1*5L+$+Q.4E@"(02R6H!&M^0CI[8RVIO8/CYIY9ZX-.S\&-79U_(V\8_*
M4<BCJ0UQH>C1K41V]Z$K5SEQ(-#KS)TP]>&HO$^TVTAQ!SY1<D56*U1MUL2[
M'0)NG[H*ZG]PM:[WGUO#1A&IY*Q*U<:9]%``6!K8RVIH)++#HM*#PRI;;_"<
M)'3=03!V/?I;55;RE\5`(+4O,C@T8>W906F)`G3%GN+FUJEAH$Y!80`T(>]`
M`'6M>&M>&$UM\?CD>B30DC\586:,L+?[CV#)'VM"S-"+W2HY:J]HVMQ"9$F]
MRM4F'&>0`?.:8(>_$0M[V&9P&`P&`P/_U??Q@,!@,!@,!@:9`_\`)%W^L[&_
MW"E&%K<\(8#`8#`8#`8#`8%'K-^2?A6FY[,*OL[I:NX=/X`),&:Q=S.>!.49
M]XB0.*8;OI(TJ2$A1R)S3F:&(?E\#@Z\?'?AC5R^&$E?R0\XZ0P]MHMV<^J[
M5LV.%RBLZ;H!.3*I@^Q]6=M(AETM6JSFZ.U)7HUF]!-?I2K:T.@:'LC:@P.B
MA-/6_*J4&C?]]2>T+'Z?L2.=$L=%N;@,7`/++]];I1EF\>2K'IO@]G3Y^60M
MGZFM\"MKTA&A<7!K@3<[:&2<BWX>\U%ZZ=A0''HB:<_1I75,$@_,-KKA)T2>
M!WFU(K,9JXBC>ZKFI,0K9:/L1G8'%X,C*1*K1HD+^%$DV=I.<9XECUJIQK=9
M?43K.9#4<G=+>M.,*JQ5[=7F-5D^I(5`;5=QB8SO"PF%0@D+\X1Y$H:3])FP
MAW)(V0XGEJ]K-A(&2//#()J&I=)<#CT"15\(U=[K'D\266L9'FX^>"C"4LHH
MJ/IY(>28YH6?8"0:&G(,+*-\NMCT+>L)MZ^$M8#`8#`8'Q4EISDYY*PLDU(:
M2:6J*4A`-.8G&`03RSP&ZV4,D96]Z'H6MAV'>_'\,#K[^/.XN3KHB-R/G*U+
MPNDVR.W&_P`4EC9$Z^B=>[GY129+(X!<(4L7:&?Z]&+4@\E2O+0O4EC,,*5'
M%^<0RC=[+=^5]79]9&$DM2^/#4S)SC?0)/=G!(W$FG>01GHEFK#B0#-\@-[\
MNM[WX:WO_AA&,;Y#"Y*N(+:GR+O[DVA.7I@-[FU.JY`$1>T!ZT@*8\\]*$12
MW9(S`^7Q"=Y-[\!>&PA:+U_S)7%K6/;L6,A,7L^S?;);)=DTY.3AD2MK$244
MJ=HR?(A1PE\(]H`HQ8!$4M&`O19AFPZ\N%Y:'(.>)^Y<NVY24XG+3V@YSA$^
MI8^5U(U1&&QUYCSFD:BVR$SMWHFMV8G:)N5(SE1+\A8!.Q"D\LT`1#3E;T-Y
M4,JOKBUOCO15/SEWQ$;#?V&P7%EB_-5T5BW/_0`B"E24_6N?+==HS&&67RFR
MJP2HM`02-+'PF3!CV!4-(4M1N.Q3I<]ML=SA\RB"64HH,IE<;3S9S:SGQNAY
M[XUDREP9$YII"AX11\Q4%V5M9!Y`P#4%DB)",`M;%K>MY66R8#`8#`I-U]VU
M$>1'BBVB0Q-VE^[<GY+3)U+0O*2!JBHFYQCT?G=\2-/M"X*'"&UY))U'$SD4
M4$H0"7;U_5UHC8!EDW4_RV_**@)RQ/.KIJ6%GMPM!<");8T.CAR$0E6T00K"
MGAY1C2BVMULG6AZ#_-UY/^U^&$Q@)[U%SM658L=T3:Y:_:*GE#B@:(Q8),A1
M/,5DSHZ`7F-K?''9B&YIGU6O"U*?1`DV<(S9`]!\=AWK"Y>FBT]W#S3?TT!`
MJAF<IF;X8WKW0*Y+3MU-L+TB;A&`.-,LA\KQKKLH:G9(_:%B=-&KM`%M.$W6
MM[T,K5YIV#-F27R2$03A_LBUW./O:]A+D+)%J?@E>/"A`J"E^I-,TN*YZZ3N
M$>6;%H9"U.0<687OSZUY0CV$9]I/E<PZ:=:?B<CJFEJ^9KCD"AO%(JWONVCH
MXQ5\VG(G10Y#<Y?3T.N5+*'M"L3)4Y:1N![0_P!T(SWH`D^!@XWF\-9IQH[B
M,FOUOH.=<NIX"4W.9)-=TM6UI'R,]S5^R$VKE]JSNRBT8T[1LHX&R2(H1[K1
MGF$(O>PA+''PTB9<,(K1E4B?K6ZF[)F,<?I&\NZ>K(_>2FD:X8F-Q=%BU!"4
M"?GIAJ>9NT<94"@",L;N]N;@>64$9ZDPS^+0WZBTC-4E;LD3@T(3Q!I<8U6H
M&W4%1R<!TR51H]H;SVIN<4#S+3GMZV\IFY4:3I<8H&L$6:/0C=^<7B1(N`P.
ML#Y?NAGOG_XX^D;8KQU<=OC1J#P<YPB#P8V.[<CFEN0FNITC12MM2N9L)D)<
M8?W!*F<M%^X;'(9(R_!0$K62M?F;8\@U!?+L*+]5TM(N/>-F+FII#&9#!K'I
M>C9FZ/H.GU1:+ZO6Z&?D.=9RU6ZO+%)V[R#=&MD53ER2.*Q*G<-F*"R\FMW\
M\7:[S*B^*[H_O.P]])?)T]`K^'/4C2SIDY4JY.F@"EQ<@)$R!*YV)]K*U.HB
MO-96],F./$Z/T[4)=`(,?6DHH3;NYY9]I./R]'%>5S`:DA<?KJKX;&X!`XJA
M"VQR(Q%G0L3`SHPC&8(I$VMY)"8H1QY@S31^78SCAB,'L0Q"%NL-TP&`P*5W
M!WG1]93);440!+NB>@D@B23*!YX8P6-8+2>JV>$@4^6DK$$'J1N#Z`AFJI6[
MLQ("=><.Q^(="+E_I%H:P[PZ<WM3=EH(>**G5FB$"F.:7E-+NA'AM$'80IK!
MZ==46H]"%`S"@C,1P9C]R4`S82Y`+>O-D7B=<U:6A>5^?N9&E>V4E5\<A:I\
M'[B5RL):E[L*=+Q'#4&.M@6/(E#M.YV[&J#1#VI=G!8=H0M^`M:\-:J6V]K`
MX0P&`P&`P&`P&!__UO?Q@,!@,!@,!@:9`_\`)%W^L[&_W"E&%K<\(8#`8#`8
M#`8'"<7%O9V]>[NZ]$U-34B5.+FYN*HA"WMS>A(&I6KUZU2,I,C1(TQ0C#33
M!!`6`.Q"WK6M[P.N>U?E+YCC<=:PT`^?WHVU+'!:UP.CN7'-GLF<R(UL>#V)
MV?G4UI5J6N&0!D7I#=JWYR,*0>D4(1&U'X:W-:];\\.@9QZ<5!O_`.0B'].R
MV2_'DR3RP8E8ET5C7E,++UZ6Z-A;G34%CA5%L/14:^L5]#$*-A;-!"2VH=FI
M%TB6#`XB3^[.`:^)G+M_^&7COG2J^7Z4Z2@-.*:WM^W:G(#+UJM^F>UAS(M>
M35*!`X1QR>/MP+@8B:T(U"\+>6L6C*`88:/7DUI&?U;MF\.YHD@E.7HI.240
M5H0Q:+)+`47H1@Q&&"T`&@AT(PP>Q"WX?B+>][_'>5E]<!@<?:M*%46A$I3A
M7&ISE92/9Q>E1B5.802>I+3[%ZPTY!RDL`QZUL(1&!UO>MBUXA1B2?)/R.SR
M&0PR+S.:W/.HN\KHX]0KGJE[DOE];Y"U+MMSJRKS:L@LG9&EP:UP!DJ`K5B8
M))Q8BA;T;KR8U?6M0Z?^2.K>=Z]A$M3@@#O+)B!I4+JNM#H&G.>9W`DKNR:=
MBPS>,65(02XEY;5A@$*]J:VIT=4:K8_.G\A1@@B2U7FCOE7F]D21V5R3G&3O
M\'VR&[8&[EFN^NNAY,"2!/;3$Y,GG\FY3HZB$3(L:O=FE'()"X>8_197F_P&
M;-6_G[1D\6M\KMAN[NIB,0ZMCL?4N;HH;$42YEX,I90U,AB[RM2`IZZ6[/NE
MU=W!&1LTDY4='DOJ"+*4`2#*\P#W*Y^4UV:X]QVU"X#%)%ROUA%7"'$I!O4P
MJ#MKFBHY'8CH4REM2IQEY\.5HR"R5JP(U_LFT"!$6J'X!+]((2]$X41ZS=>F
M.2>-NL['A?(G7S%,9'3+I!7.[+B^0O\`N@35W%I,Z,#$]R'<-E=Y2A8W*V1H
M5*5*%P8V54Y)E?E]4PE#ZQA19ELY>=GX6);4#[T](8[U=0BOHNC`TXXC?$S?
M14^O(VLCXV\LQ,6G#E":JA<Q=U3"CV[&M!JE8@,)2^_3^0T`RB2C)&_UUP]P
MD2LGXN>MXO#*'0N')5T,M=!9&F#T'8\>@3J^P;;,R@CL?3,]+VFTE2J-J$+`
M9I$F%IJ),TG%LH._+O8<UPY?ZG*S%5\H<MT5(5DNI'FN@:<E;BS*(XX2>JZ<
MKNO9"NCRM<W.:MA6/41CC0Y*F94Y-"108E&:(@9Z4DS8=B+!L(VWNM&>N`N$
M)(\NTBD7%')#_(']S7O3Z^O7.%..KR]/+JJ-7.;L[.:Z&GK7%S<5IXSCSSAC
M-.-&(8Q;%O>\&WRW&P.2^9;6K>"4]95$U?.:LK!.RI*[K^31!H=HI"TT=8=Q
M=A(CC,K3F(VLIHCHMHD^B@AT4FWY->`?PP;9SJ!%_P`6W!HXM-XM&.<X+6Q,
M[C8XZL=ZR1F0MZ8#2W9ED31*8<<UF!0Q>;QN3QMN<V]V3)PK$ZQ"4+SB!Y@"
M8>U\NNVB^'^3%?03C07;-&L;MV)'DLAFE2]*-4LM2$%=<5D)68H>+*95L?FK
M&C:;T8#WHP$^CR/?BG.4:<47F;%?E2Q;;G%X=E*SX]J5=@JV1^G'23U6NM1@
M^,5(;TE;K1#Z[>(BS#CK2_5_((O)V&V(XN&QGG)U*?4E,;58CS%!J42H7KY4
MVHQYQY)F/)\3L&S'&/O-Y7NR@DC7`X_`>D^IU$:L"#J4T=4M:!PAG7O2]K5W
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M:[7^`.=*'G7)?/5LV+2'+$\N*:UTPRB>VW&*CCBYSL&7+$.D3C.9-()A7,3G
M*RQ9$F3`,D@W-$G7%O8E9)FM^GX[K-O-=F;0SM$?;$3*PM;<R,S8G`D;6EH0
MIFUL;TI6O`M,B0(RB4J1.7K_`+("P!#K_AK",C@,!@,##2&1QZ),ZZ12M^9H
MS'VP!9CD^R%T0LK.WEG'E)23%SFY'ID20!JD\!8=F##H0QA#K\=ZU@1-8G1E
M3UDWUJZ/CO('U'<#RTL=:F5K`YY;>I6J>R$RQN6HQUA&Y:4D8#6Y6!5MT5"(
M;@I?$W9_EUXX7*R3O,[937/%H.RTN%VJ-PC:AXF%XK+&CC23&GKR2,"&(LU;
MA1N4ME+H-4UH-J5)FVUO(2N@3"SU!R<Y/H<9WRZMN@/DGHSE247PBM'I=+U6
MXR%8)@BG--41*MXS'J3;1)7(`X]9ER*7W3*SO[Z4M`2N.DLB2*SP%%?2V3UM
MF`/FK/S;G#J)LWG?Y%>^^5933?/7/49Y&XS$!K>8524=96NMVVREJ:5LTE9E
MSFMLQHCUMVTX*WDM,[.+^XMT`:O^Z&*TY$D5!3^JY:V2\WE)7QM_!)=_#O?-
M$]`2^5)YM"X,DNI&L=(T4P)2$3ZXUB]05C<GA`XR0+N&'3-'.5PT!B0I4Z(U
MS8`I:C*3JO=$)#]?J66/6KE<S`8%$[1[[K".S1VIFB8S+^N.AFH>DKI4E"%-
MKTC@RTT0R2!W3:[HM;ZJI9O`I#H)P7QU*<_(+Q(0J1>`-ESY^&B[YOZQZ8-(
M7]>7:&GZT/T2>+ESD*326-E.)(O*8)LMSIT]-'+2F90BC1D*D,620]N,\/`1
MBL'\0HNR=+HTY1M/<]PM'7=(UO$*PAB(8CP,4/94C2G5KC`A"H=G<\D'O7U\
M6^30E*]::H6*1_QFFC%O>\K.[VE7`8#`J%:W>_'M,/(XK-K\@Y\[",XK590,
M]PM>US#B!A*,)+JRK4$QL$0_6'H&O^6^&Q>.O'^$7@7+X>-GY\^\^JI7TA4H
M8$HZJYDHULKILD-7-$H:YQ0+[-9>FD;SN166-C"M:9.%:BWI`C1%N84ZQN)3
MA-"F3"5F#/S73\29]O9!\?4VMNR.(N6IY>VG#=M2RE(,]S54[(P-[NZN*UG(
M,3/SNA+`4!*[2%LV0N5%Z+*\IZ@>O3*_^F'3G>[BX>$,!@,!@?_7]_&`P&!U
M]?*9+)=">%+UD4'M153$C1-\4TGGR5!-3O:(#IQ&BWN/*'V`1V422`)9PR;4
M,@Y,6ET5'OJ.EQIR8!.U!2K^>XI%45UWK,(!\35A-=K68Q5M8'1<@I>>P2;G
M-4LF5JJ6:J>N70,Q?+P:DT<*LRI#MU<UJ(B,IC0#>6X9#JY*%RH1`R9X:R?Z
MF*Y%=&6TR/-Q1R1WS(WYB<NA(NZ]!WW6EYW,*,<LTI-.V9+&I'3\TBMJ1F+I
M.8)?%:R4-Z$#JA2-JI+%TZMQT),G+2NZ@9..'=-PM.K&FO'--3>QC9-,Y@YL
M#N80ZNQ+8BE4TB:28/[97DM<MK?MQN.<Y77B5L=#E!FDNU6U.SMAT,SRY6;V
ML=7)QBB-'GG)%"`TZ76&88B5B2C4I1BL&3[$0>-"I6(Q&E[_``WLHTP'C_@+
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MQ@BC7+Z`@V-\D:PK0@A<Y=*G$Q;)Y>[^`]Z]VYK%:CPWX>?P\-94MM[:3T=V
M'67,DXYW@<Z2O:QRZ'LHB`-:IG3:/0PMM4*6B.AGTR/W_+;(<58DTC$>-4C$
M`):Z1I=[WY="U@DW4FVOT%3U)0#]T+(FB9I@XG8EA3O30UOTT,<'P\U:G)9V
MEHA#5(WMW<QJ&X\O1"5,<;ZA0@>'FUX823>D54UUL5>LR2L<-YTZD8(,>WN+
M@*Y+9J4ZF((("4&A-R=O8+.>(S;CL<_[%K:0PF,;2>EOSF'EZV'0BV9\JL=.
M="]$53)Y"DL?KKX^>,JS->5X(.Y2=+,;HOV51GW:L#$<W0223"F&%/+W9"66
M(Q`@02DM.=ZFBA*P%^(XLDO4NH_FEV//4E5P*L*^I7OKIDUC4-+J]W;$E\G^
M-NL;9-0-KBRN1LGG;U+:;G*^$/(W+:LY#%F9R3GGIRQ$>(2_*(9G.QCJ/X$Z
M3A4C7S:`,_%_";T^M@VEVE=40&9]B=-KH\J4I5BF-N?1G02^&MR<@Y0D(.4%
M"C+RC.5I2AC"=Y0"+%L^ZM+KXX*REQHE?0]V]5]2*#0^<]JMB^91&:^VJ'Y=
MGF@J*B0T]59Z<>_'025;0K``&]:_$00BU4WZ61J7E7F6A2BRZ4Y]IFJAEAUK
M:R!5K$(PYGBUY/YJQV:6A,YKU&]EA\33SC#-^77B+?AK!MO=3YA#`8&'D$?8
M9:PO,6E+,UR.-2-K7L<@C[X@2NK,]LSJE-1.;2[-BTH]&X-S@C/&4<2:`19I
M8MA%K>M[U@5LYGX>Y/XZU+=\TTC$:H/G:A(HEB]E$[N+J\A0"4#0(3G>1.;R
MZ$,Z`Q6:,A"2<6C)&8(0"@B%O>RVV]U(UP\[4)T(S_0;TIFL+=:@DC(3IK#A
M$=E@T`1^I_,:E3RWJU;0I+$:(19R4PDXL>_,`01?C@ELZJI1G`#O61HU_'O5
M=^<U>4T!A%<2!]%TIS]H'XC/3%U;=RU]?XRD4G^`MEQB2QT(-;$$ORZV#R#?
M,?S71?:-$:V5TYRP3<D/2@V(^[.'U3G-CR@!`7OW$FYCG*A';3.`.@F"%J,N
M<X,W^&O3#XZ\1DO56?HGJ3GSIEJ7NM&VO%+`VS&[3R-B0*5#7-8BKT/T]H)M
M7\@3-,YA+CH?X>V=FY&?_P#@_'!99W$^816WJ'F:)].P!)''-W=()/X<]HYQ
M3%RQ0I)J>4S9K-XF,4VB:E4#99N@B\4SFW&[]F\M9QZ)3K91V]Z++B,N2^G)
M/83M+N=.B&AF@/85*MZ)18L2:CS!1BSH0J,*01WH:G#U)9)KQ5LX4"T`XC7F
M5QMWV8UK]`-`2-0+/F=+OX0P-*D%:US+9!&I;*H!"I-*H8ITMA\FD$58GF01
M18$S1H5<:>7%`I<6)3HW7FT8E,*'YOQ\?'`ZTII0E^4-V/??4_/_`#[".A'?
MI:,0Q"6Z/MXKZE<:DF,2@T3KI4FEL><VUWB\OJ]_9X"QKBW!L(/E#6K*<2"D
MYJ=;K88ULLDM6,X_Y#'S+2RN"N5F3^2SF<MASI8[R1.YDX0EAL.1*9"_3%VH
MN$RYT?&.I6!3*98L4)T;:E3E';+(-4E&'!%O=2W;TDM!03\TTH\U`V](=#@>
MG12-4DO%T?Z\DESL.S'1"Y"3-3G(ZT=8.-%LE$)'Y%3"IV%(H-T`0#O3.+&_
M3FS6J;8DD!KN*QKJ"RZ\E<1^W_N^SH_!:)>)+:WTEETW.WW2QS*K)'!6#[H<
MM?4%7V^UM/H*-^FE]!/_`"<''/#89=`+!?['@<QC][3>"PZ+!4:E52LD4JEU
MBEF;-&8(H4DD$J@3[8;&)*$>@@^AO#7H6@:V/0M[WXC^GZ::P?6RXI/:I]U6
MV\L$BCB=A1T<['5R*G8DL(!'@"E,8);ZY;[++D:GZ$;LSWTF7H?%S5["F#XI
M_;C>,QAH70K1$2+61N-B718;?;RUS4/;?8UGR&0I8PC=]/(%K+7&TYC8HK]F
MVG>QE%%-AA`B`$$>F,(B0"T-0;9!O`?(%"BJB\I!2\$HP'K/GV+?<P3SDF3'
MER+[L+4%L]K.\LE4_<T\F0A5HR@A<%)2I,7[<.A$EZ`.;>.W65(?GDK2:K_V
MC^-?E>YNP),QIT[*VKHQ`I)!ZCC;:ETF0-9H$K?&GF;(V1`C!O80+61@;P$E
M`!I85YOX)OAKU_\`JXUT[CWY?>^-@4]@=`,')E.N@/%7255;TH=52(X8U1B%
M[B4&E"IL<0'`TG)].3V!,FS>RC1',>O/LK')OYG4UV3<J?%AQQR1MA>(7789
MQ84=*.TT69:8D$KD;"H5A3Z<%,%9"6YK@%6"<1I];.#%F9FT=K>PF>?67&;^
MK78OA#`8%$[1[[K".S1VIFB8S+^N.AFH>DKI4E"%-KTC@RTT0R2!W3:[HM;Z
MJI9O`I#H)P7QU*<_(+Q(0J1>`-ESY^&AD\Q]-].>JO[9MXF#5HY$CT#D;E.3
M2V(Q@Y&H\!!07)T:G'%[:M$[:4T:=8WL1418#MZWHPE<7O0MC9.EYJNJ6L*1
MA;37-/U_$*R@C&#86N*0A@;8XR)AC"`)ZK:%K3IBCW!9LO0E"DS0U"@SQ&:,
M8][%LF[VD+`A:X^C^?\`GEJ^M7K=57U&WC3[5)S+!F\=BQZ\K0QE:^E(7=P3
M+W<T9I8@`+2E&F#'K80AWO7AA9+>E5A?(8V3WQ3<M<Q]2=/G*!C(;Y6RUF92
M=.F'E>41QI]M='+JH9'!L+*\V]*&1.]^J+RZ+`/0PBP9YK]EHODYMK01+WGE
MOCB.+![-TD8$$PZPM]&CT#>@)CW=[#2M3L;L8/>]CV!NDB8O6@^41G\6L<G^
M9]OF'XX(!.1!5]1WETQUNK,WI0L8K2MEQA52FK][_C/+HRATM352J2:*V(L"
M9R;'(L)8Q:%YM[\VAOB+@U91],4:R!C=+U-6]3L.@`+$T5S"8Y#$)V@;V+0U
M*>/-S>!6<(>]B$8;YS!CWL0M[%O>]DW>V;FE9UO9`64%B5]")Z"-.A;Y'0S2
M*,,I"P/9.M:)>&4+X@7::G0K6M:"H(],X/A^`L#=\!@,!@,!@?_0]_&`P&!Q
MEJ)&Y(U;<XI$R]O7ICT2]`M(*5(UJ-44,A4D5I3P&$*4RD@P0#"QA$`8!;UO
M6];P/H002F))3)B2DZ=.4600006`HD@DH&BRB22B]!`646`.@A"'6M:UKPU@
M?7`8&F0/_)%W^L[&_P!PI1A:W/"&`P&!$KC?%-M-M--#N%DQ$BY'N,.<U0UO
MIW3G2P,1:`^9;)7%J3[-.9F7^$>B5"ST"E(BC-$[,V69H(R]_#K+=?D!EUR`
MZ$HJLJLE%LV2<_3&N*_.XGM!NE.Z]CP4BQB1V'</3TTA\>Y]I*:+U@=N3>T(
ME<J?&HH18%#<:I)-+W&LS*VJN.'^C[#A$4AG4O1<LAM2QI$0C0<Y<]638;BZ
M/J3>E)BO]\^QY^?_`'%6L[.WU)04O+8S(8VC+%LG19R?RA"-GQ%BE5B\#?'C
M#6ZN1RN@^:&'S!6-=>-JU@8Y5)5RP.]"<D<+:MJ)U/)"ZB*WLU4%*O7K#->(
MQF#WXY>DY_214G0;A9-$.EQ\X5=,;5=3%9:*$P2Q&J5\TK9CO3\W-2IY]W<L
M-9G=FBA#4K-<RG#;4HTM2)Q!2EGG"`7L9SRK6.[NC:NEL<L#M7H'@OE*GD2=
MR='6J$4@D$GF,H(5-;BA0(#[OM"3U`S(=LSLH3J-_2X8J$J4)1)PF"`=H08N
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MN>+S;$H?[)?PNL]D"H6QBWLU<XJ#-[$+?CX[WXBVWNK+X0P&`P&`P&`P&`P&
M`P*L7SQ=SGT8XH938,!`W6>Q@UJ*7?73N\5A>D.-*(,(3&1NW((M8IND3)@F
M>/L359S:?X:">F-!X@V66Q7W<>^0KF#0QQ"2,/R"5&B$/942LE7&J7ZU86P`
M@!*3L]F-#:@I*YE:5-H>]%O+5#EB@>@Z,<3![$/8XOTFBD>YJ`NZ5#K$IWD-
M2WJF*.-<N>+XCJJJ;K2%)P^H<K;HB_F>WFK.%/L)NG..*WEK$6+0M*=_\!99
M_#D]6\N[OUMB,S@$Q45!TG33BLDU#W6UHPK5,9>%:<)#Q#YBUZ&3J95%/TI0
M$<C83AZ)6)]`-+V6J3IS0"7/X?'D[JD/0"&80:P(:KIWIFEU;8PWY1[NJTL4
MQ5U<R5!C)+X<\Z`6GFM2S].B.5QY\3>)2M.$91FBU))Q819G\+?80P/P$PL8
MC`@,`,1(]%G!"((A%&;++.T69K6][`/91H1>&_#?E%K?^&]8']"((PA&`01@
M&'0@B#O0@B"+7B$01:\=""+6_'6]?XX'ZP(XL*XJCJ1"-SM:TZXK)M+3^[&X
M6%.(S"T($NS!$Z4C5R-T;2`I]F@V'S[%Y?-K>O'QU@Q3%Z^5+C31ZELJV:S7
MIR1)QC*!'N4*CLWHDU4:7Y0B`3(ZSB[Y!2/YHP@T)0[$@V(7^/AH6PS6O6HM
M>.QOD/M'P(YE^-&31!I6>4*6Q>T+?@50)V_8_#19RVGX,YSZQ%9.];V,8=J$
M9I8=:#L.QBV$+^C)\_I&+MQA\L71NC`=*_)!%N>HNL]0+C6?!M8N,>V(L\&R
MC0-5W6"O0V@U^D5O>@>8M1K>Q>;>M"#K>.?)OYG7Y;/4GP1?'=73Z.:3RO)C
MT_8RA0!6X3_I^?/=H.KLIUZ8C#'B.@VQ0!YV<,H.]B6,Z@S0=;!H7E$+0F'M
M7;1$(7#J^8$,4@43C,(B[8#TVV-Q!A:XTP-Y?AK7IH6=F2HFY(#P#K\"RPZ_
M#*RV;`8%9NOKTD?.-#/]IP^(LDZEA,TIFOXS&)+)%T1CJU_NBZJ]IAH5/LC:
MX[+')L9V9?/RURD2=N5G#)3"``'F%K>BR;<=<T^^3+HBB^B*LYRM"BN=[?M"
MTUD@:$%-\<=%S&U+S85Z."2F81YUE46M"CJ8AL4B#FJC?I+%[H_(A(&X9[EZ
M1R9&?D7)9NK`[YRZLZMT8O[#M,ZCJE<O'8.1N6Y@ZMZES:3@:T)IO/IU,CC\
M]F0UB<XPE<U1`B+M&P_RQ*5X/$8ALG2YT6B="\L5BDCT49JOH*HHJ5_)1(2H
MW7D*:=C`'1RQ6<+;6V:7+-$^=0J/'M0I'K8S1C'O8LJ<W^5773Y-.7ER]4Q4
MBJLSK:3I3C4XV;DVK9==;0$T@P1)VE=HLB%+2;.`HT/EV-?)D@/'>OQ_'6-,
MORXO[I_(W:VA`KGF&FN9&0T9FR)5U+;(K,F^D9H!>U4!I7GCWT<TJ#XA&82I
ML1,(&_$&PZ%KQV./+\`XINFQ_`WIKN[H2>)AC`(^!\^@9>1*U,(%YO=MYI]8
MB<KR7(E(-^005$[-\0;%KP_BUY1L^(FJG.'^1Z!<_N&J.?JUC<Q&;HY18:QA
M+E=HKC@[!L)SG:4Q,D%ANIH=@UO0E+F;O6]>/^.#;Y6HPA@,!@,!@,!@,!@,
M#__1]_&`P&`P&`P&!ID#_P`D7?ZSL;_<*486MSPA@0E:=_UQ5<`N"=+7]AD)
ME(QM7()O%&>9P)MD+<<!H/>6AA<3I?*HS'8R\25,1X(-/*]N(/V+6_4T'^+"
MXZJGWKSH+NVO:E(XVJV]8H_:D;?+;(F[;-X?7'-A"1N`>>@A#KT=(*[E$HMA
MC"ZG-RES!5;*M+<DQ:E"%X`G'M0*+DG;'7C`*X:IJB2_(Y>5I]26M8#"F=6#
MB[E*GK/::I>8NWO"WZ2W/%:T^EDEC6S%V9Z"L"4KLN4J(\,W:C?LT_G$7H3Z
MG"V"'JJO*CYWE!S[%:E^-D+0W.S=0<*ZD?:;B3(>G^EA4,$C<ZBJ*TB%#2PF
MOQYA1C`E<TCR:$D7ET2,P/A4SGRI=![BGL^E\7G3?;_R,=Y/\:?&]Z8(YS-0
M3;Q7Q\N=D*\*],V/$QM0VM$EAQ80@E@6$KY_)D!R06]&D&A'Y,B_\1;--#^Z
M[%G+E9T:Y_X=X^ELC1I6=VM2<@>>H.AU+4C2A0IM.J6O6FCXL'Z>W^4E*F,F
MKTF+T7Y=Z]/RZV./-;B5PQ8L[%M1TCW/U7:X3P^BMA]7R1DY/K4Y&+>MG-X6
MV@&R,V<>D4^(@&:6R]<,PD7IB%O7CXU-\1+M4\(<<TF[BDM<<XU4T3$PXM2?
M/W6,I9A9*I06```GK+)FFY#.UAW@6'>Q&N`Q"%KS;WL7XX-M^6B=/_&?Q%V3
M8$.M'HNB62P)W"$Z1O;)!]=EL:4N;(@4JEZ*.RHJ*/[(FEK"D<%8SBDSB!0$
MO8AEAWHDX\HUA/U9U5X6YN;V=O0-#0@1-34U(DK<V-C<E(0M[<WH2`)D2!`B
M3`*3(T2-,4$LHHL(0%@#H(=:UK6L(YN`P&`P&`P&`P&`P&`P&`P&`P(:NWGF
MC^D(J&%WK5L-M"/)SAK&Q-*F=.M71]R&`)>GJ*/@-$OL1?R@AUZ;@UJ4BTKP
MUL!H=ZPLMG2G1G/'7G,Y0W#EGHI/<-9MFSEI_//:[V^R7;:TE^D<I;JZZK:D
MKI:L2*2(TPBTA<M0S=&3H7E\Q!>O,"+LO:C]V=L<WV)8$//L.<-_QQ?(95*)
MU*JJ<V\_122TC-&?W"17)ZHF5TU\]N=8V/0LM/-3>_;W=<Q2!F5G%.2)(D7$
M_P`PN7^8FRFOG2X<G%??5K)G2B`6BQ*'IJFE:PV+6#>Q`5\<6";UTC@4LIZ%
MRUHG%:O2@L1K6]E^@6:3H>E`$YQ"@LMJ>M1O+/\`_0KQXG=3HO5-8='WA,_2
M&8DC4.A<09G,>BCR2S/?QR73UDL1!OTSPC"5I@.4B\X->E^.]A:OI?EY*OD*
M^1SJV2=R7A9D)67QR05*I%2LV24W(%S]%Y1%'F#4G'XK#)<Y-+JQ1E>A>7N/
MNZEU2'[1EB$B=B?(:H)+3';C<DR.^+XJZY^8OH/A*@%]5=K49SCSJ-KG4>@S
MRGIY';E\*&N/6G.H\\&RE'-(^1%2U"9[;%29O-2.A9XFXLDPW85/G,%9K/Z]
M9;LY=H+1\1TLF._<]2?)'WO?IAH=>^B\;MDRAJL<3#`Z"J&I@5?@4*`Z%K6P
ME!+=`!)+&,/\6Q>;3/MGV\?F+)U1\5/QXTTN"\Q'D^JG:1Z&6?\`=EG-BVYY
M=I85L.PN!,FMY?-WI&X>(?#UB#BAA!_`'P!_#ER)?U;\K\-S<WM"%*V-*!$U
MMJ$D"9$W-R4A$A1IR]>!9"5(F`4G3DEZ_`(0!T'6O\-81S<!@,!@,"L'1/8E
M!<OD-J6S9>:HG$D*/%"*?@S2X3VYK`-(*/.&7#:SC!*^3N:0K28?KN`R26I"
M'6QJU1!>MCT62WIYO/E$[?L[I;E&[&EEO.F>?Q1=)"K%BG+]6/YG174LE-KN
MQHC829_O>QJ2.DT2Y;W$4L7T^)D"`T]0E<$17OWU.F":7N5O\S+.'4+\)ET]
MHS_K6H:IIEKKBS$M722UND36*S5:6OFPJ1R&HI_1[_/)Q:T1@$NL5_#_`/O.
M2:<2K3NIZQ02022-+ZIAV2-?K,Y>TH7/?=EK@!N[>VFRH615YM.4"XOIYAAZ
MWVX=^8I(*Z;V4W++S1B$`.S534T1X\6O,$'IA%^&G+9\1L<6^-;CUF>T<PFU
M9K>@[`2#+4:L+J6:3+I.4Z7DZUHIQ;OWB?):PQA25H`=%A9D+:23Y`^F6#>L
M&U>)N;F]H0I6QI0(FMM0D@3(FYN2D(D*-.7KP+(2I$P"DZ<DO7X!"`.@ZU_A
MK".;@,!@,!@,!@,!@,!@,!@,#__2]_&`P&`P&`P&!ID#_P`D7?ZSL;_<*486
MJX]E=V<W\&P%FL/HJ7KF%NDLA2Q:+LD>8G&4RJ1O*DA2L&4VLC66,P"1$@1'
M''JE`R$P-%Z+T9L\PDHP26].EOM;Y;NDZXG-:V571;3SCR/-X:Z(X2^=&TDX
MK;3NJ4JP'#6SF%5Z">,"EDAL<97)H5Q[<W=JR3.RY0HT::O(+"0&:U/S+OE7
MGA<%-V%)++L]W^/KIGJ^:R*6K;!ADL<8K!W&!.5KS)YDKY)9XK@2UBIG@V`J
M!*71&<F<T,NG<@))`(L2[022R]EO\KF-O"?R'WTXHWR_95&"DI8DFT[?TG=$
MRMY@8U"<THXIP:.1.2D',/-)`D`"P@3IWV2S/6A`\3#C=>7RDV3IV)%<+SJ>
MAV;TSVUU+<8%`O(NAM;RALY/J\Y#O6O.W!9^>4,2LU4D4;$,)NG&8.(C"MA!
MO>O#>Q5G?$3;4/%/)5#N/UZJ.>:JBDL$>%2?/0Q-N>K)7*`^7R*'2RI$6[SU
MU.!L/B$2EQ-$$6][UOQ%O>QMORM!A#`8#`ZY[@^6KX[Z"LZ8TU<'2\<@]EP!
MP1M<MBSE$;+4J&E:X,S9($97OFN%+VE>`YI>$YGJ)5!Q81#V7L6C`&`"U?6^
M%T:AMNO+XK.&7#4TC*EU<6$R)Y%#Y*2WN[26\,ZH1@"5>FQ^;VIY0BV,H01%
M*4Q)P!!WH0-;PG7"1\!@,#`NTJC#"<6F?)&PLR@XKUR2'9X;VXXTGSB+]8LI
M8H)&,KS@V'S:UO7CK>O^&!$3MU5R^PEE'/G2%",I2@8BR#7:X*];BSC`A\PB
MRAK)$2$P80_CO6M[WK6%R^$4OOR/_'U&M*-/';_)I!Z11[54A3]!56Y.:=1Y
MM@$4<U-DI6.18BQ:\!^)7@#_`.;PP9?#4-_*;P`;H.VCI>'2W1INR4NX"SS6
MQ-.!@1"`9IJW!8O(=.X4XP#T:)-ZH2=ECT/8?(+P&7PTQ7\O/#6@J-,4PN::
MJ2!*=:2PKDOJ^0!4A0Z-$YFHW0BE@,2DIJ+3FB4B"KWZ/HF:%_$`0=35]:CQ
MT^:?D]O3E+$\-Z'5HU*G:9(K=JP;ZX3J=Z`>9L6C;@EU=!3#V%,/82%'HJC`
MZ\P"A!UL6FGK76W\D_S?PMVY/L^,T/$9I"[-7"AAC'*G7HKE2/RV(*`R^//#
M%+(W$*1ZQFMVN+HW*492OVFV$Q%HH&RGA.)O,5E8M6?GGZ=6/#OSJ];R3JV*
MNMO@8+/:S(Y;2%JAKU95H5W#4C_83\=.'!X%J.,5P.#DI;3D"1EC[9]OO"=I
M:"?:-J0E0>-3N:U?S,=]6_EHZ3DWJ;AE`5.4,\XI*A;V>-?)E=CH-7KT=C2I
M3H)\:\;B3NM5^?P`G^L(S4^C`[,\VPZ`9=9]9Y?H7?'R4OV__MKG<2#US0E%
MAWP#VV[[(-`'7G)+%:D\YD"N"=^`MGJ?I28C0Q!`-2(K^:Y3)Y?,-^?+_,1^
M#/6MJ-JE2H%H"1@X=YZKUE!I.3LP8$<GO;Y47)T2)_2#YA[7L6MG*-")(,\N
MRS1.5S\OZ%'\V4B&6/:^XXL`8E*HPO;E\<$&V$.S/(G1!`&$]3>W%H`_-[?U
M5/X!WO:_>]:+,<I_E\]<H_+K,`A$ZWM)(P0840F5E2CN]O5*@;%HTUS/;DE!
M_&93?_=W`!@"`:,=@*T0B]F)S]>/@)R;^7Z#\6_;TW#I/9W8[>4B4@`:K*/N
M+Y(;,VB7`)%HM2VH&;N/GN*><@G_`+CYOI16SB#CCQ!T</RZ8OM/#]D_`S"Y
M">69:'0HY.4(8!+`,_.U-/*DT.O:`'I&Y=*I.H7%N.TG*,`4<$P1Q`1A"`6B
MM&EGL/;Z3K%/@ZXJCZ0QM>%MURII5$F)7-E16&AI5B>$9P3@'H7-CY?B]#M!
MS>>6M5!$G"2`G859@?+X:*T6Q/:M(M3X`>!Y%J+R&DHBZ\^V3780*Z_?VQ<=
M;T')=D2E2Y->IO4UZ&V+#9FPA=E0CE:;1:)0KWO?BI"/01A8>U^42T7UGW]S
M%9A')]]<O\F.<P.5*2*L(J62F<O$]"Q]"('FD-)+I2QO=&S^7DZ4>=RC"MU@
MKV@V>$84`T^_7V+)>971]\SW;E=M/7B0L7QL5E%[641N(2>\G'KN(I)38TR=
MR&TF-1]B1&U-<;K#@05!"XXA)(<T3B8M7?AH'M`D;]Q*W^9QV]/?Q^=P_'*X
M\OT9&:;MCF6A2%,);7P[FXNY8,V/U82N:J`RN:Q/3`_/Z*1*?:3N5JR_<[3!
M"I/-\=!`(7IAK%EWEV=1V:PZ8$Z41*6QF4I]DA4Z/CK\UO9.TXQ;``_1K8J4
M@V2,>MZT+Q\N]Z\/'*RV;`_(A!`$0QB"```[$(0MZ"$(0Z\1"$+?AH(0ZUX[
MWO\`PP(DDO0-#0LK9\QNVHHF0$HL\1TELF&L1023C])2CMF.CTE!HHU4+181
M>/@(S?EU^/X87+X5N>_D[^/QE7#:B.M:9F#N6(`1,]62@NXGC0S#@)PEZ::H
M)F;B(W2@S0-AT5L01[\-ZUO&GK?#`_\`45B4B"`RGN6^Z;N3*`%#;W6-<M3B
ML(ZY:-,$3YT<EZ6'13&:20<#831Z/WH'AO\`Q\-X,\V*X=`_(WTS42=K0OG-
MU+4/)Y0KTFA$,O'H\=H7E.C1B4@3-]?<U<BUY=LLGCJJ&4$._:OA"-.9O03U
M!9>Q'ES5GYGEIE4P_P"9OJUZ*D]RWO$.%:*7`3&D0FKJ1AFNC)(V&%[]8A27
M8$PZ`9JI&K),",M<8ZJ7<HT&PG,Z/>]EA<E]9U-JP,(^&;@".2IVL.=U2^=&
M6=)#B5,ML7IRPIG=C],%*<9)A)\H:)6[G0=V&6-.7L/G:-!#HL`=:T$`=:8>
MU\NQ./U=6<3B*FOXK7<%C,"6(536KA,?B+`S1%4V+THD2YN4QMN;TS,>A6(A
MB)-)$3LLPK>P"UL._#*RA?G7BGE/DI5,%_.-&06I%\^4)SY:OC"!1I<[`2&'
MG(V_:UP5+E*%D1'*3!DMZ89*$D8]B`4'>_'"VV]U:+"&`P&`P&`P&`P&`P&`
MP&`P&`P/_]/W\8#`8'7I\JGW)_89?@HK+9_"'(EIC*M1(*YCTND[MID036.+
MY"R/S=7KDSS]-`)6QI5#3(E[,I+6-C(M4J]Z,((.+&J_GN*2T\OOR2UY\2]@
M!?;X@L4#T0_5G-:A<WR2RIHF,4;ZGZX.:;BF$ZF;"UW+(J]D@(I'CXFADH6X
ME&WK4XEB98KV@5$SPUQ_I5Z)R#ID;7(_NE\ZE#!C'[G+^_!0K<^AR5L:EJGL
MFTT=U)*S6!/`_P`4C&J**90/A<$&0W)H/IO/#Z9(PGC'A_?DDL[H>O?@CKR9
M+9]<,#M<4\@:`$J4R:<1*V5$#4V)+2X&&8/*M8W3@Q\=*Z(:#'+3F/2X]3YA
M*];/\^+T?G_V>:WX];@^4B_[U<J>Y8Z<M-19<SK6Q4@]SZY90>UMT;7IBC)<
M]L9LJ=71L9IH62I$8@<R2P.*)49M0E.(5!+/!&[DG,=O\+^".]B'ALEW1/,<
M\[`F``>D\&SCY$XY5D:6D%G[5A3^W9:*L2PC"5*E2>,002A/Z6QBWKSC,V,%
MQGV\7'<'5W+=Y4,-G7T3\2WQ[P5^:TR9*"62;K66V18!29`G2IFE(FL*2<DC
MFA!+:0G\F@#<5`/#0/)Y/)_$_I-E[_56O,E_RZNJ=.H;*(^/B*#T(X"I!*>E
MN@G]8/P$#T3BC8WS*F0IRMA\WX;,-$+QUXZ!X>&W*?Y\UQ/??,<L,_\`TO\`
M&='"BP?GOJ6:F*S!"_\`XY@(6\!(=?\`YG9FQ?\`R>7^*\I_G[<?:+YF5B[6
MM2;XQH\V!2"\PMP;JF9+CEVC@^76@_N)!$Z9().+?COQ-'H8=?AO0OX')_G[
M-P;Y@G==H;AT1P%$4):000ABG-5Y/XE"O1P=@$>GE'019A01$C%XC+4^&O('
M7I;V(0]3E?\`/BFJ/^5MV7;-<>^.:8BB+2!++)BG#[D_A4*@G"%LT\J3]&E'
MDB&49X;$!3L'\L.M%:WL0]N3?SX?L',WR7*5)Y[G\H<43%;*3EI4<4X+K!I3
M%#!L_:@]2*36O-UBDU1H9>M:`:2`O0-_PBV+QU4V>'*%R?WZKT$Q=\K5@(3P
MA]/TXMR%RBW-Q@-"$()IB>30R:.'N]^?RB$%6$K80A\"@BT(0W]FS_Y9(7%W
M3CHI;E4E^4?KA2-.G2IW$$6KKCR%D+-%;$-2-(E;N;U21$:>:8/R&'%JS0`\
MH1",T#63^UV?_+Q[_(W\0/R*V-W!T!*:SJ&\NBH6[3*.(&*ZYVXU0BD<]$76
MD15G.KD8QIJTCIB-O'H;?I8D9T2$)J7VPQ"5@,T*8Z3]3)R]*/QY_&[,8[QU
MSVCMSH3N^JIVGK1I32*GF'H)T@,6KMP"J6&_1V>+1IH2&,_D3#`(PD]2H&$8
MQ>??G\?"N=O-X6D%\7M9+1"*?^H_D3E+6<+8EC"_=Y]%FLR[>M^H3[E,@F3>
M=Y4JG0#B]`,!H)A8?\0ZV';#V^HP;M\/_)+^(@;[(^KWH:8)@4PG;LWIMQ$G
M";L.S0D"66:=LH)FP!\V@^'CX:\?\,8>U^FMK/@T^,MW1G)))1<VE6UOB-U5
M2+IOJE><]*1FZ/.6.I0;J)1*5*A3KU![T2$.S/QUK6\8>U8QJ^!'XE690-4D
MY$;#C#"1$""ZV_T"^I]`$,LS8@)'RV'%(6=H16O`P(-&:#O8="UH0M;9#V_7
MEL(?@X^*<`@BUQW"]["+0M:%,;6&'QUOQUY@#GP@##_\=;UO6_\`CC(>WZ\M
M_;?B%^-1G5@7M'']4M2XH(PE+6TA^0JRPF@V68$"E,^%'`"86+81:UO\=;\-
MY<3VOEL0?BK^-_00Z,XGYS5&:#K0U2^LX^XKE(]:_B/6N"],I7+U9POXC#CC
M##31[V(8A"WO>YD7V_7EN:3XYOCY0A3!3<+\>@$C"3I.>+FJFCE0!)]!T4:)
M8=##%1J@.P:WLT8Q&"%_%L6]_CE3;YJ1FOD;E%D4[6,O,7/30LV4(C:MKI:M
MV]3LD>PB&3L])&BC=E#$`.]A\?#>]:_^&#;Y0QU]\>M"=><Z2CFUU:4M2Q:4
MNT:>#W^IXQ#&&0H%$:D3=(R@(!*8^L;BP.*AN"4HV(@0AE"%K6];\-Z83]67
M5%.'?@0YRX1Z,B72==W'=DPE40:I8TH6&:&004?5$RZ-N496F*M,<1:7'U4R
M1R&85Y#PZ]0.O-K>O'6YBW];,QWKY63`8#`8#`8#`8$6W)2=3]!P)TK&Z(&P
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ML>RD+6UOJ-N0)]"%ORE$E%EA_P"`=8-OE_-?%=\=`]B&NXWHE[4#%K8ETFA:
M.5.>PZ"$`"OJDD$ZN/MRPA_@*]7TP>._*'7COQ8>U\L[(.=OC9YM:A3"547P
M]0;&`TT\4ID%8T+5C4`XDCR''">W)D8D832DQW@(7J^(0"\-_AO!MOS4=,GR
M`TF^M_VWQ32EM=5&%&"2(A4#6(871Z%;I,7I/]1OFS/VVI`E#L@L&AB:W5U5
M!*#KR)S-ZT'8R_-<D-;?('T*$([>MV%\8UXL-T8?6G,(@6;>*UL'_%MLD71M
MBQU%%(JKWL.@G?;,/$H!K>_0=-?@+0XG2PU"\@<]<VF.CK5U?IB)Q(P%_>5L
MR]T>;!N6=GA*(+-4S.V)NO?IW(/7&1HST#5WLRA[WZ))8?`.A;:LOA#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8'__4]_&`P&!^#"RSBS"3BP&E&@$6:48$(RS"
MQAV$99@!:V$8!AWO6];UO6];P/Z$(0!"``0@``.@A"'6@A"$.O`(0AUX:"$.
MM>&M:_PP/U@0GT#SE2G4]<JZDO\`@3=9%=KG1J>U49=%SRW)C'5D/$I:UNE;
M`Y-+D6:D.%O>M`/"$6M[T+6];WK!+G2J?)OQJ\/<S2\RX:,Y^CE?62B<++B2
M25-[_.'-81'CIB]-!K:6E?Y0[-N@#;6TDG8_1]7R@_[7CL6]EMM^78QA#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/+,X!XZN*>R6T+*
MH>)RJ?S$YJ4RB3JU<B2+WM0R1]HBC4>N"V/2)*:<BCC`B1@%Z>A>@F+UO>_#
M"[4H(>9.>452--##I:M7>F&-.M2ME92B(L\OAR<AR7K'5P"-EE25Y2*A+G%P
M/..$=HP1AAHMBWO>\&WO>5;0_&+R@P;V=4;=</.2KUO6+_MOZ,OBF&0K7G,.
M]N&"PZPD-<F(MJ!Z,V28SC*%Y-`V'9>Q@$P]K\N0'@UR)UZ2/N7OU(E"(7H)
M17C%'3:<L0MB"3]0?JN=GE6$OQ\-#4J3S=Z_Q'O!OU'XW\>,+=Q>%@=,]VV0
MD,WKWC6\=?VW!FEQ!K96M$+6ZE':JTPT_HDZ!L`0@"+QV9O6SM[,P;]1N5??
M'=P_63L3(XSS'5*Z6I]EB3SB=Q_5J6`0(G7@6(F?V>?,)F4(/CX^(5VO'>][
MW^.]XPV^5S`A"`(0`"$``!T$(0ZT$(0AUX!"$.O#00AUKPUK7^&$?K`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]7W\8#`8#`8#`8&F0/_`"1=_K.QO]PI
M1A:W/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_];W\8#`8#`XQRU&G4)$
MJA6F(5.`S2T"8X\HI0M,3D#4GEI"1C"8I&2F+$8/0-"V$`=BW^&M[P.3@,#3
M('_DB[_6=C?[A2C"UN>$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_7]_&`
MP&`P.ASY#ZLM)T^1+AZV*VI*:6ZY1Y7#6=.%X92EM/-"-KG4D>Y0\M=@,4NC
MTOH^RHK'W$QV7+52=6Q29N2($!A*\1!J`<;G5Y5S*Y=M1B>KB2H.:YG-JHD?
M0D8MOJMTF?-=4Q"[[<0.W;,ELRRZI;7*!NS\[=64TIKUX`]F(CG.0%&MJ(EL
M3[-,4#8THWKGEW3<+1"SZ[XYIJ)SMB<&R<LK`[A21*9NVR'6,Q5;,']PKV'O
MZ]"&3#0.$1KI8V-QI`?="3&)/0$+>P;%JLWM8ZN1*AQH\:XE.G6"EUA[4D)%
M)BQ,2=NP9/ZA9"LY(@-4%!%^&AB)*V+7X[#K_#!6]X0P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&!_]#W\8#`8#`8#`8&F0/_`"1=_K.QO]PI1A:W/"&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]'W\8#`8#`8#`8&F0/_`"1=_K.QO]PI
M1A:W/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]+W\8#`8#`8$5)+UI1>
MGLA6CMVM%".G7,3-;"TN<1K:*M'4"4I:-!.EFW+2:*J2TQVA""M$3L.]"#OP
M$`>@A)#<XM[PWH'=H7HG5J=425Q;'-N5$+F]Q;UQ`%*)>@6IAFIEB)8F-"84
M:6(0#`"T(.]ZWK>!K,#_`,D7?ZSL;_<*486MSPA@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,#_]/W\8#`8#`8'F$J'AGK6)2_HX:7F9O;:BCW5O-MS,]7R:44
MK,[-MU%5,W@<VD$*JZ[%+?6B2>5:G9]JG-D2S_;06B>TR9()04X?6UFHW;..
M?AW?<45%8-(\DU35TN(9HU.V%LD*Q6R%Z(D++"BY1-Y%+FR$%[9'%M;W$F#L
M;Z0SZ$A4@1>9'XIQ"(T#QK-NU.;'&K`941Z,,OARC1SQ(7?9@H`]E[")_?W-
M]&1Y=62/Q"F&Y;+T+Q_BT#S>&O'PT.&7]C87YHAGZ#>_ZC8.#V-A?FB&?H-[
M_J-@X/8V%^:(9^@WO^HV#@]C87YHAGZ#>_ZC8.#V-A?FB&?H-[_J-@X/8V%^
M:(9^@WO^HV#@]C87YHAGZ#>_ZC8.#V-A?FB&?H-[_J-@X/8V%^:(9^@WO^HV
M#@]C87YHAGZ#>_ZC8.&,7L-C+53*I!-(FE"TN9K@<05!'WR.)9C,[-6D:GPL
MH&O1`:YA4:\=#UZA`?P\?`6APR?L;"_-$,_0;W_4;!P>QL+\T0S]!O?]1L'!
M[&POS1#/T&]_U&P<'L;"_-$,_0;W_4;!P>QL+\T0S]!O?]1L'![&POS1#/T&
M]_U&P<'L;"_-$,_0;W_4;!P>QL+\T0S]!O?]1L'![&POS1#/T&]_U&P<'L;"
M_-$,_0;W_4;!P>QL+\T0S]!O?]1L'#&-+#8S8E-3&S2)KQ&.;TX://@C[YP%
MNSRO=248?-91F_1;BEH4Y?XZUZ90?#0=?PZ'#)^QL+\T0S]!O?\`4;!P>QL+
M\T0S]!O?]1L'![&POS1#/T&]_P!1L'![&POS1#/T&]_U&P<'L;"_-$,_0;W_
M`%&P<'L;"_-$,_0;W_4;!P>QL+\T0S]!O?\`4;!P>QL+\T0S]!O?]1L'![&P
MOS1#/T&]_P!1L'![&POS1#/T&]_U&P<,8O8;&6JF52":1-*%I<S7`X@J"/OD
M<2S&9V:M(U/A90->B`US"HUXZ'KU"`_AX^`M#AD_8V%^:(9^@WO^HV#@]C87
MYHAGZ#>_ZC8.#V-A?FB&?H-[_J-@X/8V%^:(9^@WO^HV#@]C87YHAGZ#>_ZC
M8.#V-A?FB&?H-[_J-@X/8V%^:(9^@WO^HV#@]C87YHAGZ#>_ZC8.#V-A?FB&
M?H-[_J-@X/8V%^:(9^@WO^HV#@]C87YHAGZ#>_ZC8.&,:6&QFQ*:F-FD37B,
M<WIPT>?!'WS@+=GE>ZDHP^:RC-^BW%+0IR_QUKTR@^&@Z_AT.&3]C87YHAGZ
M#>_ZC8.#V-A?FB&?H-[_`*C8.#V-A?FB&?H-[_J-@X/8V%^:(9^@WO\`J-@X
M/8V%^:(9^@WO^HV#@]C87YHAGZ#>_P"HV#@]C87YHAGZ#>_ZC8.#V-A?FB&?
MH-[_`*C8.#V-A?FB&?H-[_J-@X/8V%^:(9^@WO\`J-@X<=0R3A?M(2NE<>`C
M)=69P4A:8B[MRY02TNR)T,0EK3IVX%$%.`4?H&[$0;K9)@M>7?C@X;WA#`8#
M`8#`_]3W\8#`8#`8&,>GIFC;0Z2&1.S8PL#&WJW9Z?'I>E:VAH:V\@:I>Y.C
MDN-(1-[>B3%",..-&`LLL.Q"WK6M[P*RG]Q<HID50.2BZ8R2W7PP,,LJ]>-(
M_A1O<5E#TSQJ-2=U5;9_1AD<?Y-($+8C7/@FU*I<E924L8E`]%X7+SPRS]V-
MS+&)5'84_P!P1EKDTJF3[`&9M4EN^M&2J-S-LK=V1."X#:-N9$15CO*2.DKE
MQR=`J?U!;<0>8M%HC8RL]4?3U"7P^RV-5'9C#-WJ$[T)^1MA;F1K:';P\1[3
MXQ*G)`A1RV,;D$?7(-.K28M;?>I#2/7]4`@:&6)YPA@,!@,!@,!@1?([KJ>(
M6'%JFDT^C;+9$TC<JF4;AZU>`MX7Q*$DD'RF3&DZT(#:PLX%`=&*U0B"!#T(
M(!"$`>@C[17"NUN6;#C2B7Q&Y8RY1U))HQ$U+@H3OC/LETFJ`3O$%0T;XTMJ
M_P"V9.Q%F.*!Z]+Z,J;"35A:H24HTT!<K5=_(9QG]BD60&]XV;$E#\MC@%2=
MHEJAV`O;8BCL)>K4Q8B/&2M''DE>.*:1#=C40&H,>4DN?N/8G%J!#+X7%1+4
M;DC2.+<K3+V]>F(6H%Z(\I4C6HU10#TJM(J(&80I3*2#`C+,`(0!@%K>M[UO
M".3@,!@,!@,!@<)Q<6]G;U[N[KT34U-2)4XN;FXJB$+>W-Z$@:E:O7K5(RDR
M-$C3%",--,$$!8`[$+>M:WO`JRM[JY);X_54K5WC$P1N[&]0]5J^`)?%#:^Q
MU*_-<642Q:K3M)I47AI<D?$2';R[;0M?NUA!6E'G-+T(N5(3WTK1,<6M3:^V
M9'&IP?KA2T`P(5ABLI6_W"K"A$&"L2?:3U7ES3:<2_<F)M&I4F]&:/-+V2;H
M!,?N!=(4;9]BSRIH#9#!)K#K,Y<GF<90;6A5-IK0]'QE^TC5*DB=ND`(S)TP
MVMV&W'*P-+H'V:S9"GP*PN7M-V$,!@,!@,!@,"-9'<57Q*PX#4TCF["U65:*
M>3+(#"E"K8G^2((:T'/DH<DB$D!HR&ME;$XAG*C_`$D^A^4O0]FB"#8157_9
M_+]J-"U\KZX(]*&Q!)ZVB!IR!&_`.4.UPR`N,5:I:T2MH3KGF-SYX&,+6](R
MSV=60G4*`*MITR@THN7PYSGU_P`R,]96I<SC=4&3U92DID$(LV<_4AG,$;F$
M7*;C7R,!5D$&[?'Q&8[)R`IFX*LT]69I,4$:C0BM#*LCA#`8#`8#`8#`^1YY
M*8DY2I.*3ITY1AYYYY@"B2"2@;,-..-,V$!918`[$(0MZUK6O'>!4QY[QY"8
M8#$+2<KVAP:\GSI8S5$):C"\NK.]ZJ*1.44L]\3GM34M$5"X(]M)P'-_-"6Q
MI2?34#5Z3G$FC+E\)$D/3-"Q0X*:16A&6E0=<L+Y\0DJSE037BY;"30U9$H$
MP``E&*0NSDDG[488-#[A,C`>9M2:3[55Z`ROG#>G*&L&TY32D-LIC?;/AGW'
MI_BR8IT*.+'#71I8YH0UN:MO3LDB4PI[?D*-Z*;E*LQH5K"25@23#0!V,O:>
M,(8#`8#`8#`8$;RBX*QA<]K.KI1-6-GL2XW"1-M90Q0IV.03!3$8J]3:3&-C
M<0`X\#>R1F/JE"A6=HI*6(("=F>N<268$3PKM'EZQ44A<(5<,<D*2+O]=1IU
M-1)'T.QN-N3S585>I9RE#00=)&"?6#H;0U.S:%6UK5I)I9:@6R3?(7+X?F0]
MJ<M1B,368NERQ@V.U[;1M$2I>R$O4G&EN%-%VR:KZ\;$$::W9RDDD:HJ[%KE
MI+82L]D04IV?LO:-7HD9?"P\:DC!,HY'Y?$WEND46E;(U22-2!G5DKVA]8'Q
M`0Z,SRUKDXAD+6YS;E19Y!H!;`84,(@[WK>L(S>`P&`P/__5]_&`P&`P&!KD
MLA\3GC$KBTXC+!,(RO.;E*^/2AG;WYC6GL[FC>FHU8U.B=4A5#;G=N(5$[&6
M+TSR0##X"#K>@Z>FWB3KEAIG@+G0:+G::TSSQ7]6)>CV,VX;!KUYMBP*J=&!
MUA;4V/2?FJQ%#[3D/?F,+\-I4?054C=`)B%)J-&0>!=&MFVOU,/CCN]_)K\E
M%,JST;/('%8UU`Y+GR7`61Z4$]@$=G3V94P4GA9I,]4RF;OT@9RB'H48T22>
MC<=B$(DUM-&Q+7!'$-M\N6=;<QL650M\:93&$4/CA<=DLQE:AQ`EMRW;.W(D
M#%,(VQLW.\;]E9I+:77\--510I0@&XA%I0H$``MV1VF963`8#`8#`8#`I=:G
M,JQ_ZII/I>!QRKR':!0B]F"PU#T`]BE-A+9K#XE'ZS;'%]:(D^J'./,"AD5E
M*!+#!";DRK8DJ=0(PPO"[Q8I#`>`^FI^T2LGJ9QIIJFMAO\`:<ML6QZEL^:3
ML#ZZ27G:RN;JFBD1KR14'4#77M84E#+17'-34-T?%!KB2%<>J-6'&'!B[/A'
MKY\9?3\ABKK*E$BIIAO=].8H*)7"K5M".,48J=IY9CG-CPJ9IL;4+LXO#G/E
M4=+>WF/JHT26%($AN0OJ-:F`_;8>T_IW85+`$U4576=6HW)0\(ZUKZ&0!([J
MRM$*G5-#HXVQTAR4D!-/"2H7%-VC1@T,>@B%O7FW_CE9O*0<!@,!@,!@,#7I
M7$8K.X^Y1*;QIAF$5>2BB'B-2=I0/S`[$$J"592=S:'0A4WKTX%*<`_3-+&#
M8@:WO7X8'3NLXCZW:Z"X_P":VM!SK,:GJP`UG2S`NN"P*S=;9&QSO[S@M?L<
MI0<U6@KW4Z=T*)7OZ$:9J5OIB<I!ZR9'[@:J-;-M^4\/W#+T_0GG54L2U:LN
MNM.N4G1\XGS@4M5+2&"4]!R*^;1A4!E9D3'(]HU:UY3)$2,TIM1JBVM&$_9`
M$Y.BZF]^'SY:XPM*D^@W&>R^2P9QKB#,76T7J'[?<Y$NFTI:NO.L4/5$@7V<
MUN<:9V*-.U=*VA.Q(OIB]V+=RS#EIGL1""D#%MV.S7*R8#`8#`8#`8%-[;YE
M'+^HN;>CXBPUPE>*I,M0FQG=U(,:YM,V.25-*(3`XZ2^-T9=U+FSL,BDIQPB
M%J@LA"0J4')RS3C!EF%WC%3*!XWZ=46`3/\`JU!0RB1.MVM%H6&\U=:\XF;+
M+8/!ZINVO*8HV+UQ(.>*E;ZYK6F'*R$#L@*$[OJQT=`+EBM0$9WHF1;9\/W.
M_C8'(^0^X><6:,4,A6W7:%QV%S(C-9S$D%ITV;5#'ZNA2SVR.#'&0![CZ`AS
M2#&PH%GM&U:(M.8/1IA6F&\RNWC*R8#`8#`8#`8&&D<<C\PCS]$I8R-,FBTI
M9G2.26-OS>D=V*01][0GMCRR/34O*/0N;2ZMRHPA2G.`,HXDP0!AV'>]8'3E
M+N'.JV[EBO.6*[0\[NU?+[HZHDO0C&MM:=U$LF-%7%T'9EM1*C8)-6+G*V%<
M78)='ILB03;TFE(=[1`:VMZ@1*GWQ<:V;J:I7PH^3"KZC+=&NHAW?">VXMU`
MXS!5I<X$Q>$B[&B%_32OJ\EAD)3R`H155P5EC20K2%K2N9C"A"L$26#U@#?^
MFY5'1W2!':-I7[>3%2KA!`L,NK[G)1`[6F"EWJZM7]_C#^^)7"I7+G^,LBFQ
M+A?8TF=99(A3-<,G:!"W(DPDQ)J@ZILS'85A#`8#`8#`8#`I[=7,VK"Z9Y&Z
M(C;/7Z*045.INX6#)G1()'/9%7KMS]?U;12',;TA8'%4Y(6:?W']1]BL5I$2
M<@Y:H*V-0+1)Q9>+%1Z5Y`ZJ76N99G3*&A`/3S>D!GLI>:LMV=RI`&FJ58KE
M<:#H:OZ[?.<JN;H)&:OM28,;\<><\NZE^7[=5B@PDP21."+L^&UH.*[-J^M.
MK:WIF(<[!@]\=+*9XPU6?*+2IB.-]$.?-%.TNNB#1.:9C::04Y.D\IKI0K*.
M:6Q\0F,X]IM[*.6#-1#>EZ><ZWD-.<_TE4LLD#7*Y-6-40"`/LC8F%!%F-Y=
M(C%FMA5KF6-M:9&WL3.<:@W[5*246`@CRAT'7AX94O-J9L(8#`8'_];W\8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]?W\8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]#W\8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]'W\8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8'_]+W\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8'_]/W\8&,>7IFCC6M?)"[-C$RMI.U+B[O*]*UM:!.'80[/6N"
MTTA(E)T(6M;$8,(?'>OQP-&C]TTY+7=)'XK;-9R9^</<>P9(_.XL\NZWVJ4Y
M:J]HVMSJI6J?;(DQAQGD`+R%%B'OP"'>]#$F8'R//)3$G*5)Q2=.G*,////,
M`42024#9AIQQIFP@+*+`'8A"%O6M:UX[P/B6O0FG%)BEJ0U0>DTO)(+4DC..
M0[&`O2THH(]C,2;&8$/J:UL'B+6O'\=8'[]VETJTAVI3Z6B3B5A1^L7[H24!
M@21*=)_-ZVTX3AZ!L?AY="WK7CX[P/MH01;%H(@BV`7E'K6];V`6PA'H(M:_
M[(M@'K?AO_AO6_\`C@?PPPLDLPXXP!110!&&FF""`LLL`=B&88,6]!```=;W
MO>]ZUK6L#7$<UAKCLS3?+8RNV3Z'K:1OS4IV5[I40A2^IHE4/T_<K5)9)?CX
M><TP(->(A:UL-FP&`P&!Q5:U$@(.5+U:5$F3DFJ3U"M04F((3D^79QYQQPP%
MEDE:%KS"%O00^.O'>!RL!@,!@,!@,!@,!@,#@MSHV/"72YH<4+HBVH6I-+&Y
M6G7)=JFU:H;7%-I0F,-*]P@<4AJ<X'CYBCBA@%K0@[UH.=@<=4K2H2!*5JE.
MC3`$6$:A4<6G(`(XT!)01&FB`6$1IQ@0!UO?\0A:UK\=ZP/D-R;RQ+@F+T0!
M-A(%+D$:H@(F].868<6>NT(>MI"1E$C%H9GE#L(=[\?#6\#YJ'AH2(T[BJ=&
MY,WJQ)@I5RA<F)1J1+?+[,*=28:$@X2OS:]+01;]3QUY?'`XYTCCR9T*8U#\
MS$/1_D]!G.=$)3H=ZNMB*])O&>%69Z@0[V'P!OQUK\,#(;6H]+`-VU:;3@8F
M,6@0;/*TL&C*-+(-5@2^?UQ)BSS@`$9H/DT,>M;WX[U@?,#BWFKCVPM>B,<D
MI)2E2W`5$#7)TYV]Z)//2!'M042;O6]!$(.@BW_AO`_2E>A1&)"EBU(D-7J-
M)$)2E2208M5;`,W29(`T8!*5&RRQ"\@-"%Y0[WX>&L#EX#`8#`XQ*U&I$:%.
MK2GB(5#1'A)/*-$2L*+T<:D-T`8MEJBR1:$(O?@/0=^.]>&!R<!@,!@,!@,!
M@,#'NKLU,3:N>7QR;V9G;$QRUR=758F;FUO1IP;,/5KERLPE*D3$%ZV(9A@@
M@#K7CO>L#XL3^Q2AI1OT:>FF1,;B`9C>\L3BC=FE<66<8G,,1N*`Y0C5`+/)
M&`6P#%K0P[UO\=;U@9;`QSH\-#&FTM>G1N:$>S0D:5NBY,WIMG#T(0"='JS2
M2MFC"`6]!\?'>M;_`/A@8U1,(BD1(G)7*8XE;G+U?IR]0]MA*)?Z`O(?[)48
MJ"0J]$>_`?IB%Y=_AO`RJMT;&\I.>O<4*(A8H(2)#E:M.F*5*E7C[5,G,.,`
M`]0I\/Y8`[V(?_#6\#[*U:5`F/6KE*=$C2E#/4JU9Q:=,G)+UYC#CSSA`*)*
M`'7CL0MZUK6!^R#R5))*E,<4H3J"BSR#R#`&DGDF@T84<2:7L0#"C`"T((@[
MWK>M^.L#ZX&/"[-0U/L@.;>-9[HU%[0*Q,)3[U.D*7GI/0T9LWW1*$\!PR_#
MSA*&$>]:#O6\#ZI%Z%?M5I"M2+-H59J!;I(I)4;1KB`EC.1*M$C'[=62`T.Q
M%C\!AT+6]Z_'6!R\##N\A8&`)`WU\9V4"D1@4PG=S1-H5`BM!V:$@2P\G1HB
M]##L6@^/AXZ\?\<#G%+41YYJ4A6E.4D$IE)Z<I048>2G6^MI&>:2`>S"R5>T
MQGI"WK03/3%Y=[\N_`.5@,!@,!@<;2U&)3I$%6E$LV28ITDT>5M3M.2=I,:?
MHC0_5V24HWHL0O#RA'OR[WX_A@<G`Q_U9J]+U_J;?Z'U#Z3ZWO4WI?5?>?3O
MIGJ>IY/J'U#^1Z/CZGK?P>'F_#`__]3V`&41WR(PP1??\-*+$,0@%_V:0X?I
M@V+>P@\XK:UL?D#^'CO\=X79X5"[SYF[[E7(5[1\75B"\0.40**-J6)<=QM)
M))T26^-*@YE:#FVR7==[H116S/(6F.V8$O8-A\!;WJ++-G"CL*H"_99U3R,Y
M4VPRFF7>(6%:+R]W`[?$G$N<H[7S,OYQN..A5O[PW3$E/,4TD<7@EE(;%2A,
M46L<B581#-3@+&79E=SG[#=]_P#]@4-_]F4-_JWE9V>&,L.F^JT_.'6#!8]_
M-_1JR9<W6]%X+#8M03163R"6NT$D2)O`C4L<TE*A_4NYJ@"4I)LD&]FC#L(O
M'^'8XXX=0%?T)\C/.I\GAT#C<ZE":J>#(;#^>+;VEVHF*:O)[T!24NLBDE8W
M)N=T@+LHN`H)@W1LG2<]0J;T+.,M'L[6RA1JV5M:B+_(R9;//%Q',]W.,-CT
M$DD=NA[(BJUDZ)?^>5'8T27,$"CQP(ZH./GZ:&A3NZ[2M"Q2MXA;0H`,I&\J
MC1Z<G^>6%LUF^0"G:RMZ+<\1SLDJPM=._(C:C'($2/[DB;PL!;K?,^?FX#"H
M@CFNF#!8U=NY[@D4;>VZ,[6:<D2I(Z.QC<@1N3_/R[G>9(K;3S-^M9)=K_9C
MO&WF^YQ#JIKV>I42>OR*0#%X(J9E\;CREA2+7%$[NRYV)&I5GJ`F%^H1Y0A+
M\-5F_&.N23\6JV7GWM1EK*@`5W.)K\CU%NE?O%<U=&&29:HR/]*\=3!2_P`-
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M?)175)Q-RAIKXQA,/ZAE4AH>%RV&Z:GQB+$[4ZJ;=LH5NAIG838A`08IV1O0
MAQPN383KW`.=];H61T[%:;#VAOPNFA0"N:7EO-3+6:6+PXVB7V-_?RN'#DEK
M*UAZS9B)"_\`UG;O[X"Y-[$M!K9..%O_`(ZG3H1SH)Q#TBW3]-,VZR94WL#O
M8JM<-VE4(]DQ+FA_;&B1P"N["B[`%S7+D*=OE"56^`$A,.&M4)3DNPV)^LWA
M?+"&`P&`P&!@)8@?W6+25KB<@)B4I<F!Y01J5*64F2)XR_K&Y2G9I`?'E*MO
M3OQ+,XF%J1(C#R`*@E[*$8#0MBT%0HG2O;C5*8TZ2SN*)RV+-K^S+Y+%4W)D
M3C:B3,"-Q3*'F/D2%-9[@H83GEN+,3!6ED'C2B,T:$L>PZ#LO'A%7R7/W95<
M4U([5Y.L"1A>FEI8(NAJ"$\S++[EDADDJEJ9C/FQ:MA6.$J:&.'L;OMP6EHV
M1R&!.VC$`!AAH2\$S>5/?AX8['H-WN#D9*GZ?EU*EQ%NNJKKSOWE&[>>$S)8
MSZYF1NVJ]5(;C1`V^.KV[B;I<F"D<3P*E"]X'Y"?)L.I&OUSRO\`I**[S*5)
MC5??4/5I2U!)BE('CB'IA*4X#`B.3A4!M@P2<1Q>MAT/01;!X^/AOP\,K.SP
M_OR;U,^7KQ%<U1QV/2&5.$[5U4RG,<4(/42!2R[N>NU4E4-H$Q1QQ9K9'$RM
M4(W0!>B62(S>O`.\$XL=/Q]'_(,I0]?\T2RN7NQI;=TQY(Y?*OUZ722)5];W
M,E8QJTG^P+0G5AM,/L,</=[%J%(EALC-*;W<Q+*Y$;LH@[Q"7J-;.*Q<GYHZ
M!7T10U(733MBI9'QW*>A:9@LKBU(MG<M$R6K)9'X&\U"W/M9V%&Z\ET_:?V_
M4%1!MG;.6R.<><HVX%KMH"W47F&S;=?684%,9A`NBX]:/"<T5='6QQ%R'".;
MU<9K203EGI._HC3$K8_^1='/1KL&M!5+8ZYG6JW!;)MJM`0?S%2XT&Q'#>N>
M$SR:L^XA=UD?(`54BA[B=5W'`N7]M(I/-TMN2CE%(D75A;L@BE`H:B#'I!&)
M%<T_.LY$\ZE"95](C:<D"$PG6C1C9F-7@->S*O[)Y,A9_%UNQOI^+]?.TSOO
MN)KJ<3M'93'978=F-T\42>Y8X4]2F70Z[8/)FTE$0I.5H68E04%W"T@:"C-#
MSSQBV'6-1-KIT==<HNKC2:=F1VQ*/IB(<RD15C0.22"RJ*RJP%MA0T<Z/=D"
MSG1^=G][8Y!N9AVWEGI$I8`+QJFM.DPDZ[?5]<.YR.HWU,V;OH#<1;KNWMC&
ME:8BX\L%<A@YO4JVIX*EZIF',7&^?WY"`O\`%P&^F.8?3$GU'Q!-$.,5[IZ/
M_)"Q[I:12>Q^KGU4D8?B@D\VC$Q9(PK9U\FNZ;N\7[VCTD(+KY"Y_1ZGKUK2
MFJ4?N"QQXY2)P4#&K%I1IRM]>>$?<ZVQ\AUET&OFE92?IB:B?J#TY3J43Z+U
M[I0GGQ?4L-:1CY14.\<3,\KD)'*P)JH*"H^H(1/A#&!7OWXE!(!<;?=3O\E1
M-4L#A4SGUDH8&V[+P,KEN>81'D%USJIP0^M#:<26E)F:*2F2UQ)"K$%*R&$R
M2P=V9%C,)*9,-I#22M*')_EF5U9]>G]$QZU$,#M=@?66^>Z%L&;DC<G)@0))
M-.>J.#22RSE4::4C4\P)\G3&\-BF1GZ"C-"083M27H901$V+O?&FX=5.,%L(
MWII3:IXPN<%^UP7+'DS-,$\A%!FT5JDMZP#-%5;K$/O/Q$D\S20A3K-K"VQ2
MK:O9#+0_6?#LNRLF`P&`P&!H%HL,_D\%?&.KK!159.EWTSZ'/'"&(["1L7MG
MAO6.?K1!P=V)&[_4V=.H1A\ZHKVXE&C]>81>@"#`36)6\\M5=I85<+9"76//
M\?7V(ZJZR;)678S`@3:+D$?1-RJ1-A<(.D*G^8!:08L&BU_"$LS7XX%'/D8J
M*Q)X]<T3L^!.?2'-%36\1*>A.26"+,SZ^62U'0N=L,5GI3>\O2%'9*.J9R^M
M#T9#3TYQ;GM#I0#U#DY90HU/GRPOQ[4]-XK<?5]PQNJWOEOE>X9)#U51<P2F
M&,<*D`9:PQ%C:I[>!D(C[\Y-E3I)X[)C4X6;T$J]STF"O7)TQGI:.%ZD^78)
M"(K:[*JLHV;VRW3E+(Y.[N=:I$E<-T2%6<85F+!-$77J$C^Z"GBAH+.)")P/
M"B,4^CO>R@>??A677MV;SC?MHTMRO6#_`"J+7I/&SL.!R::6`]\]-KQ7C9$$
MT9M4L#]-Z32S#;2Y1:/?5$213HUW3EGFC+&(PL0M!R-2S:Z_:SYX<:X=N>2.
ME^0998+%`KT^0(ZZX/".:3K2HHF2V0BJW=>2VB:QCT1>&]JI&=,R`"QJ":F&
MH0NPW,A8<)66H,$6WO*Y;#S)9T'@=?%7?S"XVA`=\VVM!:*@LTH(SKUFYG?Y
M#U9;4^:(;+Z,8K+AC_IXF',,KAL62O")]0%,ID3&F6N1)0O(>-[R_*XU\4]9
M]G_&QS'#+/JB;Q2R8J+GQ_G<%J"-,E]AJ9\AC*+P->JAMM^M'?1$%ASN6F)7
M,"MT=WA1_`N*4G+$01"?"<;5,DD,^02+4`C8JDB]P4=^V?-/=4_KV.4C77[>
MQVSKH9^A:L>.?%#Y2,H,M056J[.87Z2.I<`2+R"RB0J"B"TZ$0T(7*_YWE+7
M0)_R(1"MKFK>N7#K.:/3-TO;372EL-*6.GOZF$I^7ZGF%>#E21BK0M=,X@_W
MY)I*WMRLM6PL#:I1;3N:DU&E(1B<D]>T>IZ#["G4KF,G9X3.83:,_N+K&71Z
M?.D=7Q9!&IA9WQ&4'5T*G2L\:5(2P-FKU;%;86;Y2@$N2`XC6M#*$'0V<>$W
MQJ-DUK3-MO/*OQ^WSSY9+)SG2E?R25PY"R5+,Y?)T<]3-<FC3/$M,MC(;7DE
M81I6XO:Z;(F9\='A`<:@9W(Q:<2:4+W-JH_[P?(FG&WUB[2GKW5WMW/'64GI
MV,1*!QS;A+K$8>H@,/*TAO%OE+&Y;2UN?!'9O3NR]6<21MN\X')6)5KP.''T
M[.^X><;.Z%OCBE.T1:G75NC$9Z5_<%^NB@5_2-)QIQD40K5*UDND%'8-6:VX
M/2Y"J+9U*IT!Y!$C\Q!W\0-$ES51&WDCI#EB=2H%$R^^7DJH*R^)>KXN\L[`
MR;C%Z,$<Z7N*,]!-\E9SXX^'J8]6E,6`M4[;&QP2DQ]N7$'&B-$E2'$EV7O[
M:XDDGR925?T.B1I^KX*U2UWYYW#]/S(TR"35\]@[MBD<N34)E15<QZ(.#61S
M8]'+S0MS.*.?12Q"+&O,2+E6W)_GA+;[67<I]SO3$UW-U\V5H9T_8E5)EZ(Z
M.*DN^>8MP!&IW$;`2O3E7Z]20ZS7J9DVSG/A9H2Q+U"E&C`F-/-V)R;^?#18
M=8/R>N]O\HN"J+WVU+#:GI!'=R.:QY`*EY#(YAQB_OLU?'9K8($P(ZW4QWJ=
M0A;79(H7.;\G7ICC=;;F42=*:Y/\\N.=(^__`-A(F)F'W<K?13>I==.KIU%(
M"S3IJ>5E+V:LLE#S2F@D`>YDOK]%?I$:3N9Z1J=&H*`TH+&H&V;=E"<<;\)'
M.F7R&M[["X9,&>^W-_G#U\7#BYS"&09O1PQ@8$UBM;5VZ9(54><)!'H(X.#.
M<,;VVDJU7I)S!GI=[1$C/+)Q_P!JZTW6W;M5TK&&JOHIT"VS:*<I2N+2Y[D<
M2;U]BL\E4=JUTMM1MK!_E[$:0]RPR@=R-UB28)JM$YN02E!`3Q[+%A=E2AT9
M-^[457U)_;HS]Z*5[5JX90SR:QXS"%4MD!49N"*@AL6LRO(57NG\_3E68'%0
MRFRM<S*5+2680M;'9]4)=DB9SN)C_96V_P"W7[=_;F7_`%W_`*U/[U?2/H:W
MW_[2?]4S]T_W&]MZ7J?:'[<?\[]]X>A]-_G^;R?CA-G_`(?_U??Q@,!@,!@,
M!@,!@,!@,##H8\P-CH]OC:QL[>]24U`=(WA"V(DCI(#FI$!M:S7MP()+5NIK
M:W%!3IQ'C,V20'0`>`=:U@9C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&
M'8(\P11G0QZ+L;/&V!L*$2VL;`V(F=G;R1FF'C*0MK<2G1)"A'&B'L)8`ZV(
M6]_X[W@9C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&'W'F`3^7*Q,;.*4%,Y
ML>*DFVQ%M_+8%"TER/8RWC9/U$#.<XIBSQIM&:)$<6$>P^8.MZ#,8#`8#`8#
M`8#`8#`__];W\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'
M_]?WDF6%`23#"3IQ$"C2AC+-*,DK*68686+81EF`$MT(`P"UO6];UK>MZP9?
M#1+*O6'0"OIG-V@Q/93E$HV[R%'`(-(X@HF<O-:49JWZ!%DKS(&AM6/SB$G9
M:4@Q25ZQVP@#OS"#K9<JB_.OS`\G=4VLEJ>F-SI^<=.KV&1R-T9FN-1B"1-G
MK2)S9/-)NM?7Q"I9$C_+Y7J'(&S1)KV9(6UP]5&4B2#5[FK?S8['_P!QJ]_/
MD,_5#)_X[*F7PU^<7)`X/6]DV>:[IY.Q57!938,F0PY>S/3V-DB3"Y2%>0@2
MB=$B,3BK1M1H$P5"A.28=X:$8`/B+1,5IIWY$^:[Q:(?)H4]/@(?+>:)3U.=
M,'E`UHV&(0.!RQ)"9['IEM,]KG-KGD*D9QY#BC)3*4A6T*CRJA^4O1A;+$>L
M?RG<]27FBNNF6:+6KMKM"Y3>?XY5S\CK2#6>BMH`9,M(B<K.L"SXK54..7L$
M7-<TRASE*9*>D5)`@,VJ5%)Q35];N-D=?D&;4ZR&,L;Y0Z[G$NE=12Z[7.",
MD0IZ.S:#PB$3K]O'TV11ZS+O@*I]<3I`(L;:5&/N$#V@/)6-PU28\DTRIGVR
M;S\C_-#1)^-XR4Z2I[#W"PM<IJ60,K"0?'X['9*GBY4*=[1.5NB%SAJ>=2F9
MMD>:@:2JSCGY5[8P!6BSC"QEY^G.EW>U=0^6S5M4UA=;M658V=':<M#H=G8X
M'NFJ_L&1J8LA"TO>W6QFJTG)L87"9($[N[-$7<F=J.,'I2J+T2;L`S[;E>/6
M*:FK.B5/LE%W7>4\EM86%<06NIE%'MJ=BK^LI!!(O*'A[<[LNNG&\1Q;S8[6
M60E0F+E1P31CT7H)8MZ&<;K&U_W;SM/80JLX^7(Z_K5)35$W@;-K-D$$B+>5
M$NA]2T,`0N+*?,5,PC[X>JB!J;07-M1(G14H*)9U+F8!4%,,KEG=W<H$V#&J
M\W=,%,/EM$R/I%EF)4F8!UPHJ.+.RAH=I-N<?5-,OMRA-CBHV((Q$E)6E88<
M85Z6M#&7PVIS[%Y/9(;"K$>ND:19H)8[LYL,%ESM9D1;8_*7EB5FH)`V-#HM
M=2$JE;'5Y`R'(&A:$WGAV6H](?X8,OAJ44[LYBDLXMNM5]GQB#3VFI;8L7E$
M1GDFB3%(EZ*K(JS3.939@929$O<UD(;8Z[B4^[/*3'^BA6&B("2G&9@RML0=
MC\G.L)E%D-G2%)N,"A3PU1Z62Y%9435,3`_OP"!L+&Y.!+H,E.\/WN0!0IM[
M]988+R$A&/6PZ&7PPBKM7G1#*5S,NL2.(X>AH>-]%BNE1)H>"E%-=2R=.5>,
M)J*>:D@B%3FX2)M\I(0D>V/"H)"4>8<9Z.AE924=H<CPF%0RQY;TM1\>@-BI
M'U=`Y@ZV7$DD>F"2,><,D.CKH8Z:2.H6%0#VZS1(A;3JQ!3F:">()>QE\-Z9
M;_I.2.3,SL%HPIX=I%.916C&UMSZB5.#I/X2P*Y7+HBC1E&"4'/D<C"$UQ6$
M:#YB$(/7%X%[T+8R^$OX0P&`P/P886268<<8`HHH`C#33!!`666`.Q#,,&+>
M@@``.M[WO>]:UK6!I_[C5[^?(9^J&3_QV%R^%0^W_D'I3ANB'"^I@%99+*WR
M:.1@<8K5YB;C*#5$D4G)DZPI,Z/S:DVB2")WL[>S="UK>O#6\:3\VW%0N`OG
M)YK^0.XY+34(K^RZL=8S6;S9JB06HK@39'EC>S2F&Q4UF1GM$M=5(WE0IF91
MY8!%A!LA.=O8M;T'6YJW\V.WG]QJ]_/D,_5#)_X[*F7PB#HWJJJN9J`L;I&7
MJ'27U]5R=G4R9/6NF.3R'8'J1,D;3EMZ)2^L[<H4$*W\DTPLQ64/V^A;!H8_
M*`0DVXB]S^0GGA#";WL=O6R:3P>AZGJ.X5LCC#:TN2&RXY>L?=7ZJVJJ0#?D
MRI]DTN&W%($R9P+:BA."],5ZOE&884,O#3W_`.2^CFZN^99_&(?:5BJNL(G*
MIA5D`C)=61^<Z10!O85E@LKX5:5J5U$PS:&+9"2WJ6%O=G%Y6.!2@IO3+-$&
MC"T];RX\\^2:"0%9/CUO/'4KM#*@K6K+:NRP&Z%ULUM]-PFV8ZOE34NGM?3*
MVXK>9*Z*,32L/D2-NB3BJ9M(SM'E^)>]8,^TOK.VJ11]>QGBO9\D4VK*ZUU9
M#8_HFM"KK<'KIY"\-<$5R<IWVK)L1\AT1=I`C0:1#),9&XY0(\&]E%FC+FM4
MB/>U=2^6PIM)K"ZV.L[-L^14Y6/0L@8X&EIR?6)'%,I0[96<**QG&U&I%('*
M'+TK.YO$7;&IV4`+`F4F;.)\XS[8R_?D&@7/4WM>*R*F[TE\=H6NJTM>\;2@
MR6G3X+5T$M9YG++&7IX;Y;<D0LR1^@97#L>M)CT=>CTR=/H7D$(8`;$FYRD2
MM^W^:[*F-EUTDLN,12P:IFEKP^40>;RF',<JVGIE?I#-9LB9BI(O5Z@J8K?N
MRUJD*8P*+6SCB20:WO0RLF@[<X_=&)BD[?TU2"N.R>6K("P/15D1;;<ZS=`W
M-SPKB:55MRT4*0E,[PD6:2;WHX2162<$.RS2Q"&7PQC-WMQ-(71&QLG6'/KD
M\N#NQ,"%J36O#!N*MZDSHI8F!L3H]N^E!JMT?D9B`H(0[WM<'V^_`[80;&7P
MW$?6G+Q;O:+";T)31#Q238YO5N-Y]C14A17+2QK@M3\Y2X)SH`+*BC[P,*)P
M,.V$*!<,*=1LL\02]C+QP_`NN.6@L-;R@71%+ACMP/*N.U<\BLB)A;YX_-SF
MG8W5FC*G;IHMS<V=_6$-RTDO>S$3B>4E/T6H-`6(9>>&,L[L7FZI8#,K'E=J
MQ83%"&RZE[FD9G-&ZOJ]7SR:I17#'F)H(/TH=I-"'=-M`M1%_P`TE<,!(_*(
M6#*U]M[EYI/CDHG$ALZ&P&O8S^UX=3^;SVM6N-/9UNPU'.(@D;=(IJYOB!P4
MM"SPTG=43:>IV48<C`J1ATIV,K=%/67-1<G;H,BO*K'R>OT+_<&+P9AGL5=9
M3+8F;%5<X0.T7;$[ML3TG>(>A-=$8B1;"I;0"5@WM,$1NAE\-ZI:U(]>M.5-
M=T11O+=%+CK."6I&&^1IT*20H8]846:I<RHWY(V.+NVI7E*VNY0%1:=6J(`>
M$6BSC`ZT,1+QPDS`8#`XRQ:C;DIZYP5ID"),#9BE8L/*2I4Y>MZULP]0>,!1
M0-;W_B+>M8&J_N-7OY\AGZH9/_'87+X4^[;^1[F;@^G`W%:TC5RI*X2%%$HQ
M#*R&R2B8RB2+T:]Q+1HDI[TV-;<A2-S6H4*EBU6F3E%E>0(C%!A!!K2?FUKW
M"'R@<O\`R`UF^6%5[TYP9=$GPN.S&!6H9'HY+6!<J2[6-JW04+\[M#JQO*<L
MP214F5#V+9)@#0$F@$7J:M_-B\7[C5[^?(9^J&3_`,=E3+X1!?/3<8HV+U[(
MTD,F]T++3M-@IV#1:GE=:JGEZF4C;)&ZHB_JMCV+6T'0MQ":+*@GG*'@K99G
MD#H._'?E&*Z)/DBBCTHB4;B?-73,QM.2V#>M8N5.,H.<DDWA4MYU319=8Z23
M/<EZ+C]5+DY2"8H#D)K')'D*P)NP!\IH!%ZFKZ_;.M?R(UQ,V6$+*?IWH*[I
M/+8%)++>ZUK^+0)NGU8Q*(SE_K&0G6,@LNRZ]8T3\CL:(O+(2S-C@ZO2]>SK
M`HTB@!.Q[J9Y2K=?7U;T52D"N^71^>F-5G/=?1>%PQ0U,,`G2R4V6G]U'(W(
MDUS2:L(M73H22`W2[[F=F8E"<2(@TP)^P%#$FL6E[GYS:HE"9)<<T2<RNL]#
M)A,4`Z0<8Y64W.!$981#'I8D2J']RC\C8?JJY*<D>&5Q<V5P;EJ=<E5G)#0G
M;&7X;$M[6Y!;H&FM%=TW1::NEDI=82EFQEGQ#4:/EK&C&YO4?+=M.VTFW-J9
MP>_4%^;Q);]A5"\$X@F[&7K$:K_D*H)HF\EACR"8M*>(6/;-<2";*T$<,A"`
MZF.:87U9,9=MS12I6YG0O=83A,!*I`C$J-<2#RQ)RTX2U)HRMAK[M*%RAKD\
MCLBKKKYGAD;@$?M,FP>B8U%(C73]`),HVD:WA)/(M.)O%(X^;/$5HZ-2%6R2
MPC1Y8AM>@[%L(QL1_;W'21'"7%9U!1"%OLA,J5P)<NM"'HDDN(020R'N0F%2
MJ=B27$;3*2#&]8`O>QI%9)A9V@"+,T$9?#[WQTV124WJ.M6JF+>N^?W038*N
M)1>ICZ<;U"=!63?'W.4+GMUNFWZ=CB,DM+)$_H`*6J#SA:'KT]>&O,)-:-7'
M?7/=A0YML-6]CK."K*A37(YR:V)!7$,31=C/L=]J@YEDK8;/5LA0NR:;Q\]&
M!:4C/CR\T91:!S5G&:*P9>FQINY.6U]DUE6+5<$->7*W:DL>[(-)VB0,B^!.
MD$JMU;VJ7*]R\ERVUEK48C7`_96MBT4G8701XB=I-A$,K.*NSN2$-;MEP+NE
MJ.158\R)3$6NP5EFQ!+$ELH1)SEJ]@)>U#J6AV[-[<F,5J2-CT-.B+$H,T$@
M.S-#+UC7X+W%S5.[2L6ET]E1F.V77L\=((&(RF31!O>YWMGJ>#W.NE]=M*.1
MN+I(84&%SD(P+#"$QIIK4Y;`2(A&,\0R]LVQ]J<AR:(2V?Q_IFC'F%0-#%7*
M9R=NLZ(JF:,HIT#>X4:\K2G412(4M/`-,V@'O0UJTLQ*4$:@L901E\.('LWG
MLR6(&(F?L!\2<:!>^E";H*DD0%2A=8Q^9-$'<EZB?;DFDQ2HMV>`#\WH[1!(
M+,\Z@!@=%;&5RGKM;D*.0>,66_=,T<SP":.;VRQ27.-EQ-(Q/SS&2S3)(TMR
M\YT"4>YQW9.RUY'CZJ,[82C@@,&`(AE\-W8^B:*DHV@J/VQ!7DY_L$=4LI#;
M($"M0YV07"=V49"D:<DT1QTA!7NOK>T^@^?35O2K_P"CO0]DRIFP/__0]E__
M`$Z/CX_]"7&W_MAI+_R/A=OFM)LCXT^,GR`3%FK'C[B"!V$ZQQU;H;-GWCND
MIFTQ*0K$AJ=LD2R)[CC(7(@,Z@S1X4ABHDH\8-!,WL&Q!V-OFJ`<R?`%SQSA
M;HYZO4UG?,+>WEZ)FU<7USO5]B-KM$E-;1E''S(@<\HE".L9RR7*W.ST>K9D
MI34O87GZ1MO*]BD5`F-7]VNS7_IT?'Q_Z$N-O_;#27_D?*SM\UR7+AGF=EK&
M[(%1M'47SP]W94DXJ5ZF]44I`(BZE-4RC[BS%FNA40;8HKD3>TJUP5>D)JPH
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MX6ZV$P(+`_=),\P2NIM+H@-T"E2H5CRVF.2DD+F>G%HK!+/"9>PN#/[H[?J^
MVO>\UN_[<UA9=9_8/4G*7]T\!5_N+)ZYDOWJQLG[U4]]L3:._M[[),L\ZWQ1
M.BLORA\_C@ER8B6-_%JX0]N85;'T4N<IU`X=Q2V5S*)O6PI2U-<SXT67N<T/
MLQCA%AL:F8PZ7M]YGHBV,AQ:%;(0V)QD.AQ^@&DL/;Z8N0_$\)^CRIBWT"I1
MFR^M+XBEG.J6N5J!8\SFZNEB>M29O7H&.SV4BL&.+W`3HL3"`+H%:P>*0"Q(
ML$-R$P]OIG&[XTIU%DK#(X)T@QQ^XU#9T3&K,G4EI1XMZ*RV-=+2"K'V9&1V
M"W)>$[=F>9,'[.,I#6Z2203-.>5I0%V1.@#M`+&_3-V#\9Q4ZU*_+<X6H<GO
MGJ.[=G;K4A8:D_N4X\F7)NXR/T)LV%*!0X,K`_;6``0%Q]II#I,DT/2LL:Y"
M[XWUZ61H9[#KH:6.>Q!SY0DU;*GNI3)%#&65<OT_9]+`43&(H;+C"V9QR;Q>
MUEYFD*5U9%3.I(3F$+33"@##4UIA?Q2D-H8>Z,5[G$2^`L$+7QEX>JR3O#$*
MWHIUC-^N%DS?8HEG+*G<(`]S">K6P,43*$`VYMT5[1T*-))&7,7V^E:.I_C[
MZ6CL/E;-02-9<<]Z"H[M6J;JFJ9CJQBA>GSK.<H;&5&H()8MX09=3$3:Y002
M`MU8U=B.6FTD\)[,I<1)G,(EGRM?SYQQ+XWW];O14DBSW$:NCU?,+!6;*^/$
M(6MTUO:3PZ`5Q<U^Q-BA<CD"N.-#Q5](1-F2?7M(7H\Y2ZF#1DA.V,X6\8[8
MLK)@,!@8:1QR/3"//T1ES"S2F*2EF=(Y)XQ(VM"]QZ1QY[0GMCTPOS*YD*FU
MW9G=M5&IU250480H(,$68$01;UL*G_\`3H^/C_T)<;?^V&DO_(^%V^:J%V_\
M+?)74U$.%34]5G.O),T62:./A%PUKR[6ALH1-[*H..7L!0(N?6KK[)]+,T`[
MP=``\`Z\Q9FOPU,6?JRJA<!?_P"<ZG.0KCDME7=8]9]G11[K-Y@[?5UJ<LQ8
MJ/,,A<I3#7Y)/D8I=8UJ-NWEK;8TK;B]`;R3_0=#O!0`/G*.8M_>]<.WK_IT
M?'Q_Z$N-O_;#27_D?*SM\UC[&X/HAUHB?T;1=>5)S(WV+(JTDD@<ZFIV'1M&
MXK*VL*+SE$-YC\/#"B'M2I(CHT)1QZCSI`*A&!T/0=E#&W=JG27X<8:URJU6
MU@NZ3QSGJVN@ZAO%TI!B8G=H<8RTT\FL&3Q^J8/9+982)3%H61>,V3RU$%*U
M`^EA:B6Y.#18O<`F+[?7++.'Q2*D4`>:>C%SP*54H=:UHV)&:CZ?YS1=-Q-A
M0V\WQ]PD254X2"UHE-%LZCMEI'J1,,E1.S4:E')%J9<D<@Z*-"P]N=Q]2?C#
ML]FA5D5#&.L&\NI;PYKI/F*Y3)A1SE,;J?(74]<OM8/3K#;1_?)DBD5?)[&I
M,N+-,<8C(--_J`V5YQEZ'L;.\9EY^*IG=9V^W>1>TR;;_P!]20;HJ"S!,EE&
MZWB3)68VB&P:KG6F_P!RRV26IFWG]&NA1[R-<C6*"W52M`63H7M-L/;XQ_&S
MXY[ICTKHB/M'6;<MY5Y]NENMJ&<Z.M%H2'Q3IKG<DFD>;7ZZT-A[='`VOS90
M:2S^V8V].H*1I0.):L1>SL&SQRLA(.#Z2L'IZQ.D[@B,"MY3*X%14.AT1G=?
M-3\173A3#_:TB/DC<YO"YS1NBB5KK$0CT3MN3;0',11NC3Q&!]"IO$B)'7XZ
MEJMX6/S->[C%'HVX.U[<;'UBK]#I]C[CV!73]`D930K<92O0Z=*I4/!3B0L/
M2GDNQJ0!8TJ8._-H;]-0YQ^,=XI"X8=<THOQ/8TACMIR:UG9,&NY<AV^/4EY
MB8.:%!14BG]Y6Y,B#?I\=*=S5:]Q=E)YYYZ?S`*&`1<Q;>,QAD7Q1DHZ^;(-
MJ\RAF-M`5C18'G55@`,8:[ZH-Z:428*/]PQ"*#(31A9QH='[]`0-+=GG;\$N
MAK#RGXGY1-;0L^S)3U2[/SA+V^R4L,^L5V_N[C$39'U12'6=;E/0W:YUT2>8
M[6LRI%(RGLS`QQ%M?(^H\@RDKA[EP6L/;Z;/;GQCRV\1Q%\L;I!(MF9S):L'
MN93&*G?JX@EAUM:]G,5E.D6C,`K:[8C]`7-`V`IN*6RURL$MP(&)2Z)G!>`A
M42-^G!EWQ:/\S6VHTN?1:,FMYTF^0L$8C2.FM@ED35_(@F<%,^4/4U-M(UME
MQ-?R1U4*&<HED:-FHAZ3*1F&!TKQA[?3;EGQWV&*8%7$T]#Q)MO-IGM163&I
M`IH9R=ZM022ON5Y1RI*"'FK55X`>'UDET8F;@YH"PR5(L8UVDX?=+2RSO<#?
MKA@G;XS9Y(;EJVT)+U4ND;/5IL'=&B(.%4;:4I#_`!SG24<_284=9H39L1I^
M&QZ:;E:F1C3((6%R2.0_:Z<36PM*B2L/;Z=@_.=2?L!SW1-$?<'W9^RE-5A4
MGW5]*^@_<W[;PACAWW!]#^I//T;ZS]&]S[3WBOV_J>GZQOE\XJEYMJ9<(8#`
MTVP:YKVV8@[U]:D$AMF0)_\`8?7H18,79)G$'OZ4YHGMK^KQJ1H7)F<OIKRV
MIU:?UB1^BJ3EF@\!@"+05H_Z='Q\?^A+C;_VPTE_Y'PNWS5/>W?A&XJZSIC=
M<UU5E1<FSIND*&31NV*/HNM8^[$JDB%R;3F.6M<;;H>JF$.7IW01IK?MR1"]
MXG3G`.#LK81S%GZLK6^#?@KXZY`K1^BEK0FK>Q9[*'\#RZV+=E%5\ZDM2-(E
M]FVQ^#Q>4!GPXBTE@&,Y5Y7)2<N5&;&8/0"R"B6%_5J\W_3H^/C_`-"7&W_M
MAI+_`,CY4V^:U^X/CYYVLNNZFIN/5=35<4O7=_1Z\Y'4#!2\+#6MA":(]*6)
MRCCM"FL$?C24Y^W(BCC7$Q*M&$2(&MDF;V$98V]_*`(/\;=C4;NF2.=NAJ_B
M#/SQ-.DEM-L%F<Z/%DMD:J[H@,55;K5V.B?0-0O,H75V[,JSZ8^J5>CSVY4F
M2*4Y@D?N%$7=[C][^,1=&HPW-];W5&`R)_K*5UE>!MT46DMRO[?3RR])YTD*
M5;K]ELJK5<4D\7MVU9*M9]?67%K3I73:=4C6>D`S;#V^D[O'%JP/'53\F1:S
MVM6DJMA@,=4O=TU+%KSA-LLD*;!-BV.7)53\YL2651B4Z%I0I)1.S4O(5$$&
MD+0"+WYZF\ZJ01\/R1-4\FK!+>R%J(DO,_8//1!#%4`VZ$08765K5E9XW&M(
M0=:*\^)P*LOV[$@;XR-T6&*0.`S1.96P;`;,7V^F_7I\9,EMM#>#/'NE'"OX
M[?%W6+:<OC"6!2`]A-CUA<V5)SQJ(K2(G<-?+9`YP[]K=OK4I7*#H^)4X>BO
M8%VDI!V,)^NN''9OBECX@+&N;V\;+(J_R2WG.7L2"`[CASW'[CX7K'B9_CJ)
MT'.7P30:E;J^.?RUFR5.Q;<-(=E:]#WAS#V2HY<?=.2:KI[7LL[A=AK'6O:X
MKNN'2#T[^W;7$D]?3-#*54PF")CM8Z82J?V`U-X&-[<([(824!K,,$UIVQ;Z
M*LFIL\*+D_$_=S5+I%5+%<4>24_:?-75M:6S;:NJ$KVO.(ZFZ+0VA,JY@L6?
M+R72Z,RI*RN*W;3*'%1(D"8L@.UB56M](S4QKVGA?SL+A<CJ"0<]OZ9PH94F
MH-)8R!/".G.;S.IZVE9$_9HFS%+7"*'6_4AR5^C1<6T:E6C6*A",4"WL.MZ\
M15F7-5^9OB?4,+-6ND'0012NH8+63-7[BLJ<*F'LTQJKIZ6=*Q4\4&U9!.S*
M?9MRG45;8>4Y$J&J/H$ND[QI004:"8OMWPRSK\6'W`B>4K[>PCS;3I_N2I[]
M5-M:&M(I5OMN;Q2RWJ1U*E)L8Y#41M?S2$M_MD2\J6IG-K]P0I\%:@;AC#V^
MGT:?C0G\91-4QBW2C(BZ'2S>SI.ZV=*:?F5IPA[;+3IF)T:ZHUU=6MT3-)@Y
MR1BB,$:#&QS=9FZ)B34NTQR`]J'IM`-^N&]A^.C7U(+F;<05"K^\7761B@59
M-*$X_7]D']FPX"(ACDK0SHPFF?\`W-M>C1I4A>]_3BFTL&@JPL/;Z^$?(?BS
M/84E(N$9O1O03CGSG?B2H*^>G.HOJD753SC)VMM>ALF90]/9;2I?V"Q4UMJ2
M5$?(=$*ML-2EJ"'@P_TQ$L/;OA_57Q3H%[,M2KKR6&OCK#9OIT=R*Z2$-IUO
MS3M-@[D,GB*,;F)S4VP!OL]A`WZAX/,6H9AB*,<=FB---8>RNW3O!?3L;*ED
MOIL!MY7#T/#NPH3>4AC42K**U^A+ZBAM&14]/'*OM_H6+CK./-I-#,@2GM#(
M)T[$ZTO&M97@U8$PLLL^>D\\\\23B+=WCO.4Q9VC%95;SQ7,182W1ZA*YHL_
MJ+5?,-/36]88T160O;^T,;-0\,;XJ2*1D-3F>:L6;+2^WT`T9+>,=P>5E__1
M]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__2]_&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__3]_&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__4]_&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!__5]_&`P&`P&`P*J=")NCT@Y3*JSN"HJMK1
MCH:V@."NP6`PQ:PVD;&GE9![3<)>MTX,#)"*X<&]*>XI%3<M)6(SU9ANM>W*
M+.+,^5'*6NSH,R@&DQ+8LQ+ET([.Y]K&W3;R9Z]GTO%`K,MSG]B51.M9A7(V
M:+.L>FD6L50M+?7M&8_MI#@>C"@1F%H#T46YO]-UL3HJY(H;+98WV49K4@E?
M35>&UTMC]>&,U"1NFIRVPQEO8I5IB32YS+;(V-%(W<E^<5K4<7)T>@%)"`%^
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M/K<B)R!SKEACTE&[GO"Q,4Z,*MRC[NG*`J2K1B$8A(FKZM@D'>5JNM8624R5
M?$X):D8BUX/GU"73]Z8X<T-%85%`+')<T"R45,!X5350.TV[:-E=6-&0L;&Y
M:Z[-VC"`DP9S]+#W#TW)JCA\%6M\9BTL>5]"67?DK73.<;KMH!$Z69JY7S-"
MU+442DJ8^7OYEAD"0D'%H6\@A.J/./"$D)1M3.W[JOIR;SVX-0QXKJ.,4!?G
MF[8_"Y(EF#RLFI[A2SS$4*L^50M?"VIM8TL@32<_00$NRL]&<WA\X3-*]Z1#
M.&+DEA6JT6KU>PS:Z876%<PZEN>I[`9&A@R)8=6+5+Y]T6PSM\=ELD<UA,QG
M4D::Z1%H/63?1VU4!(`#4O$%7IR'CAHT/L>[%K6G8)K;KW6+>GA]C3%99-I0
MJMFBPX_$YS8\?@G-+E:<9U'HM"8U,9,@2RE<D0A;&WVIS>@)>$>U)3B@-'#$
MQ>XND%-?T^M7RQ"VK6;KMUI6Y0R^-Q.06!(8Y^\'VM$H^ED,!*CU2I70V(KB
MC7UT:&HPLI43[!.2F5A5*"(N3E@Y!?US+I!8LL066NBT=A9C!.JTK]-'JX4M
MESL+YT5+J%10@QU>XVOE!S.^M=:-CD@5-2U&YA=+(3Z&H,((1(<&-ZY,O"X[
M!MB7M=E.S@IBLM9;,F59HUR6"[1;8X+>+[7P#HRFAK`V2J$-*6-+&4"MMG*M
M>_JG4U0%,,`6Y>7JI6,K#L2RWMRKU"M@C&\0AQ#1;/*YJ]3ST+$^OWJZ3=E9
MCF^*1ZKF:&N:)@<XRD]V/W+5ZJ988,HKU$V@*8MCX=4]F6+5:^^8+$(C'F9=
M%*BM%PKFQW1X>'U.X69%><Y7>Z-O/:V.#22(L+HS-L<,-$QR1T:W!P0!"X)B
M5*080&5).F?F?;TCKK4M<I36\15L4976Q""B6.R%_P!WJ+'INIE-I219((TX
M04E-#ZH=26U000^FKE1J)(J:%JE-Y'8)*08TZ3]E6O$>AJKJI\CU>BW+W-77
M,R-BU@%2RJ*^D:B2UHI9I=-9L5"&^81:1/[#,261BC"](BVYR-\;"1G`2JR7
M'47)BQ-F=+NT"MD,%20^/.,997CG5CF#PYS52S3`2SIBT':IX8IA,.!%'%#(
MFM@?F\*AR/4NJ#SI@*PIPC.1[`;4Q@V._;"DO+U/7I(6%GA;I;,TY-4M3-!Y
M0&0Z20J^;<IF.Z2N[G,*^*(`N,99VI(<TR="(>B/.!"XIU(BER<(DKSM^UYB
MEK9N<Z>K5EEMQQ+GR?P'SV](M0U!%;U@/0U@DESQ^-JCZBQ/;0S\WN)19:-$
MY$*7![0I?4`$HU48,C1**[]L.8,_/48>((WOSM+Z>Y^'/K5=GE:QM*NT[AYT
M:;E(D#>G9H"E@BB%>Z/$6?[9R1JCPZ<C4:(`&G1"V+G:WO(72^^IJK#:1T:1
M00EPD:I@:XD>_D/$C3;:&%C5.*M["2G2D)R7MP6*')@$3HP#M#U+2\A$`#D$
M@FI9B!);V)9<*L.U8^SP1CF<7K5YFLBEKE*IY]NN[7"XFNIAH4-$#:HW5RM.
M[KS2K%5+$Y3NM"+UTGHFKO34`$CBYT33L"Q!IVIP96>!QIH<KA6L,93(K$;7
M^QY)%:VO<%.S]OE5<O$.1*XV2\JP@V-:VJ'`3.8L+1J3$ZS9(CQ)&>1=N.LC
M<(@P0Z&P)P?):R4X\@5R2SCHS#F7=BT;8=]/3>]R9!#Y08C7(HK`@A;B])!&
M*DZ[WXP@3)C-#J8@6L.WKT.J-A>28S'K4F@J\;)W*7">S%'7K4%-%.'>5>@I
M9]NIX!4;GM.;+Y5;BPL"944ITB5*3E!:CV1:5I(BXLW4W7DAM&V85$]06(,D
M#L8?1Z>*N([%/7V:0?S?.F&O'Y1(Z_#$TK6@;)$\.IBI*<E>%OMT(T>SP@-5
MZ+*J6=HRL[NVRJ\7R,E-2D;D2,N;W6PP]0GFLT`)9'N>CB]3]RF`VFJ)"EBC
MH[:<4FVTL)BI$0WDN#BK4@"ATC4#'%DG;EC1I1-G*-5VU2Z.Q2,=&7+*`3J>
MD1=X8*ZH&*\RR)PB\,2P^M'E&[R%Z1W>KVF*<U8@%*T6_5<C"3BPD1<<V6=_
MO[`ZS*)-=2:?9O6LT0UC8+,2[/QB>/3FQ+?<H516O,PQ62NJU#9%9QM;*RTQ
M*0:T.W-C0"T4-T`H+&?;@_W]39V51!O251'XLFEU=+5@Y,\3&02%`SVHJ4W"
MP,<2,31:O',3&V*9%4WF0J99N+#>TC@86G++<FY0VG#'[A?7'1KFW5FS%5K4
M\E=WPFAH2_2AWLB2QG:VPK<HPFUUC\4Q-%6NZ0B.,(B#-&D@-*-6B/T64%+H
MKS#&-;8_DN?WU<:`NB=HVEKC:@A_=#)8_&ID]C$\TG]'F,S$XJ*\;H]((P2A
M)"UA."N(>3M>X6B;2249@#&GK]I.A?3-[3.WZ@@3Y$*[@X%D]=$%C(8_+WF:
MIG2*/7-I%PP\ME=G>`Q16F>&E[=!I5P?0)+/TWDGEG:`J-2$#.-:SU3V5:-?
MQ>_45:QB$M;A$B;BKB$RQYF1ZB7-EHU]RJ^=/[E+I7!\$<68,0(BS(H)1;.<
M%0U2X2`9R;V:T8B:DDXUN77-]V[SU0[DSQ0^./-NMO)]_6NY6;.).U1UN;7.
MAX)$"75^;R$-8K(O)9JZRV=HW!&VFLK,RJ$Z-9LP"8H($^Q)+7"_O&D4<L?]
MKU\9&_/MC6Y+:_I0QQ>FX!C^Y06\6^%VTTJ`,L7926YLJ^J)*CER0L[2MQ<&
MMM=0"4'FI-FCBYPBUG[;LMVB?.;\A:DH(XJ'1A-J+W61L[A;T]7SSDQVZ'=&
M^+P)IK%EC;TV+2S42<+HUF,@E3NE<24J)*0A&4:,[;1`NZ[=M-#7[9$*.A#=
M.+'GL.8V-/+K+F#/#2H=.>?[IO1HD1KN.H@2U6K(#3PT)8B&,;6YIG!.M3+/
MQ/3)JF?;6'_ORPGU/44^@L&B;/`5SAM?)8U)K28(],9NK<OC>L[L]JAP%$EA
M88I%X40XG,"4Z4">49J=<TK!'IPMX3O5BXO%SC=RF[86X.S\RHHC,6"4OD4D
ML/!J7I7!F<&A*R.FBE[7/(;!)$D4C9I,W*1>5&>A&4L).2JU28\D\RI9BPF$
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_];W\8#`8#`8#`@"Q;M-C,XU5K#2
MMH7(_J(63,7E'!%%.(6QJC;H[N4=2!=C[;MFLR5AKDM:U(-$I`K/`L&]F^30
M@^8N,)7L@Y;C3;&Z:BIE/0;W<RER>%U$-YKM*Z/$DJ^R)"V.+Y&8B@>7`YR6
MM$T@*E8282`2]N4(?`\M(L2FD$#GM^U-G<=-A4XMY987-#>2Z+$]8V5:"F65
M:E*<7!N1J-):]G$U-<"P*UB%`4;HMI7J1#*)"/P*T'0L&5FXS(:%;(K84`;F
M:"P6LJ;E3-63^S+FF*12L4B^4PZO+(:4;,BT)/&]L[JDMAK++ULHC1SF<86$
M`A>09@?1SD?,>W359O+[0^WJ6_=E8AK]S=*^VZ2;ZMI.[3FO=114?[MY^IZ>
M2E+LT^W,];2H!B@K?JZV(<L,_6OR%M\>+(D]E<W;DE)*28P_SU^F-8[?*C62
MM2O:T\>>)2X./OX"IDJQ"J3@2''I!K#232]`&(`]:'++*&GE^M'*`QU4V4)7
M[O)ID[R.KF)0CKV*N4@L&0(1,[\_0%L,+0*G:9/;8^;2JU3<`Q<I(6;*,$(!
MOE$3EHJ1TX3>H5,X:@<>2G:NJF>]R6PXHD5TZOA5:2,;BYH=R"9L1)AK'#7L
M3LC6D^[7%)C]J"C@>;SA,UHO+%CZ/X^GT=*=IW(J>;(#"Y$$^+22VGRJ&^'A
MD4<L&Z:T9WB%G/LA4@3'#<*)D"QF<"RDY:MJ*]9&:8(E<4D&5+R>QN<T4TB\
M92SNE$EBRI,HD\+CR>3P4B:2-'.2C755(8NTEK@/CPFF!+2-28K2%F`<`IA&
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MR5.#.N6,@B"R2VH!9AB3980ZV7Y=8.7%J*]./Y!`I!T-7TMH^(,DM0Q&76S+
M`O-;QAY9W:4M:-2Q(;M=FYR\K1-""EX4@R'=4)04HT(D.][U^(Y2/'W[G-PD
MS=!(J]4HNF*J+1JQFF&Q]Q@JF3*(4VJ-'0^=MT>;CANAT60*W30FQT*)VD*,
M4^)!NMF?B.4#2CH/FII5W#9EF50\1>1UA7A&G1]F51MJRQ9]4TJ?Y?&6=##F
MQN`^3]P89A*84ZHR(\Z)FQR.&3H\YO`E.*4&#+PLQ#H%51"5LE<1KJ$L!CS`
MX]&$RYLA\>:'/]ODC>FW'X8>>WH2S0QEH0^F6G;=#$C3!!H)8-:UK"<N0AJ&
MIFMC3QAMJ^NVZ-)4AZ!+'D,*C21C3(5+V1)5*).TIVPM`2D42-,6X#+"7H`U
MI83]ZV:'0M!L#A#8@[2%BESK%(VYRR+E+R(U)W!C:ULACI+H5Z#F2Q/2E*8Y
M-)3B1_`>%.:7HX'X#\=8'(!&(T6RM<;+CS&".L?T#Z(P`:4`65G^U5:!?%_I
M;6%/I"W_`&VN:DIR#T2P>S-3%#)\@BP;T&O.555>\L9T8>*W@3K&E+)&HTHC
MSE#X\N8U$<ABI4NA[`<TJFXU`:R11:M..;4HB]D(33AC("`0A;V'%4T[42PY
MH4JZLKA4HC\.5UXP'J8/&3SF2OUZ$36N@S0::UB&VPY:V#VG-;"=@1&$;V6(
MO8/PP,GJN8(%];I,3$F%(_M3B)W1NR!N3MZSZGN+"A`5JHU$!/\`4%!,0%IM
M*$H]7T480%@\H0`T$.2?!(.J.=5*F&Q10H?2E1#V>?'F@TYX)7#0&+B74TQ&
M(;@4L&U)1&A.V/1FTQ6Q>/I@\`XQ%;UVE>GF2)H%"T\BD;BRO$A?R(LQE/3Z
M[QO8Q1UT>70M"%<Z.+`(P6T1YY@S4NQ;](0?'>!KB:AZ.11]QB:.F:H219W<
M4CP[1I-7<0(C[H[H'(]Y0NCBS%,X&Y:XHGA48K*/-+$:6I,$:$6ABV+8V^6Q
MI*WKM`G]H@@4+1)/8FM?M4D68TR?Z8?'V:)'-WHDH0%^Q.BL<;FP1/AZ8F]`
MG3[UZ)!0`A%D/Y=J6$7'(+V9VQS.L%^;'=FTN<W,:],SM3ZJ95CD@:BS"@JA
MI0F1],2@"L.5Z94&AH&SV2`P:41=^$H/]95O+&H3%*:^A$E8Q2$$N$S/\487
MEJ%*RU0UP).)N<4"E)N0@6F".TM\GN=&BV/S^;>]X1S54$A"X;H8NAL56#?$
M,@;'H:J/-"@;NVRPEH32EO=!'(Q[<$,E3Q]`6X%&^<M8!"G"=H>B2]!#\NL"
M@KZBE+:]PN)O+=.?0^]D#K'&=P13'VR!(U)ONE*K1G$2'V[8WD)@>["=Y"""
MR]>``!UH."15U9IG:,/Z:NX*G?82PGQ:&/1$1CY3M$8PJ3^U4QR,.1;>%8P,
M*A+KTQHT@RDXR_X=@WK\,#Z,5:US%T3>VQF`0F.MS2J0+6I`Q15B:$38L:D!
MC4V*V]*WH$Y"-4W-9PTQ!A80C)3CV6#>@;WK`XG[2U7]32O7[9U]]90QM9#4
M3M]F1SZFCB#CL_;A%4J_Z;[I/&UVU)GK(0#TE-]07F!OS;\0R:B`0-6L;W%5
M"8BI<&EX;Y"U+U$;9CEC8_M+.='FI\;U1B(1Z)X;&!08A3J2Q!.)1F")`+18
MMAV'S<:YKUW>':0NT$AKH_O\940M]?'&,,BUX>H<L\WNXF[.:E":M<8RJ\XO
M40'#&E'X[\0;\<#^S6NZ_LIM3,MBP:'3YG1K@.B-IFL9994VI7(M.H2%N*9"
M^HEZ4A<6E5FEA."#1FBS1AUOP%O6PR`8C%`*T+@",1X"]K>'60MJT+*VA5MS
M^_)5B)\?$*G2;1R1X>43@H)5J2Q!.4%'F`,$((Q:V&!#5%6A>HM)`UK``R*#
M,R>.0E^##H[IZA\>2%B*2,,6=--WOH^S)2AB"6E2&$D`#O>M!UK>!R(_6=;Q
M,(`1:OH1&@%R1PF18(_%&%F"7+W9M7,[K*@!;D";0)(YM#FI2J%VO^]')E!I
M0Q[`8(.PX/[/U+]88I#^UU=?7XO'`P^-/GV3&OK$=B0&Y<T`BS$Y_3/>M$<`
MTNBE+I"G&6FTG4&E^3R&##L,I%Z[K^$(V9OA<&AT001U"\-D?0Q>,LK`C8FV
M1.*%WD#<S)FE$D):T+Z[-B94L)("`M4H3E&&:$,L`M!N.`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P/_7]_&`P&`P&`P*)W$U\>!Z@CSUT5*:%,GIM51EKK:$
MW8R0L"Q()/84A5DRF`22>&>S/?'!Y4E)!H6P&EY0TQ)H]["83K1><X5CU`*:
M%=\7,9>A9"!ZW8=S.TI;(+3=Y[?3R/[ONGY>9%)5*8?)!5JPL*6PW:41)L5S
MEA>@.2EH6+H@-K<E>U08O+ARNL8>545:^KU0R*(TEJZ",\,,J'G6S-S!QH8F
MG)TB@K](4%!6(CNW;JJB2IS7`<5*U)"=Z3#)+CA)PC-F#YZ2W'VFF(9R#UX8
MMF+Q<U>&0%F46:5%HJXP%_3LZ#A;GB-&-\<*DCN`TYWD-:LS9)49I"GUD1SV
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M:7%\\.+2U>4^T7;7+BIZ-9)I/D%NO*TUA:J8E4/89%.S)O\`+<>Y-#*H<)`_
MML=0DR:P9R2C&-6M*#JO2]@--T^MPP5/Z0K2+&TM4[YFBU:S^/RFB&:WN9W1
M18KE`BVA=-K(9OC;B4=@K9%BU\K*FD163&HTC"][9C8PL1H$BE489*M':4,!
M,7SY7!NR"#>!]KG#Z#AT,IY_A:0'2C*JHB:2F?PJ'I*60I9:9$9TBLQL8SE#
MS5Q(U)&R8J]G(E!V_`!YH=$8/'"K1<!YR.N"S-_W!V0D/5V9;BJ&)9E3?6)L
M4CMH.7:]5R&>I`/\\DH^?9O5L=Z/2,S$Z(XFS1U*>R*P"<'0TLOZIH<^&P2"
MOZA1]/L*^9=%NSS8YLYY]4VFQUM172#739\V;.D;`>Z?0:75-/U-#P=SD%J+
MU;,N_<,R:.'OD!I_K(EIIYXASG3?(%`^?DL#K%(SWVV.C<BI3XE6MD=B:MD*
M+;VRUYU1(7JH)2!`8L$I;3NB;(/&R*$)F]J8BJ(TL<]F`&$.5.4#_MI2K?6=
M(IG+J)SD,N05;RTDY]?J.YXZ99E[E7T?C=]$URXSF&T-8JFXWUYGK8ZS`U4)
M+((N-$J;?Q3)S/>%KHO]+U\2QRIV)*]&UA9*F?!4571R)R(7PJ>1!>A1M?[D
MA;GY0&Q5[E*!`ECJK<QEH5IYZYL"D\B@X\1FC!5*U#4$@"&<=A)9??<*?[)7
M\]#8;7<(34I;%*HG`5##)11&9]&;AKXZ--@V>WQ-1H+"`"6,*#61,HTA;?;G
M;&4/'"],%1K4C,PA3/K8[Q`N#0M''M%,"]L>35J1*X:='U>XJGM20>V/C6:V
M>T;]-Z90W&IU(C5*O2DLM&2MYP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
=`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g842626st99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g842626st99.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``(!`0(!`0("
M`@("`@("`P4#`P,#`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,
M!PD.#PT,#@L,#`S_VP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``@`)L#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#Z9\=?%+Q/8?$36O(\1Z]%Y&IW'EA;^4!,2MC`W8XK]$?V1_VA+?\`
M:&^%%KJ#O$NLV(%MJD"]8Y0/O@?W7'S#\1VK\[K3P:OQ#_:)?07F-LNL^()+
M/S0,F+?.R[L=\9S79?L]?%#5_P!C;]HJ>SUI);>T6?\`LW6K?/R^7GY9@.^W
M(<'NI([U_./"7$%?+,<Z]=MT*DN23>J3W3\K7^:OV/WWBC(J&8X%4:"2KPBI
MQ2W:V:\[_G;N?IC7P+_P4H\:ZUX?_:)B@T_6-5L(#I,#>7;W<D29+R9.%(&>
M*^]-.U"#5K"&ZMI8Y[>X19(I$.Y9%(R&![@@YK\^/^"H'_)RD7_8'M__`$.6
MOT?Q,JRCDW-!V]^.WS/S_P`.J:EF_+-7]V6_R.'\-?#_`.,WC/0K;5-)MO'>
MH:=>+O@N(;N5HY1DC(._U!J]_P`*9^.__0)^(7_@3+_\77LW[.7_``4,\&_"
M#X)^'_#>HZ=XAFOM)@:*9[>"-HF)=F^4EP>A':NV/_!5;X?@$G2?%7'_`$ZQ
M?_'*^#P>3\/U,/"I7S&49M)M7V;2NMNC/ML7FN>PKSA1P$913:3MNKZ/?JCQ
M7XW2^-/AM^R/X#@UFY\0Z/KC:S?>>)KJ1+AD(RNXALD8Z9->O_\`!+/Q'J/B
M3X?>*I-1U"^U"2/4HU1KF=I64>4.`6)P*P/^"G/B*'QA\%_A]JUNDD=OJDYN
MXED&'5)(%900.^",UX%\(?VI-2^"/P6\1>'M!62WUGQ!>K(;_C%I`(MC;.<^
M83T/89/7%=%3,*&2\1J56HY4Z=-)=Y?NTEY7;,*>`K9OP^XTX*-2I4;?9?O&
MWYV1]$_MW?MP?\(PMWX*\'7F-4.8M3U*!Q_H8[Q1L/\`EIV8_P`/3KT^<O"_
M@'XR^--"M]3TFU\>W^G72[H+B*YFV2C.,J2PR/>M7]A[X/\`ASXW?&H6?BB_
MREM&;R*P<G=JT@.64MZ#[S#JP_&OTML[2+3[2.""..&"%0D<<:A510,``#@`
M#M7?EF3XOBN<\SQU9TZ=^6$8/:W?M\]7OHK7X<QS7"\,1AEN#HJ<[7E*2WOV
M[_DMM7<_*;QX?B7\+KJW@\1W?B_1IKM#)"EU>RH95!P2/F[&M'P9X3^+WQ%T
M1=3T%/&^K:>[M&+BWO)60LIP1G?U%>T?\%9O^1_\'_\`8/G_`/1BU[)_P3/_
M`.37+3_L)77_`*&*\/!<+PK<05<GE6FH05T[Z[1^74]G&<22HY%2S6-&'--V
MM;3>7SZ'G7[+^L^,_P!G+X-?$GQ%X\M/$-LUI!`^GKJ<C.99")%"IN)Q\[)F
MODQ_BWXL>Y,Y\3:]YQ;S"WV^7&[.<XW8ZU]9?\%5?BT8+#0O!EI<`&Y)U'4(
MU/.U3MA4^Q;>V/\`9%>53?LO2P_L)+XU-JC:JVI#4MVW]XM@1Y./INQ)].:7
M$6$KNO\`V3@)RE#"0E)MO5MOFEMVNDO1CR#%4%1_M3'0C&6*G&*26B27+'?O
M9M^J/NG]GWXG1?&+X-Z!X@CDWR7MJHN.F5G7Y90?^!AOTKY&_P""G?C+6/#O
MQQTB'3M7U2PA?1D=DMKIXE+>=*,D*0,UTG_!*GXKM/9Z]X,NK@'[.1J5A&W7
M:QVS`>P.PX_VC7$_\%4_^2\Z-_V!$_\`1TM?4<19S+'\(T\6I>\W%2_Q)V?W
M[^C/G,@RF."XJGA6O=2DUZ-77W;>J.&^'?P@^-'Q7\+0ZUX?F\1:AIEP[QQS
M#6_+W%&*L,-(#P0>U1>._"GQI^`"0ZKK%SXNT>$N$2\34VFC5CT4LKL`3Z-U
MKZ2_80_:%\#_``\_9OTO2]<\4Z-I>HQ7-R[V]Q<!)%#3,5)!]00:F_;8_:R\
M`>(_@#K6@Z/KFGZ_JFL"."&&U;S!#AU<R,>@`"^N<D5X:X?RM9.L>L;*-;D4
MK<\?BM?EM\6^F]SV7GN8O-G@?J<94N?EOR2^&]KWVVUVL9G[)_[2WB']ISP%
MKG@S5+](O%-G;B>WOU_=-?0;@'5]HPK#(&0.0W(ZY]M\(_"SQ1H_ARUMG\2/
M;-"I'E(OF*G)(`)]NPX'0<`5\M?\$K_AK?ZA\2]6\5M%)'I>GV36"2D$+/-(
MR$JI[[53)]-PK[NK[O@B-;'993QF.<G/6*=VKQ3T;MN]U?K;6^Y\3QC*E@LQ
MJ87!**AI)JR=I-:I=N]NE_D?EO\`"O\`Y/+T;_L;A_Z5&OI;_@I;^S8/$WAU
M/'ND6P-_I*"/5$C3+7%OGY93CJ8^_P#LG_9KYP^%NF72?MCZ.YM+H(/%H)8P
ML%`^U'G..E?IWJ.GP:M83VMS$D]O<QM%+&XRLB,,,I'<$$BOD^"\FI9GE>-P
M=96YIZ/LTM'\G^%T?3\79O4R[,L'BZ+^&&J[J^J^?YZGRE_P32_:3_X23PZ_
M@'5[C=?Z4AETMY&&9K?O$.Y,9Y'^R?\`9KR7_@I__P`G*1?]@>W_`/0Y:Y_X
M_?"+7?V0?VAXKWP\ETEI'-_:.BW$<;2!8R2#"QQR5R58=U(]:B_;-^(R?'/X
MBZ-XDT^RO42]T2W6>$P,6MIE>0/&>.QZ>H(/>O$S7-:\LCGDV.TK4)Q7K%72
M];:?)I]SVLLRRA'.H9M@W^ZK0;]):7^_\TT>\?LQ?L)_#SXJ?`;PWX@UBQU*
M74M3MVDG:._DC4L)&7A0<#@"N\/_``31^%1!']G:OS_U$Y?\:^//!'[6'Q4^
M'/A6RT31M4O+/3-/0QV\/]F(^Q22V,LA)Y)ZFM7_`(;F^,__`$';S_P41?\`
MQNO0P'$?"]/#4Z=?!.4U%*3Y(.[25W\75G#C>'N)*F(J5*.,2@Y-I<\M$WHM
MNB/:O^"H6@6WA3X/^`M+LPZVFG7+6L(9MS!$@"J">YP!S7D?[$'[)%O^T;K-
M]J6LW+1>'M&<130POMGNI67(4'^%0.2>IZ#N:E^./Q$\4_&7]E3PIJGB.2ZU
M'5$\27L&_P"R>6PC6"/:-JJ.Y/.*]K_X)0VLMK\.O%@EAFA)U.(@2(4)_<CU
MHIT<'G'%5.<X/V4HQDHO3:FFD[>FUPJ5<5E/#-2,)KVL92BVO.=FU?\`,^5_
MBO\`#O7_`-E#XX-:17,L%YI-PMYIE\G'GQ9RC^G3AAZY%?HC^S%^T%8?M%_#
M*VUFW$<&H0GR-1M%;/V68#D<\[6'S*?0XZ@USG[;7[-2?M!_#%FL8D'B/1`U
MQISYP9NF^$GT8#CT8#WKXD_9;^-NN?LU?%*+4/L.HOI=T1;:M:&WDR\6[E@,
M?ZQ#DC\1WKLH3J<)YTZ,KO"UMO+S]8[/O&SWL<=:-/BC)U5C98FCH_/_`($M
MUVE=;7/7_P#@K-_R/_@__L'S_P#HQ:]B_P"":DJP?LKVSNP1$U&[9F)P%`<9
M)KQ?_@J)>KXL\3>!M0TU9KVSN]*EFBEBB9@RLZD'IQP>AJW\/?B+<_"S_@FK
M?+!!>+J6MZA=:7;*D;!T,K'<^,9`"!N?7%50QT,+Q9C<9/6,:;?K[L-O7H36
MP<\3PQA,)'XI32]/>G^1X#^TQ\5#\8_CCX@UYF#6LUR8+7:>!;Q_)'@^ZC/U
M:O9KK_@I!IES\*7\'?\`"`Q)HSZ<=,$8U7[L?E[`?]7U[_6LO_@G1\`(/B7\
M5+[4M=TQ+G2-`M<_9[NWS'<32Y5`588(50Q^NVOMC_AG3P#_`-"7X7_\%D/_
M`,37'POD.=8VC5S/#UXT_;-\UXJ7,KN^Z=E=M6\O0[.)<[R?!U:675Z+J>Q2
MM:37*[*VS6MDOO/S4_9G^*K_``8^-WA_7P<VT-P(+H9'SP2?(_Y`Y^JUZ_\`
M\%3Y5F^.VB,A#*VB1D$'((\Z7D5E_P#!1'X#Q_#7XR6][HNDI:Z+KMHKQPV5
MMMBAEC^21=JC`R-K?\"->??&WQW>_%32_!<TMKJ#WVCZ&FEW9>!R6>*63:V<
M<Y0H?SKYC%.ME^"Q>18C5QG&2[.SL[>JY7\CZ+"JEC\9A<ZH*RE"47Y=5?T=
MU\ST_P#9L_X)]1?M!?">S\3OXIETLW<TT7V=;$2A/+<IG<7'7&>E4/VGOV`=
M0_9\\"?\)%::XNNZ?#,L5VIM?(DMPYPK\,P*[L`^F17U!_P3D@DMOV5='26.
M2)Q=W?RNI4_Z]^QKJ?VQ=';7?V8?&MND4DTATYI%1%W,2A#C`'^[7WU+@G*Z
MW#T<6J5JKI<U[R^+EOM>VKZ6/B*O&.9TL^>%=2])5>6UH_#S6WM?1=;GD/\`
MP3-_:`O_`!]H&I^$=5:&270(8YK&1(5C+0$E65@H`)5MO.,G=SG%?5-?GS_P
M3&U"70/VBI[>XM[F%=3TF:%&>)E4LK(X&2/16K]!J^F\/<=5Q.2P]L[R@W&[
:WLMOP:1\YQW@J>&S>:HJRDE+3:[W_%,__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 225,459</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 197,959</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndRestrictedCash', window );">Cash, including restricted cash</a></td>
        <td class="nump"><a title="nktr_CashAndRestrictedCash" onclick="toggleNextSibling(this);">26,136</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashAndRestrictedCash</span><span></span></td>
        <td class="nump"><a title="nktr_CashAndRestrictedCash" onclick="toggleNextSibling(this);">37,614</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashAndRestrictedCash</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">262,824</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">262,026</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes and Bonds [Member] | Fair Value Hierarchy Level 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">182,544</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">138,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember', window );">Corporate Commercial Paper [Member] | Fair Value Hierarchy Level 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember]" onclick="toggleNextSibling(this);">42,915</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= nktr_CorporateCommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember]" onclick="toggleNextSibling(this);">59,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= nktr_CorporateCommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value Hierarchy Level 1 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">$ 11,229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">$ 26,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash And Restricted Cash</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashAndRestrictedCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 17,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 17,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 16,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember]" onclick="toggleNextSibling(this);">1,161</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_CostOfSalesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember]" onclick="toggleNextSibling(this);">1,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_CostOfSalesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember]" onclick="toggleNextSibling(this);">1,496</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_CostOfSalesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember]" onclick="toggleNextSibling(this);">7,528</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= nktr_ResearchAndDevelopmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember]" onclick="toggleNextSibling(this);">7,910</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= nktr_ResearchAndDevelopmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember]" onclick="toggleNextSibling(this);">7,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= nktr_ResearchAndDevelopmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 8,328</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 8,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 7,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ResearchAndDevelopmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">34 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties', window );">Liability related to sale of future royalties-beginning balance</a></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" onclick="toggleNextSibling(this);">$ 128,520</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_ProceedsFromSaleOfPotentialFutureRoyalties" onclick="toggleNextSibling(this);">124,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ProceedsFromSaleOfPotentialFutureRoyalties</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments from Nektar to RPI</a></td>
        <td class="num"><a title="nktr_PartialRepaymentOfRoyaltySaleProceeds" onclick="toggleNextSibling(this);">(7,000)</a><span style="display:none;white-space:normal;text-align:left;">nktr_PartialRepaymentOfRoyaltySaleProceeds</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="nktr_PartialRepaymentOfRoyaltySaleProceeds" onclick="toggleNextSibling(this);">(10,000)</a><span style="display:none;white-space:normal;text-align:left;">nktr_PartialRepaymentOfRoyaltySaleProceeds</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash CIMZIA&#xAE; and MIRCERA&#xAE;royalty revenue</a></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(21,937)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(22,055)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(10,791)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(54,783)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense recognized</a></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">20,888</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">22,309</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">18,057</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">61,254</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties', window );">Liability related to sale of future royalties - ending balance</a></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" onclick="toggleNextSibling(this);">$ 120,471</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" onclick="toggleNextSibling(this);">$ 128,520</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties" onclick="toggleNextSibling(this);">$ 120,471</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liability related to sale of potential future royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-cash interest expense related to sale of royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non cash royalty revenue related to sale future royalties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Partial Repayment of Royalty Sale Proceeds</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from sale of potential future royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#+;/:[40(``-$G```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VL&.VC`4!=!]I?Y#Y&U%
M3.PXG5:$64S;93M2IQ_@)@\2D=B1[9G"W]<),Z@:41`J4N^&")*\=XG$V7`7
MM]N^2Y[(^=::DF7IG"5D*ENW9EVR'P]?9C<L\4&;6G?64,EVY-GM\NV;Q<-N
M()_$NXTO61/"\)%S7S74:Y_:@4P\L[*NUR&^=6L^Z&JCU\3%?%[PRII`)LS"
M.(,M%Y]HI1^[D'S>QH_W21QUGB5W^PO'7273P]"UE0XQ*7\R]:LML^<-:;QS
MNL8W[>#?Q1B,']TPGOG[@N?[OL5'X]J:DGOMPE?=QQA\V_%?UFU^6KM)3P\Y
MDM*N5FU%M:T>^_@$4C\XTK5OB$+?I=,Q[75K7G*?V#]=[/ETR*X<9/Q^T^`+
M<PB0'!(D1PZ20X'D*$!RO`?)<0.2XP-(CFR.$@1%U`R%U`S%U`P%U0Q%U0R%
MU0S%U0P%U@Q%5H$BJT"15:#(*E!D%2BR"A19!8JL`D56@2*K0)%5HL@J4625
M*+)*%%DEBJP215:)(JM$D56BR"I19,U19,U19,U19,U19,U19,U19,U19,U1
M9,U19,U19%4HLBH4616*K`I%5H4BJT*15:'(JE!D52BR*A19"Q19"Q19"Q19
M"Q19"Q19"Q19B_\E:XB%)>+3Z[__7J8Q9QHS/NPZ\E?^EWL_]-SF1CNJOP<7
MJUU7#_#G[#,Y*MU5=TWL.%WY(1SFGMH?BU?WS@X^5M`<71[@I6,VWCT;XB!R
MH:5#R^Q86^NP,=;7+E_XJBY&8T&NIOK(;CX5\I:_`0``__\#`%!+`P04``8`
M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U
MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B
M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA
M:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[
MRW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*
M<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````
M(0"8VH[SJ@(``((G```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"\FLUJVT`4
MA?>%O(.8?2S?^7-2(F?14LBV31]@D,>6B2T9C?KCM^_@4MF!YL0+<38&R7AT
MT9S[?5?"#X^_][OB9^S3MFLK);.Y*F);=ZMMNZG4]^<OMW>J2$-H5V'7M;%2
MQYC4X_+FP\/7N`M#_E%JMH=4Y%7:5*EF&`X?RS+53=R'-.L.L<W?K+M^'X9\
MV&_*0ZA?PB:6>C[W97^YAEJ^6K-X6E6J?UIIKXKGXR%?^OW%N_5Z6\?/7?UC
M']OA/]<H?W7]2VIB'/*BH=_$H5+CJ52>OM%^EFM6Y1OE"+L<0>5832[':EC.
M@EW.`I7C#;D<;V`YN9>FBW(:CKO<C&.._QZCZ[,W!^X-.[@PM\*&C&#(W$\9
ME!%PYZR,I_XQ[Q[E1MC,$\@\;=EWQZ*[8]A)-C#*AMWE!K:YS0/%=,P;<_MV
ME.T<;99U['(<*L>Q!>6@H-RD@KIBL]P=NCN>364/J<R.#DR.9S/90R8+VUB"
MC<56A$!%:+8B-%2$9BM"0T48MB(,5(1A][F!C6[9BK!0$9:M"`L5X=B*<%`1
MGLT=#[GC)Z5R:D(?5]^&/K\;NGSNO#R-=,Y.#@X.VY\.^I/=Y+#'A:TK@;H2
MMJX$ZDJS_:"A'PP].C`[AMWE!K:Y9?O!0C^X28%\S0,6')/]I)TUY)?^\?Q@
M?CHL3Y\0?9H]_FDX_EFV&"R\.XX]43@\4;#5X*$:%I-FIPZ[^E,3MNTYQ.,I
M--BP$P,#PP8>Y)VP72G0E9KM2@U=J=FNU-"5AAT=`[-CV:ZTT)5N4E=>HVXX
MA<JDY+NB'('6-&P&&@A!R[:FA=9T;&LZ:$W/SHZ'V?%L27@H"7ITT&C!9B!$
MH+#U*5"?PM:G8'VR]\K`S3+L'!N,0#9S'&2.8S/'C<PI7_US;OD'``#__P,`
M4$L#!!0`!@`(````(0"+JQU^0`4``-D3```/````>&PO=V]R:V)O;VLN>&UL
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M!%22P6!<E7-5@0HYW\62OD-E9M#<;`HR#1:_.262H85I_FP7"0W^^(YHSAFN
M$_I[\#X5#`;G-.W+?-5+)L7/)O\:]F:;JF)Z:]=I)G!*1'_G<#CIZU#DJ^;^
M:_E(2=FNM9#Y9Z8?N$$=!V"/8'N[-$IO\98('^T!>ZNI5FG*EUOBW;0)]/]&
MK&T,J!*CBL?KC$NA=#[CQ493\GQ1A@HEK"AB&GJ<WG!6N_]'($./R!O![D5I
MD_P_6_SH@4;E,U9RZ_L5/C?#J/<@657BQ6U;.:@`&*K\M`,(-QPD,O20)'R+
MAY4JYU1U\TLRSSC^(XBA1^(-%719\\;X<U66[%[IEJ?3I<9,_X@DAAZ*31!G
MY*.=1D7;3]VH@!D'R""5XU[UNZ9]K^+Y'7MVYGZ`Q$4><3.^M*300JR5MN;A
M`Y&\R"-OQDM>V,7[=\.TX;K<YE="4M$5K,PO4`?9BSSVAI,0<_D`,8P\#(>S
MT!%"/B./SRX-R<W[TK43B6SW3BR20]F8WZ$GB&3D(=EFU)['(XS1'AB'$LMQ
M`&F,]M/HIH0?S!2!C#T@AS,#@YG2H*NNL<^HS4\_-?8$A,#&'K"8(7MN1DIC
MCU(O4?8H()ZQA^=POCA^()[4:O4R?3AAR(-N)YXBK;%?/P>W+4<(<8T]7(<S
MCXSM(HH18!KTIC8L1/YV0E-'R`-XE\*[;Q?<,$&-]$X#DR#Q`!Y,YEO0H>87
M`$X\@`>%3D$H08!IT'-GWRZ=G\[I3$#G!X8ZR'+BL?Q27;H[2VBV90XZX00S
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MM>>X8!D"38/>Q/RF`UW"B2'0F0]TO\NG?I].FAN>WV_SOU''F9</]&#+CRF?
M(=$TH(F-FWV7WOP4K"SHE93]:-[I)&G6'DS&KV_E3GX!``#__P,`4$L#!!0`
M!@`(````(0"WZ]OBM@4``$D5```8````>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&ULG%A;CYLX%'Y?:?\#XCW!-N8VFDQ50-VMM)56J[T\,X0DJ"%$P'3:?[_'
M'`=\S,X,LR_MQ/Y\^,[U`]]_^-Z<G6]5U]?M9>?R+7.=ZE*V^_IRW+E__?EI
M$[M./Q27?7%N+]7._5'U[H>'GW^Z?VZ[K_VIJ@8'+%SZG7L:ANN=Y_7EJ6J*
M?MM>JPOL'-JN*0;XV1V]_MI5Q7X\U)P]P5CH-45]<='"7;?&1GLXU&65M^53
M4UT&--)5YV(`_OVIOO8W:TVYQEQ3=%^?KINR;:Y@XK$^U\./T:CK-.7=Y^.E
M[8K',_C]G<NBO-D>?RS,-W79M7U[&+9@SD.B2Y\3+_'`TL/]O@8/5-B=KCKL
MW(_\+A>!ZSW<CP'ZNZZ>>^-OIS^US[]T]?ZW^E)!M"%/*@./;?M503_OU1(<
M]A:G/XT9^+US]M6A>#H/?[3/OU;U\31`N@/P2#EVM_^15WT)$04S6Z11MF<@
M`/\Z3:U*`R)2?!__?Z[WPVGG^N$VB)C/`>X\5OWPJ58F7:=\ZH>V^0=!7)&:
MC`AM1`)[O2^V(@YX$+YMQ4-&HX-Y,10/]UW[[$#5P#/[:Z%JD-^!Y9MGR&/R
M]257@9XR\E%9&6V!%SWDY]M#+.^];Q#24D-2A$!'3!!.$=D-H9Q65G-CP0.Z
M$V>(A,W9AYS^=S9N%-4A2C$2E$"ZA%B(;(GP&362+R%Q,$&(&SYUXW7Z"@QE
M8X0O#B>S8[A2A,BQ:%3\,GLA-Q8($TB\&=#7F2CPS@4WIT3&D<4$(=%8"`(*
MU`ZCN2]E+"U/<G/?#_PDF>P3VM`[ZVDKL$4[GLQB`!$B1]J^F!\Z[F:X&XZ[
MG$OK<&YNRSB:RY]0#BEEU6YOEZXZ9%&WR*4(07*")[Z5D8SL"Q;,)8FM9NYS
M%B5S;Q+ZT?^AKPY1^HG5-"E"=&P#7\26?YD)B%ELMVYN[ON,B]E_PE\)LC'M
M7B]T!;9XSV'!BD&(#CMC$9N?BT5C`J!F$F%9R$U`S/E+@4_>0UR!Z:Q(K`Y,
M$6+,"GLA-Q9("#E,VO4Q'-%6$'VK[31&1S$.?`N0$8`?!\RJCIP"F!1S<U+N
M2E%6YY^C_IB3+IG;&@M`8W3ERBCR+41&$0ECW"K^G")D'$9S=U+Z2EO6TT<E
M(O1GPYH^8I"^9(FP`!FG`&A-FKR<`GC(9_\I=Z4]Z[FC4A'NEDBDW%`S;+;%
M2JY7='I>#JP2G/7D4)X(.:OO4XX87=,\XG8'9A01)BRP1P-%".$;-FALE?:L
MIX]*1>C/_:+KPE2S#0^E\0ZC8TT1@O'%FY!Z0X8YA#'8<,D!-%4/=4#)SWH'
M4*P@_=,;B/&&H!U`C#'@N+V2FRN4CE*3]710>\QX<F;U>,I-@=KP*`ZM&999
MB%@&UAC,+40`<O)".)6H&/S7O65PE"+JQYPP'5=3KS:"Q;%5.IDVH[,.5;N<
MUL0&CUDP=P_-@]*@]_N!RD7]L,96RF_R-GZK&$-+5S=NZ[G!Q3S4QOU<'\=]
M>%6<@T`<$._2RA%-M9(SJPA2#=+A]:-$6HC,0B2A/[-#]A:"">-EEO*W]')=
M(8FE;G)F13#5(.U'($W-QAQ0!`^2*%PX@D_21F#*2OE"2P@H![.47G_S&]%V
M)BQI3#4(/Q<V`;=*+-/[2$X(:9W/R7G)9GFC*7B7;HJE;G+#\AC85(/P\VP#
MGU=\?K8./9K1"!ZJZ3Z-&EU#%!+QV/BFH!Z\2US%4ESA>X0^/-6@9/P6V["M
M7,0>K6@`WUK5EU,#?#OGAE)7"F8-(`EK;U0/ZAX=0%;IINK*9A)'+L(XLB*<
M400/HL6[EX60L9AE!_W`&RV\\&FJ[EAEU?G<.V7[I&ZK.,1O6L6;M!1NTL9K
M)V_:@(NL:W&LOA3=L;[TSKDZP%&VC<"!#J_"\,?07L?[E<=V@"NL\<\37%E6
M<!/!M@`^M.UP^Z$NVZ9+T(=_`0``__\#`%!+`P04``8`"````"$`HW\;+?,#
M``#H#0``&0```'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R4EV^/HD@0QM]?
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M?U1I\E=:"*@V]`D[L)?R!:W?$I3@8F]P]7/3@;\K)Q&'Z)S5_\C+GR(]GFIH
M]PPRPL16R3L7*H:*0IB1/\-(L<P``#Z=/,6E`16)WIK_ES2I3QMW,A_-@O&$
M@=W9"U4_IQC2=>*SJF7^DTRL#45!_#;(%.C;\_[(7\S8;'X[BD=$38(\JJ/M
MNI(7!U8-W%.5$:Y!MH+(76;$T>?ZJU0A1PSRA%$V+BQWR$)!?UZWP8*MO5>H
M:=QZ=D./Y0@[!Q80PW)-\("WAX92Z-`?MZ%C0S.R=5%W)$#L'M8W4<.A8S(V
M+7QH6<QZBP$[>006S;`Z-+9@8='MR#/M$PIM@6N"@0(-OK]N:-ZXD&=?IF`Q
MZ5-L&K0C3]!T?#(=XY_I"'7'E'W@X+K#7YH.@QX>%9T>E^KTEP]AUWV\R,YB
M:C+NR#-OLF!S"Z%)-"3+M>9<$PS(N0GY^=)$LPUW74548O)<[QS:`M<$`R5X
M!`7-MQ8>>3046^":8*#@BU";,I]7!<UV5>96R\@S;5IF+[E/SO'N'$Y[?:(L
M'P%$LPT86(#DT6IE"UP3#!0&KZ?[B]6X;S6N-6DT`X7KBLF#4UAK'CYW$V#\
MO(F,9K<Y/A96D5I3^^0UC[[=S-9R1>>Z8H+B3'X<E":Y";JT0<ETI0B9K7!=
M,;EP'&M<-PI'PQL^M;EKOP*8-N%I0`T4KBLF#TY<C>?.AM*<-NLT:"B9J*$S
M<Y:WG.2X5I(S33$Y<<8^SDF3V>!<6JMJAYLW>(2O%.%`X;IB<N'`U;AN])/&
M\XU^:C.\K9.M<*8I)@].78WGSG[2K#;JM!CTDTST@F<?-U2;^0TZ[L3[XA(H
M;:QIWYF+ZBA"D67*B>49-\T^3/%>[3?T3SYN<"Q]AQM]U+W^!.RSR^@HOD?5
M,2V4DXD#A!R/`NAP13MU.JAEV>QV][*&'7;S]02_J`3L,\<C,!^DK+L#O$'_
M&VW[/P```/__`P!02P,$%``&``@````A`&G-82V("```"2P``!D```!X;"]W
M;W)K<VAE971S+W-H965T-3`N>&ULG%K);N-&$+T'R#\(NH\D4M1FV`Z&[.XD
M0`($098S+=&V,)(HB/1XYN_3S6J2M2@4:1^\/+XJU^NE7I/B_4_?CH?1U^Q2
M[//3PSB8S,:C[+3-=_O3R\/X[[_,I_5X5)3I:9<>\E/V,/Z>%>.?'G_\X?X]
MOWPI7K.L'-D,I^)A_%J6Y[OIM-B^9L>TF.3G[&2O/.>78UK:/R\OT^)\R=)=
M%70\3,/9;#D]IOO3&#+<7?KDR)^?]]M,Y=NW8W8J(<DE.Z2EK;]XW9^+.MMQ
MVR?=,;U\>3M_VN;'LTWQM#_LR^]5TO'HN+W[]>647]*G@]7]+8C2;9V[^D.D
M/^ZWE[S(G\N)33>%0J7FS70SM9D>[W=[J\`-^^B2/3^,/P=W9A&.IX_WU0#]
ML\_>"_3[J'C-WW^^['>_[4^9'6T[3VX&GO+\BZ/^NG.0#9Z*:%/-P!^7T2Y[
M3M\.Y9_Y^R_9_N6UM-.]L(J<L+O==Y456SNB-LTD7+A,V_Q@"[#?1\>]6QIV
M1-)OU<_W_:Y\?1C/EY/%:C8/+'WTE!6EV;N4X]'VK2CSX[]`"GPJ2!+Z)/:G
M3Q(L)E&X6*V'9)G[+/;GQTN)?))EDR0()^%Z$2R6MP5-87"JL59IF3[>7_+W
MD5W`5GYQ3MUV".YLYGJ084B:8?^_4;?#[9)\=ED>QG;GV0$M[%+Y^KC:!/?3
MKW9ZMYX3`\=^;SGADG(2F8=E437#S;?[UYH#!H!J&J=69*/43B%6>GT9U8(<
MV0FJ_TT,@,W=5K\)6?62PQA*,N8SFD1+RGI!*492EJ@6(MJNN/ZB'=GN$J)Q
M3O]W#)RH&9B$`XH#F@,&`:18N\+[%^O(#V,[%.V$L-44`P75"L"R6J#!#+ZH
M/G6;HGE:@P"BQ[:9_GH<F>EA\QX#!>D!8`-Z]*>(:>F^K'DZ@P"BP_:%_CH<
MF>E8T;IBH"`=->`:!]L/JN.:KJ_5N]0@@"A8#5'@R$S!FBD`"E)0`]<4=%S3
M];5&`0*(`G>J07VZNWLY,E.P80J`@A34P#4%'==T?:U1@`"B8#-$@2-S!6QY
MQ\!9P>H/5O9X9K^HS`0XK4S%`<T!@P!2?V!/,/VGH&)S!7Q#>U);7M(@UZ:A
MN5B/M1:(P0@MW_EB[Q44@(OB]KIF5AQ[#JX>HJ#!SJ&_\BE1/JR3I$5N@Q$J
MS-DA$N:.,',[5]U;)``3Q0)7&VX@GH050MAJ5JVZV81%*!&A!6(P0I4X8QRN
M!.R4*N$M-T">6YV;$H_`-&RN[!U%&-XNZ?;2A'(MB<'_F(IUKCE<+'@M%<N[
M<X`,V8NM$71:V+"6J$28%HC!")7CS'.X'+!<+&?--TSL;GIL,\2KL$9:.>L9
MVYY*A&F!&(Q0.<Y)A\L!_Z5RV!DX#I!)^]FI$2R''3R5"-,",1BA<IRM#I<#
M9DSE<!<*D&-[.1Q1@J,%8C!":W>&BFJ_T=?`?NUV;\_%&S:6<8`\VM?,$24X
M6B`&([1F9Z*HYIX]&:R7CK?P3.3/OG9`H),MP'9HGU(!#](",1@A8D)F_$Y,
M9'=@]T144?0`L)XQNX@]"6WM!G$'@&#"U*OF<G,$$(C!"!7"C@#]9B6\<A28
M<7_Q)"P$PFSC;1;B>L8ZM1)A6B`&(U2.72C#%UGHHOB\,"N(/0G+@;`648*C
M!6(P0FMG5G]C+8%[=V_J$$AMA8E`E$"T0`Q&:,W.1`=OZA"LEVSJ@!W38T_"
MM4O'7@?<XD28%HC!")7C3'2X'+!>*H=;G'L>1QU;($H@6B`&([1V9L\WE@_X
MZXWE4YMPW5F2D"-*(%H@!B.TY@]Y<'C%@^7RX8Z;^##2?0)F@ZHAU9*U0`Q&
MJ!QFRSV;*?@L73[\2!%R,TX$H@2B!6(P0FMW=HB6_HWE`^9Y8_EPATU"CBB!
M:($8C)":W2T=KKG?>%=1O-MS\_(DU'T:I,N\&E*S?`1B,$+E,"_NGH+Y%0\.
MV-D@]B0LH_;@ND(E.%H@!B.T9N>!O9?-W+%O/DX&$JZ9(\HG:CE:(`8CM&;G
MBOUK!@^U);2'EH`?VN9`:NM)&N3:4YNNB[KKHFDNVNFCHC[DQ/-K3BSV0NV[
M]9))?%@K5PE$"\1@A-;.;/?&P@<G[>X]<V&W`E$"T0(Q&*$U#[+;.?@F743T
MAB3VG'90$X_`74RXN/9`1@1I@1B,4`W,?F^,^S7;9:?W>"YLUR/-XS'^T942
M(5H@!B-4`K/<&Q*DU2[78KD+JYUS1`E$"\1@A-8\R&KG?:S6D_#:$58K.%H@
M!B.DYNA#5EM%,:L-^(V5)Z':/=(^#J8[18D(+1"#$:J$N6R_0T-TQ6U#?LOB
M25B)<%O!T0(Q&*&U.R/L[5P1V&9WH_0D7#.$M8@2'"T0@Q%:L[-&5'//\09#
M)0TS9/=Z<02DMM+$([!R@MD\6@41FR4EHK1`#$:H&F:SW?TFNF*O(;\S]"2L
M@ANN$APM$(,16O,@>W6/L6Z>T3P)U\P-5PF.%HC!"*UYD+U&TEY7O*U[#BX9
MHB+XW(;WF(Z+6N0R'O$M"SX9:3)298-,-Y*F&\B^(TS7A[5BE4"T0`Q&:,V#
M7#8"N[S1=[BG)CX,U\PY6G`,1FC-@UPV`KND_::9P.JA<NPY,,>;U<H=R"@E
MN4U1GM+*U`(Q&"&B%A^RX2J*V7#(GGS$G@3JEE?.FHEGM)4K@6B!&(Q0+1\R
MXL4U(^9/2SP)W@.HYDG,E*=@,=RKM>`8C%`QSC0'NYQ]5U(\>`[Y/;PGM94F
M'H&I"B/[&<)BR:*4B-("<:]J-L\D00V\>0EO`QZSRTN69(=#,=KF;^ZMRM!V
MR@9MWOC\7+WPR?`DN-/POEUSP;Z(>4Y?LM_3R\O^5(P.V;--.9NLK'%<X%5.
M^*/,S]4[B$]Y:5_!K'Y]M:_<9O;-OMG$DI_SO*S_<'?!S4N\C_\!``#__P,`
M4$L#!!0`!@`(````(0#K>%-'.`,``)@*```9````>&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;)Q676^;,!1]G[3_8/%>P)`0B))4S:INE39IFO;Q[(`)5@$C
MVVG:?[]KFY`"J8CZDH1P[CGWWG/]L;I]J4KT3(5DO%X[V/4=1.N49ZS>KYT_
MOQ]N8@=)1>J,E+RF:^>52N=V\_G3ZLC%DRPH50@8:KEV"J6:I>?)M*`5D2YO
M:`UO<BXJHN!1[#W9"$HR$U257N#[D5<15CN682FNX>!YSE)ZS]-#16ME200M
MB8+\9<$:>6*KTFOH*B*>#LU-RJL&*':L9.K5D#JH2I>/^YH+LBNA[A<\(^F)
MVSR,Z"N6"BYYKER@\VRBXYH3+_&`:;/*&%2@VXX$S=?.'5YN\=SQ-BO3H+^,
M'N6;WT@6_/A5L.P[JRET&WS2#NPX?]+0QTS_!<'>*/K!./!3H(SFY%"J7_SX
MC;)]H<#N.52D"UMFK_=4IM!1H'$#DT;*2T@`/E'%]&A`1\B+^3ZR3!5K)XS<
M^<(/,<#1CDKUP#2E@]*#5+SZ9T%8)]61!"T)?+<D.'"#>([GT32+9S,R!=X3
M138KP8\(I@8T94/T#.(E,.O*(NC/Y<H@&QUSIX-,**`EV/&\B8-HY3U#"],6
ML[486`$=)N@0'HAW&8#J,(-P,@,=U,]@<:8W26XM)#;&OM4+QWJS=[T\5:R#
MP+4WU<3!HJO'"EK,;"0X&PM.%ZB#U@[4T+4O#N*!H,5$QH``)\F\>]]K,!0W
M;/"TQ3IHJ)]T_+9@BVGU8WPVH"<?C>6GR]=!`_G0'\A;3&+*Q[[[3O6+C\CK
MH*$\'LA;S-ANO>D/5M3T?.F@J?FRF+%@,A:<;K`.&E0XFB^+L?[B./+/'>@9
MC&&U#BN>'C`3-<Q@.&$M:&K$\(5=;+H%)FJ0P6C(6E`W9=%Y$?:;<&$;F[8=
MVTVJM\S#\SJRRZP%C8W'']K*3-34K+6@"YH?VLWP-=M9"[)FAV$RZQ9<O],7
M]K,KS+ZPH8W-MB!K=N+.ST[8#.P%P9Z?%15[^H66I40I/^C#'\-.U/UK+R9;
MN)@$YD#H7L"]H"%[^H.(/:LE*FD.H;Z[`&EA;Q;V0?'&''`[KN!&8'X6<`.D
M</["7N>@G'-U>M!WE^Y.N?D/``#__P,`4$L#!!0`!@`(````(0`$A`A/\@0`
M`*$3```9````>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;)Q8VXZC.!!]7VG_
M`?$^`7-)2)1D-,'JW9%VI-5J+\^$.`EJP!'0G>Z_WS+%I6QF.I.\=(?RJ>+4
MQ578Z\]O16Z]BJK.9+FQV<RU+5&F\I"5IXW]S]]/GR+;JIND/"2Y+,7&?A>U
M_7G[ZR_KJZR>Z[,0C046RGICGYOFLG*<.CV+(JEG\B)*6#G*JD@:>*Q.3GVI
M1')HE8K<\5QW[A1)5MIH857]C`UY/&:IX#)]*439H)%*Y$D#_.MS=JE[:T7Z
M,^:*I'I^N7Q*97$!$_LLSYKWUJAM%>GJZZF45;+/P>\W%B1I;[M]F)@OLK22
MM3PV,S#G(-&ISTMGZ8"E[?J0@0<J[%8ECAO["UMQ+[2=[;H-T+^9N-;DMU6?
MY?6W*CO\D94"H@UY4AG82_FLH%\/2@3*SD3[J<W`GY5U$,?D)6_^DM??178Z
M-Y#N$#Q2CJT.[US4*404S,R01BIS(`!_K2)3I0$12=[:_]?LT)PWMC^?A0O7
M9P"W]J)NGC)ETK;2E[J1Q7\(8HK48,3KC`3`OEOW9EX4LG!^VXJ#C%H'>=(D
MVW4EKQ94#;RSOB2J!MD*+/>>(8_!UQ^Y"O24D2_*2FL+O*@A/Z_;R/?7SBO$
M-.TP.\3`EA@P3$?$/4)YK<QR(G"`[T`:0F&2]B&IWT]'SU$IZ1R]I4Y@]QV(
MCHBG"-_5(7P*B<(!HKGA/^*&4H+Z(6&,_&"PW\9MAYB@+1\5R-@4<"+0*$$)
MW!]9I;2QP>\ALTLC*#N$+-K28*'O14;H8PJ(W&CAZ2YQNNZ[S%L,ZQI_V$XF
M__G-RE!*.O_('U.&(44,":DIX$2@49I/*=TN5J5T*\N((91,`2<"C=+B$4I*
M28_2),L(F6.6W=!US1U.`5[HLOF01=SPN!ZT!L*Q1#3R:J@:'>MV/)623C[R
MC9?O$$/B:0HX$6B4EH]04DJW4HP80LD4<"+0*#&H^OO#U&KI<9HDN<-T6?:B
MP-@JL0Z(_,C<RQI@P8(Q$;H+JOW?G6F&0X-VH\@?NP7NY@Y$`CN1<"K1>:D.
M?S\OG`L?-VZ&(,K+E'"*T7FIIGX_+QP%\)H?=V^&F'YC>V&D[]M8!RS<2<:I
M@;GGC_JZ!ZK+W^\!S@;J`12=SG#'$$0C:THXQ>B\5&^_GQ=.!'!]B.QT5*O/
M2&@#E)<IX12C\U(-_GY>.!9HO*:;'#&8<6CDQCR/F;YNCDMNK!-]W0'5\`T'
M`O#_XR\YAF.".A#YX[3HMG@_2_JOR;A3&T/-J43GI3J]P>OVD&$X'VXDG`R1
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M&GEIC^U[V<#52/OS#%=A`LZU[@S`1RF;_D%=X@R7:]O_`0``__\#`%!+`P04
M``8`"````"$`6-#0M1X/```280``&0```'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6R<W5MOV\B6AN'[`>8_&+[?MG66@R0;;=:Y9H#!8`[7CJTD1MN682F=
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M?KW]\M@^[S]'T]N[MVWOOL#FGQ[N7M>;]=?M1;NYR_1`^9RO+Z\OVRU]_GC_
MT#Z#+O:SU]773^>_C3[$Y?C\\O/'74#_][#ZN2G^?K;YOOYI7Q_N_^/A>=6F
MW>ZG;@]\6:]_[TK]?4?MX$N,-KL]\%^O9_>KK[<_'K?_O?[I5@_?OF_;W3UK
MGU'WQ#[<_Z56F[LVT78S%^-9MZ6[]6/[`-K?SYX>NJG1)G+[Y^[/GP_WV^^?
MSB?SB]GB:C)JR\^^K#9;\]!M\OSL[L=FNW[Z_U0TRIM*&QGGC;1_YHV,YA?3
M\6RQ_)6M3/)6IOU6QA?CY6PTF__"8VD?]>X)M7^^/9;V81WY1.9Y</OGV^`3
MGL@B;V74[<V<U^S7\QB][YOV+V_;.?[A7*8]O9LXZG9[^_GCZ_KG6;L:VZUM
M7FZ[M3WZT'V/MRF3=O#[)/J[.=1.GFXKOW6;^73>'D?:Z;%I)_X?GY?3\<?+
M/]K)>I=K;E)-^_M[S:BN:+B5^7Q2UZBWFF[V=M]:2S`)VM__[OM85N#[.-8L
MI^*Q>-8LQO/Z\0;68#N1-7TRE^V.>M];[>2M]M;PPG[;*5UUMU/>HKI)T'ZW
M]V3$/FI8L9Q.ZV>DAFIF=8T>JA')F*&:1;T=RQKQ:!PK\(C]4,VR_DYAJ.:Z
MKHFLF5R]EU0[JCU\53NJ6U:3]@BP?X=UH]JZ8O\L9_TWV$WWFU0S?=^IC00E
M04LP$JP$)\%+"!)B`544[1'\A"BZ49_.V\#?IVI[['_/.D61:A:[P\UH<C6Y
MZG[5-4VJZ>-2$K0$(\%*<!*\A"`A%E"ETYZ93DBG&R73$4OY)M7TS[R1H"1H
M"4:"E>`D>`E!0BR@BJ(]SYX013?JT)I)-444$I0$+<%(L!*<!"\A2(@%5%&T
M30.BF!\\?'2CY*P0IZR;5#-/:V:Z6S%8,ZFFCTM)T!*,!"O!2?`2@H180)5.
M=[DB>Y;#!]=NE$Q'G$QN4DW_S!L)2H*68"18"4Z"EQ`DQ`*J**Y/BJ(;=6C-
MI)HB"@E*@I9@)%@)3H*7$"3$`JHHN@8;T^+PHMD-D_-"KII<E)=-7C7R5).+
M^L@41$,,Q$(<Q$,"))92)]7UF[^^@+K+`ZP@T?C=Y*(^A`:B(!IB(!;B(!X2
M(+&4.I:NO3LAEM05MNU/T:J(N7$S2D5E+%(4:C3$0"S$03PD0&(I=2Q=8R=C
M.6)=I7ZP?99%+%A7J2BMJ[\Y&XU231^=@FB(@5B(@WA(@,12ZJ"Z'D\&=?B\
M-$JM81V4N%:ZR45]"`U$033$0"S$03PD0&(I=2Q=OW="+*E-;'=^,7^PK(I>
M<G=-T'2WN]J#5!^4@FB(@5B(@WA(@,12ZEBZWN^$6%++6,\6<=5\,RKZRAQ+
MDK30)J-T!JLOE11&:8B!6(B#>$B`Q%+JH+HVL`QJ_S7T*'6-=4#B8O\F%_6S
MI($HB(88B(4XB(<$2"RECJ-K!<LXCKNU,$H=Y('E5+29>=Y(47E#?70:8B`6
MXB`>$B"QE#J6KBTL8SDP2U(76<Z2T12S)!6]=7V+W:JI%TTS*MK1760*HB$&
M8B$.XB$!$DNI`AK+]GA_0+MRV1:+^V$WN:B?"PU$94DACE.&XC"N,<I`+,1!
M/"1`8BEU0*=UQ>.!KG@NGN!-+LHS:3D?FDFYI@]3033$0"S$03PD0&(I=5#M
MJJF66G<$FK;GW0,SJALF9M1<WM(;IZ(^A`:B(!IB(!;B(!X2(+&4.I:N3RV/
M0,<=F,>IO=U_8,Y%92QI6"\*-1IB(!;B(!X2(+&4.I;3NN+Q4%<L^YQ<U(?0
M0%26?/QI7Y#N?M4'<8U1!F(A#N(A`1)+J8/J.E<Y?XY85JGA+<]DR[F\%]R]
M9%IUQ0U$033$0"S$03PD0&(I=2RG]<GCU/`>6%;HD_.P?D8IB(88B(4XB(<$
M2"RECD5VQ4<>;8:Z8RRK5-2'T(REJ"QI6<V&5Y4<9+`9"W$0#PF06$J=DVR7
M#YRD4K];KR9YUV(LF^(&HB`:8B`6XB`>$B"QE#H.V28?.6U2EWM@-<E6N!E+
M41`-,1`+<1`/"9!82A5+=Y>F.O;NGR6[\KJ5X=5#+LHK)%URU^>=)I?T"TU!
M-,1`+,1!/"1`8BEU/J?UQI.!WG@B;VWEHCZ$!J(@&F(@%N(@'A(@L90ZEJY;
ME:?L+L0#TR<UN?M7TR05E;%(4:C1$`.Q$`?QD`")I=2Q=+UI&<N!.+KR@ZLI
M%:75-!V\@)JDDCXQ!=$0`[$0!_&0`(FEU/G(EOA`/@.M\%R^<CE)1?V3;R`*
MHB$&8B$.XB$!$DNIXQAJ?(]81:FG;7?ZGAO$$S2^$`71$`.Q$`?QD`")I=2Q
MG-;X3E)/VQXKBECD978NJKHW<5'4Y)I^1BF(AAB(A3B(AP1(+*4.JNLS?^%P
MD]K2,J"!DW<J2@&-KY8#5XW-1/:W"J(A!F(A#N(A`1)+J0.2/?!Q3=]DJ!>6
MK_?FHGZ6-!`%T5E2O/G5"#'_#$99B(-X2(#$4NJ@AKKCPY?@D]3FEC-J.4>;
M(WOA)@_KHU,0#3$0"W$0#PF06$H5RU1VQ\?-G]VP0V\SR45]"`U$033$0"S$
M03PD0&(I=2RG-<73@:9X)B_!<U%:(.F-C?*N59-K^N@41$,,Q$(<Q$,"))92
M!]4UKN4!^LCYTPVK^\+E'$&EHGU'DF:::LJ@I&C4&(B%.(B'!$@LI0ZJZV!E
M4(>//]/4^+;/J3_ES^6+6;FH#Z&!*(B&&(B%.(B'!$@LI8Y%]LM'SI_4$N]O
M$*?HFR$*HB$&8B$.XB$!$DNI8SFM;^[FDUQ6//Z@;\[#^OFC(!IBLJ3E.?P&
M'XM1#N(A`1)+J8,ZK9.>#G32<_D2:"[J8VD@"J(A!F(A#N(A`1)+J6.1??.1
MRRJUO0>6E>R-FZD4!=$0`[$0!_&0`(FEU+&<UBU/![IE_L1"*DK+X3K=-A?W
M!/-V^@FE(!IB(!;B(!X2(+&4.J>A9OGP9?MTH%GFX0?-<AY6QB)K-&H,Q&;)
M_<+U8K</ZEW@,,I#`B264@4UD^WS_ML]N_*Z[>'U:2[*3V-Y/71]FFN*R"`:
M8B`6XB`>$B"QE#J@H4;Z^N!MU-E`([T05Y$WN:@/H8$HB(88B(4XB(<$2"RE
MCJ5K4F4W>'B!S5)ON__XG(O*6&1+K%"C(09B(0[B(0$22ZECZ;K=$V+IAM7+
M:HGCSBP5E;%(4:C1$`.Q$)<E+^'QX&NH'L,"))92)W5:WSQ++7%U.;&0=Q!S
M49F4[*05:C3$0"S$03PD0&(I=2RG]<VSU!*W\Z&_RL)/9^:B,A;922O4:(B!
M6(B#>$B`Q%+J6$[KDF<#73+752HJ8Y&B\H;Z&@TQ$`MQ$)\EK;3\#D1QG@@8
M%4NI@QKJFP__0,0L-<#5LIK)MQ;DHGQ0&+Y@:G)1GY2":(B!6(B#>$B`Q%+J
MI$YKI6<#K?1"OJ4I%_4A-!`%T1`#L1`'\5D65[L?I+RZN!(/+V!(+*5.Z;1&
M>C;02"\PGV23W.1A?6X*HB$&8B$.XK.\IS01#R]@2"RE2JE;8"><]G?#Q&E_
M(5\\S45])@U$033$0"S$07R6M.8G@WU`P*A82AW44#?=5>^_[)@/==/RU9Y<
M5`:5AO6B4*,A!F(A#N(A`1)+J6/I^MM?;QOGJ2W>?];/17T(#41!-,1`+,1!
M/"1`8BEU+%U_>T(LJ2VN3F8+^9+7/!65L4A1J-$0`[$0!_%9]B\K^7ABN9TZ
MJ*%FNKOE>&!9#373\D6,N6R=&XB":(B!6(B#>$B`Q%+J6$YKIN?'--.YJ)P_
M:*91HR$&8B$.XB$!$DNI8QEJIH\X"`\UT^*D>3-/1;F='3Q?-+FFCTY!-,1`
M+,1!/"1`8BEU4$/-].&;'/.!9GJ"996*^A":/*P7!=$0`[$0!_&0`(FEU+&<
MUCG/4^?<'M7V7*/FHCZ$!J(@&F(@%N(@'A(@L90ZEM-:Y?E`JXQ[\[DH+:O\
M<R+B*K')-7UT"J(A!F(A#N(A`1)+J8)J6^[ZM+[_++4KK[MDWG/.1=-TR5/?
M,V_>__'MP\841$,,Q$(<Q$,"))92)R/;XP/)#+7%\K7U12I*4R>]5TS.G%Q2
MS!R(AAB(A3B(AP1(+*7.1_;)!_))_7'=",H721>IJ'_R#41!-,1`+,1!/"1`
M8BEU'%V'^.O]\2(UEOL/Q+FHC"4-ZT6A1D,,Q$(<Q$,"))92QS+4#1\^;2\&
MNF'<+,Q%?0@-1$$TQ$`LQ$$\)&1)JSNW6V)YQW)4'93LCP\LI]3@ELMIX$"<
MBO*9ZCJ=J^3Q&)WR0HJ&&(B%.(B'!$@LI0YHJ%,^8B8-=,I3L5=N%JFHG$E2
M%&HTQ$`LQ$$\)$!B*74LI_7%B]3R'CCNH"_.P_J@%$1##,1"',1#`B264L<B
M^^(#RVG@3O(2LR05]4^^64A1$`TQ$`MQ$`\)D)@E+?BY^!R*.A_9(!_(9Z`Q
MGLJ7^A:IJ,Q'BD*-AAB(A3B(AP1(+*6*8RG;X./>XK0;=NB=R[FHB`6B(!IB
M(!;B(!X2(+&4.A;9`Q\9RT`OC,NH9=D+SR:#/SF1:_KH%$1##,1"',1#`B26
M4@?5-:YE][=_.;6?[8[W&"SDQ4(N2A];F]ZX(XY(32XI\Y$=M$:-@5B(@WA(
M@'2?6=\]K]WC2?FDCZ!/GR3^M'K]MFI6CX^;L[OUC^[CY<?M)>*[OG_T_6^[
M3[X7WHP^Z-WGQU^^_T/[B?0OM]]6_WG[^NWA>7/VN/K:;O+JHNL@7M-GVJ<O
MMNN7W>>7?UEOV\^BW_WU>_M_#ZS:#P6_NFB+OZ[7V[<OVJO2R_?_S>#SOP``
M`/__`P!02P,$%``&``@````A`,*/(&J2`P``N`L``!D```!X;"]W;W)K<VAE
M971S+W-H965T-30N>&ULC%9=;]HP%'V?M/\0Y;TD#I`/!%2%J%NE39JF?3R;
MQ"%6DSBR36G__:YC2.VD`UZ`7!\?SKW'OKG+^]>Z<EX(%Y0U*Q=-?-<A3<9R
MVNQ7[N]?CW>QZPB)FQQ7K"$K]XT(]W[]^=/RR/BS*`F1#C`T8N664K8+SQ-9
M26HL)JPE#:P4C-=8PB/?>Z+E!.?=IKKR`M\/O1K3QM4,"WX+!RL*FI&498>:
M-%*3<%)A"?I%25MQ9JNS6^AJS)\/[5W&ZA8H=K2B\JTC=9TZ6SSM&\;QKH*\
M7]$,9V?N[F%$7].,,\$*.0$Z3PL=YYQXB0=,ZV5.(0-5=H>38N4^H$6*IJZW
M7G8%^D/)41B_'5&RXQ=.\V^T(5!M\$DYL&/L64&?<A6"S=YH]V/GP`_NY*3`
MATK^9,>OA.Y+"7;/(2.5V")_2XG(H*)`,PGFBBEC%0B`3Z>FZFA`1?!K]WVD
MN2Q7[C2<S"-_B@#N[(B0CU11NDYV$)+5?S4(G:@T27`BF8'ZTWHP">(YFH?7
M63RMJ$LPQ1*OEYP='3@U\)^BQ>H,H@4PGS/3.OI<_Y<JY*A('A1+QP59"/#G
M91W':.F]0$VS$V:C,7`E>LP`L3TC5`$5;6H$/-#;BX92#$5/P=2/[3AK5)ML
MC4$RD/@!Q$9LQXBI;T/2,22>]Q`KC>DXC?!J&FH3G!^CC'$<]/Q=W38:,^N.
MCRKD=AA(C8`E"8Z`6=G+%57@E0OY]H[.9O%`BL9$W9E`D8\B>WUKKT?^8']J
MK8<H>;?,T@W7Z';="FSKCN.IK6NC,48)AX'4"%A20EN*NE'7756;KKFJ,8:D
M82`U`I:DR)9TV54%MJLS=E5C0NTJ"H<7V5H.DH'GJ;4\2\*^])9H]?(T.M-E
MT0ILBX[C6<^K;X7&&/4;!E(C8$E);"FW6:HV7;-48PQ)PT!J!"Q)"!K%[>7I
MT'9]QJ:>0-K5:!X,KN+67D_0L/'9Z[[1E6SEJJO?;"S2[P"SR<1&/]7.GD!&
M'4>1U(S8>E3#-O3<YB[2;?YR'SZ!3%UZVWLD-3&V+M6C#5V7+P",/\,;\('#
M&J2[<3P=.VRMS_W!O58SEOH3O3\*@_=UK5P/4'J^J`G?DRVI*N%D[*"&(P3M
MHH_JP6VC!K=N].H78&YJ\9Y\QWQ/&^%4I("M_B2"=LOUY*4?)&N[M_F.29B8
MNI\E3,@$7G?^!,`%8_+\H&:[?N9>_P,``/__`P!02P,$%``&``@````A`/%X
M"V"%`P``L@H``!D```!X;"]W;W)K<VAE971S+W-H965T-#@N>&ULE%9;;YLP
M%'Z?M/^`>"_7$),HR=0"W2IMTC3M\NR`DU@%C&RG:?_]CG%"L)-U[4N(CS]_
M/M^YP%E\>FYJYXEP05F[=$,O<!W2EJRB[7;I_OIY?Y.ZCI"XK7#-6K)T7XAP
M/ZT^?E@<&'\4.T*D`PRM6+H[*;NY[XMR1QHL/-:1%G8VC#=8PI)O?=%Q@JO^
M4%/[41!,_0;3UM4,<_X6#K;9T)+DK-PWI)6:A),:2_!?[&@G3FQ-^1:Z!O/'
M?7=3LJ8#BC6MJ7SI25VG*></VY9QO*Y!]W,XP>6)NU]<T#>TY$RPC?2`SM>.
M7FJ>^3,?F%:+BH("%7:'D\W2O0WGQ<SU5XL^/K\I.8C1?T?LV.$SI]57VA((
M-J1))6#-V*."/E3*!(?]B]/W?0*^<Z<B&[ROY0]V^$+H=B<AVPD(4KKFU4M.
M1`D!!1HO2A13R6IP`'Z=AJK*@(#@Y_YYH)7<+=UXZB4HB$.`.VLBY#U5E*Y3
M[H5DS1\-"H]4FB0ZDDS`^^-^Y$5I$B;3=[#`?;TK\#RQ3+U)E*#T#;[X6E<?
MIAQ+O%IP=G"@],!ST6%5R.$<F$_QT6J&B/TK8!`I17*K6'HNB(6`)#^M$$H6
M_A-DICQB[C0&^FK`A"8B.R%4&A1M;AN*:_=,!Q8?-`W"(.BVL!C*YWKB3SK4
M(5-'-!OH>Y_NKD!,1':)B`,3DE]"4BM<Q24D&D@,H;$I]'6!"@PU/$H"0FC@
MU0HU9M*7L$I#9AMRVU",#(9O4/'O3X(ZM'1!_U`H"*66CQJ#^E(+H94B*\*9
M!IQ%Y+:A&!D,GZ$+QCZ_'D\%-GV-(ZNL[S3F[$IF&W+;4&C#]"AO$@1G>8:O
MT_?XJL"VK^>:TKG7&'WQ#1K?V^]G>O^L);<-A<$0`L,_7$>FZ^K%\__^5(=,
M"0C9#:HQ1PE1.(NM^LY,0!0D5NOE!B`,T,S*:&$`D@E*XZ$\C?2H(6+T<GV]
ME!38U!9'=MEKC-86!6EJ[6?&?A0'5FSR\7Z8!HD5FF*\/X7/RN2ZKIFIZVVY
M4X=,?2@]UX8N/XTYM74P05;D,Q-PV?>Y!IP+%(8+=>U52ITK/3OHCV)#^)9D
MI*Z%4[*]F@M"Z,'!JD>6NW`.7R8U=0P;,#)T>$N^8;ZEK7!JLH&C@8>@C[D>
M.O1"LJ[_O*R9A&&A_[N#V9#`6S;P`+QA3)X6ZH)AVES]!0``__\#`%!+`P04
M``8`"````"$`GI.W@.X$``!5$P``&0```'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6R46-N.HS@0?5]I_P'Q/H#)A7249#2$RXZT*ZU6,[O/-'$2U`%'0-_^
M?JLP$+O<TTGZ(9T<C@\^5647>/7UK3Q9+[QN"E&M;>9XML6K7.R*ZK"V?_Y(
MOBQLJVFS:I>=1,77]CMO[*^;WW];O8KZJ3ERWEJ@4#5K^]BVYZ7K-OF1EUGC
MB#.OX,I>U&76PL_ZX#;GFF>[;E!Y<GW/F[ME5E2V5%C6MVB(_;[(>23RYY)7
MK12I^2EK8?[-L3@W@UJ9WR)79O73\_E++LHS2#P6IZ)][T1MJ\R7WP^5J+/'
M$_A^8],L'[2['X9\6>2U:,2^=4#.E1,U/3^X#RXH;5:[`AQ@V*V:[]?V-[9,
MV<)V-ZLN0/\6_+51OEO-4;RF=;'[LZ@X1!ORA!EX%.()J=]W",%@UQB==!GX
MN[9V?)\]G]I_Q.L?O#@<6TCW#!RAL>7N/>)-#A$%&<>?H5(N3C`!^+3*`DL#
M(I*]K6T?;ESLVN/:GLR=6>!-&-"M1]ZT28&2MI4_-ZTH_Y,DUDM)D4DO,AU%
MF'^W"-RNFPG\[V?"9L[4GP6+>Z8R[U6"BXKO^(L9F\VO&W)E<+I81UF;;5:U
M>+6@@,%^<\YP.;`E*`]!EB$9P_ZKJ$.X4>0;JG1:$-`&2N5E$\P6*_<%TIOW
MG-#D,)VQE0Q8OZ/*?#[1.='`P7SCK6-3-O#G^J!D&'01)K=.!P86)$1F#`\4
MCQJ>CVMOB`*2]2BP@$PE-#F^/MFMR0AF#SHG^H`S]W1._!&'V$Y,SH3(I"9E
M,1OOI,4*UHH:*RRE":SZSV.&@X"GY#R8DXB$DC/M%B;F?$N!B`(Q!1(*I`J@
MN8"53ET$O]QUALSCH&ZG&2LWH)4;2@Y\*ISI&,FNF+<#9ZCNB`(Q!1(*I`J@
M&0,3JK'/TX)D:NB2]FZRH>0$7K?>/8<%Q(R\?DE;1(&8`@D%4@70S,!F>+L9
M)%,S=%U*SF6R6PI$%(@ID%`@50!M]K#1JK._;:7@H&LK17(4%Q2(*!!3(*%`
MJ@":"WS0(JWC^GK'0307I'!"R5%<2"#H"HTV!$J.*9!0(%4`S="#;NCS%8)D
M:H2V/,E1C%`@HD!,@80"J0)HLV>PU]Z?CV[4M;+J28H1`XD,)#:0Q$!2%='=
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M^):?3HV5BV<\H?!!=D3EZ<F6+>%=%N9(\`1/51!WQPMPJ''.#OROK#X456.=
M^!XD/0??2FIY+")_M.+<O7T^BA:.,[JO1SB^XO#&Y#E`W@O1#C_P!N.!V.9_
M````__\#`%!+`P04``8`"````"$`"8SAF-P"``#E!P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6R455MOFS`4?I^T_X!X+[=P2:*0JEG5K=(F3=,N
MSXXQ8!5C9#M-^^]W;!-"R-(U+R'F?.?[SLV'U>T+:YQG(B3E;>Z&7N`ZI,6\
MH&V5N[]^/MS,74<JU!:HX2W)W5<BW=OUQP^K/1=/LB9$.<#0RMRME>J6OB]Q
M31B2'N]("Y:2"X84'$7ERTX05!@GUOA1$*0^0[1U+<-2O(>#ER7%Y)[C'2.M
MLB2"-$A!_+*FG3RP,?P>.H;$TZZ[P9QU0+&E#56OAM1U&%X^5BT7:-M`WB]A
MC/"!VQS.Z!G%@DM>*@_H?!OH><X+?^$#TWI54,A`E]T1I,S=NW"Y"0/77Z],
M@7Y3LI>C_XZL^?ZSH,57VA*H-O1)=V#+^9.&/A;Z%3C[9]X/I@/?A5.0$NT:
M]8/OOQ!:U0K:G4!&.K%E\7I/)(:*`HT7)9H)\P8"@%^'43T:4!'T8IY[6J@Z
M=V>IEV3!+`2XLR52/5!-Z3IX)Q5G?RPH[*DL2=23P+,G"2,OFB=ADOZ?Q;<1
MF03OD4+KE>![!Z8&-&6']`R&2V#6F<47,X.4M,^==C*N@);0CN=UEF0K_QE*
MB'O,QF+@!@R8:$#X(#Y$`*K3"&;0H7_7]A"!=CJ-(%H,]";(C87,36/'>K-3
MO;=U-!BZ-<HB2]*)D,7$9T+Q-4(:G+N1*684A,E$PYHS8XZS)!C,)Z6$QHU+
M^79J&CQ2G&9ES:E5G"\N-"^]1E&#1XK3B;%FJY@$LZ/Y),?L&D4-'BG.A[+9
M$;'F7C&<7U#46WQT1=ZNJ@:/%*=#:<V]XBR.AX!.<EQ<HZC!1\7H.!HV1VN.
M;1^3"VV$Y7E%C@:M)8]W>Q9.=7N0'=DH2=.IM-VV=ADQ(BKRB32-=##?Z4T:
M0L##6[OE-[#E(W/+!@,LV0Y5Y!L2%6VETY`27`,O@^$5=DW;@^*=V19;KF"]
MFK\U?$X)++/``W#)N3H<](=@^$"O_P(``/__`P!02P,$%``&``@````A`)%F
MCDS4`@``;`<``!D```!X;"]W;W)K<VAE971S+W-H965T-#`N>&ULE%5=;YLP
M%'V?M/]@\5X^`TE02-50=:NT2M.TCV?'&+`*&-E.T_[[7=LI`3)U[4N"?8^/
MS[GW<ME</[<->J)",MYE3N#Z#J(=X07KJLSY]?/N:N4@J7!7X(9W-'->J'2N
MMY\_;8Y</,J:4H6`H9.94RO5IYXG24U;+%W>TPXB)1<M5K`4E2=[07%A#K6-
M%_I^XK68=8YE2,5[.'A9,D)O.3FTM%.61-`&*]`O:];+5[:6O(>NQ>+QT%\1
MWO9`L6<-4R^&U$$M2>^KC@N\;\#W<[#`Y)7;+"[H6T8$E[Q4+M!Y5NBEY[6W
M]H!INRD8.-!I1X*6F7,3I/G2\;8;DY_?C![EZ!G)FA^_"%9\8QV%9$.9=`'V
MG#]JZ'VAM^"P=W'ZSA3@NT`%+?&A43_X\2ME5:V@VC$8TK[2XN662@()!1HW
MC#43X0T(@%_4,MT9D!#\;/Z/K%!UYD2)&R_]*``XVE.I[IBF=!`Y2,7;/Q84
MG*@L27@BB4#]*1ZZX2H.XN3_+)Y59`S>8H6W&\&/")H&[I0]UBT8I,#\;T=@
M16-O--@<`;$2JO"T7?KKC?<$J2,GS,YBH/$'3#A%Y)>(R!\@'N@:Q('EL3B=
M]@B*][9(?6@J,IQKM)"52:\VEH\V)@(@(V,!;U^LP2!P[#R9>=]9S.)\\VAC
M<O/B(S=K<.:`B7/.DWA(J:G=SF*6IFHAC(]I.!^'H_5B.80GJJ!;WY\/#9ZK
M2@9>J\IB$J,J#E;G:TTX'X>38'$^/5&5?$25!L]5S:[=6<Q)53Q/93X.1U%\
M[JZ)JN5'5&GP5%5T-FM392&V@$&XCF>M!?-/4YSBT6(4M[+L=+,O?TM%17/:
M-!(1?M"3*X02#+MVJ.Z"=!?J3IWMYS!LS;XW!&#8];BB#UA4K).HH250^NX2
MZB?LN+0+Q7OS:NZY@C%G'FOXJE%X!WT7P"7GZG6A!_+PG=S^!0``__\#`%!+
M`P04``8`"````"$`W1C"Q!8$``#;#@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6R<5UMOHSH0?E_I_`?$>P,VUT1)5ANJGEUI5SHZ.I=G`DZ""AAA
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M:JV<[=)CV?W-3U]9L3]TT.X`,I*)+?*W1R8RJ"B$F=%`1LIX"03@UZH*.1I0
MD?2U_WLJ\NZPLKUP%D2N1P!N;9GHG@H9TK:RH^AX]3^"R!`*@]`AB`?LAW4Z
MHW%`@O!V%`<9]0D^IEVZ7K;\9,'4P#M%D\H9)`N(+#/S?YD9I"1]ODBGWA70
M`MKQLHZ(NW1>H(39@-D@!G;`&4-U1'*)\,8@#O`[DX3439(>-/%Z^=])2B>=
M))WK##8(B?LRR\02Q:`1@,K\/@'I!)U6*A`18C!`C#\R4`P:`_\>!M)I94-2
MYQY$Q.C"!C%1WT7B1W$8ZA03'>#'X9B#QA"F1JW1Q\V18)T9C2+]Q1O$A#VS
MA[D7NP8@T0"Q3_SX'$%C%NK,Y(S?'A_I9#",Q\S[?;!!##(,?#<PYBM1UT,W
M(MYU?I'.[^/*2;#)R^PI8I`7"3W7Y*6NA_17#95?+T4:/J8EP3HM-5TL%V*0
M%HA?.+:K7T_4]3"<1_[U<LUU7M/:*9U,?F-\Y(<893,J!FV@"(B/6III%'JO
M6X(P@!02JD5G<46[;\\U0=G]6!0&T-`J2JG9*AU`/'=4#9VC5-3)0T10?W5N
MP7D*L$L#2*T0NO46_>U2396W3^P3:C#\*K)I;GVB"#5.KVK16=REW62*>`\@
M[!.%+6,4*S$`(1WST#G^EGK+L\_%;AHG8.@3@M0^*1;][7<I-$%YO=$G!*DL
M%(O.PM#AB=-R*<B7'UFB*BX-J/D53G2`%\Y'R=8Y&J(\D>,U=3:^IAN"(+52
MBD5G<9<$$Y33&_U2-'?85XI%8P$G_CMV=^]E?@G,#^@`PE,1]?Q@W#9(R@!0
M;]QXR!'O$GC4KEB[9PDK2V%E_"CO"10.-6<KWF$V9`'G4;@[&/9$WFVDW3DO
MP-6B2??L1]KNBUI8)=M!2'<6P?9J\7*"#QUO^@/PEG=PJ>C_/<`EDL%)UYT!
M>,=Y]_X@7W"^EJY_`@``__\#`%!+`P04``8`"````"$`L<HAN!L#```:"0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6R<5EUOFS`4?9^T_X!X+\;D
M@R1*4I6@;I4V:9KV\>R`"58!(]MIVG^_:QPH=K8VVDL;KL\].??<:V[6M\]U
MY3U1(1EO-CX.0M^C3<9SUAPV_L\?]S<+WY.*-#FI>$,W_@N5_NWVXX?UB8M'
M65*J/&!HY,8OE6I7",FLI#61`6]I`R<%%S51\"@.2+:"DKQ+JBL4A>$<U80U
MOF%8B6LX>%&PC*8\.]:T489$T(HHT"]+ULJ>K<ZNH:N)>#RV-QFO6Z#8LXJI
MEX[4]^IL]7!HN"#["NI^QE.2]=S=PP5]S3+!)2]4`'3("+VL>8F6")BVZYQ!
M!=IV3]!BX]_A5;KTT7;=^?.+T9,<??9DR4^?!,N_L(:"V=`FW8`]YX\:^I#K
M$"2CB^S[K@'?A)?3@APK]9V?/E-V*!5T>P8%Z;I6^4M*90:&`DT0S313QBL0
M`'^]FNG)`$/(<_?_Q')5;OS)/)C%X00#W-M3J>Z9IO2]["@5KW\;$#Y3&9+H
M3#(%]>?S*(@6,SR;O\^"C**NP)0HLET+?O)@:.`[94OT".(5,/>5&1U#K?\J
M%6K4)'>:I>."*B2TYVD;X\4:/8&GV1F3&`S<B`&#;<2N1V@#-6TZ"B#0.X@&
M*\:B_]Z&7IL&V]IP/+>_.;G$1#9B=XF8A#8DO80L9@/$TC^Q]6O3)S"4;]>A
MDP`W\B_&CH.)P4R[N=$.[MQ`.@I8DJ#WUUNJP1L?ZAU:&>/E4&K7N\1@EMTP
M8!S$]O'.',?F>&(?IE;N)'B=)$LR7)VQY.M<U$F.],AI9&(P4S/'@3L)_>DP
MI:.`I6_^/_ITDJO/[;+!@$FO]D>NRAXSJ!P%+)6QK?+M&=1@5YW3O,1@1C/H
M!M)1P)*BMZ7S+GK_6NBD]ZZ%P8PDN8%T%+`D+6U);[NCP:X[4WNT$X,927$#
ML,<TR_GBC.Z-T65VE'F%UU0<Z(Y6E?0R?M3[!\/,#E&S&A-8C=TB0<,!K*:6
M'.A7(@ZLD5Y%"T@-@Q@&69CE9AX4;[L7YYXK6$K=QQ)^@U!XL80!@`O.5?\`
M<X:&7S7;/P```/__`P!02P,$%``&``@````A`-?_%#^8!0``VA@``!D```!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&ULG%E=C^HV$'VOU/\0Y?T2$B#91<#5
M$MOME5JIJOKQG`T&HB48)=F/^^\[SIC$'W=)Z#XL<')FF&./?1*S^OI1GKPW
M7M6%.*_]<#+U/7[.Q:XX'];^WW^Q+P^^5S?9>9>=Q)FO_>^\]K]N?OYI]2ZJ
ME_K(>>-!AG.]]H]-<UD&09T?>9G5$W'A9[BR%U69-?"Q.@3UI>+9K@TJ3T$T
MG<9!F15G'S,LJS$YQ'Y?Y)R(_+7DYP:35/R4-5!_?2PN]35;F8])5V;5R^OE
M2R[*"Z1X+DY%\[U-ZGMEOOQV.(LJ>SZ![H]PGN77W.T')WU9Y)6HQ;Z90+H`
M"W4U/P:/`63:K'8%*)##[E5\O_:?PB6+8C_8K-H!^J?@[[7VWJN/XOV7JMC]
M5IPYC#;,DYR!9R%>)/7;3D(0'#C1K)V!/RIOQ_?9ZZGY4[S_RHO#L8'I7H`B
M*6RY^TYXG<.(0II)M)"9<G&"`N"_5Q:R-6!$LH_V];W8-<>U/XLGBV0Z"X'N
M/?.Z885,Z7OY:]V(\E\DA2H5)HE4$GA52<)X,H\6R<,]668JR[S/LK@_"U3=
M"H+7:RW1W8)BE01>KTG"T:4$.,3MC)&LR3:K2KQ[L`Q@$.M+)A=5N(3,UZG"
M@>TF[[.Y@TF329YDEK4/ZQ>FI8:&>]LDT6(5O$&3Y(JS10[\[SBAR4A=1AS/
M3`YQ.4D4FQQZY<C.DN4Q#0A`=R<>>D,7_^/^O&J49*GQFG6+`.3N!$5F(:G+
MB&.K6.)RK"S49<RFYA<QEQ+'2<<Q-$-'C]<LR;#Z-(E)U.=M!W>+G'DW+JD-
M$!N@-L`TP"@6EMWX8B5Y[<-0=/,1)U:+;9&3M"T*^\"T_>L&JA64(J<71$8$
MT1$<IB4V5,*VH*N4:W`&F^[M=I1!IMHD>C"5;)'3*TEM@-@`M0&&0(PCED1S
M<\0,';!_W*]#!MDZ'BT=R%FT-<S#\,%J_Q2O]SJ)#5`;8!I@:$A,#;?G0)+-
MVF?6?K5%"@[?)_V&%*WZX1@Z3&$W*89F>=]E><!P_\D@4WMB;TM;Y"13;)[)
MU%J-*5[7E-L`M0&F`8:&Q_^C008-:4#.58/9F"E>U`38`+4!I@&&@!!6_/VS
MT$;9$JQAWBI27V;J(,1!J(,P'3%KEP:K==#M51.B'<.>WVW4KJLHDEXSAO4(
M<3C409B.F#5+S]1J'K?KANBTNLDD,\NPMXK45YHJ!+<!N`DU-]'6=H@311V$
MZ8BI1CKH_6K0=W4U\8-M(J%FSFB0#D(<A#H(TQ&S=NF+6NT#W8,N.M`]FM6J
MFFV$A#9"'83IB%FSM,7Q-:.)&N/LW)K()R38C?2NL1'B<*B#,(4HQW8\QY0A
M;7"\##1-74;B&%Z()&76T>/,VHW2(0)1A'X@J(,P'3$52=L;KPA-TE0T-S?Y
M;8@D90'326BM]U01^H+)4`AU0MB-$%.@=,#Q`M$O38'.DYEFJFJU(*+VJQ]O
M5W80#6V$Z8@I0KJ@)F+DYHO>:8JQGJ>VH6:P2HR-$(=#'83IB%%[9!GU[>VJ
M90\]0BE2WT"I@Q`'H0["=,2LV3+H<>,=H>.:XVT__BG2S3M<Q>GUD1%1U(EB
M.F+J@QKO[Z=(1IDW3Z[]*5)?>^H@Q$&H@S`=,6NWK'N@G]"-;]M?A"2]9ALA
M#H<Z"-,1LV;IG=KZ':@9G=;L(_M!*;+M.'40HI!/O84Z(4Q'3`EW.;@\>+1:
M)9G91J%(GQN%(O3S0H9"J!/"=,14=)>9PP&PJ\B^]U.DV^<EBJ2KPMPWPZ@3
M)L^DNSL@5(9'S'A@6?+JP%-^.M5>+E[E\7$(SY4=VAUM/T7R*"KH+L#)\B4[
M\-^SZE"<:^_$]Q`ZG20PHQ6>3>.'1ES:X]!GT<"9<OOV"+\A<#A`G$Z`O!>B
MN7Z07]#]*K'Y#P``__\#`%!+`P04``8`"````"$`U7$I84<$```-#P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R<5UV/HS84?:_4_X!X7\!`($%)
M5LO'M"NU4E7MML^$.`D:P!$FDYE_WVLN'[9IIYF=AYG)\?')N=?7OO;V\VM=
M&2^TY25K=B:Q'-.@3<&.97/>F=^_/7U:FP;O\N:85ZRA._.-<O/S_N>?MG?6
M/O,+I9T!"@W?F9>NNT:VS8L+K7-NL2MM8.3$VCKOX&-[MOFUI?FQGU17MNLX
M@5WG96.B0M0^HL%.I[*@*2MN-6TZ%&EIE7?@GU_**Q_5ZN(1N3IOGV_73P6K
MKR!Q**NR>^M%3:,NHJ_GAK7YH8*X7XF?%Z-V_V$A7Y=%RS@[=1;(V6AT&?/&
MWMB@M-\>2XA`I-UHZ6EG?B%11@+3WF_[!/U5TCN7_C?XA=U_:<OC;V5#(=NP
M3F(%#HP]"^K7HX!@LKV8_=2OP!^M<:2G_%9U?[+[K[0\7SI8[A5$)`*+CF\I
MY05D%&0L=R64"E:!`?AMU*4H#<A(_MK_O9?'[K(SO<!:A8Y'@&X<*.^>2B%I
M&L6-=ZS^&TEDD$(1=Q"!&8,(<2UWO2*KX/]5;'34!YCF7;[?MNQN0-7`=_)K
M+FJ01*`\1H8^IEC_*U2(48A\$2J]%D3!87U>]J&WV=HOD--BX,3(@2TQ<8C*
M2$:&2*"0374@&[]'+!8$,$4!N9&C^/=U&<T*LFJ6A(%J)4:.;-95&<F2X3DJ
M)5U2UBN5DBV]A/XLH\3H?21&018QCJF,$5A/0*(#J0YDH\:\8*$_+YGBS?^(
M-T&&'2`50NAKV8V1X\]V=2#5@4P"%&]0U7)MB`KWX`1XOT;$I)T)JS,5:^A[
MZMK%R`F=OMX=R]'&$QR?8TAU(),`Q7+P(Y;%)-VRKUE&SJIW[+N!OU;'$QR7
M+.M`)@&*Y?!'+(M)NF5MA\3(V:!E2S>,HY)A'<@D0#$L>K-T\+U?#H*L&]6/
M#.3XO5'7"K7,JJ/N1OG1HDI'\KA[,PE0@MA\)`A!UH/0;,;(P2"(I>W*1!E5
M`TS'L<FS!"B>"6P^.?./;<A^ENY>RUL\D$*"U>)XF_F\ZCM*,C"D@ED@F8RH
MSD7[D6KF0>?8M-2S9-$<D01GV'S@K.9&,)@?26..4Z(CF8RHYD6K^;AY;%"*
M^966U)@@:3A6O'6@$9*!(&<=I\Q()G-4XZ(/2<;?WZD$NY9J6*OC>"#AH>(M
MREP9=BUMK5)M6"O";!CN0U,#$1WJ\4"PGZF!:"TF)E+3&VI$1](%)Y,1U:%H
M2(\[Q/;U?B,7UV0X=>:%3A9(ND`R&5$=BO[SN$/L5FH.]9X(#P?=H8ZD"XYX
M;HA907_2$#>`B_AT(*)C?$W@9;NF[9DFM*JX4;";>"F((W9"\143DPANO+"W
M==R-X/JVQ!,W@EO<$D_=""YS@-N3$#Q&KOF9_IZWY[+A1D5/8,&Q0EB<%I\S
M^*%CU_YF?&`=/$/Z?R_P[*1P&7<L()\8Z\8/X@NFA^S^'P```/__`P!02P,$
M%``&``@````A`,@+!9%2`P``&`H``!D```!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&ULG%;);MLP$+T7Z#\(NL<2M=J&[2!6D+9`"Q1%ES,MT381211(.D[^
MOD..%RUI8O=B2YS'QS<+9S2[?:Y*YXE)Q44]=\G(=QU6YZ+@]6;N_OKY<#-V
M':5I7=!2U&SNOC#EWBX^?ICMA7Q46\:T`PRUFKM;K9NIYZE\RRJJ1J)A-5C6
M0E94PZO<>*J1C!9V4U5Z@>\G7D5Y[2+#5%["(=9KGK-[D>\J5FLDD:RD&O2K
M+6_4D:W*+Z&KJ'S<-3>YJ!J@6/&2ZQ=+ZCI5/OVRJ86DJQ+\?B81S8_<]F5`
M7_%<"B76>@1T'@H=^CSQ)AXP+68%!P],V!W)UG/WCDPS$KC>8F8#])NSO6H]
M.VHK]I\D+[[RFD&T(4\F`RLA'@WT2V&68+,WV/U@,_!=.@5;TUVI?XC]9\8W
M6PWICL$CX]BT>+EG*H>(`LTHB`U3+DH0`+].Q4UI0$3HL_W?\T)OYVZ8C.+4
M#PG`G153^H$;2M?)=TJ+Z@^"R($*28(#20CJ#_9@%(QC$B?OLWBHR#IX3S5=
MS*38.U`U<*9JJ*E!,@5FXUD(\7G=,W#)[+DSF^Q60"M(Q],BC>.9]P0AS`^8
M)6+@!IPP01>1#1&A?X)XH.\D$ER_7J39U!493$[TUH\E0L8VS,:QK+70$0"1
M:0MX.SH&#%%L>9[&2>]DQ$3GDUL+G9.C:TXVX+D;V(P$/NFG!,VI-<=QVL\'
MFJVFC@0HT<N=-^"6A+[?:$ZLA"A(QMVP9&@>2DBND6#`+0EI]XPEFB,K@:2]
M&&5'JVD'[1),KU%@P$;!N?9#_US:6'N(P4@0?Y"L#.W#4)B9TKJP;Y>B`?>%
MD%X\$(-";DB81%U[AO:AD$E7R&6=PVSJ"PJ[!RX1@X+&2=S3FZ%YJ(=`VVI'
MYC)!=M=[B@Z@?THZV%_1U&NO;V>+8$?LUDTO'<L#Z)"O*";]:]P%A'%XOH.=
MBH:!^3_QPA;9U7@^`6O;4L]=[#01"7M]U\QJ4P9H'_O1V8X*<1#CG*J8W+",
ME:5R<K$S0];TM],J?@`LR12:.=S9WGH&'P9VW3L98"XW=,.^4;GAM7)*M@9*
M?Y1"ZY$XV?%%B\9.CY70,)'MXQ:^P!B,"7\$X+40^OABFL7IFV[Q%P``__\#
M`%!+`P04``8`"````"$`M7TAHZ`#``"/"P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6R45EUOFS`4?9^T_X!X+P0""41)J@;4;=(F3=,^GAUP$JN`
MD>TT[;_?M4T(-FO2O33EWG,/YWY@W^7]2UTYSYAQ0IN5&W@3U\%-04O2[%?N
MKY^/=XGK<(&:$E6TP2OW%7/W?OWQP_)$V1,_8"P<8&CXRCT(T2Y\GQ<'7"/N
MT18WX-E15B,!CVSO\Y9A5*J@NO+#R63FUX@TKF98L/=PT-V.%#BGQ;'&C=`D
M#%=(@'Y^("T_L]7%>^AJQ)Z.[5U!ZQ8HMJ0BXE61NDY=++[L&\K0MH*\7X((
M%6=N]3"BKTG!**<[X0&=KX6.<T[]U`>F];(DD($LN\/P;N4^!(L\"%U_O50%
M^DWPB0_^=_B!GCXQ4GXE#89J0Y]D![:4/DGHEU*:(-@?13^J#GQG3HEWZ%B)
M'_3T&9/]04"[8\A()K8H7W/,"Z@HT'AA+)D*6H$`^.O41(X&5`2]J-\3*<5A
MY4YG7CR?3`.`.UO,Q2.1E*Y3'+F@]1\-"CHJ31)V)/#;D800\,[@:1<<]<%!
MZ(5)',2SVQ)\G8ZJ3HX$6B\9/3DP<O!^WB(YP,$"F,]ET4GTA7JK3E`@2?(@
M6107E(!#<Y_723);^L_0D*+#;#0&OJ<>$YB([(R0U9>T^<#@@]Y>--3/%CV%
MB?AW+\\:99"M<6XJV(PQH8G(QHCIQ(3D8T@2]Q`C#VBIG4?TYDR>\Y!!,'V#
M.B:AG8?&1&KX9"4SVY`/#(8DF(&AI.LEE>"5"_GV+4V2I$]5]7"C,:D:BCCP
M4M.=:?=%:3XP&,*@+D-A<E!O]UP&V0(M!1N-@==>DDBMEF9G3#^9`X.A<F:J
MO%X^"3;51;%=/HV93U3];%G7G/D;3D/N_'_D2K`I=Y9,S79N-.;2SLPVY`.#
M(45>M-9!=/M;D$&WO@6-&4BR#?G`8$A*34G7FRG!9G7&S=28@13;D&O#J-V&
MK`"..KM4MS\%%64*3%+K!-YT(/VUPOUF=C?KW)$:QLA++7]N^*=>>CD\S03D
MN6[U^AT)Z-O`.&T&;]"G3:!!6F$8CXX;PQ_9">:&>WA8F?KE"3_0?WTP8*NQ
M)R-)[>^F`^G"![%WJ9S**^O\.J\@\JS&R=5)OJ3SQ][E0M#*]5ZD;_X:LSW.
M<%5QIZ!'N?,$T-#>JO>QC=S'U$;5.V`=:M$>?T-L3QKN5'@'H1-O#F<ATPN5
M?A"T5??LE@I8A-2_!UA\,=Q#$P_`.TK%^4&N;/TJO?X+``#__P,`4$L#!!0`
M!@`(````(0"Y,V,;&@,``-L(```9````>&PO=V]R:W-H965T<R]S:&5E=#4V
M+GAM;)1676^;,!1]G[3_@/P>O@*$1"%5$]IMTB9-TSZ>'3#!*F!D.TW[[W>-
M`\5D[5(>$K#//9Q[[H7+^N:IKJQ'P@5E38(\VT46:3*6T^:0H%\_[V<QLH3$
M38XKUI`$/1.!;C8?/ZQ/C#^(DA!I`4,C$E1*V:X<1V0EJ;&P64L:V"D8K[&$
M2WYP1,L)SKN@NG)\UXV<&M,&:885OX:#%07-2,JR8TT:J4DXJ;`$_:*DK>C9
MZNP:NAKSAV,[RUC=`L6>5E0^=Z3(JK/5ET/#.-Y7D/>3%^"LY^XN+NAKFG$F
M6"%MH'.TT,N<E\[2`:;-.J>0@;+=XJ1(T*VW2A?(V:P[?WY3<A*C<TN4[/2)
MT_PK;0B8#652!=@S]J"@7W*U!,'.1?1]5X#OW,I)@8^5_,%.GPD]E!*J'4)"
M*J]5_IP2D8&A0&/[H6+*6`4"X->JJ>H,,`0_=?\GFLLR0?/(#A?NW`.XM2="
MWE-%B:SL*"2K_VB0=Z;2)/Z99`[J];X/IU<&!^=@^#\'>[[MQZ$71O^7X.AT
M.G=2+/%FS=G)@HX#P:+%JG^]%3`K6R(P5R<Q&/6:3V"0(KE5+`F"1P7"!=3V
M<1,O@[7S"`7)SICM)<8S$;L>H=Q7M.EHP0&]@VCP<2SZWS7LM2FPTM:S;O4"
M<`]B_8F02\3<-2'I)20.!X@A%BH\%JL<#EYMO%ZT"H(6&VD,@A?^SIVMQ@1#
M8KOI0CI:,"1!H<>2WO9/@1,$^0YV!6$TI*JE:,S"[4KOV='=;&JI@8CMI7G,
M[V9SDS)]1X"1&UA[?6X*/,TM-H5L->:<VZ0-=F]MIJ]L&G*C]\A5X*G<Y42N
MQO1R[="+W/$Q?>8F\,CSS,J8[.D4[K_4V4AK8::EFGX.KY6W.TT%3=*+)H9O
M-0::8^C&>#EY,'978&#4J'N9/"]=K7/1PT2_+FO"#V1'JDI8&3NJ0>%#LP^K
MPPR[]=7S.%G?PFSK)H$S;,!L:?&!?,/\0!MA5:0`2M=>0,]P/9WTA61M]Y+>
M,PE3I3LMX2."P.O1M0%<,";["[BQ,WR6;/X"``#__P,`4$L#!!0`!@`(````
M(0#`],$B``0```H/```9````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)Q7
M76^C.!1]7VG^`^*]@"$?$"49355U=Z1=:;3:W7DFX"2H@!%VF_;?[[6O@V.3
M-)F\-*$Y]YYS/WR`Y=?WIO;>:,\KUJY\$D2^1]N"E56[6_G__O/\D/H>%WE;
MYC5KZ<K_H-S_NO[RV_+`^A>^IU1XD*'E*W\O1+<(0U[L:9/S@'6TA5^VK&]R
M`9?]+N1=3_-2!35U&$?1+&SRJO4QPZ*_)0?;;JN"/K'BM:&MP"0]K7,!^OF^
MZO@Q6U/<DJ[)^Y?7[J%@30<I-E5=B0^5U/>:8O%]U[(^W]10]SN9Y,4QM[H8
MI6^JHF><;44`Z4(4.JXY"[,0,JV79045R+9[/=VN_&]D\1A/_'"]5`WZKZ('
M?O+=XWMV^+VORC^KED*W84YR`AO&7B3T>RG_!<'A*/I93>!'[Y5TF[_6XF]V
M^(-6N[V`<4^A(EG8HOQXHKR`CD*:()[*3`6K00#\]9I*K@9T)']7GX>J%/N5
MG\R"Z3Q*","]#>7BN9(I?:]XY8(U/Q%$="I,$NLD\*F30,E7@D,4HNIZRD6^
M7O;LX,&R`!7O<KEZ9`$)94$S:,OY@J`2&?--!JE00'.8PMLZS>;+\`TZ5VC,
MXQA#!D0(Y(,"8'45)%<5R"!;P3P>TBN1CV.(05@"$EO`YZ5+\,J'W$/ILS1Q
MF!&CUM`B@BFYE4XN+L^QUS((UN2$,(W=7B-F3`C)7<+KK95!=H5IECH5(F:F
M1A]'L^ET^-TJ>&;S?]Y9"79YLR$OSA0QR#N?$]-XBW;^*[02;--F4>30(@9I
M'R;I],(B29=WSM+U=LL@E]^<%"P;,9J?3&/SNU5W=@^_#'+Y37W(CQ@];I)E
M%\9-X-C^>@-4E*O`3!85:-!10I*8C;1:0!P_^WSE%-JEGCC#UR"D)DD4F=-G
M4]]E9`1MZM10LLCT5U>/H$R=MRR(9H-$6X'C9-+,KR\@&5M:=L*@%2`(%9`D
MR"Y)..-Q-TA``[.;8-JL)2#HV(2)61&["7>9GKR)CXZ!V3&M`$&Z"21(C3W9
M$AS?NW$.8P/,(L.@)2!(2X@"LRFV`L<";U1PQ@N)ZX4$08."R04S(G>YH8IR
M3B0Q#+H)Z(<H(0U,C^P>W&6'Y(P?$M</-0@6<G@*R"[=C.(SIGC]KJ^BW#ZX
MSJ1!MHP+&Q$[QGC;1J@H5X8Y^C@.#;)EF--K#2663G9RC_S<GQ7:I7=/I0;-
ME3D2>)">7%B(^"Y[5%&N!L.@6X#VJ.\1A$1SL[-V_=+$;J]?HAWNV#V0\N$?
M0%A_.DT3(PZI\6T&G_J[?$?_ROM=U7*OIEM8WRB8@ZWU^"Z#%X)UZMEZPP2\
M@ZBO>WCGI/#H#X[C>UO&Q/%"OBT-;['K_P$``/__`P!02P,$%``&``@````A
M``%1,1(U!@``.1@``!D```!X;"]W;W)K<VAE971S+W-H965T-C8N>&ULE%C;
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M,.]OC*?9W7?WPW!?%EE=-=6Q'8.[B0K4G',TB2;@Z?GI4,`,9-JM.C_.[,]L
MNF>N/7E^ZA+T=Y&_-]K?5G.JWM=U<=@7EQRR#3I)!5ZJZHND)@=I@I<GQMNK
M3H'?:^N0'].W<_M'];[)B]=3"W+[,",YL>GA>YPW&604W(Q=7WK*JC,$`/];
M92%+`S*2?NN>[\6A/<UL3XS]P/$8T*V7O&E7A71I6]E;TU;E/XK$;JZ4$_?F
MQ(/H;[@[=D.?^>(!+_SF!9Z]EP^'`,%V\X!G__+#\Q`W)X'NY.%YP-+J0H%G
M'\J'YQ'=7H9G__+#\V!01DI54&9P\]&93%2-="47IVWZ_%17[Q:L8ZB"YIK*
MKL"F4-36O=A4:?3E]U_5!V4GO7R6;CIG4%@-+)FOSY$(GR9?H<RS&V>N.)#"
MGA-R#W,6=XZL:NDXIH8E-:RH84T-&VI(J&%[-PRA,1S8[LZX![;7#!/(99]0
MR*&14`_$^_?5>\^??`OG+W!Q!'.30A@+DQ$)DN#8Y'`\SM)D!,+!G)7)\0AE
M;5(B08;:F)R0"SQ48G("/\*<K<DAJ=F9#!KPWJ2$?C\.DAAZ(I+XY])*-K1@
MK>PC028P5QS>=6!9]@MJB*EA20TK:EA3PX8:$FK84L..&O::`>4$.OP#.9'L
MF0T9'UI!T.>Z6_AS10FZ7A)P6H$+'19.1*HFUF$_=$@Y+!$<1(/.W=@K'0X=
M3DM;AQD7=*5N$.YX+BG[!.$L9,3_5L==^.*2Z'<ZSKFQ9/8Z[OE>-%0;D@R^
MJP]()ME8LHCTR+FBB$XR%OD^P1<(]]PP((18)\@O&VE>2QUG44#?7^FXQT`:
M7%-K'8>B<8;$=+IO=-SS0D$2G^BXZSD.$7:+<,<)'%+4.YW`>!BY)`-[G1`R
MIJ4820>[F@>DDVPB'<GL7%&4=,*-R*=[H<.1ZY*"C7789PYY>ZG#0423LM+A
M,*(K?:W##(J&Y'2CX[[#2$83'69,"()O=1QJSB.9V>FX%_JT9O8(=[@[3!XI
M!OO/!Q23;*R8'Y%YSQ5'2>:%/"+%N$`XAS,<7@PQPD5@]$B$A[`<\/LK'>>A
MRPF^1K@7,1+?1L=]%Y83]I_H./<%(_ZW.LYX$'AD@!TB1(Y#^^P>$7@H@N$[
M@+23!VM]C_SS[[UD4^U(['/%4=J-O("'A+#0"2%\0DC5QCH^<MV(D5:W1`1/
M<"KO"A/\D-;/&A&$[P[)4<T2X9XK'$)($(%#7R`Q;A&!":[MM[HA=IC@.HP6
MR1XS.`-.7T9(0SA\/:"A9&,-!8U^KCAJ@S*"`@U)YUCHA,`Q\A/K^`@2Z)$5
MOD0$+O2YJ7T*)@2";HS7B,"$3\];&T3@+E1BG[YNB`01?-^A!XHM)L`Z)RKO
M$(')69!$[3$C8*$_E!(241Z"'U"QHY.M=T#:S/Q&TO;>AB4V+$O#LC(L:\.R
M,2R)8=D:EIUAV>L6G"!Y*OUXJV+J$*OOPP4;<M]5P/Q&BKIMW<@9>X2P0`1G
M#$6"_I&V'",Z^'-)P2PI@:Z+%27P8<UW(:\I@7$4D=8C.OZ&\NF("2709;*]
M$88JVAF6O6[!JLFCYP.JJ9,J4LTE6]6YO,N!%O83U70"J$8694P=F#+I#F1=
MD/:UHAY,F8B'_Y6)\.F(B3$BZ6;;&T&72?D<+/)J5V:NLRB9U$VMNC8K\_HU
M7^3G<V-EU9N\A75A8?16=4,\9U.X8X*K(F+?RIMC:9_T`%S<7M/7_+>T?BTN
MC77.C^#2&0=P$*C5U:_ZT5;7[G[HI6KARK;[\P17]#E<%H!XMG6LJO;^0P[0
M7_H__P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T
M:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z'
M'FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+
MT@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2
M"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VX
MB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?
MB8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7
M,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-
MK2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F
M?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPX
MVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"
M8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT
M_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R
M:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#
M$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X
M9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<
M*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,
MKG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX
M15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DW
MQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(
MGIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q
M7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9
M>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"
MG$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY
M&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HP
MF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%
MRI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8G
MB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<)
M:G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])
M`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^
M@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJ
MF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"
M5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)
MLI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI
M9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*
M6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_
M@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"V
MENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]
M</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"```
M`"$`XA9GXE,,``"E<```#0```'AL+W-T>6QE<RYX;6S477MOX\81_[]`OP/!
M:XL$J"V)HBS)L1R<=&9[P/4:Y%RT0%,4M$39C/E02>K.3M#OWIGE:U82R:6T
MU%XCY"Q1VIG?/'=VN"1OOG_Q/>VS$\5N&,STP65?UYQ@&:[<X'&F_^W>NICH
M6IS8P<KVPL"9Z:].K']_^]O?W,3)J^=\>G*<1`,203S3GY)D<]WKQ<LGQ[?C
MRW#C!/#-.HQ\.X&/T6,OWD2.O8IQD._UC'[_JN?;;J"G%*[]I0@1WXZ>MYN+
M9>AO[,1]<#TW>66T=,U?7K]_#,+(?O``ZLO`M)<Y;?9AC[SO+J,P#M?))9#K
MA>NUNW3V44Y[TQY0NKT)MK[E)[&V#+=!,M.-XI"6?O-^-=.O="T5>1&N`,0?
M_K,-D^]^E_YY\\<W;_K__O:[?_[HK/[UTS?[W_WTK=[+V1":8(-ZFI?]6K+P
M=4JYETEP>[,.@U*0(8!F"KI^#L(O@87?@3.`>/BSVYOX%^VS[<&1`<);AEX8
M:0E8&>1C1P+;=])?+&S/?8A<_-G:]EWO-3ULX`'F&-GO?!?,A`=[*8?S\GE`
M-+E,$X3!R33$(U0F'T2R\6"]3/;/!V3B>(V:>9VB/XX7DZ)>+FF\]OUB3X>G
M\"IL1?A$CP\SW;(@APSZ?50K-5A'S*:+/O`[&[.KT=DD&UI#:RQ5,LX7]^V&
M#(>63%4V,+3>CM^=39WRF55)EZ7A<T4`!IQ<+;H0NC7Q/;;P=0X_.?.$UHW%
M&%4NZ;/0*W/CO>L[L?;1^:+]&/IV@(JEDQK[-3<G<X[7#7G.!>2S*+P+A:W3
MS6G%RYFDF'8K1:ZL\>5^K;+C2J>IB_J5`+/6?IL+,F"U9W=FS_GLEY$[ZFHM
M`=60?.HY;H:R3CVM<<-J,GGKN8]!6OO'VPTL+Y>1NTG0=7.^7=@<0_#_@?M`
M?I)#9U$G>F[4Z>6P,6VT]J><>+/6CLU(;,*+829T/:]8W0]-7/_"D=L;:#0D
M3A18\$'+WM^_;F#U&T!/!)VZE_ZNX=>/D?TZ,)B"Q`;$H>>N$,7C@JVYLS7/
MXNK.6MPQO@29*(H*HI:U&'=`]&X^7<A'NIBR:;`G47S#@I=DI&]'^)),U(+_
M%M)TFE6]IBR0!3TM<;%'UK\<3Z?3R>!J,IE,S>'`-)F2'S*/=H.5\^)@VTR:
MFO81C`#!=#B97AD`I&].&*NS(A@"@/%H-!D-IH8)_[-)MWL$LG4ZTE5;E2!0
M9%6"0)%569M&1NK+(@6:OXICE2!09%6"0)%5QY(S\%BY50D"158E"!19E:W;
M),8JG`E2'*L$@2*K$@2*K"JM^,PR\%2Y50D"158E",YMU7Q9M;B[LUBK>;\R
MJZZ/V4H.UHX/8;2"/D=^;GB`J\?TV.V-YZP36"5&[N,3_DW"#?S[$"8)G'2^
MO5FY]F,8V!Z\[>4C\K\U(^&T/)R!G^G)D[M\!F9<#R?%F[+HBD.1B4RL\,VQ
MV1^;(^,J741)8NT[*W?K[TM7\#[H*Z!&U&VSX$2'0<$D<X?RS$,/K9"93W`$
M,S6SM.``\(G<)01'R)"Q/`LG*B,9(28C&2`H(QDA*B.$SJ'@RC6Y"K>P(V37
MP)8UZ??92JRUOQPF2(`?\)C&,?OZ;!QR0*.-8T1UFBL/\LM>;,P-?+&*]8"D
M#2/VY6P8<$#*AA&B,O)^<U#BHIV`Z?D`DAU]<S\_#@8P2@?F>':28):?\$1L
M>BI6V'T/B]M(GD@-%-I-5[D,.VK:ET$&DS:2Y,`:Q]09,9NO8?I?.I[W"2?D
M?ZR+&@!:7;<W+VNRD0MVU^%.)]PGAF^AGYR]3>?[]`/HN&J043E(LS<;[_7C
MUG]P(HMMN6,LV%'L6Y>?YJQ0*3^S4S6^PYIU>DKFARA,G&7"M@2R4Q55>(85
M>`89(1$\I_`W*_B#GH3U<0I_:`8=-"+H12E_<"YA_C+]`=HHN3[`!-2IZ_#(
M1`!+_AP!&$$%`MRLF04VN*<*!+"4RA&`@Y8(`$Z-5YP2!W!JKF`)/E"R!/Y=
ML80<DTO)L>Q0RJKT"_QKI+2X]'N2FDF^!4<OU0P?:@"<Q+(JQ:I*,<3L$&FE
M"N!#C0HLF'7E3'F#JIRO3"$DZ0*&4B.0!NHT(L\K2<X%GB6`>HW,)=8AQ"DP
M%:F&`'"40""&@&U/ZC$HFH&I-RB:@BD$;@X^8TQ0;^!F2$48`(^2J"CKA`$W
M8YQ1#02"J@Q)O,%0E2(I!E4YLC2%H2I%$@BJ,B2UA*H423&HRI'$%*I2)($`
M&E&2(:DE5*5(BD%5CBQ-,525(@D$51F26&+8<8KLT;9IVD0E_=/Q<?U3[67=
MV$@=5"V:P.[Y\'3UE*X<P19L+466TGAYK(W;W+%WJCV%D?L++#+Q,MDE''`B
M'2^K3MPE/?(ELC?WS@LL1=/S3B_KZEXO(,G[&[O.R".LQ%3RA^:ZKK5A+ET_
M)V`Y71&-DK-%?6-C?L<S^.9VHX<T@L#FCFH,&!:J,:"],PS2W5!2F,(DF4,4
M]D[9[D+5!!.F6*ZP0+&8?!JR6:.O$N:XFE#&'%=TRI@;H$=US&%J5L:\O=IK
M3FH*^T\7$YU1T]_FI]DN0J>JEXQ-S#KN\ZQWVAC(A_)=F^"FAA[N+E;K$%JL
MO=P*'^XDH4737M&BX=4B:?X"=^H)%D]-L,6`ME$:]:DF[EP^%E1:&RQ=&[`1
M"ZEJ6F`Y/%GR(2BH+1H";.M1RTJ8S#!'&;,F\U&%0,1S:_^ZX*I,A%36D\.I
MPG+U0$4,)P3_"%-5SL=PWR(YZ;31VW$NRVK7:C0P<]=95SBYMT+SU4\U-&O6
M^QB?!BJ]28IZ`$F=K2J9TTC,^P%2`$GSY9,15E5.TA"VT1=-I4>EZ885$=76
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M:-PVN)5(Y_;XEGM;&;!*R3<!$'=LD($O6031\M":TD#7QJ:AD36:>("M]O'`
M[1@/)ZW*V:<AQS?&!6;#W'+X5JCY<=CW*LN<9A!886?N<TX0;#\;[&`CUP/S
M5P,7^]TTO"4S/$*B_WOM0GN[Q"18G*08X/['K>O!G7ZP08=[$9?;&&YH,4\/
M9KO'ZF@5*V=L0%%:T+1M2ZM8-F'6I;0@+MO2`O9I83L$:0DMN%2Z-2UP[8P6
MO*.T8/79%A<,R6CQNA\)ZMX\9$>VSY[8$406P45IE78$S1$9,:[;TBKM"(:C
MM$#DMK1*.P)"0LL$)FUIE78$*U!:X&YM:15V-,%PA-9(4/=7!^W(^RINBA7!
M16F5=N1]%9^\TI96:4?>5U'DMK1*.P)5HB\3OFA+J[0CGR=,P3Q!]57:D=?]
M2%#WNQF5]WCL.(I(EU(I;0?OB(ZP%A&G4EJ-]_*AH)>G6$I[\?YM"OIW2J6T
M%-`C$IGPA;A$A8V&O'9-0>W.[56>=7F'P7E&!`;<[GFY]>`A4"$^0HIM^L;Z
MGPB$E_@(47IREL_:`N[A41#BXP&G41%"=R\;SP[L)(Q>-=SH79#CC3X2)/>G
M,"QTQ%,PX*,(H#_#`[?@65X:Z"75$._#N,&V#9DB%GCU#`0MEJ.!T2D:WO^P
MMFZ#!D:G9/BDBO63")GWP69;6(C/I3AUBY#XX`;/SHKW'%[#N*U!A-)'9YM$
M=N%_?$AAWT>("-[YI:#!IXCTGO/Y;6JR^O,CW.@E5R)N@B>Q@X6\",^_;A.B
M1AQ%B.`F&!$B]VX"-^C*@Y@C@;"$2(1P\45!8B>C"-+XNQT%&"U<Z.[X:(5$
MY:4L4/VO7LJ[`#&])_A(.G9_H&(]`(I:.6M[ZR7WQ9<SO7S_%W;K.W"F[%<_
MN)_#A)&8Z>7[#WA/08AB6+9"NOD0PWWJX*^VC=R9_NO=?#Q]=V<9%Y/^?')A
M#IW1Q70T?W<Q,A?S=^^L:=_H+_X+*L/G]UW#`^!.>#X>>XX?7,PR,*]C#YZB
M%V7"9N`_E<=F.OF0PF<W$@/8L*DS%Z(7%\\7O/T?````__\#`%!+`P04``8`
M"````"$`BFSN:"*C```C2@(`%````'AL+W-H87)E9%-T<FEN9W,N>&ULS)W;
M<AM'MJ;O)V+>H4*ACI$B2$J4)9_:U@Z:DMS:EB6-*+6C8\=<%(`B62T00*,`
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MFZ??/-`K_MKAH^+'Y6)SWO#.K)KUOWY630^*SP[WBD</#Q_WOWQ130[XPKY\
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M.9\O+XU+_&-1SXMR4V#5JHM)M4Z6S4C%Q`V6^9))%YL107@C_A73#A?ZQ+]?
M;E"DZY]YN\85K#=7>\6*O73K+7:MM%!;1'_4[Y?+V64]'Q@'I\CWH_^.4S+^
M752L>5U.ZGF]J:OA=B8&K\HK<;<_/M^OM]K"Y06.K2DW>)Q=SU0_ZY&AGJ<Q
MYO6BEHU%+OC?78^_7"`5"$2Q@Z3C<E6+_7,,3E4LT:@S(ZO92SMBAF1(Z+/J
MM,+$S9`F-G^+*,4MW/'"J\"Y*]Z8FV)NE@7R433(O&3P=+O9KJMBO;PJY^+O
MC2-VI2O;F3Y3NR)VS8,GU:)>KHNF8BTL;;'<#'?@&I:9S?@];#"-7)DFKJO3
M+1@)\2DNL,G-!C^@W9.D]]?U.UAZ&Q*'6WN;MWPWP'9G;HFN8;/OQS4/R"74
M;L7</@*^\`3@2>2BSX5??_GUE_YGYDS.E_,93NU_F&4%Z-V;5:?UM-[<'QCB
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M&,!K=QAQE%`!$5)1#O%#GX$#/4KZ<^.3`[VZ[1NMSMWV#9?XVSZ=*47_E:Y&
M[EQK][$;%SKZ^#C-HX]>2W"&BY-<@'-/BS<`+'?]N\0RCW(?]5GQSE'`B&5=
MSK;3C3GY@1J_,U<O0&`0HC_FZ^5BWY"Q0X+T',\G`+$+//3'>E5/A:?`%,OY
MO)PL?:VFWVYT=M#@9F3'EX%G1*+390.PE@V-2&S`B6,>$://0*9-07@RZ],(
MRB=@GGI(,(,G\Z4!W/YSWU<+]@J,SG3E[`(@J)A63J/_Y,N+55FOH^Z;;Y[S
M&*]90-)_W!<KJ,UHHZOJO_$*XUR<KI<717B+P*O_C+:Q';,F)W11%?<"GX:^
M.$'6\,38<"85=<2VX<$"6Q9M=P=DWE9&TLSF"\T5]:D=C36<;8O.,@--H\\;
MTR85-A4^3-C,4S!)L5HO/]5*GA4RMF'B3?GS$/#<^^ZWO_.:.&_,DWY7-@31
M6O"LGF\58"HBU),%8N`8H;\#/U7UV;D>+4GWE43ZP:1EAJ?8-GP/`&"S5UL3
MILGOF*GC3+OV"M.7@01CZ8[D77I/VM=][:4+XVX/&$*,SEQ1)L2DH?B*T=L%
M2<JYP&%QSYXJSLA12C[+3V6-^9E7^VSRO@GF-1%[(`\AR*2CE1C&RV;Z?5.(
M7`DBL#4$<-,K8LIRT6!B+2/:+J`O!S<RQZ1?7&<%_9>[&Z%)AD_L=%8G0ND)
MUCTG$R!X3]QB\'Z7`\M3//W)3(?['T*C9:8<\O_;CY8.&21;8T#(#C]/<!>D
M5_Q9@4.QZ[4<PSHGNRSQS7]P[Y7$[%:CA/7O?/8[LI^+A0Q[3(EYEB?EK@_[
M#!B\D?)S-[UI4+6)01`1+<9$&1OV:8HVQ?2'Y7,&._^;7HXD]6DW&=G'ZJ"%
M^93]YW9+\0-7WOX+I'&OX>$`&74?C]2&0#"Q_H;7^H]_=CU1NV89O'82<B\P
M2))NH4[26F%.RPDZND&/[WY^^$5_YO$A?`O[SW9YT5_4H`#2?7S7H@:O7>,U
M;C(<MPO0.AYE=,C='L4>-[UH6=MGTS4+.%:FF)SWY<Y$MCUQ:D_DP`RMIU)4
M?]J1NIS]=1O2Q@5I.?)12Z)$<E`)#?"I_C;D%9U[B^JN&?I9A9\FXC1O8I#U
M0J6)O]L'_96[,@I*V43FB#3V"*P\/B_)"&%B\*J&9@W%1`!X;7ZVEP#O$X$=
M[:0V^]\[D=E,_0?D5&]D5/^E_KXY+I"EN8:Y/U+<6=N6RLU>`R7>;@DLL(46
MZUWSG+3YIF<Z8P%;`8H[4O/]-2;&W`LB%&#O#!L]N0KT=Y?<'Z+/IE-/:%S/
MIK>>/Q6/IKLRWOV)7D;KIY=N-H_]U^]1@DNSVC*G547@9SIIP(]QAREOZ1A?
MW'U\\%CYW[D@&/_.%`%B%&LB]I1B!FZ#2DDV3[+@#-&,Y+:3J6>^)_E\Z46;
MK+^V?&F00_4'A5;&NMD26>,=+;V_&,N>=^EK'%EI-B1@^]M00A(FBYR""(V)
M0Y_\YZ>GY%C%5G)K9D4*`EZ)/1A8]E56ROZXIB2GV4DH3T'Z376?[?"_M"^W
M'L-D>6PR><9)0FL0>D5BH+^,:]^N6,*.]TZVJ]7<$H+D$&94Z@'?*KSPN%$N
MW\$RB`KHND#^AID,\8C$PBQ$JEYB&B4O>PH=JA0(#./9#D'J_9AMO2*4_$!F
M"UG7V!X/B$30S"[99J9:(;84$*K:SN9\O=R>G;/DK`+F*9REA?YIEO["WI&^
M7:>$ZO7B+W%(0J:X?DP+^Q/<TOW?#JN\7!0_NAVAH';[LG8'XIBD.>C8#6Q>
M],IW0YO57^=8M>T&9/1F?58N`G:PG3W97ERH?P'A/2&&I40_58&8X$JU;KF2
MMS0"C)6-1AZY)A7^&F/VZR^'O_[RG__^'\5_(17Y4'W^_%05RO>7Q:1>KK"4
M%^6T(I<R16T5T)2+J^*<9JB_;<NU5-#R+2?EHGA!^#Y%KY=[=&C,:\1N49?&
M+:4NUM1GS3XCFL](I%XRQT$1Y@I91W/!Q:I>5929S3+,UENRG-@J:ZIH4!],
M%,0HRT'=:%V\??[]54@9&,B;?1*^G16KY9S:)4T`R\5?MQ27L0'5]'RQG"_/
MKA3];61GFN*RWIQ;-7@Y^:L7P(1#:W(\2VI`*"3VT!)E!DY$#:X4?5IAHBBI
M-`=]YKV!)JIIHPG5#%$5YR2Q>#!8!97OH@Q1R5R*$2U:$DGJ*3%>:FN4Y;.N
M#+Y@@<@;`3]_A_&*?+AVF(/B"$,CZK9SNA<NXSAZ,Q^%W6(1^-2&MKF-:C9*
MD^"GQ.!%I4H]M">;/4C$ROB(<XXR;(]MM6[9V!OM6\#P`&QR3#6Z5,])`"7C
MB*6G[*J$,,\;=D&;5)E;G(WETB_*Q?84O`HH%2([6U=F*)WD9%%ST]#`C;;7
MY-=?8AN=\>6\),FX0@9^AK(--='B[J//'QU\F:`**[3UBR,M@PT=L92/U<8*
MZ5;/-Y2\)T-Q>5Y/SQGIR<'#--!EJ;Z8U&7#N%9D$/QB5\2HPT=_&+7>>[8=
M=P^?'';IJD$S$[BVH`!Z0&]1!8'M)_QC.M]2NRKN'G8(8>;R#+Z9JK`C:/**
MG2\O9,]$_>&C@X?CE!0SI.]?M_,K#-43ZS?\8J^8;#?R0#Z7UC&LT(=DN7:,
MM4IB=N%3D]P:0=NN>6Q=0/]T74_<],A$%LRX.>>)6+)I6TJRW+P:<]1<@4[#
MTLUF[@-H)P=ZK`2UZ?Q;:3/-:H(D>\5;YTP(5EJ/J0V3,'Q0.\MI\;S9F.0,
M4DPR#^A:VR46A!-6HVU>+Y48&>-<BU+E=!4JIU:N1X6-O$R/-'^FE9`AOE^2
MKYQ?[=/>QVJEU/6L1MOH(RI>5Q]IPI.,K,N5F7BB>UH+Z_*^%OI))N=534<$
M;VKPL><__+!7O-K,#HI[X=L//]QGNV"TU4FBPTA%7(V3116-&\))50%8YLSE
M&%[ZE;@$;P?;<SL^6MFZ6BRS83\<G!S\^LM,U;BU;``.6Y'#V9PF+P?EIL4)
M/#E"GU2;2Y$H(<4P8(M,P?$$W0RVK8YG\EGP,7"C=/"O`?(T-YM4E5B%.%+:
MH*O__/?_C<"GS7>K+=K0E7SXX(^V^-<09J]3$Z;VO^4CNS@8#PN1)=V5RW>;
M&2T^SB8(H[EYMO':I@F>M2J;7E=PXEJ=9<U95<S'IK88=-%2+5(<\6<2&B>M
MVQH"W?GM(;PP*LPO#Y3SL<P22>9L7,W9LMP7!I.Z@R51OY"*9`G/UJPD[8[W
M6,5*A2>(K,:"WCC'[F._)5%N63+E%&C0XA11-05A$D_$3L?<^ZC/T4V[PFR<
M-#N@M63+&"C#>\9=L>LEPBI#!!]W++%C8_009*'?5XZ#)%;![6(R0"OJ`)'N
MMZ@V>`;9OWO?'QV]U7H-PS0%/IBBG!5]X?-%^1%\$<V@F0_29=N+E2758`4X
M+M,)EUG-90['3-MX>LV&ZH6/L4V+(4=3<HIKQ7P#44'*;N905.8QVD)EWH@)
M-=<&/VCP0S.U.D@T2.^Z6YH0&NQFBPQ6O<`>XW'8@2U0=KU!*?7Z9HN3B&:`
M,&.NVBE690VOP>'@--XPJ$2+&&YHYRP'Q1LY*](.#C15(6T<#ZKG3%9?AB.]
M3T^9^2-SU#9TU@@1G\*WT$>N1Q`1FJ\DA#,LNDJUI&C,J/9Z(!)*VTMS@=N-
M7?8Z?TH\A>?EW3TI[!5.L[[6(*=YA,"L#]@?`[UGW0<9/!O[6FT1;J!Q3(-.
M!6'-K`40Q8R]M.-]L/E*!GT"GA:'LS&%V^D6$,MWX1]LGVSH2%7)347<234(
M>R,MGU-8.?-.\L1>'!X!EVI3W1U6!@KT1"NU17D2:!""FM>E`[(HL)].K+X"
M9RH_8:]I'<%[(,)*3BT7MDF>7-/N3>LUQELQ!>)AR+0CI-IJVV431PNRL"$2
MJ+]N9V<R*XP]H=9O#TW+]?I*7YH07&<N+FGHTRM,%IX5A3*I4$GS`79NA>5D
M_-!08DMMV`XC\WEKPGA-YH7_T&XCI^VR:CS:KF1;@#8*PD[GRO/%AMPLI66/
M*G[.D4::P,30HQZI\D1\M*$8-[C2,.-IO::IIYY!M!T.&'B$=]5T#JT64IK!
M_:9WLNC8[4H!MB,*7F'.:@XA,&LR=LP8#A],,]B0'`A(,YAR<[<&X'!]85;G
M1/`O$=U'AH1%,&D"U@?%B9Q[.\#4/!DFE?(/6Y59.&DWW!TC>6,M_<$T$W(Q
M$<,@)/+-ZHA5ECO^[0^[O]A+*@DNUH.F;J'0/P99!@P_)H90VJ,Y+Y[C#Y$T
M":QKY\OV;(1_\`+S%*KT6*\7">.]7!`(;DW4^_N%VLIAL>6HH8'K=-Y"LC$:
M=+I3EZ%?UU3@\1ZP<4O9QM)6Q-H5O=Z8-XZ7L61L-.D0*<LJU&Q,FI%"BRGD
MY<.J#CA^U)F]C7-]2K*4^"PQ/DQH7#WU*?#\<CV.A-@D12@".;)_,IGH(8$7
M>K1%8V4W,@.NC]6FGG0K`U@,Q+<&.WCKHFUY,5,29:]]@:U@UDQ@B<2;T0,M
M@\W.EZ]!VE90#$0[<=MK(RMJLV&U.,LC.'(J&3"#A.=5$JK74M.!X1VEO`E-
MBX3?`M,]21`0%<2UE*&/\VC5M#U]03!SEF\/&R?G@A=/*1V<AS8QK:`=W2"!
MAG5[L*_2P62]_(C2GA&?IV@8_ECB1`STT1G3!3YB#?.L)>R$NR[=Y#RV*-.5
MQN%8PQJL1/LRS]/LA@XY=UM;"WENC8J_;4DGV`($8H3:&Z)2@L4(+=$V`7_B
M#Z?!E*>U@0S.=W#1FA,G3;6V$T^18%%A3EA)&=I19,*QN@B")3B#H\J9M%7.
MJQ6J.)#1Z<MPYYRYF1&!!2""U&S#9A3CF9::('S,5+>K"L..,10&`P'(,R'/
MBNF"8+#OHL:[NX<#)%&L$&X`!"HCO)7W-O5T`^3*ET>6"2UY"'E0O(NM;,.@
M%$&A`J84L<F0:9&F&M*<KT\P@HV!B@G61EY^7[:(4R,7*U+3:Q(`-6,L^'^)
M6DY<Y+`'MP'OD^9X+U@3^FLS3JK)5D8L2:LT(#G3Z+;=Q147%7!]-MBR-T'?
M0*!R*IGYA3P8,&ZJC'+H`__;2MF'60W2J9N/<A.B0SW/EM#C`$-)%DD%<'U.
M^@PM69'3E[6V^$P.4`;:ZJ0>?KN_)(+X_>2=5XS*I&TN@J0#)Z+)ZBL;;#/O
M`I9L\CE-H$58%R4(("\(#H;(DK2V2/G_FD!=*25$K_W"Q/"T_AG^N*3E(H):
MI%R1Q@RGU\0ZBXU#VBBRPC\\HU*P7EC<VV8=<?VXUNHJJJN6&%R[42LO%N!!
M*HT4DZ6TTB:>4W-I,\/&&+-ZIC[:(#T%(B`G3AK$.:>-Y-RU?65;MAY(U9%'
M\@W:%<]BVN,G6?WA&,-)$F=-SVH^?!^1F`2$1R$'C6F-?J]J)%JI)64%&$\+
M)D'3V_,E"F&[8N+H*2Z]^7RKDJJ+7,A$Y&=)T3(_9PLW%"JC=N3;&$CO;A?A
M'S!I)B\45XUIEX'&'[3'!.R-[!A@9N[(YCI?(Q"-RJWAL<]AN"S`M>K.KC)0
MBGQQ!4)<5FN`?3#`XO#@ILS]@)8`?.&4K/S1;+F=;$ZWF.&XF6R\O-?ZDSR%
MN2P_-4S%#M\2[0TL&;QJKJAU@S-'V[&,9,O!<X`<4^S*H7J3#B(X,"FNV^(V
M597..$REVM>GNKJ4-99"IJ<%HF-?2H@T@Q!C499JTX*\S%K9Z"F1UP:D&+Y,
M5,,+GGIK:4R,:?>;!,IXM<=AL"=29!@3Q:QDY9@`RAX__,,>YY'Y'TG5X1/^
MX+MT9,[*.UKOK6?^3+D(`?";9OY,,S_Z,LQL?]QZYK[*"K=:GF2@\]8*4=^H
M\^T`>+=6;+#6H?H&J[8K#)4QW@^6$JNB9R&DP)L8^FK%J7,L1MZ'HA^RE<T4
M"U8SNA\(_)(&[L$[^\3.U?C.M)1(%6285:FVY9J?ANQ9A413$(!4""UQ0\32
M^_5B+_RE#(.E(#I$-([5#;K+6Z*0<`LI=_>O')S*?C83CE4);2P`VDHA08&5
M')"S'A(NB<$(=%!'[EP`CR@L'>2U$G@83\PP-%9"-6OQO`$RY_3V@+OD>.R$
MCR-9[^.#K@!L9KTP<.!%4'Q9[`1@Q4A)?Z,.'Z0H>2>LKNU8$@^^8KW1O*W+
MR\YV6G5="D8[0,PA9J81;-ZZ>U:8#G;K%8:]X)Z%O#HCAV`$Z'NW3[HL@#\M
M8VUQMIA6A"2KD):.?U_*46`X696PM_K+6)W\,?MM:[0`6C$LNP`0!@2J&1)S
MVR[G0.ZS82:V7;6E#OHRC!.XY;Z35&EY)9'T('B]WEKF7<9<^2)/J&%F9&/P
M.0(]K#BT39C4N2OS.+K?-<$HO3>-5VG/6$][!!^15FYYPK);4RL_8FE5'3'V
M>,P?,QM=IG5S,`RE4V(O-+NY9$P4Q:`'4K)X$)3M`9LJ2O#]45>"L;B-T0>2
M]XJ<YOXK"[".+-/?-W%OKVL+-:FUP-+T6*I[4/Q8_E5,]XX/DPE[+/1G^4EK
M%HP4**F!VBI_&4A6GMGWKZLZ($O=/4'6_\=D&I$DTDQ^!%!2J$5[7"%QM`-W
M4:NP:NX0/?:SZ`%)UNFG?44](6;(++`L7<KRRAYPFI^V#1AE''57@\`T0O]>
M@SHH7JF%T#!^=_40-MG6<U5%#6AY.0O`RAS]MC4W`[<EV,BTY2C1PG`HE/Y)
M:&KE\HSR4U,N?=EFDV2XXRMV<\1`/N+U&[RT<N>M@(()T@$9_0NDQ1:F'L%R
M$?:!;*JR!^*E'FNC\#BI1S]833,@"!&LBF;(0+D2Y&@QRD[W5)!Y].EB@M1+
MU`W6R'9RIY0:ROQ961)/D,AK<8F4^Y%*@2W`R(A)=0J9!%%W'%JQE.Y!(Y=S
M'$!:/BW7$`<=^"(R<8R11`+&BFS,/<M6E4!-\=)J=6PH3)'#I"M5?D5SN=I;
M>%,N%EA@F0(/)4\Q(&2N0B.8F&1I<94XF4]K@88WT\V2VUSH#4%LRV8;6AB5
M+A]LGQR+9=AMA=G,##U2F\D"CNO5GO4F_@WC>FOWE+X"_WR'9>+H/C*EDM]&
MB1!]:]FUC$.[M7E-0^S&"=B&A8)C*E-D94UM7A"DB_+*=@%;B[["6!1)XJ?*
M":*BT,"*WA:S0P1IO;7YIP1B1"@#FD@@5MIW2\5K\]LR&/OE21(B!0N]4IW2
M"+%6@T2J/VDY287.K18`L:CR^AYB(CQMH`XQM0H9#&']GNQ!=@1J+'7A9T*"
MIMM\YG3%!CE<B4V[.8EFXF='5,D0FP));EO@B5"CA*[B@3`-UY+,3$KIC/*B
M^IF*%QXI[8?&[D,S<:"U3MG`?<?S3GM$']0[=I!>/BE[_Y$W6PN/[#&FPIQF
MF4*^(SFLHR7N@XS_MXBC\U/EJP"?3<$E6YA`97@<;6=P)6S&*>![>8F>?@UJ
MYR')OUDT==HADI704(C:/!>:(-4N1,FV]6^/88PN+-<<`4;%P1V]I]C;@_T0
M7)J_S?&)>R*!ERS>5NI(2P[JC5G6(F2#]*`<-TD!KZ&#E!A:1T=VTI5-%TC;
MA:"S)TVL+<`1-@NAH-E0B1AWC6QJ&N#WN9S,K6FVW2Z%T:2GB-TENU=&M]8P
M,#I%@V"',\&Q#8R.0_4<M1QV!DB>$3"`P,A<R>,83@@TPS7B90I&5W\7`TU!
M6F*UN$#A57]H\XM.-;HI78S%6V>C^8>,'-LRK!\JVC+2D:VU#D`C60V@-Z\7
M5+'.-[+$OK?X12\2\;*9%2LF16<^+CQ**[N>HH`RMJBJG'!D!298/L_(3+L`
M*I%+9C$M?\Q!&&<4*TX9RX<-8QJL55"`CM,"C64FS?NUGN=/IH8ZSCC:/3.$
M.J0=P2,6%&@M&:NCC0HLH_$::V=N`'3I0N-@AC$]J0GUT3G(BSC;I2<*2<':
MMNY0G0>$`EB$4_NFBF2)=AUEH@-(K[%X8\J"W,YUDJSM,6E'KNR&L`MNXE1S
M?!R%!=JB)%C7#61N3HDO<ZC\@;)[_=.'@M%<)L?6N36X;BCD$75DA!$Y[^;H
M+6QF5.0AZV4)<'LO<SPI.)=QF>`@DI,0I[IOWWM^\C;4"MHF<Y[B8^T&M,4-
M<Z3G&PJ`<.4E&KVT@(P(@,O;B*=+[Q.A6"%.>]QG>A&4I5!3<6.Y>^%0JX#M
MV^VG,;$!SFKG%!T15`;;9"!G8&!SR01F"$KXCN1[B?,%\!$5N2'F*T>6`IN6
MC&?+-IP0L&2PA<P")'-DP@MWMJ2V\2<W"^8WO!@7'D[DPD1O>@IJG^1BI7PD
MG0T=VNDVD&0KT%<S)T7"-M!-!HL%Z"6*9<*QK@^P2I:(@#QFH0(JU,/B5X0*
M6%[;LVQ@ILGZW8)D!]72HKT?(;+4A=R6E><(TX)EC)+^T#D[<"D#E28RSE/=
MV*$6/G>@B-N1((6X:H7)^ZLY/-SI+K.&>\,M0]%9I<P>LC>:UQ57,W9A4:EU
MX-3;5.$V9I[[UNI=]SZ?0=/U]W:2`'SM1H6E@^EK:_^&PPEU9%.-9B6[MD+X
M5OU:YCC90,KYEJN23?)S(F[09?L-R?*Y2;`5!Q&7#(]9@50]V7(KO(!@6ESN
MI('CY/D:"QZ3TPIT"^2YZU'(8A;!4+?9^6`BL<GIRSBD!R2R/I-8%X%`WG(1
MUJE*47NCYRA^4O,"<%#)<`TG64X'Z%K>9AG)75UNV*38UH^^O;:33U\HT3[F
ML6U!B59</_/:E:F[7IAM4]"#D=!UPNBLFUB1'.F+_/%XW-VELU%!H=!4&WZ8
M(S9;J1%B&%R>XOJ,#3(NF#CQ,EIIEQ@#!!2D!DKZRE`K7KN#;&TG;(%]R7_/
MO&$GL0@1Q`NXM^^T"#[Y3&PWZLSZ(Y**6YW=4-6B$.$Y-D1$1X<L&R[SKY-'
MLH_C:`M;:>&KPL8\#^9ZH&1Q)_&(964*9<_M@D_1U/(ZR3VI7'HH)GI5\;E9
MW7@<*B<C;++#`\,N04CEWS.,95IE;4,::N#+M;-A*)LO.65E_%SB"=U/U>*O
M]W,*6D0+(_R]/$+)RJ'FVEFV\!A!J7>\0FY(VJN88$EZY"+VG6;W=&59?(=[
M/6:GU]W`Y6^2&+33J%HE?IBJK^[HBP<=$2E;OGL.TDNPSDU,:DRV9@%_#KS?
MD]I,A)"$41\K%!Z2:4A4"THT+QJ;8&/8!G`*B\-UARV1C-BYG^AXI;#^G;`%
M0K(FX`IYM"',/38)1LA(58RC2_,^FIQ^3_6W6N1FSC>=CT.<VIC7S6X,*]`P
M2R"@)[BSE#<+Q'?L3V>(,%E*M>,/)MY?J_49J>3GH-J\K<@+U,`9B.L+8ALP
MJT-*:.@:O<]JTT?=A5DN45[,<HNRRAQ%K^__^HN9!PYIXM/@./XDTA\\IBV4
M!*6"`_X6%B@JW(;4U^7)_+$?>>EH4'H@Q#S:>N=^J'"SU@V"*_NM5(=L4=JR
M\4'WH%E$"_(F\X_=@;'YEK82#FYS]*>4I2E$9CWT&O/@M.5/S/V%IYT_UM.;
M<<05%`H2WQPH.OGB3CGSJD@Y;PWWI-+"=,PN.%A?&D%Z=X?R!83PH"O7&!05
M/A.+>E(M2>H(8E_4^I*5*V\8RSC4#A+B0?"V:E@**4,J,JRD:S)ZN]B;3JY=
M#8D6W:A"QQCV2$D`ELF-,]E4,?6AVYLR_;RC6-!M5JC`9!D)=YPQ+[4CRS+P
MVV\P_;?1*5=8I]E+W4(&R@!8"):FA4BTU$KI(\8GM^")TYFSU2L>5<6H.[D-
MN[8;R*I,I!HVK""*V%S0,$0PPB`.8LNY17A4S^?`NW"SK]^.[5@A^@I*6J@*
M[?7BJ.'>W$^0,R?S$.[+$;3%9"`!80$666'!EQ,U[NA?&5&1#F.,%30#AO(=
MDJ:82=9KK>M*Y%AR!+6V6#@[RISK-1C2C)"%'NH_;YD9XK=,<Z,5L%8@UEK]
MS&W=D;\,@VR[!,15=26[#9$L31BUW"*2Y*`P2"F;'YED'B<CS"JWVN&V+I82
M38@-%$>51]$S@X"Q@'.\92EA%B`IY,C6_"J>_HGOV3?MZ./2%O(N094TUJWD
MWRG,R!(61.AH94K',/%V+;A*N$]N)X8"X?Z:I"X)V)IA,\R9<<R\DK5VFN\R
M+)B^E@&/[NH?5.O81B#_IBX6[$S3-CO(W\!AN2AI0:+=5=T32@U.$K.6]#ZS
M:=%@L7^A[<C\*/,<\%,GZKU`?K/Q8\%I!S,E0(F$C+,>5KF7<-B@)[-`1E.H
MJ2(B6MC7@G0CO&MY\B6$DM%P"509W`H*S>$_I3J_*5_Y#]C?P28EMEQOA$,_
MKY3,L@"?^$V3"S>#;KKX)MC#GUJ=E'?$4N1SH+&QQ9P98_R9GI"Y91,-2+3*
M8-MM$X=#8>EYVX.>7V^?+@*9_S#'3\[KU2J:NC]!I-H@*4I34NL'J2R_)5S9
M)"ER.EC0Y`-18O6!L$_!W%ND&5,_<AX:0=J@HJ'G.0=Z^RZ%3C#O&4@LW&C,
M19GTW#>#^XH[S^?VSJE56)H:/%`6P(RU=U@<ZWE.]I`V5*5P2'?&&T.T==Y:
M$%I:S%5I_;8AC*2K:^7\VS)'VQ7$RUC7T!6KV--:V8PBBUF#9LFBCS=WR>(8
MU*#>I8,1NJ_&'&EVGXI(S`+1?.WZRHQ6."K6;1!WX[#;Q\DFW69R/6.]_SJ?
MM(,2).%L75[`6A1!G702`-Y3^YPU4ANL4N,>Q_$O)EOZC\QKFC<H4;G8V7XU
MD)0@FW2^XX+6=#=XG5-&+X:4G@$U?*-)NU"*UV)P'A$H>F^&+DZ*3/A)@;;U
MB7B!HQ+(L%N#%AM8!@3OJ+X^"3ZWK2RY@44P8P_<S`;:FJ(1-MT(!MF$,2OZ
MHBE;M3`HWK)?\2B\$,^H6@9?S$C3'Q1O_5O0IC7X:.5Q>-6H=49%45I,ZT?)
MU7,]*Q/]GT4^;!:/JO=1G4C58HU)C\$SW0)V>8[C])Z_4#\*0#3ZNQZ[Y>G"
M>1RH]$C)$Z.M%[*=U"JD:6148GMQ&RRC"IO][<I8UC;>4&VG_V]\8DQ6GG7J
MRD<_44$&9_?XIKN_@=@-<9/])$EA](F\+D]B*WH(I;V.T!7>N*;!6*H/84<0
M$=L1KP\96]"T8/(DI)V'S`!?PXXX6#:;)UQ3U2P^D8D%XJIY/#XQB!P<[+1[
M<+A-*79L$_WYZ70TVVZ6(G,Z,6O6_=6BV*04"GQ^-Y0!$%:/>/EQ2Q0&%VUM
MGN$\KL)(5]Z":$!^3YMBXA9=`VC;;Z**VN=VQ7V6A#C4M5DT>"=F";;J9^%;
MXB1*,ORM-<;+&G>9^<P"R5&E?AE>Q\.LD&]=F1<V$X5`GQ-G'!"[4]33VH+H
MFYU63\E:,=YIRQ])J]!3P1^IZQ&KJKTV0Q,E$<7R+9[(?&>GU=IC6T5(G2C$
M.BC^1(LU7@\CT69$\M=DZR:4\'4RXU.XWEP&D<"Y3;;*@U[J([ZP)"]5,S7L
M8B.476RM/!1%3K,0R@-8E9<B6`D>I;I,I'Q.6-3F+,5+N8_L`A+FVNF4TSX,
MYE/PYQQB1_%$')<%N$BTP@['Y9)-MYYC]\OAZ'1,L,!F=0!XML5R_*:NVJ#6
MZ$399D==NK/>MG:_)"E1,CLGT6^UN&`U5&@9'%<OGK7%&.L6E+RW]Z&D7WY+
M:FP7JBAX50E31=,HI)`/MF')8=.,72L`0WMSU^.#+Q38VY6F/"[G=_,"&)2J
MG6X'R&;2J]\1/C+_6_F*XK.>*39]Y>0CE2:==BKQO3CP^0!UG-AM#M\QQ,SZ
M.,&DYN/[R-F?<[,I-QF?R^L7!D=US98?6N?4NS$(P&0W)IBVI_O%J*!./UH?
M1''OW<F'^X6NX0-%N^_7^B39EJG6R3(9.N[*L[006D53A(Q$,W)[JEY]3AU_
M><69%B.[B-?U%F\9H5`7Q-O[RLIXQ<%5E*.7]HKW;K6G1!B-]::KP648RG22
M5#(KZ0H-@FS5=%A)PP1A3>VY[SA,]W'_9*H>6=3#^:.W9+GI3T')9&?=L*7H
MVABHJ;I%B:@>2'4ZP1V=01@ZV#E+%Z.]/M`]_S_[L'V3#6"#-/.N<3MLB`R*
M72]Z47QU?'F+=0;#Y8:^7O`3&:)=1RJ1](`[M>GJ"PI7]=C8<%*E`Y4RD[QY
M7X<,"\).]L?O"5-OAX3!)<WV1C$GXFV'%JR&)K(%@2/?7`@=#0;;)[:@Q>%\
M2Q23KHB3@:-<!6F3BHX"C``F^SNT3OMNHASET6GQW0D7CF'PE,7`TC?TKR+3
M;74*3K2'LD*F7/?IP"@R'[)3820G&!=D,V8F5.O+F.E\SEB*C]8)=LV.?^KT
MA;2BD23"SHY0]0J7*UFS[G)%OE0Q@8F.&EF3++LJ:4O@GV6693?5I4X!1@V1
M_%_6*ZL!LDE9Y#6L0TMN*8\_)GK=A6`S52OV]'O;XITS15ONAZ$%Q-0,87`(
M#:22-U6NVM5YEZ;8+B<0V!I+3N)TNK3EPWVS3/DR=(%R`@_&8(6++;`$CV1-
M`'[X!3^B_EI<>=Q]-TU(R[4K<\G)1\JD07W;1'_:AFQCHA4R/S%P*%B['*U[
M"[<$EMU=>405E2T:*9*_LOT\@G$%Y*AZ)BJ01PV%;A@XL&`[`7>-EYU'PVR>
M4LC;8@,,3&'YU&_F1U4P";2X\"J#)[4W`\0/P*641W+<,%%+/@9VIY_0/=E`
MD*)&1LA_*LQ3GL%WV0*,S)0W[06F`9E:X3@E?CU&B,)DG-(@TB/'$J%XR9I,
M([R(+.P1^;I>3N)9+#[JS=GO.$CS)HL?@44D@72A1+P[%.ANQ\U/:</ENZ)C
MB)Y<^R3'H(T50`UMKMDV)#_7U#_OVRTP:9"P_H.8+4MWLLG6.]Q%-B3T@TR<
M'8L=ST8%^731#U`T*"`A%!8,"9+KB7+<D3FR/([[`N^SA'3T#==P2L9>/]G@
MOBK\QD/Z$+,C4*/\>6A,L^,"4D'?>L\0L.3V.,-``5_3#?9*MPR]K=;%B0!2
M'\M]9WW"ZAJS&XB0,0=2VJ)DX$@=&2AD9FWA9?C%J_WXBU>+K?TR,ER(=MBQ
MF/*(NNA$TDLV0O]GJH^'49)T)<!+E9K0[`72HJ*-RWCVE394[]Q*`=WQI,5T
MXJ](679/C=8(L"2F"=`ML30.@><V_L@)<"G7CE\$LQT4D0V_HA[KX=+.S";%
M$;7?#*:G`^JQ]!,$A&MI,8SJH7`7;'-*_+)K/-P^>WW>CSEBWGAA/SW<'G*,
MLXJOOJ\',<CA'L?'=BON9T:0KG4D^W[#W/A+=0();/3WVK#ZW"X_R[>]"W+"
MTE%8NT$R"A*1,J>+SH2/6H'IOLE\CPX/OHHADRC/`BB->_AE=N-P)FUC5UMF
MH9QNMLPX@$B&0M9\F)9]Z?>(OA^[MA]?IW+AEB*:3!^!KU(`=L-_EL.,Q_)H
MU?4+5HH/(;^)+/I''""/O6:\+8]=*6'("N/+`B$R&M'YLAU)/R-&U+G@_'K8
M-LO;9A9M-YBB_43#F%/;-2M4:.9TW,K/TW'ZU!VS!L-;!')+?I;'W*!>R;WW
MQ!HN@IBF_$).>O\-E5C)G\?[=PQN2`;'6`4GVS/@YGQ#KDIM)M@@7*S4+^3(
MQ(2V5]&52[.GBKSEC=R_`"-:?VLY''/>I=T%M!DE!L6V]("!1)IQ>^?9^!K0
M';M>`^:Q/,J\_FB])-2>+)+A2=A&UM5^20^BE):YM`@-#%TWYYZA(Q/A>'2,
MT.C;&4L<&&&>1TD&T4=_?-%A<\SJY$D=\[%)==+)<C?H[L>BO/KN2>#'FDU1
M)!H8["9]BB27RWWL#3EQ94\`,S+5"3J85L2H(6V8E`Y+YK_G2_#UGJ5ZKL=&
M8E[&B,T-+@K9"Z:]809+65`UB83+@84&)C==!HL^Q2Q?.C,33UP&\>>4CA:K
M[-A@5[7EVHM(;TIM-5M<I]T'X?@1$F._BZ!P"3HQ/HK3.GLEVC!>E'N-:G0C
M[C:L0VI0:S5#Q)LX%8:I#*+*H#4A7#FC<#04,$#+\-PY%?EK.@,5H8XH=**/
M*"\"8DB$^)7L$;?;:OG'HGCR\`]QV1#E/6-1C+VG(&)\O)QN/Y=#'""98_),
MW5_!-O(@P&,<X03S&.I0QU2,78\8&LS"@14KYTC[PS%K95/=<'6N!`U?VU+\
M,(>'5^*WA>%>^?-P`%G)B3#YY/`I^7V.,=N$B%[^A!\I=`IP&-D2@P,)OYC)
M5MC7Y!7,]T;'SND?A"386X`>IC?D!JQUJWL-.%@V_9`E6Z'=VV'G^5;XY270
MS7\JX\,/2AVD2]H=+E]W-R!0,6<,NY/06'L!88MJ!OO]CH-4N-(C=ZEB]EM.
M@N)>IQYY=7'L^NDWF^+GB_G7#4%J]>T=^*@B0'7GZ4M^\(70V=&.5OPBW?20
MC4U$9]?Q-<5W2T6?]UX<G7QW'PFS7V(ZVW(+GGH\IW9JC!U@.:-O'^?'RNX=
MG1S?+SY_^/E>X=1"I?[SEO^I'SS]IOF[O,FW=PX?WN%?U*Q14"B\@/Y#?;)^
M07;"'WE/C-]PT?UE\6Y)SD7?GF(!"(I]!'WPP`;>/'VGND#WR&^AGVF)GYM\
M`*>1ABD";^7'8XR-+M<*31(9H?]WB!S?JYC%`$7KQC'M5F(]'`=6Z?XON`I3
MG_S3F;HWV-3_E[PRTX)5<!"E$,$#;J``I4DL"?<XR!@@4Z><?B?&<1P\2;^C
MY0="GJ%G"M[2CV1\;GA'",BZ2>P>R.`LI87:E)@*"HD<Y?.L2U/>T'?G\Z#/
M"-*#ID;4^>]&NGBT/4/4<G5$T:*>C:K4![O"F',W_#Z"M'A?/^;QC"41KRK#
MPYP?T$V[C]S:_OTV9AS/<X*BC7=O'[67TTCR+>6'_RJYFD*+XC-&H!IP=/+!
M:&,2_5Q$^R^<:3A$W*8\.S`"%`MK3($ABHV1N<2J*)#S"\["-=$0AF&+A,5,
M#6X!OYL1YG>@\YD19DB];=J+GOUTN=PL"-FL!N'\`._D9'<D!!V"@Y^[R@.&
ME>.=A<0;.(U,N<7B`+"9W[@V"=W]W4WW=V!;/E%(2D!PFR=K8PXX$3-FL727
MI;8'QO]8=TMJS2^[-_K^V/Z(S0EMKKK=:/C[:2_::XQ;,6EN_#&K1_YC5O_0
MU.GEGNOSDI"GNA/=.7"S%(XD#'.>8`@^#.!@@96^Q^<B64BMWX_`+QVPGR`2
M;MG"6@Y_>OLY64-E3F=%QI%RTW6<FZ>M`>"WAOI?WNU_\-[NLC9RM3^W66=_
M",3+7Y,7G=<LFDY;NSXS7J2EWP7*,AZ.D7I3]9XQWH3BAO32>K?@GR>`==$H
M\)9:.RF]"X[6FQDC(G43$DXPH)GQFBBZ_TX![<(PE$/B.$!E`JZ6^!:^N$K!
M[2"3LDJ$+L'F"GCKMC5QS&YK`K)A>P;9C_`^1\B`7R2IK08=7D:M+3#O;)?9
M*AM660P$A`R:W@6ZY>S2[T;)NLCA*]O5I;,_DXUGZ9GNU;OMU:X#??W>?H[D
M.C@X]H,A*I^&\S8CJV+=6E3*5\D&C:5R^K]2$ME!-HO-PA@1WL<(;0QY(BT;
M8FK,V5T23*DFO\<_#[[Z]9=8HM?>W7UR\#@FH'`(;:+(X7`*:@:0?'3UD@$.
M%TM2[-<K0NISP-QW73.@%[H_UH6-#][)2B,3E:"16_[K2)7:1[Q2HPP9JBVN
M9AY_',NR@$^R)!4B[WV`$J3#'3_T97E._;R6MNF+@^+#"A>`8[+C-+8HH\M-
MF-4G%MT)81I2"5;%23H7E.:D?J@V)(P[Q"_P;6EQ(9B6'+0_"19O60U2+Q'L
M&$V3AJ%U]9@;E*F)M0M25ODN.SPA,.68*1R>;8N7,-=4V<+!SC:H`RPU2`8\
MHB%#,V!QKZ$%X;6<-="B;Q/?P&@5Q##M-;T@Y%:C!\SU&(D9]20H>_A%LQM<
M@AS!K[\4?^8"KT$AX$_<D*C+&*_ZM+U2OT__P^/XPXEACZ0>=D_P[@<!I>$@
M)\UG"'O_R:.AEF:+[S_](V8K76-LW;;])X[-9W:2([D[[3_^^L%1]R.PZ^:I
M+1YL;.#`O_\G!4?%_^Q<`2_K0>T)4761<*COE\,([8?`7MXC7$@)5`IREZ/R
M?)4.@?ZYJWRI[@\\70#3^.2X!9A)]=N`@9;I_GI^V,8/;/J=JQ@C%JSL&PD\
MN]\R]@7?>']^EU%_[%VXGS0O&"%1L=`]=;8%?]2L3K$U560/M:3J&3588$'H
MS*-(&WYWE)11]I!OIO\J@&*W+(I@<;)]NI&MVZ;B!8+N`F[8Z<_^/Y#G#XML
MW7V^Z;P!]A`?`'_(6I(6%`,7:I?T&VW%>;6$R?(DR<B""J%`X]>@'^JVJK%Y
M>C2.IRPX!EF?\0LFNJ8)3&Y"6AR*1O\3^,''0,QY\L.BQG^!DQ#UDV[2\V8P
M-7?XFK(<-X$`.1PYX#!>CNC^$5`DQ0KE-[AI*<%3$C_(I?^68%R)^!JG-G>.
MZ+6LY-2Y>XN!*SL:N]#:=LDQ*J!,>'1.JK=":W!U>'I=+9D=RV>M3/8)9LH]
MDV+F^(UULT)3=*T`!YT4R.';P>.$URR93;^+3V/(.<T3JJDN6YF+T62QBS^<
M4QNL[F6Z,+F-+6\,+5W;BO1NU\\H+Z+<LVY?%00A76STFO!R/,&NPKLIV'N7
MWUG<'_^GY?KC?KW8#RG__M=D1"D?P0YKK>Y_2]H59ZUKZ=0PR3ZQ!\\)VE;*
M>/^FAV_D$]NG1.7OG!%-"^0ID#;R?C\_OPLWS=IR#=/:S3=DOLAVC66@@0I^
M2XFV,1'0YP_]9]D/`N]\[`57#%G_DBXF_EF-3!X\ADI%7%Y_]&>Z79:;,L+-
M+F';QOB"(U673'^`5T2I7ZN,G7Y-DT*J#:GB1?_I>U]]MO?EPR_Z'W.)0?^C
M>U\^WCM\_&7_XUO3NZ=K._MO'Z,KF[4W7@?IYI*(9G#.[Q9;&0&TV5L2?.T>
M7=,Y)$4H9\HH0(8W"7$:2?VD5I_G6VEP3-7EDA-<$^:I?8%[CUOYT=`=,EJ)
M2J0&+V:N+WA+$#BGXN4SNB]K.#BSHP'J%)RA6YQV\3/.B`@ZTO`2GNYB)HRB
MDKJ@RD=QY/?-FV?!NE0G[0`$&1A0C*Y)CB[JCS!Z@4'E'#^E4S^'Y\<T.-ZV
MO^*<D]E2RWCTF&%'%ZT4QPC:(?L)%;'H>\)>8D%"V73DK!,)9Q[*\SV\S1YB
ML_OSX$_IXN@W/-EL[:H(CYV3,OHFR':).=&M0=RY?C(1HPR'.2EGB7SF4P=!
MYT2/OE>#7C\_E'6XF,<E4$"1=0TH4LM+Y#SD[^Y^<?`HI31@B%N8D/DWX^>?
M#'\F6T(>A1L:M#'MS4)&=?QQ!3^L$HU6+/)8=B`0Q,1LXFY[Q>+:VZM<",4D
M+-N4Y9#KT!7B=B.G6CL8.<8\^@59,!R8VTX;6:.A=1*D<QA^![DEED:<O64L
ME.#P;))V*G6!:L62G=#;VRJ8(U/QQRC3<^ENR1,B@!>486D0G_*C<6XO',1.
ME3FQJ\8-]2"0LMSBI"YNM(0@&Z;1VFO0XSE<&/@G<CK-)U9+,_#1O)R4%SIB
MBJ'751/LNBZ[='$:H=1K_URDG0JLHL%8V:Y921PCB=E^M-]M$&-T-N[L#$P9
M[5VZ:-B6P0^Z'WR18%E^X[%W.KH,667)\#H*%<P,LT@]+0D*UF/\09;PT6#+
MHDNQ'HC0LYF;F-R?&7U!FN+5Z?$<2/=">=PP6#12`ZP?)R?TTWDVT'@CWM\]
MS#E`7I&DYL/$$7]8GWV9?<86I5::P1I//$EF%1"X\EI)LKYS?*84^F^`J$\<
M>MUFZ#<ICW=HF4-7C5`JOWOXZ,G!P]RBM+DZ3ET@]RLE)[Q71'A[+.%W+Y!A
M*[N?;*W5S:3V_7&4OT<VE8Q,94PRDN^1GGPDS``WP*>,/JIQ^.C@X1]^_07#
M@ZFCB566UM`3LF<9.$YLU_OY_?+X``8!GS,=.(&CSYK1#&6<7F)E;=:2W!$J
M9+EB@I/@-O[4"ZLBG,1O\5,EV&%=L9X*B"K4M:&HZX>=`T0Y%V0ZI)GA&#'&
MSV(Z929T$@/CSQU?Y$-(7S]^=/`D;0U4#AC)9[(OC$JWW::VHQE;$A4T%YGQ
M6%@^5NP^T4]P6].OR3G\2C]-'U7%FF''INCLB6.3<".D-*R]X067,*TJ&@'"
M;O`[%59%6?%%LM]W'V=KDLEHNWO<4\8PV\U3&C-UR4AP';]X.7M`7<=^FU1@
MDFF9Q"EWZ;U[^,6CK$``,6.KOP6#>=.R/$AH6Q):M#RG$/ZEJ][`-@QDGKU4
M)2#\@)2.ZL><.Q"E38ZF#UD3T]JQJ?_#WKGO5GFE:?Y6MDJ4QI'`96,(4#6-
M9)R0HCH!!*1KJD?SQ[:]#>[8WA[;.X3YJV^CI1Z)*YB+X%+Z2N;W/.\Z?8=M
MFX0$JK!475UX?X?UK?4>G_<D,`-!9-#4=-$$J[D30A&IQF/X![`;0F>V&P-5
MPH1EV'KVU_.3($2VSNE24:JU&['FLM`4$NA8%RF!LP:485GH#'.-&COL0!X)
MO:H:YT2!FU8$0=,ZIG+PMCLP1JRPHH::_6FC)<U*SXN7Z`MY6#=(UMQK4H$Q
M=>!;K>'P($V&>_Z*R4`8W@\U\BU)CQ2+R6I(*\\-/%$Z4I-_H7T",:\U7TD?
M4EU29>S?33QDB6`$NL9VP:A',B[P.(0WP&<N<1J)KQR;#T5,''`SZA-B2G$7
MJ&-/0E"V`-U&Y*ADBDR)@Q"(:(].$%%1#4%K3U,>8=A!/45BH]*Y][HR&L!;
M*)BN4EUW+GX)T8V&<81'HCJ19%?2\*5-J8M'P8AM%0?"9T!I\H+UM?7?Y[L'
MLH6EG,SF>R3QJRDRE'NR@-=$I8LC6[]%\_$DK3O7]>2%FI%RW=GU2,W,>V6=
M$RV%K%-&*L[GC%;"2*H3DI6C6-@NK:[C&)PJ0W[)9JROK?V:G]JWES8-N0T,
M3"RZDEE?*WW95I^+.I>PP=&KC%,7>P9DNH$T=!RC2M@JNW9E^V.M1ZJ\M[--
MM.F94"5AO!I-DB@*RR8"ZAB"W;"L!12R1S4;O-`V0G=ZRD"#>/S2P)Y\,?OI
M;/(`=^.'"U&\+\.4''_.UO1X7Z[G^*]_%6`[Q06`EJB>9C@M#IZ$`$8&4MZS
MDY5/]6P.@@QWX$V]>[M%(M,<IMTBBH]..")C=6$'GO!R>EL\M/'?1WU\\82O
M%.C#;G%V&'M*J:4G"W2]\7L..XT:$EN5ZQV.2>G8P57HA3)@B'0UED]:7=#8
M8^&'3KB[><^_(,F13UWOSYY7^GIX66I8%9V)5W"[U7\IB1)10[,1>;X\IV[F
MQ\4FDH+Y-E&CIA+0YGM\4W%&VPW,:]U$R!QH]1M>HR4>4MB;A&@)DU3;(+<V
MSJ'KTVIM27<[]0836UO+$0)&S/:/0;KCK'@(QYZ?G5!]+-:FI`=7BN\?LNB`
M@I?QLK<C/D9K?NFDE<I5R>TL*$DLK$-"9,NR"A)#2II(/',5A#\EBO3+(#*A
ME,>FP(ZM$CXYWFJ`4Y_7^J?LN=ZVWB`T>AI_*`Y6]VV#G7BX$':,R4_64W@W
MMKOLS>IH>A\'HPVWUW`4Z[ADUMG?[!XE6Z7SM+[(C52RP=IR*DO_\H1-A^>(
MVH<EH"2)W*S7^G>LK%_?^/)6_Z]/XT87\EC[].@S9$4V4?MWQRHR/@9CB0O[
M%ZW<NGY[_6;_KUGTQ0LJ5I;<F@N>^03S!9:WAD$F]1_^I.,>A'6XAGR1Y=/V
M`89/:].WS&Z3E>>)J9.S_72/N":6]*.CG543RQ1]\^7UFW>!"4XE0D"N23VM
MO-[@4,NERF3E.YPM2:T'^$X/$_9%GNWW%M?BR8*W6JBD1?DKR%MF[?3*T19$
M(W]LN;`5NT<FQ0"7H[IKRWNLOWUM7QA?EDJ:<FLQ+[N0;C#\%,G)./26R[>2
MB9I6$3%W!/OZ.DE@&(ROT#G.:0'4,!4VR<UKE@OZ&JL%?N;Q!3`@T9(54L`X
M(8OE3#TN9&3$:FQ:,G``'T%5U_CAUC-Z5!;_Y=C@U]PYVSR`:#GM&7')D5`3
MNKR_^3'YS+V].E(8XUBV@LQO.?'P@#XLFX"!.TL")5R-'&=`*L;H8`^QY]TC
MJX8/Y2D+(9Y"RMWZC"=@ZI[@1*NQP:E*A;6F2I?E^7I94U,=Q9097Q@CIH$$
M?#)40#UJT>-$$/7UOL"^1T=^F:C>4QJ&C'LO"8,-)%WATO@@B;0=(J':QB`F
M;D(W4&2ADO1I)NBHJ=:A&-R^-&:9C)_\4FV/%?W(%K4`@K9P[$1"B74Q]VL;
MJZ0:%8792;1,>.C-R\.AWZ;\IC>39[5]YW,%AB"JI`&?>10+D'Q?;CY60MX=
MU\?\@N<XB>H)R/YLFV:-P@1O!A8<V&A7`M<.1")O+W0S=[>?K.C`GN;(R?""
M)*"?/7V4"IEFDQ<G"_*<5_@3?8R0D8SS(0AIZ;&'I?R&5MEOU!@*M`3?<*$)
M7QBWV'^ID!RSBR39V'<]-[N#_$F'VGBW1NDF@U:P7G-^T=>J;8@:OB]@%@I#
M$"$%;'L]/SG8?:W6HG(.3SDDA*A_-:L[R%/$9(&7.<>5*6'EK4??_>NCE*77
M9.$)J]PD7.86[O_T.Z*%Q-]H/GU\IK*H7)1S9_6V_KGSH<JLWOV_H*5F(?E5
M'[B@"U?<"O+Q[`<Z.+K13FIJ?<ZHP-*\,YR^[[<>)!J8K/"_32F4N6VSJ]\]
M>K;U];.K;?V/,G_B\MOZ4/T`]_;`(8]N?#M]]_;9G)[SDV_/`G<9^<D6U<K9
M_&54"]&_+J;*P([8V+X=@RAT0`R2J]B>,8<"J,`4(`6WJB]@G2WQ,<**U$YM
MTE0#D#2T/TI#S&?5CZ9.;8./>7@+K-=D=ZGW/K#.S>XYE".L>%)8P\J'XV.R
M39YMA:JC`)1360KNNF7T!2(/9Y1F_YX'@S4;"?TU&!(SJ/1*>Y0*<V=97\7.
MYRDXQHLL;9E^ICR_9$<@>S5P1!7!@RW88KOP*$KQX/&:%N1-5%J*,HZ;&?5-
M0H2H.OH)9;>#O\C*S^1IYC/S"'XN7<A2A4:R<ML;M+H\:D#JLD`*>E5/%L"P
M?%6$SY+VA>=;'O:GUCR)E2PUGI3/^0*3'A=CR-^!=.JMA<VC=<DOX?*B39N"
MT1>\(G`'61&1.TL9DMN*`)U$HH5R/,#+P@&I'Y1#-TT:SGFI!+=\I-FW2#YA
ML5N0D77BJ#X\3I'(1",5L<^'!J`2-].][.=\#&"YH&A#B$I8[WWC]6EXKEIE
M_Z?R4M[9_ZT:N@VY2AU(-R1?I5"I3>-:-)SB2_U'DK;Y[NTP[^]IAP27O:+_
ML*>Y];>W/ZP>;1W&:?_2E3O7U];6!G]=7QO^V3;ZXWEJLW6E$8Z%@[E%PI5&
M4)BA;1I1V#N)VR`P**B132LWUZ_?VQADOZ[<OG7]SMV-/DD6PBL2,SO8Q=G?
M[=_S_GR:8-=1)C7]XUD6]T]B[!Q/4\Y]3?,*\5BROC9">1%P1`O58#J(D;A4
M684%HC9UX?&7/W0QZX'.'7$1)9>N+):FJ4DQ]4F_2TT2K0IR9AJ::`!=;?@@
M`$9ONG*)R!9SJAIX+P/Q2HA$QQZHTS@^`UL_>!38!I;X;N1MB(YWC"=$(W/"
M]7N+$XC+`&+$&QH]<P'5)0"O9343+BMI#;->DF?2]7P.!6'44F"XE/F159-9
MG<@1EO$4GEK`GM'X@"8*\")58TG7T*='225LD<.F]3D=5`,KJYE?G*R0Z#:5
M$S?80FW[N+U7V+^8=B.6WR^I]^&DRCL('G6;Z%V[>7-UO:2$:5^NK:_5F%N?
M5?F\D1FZWM>"YXABKK3KE78UVY[#SBT_B403$X:=%ZY[XE&H$JZ-K)PFOTF2
MY%F"-ZO34MR5TA@'AE:6$,,F*D[>(`\%*'/D1`GR3F+)+=^B543"-DH$:?S=
MYO`0*54G9KPCXB_.NZ\QYXZU_:8DQDD";9MO`P,B&4IJ5?R9`Y.2P/U760"G
M#<2].P+;!HA2K>&%G_Z"S:2WNIB7;\/KC#4"B2GE4I_;<S"1>^%=AGR)=697
M40(G*@V<`X^9`$*=#9[14Q@>)(USY<1@A23W*>#HLIU>J7Q:;^F(6:6,B8A,
M`8H7:F`3E<)1/5>G1O"P;HAB_<[O#<.%(YB&]BI6GW8C+P,O/)%@.9B6@GO:
MAO/C5^TFZ31$!=AR.AJ6.W6>1`*`[@E'I9XAN."10D@,W[V$\IM!*[A&SP)/
MDY;B&[J/8W-('\4P('[3-H\OCR3?^"7Q2?+>$B;',SE.GR+G6U/0TQ@1O^UR
MK.#8*9^C3YI.:G]@*AXH=!1%@2Q$M_)FC80N;$OP48E'1/+U^P9[;=5SI6VN
MM(VU#;A]:OU=V[@B!#,^)#0O97HB7,1YF1J1,1I5$OG((EG=U8Z.<*JHF$PM
MO78]FP1V(S6/>\2"B)^P`U.&@1JPD77/#<D^A+.Z`**BSMRIH3@'TS?\O+U/
MQU)BHH`]Z6[AAO+":'ZOL9.26CP-B40\#Z:!L[DM=RR2V4LVE?D*<:ML,:RU
MEQ*V1S+"N;DW-9>YWX<T0$)$2CRKT13OP^`/(&V!#K"(Q=`_6;3?T=;81PJM
M,_0Q6]UMLM0!2+!BM8?V",Z-FK&NIM=VJP^LENM2O%UJGE5BL?+]\Z\(=[[:
M!YAJWYF2;NR::.\='(O&TPXH7AF@/3!#,O3*?6[=YY;F(N]J1Z09#&GU".U%
M1#S^EK@+INWVAFW46&4Z*@MHPCQB&5QIJS[.]AF3YGWH*\*8*8PZ7]"JK%*1
MX`XA"TFC]/QN^31(_(4DK$PDY&"Y8F`+7]KBWG+A%^6F;]`[F)/*S[@2IU?B
M-/<67A(_M3A5=W.+S@`$5<O>H<ILN[\'W18W,HJ!8N3%=N,CC65'/AM``B,@
MA'O1UE(7+?0<*#QFI9&>@0^N2P<I43E%$IQ!O13,DJ$XVLF01D%E$R8?,*^T
M29GRG;)1*4G+^JCD.AM]B(<S(HG`HQI-*`<50<`_XA=5X1T>D929"P1*.#<9
MASJLG87:/7MN+RJ-.O$VBBD$`->1BD]RQ_'CHK;_AZ/YZX/9[LO(&8F'4`OK
M]L!8;C)9B;W*84^%J`(1,%>;UL`7[#)-0/-H362/_%"%%]BK;6/5D:19O\:N
M:GB0D$0_"K%+^;MFZW![G!KNIA;=->Q]FCG?C=6JYJ3%,_@P+=J!RV:/$D'5
MQL9;M+;;]S3<.`3DJ(Q_JLU&4@[/O?A]:K8I&%>[G'.?]]__<':_C5H5FHOA
MJOV?_ZKF3,!%4`!=T)4OI'KD'0TG+[Y%I\:-@$\PMNRG4BHE3ZLHC\P<V1,2
MC?]![D_@&@F<SGHNGE;46TI]R\_`(PDO3E6"JFJ1=BP('A&+_'T);()(G*,$
M/7=&A2H368JM#FN7^Z%'<W2UQ</SVK:8BY_@>@4/\EC\FBYB1(BKMI^B"/76
M*DT#2XZKE'0GS[6$<-X_.[?B,I&A+O4N4^)P2O(6&%Z%%R%>N7&5:50/%J?D
MH1+EC$3E3:)U.2H$[W"_119'.)\AK,#3<);-@M/3^1'%F_0_2GC2[H!3BI1M
MJ+9/A(^"ZXY4WWN`9"%F:5]T6WDG`'#F?"0/SC.FSKSDP!-UH8(_Y\[N-#S9
MQ)\D7-4'M^N.(T7S+.;^K/E">NP1+Z3J_=S`6&QY^W*+L1ZM4`YVKZ6.UA"4
MF,HZU.(O-2^!0`DCW1YLZ;=41AP0J34@T-_+AZHM5OFLE8[+:!%P>@6-S^8'
M/P9`>L"D'N:KLK/3D^U]]L=0@#9ENJ_Y]ERK(Z4AC2$"$3,D(OP7*<?O;*I*
M#*7;X)-1Q$(7Y?Z?!.D\`]-UNWI8Z,J":63T1D,TDPB.'@0GJE[ODX-Q6D/?
MK"FK&P71<BZ01).'#,4<%C=)XE*FY($LV(.CQ5Q)(F>"+M1,#!%0*.5%)@.[
MPU<Q+FT'<'89Z0?$U*Q)NX[ULS][S:ZCCY2M?Y;+N^$:[43,:^9WZ#I)+*N@
MVG*_SD@AA_KE'$PX'=:_,0.&YE\'Z3F*YY;&5"<+=3C6^>[^*"7'*1V8;-A.
M9/L!/Y1C:$T6_37YOL*=L$ITQJR-`@X%1UUQKV)8#(5OZVP9I,S^D<J1;1Y0
M?HPK`[ZD#2?*$AUW%T?N\.=#B.45A3_7%&R=O&J_4XW)3AH-9ZO2',+7!;8$
MB$712AKDJGZ!&5$NX%C>O1`LX6/9L4E%'\:]9/=P*H'X"UM/"JJ4^H;`BX[E
M-.H8,.+#A(!5/='G1M1KO-%TW<'%T[TZ#[`X6K4J^)Y#WI9X(A]*?S1[5B<`
MICYC9C$1&FI!F<JM85LZKI/92]H@!*,&/`&-5K<R6#H0-Z1[1NTJ4(@Z#;O%
M6V"A5ZT!L5)P#(N9DZY_Y*&TH@,O*AUT!.%K^552+5I4UKI@KV3M22ADNY$0
MC1N1]3>-NM^.15MC?8-JCJ\69<9@E1-28$F7I..&A%/N(-_CO8TY>JK",.=E
MF2]E`<%#QE!C=Q6M4D5BY)2'74JW&/;#8[8ITGT="AI-Y<B:5G+><V";R!A5
MO`8Z!$(&]/4SV.[.K[3N-#[M@\Z8[3$!/Q8L$5`:[*0(8XDQ(?W9&I"&[:[1
M;`$:=0:APLY9*"N*IF-U[XZP`8K`;-':J/F"7C5L#/+,JD;4%:(L:9FN]7CN
MVY,$08A=8D=+>RHO5GT+O$ZQDL!\;U>6_N:[!VER,MO0--:H.RJA5'=Z^4)U
M8-H6U6P!A2/;?2CA%B^WV2SS%)QH*0P]HT?YS$:L+'I`%0TF%C4Y6XD5%UH*
M,0ZV?6X2<5NMT?N@TYY$`#X;/<P!T@%BCVP,Q."C+J<X.,`+.GV*MHHM,"FU
M3P-N1@!*R>CU.F<J=T:-_G`X=86NMF':V'LZQ5(MT]AV;3R&<X8R<SHW1=@$
M/+*=G'8(-8Y[.",CB/2@V<ZKHSP,6G<Z0,(1[3(FBIB'":TRLMT32>S@`%E3
M(4I"X[NOJ*JS'&GO?(;Q8KT@#QBL@EAN6;3CT7GGC"25>;);0;D(,QE8>E^>
M#\=7.%DIW_MFLA*Y3=%N3(O4`JIPI(2+UV,12*[Z<7K^J(&GF_7B%-G6_QR_
M#K9(YR`I&6U>>$DZ),O?=A=Z])6SP3)EZ#WVSQ.59/]1[T;K.0JF:ZZ"Q.CF
MTZN$WR409N*,X%W1O%`CAR7/A]_,'W`9M"8^@0>J[=#"<B!CM&:4]*AH1<(F
MPJYKVITG^0#TTHAJ[,'=:&FD;`[L]:YP/%X<D`CJYZNC88*LYB@&*L3/8#E[
MCVNT#9/[Q_>5'S[21V*4CGVGD[`L1M@]F)?_2%S(@O(X$QN??$)@@NQYWNXD
M]BXX+716%RYM3L,;$?(HNQY2P_4*[UT83T,3(@OUC+MF$2OQ3%./E)F--M''
M148+33^,L8;SU34PG,D3MGH2@`B^)OO\45?)2BI_SY].7M-",$,SCU+&4,9<
MU+8P5*D[!HT.SWHD*+>KJR6,LX15KC=T*0*B^T8[JJ4WC\E[U;.J+ZO_;(7F
M#^'$<N93AG:<]H#2H_J*W<:G-#>\5I-4N"(31+8!I"AT"`-EFB]L3JK5E<V?
M:X^:2=TY!D!:V:[?V]CP`CRUD%GF??_E*Z<5\QW:M2=N;.3)FJU3,VK[B.8U
MD2V]_BL21<#],6>FKQ/)4,4)K\MM>B4&UTEMX:8'^F\O_Q%CJ*/_CY%25J"+
M'KR1&>XSRG0;0%^D0).@!43S4YZ%$\V8]+?`:>J_\Y![?M+'Q<_R'_',97#F
M+:[A<[OVX`([G(AY60:YS!>`=V=Z\!E!^]-C&H3@9;N-9X8VJ]U=V>5G>3B6
MB%V/CC\MCE+2SY]J+`)A8SJN;2R.:0'L?('R`:E=(CL+<!<SQ;0?^C9",X*9
M%GRN2U0=B^VT@I/!G[XA/DJ2?7]7```9F<9;$!F9V@O,(3FFF>GA3RAGCTL%
MCV8+T`N>.9F5Q$70`HN^N,4,7+&$?$YT"N7LH!1ZT@"J8)-!@0$KQ-GZTW%_
M"M!F&L+5W>>(H8&.RBIL,[+9$<M+/DW&:S*!L:_"?@KC7UN_?GO-)5WRBOGS
MCN?<F,0`06@^;/*;JHEO3'T&\#BPSY413!Y!H9C^;_@(-V.-KNW=V_S4:TM?
MK8#[\GO+7B+^'<<7&6CY8L`>,4'E?\ZQ+SQ['1<1.?%(`AA?,NA'J@-\2OK#
M9R_*2&>L*:Y(/WN;2(S#8X,Q])FC!YT@SIFZ'>UC/LAP2&+3A.0<TLI*F:;L
M4LF9B#"*I@PUDZ.K-Z+H0EZ"9&>R:(0'RLZXT-F6O,X85R);/['+F*T5U!>N
MS\]H29=:-?XWSZ4X&PRP^CJ4UO_<Q.$7]/^_^@]Y#&[R[BV`O,)I[1,U1#KN
M[M_RM%3N^_K^SW]-0B--[%91?-0DB@+IH:2>-V;4WG/"EW7WX.B+@^C1.1MN
MK2VKKJVM\IQU&TOXX#3*V+A.P\3.PQUVP.;_<1^04/F_,\$R9HKGY`3/3FD)
MH&:B4N)/I2/5FMD0?G]-M&/.U_=^8D+RN+WPW$U]LN$Q>;;_\A5RY*GZF:\T
M_Z`B5B0-E;D=*]91=#>-SA]\WY-4@E8:GD85#0U.V%'Z^W65'6((>9D@L7"#
M8^F338:*Y%8+/K#EM4UF>@$;F&>:N)IO2V<F!5RW$J*'5UD+FPB_"%!22&1@
M`PCOX.M&:85O+"U/4E_?*+`R-HI$QB6&@TN?8LON5*U[[_J=.[<MU2I)2;YP
MJ]YW*N[0&4$_M+%B,C"ZF\.$HB)*[]QYI'FD\F,=(AW:'A#K3/:K\P$"T$WB
MC&=H6<58TT/UVFCQ%4HC=[HTJ?<>33^67'AD.J[9&$@.V]=RJ7HWK:U^F6_2
M9T4,0QM2*\`F>S,WE4&^L:+XAZX(!19PY`C5.N<A[\[@_)((X1BQY$^#PD3-
M0[MMK(5>,H9W)W0%NLLX\-M?WIXD9QP[NLB"]M"0T_V88+E#EE6A!N^_=4JR
MS7E*7>.QUB@IB_XGW\/=.?AX'5R_KG[%"\FI^KYHZ6A9,_(6LH0)6`-Q^W@1
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MQ`7<36*[;!]-WXX-%4L^F%-9X-4EEY&E'DW<A/7=6W2"[Y8L*]DGZ30D\BWK
M2]/JK$E+HWBI4KTC-WV._9\Z\LMQEHT=:`]KZ,AAR`,ZO<V]_;6XX@6@\-7F
M*&-/0A&%-'*[L)MK:W>3:=7;U_!G^'UMV>_:`7V*KWF,$?XD.=6)=+OG]`51
MDQU\\QZ5])8?S].!<S@]?73[^D9R'8YFK_-6>4<,&97IPMX6N>A,4E-V7M/;
M-E&&GTVL1L_QA1CN2G+SY=!!"'.[46&^Y+U,FCPV,-1P6$KU?#<5*R_'V.H2
MA;IRU+@Q4O(*XJ7:@-&W-18:2HG%XI+0>!,#S,Z#U>IK">W`Z%`*;=?VU(-S
MP&[K?A3]*O%V.F35[)]R>52@,KZ/??Y[H0^(&\1"G0.U32?*#B,`ZR(Q<FPH
M_BG..0DT\@Y41`23\QVJ?E;*0X`;)S.?;(.07("#8(V^="]-G+Y391BT3?U]
MXEIG(@/1=%E6@"<>B7Z`7WU@B050P\#+75<!-4(IW:A&U;)W]-FEP["^N"9-
M(6\R1L;7YH`U?N'+D`PY8A+&FC^6Z.'^,4WS,P;0$S.!S129-BG>#I+:EB?2
M30E#C$;V/R5S-)_.>0!.HN4GS!H7'T'^OHH>A<WGI3_%_3@KRE&*?S!M>`%M
M,&=+VS)C_V0`\>U:;D82<D55O$RGG$%$6>P&#*#H8)LXYJ`03*R8@)V.)S,H
M-_&JN;T,%HQN'<A++O$Z,Q%*D<+1;MO7<B6OJP?B'!-_42((*OZS#N!;0K[I
MJT"8G#IE&U=G+Q<(&L7TILWJ@0+:87HKT>=4E99RPMEU%>AF8JL<7\YN5?G/
MG=8@Y2=;K\T&2'+ZVS,3Q7FDL]8>Y_6:[822:'Y!](D=7-M\3KXM#D+WY1]3
M:P8^)[N\&]E-0RV*YIW_"_;#8<8@,%&1VOK*6.Z^-'^*%@I!YW>,2IGVC"ZO
MX:2>:_QW3V]QEN>??N%2B^RQ`5#?P"ALOV!@PD@F9NBTUN!6+3$@7@M[4<QV
M.)R<,_N'7#PZQ6^40P;_%#))S#%"3HK:`'ALW+K#W,>UPF`QF:(JJM]:,8D8
MI%TE+>>H^6]FI`M$/"UMBC=`6JY=FCB:V`H@9^:@R%`,W$([U'UP5TUZ!QV_
M$O@"<?-TKM]C<K7^21[4@9A&&99F\/RLD$2QU,D*995T(`MR#BV?"RUMC^=\
M/#`<PF:L2/[]JQEY/I)Y'*B8!$@__*O(=)?V`1JH!@O'*Y&205#:+<=C:`8C
MW=+@<.0%\!6RXZ.Q@LM8D3"BD#%R,#QIW%"4U=7X2L1!=".V\^Z./(&"W?CJ
M(GU8IA.AK40Y4W]'EOL<HT"/EO&U*?'OH1JZWK/`M%E%_K$'N.(LV[EYVJ.7
M"%PR"W25#`B+=M-/`.82&NNK:I4>2]:!HL:)_8I1XT(,#60BL%S]GG[<38_W
M1ZVJ'RBY)=[O,!Q$Q,^>?Y\WK-?C+K<!&EA="$L^:T-;X<_3:0-R\224!@?:
ML0['D(Q1"=/;J6H'5N=EPPW/`>^(L"A$04L[N`G)4OA"3J6^>.@#=2-`NL-'
M?NG#'25(Y).Q@=0<V\%!O3Z[1][F>#.*)!W:*/^$WFODO<2G.`.*2<TSH$4]
M&T[79%:/^BXV6M,`7=<LLQ9RBM_CZ>GN]']/OCD@??F`:*1\?G7I^H$X(-L]
M_(2^F?R$2T[&/:L!F/4('DI)!Q(C>G@YZX1I852$G)+Q162XV+#FC*Q30UQF
M"R$KX)CTUB&Z;6(.$*3\HWQUTD;Y)J2F/@`6ZP4.$J+`K@RL?\A=?!HXLZU/
MGRP^2[+_`U_X([T:Z8<<G[G,/94/SV]/>9Z+T\D0N+0GSSGMO*(WN&=W\1"Q
M7XN#2!U;1`W<^"_%/VMW_\0*FR4N\9"]Q+6?M\0$-JS?\PO7Q)6.:TO^AVY0
M,J.U`8M=OW?OUC@MA0W7JDDLB;8_IE^POO8G/Y6ORI_%(^^2G'*!4Y\"3;V=
MU_X-Y8?>6R8[D`"C-[3+\T/(E-LMZB_E:V)5*_HI5Q%'D(VP;CQB/]X'?]#K
MPU>/0UQ+Q]-^HZEI(%N'%GDB/*\DD6F<L[GQN`(OF5N@_*)@EIKKU0+6%V8K
MW"\YQWC'<XNH#I(A.U)#7Z[_%X1QU)GPIM#&R8^3@"D+08T7EV?<#X@#;)R>
M,0<&"*F_RQ=OU"_\9&_;\B_SS\VR(62V#]5[E`1;_G#$($95]@$ETZ(1ZJ6T
M81A0=EB,A%1)UU%[`XK[.OF6$:BJ);&BSZXB<1HF^B$WO+4HB$OX2?]YRG]M
M-_WW/W13_,'+?IWN^TOR!9>(F@SHBCG/V\S)BK#H+SK>%)"Z@!&0WIL;-.;/
M:NR1D@O5I.F9LF@8O;HUIUD*]+!^[RY#Q;Z79V+5K"<BM7.J1#$_N73@Y]4$
M\8+9A*LL:2%\+\A,QI;A('^/T'-G?O#^`FX5GDT113Y\[EQ&,3HF714.*.#Y
M:Z5GO]H_QD[@V2D]-W?X?44YRTNUPRK!:$0G0AC?)DUXYU/"K2>2B5/#R,:#
MG%TA@$V&ME9:,9[AIZ^6<PEH)"PH"9\C/XY'G,QNI'_P\O+EK`5;K<X#5KW"
M_BE^2<182=I)E8?H]+/)W=N_SP=(&0@GQ-+UJ!WR:J0]DP>6#,/]$]R)7>S&
M=%6\WN5Q"<9(7W8PO>#"Q-+P7I,L>&MM?>6'+R`@*3(_=<C09_=Q,CS_AU=-
M)^D6]%Z^Y5@6%&5T)S-L@I'CEYU6-A,)!ZB'-4>`V+/S].VRAF,GOES+NX-%
MG!JRR?(ML=7TN5+$"_J%[:L>!G))I37ICLBZ0LK-7T>.E5EAP"^D`+CFK2F,
M"NI.W^@/8YN=ZK0P%.QB&+*24H?4_#'",J7.MV>OI@>0%OXS!%CHU;AC?*YJ
MT*(8EXNN;92\H^;:U<G#])7O6P%,?!Q`+R8$456\MGHOQ\0U7'PX6YP+FEI3
MMK&,%I>>M<M1-CX2?A2`%Z+8J=F0$!DGBX$>V<+]?NF';&GOF*SZ7`ZP8YIC
MI/>D[5<;9A+_O4S&'J<PY'22WL-'#-_S`&QGC_QAO6^RLO5H*PQB'3W.7_XW
MN7T*CF<$`CISV4S*Y801*FRF*EJJ0F!2-F+$S,Q]#Z()F2!7(1HR+,URD?EH
MR[G$]&[+RF8\O',<RY)87F28R,Z<0TG-%.7M^"J\GQ(UX1*M:(0ED_B2WL`[
MA%HG.W$P/O4X&/YGDK\8?YIS+W;2*B,+LW^][*YBIQGX"`7@3_0.P$&6(-Q/
M`AL0=/9IA0E*H2A#AR\3A27L.I5X\L=.=R7C'JU&+3O$)ZM:A[S7$*HNT[/_
MR>=(U.2HA]YBL<L5FF"Z9!,,<`+)P."]LY!S<*1P=8K4!E\HQ>X@PAAZH@#-
MF(2V,[+#[<.[1M39_:J]\[<YC4Y+OORI22\5"BY;S+?H<YOCB3QJ[3U$O/R8
MPI\W@B:%NC4ES,+\)1$E,VSCY+3`O&(L%24TJCME>K:7GTU)/6,Z^68.%O_,
ML"O_+S+1M,)SG\MF.Q4N\@G3D`=B6(`.[GHMC9_)=8RVFYV_7GW[K5?[L[T)
MJ1\["P?SGZ3H<6DO(X>/$59FOAPY<8#FM`@Q(:H@'EAED.)-]7V`P%Y%S9B2
MY56(D<!N=QNE;HR)/^Q2=L)X0`0N7"[EH8CEL!A,6-C<Z<+.36I>'I$-.6O:
MZ1@5#[,=(&$=6N-)"U?L\PTMI)<PFH#MPX,*/$'RX_G,J8#_HO+PIR@)I]@B
M9WA+_V\::4%"AJ0$B3-DXQZS$0^)"3.9`U#$Y:4^.""P]]W,L\[YJE?%W\E^
M.C+U&S"N62]BBLL$[2@'2SA+&G;V]SWXQ]XD+V\C9K_LJ!D4O91M9/+?@)RQ
M_9'R298EN^\W9Z;(QU4Q4/9VK/DNYK'6/<OB$KZ#JV06*/HSCFXD'G)Z1(^'
M1KG=W3G@1BDC+-*6YP.*");/VO!<U=((S8%=]VVT`K)0(*FL*<?=S!,,!R#R
MDQ,&M^[_'TLF9DQC0E,^`<RN,Y5PD:Q!2!3)]1#[`)&"1'G.'^VNG%XX<WR=
MI&HE;_^<!>+WV!UF$8Y?X9K6GC)+BXZK""2M%O.96$W9`G]7<R?Z2A\I])=T
M!7;_8'YL@TG?KYP`A>6(D,<FM0^R144%GW*X)\>$DP[IH(C:4L<'W4S3V%*-
MK-XH2C4@M;NA.Q;6K$1[KLYA4<M[:C1L"OHT)J7S=T4*[>*8&`EF)(I+2^=6
M>AOAP"ND5?]6>D&1I>'F@>4B;M""\Z7%5Z]=<=E!+JA5V%)*2`$\Y2B[?OKU
M-Y0MF6YRP8C5DWI)T7KV<)O(='BW,CGRAONAG3W'S/O1U1[D@(M9,D;0DG-[
MEFQ/#;5'\I/=S>0)R*5ST;G."L[K]*K%8$K$C&^K09RDM/-9D87,FW$[66PN
M\I&N"V>5#^N\-J@M;*^E7Y9\-Y5N.5;L6':\2CO"7KKX.PXF>0U=VBC?HK>W
M[]13M%.U7]9`-CR"M)A==K)K+\^$JQ/LOJ#NJTFO<6,3M:E-4.<@((E09X#;
MAK^0GJ&UZ!`L?<:>GT(XIU_\L6]<>W#6U\;U.Y'0_G5/XP3[?RXB;?"#RDC^
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M[=;ZC2]OWUZ?K&P>[O]`6?01'PT$/1O47&SN[;T!>5ZZ*4^^>_+XQ:?(+<V>
M/)&3V=T$'^BF(U$=32[TE)RF\^R,"$L5PZ88-<>E5U:_?ERV4FLP5A,6L(<Y
M"H(]G+511R6O;ZRM;E00/E[BZ]SR"8M%;1BUS&H`Q<(2(XAO'TQ%"R"_W09B
MLJM2$LZYYKIP`2![Y69@GU=#N_=`#&.,Z`"W=,N58OSXBG'EN&9NE'I3#'1,
M79R&^4^4V86[=V73_.X3,S.7V#3GG&@ZPWM?1-NP5M(D2PA7&1^O"=*5OLKM
MQ1(9*:1)$6;NT@G5;#L`[AQ]72-0X,!5Q*?S`SK["_S?K!Y,4IVML96D[=#)
MX0?]1YD=^[]>9L<?E\LDO?7C&'8C/M2OMP5+C+N5*@SF/Q%C.)M]0;',>XJ.
M@&&62OW/>X>7<'/BR_,V.W-UL3:+06-N0HD_)WU_ILIH97*2_4@4OX,XJ@=Q
M#T@,$Z%A5N`&;,#*O)Q_!9-[C&VW%]008S&R'V4L;2@#>Y<U1&8F:\B9@LU3
M"=>5(;P&DPYHO/TCY7"@5=&2%`$54Q9N;(-J8G$$51&%C&\P/I8_)UXHXX?^
M$H(.O;(`=90&-!QNA1!+DDY=&I7;G)[/M<N%PR<C&/[QP16[F5<@UR>.J(!O
M5U&A[`M9%<1?7)0J+T>QHL"'Z3@T5V$F?H&1VXPQ7RI<@9&QY.%NC-HW6H8!
MCUV*0A4"CPR^I;KIBL$G1;UD.ZS(F@^+GHK!K[S#3P/)/M\HZ3*YJ_%0^B1I
M]0)VBMXPPO=V)SVP6`$IS<5963IWU:S24[`SP7SMGA5WND=AF(4*V)H8#G_C
M+0.$9DUK'/T%[`839%D`,J525OQC>L`GW*+W589:O*!K=_BH\A<6,(:"-*C'
ME7SY^(C'E7SY=")EY\N72V$13BAQYO3[@0]V7WH`Y3)`XDGC0KU[N^XL88&_
M$E??DWV(Z>*$D5/RJLDU%(5]I<&UF[M`1FD2BA(.'WZU24CP&)].S7.NA,''
M%P8R176*9]2Z>XB:=,7\>'^^OWN#KB>>I8I,9[X0#J231I\\VG+KP>FNYH[H
MK_8K;;KN4$9RM+\3J55.UY#CN4]B+Q14=1,>>`0/6AM94Q86Y&C*^*&(`^+X
MFCC^-P.KZ^-8HA\[N.C&316#VB:/B/)Q4MER7MG7"XVGQO:`'^>4QY912AED
MB$)E!48V%R1NT/8W#A1(4@10[M\J?00IE.*H/QR%4&WG9*]74XD(%C[=51XO
M=2K).8(,F:4Q_8F%_3A;.?W"MDN_U!@9X@S`$"-JHH5D*0!/*YTP;]SA"?HL
M.<53*D):DT4Y@,#^X"3&35**5,2,&NK$5O(L.Z6DCYE>.4$&P*<LQ30>9AMW
MM5;>DYVS>8!1Z[=Z_:YT%/TO%$M>R<J/+RM)%X=]:'/\"B$5<<\2\JO].43#
M=,(G25UG>>U.:S)G\G+O,J[#6^A&!,3-3`?(6"7M(NH@IRL2^/@DH/RGL&R.
MC\%80X*ZB)T:`##F*.146(`+DV2%G3N"S%4F72EA5VP@5UQZ,$I`K3@Z;H,0
MR@%D$5"1B(]P.?H!Y'OR7__^G]^6*7N-/V:I1&L;)$PC!4O4/4>R_^O?_Z^D
MK&B^)A'SGLZX(I5>9AT_V8@VPGE"$9!)%Y3'*55>@%[L+N>V"?$Q_[Y$W8<%
M?L*>AEPX"SIZJ)]/HX(D5U+**D$">O.=W0A\WB&`.55T)S3.0_>SB[-C*D@.
M]STG2>G*IV>+W92BK(C!E3918&A)I&]@</Y*,!_'F6I%LNEMG`;S6NQ[6;L:
M/LH&4I!/GL%$_8:3PVW6A*IQ(LP1I5"1A?SWQ6K_L,FR259_O_I\M6\,Y.97
M2`([8BB45-']VK*`D.494R@0!L3R#`'(D)UL;.0*;[+12?631(A0`\E1,5:U
M9W5`'[[3=:<2+;6A3X@.HHNYBVG?@IZ^I/:"Z;1D0$V/47049)[_,OQ"E(FK
M?1%T'GN`I$O*TI]J1Q/RE`[+]&QTU71LBYE&1:Y,U,/RY`[PC_.?1YWB($EK
MLDM;!W-&3]9BF]DWCL8(ZO'FXHNXEA]92W/',N3DK_@@J859ZX9<`E[E^X>K
MI:D3421O#!.7.:<:T#%7?^;Z\QJ#&+IX='+;TA%PAI:'%VQBRY+RLZ]U<&\.
MYN<^504[A]-_@ZZ*NVUWG6-<4!).A0KT(DC>U6<MP23W,?'_".R>"YGPGT%1
M--RU^":)<N6#7J4?_GWDL)6LE]'TLY\+^?:P!O"10?C'J24:V26Z#SMAX`U$
MJ34N,*+WR"76)66%5DI7YL4G58NC<[Q"#CZ^N;\\TJ/"P--E]D-3>J.T@]\B
M`W195<_ETQ,_<+NQ$>S]-\__-!LM*>[Y%#:FBZX\ZC:'NV-\"7.BUEB7C,=V
M%K.@`<M]^KM@GY=ZB<A+,BDNS6'TKTNR%TMV)39S[CLSGGW86"A.6KRH!)GV
M*`7MZE<S5],X%W=CN2TC[G_PJ-+]#@(I+R'.*W75]<&74VK:HGB&@/"(`NQ%
M`FW<K1B3?30UHY1#U#F"J.\6NI?@+->N.YYTJ;-5X.DS/:XET)1X$Z.MH(!E
M*'&S\48#]]T829$QV-AF&KG*Q+GH]'TJD#JUST-,X"9T&HWY8*.WU$]E(%0"
MDR-#^A+4P1J3OT*@KSC.$-VUC;9%FFF2OV;:8M!<H,:1FN18H>;6NO=]CK!Q
M?:\`[/;J>LE`:N2'T?,BP@IB3N;W3RKOB#!-ZN3&!X:;GY>BV!T-PD3<[+9F
M&>0KDNL7IG/!::%])36`NK*W.S_<P+^OO-`3JZ7-0+/8SY3.[R\S>UH%QE'$
MY,&>`CNC60$0^-%B3PW=C6N7XVXT5C_IWG!,O2U&=')XY_6Z(%`7$%7(O3AM
M87*3[Y;8!/_X^B0ID-:H$+M<?"JZ:FXX46-1X&=D$J@,854Q"L@:6D7=/A%-
MN^KEE1DJ=2<Y17FP\9)JT<%'$]E4(Y&EVO<NLO!:<@M5Z9OS%G8]J<,+4CC;
MQ`')8F&/509?NWFSP9[0F4E.JR?'C?#C1UQI0U%:WY2&ESCV[DW#IF0[J5*J
M=H=0`:V_:.UW78T?VE8^4+`<":7HE+=P52V'U8;LTJ@0RD0G[.6N>=`U.1C*
MD)#7S]\118-6+^2*A3;/T@^("O,JU;9Q7MR7YFBZTF4U[:=YS5@6&)2/MFX7
MQZL^9ZEMFE/B@8Y30;#"F#$R7<L>6Y+MB,^4^Y:8!]NS-[",E5:T!#QHC[82
M$D>>M5GGT-Z]76+6X3<`FPGB-U>=)W>%IB,>X0Q0R(5"F+E?$,2W-U7*&$C_
M8LS?=1?<*<&*-QK9JS<50LXV1)YIH!^KK!<K[E)EJ47Z3@+17,'8W32WXW`&
M*J5[J.[FLOVIB2=;%(H9O%0+15@GZJ6Z[SZ<D2X%L]=(F\A=+!L8ZT*,67=7
M_ZK9(*>&=&W*N*E?3&+2S5FL+;N3!0]MDB_MGVE]+2N/\D=M[(DHTAUUP_B#
ME*J?I6D@;\RT^D)=MV`OS-'-7-?\B-J_RM_E/!9_C-I)\W_[.FUMCQYT2LF8
M=L/]EJ.^A#_3@22M75!\`(W>'T3,G(R*=/8N]Y]<NWFGD:E=D0&9Q>.4X=!@
MDGJU32OIA,X:)G&4'\CN7%];O=/T]LVB\=+V)5FT6FK>-6:H0<>)LAH"*C1)
MG4\YPF0WG>[3!XC_4SC[_J.C;K&AX%VU18.75--GR=_JJXO%_G*SYS.U5Y<(
M7@F@SU05W1\S#1*Q07E);AQ,$0^=@A95PSJSU%.PNXP-#UQ;OUNG35O4C`AX
M)`GF3715)\2M'L+17(Z10>Z#2D`X/YFUJ"^XI?\!'6QW$<0I?2M)JS(O]8JV
M?W>L&L23'V>_NV\=\9G2]A)N!T>),&K;S1$!FWO'3+=)X.S@;89?N^JM0^"%
M2B.?$''MKJ=!F%!YYT4#:X??4Z<;;DPY$-@S,J)`T`J`4B*)7:7349!6^_I=
M=I`5AAZ";T9^!^81QLRF+\DPR<]$;&ZMJOTL,7F97'DWBSJO?/PS0)OW5:KJ
M9BU9(/E0C9LQ\]0Z=DGOK-\J-),Z<_VA-N8JV6HE`&!#H$TO70/(PA;HHB<:
MR)7]YM&"X^L%#A;!=8U4_25YX\4B"<1EL#^3YYL6(<,?MN8,&$[>W\K9G!;=
MZF_<:\$3MWT1%HQ[MPIG<\1,',?X7`X.RMD_%/QF_^1DRM3<L#;K-DTV:T8=
M8(%,=$SPQFX^F^V\.E*^)#D8(P"">*)\:K`S+G`W02.:S/IKV[)K)5;IA=HT
MA=M3K4,I!(^-U!5ICUQ)<RG8/.LS^#+=NZ06?`<[W'UKFX6IN.PE;=H8\?$&
M)<[JA@&3U-64Y[]H-Z"9)H`)GU.WCC4[AIV7[,`W6M"?E@1598.Q`2$^@EJS
MU=JVX)?WEJ1/:^>RL/,$3C]](=*JKMWL)0$U7UU]RDXZ3(=2#,DL@6/:1Q40
M"YR%9>8!S[VLB92RU7M>2IR(:Z.I=KA"I8NOX"Q)WXN2+`H_0%BXUR(DI[-U
M\6^=(!O;^4[N=//'P(@XN21>G"92^Y:`QB?JJB5:Y`ARI&*X^?$-IYG'V^$[
M=5L3]3XE.C2;;$R.]W\,&R_3(,-IL-90;KG/8'A.^&;VA_`633:SHUWG-8:9
M"/E!1QYG(E(]MO-NEYT'080S\9A:H]"@65V1P7-?`6/])&+2]0+Q^2_4&(M&
MFI$V::1--FC-M:5"R15#^,8Q&(9?&<`Z.^FH\_!O>7+^Q,)>\6F"&W0,VH7^
MUX3L"*A/J$7M1UW`#J46IE9WU^Y6[Y>)N:P]DO`E^&S`TFQNML<W\*9D:K>/
MM`'!.A.)^-W9($Z^<^>MLAXTS4*3K+5/VKF(Y>2!-Y*#S2WQ3N8(21)Z3E]:
MA79/_BP$/+05+K`B=IE!R=0/8P+MAQ9+I@(W88?9<M!!YR;@8][QH&'E;Z6S
M/]U>F-H!]1/[=1+<EUC/2PR6IB2."9V"+F!/D8]H$-FB=O3Z!V8+]<3BKFR`
M\'ON=E0(0"K)]H[94#WE-:9%20UJJK(KSX^GG3*U)HB\:]Z\7$PIKSQC%$A]
MH.LOQ]>4J2Z:'9?$BN9F:W03H!NF^IOBG]^UX:OKDV_W&83%RI;:0[Z+NLCO
MK6/%C8WB7+9I>8'>U_IQYN7R_MB(M*D(#ME'DJ+G=H!?>3H_("OZA"FXK`.Q
MS@@2-CN^#5'0GE=WCV/ON1:1X^!:,4=!(PT,2-(TJV-)@Y?YPGB9SZ>SFY/G
M.EZ7*NM;ZK-$$X0,:6OKF;F3/R](GO\1;X0N6YN,59@>3CD`7O\P7<1^6WEF
MBJM^@@PA*>BQ0-1D)95W:!RV'L=G9F1T9*$FBAST4?F/IQ1HS&U,?1-+8#WN
M`>AIB^OG=`Y.[QEND^B?V$I>S_X)"A%CC0P?F"<=EC1W/)I3%W+O-0^?9?T^
M^K1?0I5-NL"UVZWUEK/NDUX9ZXVROB;=A_99G!R9(G3<A<QUVMJ52MEYDWOX
M9Y^26T+.$W?$R!HSX.EWR5GGV9LUJO4LYK)6-&";@1.OO='UR$R!,PPN5[KK
M6'>F!SNRQ>']8O8Y8]!W:@B%\]85<R.'W'W<H@!1]C?'.W[NCJ+ID72=5+]F
M/ZPZ]A&(23\IEX>B"D(H^X>+PS)0T4[!OCL#X`4\VFLC2C8OQNAM\%X-19#`
MC4%=_*^Z]PRK:(R9)IQ:LM:WB<]0Y\Z_O0=\[<+6SN5/O'EJ?7'FQ0&)]ZR'
ML_LO.&*)V7S'^6I`9H^E0E)IS)QVOP.<$J2_3\KYVU)RZ=,ZU37;TZ,?3A;'
M9SLPK&9[T3D4LX]_B2^SG<N].PST\MDSV%-79O-8I)`EER4^H\\/SA$9NC7-
M@@L!$=GER$*3C-:`=1G.M@D4QZ(($`=X;:GIM1Y*K%=Y%B5.$2.&7O:>GD:+
M$_N`:C5=S[7YF8:K<BXBT$1+*$JCZ]MOTRUATO,,7CXF4U/7U:Q/F!**XV(I
MW&5&W3^@@U`"`]Y&&\3.:.BFR*)&1B\@#"V#4^(T:9FQPS)`YRX;+O7H$NP@
M[&J*.RY27Y8KT(@4N#Z8K1+.)W4U)2JZ1TX50H1)??L'\IN\Q0Z^"9!+WB-!
MU,3@F9I$!*D_MI32@$\^"#9X\][JS27@8&OB0]G1D.'\?*YJ5FKPNX[Y@X7;
MHF5X[:)?V\?_5I[%@\V+FM.SDBXN6+SZM=&<X)WYC<9_[$*`_`8Y'<[M=%?#
MV+;MV%Y,5OS7#G:'%2X5`!3^Y@;<<)A4WKX;ZLL4B0[[I0P*@D??U::)S>),
MLUTNEC53U;P.^VBVO6"T$P8J=VJX7H(Z2F`JOS&[R`+2U`D>4NN_^U!ED2D]
MI3C\_04-(3370B(*X;X*;)LATQ#-6CM3\;C)'M;IT4OA2L=L.JD^"1S*D8<2
MZB**IFYQ\85EMA6,6[XLIA5XNS01B9FY:1;1,8F*TY>9_7?5IDE3@Q$!15$%
M"((/@*A"AD33'N1*-=?&>]VI7JXR,=896<-WXL0&@ZLD9:[1P[_>T&8M46U*
MG+VVF&LWO``1619@PB28S0?,<C?Z:1NB"IS)Z#R@?RS!<+"-$B6$RN[T1R)W
M?;%M72B2.P0Z9O(7)ARN"\+];#\,N0HK835.OF',RHTC%<H*63D^FBU0CF2B
ML#F;;/"!4S"\\=E:<9^(ORQ`L_0A5N7.3^MN",<2"\U*KCN.B\V5^HZ*W"3/
MQS]Y(,XQ5NI2./0^V)J(`(T2N1H\/>&O'0M>ZQH]M7%@--LB[2V?!M#:XZ@+
M4"P;10/(BCWJ92]C%MX5I#:,A?T,=?=PMGT">*%\GIMW/["^>W+\"N='<1)Z
M@)3038%S,ICTZU7FW/\CW>5^1$Q]@F-E\M=_9"B-9406'2ZE$N_EXR,@`"!Z
M"GO\,"<K]>]?@)19Q)50(L%>;"@D.3'6A?&G,,'J/8U>&.UB7H`ZUI3Y'(XX
M!VJJ83E]1Y();<E20C]DW'ZFQ$%ISP@:J#TM9V[=(?$MA5>`MK"5]C$=))78
M0/Y?/4O7@!0[1WJNVC:<L_O37*J@AY1E#\4QRH>V^WR/Z<D13NH;.M09#U#_
MS+K=`5>#C&!;"*W^UO,(LG&V-9A3NIE!W8B[TS-,T5>'I)A3.MG\QDC8Y[O7
MP1(=+HB=JEMNKJB6+(;FO=4[MXLN;I!'G/9.D91#JQ%T\`F5LX"\L\%&8[\/
MX@^3"'>OK*F3*_,S[`-Z0**^W]LX.'<;D]W8NII60Q>9C\E6O+=:MYSMRQ:G
M_)0T[38AHH[*U].S?*J#Q'KA]:Q=&I?*WF%O+FYQ-(?]-DHC!!"13E.#SY2G
MEH3SC#0A>U2FD](5(J?A0*'MI7E4([/R9$+]%N7MR\;P?9)5W-DU7(N22)Q+
M@+>B)%+<L[6'LL;(L:HBFB(&V8XHG*RD4_BB8\X%;*A21@"9N#XD9V<RC6>G
MEPRR'(`-LS`SWP<Q[:K5`8XS679X_^#E=DN8;^5X!GXS.P53V)V!2V-@9`^0
MJ`.000`'^10E`5\`N>].A7JTX\RQ+XX5T\OQYYKH,YW\.#]8T&8,#D=7)C-1
M_^]@#JX@D_%3'6N9I<FOXY/=?_?6$U8RFB;LB1U2"I9VY8C^GVJD5GLT\B/Y
MCNR9NJ6=&'8_5582P:Q7;TA-.F60O7*J%)7&9@;A`_GL0&%'TYS3E-%O=3_;
M5I_/O=D-RH5HX4UL`3P?R&5O2@[1ZKNWJ.&_+%*%#S&=Q-`E;D'V)#[!>PN2
MQ[,?((D1U6_WT]A'L:PJ3"<"S"9,T>XA,T9,C+Q6[@('[6ZO%IV_03&+)&J*
MQQ,2JWF"G<SR[IC\[F'I379S-@C;9">J"^A?KCV]]N7JG6*(\;X!MC.2=2=T
M3TL]+QUJ8P"\?;5P,?-%-Z(2SN@#F#Z].[I=KO^1*B@+'JJGT=Y/830:S=+O
M?7IT2ABHWEX:B'5!=>C;H3>^9&@&`Y^.5(M&0D=\.KEAB4,4/AX^P^=^>BI4
M1R$Q:RF62LRJNXP6"$A+ASDZ4'2%(:_=:Q!C]J=28*8Z&WY\CP+[Z#E;,?':
M?(7ASC89KCR$334=I]X!YB!2'GW2[YT*U\^(98NR"6RB9_7#!#I_N)F,S).%
MY]IQ79<""BMT9(BVNWM=HI3)]UL/NK#.".(;)GN#]UZ[O=&@EZRA16V;#?O4
M,FK_/WGGNMO&D>7Q5R$&R2X#2!Y1$F5K!Q-`ENW$.[*M2')F,X/%0A?*UD0F
MM2*5V,`^QCY`GF`?PD^VO_\Y5=7%JFY2M#.9#_,ED=G=5:>J3IW[94Z@GY,P
M%%KJ\>607LPBXP\/>M].?D:8O5WKO;$`3-TD*Z.I3K\6Y%HLG'_JG48YB4,&
M.<L1;?X8\N-BYR'LBH&,SDH?[W9R=GKF84ORQQ`K)E(/D!9.JG_XR,W&UZ3E
M:GI^/9DJO(</Q?;A.A[(<A1\2_MP+7#F&`DAIJT?1DWLKWL$A]["F_ZSQ-N7
M6(:Q;`RH-/V_O>/9A!H8CTTAR.<H/_HS#KDIS5+QR.@#UR!.?X8[ACABH:M,
M31:HI6JGYCNYAG1%#BBKUKL)__'JV8V'FOOH,.T^"/#X\)QVL^80W]Y3!6_X
M523\_.N2).?)S]->W^XU3)H[/_WJW\H5G%AH<PY^/G[Y]EYG++M[4.[&&1#Y
M0-Q9#D5']L5PT&X/N".NP&J[=`$#08-P>M@S)(PM\T(H(G]EWA`;$+>&K`HL
MB5!:!3:-+M9/^;?5G)7L0GCZ96^3^BOF**RP[?&U:J$<G[^E^>T4<\CT[IT5
M%)J6&W/"=?$=-RSVQ&`J0LP,\>>'\0`2?-%7]&(G\7I"0!/B01K;N8\LS#&F
MR@8A"N96-1/`-F`>4;M@\H%X-Y'R"T*7STF#<#0DJ,1$KVHU/RBF^:F"4DOP
MYR@TDC>-T9>_LK7\E<WRE;VP^33O^''=XO541@NI<]8CM'U4OO[EQU_*GYX@
M8%Z,6/2'J]%UM9`X/C(_1,$")`DU86O*8>*+$2UZ$2T23DDF+;\:*K3#4*5^
M@ONW]8E0(P[>L6QYZY/U`1+84RWEC[_(90NE^^!+%<G&\<IU)F!>]7^\2(#(
MJ&&$M4DQHZGE"D"!N(`8N!F!G4V"27-IM$"ADB;,[YS1+Y,OC$./Q3JP95&*
MX"+L/<2+$I&]"R4;A/%T!9$\FE>BY(CW%&%H9)%O'GSP!\U(FA0/3`XPN[JB
M>O*#%6"XS;]$)Q0))6(Z)N:G`\K.N-R_"R+&/O3(%^'D+6T(FF\*"QZA4PWM
M8L0[/-CASK1N9B`=V3B^M9^WLR7J/!,OY`P,>Q1\!T&;NY#2@I&571?6?>>O
M4%`H[(N)<#6)2UME1SV'88B.Q@?O3J$]#"G::Z2K26,*6!')B4ES,44H;HGX
M_#F^*^?`&B@49*-&`EM=D:#CC$_.\0=7/`6!:2$ZGZ?'AX?&V,8($C%3+*+5
M:IM5PW'WSG)T0`4#"4>&A07MH;5*@2W/Z(3S48T?13PJ'/9&2&U1K.@D:2B[
M16&_$&I\J"`S=4L"\RS:>B;3B<-O,MB+',;]FTJ:L9/*3\[.]6K,56)_4"-K
M_O[2I.MR.9/+\A>3EBJV]N?(-,O7`_DL?W[ZWDNNE;\?:AWECUJ635L^.(HJ
M:_E@OT':\M$!Q.SC+P@['W_Y`38W_:I\82]6>2\?/.<B$*1Z=3[_P%P`WXO=
M^N^9=??L']9(OC\(ZP*:+"[NU=U,ZJ='0C8]3%)R<\6I'=NGL7_W_,IG7\?'
M\2Y7;+:_O?9H6#'W^!GH>#E2&LC'7_[E]-W-'P*1J,6._F!MN#FH9E^RFDHT
M^=[DQH^_./E1;3P7"473Q"5K8EI.&?#6+OB]/DC8!#T*Z!-D,XQDD3:(J,=8
M5:[QV6CV\X@8=OT<=Q9"HAL>N/#$B9#6H9>DZ)B$:%W,FU<KY@47J]=8T3S1
ML"CN)"G8I(9U!4I@<$L"9D-QQ"M=G(S(0LCOG'4'2?N>+,N(.5:H(5$87VP_
MV"6M6TO]8NO!+NR,7=/1H2!=H[(*6-<IR@W.((J[B&3R>3#1V3;Y*`VV80K^
M"S"BM&0_U;!&"87^2<TV9J`&W>8SX1P@@$83'G#2?&V0066;R2MY49\Y2$NT
M?SZ&!X\PJ;_O/6GTZJ4Z,C*PE.3FZU'%.`XF!+N?F8S7ZY^-QJ/+J]E7LDP0
M_B1S)R2"FV.SST[?HUN%N%:/D&\T*<D((5]DB2+[A)4@PA14?/9U?[BSMEVK
M,_W!SF!M8^=1N27]P</MM<UA]3M"&KQP7+T^W%[;WJS>[@^&NVL/6T<?K&UO
M[Y;#',YMS**-U;VXUX8B)L@H:3JWB$FSITLV<E\-5L:SRE+P;'2!XGQ=@MX?
M;#TL?ZN8[_&L1;GK;S^J6(B;(P((Y;!\4#&+)Z&\:@5N?WNS&KU?[WQ_JQJR
MOS.L9A[LE#\YI''Z\BF@5KO2'PXJB'2<W`6A%M?%KDEV2\QTL]CXOBW=,21A
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M456CXAS]S;7=K4I@[>^L;3ZL?QWN5K<WWDCC:ECL1I!`,<;8/9`"'R7DZ9,Y
MCH2%XEIF%J&IS.W:-[>\&$UU=&-@7P<R[NWM!ZZR&W]-A,-&QUT#=^-.XH>:
MDP+M&Z%ZN`;@-';`"/%UZ'<8B\$H^6&LW!,NN1RQ^C`DA/D2FPM%9+IB60`G
MOS?Q9>S)6<9BQF(EKZ!X7\22U5IR`$A#Q=NBQ>EB6C:*!`C>8V6FH-[[_J5-
M;R:I:/A+MCU0#]9J.SZWS>5!)MP2A)X+V(%EQ\11B82$=)A4LZ0<<9]:/"IE
MH5I4B%*.N<&R7.&1IL=$YX=!PA^1[-?52[!ZI.L9>?PWN`'03P`UI0J6T[=L
M4I2J[G'CI;T61,%0HN5\RXG[0Z3SG=WZ1@\?[:QM;%>_.S>\Q\`M+V9X7H(A
M!+C'H$<C'9$O=0$.BU..\)U@/IYY&[)P_!RK/.28-6/=>5VEX)_2`37WTR/&
MA>J4A_6L4U*NB"OAPD7#HIP&^MNMN''P8([DX"-%\><MZ^N9X?5,RJ)[A2:7
MEY`%XXZF9A:GZNI2"T;H]LN([)P5KW*C&KCJA3/F4=(@[J]%V<=NC^16%&I;
M!QQR5',U;I`JWILQ%PNM6EEGE=38LX8$)WD(A?R,R]RBXAH8E>:[Q4W%(,F:
MD7C,)!<<<Z)TR5MH]RZ8JZS*C:RPGH=.+:YK*ZZ3,,HHZ[GU.!/5I87RA7G[
M114[9_`<UM"XS>F0PQ3]XU!R,ZLCJ=%Y4'1&Q1)4"<`I3J7!OT8L"TENC)00
M*Z`\P)@<*9__%?*;"4UH:1+EA+"F$2##.Q!G9E<D1H'+P$GP:?2_&<*S6`OQ
M4<$1LNH3DCK.-J?$D3;(RM%ZV!W[=3M2&MYKM#?87Y.9IWM!%@Z7)8$?I%S`
MMP3UZ`>`RQ+<H9%^OIJZI^#G6!0SRS<O`5H4M:QW,PR+L(^Q+]ME2_`#-*T6
M[RR]4Q[;F7E)`5VVBJB`:RG6;S*NA*D)0;,KI\0"CE.\+9*W#V24W%TCXHIM
MYB4#@O0>CT_?!*[%3H'\Z;.(%TZ[\EVM,$6$\Q5\!@P&7TT;U[&>,/:^R5V]
M_5Q>*>ENMY\7A\_;4PBBB40+>+,QFB@P-.C2""QL7D$+!FL#NFLTY`@.*2E'
M>@,OAVQIOTX$#>JRPHCQ?+*=\H@\6G3R"6P_29=>)-4M6D(-XL.-/+F;]B01
MKG(IFU2(3'AR,0'3A&2IC+<Y_*^O?L34I3,F0)NG`*5^`6PN)^75+`)>LG\>
MYL-*.P0T]Y/YNA:LB2)OW3LXY+[*:=IPTJFD.Q8I^A</4]!U[I\>.O*6`C'G
ME-U:HD,0CK@;E`LR*CNGQ-+L^SRI-E2'(`[L[=6->GC;#97BDNP:F.^]0>R1
MRC[@'-_'GRZ8![N/=FPKITQRC>?;@6Y&J"[-GX7;W/:XTB3PQ>M8(\1<GG`,
MZ5BPQ;L.D0G/]QB>A@P-&OD-<)]LP'UG4!<PN\9?&Z$GQ5&893&>V0*^&#S,
MI8!EUVISQX0+Z'5.E\1.LM,4>DRI'3%_GE@4[]!FP.<SU9,M:<SK/%9$@P?[
M1R4QQV/A%GCOW_K><K^PE&-(UW_,7.WWX69"8"@D617I]$RWB/^'B`,A*P+!
M*34'&2`3&N;"6'+0&@%1<7Z!<26,*O0MQ@QOB/,"B<XIW!U//`.?PEWE!:(+
MH2:81-A;H?*,"P)Y,%L-T*?`&J,`2?A4C*[7IH0:H;NYAFH\BRTUS[_*?)P%
MR]#HP@,'W<;'\(9.F(7N"(AN$]Q.WQ`]BAM%8QO[U.8G:4![8PIB),_&X9"?
M<'X:T6ABO(0C+<!%HU<H>&UUF8S>@''-(C5/6J@6$\U8'R@+,IM=LZUAJUVB
M=TY\>O&WNZE7_M'Y:PE=0SJ/Y48J^IFAN#C-UZ(F^KC&.XDH@BTG><("-P*P
M^T@O3N!]:#%CC0YQG+YES-GUZ8?J8H#O5$\P7`[*-8<_HS94PB<=Q!H<'/?O
M!,WE-)7]<F>%B7QS6DD-.<@I]"]HD!-MA3U,*6L4"RDZ'GI^I?;A(IC:;>GN
MB/<H8V&S]@XD;]IMC]Z?6H49B+;AGHFB"?_NT,;`VN8=[8_+K*S-&0^$!%Z1
M//[:1#5QXZ'WEX#Y;[?MHN&VL2Z+A=-WR2EOMUV_@!B=UWW>,U\[UQ\K>\%B
MJ\].4>9KF]O)'-YF%,8H&5JH%E42QKU0C&M:V4..U$;=)*+RF\Z)\"^RC6W3
M-(-9R&,0/\N!^P^W*Z/UL5TY(V'EZP>G-U.G>^*VF'1U=S(N7[[_U)W6'=NW
M=ZUJ96_>4@%"-%R:[&0,0:24%,9>*T!L$G+,U^D^2-%`Z+_IPKJT%Z/P=T;'
MQS2&(R!]1+4J@O+&L[?<`>CQA5?S5$71\RM*8B@*`[*36]!,5C$>TPV!Q1()
M&;-IT+QMG@>])ZOY+^V.>100RED.2V)N+++A;583-G&0D,.P#/NK*W4\>J-#
M[QU%\V-YFM4+O:6^Q"WS)7[\I?JT'!NJZ+S2Y'WU(3]3'6P5U9H&N%R6N:3X
MGW!0.EQT)8AJS5*!;%G>9N`[]9JY_5GE;47:Z'?3[4%<'(I@&WV]),1`U<8<
M(KT75']3,QLY*X"*L)Q%DQ`S)T`QXQ!TBJ')V6X43-4H;/+NZMQ)<K!;$N\#
ML>)U.37!1)=>[,R$1%PNY`1@1/KP:N("<#[E@$?*?!CQ]8P$'1.9O:JUT?=<
M@6117#5B!ITIQ++:O='XIZO;R5C'WA!OS"BW(PP5ZEG&7612XFG9(>UYR[&<
M40>.7=BG.]AECTB+<TKT<,5>7=+``MJO&0DG"\,8@LU&I^^8SD4L?=LZ+G?3
M*3PY)(T1>RW/Z,C.7-/<W%USX608:1Y46/Z*^6*!7K,8W@*MHNI5U5EAA>8A
MH[``>Y(X,J)VGHZFR<ZNK-:(UV3G^"Z01:A%"M;L*03]+WC[SN'<I"W8%AQ-
MSCG7%#W"C,/-+]=Z@QW^H^$&@R^C'!*@FP^9"-U(&$/$GH.[8(@GH_.1LBM2
M)!!)W5%/LF78K`8$,D0#ELWH57ERB#8?`<SF0&`]_-*AVO@UH-HJH+)4#M\0
M+3UF0>6@;&T(E*T`Q:^R-YL5*L2M`H/?C%1J_(:2;1+0J7I41.S&XG-VR82R
M-R&!R6VSC??=HPC-R0.IP:P9<:UEDB6>^M?TN>*0CZ5-5EK3TSLY&DHJBA>S
MQ@DB27:V'D")T9-5Q0=-@FLY9ZC=U79#;9R!89:83'YL@M%MO<&O86B1'!H6
M\A.[8@41?0YL>_V+AW-Q+-7L`\VN%(=LI"#DMBUHBP4-'RY>T".A\M]S08VE
MO64[![K:K0LJ#^S8*E%RRM_=@5`CM3I[EOR`3PBQ+3]H>^]Y$R&Z4J#/M@?Z
M+(6AUW\]/KW#FSNZJ$(_3J!("["_$=W"`+'+D@AM6BB:\ZEEWQDSN"&?45@J
M9+R+$T-AC75;&*^<)7Z[SBQ<5]:T8.$=<3'93J0#?6Y6"P*CN<Z\HE\B&/EP
M(D+!>L![*$*-;HAA#QH[G1I340]=?("(2`H"8P4:,!^H@4L&\BM7B(R)R:<(
M=T"'P&U[C93OGCMC,%HT95_#\;LFZ9S:`[PU#>KRW&<(-D@5"L$P>4F`1-7X
M"3_QV#_2TESB\#P)EWG9-;7RY!WLSV'J]=ED/?QI[!9FB#2>Z)W+09)/(H!F
M!AN;;1WQ@@)SXS>8&9R;?9C<Q1Y7>@/-""'!C9OQ<\X/XJ"?1Q$$G1&:.;Q4
M!=#!@<@1@Q\O$]\>]/9#35BP$D&/@_E)J<K,`QN!\++/T".KYH@<DN&:F0E-
M#,$IX^9G.R'#'V1H6H%-O=^.[[&P+NQGDU7'69);Q*3"!@,5I_L=I4N:`7P%
M0134)L00=T!T"PH@MH'M)NS`-CBO9N?-0\ZV2=W7WX@:(*LNC_B5D=^0"(;&
M+4-9%EJ>H6G%!Y^Y!OZ#!`LIVR7-*9YOE<^_JZ(TOJN4RN_JKZIYCMA.BQT1
MUN:9FET>^5?)!<+UE3&EKVVI:%1_BQC!C0JD_B:Q*'7D5W_KX=KVHRH8I[\]
M7!ML5'%B_:W-M9V-.J)LA]#G^M>MX=JCW6K=+SG/Q0O8)CYFH]IEF[L.SQ.D
M.X^J_5:DTL9._?/VYMK#.O:(`,JUX7;+VP_7=H95N%.U@@;S4DQ[$USV&()\
M7B)1?^-!RU(V'FS66\Z;]=9N/&A9Q,:#&IN9:+O:RB=7UPI0*X%JN*W=/=`M
M9FJ$CF8R/(RYW'YIG>R:A"YRRLW$9JZXM>;#X`W$LF6FD>HNOKI]`RD-+AK=
M@^,F_R0/Z]EKW-44AD9A1?]3MP/[J[H!^[)':K3GY@46^3."0;VE'XFN4[S@
M,8H;W6=MG!/]4M^CE4998ZY8EMX^?$J>+"9HFUJ@<-M1F"R87\_+K3^$B"-8
M7%D!@95F+D?2FBE:AEK8[UC880K:.4Q!.P+WQOA$UU<'BKQ@USL&?79G.OR+
M4+`^Y2B+\86XHYX/40)<?&DO]>:^;PA?^P@Q&NX#NYQB)6)05!C^*%60ZEI!
MAGJM`QZB`2.#G%+:T->:ABQ79$E89-EB#)[^:T];2\;TXFGC'4"(WR?1$6'`
M!O&4(H6AW?:>DU1KMIS79F5^^E[&%"24,#Z?82(+V>,ZV&D)U@$6BC&BE=!Q
M'R,RGBRYU)DKE:_K/M_P,8;ZN2\UUBN$KUNVWCR6\Y-:WM&+5]_OO3QY_B=_
ME*4>Q5(PNU"XWY&&1`X^ZV2T=Z,__FZ@7VZ?(?9)-?OC[T[(#)WV7E+(Y8A&
M9F,]O<06CWQAC^WUWUL#'5H$O.B<:[#Q:\[450GHY9].CM8'@T=?V6;_\VV`
M-<M8OU!D#)+*&:J/X1DV/.P.[WK]L#^[@73G"6"&,EU-7_]N&//Q__ZQ&*-[
MU-77];=8=,J_L^WO;)+UVX/25<_J-X5D]K51XY8:&MUDO:/H!C9CD>G*EN43
M>%8S5Z8AY4$;,`-+YO1`>71#Q-*B&//U&CRM<5TYK&(>+ZQ>PUY6K^&U@AP0
M[7#(>@\<VI>02O=]K-7P--9J<`85TB3GR7[8KS(/.53&#0P+@4G\%,6\E5O9
MA"WB-)])]\%'N$`:.9`8^CAD;#V.&5L(/EG&5CY0"7[_$[YIQNLU$V4"R;Y;
M,+3K0:#!X%!.G`N]XNC8"R2\(A8\B7'L\HYR8#&P/LHJB+*+!A-.-8/)"%/'
M/;B<$4-N1)+,?!"UM=DG!,:_SN-B!'G8V!K6TAW7>;."H*'XX6\:._8>=NQJ
M_<O,C9US-)K08OODB2Q1"$23GW6LKEIDUO!_=GO@KV.P^1PE<3WO!O8\,ZKV
MGZ`)7EU_A;7W^$GOBTJ'M%S^8&VB4+3[$K!/W8W1%;F0DGD5RAN-;K4V/8"X
MRN_>7J3F*+J=_TL>A!)S]W&O0>6J:`IJ!S[H;0VL?$9EX;&'@XZ'<YNXQ]6.
MZLXKBD9D[O\V3?NO!VKB^ERFQZK25-)5/>(ZZ=JX%Z.N/4VZ=KE,W!ZC,PP1
M<GR7SXZIG8@V8!_#D<9H7VR_%:BJ#!<OZ"RK-FD8':75RR/JX=?W`4K,CB`L
M#,P$FEM`.;SU7":$4:/#E]"=4-XQ!E:4SUXL@F)^&@+%;F?K@K8<Y$!89M&T
M,AFWA;QX,0RQAN0&)R+(POK9+VF,[T[_QG_#;U92:X1-`F-'.=DAA2[@,RHD
MQ7`M'V13`,[G?$Z-Q,_Z7/M>#M#LA%O#18OON%5$'EK24-B.-Y/)A<SXY><I
M=DB+]Q`C+%B8O+5E*]IHH_V#`?(=-?L9HWDJA(>\JSNTK.2@N(+^='-*R.9$
MK-Y?7YC[N[J"L:Y)*LQTX>8]OSMNY+(V`Q?:"#6$CB]$TWICL2LAB.OIFCO:
MDDS/U7UQ(Q+&+EO;A5+W\),0-44J635XN+9=@^-8Q%!G9,#L=8#_4F2``*-1
M*J/ZL'-?.BA(#)A5.&D)4?LGB:S(Q%E^D@C@O8R-Z\C5*Q@G5S4K]I:Q-?SE
MB8%49N%&UGE.E.SMG1'SM<Q%ZV*G&I!;@"#6*7IK][[!O'O#G9LN")!::=6]
M3^;:JTVSB*^ULQ115;&L_&HU/*9$C1-B>42Y$1=N>Q(;RA>JFYLPS1C8:K.]
M"GRB:[*]GY!W1/W5ZVU]JIS1AC,3((N]LH3O`)O>=6\@#FD%Y'N;J5)MM19_
MEQ?BNWP62\/6X\Y8H+$NW-<MXL\J=P1L^73K^=(+TRB_BBEJT[IZ+ZRP'<0)
M2^J19!VK*"/UZ>5$ZD_X07X@KL@B62HT<AH%,J<A'D_4OS12R-[_Y-KXMW2+
MD0>12N%V4)OIO7+#8XLH)92DRL*'IW+4?.[0"+FC#W12D;B'9?S^T`[2U"6T
MHJ3NPE@W%TYP9RR1V",K(F:NQ:T!DBQV>WS6Z(M.]8EJ*)'I+K?337M<$7$)
M*BE:[D.$N"VYFD3&4?7!X[R#J/E*Y(7H/2?$D6!/E\WC>9>3';@[0(XC&6B<
MCW>]_"*U`I>LM?S]9P3\7\E!)&[R7G]XR(>[#I9_'W>BZVQCE#G.F564O'@T
M9IP.AK9R7UX1,ZLV@5QN`CL0`,PZ1O4!DKI0_Q`9D]CS&9\B(,5BPA2>-%QI
MTPJVG)^4$QV(4ABUB`C0=7"@`M8\84(/^&_?5.),J[SUR?QX8Z$.;*20#=PW
M)I#:)"^AD1`'$BEUF\C+L+Q>.Y2Q28:I0'RY14DI,S<UDZ*(+1BH_'Q>0T+-
MR,[?9P8_T!TH:7$#$C8I]O:P'`U38)K[.%_$2UM$U^$=C69DB-KAK;R`:OW3
M%OVZA-/2$9'E6\O9)G^D54,N/[4N!VZ+&*+'>FZ+=6/RMG6#;KD]ZAPFS!WI
M=H5%]QFTMW#,VHS3ICX4E4I*T-W)_.E"*"WZD+&].=]N.?CTOR\KLATF7,1$
M,OP['UDW6DD;M[K'X)QE@F`=\4149;G'%/QK>>U+&(X).R-CFE@-0OO.O;#P
MW`<,)>H3W79M:D_P@?..65X$"7@/HQM=W6"P1@Y`ML!(UFN;C(MK@%5"Y..Y
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MP8"2CS*+R^1D)C;PW56G&,H?[=M;)M$H+\QBSJ!Q-%8`VZ-3)9(>==K!CGI]
M4==UV_/$_)1&UF;RP;0/AY.1]?B<]&F`HG'3J//"!+3'MGHAUP]&UO3]F,BX
MU.#%\E88M=RUENED)NAB^2M-UV9;C7**I$-#\A3KXT74CPZ?=T^NE*L1ZJ<9
M#<UB@-SAY:6(/%8+@HHLGTCG5V(J[,G;)&12<QSB!C''0ZDN/93*QVQQ8>X_
M?_&7YWN&"1&3NK8*97O]7(:#-)C#G="Q/(K5KM)Z\IBP!ZV?=@>(+:5)6]L+
M!657D^*D"EI\<I\*I_$#18DGS26>0;GSZV?+\G_3!ONA/'Z0'\OC!PDOV@+!
M9E^O!`S"%W1!M[TCF59FC*N0#2_41J)VTF6AH9],M"UN8'ZL^Y#0#M7Q,%X^
MR1H1VNPH1&^5%PDQ&=\I8P'GU?@-PMLU4M4YXE0>%:Y51M)GWD?RB''(E4@M
ME]J[,2'](:<@4U^[+D[W)\B!UX%;MMQ-L\F[>R%RTOWKTROR$[IF:H")$N*3
MV.Q#RXM)E`5`'E`LU4JUSLH%"RM7A^3%"-U7*1DDY)VC87C9B10_NF0=YI<I
M`SP_&>G^_934&36(;\M&`!*YFV-E_T78B)&DA5P+]Z#%L+CS'\N].X+SA:!D
M=S6]QDK#;$W-\O*+:!;?WACT?Z0&,GL8F[=0X6@TY_1RY@N](9VH'(?[6X<X
MD=/!E9CK[1OFH61$5`)O,.Z5HQU#<N`[YQC8@MSBTH4Q:.IJ>Y)N=5>B+%(]
M6#Q>"("JOJ*XC22;ZG?38Z<5B!(>U"H*`U*$D'.V-.)R?9M1G;#&*A*NE*%U
M<WTG*YK5'D*%>8/8Q2418R6FBHVH1I$H=9@EA3]/;\MBVGEK,^.:^BA.U;R!
MB:,[P3;9VJQX4?5J_19*T5:U3D?YKV2\:T"OJP"C"D4A_.@X5L^98L:(J8;)
M[M^U>N]UY$5$4NFPNCK^1:S\[JJIS`IU'ZMRRQZUV]M,*+W'3F*N3^%R733Q
MF"J;JIJ?8>P\O!V+W/YLT!+M[0+-&TF5>T*UD@UY-M8CN9;YEJV\)S9UT)PN
M&/:\^DS')J3==?*5&.Y"?.;@=$M"M$.RY&&]XQ@BNI2KQG[FZD>@2('JJ7^?
M>B:<409`69SO@DO;#8#U(!ZG$A<+?MP7E<JAFIB'G,"W7\X6?*HO*>H8MWH/
M-TD,-/0]C;"6`!S0-U7YCTUFSN5($3I4^Y'<IG\8>W59!<+&!/P>1*5J_M<R
M&/U,\(Y>,GF)Q$3XEC@TM1TLK*7Z""Z2>!L>3"=,D`H5KO40&,4+&6.`MX0K
MS^`-ZQ$)JH:UA=?LW2.F_AZ9&DOU@YR$LN@&_KVFBYP"(O/WHNIH-VBA3;W!
MI4R0\J@H&7G92JM\2;6+VW.%O'%'\B8M'2'`K:,>Q6XXO>2.-DJ?C,F&!]TY
M+;W^4[6Y-M4@`_;(RUL#*>=,ALK=NW%E"H[.]O70[D?5.WP]A_'FWV-5@=C-
M'8*H#5?GYD9>-FIE<`X>\O:!9I66!=3)6[N'>XDUX9.&O%>:SSHJ+$10I4B7
M)/0LQ<TXWQXW=7ZL9&I8[/;.2W7L/4Y;!7&,B3,G+WHQ9:1(J>')O7--TL@E
M*?/B')'0,6](/S'BL\SL\/CT/7)&[UMBNV9O\2PTIB,&>KSW'[U'PV&O_^WH
MW81Z&VA37W6"L?<.TUMAKV6,F(S1^9V7-LD`.#C83R\;$#]L#]9WAL,!/>;?
M7?V(R5]5R=YBHEL`S%QO^FQO0D)&FJ#<3+=5Q`_*IQ%91-8[D>63-:FMA5:4
M+/9IH_++N-%UMRNR%@TM^*VVRB7EPU8-`LP71')QJVZ7?3FHBI"G>/\8[YZ3
M^H5J8&E<FZO0;&9=#_3/K0O)BEDQPW@'TX&#4:^/[6H\?<T9IG"2@U/J$;Y-
MKY7;E*PJR;B<1Z0V'2-SJ&1)0A^E1?L=]BN%)CA70F8SMB0L$CN_'LDM/Z6O
M*>F`D%^3.>ZW$A1>/O6J,YVPM^V!EZ1!;4)G1D[I0OB*ML0;\!2R0<0QGSK_
M[!Y!/C7QE;L;[+#8YK7J=%Y1XZU66TV\C)`1K#_!:,1$B+06"FU1#RWGV#SD
M:`)PTF;A?]+>,%LIW!-53MP8`;>Z,DMA`\<R]2KHCHWI/(@VW8:F^TSP.FQG
MDI,R4<K@WNAV45?C1X[1A08+:72YQ1$B\S&`\?ZQV0N($I+X=6BQ)UN-I1`5
MI.YKLG#2S]WB)US.ZXF'"378F/P?'2>_#*3/.917-V\I^S:C,AYDZ?8F)C?'
M(V'!SY3_1?V0^%.Y\;^Y)"):^AEHN!S>SJ4VSHK&Y,*9657<9,F'&IAT3KR+
MV]7*#2M4:6&GE=HB[AZKR]W%!VB)VG:!Q#9&^7VTU#0.H3EHDB>G_&Z%A0O/
M:9V>P"+PX>)J\M,I]9RQHN$3NQQAO#@V8%\B<X>`DXO.G>MF9!`\3^"$J-=L
M;(4U`!Y6O!\5*T>/;TNCAM&>Q7@,#+V61MV%QJU7$VU<UD88205(B]Q9OI.D
MD5"I1X0_]&<O7S7MN2U5%@_:DJ38I;I&KM_.J6"Y<+1(#Y:ZDZG/^\+81<*4
MO0#!_8;<D6GO6-&47;N.8:NIYY,?0=<'WY"7>LM%$3_?NY`[&QLG/!?K;=<G
MG1OXR2+S\SRY+=11XE:[)<'RWU;)>3NQUA)S=6,EGR'H>`2E48,288X2*O6L
MKFQG>_ORP\T073\((04[P/NA$H22WA_[EILML>P26H[M*R%R`*L5]7NR\H"A
MC!9&>[,>5-?I:<I]N5S0/+.<;\')_B8)W.GJE8`-PR:'N(VI(CC:MCF\5WZ^
M8%WV*$J_>X0,J%?UPASQ!&2OGW_<R(%KJ"9MV9R9+<J,A&NY`8M\EJ6N;VL\
M+<G+*!!FSF#TBGUDRV6W3+@,;[H_0?+S%L1&*KQ)>4W&6[YO_'AKRD*5:;7#
MGUY__#T>%QB:B--32A98Y2+8N'Y>OMA@6FO+-4S7L<,,=Q.)SZIGM,K`X2PZ
MO`J?,%(G-?B$L>:/>U_F:WH"E)N^RL#WQX,51LT01$;]B"#D^54(LL*HJV!.
M8TR63*9("K5A4?/T.=PI=RYXSBA"'!RVU"5N)6D5V(LF[-B.MON2`-B(`&P.
M/A^`!3L7T@9ZPSC?8+=UOJ81.)'?@?%9'8Z%^[G@JQ4V9<$H"U:&T[&I!H)1
M>\6Z'QE#:6<<Q?CWJ0NRZIB9>WV5W)4C#,X]9`WI:!;"(GL+:>G68N`9W=/4
M<)U$F\!0^46>U%YRD=[3."_+6&O/VO)6L5,6ABZ;CZ==F_NNJX&KT,IE0DK0
M>H]7=(HF2LTTA99R..)'D=@N[72W=[S?&PZ&QL0>#JHBETFIJ5JIM2Q.:.85
M4*R`ZAA5,13A#6WBY*RLVJQU#\1J@[[`OK7UCGT6VOFVM#XJ1UWPZIH\KE=2
M*X"OK8S`7(46%LBJK',S,@ZL6(5?.]M-A.J.^BCK>5("][+J1%&^$<'OTGH4
MZI]%N^N.6PH'C-)PFO\K\B6<4#GZDJ^7;E`@`5IE>61+OS6[<J<VMQ?*:@)[
MZHCF%UHQJ_,KQIL^!N5>')R\+!<8`#RQ\CS*F(PD<84Z1*L2K;QDR#X:'I'.
M]Z]3M.ID<RC*,E,1H14&0N^/$:(?%FK\&K_ISI21).7QLDB[1.0"Q[XVY6ET
M?D]\"7BJ*[C@:Q%NM4_ON@I59Y'/2%.R$/V<Y2PRA#0*0H.7J15(Z!-2;D7S
M#1@9423TJ%GV+38NR`_ZH!%\(HS,TMR:]:J@17B?W;5&%2R!P:B11?WH@LUG
M#^&\:)FP'(705!J0=IU.=-7%Y]@><TME_+D<-`,MFM<LXCZTY2A?;YE%?3>Z
M1F]Y?=Y]<8_QW6R_P@RART7AS2YG:L/F""Y6O**\U]+;GB7>U860\X>U0TJ>
M1HJ*,&G1&Z,$^<CJ-EF";@,>DEA&!.,VR;A_+]1<;<SD>(SSE"`N[W"PWMF`
M8>D>!^YBE\TRA+J3N,1X86UBRUZIW,*%IS+`-"#_?CJ=??W_`@```/__`P!0
M2P,$%``&``@````A`(X6'ZM/`P``^@H``!@```!X;"]W;W)K<VAE971S+W-H
M965T,RYX;6R4EEUOVC`4AN\G[3]$N6\2$R"`@*JDZS9IDZ9I']<F<8C5)(YL
M4]I_OV,[3;%)&?2"$OOURW..G>.SO'VN*^^)<$%9L_)1$/D>:3*6TV:W\G__
M>KB9^9Z0N,EQQ1JR\E^(\&_7'S\L#XP_BI(0Z8%#(U9^*66["$.1E:3&(F`M
M:6"F8+S&$A[Y+A0M)SC7B^HJ'$71-*PQ;7SCL."7>+"BH!FY9]F^)HTT)IQ4
M6`*_*&DK7MWJ[!*[&O/'?7N3L;H%BRVMJ'S1IKY79XNONX9QO*T@[F<TQMFK
MMWXXL:]IQIE@A0S`+C2@IS'/PWD(3NME3B$"E7:/DV+EWZ%%BF(_7"]U@OY0
M<A!'WSU1LL-G3O-OM"&0;=@GM0-;QAZ5]&NNAF!Q>++Z0>_`#^[EI,#[2OYD
MAR^$[DH)VSV!B%1@B_SEGH@,,@HVP6BBG#)6`0!\>C551P,R@I_U_P/-9;GR
MXVDP2:(8@=S;$B$?J++TO6PO)*O_&A'JK(S)J#.)@;Z;'P6CV01-IO]W"0V1
M#O`>2[Q><G;PX-3`;XH6JS.(%N"L(HLA/\.104AJS9U:I)>"6L!V/*T3M`R?
M((-9)]D8";P`O61D*])311SUDA#P>D:(_'I&M<AA=`@V1C+3659QI4<#%@`D
MYGH`M0B2>92!).[CTWG<&,GX#>!HP`(8VP#G=T>)5S[$TJ<^&3L_;"2)WKJW
MI&NH='C.PH%#>YR/\SA*[.!,'!PCF6L<].G&H4W?G;:@IM=`*;$#-76@C&1J
MH"+XL^?3]^<MK.0:+"5VL!+[9S=&,A[<NN$Y"T==24?O^_FM4V('9^;@&,DP
MSO"<A3._!D>)'9RY@V,DPSC#<Q8.@M)W>7JTV@::.:=DTVG>/=OOS]M@3IT^
MOV_(U-;C$C`[*=!&8\YWK,ZW@YYV+H,*&T[5S8L/%3)5UH)S*W.GZ5X^N":1
M\W:FM@)-Q_.WJF'#J9IZ.9RIP!:<6[6ATU#G\!R<I1B",ZV&N8EKPG<D)54E
MO(SM51LQ@K>['S4MS@8MX+Z"UL(93Z'UT>-A/P&=1XMWY#OF.]H(KR(%6$9!
M`F64F][%/$C6Z@MRRR3T'/IK"3TF@9LP"D!<,"9?'U1WU'>MZW\```#__P,`
M4$L#!!0`!@`(````(0!UXPK3EP8``'H<```8````>&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULG%G;CMLV$'TOT'\0]+Z6>-/%6&\0*4@;H`6*HI=GK2VOA=B6
M(6FSR=]WJ.%*Y&CME?J2K,7CX>%PYAR9O/_P_73TOI5-6]7GC<]6H>^5YVV]
MJ\Y/&__OOS[?);[7=L5Y5QSK<[GQ?Y2M_^'AYY_N7^KF:WLHR\Z#".=VXQ^Z
M[K(.@G9[*$]%NZHOY1E&]G5S*CKXV#P%[:4IBUW_I=,QX&$8!:>B.OL88=W,
MB5'O]]6V_%1OGT_EN<,@37DL.N#?'JI+^QKMM)T3[E0T7Y\O=]OZ=($0C]6Q
MZG[T07WOM%U_>3K73?%XA'5_9[+8OL;N/TS"GZIM4[?UOEM!N`")3M><!FD`
MD1[N=Q6L0*?=:\K]QO_(UKGD?O!PWR?HGZI\::V_O?90O_S25+O?JG,)V89]
MTCOP6-=?-?3+3C^"+P>3;W_N=^"/QMN5^^+YV/U9O_Q:5D^'#K9;P8KTPM:[
M'Y_*=@L9A3`KKG2D;7T$`O"O=ZIT:4!&BN_]_R_5KCML?!&M5!P*!G#OL6R[
MSY4.Z7O;Y[:K3_\BB)E0&(2;(`+8FW&^XHEB*GH_2H",^@5^*KKBX;ZI7SRH
M&IBSO12Z!MD:(K^](EB*QG[4X/XK0+:%;?CVP)/[X!MD;FL@&4*@\$>(B\BG
M"!$.D`!H#=Q@Q38WG74!>W>;H_X2X9@.X?ME9`A)^NSJ=>76`X<`),0F<'MB
M#0:"ULH%(Q,C1(X36P^<B>62B35XX\,:AI0+3B9&2-QO&>,B4NYX;H^+-(SB
M8=RA!<4Z/Q\:3&B)(2QN!$(BK"05AF,=].,YCO?Y<GA$2WAH,.$A"0^$&!Y<
M244J)K<!+(U3"^`0BUUB\RI6?XD0)/N3(00)BB@<MP?S9`]SSD?V#CGM1K-;
M78,)J8AD#2%(BO%4D:++G7$AK7&'5KJ$E@836B09&4*05I(P,IS;PXK%8Z8=
M4@QT9GZR>C2A-1%&'7'CFR)+$K!P-Y^YB6(0*@;,@'#)+1-M%%Q''V@C,L18
MRF2>O)*Q>]/EHK5S=E4Q5%J'RUBM*`H&@S.#1T8DD[D#B*(T'MO9I:;5=3XU
MU&*;FB0[E#'$&&J1"HG`YS<`+K5%`L^F"B_)S)G!(+5(6<V&$N&,0U>,2W.)
M+9)X_0Y$VE&.-6NVTQ9Y*5G$"?7<1$'J4@O%V+,NN46ZSU"T8<L&7Y23ND>,
M7??6$W=RHNVW7P;85-3E6*8F,XYL0Z4/W6ZVS!Y/&;LF58MTG4V%78Z!#3%;
MN54L28?F)@9N&)-@F`-S-V6+I)U-M5U2RS$84^623:3!5O>(6_OM$..+U+U'
MN^HNQPK%E!D,$HOCD!)SQEF4AF/.76:+I)U/I5V2F3.#,2E+)WYX?=PE1G1^
MWJL-G^H]K:;,8)"@5(P(2.Z,"R7&FG`)+E)[/E5[-4JBV5-;[;F4,6U0$P29
MPUMU=*4/.%'[F;F;JKXBTIGUD3>^I5_FB2G$J[:M?S'.]\8>[78`-9C,8'!B
MI:R?$*AFSC@+53*VD+N/BT2>HUS;KJW(-F4&@\PB&=+FS1U`FG#+H5QJBRR`
M3RW`$DI38K;$PV&`O5\F;3<0+CEB`S.+;&H':I0F0]*V`\D$M0-NCR>AU>`N
M0>(&,PE.74&-"F`((L;N`ML'8LCJV-L.)WV<8+?!/$[]MT@[C-6,G`P&BXYQ
M*#K2NSE!,,6OD5SD"6+J"8IZ@L$8D8C@W6(P<*PZ!Y!PD5Q1-D%<X?9+48\F
M>2/%E!F,R9N,K5XTU-!2#"#E5C6X6[O(#\34#Z)Q.\R6VGX@0\430CXW49";
M`LNX=K(EB".\D[>I$T1DQ[(^HG:"\6TWHDYZ&^-F;Y$_"'S'A_P,K]H156&#
ML9K4?N).3BQ`=V4,4[R3I:D56(9LMA`QM[-T$^,2)88PD^C4&.B!7"80(_'$
MCN0R=T?'4G#)$4-X)WM3(XBHS@I;Z%G")4N)5^0N))+P4C2VD4OO?]F!F-H!
M?=/(#`:[\`Z.QXDVYP3`DBL9E,0=;F>P1[OJ1H\N,H-YI18GD0BIB%",X"(=
M"\#)H5SD##V:$"239P:#!$4DZ$ER[@#NDC2U?K:ZW(@US+-6N,6A)PK6404V
ML<'@:?:;)PHNXJT3!;SJP9N04]D\E7EY/+;>MG[6US@<VFYXBE=,&5MG_0T3
M>9[#U5/_/!@&X.;G4CR5OQ?-4W5NO6.YAY#A2BM8@W='^*&K+_U%Q6/=P9U/
M_^<![OA*N)$(5P#>UW7W^D'?3@VWA@__`0``__\#`%!+`P04``8`"````"$`
MGNTT(J@$````$@``&0```'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R4F-N2
MJC@4AN^G:MZ!XG[+25`L===6Y"13-34UAVL:HU(-Q`)LN]]^5@C2R6+O[O:F
M:;_\^4U6U@J)R^^O9:&\D+K):;52C8FN*J3*Z"&O3BOUG[_];W-5:=JT.J0%
MK<A*?2.-^GW]^V_+&ZV?FS,AK0(.5;-2SVU[66A:DYU)F383>B$5M!QI7:8M
M?*Q/6G.I27KH.I6%9NJZHY5I7JG<85%_Q8,>CWE&/)I=2U*UW*0F1=K"^)MS
M?FGN;F7V%;LRK9^OEV\9+2]@\907>?O6F:I*F2VB4T7K]*F`>;\:TS2[>W<?
M1O9EGM6TH<=V`G8:'^AXSJ[F:N"T7AYRF`$+NU*3XTK]82P20U>U];(+T+\Y
MN37"_TISIK>@S@])7A&(-JP36X$G2I^9-#HP!)VU46^_6X$_:^5`CNFU:/^B
MMY#DIW,+RVW#C-C$%H<WCS091!1L)J;-G#):P`#@KU+F+#4@(NEK][SEA_:\
M4BUG8L]TRP"Y\D2:UL^9I:IDUZ:EY7]<9/16W,3L32P8?=]N3LRY;=C.`R[3
MW@6>@\N7AP"#[>8!SZ'SP_-P>I.9:/+P/*"TNJ'`<QC*E^?A]IWA.71^>!Z0
M</VJPLJ\VWQU)AK/D2[EO+1-U\N:WA2H8\B"YI*R7<%8&&!]3S:>&D/Z_2K[
M(.V8RP]FTYE!8C50,B]KUS&7V@ND>=9K-EP#(1PT\ZDE:[9W#<MJ9NQAL,/`
MQR#`(,0@PB"^@_>A&?+`]G?%?6")`#2(Y1!0B.$HH!8LWL^K]QX_UDN.G^G*
M(]C\1"(KMF.%ZZ``>V/-5';9C14S1Y<U_EAC(4DPEK@.^JIPK)E/'?FKHK%F
M9J/0Q&,-RKW]6($'G(PE<WL8B[3$L"=*2_SQTC(U;,%"VKO.NW&7Y1NNF78[
M,$O[+08>!CL,?`P"#$(,(@QB#/88)`*08@([_`,Q8>J5"A$?M@(7%=R&2V;=
M7F*XMHW:MU*[9<YG2.")`K9-HDK8B>V&.\/]?;'=,@R<F('8[NBNCI(R%-LM
M:XZWPTAL-RU=1\412^VZ/M-G0S9V2;,7!<9T[IHH`HDHF!N&$&)IZ>#]*BT=
M>P5\OF.Q7F@)'52[&ZX1TAH##X,=!CX&`08A!A$&,09[#!(!2+&!XX,4FX]+
MG:D_*W6N$6*"@8?!#@,?@P"#$(,(@QB#/0:)`*28P%'J@9@P-<H3E*<;+A%"
M@H&'P0X#'X,`@Q"#"(.8`Z?;<BS3-E!%[L7VJ6E;:!=/Q'9K:O^JWM@]#1^Y
M/J\WU@O%T4$[PH9KA$!BX&&PP\#'(,`@Q"#"(,9@CT$B`"FWX(PLQ>;C>F/J
MS^J-:X288.!AL,/`QR#`(,0@PB#&8(]!(@`I)NSH_T!0.CG*%%QQO4:(RHAX
M([(;$7]$@A$)1R0:D;@G_=O>F1LN>EOO987NP`M5?AVR*SG+!NXQ=1S]_43*
MP\DOW/SV4Y+Z1+:D*!HEHU=VF3:A[`?*+_H;8P%7!3CQ(QZS'P`8UX8&N']?
MTA/Y(ZU/>=4H!3F"I3Z9P7NEYC=X_J&EE^Z8_T1;N'EW_Y[AEQ8"9SY]`N(C
MI>W]`_N"X;>;]?\```#__P,`4$L#!!0`!@`(````(0!B?*D['@4``&@5```9
M````>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;)1878_J-A!]K]3_$.7]D@\@
M?`BXNHFU[95:J:KZ\9P-!J(E,4JRR]Y_W['')/:$DK`/N\OX>#B>,SD#WGS]
M+,[.!Z_J7)1;-YCXKL/+3.SS\KAU__[KY<O2=>HF+??I691\Z_[@M?MU]_-/
MFZNHWNH3YXT#&<IZZYZ:YK+VO#H[\2*M)^+"2U@YB*I(&WA9';WZ4O%TKS85
M9R_T_<@KTKQT,<.Z&I-#'`YYQIG(W@M>-IBDXN>T`?[U*;_4MVQ%-B9=D59O
M[Y<OF2@ND.(U/^?-#Y74=8IL_?U8BBI]/<.Y/X-9FMURJQ>]]$6>5:(6AV8"
MZ3PDVC_SREMYD&FWV>=P`EEVI^*'K?LM6+-PY7J[C2K0/SF_UL;_3GT2UU^J
M?/];7G*H-N@D%7@5XDU"O^]E"#9[O=TO2H$_*F?/#^G[N?E37'_E^?'4@-QS
M.)$\V'K_@_$Z@XI"FDDXEYDR<08"\-LI<MD:4)'T4_V]YOOFM'6GT62^\*<!
MP)U77C<ON4SI.ME[W8CB7P0%.A4F"762&;#7Z^$D7,Z#>32<Q4-&ZH`L;=+=
MIA)7![H&WK.^I+('@S5DOIT,>;1G_;^CPAEEDF\RB\H%IZA!GX_=:K;<>!]0
MTTQC8L3`(]%B`AN1W!"R@#(M,P(>\&U)0RDHZ2F(>E^.&T>YR>88KFP"\1V(
MC4CZB*EO0U@?LIRW$.L84_L8C^E+,/2-4;[5C/)'S$RUC2Q@0@/,"%A40/KG
M*RHW;5TX;ZOH:DZJ$2-FIGJ"ZGU;:_4V`A8[>$B>9R<W47:$08P89!>V(JGF
M2VYK+3LC8+&+;':/991@RHJ\<XR82-4,3"(B3U)BKD?1:C&SF3-<5VU@$5T\
M0U2"*=&I_48Q8HQ^HP%F!"PJ<C(:MO.X9A(\U/J(,:C0`#,"%I75,U0DF%:%
MRH<8E"^:+GSR2"3F^GPQI>L,U_OR!6!Q9M&D5P_;GMI%*9..B35HX:N>\R?$
M6!*ZOB0MR33@#FGIX:.5#M#Q;4OIW%,]F+$&&5KW(LR,6&H'TI['\T$S?^RZ
M*N76-?G@MB["3(S-1SKR>#[HWW9]:/\%"-(-V.\_:WW16V=Z_8Z6TI\-KB,;
M$%W=YMQK0`2U#4B,.@GH.CDTTX`[I*5M/T\:S=XF'1'[DQ\!P0TZF9->A)D1
M6WCIT@:OQQ88H*</-*)A_#C#]+:.(3,C-A]IU>/YH+';]5G0^B"H%75.1$L"
M`@A(!J8!=U25;CZ>+7J_S9986!P8`T)7CT:8B;&K)TU[/!^T^`$UC3F@^=`(
M"XR(Q2<DL^)Q=RDTG1%$BUB#6C4#\C@D%!"2AYA10/=QPN;^U,@([XT,,K]B
M#>J>@Z0786;$Y@-],U[;4**'/JUHD,D'MW419F)L/M+?1_=:B-/`[OV>M@CJ
MM"72)3I+"PB7OO732:E:E?7P'<`^"QDI`WUZ9Y1$Y.-5'"*HJV32BS`S8O,A
MTV*`#PZ`Q\^Q_')N3XE>A)D1F\]34R+$`3"@=6]*Z&VMN$1\IM=516UV9&:,
M^T`0WID=$7G/6(-,%7%;%V$FQN;UU'0(T>8'5*2S(-';3#X&QN8C;7K\$XNF
M/J"BX?PX'>`"S.XS>24F(YVN79&1'EYXX7U0P:LC3_CY7#N9>)>760%\&6BC
M>-$6PT6;NI7RV@6XY[JD1_Y[6AWSLG;._`!;_<D"NK["FS)\T8B+NGUY%0W<
M<*E_3W"CR>&:PI\`^"!$<WL!7[F]]HYT]Q\```#__P,`4$L#!!0`!@`(````
M(0"+@/R7<`0``$`0```9````>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;)17
MVXZC2`Q]7VG_`?'>@>*2FY*,)I1Z=Z0=:;7:G7DFI)*@!BH"TNG^^[4QD*HB
MD\M+=V,?W*?L4S9>?/G(,^M=E%4JBZ7-1JYMB2*1V[38+^W__GU]F=I65<?%
M-LYD(9;VIZCL+ZO??UN<9?E6'82H+8A05$O[4-?'N>-4R4'D<3621U&`9R?+
M/*[AL=P[U;$4\;9Y*<\<SW7'3AZGA4T1YN4C,>1NER:"R^24BZ*F(*7(XAKX
M5X?T6'71\N21<'E<OIV.+XG,CQ!BDV9I_=D$M:T\F7_;%[*,-QF<^X,%<=+%
M;AX&X?,T*64E=_4(PCE$='CFF3-S(-)JL4WA!)AVJQ2[I?V5S;GGVLYJT23H
M1RK.E?*W51WD^8\RW?Z5%@*R#77""FRD?$/HMRV:X&5G\/9K4X&_2VLK=O$I
MJ_^1YS]%NC_44.X03H0'FV\_N:@2R"B$&7DA1DID!@3@IY6G*`W(2/S1_#ZG
MV_JPM/WQ*)RX/@.XM1%5_9IB2-M*3E4M\Y\$8FTH"N*U00)@W_J]D3<-63B^
M'\4A1LT!>5S'JT4ISQ:H!OYG=8Q1@VP.D;N3$8_^K+\Z*IP1@WS%*$TL.$4%
M]7E?S0)_X;Q#3I,6LR8,7(D>PW1$U"$P@1B6*P8'^/:D(14F:1^*>KT<'4=\
M2>?HS70"ZRL0'1$-$;ZK0_@0,@U[B'8,7S_&;?H(!MTHZ9L%01^WR=>:,$$C
M&TQ@9!JX8M"H0.G5C-ZF@N"E#>?L*QF.)P85PDP:+;"Q/S;4$&G^P#7?YYK?
M#R?C/K[&&Z[/X[P1;/">&-5;$R9H>!N^Z(:/7_=I7,?/<$6PR=4L-V&N<[WA
MX]=]&M?),UP1;'*]2)ZD21A%FJ:!=P;L'B_,OPA*(X8C5>E7MX6*8)/814A$
MC##CIN#>)/2\7FB-/U+]5X3,-;\F9(WW[!G>"-9YSWPSH811$FH:N&+0J#!H
ME8_GL$'?:SPM2&$SL'#5HO/!-J_4%&?0_7;.:#BH76@6F$EJ071%0M>LK>8.
M)A?)-:7GFMN;7J:%3A\;_O/T:4SH]$UM,@*I:>TL>$N@K>IBY?T+Z/[5%6(X
M!!3"M^]0@S;%>$D%7:(6I!)5)DV;3<6B)Q![_>-\:#)`L'[Z#`<A(Y#*Q[1P
M%:/SP5ZN\'E0CS0!]((.]$@@ZC9C%@R^@-0QXD\--\=O3F@,)&=?D;/.'_O[
M\_QI*NC\#7VM&8&(?^B%4UU_4>N_Y)VK%ITE]GN%Y1T5TG30V1GW=<VZ$=)]
M0$8#"U<M.A]LY(_SH;9_1X4$NF0C8J:%JQ:=#[9OA<^#*J2FK^=I4$5E,M"0
M8YT%^\94$59[=3LW+DG:A_A3HP16-'.NP1*D2VC=@NC+\642F#V[]5^2BIL?
MW8J>'2URM.?DHMR+2&19927RA$L:@UG?6VF!7,,"V6Q;3N^`_>T8[\7WN-RG
M165E8@>ONJ,)7,&2-D!ZJ.6QV2HVLH;-K?GS`)NZ@,]O=P3@G91U]X`$^]U_
M]3\```#__P,`4$L#!!0`!@`(````(0";-K'SY0(``*$'```9````>&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;(Q576^;,!1]G[3_@'@O8+X2HB15$]2MTB9-
MTSZ>'3!@%3"RG:;]][NV$Q*3KNU+$NSCDW/.O;XL;Y^[UGDB7%#6KUSD!:Y#
M^H*5M*]7[N]?]S=SUQ$2]R5N64]6[@L1[NWZ\Z?E@?%'T1`B'6#HQ<IMI!P6
MOB^*AG18>&P@/>Q4C'=8PB.O?3%P@DM]J&O],`A2O\.T=PW#@G^$@U45+4C.
MBGU'>FE(.&FQ!/VBH8,XL77%1^@ZS!_WPTW!N@$H=K2E\D63NDY7+![JGG&\
M:\'W,XIQ<>+6#U?T'2TX$ZR2'M#Y1NBUY\S/?&!:+TL*#E3L#B?5RKU#BSQU
M_?52Y_.'DH.X^.V(AAV^<%I^HSV!L*%,J@`[QAX5]*%42W#8OSI]KPOP@SLE
MJ?"^E3_9X2NA=2.AV@D84KX6Y4M.1`&!`HT7)HJI8"T(@$^GHZHS(!#\K+\/
MM)3-RHU2+YD%$0*XLR-"WE-%Z3K%7DC6_34@=*0R).&1)`;UQ_W0"^<)2M+W
M67RC2!O,L<3K)6<'!YH&_E,,6+4@6@#SR9G1,7K]GU7PJ$CN%(OF`A<"RO.T
MSD*T])\@T^*(V1@,W(@1,T%L3P@5H*+-+Q9\T#N*ABBFHB,HZNOE.&E4AVR-
M83:1^`K$1FRO$5%@0_)KR#P9(9:-R+;QMGP%AKZYB"_.HI%7Y[4QF%BWC0IP
M.UW(+Q8L*5#ZRT3?EJ+`*Q=\CI6,LW0BQ6!FNA=NDC1&L0W86@"4HB"=VXC<
M1LSB,#DC+/%PASXN7H%M\4DP*>'&8%(M'F7SB;>MM1U-3^>7V^$\.#>9)3JU
M1:N+]WX/JT.V>!1,@MT8S"GY.`[/J>DNV5H`E&2SJ^1MQ`S%\=2$&95FDG2$
MUV1+VE8X!=NK,8@@N7'53.@-3&@]S_QQ`R;D@&OR'?.:]L)I205'`V\&^7$S
M8\V#9(.^MSLF83;JGPV\"@DT>.`!N&),GA[4%!]?KNM_````__\#`%!+`P04
M``8`"````"$`X)+:/:T#```F#```&0```'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6R45EN/VCP0?:_4_Q#E'1+GPDU`58BVK=1/^E3U\FP2`]8F<62;9???
M=VR'K&UVM^P+))[CDS,7CV?YZ;&I@P?"!67M*D3C.`Q(6[**MH=5^.OGW6@6
M!D+BML(U:\DJ?"(B_+3^^&%Y9OQ>'`F1`3"T8A4>I>P6423*(VFP&+..M&#9
M,]Y@":_\$(F.$USI34T=)7$\B1I,V]`P+/@M'&R_IR4I6'EJ2"L-"2<UEJ!?
M'&DG+FQ->0M=@_G]J1N5K.F`8D=K*I\T:1@TY>+;H64<[VKP^Q%EN+QPZY<K
M^H:6G`FVEV.@BXS0:Y_GT3P"IO6RHN"!"GO`R7X5?D:+`J5AM%[J`/VFY"RL
MYT`<V?D+I]5WVA*(-N1)96#'V+V"?JO4$FR.KG;?Z0S\SX.*[/&IEC_8^2NA
MAZ.$=.?@D7)L43T51)004:`9)[EB*ED-`N`W:*@J#8@(?M3_9UK)XRI,)^-\
M&J<(X,&."'E'%648E"<A6?/'@%!/94B2GB0#];T]&2>S'.63?[-$1I%VL,`2
MKY><G0.H&OBFZ+"J0;0`YHMG1L?@ZVNN@H^*Y+-BT5S@A8#\/*SG2;*,'B"F
M98_9&`P<B0&#7,3V@E`!5+2%M1"!WD$TA,(7G4)27T['1:/:Y&I,YJZ`S0L0
M%[&]1J2Q"RFN(;-\@#ANI*X;;\M78*@;*WQY/!EX=;PV!I/ILE$!W/H+A;7@
M2('4VQ%]6XH"KT+P<\AD'D\]*09C2?$7"K,PU=4R0NDS@2,,SL?MPA38$X:\
M]&P,)M.?]0OP#5OQLLW1.GF/5@7VM,:^5H,Q6D?9S#M16V.>&%=FZ<Q-0>&8
M8ZO8'='3]XA68$\T\E1M#&80[<?8F`?1WA$L[-VS>3JXY&A6]ZK5M-ZN5@7V
M#@[*!EYS<`S&JE9_H;`6'"GS]TA18"]\5P?'8$SXO'K8VK;,;["%;1W99D<P
M@D9Y>_`TVI-\=:1ZD!6^845=!9F?8\<ZLLRN4-7];\XR,G>%VY2\^&UZ4%^;
MJ5^:KGGRW+7[V\A\HM^-GINO*UOU_]MEF]O"D9U<R3:@5V7;YLR_%`IDFZ&+
MO-)H87YZCVYSD=BZ4>P%;*,I5V'?XG._4VP=>Y)DWGXUTJGS8O;;CIF`FW'-
M3#,-X0>R)74M@I*=U"B&H"T.JV9,W*@Q40]Z@P&FM`X?R'^8'V@K@IKL86L\
MGD*WYV;.,R^2=7IVV#$)\YE^/,(\3N"2C<<`WC,F+R]JDAPF_/5?````__\#
M`%!+`P04``8`"````"$`70L_U@0%``!)$P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6R<6%UOJS@0?5]I_P/BO0&;?)0HR54!=?=*N])JM1_/E#@)
M:L`1T*;]]SO#&+!-;I)N'YID?#PY/F//(5Y]^RB.SKNHZER6:Y=-?-<192:W
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M@LG>:/9S6X$_*F<K=NG;L?E3GG\5^?[00+EGL")<V'+[F8@Z`T4AS83/,%,F
MCT``_CM%CEL#%$D_VM=SOFT.:S>83V8+/V``=UY$W3SGF-)ULK>ZD<6_!&(J
M%27A*@F\JB0LG/#'&9O-OY`E4%FF0Q9^=Q:/UM7*E*1-NEE5\NS`W@/F]2G%
MG<R6D+G3AU;3*_8CP4`I3/*$6=8N'!K0HH8JOV]"'JR\=ZA,IC#1&,-,1-PA
ML`R8-M$"'O#M28.0.NG+Q>RX(1BY=5DC"D#NGBRWB(P1@6]"DC'D<=9##+)0
M-YTL*CS]X0[L2.,DV&L:QY!/^_RM.A%AVL/3!F([D&@!@Q(46J=T73\$KUU8
M;R]7R(>E$A7"+/RV]/XDL,9C&A^H)EK`8`;"W,\,P3:SN24281:T)Q<^_IF(
M6$?,V.,%2$*0EK[!=FZRQ=+.H45=UQ,GV:P7)J>(,/.6=3";7^`4WX8D!!G3
M7IBTK]-%L$WWT:)+F"E5WQR+:8R6,N5@?Y;^B0YXL!"&VNC)5JL*;JJ-DVSZ
MH4DQ(HQ2.[PD-B&T_:L%#(ZAR?&ZM`BVN-E])B(,<>-A$(STBW7$G"_&B$1'
MS$*FIS#(,U!35_@Z^Q9MT[=:>J1`Q)\M+AY`A='4U2,F0W2$+^\!1CYBM+#`
MZOF1`M$FYCZW&DG<CW<^DN@1DR6:@\7R=LMG9"DFRY&)$@C:Y]"-`\L88I5)
M%[2;!N1-JF@1&M4;)2=#,2E:O3YBFNN0+XTBB1XQ^:`Q:'SN<TM&=@)?/*@R
MLDL%&E2)1Y%$CYB\T`(L7K>;#SYICDZXM;$B!5)'A`47+2A6J(%]HD=,KMCW
MO\Z5W,*LK>U+K+,4?,3C/K.,(.['AT/2S1CM/.S[&LL;.X]<PF1G.4G$="N9
MMGW<=IM8870=:58;,77$)J\QQ+UX1\W)&DRFEDX1Z_Q#Z6@Y4MR/#SIV,T8Z
M8G?76-[0D;S`9&=]>\0(-&@4CR*)'C%4XY:)W'>"VUFW'G@52.,UBB1ZQ.3U
MOZR#7[(.^P0K$)W@A1_B0\YHXRG00#[1(R95*(]>TOLV'L=9MA_;!UB!.I=C
M5O..^_%^X^D1DZ5E'7>RO&`A4_L@<P*IELBG%Q^`%4@7E*:U$9.JY2K7SPC<
M1XR%'%$D$/VPX/PR0\+H#+4(,:2;"_I)7HAJ+V)Q/-9.)M_P5H+#(W4?[6],
MGCC^F+7B$=RDM-<.7C\`%QFG="]^3ZM]7M;.4>P@I3]9@"M5=!5"'QIY:B\"
M7F0#5QCMVP-<60GX">Y/`+R3LND^8/OI+\$V_P$``/__`P!02P,$%``&``@`
M```A`(@K39OD`P``?`P``!D```!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL
ME%=-CZ,X$+VOM/\!<4_`YC-1DM$$U+LC[4BKU>[,F8"3H`:,,.ET__LMNPA@
MIZ<G<^ENJ.?'JU=ENWKSZ;6NK!?6B9(W6YLL7=MB3<Z+LCEM[?_^?5K$MB7Z
MK"FRBC=L:[\Q87_:_?[;YLJ[9W%FK+>`H1%;^]SW[=IQ1'YF=2:6O&4-1(Z\
MJ[,>'KN3(]J.985:5%<.==W0J;.RL9%AW3W"P8_',F<ISR\U:WHDZ5B5]:!?
MG,M6W-CJ_!&Z.NN>+^TBYW4+%(>R*OLW16I;=;[^<FIXEQTJR/N5^%E^XU8/
M=_1UF7=<\&._!#H'A=[GO')6#C#M-D4)&4C;K8X=M_9GLDZ)9SN[C3+H6\FN
M8O:W)<[\^D=7%G^5#0.WH4ZR`@?.GR7T2R%?P6+G;O63JL#?G56P8W:I^G_X
M]4]6GLX]E#N`C&1BZ^(M92('1X%F20/)E/,*!,!/JRYE:X`CV:OZ?2V+_KRU
MO7`91*Y'`&X=F.B?2DEI6_E%]+S^CB`R4"$)'4A\4#_$Z9+&`0G"G[,XJ$@E
MF&9]MMMT_&I!U\`W19O)'B1K8+YEACK&7'^4*N0H23Y+%L4%60BHS\MNY9.-
M\P*>Y@-FCQC8$B/&0"0WA#10TJ:S%P[H'46#%:9H#XKZ?CEN&N4B72-=&1+?
M@>B(Y![AN3HDO8?$P0C1TO#T-#Z6+\'0-S/[`CKQ*K_VB/%5VT@#$_-%.GNA
M28'2SQW]6(H$;VW(<ZQD0,,Q192"F$CUPH*LW,"P*=$`0;`B1C%2#1"ZKAN-
MG]"DPPYZ7+H$&]+-`NX1XROI9HO.8V9*Z3RX\./WY8:_(E>"3;ETY$6G$1.B
M7!)[IN1Y/`A<WUB?SN-^Y/E3'32;(UVW/"A^ON?D(ET_<0U]>\2@_L@C1CC1
MPK$[N8I'Q#P<>G3J,DV\O(AGI]S'[2W!AFAJ?':/&!1-8\_P-,$PMA"-C)12
M+>I-.T>3O/H5R1*L2PX\S^@3Q,P.!_-%BB\PJ3`@/_"2P$G[N)D*;4KS#6D#
M"/U:D&FCJQHG>GA68VP!(TRGY9JA1-XF#S>!0INZS2X80.C8@JY,SQ,=$-+(
M*$HZ`(;,X10<G=&URTOE<>UX!<T/:)^8=P5!T/!E/YY<&TS'..9&:#RUZ>#Z
M?'T<3B75A<L+YW'A>#W-A1/W3CB"AJLE(.;>@T%0;@:,4^H;Z^6@.,5]=\H+
MA>,0B#-2S;H32UA5"2OG%SG@$3AFQ[<X?.[E\*G&QS$`LU^;G=C7K#N5C;`J
M=H2E[C*""Z+#Z1$?>MZJB>3`>YCZU)]GF/(97-WN$L!'SOO;@YQ/Q_\;=O\#
M``#__P,`4$L#!!0`!@`(````(0!`'VCN``0``(\-```9````>&PO=V]R:W-H
M965T<R]S:&5E=#8R+GAM;)1778^;.!1]K[3_`?$^`0/F(TI2-8QFMU(K5=5N
M^TR(DZ`!'&$RF?GW>^U+`)O)-)F'3/`]/C[W@^N;Q>?7JK1>6",*7B]M,G-M
MB]4YWQ;U?FG_]^_30VQ;HLWJ;5;RFBWM-R;LSZN_/BW.O'D6!\9:"QAJL;0/
M;7N<.X[(#ZS*Q(P?60V6'6^JK(7'9N^(8\.RK=I4E8[GNJ%3945M(\.\N86#
M[W9%SAYY?JI8W2))P\JL!?WB4!S%A:W*;Z&KLN;Y='S(>74$BDU1%NV;(K6M
M*I]_W=>\R38E^/U*@BR_<*N'"7U5Y`T7?-?.@,Y!H5.?$R=Q@&FUV!;@@0R[
MU;#=TOY"YBF);&>U4`'Z5;"S&'VWQ(&?_VZ*[;>B9A!MR)/,P(;S9PG]NI5+
ML-F9['Y2&?C16%NVRTYE^Y.?_V'%_M!"NBEX)!V;;]\>F<@AHD`S\ZADRGD)
M`N#3J@I9&A"1[%7]/Q?;]K"T_7!&(]<G`+<V3+1/A:2TK?PD6E[]1A#IJ)#$
MZTA\4-_9O9D74T+#/[,XJ$@Y^)BUV6K1\+,%50-GBF,F:Y#,@5EZ%ESU#%R2
M>[[(36HKH`6DXV65!-[">8$0YAUFC1AX`WJ,@4BG"-_M21S0UXL$UTV1/B3Q
M_?!?1,I-ND@OZ>F5'VN$Q"K,TK%TM*`)@,B,!7Q\L`1#AD>>TR`P3D9,,)P\
M6M!.#NXY68*7-CC1QYP&U#@9,9'*6N#Y413J@'0,\!/BQP.#I@RJY/:82+"I
MS#AXC9A0*0OEGR%,LY/(C7J[IBN\1Y<$Z[I($/>\6"6(05U>$E'#GH[M/J7Q
M8-=T1??HDF!#ES?PHB[$=+I(8NI.-3M-PN']TW3)2VK4`3ZN;0G6==%@R`/J
M0DRGRR74U^.9:O;8I<-^35=RCRX)-G69\4(,ZB)!E`QUK72GFCT*XRNZ"'2>
MVP.FT*8RLP]U()06>Z,*0F6:G03AM5>2&-W\XUPJM"&-#AT8D]F!+M)"HY&E
MNIW&PWXMF41VUINK3*%U90$QTK7N0%V=><1(=ZK;J3\$75<F.^](F;P!_WRY
M$.S76JNE1"_T=0="A32A\:2EZ8@X),FU^!GWP(TJW[D0Z-`&N@PC"%4^@,QP
M)**K/QT2AVYP3>==MX*<H<S7ED[RC*!`W0MD<EUU')UY5+]ZEN^Z%<CT6J#4
MN([6'0@/'L+110P93*.NZ:X;`>;;::R&%M7E$D%XN[\3*\T\B17.OS@>5JS9
MLY25I;!R?I*SK0<)Z%=Q[EZ3.<Q0,.\:ZRG,XVK=Z0TP#A^S/?N>-?NB%E;)
M=D#ISB)(;H,#-3ZT_*B&M@UO81!67P_PPX?!=.;.`+SCO+T\R)&]_RFU^A\`
M`/__`P!02P,$%``&``@````A`-5=F"5C!```:@\``!@```!X;"]W;W)K<VAE
M971S+W-H965T,2YX;6R4EUV/JS80AN\K]3\@[A,PY%M)CA;0MD=JI:KM.;TF
MQ"1H`:>8W>S^^\Y@;&QSNB(W^1A>OWZ8L0>\__)>E<X;;7C!ZH-+YK[KT#IC
MYZ*^'-QO?S_/-J[#V[0^IR6KZ<']H-S]<OSYI_V=-2_\2FGK@$/-#^ZU;6\[
MS^/9E58IG[,;K>%*SIHJ;>%O<_'XK:'IN1M4E5[@^RNO2HO:%0Z[9HH'R_,B
MHPG+7BM:M\*DH67:`C^_%C<NW:ILBEV5-B^OMUG&JAM8G(JR:#\Z4]>ILMW7
M2\V:]%3"?;^319I)[^[/R+XJLH9QEK=SL/,$Z/B>M][6`Z?C_ES`'6#:G8;F
M!_>)[!*R<;WCODO0]X+>N?;;X5=V_Z4ISK\5-85L0YW:]/07+6G6TC-4SG6P
M(B?&7G#H5PCY,`GO!#@)_U=.\Q3@+)Z:1O\MIWSNRO9'XYQIGKZ6[9_L_BLM
M+M<69EI"&C`;N_-'0GD&98"YYL$273-6@@5\.E6!ZPG2F+X+NN+<7@]NN)HO
MUWY(0.Z<*&^?"[1TG>R5MZSZ1XA(;R5,@MX$ON_B>D#F:^)OP_5TD[`W@>_>
MA`3S8+,DR]4#*(O>!;ZERV*RBR>2T^4]2=OTN&_8W8%5#[?/;RGN(;(#9YED
MD1*5]O_+.J0;39[0Y>#"=H6$<BC]V]'?>V]0W*Q71$(!GTI!3$4L%5A)-$VT
M@`>T"AEJH2/_>#U(,A0CF72-1$`'"2R0L2(T%<E8L5`*`Q4JKJ-B=D/8/9\C
MXR#0::E:*O<N,Y%0+-1-Q78@T0(&$)18!_H<!,4'%VY6U6QE@0@%?"K%VE3$
M4B'SGV@!@PRVTW0R%)MD&W/>2"@$V>E'*S*6"D6F!0RRU2-D*#;)MA:94"P[
MI@4\B(:ETQ4W%M>'XB9:P.!:/\*%8I.+V%M42!8=6.`3FTM>5OG2`@87/K6U
MEO+Y&D.QQ64UADA(]$5&["TK)8I-"QALVT?84&RQ69T@$A*#S<Z;E"@V+6"P
M$>@,TQ/7J2TZNT_T&@//VL*QTB@^/6("8D>>7%DB^K?>/HC5':)>(];<UE^M
M?6NWQ$HQX`G?;H.8>-B6I^.))F[@V4V$"`WBY<?9C`2S$!9GCL^W&1F12O%`
MJD5,4FS/TTE%,S=(K<DC(AO^T(D#:W_'2C,`RE$0,0%AR3P`B&IS*0;V)B9"
MHR_%,:#4#(!:Q`3$9CT]@Z*UZQD,K!82X:LEW(0!:.WV6&D&0#EJE$'LVM,!
M18\W`*T^$A'Y'-!*;&WX6&D&0#EJ!(CM6P.<]FY"1-,W0*V.$O6:X0D6]Y%5
M]V@A(0DW9&7W\$0?9M8:F[E&^OD#!<XQH\4X:CO:XT$\=/M1`S.>A]!G+9CA
M17V["->;84\)1'&2$6_4%6TN-*9ER9V,O>+)A,!@%55'K?X,I"[`H>667NCO
M:7,I:NZ4-(>A_AP/&(TX]H@_+;MU[^LGUL)QI?MYA3,MA7=E?P[BG+%6_L%J
MJU/R\3\```#__P,`4$L#!!0`!@`(````(0`A$/^\JP,``.8+```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;)266V_:,!3'WR?M.T1Y'XES!01,*U6W
M29LT3;L\F\2`U22.;%/:;[]C.P3;;-"]M,3Y^^1W+CX^B_?/;1,\$2XHZY8A
MFL1A0+J*U;3;+<.?/Q[>3<-`2-S5N&$=688O1(3O5V_?+(Z,/XH](3(`"YU8
MAGLI^WD4B6I/6BPFK"<=O-DRWF()CWP7B9X37.M-;1,E<5Q$+:9=:"S,^6ML
ML.V65N2>58>6=-(8X:3!$OC%GO;B9*VM7F.NQ?SQT+^K6-N#B0UMJ'S11L.@
MK>:?=QWC>-.`W\\HP]7)MGZX,-_2BC/!MG("YB(#>NGS+)I%8&FUJ"EXH,(>
M<+)=AA_0?(WR,%HM=(!^47(4UN]`[-GQ(Z?U%]H1B#;D265@P]BCDGZNU1)L
MCBYV/^@,?.-!3;;XT,CO[/B)T-U>0KIS\$@Y-J]?[HFH(*)@9I)HC(HU``!_
M@Y:JTH"(X&?]_TAKN5^&:3')RSA%(`\V1,@'JDR&0740DK6_C0@IJ-%(,AA)
M@7YXGTR2:8[RXK:5R!!I!^^QQ*L%9\<`J@:^*7JL:A#-P;+RK(#X_-TSH%%[
M/JA->BNH!:3C:57&V2)Z@A!6@^;.:.`$C)K$5:PO%6D\2B+@&R'!=1\RO0FI
M-KF0R6PTK_VX,Y*I#K-R;&TM.``0&1\@^V?^3U%2FR#35@3*./<(C"8[$U@+
M#D'F$ES/CQ(O0W#F'/L\];YL-*7.7I+D6>X%9VT+T*R<60*'#.)@Q^8ZF1+[
M9'Y,C*8P9`5*"Y=\;;]/RP*=*\_A*EPN5=FWBT9M\O@R/W)&<^)+ILD90)?5
MVA/$R=D#A["\)+Q=56J32UC&9_NFKHW&JBIKP2%0%Y1W^F\3J$VWZMIH+`)K
MP2&8N037JT>)7=^3B[HV&I,=-(7"]K/C"%+5/\?Z<L@0=)C_#X[>Y3*6<3E^
MP>1G$%GAL5=<BK\TZ-LI0J:W7N\]@\BF,-OTBDNA&J-5*-?3A$P;O=Y_!I%)
M5);,K#284^0(\EEF)=)E4RW38GO=04>FT=J,93SU\V1UXP'*6G$IO`:M*%Z1
M)]-DP>C8J2_O"&1$=IZL%9?BOYJQ&F$NSI-W7.X&D;DH$$K\2U0-7LK*<),4
MF74B#9L9J\S4T1*^(VO2-"*HV$&-3`GT^7'5C'-W:`Y7,\P^WOH:QCR]'HTO
M8,KJ\8Y\Q7Q'.Q$T9`LFXTD)3-S,:>9!LE[/`ALF8;[2/_<P3Q.X].,)B+>,
MR=.#F@3'"7WU!P``__\#`%!+`P04``8`"````"$`XB@E2F4#```J"@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R<5FUOFS`0_CYI_P'QO;P&$E"2
MJ@UAJ[1)T[27SPXXB57`R'::]M_O;"<$3+>F^Q+B\W,/]]R=S\QOG^O*>L*,
M$]HL;-_Q;`LW!2U)LUO8/W_D-S/;X@(U):IH@Q?V"^;V[?+CA_F1LD>^QUA8
MP-#PA;T7HDU=EQ=[7"/NT!8WL+.EK$8"EFSG\I9A5"JGNG(#SXO=&I'&U@PI
MNX:#;K>DP!DM#C5NA"9AN$("XN=[TO(S6UU<0U<C]GAH;PI:MT"Q(141+XK4
MMNHB?=@UE*%-!;J?_0DJSMQJ,:*O2<$HIUOA`)VK`QUK3MS$!:;EO"2@0*;=
M8GB[L._\-)_:[G*N\O.+X"/O_;?XGAX_,5)^(0V&9$.99`$VE#Y*Z$,I3>#L
MCKQS58!OS"KQ%ATJ\9T>/V.RVPNH=@2"I*ZT?,DP+R"A0.,$D60J:`4!P*]5
M$]D9D!#TK)Y'4HK]P@YC)YIZH0]P:X.YR(FDM*WBP`6M?VN0?Z+2),&)9`+1
MG_8#)YA%?A2_@P7>IT*!YYG%=R9!-)V])Y;XQ`+/,\OUL;@Z.RK9&1)H.6?T
M:$$#@W[>(GD<_!2899:G?\TRI%?ZW$DGY0IH#IWQM(P3?^X^03F+$^9>8^`P
M=IA@B%B-$:$WA&1CR"P:0M9C2!Q/AYC\%4QRB<:%5'3Y@(J;^0BA=U_ONG,^
MI-,P'T$R#.%>0V:JNV0.5Z8A,PUKTY#W#(.8P_^)63K!F>C5)TY"(VB-F5R"
M-@V9:5B;AKQG&`0-1ZJ?Z'\G6((7-NCOFBF\U$_UY+V&3%4W^D$8&WVRZN^'
MB6?V2-;?#Z)):/306N]?<I'W'?P(QDJ7O(%..$S7ZY1@0^>DH]4Z-216.@,(
M-#(Z;=4'^,DT,0&9!ER4K$U#WC,,M,"`N%Z+!!M:S/[2D).6R/.,X[]Z8S_3
M^STE;SCD/8>!L.E0F)R";Y]ZZ304&$Q,A1JCNS*(@UE@E'-E`+P@'M8[TX">
M1M,`E[",0R&T*'VGZC%?8[;#*UQ5W"KH0=Z7$;1.9]57^;V?PH"".]2PK_P4
MYM38GODIC*NQ?>VG,+7&]AP^%93=[5X`5W6+=O@K8CO2<*O"6PC-<^3=P_1E
MKQ>"MFJR;JB`2UK]W<,W&881ZCD`WE(JS@MXL=M]Y2W_````__\#`%!+`P04
M``8`"````"$`JZN/)9H"``"D!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6R45=F.FS`4?:_4?[#\/AC(0H)"1DFC:4=JI:KJ\NP8`]9@C&QGDOQ]
MKS&#LJG-O!A\.3[G;KXL'@^R1J]<&Z&:#$=!B!%OF,I%4V;XU\^GAQE&QM(F
MI[5J>(:/W.#'Y<</B[W2+Z;BW")@:$R&*VO;E!##*BZI"53+&_A2*"VIA:TN
MB6DUIWEW2-8D#L,ID50TV#.D^AX.512"\8UB.\D;ZTDTKZD%_TTE6O/&)MD]
M=)+JEUW[P)1L@6(K:F&/'2E&DJ7/9:,TW=80]R$:4_;&W6VNZ*5@6AE5V`#H
MB'?T.N8YF1-@6BYR`1&XM"/-BPROHG2=8+)<=/GY+?C>G+PC4ZG]9RWRKZ+A
MD&PHDRO`5JD7!WW.G0D.DZO33UT!OFN4\X+N:OM#[;]P4586JCV!@%Q<:7[<
M<,,@H4`3Q!/'Q%0-#L"*I'"=`0FAA^ZY%[FM,AR/@W$\2681X-&6&_LD'"=&
M;&>LDG\\*NJY/$O<L\"S9QE-@TD2CNX@(=ZC+L`-M72YT&J/H&E`TK34M6"4
M`O'MB"`4AUTY<(:AJ<%7`U5X7<:SZ8*\0NI8CUE[#*P#)AH0!$0'95"[7]F!
MG;++K7-E[0VG,O%MF=%[9!PXP[`.SL>S9.#URAXS[AKF-)[Q>X0<&%(^/5.Z
M3&4/@G8]<6<VN'.636BCTVRZ#HUGD6O'_]34'>P\&5+;6R##)[+SV[(0P*7L
M:`[&?_>1.W6NV5O.-.?A;<WD6C-)[HC4G3M7[2WGJI?MZJ>"OS22ZY)_XG5M
M$%,[=^-CN`:#=1A&J]BUQZ5]G*ZZ(46&#S`D6EKR;U27HC&HY@50AD$")=!^
MS/B-52UX#I-"69@.W6L%?P,.-R$,`%PH9=\V($R&_\OR+P```/__`P!02P,$
M%``&``@````A``,I6[B:"```GB8``!D```!X;"]W;W)K<VAE971S+W-H965T
M,34N>&ULK%K;;N,V$'TOT'\P_%Y;5]^0I%A;8EN@!8IBVSXKMI((:UN&I&QV
M_[Y#<DB1,UI;6?0ECH^&1W,X0\Y0UMW/7T['R>>R::OZ?#\-9\%T4I[W]:$Z
M/]]/__XH?EI-)VU7G`_%L3Z7]].O93O]^>'''^[>ZN93^U*6W008SNW]]*7K
M+IOYO-V_E*>BG=67\@Q7GNKF5'3PM7F>MY>F+`YJT.DXCX)@,3\5U7FJ&3;-
M&([ZZ:G:EUF]?SV5YTZ3-.6QZ,#_]J6ZM(;MM!]#=RJ:3Z^7G_;UZ0(4C]6Q
MZKXJTNGDM-_\]GRNF^+Q"+J_A$FQ-]SJ"Z,_5?NF;NNG;@9T<^THU[R>K^?`
M]'!WJ$"!G/9)4S[=3S^$&Y$$T_G#G9J@?ZKRK77^G[0O]=LO377XO3J7,-L0
M)QF!Q[K^)$U_.T@(!L_9:*$B\&<S.91/Q>NQ^ZM^^[6LGE\Z"'<*BJ2PS>%K
M5K9[F%&@F46I9-K71W``_DY.E4P-F)'BB_I\JP[="_RWGB51NER%8#]Y+-M.
M5))S.MF_MEU]^A>MD$NS1,@"G\@2+V;I,HC?0Q(C26))5K-5FB:+U1(\N7)W
MN*HTP"?>/5K.EF&PCF\,7.!`^,2!Z]YK?L.YGCL5BJSHBH>[IGZ;0'[#Y+27
M0JZ6<`-<)@::P4;E6T&!:$B2#Y+E?@H+$Z:[A4SZ_!"MH[OY9XC^'FVVW";T
M+7;&0H9:TF84R"D@'&`.BJPLB.;_($NR2%G&H:T!')U$@[$P0S(*Y!00#N!I
M@*1R-0PO"Q,!:7P_A;].!&+?MRW:+*R>'4,RAN0,$2[B>0SI/]YC:0Q9!TGG
MN$R31AO%2\\H\77MK)&==(;D#!$NXJF`M3A>A316*LR]MQI)(3,=72EQV1J9
M81E#<H8(%_%<ADET79:K>!'/^BUD]$*61+X<C<3^VEX0.=;(RF%(SA#A(IX<
M"#>5$Z]D$<"M=+0<2>3+T0B1LR1RK)&5PY"<(<)%/#FR87'VV.L+61K[+FN$
MN+PB+ELCZS)#<H8(%_%<7OLNZ[*@$NJZ]W*<[[U&DGX3W3$D8TC.$.$BGJLA
M-![CIU=9^QX:*.KW10YE',HY)#S(=U.6JM%9$.K"!KNCB><6H<3?6-8D#X:L
M%F17S=`H5?V9*K4YAT1/!3[X6F3)&J]%%SA/"T)KW2L$(=T?0VT0P8?=1;F,
M`:,H(6)S0Q6K>Z7IDA@(8P`%8>A>OG)9^\8KUY724ZXAV,M4EQ2$="L-<<QU
MY=;(I$>.XZ*%(DZB!=DAA"&&7?2V3%D<'9G.^N]>JOVG;0T4D(@#FX&<9FP*
M=87UU"-DXTYWWE`;W(B[->K5:RA.E/IP2?))&%XPNRU>EEE'_(!(%3Y4J8NR
MIU)#26P7[TZ>:V!C!&CP_MCNHE%BQ^5F7`\)`REV/SEE01WON"Z_GN,:DH76
MSE(<!'2+P8']?ID!B=KW>RA'"/,Q#-@:%V:0>S=GC?O29'%UI'U?0NH*[2E&
M"*J+HY@=3+059*5)N"QD4(X0Y*#+Q78;'.A:1<M^&_=ERP+MR+Z1BKJ<>_HT
MY*6BA7HWG6G'5$2C/N_RD$'"0`.I*,NUX[B,5Y3.(-0W).@R[TG0$$E*<K;9
MA3C0#1&#<K3"I%PM4A)I86C&Y&1$&H_ORDE%XO<C!@+WG9RDAQZT<G.20SE"
M)"?I[F@&CLK)Z%V-C+(F^G1OX^8D6EW?'HV1DY,<$@;B.2F+"LW),%5-[?BB
MIDB('FQ#W)R)`UK7S4`G07NH#S3O7]#*%/8P[O<*M5:%H7'O[RQH;T.)9.-`
MUJ4[!Q_KR[<*NU/S%`N9!-V1>$&U4"_/\4MO-$B5Z`=\\JE/SB%AH(&@0LZZ
M@JYO+Y&T)HYK*.WCLD,K!\HXE'-(>)`_[Q"<=[@IK8F;&O(>*\0!;9_D)@D#
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M@8\KRJV16?@YCH,]21(G*_H#B3#$L(</$?LR21V_(5-78D\F0C;`M)3$VL"+
MG3/INGKW1KU,'(>/6X*8$`LS9E0T97$>O77(+I>4382@O&$T:6TQ8ZY'$XG[
M'B$WQ#J::;AB,G',J&C*LCU>IB[R7C01LM&DA2C6!C>B:8WZ:"*$T8P3<@P1
MAAC4WD[:@5;";3Y'/56*>1>!D`UR1#:0G1ES/<A([`89NPR=/4E*S_*&%R;I
MMOAW=1SR%R^:RAIR.VRTNGYL,D;.L8E#PD"\PY8MCIN<3L,Q_MBD2$BYQ'[$
M.^:&+'3:"A+7Y&2&7%XN#U05'*@S-TH7=/,2AF=4ZI(>AD["N'-3S'L;A+RH
M:JL;444CY]QDJ'I(&(A'%5[L8%']OM_8%),?6H3D!-MU$8?D6<NNM[*AY5#.
M(?E2BEP<0`\#=5G4+YGH-QM.9?-<[LKCL9WLZU?Y`@D\U7FXL[!^NV4;+3>R
MS08*=F4%5Q0YO9($YI48>@7(!KF`:I!IO8%?M(;NG<"]U5*E=XA2N*)BRZXL
MX(KJE\D5^*%G(W_9X??)XF"30__(K\!;/Q_48B-<6W@;:(AI&\'-!WBV\09>
M%!C@3S8?((#\PA:4#PH'W8.R0;42/;>>PMM!E^*Y_*-HGJMS.SF63Q#\0#WA
M:?3[1?I+AT\Y'NL.7@N"_(`77^`]L!*>/@3R&>5377?F"S@ZMV^6/?P'``#_
M_P,`4$L#!!0`!@`(````(0#4,ER@*0@``,,C```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;*R:76_J.!"&[U?:_X"X/X4D?)2H=%7R'>U*J]79W>L4
M0HD*!"5I>\Z_WW%LQ_9,H%#MS>'TR7@\?CVV)X:'WWX<]H/WO*J+\K@<6G?C
MX2`_KLM-<7Q9#O_^'GZ['P[J)CMNLGUYS)?#GWD]_.WQUU\>/LKJM=[E>3,`
M#\=Z.=PUS<D=C>KU+C]D]5UYRH_P9%M6AZR!/ZN747VJ\FS3-CKL1_9X/!L=
MLN(XY![<ZAH?Y79;K'._7+\=\F/#G53Y/FL@_GI7G&KI[;"^QMTAJU[?3M_6
MY>$$+IZ+?='\;)T.!X>UF[P<RRI[WL.X?UB3;"U]MW\0]X=B795UN6WNP-V(
M!TK'O!@M1N#I\6%3P`B8[(,JWRZ'3Y:;VI/AZ/&A%>B?(O^HM?\/ZEWY$57%
MYO?BF(/:,$]L!I[+\I69)AN&H/&(M`[;&?BS&FSR;?:V;_XJ/^*\>-DU,-U3
M&!$;F+OYZ>?U&A0%-W?VE'E:EWL(`/X='`J6&J!(]F,YM*'C8M/LED-G=C>=
MCQT+S`?/>=V$!7,Y'*S?ZJ8\_,N-+.&*.W&$$_@43A87[2?"'CZ%O356G5[H
M"$)JHX7/GF@O-)R)AO`I>[2NZG$N&L+G54.#==5&")^RH^N&!HJU#>'SMJ%9
MD#-M2_8?V>?%P8UX#K0IY6=-]OA0E1\#6*<PR_4I8ZO><IDWF4Q<V"Z]SF47
MI!7S\L3<+(>@`"1.#4OB_1&RZ6'T#FF\%C8K:F.9%IZT8#G+W/H8!!B$&$08
MQ!@D&*0:&($LG3:P0/X/;9@;IHT<U4H")1:2RI,6LHF/08!!B$&$08Q!@D&J
M`4,(6.2&$/T[C<P%9@U[BI8+]L(Q9WHE;&:=*!XA/B$!(2$A$2$Q(0DAJ4Z,
MH<-^=</0F36L)-AR+JP#;N3`]J(9(8&\SJA+`4("0D)"(D)B0A)"4IT8<L`N
M;,C!MHO[!3MGQ&%Q]8[!/+52R0&N.'',361B)H[7&<EF/B$!(2$A$2$Q(0DA
MJ4X,76#&B2[V]`[L;]Q(F2-3%DZ0+%,D2V?4R4)(0$A(2$1(3$A"2*H30Q;(
M<4.6RQL'LS;'SHFS4-L$(3XA`2$A(1$A,2$)(:E.C(%"TMXP4&9M#I23MFAL
M3SX/`Q^#`(,0@PB#&(,$@U0#QOB@1+EA?,S:'!\G3EO8\@%V1.V",W0,^L(&
MSF=MIYR9J1]T1C+UP\ZU)%%'E"/<6=SY43:.-3<[2SHCZ3KM7`,Q)&/5U`V:
MM>:F:`+IJE'D2Z2K9$]0:14H*QEY*)&:E(BB6"+=O6/=(UV4E72?2L1?9O2Z
MRF(%EUYT7MX66G.D#/,`-88*W1-6&O(ELMJ"U!Y;Z#`)E(&,.I1(>8XHBB72
M12&:)\I*ND\EZA&%%5^Z*+P2OYO#&=+LBO7KJH1%`!WVB.7``$4=SDLXJ$!D
MERN+(TT8CR)?(%MMM0%%(6T8412KANQ%@.J>*`,996JX,=<1J\VP,/QL[9$"
M*I%."U[4&5H(!(M6VU$69C)[%K>R]=G%VX4OC4#=SI4]03M8(*W8#+T_6O;]
MU!Z;O8721&W^D427`HBE$=1JYP-(A-44AM19.3B&5/F""3'59Z6@KOXGFO/*
MT="<HZD>IV.C_<FS1$,X8;LXJ>;"B-]JL#?$0+2;LE72O7KB\872NVH8272I
MPU@:V=UR2@2R9V)&)^,QFM%4MM)CTL9BZ@M&M^C+S-%>R-$4BC!-`92('KL@
M@H:?Y+0P4L,-1#O'G#WTMA)*[[J5/4?K*I)6E].:Q)#TQX`V\U1Z/Q>#*3LK
M6?6T9KOM59L*KW6-!.<()3BNT*%%.W.7\LV71OH$\'8.R*)-+RJ"0ME0M^J9
M@"MBB*4K%4,B$(H!U4:I;'@N!G,"6"F-)\":WGK<,2]H.7"$E@.J5SR+6WVR
M'(214B*0[?A^;H_O[Y'G4%KH::@M_O:8CJ31Y95`ND]D.][]#"YLR2H0C<YT
M;\X!J_;U.?AD;^<O!S#-\M1>60(Y'?(44OF*Q^\+(WO>M0LH"I4KV6&DT'GO
M,7654)0J5^3,8S6]KDN[.<S:6XX;2C'^9F#(Q1&[+='6,MHF/4LTA)GLK*B"
MPNB3\D-T*`^K\62.#MY0]J;'A'N+I-&ED&)I=#&D1%AUYR<-*96.SH1DY+"-
MW[)PV?R]/)TKF[5:L75C;B02:;FMT(69$4:VNO`-*`J5JRZW%3KO/::N$HI2
MY0KG-MOQ:&Y_Y::J]80D8\[AM0QVA2YS'0>51YYH"%9RZ#Y%`44A11%%,44)
M1:F!S(QB[TMD]7])(>8)*<014@BM2<_NK)1"!`74*J0HHBBF**$H-9"I$'L_
MP@I9]OP+UYVV>"'3SA2!D$2XGE562B+N2\NK@%J%%$44Q10E%*4&,B6"\Y=(
MY-Q_Y:(<ODHF6<01D@@5Y9YHJ.GA4Q10%%(44113E%#$O@@76T*W$_$OMOFW
MD(>\>LF]?+^O!^ORC7UIW1X,'>;?J*]L]I5Z^P4T>6+#D[9`(T\<>-)NWN3)
M1'Y!CYZD"Y==1$"DZ`%\I?_4QU<05W]8T$./GQ7$U!?2TP3\MQ<`J.,5A-K+
MIRY\&4$#7<U<N(WOX7,7+J\I#Q<NN]2A#Z*%RZYVZ(-XX<(M:`^WQFX"=WY]
M3RQXTB<3W!3!D[Y>5@N775Q19]["9==7](&_<.$JN(=#7.SVL^^)!4_ZXH+;
M,'C2]C+J)@1^0G'*7O(_LNJE.-:#?;Z%;!VW+RP5_Q$&_Z,1!<=SV<"/)]K:
M8P<_ELGAM@)^%C`<;,NRD7]`4*/NYS>/_P$``/__`P!02P,$%``&``@````A
M`)-^#8ND`P``M@P``!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULE%==
M;]HP%'V?M/\0Y;T$)P0*`JIV5;=)FS1-^W@VB0&K21S9IK3_?O<Z(8V=!-@+
M(I?K<^ZYUSXQR[O7//->F%1<%"N?C,:^QXI$I+S8K?S?OYYN;GU/:5JD-!,%
M6_EO3/EWZX\?ED<AG]6>,>T!0J%6_E[K<A$$*MFSG*J1*%D!OVR%S*F&1[D+
M5"D93<VB/`O"\7@:Y)07?H6PD-=@B.V6)^Q1)(><%;H"D2RC&NI7>UZJ$UJ>
M7`.74_E\*&\2D9<`L>$9UV\&U/?R9/%U5PA)-QGH?B43FIRPS4,'/N>)%$IL
M]0C@@JK0KN9Y,`\`:;U,.2C`MGN2;5?^/5D\A,0/UDO3H#^<'57KNZ?VXOA9
M\O0;+QAT&^:$$]@(\8RI7U,,P>*@L_K)3."']%*VI8=,_Q3'+XSO]AK&'8,B
M%+9(WQZ92J"C`#,*8T1*1`8%P*>7<]P:T!'ZNO)#(.:IWJ_\:#J*9^.(0+JW
M84H_<83TO>2@M,C_5DE&45!AF=(>J:;KI11'#^8-V:JDN'O(`H#[:X$B,/<>
MDU<^[$>@4=#`EW4439;!"XA.ZIR'*@<^FQS29`1`VC`#V_7,F(S,V!4LY:$*
MM&G"?IK(IL&F1S"Z\T)Q$>2U1$11W.!7%50Y$S/RMJZ)37B>").A]5.+R6UI
MG015-SV-HFE3CM55V`G7=Q63#7O3UCK2[FL4S?JIH.@VE=G.LSGNW0O=Q84V
M;1V!H;84WO;3SFS:\_W%9)NJCM@*Y_U4Z+RMPX$*YQ?W#BZR*>N(I6XR[J><
MVY3GU6&R355'+'63@0-(0(HK+XSCT>SB`,U*F_@4LD4.G$D"];69SZLTV0X;
M`D#(UAGUMY2@5_SW&,TJAQ6!(&1K?#^MUD$DCO%<T%BY"1A!<Q0-0$?CNPO9
M;([KX%8-;\D5AY$T%O3.7(=LG0.&@V\PM[LA'+(+>FNC:>NM0_9,![P''=-E
M)5-X'5XD[IJ/P>J,=<!]B&,_IM&1>6-?DMSU(@/681XP(]+C1E<TNFM'!LC=
M6/&`'Q''D(S+C\-K3*+K3@;,U1L/V%/HV-/Y#66R`;JUH4XA:T/%`Y84HJ,X
M)A'-8;-<H,5E#FT=LDY/['I3=4NLKF(YDSOVB669\A)QP!M@")>K)MK<3N]#
M=`<W/EG<0_'P0]#\`K?&DN[8=RIWO%!>QK:`.38SD]6]LWK0HH3:X>XH--P7
MS=<]_#]@<,$:XU':"J%/#TC0_.-8_P,``/__`P!02P,$%``&``@````A`)VH
M#7_Z#```!D0``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK)S;;N,X
M$H;O%]AW,'P_L67YC"2#CG4^8;&8W;UV.TYB=!P'MKM[YNVW**I$L7[&W6[,
M39Q\+!;)GR6*)=&Y_?W/_6OOV_9XVAW>[OK>S;#?V[YM#H^[M^>[_G_^B'Z;
M]WNG\_KM<?UZ>-O>]?_:GOJ_W__S'[??#\<OIY?M]MPC#V^GN_[+^?R^'`Q.
MFY?M?GVZ.;QOWZCDZ7#<K\_TY_%Y<'H_;M>/=:7]ZV`T'$X'^_7NK:\]+(\_
MX^/P]+3;;(/#YNM^^W;63H[;U_69^G]ZV;V?V-M^\S/N]NOCEZ_OOVT.^W=R
M\7GWNCO_53OM]_:;9?K\=CBN/[_2N/_TQNL-^Z[_`/?[W>9X.!V>SC?D;J`[
MBF->#!8#\G1_^[BC$2C9>\?MTUW_D[>LQEY_<'];"_3?W?;[J?-[[_1R^!X?
M=X_%[FU+:M,\J1GX?#A\4:;IHT)4>0"UHWH&_G7L/6Z?UE]?S_\^?$^VN^>7
M,TWWA$:D!K9\_"O8GC:D*+FY&4V4I\WAE3I`/WO[G0H-4F3]9_WY??=X?J'?
M%C>C^<2;3,F^]WE[.D<[Y;/?VWP]G0_[_S56C2_M9=1X\:G[NMR?WDQF0]^[
MPLFX<4*?[&1\,Y],QM/YC+IRH7DJK0=!GTW-D7<S\X8+_P<5ITU%NAJ:BK.+
M#2T:>_KDAH8WWGA8:W6A@Q[-JY:9=/RIECR65/W2U/!_4@Z/ID&W9N;#FYOY
MN-11G@3/S()3DH&.HSHL@_5Y?7][/'SOT;5.`SR]K]7*X2V5$PY(W6@;HA]%
M*(6F\O))N;GKT[Q0[)WHLOIV[T_&MX-O="EL&IL'M/%LBQ5;J+A7;@,)0@DB
M"6()$@E2"3()<@D*"4H)J@X8D+2MOA0.?X>^RHW2EY5Y8&`$'PDQV8*K!!*$
M$D02Q!(D$J029!+D$A02E!)4'6")2=>'):9[U>285-9W??K9B<F)+=)#8S-M
MA5T!"8"$0"(@,9`$2`HD`Y(#*8"40*HNL22D2_P*"94UK0RT[G8TE->U-O)I
MW>D836VA5ZU1&XY`0B`1D!A(`B0%D@')@11`2B!5EUBRTJWL"EF5=2TKB_&@
MR816D8Z&,Z%A:\35`B`AD`A(#"0!D@+)@.1`"B`ED*I++`TIRBP-U:UH-+DA
M^RMO1LJ1+:\FOGU_F@MY6Z-67B`AD`A(#"0!D@+)@.1`"B`ED*I++'GI^K3D
MO;QX*FM;0TU$B"Z$AJU1JR&0$$@$)`:2`$F!9$!R(`60$DC5)9:&*@V3NZ5?
M"E'ER)97$SM$IT,A;VO4R@LD!!(!B8$D0%(@&9`<2`&D!%)UB24O[=,M>2^'
MJ+*V-=3$#M&IW&2V1JV&0$(@$9`82`(D!9(!R8$40$H@59=8&JK<Y0H1:W-;
MQ0:)4)3;2V/5ZH@H1!0ABA$EB%)$&:(<48&H1%19R)94;>Z[E_WEN/1T+D"[
M)E;FH4&348M6B`)$(:((48PH090BRA#EB`I$):+*0K9^:C]_A7YZ^V_IIY%^
M,E.GABN5:-/EWT$!HA!1A"A&E"!*$66(<D0%HA)192%;/[6;OT(_O?FW]--H
M0BNOV5].?7%W40\B2-()K2"MU51<]P$;T0+4&OE3D1.$QHJO@8A1_8"LGL/8
M(.-+-IBPD=V@V+REQHH;S!B9!G.#/FZP8".KP9G0H316W&#%2#\"[#X%4$]6
MKIE!G6=8,Z@1S2`WMZJ=UM/%*&!D=7TJDM[06''%B)'1*D:4,++=BSU@:JS8
M?<;(N,\1%8PL]S,1I:6Q8O<5(X?P*MNXXM+1R8DE?).O=(5OD!E-H)[AJDO'
MZOI4),&AL>*N1XR,KQA1PLAR/Q.[P]18L?N,D7&?(RH86>[EQJDT5NR^8N00
M7N4A5PBOTQ9+>(VLB&^0&4U`-1S"B\PY-%;<]8B1\14C2AA9RLS$EC(U5NP^
M8V3<YX@*1K9[L9B6QHK=5XP<PJODY0KA=:Y#_MCW@]>D/]V(;Y`93<!6B[9B
MB"AB9"K&B!)&QE>**&-D?.6("D:VI&()+(T5#[MBY)!4)2Q=2?5#\AOUMN+\
MLMM\>3C0K9!V?8Y]H4\/PYM'Y#KML936R`KQ!IE!!IY&8S-%(:*H073SYA'%
MB!*LF"+*L&*.J#`5S<W4GXDUKS16W*_*\F7O=&C60&F=8#NTI9=5K;BJHDAC
M&F0'@E@95IZV&M%NLMW.R"U(8(QX#"$C-;_?[KWY="@6A8@MZ,;]H>>8C2XU
MG[B,1F.Q(4D;*W^L>S2\F8H]4L9^+O4H9Z-+/2J,$0M2,M*"C.:>Z%_%!A^T
M;L7!2":Q];/`J7HG>L455WNQ@Z)!M9_V3=5,"+7BBI<T"(P1:Q"R]VD]!;Z_
M$"MYQ'74,+AY&6TQ&UUJ/7$984PT5KZZ4+[=+VXF8E(R=G.I0SD;7>I0P4;Z
MK;5Z>U<V:-)U[H_$KJ6R*MI1<%W>/<*\NT%COUT45P9]/`4!&XW;>B&BB)'Q
M'AOTL?>$C8SW%%'&R'C/#?K8>\%&QGN)J&)4>[=5IVF&-=B;7'FW4PNJ6)`9
M=1=DSQ/9PZJQH@^^K`)$(:-FM?$6"W&'C]CB@^5&)Z!L9!I+##(:.RXL/3RS
MV(KF,W9SJ?F<C4SS!:*2T8<K*QM\T)8]N_)9@MS+_'%X_V@OT[G?CO`90X.L
M:TU;$3):RN4NX'IFX0@118S,U1`;]+'WQ!AQ.*6(,D2Y01][+]C(]+U$5#%R
M7&LT9=:U=GF7,U+FXH:FD6\VAZO&JH,"1"&B"%&,*$&4(LH0Y8@*1"6BRD)V
M--.MQ=)/1;,_K_<)/Y!2U112:C0=UC?+W\1^;J7V#%2#BDU`^#.S?-D=4VEI
M-V7X06]T%MO-#49-8DLWM7:KX,_%S7-EK#B\`T0AH@A1C"A!E"+*$.6("D0E
MHLI"MJ0RL>W,]94OB$>8]#;(?NDQAQC0%<G*R`TH-+[8*D(4(TH0I8@R1#FB
M`E&)J+*0+;?*.KL1K.16K]:NU5IGKU9H:R2T%EO3U:BU8A4#1"&B"%&,*$&4
M(LH0Y8@*1"6BRD*VUBH)_3NTULFLI;5&0FOQ3'4U:JV,UH!"M(H0Q8@21"FB
M#%&.J$!4(JHL9&GM.U/+7SEF4GNR;R$-$FJ++'!EK%JU$86((D0QH@11BBA#
ME",J$)6(*@O9:E^7POF8PC7(?JD_%]OME;$RDFI?5)%1B%81HAA1@BA%E"'*
M$16(2D25A6Q)7?E9L^>Y<FWV,4EKD(A@\5!O9:Q8VP!1B"A"%"-*$*6(,D0Y
MH@)1B:BRD"VW3)@N[^1\3(P:U'WYCRA`%"**$,6($D0IH@Q1CJA`5"*J+&3K
M)U,<M8_XI3-3E&S++7N#1+3*9[S&RD1KDS:9C5R(5A&B&%&"*$64(<H1%8A*
M1)6%;+5E0O2#:,4LB)X5*I7%>BN?D!HK(VE;D5&(5A&B&%&"*$64(<H1%8A*
M1)6%;$EE*O?K>0>EY!#!&HD(-EFE/NS25"0KUC9`%"**$,6($D0IH@Q1CJA`
M5"*J+&3++=.\'T0PIG+J)#I$\$)FSL;*2-I69!2B580H1I0@2A%EB')$!:(2
M464A6U)7*O=K2S`F<RIR26T[@!<R<396+&V`*$04(8H1)8A21!FB'%&!J$14
M6<A66R5.W63N!P&L\ZQNSN9K9"_!"YD?&RLC:5N148A6$:(848(H190ARA$5
MB$I$E84L2<>NG.W7MKRU*SMI:Y":4?.D;2%39&/%V@:(0D01HAA1@BA%E"'*
M$16(2D25A6RY9=*F[G@S^H;HU0]_Z'2FO.$U2*@M4V1C9=36OJ@BHQ"M(D0Q
MH@11BBA#E",J$)6(U)>*FV62>J_5UE\2UM_&W&^/S]O5]O7UU-L<OJHO`--;
MT_O;%NMO)S_XBZ6Z3,B%+!D/Z8O+]=D/*&F_TBQ+?)^\U2\EH&1,)?4+1"B9
M4$G]N@-*IE12OX:`DAF5S%R]]N=44D^HK#.B.O1PTC'2$=6A1VFN$E*''OPX
M2GQ2AQY2N$I('<JU724C*JG?S,F^40><[5/SSM8]:IU.ESO:\*AU.C?M*!G1
M#-![#U<)Z4Q/R;&$SI^2-U?/Z%OMGYPC4<T[/#W0T)WV*F`<]I_&RT\4X-BE
M!QJ%<Q`41<X@HK&YAO9`T>`*!CKCNU2GE;!E.NJ[5(>6L(3.]R[5Z5U7R9A*
M7/VE$Y)4XNHQ'>&C$E>?Z20:E;AZ32>GJ,35-SHDO50GN;!O=%9ZJ0YT80D=
MD%ZJX\^NDC&5N,9#!TJIQ#4>.O%():[QT"D]*G&-ATZ548FK;P_4MP=GR8I*
M5LX2.F&^5.?'<3QTO)E*7..A\[=4XAH/'1"E$M=XZ`0CE;C&0R?NJ*0>SZ"]
M]NF_,+ROG[?E^OB\>SOU7K=/M$@/ZU,11_U_'/0?Y^;]^>?#F?[]`NTTZ#OU
M]/\VMG0@9JCNH$^'PYG_H"$.VO_@<?]_````__\#`%!+`P04``8`"````"$`
M-85/.FD$``!,$```&0```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R46%V/
MFS@4?5]I_P/BO8!)("%*4@U?;:5=J:K:W6="G`0-X`B3R<R_WVN;#]MDTV0>
MDG`X/MQC7]^+9_WYO2J--]S0@M0;$UF.:>`Z)_NB/F[,7S_33TO3H&U6[[.2
MU'AC?F!J?M[^^<?Z2II7>L*X-4"AIAOSU+;GE6W3_(2KC%KDC&NX<R!-E;5P
MV1QM>FYPMN>#JM)V'<>WJZRH3:&P:A[1((=#D>.8Y)<*UZT0:7"9M1`_/15G
MVJM5^2-R5=:\7LZ?<E*=06)7E$7[P45-H\I7WXXU:;)=";[?T3S+>VU^,9&O
MBKPAE!Q:"^1L$>C4<V`'-BAMU_L"'+!I-QI\V)@O:)4BS[2W:SY!_Q3X2J7?
M!CV1ZY>FV/]5U!AF&]:)K<".D%=&_;9G$`RV)Z-3O@+?&V./#]FE;'^0ZU=<
M'$\M++<'CIBQU?XCQC2'&049R^5AY*2$`.#3J`J6&C`CV3O_OA;[]K0Q9[[E
M+9P9`KJQP[1-"R9I&OF%MJ3Z5Y`0"VH0<3L1^.Y$D&^AN>,_H3'K-.:CAFNY
M2P]YSZA`S-P.?/>1>-;<]1;+9_SXG0I\]RKH815;S#!?L#AKL^VZ(5<#=@',
M(3UG;$^A%2BSE9K!>HMY'=;N_Y8.IIN)O#"5C0G;%X93R+>WK1_,U_8;Y$C>
M<<(I!ZF,J&>P562RL0XD`H#/\3G^3%5)>PY+4#`Y.(4\D)W>SL7>$",S0WTH
MH0#D)[OJ<Z,I8^:HE'A*67HJ)9E2?-]7.>DMSF+@**8A@673_?+>-\\&01K(
MLQQH<8:",Q\F*-*!6`<2'4@E0`D:=MOS0;-!&Q.F9DR-0)NX4'#@4^*,$\=S
M+NHY_<K'.I#H0"H!B@_8[\_[8(-T'\MA<7F,H>#`8R4?@<J)>L[@0P<2'4@E
M0/$!=4'V<3]Y&%F-?^%H^R`4G`4O%"Z"^_"GA:]0@AN,6&9X\QN,1##&'$TE
M0#&X>,8@(ZL&9UH)"@7%%_X\'IKN3U#&V&(=2'0@E0`E>O;6))7P^\O#R&KT
M"T>KPZ'@S'GX>MQW[L7]O3[E$AU()4"Q$#QC@9%U"UHQ#@7GMH4[]^+^WF!!
M!U()4"P@Z)J/+P-GZR;T-.I(71[=2O'H]Y2XHXRIEDR05$945ZR;2LGU6`-!
MH@<KQ7BI%[&.-,8539!X@B03))41-7;6)Y^/7717Z$U2<=6['Q(D.78=B2><
M9(*D,J+&SGJC%/O]38U$)X40AI@G-:GC=$7W=E'J.*.M>((D$R25$=4$:XR/
MFQ!M5#;A+[6N%B)!6CBB.%E(V_A11Y`MB"$CDDPXZ1U9U1%KD8\[$@U5<11H
M!35DYR(H9QXW-'>#F5:-HXXPQA]/D.1W(NRTQY["180C<7@39X$*-T<<X;*D
M1DXN[&#F0C@#.AP:7USVOJ?A(5K!BSK@]G`#SG+G[(C_SIIC45.CQ`>0=*P%
M!-&(TZ"X:,F9GT!VI(53'/]Y@E,[AG=_QP+R@9"VOV`/&/X/L/T/``#__P,`
M4$L#!!0`!@`(````(0!U$9,1-`@``-8D```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;*Q:VV[C-A!]+]!_,/S>V))L^8(DQ=JZHP6*8ML^*[82"VM;
MAJ5L=O^^0Y%#BC.Q8G?[LMX<GYGA'`Z'I*7[7[\=]H.OQ;DNJ^/#T+D;#P?%
M<5-MR^/+P_"OS]$O\^&@;O+C-M]7Q^)A^+VHA[\^_OS3_5MU_E+OBJ(9@(=C
M_3#<-<UI.1K5FUUQR.N[ZE0<X9OGZGS(&_CS_#*J3^<BW[9&A_W('8_]T2$O
MCT/I87F^QD?U_%QNBJ#:O!Z*8R.=G(M]WL#XZUUYJM';87.-NT-^_O)Z^F53
M'4[@XJG<E\WWUNEP<-@LTY=C=<Z?]I#W-V>2;]!W^P=S?R@WYZJNGIL[<#>2
M`^4Y+T:+$7AZO-^6D(&0?7`NGA^&GYQEYDZ'H\?[5J"_R^*M[OQ_4.^JM_A<
M;G\KCP6H#?,D9N"IJKX(:KH5$!B/F'74SL`?Y\&V>,Y?]\V?U5M2E"^[!J9[
M"AF)Q);;[T%1;T!1<',GA[&I]C``^'=P*$5I@"+YMX>A"X'+;;-[&'K^W70V
M]AR@#YZ*NHE*X7(XV+S6377X1Y(<,2CMQ%-.X%,Y6?3R)XH/GXKOC$W0GD`P
MI':T\/G.:'L,?64(GQC1N2KB3!G"YU6IP;IJ1PB?&.BZU$"QUA`^;TO-@9II
M+<5_,&9O<B-9`VU)!7F3/]Z?J[<!K%.8Y?J4BU7O+(4W+"8IK"ZO2]4%%2&\
M?!)N'H:@`!1.#4OBZZ/KS^]'7Z&,-XJSXAS'9JR1(0I-N`TH$%(@HD!,@80"
M*06R#C`"6;0VL$#^#VV$&Z$-9K5"H",6$0(9:!)0(*1`1(&8`@D%4@ID'<`2
M`A8Y$\*#8GF_XV!-""OH+59-+.Q$5XKC:W'6#`D8$C(D8DC,D(0A*4.R+F))
M`'W+DJ`_=<&&%06MIV<]2)(';<:09F-;H+4FZ5)@2,B0B"$Q0Q*&I`S)NH@E
M!W3C&^00[%8.3&(E$<]J&#/:#C0)S0*&A`R)&!(S)&%(RI"LBUBYPZS>D+M@
MV[E+Q%N8FF=(P)"0(1%#8H8D#$D9DG41*U&HS!L2%6P[48E,3)X4""@04B"B
M0$R!A`(I!;(.8.4'U6?E)_>^NQG,?+,K-U]6E3P&O;/6/=CCY,XGG-AI*V1F
M\M:(6>F^:R_T0')<.`N8;C`A*R+4)%P1$4-BAB0,21F22<1I!VV)!`/Z<9&$
M$ULDA71$TH@1@(DD.9.%/&&,G8DM8JB_U_IHKXC$&KD<)]%^VI/,V/'L.*G^
M'KUFVBL@EG[B4&4)^$XUP;D;RZFEVU(A!"%,:<Q(_:P5RX7#C&8Q_9`$&[TF
MN1/B*D26*/*OCS/7=<E1+D(&[`_:#PT6(ZEO1`F2>D>4(DN-R/'&OCTC&3(N
MC,B>$G'@ZQYZ/Y@2>3Z$W1QG>^5(2-R7=/[NC%3)6K%@41D652E`DJN]A^C=
MEV7N+V93.]L(C;KQJ><827WA$R29\"D-[[ND#65H="&\+;8X5-X@MCR#6F(K
MR*Y_LO37CF1]4/^*9+(-T4Z6ECMU';(<(F1<**UV&XB1U%_L+'R*=BJ\YR_(
M$3E#QH7PMMCB_-H5^S]M:8X\!5MS("%2\*0LUVC85W$!DKISH+RK@O<F4U)Q
M$1I=J#@U!VK<?>$3]&3"IPIR,;SKD<0R-+H0WIX#F"AK#C[H+H).&KZ"/-T2
MUHZ&^EJ))+EF4PV570>*C"ML9[&!+GM/N*N40YEQQ39"$,_21=2F.[T#^`.%
MA"%12$%V2R![PEK\*`:&'[0$13+U$**=7)/.9#;WB>L(*:"XW@!X`[XB?H*>
M3/P4(8P_F?MD/61(N1#?+DAQP/_QIB"O"593D!!I"C-[KUJ#13M]?:LR0))1
M(520!R)JB=T9.XDH[S:+]-`8W?>-(4&2&4/Z[ACFY(Z>H>&E,=BS`6.P9N.#
MXA=T4OP*ZK8'#1FM:#D&XAPBED.W/3`H4BSH>*8]7.$]X=Y3#F66=UL7<0.A
M57I5>U!7E^[Q3$%6>YB3-;1V).N#]J!(IBA"M)/+<SH93TFY1<BXL#K5;G5%
M^`0]F?`I0C*\/Y[1VTF&C`OA;=E!(R:[,[WQ$NP(+Z1*)60WASDY6ZW1$"I,
M+W)>N,J[$2%4=FK+=GQOS.9`&747)?4<7Q,^09()G]KA?9?WY_[HUA2XM]T0
M6[JM-4)FS:X-U".L(G4[`H<BXTIW!`-=]IYP5RF',N.*'AC$POSQTFR]$+G4
MA0[F2!>=1^IGK>SZNP.2X%RO/?'[-++DBH4';?312(2,"RM6-@PD]5XQD-0[
MHA19JH?`#9-<IS)D7!B17<#B6D-;=[>'?*Y.,`,?G?-<>3N"W13K;(50M[`5
M"\[Z6G*ZK@-EYYJ'+B&'(NX]-M!E[PEWE7(H,ZY888M["M7+]]J>>^-S-U==
M>;J:2<C^;7U.?YM0AL!"L0,.A1R*.!1S*.%0RJ',@NR2@KIC$LG3P*T*"4]D
M_4N(*$16P-K5+*,0@T+.BC@4<RCA4,JAS()LA6!CLQ3J/T>*?9C*("$B`[GZ
MKI6A52C:$)4).2OB4,RAA$,IA\3K%&+T<A!2!OEZA'R6?2C.+\6ZV._KP:9Z
M%:\^P#7T\5[#\KV,E;^$9QTP9(J['KRPT;88]LT$OFD?8+!OIOB2!_DFF"_A
MYW4>)5@LX>=ICB>+)?R<S'%XB^13>^(@_E?P=DG[*@;%71C0.WY6D-Q[N7V:
M@/_V+17J"')^-V7(N.6/M`&\57+*7XK?\_-+>:P'^^(9I!^W?>PLWTN1?S2J
M_S]5#;Q/TFX%.WA_J(!'_/"FQ'#P7%4-_@%*C/0;28__`@``__\#`%!+`P04
M``8`"````"$`)S+_^=4%```<%P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
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M_D2J].D(>;^9=IIQW^T7Y+XLLHK49->,P)W!)HISGAMS`SRM%ML",J"R:U6^
M6^J/IIN84]U8+5J!_B[R2SWX7ZL/Y!)6Q?:WXI2#VE`G6H$G0IZI:;RE"`8;
M:'305N"/2MOFN_3EV/Q)+E%>[`\-E'L*&='$W.V[E]<9*`IN1E8[C8P<80+P
M5RL+VAJ@2/K6?EZ*;7-8ZM9L-)M.;6?V`&Z>\KH)"NI3U[*7NB'E/\S*I+,2
M7JS."WQV7DQG9%O3AYD)4>^-G'0C[7[D(/R=D."VG3A\=B&=D6F/G0_B.=TP
MZ'\^T\_%FW<#X?,K\4RH*!.8EK;3[FY$@U6H+;B7-NEJ49&+!JL(2E"?4[HF
M39>ZY:5F(HGBWZH]E(MZ>:1NECKD#U6MH6%?5Q-G8;Q"CV6=R1J;F++%AEO0
M)J!>/17X*@A4$*H@4D&L@F0`#%!%2`-]]W](0]U0:7A6:PYZK2Q%"&[!AW@J
M\%40J"!40:2"6`7)`$A"P'*2A+B^#?!6H-9+'?Z*5K`<)<%U9^,(43:(>(CX
MB`2(A(A$B,2()$,BI0X[R!=2I]:PD&`[$+FC9<!L)@\#&\N9*`T@C$0'(.(C
M$B`2(A(A$B.2#(FD!FR+7U"#6K=J\"36C$R&VX3EV$KNPH@/\Q#Q$0D0"1&)
M$(D1289$RAV**N7.-LH1?9[=7P]TH"P#(W:_)6P0\1#Q$0D0"1&)$(D1289$
MRAF:5,KY?J+46DZT(U:_S!'Q$/$1"1`)$8D0B1%)AD1*E!Y<\5.P+6YS*++G
M-6&GE2L"3.!IQYZ!U(F</R,V.];0)]I&D'Z'4#='K[.!JHA=Q+*59Z4OC/@J
M"1`)$8D0B1%).M).6A()#BG_723J1!:)D:%(@O0"()$ZFX?VK&&-3647\<7O
M0A_AE9-0D-MQ(N&'GFD@CK)3Q^)W[C417H%(^M'CE23@E6Z"@R9OI]9<EHHC
M"-&WAC-5-M#.RH+'N;!"^ETSLFSE.>US*]KDD#Z\ALFQ`FX`CXR;L4)N=&]"
MT34C-*&86[$)3>;V@SRAA!O<F)!<$'KR&R[[#PK"#HKP>.>U7IL,T=<#D;[E
M*"??36=EWLO?ZXVX=Y][=UKUI^9,23;@8X;AU4J'W.A>]*@WXM%C.;ICVDI:
M"1]S([HL-427I!X\/C^_PU(%E=V#(WE)*$)M.JL/E@3S#D9<`Y^/8^TVG:IK
M+>`&-]JM?3"$W.A^!5#TF(_KFGTRG:O-WHVY$5VN`#WC?J'9V9%8:G:&[(G0
M9V,*U/>_VH`>-[+%.!^C@*/>>]BCV]XC;M1[CS%*.&J]R[J`>)(N_ZXSJ1=E
MLV9(VAO4MX&-V8WK>\[K49\UV@C]SLIB>X-IS:?*WAUP/S>69]>:*'[$QPV[
M%<6/E?@36XV?<#\WXLM%`*.[1?A!SJ#N1T=M>D>E5H$AJ6D%Z@7&3=L9L>LM
M>G;S.^]VCP*.ADW[">\1']>[BC&B5WPT'39WIA>[LF,W.&5>[?--?CS66D9>
MZ'4<[,BKA<#LKG#MN'#`AQU-X=[,A</?%3YWX?"$>31WX;"#.=Q%/K;=J_A?
MTSO**_9KRX6+!NQG/7'A-1SS1]M]!"'P#VO;A3?5*WSJPEL<<$/,".XFS^D^
M_SVM]L6IUH[Y#L0:M\?[BMUNLB]-UV5/I(%+R;;A#G`+G4/UQR,HQHZ0AG^A
M`<2]]NHG````__\#`%!+`P04``8`"````"$`^`$#*[P-``"810``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLG-MNXS@2AN\7V'<P?#^Q)1\2&YT,
MVCH?L5C,[EZ['2<Q.HX#VWV8MY^BR!)%_I(<]\Y-I_/Q9Y$J%L]2/OW^<_\Z
M^+X]GG:'M_NA<S,>#K9OF\/C[NWY?OB?/\+?[H:#TWG]]KA^/;QM[X=_;D_#
MWQ_^^8]//P['KZ>7[?8\(`MOI_OAR_G\OAR-3IN7[7Y]NCF\;]\HY>EPW*_/
M].OQ>71Z/V[7CU6F_>O('8_GH_UZ]S:4%I;'C]@X/#WM-EO_L/FVW[Z=I9'C
M]G5]IOJ?7G;O)[:VWWS$W'Y]_/KM_;?-8?].)K[L7G?G/RNCP\%^LTR>WP['
M]9=7>NZ?SG2]8=O5+V!^O]L<#Z?#T_F&S(UD1?&9%Z/%B"P]?'K<T1,(MP^.
MVZ?[X6=G64Z=X>CA4^6@_^ZV/TZ-_P].+X<?T7'WF._>MN1M:B?1`E\.AZ]"
MFCP*1)E'D#NL6N!?Q\'C]FG][?7\[\./>+M[?CE3<\_HB<2#+1__]+>G#7F4
MS-RX,V%I<WBE"M"_@_U.A`9Y9/WS?NA2P;O'\\O]<#*_F=V.)P[)!U^VIW.X
M$R:'@\VWT_FP_Y\454]4&YDH(_13&;F[N77&B\DMV>C)-U7YZ*?*YXP_E)',
M5K6FGRVU[BEQKC+2S^M*O%49Z>=5CTC]K*HI_;RNP(7*2#^O>T2'8J@J4OSG
MNC(=C@;QGZL>TZ'XD87J0/I@6SH</>(_5SXJ!Y#ST0@:R?"O>I._/J\?/AT/
M/P8T1-$#G][78L!SEL(:]R,92W7/ZNI8U*.$E<_"S/V0&IOZS(E&@^\/[F3^
M:?2=>O!&:5:H<4R%QPK17859WP:!#4(;1#:(;9#8(+5!9H/<!H4-R@88D6MK
M_U)8_!W^%6:$?]DS*P8-AUO.9`5G\6T0V""T062#V`:)#5(;9#;(;5#8H&P`
MPYG440QGM@_V')-"3<.Z$9.WII-62C.O'>L!\8$$0$(@$9`82`(D!9(!R8$4
M0,HF,5Q(7?P*%PHUC0PT:_3T:RF:T`S1$-V9CO9J41V.0`(@(9`(2`PD`9("
MR8#D0`H@99,8;J4)^0JW"G7E5G;&2I*).8`N+!_6(L[F`PF`A$`B(#&0!$@*
M)`.2`RF`E$UB^)"B[`H?"K7I0TDF"]V7@?A``B`AD`A(#"0!D@+)@.1`"B!E
MDQ@.HQYWA<.$VG28)%/M+QOX-@AL$-H@LD%L@\0&:0,8ST>]P7@^N3:Y$8OK
M\\MN\W5UD"OTEFE@0FL0N3(11LS'5N16/W=-]`@V=\W.YTN-2\M2/<I-QZ8H
MJ$7<0T,@$9`82`(DE<2I*FTXB2ID.*G%&;2C86\(M>D-22;5;JORF%<3_:3@
M#:6AB;KA#6LY%]2BVAN*3&K71S71ANS"XMJ.UKA3J["D%G%AJ2)R']E<DXD-
M@N&S7PJLRHKI2X6:SD3D*T2A5*V3Q\[4BB(MX&<)T4R$*-89E>6):3G1`K:<
M&F:,R!*;(<--_:%5R2U_R%6Q0RU1A\G$ZEB>RN>2MA;9(>"SR`PXRU3`*M'[
MOS\XM`69F0X(64$3>6=A$8OZ:A2SJ+=&":MDC2:+\=Q:@::LZ*B1V2)B8=S<
MK5UH$2&W6D0B<<91/__$BC]/;&I%/AJ7:Q&VB!*Y=5\.5#YW+@/;G4UGUA(F
M9-/-\FW3$8OZRH]9I,M/S/*=Q>W"+C_E7!WEF]X6B^BFMW]MF)!+<5I#<Y=;
MB0V_\*_1+:RNZBG1A6XA+;G:"0'GDQ'GSL9C:Y(*6=$1<=4D$+&HOP]`\0GG
MZRP^945'\683D,AH@@L!+^16P"NDIQQ/'',(%56^)[RER-6KA$#E:Z!0F^+&
MC33JMAZCJ011JDV1==,O%+^&7T1HNG-QU'G%TDB<E]KNDL@8']PIQ*;*V-=!
M?;9.XT3M9G<*0[8J4(T9<_?.M8:CD`V1LC:$8\8'JA2SI=XJ)4K%P]C<';O6
M45;*ACJJ9+:56+_W#2-_'-XI&B^>L,EM@#&.*-2,[1IU^\H7^WEJ=U<?)P6(
M0H6HF^C8_H#U&$TEB%+#NNDOL1VP_>7.;LC7UQY*"DO6<""1N=&>6A'GB9F/
M,I**']U'%"`*$46(8D0)HA11ABA'5"`J#61Z6VPL_AYOJRU*<Z*3R/*VM2;S
MG%JEO0TH0%6(*$(4(TH0I8@R1#FB`E%I(-/;8D_R]WA;[FZH&['35F(](:-6
M]WUW:@U=GE9Q1A]1@"A$%"&*$26(4D09HAQ1@:@TD.%MU][G]:\>*KDY7"AD
M!;"UA/>TJG8IH@!1B"A"%"-*$*6(,D0YH@)1:2#3I31/&0%\P:5";KE4HN8Q
MG5CCBL#5)W<^H@!1B"A"%"-*$*6(,D0YH@)1:2#3?V+7U!P`+OA/;;(:O9S6
M^L)9C5,[(#Z0`$@()`(2`TF`I$`R(#F0`DC9)*;+Q";C"I?)/4ES8'0E:A[+
M:*3'2GM-Z;.(PK->>+I3ZV8CT"KN_2$C?:@6::1MV07&+#(+M/9OB59Q@2FB
M#%&.J$!4,L)S,U?LB9HM\4L;XLJ*-2;(S9;10(!\E7%B>L<Z80BTBKT3,FHV
M!YB/E8J.Y3AC@BA%E"'*$16(2H7D8YLQ+W8S34]?&";4YJ<Y3$ADN+1&W2'H
MBYV?&(L-)\^L$`RTBGT5,FHZ^0,%QIS/W)/9I[M:Q06FC/3^)-.H^PES%O46
M6&@5%U@R:ND88E_4;*Y?ZQAJ=]5L18F,5@3DTTY5M%DC<@-$H4(-6Q&B6&=L
M/YQ.M(`=DZ*9#%&N,[8?3A=:P)9+PXS90^Q=XH4>@EM!.L<17A/+1SVZSZS`
M\Y1*S.BURAZW?18UCN$4FDSE6:AU#,T9:!3JM!JQJ*_HF$5F-%NG+`FKU,'X
M'1W-6GO>E"5]5<I8U%>EG$6]52I8I:HTN9LYUL:P9$E'E<QX$#O&_[\+RGVG
ML7B02'3^NJG<F>5@C\Y2JF"BF*I5&"9*U`P3B2;BAH[>F;+#1&5HEFU;C3Y2
M=,PB772B$'4Q4?347=C^3SE37_$9B_J>/&>1+KXPBY\MIG9$EIRIHWBS^>V-
M]87A`'?/XF97#`=Z.O$TZFM4R!?H?#R0A8@BC;JMQTI$/8%-)8A2;8I5F4;=
MUG,T52`JM2FR;GB=YA*ST_5[O9*;*S]&Y,2ZW[@S^[Q9J?H'81;I!4B`*$04
M,>H;U&(6Z0A.&*FKCI;KKI0E'2-8==62L:BO_)Q%NOR"D1I!6ZZ[2I9TE&\V
M)I5OC*`7&E/(K<:4R!HJK8G&$TM+D;%OP/!9I!\W4$@-E=8\'7*&CL%"7FJQ
MJ*_HF$6ZZ$0A-50ZCNM:NXZ4,_45G[&HK_B<1;KXPBS>G4_M#E)RIH[BS7:F
M>=EHYU]:K$Z$%:OY%3+[LC6I>RKCA;XL3=&9``]H@<I'"ZKF2&&=;H9LO:F"
M&9-%%(CUH&.+8A;I*B2,5(>?._8KSBDK^HK/6-17?,XB77S!2!8_N9W;+XZ4
MK.@HW@R#ZXY5)GBLPJ@Q8VK4[5E?BW3C*NO:5(BJ2*-NZ[$2-6=,1*DVQ77(
M-.JVGJ.I`E&I3<&,24T#G>_JBUO1">S.)Y$Y]L+%+6?L&X%\)=(GC`&0$$CT
M$=,QBZA[UST/[H03I5+#K=MR)YRRH8X!3TVLRDU]3YNSI=XJ%5`EN!,NV5!'
ME<S.1R((`V>F7VW\V)TPS840!PKIGN2QBOI8[71[N/.UB#M$@"A$%&G4;3U6
M(EK1L_4$4:I-L2K3J-MZCJ8*1*4V!9U2G)\T]XX75C[RN*6Y29RH0QE]=.,A
M\A$%B$)$$:(848(H190ARA$5B$H#F=%,'>P:_PFYM720:$K[B3I$W9E]SR8^
M,:",I.+X\!$%B$)$$:(848(H190ARA$5B$H#F2X5._]F2%8O^/S*2Q#B[M+V
MMD26MZU[#4]E-+Q=9^0&"%`5(HH0Q8@21"FB#%&.J$!4&LCTMMC#-[U]80!0
M6W[=VU=T=ZE"LQG`UB[!TRKVGX\H0!0BBA#%B!)$*:(,48ZH0%0:R'"I"*XK
M7%K)S3%!(=%J>DR86S<1GE;5+D44(`H118AB1`FB%%&&*$=4("H-9+I4;)P_
M'J7T];7=\16R7&IMI3VMTBZ5MB@CHP!5(:((48PH090BRA#EB`I$XCMTX0E9
M>^E2^5VY_!)VOST^;[WMZ^MIL#E\$]^,3\6K^366'[2O)O.EF`/)`9!R2RG5
M"1VDW%%*Y31(65!*==5HITS'].5\-<5!2OU-O9TR6])G52TUHRJWUMBA&M,!
M3$L.AVI,[R^UI5"-Z;*D)<6E&M,K(YA"%W)+<16$*70+MQ1W;&TI<TIIRT,7
M<%1.6PK]L8'/U4;9]@LYK/IBW^8N&6HI>S6A1FGAGZ?+SQ1$6-G5E-JJA=.5
MW%+<P6$.>C=@*:[B,(5>$5A&="6,*?1>`+FD+84NZ^E)VE)6Y*Q5:SD>I7BM
M*1&EB#O!MAK,EDEK<]&%(:6TY4D72_%Q"1I;4:57K97V*,5K3:%W,<BA;6U#
MKP502IL+Z"Z;4MIBC.Z.E^+6LJUN%#)T-H4I_MV2/LM"OEHL5ZV/Z2V67FN"
MOUC2IU%HB3X,6@:M.<+%4GP!A%FBQ5)\!X0)\6))7T2U<"I#?`5$*:.Z4]#?
MQ7A?/V^+]?%Y]W8:O&Z?:`RD/TA!6\FC_,L:\I>S>E'YR^%,?Q&#9FOZ<P'T
M%U"V]*7^6+R>^W0XG/D744#]-U4>_@(``/__`P!02P,$%``&``@````A`+%\
MQH9M`P``7PH``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<5MN.FS`0
M?:_4?T"\)V`N@41)5@MHVTJM5%6]/#O@)-8"1K:SV?W[CC%)L+,W[4L"]IG#
MF3/CR_+FL:F=!\(%9>W*15/?=4A;LHJVNY7[Y_?=)'4=(7%;X9JU9.4^$>'>
MK#]_6AX9OQ=[0J0##*U8N7LINX7GB7)/&BRFK",MS&P9;["$5[[S1,<)KOJ@
MIO8"WY]Y#::MJQD6_#T<;+NE)2E8>6A(*S4))S66H%_L:2=.;$WY'KH&\_M#
M-RE9TP'%AM94/O6DKM.4BV^[EG&\J2'O1Q3A\L3=OUS1-[3D3+"MG`*=IX5>
MYSSWYAXPK9<5A0R4[0XGVY5[BQ8%\EUOO>P-^DO)48R>';%GQR^<5M]I2\!M
MJ).JP(:Q>P7]5JDA"/:NHN_Z"OSD3D6V^%#+7^SXE=#=7D*Y8\A();:HG@HB
M2G`4:*9!K)A*5H,`^'4:JEH#',&/_?^15G*_<L/9-$[\$`'<V1`A[ZBB=)WR
M("1K_FD0&J@T23"01*!^F`^F01JC>/8VBZ<5]0D66.+UDK.C`UT#WQ0=5CV(
M%L!\RDSK..?Z4JJ0HR*Y52P]%V0AH#X/:^3/E]X#>%H.F$QC8$E<,"8B/R&4
M@8JV&`UXH/<L&JRP18=0U.?+<=*H@DR-@2WQ&8@E\1H1^B:DN(:D\1EBI!%^
M)`T5!/TSMA%9$C*-B?KV44;F]D`Q&C`D00N,G7W=405>N9#OI:+^[)QJ7\),
M8Y*^)R9Q.$<6(#<`:!;X*#0I"A.1H#1^P4]82^\7K\"VC\C\<J8Q(Q_M@6(T
M8/@X,Z6H9?5VAZH@RT\46)(T)M)^SB]&]&[GQFPP2\W@0D_/]`(-1K4RM"?7
MVB/(\_5>4$&V=JN0F<:,[#P-J`TC2JPN+L:SD_&TH5:=L=8&]K;3*LA6&YEF
M91HS.!W,K=[(];3V<H+\P.KK8AP^6J"&]OE'M*L@6[O5!YG&#-K#U-*6&]-I
M8&5>C*>3Z!)L:(?SUC#^]?;HT;;J"[/>*P;0:;.(0M_J_MQ$P&Z1AHE9-G4/
M4/X,)"A!XY-(9Z#/>7T,-H3O2$[J6C@E.Z@S','R.(_J^T6F[A?]#>$\`<=[
MAW?D!^8[V@JG)EL(]:<)+!2N+PCZ1;*N/W0V3,+!WC_NX2)'8%?VIP#>,B9/
M+^H*<KX:KO\#``#__P,`4$L#!!0`!@`(````(0#"(%8VB`8``#\;```8````
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULG%G;CJ,X$'U?:?\!\9Z`(=RB3H^&
MBW='VI56J[T\TX0DJ$.(@)Z>^?LM8P-V.9,F^S*9')^J^%257=7P].E;?3:^
MEFU7-9>=2=:V:927HME7E^/._/LON@I-H^OSRSX_-Y=R9WXO._/3\\\_/;TW
M[6MW*LO>``^7;F>>^OZZM:RN.)5UWJV;:WF!E4/3UGD/7]NCU5W;,M\/1O79
M<FS;M^J\NIC<P[9=XJ,Y'*JB3)OBK2XO/7?2EN>\A_UWI^K:C=[J8HF[.F]?
MWZZKHJFOX.*E.E?]]\&I:=3%]LOQTK3YRQET?R.;O!A]#U\T]W55M$W7'/HU
MN+/X1G7-D159X.GY:5^!`A9VHRT/._,SV5(G,*WGIR%`_U3E>R?]W^A.S?LO
M;;7_K;J4$&W($\O`2].\,NJ7/8/`V-*LZ9"!/UIC7Q[RMW/_9_/^:UD=3SVD
MVP-%3-AV_STMNP(B"F[6CL<\%<T9-@#_&G7%2@,BDG\;/M^K?7_:F:Z_]@+;
M)4`W7LJNIQ5S:1K%6]<W];^<1(0K[L013N!3.(D6V[K"%CZ%K>.MG=`CGO_`
M#C;""^SY_\OPA1/X'+?RH0Z+QW-(3YKW^?-3V[P;4/,0L>Z:LQ-$MN!PS`N/
MXI2I'R4*,L2<?&9>!E^0@PZJZ^LS(<&3]14JHA"<F'/@0$N<2.4D-SB.K7+2
M6QRB<K);'$?ET%L<=^)8$)\I2%`P<I!N%^T8"T;&L0@GOT.\8LX)A^ID`4PP
MD&(@PP"5`&6S4*'+-\O(.Q-<S4EQ-FBSG!/PM$9!2%"T$X6`%E-ET8N"C8."
MD<F,%2'VG(0A6%1==Z/0<[QIBXIT.%ZR=%;,+EQ5]_/%C'`(9O\\7YRSF?/%
M`5^4^F83(HL46V08H!*@B("[X7$1S`B+\*<@<1&<P_>\T<YGPI=GC>E]?H;Y
M5`(407"M/"Z(&6%!^$;AG'G'R0BP"R@(4!VGXRKK+NS091B@$J`H"%0%]^N)
MD?'.4<G'G"/*QR<1O@?Y^JPL_<`@PP94`A0I;*"2[OO[4A@92T%;C3EG,YR$
M8(-J+AE7QYBG&,A&8,@9MJ?C*ILMY!L9&MYR&8R,9-AHHS'G\(RL2$!"#YWH
MA#.DG&`@PP"]YU210^"66JYG8"-!+FJ3L2")XQ[8!-5@(@@\<_A.3Q5SXA,X
M3N@\98J#E>NAXTD5%RO"IK5PWJ6JGS7CQ65)>.M6NI:+^DXL2'.^$H&(4T>@
MBZ!:3C6;3$.HC*@:6$.6-"SK/H2W<46+@XM3D/C.0\?64LF=S%K3#RPRL3Y;
M4!E1=;'^^[@NWK557:A"8L))\RX2@8@<.2XZA*EFD6D(E1%5"6NYDI+[EQ_A
M#5I5@"(?"Y+8;Q#HJ9':_-!UTH],,D&8HT)E1%7$>NYR1;Q#JXK0&8C97V5P
M6_)K817B:3"9UJ<K74.R"6&7NNZ#3NOX6B>L`R_7P_NUHD>[V`>7.Y-G:$5\
MQR9HP$P$90YXJB&9AM"[CM4LL6:\7!5OW8HJ%_WQ$A-.$JK"*,)3<R(8/[K>
M97OB;US?GZ]F/AVI/T%(B&Y8B@B!Z[C1'%HU`JR/+X\`[_IJ!&;/?)HETF@P
M((E`Q%D$41'J6*EFDVD(E1%5`^OFDH:%]SN?`50M:%\QD0<%0GS/11T@$0R1
M376P3W5S=&UFD_EX:*F,*#*=AT:1@8U'$?3KL2#-YRL1"$]5%`3((M4L,@VA
M,J(J0,/$LD0Y-X8*K1$+$M_WQH]"E,E$$&[G2;-&-9U-UE.:9$05"17U>#4Z
MS`JER\%=69#D='$S(3O:((M4L\@TA,J(J@3-%_>[LG-KKL!=69#$30"S+]IP
M(@BSQ/0CDTPSH3*B*GIHSG!NS1FX*PN2Z,INB.^':7VLG%1#L@D9NK+F@T[K
MN"NS!YQRK7V0H1M3AM:5!Y=35_;<B&B*QCED5H213'B9TTCO^55S]-"DX=R8
M-/`='0L2?U#F^BYNVHE"P%-(JJ["X$4B="UF"@7^HO)175-$"$+?M>=24@/P
MT%`"[P:TB\-%OQX+TIR.1"#B(,+#>ISF5+/)-(2]F.`CZ528_#T#?Y!=E^VQ
M3,KSN3.*YHV]0_#@8<2$\O<;,=G&#GM\A_"$;.'9JXZG9`N/8'4\(UMX$JOC
ME+T_8;@U_0"\OKCFQ_+WO#U6E\XXEP?8FKT.H(I;_@*$?^F;Z_"X^*7IX<7%
M\-\3O*@JX0F5O0;RH6GZ\0O[@>G5U_-_````__\#`%!+`P04``8`"````"$`
M_BWZ-#H"```2!0``&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)Q4VXZ;
M,!1\K]1_L/R^&')?%%AM%*5=J95652_/CC%@!6-D.[>_[[&=T,TFK:*^!!SF
MS)DY<V#^=)`-VG%MA&HSG$0Q1KQEJA!ME>$?WU</,XR,I6U!&]7R#!^YP4_Y
MQP_SO=(;4W-N$3"T)L.UM5U*B&$UE]1$JN,M/"F5EM3"45?$=)K3PA?)A@SB
M>$(D%2T.#*F^AT.5I6!\J=A6\M8&$LT;:D&_J45GSFR2W4,GJ=YLNP>F9`<4
M:]$(>_2D&$F6OE2MTG3=@.]#,J+LS.T/5_12,*V,*FT$="0(O?;\2!X),.7S
M0H`#-W:D>9GAYR1=C##)YWX^/P7?FS?WR-1J_TF+XHMH.0P;8G(!K)7:..A+
MX?Z"8G)5O?(!O&I4\))N&_M-[3]S4=46TAZ#(><K+8Y+;A@,%&BBP=@Q,=6`
M`/A%4KC-@('0@[_N16'K#`\GT7@:#Q.`HS4W=B4<)49L:ZR2OP(H.5$%DL&)
M!*XGDF02C0;CZ>P.%A(4>8-+:FD^UVJ/8&F@I^FH6\$D!6;G;/179V#)U3R[
M(E\*:`-I[/)D.)N3'8R0G3"+&Y@>0:!YKP"ZOE<PA(1NS_:LP!5=*A@\]O1>
MY.(&I$=<"!C^CP!7!#%B]&8$[Q4$C-_+BX:CRX;_=NK`&08S?QJ-XMY(L!HP
M4Y_$))GV3T/7L-8A]8Y6_"O5E6@-:G@)G'$TA;QU6.IPL*KSLUTK"\OH;VOX
M]G"(/HX`7"IESP?WVO1?L_PW````__\#`%!+`P04``8`"````"$`EC&SXHD(
M``!$)0``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;)Q:VV[C.!)]'V#_
MP?"[8_&F2Y!D,!+1.P/,`(O%7IX=6TF,MBW#4CK=?S]%%6VR2DHB=S^D$_*P
M=*I8K$-1O/OU^WXW^U:?VFUSN)^+FV0^JP_K9K,]/-_/__N?+XM\/FN[U6&S
MVC6'^G[^HV[GOS[\XY>[M^;TM7VIZVX&%@[M_?REZXZWRV6[?JGWJ_:F.=8'
MZ'EJ3OM5!W^>GI?M\52O-OV@_6XIDR1=[E?;PQPMW)ZFV&B>GK;KVC;KUWU]
MZ-#(J=ZM.N#?OFR/[=G:?CW%W'YU^OIZ7*R;_1%,/&YWV^Y';W0^VZ]O_W@^
M-*?5XP[\_B[T:GVVW?\Q,+_?KD]-VSQU-V!NB42'/A?+8@F6'NXV6_#`A7UV
MJI_NY[^)6ZOS^?+AK@_0_[;U6QO]/FM?FK=_GK:;/[>'&J(-\^1FX+%IOCKH
M'QO7!(.7@]%?^AGXUVFVJ9]6K[ONW\W;[_7V^:6#Z3;@D7/L=O/#UNT:(@IF
M;J1QEM;-#@C`S]E^ZU(#(K+ZWO__MMUT+_=SE=Z8+%$"X+/'NNV^;)W)^6S]
MVG;-_O\($MX4&I'>B`;VOE_>R-P(DWYN98F,>@?MJEL]W)V:MQED#3RS/:Y<
M#HI;L'SV#'E<?'W/5?#1&?G-6>EM@1<MS,^W!Z'%W?(;Q'3M,25B8$D$#$54
M9X0+H#-KHX8E\+V0AE!PT@HF=7PZSAS=(,I1%I1`.0*AB&J(4`F%V"$D-Q<(
M<4-1-SZF[\"0-W'XM+S8[>-5(D;W:>,"6/$&&S40*C#U<40_IN+`]W/P,\QD
MDC(JB,GZ7%@850@&J`A`I#(1BIJP%)&)W+P31UA#,7F7PY^G@QO$X\D8E(B)
MXLD;;-1`XIG^#"4WB,8UYQF*D!3#*D6A,AJTB@)D$L4,UQ0!B"0KPCHE'F0_
MXX$;1#T02;"/28H8=$$F>9XS#TB_5`D+@8W[19Z8$`'"WVEO5-@^SF@'9KPE
MXU4B!GF++!'AN;U?%>W/$C;>DOY4%,$OPKNXAK<#,]Y:TWB6B/&\92$Y;]*O
M9186&28,[3>17X2W@`(\/>`]FC-G3RX]2/LBDK)*6Y'^-&6.6]_M,\W(,)P2
M=RHS.5,$:A*MPZRVE1X4%8Y!BXU;*!\G(-/YH-R08JS9%)<"01B)A5`9R\V*
M`)3)F$/6]_N9R-/P`$K=R<MTZBA&,77%'ER*LV"Y/85)PA3BFO/=Z)C.^9JT
MI']ATDAC*'&G-=.)HS+%Q(>['<3XD"M9L.RL1`Q(M63:8VD_;!4ORYHR=PHT
MG3GJ%6'.B)5N8PM%Q3-/E0F%R@<]!I!"A@7#&_#)(F38I5#F3HFF,T?=(LP'
M]8)H6VX2!JA$##"0+Y>8>N9Q_T(G*L2&4G<:-)TZ*A:A/LASQ&#,9,:2H1*Q
MZ"U$(9AGE@"$+D(_)>Y$:#IQE"Q"/*S\/F2EB&5M48B"`2H/.!?QB)F/>6S`
MF*AV4>9.AJ8S1]$BS%G-*P5BXB)];G'%9B%2-DG6C\"5861410E5>942]FBN
MA)RK!_DUJ0=:5U&`D"K:7F"<*:)0^3NY+9D<3MM-]Z.H%X:%K_08[T26P#^Z
M_BJ"&`%8#^CGC,8<IGIZ>DB'IFQAS5`RI0=YND+E?"=;$02\X82(^I#C8]""
MBG=6E/M5JBF'JBD,"V3I06?NVIT74?<J"E$YY#-%6(H0LLBB*:4>7"6?$I4/
M_`COCX:5XM*#HM4Y:+%Q"^5SE2BZTQ.>#2:(%M8Y#\*(2IT5O)!5!*&@1@_D
MA2*2+,]#R"E_IT.3BYU$U8J+G3!,04H/\AD!<REYR"L&2?,D977(4@AD?)J&
M0%$7KI)(.91(8=AR*CW(3P&49Y8S%07$T?7K,591$^^"*?6K1%(.15(-@H^8
M.)EYB_5VSA,$>]VPJ"D]IH03"_10$04_&R@E@CR'HN#O`14%Z"0Z//`A)A9$
M8O(0"^*%.Z")4WR:%_TH5KBCHH1+U8.\%RHS&4\4@M!%,3AC(``A5/+>RZ-B
M:OGQ,4./9H=.T?F%IX]OF%&R^&&AQ<8M-*Q7Z:`:T4'#UGSI0>=P&OZ.5E&`
M+(I0$C`I&$!'AU:4/!/"B3DQ)HA<S!6"T`DATA$O$!$'.6JA/)G<.9X:1.23
MR4?9(V6:'VF4"D$^V&X+1$6YH@`U`%@"$*(PT0$;]8*)Y$0O1L22%^)2(2C$
MLAJT6-^"GF99H8.GE";3PHE),:*)D53YE8:@F"9OL0I;_(2(3.KD'=%63/$F
M$AU1OC343$\T%BZ=%M'>O0=4_;//[^PYG*K2K+&D7XOHG(3&FBG?1!>&"CC8
M"Y<*07X!&CGB0XR0DG\PL,2"A-U)J.K4B9_21S6BCVEXB_;S@*#SR0:7C<H;
MP7XU*(/QZ&CE$_;ZIW2Q'\5TD;^^EA[D4UFF6<(85@0A5#KXMD4!"7R^O"0:
M]8+)XK1$TJA\M$*&U89SX$'HA2J2Z"P2UP(!2!.K30^P!``[91'"0)U@6CK1
MB1%-Y?OH4B/(KP:I>*95!##BI24`ZB5UPHE8]"HQT0F4/O@97M%2KJDZTD<?
M>MYB8PSEQ33T8^W4(]J9!<'PF1%KI\BT#LGIZ5&`*9@%ZQ^#TU+`-\EWLILI
MYR?<1Q23[TA+MWV`=U"L'`4_2:A\M\^71+!7(\OZY3NE43LQNSX94`)),F1A
MS?C@<^6L^H<YERZ?\^,6F@PCTOGYADJ/2"<_.2T]""-G9'2,[G,BEE8X)@E3
MWO=;/[[W@G(>T<H)G$>T,F.S6<)5%DR&<^2J08N[[N(P^(%=0P$(DH\T\3(+
MWO78UZ?GNJIWNW:V;E[=114!W]0NK7B)IH1+-/V-D^6E`^ZP'%?/]5^KT_/V
MT,YV]1,,36XR2-83WH+!/[KFV-^L>&PZN+W2__H"MY5JN(*0W`#XJ6FZ\Q_@
MT_)R_^GA;P```/__`P!02P,$%``&``@````A`&&38T-*`@``B04``!@```!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6R45-N.VR`4?*_4?T"\K[$3YZK8JXVB
MM"NUTJKJY9E@'*,88P&Y_7T/D+BYK*JL'V(3SYDS,QP\>S[(&NVX-D(U&4ZB
M&"/>,%6(9IWA7S^73V.,C*5-06O5\`P?N<'/^>=/L[W2&U-Q;A$P-";#E;7M
ME!##*BZIB53+&WA3*BVIA:5>$]-J3@M?)&O2B^,AD50T.#!,]2,<JBP%XPO%
MMI(W-I!H7E,+^DTE6G-FD^P1.DGU9ML^,25;H%B)6MBC)\5(LNGKNE&:KFKP
M?4A2RL[<?G%'+P73RJC21D!'@M![SQ,R(<"4SPH!#ESL2/,RPR_)=#[`))_Y
M?'X+OC<7S\A4:O]%B^*;:#B$#=OD-F"EU,9!7POW%Q23N^JEWX`WC0I>TFUM
M?ZC]5R[6E87='H`AYVM:'!?<,`@4:**>E\%4#0+@%TGA)@,"H0=_WXO"5AGN
M#Z/!*.XG`$<K;NQ2.$J,V-98)?\$4.)$=22]$PG<3R3),$I[@]'X`182%'F#
M"VII/M-JCV!HH*=IJ1O!9`K,SED?\GG?&:AQ-2^NR)<"VL!N[/)D-)B1'43(
M3ICY.Y@.0:!YIP"Z7BKX?V<'ONT\['B]NOD]9OQ/W%7K_D=:.S"$@]&%Z=%-
MZX!)_3!=>DP_TLB!,PPN+AJ-;QH%S,1GGT9I?'6E'?C*+8S:XT$[\*V(2<<;
M@@Z8LXC;C,-I"L/6TC7_3O5:-`;5O`1C<32"<AW.4EA8U?JM72D+9\`_5O#)
MXS!Q<03@4BE[7KC3VGU$\[\```#__P,`4$L#!!0`!@`(````(0#`/'\V;@8`
M`-D?```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)R9WV_;-A#'WP?L
M?Q#T7DLD)<4VXA3IBFX%5F`8]N-9D65;J&49DM*T__V.)TH1CZ3%["6)+W?W
MY=V1'\OF_?OO]3GX5K9=U5QV(5O%85!>BF9?78Z[\.^_/KU;AT'7YY=]?FXN
MY2[\47;A^X>??[I_:=JOW:DL^P`R7+I=>.K[ZS:*NN)4UGFW:J[E!?YS:-HZ
M[^%E>XRZ:UOF>PRJSQ&/XRRJ\^H2#AFVK4^.YG"HBO)C4SS7Y:4?DK3E.>]A
M_=VING9CMKKP25?G[=?GZ[NBJ:^0XJDZ5_T/3!H&=;']?+PT;?YTAKJ_LR0O
MQMSXPDA?5T7;=,VA7T&Z:%BH6?,FVD20Z>%^7T$%LNU!6QYVX2/;?LA$&#W<
M8X/^J<J7;O9WT)V:EU_;:O][=2FAVS`G.8&GIODJ73_OI0F"(R/Z$T[@CS;8
MEX?\^=S_V;S\5E;'4P_C3J$B6=AV_^-CV17044BSXJG,5#1G6`#\#.I*;@WH
M2/Y]%W(0KO;]:1>*;)7>Q8*!>_!4=OVG2J8,@^*YZYOZW\&)X:*&7+BTCWF?
M/]RWS4L`\P;O[IK+W<.VD'A<TY!A6J5KD;`ZF>119MF%L%%!OX/.?GM@Z_@^
M^@;=*)3/A\$'?K[Z3!X1K&9:$BQCOB1[>T9EZ2R59;OD4CX,AKD,M\N(M\A(
M9^CW?/%K-N4=E`>?!-L]KR?1A62+>29'[)C\6)J,@[%DFBCMJG*"S?C:UK6C
M8E#T;ZQT1O6IL\HR;RU;BZD)V@QAT7,IW%8Q7]TM%BT#=5EE@;G.*DSLLG>F
M+%\SCU[+0%U66739U"XK"4T.$8?XVSM7!NF2RJ(W.+-+;DQ)YM5@&:C+*HM>
MZ9U=EL%&,TH5"*R%<C%2%QY-NO+:H0QMH<I)O%G!]KC=9R8#B;`RZ<(;AS!X
MS847U*0W45,F?&O13@E[$X/0FZ0>F"-+?#T<FU=&Z&H6$/GM&3:A:(+!:-):
MN'E%HJY,R(,(7#P@\KV1MM+&H(T#=Y*<\\$AA%BZ6F00!I)&VRBT<<"/2790
M'K`[#V$%G>SU[0QSP5KT/COPQRP@8GSMP3^,)"4K'.G*#@(R&X_N-C[*)I`P
MF5&S`X3<1J3%O851>KVC23]+#@YR21`ZX@T<D]MTP#`B:V/1Q@%!+E%"99>+
ME5%$59GT8AT$Y`13>)`R>/9<+%?A:;:?,1>9+7P.L:.7$V(M-->D%"8`-1.]
M\O&+=I)MH"L+&@I`\XJ4"6(G!O/804).F+2@IJ@S5U.F^>!X[""@?`@QBDR%
MQV,81I(MH^"DU^E`(/_?),)(HFPA$8\=#.06$H&S3\TFB3"9L5L=#!2$1+=G
MB]YZG:-)GZV#>T)R@Z!`K(4'<3&2*,MD1IT.]@G)#J+,E]F'84169C)D'>P3
MA$(+[371@PE`S82!>!-GT)L4HM`#OR8&K%WMLY`G2Y9A*DSTC";]2#HH+MZ$
M'O0F12KTS(ODS(%N84&/WS'$2*)L0P]S(%80]"SL$\66&6(Q`2Q`K].!6&'#
M39IZX`8C29V*0-H\F0.Q"<&-?%<6@GL``"-UY=&D*SL0F]C0$V<>-6,D4;:A
MASD0FTA@$/0PF?3VD#&,R,I,8-(+=K`V>1-ZT)NH*1J9Z$DD.6A%/A]2,)"H
MR%Q&30X,)01#"QTTX8,)0`VZ/S&/,P>\$P(?W*RPVQ=4%7%FAQ,3&34ZD)<0
M""VH*<K,U91)JY$[D)<0\'@_)F,@&:7MD8<[B)=8&.3UU0@&$F$;@K@#?BE!
MT.W^HK>N-IKT_CJ`EX*7<52\OO/"2*(LDX%).__<`;S4@AV_9RV,),HV\G`'
M\%)"'KFG>+9>?EK`0"*L(*27[$!>2KBT,%I%GMG1P02P`'VT#ABE!$98IN3H
M@JQ))<QDS-5!I910:4'-I!$F,(ITT"@E-/(MTL029J)%"@>64AN6O#X$8B3(
MS*=JXY)P<"DE7%IHKR+/7$V9YGN(,<>.S0B,$+]>=6*D7N=HTLZ*<&`P(V"Z
M72=Z$S4%HWF=7#@PF%E@Y/$,A&%$UD8BX6`@W(R:]/7Y$@@#B;"-1((B<+A(
M'6XKZ[(]EK^4YW,7%,VSO"3E<,TX6:<+W$<NOSJE]F3[.%SL1M-_X&+UFA_+
M+WE[K"Y=<"X/D#/&1]AVN)H=7O3-%=8.UZM-#U>J^.<)KM!+N&J,)84/3=./
M+T`YFB[E'_X#``#__P,`4$L#!!0`!@`(````(0!'%?Y(+Q,``"MF```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*R=VW+;2)*&[R=BWD&A^Z8($CR&
M[0D+Q/E`$C&S>RU+M,UH252(M-W]]I,%5*)0^8.0Z-V^:-)?_959J*PS`.K#
MO_YZ>KSZN7L][@_/'Z^=P?#Z:O=\?WC8/W_[>/V??P=_S*^OCJ>[YX>[Q\/S
M[N/UW[OC];\^_?,?'WX=7O\\?M_M3E=DX?GX\?K[Z?2RO+DYWG_?/=T=!X>7
MW3.E?#V\/MV=Z)^OWVZ.+Z^[NX<JT]/CS6@XG-X\W>V?KVL+R]?WV#A\_;J_
MWZT.]S^>=L^GVLCK[O'N1.4_?M^_'-G:T_U[S#W=O?[YX^6/^\/3"YGXLG_<
MG_ZNC%Y?/=TOXV_/A]>[+X]TW7\Y[MT]VZ[^`>:?]O>OA^/AZVE`YF[J@N(U
M+VX6-V3ITX>'/5V!JO:KU]W7C]>?G64Y<:YO/GVH*NA_]KM?Q];WJ^/WPZ_P
M=?^0[9]W5-L4)Q6!+X?#GTH:/RA$F6\@=U!%8/-Z];#[>O?C\50>?D6[_;?O
M)PKWA*Y(7=CRX>_5[GA/-4IF!J.)LG1_>*0"T/^OGO:J:5"-W/WU\7I,CO</
MI^_T;3J8S(9CA^177W;'4[!7)J^O[G\<3X>G_ZU%U14U1EQMA#ZUD?G`'4UF
M\\I(3T9R47FGSP[O/1FG.B-]ZHR..QC-)\YDJLK=DW.F<]*GSDG?>O344:HB
MTN=EU[;0&>GSLFMSJ!%4+M67"Z_.X7BJ+^^Z/F?$WNC+95?H4*.I"]K=>GIJ
MU>$FH[Y<>HW<:E0[?]\U<G-Q3'MY9PMUN+VH+]K9V'E?ZW:X[:@O[ZK:F[IW
M5IU]=7>Z^_3A]?#KBD90BN;QY4Z-Q\Y26>-N7E=QT_'/]7OJ\,K*9V7FXS7E
MIRY]I,'JYZ?1:/SAYB<-,/=:<XL:QU9XK%"CB3*[DL"7()`@E""2()8@D2"5
M(),@EZ"08"W!1H*M!&4+W%!XFAA1__G_B)$RHV+$M7O+H!4T$1!6<):5!+X$
M@02A!)$$L02)!*D$F02Y!(4$:PDV$FPE*%O`"@B-2A`0E\:,[KF1^XC*5<V'
M31]QW8E=X;=:,VV"Y`%9`?&!!$!"(!&0&$@")`62`<F!%$#60#9`MD#*-K%"
M0J.]%9+^4"@UC7@T:#>QP/&J%HUI>&Y$KCNU`^8UHJ:+`/&!!$!"(!&0&$@"
M)`62`<F!%$#60#9`MD#*-K'"0YWC@O`H=14>KM3;FHS;$XSKSD0L&A%G6P'Q
M@01`0B`1D!A(`B0%D@')@11`UD`V0+9`RC:Q8D&M_H)8*+4=BYJ,%V:,`K("
MX@,)@(1`(B`QD`1("B0#D@,I@*R!;(!L@91M8E4\C2075+Q2VQ5?$]?4NP0K
M"7P)`@E""2()8@D2"5(),@ER"8H6L.J(>KA51_5Z=#"CUGSZOK__\_9`@S$M
ME#K&]S&M.^O5J#)B5YTF,U-W#3&C^W1D#RBK6C.BC9:9`89#6^0W(AYU`B`A
MD`A(#"0!D@+)@.1`BIK0/H-*:%4V7=C_O;*5$;NR-6E5=D-,14)EUQIW4>\>
MAHXKZKE);^JYL<HD;,AY/U%CI]JE#!VQ38F;=+::-%:9I`TY[R=K[&@_HG'E
M33I;+1JK1*PXJ?VZ%:B.UD^G$]S\*[D=$D;DHFG*"W'EGA:-J'LU(@@3BVAM
MW(A&KK@XGU6J3_[\Y#A3L=4+6$`KAL:,]!6RJ*]`$8MZ"Q2S2A=HM!"+AX0%
M?05*6=17H(Q%O07*6:4+Y"[$RK)@P9D"V0V$"G1)`U%RT4!JI,ZXFG@L1!?T
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MV=`1LV#`=LX,1KHGZDOI*U'$EGI+%&N5GAF<V6PH+C]A.WTE2EG45Z*,1;TE
MRD6)ILYB84]6!=LY4R*[QY*HM^W\^_!"W;%S/]->T2DS8L+6J-V3&V0:@9Q%
M5^K>!ID:F7-@'U&@$74*[FNA0>>M1V@J1I084VP]->B\]0Q-Y8@*8PIZLMJ:
M7S!^UCMY:_S4FWO:4C7]S'5%"_'4P2+5,1U7\?6M$/F(`D0AH@A1C"A!E"+*
M$.6("D1K1!M$6T2EA>S.0MWWDO`HN>@4-:+[XJWP3,1ZSU/K5\I8WSW7-YH`
M^:@*$(6((D0QH@11BBA#E",J$*T1;1!M$946LL.CSA$NZ#WZV*&]^JB1?8P[
M$2LB3]V&E+T'D(^J`%&(*$(4(TH0I8@R1#FB`M$:T0;1%E%I(3L\ZOC@@O#H
MTX9V>&K4/MEU`*T0^8@"1"&B"%&,*$&4(LH0Y8@*1&M$&T1;1*6%K%B,+CNP
MJ>3V2*91Z[`7R`J(#R0`$@*)@,1`$B`ID`Q(#J1H$[O*:,R^H/FJ3:@8_#4:
M5\\U5<.Z9Y"9#V!%Q")[TA#;=-^H>$X/&!F'(:*(4:_YV*C8?,+(F$\198QZ
MS>=&Q>8+1O5C8-;S!FH[WAY)?FO#0R<`$*$:61$"M-(9[6/WB3BL](V*KRC0
MJ&4^1!29C*9-N!-QU!4;%9M/T%:**#,9V^;%44IN5&R^L&S97>.R;?\(M_V,
M:#0WR]:).''TM$HUC$:%O:6V3J7EDOLZW]BM#WL'PF[`=FG;V-AU)V+K&;*J
M?@)0/?X3,3*^8MO7<""6W@EGZ?65LLKXRA@97_D;O@K.<LZ7'42U:6YWJOZS
MFY&2BRFA1O9QP43LESW.2`O:IK(QB-JZN5A?YQNKVP@_/XDE<\!6:?/86.T(
MH39K3HDBSF@\Q;V>$L[0ZREEE?&4,3*>\EY/!6<XY\D.G]HV7Q`^)1?AT\CN
M@Z+]>BJZE/&-/JA%YE)]G4_WP8F#G5#GH1#U1;!QS[T[XA(99['M;.H,Q&29
M<)Y>9RFKVKT0KBP7SD;26<%FSCFSXWC9$0`=3$$<:Z2\FHJ<B@[C<<;^;JBM
MFZKU=3[JAFWK8HL4L/6V2G;RD$6FCT2,C,/X70X3SMCG,&61<9@Q,@[S;H>B
M!16<\8Q#.Z9J\][NFVJ],IH,*.^%C['2^3:$NT;VGG4J5B.>SM@^\4'D(PH0
MA8@B1#&B!%&**$.4(RH0K1%M$&T1E1:R(Z?V]>W(O3$IUL<`=(+$H],MG6.J
MB(GPB-6<9U2<<87(1Q0@"A%%B&)$":(4488H1U0@6B/:(-HB*BUDAT?M_B\(
M3WU88(6G1B(\8C7LJ:5^'403'D`^J@)$(:((48PH090BRA#EB`I$:T0;1%M$
MI86L\-!&YY+P5')[3:+1Q`S/'J(5(A]1@"A$%"&*$26(4D09HAQ1@6B-:(-H
MBZBTD!T+VC1=T%7&2BYB42/[['HJ]E*>SM@^NT;D(PH0A8@B1#&B!%&**$.4
M(RH0K1%M$&T1E1:RPR./-/HGFC&>76@D1C*QB?6,JAG)$/F(`D0AH@A1C"A!
ME"+*$.6("D1K1!M$6T2EA>SP7';",<83#HW:9]>(5HA\1`&B$%&$*$:4($H1
M98AR1`6B-:(-HBVBTD)V+-0F_OV3/NTX822K4>OL6HL,60'Q@01`0B`1D!A(
M`B0%D@')@11`UD`V0+9`RC:QJYYV+)=4O9*+2:1&-$_Q^..IK:1:7-%BH=FO
MRKWBBD7MHS]W*LZ6?*-BZP$CXS`TZ+S#B$66PYG8Y\9&Q0X31L9A:M!YAQF+
M>AWF1L4."T;&X=J@\PXW++(=BO.>K5&QPY)1Y=!N'Y<=7HSQ\$(CJWW4JA9:
ML<HJ^E04W3<J+GK`R-15B"AB9)F?B1.`V*C8?,+(F$\198QZS>=&Q>8+1L;\
M&M&&D65^+LY_MD;%YDM&'7&5!QAOK$[PE$*]I59W<G;G(5HQLHH^$T7WC8IM
M!8Q,S82((D:V>7%4$AL5FT\8&?,IHHR1;5XLD'.C8O,%(V-^C6C#R#(_%R/2
MUJC8?,FH(ZZ7'6^HM:4<S_7QABFZIU56?]4J<Y#JL\J@@)&Q%2**&%G5,!,'
M*K%1<34DC(SY%%'&R#8OEM&Y4;'Y@I$QOT:T860N>XNH9%39LD=8=>S07OS\
MUJU/6H5"(/5YABF^IU56(&L5;?GYNGVM:J$`,X:((I/13%+N3!R]Q$;%'A.T
ME2+*3,:V>;%BR(V*S1=H:XUH@QFWB$HKHQ5(][*SD4IN+Z4844B:=9,KG][W
MM*K_?@V+S#&+SZA^+GPTG$Y$9`)6M&]KR'5;R*)V=Y*BB$6TJ6VN!!X.CK6*
M%J?J!N!B,!0C:\)F^@J4LJBO0!F+3&?($16(UHSZK&]89*QO$946LIL.6;?&
M@/[9V%5RT71J-&G7E#L7$Z''&6GJ;L(B8[=B4;OIU-;I#HD*U&PFWV`+.`\M
M_,\:#EG4YSUBD?$>:T2+U.K-KO%`OKB4<*8^]RF+^MQG6F2VC3F0`LCZ/:8W
MD&T+I&P3NX5<=IKDXFF21A-:>S<A<N=BEO6TZHW!I;;>?B!#YU/[S)9U&&!T
MQK9J-!.K_/`]98A8U&XGM?5F.'%%\T\X3]N];/XIBZC)-U<B11F+3(?/$16(
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M&31DNPK93-^H&[&(9I'&4L>:M?:G)QEG.!`%2MA,7X%2%O45*&.1J8]<(^W=
MA950P7GZO*]9U.=]PZ+>ZMBRJ@Z00S^2*%]-*EERIDAV,Y7'C;*9ON_E-1>/
M(1FUAR2MHD&W";AL.BN=CYY8X([G(PK0>FC0>>N1$;'U&%&"*#7HO/7,B-AZ
MCJA`M#;HO/6-$;'U+:+20G:L:7*$(:E^ANJ-[8_**$:A&ME/R,FIVW-U1OKH
M";@6F5[GZWQZ^S-RQF,QO@5LF0:'LY9#%O6YCUC4V^UBK>(MT7#@BE/#A.WT
ME2AE45^),A:9"LEM]^Y@/E^T_Q-+MH(M])5ES:*^LFQ8U%L[6ZW2\7(<9RAO
M\Y1LZ$R1[(9ZV9FJBV>JC*Q)<B%.P3VM>F.2K*U;>R^-]!@\'@Y%``*V?&8(
MKM^Q9E'?K!"QJ#<`L5;I:6H.C\RSE;[RI"SJ*T_&HG;CK*M#.Q\/Y(^V%9RG
MS_N:17W>-RSJK8TMJ^KXS"?SL=A3E*PX4R*[-:H#V_9Y\1N#I9*+P;)&='.(
M!VZ/?@-)J5IHA<A'%"`*$46(8D0)HA11ABA'5"!:(]H@VB(J+63%8B*/?-5R
M13U.U1^3*IL=$XVFP^J,ZP\QFGLFV<PO[L*H[%)1`:P6HDKU6P\GJTL1C4<C
M=3^CF>G<A;B3ZAD5-[$5(A]1@"A$%"&*$26(4D09HAQ1@6B-:(-HBTC]AGK5
MV:HE91VY^C?1ZY])?MJ]?MMYN\?'X]7]X8?ZO?/IC%I%@^L?8[\=#Y?JX4"J
M7TBAWVFGY]*Z4D:44@V5D&=,*=7:6*:XBZ7J`1W6)LWOP<L\SFRIWNKNR./,
M*:6Z<,A#?NCUUHX\([)6'PG(/".R5J_,(86LU3>P1`H]ZT!7VN6'?M[^<V?=
MT&5VUB959J=>567'=7QVEY\I]!T7Z%(-=W$J:?4[]^(2;J?+LAJ[)7<HH7X4
M6J30$R5+=1<,?=.#)4MU,PQ3Z&F2I7I6I"ME2BE=):`[VI32%7BZ34HI78&G
M^VZ4TE4">LIFJ>X#8@GHT9JE>G"F*V5**5UEHYOYE-)5-KI#3"E=9:-;CI32
M50)ZFFBIGA7"$M"S)I3250)Z6H%2NDI`M\`II:L$=$^54KI*0(\E+=6-4RP!
MO6>[5.]V8LHMY;GMS$//;"W5[6',0P]J+=5C6%TI4TKINE)Z[(-2NJYT15>J
MGA3HLK:@E*X2T!-?2W4'&O/0@U]+=2,:4^@=Z&5,*^FNE!&E=-4.O?Z\5*_<
M8AYZ"WJIWKS%%'H9>JE>=>Y*&5%*5YX5-;?.&J`*Z+P6:@)=/*/&V<5OJ4RW
MG9[I[?2EUYFRHA3UPCE>![T<32E=UT%OHR_5&]"8AUY*7ZH7H2GEIAF*Z$]U
MO-Q]V^5WK]_VS\>KQ]U7FMJ&U0_)O=9_[*/^QTG_/M&7PXG^2`<MD^A/!-`?
M9=G1Z[ETVG9]]?5P./$_E(/FS[Q\^J\`````__\#`%!+`P04``8`"````"$`
M+=L<:N$/```A7```&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RLG%MS
MVSH.Q]]W9K]#)N\GL24YMVESIK%UO\[.V=UGUW$:3Y,X8[N7\^T7%$E1P%]Q
M8V]?ZN9'@)``$B1H61_^_/G\=/)]N=FNUB\?3\=GH].3Y<MB?;]Z^?+Q]-]_
M17]<G9YL=_.7^_G3^F7Y\?3OY?;TS]M__N/#C_7FZ_9QN=R=4`\OVX^GC[O=
MZ\WY^7;QN'R>;\_6K\L7:GE8;Y[G._IS\^5\^[I9SN];I>>G<V\TNCA_GJ]>
M3G4/-YOW]+%^>%@MEK/UXMOS\F6G.]DLG^8[NO[MX^IU:WM[7KRGN^?YYNNW
MUS\6Z^=7ZN+SZFFU^[OM]/3D>7&3?GE9;^:?G^B^?XZ#^<+VW?X!W3^O%IOU
M=OVP.Z/NSO6%XCU?GU^?4T^W'^Y7=`?*[2>;Y</'TT_CFV8R/CV__=`ZZ#^K
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MXVXTT7^,YOCR7<X9VS&D_G.843N(QH>.HK$=1NH_A]FT8T=-M0-OU`Z?\3O'
MS[F>L6T"F,UW\]L/F_6/$\JJY./MZUSEZ/&-ZLQ.?3T$NV3P5BZ@)*!Z^:2Z
M^7A*@XNF^982V/=;_WKRX?P[)9V%D;E#F3&7F%H)E6%4MS,)0@DB"6()$@E2
M"3()<@D*"4H)*@EJ"9H>."?G=Q&@H?H[(J"Z41&POKNSP(7$$^ZV$E9E)D$H
M021!+$$B02I!)D$N02%!*4$E02U!TP/,W32_P=T!3<#AM<Z.;Z5%JQH;WQ?<
MG7=&YJ(+P13(#$@()`(2`TF`I$`R(#F0`D@)I`)2`VGZA+F;DB)S]WXW*VG*
M1)2']N01+>33"M@3NN3!F'9"W>`&$@*)@,1`$B`ID`Q(#J0`4@*I@-1`FCYA
MKJ=!S5RO4KM_I79P9E?T[NRN>FK#8IUYIXG/$_Z5B$$G9-5F0$(@$9`82`(D
M!9(!R8$40$H@%9`:2-,G+`8TDED,]@]_)<W]K(GP\[7P<R?4^1E(""0"$@-)
M@*1`,B`YD`)(":0"4@-I^H3YF9+!`7Y6TMS/FOC7+G<#F0$)@41`8B`)D!1(
M!B0'4@`I@51`:B!-GS"GTNP^P*E*FCM5D\#Y5(*9!*$$D02Q!(D$J029!+D$
MA02E!)4$M01-#S`O4N7$O*AWV&>7E#-VCZO%U[LUY67:'`ZD!I]VTGI_K3KA
MSC7DTGD7R`Q(""32Q*./;C4-1B.>8>).R&:8!$@*)`.2`RF`E$`J(#601I-Q
MZP[F?E6(_O_^;WOA`3#H@D+7\QR4-,H\*;HXS6Q?-&!ZBF)S'EHIIQ@9%%RW
M!98W&@<B3$Z@BQ-VDR+*G*(JW:AGG_><.P';<X'=E(@JIVAZ%O=9.P';<\.Z
MX<%4190L5P/_C.;2P/2AG8Z=/^I004P@BVCD],(@;GQJI#Q]5J6+4MV71Q5&
M3U'$(D3%R**^HA<(A\162DW^[[?CT60T$H,JL2*T]>NNX$+TDUHA=^6917LO
M(+=2^@*\R6@L*IW"2NRS7UHA9[^R:*_]VDCY0>N`B=CM-+:3-XSS\4*6V'CY
MQ2A1XF*6:Z0VS9VK@Y$XVIBJ\R8YRPVBCYZB\&2(BI%%7I?98X.\"STDO*M`
M7$!BE?J7B2,"KC*S>LY8+HQ=^5=B9!56:9^QT@JY_%59Y(S5W-CE.!`.:JS.
M&[9XM%45VL\.OXBV+EJIVK29YTZ=_JDX\IP@:TLCQ7*"5A0Y011$(2I&%CF?
MQ!;9!.!-1#^)E7AC"K1;AM0*N?F76>2,Y1898Y<C"+:YLWVV2MN+LU59Y&S5
M%FE;%YXO[JNQ`F_8XL$FH4."K<3%U-9(3&V1;J;J6%=.;8/8U!Z+/5.(BI%%
MSB>Q069J4ZX7W216YXT)8&(-%YE9/6<KE[9\D44*J[//5FF%^A.[<XB=2;6T
M)>^KL=V\88O'FH0.B;42%[$VB$WLL5A7I^H@GA39Q#:(QUI,DA`5(XN<_V.+
M]/@/+L<BL216@-S9K1F8Q>$B,ZOG;.46F7D]\:[%SJ:P$ON,E5:H/[$[C[A@
M&Z2->=>7PK&-[>8-6SS8JL@_((OK,P&6Q37B$UMN::?JE%%.;(-XL&%G!XJ1
M[4M_.:IVB;%!$W)-%TO?@]EM^NI+8<3!8&8-]B.NI4PFH:549++"ZNRS55JA
M_NPVYIVMVD@96]Z5)VPUMILW;/&`JP.(?L"/JI"IPH));Q"?]"+I38TBF_1:
MT6N_-6\S;(A2D47.+[%%=M8%%V*)2ZS$&S/!I'-CW\VZS.HY8[E%VAC%0-Q9
M807VV2JMD+-56>1LU19I6Y.K*S$I&BOPABT><'54T@_X+_9I^F2%AI1-.'=C
M@_P.31'-$(6((H,\-^)C1`DJIH@R5,P1%:A8(JI0L4;4,$7N91KVS,O'32O5
MBUA+-6+I]5HDMJG:0LOLJI$[#PQ1*+*HGX(':F1S":8@FOC>E<A`B>WHC0QD
M)AI<96;U]EY`;J1,`KP:75V*+4%A^]EGO[1";NQ5%NVU7W/[_FCLB;U$8_MY
MPSX;*I3H]@^5O]:O-`9^=<C2=L/'BD6]B8IHABA$%!GDN>^X8T0)*J:(,E3,
M$16H6"*J4+%&U#!%[OVA0RV?0G+@,QBT@LFI:A#[_BB0QSE3)V43[`Q1B"A"
M%"-*$*6(,D0YH@)1B:A"5"-J&.(1H<G'4N?^!4I5_2)'&C1Q2^@4T0Q1B"A"
M%"-*$*6(,D0YH@)1B:A"5"-J&.)>5B<+[]\&>.9LIK<-,(@>C71[[$!655,G
MY8:W[DL_4ZDW>"@5(8H1)8A21!FB'%&!J$14(:H1-0QQQ],FC3E>[0PFE^U7
M4H?F'-652/D:B9PC]L%3KY-R00$4HE2$*$:4($H198AR1`6B$E&%J$;4,,2#
M0@LU!H4>F3Q\'5`]B9AH)&(BMDQ3M:,C19)R,0$4HE2$*$:4($H198AR1`6B
M$E&%J$;4,,1CHBK??H92$R48'1,34T/WDY=&/";R@&!*.TR(":`0I2)$,:($
M48HH0Y0C*A"5B"I$-:*&(1X351O_GIB8XX%^3#02,1&G65,J%2$F@$*4BA#%
MB!)$*:(,48ZH0%0BJA#5B!J&>$QD0:]+S<,S%U;ZM-M7ON9+O">*K:F3<IFK
M4[0H1*D(48PH090BRA#EB`I$):(*48VH88A'1!6V<I8<]_"?>C1$+B<:B6DB
M#IBG1I$M)YVB"PJ@"!5C1`FB%%&&*$=4("H158AJ1`U#+"BJIOM-06F[XFN\
M02(HXIQNZJ1L!&:(0D01HAA1@BA%E"'*$16(2D05HAI1PQ`/RF#U?=1CLCX6
MX`:)H(B#VJF3<D'1??4F3XA2$:(848(H190ARA$5B$I$%:(:4<,0#XHLP-6"
M<ESZ\K$X-T@$13QY,'52+BBZ+Q840!$JQH@21"FB#%&.J$!4(JH0U8@:AGA0
M#JO7?:S7#1*+N3BYG#HIYWBLUU$J0A0C2A"EB#)$.:("48FH0E0C:ACBCE>%
ML5S,O6-*0WJF2J[E!HG)(,MU)^5B@N4Z2D6(8D0)HA11ABA'5"`J$56(:D0-
M0SPFJC"6,5$#^\`#%%\7V/TOMPP2$9'%NI-R$<%B':4B1#&B!%&**$.4(RH0
ME8@J1#6BAB$>$546]R.R_]#6UU4T<[Q&/#WY\ILMHTA2SO&=HD4A2D6(8D0)
MHA11ABA'5"`J$56(:D0-0]SQJO;M.UXMUA?^,<>)ZD==HM8PB,\&7Y;D3LI&
M8(8H1!0ABA$EB%)$&:(<48&H1%0AJA$U#/&@#)7D1^Z@L"I7T=`GA;V#=U]6
MY4[*!:53M"A$J0A1C"A!E"+*$.6("D0EH@I1C:AAB`=%U;K]F?*+%*5+8Y:B
MNFJY[WA9>=/OF$QXK)=GB$)$$:(848(H190ARA$5B$I$%:(:4<,0<WP@*^_]
MCF_%>75MD%@;9'7MI#K'(PH118AB1`FB%%&&*$=4("H158AJ1`U#W/&_K[H.
ML+HV2$TX6G*V[=/Q@7RJ=>JD7%"PND:I"%&,*$&4(LH0Y8@*1"6B"E&-J&&(
M!V6HNCZJG@BPN#9(Q$06UT[*Q00JZ1"E(D0QH@11BBA#E",J$)6(*D0UHH8A
M'I/#BNL`BVN#1(:2Q;63<H['XAJE(D0QH@11BBA#E",J$)6(*D0UHH8A[OBA
MXOJXC5*`U;5!8C;(ZMI)N:!@=8U2$:(848(H190ARA$5B$I$%:(:4<,0#XJL
MKG^Q7F,1K5[I@3M4640[*>?X3M&B$*4B1#&B!%&**$.4(RH0E8@J1#6BAB'N
M>%E$'_E-7H#5M4$\/P6RNG92UOTS1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J&&(
M1V2HNCYNL<;B.M"(IZ=`%M=.RL6D4[0H1*D(48PH090BRA#EB`I$):(*48VH
M88C'1%6Q[Z_C`EWT]NLX@X3C90'MI*R79XA"1!&B&%&"*$64(<H1%8A*1!6B
M&E'#$'?\804T_5)>'B<9Q+/06'XAYZ2<XW5?I&A1B%(1HAA1@BA%E"'*$16(
M2D05HAI1PQ!S_$06T&I=."H+M3WQVMH@,1GDH8:3L@&8(0H118AB1`FB%%&&
M*$=4("H158AJ1`U#/"9#M?5Q,<'26DT0V#\%\KS#2;F8=(H6A2@5(8H1)8A2
M1!FB'%&!J$14(:H1J7>QNO,U'1/];E7]:L7GY>;+<KI\>MJ>+-;?U'M3::=[
M^Z'#^J6N=\'5C4IUY"9HN::6]EU$LF4RHC?!MC]+@Y;N';&R)?"HM_9!=&CQ
MJ:7]:0:T!-32_E('6B;4TO[.$5HNJ*5]F`Y:+JFE_8V+;/%)A[Y9&/"!3SIT
MO#W40GZC7#'40GZC0\"!EH#\1J=40RWD-SHJ&6CQ28>>&QEJ(1UZ>&&HA7Q-
MWZ`/M9"OZ2O>H1;R-7W1.-1"OJ8OO`9:/-*A9XF'6DB'GF@=:B%?TW.50RWD
M:WJZ;ZB%?$U/F0VUD*_I4:>!%KJ`0?MD?M`Z&1^V35ZFWV@,6/#(R_2[@J$6
M\C(]^(XMT?4-O35H@(]'-S&]<`9;Z*4X-^J]-]A"+[6Y4>^MP19Z4?.GP>NB
M6QF^$[K<@7[NU&`9X)^"FT^4?-#PG9JOBI]W,XQ>T/PZ_[(LYYLOJY?MR=/R
M@1+1J/U6;J-?\:S_V)G?=GU>[^C5S+0RTTM@Z57<2_H1<_ND\\-ZO;-_*`/=
MR[UO_P<``/__`P!02P,$%``&``@````A`,Y7V+T_!P``V!\``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&ULK)E=;^(X%(;O5]K_@'(_0$+XB@JC`OG^
MT&HUNWN=AE"B`D%)VL[\^SV.XSCV"4P[FIM2'EX?VZ^/'3M^^/K]?!J\I469
MY9>5H@['RB"])/D^NSROE'^^65\6RJ"LXLL^/N67=*7\2$OEZ_K//Q[>\^*E
M/*9I-8`(EW*E'*OJ:HQ&97),SW$YS*_I!7XYY,4YKN!K\3PJKT4:[^M"Y]-(
M&X]GHW.<710:P2@^$B,_'+(DW>7)ZSF]5#1(D9[B"MI?'K-KR:*=DX^$.\?%
MR^OU2Y*?KQ#B*3MEU8\ZJ#(X)X;[?,F+^.D$_?ZNZG'"8M=?4/ASEA1YF1^J
M(80;T8;B/B]'RQ%$6C_L,^@!L7U0I(>5\J@:D3I71NN'VJ!_L_2][/P_*(_Y
MNUUD^R"[I.`VC!,9@:<\?R%2=T\0%!ZATE8]`G\5@WUZB%]/U=_YNY-FS\<*
MAGL*/2(=,_8_=FF9@*,09JA-2:0D/T$#X._@G)'4`$?B[_7G>[:OCBM%FP_G
MZG@YF4.4I[2LK(R$5`;):UGEY_^H2&U"T2!:$P0^FR"3V7`Z'T]4J/->P4E3
M4&\+JK.AMIBJT]E/2D+<NMWP^;DJ9TU!F`!-P8]6N6Q*PN?GJE1A5*G)W*"/
M5JHRB\@_GZP67*75?MC>$<V..MEV<16O'XK\?0`S&,:_O,9D/5`-%<*Q-*-)
MT2;>K;R#A"-1'DF8E0+60TJ5,%G>UM/YXF'T!@F>-)H-UJBB8LL4))M)V)T,
M3!E8,K!EX,C`E8$G`U\&@0Q"&40=,`)K6W\A,7Z'OR0,\9<YLV&`&ZY)9C(%
M*[*3@2D#2P:V#!P9N#+P9.#+()!!*(.H`P0S8:8(9O:OA2PGB7JEP-].3BY%
MDS:-9M8:NT5DAXB)B(6(C8B#B(N(AXB/2(!(B$C4)8*%,,4_82%1P\H`2VO'
M0WE>4]%DWA4MQJ+1VU;4IB,B)B(6(C8B#B(N(AXB/B(!(B$B49<(ML+32K"5
M+*/:=-@^)#^\D))`M>/,IPTE$V%M7<@K9RMBQ7:(F(A8B-B(.(BXB'B(^(@$
MB(2(1%TBV`L)^'OL)8%$>RF1[)77TE;4VHN(B8B%B(V(@XB+B(>(CTB`2(A(
MU"6"O3!U!7OOKZM$+7I(B>3A1%H!6E'K(2(F(A8B-B(.(BXB'B(^(@$B(2)1
MEP@>DG,7WD@-R6;[OIVDH&@G)3I_VF\1V2%B(F(A8B/B(.(BXB'B(Q(@$B(2
M=8G@'6R\!>_N&T;4HF$-T?A3')$=(B8B%B(V(@XB+B(>(CXB`2(A(E&7"(:1
M@X?@&-VVU]E6';/D99/#`PCVI#U.3F![WFS:2131R3KP2M'I,9#LP;<<\4W`
M3%H@=TP$2TR[4]#'TB;`Y"JV!E@8V1@Y&+D8>1CY&`48A1A%#-5&B-Z3K?Z-
MF?X)[^F!`;96S(J-2I'@?8NXK=C[1C2OSUW:6-7%E==D@>NW%?706PSQ<;8Y
MNEV7PT1M7=(J[W(!ZY?'$*_+Y^AV70$3M75)21=R`:LK8JAGV,BAHCML/5,#
M7DVT<X.>083Q:1#,RC;'IPO)[*U*51I\M"H\9#TB39?Z9[)09,:^K2?:5!Y9
MBRE@7WJS,IN)[K7(Z1.A%KE,15ND:]/)5,PUCRGNM<AGHGLM"OI$J$4A4S4>
MZ=.EM#6.F.)&B\2Y3<Y-W23YM765GKZ$W*&(O/MJ!VJZD,S;DE=!9$&^Y\N.
MBUC6FPW29G6BJ+.%NI3FI<5*=1L@IZ7-1/?J=[B(U>]*]8]GD\5,SHNF:_?J
M]WEH[I+<R("+6/VA6+\^F\E/GH@5NE&]F`3DE-=-@I^L%$0N/44ITB?MXKXE
M[]9`!>AVUW9,I+?E3(PLAGATFZ/;T1TFXM%=C#R&>'2?H]O1`R;BT4.,(H;J
MZ*+K,#2"Z[\V]4@4:3`:U%VVY45B2]ZL0SE8M5E2[3CBO4;KC\E4=/V!.Y+Y
M>"ZFOL4DD`'MW)>SVF8BW@"'(UX.-<!E*MH`55\L-6D%])CD7@-\)N(-"#BZ
MTX"0J6@#%JHJFQLQQ8WZQ30@A]3NY)/3X%M^A?'MW=EV']_TK"LLP10)D[)%
MO(/RR.P@1CUSZ24+V1*;&%D,\6EC<W0[NL-$/+J+D<<0C^YS=#MZP$0\>HA1
MQ%#/I"3'77DT?NF]%ER5H8G9GJ5Y#Z;R@V/;%(27"WQFM@49,K'*PLC&R,'(
MQ<C#R,<HP"C$B%P:$B=HAVCNTTM`>B]S3HOG=)N>3N4@R5_)!1],G_5#B^GM
MXV9JP-LRZ+[,9P:\YNGA<P->7?3PA0''\AZN0@%H*?X%CGH&.3#U_:(:Y*R!
M?X%C@T%.!O@7V.1#M+Y?X'[UL5Z+Y!Z2>]>>2!O-@'L#7,-F8L#;<,P?=>.Q
MMX,;W8#WO%!@U-8,]ZK7^#D-X^(YNY2#4WJ`81G7I^V"WLS2+U6S-CWE%=RH
MULO4$6[04U@SQN1=\"'/*_:%5-#>R:__!P``__\#`%!+`P04``8`"````"$`
M/RDRKE0A```%OP``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RLG=MR
M&SF2AN\W8M_!H?NU6#R)5-C>:+/.I]C8V,.UVI9M1=N60U)/S[S])HA,'/*O
M`DGMS,7(_?%'(BN1B0)01>G=O__]Q_<W?[M_>GYX_/G^*GN[N'IS__/3X^>'
MGU_?7_WW?Y7_MKMZ\_QR]_/SW??'G_?OK_YQ_WSU[Q_^]5_>_?7X],?SM_O[
MES=DX>?S^ZMO+R^_;J^OGS]]N_]Q]_SV\=?]3_KDR^/3C[L7^L^GK]?/OY[N
M[SX?&_WX?KU<++;7/^X>?EY9"[=/Y]AX_/+EX=-]_OCISQ_W/U^LD:?[[W<O
MY/_SMX=?SV+MQZ=SS/VX>_KCSU__]NGQQR\R\?O#]X>7?QR-7KWY\>FV^?KS
M\>GN]^]TW7_/UG>?Q/;Q/\#\CX=/3X_/CU]>WI*Y:^LH7O/^>G]-ECZ\^_Q`
M5V#"_N;I_LO[J]^RVS'+UE?7']X=(_0_#_=_/0?_?O/\[?&OZNGA<__P\Y["
M30-EAN#WQ\<_C+3Y;!`UOH;6Y7$(_N/IS>?[+W=_?G_YS\>_ZON'K]]>:+PW
M=$GFRFX__R._?_Y$(24S;Y<;8^G3XW=R@/[_S8\'DQL4DKN_'W_^]?#YY=O[
MJ]7B[7JYN=EEI'_S^_WS2_E@;%Z]^?3G\\OCC_^UJHQM62M+MD(_Q<KV[>9F
ML;K$R(J-T$\VLGM[DRWVJQMR)-'YFMO13VZ7+=YFZ\767$"B'7UZO'3Z.>%T
MHN&6&])/Z3`[I\,;;D<_+[I`*M:CH_13^COK`O?<CGY>=H$9I:'-"I.//.!G
M76+F\HG^<=%%9I)#YA_2YUF7F4GBF']<>*&2.U2BTC1+7>BU+9]C->9W+W<?
MWCT]_O6&YCBZW.=?=V;&S&Z-,:E#FT:N,N<*DRK26/G-F'E_10--)?=,T\G?
M/BR7^W?7?Z,9X!-K/J(FBQ4'49AR-V9S#0H-2@TJ#6H-&@U:#3H->@T&#<8`
M7%-H77PI*?X9\35F3'PE,A\%!`%7P12%-,DU*#0H-:@TJ#5H-&@UZ#3H-1@T
M&`,0!9/J)`KF],U"<M*HZ;80Y.1ZOXJ#])$U6Q?8`Y`<2`&D!%(!J8$T0%H@
M'9`>R`!D#$D40BKQ"T)HU#0ST`TC4==6M**[@Q.M]^LXT`<G<ND(I`!2`JF`
MU$`:("V0#D@/9``RAB0**]V++PBK41_#*L'X:,DJG$#7^XV*H1-)LQQ(`:0$
M4@&I@31`6B`=D![(`&0,211#RK(+8FC4<0PM6>U]+0/)@11`2B`5D!I(`Z0%
MT@'I@0Q`QI!$`:.*NR!@1AT'S)+C(O]XNSUHD&M0:%!J4&E0:]!HT&K0:=!K
M,&@P!B"*$554%".[OGEKEN8OWQX^_?'QT6X2)FXE*UK'V-6-,1*'CLF-SS5'
M_"RX7<8%G%O-DM:U?J9<+&)1X412Y260"D@-I`'2`NF`]$`&(*,EV?'BHV#3
MA?W_@VV,Q,%F$@3;$1]("+;5K/=V-;K(U!VI<)^[.#NK0BI'YONIG9WCJG>1
MJ25&XSX7JZVS*J1S9+Z?WMGA?E1R#>YSL3HZJT2B<3+[I&B@)K*?-J&2_D=Y
M/"2"J`N?ROMMG,H'5BUI<>Q4,$XBHD6?$RW7ZNH*5JWH#NQ4Z_U-W&$IMD+5
M\D9M1"I1I=RJ191TJYEV:Q>[U8JMI%N=J%)N]2)*NC5,NZ7B,(JM.;?BG#$[
M'-PI7CB3FGVVJFY&YM##C>Q&SXH':4CSO%-A*K'UI9N6"[&^/4X#V7ZG<K04
MPV'WVG`EHE3OM8A\[XWJ?:4OJY4VJ=X[$:5Z[T7D>Q_BWI>[!20`QVNF]WC\
MS:8L'/\3<X:1JSF#T<J-SL&<F1@5;5<2HVI%2S__%]PN0*4W)?-?Y=&\]1I-
M-8A:;TJL=Q[-6^_1U(!H]*9@IC8;N3#J9OVRW)HST0O6+R:^>C`8A1-XME#W
MR`,W/#&!6U-+&B8WB!,3N%5%$_AFH4Z`2NEP;DHZKL<J45'ZNAYUS=8B2KK5
ML$JYI>X^K=A*NM6)*N56+Z*D6\.T6VII,8JM.;?B`B85I%*V\1/X?SW^HE(\
M>=)GS*C"9A06MD/S(Y2;\T8RM?3'6@6BDA%=JY1>Y=&\]1I--8A:;TJL=Q[-
M6^_1U(!H]*:@L*F`H]$X,9T:N8JZ19LPVS98P4XEUY>;QRQDBQH**A"5B"I$
M-:(&48NH0]0C&A"-$8H3W&R4P[GR1$CMOIH.MR0,'\U!%T4F.H;9+/0QC%=)
MPQQ1@:A$5"&J$36(6D0=HA[1@&B,4!Q2LZV^(*1&KK+4HO!4AC:.QRC[@YH<
M48&H1%0AJA$UB%I$':(>T8!HC%`</[-5OB!^O+,.4]*BX)`FTR0'4@`I@51`
M:B`-D!9(!Z0',@`90Q*'S.Q:PY"]ZL0FX[UO&$E&?AEY$!4EY.PZ(F?1B5,;
MKY))H414(:H1-8A:1!VB'M&`:&1$64NN1K%?ZG.!5\7^:"6>!00%L?<H$7L6
MS1_B>($+NS<LJ/)HOJ_:FYHYR/$",=QZPX(ZC^;[ZKVIF<,<+Q##HS=,*!XV
M6@)$)9.^\9G5O)JE!86[@<U";94/K#(_YLM%1,?7/X[+]0)1B:@2E+)>B\A;
M;Q"UB#I!*>N]B+SU`=$8H7@@S$XUG+M.#(21JT*Q:$,K8Q?BS4(=<QW,5LLT
M3,Y;(J+5GC.%VS)6;4+5:JG.I,LI6WK#58DHY54MHK`_\*HYRZMVRI;VJA-1
MRJM>1!37^5@-K%J%OF\6ZK!O%%NQRA^]Q!EC=L479`SOVH/;VM*B#2U=G>N;
M3`W@@54F=9U*ARH7D3]"*AC1]MA,5'JW+@W";-56*Q&ENJY%Y+MNDEVWTB#5
M=2>B5->]B'S70[+K41K,=!V/+XFB\7W='=5841.%16JB@&'GAJGDSY<L\@$H
M&,69GL'P<\,PT_&T7<RG?*A%Y'UH&"WYY':W4H762INP>YU]G8A2O?<B\KT/
MJO>%?IMIE#8SO<=90*(H"T[<%XQ<#3<C?PAR,$>`1D7UGRAI*PH.2@MN%Z#2
MFY+51N71O/4:336(6F]*K'<>S5OOT=2`:/2F8%FDSP->5WMX3$`I>8Q\M%K*
MU)GA@54GIEQKBNX9$IN"V\4GDOJI8BG6J03=Z$_4'IM/38"UF/(^-(+,(W":
M]G<K?_LZ+NE:$83=8^V=T7LOEGSO`R.^Z>ST2UNC-)GI/"X]*OQ+2L_(5>DQ
M"DO/(1]\??4Y%9@Q%=19@:AD%)YN>C1OO493#:+6FY+TZCR:M]ZCJ0'1Z$U!
MZ5UV[D$GP!!UBTQUN_S>Z&?X!VE(H78J'`A]8%)P,W^H4@*ISC%=0[,&2`ND
M.\=T#\T&(&-(XJPW9QT7+"OY:"1<5EH4+RMQ(V)5)^8X%OEP%^8PA6IC$]Z[
M)G8=KN'\Z%9L*NE"+2(_R32,>))9+]7TW4J3F4GF.`UV(DK-K[V(?.>#[]Q?
MV293!\VC-`Q=V`0/<:,A7^FSF_0:XRB/)SI&\9(2=A+2,%ER(K+?W#"O<A=B
M/2QH''+?T`=&%W0EHI0+M8A\U!M&M*HU=[6UOJ=)B]!#W7<GHE3?O8A\WX/O
MVU_8)E,G+*,T#%V8'W'*NJC(7[6^61DK*A$L4K6O]Q;<,%EXN8A\)`I&:GVC
MCCA*:1CF/JYO1)6JOUI$WH=FV@>]P9"&21\Z4:5\Z$7D?1BF?5!).4K#.1_B
M.<"<"YT_[:_X&"F8]@4%BQV/?.;JLLA91"L"66@4B$IO2E251_/6:S35(&J]
M*;'>>31OO4=3`Z+1F]*+G94Y@0FC_KHZM.<X]"Q.O/]X-$PKR&@VT&=S!U:E
M#P-%Y/.O8*3V^%"'[%;HPT0=LBHU*];H0^-].,[(^L2YE29A[SKW.A&E.N]%
MY`,P^,Y]<FR6ZI!CE(:A"V$`X@*D,HU2X<1-V,C5W,LH+$"'O)\Z"+F93M5N
M`U')*-QM>#1OO493#:+6FY(4[CR:M]ZCJ0'1Z$U!`=+81%%_70$:*VHP&-$Z
MU&TO,G@?P%20"7WJ!I"+*'G"7+#*7*KK<*.7IJ78"E5A2MJ7I$25<JL64=*M
M1E3V.&"Y7*N5:BN"T".=HIV(4@[U(DHZ-+"*XC0Y;XQB9<:?N&;-*45J^C[O
MO:B5/>R(YF]&82T[Y`=8!RIG4[2[DSHJ$)72H;=>>31OO493#:+6FQ(?.H_F
MK?=H:D`T>E-0RS2+1Z-Q8@8U<E6T%FW\3'\PWTTC58!R1`6B$E&%J$;4(&H1
M=8AZ1`.B,4)Q-E]V\F)>==+QLRA^"6JI7CT\<$/Z(?F1(RH0E8@J1#6B!E&+
MJ$/4(QH0C1&*0VJ.(<()XD1*VE.+:"*PR'013.OZ95MZ1\J,!:E\2`$5J"H1
M58AJ1`VB%E&'J$<T(!HC%(5T?=EAQ5$>5SDCZD*"=4"4(RH0E8@J1#6B!E&+
MJ$/4(QH0C1&*XT?WT`M2<FWD*GX6^3.Y`XL\R8$40$H@%9`:2`.D!=(!Z8$,
M0,:0Q"$SF]VPBE^U2%P;*RJ2C/S6]R`JNNVX>H>[/(O,(9\3K?471`JODCPO
M$56(:D0-HA91AZA'-"`:&4V\5[;^I^R0CU94[-V^4Z)S$%4Z]K;=_'ME;(4$
M8KCTA@55'ODAU.-<>U-FK;K$+PAZ@1ANO6%!G4?S??7>%/>E3K4'+Q##HS=,
M*"X96CY')9.^\:V-7(T/HS#'-TNU>SAPP_0&2D3^W:P"48FH$I3:=M0B\M8;
M1"VB3E#*>B\B;WU`-$8H'@B]P3TQ$+B37?,>E7ZXR6:S5,?/!U:ECY)$E-RA
M%:PR&[&@0WVZ)+9"%>YD194JZ5I$2;>::;?TP:_82KK5B2KE5B^BI%O#M%OZ
M+%ALS;D5YXS>UI[(&=R^KAE%Q;O2CP%8=:)XK:GP-0=NQUMX=>I6BM69#;P]
MX1!1JO9J$?GM8!-WO5%7U$J+5-^=B%)]]R+R?0^^[Z`N5NKR1VD8NA#613S2
ME("73--&KJ9IB^*#YI6Z=QS6W)!^N)+6=[M<1/Z2"T;TUH:Y*67T-HFZW%(:
MA8FM+5<B2G5?B\AWW\3=;^@K4NK"6FF4ZKX34:K[7D2^^R'N?GVSTL\=1VDT
MTWT\UGI[;U:QR\U;:GNBOG&COV84UG>FOY%Y8-6)^K:FHOIF9,\,;U;P]J`8
M#G,<!YVMI,JL%DL^ZHT@[GVGW])M19#JO1-1JO=>1+[W09#M?0N/N4<1S/0>
M#SF-SR7E;>2JO"V*RCM;JIO>@=:ZQX:I!,]%Y"^V8,3EO=SI>:.4-C/YS7/Y
M&;W78LGWWC"B=<9QQ7NCII96FJ0Z[T24NO1>1+[S076^4NNI49K,=!X-\^:R
M(Y&C/!YF011)-S]O5OK@CE7I>A:1/PPH&)UX9<<W]#Y`48LH55:UB+P+S5DN
MM+[AO`N=B%(N]"(*1EP05S:\:#^*X)S*-E_=O:"RCW(UY,:"?D*\T@>+TC"5
MWKF(_,46C.(U_$KMWDII&"9YN%:Q]2VJE`^UB+P/S;0/JM!::9CTH1-5RH=>
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M336(6F]*K'<>S5OOT=2`:/2F](&F^99C%/57/0,X6E&#80P3"B=C?%&$&YZ8
MC*TIFHQ](.`+D@6;BN=G>%%$.J2\<`DQ,3]SCZFYL1932;<:4=GET<2+(B((
M/=(IVHDHY5`OHJ1#`ZMF7Q01*S/^Q#6K3]1T]ISWHHAYK5;7,J.PEAWR0Z<#
ME;.I\$411*5TZ*U7'LU;K]%4@ZCUIGPMG^%[CZ8&1&-D/1X-FKZC6CZQ@C)R
M5;06F76;JXZ-/APZ;)Q*KB]'5"`J$56(:D0-HA91AZA'-"`:(Q2'U!RVA(M2
M?[ATX:^#W]ACF_`="$;Q.Q!KV)W:AN$[$+ZA#$"!J$14(:H1-8A:1!VB'M&`
M:(Q0'&USXA%&^T0"&[E*8(O"=R`V@')$!:(2486H1M0@:A%UB'I$`Z(Q0E'\
MMI<=F!SE<?P8^1.&`Y`<2`&D!%(!J8$T0-J0Q)=*4U24*OK.<]9O,=X:*RH"
MC()W%T1%TYZ;%>'&PZ+HW87E6FV+"J^2RBT158AJ1`VBEM'$^P9;L^,,2^MU
M\3)65+P8A?%R*!4O*Z+S0'XNK_8.Q='C]U<D\*%RA@55K$H^GZV]*>Y+S;&-
M%XCAUALF%*>>WJVF9ZDM;DL%T<SD$FJS5@$XL"J]-A:1?XY>("H158+"6[U.
MZEI$WGJ#J(U0'"JS_0JS[D2HC%REET71#GZC7[8^;+EAND)91$GDHH[;"#;%
M&^KU<G5SHX[62NF--@G.D`Y=):*42[6(DBXUL4NK?;;:J1/'5@S-N!0/BMG<
MN$&A6\:)0;%[H7#ALF44YZ\*TX%5)_+7F@H/VJ0='RAOZ7_Q+X\N14$#FA@`
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M`,)9IVCF+X?I2=FB:$K8;-1;I@=IF"K*7$0^"@6C^,$[+.^D85B9^*A/5"D?
M:A%Y'YII']093BL-YWR(1\/LC\().KTQO^'M5#@3,PJG!X?F"SAG4]'T8-L%
MJ)0.O?7*HWGK-5IO$+7>%$P/-#917%YWXS)6U%S!*)XKU-G*X<:JDK6:B\AG
M2,%(7N>'8R1I,E.H/%&<T7DMEGSGC>I<KX=::3+3>9R79@MT05[RCBG,2T8^
M<PXW#LUG3LZB(`D+1*4WY6];9UBOT52#J(VLQW$Q>XHP+J_+2V-%Y:5%:O94
MIV"'&VY(&>(6OGCC9U'P:\>XG7G.[]K!^]BE6`]5VGHEHI0+M8B\"\U9+K11
MPRCRN\MV:$=Y'&)!049ZY..BKSAG49B1B$IORF6D1_/6:S35(&J]*3U3[J+=
M%-7VJS+R:$6%:W*3I3;9!VZ8GBE%E#SS+E@U.WF*E9GYRTZ>(B+G7:;K$:U%
ME/2G4?[`?"I69OR)L]?L1=R\,3%*Y[TUL^,M33#/"@JSFE6T<9B-0<[MPK=F
M$)5HO?)HWGJ-IAI$K3<%61UMFSA>J]WQ+[Y=^!;&#K=4C.*W,/0I^,&KI*)S
M1`6B$E&%J$;4(&H1=8AZ1`.B,4)Q>E*$(3WM;NS2:!M+:B*Q2$5;GXSMG,I'
M&U"!JA)1A:A&U"!J$76(>D0#HC%"<;3I!AM%.[WHWQFY"JE%\4M;6[4M/'!#
M4OF0NH:""E25B"I$-:(&48NH0]0C&A"-$8I#:K8N>GY]Y7S!NZ=PCK4HSN"M
M/F#8.97$-D=4("H158AJ1`VB%E&'J$<T(!HC%(?;;%%TN%\W7]C-3OBH>6>1
MBK8^2/`J'VW74%"!JA)1A:A&U"!J$76(>D0#HC%"<;3-SB:,]HGY@C="80);
MI.8+]7#LL',JB5^.J$!4(JH0U8@:1"VB#E&/:$`T1B@.J=DCA2$UJ^97SA>\
MW0K#;9'*8'50=-@YE0\WH`)5):(*48VH0=0BZA#UB`9$8X2B<.^CS1O=UM,9
M?)3'=SQ&*J3ZW,:K7$@1%8A*1!6B&E&#J$74(>H1#8C&",4AU?N^$R'EW5R0
MI7N+Z&M;$JP#HAQ1@:A$5"&J$36(6D0=HA[1@&B,4!P_O2,[$3_<>>TM4BFI
MCVR\2J*<(RH0E8@J1#6B!E&+J$/4(QH0C1&*0ZHW;2="BANSO47AN]R(<D0%
MHA)1A:A&U"!J$76(>D0#HC%"<?S,?B>\*9V(G]T>A4NGO47!N]Q`<B`%D!)(
M!:0&T@!I@71`>B`#D#$D<<CT5NI5IU][W&$)"MYQ]FC^X"-GT8EWPKU*)H42
M486H1M0@:A%UB'I$`Z*1T<3[Y?NI/=?%3Q*/5M2]GG=@8>P=2L7>BN;?+^>^
MPO?+I7O?5^71?%^U-S7S?KD7R!"WWK"@SJ/YOGIOBOM2>Z'!"\3PZ`T3BDM&
M[]U.S#*X0=LSHL6J.U_<;/7),*O2)\,BHENI,X4O:(O*/@+/MJNMVKJ4HJ#Y
MS]G1Q[Z5B))GPR)*>M2(BCU:+_3EMZ)(>=2)*.51+Z*D1X.HV*/51C]\'$4Q
MXU&<))=M.?>XY604/]#:JA=Y#M*0,FIVW'(6^;M:`:0$4IUCNH9F#9`62'>.
MZ1Z:#4#&D,3Q-QO!"Y8"=M\8+048Q46J3UWW5G6B2%GDOQ)22#N/2D25H%1Z
MUR+RIAI$+:).4,IZ+R)O?4`T1B@:B&QQV=;5ZN/[F3#SE7R7Y?CWC$66?NW9
MJ?RVK1#&OY1ALU`WB%($&2UTG`<P/SI5JAIKI_(.-,+8@?6-NAFT(D@ZT#E5
MRH'>J;P#@S!V8+E3B3Z*8,X!->B44Q>4'_V^.-+K0;?,?'?;A1Q^4])!FJ8K
MT*G\)=.@VP[H#_&:9<$VT]\\I%%G19AW$Z/.*OKA'-4J&G56>0]HU"WC)[:K
MG3H1IU'G1BD':-1913]F':!19Y5W@$;=,G%`YSV-.C>:<4"-NMG0GS_I9@NC
MUZ-N67S;N]%/9ES35*+G3N5?HZ!1MQV<>)5#9'/I;A^6.U7*#1IZOD[O!@W]
M.6Y0`KBF\T-+"<"JE!N4`,Z6K'(I`<YQ@]+`-9UT0Z7!9<<8V0+/,1R+[K[Z
MU_)1\=NFIXJ?5?X>1FD`C,H=6.58JK9HA*$EC3`P&DY@-'C,4CW0X$%+&CQ@
M-%(A4^-"17Q1>1J]+D_+XO+<JIL%C0LW324DE:=5!>M21#0J6D6#<H9Y&A3=
MD,9$(QH2C6A$SC!/(Z(;TH!H1.,1(#4<^N@EO8^D7P0T,1R6Q?=(_>5+&@XK
M.U4FK(K&@SN@K'*W%GSQS75`%^MD^A9(PW:&&S1LK/+W*1HWR_@^1?O7^*LJ
M-(K<R/M.PWA&=S2,T!V-8]3=2BW&:%##WM2HFC.42^Z!?#`3/%?(%I;%RUWX
M$ZHB.[7<Y0Y\.&GRLXR_L$V_2E]M*ZGHN!5=:&I`694J<QI09TON.S2@EJ7O
MPC2LKNF\&S309[A!`^ULB1LTT.>X0>/MFDZZH3*`HG%1!AB]GF8M4W6-JR`K
M.U77K/*U01G`'9RJ:]=T\L)E%72&&Y0&K/*)2&E@&=?U3J\_*0'.<(`2X`P'
M*`&<K2`!+#._=,_E.<QOE`"NJ9<%\YM*@,O.?K(%'OX(B^^S-VI;2A,[-R7W
MG/N!7\?QH?LLJWSD*0$LB[\/<J./!446+8/Q"R%.EO*#,H#]B-;!EIV<"%S3
M^0NE/&!5R@W*`V<KR(-SW*`\<$TGW5!Y8(Y]+KD5V&.B\!`J6S"+U\'Z30B1
MG9H(K+%E-!%8EBX`NA^XII,7+A,!JU)+64H#9TOB3Q/!.6[0=.":SKM!:7"&
M&Y0&SI:X0?>#<]R@-'!-)]V(TR#3!V"O>L26'<VHVP0S-4OHESI<TU19Y$[E
MJ[,0EJ[.4F31+*&GH<JI4F[43N7=:(2EW6A%EG2C<ZJ4&[U3^3ES$!;/F?IO
M`HPBB]P(YTR5'N:$Y8)9(C-ZG0?,@G?8,]&%=S8])C3HMF7XW8P)1B,,/=!X
M.C99!<<Y@<83>J#Q!$:#YZQ).=)0.3;?`PT56*.A`D;CXJQ1#VH0S/E&.`BO
MK%$^)@D7\QDSFC+<+1J>+1TREIV8P45%-ITQ?-SGC-F3S>4-_O%?)TGOV*0_
MBISK3R<1#;&]Q/0OFZ519QD_8<.GD)0$+$EY16G!JI17E!;G>$69$GN%3R(I
M<=)>J52B@DNFTGG?5,G,[U^&.F<6U;EC\T-$=6Y5X;=5)AC5N;,F54AU[MA\
M#Y0$T`.-.#`:8F=->J`!=6R^!QI0L$:C!XR&RUG#.C>G,;K.7_7>=9894WH>
MMBQ^HTT_RZ%:=S()`0T0,+K[`J,!`D8#!(R&`Q@-!S`:#F`T',`H^,`H^,`H
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MW_YFZ@^]_4AI.<7S]?+6_`U6;)&O5[<%_4U/_(3^$NEM,_D)_=U0LC;5)M]F
MM^9WKZ*U?+N\-;^V%#^AWT!*;:8^R7>WPU3FY7L:K"E+>QJJ"=[O::`F>)[1
M!_3+4-"G?+FX+993E5+3)\WD)SU],MA/KEU*/G]X]^ONZ_UP]_3UX>?SF^_W
M7V@F7+PUO_KBZ>&K67S:_WAY_$6WF*LWOS^^O#S^./[SV_W=Y_LG(R#QE\?'
M%_D/<O?ZK\>G/XZS[8?_$P```/__`P!02P,$%``&``@````A`$0,\=78$```
MUE4``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK)Q9<]LX$L??MVJ_
M@\OO(^N@9%F59"N2>!\Z:H]GQU82U=B6RU*2F6^_#1+-)OI/T?;LSL/(^>&/
M;@`-@`!X?/C''X\/%S]W+\?]X>GCY:#7O[S8/=T=[O=/WSY>_NN?P6_3RXOC
MZ?;I_O;A\+3[>/GG[GCYCT]__]N'7X>7WX_?=[O3!5EX.GZ\_'XZ/<^NKHYW
MWW>/M\?>X7GW1"E?#R^/MR?ZY\NWJ^/SR^[VOLST^'`U[/<G5X^W^Z?+RL+L
MY2TV#E^_[N]VR\/=C\?=TZDR\K)[N#U1^8_?]\]'MO9X]Q9SC[<OO_]X_NWN
M\/A,)K[L'_:G/TNCEQ>/=[/XV]/AY?;+`]7[CX%W>\>VRW^`^<?]W<OA>/AZ
MZI&YJZJ@6.>;JYLKLO3IP_V>:F":_>)E]_7CY>?!;.L-+Z\^?2@;Z-_[W:]C
MX^^+X_?#K_!E?Y_MGW;4VA0G$X$OA\/O1AK?&T29KR!W4$9@_7)QO_MZ^^/A
MM#W\BG;[;]]/%.XQU<A4;';_YW)WO*,6)3.]X=A8NCL\4`'H_Q>/>],UJ$5N
M__AX.2+'^_O3=_IKTAM?]T<#DE]\V1U/P=Z8O+RX^W$\'1[_4XD&UE1EQ+-&
MZ-<:&?:N!_V;T379Z,A'J:5S^K7Y!L/.#!.;@7ZYM)WZ:ZNG7W;0FX['WF3Z
M2LEH>)0EH]]WU>C&YJ-?=MA=HP%%O/1D_GA3G08<,O,'.WE;K4SK5L[HCW?5
M:T#]H\HI'>656`VX5Y@_WE8S[@\#B>_@C37C2`\DU),W]<$!A]K\\:;FO*J&
M4#DBE[>GVT\?7@Z_+FB:HW@<GV_-I#F8&6L\%JL14(_.<X.31J6Q\MF8^7A)
M^6G<'6E&^?EIXHT^7/VD6>#.:N:H&;B*!2O,D#=FEQKX&@0:A!I$&L0:)!JD
M&F0:Y!H4&JPT6&NPT6#;`%<4GCI&U/'_'S$R9DR,N'7G#"1H0Q405G"6I0:^
M!H$&H0:1!K$&B0:I!ID&N0:%!BL-UAIL--@V@!,0FD\@(!Y-!.T7,!XC)E=Y
MT:K'B.>-W0:?6\VD#M("R!*(#R0`$@*)@,1`$B`ID`Q(#J0`L@*R!K(!LFT2
M)R0T7SLAZ0Z%4=.,1U-V'8N)YZE85**1.ZFI@"UJ43U$@/A``B`AD`A(#"0!
MD@+)@.1`"B`K(&L@&R#;)G'"0X/#"4]UF>F9%4UWI$S&,E+<OO.*>#*/+8`L
M@?A``B`AD`A(#"0!D@+)@.1`"B`K(&L@&R#;)G%B0+W=B4%WPQNUV_"6E!N#
M\O*\`+($X@,)@(1`(B`QD`1("B0#D@,IFL1I,%J6.0W6Z+2G[_N[W^>':I?1
MTI`C6@-5*R-CQ&W'BGC5=L0L<Q8U:4Q'ZE*\M!HJ;#UE>?V^.V7YM8A'2P`D
M!!(!B8$D0%(@&9`<2&%)67FGL6F:_=\;VQAQ&[LBS<:NB33D1#>VU5R7*]EA
M?Z`N#7Z=7K=S;95)6)/S?J+:CEDQDQ^U9([K=+::U%:9I#4Y[R>K[5@_JKYY
MG<Y6B]HJ$2=.M$MTXM32^6D7SKW?J-V`6$(_=3^^4=5>5)HA+;]J#82H13/T
M5+U\*S*C\>>GP6"B-AR!3:?+UEE'88LC79BH10.%B=W"#&^NW<&;O*$P:8LC
M79BL10.%R=W">#<3MS!%=V&<'F%.`=[1)4JYVR<L,J<W=1QNU)A;<+[.7B$B
M[LD^&Y^4G>!Z/)RZ50TX3].[;M2015W>(Q&Q]UAYOQFH*3OA/%W>4Q9U><]$
MQ-YSY;T_50.DX#QGO+MQ-OM3/"LH%W%OOQZ:$R`U)3"B/B?AUPMM*^J>%$3$
M3>`SJN:`Z0C#7Q5HV#D)L)6N`$0B8N\Q(^M]W%<S4,*"+N\IB[J\9R)B[SFC
MROOU9*B\%RPXX]T-/WEWPM\]\YN3-AWG"GDCV=U:%2$)O1Y[2Q9Y=3X?4<!(
MK(>"SEN/6"368T0)([&>"CIO/6.16,\1%8Q*ZVZKFQWO_S[HJGTS;7BY;\S-
MZ2C%QYES/4_-C0NKHO)QQJ4@J39<7WPV7\VZ@^O^0%WN`K9S9NHI5\\AB\1_
M)*C#?ZS]7_=5U1*VT^4_99'XSP1U^,^5_\G@YL:][!1LYXQ_MQ?0`.WL!?\\
M/-,E];7-M#G5UF.R0LZ8K)%4$,>D%57W9\PNQK?6Z2",^TK`2$9-*.B\]8A%
M8BI&E#`2ZZF@\]8S%HGU'%'!J&5,4LB<:+PR$QIYN>!IE,E3"ZZYN0%&*N>X
MR1NK"7LA*F[C)2(?48`H1!0ABA$EB%)$&:(<48%HA6B-:(-HZR!W_)@]_IE9
M])7@V=.!YLQ9H>8)E#E)I.`UT!*1CRA`%"**$,6($D0IH@Q1CJA`M$*T1K1!
MM'60&Q9S&M`,RRNQJ`X/R!YW_KFY=6;&ELS/"T1+1#ZB`%&(*$(4(TH0I8@R
M1#FBPD%N^YE=^CO:K]K4.^U7H7%YP[XZU#-W`:E)"36F*[5O6+*HN63WQDKE
MBXH#%C`2AR&BB%&G^5A4;#YA).931!FC3O.YJ-A\P:AZOJ%YCVY`MIQ0_*7#
MPM**VAL;PV4XN!0+JVH$;6F11_-0O87RQNI<Q1<5VPK05H@HDHQ-\VJ''HN*
MS2=H*T642<:F>;4#S$7%Y@O'EC,TAN\[E"CE;L,S<CN)NFPOK*I[6RHB+KEO
MT<BKCJ9ZRF[`66B9U0BH6D.'K)+I+T(4N[[Z/;4233A+IZ^45>(K0Y2_XJO@
M+.=\N4'4)P[=UX<A'BU8Y.YRQFHKL.",7?OKI8@DB)7#D3GO_/E)G>P$G*&Y
MP/?&$$);:&G6B#,*BBUJ]Y1PADY/*:O$;(8H[_14<(9SGMSPO>_$P(PA<RUO
M7-X9N6-0]=^%5;TR!BOK))+P5<B.P?$`!Z'-<ZZS5GM4<<^6(T2Q1=;99-!3
M%\N$\W0Z2UDEU<@0Y<K94#LK.,\Y9VX<]1G$*\,0#QN&;8<-$S5@%E9E#D/J
M.0\VGB+BUO8MHL$A^3PXZ^>,396V'K)(FC="%+_)8<(9NQRF+!*'&:*\W:'J
M005G/./0C2E%WEFOO!)3(R_'IC3QQ%-SV=R<H9+*W<-.E&HA*H[@$I&/*$`4
M(HH0Q8@21"FB#%&.J$"T0K1&M$&T=9`;,0JK$['&"O.5X)F<:F*M4&/#NC#7
M2%(UT!*1CRA`%"**$,6($D0IH@Q1CJA`M$*T1K1!M'60&Q:S]7_['FQ8G10X
M%SF+9`I8L$K0$I&/*$`4(HH0Q8@21"FB#%&.J$"T0K1&M$&T=9`;B_>=)PSQ
M/,&BQM9J(:@Q]:FI=\DB9Z$R4>M,7U0\\P6,9,,:"CKO,&*1X_!:'1?&HF*'
M"2-QF`HZ[S!C4:?#7%3LL&`D#E>"SCM<L\AUJ-9^&U&QPRTCW*0/WW=>4LK5
MO%D?CK"[A54UNLR2D5/TB2JZ+RJV%3"2M@H118P<\]>J2\:B8O,)(S&?(LH8
M=9K/1<7F"T9B?H5HS<@Q/U5KP8VHV/R644M<R=9[YF`C5W&M4".(BR&@)2-*
MJ1>HWK4JNB\J+GK`2%HF1!0Q<LVK0YQ85&P^823F4T09(]>\.GC(1<7F"T9B
M?H5HS:AI?J)O*&Y$Q>:WC#"NH_<=XI1R-ZX6->.*:,GH1O:&B`)&T@PAHHA1
MLQF\:WU4)BINAH21F$\198Q<\VJ)G8N*S1>,Q/P*T9J1M,0&T9912\3TB4UC
MD?KV9T1&>)!CD1/(2M5`2ZNB8U"NMX\H0%LAHD@R-@>[.I2,1<4>$[25(LHD
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MHP^IY5K`&9NJECYD"]\5Q8A-211C*4/U%'QOJGIGPIF:_G4$4Q9UN<]$Q$V0
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M'U'`J#F5O,%ZA/EB1`FB5-#YLF<BXM&2(RH0K02=M[X6$5O?(-HZR(TU#758
M8PS'/;HL=M]@&YF,:FE:(7/?J![/GK[P+CBC]/(E(M\BNV$9#D8C-0L%G*GI
M37><D$7B+!(DI6R9/:JZT'75SAZ>NL^0L)TN_RF+Q'^&*+?(.O-ZT^E-\S^U
M="K80I?G%8O$\UI01\TW5F5;?C`8]/4MEBT;.E,`IX-Y[SO/+.5NMV)$$9%N
M=:-.H!=6U;PH(?(9V9ERU.^KQ@U8<6:BK!Y_89$T;B1(2HG=RJKLA6(*CZ6Q
ME2[O*8O$>X8H=UV->OK)A8+S=/E:L4A\K05UU'3#JJJEI^/I2%^26''&O]N+
M]!EK]^1$[S[KR<DB6E3Q1+E`M$3D(PH0A8@B1#&B!%&**$.4(RH0K1"M$6T0
M;1WDQH)V0W#)&%.+OQ(3DTV-[`I-^N4D^YN:81?T/3:3@Y*EHWDWHJI*57UR
MK?K`T^/NY=MNL7MX.%[<'7Z8SZF5MFM<?>MM/IC,S!/ZU!%4RN>A-_M<?09.
MI=!S/C/SH`KFF0_'E%*^5Z/S>.:C<N5K_RJ%[M?.S$$T6J/OT'TNQYK*,2=3
M;?KYD)RWV)F/R$$+_TP5I+=\T/&<ZM?*J79ME?L\&%-)VUS0:SU4UK8\=%]\
M9L[RT3O='I^9(WU,H7OB,W/'NRUE2BGE-U%48]%].4HI[^?HE%%_9N[NM%@;
M#2BEK03TK,#,W,W`//2`P,S<_F]+F5)*6]GHEB2EM)6-[G/-S%VL%FM4-G-;
M!%/HF8B9>>*A+65**6TEH'NNE-)6`KJ1-XM;2T!WABBEK03T<,7,W/[!$M";
M`S/SM#JFS"G/O#4//7DR6[2FT.,F,_,P"5JC1P\HI:VF=/.:4MI*0+<_9WYK
M3>E^&J6TU8>>6YF9^VA8`GI\969NIV$*O=4Q,^]LM*50%%I;AU[HF)F7"#`/
MO=<Q,^\28`J]WC$S+V^TI5!_:\VSI,[;VI[4G&V6(JI*&\_(=1N?4YGFK9X7
ME&+>Z,#2TDLV,_,*35L*Q;(U#[U?,S/O=&`>>LUF9E[MH)2K>B*@KVH^WW[;
MY;<OW_9/QXN'W5>Z3/3+-_I?JN]R5O\XV==+OQQ.]#U-NG#1AP+I^ZD[>NV3
MSA(N+[X>#B?^AW%0?Y'UTW\%````__\#`%!+`P04``8`"````"$`9)^/#F,=
M``"(I@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RL7=ER',>.?9^(
M^0<&WZ_(7JH7AJ0;9*U96TQ,W)EYIJF6Q+#(5I#TM?WW@^P$"IE`578W;3]8
MTNF#I9``<JEL\N,__WCZ<?'OW<OKX_[YT^7LP_7EQ>[Y8?_E\?G;I\O_^5?Q
MC\WEQ>O;_?.7^Q_[Y]VGRS]WKY?__/R?__'Q]_W+KZ_?=[NW"]#P_/KI\OO;
MV\^;JZO7A^^[I_O7#_N?NV?XY.O^Y>G^#?[Y\NWJ]>?+[O[+0>CIQ]7\^GIU
M]73_^'SI--R\G*)C__7KX\,NVS_\]K1[?G-*7G8_[M_`_]?OCS]?2=O3PRGJ
MGNY??OWMYS\>]D\_0<4OCS\>W_X\*+V\>'JX,=^>]R_WO_R`Y_YCMKQ_(-V'
M?RCU3X\/+_O7_=>W#Z#NRCFJGWE[M;T"39\_?GF$)[!AOWC9??UT>3N[Z;?;
MRZO/'P\!^M_'W>^OWM\O7K_O?R]?'K^TC\\[B#:,DQV!7_;[7RW5?+$0"%\I
MZ>(P`O_U<O%E]_7^MQ]O_[W_O=H]?OO^!L.=P!/9![OY\F>V>WV`B(*:#_/$
M:GK8_P`'X/\73X\V-2`B]W]\NIR#X<<O;]\_72Y6'Y+U]6(&](M?=J]OQ:-5
M>7GQ\-OKV_[I_QQIAJJ<D@4J6;*2#_--,DM65DE$$#X]6(<_T?ILP=8C@BL4
MA#_)[9/DUB@'Z3_(G>3I%@7AS_,\G<&0'I[1_F6P.40X\HPS&IN9-SBGQ75&
M(V+_<J:_,(C.7W\T(_Y>N8PZ)&AV_W;_^>/+_O<+J'IP__7GO>TALYL9**/4
M=(\\).M4KD*26BVW5LVG2Q@P2,-7*+!_?UXMMQ^O_@U%\8"<.\V9A8R4&+8"
MK-I,`KD$"@F4$J@D8"102Z"10"N!3@*]!UQ!:(?X0E;\'?&U:FQ\*3)W!'#`
MYR*8Q""13`*Y!`H)E!*H)&`D4$N@D4`K@4X"O0<$P80Z"8(YWC\I)RT;.J67
MD\OM(@S2'7)60V!3A60*R152**142*40HY!:(8U"6H5T"NE])`@AE/@9(;1L
MZ`S0P+FNDVL10T=:^,6_W"8A*1U(0SHJ)%=(H9!2(95"C$)JA30*:172*:3W
MD2"L,#>>$5;+/H25@G'GD,5A#7)H?:E",H7D"BD44BJD4HA12*V01B&M0CJ%
M]#X2!`Q2ZHR`6788,(<LN6XED$D@ET`A@5("E02,!&H)-!)H)=!)H/>`($:P
M#@IBY.;F#VL(ZMOWQX=?[_9NT3?2!A<P![N9V2H)0X?(FF,W(%Z9B^DD<YPY
M+*V&5K"\%JT@'TB4V(5"2H54"C$*J172**152*>0WB&SP\,'P;9[+;T0.C/8
M5DD8;$2\8`\(!W(E@^TXR^UA)36_GBW#;IH/GP]Q'K024@[(M)UJT&-7;&!'
M3(]F^)RTUH-60IH!F;;3#GK0CGC>;OB<M/:#5D""<8($#,9I)/EA/T/9;]GA
M@"`2Y/%V%<8W=:0Y+.J&9%=CA!Q8JPR<^5(\6.Y("Y@W!M)RNPZM%:C))\W7
M8O5<GN!2=8I+9M2E3>A2?8I+S0DNM:>XU(VZ)`+0'W$I2!*[C0NRY%VM\Z`E
MS!Z$[(YY&-!$ML&4!*'9#"R5/T2:#WTX)^VK0]W/MAN1EP7)^.:EXI)(,>L5
MD=BZ$=87\K%JDHE9;X@4L]X2B:UWH?7YYEJ./\E,6`_'WV['_&X>[Q)V$R_:
M!$&+8712AF*CZE3-N>'G*.=!!:NBAE<R-*V]TJJ,AFI61=H;AJ:UMUI5IZ&>
M5<G6;(]`@JC;JINO[)G6&0N6@Q91=6Y#.(,6,-33[%I,BBD*QKLVD>)M&UE!
MWTZNQ7%%0;KBC9M8L<FD(E+4+3/NEIAS:M(5=:LA5LRMEDA1M[IQM\1:HB==
M4VZ%!6PWL'X!RP;^K_U/R)&CQU)N'PP;6*J$.WO89FO=+^P!XO22735#N3F?
MP>0:*K3VDJ%I[9569314LRIZG(:A:>VM5M5IJ&=5JK!AS(+1.-).+?U0P9Y/
MB:B>.WO:"*S@W""YEN<&S*)'SC24:ZC04*FA2D-&0[6&&@VU&NHTU`=0F//0
M)H,H>SE_).!64K1,!RTY75/[Q@%8'I1I*-=0H:%20Y6&C(9J#34::C74::@/
MH#"4=DOMMX\C\7,[\*!-(,0KE-0>@]DH,Y1I*-=0H:%20Y6&C(9J#34::C74
M::@/H#!^=IOLQ\]+Q=./'F"7K=+204OW:LJ>\:?(`LCK%F).RX@$0S"L`/3Q
M`[.H610:*C54:<AHJ-90HZ%60YV&>H(.@0AC;[>^?SWVN('V9S[<9?NQ'R`.
MJY[YD+2>.HV8#00.^Z"8H))8L7&NB#38$JL(PP127!/$S]4P-/U<+9$&6R+I
M.B:0K9Z@D6&S^U-_V(ZT'+>=A1(DW7=V>6O[B[_*3:[%%C!%UMQ?DNDA<ZJ`
M1-ISEB.HT%#)T'3@*B:1*J.A6D,-0]/:6R:1]DY#?0`%]3.7>__X0!SHX=R)
M4.*O5)-K<6J3DF!T((@$4^_0M_0I$1GT68NY.%PMQG3)D2^)%/.J(I)O3WEE
M3O*J'M,EO6J(%/.J'2,IKSID+7S?DVMQ?M63KI#%1PIAQD!+.J-T[093K+80
M2OSI*9F)`4R1%2]=)E'ZYPC!;M0>GXIU=$$"?K;*`2B)%!N`BDEDVD1-UR00
M,]T0*6:Z91*9[J*F>Q*8,!V.+Y@.QO==JQD[;'+8'20:A1IV%(0_AAX@!R@C
M[5['1BC,])D:?M3N9[H^/6;UTSY43*)!,`C-\41RLQ"%5I.,;UX^7$.D6`1:
M)I'U3EB_GG,!'UYN]20S83W,`GFD<&1>T$<'<P<MO:,#AJ;CFA&)WU;F&BH(
M8NTE0]/:*R*Q=J.AFB#6WC`TK;TE$FOO--03=-`>1AT*]&^H/:M%3-((!:NE
MF5C"I7/'@CRAI,HTE",4'O?)EV$%"8+*H8Y'*DU9K$B0G3`$V?>TT-(W"Y'9
M-1%\8[JNE*V6Y-A6AQ!.'QMY!Z8GD0E3X7!"I07#>:2(+%V,FX."(AH@#JQ\
MULP>(H.J)2=BKJ&"($[SDJ%I[1616+O14$T0:V\8FM;>$HFU=QKJ"1HI(GOR
M</K>`KJUBKJ#K(DA=Q/Y6CDE04Z>3$.YA@H-E1JJ-&0T5&NHT5"KH4Y#?0"%
MB2Q/.(XDLC[*@/<Y-LKAFD_O$APK:$`(<3;DI`LFF&%X1C8`@R"S9)V4J,HS
M6&G(((0]83D7?;,FD8F><)A]&R)QNK0:ZM@4>PVWCL,7SCT)^@83[QU@.'CV
M=.&,>G"'$?Y>&X[Q#X,7F-,+=A3D!\Q0$(X>:4+)29=?6R.#A[I\EAX\9;`B
M@^R#00@6AG;RD/=L:Y*(66J(Q&I;#75LR1\[<231DZ!O<'KL[-&$/W;O6XR[
M`XY@2!TDZE$MQAW+*X_,WFF"0O:@'"&Q(!`G``4)^DDTLB!0ZBL2Y.";<8MJ
MM8VZHA8;K;[54#=N4:Q#>A*<LAC4Y>*\HY<#/5P=(.2O#ACB')2%DQ')ZZD:
M*@CB^;MD:%I[1236;C14$\3:&X:FM;=$8NV=AGJ"].I@(8\OWE51!RUB,-Q!
M1[AHD,=2*0ER,F<:RA$2FUE9423H=Q)=4<1BBY6&#%L\=$EYD%J3B&]+YE5#
M)#;5:JAC4SS,R5SLU'L2]`WZ#Q>6DMW6^VTROCY9X"F`=YR,4%!*C@40^RD?
M.2,Y3L=<0P5!G.PE0]/:*R*Q=J.AFB#6WC`TK;TE$FOO--03-%)*=H?O1_U]
MI>3."?S):8$0].]A@3=3+[N1Y<U$&4,LJ`Y%<V2%\Y5<U!6D:ZJ7'U9U);$X
MY2N&(DX88KD][7R^%&N\F@B^?9E^#9'8?,M0Q'R'+%K2RGKO2<N$];#Z@!3-
M@].NG]CQ$-M?A(*J=*PC58DD;]U)JA@J".*Z*1GBX,F@5T1B549#-4&LO6%H
M6GM+)-;>::@G:*0JH6.JT9@G'P`^\VMJ=OIQ`^*YFXC-SQVRPILI<WG=C%FT
M$\@TE&NHT%"IH4I#1D.UAAH-M1KJ--0'4%@.YYT_+/3Y`T+^%UPTE&DHUU"A
MH5)#E8:,AFH--1IJ-=1IJ`^@,'YVX^Y/*T<F<[?/#^8/!_&\EBXDDBDD5TBA
MD%(AE4*,0FJ%-`II%=(II/>1,&1V)^R'['TS,>ZG_6410GQ!-[6%;KL"1'28
MG&6+S)!D]T,#2=]`818UA4)#I88J#1D-U1IJ--1JJ--0CQ`\-;@:QM[N,O]Z
M[-U>-<ABA/S8#Q"'5<?>D::_#P-]Q8X@$#CL@V*"2F1%Q[EB57;;,/*=&":0
MXIH5$]0P-/U<+:M"6V(FZIA`BGM6#%`P;,OS=M\'>KCA(PA"-^1X,A?+N!19
M]@WLP%)#1J3##T8X+"QS#14:*@F*::^(Q-J-AFH--03%M+=$8NV=AOH`"@?"
M[IO]^HFW>WOS3:P2$1([;W'NEI)@M&\1R7_WJC<0R+)+@&%,D[G<GI,NG^7O
M8-T&@E@QMRHB1=TRXV[)4S'2%76K(5;,K99(4;>Z<;?DT1GIFG(KS!F[-3\C
M9RQ=%"]"0?$NY/GGTK&.%"^2>`^6HQPLTFVK$D<;!6F%3<J0/K(EE$2*U5Y%
M)#9M0M/RZ^<U2<1L-T2*V6Z)Q+8[MLT/EBS$X_<DZ+O@UT4XTO*,X4AWT(<)
M=J<(@Q]VAX68.U)D16>[C$C\R#EIQRL?\&Y:/&Y!0GYBZ]%&OV/E5I$F-F]"
M\TER+;]369-0S'Q#I)CYEDALO@O-+]<+^7JE)Z$)\^%8VUV[7]5V%>MVKD=&
MW0J*^D;(K^^9_$Y2"N_'#[D12_2,2/S<.4'N\&:]4/>,B`#Z(R5^@O6*-+%U
M0Q!:W\C[?#418M8;(L6>O2426^\(<M97ZMU=3X0)Z^&00UX$0WYDH"U=#+2#
M@O*>S<6DERY1,);@&9'X87.$X,WX8<VYD7VC(!G0'QGH$ZQ7I(FM&X1@G7&P
MOA:MI2:1F/&&2+%';XG$QCMA?"'64SV)3!@/A_F\(Y&E/A(AR*_G9"'NNZ?(
M.C)?.^UPD8>V"3G*)="%AU%4B5V0]HG$QO4<:H^55<6:R`5SD@LU"[*C<C)I
MB!1SH262/^+H.E:VNI+;D\Q$`,(AAWP[I[(M752V@X+*3A;R8'&)@O#','0R
M(AF1^&%SA,(U_$+LW@H2])/<7ZO@F)_@0T6JV`<S[H,HM)H$HSXTQ(K%H242
M^]"-^R#V,CT)3OD0#KT\C3K2U/6Q$WSK[I`-8;6KINY81ZH=2?S(.6JW1^A#
MRB3R3F&!+'O?;V"-#/T)/E2DBGTPHSXLQ?ZC)L&H#PVQXO6NXM"-^R`FF9ZT
M3_D0#CV,6%#U[SJ(A),IU0P<%#2#I;P7E9)@K`@R(O%HY`B%S4"^DBY(<*H(
ML!F@\S$?*E+%/AB$<*D!2QC5!U"Q;UYVNH84QZRW1&+K'4*XU-BL1)OM263"
M>)`$R7E':P=ZV/H)XG=G*4-<CO+I,R3!]3B:5W,-%:R*6"5#T]HKK<IHJ&95
MI+UA:%I[JU5U&NI9%6@/HP[E_]=++[%:Q&`@!.DW-$+]-AX%X\V82'!B,JC2
MQVO("ONS>C]/NJ;ZDJM&8L5Z8T6DJ%N&6&YY-/+&G@B^1S)%&R+%'&J)%'6H
M0Q:>,BW5.WS2,N%/F#WV$$ONO6<)_T2OT][A)U:-2!^$_%H>($X#&:@,5<%U
M2:JC7$,%&63M)4/3VBNMRFBH9E7D0\/0M/96J^H"*`R]/?OQ0Q]?+ME-B@NQ
MYT`B=D)WR%KY1;M*1%=/F47/EVDHUU"AH5)#E8:,AFH--1IJ-=1IJ`^@,,I0
M!>=$V=)%(CL(7BE1L%+[739@>5"FH5Q#A89*#54:,AJJ-=1HJ-50IZ$^@,+X
MP<Q_3OPL7<3/0;SM3A.)9`K)%5(HI%1(I1"CD-I'PD>U^V"_(-^UB+57JV4$
M$.+E24JLV'HM0U+P-GV^%`OUG%F4GX6&2@U5&C(:JA$:>0.>@/-_0[RL%I$Q
M"/GQ&B"O^XG#_.S@T.$%-[XI%GTO9P*':E!,4(FLZ#N!BE6A+=&)#1-(<<V*
M`0I3S^[2_-0[,A>X39U_:R!!R&_\R5($($76D=4:;AGYS6Y.<@P5&BH)BJUQ
M*B*Q*J.A.H#"4-GMT!FALG217@X*]I2)O(>9)B@(^3&L6?5B!4FPL!E((PM;
M-.A.DY?SQ7HM-GD%68/.."B2UDHBQ5RJB!1UR2`+=YV+[6RQ$6=@-2F:<"D8
ME-5Y6[\#/1P4@B!40P"2I0A3BJQX_A*)M[DY07C$N8+_PJ]6%<2`F7VPKP:`
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MK".9C21^VISD7&K-EFOYZQ(*8H!LI&>?8+XB36S>$(3FUZN-"C9JGC`?!AM&
MY)Q@6[H(MH-$9HOK5.D*!6.IE1&)GS9'"'OV9BY[9D$RH#\2ZQ.L5Z2)K9O0
M^FRY4HL1$IHP'\9:[N/BB^F5WK`1%"2VO%.5(NM(8COM0<M&R&769BX/W0M2
M/)%8V$102[QC*^N&E*/U9"-?/A%APGH8:LBS(*W?M65>62TBVQT49+M^[T."
M\6Q'[9QO.<K1"F4^$RN$@A1/I!N.`"J.6:]($ULWPKIZ!5F3S(3U<`3.VSFN
M],Z1(#Y*31F:+O8,2?Y+%PT5K(KFZ)*A:>V55F4T5+,JN:.V)Z`J,T^Y5'80
M%,EH=0$4M@-Q#I.BX)%VX%0%[0`A5Y#)-MGHS0E2)DH2TQ%)\8:@[!OR&^UO
M5K.M:@EQ^T%"KN56\%TMX:`E'`6$@I:0R*^EI208*\J,2%R4.4+AJV"UO"-!
MOS+UY0!BQ7RHB,0^F'$?Q!E.38)3/H2C87=ZIV]?UI8NPHZ0UQZ(!<O8R;5`
MAB2_/6BH8%5#>V!H6GNE51D-U:Q*MH>UW<KX<7E?EKH-D7\.=U"L>H4X6TF1
M%>\51.(,R1&B"^;J&(E$HHV"2-%&020V;H1QN1ZJ263">)B7Y^WTUGJG1Y"?
ME\B*YZ4C!7FIH$)K+QF*Y:5295#.,UBS*I67$+R_(2^M%E'&#A+=4YR"I6L4
MC'6NC$C\3>4<(?MJ9>@(^B(E"S)+GA>41(JY4!&)73`GN5`'@F%&@N]!Y..[
M!OO[Q62($?(S<H"FGSA#55Z"Y!HJR"!K+QF:UEYI549#-:M2&6FW$'^]4[J-
M2-`I$8*UQ9`SB3S12->X@XDUJXQ(T(X'5?H8'EG3S1--00T,6G1ZGN!/=9(_
M1OBC^VG<GS![H5RBHW3:/8ZU52,:!T*<=RFQXGW6R?GW.%#.@PI6Q?/_8'!Z
M&"JMR@10&)SS]DCK88_D.9"(*?P.6?8+PD.V)'+EGC*+GB_34*ZA0D.EABH-
M&0W5&FHTU&JHTU`?0&&4[2;!;Q1'&JC;4P0=P4'>M8ITK:!,0[F&"@V5&JHT
M9#14:ZC14*NA3D-]``7QV\B-4SQ^!WI8J@AY-RT4DBDD5TBAD%(AE4*,0FJ%
M-`II%=(II/>1,&1V;^*GW+M6\1O<X7CO;`CR;B`PQ/4N9X<,24=N;#"+FD*A
MH5)#E8:,AFH--1IJ-=1IJ$=HY/;'YF_901VTB"S&394?^P&*Q=Z1X,;RQ.T/
MM`4$#ON@F*"2/()9:.CK<IPK5C5Q^X,)I+AFQ00U#$W;:ED5VA+77CHFD.*>
M%0,4EHS=H/@E<Z3+N/V,WZ4W"$%G'@*4K,3+D119\1TND6`4!E5ZW48L=T`U
M6RU6XJY-08SHRHU(L95D1:2H1X98Z!%<P16/7Q,CYE%#I)A'+9&B'G7$0H\6
MB3P:Z(DQX5&8)$`Z)TDL712Q@\+MYDH<LZ<;%(S56H8DGM5RA10**4]172DQ
MHY!:(<TIJELEUBFD]Y$P_N?M13=Z+TI06*3R;2&RCA2ITPZ_+(3:2TYR#!4:
M*@F*I7=%)%9E-%1KJ"$HIKTE$FOO--0'4#@0=@MV1K=T.[:@6SK(7K`=6IS^
M-3D;%(P7`I+X2"Y'.?SZ3G(MIH:"],(0#M;E9%82*6:\(A(;-Z'QY5KU0/0W
M9KPAO3'C+9'8>!<:GV]$:O<D,F$\'&4P?LXH6[IH=PZR=V6'.*OOT:8;QSI2
M;DCB9\U)SC7WU4Q>`2Z(X">9'N83K%>DB:T;A/#89+$1[[UJ$HD9;X@4KU;U
MZ)TP+A.\)[T3QL-A/N\88#,<`U#?NT,HG-76XFU92H+P-$,RR-'(B,0GF#E"
M1PY167!:>TFDF`L5D=@%<Y(+-0M.N]`0*>9"2R1VH3O)A9X%1UT(Q]V>(9S1
MQ-V10]#$$0IF4_EC&=*-8QTI;R3QC)23'$.%ADJ"8A54$8E5&0W5&FH(BFEO
MB<3:.PWU`10,Q/:\$XX#/>RS"(4%N!*]/R7!6.IE2/*6E0HI%%*>HKI28D8A
MM4*:4U2W2JQ32.\C8?QA=,\HA*VEB_@[*)SGY&7F%`7CA4`D?P!0NW^NK-\B
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MK$-!R*"71(I56T4D=L&<Y$+-@M,N-$2*N=`2B5WH3G*A9\%1%\*"MZ<E_JS^
MKG=96SQS\=YE(23Z@'B=G9)@K`8S(G$-Y@C%:[!@P=%`8.='WV,N5*R)9WPG
M%W>A9L%I%QHBQ5QHB<3=L$,H[(;RYS/V)`A%-12%WPW#?``?@GR(OZC96KKH
M`PAY-S>(Y<]3LBPS)/GWD314L"H:B)(A?CZIO=*JC(9J5D7:&X:FM;=:5:>A
MGE6!]C#J\HSH?56HCXZV"(5-66PO4F0=:<I.%=PAYT#HMV:DRAT:SM>)^DDZ
MQ(CW:#06:Y`5:8IZ9(B%[ZCT>[R:&#&/&B+%/&J)%/6H(Q9ZI-_C]<28\"C,
M'7NT$^O@I]W!VKH3(O_\B2"_DI$5KV1'\BY<Y:C*@PJMO62(4TQ7LM)NM/::
M57$EG^![JU5U&NH#[6XTKEZ_[W9OV?W;_>>/3[N7;[MT]^/'Z\7#_K=GZ+IP
M7\N#+UYV7S]=WB:+FUNX/@8.#@+N$_AY.C?VA\N,?;*$3PXK`B%SN][<W()?
M(S+PB;U`-?;)%CX9E4G`S(C$[6QY<PN;G1%=\$D_&_\$E+E?RBE]7B0WM_"C
MBD:TP2?VE]Z,?;*"3PX+#:$-KL'<V,LD6B;;S&]RN)R@/X$K%3=F]!.X``':
MQF1N9S>W8_C=#!YSQ,;=_*8?Y<,@CXWQ+81X-O;!'41X+,#P^T]N[&\1T8^7
M+;8WN;O8)H(%OTOCQHQ^`K_Y`K2-)07\9)@;^[-:1NPDZQO[8T[T)_`32T!F
M[)-L?=.-XAL8JS%-&QBI$;R%AQ_#LQD8<#>(Q+-G,S`Q&Y.IX!,S^DD+GW3N
MDZM!W>OGCS_OO^VZ^Y=OC\^O%S]V7Z'4KP\_Q>SE\9N=P]T_WO8_88UT>?'+
M_NUM_W3XZ_?=_9?=BR7`LNSK?O]&_X`07OV^?_GUT$X^_[\`````__\#`%!+
M`P04``8`"````"$`/WT(74X&``#1&0``&0```'AL+W=O<FMS:&5E=',O<VAE
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MJ-;)8ML[7O(B>CW#<W\SS"AFVO4?2#Y+XR(O\T/5!3F==A0_\T2?Z*`TG^Y3
M>`)B>Z=(#C/MQ;!WQD#3Y]/:H'_2Y+-L_=XI3_GGIDCW07I)P&T8)S("KWG^
M1D*]/4'06$>MG7H$_BPZ^^00O9^KO_)/-TF/IPJ&VX(G(@]F[[^ODC(&1T&F
MV[>(4IR?H0/PLY.EI#3`D>A;_?F9[JO33.N/NB.C-QF,0.4U*2LG)9):)WXO
MJSS[EP89C105Z3<B\-F(#"#=V#*L(21]U'+0M#1Y2_.YAB!;]QL^FY2&U37[
MUFAL_"#EL&D),Z!I^63*2=,0/G\RI0'#2ET6#CV9%&JG:0J_L+2#YY[4`%=I
MVF?MU6EUU,6VBJIH/BWRSP[,8!C_\AJ1]<"PB2PK,UH4O/#NU1T4'%%Y(3(S
M#9R'DBIALGS,A]9PJG]`@<=-S`+'&'+$DD60:B:R*Q6L5>"H8*,"5P6>"GP5
M;%40J"!4P:X%=+"6^PMU\7_X2V2(O\R9!0/"\+YB)HM@358J6*O`4<%&!:X*
M/!7X*MBJ(%!!J()="TAFPDR1S+R]%K*:)-$S#7[RFK1&$]FD11,SY,8N$5DA
MLD;$062#B(N(AXB/R!:1`)$0D5V;2!;"%/\)"TDTK`RPLG(/A]9(\9`&#=J3
MWQH/Y*`E#^+EB,@:$0>1#2(N(AXB/B);1`)$0D1V;2+9"F\KR5:ZC';)J_9Q
MD9*&M</,EP4EIICK2T16B*P1<1#9(.(BXB'B([)%)$`D1&37)I)W4%V2=X\-
M(]&R80WIBSF,R`J1-2(.(AM$7$0\1'Q$MH@$B(2([-I$,FRD&-8JMNJ4QF^+
MG&[L;A@Y@'<S?6,3$=E'2DRZ`R2OWR4GK>FOO&9630QTEB\19J\GS_XU#V)5
M[B"R0<1%Q$/$1V2+2(!(B,BN(?7#2V:3\Q3>(-4S^WFSB8AL-B5MLSD11@Y5
MLYN84;W#ZO<,4_&9?\]]YJJ,;#BYG\?E.F0G!WF4U=SCWS-5GZLRLN7D?IZ`
MZS1YE.<-^?=,=<=5@4CC!)MW:9QN%#^<'UCUDVAY0!H"'[R.K;'B[Y(&]6%_
MPH/0&-V(Z9O*@ZV;(#(=/^:#OJ6.I-,$P`OG;J;-C4QJ;]P;,:@WGM0;.&L-
M++FN_"=ZL[V12>U-<",&]2:4>C,PK8ER3-@][HU4%>2`)I7%+ZV5M8I<+@TB
M1U(^0-98\6W)&CXL&!'$JGS-U(=U?1C#L3%1IJ##6K4[H/J]84&/\KLBB.7W
ME/R]X6"LG.9\UNI1_BT+>I0_$$$L?RCG-X=#]8VR8XWNI)>+@!S.VFOXX[7!
MH&<YV/6R_BP:9-;W/?7[<RF0*`#5_Q4+,KG4&B.'(:&^$>B^NLN"A+J'D<^0
M4-\*=%\]8$%"/<1HQU"M+KL.@RZY_FM3CZ@H4Z]!L`SPJ:>N$4N#!L%2S09Q
M)9!HAU:?-8NB2S-<>HYZRH''82$/%V<6)#K@"O2@`QZ+HATPS/&DKRR`/@MY
MU($M"Q(="`1ZT(&01=$.C`U#-7?'(N[DE\N`'$7;DT\M@Z_Y%<;W1^<D<EVF
MU@%%TJ3D2#P@GI1-$+TU)1O==:-N"N0P)*;-1J#[ZBX+$E(>1CY#0GTKT'WU
M@`4)]1`C<B]-S*+.T-&@]\STZB]+BF.R3,[GLA/G[^0.&6;Q?,HQO>!>6#:<
MV6#V*'PULF'_?(./[75]:%7BW;$-^T4<'XQMV-]A#A?K+W7-*CH+<N%^(W[1
MM^'"".LL!C9<@V#^8MHO8!#^8F':<,`'KO/,<*%^C8Y)&!7']%)VSLD!S.K5
MF_^"7LG3/ZJFAE_S"J[2ZW(^P;].$JBM7A=>48<\K]@?)`'_9\S\/P```/__
M`P!02P,$%``&``@````A`*;046`Q#P``#DX``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&ULK)Q9<QLY#L??MVJ_@\OO8ZMU2Y5XB[KO^WY3;"56Q;9<
MDI+,?/L%U0VRB7^'D6MW'D;*3R```B#(;K7UZ3]_O[[<_-P=3_O#V^?;X"YU
M>[-[>SP\[=^^?;Z=SQI_%6]O3N?MV]/VY?"V^WS[S^YT^Y^'?__KTZ_#\?OI
M>;<[WY"&M]/GV^?S^;U\?W]Z?-Z];D]WA_?=&WWR]7!\W9[IG\=O]Z?WXV[[
M=!GT^G*?3J7R]Z_;_=MMJ*%\O$;'X>O7_>.N=GC\\;I[.X=*CKN7[9G\/SWO
MWT^L[?7Q&G6OV^/W'^]_/1Y>WTG%E_W+_OS/1>GMS>MCN?WM[7#<?GFA>?\=
M9+>/K/OR#U#_NG\\'DZ'K^<[4G<?.HIS+MV7[DG3PZ>G/<U`A_WFN/OZ^58%
M9=4*2K?W#Y\N$5KL=[].L?<WI^?#K^9Q_]3;O^THW)0HG8(OA\-W+=I^TH@&
MW\/HQB4%H^/-T^[K]L?+>7+XU=KMOSV?*=\YFI*>6?GIG]KN]$@A)35WZ9S6
M]'AX(0?H_S>O>UT;%)+MWY?77_NG\_/GVTS^+E=(90(2O_FR.YT;>ZWR]N;Q
MQ^E\>%V&0D&D*E22CI30:X(2S\!,-)!>$P9>:3T;*:'72$GZ+EW,!;F\GH+'
M.GUZF3N]1@-I67CD\Y$\O1I#V72N4+S$RC.P$`VDUVA@$-P5@E0I4_![2/Y<
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MT$1/[UM]0`K*6AMONV&`S4;\NWV8-F"M16DUGV\I,;3%GNCT\/,AGRM^NO])
M&_YC)%-!F<"5J+*$WMVUVIH$=0D:$C0E:$G0EJ`C05>"G@1]"082#"4823"6
M8"+!5(*9!',)%A(L)5A)L)9@(X$RZ>7$*)-,0R!Y"K*G('T*\J<@@73LC(J+
M;-U3V9K:I97V_ZA=K4;7+D^EPL`6<UH4*DOPD)H$=0D:$C0E:$G0EJ`C05>"
MG@1]"082#"4823"68"+!5(*9!',)%A(L)5A)L)9@(X%20$PR.56J"C*0/07I
M4Y`_!0E4\0PZA4I]'0I5[T[)US;<4_4HNHJ)]=1<4?;42"9OBK<*I`:D#J0!
MI`FD!:0-I`.D"Z0'I`]D`&0(9`1D#&0"9`ID!F0.9`%D"60%9`UD`T0I1!5$
MF%:%>5686(6959A:Y>36*5TZ$D#IIG-WYFKOZA."5D2'##IVQHX();>O5D*A
MC'..R*=<H:H1XB5=`U('T@#2!-("T@;2`=(%T@/2!S(`,@0R`C(&,@$R!3(#
M,@>R`+($L@*R!K(!HA0BFVC.H<*T*LRKPL0JS*S"U"HGMTZ%4RE#A0>Y.WU#
MP]^?]<!+1?,<*B')VJ-$%4@-2!U(`T@32`M(&T@'2!=(#T@?R`#($,@(R!C(
M!,@4R`S(',@"R!+("L@:R`:(4H@PJPK3JC"O"A.K,+,*4ZN<W#JU2MW3J55_
M@6IIMT`CDK;'!2`U('4@#2!-("T@;2`=(%T@/2!](`,@0R`C(&,@$R!3(#,@
M<R`+($L@*R!K(!L@2B&J(*HBPKPJ3*S"S"I,K7)RZQ0HW1IR"C2\G7!IIN?G
M_>/WRB&\!Y]0N!FZ;1#>3-!*W+H-23:\6:_O#%0-B1TGQ%5:+9*A6)@C1ZXD
M[CG4C1!W\0:0)I`6D#:0#I`ND!Z0/I`!D"&0$9`QD$E$;!"G0&9F5#QD(JYS
M(\0A6P!9`ED!60/9`%$*4041EX.]#E(V^^REPEPK3+;";"M.]R5T3KW32?5_
MKW>MQ*WWD,3KW1";F+S(2RV2H?#$ZCWCGI[K1HC#TC"JF32!M,RHN.JLJ[IM
MA%A1!Q1U@?3,J+CJG*NZ;X18]0`4#0VQBF2(1D:/E<F5\JZQL1%B8Q.CFLD4
MR,R,BJL6T9\;(5:T`$5+("LS*JY:1']MA%CU!A0IA:ABQL65B_BKJI%B[8K+
MS?83Q<450UQ=;E&*B"NNN((YF"@N.5QS]$6`L^82]A+Z/H0W$RWM+JZ(T(M9
M)L6"6P+54$9_#V1D9"W5$F326;$FZY&0WMQ^/N0*)1'81O0Y72+]UE#3&.+8
MMPRQH\!TVS5=3`G7.E>8[AI#;+IGB,=TWS&=3\D5-KC"]##!D$S!*$$&XC!V
MG"EDY?V$R17.3(TACL/,$$\<YH[I("@&XE[&X@K;2V.);:\,\=A>N[93F;1H
M&)LK;"ME3+%Q53'(8UWQ"@H+/\CF"Z+\%*\?7^DK7C_VBD7QDHFO34BZXD43
MVB^FLB+RBM?0;\P[N[Q^J.`#+><B[O:<"%%?LD&31]$JCXO/3)9\+4D(IE]G
M>_E+WPE*A8(X]S983]PC::S)0C;\+8OL3,!^V[6OOP85.V&']?CL=UG(VN]9
MY+'?=^T'F711!F#`BGP.#%G(EY)1DA"$9"Q<*N5R(B43UN/S:,I"-B0SBSPA
MF;OVTYE42C2$!>OQV5^RD+6_LLAC?^W:SV2*LMHVK,=GG[Z+U(N15I=U@+Z-
M-,SC@>(%1L\^7+ZA3I52X@8T?6<9:?+ZP,LK[H-94/%2@2J@KS=#`Y$/F8!:
MHWOVH.\[_3ZXK4E_.1K_`M]_&M+/.(GC$"-JZ^8(4A*KM1H)^0]$24(0@3I+
MA9VY4$J)LU>#!7[3F2_W")HL9*N@99&=")AOLU1T(@M2XBNU#@OXS'=9R)KO
M6>0QWV>IT'PIG1;[TH`%?.:'+!2O-;F<1DE"$(\Q2X4.Y=,E$8\)"_@<FK*0
MC<?,(D\\YBP5F@^"?%YTQ05+^.PO6<C:7UGDL;]FJ:@<4H$POV$!GWEJ2N&Z
MHO5ASTF6>1R@IA0-C2)`.Y58$-24(A&O#V9AQ7PP:RE>*%`#U)0<'XHE>4:F
MGN1WP>U)9.TC/4F+B^-2B)SC4JXDXE*E]AOM!#;`<A74DH0@`O5(BKMRD;8G
MMRLW6(]O8VBRD$U!RR+K)-AO"_OY`ERML1Z?_2X+6?L]BSSV^\)^EIY^=^<_
M8#T^^T,6HL28O41F9)0D!!$9"X^*V9(XKDQ8C\^C*0O9B,PLLDZ"_;EK/YO+
M!Z(B%JS'9W_)0M;^RB*/_;5K/Y>F`YN;D0WK\=FGSF062:PS&>;Q@#I3*!8M
MBFRF%(@44&>*-'E]X-5%PL8'LYY(@2D5R`)U)M>'8CHKTD"MR>^#VYKTHQ4?
M."Z%3V+04POL>$4_IJV[5?RXE).;9C62^L-Y*53E"$$(ZI$J_7"F"52N)`ZN
M#388ETH7A%23I6PB6A99]>!$.\F)O.P1'=;E=:++4M:)GD4>)_HL%>Z41;JE
M(3;K`4O$'9#]9\A"\<J30J,D(0C+.))R<I-/":\FK"ON%>1FRE(V+#.+/&&9
M)SLA;K<L6)?7B25+62=6%GF<6"<[(2XC-JS+ZP3U++,P>-G1)9YA'C>H9X5B
M(B/8MR)M?D=X[<6/=6:EQ<L'*H,:5Z(CXO8O-:\_..)V+W+W(]U+BXN#58B<
M@U4^):Y`JT$T,#Y%N4)J24(0AWHDE7$V"+SDBPS&I6"%-*U%+HN619ZJ:"<[
M(3:2#NOR.M%E*;M">A9YG.A'4M%N6DCE4Z(8!JPG[H`,^Y"%?+D9)0E!;L:1
ME,B-V#,FK"ON%>1FRE(V+#.+/&&9)SH!]\E9E]>))4M9)U86>9Q8)SLA^OB&
M=7F=H.YE5@^7*74OPSQN4/<*Q=R,!**5TZGKFN5"3]L;H\:1AF4^1WBI"4=$
M.Z?N]0='W.Y%<?M(]]+BHGM%*'[VRLM#:57_U2@-=(Y5<AG5K!#'IHZH@:B)
MJ(6HC:B#J(NHAZB/:(!H:)%-K)SUR`KQK,<1RMLU,T$T131#-$>TB%!L!UTB
M6B%:(]H@HL5FDLTSHL6&+%841BZA!FC-X-B$*J#M'>7<.G!+7S^/]8'+CNCQ
MK?AE1XARM.#,54`^$#M(53]>K=>,;W.H)0G!YE"/I$0'$">%!NNB:!BW8'-H
MLI2ML99%L8'RV_-VLA/B/E"'=7F=Z+*4=:)GD<>)OG5"?VN0NLOE4LY_XG`Y
M8*UQ=^1*'+*0+U.C)"'(U-CZ9V<!=RLFK"ON%61JRE(V2#.+K'IP8I[LA#A+
M+%B7UXDE2UDG5A9YG%@G.R%J=L.ZO$Y09S%KR72,BF4>-V@;#X>Z:T?>Z:=M
M/++@=X17HGOWQ#CG<X07GG!$G&MH&_^#(VXOTX_??:"7A4_KD0D.8T7_S3EU
MJ1Q9-4TCGQ:GG&HD]8=M/%3E"$%QUB-5[D5A(.JBP0;C+1962).E;'&V+++S
M`2?:R4Y`+XLFY'6B:RUR4'L6>9SH6R>B7B:.=`-6$[>/S2LAZE)HQ)KB'0ZB
M,K8.6;<3FM<U49E:BQR5F456/3@Q3W8"FM<U3BRM179B99''B76R$Z)(-ZPK
MGA\H4FI>)D/L!1V+#/.X0<TK%',72T+SNB8:=)XR1HTC9J%Y*X..6(F.8//Z
M@R-N\]+/,7Z@>86//3K-*T09V\^J^A<QJ)_%4`U1'5$#41-1"U$;40=1%U$/
M41_1`-$0T0C1&-$$T131#-$<T0+1$M$*T1K1!A&M&D@DK1ID"0FGS1SE$E).
M?_".<@E)ISTY+N?6L'X`+U[#^H\L,D7]LTA_^(LU_:6%OCRPM5N)4#YU>23F
M+[&ZJO9CVS/R:;MIA(Z%/^H4_J[$Z^[X;5?=O;R<;AX//_0/-I&.AT\&AS\G
M19>=97VY2$U!?*)_:.JRMPI>N?P`5<*`2II^F2IQ1(8^R"2,4-FR(J?0=H4^
MH#\43/@@1Q\D>4OE09]0KG!,K5`>7YYG%A.9%<KZ;PP2!A3+]``U\E:Q3(_6
M(^\5R_1<//)1L3Q.XK-BF9X_1_E5L4P/CR-7%9H;/?B=\$F#/J%GMNF3>S,[
M^C&N]^VW77][_+9_.]V\[+Y2[E.7/_TYAC_G%?[C?'BGFJ"?Y#J<Z6>X+F^?
MZ7?7=O17/71M=7OS]7`X\S^T`?-+;@__!0``__\#`%!+`P04``8`"````"$`
MN?OD!,L&``#N'@``&0```'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R<6=N.
MHS@0?5]I_R'B?9)`$I*..CT:L+T[TJRT6NWEF2:D@R8)$=#3,W^_9<J`747G
M,B]-YW`HZKAL'QL_?OQ^/(R^9665%Z>-YX^GWB@[I<4V/[ULO'_^5A]6WJBJ
MD],V.12G;./]R"KOX].OOSR^%>77:I]E]0@BG*J-MZ_K\WHRJ=)]=DRJ<7'.
M3G!G5Y3'I(:?Y<ND.I=9LFT>.AXFP70:3HY)?O(PPKJ\)4:QV^5I)HKT]9B=
M:@Q29H>DAORK?7ZNVFC'])9PQZ3\^GK^D!;',X1XS@]Y_:,)ZHV.Z?KSRZDH
MD^<#Z/[NSY.TC=W\8.&/>5H65;&KQQ!N@HERS0^3APE$>GK<YJ!`-_NHS'8;
M[Y._5K.9-WEZ;!KHWSQ[JZS_1]6^>/NMS+=?\E,&K0UUTA5X+HJOFOIYJR%X
M>,*>5DT%_BQ'VVR7O![JOXJWW[/\95]#N1>@2`M;;W^(K$JA12',.%CH2&EQ
M@`3@[^B8ZZX!+9)\;ZYO^;;>;[Q9.%XLIS,?Z*/GK*I5KD-ZH_2UJHOC?TCR
M32@,$I@@<#5!_.7=068F"%S;(,'=0>8F"%S[(,%JX2_"._2`\J91X-I&68SG
MP6*YNJ=50A,%KFT4_^8H$ZQ34W:1U,G38UF\C6`L026J<Z)'IK^&R&V]L3I=
M#WBO`T#E=9!/.DH3"VI;0:_]]A2&_N/D&_2TU'`BY,!$T7$((VX9NEOIL(("
M<N@],_<]JN7H;@XB.Z70FZC2&8R/X9[="M,/46&!^\*(<P@CYHS9U`TBD&*W
MSFKA4B2GA&'H<M009]EQG/:`@6&WQ^5VT&3=#FUIHA;HJQF&\^Y%3?GB(0X1
M)9"SZ@)+"B@+</*',7E[_IKLY-\"=OXDM[CEM*(%`E:R%%`6X"0+0]].5@^S
M.6"7&UT_!!.H-6+"<.6V<82<>==^,04$!20%E`4X2<-\0).^/F+T0QL/^F$W
MS,/P@22-G&4S401AL`KFTRD9$#'A3(.0<01R>O&2`LH"'&E+5]KE.F@RD;0D
MZ4;("1M)_L)?0;),$G+Z=`4%)`64!3CYZ_66-6U?SE^3:?YD[HV08_(/%DWZ
M1&-\`T<@I]<H*:`LP)'T<(\D378ES8@/1$A!1>\(0DJ?K*"`I("R`"=['ZS$
MKLAM([QYRM41+HE[1(8$4TL_I)9$;=R1NLF*(9(ARD9<.=I%K0ZFY5P?^SYZ
MKS/XE\05(D-RY="IMR/U<C!V7RS).,I&7#G:%^^7@V[JRB&.&_E(FC<CGU7E
MPDW1/=EJE`Q1-N(JTK9XOR(T4U=1OSYH;#ORD;2<-I*F8U+`F-XGHH6Y;U<*
M(_:(LCFN+NV@]^M"WW5U4:OTD=3IFI$Y,*:$`&=QG`OA+Q.*`7M9TD3H$64C
MKE#MNO<+1:]VA5)[U1LVF!T[H3X;781P52CR>UG2O*)'E(VX0K4'WR\4G=L1
MNB*&%/FMO>L=!ZMF>[,=7J*CMXADB+(15X:VXOMEH(&[,DBFD8\DM*KYLNEO
M[HHI-I2^O05#)$.4C;ABM`G?+P:MVQ7#W`I)7>=C?<_R?[/+HXCT*:)LQ%6B
M#=E2<GDEY*-]NPK(L(X,J6_KF"&"(9(ARD:<G(.?6BLT3UW;#AB2E3M#!$,D
M0Y2-N+D/+`RN[V2"@87!BOA*9$CHI($_)M-:[-Z?CHEO">>^OQJ3^5]V]]OA
MKVS$50D]Y/9>%6@V6<71W7MD2'9E\+$>$8PC&:)LQ,UY8$5P0V70FN%OO[AD
MF\R`^G?,$,$0R1!E(V[N/^7ZP8#KK^CZS)"&UV?=S;9+"(9(AB@;<65HG[QY
M,M)?$%FW(9TZ,J2^D\0,$0R1#%$VXN8\8,\W=!LTURO=ACIP'%!$,$0R1-F(
MF_M/>7(PY,FLVR`)NPTI2FPB]$41#)$,43;BRM!V9W6;VS9;`9JDZV5DSHL,
MJ<\T9HA@B&2(LA$W=^*_M^U[`_3A*]T'27;N%!$F4,^1#%$VXN2N-[1VNU]>
M.S1L,LLOZ5+.D/I\8H8(ADB&*(.\]SW&E4$L^8J,(2LF5AO-D-0MXGRRRHL-
MH=<I&"(9HBZ$=17=9;^S`?M]H%L%0UHT>]IY\,`V?X9@*Z+^+*\%47805Y%V
M4&N(7ZD1^JT]M-GG+3@%;#9YC:!WOF\9CJT)G^H1R3CZ?%%';C@H`H\+\=SH
MF)4O69P=#M4H+5[U4:">(SL4CRDC?PV'-V"J!!?!&CZB<UP&:SF$JV`-G]2!
M/^D"P6GC.7G)_DC*E_Q4C0[9#E*`Q2"8:8GGE?BC+L[-P<US4<,Y8_/O'LZ5
M,SA7FHZ!O"N*NOVA7]"=5#_]#P``__\#`%!+`P04``8`"````"$`ACHF*%4(
M``!^(P``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6RLFEUOXKH6AN^/
M=/X#XGZ`$$@@:KM5R!?YTM;6['VN*:0E&B`52=N9?[^7XRP[]@I,*YV;4IZL
M]=I^_9'8X>Z/GZ?CX#V_5$5YOA\:H\EPD)]WY;XXO]P/__[N?UL,!U6]/>^W
MQ_*<WP]_Y=7PCX?__N?NH[S\J`YY7@]`X5S=#P]U_>J,Q]7ND)^VU:A\S<]P
MY;F\G+8U?+V\C*O72[[=-TFGXW@ZF5CCT[8X#[F"<_F,1OG\7.QRM]R]G?)S
MS44N^7%;0_VK0_%:H=II]QFYT_;RX^WUVZX\O8+$4W$LZE^-Z'!PVCF;EW-Y
MV3X=H=T_C=EVA]K-%R)_*G:7LBJ?ZQ'(C7E%:9N7X^48E![N]@6T@-D^N.3/
M]\-'P\F,Y7#\<-<8]$^1?U2=_P?5H?P(+L4^*<XYN`W]Q'K@J2Q_L-#-GB%(
M'I-LO^F!/R^#??Z\?3O6?Y4?85Z\'&KH[CFTB#7,V?]R\VH'CH+,:#IG2KOR
M"!6`OX-3P88&.++]>3\TH>!B7Q_@/VLTMR>F`>&#I[RJ_8))#@>[MZHN3__C
M048KQ45FK0A\MB*&.3)F$XMIW,B#JTWA\-GF+3Z39K5IMDB;RBK?*`[&?%,<
M?+;%S3Y3W+)-@T]LW>?*,Z`WFP(-L*]-_63F%#/A'RS4&BWF\YFUL&^;:D!7
M\E)EGT+5;_AB8/^Q?SY3SS$?1,V8=+?U]N'N4GX,8*)#.ZO7+5LV#(>)X6CD
MA8OQ>6UXPKAD*H],YGX(W00CKX(Y]?Y@F?.[\3O,@UT;LZ(QAAJQQ@@VZ)FL
MJP-/![X.`AV$.MCH(-)!K(-$!ZD.L@X8@[7"7Q@-_P]_F0SS%YU9(9"&3S4S
M,0)37!UX.O!U$.@@U,%&!Y$.8ATD.DAUD'6`8B9,#\7,_B43QR2+;I9),2;-
MN3XFVQA+&+LFQ"7$(\0G)"`D)&1#2$1(3$A"2$I(UB6*A3#%%0O9?)_.1V*!
M^O2,9T*P:,#*+NRU3$L=@RL>9';7!=/2!ZH($B.5$(\0GY"`D)"0#2$1(3$A
M"2$I(5F7*(Z#M8KCMP<MBVYL13-6G,RG<H@2XA+B$>(3$A`2$K(A)"(D)B0A
M)"4DZQ+%,!A27S",1:N&<3+C#SSL-K(FQ"7$(\0G)"`D)&1#2$1(3$A"2$I(
MUB6*8?!4]07#6+1J&"=S=9::ZE1>MT'P@"3GNS:3W38&GEU$C&G-5"%/!.$(
M]X4TDD`0*:0O&Z'0D3&FM5`+VX@@E(Z$-))8$"FD%Y8('1ECVEKS4Q&$TIF0
M!J)T&7C]A2YCT6J7<0)=AD6M6]+L/?C#4TO4WM!N@)X(0B&?"`6$A"*K8X>U
MU+P702@=$:&8D$1D=:1M;3"F(@BELZZ0XC0T_PM.LVC5:4ZZ3K>DXW1+X*,S
M[K5[H2>"L,X^$0H("4561]J>:$Z+()2.B%!,2"*R.M*6]DB>BB"4SKI"BM-L
M\_0%JYMPU>L6=<U&U'$;$52D8[>M>N+)**RYCTAJ!12%B!1Y6_-E(Z-0/D(D
MY6.*$D2JO+9(IC(*Y3-$C;QJ/-M\=#=QMQ\QV-Y6&^0M4HSG47/9&A>CFL.1
M9HWQ*/(1R<2`HA"1U-I0%"&26C%%"2+54FVE2V64M+3;1M52M@7I6LKWQ2.V
MDZ\/Q>['JH2Q!^D]5INP_VUWQ7PC`P_)6.3*X$AQND6RD6X;-9.)'D4^:LG$
M@**0)FXHBFAB3%$B$SM3S]96NE1&8;,S14MUFFU5=*?YCJ3'6SB>$N;R/8YB
M;HO4@:"M#&MVW`+C?PJVB_5#O^&[,@C;X"%B_?O^8"RLB;8H^!@!>X&KR@$&
MW2H^[`N:SK0'CDT;9<YXC28C_?DG0IU;-8HQZ%:-$AF$AJ2(N"'3A:'5+\.`
M*Z6KXX!MH,@XL-@9Z%=F'%/1;BH<-3IX.&7:VH/BFIU]L<1;'K@R"#WP6C2U
MFBXPS:6VDON8PYJ!Q>NC+<"@6Z6'?4$]8X(WQ&03Y?UA.9IKG1*AS*T*Q1AT
MJT()!O%3:K;32ELT[XJ;4^UY)5,2U5$`B<HH^,T:P,*U[N9H9HHU=\U.UR$*
MT/4N<#%H)O(\BGQ$4CV0Z+IZB$%2?4-1A$BJQQ)=5T\P2*JG%&6(&G75=;:U
MU.>>,?_JW8YO4)4%N47=!=DPM(W"FATB0?_`@HS3RJ7(0]2N-L9RJ=WA?8R`
M&7!CJI'"0LSK#O:>B<43Y6*K%1^AS*WB8PR2;4TH2A%=7UG;5EPI2^U=M@N]
MU;O?R]=KSS+=^RW?S$+5L)=6!D?*7!/H>A^XF"<7#H\B'Y&<#8%$U]5#&805
MW5`4411+=%T]P2!9]Y2B#%'/7&,[U6YO_&:%XQM;Q76.3-D1:X,@ER*/(I^B
M@**0H@U%$44Q10E%*469@M31#&N)XA][,C<7S7/";ZQDF=K-@B-KTMPLOVG/
M<VMX#<PRX+(<$*8MER]>,?ZFE[]5.^67EWR='X_58%>^L;>X)IO#`O-7S)D-
MKYB;%4"[`.^>'_OXBKV39O-.BU]-'7A9TL--!UX!4/XX<Q[YNVU=:.;`"39-
M6,T=.*CMX<8":M0</VE*D>VPS01-B6V';2GHA<1VX.BLAR\<..CIX4L'CB5Z
MN#%QV,:Y[XH!5_H,A!T-7.FKE6\[;(-%Q0+;8=LL>B&T'3AO[.$+9]/7CG#I
M;/K:`2<0#CM?Z%$R#+C2UP[8Y<&5OEJM;(=M.JG8VG;6O1=<VX%#6IK@+ARO
MKQWNTH'#K9YX:`<[ANF[8L"5OG;`SA>N--4=BX$%OWYXW;[DZ?;R4IRKP3%_
MAGDU:9Y.+OSW$_Q+W=['GLH:?O?0W-(.\#N7'!Y,)^P-UW-9UO@%*C46OYQY
M^!<``/__`P!02P,$%``&``@````A`!R@`HN_"```/B@``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULK)I;<^)*#L??MVJ_`\7[`=^X5I)3X6+`8'!M
MG7/VF1`GH09P"CN3F6^_:G?+[9:P`ZE]&28__BVU);7<;GSWYZ_CH?$S/J?[
MY'3?M%M6LQ&?=LGS_O1ZW_S[+_^/?K.19MO3\_:0G.+[YN\X;?[Y\.]_W7TF
MYQ_I6QQG#;!P2N^;;UGV/FRWT]U;?-RFK>0]/L$W+\GYN,W@S_-K.WT_Q]OG
M?-#QT'8LJ]L^;O>GIK0P/%]C(WEYV>_B2;+[.,:G3!HYQX=M!O-/W_;O*5H[
M[JXQ=]R>?WR\_[%+CN]@XFE_V&>_<Z/-QG$W7+R>DO/VZ0#7_<OVMCNTG?_!
MS!_WNW.2)B]9"\RUY43Y-0_:@S98>KA[WL,5B+`WSO'+??/1'D9VO]E^N,L#
M],\^_DQ+_V^D;\GG[+Q_7NU/,40;\B0R\)0D/X1T\2P0#&ZST7Z>@>C<>(Y?
MMA^'[#_)YSS>O[YED.X.7)&XL.'S[TF<[B"B8*;E=(2E77*`"<"_C>->E`9$
M9/LK__S</V=O]TVWV^KT+-<&>>,I3C-_+TPV&[N/-$N._Y4B6YF21AQE!#[1
MB->R/:M[@PU7V8!/9<-N]3L=K]OO73\13QF!3YS([5<#[O*0=`LCWYA)3QF!
M3S63VR<":U3F1E2%BOOM,;&+%,-_E)E.JV=;`_>&R-J88UO']AMA$:4IKPG^
M\_W)0&JDE>_DJ"V70+ZB)MML^W!W3CX;T*8@/NG[5C0]>VB#95Q+LO*+U56U
MN&!5"2N/PLQ]$Y('ZR:%CO#SH>OV[MH_817OE&;$-;:I&*-"+%EA=D+!E`*?
M@AD%<PH6%`04+"E841!2L*9@0T%4`FT(?I$!*++_1P:$&9$!C-T(@4Z)0\*-
M"APRH6!*@4_!C((Y!0L*`@J6%*PH""E84["A("H!(]S0:UFX/5B8EV\>6-]B
M%-PF2O7M#KIF.$=*TRU2,&9DPLB4$9^1&2-S1A:,!(PL&5DQ$C*R9F3#2%0F
M1KBA<QKAK@^S4$,G@CY4ZB-]$F<I<LO-QAT,3-&X$!7%S<B4$9^1&2-S1A:,
M!(PL&5DQ$C*R9F3#2%0F1NBAJ&\(O5#GH<>`C23I.+J>&9DP,F7$9V3&R)R1
M!2,!(TM&5HR$C*P9V3`2E8D15"C-&X(JU&90%2D%E9$)(U-&?$9FC,P963`2
M,+)D9,5(R,B:D0TC49D8084-HQ%4N0EIB:U:]K;?_1@E<CM^H7FXL-F06Q!A
MQ(RU))[<MXO]Q+@@I?Y"[HJ30H,+85J0ZE&^TL`E%IW+LRRS*<T*$9J>,[)@
M)&!DR<B*D9"1-2,;1B)%\I`9*1+/SGR?>&.*A!$S19)TP&TI;'1;*$601RWJ
MTJPI#=SU2X:(:'J%(5]I>ODFUK%LC^2P^+[(86$5R:(@>C)TPD%A1VR6P8]K
M^ED6WZ/556$525B0:C_KPH[R0V*R*;Y'JU%A%8A1`X,+->`"O+`LX2$8UZ48
M929=$?@HY8I<_UB*G')":0PGES0NV0E,+XE($'RIZ8I^@\\OCD=$,R7JYI5A
M6QW+(H4Z5XIR-=,Y+ZZ83G#-=);&=)R.99/]Z.J*V817S&9]S6PV2M3/@],A
M.8CJIV(4F0T/_D:GJ:^N7&Z6ET+B'*;(IF=US/4UQH&U!791Y)&V/KVH(M7C
M:Q$NM)E"CJHHI^^12<YQ4/E26$6AJ.Y*`BU"]TOBON_VR9Q7.*C.?8BB.O=K
M+4+W&]-]S_9(_48XIL*[637BZ;I\?_JB:N3#.#QHX'1&XLA(]"DHU5+5D#.,
ML5+5MZ5+(L\BCS'32RJ:6U^+<*(S1&+G\_/!MIP.L3Q'!3P9%)="+2]05)>V
M0(O0_1*1<M^S6-'(0#IUWD.T4N=]K47H?8-(>N\Z+KGV"`45WLVB`>^W%(V0
MDU8C$6DUI/N-Q3FB&`@?E?F87!1YY`XSO:@B&?"U".,V4TBU&KAUD1XVQS$5
MBRW?8B]05'<A@1:A]R7U[I(^M\(Q==Y#%-5Y7VL1>M]0[_3:(QQ3X=VL&7'2
M<4.CD0<C1J-1R&@T-DGTV):J+QK-!9%GDW*87F/*UR*,VPR17&M>SR;-<(Z"
MBK6F:N;"'&DS"M"2?BQ>(E)]IN,,R`YQA8HZ]R&*ZHNFF"->_`;'2??.H$<2
M%*&@PKM9-""ZI6B$G#0:B<Q&0Y\9QN)WBJ\;S241W>Q.KS'EHTC^R":>L&<*
M=<IKR758MU%S**MH42S0>EWJ`BW"U"T54KT.-A:D'Z]P3)WW$$5UWM=:A-XW
MIG>G[Q#O$8ZI\&X6#HB,POG6R8CX`8K6DT)F$R)M>:P&?M&$I"D080RFUXSS
MM0C'S1#AFH<?0LU=^QP54#^5M](%BNI2%V@1NE\BDNXA<R0>*Q34>0]15.=]
MK47H?8-(>N_T^^3D(4)!A7>S<,19VPVW*74T5]X/2^2Y15K'XEP>Z@A0=?`G
M6H17-M6H>IR/(J_P-^-HCDC/:J%1M?4`1=KZDJ,5(FT]U*C:^AI%VOJ&HPA1
M;MW,ECAV*V?K>\M<'MZ!&XS\R);(N&T,2#,>*Q'L@G#<A*,I1[Y&.C;\V$2I
M\"FWXSI]TA+G:`@Z2<VJ5I>GIQG@N/)28Q-8FA/H6_T>V2&MT$Z=_Q!%VO]:
M(SUOYG]C^G<MVR$;J0CM5/@W:T4<S]75RE_).^P=OCJ5@_=SV#U!'?SIZA\K
MU1<KGHV;7C/.1U%Y]Z!,:31'E9[50B,==KI["%"D32TY6B'2UD.-JJVO4:2M
M;S@2+T&IA@DK2V91OM0D7\$XQN?7>!P?#FECEWR(%Y;@Z?7AKL#R;:I19P@_
M1X$!POW>$`[P+_#^<):_!D#T07\(A\I<O^X/X1"8<WB+ZS&O=6)G)-[NNJ`?
M.4/XT9W;&;E#^'F8\T=O^`@!XE^,O"'\J`F\77B&M[?>MZ]QN#V_[D]IXQ"_
M0+"L_->'LWS_2_Z1J=I_2C)X;RM?!F_PGEX,.U.K!:OK)4DR_$,X*-[\>_@?
M````__\#`%!+`P04``8`"````"$`;*L<N9$'``"\'P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6RL66V/VS8,_CY@_R'P]R9^32[!Y8I+;&T%.F`8
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MQ$9=SLO9<@:6'NYW%3!`MT^:<K_V'H,5BT)O]G#/'?1/5;ZUVO\G[:%^^ZVI
M=I^K<PG>ACAA!)[J^@5%/^T0`N69H\UX!/YL)KMRG[\>N[_JM]_+ZOG00;@3
M8(3$5KOO:=D6X%$P,PT3M%341]@`_#LY59@:X)'\V]H+8>%JUQW67C2?)@L_
M"D!\\E2V':O0I#<I7MNN/OTKA`(R)8Q$9"161N+I(O"7T0)L7-&#;_GB\)<6
M#^+I79+$\[L;FG/2A+^D.;C23+#ESDOS+G^X;^JW"60D\&DO.>9WL`(;TFMB
MK\J//W(C^`^-/**5M0='"3S40NR_/LPC_W[V%>)5D,S&E0E,B:V4P."@V=0&
M,AM@&C`#1HH61/%_H(56D);<T$8"/<_0XB`EI$IJ`YD-,`TP.$`RZ1R&$UE&
M`(4A9;4(A,O(W-N&9.:*S]9!4@?)'(3IB+%C2'M]QYA,83)5"3DZG=`.)"3D
MHY9/5K9LA%"D)UVXO#,I;Y60BH>#9`["=,0@"%1L@D$RQ2-Z/3JHQPG);6P$
M$O>YM760U$$R!V$Z8FP5G*=O]?K^4-C<'R&\8//#N'60U$$R!V$Z8NQO\9[]
MH;"Y/X'$</Y5BH3+I17]`:&Y=6!3(9/PYL*)9@["E!T(GT$"AP>M>EYW,@J;
M)`A9\HH9^D%B[5]\'T*!4"2=_0_(A+%%,B.AB"^4)`OK>T;?0]X/+6107KZ'
M,@J;E`4"+16;!%">6Y1)XRIE)2-/4T96Y]QJ',ZM,L!(`P[+37X!3!YZ3$5'
MY&>\.U3%RZ8&$Y!V`[%&]U(_1",F<6X7(!7LA<6<!*Y'NQ=2W`F*8DX^6%A)
MQ*3*F.`&V$]')S27MEB*AAQ'?8\A*8`&G4^=GO1BI9=)O1YB$N+6C:P,L(F.
MW[AHN=!@I!<WW`"V*VV7D6_-,%N2@C]2,76A3-H2Z1CXSL%F4DE?33O9)C5L
MMQJUGTM(T;,-Q@3!V5"'(O*M+KL-A!1D9<_8@3*2@AS4;=E51MK2I<)%7[1-
MVB"ETQXX;[R*T(%#:2L5!62DHH+Z;6INIU0DH3[OLL"!F(0&4A%;LA4O,07=
MH(!Z%@4!64EIC75;O.6@HAXB!\I(*A1)>3=/K$@S:09453YHSC&#@VW=XDB#
MT#N*),T&^BDDR,S)V*Z40LK(20?*<'P$MU@YZ51'4H0(*]8_SDD<!#3:-P(J
MQ@;CS-$DH9='!?4;T-Q..4E">DXZ$`N4*3BK9KRPP6L;_[D:(J8$@P\-#GK.
M1+[=TP-2U!-403UK=VPA1<K9.(CZ6L']PJ1E?7W->:8/<`BXXH,O]04.T6!C
MUPL-C1)ZT@K(*#0*ZNEI^Z*@DI#X-0(OO!E,!YBS<0\Q";F%)AR85'[JNL4-
M\<JC[3:RJO>&I(P+5^1;$=GV4JI?N%#F0LR`C,"%UE"B)>_U`\@5S8I*D'[O
M<J'4A3(78@9D[OA=TPA.?%;AEU!_8K8NE+I0YD+,@,QM8B/73L0-;]*\H&5^
M**`;M[`A*><PD)!^#W,AUINR*UR(+7H\%]'0]5+&#4"RJ/G<ZA1;$D!WJD[A
MTA"&#2&WKDE3XCX6+Q)KSF120.]*VEIF%+'7CV>.TM:9$!`O<H-W,IP_4.<Z
M<R4D#WY&>K)\WRVMDL*D85`=<JE)$QOU>)JBK1L!)D@%V+Z`P3Z1IA$[S>FB
M:/="/4W2H]NU'UF&F=09%4WLX>-IBHYOT!10'TWK+KP-2>=Z-)503Y,,BP$R
M">X<FJ0S*IK8_\?3I&E!+ST$J6@ZC4@(W(BF$NII$D31C&)K^F0A"8R*)O9S
MC:;6NL;/R:$8"HP@"T@%.;0*R%;J7`\R&>Z[3$9ZD?A])DZ<$TLJ8V(<6?/)
M]?;"I<W"1)`^6/708,409U0*:=.R"S$)N8-5]..!8WS4N!&+C_B1`R<Z5>ZB
MP`X=*4+BRIQ,>ZA7=+N*E!*9&R9SNW@Q*3$F=>&M[FKJCAN7N17+"V@89ESM
M#D12`/7\[,VG4JB?C3,7PB?&WKIH(.+)4+QZG<KFN=R6QV,[*>I7?`Z$KO9P
MKV#Q5@FS[@H'4@B`\PT\8\+@YWZ3+E;PR_$`'D:K#.86]QMX$7WD0;;7@"6&
M5MB$L/2`G4T$+ZL#^&.\>H1<<Q?>Q"MXXAC`DQ6\)[CX([CC$1P+W\S47N'M
M])(_EW_DS7-U;B?'<@_.]/GOI(UX?14?.KI6/=4=O)J"O^&1$5[)2[CN^/@T
MM*_K3G[`!=2[^\-_````__\#`%!+`P04``8`"````"$`VBN/_ZT/```O40``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RLG%ES&SFOAN]/U?D/+M^/
MK6XMEEQ)OJ+V?=_O-+82J\:V7)(RF?GW'ZAND$V\;4:J<W(1M1^!`$B`('M1
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M*0TOM)Z+E=!GK"31`X]QZM^YZ_09MPO#NUR8?RB>^^YI68A;TF?<\N$NR&4*
M>L@\S1[B9O3)O0WM6'L:TFP]>TJ?5_6P%+>CSRM[&%`B1GFA,S**^45]#$Q"
MT<%UO0PXC?3!5?T,.(_T`?<T>UDL`TZ?P$;SLOP).)[Z@*U>F$$!AU0?Q&TO
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MZ$LPD&`HP4B"L003":82S"282["08"G!2H*U!,J$EP.C3#`-@>`IB)Z"\"F(
MGX(`JF0$[REM3>[2A/O_R%VM1N<N=Z7,P"9S*!*5);A)58*:!'4)&A(T)6A)
MT):@(T%7@IX$?0D&$@PE&$DPEF`BP52"F01S"182+"582;"60"D@)I@<*E4!
M&8B>@O`IB)^"`-()E<TD)U&IOD.BZB4J_62(:ZIN1:<]3DTMNHE8CF4*)GDK
M0*I`:D#J0!I`FD!:0-I`.D"Z0'I`^D`&0(9`1D#&0"9`ID!F0.9`%D"60%9`
MUD"40H1151A6A7%5&%B%D5486N7$UDE=VA(XJ>M/62U-.PG:9WKV`9%0EO:4
M":&2F]@5(\3SM@JD!J0.I`&D":0%I`VD`Z0+I`>D#V0`9`AD!&0,9`)D"F0&
M9`YD`60)9`5D#40I1&5$&%:%<5486(6151A:Y<3626,Z:W+26&]SP_R=N2YR
M\497*SIG..=E.2)99^];RHAT-D+<K`JD!J0.I`&D":0%I`VD`Z0+I`>D#V0`
M9`AD!&0,9`)D"F0&9`YD`60)9`5D#40I1#;0'$-502F,J\+`*HRLPM`J)[9.
M.E.!A70.\G</Y(^_0.N&;OI&)&>WOQ4@52`U('4@#2!-("T@;2`=(%T@/2!]
M(`,@0R`C(&,@$R!3(#,@<R`+($L@*R!K($HA*B/"L"J,J\+`*HRLPM`J)[9.
MKM(Z[^2J/T&UM)N@,0GM%A=(%4@-2!U(`T@32`M(&T@'2!=(#T@?R`#($,@(
MR!C(!,@4R`S(',@"R!+("L@:B%*(RH@JB#"N"@.K,+(*0ZN<V#H)2BNWDZ#1
M);!S,3V][)[^*N]ILT#71%(2-TN7NJ(+8%J)F[<1R45WI/35K(HA=N-;$%<6
MJK$,S5^[.2Z)ZV0U(\0K41U(`T@32`M(&T@'2!=(#T@?R`#($,@(R#@F=A`G
M0*:F57+(Q+C.C!`/V1S(`L@2R`K(&HA2B,J(.!WLN;NRT6<O%<9:8;`51EMQ
MN,]#Y^0[75?_O^>[5N+F>T22^6Z(#0SD>RQ#<S^1[UEW]UPS0CPL=:.:20-(
MT[1*JLZYJEM&B!6U05$'2->T2JK.NZI[1HA5]T'1P!"K2`[1T.BQ,OE2P34V
M,D)L;&Q4,YD`F9I62=5B]&=&B!7-0=$"R-*T2JH6H[\R0JQZ#8J40E0V[9+*
MQ?BKBI%B[:J*NCBY;(E1G%UN4HH15YQQ#V9CHCCE<,[I^];.I$M93.C6'J\F
M9W%W>C&B'IB9(F^Q5&(A?4O3",E\JJ8)A3E1,&LLI9<XNIOS4!+#6V<!.LO_
MU%:#A>SNK6F1;0?F6RP5FR]FA']M%O"9[["0-=^UR&.^QU*1^4)&SK<^"_C,
M#UC(%XYAFA",QXBE(H<><@5QA6',`CZ')BQDQV-JD6<\9BP5F0^"8B#LSUG"
M9W_!0M;^TB*/_15+Q?8SV5"4DC5+^.S3C2P]#^G2CW6`;F49YO%`F;D5NY`K
M/(B4I!M>L2:O#V9F)7PPDRF9*9`$=&\L-A#Y4,SD1!3H7IG?!6<CH)^)N:8H
M1?<%Z>HNU]/R68.^DI:H`7*W6HF%]-,SGQ:*:IH0#$"-[17.12DH/3R(K7&=
M]20]DA6PP4(V`DV+K)-@O^7:#XOY0"R6;=;CL]]A(6N_:Y''?L^U'V3#HAR`
M/BOR.3!@(5](AFE","0CX5(IGQ<A&;,>GT<3%K)#,K7(,R0SUWZ8S61$99BS
M'I_]!0M9^TN+//97KOULMBBS;<UZ?/:I,L6SRSI`E<DPCP=4F2(Q>KQ'+]6T
M6&7$W12J3+$FKP\\O6BF\@RG&_07^<!3*O8A&P0YN5\R4^P3']S21)EY36G2
MXF*_%*/D?JDD9FM%UZ1H.;`#+.-731.">5!CJ:@T/Y0RXO&7.@OX%H<&"]D(
M-"VR/H+Y%DM%YO-!1MPI;K.`SWR'A:SYKD4>\SV6BLR7PE`L3'T6\)D?L!!%
MY=.58I@F!.,Q8JG(H4)8$N,Q9@&?0Q,6LN,QM<CZ".9G+!69#X)"053%.4OX
M["]8R-I?6N2QOV*I.!TR@3"_9@&?>2I*9GZ8@E"VS.,`%:6X:3P"M%*)"4%%
M*1;Q^F`FEAT#*DK&+Y\/9C9%/A1+<M-,VR6_"VY-TG?JD\_*_>8<+KJQ[VR7
M(N1LE_(E,2X5_;"P+F;DVJ>SH)HF!&E8BZ6X*A=I>7*O&]19SR=%^7QQL\%"
M-@1-BZR38+\E[!<>\#0N[JS/?L<:XS3L6N2QWQ/V<_0K$+?_?=;CLS]@(5]$
MAFE","(CX5$Q5Q+;E3'K\7DT82$;D:E%GA&9N?9S^4(@,F+.>GSV%RQD[2\M
M\MA?N?;S(6W8W(BL68_//E4F,TDX)6B[9)C'`ZI,D5@\*7+94B!"0)7I@JRD
MIQF-/>.#F4_)5($LH!,YUX=BF!-AH-+D]\$M351"KRE-6EQLEV*4W"[EY:)9
MT3]*^/U^*44(AJ`6J]+/')LJER^)C6N=#2:EP@<AU6`IFXU-BZQZ<**5YD1!
MUH@VZ_(ZT6$IZT37(H\3/9:*5RFZMB$6ZSY+)!V0V]0!"R4S3PH-TX1@6$:Q
ME!.;0D9X-69=2:\@-A.6LL,RM<@S++-T)\0UESGK\CJQ8"GKQ-(BCQ.K="?$
M:<2:=7F=H)I%WT>SQ]2+LF4>-ZAF14U%1+!NQ1;\CO#<2UX%,S,MF3Z0&52X
M4AT1UX:I>/W&$;=Z4:F_IGII<5&](N1LK`H9<09:T;\_U`V3790SI)HF!.-0
MBZ6RI-%4KP*>\L4&DU(P0QK6(J=%TR*K'IQHI3LA%I(VZ_(ZT6$I.T.Z%GF<
MZ,52\6KZD"ED1#+T64_2`3GL`Q;RQ6:8)@3#,HJE1&S$FC%F74FO(#83EK+#
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MO)(WD"*43VY8"H%802KZA\R_7[A3A&!QJ,6J1`40.X4Z&_RL`,2718Q%'OPF
M-TPN8^!$*]T)<1VHS;J\3G18RB9ZUR([9\")GG5"WS7(W.7S&>>?V%SV66O2
M'5E_!BR4[+\4&J8)@7\CZY_M!5RM&+.NI%>P9DQ8R@[2U"*K'IR8I3LA]A)S
MUN5U8L%2UHFE11XG5NE.B)Q=LRZO$U19(&FILACF<8.6\4C,G3OR2C\MX[$V
MOR,\$VDWSK.'EO&+'&FD.R+V-;2,_\81MY;I)_2NJ&71`WU4+]G[LGYE`E6I
M/)50LVLHA&*74XFE?O.(3J3*$8+DK,6JW)/"0.1%G0TF2RS,D`9+V6@T+;+]
M`2=:Z4Y`+8L[Y'6B8RWRH'8M\CC1LT[$M4QLZ?JL)FE?UJ4!"_F+UR6A&5F'
MK-LIQ>N249E8MWA4IA99]1":6;H34+PN<6)A+;(32XL\3JS2G1!)NF9=R?A`
MDE+Q,H//7E#Q,LSC!A6O2,R=+"G%ZY+1H/V4,6H<,1,MF3X0%-IBI3J"Q>LW
MCKC%BTX=KBE>6EQ<08E0UM:SBGZ3"TDE4!51#5$=40-1$U$+41M1!U$740]1
M']$`T1#1"-$8T031%-$,T1S1`M$2T0K1&A'-&@@DS1ID*0&GQ1SE4D).*S?*
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MHO?4G0]?Z,6$6_I%$)UTW=Y\W^]/_(<V8%YU^.V_````__\#`%!+`P04``8`
M"````"$`^.FZLQD'```?(0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6R<FEUOHS@4AN]7VO^`N)\$&TA"E&34[FAV1]J15JO]N*:$)*@A1$"G,_]^
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M12J:*R0`/X.Z8EL#.I)_WX<4A*MC?]F'\6J1KJ.8@'OP5';]YXJ%#(/BI>N;
M^M_!B?"DAE@\M4]YGQ]V;?,:P+S!N[OG;/>0+00><QHBR"Q=24)V+,@#B[(/
M8:."?@>=_798T62W_`;=*(3/X^`#/Z4/D1Y+R$:F!&GH*=G;,RHS9Z;,VL52
M>1P,N@RUR\3OD6'.T&\]^8U*?U`>?!+>;KV>Y#U"S!EFL4)*L:Q@4!).>I%D
MHYQ0-V%KZ-WD`X[H8NW<>&-GV4*>B6RML$"'U0@W:LQ(%@HP9>F&L(WMV.^C
M+%N(984%RZ:R)4AV;9$%V]M[B"V:]'PE!8:>"R?<<^6$LF#$-D\JKYZSA;AX
M8<'%KV5N2#:;RM*8PV2F`6PAEA46++NQRQ(@H5EN$F4+F-O;?><+L>YHPL*9
M0QB&H0O/J#%O<\Q9)$,/8R;""\U9\T(-)Y"FGH#_R<57&J6S8&!"I6<*,EC9
MH!=3IK,;G0R(PG3)%!]%"X07;H'RPHD8=.,M(.EB]CPGDG22+Z,)=\#!-7;E
M-'M/R=I#6&!LI:X9/-:D]0ZRL>Z9PH1N/-#&5QI#M\$M<\"-,`:97%EG/LH2
M<:K9PH2;[0`:L1#-8[M)G&D7C$S!2VPWX86WF_+"V\W&N`RVTLRY/R4<L2$N
M<R".6A`W7S]?Q>>MUZ]@-M0_>N'ZE1>JGX+79`NLX#9PK@-\(=Y[HTG?`?!(
M((&(A<%K(IR!\>W&4[;,D!4F^"5O(VCDX!PU.#>C9N$;C12Y1,,M?-.]<-TV
MOJ6QQ_T3G0)N-.'2'8!CMTJ3CGMQAJ\TFBZ@AY4=A*,6PM$H\:E9X$QC*P\&
MR6!E!^'8.:77/#-N235])RF$B7$++_W\HI'RPN.V@"[>Q!Z(I1)V$K&C"9?N
M(!O]?V3CRXQ96\A&(P?98H-L;W><>V.UT11/GGMB@U4SH9FW$5J8X$22I-@X
MVA=#D_6=P^Y#5LD\%_DZ0Y:%`A,>FP/(\;L`Q;T--4$CO4A*'!2.+33R.S/Y
M2D-9``K521P@C@T:S0Q3X$;C``\`">`Z%9O1:1C;")2F'@3B*XTZ+?=8E#BH
M&QL$8OLHCJD'`/A*0UF@!W?80=W8AIYHY5/S%#T\&"2#E1W4C2WH(0F<?#-#
M%IS1AVQ##W&P-GD7>K@W;N]HFJ*')6_2@/@\E?"%AHJ@$&ZE`T,)>.G";W>0
M>W,U!3A*%*F'"]CH!7E(#.I>Z,Q)#![Q_0M3F4E$0$@;)0\TV4$."B8&EV;4
M!'C@O%0%484\4;;P0F5K7KAL`T_\,=3GOCB9DFHTH8%3!Q<3"ZF\OOS@"XV=
M9@,5=2`R,4`UTW)!(MQRQ4#1<N&%6ZZ\<,LMO")>WW(E4UZ-)MQS!RD3"Z_\
M;M+X2J/I-F11!RE3`UELF]'59OXV@R_$PJ,)E^Q@9<H@I#WZOSUM[LW5]!-,
M(6N8]NB%IZV\T+13`VR\<L:(F4S8,J-N8<)U*^AA60-G,VH28WK=BEFB;N&%
MZU9>.`&#;+YU2\3)IX%4F%#=L:(>EK7QS.NQ,YT";31A90?04@-H,QT7R-*Y
M0K0+ONBX\-([KGOAT@VP<93[E2XAIYHN3+AT!U)3@V@SI4N*:9LM5K`4I0LO
MO72J>>'2+6#SN!%+!<*TJ_=HPG4[>`HO/1%<>,=]+IY\(3Z[1Q,6-G$ZO",=
M7D3697LN?RFOURXHFA?V_A.^)SWLI%F\G$W)]@$@!).='(GA"']A.CFR@B-K
MZYK-]F%XUVNNH='V`;ZULNA0T(%O,VQ'UML'N'.T'$DH'.'WIZ9.DL`1:[0$
MHL'%P1(-6F#-#$)9(T$@>*%B"P21X-G`=@2*A.^9;4>@9?"E*1Q9REK@]?0]
M/Y=?\_9<W;K@6IY@?!%_9&F'%]S#A[ZYPUCA)773PXMI_N<%_A&AA!>V$;MX
MGIJF'S\P`?FO#8?_````__\#`%!+`P04``8`"````"$`@40+!Q,'``!J'```
M&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RL65MOZD80?J_4_X#\?L`7
MP&`%JH#O:J6J.FV?'6."%<#(=I)S_GUGO!?OQ1"0^A*'SS.?9[Z=W9VUGW[[
M<3J./HJZ*:OSRK#&IC$JSGFU*\^O*^/O[^&WA3%JVNR\RX[5N5@9/XO&^&W]
MZR]/GU7]UAR*HAT!P[E9&8>VO7B329,?BE/6C*M+<88[^ZH^92W\K%\GS:4N
MLEWG=#I.;-.<3TY9>38(@U??PU'M]V5>^%7^?BK.+2&IBV/60OS-H;PTC.V4
MWT-WRNJW]\NWO#I=@.*E/);MSX[4&)UR+WD]5W7V<H2\?UC3+&?<W0^-_E3F
M==54^W8,=!,2J)[S<K*<`-/Z:5="!BC[J"[V*^/9\E)K84S63YU`_Y3%9R/\
M/VH.U6=4E[O?RW,!:L,XX0B\5-4;FB8[A,!YHGF'W0C\68]VQ3Y[/[9_59]Q
M4;X>6ACN&62$B7F[GW[1Y*`HT(SM&3+EU1$"@+^C4XFE`8ID/U:&#0\N=^UA
M93CS\<PU'0O,1R]%TX8E4AJC_+UIJ]._Q,BB5(3$H21PI233\6(VF\X7+I#<
M<)Q21[A2Q]G8M<RE\X4?L'91PY7ZV>9X:L_<11?VC2?.J2=<J>=\;$W-.69[
MP\VE;G!]+$.89UVD<'THPR7U@^N#&5I00]TC\9\[<IR0BN@*S,_:;/U45Y\C
MF+4PYLTEPS7`\I"+E1:1B1?;M5J#(D.69Z19&9`_E%$#$^1C/7><I\D'%'5.
M;3:ZC25;;)D%5C#2^BH0J$"H`I$*Q"J0J$`J`!.0A6L#T^7_T`9I4!N6U88!
MO5BV(@2S8"Z^"@0J$*I`I`*Q"B0JD`J`)`1,>4F(X76'U0):PPHCU(*]5&N!
MVLRY*%L-\34DT)!00R(-B34DT9!41*348=&24L?Y8<_&?"&Y>X8@$4PR6)*$
M*3*5QWU#C!QQ'CG63#;:<B->'1H2:$BH(9&&Q!J2:$@J(I)2((FDU.TB0>M.
M#I;$AB#.LB\)#?$U)-"04$,B#8DU)-&05$2D1&$('T@4K>5$"3+M\U0!7P4"
M%0A5(%*!6`42%4@%0,H/MK\'\D-K.3^".%U+TRWC6XX(M:\L>3ZU@;68SP_'
MFLNE'W`C5C4AIV9(Q)&>:*X\+.8\O8UCN?+#$F[$J%-.#8@D&4S8!R1#:UDR
M@HB2:8A/$5$@>ZKLH`$W8C&'&E&D(3'W$N58*')P(T:=BD22'-#//"`'6LMR
M$$240T-\BEA=LV&;EK*4!OP^"S?4."(-B;E7KX0F<L*-&'4J$DE*8$LE24'Z
MJS&VONVAS-\V%90[C.G`:NE`:K2[0A99HHX8=EEAENF03R&[7U0#'0IUQTB'
MXMX1VSM=\:0WX+I(-+(PV'2IC2?96`>D@,:=:X&.BA84@E$0UHZE7+];BUC9
M<.%6ZL+@,R/HA+B1/566CX!9X0A]K"U[,;--^6DA,^F7^8A!MP*(F1%LL]<#
M2*C5#-H6;N6H,:0]%PR(K#YV>J+Z7VA.&D-H7MC(;BP"S<0X'5M9CK;4RH*%
MD\>I:T[9R<D5^_Z`L>,L80<*+;^0L?>.$8-N/3!F1C9/)Z&0/:<C.C5-9413
MYB7&).0BZXO]Y`/ZDO93TI=`,]BD!0640MQ:Q.J+FJ9&?;H!]7/DT5.:])"Q
MBU:VJ\RKB%G=+FLMAF0X!F493QG[M1ADV<%*DKWOUK\H<'14%A4"*06N]N(6
M=;Q5;SXS$@>`^#EB,3FVTNZ$S%&T&AB`.V*(&54?0T(A)0:E"TJ9X[48Y`$`
M*VT`+'C=@][W;W?(HHP&@93IH+0H6WPG!HY?3`=JU"L1,#^RGMOF8J$PA\P"
MI.;349C\W38=,:/;,T%[?,+\R./G\'9+FP74Z<KCY3'`OOZ!M8<<`Z2UAT(.
M7Q^W>&[%(8%I?#5_GQK9+O<+="CLJ=AF$O70=?98ITIT*.VIM#T/NW=1EVYQ
MF.,;TT=J$UF4VB10Q]-O5LHRN<4]$!WA<D-!:@0[(C<::#_H`]EF94Y=9>,-
MV=,P-Q:37J]WA!0SIILA)=2*[Y]Z2"DCNA*27,-XM%#'2EQ'OE<7T'*P;19[
M17)"@9I@I;:!U_2TD!FT[:'K6OG4R.Y?XP4Z%/94C#WJH>OLL4Z52!`1AWP?
M(*]O3T7]6FR+X[$9Y=4[OONW3>A=.$P^3*0N?)CHC@C*#?AB\=PM@`J^P2\9
MJ):*VQZ\'1S`'0_>G>GX\]1[A@ST&YNI!Z^0!O"9!V]<=#QT/3R?Z#<BU\-3
MBGXC=CTXN@_@"R\9BBA>>G"B&["W3`_/-/J=C>MM!F]L76\[>,-W/7AWH3/Y
M"P^.[`/XTH,#[``.,>$)#NY,^`C!EYY+]EK\D=6OY;D9'8L]5(/9[;DU^59$
M?K1TSKQ4+7SCZ:;/`;[I%=!PF_A"<U]5+?N!#^!?"=?_`0``__\#`%!+`P04
M``8`"````"$`Q81*#&P'``!F(```&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6RL6EMSXC84?N],_P/#^P9L@[E,R,Z"[]/.=#K;]MD!$SP!S-A.LOOO
M>V3I2-91[$#:ER5\?/J.=&Z6K+W_^N-T'+QF9947Y]70NAL/!]EY6^SR\]-J
M^-?WX,M\.*CJ]+Q+C\4Y6PU_9M7PZ\.OO]R_%>5S=<BR>@`*YVHU/-3U93D:
M5=M#=DJKN^*2G>&7?5&>TAJ^ED^CZE)FZ:X9=#J.[/'8'9W2_#SD"LOR&HUB
MO\^WF5=L7T[9N>8B979,:YA_=<@O%:J=MM?(G=+R^>7R95N<+B#QF!_S^F<C
M.AR<MLOXZ5R4Z>,1UOW#FJ1;U&Z^&/*G?%L65;&O[T!NQ"=JKGDQ6HQ`Z>%^
ME\,*F-L'9;9?#;]9R\2VAJ.'^\9!?^?96]7Z>U`=BK>PS'>_Y><,O`UQ8A%X
M+(IG1HUW#(+!(V-TT$3@CW*PR_;IR['^LWB+LOSI4$.XI[`BMK#E[J>755OP
M*,C<V5.FM"V.,`'X=W#*66J`1](?JZ$-AO-=?5@-'?=N.AL[%M`'CUE5!SF3
M'`ZV+U5=G/[AI&9%4L01(O`I1*R;-29"`SZEQGPZG;CSV?43`6:S&O@4(K<O
MQA4:\"DTP#=7.F(FQL*G7,2MSH3*;-8`GU+C9D<LA`A\?MH1%B1C,Q/VQ[6N
M&/'\:M+52^OTX;XLW@;0`R"#JDO*.HJU9(*8J#RM9.IV92ZD+%/YQF160_`-
M)&4%Y?;ZX-J+^]$KE,A6<-8FQ](9&V2P>F"R'@5\"@04""D042"F0-("1N`6
MZ1M(L/_#-TR&^097M49`.<LFCD`&#O$HX%,@H$!(@8@",062%J`Y`AJ(X0@'
MDN7];H8YP49!WVKEA.W2G!`<5SIG8R">@?@&$AA(:""1@<0&DK01S070_S07
M]"^=L:&BH%?)>K#=N1[D-2<Y[:*Q9[0D)$FF@H'X!A(82&@@D8'$!I*T$<T=
MT,EO<`=C-^[`1:PYXBQ4W`W$,Q#?0`(#"0TD,I#80)(VHBT40GC#0AE;7RA'
M)FJ=%/`HX%,@H$!(@8@",062%J"M#QZ)VOIX_[]C#_?ZD&^?UP7?9KR3[P[T
M>=[]F8B^;(',U+HEHDK")6W/XQP;GHZJ;":D(GQ)PF0*#"0TD,A`8@-).&(U
MD]:<!"7ZWYW$1'0G":3E)(DH!QA.XIS)HGG*VF-KHK<57_XN_2-5$0DETFTG
MDCKL:0YV'-U.+']'U42J`J+Y#P*J^>^=9()M+6838^N.$HB6%S.2/!M.LN%A
M+I/'\)W@P'-.<NP)$?(%B:7WZ\/,MFW2N`-!@.8H5:BE\(K91-?,)M9G8SEC
M5X]#TC\;+0YL@W=#(!JZ'@D!L4.(7+L](ZFQP8%04))%/>0AR98]PD=UE^>V
MNYA-]<4&.*AMGRJ'2.HS'R%)F8^I>=<FO2?!01WF=6>S;65[:]V?]1;?A<*>
M`>MIC1!$6+K1GI%ZWPA6?^(C2:W61XCGN3VU+5((`3)Z$QU)?747(4F9CQ$2
MYAUW0?:&"3(ZS.O.9EO7MK,_]1RS^`98BP&'2,*3M-S@P+Z,\Y"DG.`+R!8)
M[TRF).,"'-21<<WS-T12G_D(2<I\3,W;#EE8@H,ZS.LQ8)OG=@P^2'B^U]:<
M+2!'UL#&DI"J`5KPGB#9ZDGJFU"@I+#"0@5UJT>F5&Q"B9*B3S^+[:+;?F&Y
M:4_OP*<?>(@-)/U70'I+((^$36,1;/35I(<DE0\^0KPFK<EL[A+I`"D=12GR
MD<^RUWZ$2LI^C!#:G\Q=4@\)4CKLZPD)'C8<;TUOW-RRUW8T"APB36&F/ZLV
M.+"O*CTD*2_X`G+`2*OMTTT(#M19I(>&R.J;0X0D-8?XW3G,Q_H*$QS8-0<]
M&NP(TBZ##Y*?GUBT]B"@=GN0D/*5V1XX26L/!A2`I2;.2CU44+=Z)$@M]=B$
M$B5EM`>(C>:7J]L#&TC:@X"T]C`G-;2!$PX;V%N>'I)44O@(\?*<3L93DFX!
M,CJJ4W2'*\Q'J*3,QPAQ\^YX1H\D"3(ZS.OIR$XK[73\W(Y!G'G:NS8.Z<UA
M3O96&TL>EKI3RT.2<H(O(+%CL%QG;,1`*+>+DI9$B,H0"MEC*"E"DC(?Z^9=
MV^S/_=;U$+"C2SL$'W0$1B?Y+B!5LQM+0MTK\P2I5;.^"05*2FT8KE"/3*G8
MA!)-7?.+38]IGTK-1D5W%T*P"!EUA^3/1I#ZNP.2^D_2R.(5"[=7]!UH@(R.
MBN4-`TE]VYD(2;TSBI$E>@B<,,EQ*D%&QXST0+$S6SN!::"^%Q>(P$?[/.9J
MDM@(M1);02IXM&0]0;+5;8-O0H&2DHFMH&[UR)2*-8@[AU^*\ENF4U8^99OL
M>*P&V^*%77C"$?KA7L+\-M:;+>%U',R%XO,EO,XR\6B^A-=/)@ZWNM^:9D5T
MUG#;VUR-4MR&6^!W=-;.$FX"WM&?@/Z[0I,EO"LW!ZRG2WBU#/A(6H9;WDOZ
ME/V>ED_YN1H<LSTX9=SL24M^3\R_U")U'HL:[G>;+#K`?7X&UV)C=G38%T6-
M7Y@!^3\$'OX%``#__P,`4$L#!!0`!@`(````(0!2_=)_@0L``(4V```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*R;6W/J.!+'W[=JOP/%^P"^0,"5
M9"KX?JVMK=G=9T*<A#J`4T#.Y=M/RU);EMKV@=2^S)S\_%>WW&K)4MO<__GS
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MX126,9X^WM<!^N^N_'%N_7MT?J]^A*?=2[8[EA!M&"<V`L]5]8U)XQ>&H/&4
MM`[J$?C7:?12OFX^]Y=_5S^B<O?V?H'AGL,=L1MS7GYYY7D+$04S$W/.+&VK
M/70`_CLZ[%AJ0$0V/Q_&)CC>O5S>'\;68C*_FUD&R$?/Y?D2[)C)\6C[>;Y4
MA_]Q47U'C1%+&+$;(^;$-N=WR]K(0$-P47N'_POOR\ER/K<7RSM``PT7HB&D
ML6AXI<>5:`C_%PU7$\.>+=C=#O@S8&#JGK)_W.;1P!"S?V#386<P&-R9')4K
M;\_`H6#_N.D&8>RXSVL'<<HSJ4Y,;W/9/-Z?JA\CF.UPF^>/#5L[#,<`:YB2
M/+Q-DO;E*"0GL_+$S#R,88`A_<XPL;X_PB#=3[_#9-@*S9IJ#%7AHH)E/C/K
MZ<#70:"#4`>1#F(=)#I(=9#I(-=!T0)3"&T37TB*_T=\F1D67XS,&H$,N*D%
M$Q78Q-.!KX-`!Z$.(AW$.DATD.H@TT&N@Z(%E&#"-%&"V;UN8DXR-:R0K9PT
MK3LU2&NA632!=0GQ"/$)"0@)"8D(B0E)"$D)R0C)"2G:1`DA3'$EA&R^F_-)
MLZ!>/>.9(5@T8&UO3?F%%EXNLMKK@FFM5)';B)I,)<0G)"`D)"0B)"8D(20E
M)",D)Z1H$R7B$%H2<6,^8<_,X?QE#>L(8US6G-AR&7`)\0CQ"0D("0F)"(D)
M20A)"<D(R0DIVD2)'627$KOA@#&U&C!!3#F]"?$(\0D)"`D)B0B)"4G:1+G1
M.^U&^6.X3I++^V[[;5WQ?5U'`"QXW/*',#.BWC\G-M\`LB>JVY#VM%4GI"<T
MT-EF:IOV3!7YC0BS,R`D)"0B)"8D$:3NM!(D=@QJ[U4Z@@$[0XP&4ZO1X&1>
M[]'KB+D-D7>ZT)ZC'M<L8$5M14/;N?B-J(F&(':3>F%#I"'=6=38D1K3UIS%
MC0B=)9SP.U-"!CMG)61?RBMF1(TD)^U($N)Q8B_JW:`Y,VPM@9KK>!<!L1$2
M$C6MV!X3K%JJU;BYCE:3M@TE-NQTH`1G.)]JN1H&1."BR0U+RQ]7B$S8U#0B
M?=R]+I%I:Z9\5+$I__W1,*V%ML<.4`%/HUYG(8J&>A1UB4B/8E3Q'EFKV4+;
M826HZ.F1.B)L%WW]#&=G-"TQ!6('Q.;^+2WS7&PW=/^>%&$F^6A<I+0YM^?:
M7B;`5FW_^F"'*!KR'TD1^H]5_\;J;J7[3[!5CW\UVN!?B?:7%@>#6=&FA4#*
MM-`FJBO:_69:<$L@PB#XV(YGG#F?S;0G4X"*GHRK5_X01>"@211]H"(I0O<Q
MHE[W"2IZW*M#P/;I-R0\W];#IAO[LV:E`PB_;37(E:C_UCP4R>>33U&`2%H/
M)>JW'J%(6H\I2A#5UM6X0/"4N-3'E`6KBHVNWP^Q>H:>FAPIZX-ID]P4#67:
M>6BKG2]D.?2%RA0KQ,)<FMKB$Z"AGADJLI-T(,)V@QV(20=FIG8F2]!03P?4
M<0`1&0=Q>*G'X:_J`^;^[TXRK,:I#P1'2MXVJ#^S/&'*YN51MJ7U*0H0M?/V
M"NL1MI/68XH21!UYRS;X-\QG<1YH[[07IO8$7;,S-D1//47;FLJ5*EP;/(I\
MB@**0HHBBF**$HI2BC**<HH*!:E9R4X(-T29'RC`'D9F;7!DK1KD4N11Y%,4
M4!12%%$44Y10E%*449135"A(C1\[+MP0/WZZ4.+'D5S>74,G'B$^(0$A(2$1
M(3$A"2$I(1DA.2%%FZ@A8Z>(&T+&#QU*R#BR6J=/HT%#"YX0P2+;;%1,>ZD>
M>WPT)4_Z`2+I,)1(VJ*;GDZ'VB8K1E/284)12E%&44Y1@8B_3U,*ZOJI[4N[
M5I-947>M`K4'B"(/D3H<VC'`ERI<<@)$K>&@*!+(E`M33%%"44I11E%.42$0
MOVTEYTUVO&KG?!WIU1=JQ;4E+=K,.#S49#A<H0+4GYT>BI3XS[7L]*5*QI\X
M#%$UY#!"D;KOTDLR4H4.$T1R#Y)*U'^'&8H&'>92A0X+1!US!FS1D>0UZ.NW
MT^RHIL\9CI11),@3#5M)[5,4"-2R%5(4R8:B`*3MKV,IP,`DU$Q*428;=I>6
M<BE`RX5B1IT\MYWL3'JR0P3+L5SXYUKBN4+%QKY1Z4NZAR)YGO$%LFQ>GE,?
M)P$V@&-(K]4014.N(Q1!5C26R+DI1I4H;"VAM**-:X*2H2ZE*!KJ4H:BP2[E
MJ!)=LI9S0RNV%2CIZ9*:#^Q$1Q;3FZ<@LZ(MI!RI)]JY5CET3=$0]KW-,-`T
M$:)VFG!DL;(ZU%OU-!$-X&C5:S6\QG6$(NDZ%DB<I6USI<<_P49#[E,4#=UY
MAB+I/E?=SU>VGI$%-NIQKPX_.WVVAW^XULQ&4Q]G@>3CQ$45K!V]X?>D"%<M
MGZ*`HE"B?NN1$)EWS4$JIBB1IK`/J43]UC-J*J>HD*;`NAKUVX[CD&HDZ@*I
MB[!>+Q(-?[,(<U.PW\(@^-A.HH"B$-'0HA:A2&9PC$B4*CO*U0E*8![W9E"*
MHB'_&8JD_QR16$$[RM4%2GK\JX/)SNPW3"%^Q&\?P2!+V?BR?&GN%J*B+FJN
M4+'C<Z.B2Z6P+F_7%^W$4JD]IP.TVO:M6PU1-.0Z0I%T'0L$T:S?"QFFJ1U(
M$FPTY#Y%T9#[#$72?:ZZ-Q?V7)L@!3;J<:^.LUZ=^-H!CQ8M3('4N:P]U%VA
M^LU<YJ9@^R?G,D>PH9)I8\ZUXFN`UMLJF@;"^M"$B]"2[$*,2$SXA6%I[A-4
M#+E/433D/D.1=)\CXNZMNX7^RK=`18][-0U8&>*&Z<[DVLY(H/83LT%RD/3P
M>W!.J4W)=CY%`46A1/W6(R&"&8&I$U.42%.H2B7JMYY14SE%A30%UI6HL\.W
M$O4OO7BIK:B#(9"Z]I(7+]AP:`7RA$@6'WU"`D+":TQ'*!H\&L1")99;L^,M
M3X*&>A:\^BU/BJ*AN\U0--BEG'2)O/<IT%!/E]0T@+E/TN#V]S[P+;T^*1')
MR>5*U)_8GA3AA/`I"B@*)>JW'@D1K$]H/:8HD:90E4K4;SVCIG(%\=#S7PWP
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M/F2C/%HZ\"E?!U\Y\!D;\&F30O`CH(_-6YEO3F^[XWFT+U]A29C5GX>>^,^(
M^!\7\3K^N;K`SW_@"0P_Z("?>Y7PFGS&ZO:O577!/YB#Y@=DCW\#``#__P,`
M4$L#!!0`!@`(````(0!%->".J04``/X5```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;*R86X^B2!3'WS?9[T!X'Q%$VB;JI%6NV4TVF]G=9QI+)2UB
M@)Z>^?9SBKI`U5&F.[,O;?OSU/_4N511U/+SM_)L?"5U4U27E6E/IJ9!+GFU
M+R['E?G/E_#3PC2:-KOLLW-U(2OS.VG,S^O??UN^5?5+<R*D-4#ATJS,4]M>
M?<MJ\A,ILV927<D%?CE4=9FU\+4^6LVU)MF^&U2>+6<Z]:PR*RXF4_#K]VA4
MAT.1DUV5OY;DTC*1FIRS%N;?G(IK(]3*_#UR95:_O%X_Y55Y!8GGXERTWSM1
MTRAS/SE>JCI[/D/<WVPWRX5V]P7)ET5>5TUU:"<@9[&)XI@?K4<+E-;+?0$1
MT+0;-3FLS"?;3VW7M-;++D'_%N2M&?QO-*?J+:J+_1_%A4"VH4ZT`L]5]4)-
MDSU%,-A"H\.N`G_5QIX<LM=S^W?U%I/B>&JAW'.(B`;F[[_O2)-#1D%FXLRI
M4EZ=80+PUR@+VAJ0D>Q;]_E6[-O3RG06D\5\[GJ+!Y!Y)DT;%E33-/+7IJW*
M_YB5S;68BL-5X).KV-[$=>8/"QN\CHV<\9%N/W+@?L0ER'83AT_NTIO8[M3[
MB3^/#X/^%S-]G[]'/A`^/^+/AHJR!-/2\MR->K18A;J"[[(V6R_KZLV`500E
M:*X979.V3V5%J5F29/'OU1Z*3E6>J,S*A/BAJ@TT[->UYRR6UE=HLIS;;+"-
MK5ILA07M*"J[TT&@@U`'D0YB'20Z2`?`@K3(W$#C_1^YH3(T-R*JC0!]LAPM
M$<)"#-GI(-!!J(-(![$.$AVD`Z`D`M:3DHC;^X#H!6J],N&O[`7'TP+<<!M/
M)F6+R`Z1`)$0D0B1&)$$D71(E-!A"_E`Z-0:5A+L!S+VF:?6=L-L9L.UXGBN
M:K251K(#$`D0"1&)$(D121!)AT3)!NR+2C;8;C&AF_IX3]"!76)$/!M&W'Y9
M;!'9(1(@$B(2(1(CDB"2#HD2,Q13B7D\4&JM!LJ)T[<Z(CM$`D1"1")$8D02
M1-(A40)]T`(=%+<]%?G+IF*/[!L)F,&6SQX$5$2-GQ&7/=OIKKZ5I%\E^@:Q
MXS8P6;F2'%=[7@322'15B$B$2(Q(@DC*23=I)4GTB(N?E]T*>'^2J(B:)$:&
M29*D3P!*$K=YZ!ZXSM36=I%`_B[S(U4%B22Y[R>6.O3!#GYFZFZ5R-^%:BI5
M@2CY@Y..DK\;S02'+=%-U%I-%"?PT?>%-U?GLV5&#CS.I!'*W0T;Q]4>4P$W
MHNT-@<-;B.HHY+_#?GG7473#D3Z9^(8-FDRB3&;VZ#ZHDTG')Z-4@9[T/E"&
MSERM`T?T8"Q#=SSM6;<5`T<KT1N)]@F$NM<E?FXOM%A#,6;H7L]J)(S&O,>]
MD?">J-X]V]7"2L68.][55-/3Y2_O&#8[H\+)0LQR(Q"4?5`!+5%;;C6^%GHC
MH1X(Q%I_/M?76"@,1GM?&(U7@,4&4Q3>$S&.>9_-YH]:KPN#.][5"H!WI0+C
M>XY-S;5F9\B=R1ENN16@/OMZ`^Z$4?>JWCT?`XQ"@7KUJ$?WU6-AU*LG&*4"
M=>IJ7NBA]]<[DQV=E<YD2-D;]&/PUN;C^JKO>M1'C;;!@%LY;&^PG<>YMFN'
M0N?.\NP*$0FCWG_<HQ'_B>9_YNK^4Z%SQ[]:!'K6'BO"E^H*S?BS\S7<!J&F
M94AI6HGZ`''3<B-VL4,/;`%7=WL4"C1LVG>HQV)<+Y5@1"^W:#AL[BQ?[+**
MW5V4I#Z2+3F?&R.O7NE%%.S(ZZ7$[)9L]^##R0[V%)TO?#@981XO?#C)8`ZW
M;4]=EV@Z&WH+=\-^X_CP)HUU-C,?WC,Q?W+])P@8_[!Q?7@5N\'G/KRN`+?D
MC.#V[9H=R9]9?2PNC7$F!TC*M#N6UNS^CGUI>3<]5RU<NW6-=8)[5@)5GDZ@
M7P]5U8HOU(&\N5W_````__\#`%!+`P04``8`"````"$`9%'/QY8```"J````
M$````'AL+V-A;&-#:&%I;BYX;6P\CL$*`B$41?=!_R!OWS@SBXA0!PKZ@OH`
M<5ZCH$_Q2=3?9YLV%PX7SKUJ>:<H7E@Y9-(P#2,())?70)N&Q_UV.('@9FFU
M,1-J^"##8O8[Y6QT5V\#B6X@UN!;*V<IV7E,EH=<D'KSS#79UK%NDDM%N[)'
M;"G*>1R/,G4!&.5$U7"99A"AGP`1?RF-DO\5\P4``/__`P!02P,$%``&``@`
M```A`"`?`M_Y`P``=0\``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````G%??;^(X$'X_Z?X'E/=M
M:+="IRJP:FE[6XE>N0W=>[1,,H"%8^=L@TK_^ATG%))E<$N?"/9\\\O?S-C)
MMY="=M9@K-"J'YV?=:,.J$SG0LW[T?/D_LM?4<<ZKG(NM8)^M`$;?1O\^4<R
M-KH$XP38#JI0MA\MG"NOXMAF"RBX/<-MA3LS;0KN\*^9QWHV$QG<ZFQ5@'+Q
M1;?;B^'%@<HA_U+N%$:UQJNU^ZS27&?>/_MSLBG1X4%R79929-QAE(-'D1EM
M]<QU[EXRD$G<W$S0NQ2RE1%N,^@F<?-ODF9<PA`5#V9<6DCB_4+R';A/VI@+
M8P?)VEVM(7/:=*QXQ;1=1)TIM^#=Z4=K;@17#MWR8O6?ZEN6UIG!?]HL[0+`
MV21&@7JQ^FS*-K_%Y:#7JR3PJRWI-=2>X$;;QXEP$NS3;,R-(USN]9H^5U[4
M'M<.O9TB0VZP.^4P7^Q!U:<M=-/S70Q#K:R6(N<.<G;#)5<9L/0@TH_(LS%_
MWT3JT))GFF5ZQIY*/+"=;I_Z.I"65VW(4!>G0E+W@=C;5A!R?JJ9(6^1XT/!
M<$N;>3)SKL1K51S5:::KHN!FXY.6"MHS;A>5Z(-:@W5UCH5BC]PLP9$0+ZFP
M(#;D[K:;;-@86>%J3OV_$J773`)24$(;5I4JLND?[8#.R`BP[HYL"3X5TA/W
M!\B*E$ZS%$O<1WY/FD5&%&(;KR<^DL=AU6/+Q$9((O!TL^5"RQQ[++O#F!R=
M@1%V1F6A"GVHI>13;>HCN9X;FKF5ZAL,S_M18+NU%8!TXP&;>@%LPE^.^0ES
MGVQ,1:FQK:LYJ28%B6T-#?Z[PJX!1F[8O5!8R()+=DM"PO2B*8GT#O"+QNP(
MAD%.L;&1SH1XQB8DI"902.DHR"/:6X(681,A=@1,'-(C9*;)DI!<^CM9PL(A
MSM"^ATES01Y4F#2?P7S]A)U+$K,GY_[K%AP7>/W8->_]3`K2='PZY)J$4#V4
M7>>Y\-<D3D*VQ;`3DHV9KU@(<K]R*P/L42A1K`J<WYMJ:IP`J6P?&_SA&J0/
M/XPY<OBA`4`G@"KU?0+)!%"0>BK[.4U"PO/C6`)"785.P)&AP^IUTK5CD#H)
M)T%N),^6Z4F0RCI],JUV-]+6LAO`&RS@CX(9::4%J<2$8UBN:^%?4.]#]@>_
MK9SW(7N36T/O0U(Q5P+?6OXNY:\&])UTKQ@L>U8&,HVP5YSN>$V@,W;8^)L!
MD8X=0GX`7@57P*8;]O<12&ABM+C<>M_\]J(9";6TS^5$W^+E[NW)UEY,T@4W
MD.-CYFU_OY!\Q]>:D5[)<,'QDI>_R1QN^`?FS_H5/3B_/.M^[>+;L;&6Q-N6
MCM?$P2\```#__P,`4$L#!!0`!@`(````(0!PK8MU,@$``$`"```1``@!9&]C
M4')O<',O8V]R92YX;6P@H@0!**```0``````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````"<D4%/PR`8AN\F_H>&>TMIXZ*D98F:G5QBXHR+-X1O*[%0`FBW
M?R_KNCJC)X_D?7EXOH]JOM-M\@G.J\[4B&0Y2L"(3BJSK='S:I%>H\0';B1O
M.P,UVH-'<W9Y40E+1>?@T7467%#@DT@RG@I;HR8$2S'VH@'-?18;)H:;SFD>
MXM%ML>7BG6\!%WD^PQH"ESQP?`"F=B*B$2G%A+0?KAT`4F!H08,)'I.,X.]N
M`*?]GQ>&Y*RI5=C;.-.H>\Z6XAA.[9U74['O^ZPO!XWH3_!Z^?`TC)HJ<]B5
M`,0.^VFY#\NXRHT">;MGNS?7)MXW%?Z=55(,=E0XX`%D$M^C1[M3\E+>W:\6
MB!4YN4KS(BUF*T)H?D-+\EKA4VN\SR:@'@7^33P!V.#]\\_9%P```/__`P!0
M2P$"+0`4``8`"````"$`RVSVNU$"``#1)P``$P``````````````````````
M6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"
M```+`````````````````(H$``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````
M(0"8VH[SJ@(``((G```:`````````````````+`'``!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(````(0"+JQU^0`4``-D3```/````
M`````````````)H+``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`
MM^O;XK8%``!)%0``&``````````````````'$0``>&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L!`BT`%``&``@````A`*-_&RWS`P``Z`T``!D`````````
M````````\Q8``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"+0`4``8`
M"````"$`:<UA+8@(```)+```&0`````````````````=&P``>&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+`0(M`!0`!@`(````(0#K>%-'.`,``)@*```9
M`````````````````-PC``!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!
M`BT`%``&``@````A``2$"$_R!```H1,``!D`````````````````2R<``'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"+0`4``8`"````"$`6-#0M1X/
M```280``&0````````````````!T+```>&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;%!+`0(M`!0`!@`(````(0#"CR!JD@,``+@+```9````````````````
M`,D[``!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L!`BT`%``&``@````A
M`/%X"V"%`P``L@H``!D`````````````````DC\``'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"+0`4``8`"````"$`GI.W@.X$``!5$P``&0``````
M``````````!.0P``>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+`0(M`!0`
M!@`(````(0`)C.&8W`(``.4'```9`````````````````'-(``!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L!`BT`%``&``@````A`)%FCDS4`@``;`<`
M`!D`````````````````ADL``'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"+0`4``8`"````"$`W1C"Q!8$``#;#@``&0````````````````"13@``
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+`0(M`!0`!@`(````(0"QRB&X
M&P,``!H)```9`````````````````-Y2``!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L!`BT`%``&``@````A`-?_%#^8!0``VA@``!D`````````````
M````,%8``'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"+0`4``8`"```
M`"$`U7$I84<$```-#P``&0````````````````#_6P``>&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+`0(M`!0`!@`(````(0#("P614@,``!@*```9````
M`````````````'U@``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`
M%``&``@````A`+5](:.@`P``CPL``!D`````````````````!F0``'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"+0`4``8`"````"$`N3-C&QH#``#;
M"```&0````````````````#=9P``>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;%!+`0(M`!0`!@`(````(0#`],$B``0```H/```9`````````````````"YK
M``!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L!`BT`%``&``@````A``%1
M,1(U!@``.1@``!D`````````````````96\``'AL+W=O<FMS:&5E=',O<VAE
M970V-BYX;6Q02P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P``````````
M``````#1=0``>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#B
M%F?B4PP``*5P```-`````````````````)9\``!X;"]S='EL97,N>&UL4$L!
M`BT`%``&``@````A`(IL[F@BHP``(TH"`!0`````````````````%(D``'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A`(X6'ZM/`P``^@H`
M`!@`````````````````:"P!`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M`0(M`!0`!@`(````(0!UXPK3EP8``'H<```8`````````````````.TO`0!X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`GNTT(J@$
M````$@``&0````````````````"Z-@$`>&PO=V]R:W-H965T<R]S:&5E=#8U
M+GAM;%!+`0(M`!0`!@`(````(0!B?*D['@4``&@5```9````````````````
M`)D[`0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L!`BT`%``&``@````A
M`(N`_)=P!```0!```!D`````````````````[D`!`'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"+0`4``8`"````"$`FS:Q\^4"``"A!P``&0``````
M``````````"510$`>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+`0(M`!0`
M!@`(````(0#@DMH]K0,``"8,```9`````````````````+%(`0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L!`BT`%``&``@````A`%T+/]8$!0``21,`
M`!D`````````````````E4P!`'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"+0`4``8`"````"$`B"M-F^0#``!\#```&0````````````````#040$`
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+`0(M`!0`!@`(````(0!`'VCN
M``0``(\-```9`````````````````.M5`0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L!`BT`%``&``@````A`-5=F"5C!```:@\``!@`````````````
M````(EH!`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````
M(0`A$/^\JP,``.8+```9`````````````````+M>`0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L!`BT`%``&``@````A`.(H)4IE`P``*@H``!D`````
M````````````G6(!`'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"+0`4
M``8`"````"$`JZN/)9H"``"D!@``&0`````````````````Y9@$`>&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0`#*5NXF@@``)XF
M```9``````````````````II`0!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L!`BT`%``&``@````A`-0R7*`I"```PR,``!D`````````````````VW$!
M`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"````"$`DWX-
MBZ0#``"V#```&0`````````````````[>@$`>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+`0(M`!0`!@`(````(0"=J`U_^@P```9$```9````````````
M`````!9^`0!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@`
M```A`#6%3SII!```3!```!D`````````````````1XL!`'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"+0`4``8`"````"$`=1&3$30(``#6)```&0``
M``````````````#GCP$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M
M`!0`!@`(````(0`G,O_YU04``!P7```9`````````````````%*8`0!X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`/@!`RN\#0``
MF$4``!D`````````````````7IX!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"+0`4``8`"````"$`L7S&AFT#``!?"@``&`````````````````!1
MK`$`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`,(@
M5C:(!@``/QL``!@`````````````````]*\!`'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+`0(M`!0`!@`(````(0#^+?HT.@(``!(%```8````````````
M`````+*V`0!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"```
M`"$`EC&SXHD(``!$)0``&``````````````````BN0$`>&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`&&38T-*`@``B04``!@`````
M````````````X<$!`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`
M!@`(````(0#`/'\V;@8``-D?```9`````````````````&'$`0!X;"]W;W)K
M<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`$<5_D@O$P``*V8`
M`!D`````````````````!LL!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"+0`4``8`"````"$`+=L<:N$/```A7```&0````````````````!LW@$`
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(````(0#.5]B]
M/P<``-@?```9`````````````````(3N`0!X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L!`BT`%``&``@````A`#\I,JY4(0``!;\``!D`````````````
M````^O4!`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"```
M`"$`1`SQU=@0``#650``&0````````````````"%%P(`>&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0!DGX\.8QT``(BF```9````
M`````````````)0H`@!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`
M%``&``@````A`#]]"%U.!@``T1D``!D`````````````````+D8"`'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q02P$"+0`4``8`"````"$`IM!18#$/```.
M3@``&0````````````````"S3`(`>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;%!+`0(M`!0`!@`(````(0"Y^^0$RP8``.X>```9`````````````````!M<
M`@!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!`BT`%``&``@````A`(8Z
M)BA5"```?B,``!D`````````````````'6,"`'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"+0`4``8`"````"$`'*`"B[\(```^*```&0``````````
M``````"I:P(`>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(
M````(0!LJQRYD0<``+P?```9`````````````````)]T`@!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`-HKC_^M#P``+U$``!D`
M````````````````9WP"`'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M+0`4``8`"````"$`^.FZLQD'```?(0``&0````````````````!+C`(`>&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0"!1`L'$P<`
M`&H<```9`````````````````)N3`@!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L!`BT`%``&``@````A`,6$2@QL!P``9B```!D`````````````````
MY9H"`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`
M4OW2?X$+``"%-@``&0````````````````"(H@(`>&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+`0(M`!0`!@`(````(0!%->".J04``/X5```9````````
M`````````$"N`@!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!`BT`%``&
M``@````A`&11S\>6````J@```!``````````````````(+0"`'AL+V-A;&-#
M:&%I;BYX;6Q02P$"+0`4``8`"````"$`(!\"W_D#``!U#P``$```````````
M``````#DM`(`9&]C4')O<',O87!P+GAM;%!+`0(M`!0`!@`(````(0!PK8MU
M,@$``$`"```1`````````````````!.Z`@!D;V-0<F]P<R]C;W)E+GAM;%!+
4!08`````3`!,`+T4``!\O`(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) (USD $)<br>In Millions, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">$ 51.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over a weighted-average period</a></td>
        <td class="text">2 years 1 month 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 6.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);"> 4.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);"> 3.92</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">25.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4.5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Estimated fair value of options vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 15.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);"> 14.1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);"> 15.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments for Operating Leases (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 4,750</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">4,892</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">5,037</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">5,187</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" onclick="toggleNextSibling(this);">5,344</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2020</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" onclick="toggleNextSibling(this);">452</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 25,662</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock', window );">Loss Before (Benefit) Provision for Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Loss before
 (benefit) provision for income taxes includes the following
 components (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Domestic</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(56,414</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(161,068</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(174,258</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,986</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,300</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,809</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Loss before (benefit)
 provision for income taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(54,428</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(159,768</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(171,449</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">(Benefit) Provision for Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The (benefit) provision for income taxes consists of the following
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Current:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(137</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(482</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Current</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(481</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred:</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">422</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(422</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(49</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(65</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Deferred</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(487</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 (Benefit) provision for income taxes</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,245</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Provision Related to Continuing Operations</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Income tax
 provision related to continuing operations differs from the amount
 computed by applying the statutory income tax rate of 35% to pretax
 loss as follows (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. federal provision
 (benefit)</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">At statutory
 rate</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19,050</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(55,919</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(60,007</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(48</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Change in valuation
 allowance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,831</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">55,042</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">47,349</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash interest expense
 on liability related to sale of future royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,311</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,808</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,320</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,832</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">271</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">236</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign tax
 inclusion</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,510</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign tax
 differential</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(17</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(20</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(227</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research credits</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,933</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,273</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(591</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(487</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,286</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">864</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Benefit) provision for
 income taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(512</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">406</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets and Liabilities</a></td>
        <td class="text"><div>
 <font size="2">Significant components of our deferred tax assets
 for federal and state income taxes are as follows (in
 thousands):</font>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax
 assets:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net operating loss
 carryforwards</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">423,776</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">391,385</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and other
 credits</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">66,666</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61,707</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">29,758</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,588</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,948</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,962</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Sale of future
 royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,153</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,057</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capitalized research
 expenses</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,795</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,687</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reserves and
 accruals</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,288</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,685</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property, plant and
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,264</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,580</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,218</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,539</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets before
 valuation allowance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595,866</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">586,190</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Valuation allowance for
 deferred tax assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(595,690</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(586,040</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax
 assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">176</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">150</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax
 liabilities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net deferred tax
 assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">176</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">150</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have the
 following activity relating to unrecognized tax benefits (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Beginning
 balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,363</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,067</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,576</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax positions related to
 current year</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">502</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">477</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">289</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,141</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">381</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">302</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax positions related to
 prior year</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">636</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,258</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">802</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions &#x2014;
 foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(742</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Settlements</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Lapses in statute of
 limitations</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(137</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Ending balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,522</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,363</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,067</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income loss before provision for income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_IncomeLossBeforeProvisionForIncomeTaxesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail) (Stock Options [Member], USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">20,655</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Shares, Options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">7,713</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Options exercised</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(4,852)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Options forfeited and canceled</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(1,521)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">21,995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Vested and Expected to Vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">21,338</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">13,007</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 9.06</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 13.96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Options exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 9.43</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Options forfeited and Canceled</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 11.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 10.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 10.41</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 8.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life, Outstanding</a></td>
        <td class="text">4 years 11 months 16 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, Vested and expected to Vest</a></td>
        <td class="text">4 years 10 months 21 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, Exercisable</a></td>
        <td class="text">3 years 5 months 19 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 112,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to Vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">111,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump"><a title="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 85,839</a><span style="display:none;white-space:normal;text-align:left;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercisable Intrinsic Value</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisableIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Estimated Fair Value at</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,365</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,067</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Short-term investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">225,459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">197,959</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash and investments in marketable securities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our portfolio
 of cash and investments in marketable securities includes (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="56%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;
 Value</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Hierarchy</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Level</b></font></td>
 <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Estimated Fair Value
 at</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Corporate notes and
 bonds</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">182,544</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">138,515</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Corporate commercial
 paper</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42,915</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59,444</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Available-for-sale
 investments</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">225,459</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">197,959</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market
 funds</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,229</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,453</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash, including restricted
 cash</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">N/A</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,136</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37,614</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total cash and investments
 in marketable securities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,824</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,026</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDGDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 28, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated</span><span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">$ 117,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RestrictedStockUnitsOutstanding', window );">Restricted Stock Units outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_RestrictedStockUnitsOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_RestrictedStockUnitsOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">300,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">300,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage', window );">Maximum 401(k) per employee, percentage of annual salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage" onclick="toggleNextSibling(this);">60.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense in connection with 401(k) retirement plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SeverancePaymentPeriodForExecutives', window );">Severance payment period for executives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SeverancePaymentPeriodForEmployees', window );">Severance payment period for employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashSeverancePaymentForToChiefExecutiveOfficer', window );">Cash severance payment for chief executive officer</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months base  salary plus annual target incentive pay<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember', window );">2012 Performance Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional new shares available for award grants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized[us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember]" onclick="toggleNextSibling(this);">5,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized<br>/ us-gaap_AwardTypeAxis<br>= nktr_TwoThousandTwelveEquityIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare', window );">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare[us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember]" onclick="toggleNextSibling(this);">1.5</a><span style="display:none;white-space:normal;text-align:left;">nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare<br>/ us-gaap_AwardTypeAxis<br>= nktr_TwoThousandTwelveEquityIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears', window );">Maximum term of stock options under equity incentive plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember', window );">2012 Performance Incentive Plan [Member] | Employee [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember', window );">2012 Performance Incentive Plan [Member] | Director [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_TwoThousandNonOfficerEquityIncentivePlanMember', window );">2000 Non-Officer Equity Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears', window );">Maximum term of stock options under equity incentive plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPurchasePriceOfStock', window );">Percentage of purchase price of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PercentageOfPurchasePriceOfStock[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPurchasePriceOfStock<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution', window );">Matching 401(k) employer contribution, maximum amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">3,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | 2012 Performance Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for stock options grants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">10,347,140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_AwardTypeAxis<br>= nktr_TwoThousandTwelveEquityIncentivePlanMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">3,100,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,775,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,775,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Legal, accounting fees, filing fees and other offering expenses</a></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UnderwritersCommissionsAndDiscount', window );">Underwriting commission and discounts</a></td>
        <td class="nump"><a title="nktr_UnderwritersCommissionsAndDiscount[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 7,500,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UnderwritersCommissionsAndDiscount<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance in equity compensation plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">24,806,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashSeverancePaymentForToChiefExecutiveOfficer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Severance Payment For To Chief Executive Officer</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashSeverancePaymentForToChiefExecutiveOfficer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum contribution per employee annual salary percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_MaximumContributionPerEmployeeAnnualSalaryPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfPurchasePriceOfStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of purchase price of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfPurchasePriceOfStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock, shares designated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RestrictedStockUnitsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Stock Units Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RestrictedStockUnitsOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SeverancePaymentPeriodForEmployees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Severance payment period for employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SeverancePaymentPeriodForEmployees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SeverancePaymentPeriodForExecutives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Severance payment period for executives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SeverancePaymentPeriodForExecutives</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award award exercise period maximum years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodMaximumYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Maximum Years</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximumYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation plan's share limit for every one share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UnderwritersCommissionsAndDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriters Commissions And Discount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_UnderwritersCommissionsAndDiscount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of payment into the fund established for purposes of making future disbursements to the individual in accordance with the terms and understanding of the deferred compensation arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the cost recognized during the period for defined contribution plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_TwoThousandNonOfficerEquityIncentivePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_TwoThousandNonOfficerEquityIncentivePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_TwoThousandTwelveEquityIncentivePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 11.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 13.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 13.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation related to purchase of equipment</a></td>
        <td class="nump"><a title="us-gaap_PurchaseObligation" onclick="toggleNextSibling(this);">7.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PurchaseObligation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EquipmentPurchaseObligationPayableTerm', window );">Obligation related to purchase of equipment liability payable term</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss', window );">Impairment charge</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember]" onclick="toggleNextSibling(this);">$ 1.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LandAndBuildingMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EquipmentPurchaseObligationPayableTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equipment Purchase Obligation Payable Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_EquipmentPurchaseObligationPayableTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss recognized as a result of the initial and subsequent write-down of a long-lived asset's carrying amount to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 11, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 12,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 39,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 25,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 15,312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">225,459</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">197,959</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">$ 262,824</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">$ 262,026</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EA5AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">$ 153,289</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">$ 80,872</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">$ 30,127</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember]" onclick="toggleNextSibling(this);">105,001</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember]" onclick="toggleNextSibling(this);">25,016</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember]" onclick="toggleNextSibling(this);">59</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS and MIRCERA [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember]" onclick="toggleNextSibling(this);">12,845</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PegasysAndMirceraMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember]" onclick="toggleNextSibling(this);">18,382</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PegasysAndMirceraMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember]" onclick="toggleNextSibling(this);">7,146</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PegasysAndMirceraMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxterHealthcareMember', window );">Baxter Healthcare [Member] | BAX 855 (Hemophilia) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">10,258</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">1,702</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">6,238</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. [Member] | Neulasta [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AmgenIncMember;us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AmgenIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_NeulastaMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AmgenIncMember;us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember]" onclick="toggleNextSibling(this);">5,035</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AmgenIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_NeulastaMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AmgenIncMember;us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AmgenIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_NeulastaMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | BAY41-6551 (Amikacin Inhale) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember;us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember]" onclick="toggleNextSibling(this);">4,717</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember;us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember]" onclick="toggleNextSibling(this);">15,293</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember;us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember]" onclick="toggleNextSibling(this);">2,971</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AffymaxIncMember', window );">Affymax, Inc. [Member] | OMONTYS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AffymaxIncMember;us-gaap_TypeOfArrangementAxis=nktr_OmontysMember]" onclick="toggleNextSibling(this);">7,149</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AffymaxIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_OmontysMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_AffymaxIncMember;us-gaap_TypeOfArrangementAxis=nktr_OmontysMember]" onclick="toggleNextSibling(this);">2,829</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AffymaxIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_OmontysMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_OtherPartnerMember]" onclick="toggleNextSibling(this);">$ 15,468</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_OtherPartnerMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_OtherPartnerMember]" onclick="toggleNextSibling(this);">$ 8,295</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_OtherPartnerMember</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue[dei_LegalEntityAxis=nktr_OtherPartnerMember]" onclick="toggleNextSibling(this);">$ 5,884</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue<br>/ dei_LegalEntityAxis<br>= nktr_OtherPartnerMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AffymaxIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AffymaxIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxterHealthcareMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxterHealthcareMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_RocheMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_RocheMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Income Tax Provision Related to Continuing Operations (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>U.S. federal provision (benefit)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">At statutory rate</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (19,050)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (55,919)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (60,007)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(48)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">11,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">55,042</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">47,349</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" onclick="toggleNextSibling(this);">7,311</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" onclick="toggleNextSibling(this);">7,808</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" onclick="toggleNextSibling(this);">6,320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">2,832</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">271</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">236</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign', window );">Foreign tax inclusion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" onclick="toggleNextSibling(this);">6,510</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxSettlementsForeign</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax differential</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" onclick="toggleNextSibling(this);">(17)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" onclick="toggleNextSibling(this);">(20)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" onclick="toggleNextSibling(this);">(227)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(2,933)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(6,273)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(591)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">(487)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherAdjustments</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">1,286</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherAdjustments</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">864</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (512)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 2,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlementsForeign</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYBBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyAgreementContingentPaymentDescription', window );">Royalty agreement contingent payment description</a></td>
        <td class="text">As a  result of worldwide net sales of MIRCERA for the 12 month periods ended on  December 31, 2013 and 2012 not reaching certain minimum thresholds.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOnRoyaltyLiability', window );">Annual interest rate</a></td>
        <td class="nump"><a title="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" onclick="toggleNextSibling(this);">17.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_EstimatedAnnualInterestRateOnRoyaltyLiability</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember', window );">Milestone Scenario One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne', window );">Payment made for milestone not achieved year one</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PaymentMadeForMilestoneNotAchievedYearOne[us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember]" onclick="toggleNextSibling(this);">$ 3.0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PaymentMadeForMilestoneNotAchievedYearOne<br>/ us-gaap_ContingentConsiderationByTypeAxis<br>= nktr_MilestoneScenarioOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember', window );">Milestone Scenario Two [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo', window );">Payment made for milestone not achieved year two</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PaymentMadeForMilestoneNotAchievedYearTwo[us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember]" onclick="toggleNextSibling(this);">7.0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo<br>/ us-gaap_ContingentConsiderationByTypeAxis<br>= nktr_MilestoneScenarioTwoMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross[us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember]" onclick="toggleNextSibling(this);">124.0</a><span style="display:none;white-space:normal;text-align:left;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PurchaseAndSaleAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties[us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember]" onclick="toggleNextSibling(this);">4.4</a><span style="display:none;white-space:normal;text-align:left;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PurchaseAndSaleAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember', window );">CIMZIA and MIRCERA [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera', window );">Non-cash royalties from net sales</a></td>
        <td class="nump"><a title="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera[us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember]" onclick="toggleNextSibling(this);"> 21.9</a><span style="display:none;white-space:normal;text-align:left;">nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_CimziaAndMirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera[us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember]" onclick="toggleNextSibling(this);">$ 22.1</a><span style="display:none;white-space:normal;text-align:left;">nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_CimziaAndMirceraMember</span><span></span></td>
        <td class="nump"><a title="nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera[us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember]" onclick="toggleNextSibling(this);">$ 10.8</a><span style="display:none;white-space:normal;text-align:left;">nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_CimziaAndMirceraMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOnRoyaltyLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated Annual Interest Rate On Royalty Liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOnRoyaltyLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment Made For Milestone Not Achieved Year One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment Made For Milestone Not Achieved Year Two</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from sale of potential future royalties gross.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyAgreementContingentPaymentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty agreement contingent payment description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RoyaltyAgreementContingentPaymentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty Revenue And Non-cash Royalty Revenue From Cimzia And Mircera</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RoyaltyRevenueAndNoncashRoyaltyRevenueFromCimziaAndMircera</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transaction costs related to sale of potential future royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_CimziaAndMirceraMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentForTransactionCosts', window );">Future royalties transaction costs</a></td>
        <td class="nump"><a title="nktr_PaymentForTransactionCosts" onclick="toggleNextSibling(this);">$ 4.4</a><span style="display:none;white-space:normal;text-align:left;">nktr_PaymentForTransactionCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Senior secured notes issuance costs</a></td>
        <td class="nump"><a title="us-gaap_PaymentsOfDebtIssuanceCosts" onclick="toggleNextSibling(this);">$ 4.5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfDebtIssuanceCosts</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentForTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment For Transaction Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PaymentForTransactionCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 423,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 391,385</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credits</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">66,666</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">61,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">29,758</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">35,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">21,948</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">25,962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties', window );">Sale of future royalties</a></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">20,153</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">28,057</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsCapitalizedResearchExpenses', window );">Capitalized research expenses</a></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" onclick="toggleNextSibling(this);">14,795</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsCapitalizedResearchExpenses</span><span></span></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsCapitalizedResearchExpenses" onclick="toggleNextSibling(this);">17,687</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsCapitalizedResearchExpenses</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" onclick="toggleNextSibling(this);">8,288</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" onclick="toggleNextSibling(this);">14,685</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment', window );">Property, plant and equipment</a></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" onclick="toggleNextSibling(this);">8,264</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment</span><span></span></td>
        <td class="nump"><a title="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" onclick="toggleNextSibling(this);">8,580</a><span style="display:none;white-space:normal;text-align:left;">nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">2,218</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">2,539</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">595,866</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">586,190</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(595,690)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(586,040)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNet" onclick="toggleNextSibling(this);">176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNet" onclick="toggleNextSibling(this);">150</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 150</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsCapitalizedResearchExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred tax assets, capitalized research expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DeferredTaxAssetsCapitalizedResearchExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred tax assets depreciation property and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Assets From Sale Of Future Royalties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DeferredTaxAssetsFromSaleOfFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences net of deferred tax asset attributable to deductible temporary differences and carryforwards after valuation allowances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>34
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V]M/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?4W1O/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O
M;&ED871E9%]3=&%T96UE;G1S7V]F7T-A<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F
M7T-A<S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/
M<F=A;FEZ871I;VY?86YD7U-U;6UA<GE?;V9?4VD\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#87-H7V%N9%]);G9E<W1M96YT<U]I
M;E]-87)K970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y);G9E;G1O<GD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y0<F]P97)T>5]0;&%N=%]A;F1?17%U:7!M96YT/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5N:6]R7U-E8W5R961?3F]T
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,96%S
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,:6%B
M:6QI='E?4F5L871E9%]T;U]386QE7V]F7T8\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N
M8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T
M;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y,:6-E;G-E7V%N9%]#;VQL86)O<F%T:6]N7T%G<F4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D
M7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-E9VUE;G1?4F5P;W)T:6YG/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5L96-T961?475A<G1E<FQY7T9I
M;F%N8VEA;%]$/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^3W)G86YI>F%T:6]N7V%N9%]3=6UM87)Y7V]F7U-I,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-A<VA?86YD7TEN=F5S=&UE
M;G1S7VEN7TUA<FME=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);G9E;G1O<GE?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?4&QA;G1?86YD7T5Q=6EP;65N
M=%]4/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&5A
M<V5S7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DQI86)I;&ET>5]296QA=&5D7W1O7U-A;&5?;V9?1C$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U
M:71Y7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DQI8V5N<V5?86YD7T-O;&QA8F]R871I;VY?06=R93$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;E]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4V5G;65N=%]297!O<G1I;F=?5&%B;&5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5L96-T
M961?475A<G1E<FQY7T9I;F%N8VEA;%]$,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?4W5M;6%R>5]O
M9E]3:3(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M87-H7V%N9%]);G9E<W1M96YT<U]I;E]-87)K970R/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,W
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S:%]A;F1?26YV97-T;65N='-?
M:6Y?36%R:V5T,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D-A<VA?86YD7TEN=F5S=&UE;G1S7VEN7TUA<FME=#0\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,SDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E;G1O<GE?26YV96YT
M;W)Y7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!R;W!E<G1Y7U!L86YT7V%N9%]%<75I<&UE;G1?4#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7U!L86YT7V%N
M9%]%<75I<&UE;G1?03PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-E;FEO<E]396-U<F5D7TYO=&5S7T%D9&ET:6]N83PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E<U]!9&1I=&EO
M;F%L7TEN9F]R;6%T:6]N7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DQE87-E<U]&=71U<F5?36EN:6UU;5]087EM96YT<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970T-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E<U]&=71U
M<F5?36EN:6UU;5],96%S95]083PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DQI86)I;&ET>5]296QA=&5D7W1O7U-A;&5?;V9?1C(\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,:6%B:6QI
M='E?4F5L871E9%]T;U]386QE7V]F7T8S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I
M97-?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O
M8VMH;VQD97)S7T5Q=6ET>5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]3=6UM
M87)I>F%T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#4Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3&EC96YS95]A;F1?0V]L;&%B;W)A=&EO;E]!9W)E,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQI8V5N<V5?86YD7T-O;&QA8F]R
M871I;VY?06=R93,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-3,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]3=&]C:T(\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;E]!9&1I=&D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]";&%C:U,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O
M;7!E;G-A=&EO;E]3=&]C:U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3<N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y);F-O;65?5&%X97-?3&]S<U]"969O<F5?0F5N968\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X
M97-?0F5N969I=%]0<F]V:7-I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3DN:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?061D:71I;VYA;%]);F9O<FT\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?
M5&%X97-?26YC;VUE7U1A>%]0<F]V:7,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?4VEG;FEF:6-A;G1?0V]M
M<&\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O
M;65?5&%X97-?56YR96-O9VYI>F5D7U1A>%\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C,N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y396=M96YT7U)E<&]R=&EN9U]!9&1I=&EO
M;F%L7TD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M96=M96YT7U)E<&]R=&EN9U]2979E;G5E7V)Y7T<\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C4N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y396QE8W1E9%]1=6%R=&5R;'E?1FEN
M86YC:6%L7T0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#8V+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y
M;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\
M>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T
M4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R
M;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%
M>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@
M(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET
M:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T
M9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7
M;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5554%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I
M;VX@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N
M(#(P+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1&]C=6UE;G0@06YD($5N=&ET>2!);F9O<FUA=&EO;B!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$P+4L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)"3(P
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y&63QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A
M9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DY+
M5%(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DY%2U1!4B!42$5205!%551)0U,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,#`P,#DP-C<P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E
M;&PM:VYO=VX@4V5A<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DQA<F=E($%C8V5L97)A=&5D($9I;&5R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,2PS.#$L-C$R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B
M;&EC($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M-C(U+#DT,RPW.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D
M,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%43-!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI
M9&%T960@0F%L86YC92!3:&5E=',@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@
M87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$R+#,V-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SDL,#8W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D
M(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(U+#0U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Y-RPY-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4L
M(&YE="!O9B!A;&QO=V%N8V4@;V8@;FEL(&%T($1E8V5M8F5R(#,Q+"`R,#$T
M(&%N9"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8P
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#DU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.#$W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C
M=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@X+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U-RPX.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@<&QA;G0@86YD
M(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,"PS-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV-BPY-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW-BPU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW-BPU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU-3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$W,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0Q+#8R,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S
M-"PU,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW,#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$Q
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C<G5E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L-S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30L,C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C0S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&-L:6YI8V%L('1R:6%L(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#<P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V+#DP-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DQ-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A
M;"!L96%S92!O8FQI9V%T:6]N<RP@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3,V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E+"!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T+#0W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(S+#8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71Y(')E;&%T960@=&\@
M=&AE('-A;&4@;V8@9G5T=7)E(')O>6%L=&EE<RP@8W5R<F5N="!P;W)T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PU-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PP-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY."PR,C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E;FEO<B!S96-U<F5D(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!L96%S92!O8FQI9V%T
M:6]N<RP@;&5S<R!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PP-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!R96QA=&5D('1O
M(')E8V5I<'0@;V8@<F5F=6YD86)L92!M:6QE<W1O;F4@<&%Y;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI='D@
M<F5L871E9"!T;R!T:&4@<V%L92!O9B!F=71U<F4@<F]Y86QT:65S+"!L97-S
M(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(P+#0W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R,2PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64L(&QE<W,@8W5R
M<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M-BPY,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,BPS.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R(&QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L-S(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,C4V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0P-2PR.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,C0L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y("AD
M969I8VET*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP,#`Q('!A<B!V86QU93L@,3`L
M,#`P('-H87)E<R!A=71H;W)I>F5D+"!N;R!S:&%R97,@9&5S:6=N871E9"P@
M:7-S=65D(&]R(&]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N
M9"`R,#$S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"`D,"XP,#`Q('!A<B!V86QU93L@,S`P+#`P,"!A=71H;W)I>F5D.R`Q,S$L
M,C$V('-H87)E<R!A;F0@,3$V+#0Y-"!S:&%R97,@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C
M=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87!I=&%L(&EN(&5X8V5S<R!O9B!P87(@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.#(T+#$Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0S+#8V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T
M960@;W1H97(@8V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#4V-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$X,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC
M:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S@V+#,P.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#<S,BPS.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC
M:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPS,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.2PY
M,#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U
M:71Y("AD969I8VET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T-#$L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T,S0L-3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P155#044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H
M55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE
M;G0@;V8@1FEN86YC:6%L(%!O<VET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A;F-E(&9O
M<B!A8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&1E<VEG;F%T960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R
M960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S$L,C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$V+#0Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,2PR
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,38L-#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,V(Q-F5F.&)?8S@Q,E\T9#(W
M7SED-F5?9C!E,&9E-#$Q9#4X+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15E004<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A
M=&5D(%-T871E;65N=',@;V8@3W!E<F%T:6]N<R`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY2979E;G5E.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]D=6-T('-A;&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U+#$U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#0L.#0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-2PS
M.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)O>6%L='D@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#@W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@<F]Y86QT>2!R979E;G5E
M(')E;&%T960@=&\@<V%L92!O9B!F=71U<F4@<F]Y86QT:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PY,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPP-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PW.3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI
M8V5N<V4L(&-O;&QA8F]R871I;VX@86YD(&]T:&5R(')E=F5N=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,RPR.#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PX-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PQ,C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,#`L-S`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30X+#DR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@Q+#$Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@8V]S
M=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;W-T(&]F(&=O;V1S('-O;&0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(X+#4S,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#4P.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#0R.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#<L-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DP+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T."PV-S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN
M:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PY
M,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,"PU,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,2PV,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G0@;V8@;&]N9RUL:79E9"!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;W!E<F%T:6YG(&-O<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$W+#$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V.2PP-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C(L,SDR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$V+#0X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,C`L,3,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$T,2PR,#$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;BUO<&5R
M871I;F<@:6YC;VUE("AE>'!E;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#8Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X+#0U,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PT.#DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.;VXM8V%S:"!I;G1E<F5S="!E>'!E;G-E(&]N(&QI86)I;&ET>2!R96QA
M=&5D('1O('-A;&4@;V8@9G5T=7)E(')O>6%L=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C`L.#@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R+#,P.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PP-3<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E
M<F5S="!A;F0@;W1H97(@:6YC;VUE("AE>'!E;G-E*2P@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$R-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,CDX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M;F]N+6]P97)A=&EN9R!E>'!E;G-E+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,W+#DT,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S.2PV,S@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S`L,C0X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@8F5F
M;W)E("AB96YE9FET*2!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-30L-#(X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U.2PW-C@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<Q
M+#0T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/BA"96YE9FET*2!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3$R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,C0U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-3,L
M.3$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,38R+#`Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$W,2PX-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N
M970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XT,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$N-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$N-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<VAA
M<F5S(&]U='-T86YD:6YG('5S960@:6X@8V]M<'5T:6YG(&)A<VEC(&%N9"!D
M:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(V+#@W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q-2PW,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L.#(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E$044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V]M
M<')E:&5N<VEV92!,;W-S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G0@;V8@0V]M<')E
M:&5N<VEV92!);F-O;64@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@U,RPY,38I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-C(L,#$S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<Q+#@U
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@=6YR96%L:7IE9"`H;&]S<RD@9V%I;B!O;B!A=F%I;&%B;&4M9F]R+7-A
M;&4@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YC;VUE('1A>"!P<F]V:7-I;VX@*&)E;F5F:70I
M(&]N('5N<F5A;&EZ960@9V%I;B!O;B!A=F%I;&%B;&4M9F]R+7-A;&4@:6YV
M97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!F;W)E:6=N(&-U<G)E;F-Y('1R86YS;&%T:6]N("AL;W-S*2!G
M86EN/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP,C8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDL(&YE="!O
M9B!T87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,C0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#4T+#,P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#$V,BPX,S<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-S$L,3`Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?
M8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q
M,60U."]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S64%)/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S
M(&]F(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$969I8VET*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<SPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E1O=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D-O;6UO;B!3:&%R97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^0V%P:71A;"!I;B!%>&-E<W,@;V8@4&%R(%9A;'5E(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M
M=6QA=&5D($]T:&5R($-O;7!R96AE;G-I=F4@26YC;VUE+RA,;W-S*2!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!8V-U;75L
M871E9"!$969I8VET(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92!A="!$96,N(#,Q+"`R
M,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y-RPX,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+#4Y-RPT,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$L,3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PS.3@L-3(U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG
M($)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L-#@U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D('5N
M9&5R(&5Q=6ET>2!C;VUP96YS871I;VX@<&QA;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L,3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@=6YD
M97(@97%U:71Y(&-O;7!E;G-A=&EO;B!P;&%N<RP@4VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,3DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92\H;&]S<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,2PX-34I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<Q+#@U
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#`Q.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,3<L-S0T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-3<P+#,X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@
M,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U+#(U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F5S(&ES<W5E9"!U;F1E<B!E<75I='D@8V]M<&5N<V%T:6]N('!L86YS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(P.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R97,@:7-S=65D('5N9&5R(&5Q=6ET>2!C;VUP96YS871I;VX@<&QA;G,L
M(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<L-S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L-S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C;VUP<F5H96YS:79E
M(&EN8V]M92\H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@X,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,38R+#`Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-C(L,#$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@1&5C
M+B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#DL
M.3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PV-#,L-C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PQ.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW,S(L,SDS*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N
M8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,38L-#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(&-O;6UO;B!S=&]C:RP@
M;F5T(&]F(&ES<W5A;F-E(&-O<W1S(&]F("0V,3<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q-BPU,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V+#4S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM
M;VX@<W1O8VLL(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PW-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@=6YD97(@97%U:71Y(&-O;7!E;G-A
M=&EO;B!P;&%N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L
M.3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0V+#DX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!U;F1E<B!E<75I='D@8V]M<&5N
M<V%T:6]N('!L86YS+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L.30W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`Q-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M8V]M<')E:&5N<VEV92!I;F-O;64O*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4S+#DQ-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,RPY,38I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L
M86YC92!A="!$96,N(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,V+#,S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.#(T+#$Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PU-C<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#<X
M-BPS,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P
M,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,2PR,38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB
M7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T
M,3%D-3@O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T4^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@
M;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*$1E9FEC:70I("A087)E;G1H971I
M8V%L*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=&%T96UE;G0@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F
M930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X
M8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E
M=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%1T1!23X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4S+#DQ-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$V,BPP,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q-S$L.#4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R
M96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I
M;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]N+6-A<V@@<F]Y86QT>2!R979E;G5E(')E;&%T960@
M=&\@<V%L92!O9B!F=71U<F4@<F]Y86QT:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R,2PY,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L,#4U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#<Y,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H
M(&EN=&5R97-T(&5X<&5N<V4@;VX@;&EA8FEL:71Y(')E;&%T960@=&\@<V%L
M92!O9B!F=71U<F4@<F]Y86QT:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PX.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,BPS,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ."PP-3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,#$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3<L-S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L.3(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,C<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L
M-3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!N;VXM8V%S:"!T<F%N<V%C=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4V,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4R,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N
M9V5S(&EN(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B
M;&4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-S@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPU-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@X-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L.#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-2PV,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,CDT*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-#(S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP,S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L
M,S4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!C;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-3`U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#@Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP,S0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R
M=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#DQ-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!C;&EN:6-A;"!T<FEA;"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PQ.3<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3DU*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-30W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1E<F5S="!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PR-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-C8T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#,Y.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#,X-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI
M86)I;&ET>2!R96QA=&5D('1O(')E8V5I<'0@;V8@<F5F=6YD86)L92!M:6QE
M<W1O;F4@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-S`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W1H97(@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$S+#@P,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$V-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,30R+#`P-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."PU,C<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(Y+#<U-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U
M<FET:65S(&]F(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-#<L.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$Y+#$X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-RPX.#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E<R!O9B!I
M;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDW
M+#(U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-C@L,#8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$V-"PV-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!O9B!I;G9E<W1M96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L-C8Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX.#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,W
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<')O<&5R='DL('!L86YT(&%N
M9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL
M.3<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0L,#DQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$P+#4X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"`H=7-E9"!I;BD@<')O=FED
M960@8GD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,W+#4W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT.2PY,#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3,L,#(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A
M<V@@9FQO=W,@9G)O;2!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O9B!C
M87!I=&%L(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S+#4S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#DY,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#0S-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O
M;6UO;B!S=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L-3,V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XH4F5P87EM96YT(&]F*2!P
M<F]C965D<R!F<F]M('-A;&4@;V8@9G5T=7)E(')O>6%L=&EE<RP@;F5T(&]F
M("0T+C0@;6EL;&EO;B!O9B!T<F%N<V%C=&EO;B!C;W-T<R!I;B`R,#$R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3DL
M-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F('-E;FEO<B!S96-U<F5D
M(&YO=&5S+"!N970@;V8@)#0N-2!M:6QL:6]N(&]F(&ES<W5A;F-E(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RPY-#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y
M;65N="!O9B!C;VYV97)T:6)L92!S=6)O<F1I;F%T960@;F]T97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,BPT,#<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M('-H87)E<R!I<W-U960@=6YD97(@97%U:71Y(&-O;7!E;G-A=&EO;B!P
M;&%N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L.3@T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#$Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3(L.3@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPR,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-BPX,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5F9F5C="!O9B!E>&-H86YG92!R871E<R!O;B!C87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="`H9&5C<F5A<V4I(&EN8W)E87-E(&EN
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(V+#<P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',@870@8F5G:6YN:6YG(&]F('EE87(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#`V-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#0S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#,Q,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@;V8@>65A<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,S8U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL,#8W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-#,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&-A<V@@9FQO=R!I
M;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L-#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-3DP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PV,C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I
M9"!F;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!S8VAE
M9'5L92!O9B!N;VXM8V%S:"!I;G9E<W1I;F<@86YD(&9I;F%N8VEN9R!A8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&%C<75I<F5D('1H<F]U9V@@
M8V%P:71A;"!L96%S97,@86YD(&]T:&5R(&9I;F%N8VEN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T:7)E;65N="!O
M9B!C;VYV97)T:6)L92!S=6)O<F1I;F%T960@;F]T97,@:6X@97AC:&%N9V4@
M9F]R('-E;FEO<B!S96-U<F5D(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0R+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E
M-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB
M7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T
M,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5&1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A087)E;G1H
M971I8V%L*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-T871E;65N="!O9B!#87-H($9L;W=S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1G5T=7)E(')O>6%L=&EE<R!T<F%N<V%C=&EO;B!C;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;FEO<B!S96-U<F5D(&YO
M=&5S(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R
M-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I
M;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI
M8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T
M:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q
M,G!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CY.;W1E)B-X03`[,28C>$$P.R8C>#(P,30[#0H@
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M/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^5V4@87)E(&$-"B!B:6]P:&%R;6%C975T:6-A;"!C;VUP86YY(&AE
M861Q=6%R=&5R960@:6X@4V%N($9R86YC:7-C;RP-"B!#86QI9F]R;FEA(&%N
M9"!I;F-O<G!O<F%T960@:6X@1&5L87=A<F4N(%=E(&%R92!D979E;&]P:6YG
M(&$-"B!P:7!E;&EN92!O9B!D<G5G(&-A;F1I9&%T97,@=&AA="!U=&EL:7IE
M(&]U<B!014=Y;&%T:6]N(&%N9`T*(&%D=F%N8V5D('!O;'EM97(@8V]N:G5G
M871E('1E8VAN;VQO9WD@<&QA=&9O<FUS('=I=&@@=&AE(&]B:F5C=&EV90T*
M('1O(&EM<')O=F4@=&AE(&)E;F5F:71S(&]F(&1R=6=S(&9O<B!P871I96YT
M<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N
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M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+`T*('=E(&AA9"!A<'!R;WAI;6%T96QY
M("0R-C(N."!M:6QL:6]N(&EN(&-A<V@@86YD(&EN=F5S=&UE;G1S(&EN#0H@
M;6%R:V5T86)L92!S96-U<FET:65S+"!O9B!W:&EC:"`D,C4N,"!M:6QL:6]N
M('=A<R!R97-T<FEC=&5D(&EN#0H@<F5L871I;VX@=&\@;W5R(#$R)2!S96YI
M;W(@<V5C=7)E9"!N;W1E<RP@86YD("0Q-3$N."!M:6QL:6]N(&EN#0H@:6YD
M96)T961N97-S+B!4:&4@:6YD96)T961N97-S(&EN8VQU9&5S("0Q,C4N,"!M
M:6QL:6]N(&EN(&%G9W)E9V%T90T*('!R:6YC:7!A;"!A;6]U;G0@;V8@,3(N
M,"4@<V5N:6]R('-E8W5R960@;F]T97,@9'5E($IU;'DF(WA!,#LQ-2P-"B`R
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M86YD#0H@3F5K=&%R(%1H97)A<&5U=&EC<R!52RP@3'1D+B`H3F5K=&%R(%5+
M*2X@06QL(&EN=&5R8V]M<&%N>2!A8V-O=6YT<PT*(&%N9"!T<F%N<V%C=&EO
M;G,@:&%V92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+V9O
M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2
M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL
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M(&EN('1H90T*('-T;V-K:&]L9&5R<R8C>#(P,3D[(&5Q=6ET>2`H9&5F:6-I
M="D@<V5C=&EO;B!O9B!T:&4@8F%L86YC92!S:&5E="X-"B!4;R!D871E+"!S
M=6-H(&-U;75L871I=F4@=')A;G-L871I;VX@861J=7-T;65N=',@:&%V92!N
M;W0@8F5E;@T*('-I9VYI9FEC86YT('1O(&]U<B!C;VYS;VQI9&%T960@9FEN
M86YC:6%L('!O<VET:6]N+B!!9V=R96=A=&4@9W)O<W,-"B!F;W)E:6=N(&-U
M<G)E;F-Y('1R86YS86-T:6]N(&=A:6YS("AL;W-S97,I(')E8V]R9&5D(&EN
M(&]P97)A=&EO;G,-"B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X
M03`[,S$L(#(P,30L(#(P,3,L(&%N9"`R,#$R('=E<F4@;F]T#0H@<VEG;FEF
M:6-A;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^5&AE('!R97!A<F%T:6]N#0H@;V8@8V]N<V]L:61A=&5D(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:"!5+E,N#0H@
M9V5N97)A;&QY(&%C8V5P=&5D(&%C8V]U;G1I;F<@<')I;F-I<&QE<R`H1T%!
M4"D@<F5Q=6ER97,@;6%N86=E;65N=`T*('1O(&UA:V4@97-T:6UA=&5S(&%N
M9"!A<W-U;7!T:6]N<R!T:&%T(&%F9F5C="!T:&4@<F5P;W)T960@86UO=6YT
M<PT*(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@86YD(&1I<V-L;W-U<F4@
M;V8@8V]N=&EN9V5N="!A<W-E=',@86YD#0H@;&EA8FEL:71I97,@870@=&AE
M(&1A=&4@;V8@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<PT*(&%N9"!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!R979E;G5E(&%N9"!E
M>'!E;G-E<R!D=7)I;F<@=&AE#0H@<F5P;W)T:6YG('!E<FEO9"X@06-C;W5N
M=&EN9R!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS(&%R90T*(&EN:&5R96YT
M;'D@=6YC97)T86EN+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F97(@;6%T
M97)I86QL>2!F<F]M#0H@=&AO<V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N
M<RX@3VX@86X@;VYG;VEN9R!B87-I<RP@=V4@979A;'5A=&4-"B!O=7(@97-T
M:6UA=&5S+"!I;F-L=61I;F<@=&AO<V4@<F5L871E9"!T;R!E<W1I;6%T960@
M<V5L;&EN9R!P<FEC97,-"B!O9B!D96QI=F5R86)L97,@:6X@8V]L;&%B;W)A
M=&EO;B!A9W)E96UE;G1S+"!E<W1I;6%T960@<&5R:6]D<R!O9@T*('!E<F9O
M<FUA;F-E+"!T:&4@;F5T(')E86QI>F%B;&4@=F%L=64@;V8@:6YV96YT;W)Y
M+"!T:&4@:6UP86ER;65N=`T*(&]F(&EN=F5S=&UE;G1S+"!T:&4@:6UP86ER
M;65N="!O9B!G;V]D=VEL;"!A;F0@;&]N9RUL:79E9"!A<W-E=',L#0H@8V]N
M=&EN9V5N8VEE<RP@86-C<G5E9"!C;&EN:6-A;"!T<FEA;"!E>'!E;G-E<RP@
M97-T:6UA=&5D(&EN=&5R97-T#0H@97AP96YS92!F<F]M(&]U<B!L:6%B:6QI
M='D@<F5L871E9"!T;R!O=7(@<V%L92!O9B!F=71U<F4@<F]Y86QT:65S+`T*
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M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU4
M3U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>"<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^
M4F5C;&%S<VEF:6-A=&EO;G,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M:71I97,@;W(@<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U:71Y("AD969I8VET
M*2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^0V%S:"P@0V%S
M:`T*($5Q=6EV86QE;G1S+"!A;F0@26YV97-T;65N=',L(&%N9"!&86ER(%9A
M;'5E(&]F($9I;F%N8VEA;`T*($EN<W1R=6UE;G1S/"]I/CPO8CX\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.
M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E=E(&-O
M;G-I9&5R(&%L;`T*(&EN=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@<V5C=7)I
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M9"!A<R!S:&]R="UT97)M(&EN=F5S=&UE;G1S+CPO9F]N=#X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X
M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=F5S=&UE;G1S(&%R
M90T*(&1E<VEG;F%T960@87,@879A:6QA8FQE+69O<BUS86QE(&%N9"!A<F4@
M8V%R<FEE9"!A="!F86ER('9A;'5E+`T*('=I=&@@=6YR96%L:7IE9"!G86EN
M<R!A;F0@;&]S<V5S(')E<&]R=&5D(&EN('-T;V-K:&]L9&5R<R8C>#(P,3D[
M#0H@97%U:71Y("AD969I8VET*2!A<R!A8V-U;75L871E9"!O=&AE<B!C;VUP
M<F5H96YS:79E(&EN8V]M92`H;&]S<RDN#0H@5&AE(&1I<V-L;W-E9"!F86ER
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M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY);G1E<F5S="!A;F0-"B!D:79I9&5N9',@;VX@<V5C
M=7)I=&EE<R!C;&%S<VEF:65D(&%S(&%V86EL86)L92UF;W(M<V%L92P@87,@
M=V5L;`T*(&%S(&%M;W)T:7IA=&EO;B!O9B!P<F5M:75M<R!A;F0@86-C<F5T
M:6]N(&]F(&1I<V-O=6YT<R!T;R!M871U<FET>2P-"B!A<F4@:6YC;'5D960@
M:6X@:6YT97)E<W0@:6YC;VUE+B!296%L:7IE9"!G86EN<R!A;F0@;&]S<V5S
M(&%N9`T*(&1E8VQI;F5S(&EN('9A;'5E(&]F(&%V86EL86)L92UF;W(M<V%L
M92!S96-U<FET:65S(&IU9&=E9"!T;R!B90T*(&]T:&5R+71H86XM=&5M<&]R
M87)Y+"!I9B!A;GDL(&%R92!I;F-L=61E9"!I;B!O=&AE<B!I;F-O;64-"B`H
M97AP96YS92DN(%1H92!C;W-T(&]F('-E8W5R:71I97,@<V]L9"!I<R!B87-E
M9"!O;B!T:&4@<W!E8VEF:6,-"B!I9&5N=&EF:6-A=&EO;B!M971H;V0N/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!
M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y
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M>7!E(&%N9"!I<W-U97(N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/CQI/D%C8V]U;G1S(%)E8V5I=F%B;&4-"B!A;F0@4VEG;FEF:6-A;G0@0W5S
M=&]M97(@0V]N8V5N=')A=&EO;G,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
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M=F%B;&5S(&9R;VT@<')O9'5C=`T*('-A;&5S(&%N9"!R;WEA;'1I97,L(&%S
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M=&]R:65S(&%N9`T*(&%S<V]C:6%T960@8W)E9&ET(')I<VLN(%=E(&AA=F4@
M;F]T(&5X<&5R:65N8V5D('-I9VYI9FEC86YT(&-R961I=`T*(&QO<W-E<R!F
M<F]M(&]U<B!A8V-O=6YT<R!R96-E:79A8FQE+B!!="!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$T+`T*('1H<F5E(&1I9F9E<F5N="!C=7-T;VUE<G,@<F5P<F5S
M96YT960@-#`E+"`S,24L(&%N9"`Q-24L#0H@<F5S<&5C=&EV96QY+"!O9B!O
M=7(@86-C;W5N=',@<F5C96EV86)L92X@070@1&5C96UB97(F(WA!,#LS,2P-
M"B`R,#$S+"!T:')E92!D:69F97)E;G0@8W5S=&]M97)S(')E<')E<V5N=&5D
M(#,P)2P@,C@E+"!A;F0@,C@E+`T*(')E<W!E8W1I=F5L>2P@;V8@;W5R(&%C
M8V]U;G1S(')E8V5I=F%B;&4N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/CQI/DEN=F5N=&]R>2!A;F0-"B!3:6=N:69I8V%N="!3=7!P;&EE<B!#
M;VYC96YT<F%T:6]N<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G9E;G1O<GD@:7,-"B!G96YE<F%L
M;'D@;6%N=69A8W1U<F5D('5P;VX@<F5C96EP="!O9B!F:7)M('!U<F-H87-E
M(&]R9&5R<R!F<F]M#0H@;W5R(&-O;&QA8F]R871I;VX@<&%R=&YE<G,N($EN
M=F5N=&]R>2!I;F-L=61E<R!D:7)E8W0@;6%T97)I86QS+`T*(&1I<F5C="!L
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M;VX@:&ES=&]R:6-A;"!E>'!E<FEE;F-E(&]R('!R;VIE8W1E9`T*('5S86=E
M+B!);G9E;G1O<GD@<F5L871E9"!T;R!O=7(@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%C=&EV:71I97,-"B!I<R!E>'!E;G-E9"!W:&5N('!U<F-H87-E
M9"X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS
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M;B!T:&4@979E;G0@=&AA=`T*('-U<'!L:65S(&%R92!D96QA>65D(&]R(&EN
M=&5R<G5P=&5D(&9O<B!A;GD@<F5A<V]N+"!O=7(@86)I;&ET>2!T;PT*(&1E
M=F5L;W`@86YD('!R;V1U8V4@;W5R(&1R=6<@8V%N9&ED871E<R!O<B!O=7(@
M86)I;&ET>2!T;R!M965T(&]U<@T*('-U<'!L>2!O8FQI9V%T:6]N<R!C;W5L
M9"!B92!S:6=N:69I8V%N=&QY(&EM<&%I<F5D+"!W:&EC:"!C;W5L9`T*(&AA
M=F4@82!M871E<FEA;"!A9'9E<G-E(&5F9F5C="!O;B!O=7(@8G5S:6YE<W,L
M(&9I;F%N8VEA;"!C;VYD:71I;VX-"B!A;F0@<F5S=6QT<R!O9B!O<&5R871I
M;VYS+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y,;VYG+4QI
M=F5D#0H@07-S971S/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.
M1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E!R;W!E<G1Y+"!P;&%N=`T*(&%N9"!E
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M('1O('-E=F5N('EE87)S+B!,96%S96AO;&0@:6UP<F]V96UE;G1S(&%N9`T*
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M+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY';V]D
M=VEL;`T*(')E<')E<V5N=',@=&AE(&5X8V5S<R!O9B!T:&4@<')I8V4@<&%I
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M;F<@86X-"B!/8W1O8F5R)B-X03`[,2!M96%S=7)E;65N="!D871E+CPO9F]N
M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E=E
M(&%S<V5S<R!T:&4-"B!I;7!A:7)M96YT(&]F(&QO;F<M;&EV960@87-S971S
M+"!P<FEM87)I;'D@<')O<&5R='DL('!L86YT(&%N9`T*(&5Q=6EP;65N="!A
M;F0@9V]O9'=I;&P@:6YC;'5D960@:6X@;W1H97(@;F]N+6-U<G)E;G0@87-S
M971S+`T*('=H96YE=F5R(&5V96YT<R!O<B!C:&%N9V5S(&EN(&)U<VEN97-S
M(&-I<F-U;7-T86YC97,@:6YD:6-A=&4@=&AA=`T*('1H92!C87)R>6EN9R!A
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z
M(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/CQI/E)E=F5N=64-"B!296-O9VYI=&EO;CPO
M:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY/=7(@<F5V96YU92!I<PT*(&1E<FEV960@9G)O;2!O=7(@87)R
M86YG96UE;G1S('=I=&@@<&AA<FUA8V5U=&EC86P@86YD(&)I;W1E8VAN;VQO
M9WD-"B!C;VQL86)O<F%T:6]N('!A<G1N97)S(&%N9"!M87D@<F5S=6QT(&9R
M;VT@;VYE(&]R(&UO<F4@;V8@=&AE#0H@9F]L;&]W:6YG.B!U<&9R;VYT(&%N
M9"!L:6-E;G-E(&9E97,L('!A>6UE;G1S(&9O<B!C;VYT<F%C="!R97-E87)C
M:`T*(&%N9"!D979E;&]P;65N="P@;6EL97-T;VYE('!A>6UE;G1S+"!M86YU
M9F%C='5R:6YG(&%N9"!S=7!P;'D-"B!P87EM96YT<RP@86YD(')O>6%L=&EE
M<RX@3W5R('!E<F9O<FUA;F-E(&]B;&EG871I;VYS('5N9&5R(&]U<@T*(&-O
M;&QA8F]R871I;VYS(&UA>2!I;F-L=61E(&QI8V5N<VEN9R!O=7(@:6YT96QL
M96-T=6%L('!R;W!E<G1Y+`T*(&UA;G5F86-T=7)I;F<@86YD('-U<'!L>2!O
M8FQI9V%T:6]N<RP@86YD(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*(&]B
M;&EG871I;VYS+B!);B!O<F1E<B!T;R!A8V-O=6YT(&9O<B!T:&4@;75L=&EP
M;&4M96QE;65N=`T*(&%R<F%N9V5M96YT<RP@=&AE($-O;7!A;GD@:61E;G1I
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M:7,@<F5C;V=N:7IE9`T*('-E<&%R871E;'D@9F]R(&5A8V@@:61E;G1I9FEE
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M"B!A<W-U<F5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G
M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D%T('1H90T*(&EN8V5P=&EO;B!O9B!E86-H(&YE=R!M
M=6QT:7!L92UE;&5M96YT(&%R<F%N9V5M96YT(&]R('1H92!M871E<FEA;`T*
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M86QO;F4@8F%S:7,N(%=E(&1E=&5R;6EN92!%4U`@9F]R('1H92!E;&5M96YT
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M96UE;G1S+B!3:6YC92!W92!A<'!L>2!S:6=N:69I8V%N=`T*(&IU9&=M96YT
M(&EN(&%R<FEV:6YG(&%T('1H92!%4U!S+"!A;GD@;6%T97)I86P@8VAA;F=E
M(&EN(&]U<@T*(&5S=&EM871E<R!W;W5L9"!S:6=N:69I8V%N=&QY(&%F9F5C
M="!T:&4@86QL;V-A=&EO;B!O9B!T:&4@=&]T86P-"B!C;VYS:61E<F%T:6]N
M('1O('1H92!D:69F97)E;G0@96QE;65N=',@;V8@82!M=6QT:7!L92!E;&5M
M96YT#0H@87)R86YG96UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0
M.B`Q.'!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/
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M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
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M<V-R:6)E9"!A="!.;W1E)B-X03`[-RP@<F5V96YU92!I<R!R96-O9VYI>F5D
M#0H@=VAE;B!E<W1I;6%B;&4L(&]T:&5R=VES92P@<F5V96YU92!I<R!R96-O
M9VYI>F5D(&1U<FEN9R!T:&4@<&5R:6]D#0H@:6X@=VAI8V@@=&AE(')E;&%T
M960@<F]Y86QT>2!R97!O<G0@:7,@<F5C96EV960L('=H:6-H(&=E;F5R86QL
M>0T*(&]C8W5R<R!I;B!T:&4@<75A<G1E<B!A9G1E<B!T:&4@87!P;&EC86)L
M92!P<F]D=6-T('-A;&5S(&%R90T*(&UA9&4N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQI/DQI8V5N<V4L(&-O;&QA8F]R871I;VX-"B!A;F0@;W1H
M97(\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY4:&4@86UO=6YT(&]F#0H@=7!F<F]N="!F965S(&%N9"!O=&AE
M<B!P87EM96YT<R!R96-E:79E9"!B>2!U<R!I;B!L:6-E;G-E(&%N9`T*(&-O
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M=`T*(&%C=&EV:71I97,L(&%N9"!M86YU9F%C='5R:6YG(&%C=&EV:71I97,@
M9G)O;2!D979E;&]P;65N="!T:')O=6=H#0H@=&AE(&-O;6UE<F-I86QI>F%T
M:6]N(&]F('1H92!P<F]D=6-T+B!':79E;B!T:&4@=6YC97)T86EN=&EE<R!O
M9@T*('1H97-E(&-O;&QA8F]R871I;VX@87)R86YG96UE;G1S+"!S:6=N:69I
M8V%N="!J=61G;65N="!I<R!R97%U:7)E9`T*('1O(&1E=&5R;6EN92!T:&4@
M9'5R871I;VX@;V8@=&AE('!E<F9O<FUA;F-E('!E<FEO9"!A;F0@=&AI<PT*
M(&5S=&EM871E(&ES('!E<FEO9&EC86QL>2!R92UE=F%L=6%T960N/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]N
M=&EN9V5N=`T*(&-O;G-I9&5R871I;VX@<F5C96EV960@9G)O;2!T:&4@86-H
M:65V96UE;G0@;V8@82!S=6)S=&%N=&EV90T*(&UI;&5S=&]N92!I<R!R96-O
M9VYI>F5D(&EN(&ET<R!E;G1I<F5T>2!I;B!T:&4@<&5R:6]D(&EN('=H:6-H
M('1H90T*(&UI;&5S=&]N92!I<R!A8VAI979E9"P@=VAI8V@@=V4@8F5L:65V
M92!I<R!C;VYS:7-T96YT('=I=&@@=&AE#0H@<W5B<W1A;F-E(&]F(&]U<B!P
M97)F;W)M86YC92!U;F1E<B!O=7(@=F%R:6]U<R!L:6-E;G-E(&%N9`T*(&-O
M;&QA8F]R871I;VX@86=R965M96YT<RX@02!M:6QE<W1O;F4@:7,@9&5F:6YE
M9"!A<R!A;B!E=F5N=`T*("AI*28C>$$P.W1H870@8V%N(&]N;'D@8F4@86-H
M:65V960@8F%S960@:6X@=VAO;&4@;W(@:6X@<&%R="!E:71H97(-"B!O;B!T
M:&4@96YT:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E(&]R(&]N('1H92!O8V-U
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M(&%N9"!I<R!R96%S;VYA8FQE(')E;&%T:79E('1O(&%L;`T*(&]F('1H92!O
M=&AE<B!D96QI=F5R86)L97,@86YD('!A>6UE;G1S('=I=&AI;B!T:&4-"B!A
M<G)A;F=E;65N="X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M=&5R:6$@=&\@8F4@8V]N<VED97)E9`T*('-U8G-T86YT:79E+B!!<R!A(')E
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M:6QE<W1O;F4@:7,@86-H:65V960N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
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M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/
M3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA!,#L\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0
M.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].
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M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!
M4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y297-E87)C:"!A;F0-"B!$979E
M;&]P;65N="!%>'!E;G-E/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4
M+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9`T*(&1E=F5L
M;W!M96YT(&-O<W1S(&%R92!E>'!E;G-E9"!A<R!I;F-U<G)E9"!A;F0@:6YC
M;'5D92!S86QA<FEE<RP-"B!B96YE9FET<R!A;F0@;W1H97(@;W!E<F%T:6YG
M(&-O<W1S('-U8V@@87,@;W5T<VED92!S97)V:6-E<RP-"B!S=7!P;&EE<R!A
M;F0@86QL;V-A=&5D(&]V97)H96%D(&-O<W1S+B!792!P97)F;W)M(')E<V5A
M<F-H(&%N9`T*(&1E=F5L;W!M96YT(&9O<B!O=7(@<')O<')I971A<GD@9')U
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4
M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G
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M(&)E(&-H86YG97,@:6X@97-T:6UA=&5S(&%N9`T*('=I;&P@8F4@<F5F;&5C
M=&5D(&EN(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!I;B!T
M:&4-"B!P97)I;V0@9FER<W0@:61E;G1I9FEE9"X@1'5R:6YG('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+`T*('=E(')E8V]R9&5D(&$@<F5D
M=6-T:6]N(')E;&%T960@=&\@<')I;W(@<&5R:6]D<R!O9B!A<'!R;WAI;6%T
M96QY#0H@)#0N-R!M:6QL:6]N('1O(&]U<B!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@97AP96YS97,@<')I;6%R:6QY#0H@<F5L871E9"!T;R!O=7(@0F5A
M8V]N(%!H87-E(#,@8VQI;FEC86P@=')I86P@9F]R(&5T:7)I;F]T96-A;@T*
M('!E9V]L+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y3=&]C
M:RU"87-E9`T*($-O;7!E;G-A=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P
M>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3=&]C:RUB87-E9`T*
M(&-O;7!E;G-A=&EO;B!A<G)A;F=E;65N=',@:6YC;'5D92!S=&]C:R!O<'1I
M;VX@9W)A;G1S(&%N9`T*(')E<W1R:6-T960@<W1O8VL@=6YI="`H4E-5*2!A
M=V%R9',@=6YD97(@;W5R(&5Q=6ET>2!I;F-E;G1I=F4-"B!P;&%N<RP@87,@
M=V5L;"!A<R!S:&%R97,@:7-S=65D('5N9&5R(&]U<B!%;7!L;WEE92!3=&]C
M:R!0=7)C:&%S90T*(%!L86X@*$534%`I+"!T:')O=6=H('=H:6-H(&5M<&QO
M>65E<R!M87D@<'5R8VAA<V4@;W5R(&-O;6UO;B!S=&]C:PT*(&%T(&$@9&ES
M8V]U;G0@=&\@=&AE(&UA<FME="!P<FEC92X\+V9O;G0^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!U<V4@=&AE#0H@0FQA
M8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"!F;W(@=&AE(')E<W!E
M8W1I=F4@9W)A;G0@=&\-"B!D971E<FUI;F4@=&AE(&5S=&EM871E9"!F86ER
M('9A;'5E(&]F('1H92!O<'1I;VX@;VX@=&AE(&1A=&4@;V8-"B!G<F%N="`H
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M('1H97-E(&%S<W5M<'1I;VYS(&%N9`T*(&UE=&AO9&]L;V=I97,L(&%N9"!W
M:&EC:"!C;W5L9"!M871E<FEA;&QY(&EM<&%C="!O=7(@9F%I<B!V86QU90T*
M(&1E=&5R;6EN871I;VXN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
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M92!F;W(@<'5R8VAA<V5S('5N9&5R#0H@=&AE($534%`@:7,@<F5C;V=N:7IE
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M;VX@;W5R(')E<&]R=&5D(&-A<V@@9FQO=W,N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G
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M('1O('1H92!R97!O<G1E9`T*(&YE="!L;W-S+B!"87-I8R!A;F0@9&EL=71E
M9"!N970@;&]S<R!P97(@<VAA<F4@87)E('1H92!S86UE(&1U92!T;PT*(&]U
M<B!H:7-T;W)I8V%L(&YE="!L;W-S97,@86YD('1H92!R97%U:7)E;65N="!T
M;R!E>&-L=61E#0H@<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!W
M:&EC:"!W;W5L9"!H879E(&%N(&%N=&DM9&EL=71I=F4-"B!E9F9E8W0@;VX@
M;F5T(&QO<W,@<&5R('-H87)E+B!$=7)I;F<@,C`Q-"P@,C`Q,R!A;F0@,C`Q
M,BP-"B!P;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S(&-O;G-I<W1E
M9"!O9B!C;VUM;VX@<VAA<F5S#0H@=6YD97)L>6EN9R!O=71S=&%N9&EN9R!S
M=&]C:R!O<'1I;VYS(&%N9"!T:&5R92!W97)E('=E:6=H=&5D#0H@879E<F%G
M92!O=71S=&%N9&EN9R!S=&]C:R!O<'1I;VYS(&]F(#(Q+CD@;6EL;&EO;BP@
M,C`N-R!M:6QL:6]N(&%N9`T*(#$X+C@@;6EL;&EO;B!D=7)I;F<@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9`T*(#(P,3(L
M(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M/&D^26YC;VUE#0H@5&%X97,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V4@86-C;W5N="!F;W(-"B!I
M;F-O;64@=&%X97,@=6YD97(@=&AE(&QI86)I;&ET>2!M971H;V0N(%5N9&5R
M('1H:7,@;65T:&]D+`T*(&1E9F5R<F5D('1A>"!A<W-E=',@86YD(&QI86)I
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M5"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!U=&EL:7IE(&$-"B!T=V\M
M<W1E<"!A<'!R;V%C:"!T;R!R96-O9VYI>F4@86YD(&UE87-U<F4@=6YC97)T
M86EN('1A>"!P;W-I=&EO;G,N#0H@5&AE(&9I<G-T('-T97`@:7,@=&\@979A
M;'5A=&4@=&AE('1A>"!P;W-I=&EO;B!F;W(@<F5C;V=N:71I;VX@8GD-"B!D
M971E<FUI;FEN9R!I9B!T:&4@=V5I9VAT(&]F(&%V86EL86)L92!E=FED96YC
M92!I;F1I8V%T97,@=&AA="!I=`T*(&ES(&UO<F4@;&EK96QY('1H86X@;F]T
M('1H870@=&AE('!O<VET:6]N('=I;&P@8F4@<W5S=&%I;F5D('5P;VX-"B!T
M87@@875T:&]R:71Y(&5X86UI;F%T:6]N+"!I;F-L=61I;F<@<F5S;VQU=&EO
M;B!O9B!R96QA=&5D(&%P<&5A;',-"B!O<B!L:71I9V%T:6]N('!R;V-E<W-E
M<RP@:68@86YY+B!4:&4@<V5C;VYD('-T97`@:7,@=&\@;65A<W5R92!T:&4-
M"B!T87@@8F5N969I="!A<R!T:&4@;&%R9V5S="!A;6]U;G0@=&AA="!I<R!M
M;W)E('1H86X@-3`E(&QI:V5L>2!O9@T*(&)E:6YG(')E86QI>F5D('5P;VX@
M=6QT:6UA=&4@<V5T=&QE;65N="X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^/&D^0V]M<')E:&5N<VEV90T*(&QO<W,\+VD^/"]B/CPO9F]N=#X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G
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M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E)E8V5N="!!8V-O
M=6YT:6YG#0H@4')O;F]U;F-E;65N=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@36%Y(#(P,30L
M#0H@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H
M1D%30BD@:7-S=65D(&=U:61A;F-E#0H@8V]D:69I960@:6X@06-C;W5N=&EN
M9R!3=&%N9&%R9',@0V]D:69I8V%T:6]N("A!4T,I(#8P-BP@/&D^4F5V96YU
M90T*(%)E8V]G;FET:6]N("8C>#(P,30[(%)E=F5N=64@9G)O;2!#;VYT<F%C
M=',@=VET:"!#=7-T;VUE<G,\+VD^+`T*('=H:6-H(&%M96YD<R!T:&4@9W5I
M9&%N8V4@:6X@9F]R;65R($%30R`V,#4L(#QI/E)E=F5N=64-"B!296-O9VYI
M=&EO;BP\+VD^(&%N9"!I<R!E9F9E8W1I=F4@9F]R('!U8FQI8R!C;VUP86YI
M97,@9F]R(&9I<V-A;`T*('EE87)S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E
M<B8C>$$P.S$U+"`R,#$V+B!792!A<F4@8W5R<F5N=&QY#0H@979A;'5A=&EN
M9R!T:&4@:6UP86-T(&]F('1H92!P<F]V:7-I;VYS(&]F($%30R`V,#8N/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!
M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M26X@075G=7-T(#(P,30L#0H@=&AE($9!4T(@:7-S=65D($%C8V]U;G1I;F<@
M4W1A;F1A<F1S(%5P9&%T92!.;RXF(WA!,#LR,#$T+3$U+`T*($1I<V-L;W-U
M<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!%;G1I='DF(W@R,#$Y.W,@
M06)I;&ET>2!T;PT*($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N8V5R;B`H05-5
M(#(P,30M,34I+B!!4U4@,C`Q-"TQ-2!R97%U:7)E<PT*(&UA;F%G96UE;G0@
M=&\@979A;'5A=&4@=VAE=&AE<B!T:&5R92!I<R!S=6)S=&%N=&EA;"!D;W5B
M="!A8F]U="!A;@T*(&5N=&ET>28C>#(P,3D[<R!A8FEL:71Y('1O(&-O;G1I
M;G5E(&%S(&$@9V]I;F<@8V]N8V5R;B!A;F0@=&\-"B!P<F]V:61E(')E;&%T
M960@9F]O=&YO=&4@9&ES8VQO<W5R97,N($%352`R,#$T+3$U(&ES(&5F9F5C
M=&EV92!I;@T*(#(P,38@=VET:"!E87)L>2!A9&]P=&EO;B!P97)M:71T960N
M(%=E(&1O(&YO="!B96QI979E('1H92!I;7!A8W0@;V8-"B!A9&]P=&EN9R!!
M4U4@,C`Q-"TQ-2!O;B!O=7(@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S('=I;&P-"B!B92!S:6=N:69I8V%N="X\+V9O;G0^/"]P/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E
M7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#87-H(&%N9"!);G9E<W1M
M96YT<R!I;B!-87)K971A8FQE(%-E8W5R:71I97,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!$
M:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($EN=F5S=&UE;G1S(&EN($UA
M<FME=&%B;&4@4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DYO=&4F(WA!,#LR)B-X
M03`[)B-X,C`Q-#L-"B!#87-H(&%N9"!);G9E<W1M96YT<R!I;B!-87)K971A
M8FQE(%-E8W5R:71I97,\+V(^/"]F;VYT/CPO<#X-"B`\(2TM('AB<FPL8F]D
M>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H
M(&%N9`T*(&EN=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@
M:6YC;'5D:6YG(&-A<V@@97%U:79A;&5N=',-"B!A;F0@<F5S=')I8W1E9"!C
M87-H+"!A<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%
M.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/D5S=&EM871E9"!&86ER(%9A;'5E#0H@870\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C
M96UB97(F(WA!,#LS,2P\8G(@+SX-"B`R,#$T/"]B/CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$
M96-E;6)E<B8C>$$P.S,Q+#QB<B`O/@T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H
M(&%N9"!C87-H#0H@97%U:79A;&5N=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,3(L,S8U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,SDL,#8W/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4VAO<G0M
M=&5R;0T*(&EN=F5S=&UE;G1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
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M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E)E<W1R:6-T960@8V%S:#PO9F]N=#X\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(U+#`P,#PO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,C4L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1O=&%L(&-A<V@@86YD(&EN=F5S=&UE;G1S
M#0H@:6X@;6%R:V5T86)L92!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C(V,BPX,C0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z
M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V4@:6YV97-T
M(&EN#0H@;&EQ=6ED+"!H:6=H('%U86QI='D@9&5B="!S96-U<FET:65S+B!/
M=7(@:6YV97-T;65N=',@:6X@9&5B=`T*('-E8W5R:71I97,@87)E('-U8FIE
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M(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q,RP@86QL(&]F
M(&]U<B!I;G9E<W1M96YT<R!H860-"B!C;VYT<F%C='5A;"!M871U<FET:65S
M(&]F(&]N92!Y96%R(&]R(&QE<W,@86YD('=E<F4@8VQA<W-I9FEE9"!A<PT*
M('-H;W)T+71E<FTN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^1W)O<W,-"B!U;G)E86QI>F5D(&=A:6YS(&%N9"!L
M;W-S97,@=V5R92!N;W0@<VEG;FEF:6-A;G0@870@96ET:&5R#0H@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q-"!O<B`R,#$S+B!$=7)I;F<@=&AE('EE87)S(&5N
M9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@
M=V4@<V]L9"!A=F%I;&%B;&4M9F]R+7-A;&4-"B!S96-U<FET:65S('1O=&%L
M:6YG("0R,2XW(&UI;&QI;VXL("0R+CDF(WA!,#MM:6QL:6]N(&%N9"`D-2XT
M#0H@;6EL;&EO;B!R97-P96-T:79E;'DL(&%N9"!R96%L:7IE9"!G86EN<R!A
M;F0@;&]S<V5S('=E<F4@;F]T#0H@<VEG;FEF:6-A;G0@:6X@86YY(&]F('1H
M;W-E('!E<FEO9',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!C87-H#0H@;V8@)#(U+C`@;6EL
M;&EO;B!I<R!R97%U:7)E9"!T;R!B92!M86EN=&%I;F5D(&EN(&$@<V5P87)A
M=&4@86-C;W5N=`T*('5N=&EL($IU;'DF(WA!,#LQ+"`R,#$U('5N9&5R('1H
M92!T97)M<R!O9B!O=7(@,3(E('-E;FEO<B!S96-U<F5D#0H@;F]T97,@9'5E
M($IU;'D@,C`Q-RX@57!O;B!R96QE87-E(&]F('1H:7,@<F5S=')I8W1I;VX@
M;VX-"B!*=6QY)B-X03`[,2P@,C`Q-2P@82!C;W9E;F%N="!O9B!T:&4@<V5N
M:6]R('-E8W5R960@;F]T97,@<F5Q=6ER97,-"B!T:&%T('1H92!A9V=R96=A
M=&4@8F%L86YC92!O9B!O=7(@=6YR97-T<FEC=&5D(&-A<V@@86YD(&-A<V@-
M"B!E<75I=F%L96YT<R!A="!T:&4@96YD(&]F(&%N>2!T=V\@8V]N<V5C=71I
M=F4@9FES8V%L('%U87)T97)S(&UA>0T*(&YO="!B92!L97-S('1H86X@)#(U
M+C`@;6EL;&EO;BP@<W5B:F5C="!T;R!C97)T86EN(&-O;F1I=&EO;G,@*'-E
M90T*($YO=&4@-2DN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^3W5R('!O<G1F;VQI;PT*(&]F(&-A<V@@86YD(&EN
M=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!I;F-L=61E<R`H
M:6X-"B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z
M(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^
M#0H@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0U-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G
M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@<F]W<W!A;CTS
M1#(@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1F%I
M<B8C>$$P.PT*(%9A;'5E/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M8CY(:65R87)C:'D\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DQE
M=F5L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@<F]W
M<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY%<W1I;6%T960@1F%I
M<B!686QU90T*(&%T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P
M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!,#LS,2P\
M8G(@+SX-"B`R,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q
M+#QB<B`O/@T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L
M92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@;F]T97,@86YD
M#0H@8F]N9',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXR/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$S."PU,34\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#
M;W)P;W)A=&4@8V]M;65R8VEA;`T*('!A<&5R/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-#(L
M.3$U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXU.2PT-#0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%V86EL86)L
M92UF;W(M<V%L90T*(&EN=F5S=&UE;G1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,C4L-#4Y/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXQ.3<L.34Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^36]N97D@;6%R:V5T#0H@9G5N9',\+V9O;G0^
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXQ,2PR,CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
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M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D-A<V@L(&EN8VQU9&EN9R!R97-T<FEC=&5D#0H@8V%S:#PO
M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,C8L,3,V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-RPV,30\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1O=&%L(&-A
M<V@@86YD(&EN=F5S=&UE;G1S#0H@:6X@;6%R:V5T86)L92!S96-U<FET:65S
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C(V,BPP,C8\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`R<'@[($)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,"XU<'0@<V]L:60[
M($U!4D=)3BU43U`Z(#!P>#L@3$E.12U(14E'2%0Z(#AP>#L@5TE$5$@Z(#$P
M)2<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+51/4#H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y,979E;"8C>$$P
M.S$F(WA!,#LF(W@R,#$T.SPO:3X@475O=&5D('!R:6-E<R!I;B!A8W1I=F4-
M"B!M87)K971S(&9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`V<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQI/DQE=F5L)B-X03`[,B8C
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M:&4@9G5L;`T*('1E<FT@;V8@=&AE(&%S<V5T<R!O<B!L:6%B:6QI=&EE<RX\
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M9"!T:&%T(&%R92!S:6=N:69I8V%N=`T*('1O('1H92!F86ER('9A;'5E(&]F
M('1H92!A<W-E=',@;W(@;&EA8FEL:71I97,N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^06QL(&]F(&]U<@T*(&EN
M=F5S=&UE;G1S(&%R92!C871E9V]R:7IE9"!A<R!,979E;"`Q(&]R($QE=F5L
M(#(L(&%S(&5X<&QA:6YE9"!I;@T*('1H92!T86)L92!A8F]V92X@5V4@=7-E
M(&$@;6%R:V5T(&%P<')O86-H('1O('9A;'5E(&]U<B!,979E;"`R#0H@:6YV
M97-T;65N=',N($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q-"P@,C`Q,PT*(&%N9"`R,#$R+"!T:&5R92!W97)E(&YO('1R
M86YS9F5R<R!B971W965N($QE=F5L(#$@86YD($QE=F5L(#(@;V8-"B!T:&4@
M9F%I<B!V86QU92!H:65R87)C:'DN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^070-"B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$T(&%N9"`R,#$S+"!W92!H860@;&5T=&5R(&]F(&-R961I=`T*(&%R
M<F%N9V5M96YT<R!I;B!F879O<B!O9B!A(&QA;F1L;W)D(&%N9"!C97)T86EN
M('9E;F1O<G,@=&]T86QI;F<-"B`D,BXT)B-X03`[;6EL;&EO;BX@5&AE<V4@
M;&5T=&5R<R!O9B!C<F5D:70@87)E('-E8W5R960@8GD-"B!I;G9E<W1M96YT
M<R!O9B!S:6UI;&%R(&%M;W5N=',N/"]F;VYT/CPO<#X-"B`-"B`-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B
M,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F
M,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV96YT;W)Y/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5N
M=&]R>2!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY.;W1E
M)B-X03`[,R8C>$$P.R8C>#(P,30[($EN=F5N=&]R>3PO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);G9E;G1O<GD@8V]N<VES=',@;V8@
M=&AE(&9O;&QO=VEN9R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#`E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#8@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M4F%W(&UA=&5R:6%L<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#(P
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPY-#<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(%=O<FLM:6XM<')O8V5S<SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,3@W/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,30V/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&:6YI<VAE9"!G;V]D<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-38U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,S4Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@26YV96YT;W)Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#DU,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3,L-#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q
M9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X
M,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N=#QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@
M,3AP>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^/&(^3F]T928C>$$P.S0F(WA!,#LF(W@R,#$T.PT*
M(%!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT/"]B/CPO9F]N=#X\+W`^
M#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^4')O<&5R='DL('!L86YT#0H@86YD(&5Q=6EP;65N="!C
M;VYS:7-T<R!O9B!T:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO9F]N
M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4
M+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*
M(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L
M:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/"$M+2!"96=I;B!486)L92!(
M96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,24^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L
M,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)U:6QD:6YG(&%N9"!L
M96%S96AO;&0-"B!I;7!R;W9E;65N=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-S(L,C(X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S$L,S`V/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&%B;W)A
M=&]R>0T*(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
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M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C8L-C(Q/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^36%N=69A8W1U<FEN9PT*(&5Q=6EP;65N=#PO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,C,L-CDY/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^1G5R;FET=7)E+"!F:7AT=7)E<R!A;F0-
M"B!O=&AE<B!E<75I<&UE;G0\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXR,RPT-3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!R96-I86)L92!P<F]P97)T>2P@<&QA
M;G0-"B!A;F0@97%U:7!M96YT(&%T(&-O<W0\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-#<L.#8V/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^3&5S<SH@86-C=6UU;&%T960-"B!D97!R96-I871I;VX\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH.3,L.#`W
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*#@T+#$T.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5P<F5C:6%B
M;&4@<')O<&5R='DL('!L86YT#0H@86YD(&5Q=6EP;65N="P@;F5T/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-30L,#4Y/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXV,"PW,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VYS=')U8W1I;VXM:6XM<')O9W)E<W,\
M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPS
M,#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C8L,C8Q/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E!R;W!E<G1Y+"!P;&%N="!A;F0-"B!E<75I<&UE;G0L(&YE=#PO9F]N=#X\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M,CXV-BPY-S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2
M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY"
M=6EL9&EN9R!A;F0-"B!L96%S96AO;&0@:6UP<F]V96UE;G1S(&EN8VQU9&4@
M;W5R(&UA;G5F86-T=7)I;F<L(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT
M(&%N9"!A9&UI;FES=')A=&EV92!F86-I;&ET:65S(&%N9"!T:&4@<F5L871E
M9`T*(&EM<')O=F5M96YT<R!T;R!T:&5S92!F86-I;&ET:65S+B!,86)O<F%T
M;W)Y(&%N9"!M86YU9F%C='5R:6YG#0H@97%U:7!M96YT(&EN8VQU9&4@87-S
M971S('1H870@<W5P<&]R="!B;W1H(&]U<B!M86YU9F%C='5R:6YG(&%N9`T*
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M+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@=V4@:&%V90T*(')E8V]R9&5D
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M;6%T96QY('1H<F5E('EE87)S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.
M1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/DEN($IU;'D@,C`Q,BP-"B!W92!C;VYS
M;VQI9&%T960@;W5R(%4N4RXM8F%S960@<F5S96%R8V@@86-T:79I=&EE<R!I
M;G1O(&]U<@T*(&5X:7-T:6YG(%-A;B!&<F%N8VES8V\@9F%C:6QI='D@86YD
M(&-E87-E9"!U<V4@;V8@86YD('!L86X@=&\@<V5L;`T*(&]N92!O9B!O=7(@
M8G5I;&1I;F=S(&QO8V%T960@:6X@2'5N='-V:6QL92P@06QA8F%M82!T:&%T
M('=A<PT*(&1E9&EC871E9"!T;R!R97-E87)C:"!A8W1I=FET:65S+B!4:&4@
M86YN;W5N8V5M96YT(&]F('1H:7,-"B!C;VYS;VQI9&%T:6]N('!L86X@:6X@
M36%R8V@@,C`Q,B!T<FEG9V5R960@=&AE(')E8V]G;FET:6]N(&]F(&$-"B`D
M,2XW)B-X03`[;6EL;&EO;B!I;7!A:7)M96YT(&-H87)G92!R96QA=&EN9R!T
M;R!T:&5S92!A<W-E=',@:6X@=&AE#0H@>65A<B!E;F1E9"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$R+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@
M-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/D1E<')E8VEA=&EO;@T*(&5X<&5N<V4L(&EN8VQU
M9&EN9R!D97!R96-I871I;VX@;V8@87-S971S(&%C<75I<F5D('1H<F]U9V@@
M8V%P:71A;`T*(&QE87-E<RP@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q,@T*('=A<R`D,3$N-R8C
M>$$P.VUI;&QI;VXL("0Q,RXP)B-X03`[;6EL;&EO;BP@86YD("0Q,RXX)B-X
M03`[;6EL;&EO;BP-"B!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-"B`-"B`-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?
M.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5N:6]R(%-E8W5R
M960@3F]T97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1&5B="!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5N:6]R(%-E
M8W5R960@3F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T
M=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@/&(^3F]T928C>$$P.S4F(WA!,#LF(W@R,#$T.R!396YI
M;W(@4V5C=7)E9"!.;W1E<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@3VX@2G5L>28C>$$P.S$Q+"`R,#$R+"!W92!I<W-U960@)#$R-2XP(&UI
M;&QI;VX@:6X@86=G<F5G871E#0H@<')I;F-I<&%L(&%M;W5N="!O9B!S96YI
M;W(@<V5C=7)E9"!N;W1E<R`H4V5N:6]R($YO=&5S*2!W:71H('1H90T*(&5N
M=&ER92!P<FEN8VEP86P@86UO=6YT(&1U92!O;B!*=6QY)B-X03`[,34L(#(P
M,3<N(%1H92!396YI;W(@3F]T97,-"B!B96%R(&EN=&5R97-T(&%T(#$R+C`E
M)B-X03`[<&5R(&%N;G5M('!A>6%B;&4@:6X@8V%S:"!S96UI+6%N;G5A;&QY
M#0H@:6X@87)R96%R<R!O;B!*86YU87)Y)B-X03`[,34@86YD($IU;'DF(WA!
M,#LQ-2!O9B!E86-H('EE87(N(%1H90T*(%-E;FEO<B!.;W1E<R!A<F4@<V5C
M=7)E9"!B>2!A(&9I<G-T+7!R:6]R:71Y(&QI96X@;VX@<W5B<W1A;G1I86QL
M>0T*(&%L;"!O9B!O=7(@87-S971S+B!);B!C;VYN96-T:6]N('=I=&@@=&AI
M<R!T<F%N<V%C=&EO;BP@=V4@<F5T:7)E9`T*("0T,BXU(&UI;&QI;VX@;V8@
M<')I;F-I<&%L(&%M;W5N="!O9B!O=7(@8V]N=F5R=&EB;&4@<W5B;W)D:6YA
M=&5D#0H@;F]T97,@9'5E(%-E<'1E;6)E<B`R,#$R(&EN(&5X8VAA;F=E(&9O
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M;6)E<B8C>$$P.S(X+"`R,#$R+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
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M;"!*=6QY)B-X03`[,2P@,C`Q-2!A;F0@:7,-"B!C;&%S<VEF:65D(&%S(')E
M<W1R:6-T960@8V%S:"!O;B!O=7(@0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE
M971S+@T*($9R;VT@2G5L>28C>$$P.S$L(#(P,34@=&AR;W5G:"!T:&4@<75A
M<G1E<B!E;F1I;F<@2G5N928C>$$P.S,P+`T*(#(P,3<L('1H92!A9V=R96=A
M=&4@8F%L86YC92!O9B!O=7(@=6YR97-T<FEC=&5D(&-A<V@@86YD(&-A<V@-
M"B!E<75I=F%L96YT<R!A="!T:&4@96YD(&]F(&%N>2!T=V\@8V]N<V5C=71I
M=F4@9FES8V%L('%U87)T97)S(&UA>0T*(&YO="!B92!L97-S('1H86X@)#(U
M+C`@;6EL;&EO;BP@<W5B:F5C="!T;R!C97)T86EN(&-O;F1I=&EO;G,N(%1H
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M,3`Q)2!O9B!T:&4@<')I;F-I<&%L#0H@86UO=6YT('1H97)E;V8L('!L=7,@
M86-C<G5E9"!A;F0@=6YP86ED(&EN=&5R97-T('1O('1H92!D871E(&]F#0H@
M<'5R8VAA<V4N($EN(&%D9&ET:6]N+"!U<&]N(&-E<G1A:6X@87-S970@<V%L
M97,L('=E(&UA>2!B92!R97%U:7)E9`T*('1O(&]F9F5R('1O('5S92!T:&4@
M;F5T('!R;V-E961S('1H97)E;V8@=&\@<'5R8VAA<V4@<V]M92!O9B!T:&4-
M"B!396YI;W(@3F]T97,@870@,3`P)2!O9B!T:&4@<')I;F-I<&%L(&%M;W5N
M="!T:&5R96]F+"!P;'5S(&%C8W)U960-"B!A;F0@=6YP86ED(&EN=&5R97-T
M('1O('1H92!D871E(&]F('!U<F-H87-E+CPO<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@8F%S960@
M;VX@82!D:7-C;W5N=&5D(&-A<V@@9FQO=PT*(&%N86QY<VES('5S:6YG($QE
M=F5L(#,@:6YP=71S(&EN8VQU9&EN9R!F:6YA;F-I86P@9&ES8V]U;G0@<F%T
M97,L#0H@=V4@8F5L:65V92!T:&4@)#$R-2XP(&UI;&QI;VX@8V%R<GEI;F<@
M86UO=6YT(&]F(&]U<B`Q,B4@4V5N:6]R#0H@4V5C=7)E9"!.;W1E<R!D=64@
M2G5L>2`R,#$W(&ES(&-O;G-I<W1E;G0@=VET:"!I=',@9F%I<B!V86QU92X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY497AT($)L;V-K(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY.;W1E)B-X03`[
M-B8C>$$P.R8C>#(P,30[($QE87-E<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P="<^#0H@/&(^
M/&D^0V%P:71A;"!,96%S97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%=E(&QE87-E(&]F9FEC92!S<&%C92!A="`R,#$@26YD
M=7-T<FEA;"!2;V%D(&EN(%-A;B8C>$$P.T-A<FQO<RP-"B!#86QI9F]R;FEA
M('5N9&5R(&$@8V%P:71A;"!L96%S92!A<G)A;F=E;65N="X@56YD97(@=&AE
M('1E<FUS(&]F#0H@=&AE(&QE87-E+"!R96YT(&EN8W)E87-E<R!U<"!T;R`S
M)2!A;FYU86QL>2!A;F0@=&AE(&QE87-E#0H@=&5R;6EN871I;VX@9&%T92!I
M<R!/8W1O8F5R)B-X03`[-2P@,C`Q-BX@07,@;V8@3F]V96UB97(F(WA!,#LR
M.2P-"B`R,#$P+"!W92!C96%S960@=7-E(&]F('1H:7,@<W!A8V4@87,@82!R
M97-U;'0@;V8@=&AE(')E;&]C871I;VX@;V8-"B!O=7(@4V%N)B-X03`[0V%R
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M;&EO;B!A<R!O9@T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30N/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S(&]F($1E8V5M8F5R)B-X03`[
M,S$L(#(P,30@86YD(#(P,3,L('1H92!G<F]S<R!A;6]U;G0@;V8@87-S971S
M#0H@<F5C;W)D960@=6YD97(@8V%P:71A;"!L96%S97,@=V%S("0R+C<@;6EL
M;&EO;B!A;F0-"B`R+C,F(WA!,#MM:6QL:6]N+"!R97-P96-T:79E;'DL(&%N
M9"!T:&4@<F5C;W)D960@=F%L=64@;V8@=&AE<V4-"B!A<W-E=',L(&YE="!O
M9B!D97!R96-I871I;VXL('=A<R`D,2XR(&UI;&QI;VX@86YD("0Q+C`@;6EL
M;&EO;BP-"B!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($9U='5R92!M:6YI;75M('!A>6UE;G1S(&9O<B!O=7(@8V%P
M:71A;"!L96%S97,@870@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$T(&%R92!A
M<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/
M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X."4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3Y996%R<R!E;F1I;F<@1&5C96UB97(F
M(WA!,#LS,2P\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$U/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C4L-3<R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PR
M-C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-S4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%1O=&%L(&UI;FEM=6T@<&%Y;65N=',@<F5Q=6ER960\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PP,34\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE<W,Z(&%M;W5N="!R97!R
M97-E;G1I;F<@:6YT97)E<W0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PS-C0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!0<F5S96YT('9A;'5E(&]F(&9U='5R92!M:6YI;75M(&QE87-E
M('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PV-3$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE<W,Z(&-U
M<G)E;G0@<&]R=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T+#4Q,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($-A<&ET86P@;&5A<V4@;V)L:6=A=&EO;BP@;&5S<R!C=7)R96YT('!O
M<G1I;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PQ,SD\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B
M;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P
M<'0G/@T*(#QB/CQI/D]P97)A=&EN9R!,96%S93PO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3VX@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,#DL('=E(&5N=&5R960@:6YT;R!A;B!O<&5R871I;F<@<W5B;&5A<V4-
M"B`H4W5B;&5A<V4I('=I=&@@4&9I>F5R+"!);F,N(&9O<B!A(#$R-BPR.#4F
M(WA!,#MS<75A<F4@9F]O=`T*(&9A8VEL:71Y(&QO8V%T960@:6X@4V%N)B-X
M03`[1G)A;F-I<V-O+"!#86QI9F]R;FEA("A-:7-S:6]N($)A>0T*($9A8VEL
M:71Y*2X@56YD97(@=&AE('1E<FUS(&]F('1H92!3=6)L96%S92P@=V4@8F5G
M86X@;6%K:6YG#0H@;F]N+6-A;F-E;&%B;&4@;&5A<V4@<&%Y;65N=',@:6X@
M,C`Q-"P@869T97(@=&AE(&5X<&ER871I;VX@;V8@;W5R#0H@9G)E92!R96YT
M('!E<FEO9"!O;B!!=6=U<W0F(WA!,#LQ+"`R,#$T+B!4:&4@4W5B;&5A<V4@
M=&5R;2!I<R`Q,30-"B!M;VYT:',L(&-O;6UE;F-I;F<@:6X@075G=7-T(#(P
M,3`@86YD('1E<FUI;F%T:6YG(&]N#0H@2F%N=6%R>28C>$$P.S,Q+"`R,#(P
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M87AE<R!F;W(@=&AE($UI<W-I;VX@0F%Y($9A8VEL:71Y+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!/=7(@9G5T=7)E(&UI;FEM=6T@;&5A
M<V4@<&%Y;65N=',@9F]R(&]U<B!O<&5R871I;F<@;&5A<V5S(&%T#0H@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q-"!A<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A
M;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V
M."4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$.#@E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^665A<G,@96YD:6YG($1E8V5M8F5R)B-X03`[,S$L/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@,C`Q-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<U
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.#DR/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$W/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PP,S<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(#(P,3@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU+#$X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@,C`Q.3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4L,S0T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#(P/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#4R/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!F=71U<F4@;6EN:6UU;2!L96%S92!P
M87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-2PV-C(\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5V4@<F5C;V=N
M:7IE(')E;G0@97AP96YS92!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E
M<B!T:&4@;&5A<V4-"B!P97)I;V0N($9O<B!T:&4@>65A<G,@96YD960@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,RP@86YD(#(P,3(L#0H@<F5N="!E
M>'!E;G-E(&9O<B!A;&P@;W5R(&]P97)A=&EN9R!L96%S97,L(&EN8VQU9&EN
M9R!O=7(@36ES<VEO;@T*($)A>2!&86-I;&ET>2P@=V%S(&%P<')O>&EM871E
M;'D@)#,N,B8C>$$P.VUI;&QI;VXL#0H@)#(N.28C>$$P.VUI;&QI;VXL(&%N
M9"`D,BXX)B-X03`[;6EL;&EO;BP@<F5S<&5C=&EV96QY+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B
M,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F
M,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&EA8FEL:71Y(%)E;&%T960@
M=&\@4V%L92!O9B!&=71U<F4@4F]Y86QT:65S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1E>'0@0FQO8VL@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:6%B:6QI='D@4F5L871E9"!T;R!386QE(&]F($9U='5R92!2;WEA
M;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q
M.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#<@)B-X,C`Q-#L@3&EA8FEL:71Y#0H@
M4F5L871E9"!T;R!386QE(&]F($9U='5R92!2;WEA;'1I97,\+V(^/"]F;VYT
M/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU4
M3U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;@T*($9E
M8G)U87)Y)B-X03`[,C0L(#(P,3(L('=E(&5N=&5R960@:6YT;R!A(%!U<F-H
M87-E(&%N9"!386QE#0H@06=R965M96YT("AT:&4@4'5R8VAA<V4@86YD(%-A
M;&4@06=R965M96YT*2!W:71H(%)022!&:6YA;F-E(%1R=7-T#0H@*%)022DL
M(&%N(&%F9FEL:6%T92!O9B!2;WEA;'1Y(%!H87)M82P@<'5R<W5A;G0@=&\@
M=VAI8V@@=V4@<V]L9"P-"B!A;F0@4E!)('!U<F-H87-E9"P@;W5R(')I9VAT
M('1O(')E8V5I=F4@<F]Y86QT>2!P87EM96YT<R`H=&AE#0H@4F]Y86QT>2!%
M;G1I=&QE;65N="D@87)I<VEN9R!F<F]M('1H92!W;W)L9'=I9&4@;F5T('-A
M;&5S+"!F<F]M(&%N9`T*(&%F=&5R($IA;G5A<GDF(WA!,#LQ+"`R,#$R+"!O
M9B`H82DF(WA!,#M#24U:24$\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U14
M3TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^+`T*('5N9&5R($YE:W1A
M<B8C>#(P,3D[<R!L:6-E;G-E+"!M86YU9F%C='5R:6YG(&%N9"!S=7!P;'D@
M86=R965M96YT#0H@=VET:"!50T(@4&AA<FUA("A50T(I+"!A;F0@*&(I)B-X
M03`[34E20T5203QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX
M97@G/B8C>$%%.SPO<W5P/CPO9F]N=#XL#0H@=6YD97(@3F5K=&%R)B-X,C`Q
M.3MS(&QI8V5N<V4L(&UA;G5F86-T=7)I;F<@86YD('-U<'!L>2!A9W)E96UE
M;G0-"B!W:71H($8N($AO9F9M86YN+4QA)B-X03`[4F]C:&4@3'1D(&%N9"!(
M;V9F;6%N;BU,828C>$$P.U)O8VAE($EN8RX-"B`H=&]G971H97(@<F5F97)R
M960@=&\@87,@4F]C:&4I+B!792!R96-E:79E9"!A9V=R96=A=&4@8V%S:`T*
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M.B`P+CAE>"<^)B-X044[/"]S=7`^/"]F;VYT/@T*(&%N9"!-25)#15)!/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/'-U<"!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F%S96QI;F4[
M(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^)B-X044[/"]S
M=7`^/"]F;VYT/@T*('!R;V1U8W1S+"!A<R!A(')E<W5L="!O9B!O=7(@;VYG
M;VEN9R!M86YU9F%C='5R:6YG(&%N9"!S=7!P;'D-"B!O8FQI9V%T:6]N<R!R
M96QA=&5D('1O('1H92!G96YE<F%T:6]N(&]F('1H97-E(')O>6%L=&EE<RP@
M=V4@=VEL;`T*(&-O;G1I;G5E('1O(&%C8V]U;G0@9F]R('1H97-E(')O>6%L
M=&EE<R!A<R!R979E;G5E(&%N9"!R96-O<F1E9"!T:&4-"B`D,3(T+C`@;6EL
M;&EO;B!I;B!P<F]C965D<R!F<F]M('1H:7,@=')A;G-A8W1I;VX@87,@82!L
M:6%B:6QI='D-"B`H4F]Y86QT>2!/8FQI9V%T:6]N*2!T:&%T('=I;&P@8F4@
M86UO<G1I>F5D('5S:6YG('1H92!I;G1E<F5S=`T*(&UE=&AO9"!O=F5R('1H
M92!E<W1I;6%T960@;&EF92!O9B!T:&4@4'5R8VAA<V4@86YD(%-A;&4-"B!!
M9W)E96UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^5&AE(&9O;&QO=VEN9PT*('1A8FQE('-H;W=S('1H92!A
M8W1I=FET>2!W:71H:6X@=&AE(&QI86)I;&ET>2!A8V-O=6YT(&1U<FEN9R!T
M:&4-"B!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(&9O
M<B!T:&4@<&5R:6]D(&9R;VT@=&AE#0H@:6YC97!T:6]N(&]F('1H92!R;WEA
M;'1Y('1R86YS86-T:6]N(&]N($9E8G)U87)Y)B-X03`[,C0L(#(P,3(-"B`H
M:6YC97!T:6]N*2!T;R!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T("AI;B!T:&]U
M<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,24^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<B!E;F1E
M9#QB<B`O/@T*($1E8V5M8F5R)B-X03`[,S$L/&)R("\^#0H@,C`Q-#PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED
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M>$$P.S,Q+#QB<B`O/@T*(#(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,:6%B:6QI='D@<F5L
M871E9"!T;R!S86QE#0H@;V8@9G5T=7)E(')O>6%L=&EE<R`F(W@R,#$T.R!B
M96=I;FYI;F<@8F%L86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\
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M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E!R;V-E961S(&9R;VT@<V%L92!O9@T*
M(&9U='5R92!R;WEA;'1I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,C0L,#`P/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^4&%Y;65N=',@9G)O;2!.96MT87(@=&\-"B!24$D\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-RPP,#`\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXH,3`L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N
M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/DYO;BUC87-H($-)35I)03QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L
M871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P/CPO9F]N=#X-"B!A
M;F0@34E20T5203QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX
M97@G/B8C>$%%.SPO<W5P/CPO9F]N=#X-"B!R;WEA;'1Y(')E=F5N=64\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C$L.3,W
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*#4T+#<X,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.;VXM8V%S:"!I;G1E
M<F5S="!E>'!E;G-E#0H@<F5C;V=N:7IE9#PO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
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M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M-C$L,C4T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/DQI86)I;&ET>2!R96QA=&5D('1O('-A;&4-"B!O9B!F=71U
M<F4@<F]Y86QT:65S("8C>#(P,30[(&5N9&EN9R!B86QA;F-E/"]F;VYT/CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$R,"PT-S$\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M,CXQ,C`L-#<Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^
M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!
M1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^4'5R<W5A;G0@=&\@=&AE#0H@4'5R8VAA
M<V4@86YD(%-A;&4@06=R965M96YT+"!I;B!-87)C:"`R,#$T(&%N9"!-87)C
M:"`R,#$S+"!W92!W97)E#0H@<F5Q=6ER960@=&\@<&%Y(%)022`D-RXP(&UI
M;&QI;VX@86YD("0S+C`@;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!A<PT*(&$@
M<F5S=6QT(&]F('=O<FQD=VED92!N970@<V%L97,@;V8@34E20T5203QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!0
M3U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P
M/CPO9F]N=#X-"B!F;W(@=&AE(#$R(&UO;G1H('!E<FEO9',@96YD960@;VX@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q,@T*(&YO="!R96%C:&EN
M9R!C97)T86EN(&UI;FEM=6T@=&AR97-H;VQD<RX@07,@;V8@1&5C96UB97(F
M(WA!,#LS,2P-"B`R,#$T+"!W92!D;R!N;W0@97AP96-T('1O(&UA:V4@86YY
M(&9U<G1H97(@<&%Y;65N=',@<F5L871E9"!T;R!T:&4-"B!0=7)C:&%S92!A
M;F0@4V%L92!!9W)E96UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@
M82!R97-U;'0@;V8-"B!T:&ES(&QI86)I;&ET>2!A8V-O=6YT:6YG+"!E=F5N
M('1H;W5G:"!T:&4@<F]Y86QT:65S(&9R;VT@54-"(&%N9`T*(%)O8VAE(&%R
M92!R96UI='1E9"!D:7)E8W1L>2!T;R!24$D@<W1A<G1I;F<@=VET:"!R;WEA
M;'1I97,@87)I<VEN9PT*(&9R;VT@<')O9'5C="!S86QE<R!I;B!T:&4@9FER
M<W0@<75A<G1E<B!O9B`R,#$R+"!W92!W:6QL(&-O;G1I;G5E#0H@=&\@<F5C
M;V=N:7IE(')E=F5N=64@9F]R('1H97-E(')O>6%L=&EE<RX@1'5R:6YG('1H
M92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,@
M86YD(#(P,3(L('=E(')E8V]G;FEZ960@)#(Q+CD@;6EL;&EO;BP-"B`D,C(N
M,2!M:6QL:6]N(&%N9"`D,3`N."!M:6QL:6]N+"!R97-P96-T:79E;'DL(&EN
M(&YO;BUC87-H#0H@<F]Y86QT:65S(&9R;VT@;F5T('-A;&5S(&]F($-)35I)
M03QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L
M:6YE.R!03U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%
M.SPO<W5P/CPO9F]N=#X-"B!A;F0@34E20T5203QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L
M871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P/CPO9F]N=#XN/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!
M1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
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M<V4@86UO=6YT<R!L97-S('1H92`D,3(T+C`@;6EL;&EO;B!P<F]C965D<R!W
M92!R96-E:79E9`T*('=I;&P@8F4@<F5C;W)D960@87,@:6YT97)E<W0@97AP
M96YS92!O=F5R('1H92!L:69E(&]F('1H92!2;WEA;'1Y#0H@3V)L:6=A=&EO
M;BX@4VEN8V4@:6YC97!T:6]N+"!O=7(@97-T:6UA=&4@;V8@=&AI<R!T;W1A
M;"!I;G1E<F5S=`T*(&5X<&5N<V4@<F5S=6QT960@:6X@86X@969F96-T:79E
M(&%N;G5A;"!I;G1E<F5S="!R871E(&]F#0H@87!P<F]X:6UA=&5L>2`Q-R4N
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M;B!O=7(@;W)I9VEN86P@97-T:6UA=&5S+`T*('=E('=I;&P@<')O<W!E8W1I
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M4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^)B-X044[/"]S=7`^
M/"]F;VYT/@T*(&%N9"!-25)#15)!/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@
M0D]45$]-.B`P+CAE>"<^)B-X044[/"]S=7`^/"]F;VYT/BP-"B!M;W-T(&]F
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M;B!5+E,N(&1O;&QA<G,-"B`H55-$*2!W:&EL92!S:6=N:69I8V%N="!P;W)T
M:6]N<R!O9B!T:&4@=6YD97)L>6EN9R!S86QE<R!O9@T*($-)35I)03QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!0
M3U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P
M/CPO9F]N=#X-"B!A;F0@34E20T5203QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G
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M/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)
M5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P/CPO
M9F]N=#X-"B!A;F0@34E20T5203QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D52
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M3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O
M;G0^#0H@86YD($U)4D-%4D$\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U14
M3TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^#0H@87)E(&UO<F4@=&AA
M;B!E>'!E8W1E9"P@=&AE(&YO;BUC87-H(')O>6%L='D@<F5V96YU97,@86YD
M('1H90T*(&YO;BUC87-H(&EN=&5R97-T(&5X<&5N<V4@<F5C;W)D960@8GD@
M=7,@=V]U;&0@8F4@9W)E871E<B!O=F5R('1H90T*('1E<FT@;V8@=&AE(%)O
M>6%L='D@3V)L:6=A=&EO;BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
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M=V4@=V5R92!T;R!B<F5A8V@@;W5R(&]B;&EG871I;VYS+"!W92!C;W5L9`T*
M(&)E(')E<75I<F5D('1O('!A>2!D86UA9V5S('1O(%)022!T:&%T(&%R92!N
M;W0@;&EM:71E9"!T;R!T:&4-"B!P=7)C:&%S92!P<FEC92!W92!R96-E:79E
M9"!I;B!T:&4@<V%L92!T<F%N<V%C=&EO;BX\+V9O;G0^/"]P/@T*(`T*(`T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y
M9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A
M;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0
M.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E)B-X03`[."8C>$$P.R8C>#(P,30[
M#0H@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+V(^/"]F;VYT/CPO
M<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>"<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^
M4F]Y86QT>0T*($5X<&5N<V4\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V4@:&%V92!T:&ER9`T*('!A
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M,#MM:6QL:6]N+`T*("0T+C$F(WA!,#MM:6QL:6]N+"!A;F0@)#(N.28C>$$P
M.VUI;&QI;VX@9F]R('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[
M,S$L(#(P,30L(#(P,3,L(&%N9"`R,#$R+"!R97-P96-T:79E;'DN(%1H92!O
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M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S
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M96UB97(F(WA!,#LS,2P@,C`Q-"P@=&AE<V4@8V]M;6ET;65N=',@=V5R90T*
M(&%P<')O>&EM871E;'D@)#$V+CDF(WA!,#MM:6QL:6]N+"!A;&P@;V8@=VAI
M8V@@87)E(&5X<&5C=&5D('1O(&)E#0H@<&%I9"!I;B`R,#$U+CPO9F]N=#X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y,96=A;`T*($UA='1E<G,\+VD^
M/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O
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M9"!O<B!O;B!O=7(@8V%S:`T*(&9L;W=S(&%N9"!L:7%U:61I='DN/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D9O<F5I9VX-"B!/<&5R871I
M;VYS/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G
M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/E=E(&]P97)A=&4@:6X@80T*(&YU;6)E<B!O9B!F;W)E
M:6=N(&-O=6YT<FEE<RX@07,@82!R97-U;'0L('=E(&%R92!S=6)J96-T('1O
M#0H@;G5M97)O=7,@;&]C86P@;&%W<R!A;F0@<F5G=6QA=&EO;G,@=&AA="!C
M86X@<F5S=6QT(&EN(&-L86EM<R!M861E#0H@8GD@9F]R96EG;B!G;W9E<FYM
M96YT(&%G96YC:65S(&]R(&]T:&5R('1H:7)D('!A<G1I97,@=&AA="!A<F4-
M"B!O9G1E;B!D:69F:6-U;'0@=&\@<')E9&EC="!E=F5N(&%F=&5R('1H92!A
M<'!L:6-A=&EO;B!O9B!G;V]D(&9A:71H#0H@8V]M<&QI86YC92!E9F9O<G1S
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y);F1E;6YI9FEC
M871I;VX-"B!/8FQI9V%T:6]N<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE#0H@8V]U
M<G-E(&]F(&]U<B!N;W)M86P@;W!E<F%T:6YG(&%C=&EV:71I97,L('=E(&AA
M=F4@86=R965D('1O#0H@8V5R=&%I;B!C;VYT:6YG96YT(&EN9&5M;FEF:6-A
M=&EO;B!O8FQI9V%T:6]N<R!A<R!F=7)T:&5R(&1E<V-R:6)E9`T*(&)E;&]W
M+B!4:&4@=&5R;2!O9B!O=7(@:6YD96UN:69I8V%T:6]N(&]B;&EG871I;VYS
M(&ES(&=E;F5R86QL>0T*('!E<G!E='5A;"X@5&AE<F4@:7,@9V5N97)A;&QY
M(&YO(&QI;6ET871I;VX@;VX@=&AE('!O=&5N=&EA;"!A;6]U;G0-"B!O9B!F
M=71U<F4@<&%Y;65N=',@=V4@8V]U;&0@8F4@<F5Q=6ER960@=&\@;6%K92!U
M;F1E<B!T:&5S90T*(&EN9&5M;FEF:6-A=&EO;B!O8FQI9V%T:6]N<RX@5&\@
M9&%T92P@=V4@:&%V92!N;W0@:6YC=7)R960-"B!S:6=N:69I8V%N="!C;W-T
M<R!T;R!D969E;F0@;&%W<W5I=',@;W(@<V5T=&QE(&-L86EM<R!B87-E9"!O
M;B!O=7(-"B!I;F1E;6YI9FEC871I;VX@;V)L:6=A=&EO;G,N($EF(&%N>2!O
M9B!O=7(@:6YD96UN:69I8V%T:6]N#0H@;V)L:6=A=&EO;G,@:7,@=')I9V=E
M<F5D+"!W92!M87D@:6YC=7(@<W5B<W1A;G1I86P@;&EA8FEL:71I97,N#0H@
M0F5C875S92!T:&4@86=G<F5G871E(&%M;W5N="!O9B!A;GD@<&]T96YT:6%L
M(&EN9&5M;FEF:6-A=&EO;@T*(&]B;&EG871I;VX@:7,@;F]T(&$@<W1A=&5D
M(&%M;W5N="P@=&AE(&]V97)A;&P@;6%X:6UU;2!A;6]U;G0@;V8-"B!A;GD@
M<W5C:"!O8FQI9V%T:6]N<R!C86YN;W0@8F4@<F5A<V]N86)L>2!E<W1I;6%T
M960N($YO(&QI86)I;&ET:65S#0H@:&%V92!B965N(')E8V]R9&5D(&9O<B!T
M:&5S92!O8FQI9V%T:6]N<R!O;B!O=7(@0V]N<V]L:61A=&5D#0H@0F%L86YC
M92!3:&5E=',@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!O<B`R,#$S
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y);F1E;6YI9FEC
M871I;VYS(&EN#0H@0V]N;F5C=&EO;B!W:71H($-O;6UE<F-I86P@06=R965M
M96YT<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY!<R!P87)T(&]F(&]U<@T*(&-O;&QA8F]R871I;VX@
M86=R965M96YT<R!W:71H(&]U<B!P87)T;F5R<R!R96QA=&5D('1O('1H92!L
M:6-E;G-E+`T*(&1E=F5L;W!M96YT+"!M86YU9F%C='5R92!A;F0@<W5P<&QY
M(&]F(&1R=6=S(&)A<V5D(&]N(&]U<@T*('!R;W!R:65T87)Y('1E8VAN;VQO
M9VEE<R!A;F0@9')U9R!C86YD:61A=&5S+"!W92!G96YE<F%L;'D@86=R964@
M=&\-"B!D969E;F0L(&EN9&5M;FEF>2!A;F0@:&]L9"!H87)M;&5S<R!O=7(@
M<&%R=&YE<G,@9G)O;2!A;F0@86=A:6YS=`T*('1H:7)D('!A<G1Y(&QI86)I
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M<&%R=&YE<G,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@<&%R="!O9B!T
M:&4-"B!S86QE(&]F(&]U<B!R;WEA;'1Y(&EN=&5R97-T(&EN('1H92!#24U:
M24$\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E
M;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!
M13L\+W-U<#X\+V9O;G0^#0H@86YD($U)4D-%4D$\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^#0H@
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M87)T:7,@:6X@,C`P."P@=V4@86YD($YO=F%R=&ES(&UA9&4-"B!R97!R97-E
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M=&%N=&EA;`T*(&EN9&5M;FEF:6-A=&EO;B!L:6%B:6QI=&EE<R!D97!E;F1I
M;F<@;VX@=&AE('1I;6EN9RP@;F%T=7)E+"!A;F0-"B!A;6]U;G0@;V8@86YY
M('-U8V@@8VQA:6US+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS
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M9R!L:6%B:6QI=&EE<PT*('5N9&5R('1H92!396-U<FET:65S($%C="!O9B`Q
M.3,S+"!A<R!A;65N9&5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CX\:3Y$:7)E8W1O<B!A;F0@3V9F:6-E<@T*($EN9&5M;FEF:6-A=&EO;G,\
M+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M:6%L#0H@)#$L-3`P+#`P,"!P97(@:6YC:61E;G0@9F]R(&UE<F=E<B!A;F0@
M86-Q=6ES:71I;VX@<F5L871E9"!C;&%I;7,L#0H@)#$L,#`P+#`P,"!P97(@
M:6YC:61E;G0@9F]R('-E8W5R:71I97,@<F5L871E9"!C;&%I;7,@86YD("0U
M,#`L,#`P#0H@<&5R(&EN8VED96YT(&9O<B!N;VXM<V5C=7)I=&EE<R!R96QA
M=&5D(&-L86EM<R!R971E;G1I;VX@9&5D=6-T:6)L90T*('!E<B!O=7(@:6YS
M=7)A;F-E('!O;&EC>2X@2&]W979E<BP@;F\@87-S=7)A;F-E<R!C86X@8F4@
M9VEV96X@=&AA=`T*('1H92!C;W9E<FEN9R!I;G-U<F5R<R!W:6QL(&YO="!A
M='1E;7!T('1O(&1I<W!U=&4@=&AE('9A;&ED:71Y+`T*(&%P<&QI8V%B:6QI
M='DL(&]R(&%M;W5N="!O9B!C;W9E<F%G92!W:71H;W5T(&5X<&5N<VEV92!L
M:71I9V%T:6]N#0H@86=A:6YS="!T:&5S92!I;G-U<F5R<RP@:6X@=VAI8V@@
M8V%S92!W92!M87D@:6YC=7(@<W5B<W1A;G1I86P-"B!L:6%B:6QI=&EE<R!A
M<R!A(')E<W5L="!O9B!T:&5S92!I;F1E;6YI9FEC871I;VX-"B!O8FQI9V%T
M:6]N<RX\+V9O;G0^/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W
M7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K
M<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^3F]T928C>$$P.SDF
M(WA!,#LF(W@R,#$T.R!3=&]C:VAO;&1E<G,F(W@R,#$Y.R!%<75I='D\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0G/@T*(#QB/CQI/E!R969E<G)E9"!3=&]C:SPO:3X\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5V4@:&%V92!A=71H
M;W)I>F5D(#$P+#`P,"PP,#`F(WA!,#MS:&%R97,@;V8@4')E9F5R<F5D(%-T
M;V-K('=I=&@-"B!E86-H('-H87)E(&AA=FEN9R!A('!A<B!V86QU92!O9B`D
M,"XP,#`Q+B!);B`R,#$Q+`T*(#,L,3`P+#`P,"8C>$$P.W-H87)E<R!W97)E
M('!R979I;W5S;'D@9&5S:6=N871E9"!397)I97,F(WA!,#M!#0H@2G5N:6]R
M(%!A<G1I8VEP871I;F<@4')E9F5R<F5D(%-T;V-K("A397)I97,F(WA!,#M!
M(%!R969E<G)E9`T*(%-T;V-K*2!I;B!C;VYN96-T:6]N('=I=&@@;W5R(%-H
M87)E(%!U<F-H87-E(%)I9VAT<R!0;&%N("A2:6=H=',-"B!0;&%N*2!T:&%T
M(&5X<&ER960@;VX@2G5N928C>$$P.S$L(#(P,3$N($]N($UA<F-H)B-X03`[
M,S`L(#(P,3(L('=E#0H@9FEL960@82!C97)T:69I8V%T92!O9B!E;&EM:6YA
M=&EO;B!O9B!T:&4@4V5R:65S($$@4')E9F5R<F5D(%-T;V-K+@T*($%S(&]F
M($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P,3,L(&YO('!R969E<G)E
M9"!S:&%R97,@87)E#0H@9&5S:6=N871E9"P@:7-S=65D(&]R(&]U='-T86YD
M:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^0V]M;6]N(%-T;V-K/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!*86YU87)Y
M)B-X03`[,C@L(#(P,30L('=E(&-O;7!L971E9"!T:&4@:7-S=6%N8V4@86YD
M('-A;&4@;V8-"B`Y+#<W-2PP,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O
M8VL@:6X@82!P=6)L:6,@;V9F97)I;F<@=VET:`T*('1O=&%L('!R;V-E961S
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M<FEN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D5Q=6ET>2!#;VUP96YS871I
M;VX@4&QA;G,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,30L('=E(&AA9"`R-"PX,#8L
M-38U(')E<V5R=F5D('-H87)E<R!O9@T*(&-O;6UO;B!S=&]C:RP@86QL(&]F
M('=H:6-H(&%R92!R97-E<G9E9"!F;W(@:7-S=6%N8V4@=6YD97(@;W5R#0H@
M97%U:71Y(&-O;7!E;G-A=&EO;B!P;&%N<R!A<R!S=6UM87)I>F5D(&EN('1H
M92!F;VQL;W=I;F<@=&%B;&4-"B`H<VAA<F4@;G5M8F5R(&EN('1H;W5S86YD
M<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].
M5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T
M:#TS1#0X)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[(%=)1%1(
M.B`T.2XQ<'0G/@T*(#QB/E!L86X@0V%T96=O<GD\+V(^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*
M(#QB/DYU;6)E<B8C>$$P.V]F)B-X03`[4V5C=7)I=&EE<R8C>$$P.W1O)B-X
M03`[8F4\+V(^/&)R("\^#0H@/&(^27-S=65D(%5P;VX@17AE<F-I<V4@;V8\
M+V(^/&)R("\^#0H@/&(^3W5T<W1A;F1I;F<@3W!T:6]N<SPO8CX\8G(@+SX-
M"B`\8CXH82D\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/E=E:6=H=&5D+4%V97)A9V4\+V(^/&)R("\^#0H@/&(^17AE<F-I
M<V4@4')I8V4@;V8\+V(^/&)R("\^#0H@/&(^3W5T<W1A;F1I;F<F(WA!,#M/
M<'1I;VYS/"]B/CQB<B`O/@T*(#QB/BAB*3PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^3G5M8F5R)B-X03`[;V8F(WA!
M,#M396-U<FET:65S)B-X03`[4F5M86EN:6YG/"]B/CQB<B`O/@T*(#QB/D%V
M86EL86)L92!F;W(@27-S=6%N8V4@56YD97(\+V(^/&)R("\^#0H@/&(^17%U
M:71Y($-O;7!E;G-A=&EO;B!0;&%N<SPO8CX\8G(@+SX-"B`\8CXH17AC;'5D
M:6YG(%-E8W5R:71I97,@4F5F;&5C=&5D/"]B/CQB<B`O/@T*(#QB/FEN($-O
M;'5M;BAA*2D\+V(^/&)R("\^#0H@/&(^*&,I/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!%<75I='D@8V]M<&5N<V%T:6]N('!L86YS(&%P<')O=F5D
M(&)Y('-E8W5R:71Y(&AO;&1E<G,H,2D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M9VAT/C$P+C8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L.#$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%<75I='D@8V]M
M<&5N<V%T:6]N('!L86YS(&YO="!A<'!R;W9E9"!B>2!S96-U<FET>2!H;VQD
M97)S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.30\+W1D
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M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(Q+#DY-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`N-3`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPX,3(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#)P=#L@0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($U!4D=)3BU43U`Z(#!P=#L@3$E.
M12U(14E'2%0Z(#AP=#L@5TE$5$@Z(#$P)2<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O
M<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T
M)2!A;&EG;CTS1&QE9G0^*#$I/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L
M:6=N/3-$;&5F=#Y);F-L=61E<R!S:&%R97,@;V8@8V]M;6]N('-T;V-K#0H@
M879A:6QA8FQE(&9O<B!F=71U<F4@:7-S=6%N8V4@=6YD97(@;W5R($534%`@
M87,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+CPO=&0^#0H@/"]T<CX-
M"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3XR,#$R(%!E<F9O<FUA;F-E
M($EN8V5N=&EV92!0;&%N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!/=7(@,C`Q,B!097)F;W)M86YC92!);F-E;G1I=F4@4&QA
M;B`H,C`Q,B!0;&%N*2!W87,@861O<'1E9"!B>2!T:&4-"B!";V%R9"!O9B!$
M:7)E8W1O<G,@;VX@07!R:6PF(WA!,#LT+"`R,#$R(&%N9"!W87,@87!P<F]V
M960@8GD@;W5R#0H@<W1O8VMH;VQD97)S(&]N($IU;F4F(WA!,#LR."P@,C`Q
M,BX@3VX@=&AE(&1A=&4@;V8@87!P<F]V86PL(&%N>0T*('-H87)E<R!O9B!O
M=7(@8V]M;6]N('-T;V-K('1H870@=V5R92!A=F%I;&%B;&4@9F]R(&ES<W5A
M;F-E('5N9&5R#0H@86QL(&]T:&5R('!R979I;W5S;'D@97AI<W1I;F<@<W1O
M8VL@<&QA;G,@*'1H92`R,#`X($5Q=6ET>0T*($EN8V5N=&EV92!0;&%N+"!T
M:&4@,C`P,"!%<75I='D@26YC96YT:79E(%!L86XL(&%N9"!T:&4@,C`P,`T*
M($YO;BU/9F9I8V5R($5Q=6ET>2!);F-E;G1I=F4@4&QA;BD@8F5C86UE(&%V
M86EL86)L92!F;W(@:7-S=6%N8V4-"B!U;F1E<B!T:&4@,C`Q,B!0;&%N+B!)
M;B!A9&1I=&EO;BP@-2PS,#`L,#`P(&YE=R!S:&%R97,@=V5R92!M861E#0H@
M879A:6QA8FQE(&9O<B!A=V%R9"!G<F%N=',@=6YD97(@=&AE(#(P,3(@4&QA
M;BX@3F\@;F5W(&%W87)D<R!W97)E#0H@9W)A;G1E9"!U;F1E<B!A;GD@;V8@
M=&AE('!R979I;W5S('-T;V-K('!L86YS(&%F=&5R($IU;F4F(WA!,#LR."P-
M"B`R,#$R+B!!;GD@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!S=6)J96-T('1O
M(&]U='-T86YD:6YG(&%W87)D<PT*('5N9&5R('1H92!P<F5V:6]U<R!S=&]C
M:R!P;&%N<R!T:&%T(&5X<&ER92P@87)E(&-A;F-E;&QE9"P@;W(-"B!O=&AE
M<G=I<V4@=&5R;6EN871E(&%T(&%N>2!T:6UE(&%F=&5R($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3$@87)E#0H@86QS;R!A=F%I;&%B;&4@9F]R(&%W87)D(&=R
M86YT('!U<G!O<V5S('5N9&5R('1H92`R,#$R(%!L86XN/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!P=7)P;W-E(&]F('1H92`R,#$R
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M87=A<F1S('5N9&5R('1H92`R,#$R#0H@4&QA;BX@4'5R<W5A;G0@=&\@=&AE
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M<F%N=&5D('1O(&]U<@T*(&5M<&QO>65E<R!U;F1E<B!T:&4@,C`Q,B!0;&%N
M(&%S('=E;&P@87,@86QL(&]T:&5R('!R979I;W5S;'D-"B!E>&ES=&EN9R!S
M=&]C:R!P;&%N<R!W87,@9V5N97)A;&QY(&9O=7(@>65A<G,[('1H92!R97%U
M:7-I=&4-"B!S97)V:6-E('!E<FEO9"!F;W(@<W1O8VL@;W!T:6]N<R!G<F%N
M=&5D('1O(&]U<B!D:7)E8W1O<G,@=V%S#0H@9V5N97)A;&QY(&]N92!Y96%R
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@;6%X:6UU
M;2!N=6UB97(@;V8@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@=&AA="!M
M87D@8F4@:7-S=65D#0H@;W(@=')A;G-F97)R960@<'5R<W5A;G0@=&\@87=A
M<F1S('5N9&5R('1H92`R,#$R(%!L86X@:7,@,3`L,S0W+#$T,`T*('-H87)E
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M:79E<F5D('5N9&5R('1H92`R,#$R(%!L86X@=VEL;`T*(&%G86EN(&)E(&%V
M86EL86)L92!F;W(@<W5B<V5Q=65N="!A=V%R9',@=6YD97(@=&AE(#(P,3(@
M4&QA;BX-"B!3:&%R97,@:7-S=65D(&EN(')E<W!E8W0@;V8@86YY(&%W87)D
M+"!O=&AE<B!T:&%N(&$@<W1O8VL@;W!T:6]N(&]R#0H@<W1O8VL@87!P<F5C
M:6%T:6]N(')I9VAT+"!G<F%N=&5D('5N9&5R('1H92`R,#$R(%!L86X@=VEL
M;"!B90T*(&-O=6YT960@86=A:6YS="!T:&4@<&QA;B8C>#(P,3D[<R!S:&%R
M92!L:6UI="!A<R`Q+C4F(WA!,#MS:&%R97,@9F]R#0H@979E<GD@;VYE('-H
M87)E(&%C='5A;&QY(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&%W
M87)D+B!790T*(&1I9"!N;W0@9W)A;G0@86YY(%)352!A=V%R9',@9'5R:6YG
M('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P
M,3,@;W(@,C`Q,B!A;F0@;F\@4E-5<R!A<F4@;W5T<W1A;F1I;F<@870-"B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!4:&4@,C`Q,B!0;&%N('=I;&P@=&5R;6EN871E(&]N($%P
M<FEL)B-X03`[,RP@,C`R,BP@=6YL97-S(&5A<FQI97(-"B!T97)M:6YA=&5D
M(&)Y('1H92!";V%R9"!O9B!$:7)E8W1O<G,N(%1H92!M87AI;75M('1E<FT@
M;V8@82!S=&]C:PT*(&]P=&EO;B!O<B!S=&]C:R!A<'!R96-I871I;VX@<FEG
M:'0@=6YD97(@=&AE(#(P,3(@4&QA;B!I<R!E:6=H=`T*('EE87)S(&9R;VT@
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D]T:&5R($5Q=6ET>2!);F-E;G1I=F4@
M4&QA;G,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($EN(&%D9&ET:6]N('1O('1H92`R,#$R(%!L86XL('=E(&AA=F4@;W1H97(@
M97%U:71Y(&EN8V5N=&EV92!P;&%N<PT*('5N9&5R('=H:6-H(&]P=&EO;G,@
M9W)A;G1E9"!R96UA:6X@;W5T<W1A;F1I;F<@8G5T(&YO(&YE=R!O<'1I;VYS
M#0H@;6%Y(&)E(&=R86YT960@96ET:&5R(&%S(&$@<F5S=6QT(&]F('1H92!A
M<'!R;W9A;"!O9B!T:&4@,C`Q,B!0;&%N#0H@;W(@<&QA;B!E>'!I<F%T:6]N
M+B!4:&5S92!P;&%N<R!I;F-L=61E.B`H:2DF(WA!,#MT:&4@,C`P."!%<75I
M='D-"B!);F-E;G1I=F4@4&QA;B`H,C`P."!0;&%N*2!W:&EC:"!W87,@861O
M<'1E9"!B>2!T:&4@0F]A<F0@;V8-"B!$:7)E8W1O<G,@;VX@36%R8V@F(WA!
M,#LR,"P@,C`P."!A;F0@87!P<F]V960@8GD@;W5R('-T;V-K:&]L9&5R<PT*
M(&]N($IU;F4F(WA!,#LV+"`R,#`X.R`H:6DI)B-X03`[=&AE(#(P,#`@17%U
M:71Y($EN8V5N=&EV92!0;&%N#0H@*#(P,#`@4&QA;BD@=VAI8V@@=V%S(&%D
M;W!T960@8GD@=&AE($)O87)D(&]F($1I<F5C=&]R<R!O;@T*($%P<FEL)B-X
M03`[,3DL(#(P,#`@8GD@86UE;F1I;F<@86YD(')E<W1A=&EN9R!O=7(@,3DY
M-"!%<75I='D-"B!);F-E;G1I=F4@4&QA;BP@86YD('=H:6-H(&5X<&ER960@
M;VX@1F5B<G5A<GDF(WA!,#LY+"`R,#$P.R!A;F0-"B`H:6EI*28C>$$P.W1H
M92`Q.3DX($YO;BU/9F9I8V5R($5Q=6ET>2!);F-E;G1I=F4@4&QA;B!W:&EC
M:"!W87,-"B!A9&]P=&5D(&)Y(&]U<B!";V%R9"!O9B!$:7)E8W1O<G,@;VX@
M075G=7-T)B-X03`[,3@L(#$Y.3@L(&%N9`T*('=H:6-H('=A<R!A;65N9&5D
M(&%N9"!R97-T871E9"!I;B!I=',@96YT:7)E='D@86YD(')E;F%M960@=&AE
M(#(P,#`-"B!.;VXM3V9F:6-E<B!%<75I='D@26YC96YT:79E(%!L86X@;VX@
M2G5N928C>$$P.S8L(#(P,#`@*#(P,#`-"B!.;VXM3V9F:6-E<B!0;&%N*2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4'5R<W5A;G0@=&\@=&AE(#(P,#@@
M4&QA;B!A;F0@=&AE(#(P,#`@4&QA;BP@=V4@<')E=FEO=7-L>2!G<F%N=&5D
M#0H@;W(@:7-S=65D(&EN8V5N=&EV92!S=&]C:R!O<'1I;VYS('1O(&5M<&QO
M>65E<R!A;F0@;V9F:6-E<G,@86YD#0H@;F]N+7%U86QI9FEE9"!S=&]C:R!O
M<'1I;VYS+"!R:6=H=',@=&\@86-Q=6ER92!R97-T<FEC=&5D('-T;V-K+`T*
M(')E<W1R:6-T960@<W1O8VL@=6YI=',L(&%N9"!S=&]C:R!B;VYU<V5S('1O
M(&5M<&QO>65E<RP@;V9F:6-E<G,L#0H@;F]N+65M<&QO>65E(&1I<F5C=&]R
M<RP@86YD(&-O;G-U;'1A;G1S+B!0=7)S=6%N="!T;R!T:&4@,C`P,`T*($YO
M;BU/9F9I8V5R(%!L86XL('=E('!R979I;W5S;'D@9W)A;G1E9"!O<B!I<W-U
M960@;F]N+7%U86QI9FEE9`T*('-T;V-K(&]P=&EO;G,L(')I9VAT<R!T;R!A
M8W%U:7)E(')E<W1R:6-T960@<W1O8VL@86YD('-T;V-K(&)O;G5S97,-"B!T
M;R!E;7!L;WEE97,@86YD(&-O;G-U;'1A;G1S('=H;R!A<F4@;F5I=&AE<B!O
M9F9I8V5R<R!N;W(@9&ER96-T;W)S#0H@;V8@3F5K=&%R+B!4:&4@;6%X:6UU
M;2!T97)M(&]F(&$@<W1O8VL@;W!T:6]N('5N9&5R(&%L;"!O9B!T:&5S90T*
M('!L86YS(&ES(&5I9VAT('EE87)S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^
M16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;CPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@1F5B<G5A<GD@,3DY-#QB/BP\
M+V(^(&]U<B!";V%R9"!O9B!$:7)E8W1O<G,@861O<'1E9"!T:&4-"B!%;7!L
M;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N("A%4U!0*2!P=7)S=6%N="!T;R!S
M96-T:6]N)B-X03`[-#(S*&(I#0H@;V8@=&AE($EN=&5R;F%L(%)E=F5N=64@
M0V]D92!O9B`Q.3@V+B!5;F1E<B!T:&4@15-04"P-"B`R+#4P,"PP,#`F(WA!
M,#MS:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!H879E(&)E96X@875T:&]R
M:7IE9"!F;W(-"B!I<W-U86YC92X@5&AE('1E<FUS(&]F('1H92!%4U!0('!R
M;W9I9&4@96QI9VEB;&4@96UP;&]Y965S('=I=&@@=&AE#0H@;W!P;W)T=6YI
M='D@=&\@86-Q=6ER92!A;B!O=VYE<G-H:7`@:6YT97)E<W0@:6X@3F5K=&%R
M('1H<F]U9V@-"B!P87)T:6-I<&%T:6]N(&EN(&$@<')O9W)A;2!O9B!P97)I
M;V1I8R!P87ER;VQL(&1E9'5C=&EO;G,@9F]R('1H90T*('!U<F-H87-E(&]F
M(&]U<B!C;VUM;VX@<W1O8VLN($5M<&QO>65E<R!M87D@96QE8W0@=&\@96YR
M;VQL(&]R#0H@<F4M96YR;VQL(&EN('1H92!%4U!0(&]N(&$@<V5M:2UA;FYU
M86P@8F%S:7,N(%-T;V-K(&ES('!U<F-H87-E9"!A=`T*(#@U)2!O9B!T:&4@
M;&]W97(@;V8@=&AE(&-L;W-I;F<@<')I8V4@;VX@=&AE(&9I<G-T(&1A>2!O
M9B!T:&4-"B!E;G)O;&QM96YT('!E<FEO9"!O<B!T:&4@;&%S="!D87D@;V8@
M=&AE(&5N<F]L;&UE;G0@<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^
M-#`Q*&LI(%)E=&ER96UE;G0@4&QA;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5V4@<W!O;G-O<B!A(#0P,2AK*2!R971I<F5M
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M82!M87AI;75M(&]F("0S+#`P,"!P97(@<&%R=&EC:7!A;G0N($9O<B!T:&4@
M>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S+"!A
M;F0@,C`Q,BP@=V4@<F5C;V=N:7IE9"`D,"XY(&UI;&QI;VXL#0H@)#$N,"8C
M>$$P.VUI;&QI;VXL(&%N9"`D,"XY)B-X03`[;6EL;&EO;BP@<F5S<&5C=&EV
M96QY+"!O9@T*(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&EN(&-O;FYE8W1I;VX@
M=VET:"!O=7(@-#`Q*&LI(')E=&ER96UE;G0-"B!P;&%N+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP
M="<^#0H@/&(^/&D^0VAA;F=E(&EN($-O;G1R;VP@4V5V97)A;F-E(%!L86X\
M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($]N($1E
M8V5M8F5R)B-X03`[-BP@,C`P-BP@;W5R($)O87)D(&]F($1I<F5C=&]R<R!A
M<'!R;W9E9"!A($-H86YG90T*(&]F($-O;G1R;VP@4V5V97)A;F-E($)E;F5F
M:70@4&QA;B`H0TE#(%!L86XI+B!4:&ES($-)0R!0;&%N(&AA<PT*('-U8G-E
M<75E;G1L>2!B965N(&%M96YD960@82!N=6UB97(@;V8@=&EM97,@8GD@;W5R
M($)O87)D(&]F#0H@1&ER96-T;W)S('=I=&@@=&AE(&UO<W0@<F5C96YT(&%M
M96YD;65N="!O8V-U<G)I;F<@;VX@07!R:6PF(WA!,#LU+`T*(#(P,3$N(%1H
M92!#24,@4&QA;B!I<R!D97-I9VYE9"!T;R!M86ME(&-E<G1A:6X@8F5N969I
M=',@879A:6QA8FQE#0H@=&\@;W5R(&5L:6=I8FQE(&5M<&QO>65E<R!I;B!T
M:&4@979E;G0@;V8@82!C:&%N9V4@;V8@8V]N=')O;"!O9@T*($YE:W1A<B!A
M;F0L(&9O;&QO=VEN9R!S=6-H(&-H86YG92!O9B!C;VYT<F]L+"!A;B!E;7!L
M;WEE928C>#(P,3D[<PT*(&5M<&QO>6UE;G0@=VET:"!U<R!O<B!A('-U8V-E
M<W-O<B!C;VUP86YY(&ES('1E<FUI;F%T960@:6X@8V5R=&%I;@T*('-P96-I
M9FEE9"!C:7)C=6US=&%N8V5S+B!792!A9&]P=&5D('1H92!#24,@4&QA;B!T
M;R!S=7!P;W)T('1H90T*(&-O;G1I;G5I='D@;V8@=&AE(&)U<VEN97-S(&EN
M('1H92!C;VYT97AT(&]F(&$@8VAA;F=E(&]F(&-O;G1R;VP-"B!T<F%N<V%C
M=&EO;BX@5&AE($-)0R!0;&%N('=A<R!N;W0@861O<'1E9"!I;B!C;VYT96UP
M;&%T:6]N(&]F(&%N>0T*('-P96-I9FEC(&-H86YG92!O9B!C;VYT<F]L('1R
M86YS86-T:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M<F%N<V%C=&EO;BP@*&DI)B-X03`[=&AE($-H:65F#0H@17AE8W5T:79E($]F
M9FEC97(@=V]U;&0@8F4@96YT:71L960@=&\@<F5C96EV92!C87-H('-E=F5R
M86YC92!P87D-"B!E<75A;"!T;R`R-"8C>$$P.VUO;G1H<R!B87-E('-A;&%R
M>2!P;'5S(&%N;G5A;"!T87)G970@:6YC96YT:79E#0H@<&%Y+"!T:&4@97AT
M96YS:6]N(&]F(&5M<&QO>65E(&)E;F5F:71S(&]V97(@=&AI<R!S979E<F%N
M8V4@<&5R:6]D#0H@86YD('1H92!F=6QL(&%C8V5L97)A=&EO;B!O9B!U;G9E
M<W1E9"!O=71S=&%N9&EN9R!E<75I='D@87=A<F1S+`T*(&%N9"`H:6DI)B-X
M03`[;W5R(%-E;FEO<B!6:6-E(%!R97-I9&5N=',@86YD(%9I8V4@4')E<VED
M96YT<PT*("AI;F-L=61I;F<@4')I;F-I<&%L($9E;&QO=W,I('=O=6QD(&5A
M8V@@8F4@96YT:71L960@=&\@<F5C96EV90T*(&-A<V@@<V5V97)A;F-E('!A
M>2!E<75A;"!T;R!T=V5L=F4@;6]N=&AS(&)A<V4@<V%L87)Y('!L=7,@86YN
M=6%L#0H@=&%R9V5T(&EN8V5N=&EV92!P87DL('1H92!E>'1E;G-I;VX@;V8@
M96UP;&]Y964@8F5N969I=',@;W9E<B!T:&ES#0H@<V5V97)A;F-E('!E<FEO
M9"!A;F0@=&AE(&9U;&P@86-C96QE<F%T:6]N(&]F('5N=F5S=&5D(&]U='-T
M86YD:6YG#0H@97%U:71Y(&%W87)D<RX@26X@=&AE(&5V96YT(&]F(&$@8VAA
M;F=E(&]F(&-O;G1R;VP@;V8@3F5K=&%R(&%N9"!A#0H@<W5B<V5Q=65N="!T
M97)M:6YA=&EO;B!O9B!E;7!L;WEM96YT(&EN:71I871E9"!B>2!T:&4@0V]M
M<&%N>2!O<B!A#0H@<W5C8V5S<V]R(&-O;7!A;GD@;W1H97(@=&AA;B!F;W(@
M0V%U<V4@=VET:&EN('1W96QV92!M;VYT:',-"B!F;VQL;W=I;F<@82!C:&%N
M9V4@;V8@8V]N=')O;"!T<F%N<V%C=&EO;BP@86QL(&]T:&5R(&5M<&QO>65E
M<PT*('=O=6QD(&5A8V@@8F4@96YT:71L960@=&\@<F5C96EV92!C87-H('-E
M=F5R86YC92!P87D@97%U86P@=&\-"B`V)B-X03`[;6]N=&AS(&)A<V4@<V%L
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M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?
M9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B
M,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S
M+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY,:6-E;G-E(&%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@
M;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%N9"!#
M;VQL86)O<F%T:6]N($%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E)B-X03`[
M,3`F(WA!,#LF(W@R,#$T.R!,:6-E;G-E(&%N9"!#;VQL86)O<F%T:6]N#0H@
M06=R965M96YT<SPO8CX\+V9O;G0^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y("TM
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/
M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E=E(&AA=F4@
M96YT97)E9`T*(&EN=&\@=F%R:6]U<R!C;VQL86)O<F%T:6]N(&%G<F5E;65N
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M<&%R=&YE<G,@=VET:&]U=`T*('-I9VYI9FEC86YT(&9I;F%N8VEA;"!P96YA
M;'1Y+B!/=7(@8V]S=',@;V8@<&5R9F]R;6EN9R!T:&5S90T*('-E<G9I8V5S
M(&%R92!G96YE<F%L;'D@:6YC;'5D960@:6X@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT#0H@97AP96YS92P@97AC97!T('1H870@8V]S=',@9F]R('!R;V1U
M8W0@<V%L97,@=&\@;W5R(&-O;&QA8F]R871I;VX-"B!P87)T;F5R<R!A<F4@
M:6YC;'5D960@:6X@8V]S="!O9B!G;V]D<R!S;VQD+CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q
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M.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#0P)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*(#QT9"!W:61T:#TS1#,Y
M)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/EEE87(@
M16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(')G8B@P+#`L,"D@,7!X('-O;&ED.R!724142#H@,C9P="<^#0H@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^4&%R=&YE<CPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`Q<'@[($U!4D=)3BU43U`Z(#!P
M>"<@86QI9VX],T1C96YT97(^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^06=R965M96YT/"]B
M/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY!<W1R85IE;F5C82!!0CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
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M8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^
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M(#`N.&5X)SY433PO<W5P/CPO9F]N=#X-"B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CYF:7AE9"UD;W-E
M#0H@8V]M8FEN871I;VX@<')O9W)A;2`H3DM44BTQ,3DI/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,3`U+#`P,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(U+#`Q-CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C4Y/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F]C:&4\
M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/E!%1T%365,\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E
M.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^#0H@86YD($U)
M4D-%4D$\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF
M(WA!13L\+W-U<#X\+V9O;G0^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXQ,BPX-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
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M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPQ-#8\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY"87AT97(-"B!(96%L=&AC87)E/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY"05@@.#4U("A(96UO<&AI;&EA*3PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,3`L,C4X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BPR
M,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY!;6=E;BP@26YC+CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
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M251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+#`P,#PO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^-2PP,S4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C4L,#`P/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M0F%Y97(@2&5A;'1H8V%R90T*($Q,0SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0D%9-#$M
M-C4U,2`H06UI:V%C:6X@26YH86QE*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^-"PW,3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
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M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPY-S$\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!
M9F9Y;6%X+"!);F,N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/34].5%E3/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M/'-U<"!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE4
M24]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^)B-X044[/"]S=7`^/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^-RPQ-#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C(L.#(Y/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M3W1H97(\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PT-C@\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C@L,CDU/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,
M:6-E;G-E+"!C;VQL86)O<F%T:6]N(&%N9`T*(&]T:&5R(')E=F5N=64\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
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M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C,P+#$R-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A
M8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@;V8-"B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$T+"!O=7(@8V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G1S('=I=&@@<&%R=&YE<G,-"B!I;F-L=61E9"!P;W1E;G1I86P@9G5T=7)E
M('!A>6UE;G1S(&9O<B!D979E;&]P;65N="!M:6QE<W1O;F5S#0H@=&]T86QI
M;F<@87!P<F]X:6UA=&5L>2`D,3,P+C,@;6EL;&EO;BP@:6YC;'5D:6YG(&%M
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M('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L
M:6YE.R!03U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/E1-/"]S
M=7`^/"]F;VYT/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/BAP<F5V:6]U<VQY#0H@<F5F97)R960@
M=&\@87,@;F%L;WAE9V]L(&%N9"!.2U12+3$Q."D@86YD#0H@34]604Y424L\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^
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M>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!1$1)
M3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^/&D^07-T<F%:96YE8V$@04(\+VD^/"]B/CQI/CH@34]604Y424L\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@
M4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO<W5P/CPO
M9F]N=#X-"B`H;F%L;WAE9V]L(&]X86QA=&4I+"!P<F5V:6]U<VQY(')E9F5R
M<F5D('1O(&%S(&YA;&]X96=O;"!A;F0-"B!.2U12+3$Q."P@86YD($U/5D%.
M5$E+/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F%S
M96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^5$T\
M+W-U<#X\+V9O;G0^#0H@9FEX960M9&]S92!C;VUB:6YA=&EO;B!P<F]G<F%M
M+"!P<F5V:6]U<VQY(')E9F5R<F5D('1O(&%S#0H@3DM44BTQ,3D\+VD^/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!
M1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!397!T96UB97(-"B`R,#`Y+"!W92!E
M;G1E<F5D(&EN=&\@82!L:6-E;G-E(&%G<F5E;65N="!W:71H($%S=')A6F5N
M96-A($%"#0H@*$%S=')A6F5N96-A*2P@87,@86UE;F1E9"!B>2!!<W1R85IE
M;F5C82!A;F0@=7,@:6X@075G=7-T(#(P,3,L#0H@=6YD97(@=VAI8V@@=V4@
M9W)A;G1E9"!!<W1R85IE;F5C82!A('=O<FQD=VED92P@97AC;'5S:79E+`T*
M('!E<G!E='5A;"P@<F]Y86QT>2UB96%R:6YG+"!A;F0@<W5B;&EC96YS86)L
M92!L:6-E;G-E('5N9&5R(&]U<@T*('!A=&5N=',@86YD(&]T:&5R(&EN=&5L
M;&5C='5A;"!P<F]P97)T>2!T;R!D979E;&]P+"!M87)K970L(&%N9`T*('-E
M;&P@34]604Y424L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]4
M5$]-.B`P+CAE>"<^5$T\+W-U<#X\+V9O;G0^#0H@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^86YD#0H@
M34]604Y424L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-
M.B`P+CAE>"<^5$T\+W-U<#X\+V9O;G0^#0H@/&9O;G0@<W1Y;&4],T0G1D].
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M;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO
M<W5P/CPO9F]N=#X-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CYA;F0@=&AE#0H@34]604Y424L\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F%S
M96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^5$T\
M+W-U<#X\+V9O;G0^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^9FEX960M9&]S90T*(&-O;6)I;F%T
M:6]N('!R;V=R86TN($%S=')A6F5N96-A('!A:60@=7,@86X@=7!F<F]N="!P
M87EM96YT(&]F#0H@)#$R-2XP)B-X03`[;6EL;&EO;BP@=VAI8V@@=V4@<F5C
M96EV960@:6X@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F#0H@,C`P.2!A;F0@=VAI
M8V@@=V%S(&9U;&QY(')E8V]G;FEZ960@87,@;V8@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,"X-"B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!A
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M4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^5$T\+W-U<#X\+V9O
M;G0^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^86YD('1H90T*($U/5D%.5$E+/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!0
M3U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/E1-/"]S=7`^/"]F
M;VYT/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/F9I>&5D+61O<V4-"B!C;VUB:6YA=&EO;B!P<F]G
M<F%M+"!R97-P96-T:79E;'DL(&)A<V5D(&]N(&1E=F5L;W!M96YT(&5V96YT
M<R!T;PT*(&)E('!U<G-U960@86YD(&-O;7!L971E9"!S;VQE;'D@8GD@07-T
M<F%:96YE8V$L(&%S(&1E<V-R:6)E9`T*(&)E;&]W+CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!0041$24Y'+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D]N#0H@4V5P=&5M8F5R)B-X03`[,38L(#(P,30L('1H92!5
M;FET960@4W1A=&5S($9O;V0@86YD($1R=6<-"B!!9&UI;FES=')A=&EO;B`H
M1D1!*2!A<'!R;W9E9"!-3U9!3E1)2SPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO<W5P/CPO9F]N=#X-"B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CYF;W(@=&AE#0H@=')E871M96YT(&]F(&]P:6]I9"UI;F1U8V5D(&-O
M;G-T:7!A=&EO;B`H3TE#*2!I;B!A9'5L="!P871I96YT<PT*('=I=&@@8VAR
M;VYI8RP@;F]N+6-A;F-E<B!P86EN+B!/;B!$96-E;6)E<B8C>$$P.SDL(#(P
M,30L#0H@07-T<F%:96YE8V$@86YN;W5N8V5D('1H870@34]614Y424<\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@
M4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U
M<#X\+V9O;G0^#0H@*'1H92!N86QO>&5G;VP@8G)A;F0@;F%M92!I;B!T:&4@
M175R;W!E86X@56YI;VXI(&AA<R!B965N(&=R86YT960-"B!-87)K971I;F<@
M075T:&]R:7-A=&EO;B!B>2!T:&4@175R;W!E86X@0V]M;6ES<VEO;B`H14,I
M(&9O<B!T:&4-"B!T<F5A=&UE;G0@;V8@;W!I;VED+6EN9'5C960@8V]N<W1I
M<&%T:6]N("A/24,I(&EN(&%D=6QT('!A=&EE;G1S#0H@=VAO(&AA=F4@:&%D
M(&%N(&EN861E<75A=&4@<F5S<&]N<V4@=&\@;&%X871I=F4H<RDN($%S(&$@
M<F5S=6QT(&]F#0H@=&AE($9$028C>#(P,3D[<R!A<'!R;W9A;"P@;VX@4V5P
M=&5M8F5R)B-X03`[,38L(#(P,30L('=E('=E<F4-"B!E;G1I=&QE9"!T;R!A
M("0S-2XP(&UI;&QI;VX@;F]N+7)E9G5N9&%B;&4@<&%Y;65N="!F<F]M#0H@
M07-T<F%:96YE8V$L('=H:6-H('=A<R!F=6QL>2!R96-O9VYI>F5D(&%S(')E
M=F5N=64@:6X@4V5P=&5M8F5R#0H@,C`Q-"!A;F0@=V%S(')E8V5I=F5D(&EN
M($]C=&]B97(@,C`Q-"X@26X@861D:71I;VXL('1H92!&1$$F(W@R,#$Y.W,-
M"B!A<'!R;W9A;"!O9B!-3U9!3E1)2SPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO<W5P/CPO9F]N=#X-"B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CYE>'1I;F=U:7-H960-"B!O=7(@8V]N=&EN9V5N="!O8FQI9V%T:6]N
M('1O(')E<&%Y('1H92`D-S`N,"!M:6QL:6]N('!A>6UE;G0@;6%D90T*('1O
M('5S(&)Y($%S=')A6F5N96-A(&EN($YO=F5M8F5R(#(P,3,@869T97(@=&AE
M#0H@34]604Y424L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]4
M5$]-.B`P+CAE>"<^5$T\+W-U<#X\+V9O;G0^#0H@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5W($1R
M=6<-"B!!<'!L:6-A=&EO;B!W87,@86-C97!T960@9F]R(')E=FEE=R!B>2!T
M:&4@1D1!+B!!<R!A(')E<W5L="P@:6X-"B!397!T96UB97(@,C`Q-"P@=V4@
M9G5L;'D@<F5C;V=N:7IE9"!T:&ES("0W,"XP(&UI;&QI;VX@<&%Y;65N="P-
M"B!W:&EC:"!W87,@<')E=FEO=7-L>2!R96-O<F1E9"!I;B!T:&4@;&EN92!I
M=&5M("8C>#(P,4,[3&EA8FEL:71Y#0H@<F5L871E9"!T;R!R96-E:7!T(&]F
M(')E9G5N9&%B;&4@;6EL97-T;VYE('!A>6UE;G0F(W@R,#%$.R!O;B!O=7(-
M"B!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E="!A="!$96-E;6)E<B`S,2P@
M,C`Q,RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!<R!P87)T(&]F(&ET<PT*
M(&%P<')O=F%L(&]F($U/5D%.5$E+/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L
M871I=F4[($)/5%1/33H@,"XX97@G/E1-/"]S=7`^/"]F;VYT/CQF;VYT('-T
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M24]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^5$T\+W-U<#X\+V9O;G0^
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M96QA=&EV93L@0D]45$]-.B`P+CAE>"<^5$T\+W-U<#X\+V9O;G0^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^:6X@=&AE(%4N4RX@8GD-"B!!<W1R85IE;F5C82!W:6QL(&)E(')E
M9'5C960@8GD@=7`@=&\@='=O('!E<F-E;G1A9V4@<&]I;G1S('1O(&9U;F0-
M"B`S,R4@;V8@=&AE(&5X=&5R;F%L(&-O<W1S(&EN8W5R<F5D(&)Y($%S=')A
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M="!F<F]M('5S('1O($%S=')A6F5N96-A+CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!0041$24Y'+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/E=E('=I;&P@8F4-"B!E;G1I=&QE9"!T;R!U<"!T;R!A;B!A9&1I=&EO
M;F%L("0Q-#`N,"!M:6QL:6]N(&]F(&-O;G1I;F=E;G0-"B!P87EM96YT<R!U
M<&]N('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4@;V8-"B!-3U9!3E1)2SPO
M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SY4
M33PO<W5P/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXL("0Q,#`N,"!M:6QL:6]N(&]F('=H
M:6-H('=I;&P@8F4@<&%Y86)L92!U<&]N('1H92!F:7)S=`T*(&-O;6UE<F-I
M86P@<V%L92!I;B!T:&4@52Y3+B!A;F0@)#0P+C`@;6EL;&EO;B!O9B!W:&EC
M:"!W:6QL(&)E#0H@<&%Y86)L92!U<&]N('1H92!F:7)S="!C;VUM97)C:6%L
M('-A;&4@:6X@;VYE(&UA:F]R($5U<F]P96%N(%5N:6]N#0H@8V]U;G1R>2X@
M5V4@87)E(&%L<V\@96YT:71L960@=&\@<F5C96EV92!U<"!T;R`D-S4N,"!M
M:6QL:6]N(&]F#0H@8V]M;65R8VEA;"!L875N8V@@8V]N=&EN9V5N="!P87EM
M96YT<R!R96QA=&5D('1O('1H90T*($U/5D%.5$E+/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)
M5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/E1-/"]S=7`^/"]F;VYT
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M(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO<W5P/CPO9F]N=#X-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CYA;F0-"B!-3U9!3E1)2SPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SY433PO<W5P/CPO9F]N=#X-"B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CYF:7AE9"UD;W-E#0H@8V]M8FEN871I;VX@<')O9'5C=',N/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!1$1)
M3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/CQI/E)O8VAE/"]I/CPO8CX\:3XZ(%!%1T%365,\<W5P('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E
M.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X-"B!A;F0@34E20T5203QS
M=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)5$E/
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M<&QY(&%G<F5E;65N=`T*('=I=&@@4F]C:&4L('5N9&5R('=H:6-H('=E(&=R
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M8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^
M)B-X044[/"]S=7`^/"]F;VYT/BX-"B!!<R!A(')E<W5L="!O9B!2;V-H92!E
M>&5R8VES:6YG(&$@;&EC96YS92!E>'1E;G-I;VX@;W!T:6]N(&EN#0H@1&5C
M96UB97(@,C`P.2P@4F]C:&4@:&%S('1H92!R:6=H="!T;R!M86YU9F%C='5R
M92!A;&P@;V8@:71S#0H@<F5Q=6ER96UE;G1S(&9O<B!O=7(@<')O<')I971A
M<GD@4$5'>6QA=&EO;B!M871E<FEA;',@9F]R#0H@4$5'05-94SQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)
M5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P/CPO
M9F]N=#X-"B!A;F0@=V4@<&5R9F]R;2!A9&1I=&EO;F%L(&UA;G5F86-T=7)I
M;F<L(&EF(&%N>2P@;VYL>2!O;B!A;@T*(&%S+7)E<75E<W1E9"!B87-I<RX@
M26X@8V]N;F5C=&EO;B!W:71H(%)O8VAE)B-X,C`Q.3MS(&5X97)C:7-E(&]F
M#0H@=&AE(&QI8V5N<V4@97AT96YS:6]N(&]P=&EO;B!I;B!$96-E;6)E<B`R
M,#`Y+"!W92!R96-E:79E9"!A#0H@<&%Y;65N="!O9B`D,S$N,"8C>$$P.VUI
M;&QI;VXN($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30L('=E#0H@:&%V
M92!D969E<G)E9"!R979E;G5E(&]F(&%P<')O>&EM871E;'D@)#4N,2!M:6QL
M:6]N(')E;&%T960@=&\@=&AI<PT*(&%G<F5E;65N="P@=VAI8V@@=V4@97AP
M96-T('1O(')E8V]G;FEZ92!T:')O=6=H($1E8V5M8F5R(#(P,34L('1H90T*
M('!E<FEO9"!T:')O=6=H('=H:6-H('=E(&%R92!R97%U:7)E9"!T;R!P<F]V
M:61E(&)A8VLM=7`-"B!M86YU9F%C='5R:6YG(&%N9"!S=7!P;'D@<V5R=FEC
M97,@<F5L871E9"!T;R!014=!4UE3/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@
M0D]45$]-.B`P+CAE>"<^)B-X044[/"]S=7`^/"]F;VYT/BX\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@4$%$1$E.1RU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D525$E#
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M<&%Y;65N="!O9B`D-2XP(&UI;&QI;VX@86YD(&%N#0H@861D:71I;VYA;"`D
M,C(N,"!M:6QL:6]N(&EN('!E<F9O<FUA;F-E+6)A<V5D(&UI;&5S=&]N92!P
M87EM96YT<PT*('5P;VX@;W5R(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@;6%N
M=69A8W1U<FEN9R!R96%D:6YE<W,L('9A;&ED871I;VX-"B!A;F0@<')O9'5C
M=&EO;B!M:6QE<W1O;F5S+"!I;F-L=61I;F<@=&AE(&1E;&EV97)Y(&]F('-P
M96-I9FEE9`T*('%U86YT:71I97,@;V8@4$5'>6QA=&EO;B!M871E<FEA;',L
M(&%L;"!O9B!W:&EC:"!W97)E(&-O;7!L971E9"!A<PT*(&]F($IA;G5A<GD@
M,C`Q,RX@4F]C:&4@=VEL;"!A;'-O('!A>2!U<R!A9&1I=&EO;F%L(&-O;G-I
M9&5R871I;VX-"B!F;W(@86YY(&9U='5R92!O<F1E<G,@;V8@=&AE(%!%1WEL
M871I;VX@;6%T97)I86QS(&9O<@T*($U)4D-%4D$\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^#0H@
M8F5Y;VYD('1H92!I;FET:6%L('%U86YT:71I97,@;6%N=69A8W1U<F5D('1H
M<F]U9V@@2F%N=6%R>0T*(#(P,3,N)B-X03`[4F]C:&4@:&%S('1H92!R:6=H
M="!T;R!T97)M:6YA=&4@=&AE('1O;&PM;6%N=69A8W1U<FEN9PT*(&%G<F5E
M;65N="!D=64@=&\@86X@=6YC=7)E9"!M871E<FEA;"!D969A=6QT(&)Y('5S
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT
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M(&]B;&EG871I;VX@=&AR;W5G:`T*($1E8V5M8F5R(#(P,38@86YD('1H92!D
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M#0H@;65T:&]D+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!H
M879E(&1E9F5R<F5D(')E=F5N=64@;V8-"B!A<'!R;WAI;6%T96QY("0Q,"XW
M)B-X03`[;6EL;&EO;BP@=VAI8V@@=V4@97AP96-T('1O(')E8V]G;FEZ90T*
M('1H<F]U9V@@1&5C96UB97(@,C`Q-BP@=&AE(&5S=&EM871E9"!E;F0@;V8@
M;W5R(&]B;&EG871I;VYS('5N9&5R#0H@=&AI<R!A9W)E96UE;G0N/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%!!1$1)
M3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
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M;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!
M13L\+W-U<#X\+V9O;G0^#0H@86YD($U)4D-%4D$\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E
M;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^+`T*
M(&%L;"!O9B!W:&EC:"!W97)E(&1E;&EV97)E9"!I;B!T:&4@;&%S="!Q=6%R
M=&5R(&]F(#(P,3,L(&9O<B!T;W1A;`T*(&-O;G-I9&5R871I;VX@;V8@)#$X
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M(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^)B-X044[/"]S
M=7`^/"]F;VYT/@T*(&%N9"!-25)#15)!/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/'-U<"!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV
M93L@0D]45$]-.B`P+CAE>"<^)B-X044[/"]S=7`^/"]F;VYT/@T*("UR96QA
M=&5D(&%R<F%N9V5M96YT<R!D97-C<FEB960@86)O=F4N($%S(&$@<F5S=6QT
M+"!W92!A;&QO8V%T960-"B!T:&4@)#$X+C8@;6EL;&EO;B!C;VYS:61E<F%T
M:6]N('1O(&5A8V@@;V8@=&AE<V4@87)R86YG96UE;G1S(&%N9`T*(&1E=&5R
M;6EN960@=&AE(&%M;W5N=',@=&\@8F4@<F5C;V=N:7IE9"!O<B!D969E<G)E
M9"!B87-E9"!O;B!T:&4-"B!E<W1I;6%T960@<V5L;&EN9R!P<FEC97,@;V8@
M=&AE('5N9&5L:79E<F5D(&]B;&EG871I;VYS+B!!<R!O9@T*($1E8V5M8F5R
M)B-X03`[,S$L(#(P,30L('=E(&AA=F4@9&5F97)R960@<F5V96YU92!O9B!A
M<'!R;WAI;6%T96QY#0H@)#0N-B8C>$$P.VUI;&QI;VX@<F5L871E9"!T;R!T
M:&5S92!A8W1I=FET:65S+"!W:&EC:"!W92!E>'!E8W0@=&\-"B!R96-O9VYI
M>F4@=&AR;W5G:"!$96-E;6)E<B`R,#$V+"!T:&4@97-T:6UA=&5D(&5N9"!O
M9B!O=7(-"B!O8FQI9V%T:6]N<R!U;F1E<B!T:&4@;6]D:69I960@87)R86YG
M96UE;G1S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y"87AT
M97(-"B!(96%L=&AC87)E/"]I/CPO8CX\:3XZ($)!6"`X-34O2&5M;W!H:6QI
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M;W)P;W)A=&EO;B`H=&]G971H97(@<F5F97)R960@=&\@87,@0F%X=&5R*0T*
M('1O(&1E=F5L;W`@<')O9'5C=',@9&5S:6=N960@=&\@:6UP<F]V92!T:&5R
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M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;F1E<B!T:&4@=&5R;7,-"B!O9B!T
M:&ES(&%G<F5E;65N="P@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@
M=V4@87)E(&5N=&ET;&5D('1O#0H@=7`@=&\@)#(P+C`@;6EL;&EO;B!O9B!D
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M"B!!=6=U<W0@,C`Q-"P@0F%X=&5R(&%N;F]U;F-E9"!P;W-I=&EV92!T;W`M
M;&EN92!R97-U;'1S(&9R;VT@:71S#0H@4&AA<V4@,R!P:79O=&%L(&-L:6YI
M8V%L('1R:6%L(&]F($)!6"`X-34@=VAI8V@@;65T('1H92!P<FEM87)Y#0H@
M96YD<&]I;G0@9F]R('1H92!C;VYT<F]L(&%N9"!P<F5V96YT:6]N(&]F(&)L
M965D:6YG+"!R;W5T:6YE#0H@<')O<&AY;&%X:7,@86YD('!E<FEO<&5R871I
M=F4@;6%N86=E;65N="!F;W(@<&%T:65N=',@=VAO('=E<F4@,3(-"B!Y96%R
M<R!O<B!O;&1E<BX@07,@82!R97-U;'0@;V8@=&AI<R!0:&%S92`S(&-L:6YI
M8V%L('1R:6%L(&UE971I;F<-"B!I=',@<')I;6%R>2!E;F1P;VEN="P@=V4@
M86-H:65V960@9&5V96QO<&UE;G0@;6EL97-T;VYE<R!T;W1A;&EN9PT*("0X
M+C`@;6EL;&EO;BX@1VEV96X@;W5R('-I9VYI9FEC86YT(&5F9F]R=',@:6X@
M=&AE(&1E=F5L;W!M96YT(&]F#0H@=&AI<R!P<F]D=6-T+"!W92!C;VYS:61E
M<B!T:&5S92!M:6QE<W1O;F5S('1O(&)E('-U8G-T86YT:79E(&%N9"!W90T*
M(')E8V]G;FEZ960@=&AE(&UI;&5S=&]N97,@:6X@=&AE:7(@96YT:7)E='D@
M:6X@=&AE('EE87(@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+B!!
M<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!D;R!N;W0-"B!H879E
M('-I9VYI9FEC86YT(&1E9F5R<F5D(')E=F5N=64@<F5L871E9"!T;R!T:&ES
M#0H@86=R965M96YT+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!X.R!0041$24Y'+4)/5%1/33H@,'!X.R!-05)'24XM5$]0
M.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y!;6=E;BP-"B!);F,N/"]I/CPO
M8CX\:3XZ($YE=6QA<W1A/"]I/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)A<V5L:6YE.R!03U-)5$E/3CH@<F5L871I=F4[($)/
M5%1/33H@,"XX97@G/B8C>$%%.SPO<W5P/CPO9F]N=#X-"B`\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/
M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN($]C=&]B
M97(-"B`R,#$P+"!W92!A;65N9&5D(&%N9"!R97-T871E9"!A;B!E>&ES=&EN
M9R!S=7!P;'D@86YD(&QI8V5N<V4-"B!A9W)E96UE;G0@8GD@96YT97)I;F<@
M:6YT;R!A('-U<'!L>2P@9&5D:6-A=&5D('-U:71E(&%N9`T*(&UA;G5F86-T
M=7)I;F<@9W5A<F%N=&5E(&%G<F5E;65N="`H=&AE(&%M96YD960@86YD(')E
M<W1A=&5D#0H@86=R965M96YT*2!A;F0@82!L:6-E;G-E(&%G<F5E;65N="!W
M:71H($%M9V5N($EN8RX@86YD($%M9V5N#0H@36%N=69A8W1U<FEN9RP@3&EM
M:71E9"`H=&]G971H97(@<F5F97)R960@=&\@87,@06UG96XI+B!5;F1E<B!T
M:&4-"B!T97)M<R!O9B!T:&4@86UE;F1E9"!A;F0@<F5S=&%T960@86=R965M
M96YT+"!W92!G=6%R86YT964@=&AE#0H@;6%N=69A8W1U<F4@86YD('-U<'!L
M>2!O9B!O=7(@<')O<')I971A<GD@4$5'>6QA=&EO;B!M871E<FEA;',-"B`H
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M;65N="!I;B!T:&4@9F]U<G1H('%U87)T97(@;V8@,C`Q,"!I;B!R971U<FX@
M9F]R#0H@;W5R(&=U87)A;G1E96EN9R!T:&4@<W5P<&QY(&]F(&-E<G1A:6X@
M<75A;G1I=&EE<R!O9B!0;VQY;65R#0H@36%T97)I86QS('1O($%M9V5N(&EN
M8VQU9&EN9R!W:71H;W5T(&QI;6ET871I;VX@=&AE($%D9&ET:6]N86P-"B!2
M:6=H=',@9&5S8W)I8F5D(&)E;&]W(&%N9"!M86YU9F%C='5R:6YG(&9E97,@
M=&AA="!A<F4@8V%L8W5L871E9`T*(&)A<V5D(&]N(&9I>&5D(&%N9"!V87)I
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M:6=N:69I8V%N=`T*(&%D9&ET:6]N86P@<&%Y;65N=',@8F5C;VUE('!A>6%B
M;&4@=&\@=7,@:6X@<F5T=7)N(&9O<B!O=7(-"B!G=6%R86YT965I;F<@=&AE
M('-U<'!L>2!O9B!A9&1I=&EO;F%L('%U86YT:71I97,@;V8@=&AE(%!O;'EM
M97(-"B!-871E<FEA;',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^5&AE('1E<FT@;V8@=&AE#0H@86UE;F1E9"!A
M;F0@<F5S=&%T960@86=R965M96YT(&5N9',@;VX@3V-T;V)E<B8C>$$P.S(Y
M+"`R,#(P+B!);@T*('1H92!E=F5N="!W92!B96-O;64@<W5B:F5C="!T;R!A
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M<R`H=&AE($%D9&ET:6]N86P-"B!2:6=H=',I+B!!;6=E;B!M87D@=&5R;6EN
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M=&AE($9A8VEL:71Y#0H@9&5S8W)I8F5D(&AE<F4N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@;V8-"B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!H879E(&1E9F5R<F5D(')E=F5N=64@
M;V8@87!P<F]X:6UA=&5L>0T*("0R.2XR)B-X03`[;6EL;&EO;B!R96QA=&5D
M('1O('1H:7,@86=R965M96YT+"!W:&EC:"!W92!E>'!E8W0@=&\-"B!R96-O
M9VYI>F4@=&AR;W5G:"!/8W1O8F5R(#(P,C`L('1H92!E<W1I;6%T960@96YD
M(&]F(&]U<@T*(&]B;&EG871I;VYS('5N9&5R('1H:7,@86=R965M96YT+CPO
M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y"87EE<B!(96%L=&AC
M87)E#0H@3$Q#/"]I/CPO8CX\:3XZ($)!630Q+38U-3$@*$%M:6MA8VEN($EN
M:&%L92D\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY);B!!=6=U<W0@,C`P-RP-"B!W92!E;G1E<F5D(&EN=&\@
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M87EE<B!I<R!R97-P;VYS:6)L92!F;W(@;6]S=`T*(&9U='5R92!C;&EN:6-A
M;"!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@8V]S=',L(&%L
M;`T*(&%C=&EV:71I97,@=&\@<W5P<&]R="!W;W)L9'=I9&4@<F5G=6QA=&]R
M>2!F:6QI;F=S+"!A<'!R;W9A;',@86YD#0H@<F5L871E9"!A8W1I=FET:65S
M+"!F=7)T:&5R(&1E=F5L;W!M96YT(&]F($%M:6MA8VEN($EN:&%L92!A;F0-
M"B!F:6YA;"!P<F]D=6-T('!A8VMA9VEN9R!A;F0@9&ES=')I8G5T:6]N+B!)
M;B!T:&4@>65A<G,@<')I;W(@=&\-"B`R,#$T+"!W92!R96-E:79E9"!A;B!U
M<&9R;VYT('!A>6UE;G0@;V8@)#0P+C`F(WA!,#MM:6QL:6]N(&EN(#(P,#<-
M"B!A;F0@;6EL97-T;VYE('!A>6UE;G1S(&]F("0S,"XP)B-X03`[;6EL;&EO
M;BP@:6YC;'5D:6YG(&$@)#$P+C`-"B!M:6QL:6]N(&1E=F5L;W!M96YT(&UI
M;&5S=&]N92!W:&EC:"!W87,@86-H:65V960@:6X@,C`Q,R!A<R!A#0H@<F5S
M=6QT(&]F('1H92!S=&%R="!O9B!T:&4@4&AA<V4@,R!C;&EN:6-A;"!T<FEA
M;"!B>2!"87EE<B!I;B!T:&4-"B!T<F5A=&UE;G0@;V8@:6YT=6)A=&5D(&%N
M9"!M96-H86YI8V%L;'D@=F5N=&EL871E9"!P871I96YT<R!W:71H#0H@1W)A
M;2UN96=A=&EV92!P;F5U;6]N:6$@:6X@07!R:6P@,C`Q,RX@26X@861D:71I
M;VXL(&EN($IU;F4@,C`Q,RP-"B!W92!P86ED("0Q,"XP(&UI;&QI;VX@=&\@
M0F%Y97(@9F]R('1H92!R96EM8G5R<V5M96YT(&]F(&ET<R!C;W-T<PT*(&]F
M('1H92!0:&%S92`S(&-L:6YI8V%L('1R:6%L+CPO9F]N=#X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X
M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN(&%D9&ET:6]N+"!W
M90T*(&%R92!E;G1I=&QE9"!T;R!R96-E:79E(&$@=&]T86P@;V8@=7`@=&\@
M)#4P+C`@;6EL;&EO;B!F;W(-"B!D979E;&]P;65N="!M:6QE<W1O;F5S('5P
M;VX@86-H:65V96UE;G0@;V8@8V5R=&%I;B!D979E;&]P;65N=`T*(&]B:F5C
M=&EV97,L(&%S('=E;&P@87,@<V%L97,@;6EL97-T;VYE<R!U<&]N(&%C:&EE
M=F5M96YT(&]F(&%N;G5A;`T*('-A;&5S('1A<F=E=',@86YD(')O>6%L=&EE
M<R!B87-E9"!O;B!A;FYU86P@=V]R;&1W:61E(&YE="!S86QE<R!O9@T*($%M
M:6MA8VEN($EN:&%L92X@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@
M=V4@:&%V92!D969E<G)E9`T*(')E=F5N=64@;V8@87!P<F]X:6UA=&5L>2`D
M,C`N."!M:6QL:6]N(')E;&%T960@=&\@=&AI<R!A9W)E96UE;G0L#0H@=VAI
M8V@@=V4@97AP96-T('1O(')E8V]G;FEZ92!T:')O=6=H($9E8G)U87)Y(#(P
M,C@L('1H92!E<W1I;6%T960-"B!E;F0@;V8@;W5R(&]B;&EG871I;VYS('5N
M9&5R('1H:7,@86=R965M96YT+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!X.R!0041$24Y'+4)/5%1/33H@,'!X.R!-05)'
M24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y/<&AT:&]T96-H($-O
M<G!O<F%T:6]N/"]I/CPO8CX\:3XZ#0H@1F]V:7-T83PO:3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)
M3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O
M;G0^#0H@/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!A<F4@82!P87)T>0T*
M('1O(&%N(&%G<F5E;65N="!W:71H($]P:'1H;W1E8V@@0V]R<&]R871I;VX@
M*$]P:'1H;W1E8V@I+"!D871E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#`V
M+"!U;F1E<B!W:&EC:"!/<&AT:&]T96-H(')E8V5I=F5D(&$-"B!W;W)L9'=I
M9&4L(&5X8VQU<VEV92!L:6-E;G-E('1O(&-E<G1A:6X@;V8@;W5R('!R;W!R
M:65T87)Y#0H@4$5'>6QA=&EO;B!T96-H;F]L;V=Y('1O(&1E=F5L;W`L(&UA
M;G5F86-T=7)E(&%N9"!S96QL#0H@1F]V:7-T83QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQS=7`@<W1Y
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M3CH@8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE
M>"<^)B-X044[/"]S=7`^/"]F;VYT/BX-"B!/;B!-87DF(WA!,#LQ.2P@,C`Q
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M3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^+@T*(%5N9&5R(&]U
M<B!A9W)E96UE;G0@=VET:"!/<&AT:&]T96-H+"!W92!R96-E:79E9"!A("0Q
M.2XW-2!M:6QL:6]N#0H@<&%Y;65N="!I;B!C;VYN96-T:6]N('=I=&@@=&AI
M<R!L:6-E;G-I;F<@86=R965M96YT(&EN($IU;F4@,C`Q-"X-"B!!<R!O9B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!H879E(&1E9F5R<F5D(')E=F5N
M=64@;V8-"B!A<'!R;WAI;6%T96QY("0Q."XY(&UI;&QI;VX@<F5L871E9"!T
M;R!T:&ES(&%G<F5E;65N="P@=VAI8V@@=V4-"B!E>'!E8W0@=&\@<F5C;V=N
M:7IE('1H<F]U9V@@36%R8V@@,C`R."P@=&AE(&5S=&EM871E9"!E;F0@;V8@
M;W5R#0H@;V)L:6=A=&EO;G,@=6YD97(@;W5R(&%G<F5E;65N="!W:71H($]P
M:'1H;W1E8V@N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@861D:71I;VXL
M('=E#0H@87)E(&5N=&ET;&5D('1O('5P('1O("0Y+C4@;6EL;&EO;B!I;B!A
M9&1I=&EO;F%L('!A>6UE;G1S(&)A<V5D#0H@=7!O;B!/<&AT:&]T96-H)B-X
M,C`Q.3MS('!O=&5N=&EA;"!A8VAI979E;65N="!O9B!C97)T86EN(')E9W5L
M871O<GD-"B!A;F0@<V%L97,@;6EL97-T;VYE<RX@5V4@87)E(&%L<V\@96YT
M:71L960@=&\@<F]Y86QT:65S(&]N(&YE=`T*('-A;&5S(&]F($9O=FES=&$\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN
M93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\
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M4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U
M<#X\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[(%!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!!<')I;"`R,#`T+`T*
M('=E(&5N=&5R960@:6YT;R!A(&QI8V5N<V4L(&UA;G5F86-T=7)I;F<@86YD
M('-U<'!L>2!A9W)E96UE;G0@=VET:`T*($%F9GEM87@L($EN8RX@*$%F9GEM
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M8F%S96QI;F4[(%!/4TE424]..B!R96QA=&EV93L@0D]45$]-.B`P+CAE>"<^
M)B-X044[/"]S=7`^/"]F;VYT/@T*("AP96=I;F5S871I9&4I+B!/;B!&96)R
M=6%R>28C>$$P.S(S+"`R,#$S+"!!9F9Y;6%X(&%N9"!486ME9&$-"B!0:&%R
M;6%C975T:6-A;"!#;VUP86YY($QI;6ET960@86YN;W5N8V5D(&$@=F]L=6YT
M87)Y(')E8V%L;"!O9B!A;&P-"B!L;W1S(&]F($]-3TY465,\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)
M3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O
M;G0^)B-X03`[9')U9PT*('!R;V1U8W0@87,@82!R97-U;'0@;V8@;F5W('!O
M<W0M;6%R:V5T:6YG(')E<&]R=',@<F5G87)D:6YG('-E<FEO=7,-"B!H>7!E
M<G-E;G-I=&EV:71Y(')E86-T:6]N<RP@:6YC;'5D:6YG(&%N87!H>6QA>&ES
M+"!W:&EC:"!C86X@8F4-"B!L:69E+71H<F5A=&5N:6YG(&]R(&9A=&%L+B8C
M>$$P.TEN($IU;'D@,C`Q,RP@069F>6UA>"!T97)M:6YA=&5D#0H@=&AE(&QI
M8V5N<V4L(&UA;G5F86-T=7)I;F<@86YD('-U<'!L>2!A9W)E96UE;G0@=VET
M:`T*($YE:W1A<BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY792!H879E#0H@<F5C96EV960@;6EL97-T;VYE(&%N
M9"!R96QA=&5D('!A>6UE;G1S('5N9&5R(&]U<B!A9W)E96UE;G0@=VET:`T*
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M;6)E<B8C>$$P.S,Q+"`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CX\:3Y/=&AE<CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE('EE87(-"B!E;F1E
M9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!T=V\@;V8@;W5R(&-O;&QA8F]R
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M+C`-"B!M:6QL:6]N(&]F(&UI;&5S=&]N92!P87EM96YT<RX@5V4@8V]N8VQU
M9&5D('1H870@=&AE<V4@<&%Y;65N=',@87)E#0H@<W5B<W1A;G1I=F4@;6EL
M97-T;VYE<R!A;F0@<F5C;V=N:7IE9"!T:&5M(&EN('1H96ER(&5N=&ER971Y
M(&EN('1H90T*('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"X\
M+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@
M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY);B!A9&1I=&EO;BP@87,-"B!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
M+"!W92!H879E(&$@;G5M8F5R(&]F(&-O;&QA8F]R871I;VX-"B!A9W)E96UE
M;G1S+"!I;F-L=61I;F<@;W5R(&-O;&QA8F]R871I;VX@<&%R=&YE<B!50T(L
M('5N9&5R('=H:6-H('=E#0H@87)E(&5N=&ET;&5D('1O('5P('1O(&$@=&]T
M86P@;V8@)#4S+C@@;6EL;&EO;B!O9B!D979E;&]P;65N=`T*(&UI;&5S=&]N
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M(&-A;FYO=`T*(&5S=&EM871E('1H92!P<F]B86)I;&ET>2!O<B!T:6UI;F<@
M;V8@86-H:65V:6YG('1H97-E#0H@;6EL97-T;VYE<RX\+V9O;G0^/"]P/@T*
M(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?
M-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,C`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"
M87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I
M;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DYO=&4F(WA!
M,#LQ,2`F(W@R,#$T.PT*(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO8CX\
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M>F5D(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P
M>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT
M97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@
M/'1R/@T*(#QT9"!W:61T:#TS1#8W)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^
M665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;W-T
M(&]F(&=O;V1S#0H@<V]L9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,CDW/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PT
M.38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY297-E87)C:"!A;F0-"B!D979E;&]P;65N=#PO9F]N=#X\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<L-3(X/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPP.#(\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY'96YE<F%L(&%N9`T*(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^."PS,C@\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C@L-3`Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^5&]T86P@<W1O8VLM8F%S960-"B!C;VUP96YS871I;VX\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<L,#$W/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,3<L-S`X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,38L,3DY/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@;V8-"B!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$T+"!T;W1A;"!U;G)E8V]G;FEZ960@8V]M<&5N<V%T
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M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/
M3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@
M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A8FQE
M($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#,Y)3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY996%R#0H@16YD960\+V(^/"]F;VYT/CQB<B`O/@T*
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L)B-X03`[,C`Q-#PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^665A<@T*($5N9&5D/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,3X\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3,\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@
M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^079E<F%G92!R
M:7-K+69R964@:6YT97)E<W0-"B!R871E/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XV/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XY/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XY/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1I=FED96YD
M('EI96QD/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,"XP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P
M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%V97)A9V4@
M=F]L871I;&ET>0T*(&9A8W1O<CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C4Q+C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,2XR/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C(N,CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!=F5R86=E('=E
M:6=H=&5D(&%V97)A9V4-"B!E>'!E8W1E9"!L:69E/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2XR)B-X03`[>65A<G,\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C4N,B8C>$$P.WEE87)S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+C`F(WA!,#MY96%R
M<SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO
M='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@879E<F%G90T*(')I
M<VLM9G)E92!I;G1E<F5S="!R871E(&ES(&)A<V5D(&]N('1H92!5+E,N)B-X
M03`[=')E87-U<GD@>6EE;&0-"B!C=7)V92!I;B!E9F9E8W0@870@=&AE('1I
M;64@;V8@9W)A;G0@9F]R('!E<FEO9',@8V]M;65N<W5R871E('=I=&@-"B!T
M:&4@97AP96-T960@;&EF92!O9B!T:&4@<W1O8VLM8F%S960@87=A<F0N(%=E
M(&AA=F4@;F5V97(@<&%I9`T*(&1I=FED96YD<RP@;F]R(&1O('=E(&5X<&5C
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M>'!E8W1E9"!L:69E(&]F('1H92!S=&]C:RUB87-E9`T*(&%W87)D+CPO9F]N
M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9O
M<B!T:&4@>65A<G,-"B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R
M,#$S+"!A;F0@,C`Q,BP@=V4@97-T:6UA=&5D('1H90T*('=E:6=H=&5D+6%V
M97)A9V4@97AP96-T960@;&EF92!B87-E9"!O;B!T:&4@8V]N=')A8W1U86P@
M86YD('9E<W1I;F<-"B!T97)M<R!O9B!T:&4@<W1O8VL@;W!T:6]N<RP@87,@
M=V5L;"!A<R!H:7-T;W)I8R!C86YC96QL871I;VX@86YD#0H@97AE<F-I<V4@
M9&%T82X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY3=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;B!R97-U;'1I;F<@
M9G)O;2!O=7(@15-04"!W87,@;F]T(&UA=&5R:6%L(&EN('1H92!Y96%R<PT*
M(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,L(&%N9"`R,#$R
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[
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M97(@;W5R(&5Q=6ET>0T*(&EN8V5N=&EV92!P;&%N<R`H:6X@=&AO=7-A;F1S
M+"!E>&-E<'0@9F]R('!R:6-E('!E<B!S:&%R92!A;F0-"B!C;VYT<F%C='5A
M;"!L:69E(&EN9F]R;6%T:6]N*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM
M5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-34E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/DYU;6)E<CPO8CX\+V9O;G0^/&)R("\^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^/&(^;V8\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/E-H87)E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L
M,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960M/"]B/CPO9F]N=#X\
M8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY!=F5R86=E/"]B/CPO9F]N=#X\8G(@+SX-
M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY%>&5R8VES93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^4')I8V4\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/G!E<@T*(%-H87)E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY796EG:'1E9"T\+V(^/"]F
M;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D%V97)A9V4\+V(^/"]F;VYT/CQB
M<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/E)E;6%I;FEN9SPO8CX\+V9O;G0^/&)R("\^
M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^/&(^0V]N=')A8W1U86P\+V(^/"]F;VYT/CQB<B`O/@T*
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/DQI9F4F(WA!,#LH:6XF(WA!,#M996%R<RD\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/D%G9W)E9V%T93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^26YT<FEN<VEC/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M8CY686QU93QS=7`@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)A<V5L:6YE
M.R!03U-)5$E/3CH@<F5L871I=F4[($)/5%1/33H@,"XX97@G/B@Q*3PO<W5P
M/CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%
M;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@
M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D]U='-T86YD:6YG(&%T#0H@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CDN,#8\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^3W!T:6]N<R!G<F%N=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-RPW,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$S+CDV/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]P=&EO;G,-
M"B!E>&5R8VES960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXH-"PX-3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY+C0S/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D]P=&EO;G,-"B!F;W)F96ET960F(WA!,#LF86UP.R!C86YC96QE
M9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q
M+#4R,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C$Q+C@Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D]U='-T86YD:6YG(&%T#0H@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q-#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$P+C4P/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXT+CDV/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
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M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5F5S=&5D)B-X03`[
M86YD(&5X<&5C=&5D('1O#0H@=F5S="!A="!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$T/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,C$L,S,X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,3`N-#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0N.#D\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^17AE<F-I<V%B
M;&4@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3,L,#`W/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M."XY,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#)P>#L@0D]21$52+4)/5%1/33H@<F=B*#`L
M,"PP*2`P+C5P="!S;VQI9#L@34%21TE.+51/4#H@,'!X.R!,24Y%+4A%24=(
M5#H@.'!X.R!724142#H@,3`E)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^
M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T)2!A;&EG;CTS
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M8V5M8F5R)B-X03`[,S$L(#(P,30N/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2
M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4
M:&4-"B!W96EG:'1E9"UA=F5R86=E(&=R86YT+61A=&4@9F%I<B!V86QU92!P
M97(@<VAA<F4@;V8@;W!T:6]N<R!G<F%N=&5D#0H@9'5R:6YG('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q
M,B!W87,-"B`D-BXU,"P@)#0N.34L(&%N9"`D,RXY,BP@<F5S<&5C=&EV96QY
M+B!4:&4@=&]T86P@:6YT<FEN<VEC('9A;'5E(&]F#0H@;W!T:6]N<R!E>&5R
M8VES960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$T+`T*(#(P,3,L(&%N9"`R,#$R('=A<R`D,C4N.2!M:6QL:6]N+"`D
M-"XU)B-X03`[;6EL;&EO;BP@86YD#0H@)#$N.28C>$$P.VUI;&QI;VXL(')E
M<W!E8W1I=F5L>2X@5&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F#0H@;W!T
M:6]N<R!V97-T960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$T+"`R,#$S+`T*(&%N9"`R,#$R('=A<R`D,34N,B!M:6QL
M:6]N+"`D,30N,28C>$$P.VUI;&QI;VXL(&%N9`T*("0Q-2XW)B-X03`[;6EL
M;&EO;BP@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W`^#0H@#0H@#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O
M;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CY.;W1E)B-X03`[,3(F(WA!,#LF(W@R,#$T.R!);F-O;64@5&%X97,\
M+V(^/"]F;VYT/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,;W-S(&)E9F]R90T*("AB96YE
M9FET*2!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<R!I;F-L=61E<R!T:&4@
M9F]L;&]W:6YG#0H@8V]M<&]N96YT<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3
M25I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG
M;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A
M9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3DE/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-
M"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D1O;65S=&EC/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B@U-BPT,30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^*#$V,2PP-C@\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$W-"PR-3@\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F]R96EG;CPO
M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L.3@V
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
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M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPX,#D\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQO<W,@8F5F;W)E
M("AB96YE9FET*0T*('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U-"PT,C@\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M*#$U.2PW-C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*#$W,2PT-#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/CQI/E!R;W9I<VEO;B!F;W(@26YC;VUE#0H@5&%X97,\+VD^/"]B
M/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^5&AE("AB96YE9FET*0T*('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S
M(&-O;G-I<W1S(&]F('1H92!F;VQL;W=I;F<@*&EN#0H@=&AO=7-A;F1S*3H\
M+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@
M1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q
M-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@
M5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D-U<G)E;G0Z/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9E9&5R86P\+V9O;G0^
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*3PO
M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T871E/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3PO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9O<F5I9VX\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#@R/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,2PX,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,#(Y/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!#=7)R96YT/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#0X,3PO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C$L.#,Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX.3,\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E
M9F5R<F5D.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&961E<F%L
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^-#(R/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#(R
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*3PO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T871E/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T.3PO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/BD\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&
M;W)E:6=N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*#,Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^*#8U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$V/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^5&]T86P@1&5F97)R960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXH,S$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,#8\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B@T.#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH0F5N969I
M="D@<')O=FES:6]N(&9O<@T*(&EN8V]M92!T87AE<SPO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L,C0U/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^-#`V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X
M)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^5&AE(&9O<F5I9VX-"B!B96YE9FET('!R;W9I<VEO;B!I;B!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&ES(&1U90T*('1O
M('1H92!R961U8W1I;VX@:6X@=&%X97,@<F5L871E9"!T;R!A(&9A=F]R86)L
M92!D971E<FUI;F%T:6]N#0H@<F5C96EV960@9G)O;2!);F1I82!P<F]C965D
M:6YG<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY);F-O;64@=&%X#0H@<')O=FES:6]N(')E;&%T960@=&\@8V]N
M=&EN=6EN9R!O<&5R871I;VYS(&1I9F9E<G,@9G)O;2!T:&4@86UO=6YT#0H@
M8V]M<'5T960@8GD@87!P;'EI;F<@=&AE('-T871U=&]R>2!I;F-O;64@=&%X
M(')A=&4@;V8@,S4E('1O('!R971A>`T*(&QO<W,@87,@9F]L;&]W<R`H:6X@
M=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-C,E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R($5N9&5D#0H@1&5C96UB
M97(F(WA!,#LS,2P\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G
M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^
M#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O
M9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E4N4RX@9F5D97)A;"!P<F]V:7-I;VX-
M"B`H8F5N969I="D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^070@<W1A='5T;W)Y#0H@<F%T93PO
M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B@U-2PY,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^*#8P+#`P-SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3=&%T92!T
M87AE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C4P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#@\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0VAA;F=E(&EN
M('9A;'5A=&EO;@T*(&%L;&]W86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-34L
M,#0R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXT-RPS-#D\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.
M;VXM8V%S:"!I;G1E<F5S="!E>'!E;G-E#0H@;VX@;&EA8FEL:71Y(')E;&%T
M960@=&\@<V%L92!O9B!F=71U<F4@<F]Y86QT:65S/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPS,3$\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C<L.#`X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T;V-K+6)A<V5D#0H@
M8V]M<&5N<V%T:6]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,BPX,S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
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M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,C,V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F]R96EG;B!T87@-"B!I;F-L
M=7-I;VX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXV+#4Q,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D9O<F5I9VX@=&%X#0H@9&EF9F5R96YT:6%L/"]F;VYT/CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$W/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*#(P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^*#(R-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!C
M<F5D:71S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*#(L.3,S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#8L,C<S/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#4Y,3PO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT
M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<CPO
M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T.#<\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
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M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.#8T/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH0F5N969I="D@<')O=FES:6]N
M(&9O<@T*(&EN8V]M92!T87AE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C(L,C0U/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-#`V/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D1E9F5R<F5D(%1A
M>"!!<W-E=',-"B!A;F0@3&EA8FEL:71I97,\+VD^/"]B/CPO9F]N=#X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0
M.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5F97)R960@
M:6YC;VUE#0H@=&%X97,@<F5F;&5C="!T:&4@;F5T('1A>"!E9F9E8W1S(&]F
M(&QO<W,@86YD(&-R961I="!C87)R>69O<G=A<F1S#0H@86YD('1E;7!O<F%R
M>2!D:69F97)E;F-E<R!B971W965N('1H92!C87)R>6EN9R!A;6]U;G0@;V8@
M87-S971S(&%N9`T*(&QI86)I;&ET:65S(&9O<B!F:6YA;F-I86P@<F5P;W)T
M:6YG('!U<G!O<V5S(&%N9"!T:&4@86UO=6YT<R!U<V5D#0H@9F]R(&EN8V]M
M92!T87@@<'5R<&]S97,N(%-I9VYI9FEC86YT(&-O;7!O;F5N=',@;V8@;W5R
M(&1E9F5R<F5D('1A>`T*(&%S<V5T<R!F;W(@9F5D97)A;"!A;F0@<W1A=&4@
M:6YC;VUE('1A>&5S(&%R92!A<R!F;VQL;W=S("AI;@T*('1H;W5S86YD<RDZ
M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W
M-B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A
M8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8Y)3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q
M+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR
M,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@
M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5F97)R960@
M=&%X#0H@87-S971S.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^3F5T(&]P97)A=&EN9R!L;W-S#0H@8V%R<GEF;W)W
M87)D<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M-S<V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
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M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A
M<F-H(&%N9"!O=&AE<@T*(&-R961I=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXV-BPV-C8\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8Q
M+#<P-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D1E9F5R<F5D(')E=F5N=64\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXR.2PW-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E-T;V-K+6)A<V5D#0H@8V]M<&5N<V%T:6]N
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C$L
M.30X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXR-2PY-C(\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY386QE(&]F(&9U='5R90T*(')O
M>6%L=&EE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C@L,#4W/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^0V%P:71A;&EZ960@<F5S96%R8V@-"B!E>'!E;G-E<SPO9F]N=#X\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T+#<Y-3PO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,3<L-C@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^4F5S97)V97,@86YD#0H@86-C<G5A;',\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,30L-C@U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4')O<&5R
M='DL('!L86YT(&%N9`T*(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C@L,C8T/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D]T:&5R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,BPR,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L-3,Y/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D1E9F5R<F5D('1A>"!A<W-E=',@8F5F;W)E#0H@=F%L=6%T
M:6]N(&%L;&]W86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C4Y-2PX-C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C4X-BPQ.3`\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY686QU
M871I;VX@86QL;W=A;F-E(&9O<@T*(&1E9F5R<F5D('1A>"!A<W-E=',\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B@U.#8L,#0P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO
M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!D
M969E<G)E9"!T87@-"B!A<W-E=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ-S8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4
M;W1A;"!D969E<G)E9"!T87@-"B!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
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M;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&1E9F5R<F5D('1A
M>`T*(&%S<V5T<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M,CXQ-S8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ-3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY296%L:7IA=&EO;B!O9@T*(&]U<B!D969E<G)E9"!T87@@
M87-S971S(&ES(&1E<&5N9&5N="!U<&]N(&9U='5R92!E87)N:6YG<RP@:68@
M86YY+`T*('1H92!T:6UI;F<@86YD(&%M;W5N="!O9B!W:&EC:"!A<F4@=6YC
M97)T86EN+B!"96-A=7-E(&]F(&]U<B!L86-K#0H@;V8@52Y3+B8C>$$P.V5A
M<FYI;F=S(&AI<W1O<GDL('1H92!N970@52Y3+B8C>$$P.V1E9F5R<F5D('1A
M>`T*(&%S<V5T<R!H879E(&)E96X@9G5L;'D@;V9F<V5T(&)Y(&$@=F%L=6%T
M:6]N(&%L;&]W86YC92X@5&AE#0H@=F%L=6%T:6]N(&%L;&]W86YC92!I;F-R
M96%S960@8GD@)#DN-R8C>$$P.VUI;&QI;VX@86YD#0H@)#4Q+C@F(WA!,#MM
M:6QL:6]N(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q-`T*(&%N9"`R,#$S+"!R97-P96-T:79E;'DN(%1H92!V86QU871I
M;VX@86QL;W=A;F-E(&EN8VQU9&5S#0H@87!P<F]X:6UA=&5L>2`D,S4N-B8C
M>$$P.VUI;&QI;VX@;V8@:6YC;VUE('1A>"!B96YE9FET(&%T(&)O=&@-"B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S(')E;&%T960@=&\-"B!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@86YD
M(&5X97)C:7-E<R!P<FEO<B!T;R!T:&4@:6UP;&5M96YT871I;VX-"B!O9B!T
M:&4@86-C;W5N=&EN9R!G=6ED86YC92!F;W(@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N('1H870@=VEL;`T*(&)E(&-R961I=&5D('1O(&%D9&ET:6]N86P@
M<&%I9"!I;B!C87!I=&%L('=H96X@<F5A;&EZ960N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YD:7-T<FEB=71E
M9`T*(&5A<FYI;F=S(&]F(&]U<B!F;W)E:6=N('-U8G-I9&EA<GD@:6X@26YD
M:6$@87)E(&-O;G-I9&5R960@=&\@8F4-"B!P97)M86YE;G1L>2!R96EN=F5S
M=&5D(&%N9"!A8V-O<F1I;F=L>2P@;F\@9&5F97)R960-"B!5+E,N)B-X03`[
M:6YC;VUE('1A>&5S(&AA=F4@8F5E;B!P<F]V:61E9"!T:&5R96]N+B!5<&]N
M#0H@9&ES=')I8G5T:6]N(&]F('1H;W-E(&5A<FYI;F=S(&EN('1H92!F;W)M
M(&]F(&1I=FED96YD<R!O<@T*(&]T:&5R=VES92P@=V4@=V]U;&0@8F4@<W5B
M:F5C="!T;R!5+E,N)B-X03`[:6YC;VUE('1A>"X@07,@;V8-"B!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$T+"!5+E,N(&EN8V]M92!T87AE<R!H879E(&YO="!B
M965N('!R;W9I9&5D(&]N#0H@82!C=6UU;&%T:79E('1O=&%L(&]F("0S+CD@
M;6EL;&EO;B!O9B!S=6-H(&5A<FYI;F=S+B!!;GD-"B!I;F-R96UE;G1A;"!T
M87@@;&EA8FEL:71Y('=O=6QD(&)E(&EN<VEG;FEF:6-A;G0@9'5E('1O(&9O
M<F5I9VX@=&%X#0H@8W)E9&ET<R!T:&%T('=O=6QD(&)E(')E86QI>F5D('5P
M;VX@9&ES=')I8G5T:6]N+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL
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M,C`Q-"P@=V4@:&%D(&$@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R
M9`T*(&9O<B!F961E<F%L(&EN8V]M92!T87@@<'5R<&]S97,@;V8@87!P<F]X
M:6UA=&5L>0T*("0Q+#$S,2XX)B-X03`[;6EL;&EO;BP@<&]R=&EO;G,@;V8@
M=VAI8V@@=VEL;"!B96=I;B!T;R!E>'!I<F4@:6X-"B`R,#$X+B!!<R!O9B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!W92!H860@82!T;W1A;"!S=&%T92!N
M970-"B!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0@;V8@87!P<F]X:6UA
M=&5L>2`D-S`Y+C(F(WA!,#MM:6QL:6]N+`T*(&]F('=H:6-H(&%P<')O>&EM
M871E;'D@)#$R-"XV(&UI;&QI;VX@9&]E<R!N;W0@;65E="!T:&4@;6]R92!L
M:6ME;'D-"B!T:&%N(&YO="!S=&%N9&%R9"!A;F0@:&%S(&YO="!B965N(&EN
M8VQU9&5D(&EN(&]U<B!D969E<G)E9"!T87@-"B!A<W-E=',N($]U<B!S=&%T
M92!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S('=I;&P@8F5G:6X@=&\@
M97AP:7)E#0H@:6X@,C`Q-2X@571I;&EZ871I;VX@;V8@<V]M92!O9B!T:&4@
M9F5D97)A;"!A;F0@<W1A=&4@;F5T(&]P97)A=&EN9PT*(&QO<W,@86YD(&-R
M961I="!C87)R>69O<G=A<F1S(&%R92!S=6)J96-T('1O(&%N;G5A;"!L:6UI
M=&%T:6]N<R!D=64-"B!T;R!T:&4@)B-X,C`Q0SMC:&%N9V4@:6X@;W=N97)S
M:&EP)B-X,C`Q1#L@<')O=FES:6]N<R!O9B!T:&4@26YT97)N86P-"B!2979E
M;G5E($-O9&4@;V8@,3DX-B!A;F0@<VEM:6QA<B!S=&%T92!P<F]V:7-I;VYS
M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/E=E(&AA=F4@9F5D97)A;`T*(')E<V5A<F-H(&-R961I=',@;V8@87!P
M<F]X:6UA=&5L>2`D-#`N,"8C>$$P.VUI;&QI;VXL('=H:6-H('=I;&P-"B!B
M96=I;B!T;R!E>'!I<F4@:6X@,C`Q.2!A;F0@<W1A=&4@<F5S96%R8V@@8W)E
M9&ET<R!O9B!A<'!R;WAI;6%T96QY#0H@)#(R+C8@;6EL;&EO;B!W:&EC:"!H
M879E(&YO(&5X<&ER871I;VX@9&%T92X@5V4@:&%V92!F961E<F%L(&]R<&AA
M;@T*(&1R=6<@8W)E9&ET<R!O9B`D,3<N-R8C>$$P.VUI;&QI;VX@=VAI8V@@
M=VEL;"!B96=I;B!T;R!E>'!I<F4@:6X-"B`R,#(V+B!4:&5S92!T87@@8W)E
M9&ET<R!A<F4@<W5B:F5C="!T;R!T:&4@<V%M92!L:6UI=&%T:6]N<PT*(&1I
M<V-U<W-E9"!A8F]V92X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M/&D^56YR96-O9VYI>F5D('1A>`T*(&)E;F5F:71S/"]I/CPO8CX\+V9O;G0^
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M('-H;W5L9"!A;GD@;V8@=&AE<V4@=6YC97)T86EN('1A>`T*('!O<VET:6]N
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M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&
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M:&4-"B!F:7-C86P@>65A<G,@96YD:6YG(#(P,#D@=&AR;W5G:"`R,#$T+CPO
M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&
M3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P
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M.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,3X\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S
M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0F5G:6YN:6YG#0H@
M8F%L86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M-BPS-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ-"PP-C<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY487@@
M<&]S:71I;VYS(')E;&%T960@=&\-"B!C=7)R96YT('EE87(\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^061D:71I;VYS.CPO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&
M961E<F%L/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^-3`R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT-S<\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(X
M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO
M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E-T871E/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^-BPQ-#$\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,X
M,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,S`R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5D=6-T:6]N<SPO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
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M;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY487@@<&]S:71I;VYS(')E;&%T960@=&\-"B!P<FEO<B!Y
M96%R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/D%D9&ET:6]N<SH\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\
M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^1F5D97)A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
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M1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY3=&%T93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C4L,C4X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F]R96EG;CPO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
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M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
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M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
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M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E
M9'5C=&EO;G,@)B-X,C`Q-#L-"B!F;W)E:6=N/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#<T,CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3
M971T;&5M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY,87!S97,@:6X@<W1A='5T92!O9@T*(&QI;6ET
M871I;VYS/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
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M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^*#$S-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D5N9&EN
M9R!B86QA;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
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M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T+#`V-SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y
M("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT
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M960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R+"!N
M;R!S:6=N:69I8V%N="!I;G1E<F5S="!O<@T*('!E;F%L=&EE<R!W97)E(')E
M8V]G;FEZ960@<F5L871I;F<@=&\@=6YR96-O9VYI>F5D('1A>`T*(&)E;F5F
M:71S+CPO9F]N=#X\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-E9VUE;G0@4F5P;W)T:6YG/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E9VUE;G0@4F5P;W)T
M:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5G;65N="!297!O<G1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/DYO=&4F(WA!
M,#LQ,R8C>$$P.R8C>#(P,30[)B-X03`[4V5G;65N="!297!O<G1I;F<\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5V4@;W!E<F%T92!I
M;B!O;F4@8G5S:6YE<W,@<V5G;65N="!W:&EC:"!F;V-U<V5S(&]N(&%P<&QY
M:6YG(&]U<@T*('1E8VAN;VQO9WD@<&QA=&9O<FUS('1O(&EM<')O=F4@=&AE
M('!E<F9O<FUA;F-E(&]F(&5S=&%B;&ES:&5D(&%N9`T*(&YO=F5L(&UE9&EC
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M=6QM;VYA<GD-"B!T96-H;F]L;V=Y+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!/=7(@<F5V96YU92!I<R!D97)I=F5D('!R:6UA<FEL>2!F
M<F]M(&-L:65N=',@:6X@=&AE('!H87)M86-E=71I8V%L#0H@86YD(&)I;W1E
M8VAN;VQO9WD@:6YD=7-T<FEE<RX@07-T<F%:96YE8V$L(%5#0B!A;F0@4F]C
M:&4-"B!R97!R97-E;G1E9"`U,B4L(#$V)2P@86YD(#$Q)2!O9B!O=7(@<F5V
M96YU92P@<F5S<&5C=&EV96QY+"!F;W(@=&AE#0H@>65A<B!E;F1E9"!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$T+B!2979E;G5E(&9R;VT@4F]C:&4L(%5#0BP-
M"B!!<W1R85IE;F5C82!A;F0@0F%Y97(@<F5P<F5S96YT960@,C@E+"`R,24L
M(#$W)2!A;F0@,3`E(&]F(&]U<@T*(')E=F5N=64L(')E<W!E8W1I=F5L>2P@
M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,N#0H@
M4F5V96YU92!F<F]M(%5#0BP@4F]C:&4@86YD($%F9GEM87@@<F5P<F5S96YT
M960@,S`E+"`R,R4@86YD(#$Q)2!O9@T*(&]U<B!R979E;G5E+"!R97-P96-T
M:79E;'DL(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*
M(#(P,3(N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E=F5N
M=64@8GD@9V5O9W)A<&AI8R!A<F5A(&ES(&)A<V5D(&]N('1H92!L;V-A=&EO
M;G,@;V8@;W5R#0H@<&%R=&YE<G,N(%1H92!F;VQL;W=I;F<@=&%B;&4@<V5T
M<R!F;W)T:"!R979E;G5E(&)Y(&=E;V=R87!H:6,@87)E80T*("AI;B!T:&]U
M<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@
M=VED=&@],T0W,24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*
M($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N:71E9"!3=&%T97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S(L-3$T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT,BPU,S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,T+#4Y,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@175R
M;W!E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,38X+#$Y,SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#8L,S@V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0V+#8P,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A
M;"!R979E;G5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P,"PW,#<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$T."PY,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@Q+#$Y,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
M+"`D-C,N,R8C>$$P.VUI;&QI;VXL(&]R(&%P<')O>&EM871E;'D-"B`Y,"4L
M(&]F('1H92!N970@8F]O:R!V86QU92!O9B!O=7(@<')O<&5R='D@86YD(&5Q
M=6EP;65N="!W87,-"B!L;V-A=&5D(&EN('1H92!5;FET960@4W1A=&5S(&%N
M9"`D-RXQ)B-X03`[;6EL;&EO;BP@;W(-"B!A<'!R;WAI;6%T96QY(#$P)2P@
M=V%S(&QO8V%T960@:6X@26YD:6$N($%T($1E8V5M8F5R)B-X03`[,S$L(#(P
M,3,L#0H@)#4W+C,F(WA!,#MM:6QL:6]N+"!O<B!A<'!R;WAI;6%T96QY(#@X
M)2P@;V8@=&AE(&YE="!B;V]K('9A;'5E(&]F#0H@;W5R('!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0@=V%S(&QO8V%T960@:6X@=&AE(%5N:71E9"!3=&%T97,@
M86YD#0H@)#<N-R8C>$$P.VUI;&QI;VXL(&]R(&%P<')O>&EM871E;'D@,3(E
M+"!W87,@;&]C871E9"!I;B!);F1I82X\+W`^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-E;&5C=&5D(%%U87)T97)L>2!&:6YA;F-I86P@
M1&%T83QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T:6]N($1I<V-L
M;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A
M=&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P
M="<^#0H@/&(^3F]T928C>$$P.S$T)B-X03`[)B-X,C`Q-#L@4V5L96-T960@
M475A<G1E<FQY($9I;F%N8VEA;"!$871A#0H@*%5N875D:71E9"D\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T
M86)L92!S971S(&9O<G1H(&-E<G1A:6X@=6YA=61I=&5D('%U87)T97)L>0T*
M(&9I;F%N8VEA;"!D871A+B!);B!O=7(@;W!I;FEO;BP@=&AE('5N875D:71E
M9"!I;F9O<FUA=&EO;B!S970@9F]R=&@-"B!B96QO=R!H87,@8F5E;B!P<F5P
M87)E9"!O;B!T:&4@<V%M92!B87-I<R!A<R!T:&4@875D:71E9`T*(&EN9F]R
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M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*
M(#QT<CX-"B`\=&0@=VED=&@],T0T-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI
M9VX],T1C96YT97(^/&(^1FES8V%L(%EE87(@,C`Q-#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D9I<V-A;"!996%R(#(P,3,\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^43$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/E$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1
M,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M430\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E$Q/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1,CPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^43,\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E$T/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!0<F]D=6-T('-A;&5S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C4L-SDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#@P,CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPP.38\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C<L-#8P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ,2PX,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#,R-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,30L-C<R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XX+#`T,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T
M86P@<F5V96YU93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3,R+#@W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3DL-34Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-C`L.3`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M,2PQ-#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($-O<W0@;V8@9V]O9',@<V]L9#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW+#DP-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PQ,#@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,C(P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV+#(Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3$L-C8Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#`Q,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(L.#<W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XX+#DV,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C,X+#,S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S8L-S`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-"PR,#`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,X+#0Y-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-#4L-C$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M,BPR,S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0S+#DQ-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-#@L,C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/<&5R871I;F<@:6YC;VUE("AL
M;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S8L-#`R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#(R+#DQ-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@P
M+#,R,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,W+#0X.#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@T-2PQ,#8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,S(L-C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-3(U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#,U+#@Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
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M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S(L-C,W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-S`L-C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH-#4L-C@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4U+#`V,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@T,BPW-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,38L
M-30S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#0W+#8U.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O;64@*&QO<W,I
M('!E<B!S:&%R92@Q*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F%S:6,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,S<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,"XR-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-34\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@P+C,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#`N-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XS-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@P+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N-#$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$:6QU=&5D/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C,W/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#`N,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C4S/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XS-3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@P+C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,S<\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,"XQ-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C0Q/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,G!T.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@34%21TE.+51/4#H@,'!T.R!,24Y%+4A%24=(5#H@.'!T.R!72414
M2#H@,3`E)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#XH,2D\
M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/E%U87)T97)L
M>2!L;W-S('!E<B!S:&%R92!A;6]U;G1S(&UA>0T*(&YO="!T;W1A;"!T;R!T
M:&4@>65A<BUT;RUD871E(&QO<W,@<&5R('-H87)E(&1U92!T;R!R;W5N9&EN
M9RX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?
M-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O
M5V]R:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04)!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/CQI/D]R9V%N:7IA=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P
M>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!A<F4@80T*(&)I
M;W!H87)M86-E=71I8V%L(&-O;7!A;GD@:&5A9'%U87)T97)E9"!I;B!386X@
M1G)A;F-I<V-O+`T*($-A;&EF;W)N:6$@86YD(&EN8V]R<&]R871E9"!I;B!$
M96QA=V%R92X@5V4@87)E(&1E=F5L;W!I;F<@80T*('!I<&5L:6YE(&]F(&1R
M=6<@8V%N9&ED871E<R!T:&%T('5T:6QI>F4@;W5R(%!%1WEL871I;VX@86YD
M#0H@861V86YC960@<&]L>6UE<B!C;VYJ=6=A=&4@=&5C:&YO;&]G>2!P;&%T
M9F]R;7,@=VET:"!T:&4@;V)J96-T:79E#0H@=&\@:6UP<F]V92!T:&4@8F5N
M969I=',@;V8@9')U9W,@9F]R('!A=&EE;G1S+CPO9F]N=#X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X
M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]U<B!R97-E87)C:`T*
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M<F]U9V@@8V%S:`T*(&=E;F5R871E9"!F<F]M(&QI8V5N<VEN9RP@8V]L;&%B
M;W)A=&EO;B!A;F0@;6%N=69A8W1U<FEN9PT*(&%G<F5E;65N=',@86YD(&9I
M;F%N8VEN9R!T<F%N<V%C=&EO;G,N($%T($1E8V5M8F5R)B-X03`[,S$L(#(P
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M#0H@<')I;F-I<&%L(&%M;W5N="!O9B`Q,BXP)2!S96YI;W(@<V5C=7)E9"!N
M;W1E<R!D=64@2G5L>28C>$$P.S$U+`T*(#(P,3<L(&)U="!E>&-L=61E<R!O
M=7(@;&]N9RUT97)M(&QI86)I;&ET>2!R96QA=&EN9R!T;R!T:&4@<V%L92!O
M9@T*(&9U='5R92!R;WEA;'1I97,N($%S(&ES(&9U<G1H97(@9&5S8W)I8F5D
M(&EN($YO=&4@-RP@=&AI<R!R;WEA;'1Y#0H@;V)L:6=A=&EO;B!L:6%B:6QI
M='D@=VEL;"!N;W0@8F4@<V5T=&QE9"!I;B!C87-H+CPO9F]N=#X\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VXL(%!R:6YC:7!L97,@;V8@
M0V]N<V]L:61A=&EO;B!A;F0@57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/CQI/D)A<VES(&]F#0H@4')E<V5N=&%T:6]N+"!0<FEN8VEP;&5S(&]F($-O
M;G-O;&ED871I;VX@86YD(%5S92!O9@T*($5S=&EM871E<SPO:3X\+V(^/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!
M4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/
M=7(-"B!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D
M92!T:&4@9FEN86YC:6%L('!O<VET:6]N+`T*(')E<W5L=',@;V8@;W!E<F%T
M:6]N<R!A;F0@8V%S:"!F;&]W<R!O9B!O=7(@=VAO;&QY+6]W;F5D#0H@<W5B
M<VED:6%R:65S.B!.96MT87(@5&AE<F%P975T:6-S("A);F1I82D@4')I=F%T
M92!,:6UI=&5D(&%N9`T*($YE:W1A<B!4:&5R87!E=71I8W,@54LL($QT9"X@
M*$YE:W1A<B!52RDN($%L;"!I;G1E<F-O;7!A;GD@86-C;W5N=',-"B!A;F0@
M=')A;G-A8W1I;VYS(&AA=F4@8F5E;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED
M871I;VXN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M4RXF(WA!,#MD;VQL87(@=VEL;`T*(&%F9F5C="!T:&4@=')A;G-L871I;VX@
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M9F]R96EG;B!C=7)R96YC>2!T<F%N<V%C=&EO;B!G86EN<R`H;&]S<V5S*2!R
M96-O<F1E9"!I;B!O<&5R871I;VYS#0H@9F]R('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q,B!W97)E(&YO
M=`T*('-I9VYI9FEC86YT+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.
M5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1H92!P<F5P87)A=&EO;@T*(&]F(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I
M=&@@52Y3+@T*(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC
M:7!L97,@*$=!05`I(')E<75I<F5S(&UA;F%G96UE;G0-"B!T;R!M86ME(&5S
M=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE(')E<&]R
M=&5D(&%M;W5N=',-"B!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S(&%N9"!D
M:7-C;&]S=7)E(&]F(&-O;G1I;F=E;G0@87-S971S(&%N9`T*(&QI86)I;&ET
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M971S+`T*(&-O;G1I;F=E;F-I97,L(&%C8W)U960@8VQI;FEC86P@=')I86P@
M97AP96YS97,L(&5S=&EM871E9"!I;G1E<F5S=`T*(&5X<&5N<V4@9G)O;2!O
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M<F5F;&5C="!C=7)R96YT(&EN9F]R;6%T:6]N(&%N9`T*(&%N>2!C:&%N9V5S
M(&EN(&5S=&EM871E<R!W:6QL(&=E;F5R86QL>2!B92!R969L96-T960@:6X@
M=&AE('!E<FEO9`T*(&9I<G-T(&ED96YT:69I960N/"]F;VYT/CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8VQA<W-I9FEC871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-L87-S:69I
M8V%T:6]N<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@0V5R=&%I;B!I=&5M<R!P<F5V:6]U<VQY(')E<&]R=&5D(&EN('-P96-I
M9FEC(&9I;F%N8VEA;"!S=&%T96UE;G0-"B!C87!T:6]N<R!H879E(&)E96X@
M<F5C;&%S<VEF:65D('1O(&-O;F9O<FT@=&\@=&AE(&-U<G)E;G0@<&5R:6]D
M#0H@<')E<V5N=&%T:6]N+B!3=6-H(')E8VQA<W-I9FEC871I;VYS(&1O(&YO
M="!M871E<FEA;&QY(&EM<&%C=`T*('!R979I;W5S;'D@<F5P;W)T960@=&]T
M86P@<F5V96YU92P@;W!E<F%T:6YG(&QO<W,@;W(@;F5T(&QO<W,@;W(-"B!T
M;W1A;"!A<W-E=',L(&QI86)I;&ET:65S(&]R('-T;V-K:&]L9&5R<R8C>#(P
M,3D[(&5Q=6ET>0T*("AD969I8VET*2X\+W`^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H+"!#
M87-H($5Q=6EV86QE;G1S+"!A;F0@26YV97-T;65N=',L(&%N9"!&86ER(%9A
M;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D-A
M<V@L($-A<V@-"B!%<75I=F%L96YT<RP@86YD($EN=F5S=&UE;G1S+"!A;F0@
M1F%I<B!686QU92!O9B!&:6YA;F-I86P-"B!);G-T<G5M96YT<SPO:3X\+V(^
M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S
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M=',@=&\@9G5N9`T*(&-U<G)E;G0@;W!E<F%T:6]N<R!O<B!T;R!M86ME('1H
M96T@879A:6QA8FQE(&9O<B!C=7)R96YT#0H@;W!E<F%T:6]N<RP@87)E(&-L
M87-S:69I960@87,@<VAO<G0M=&5R;2!I;G9E<W1M96YT<RX\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/
M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G9E<W1M
M96YT<R!A<F4-"B!D97-I9VYA=&5D(&%S(&%V86EL86)L92UF;W(M<V%L92!A
M;F0@87)E(&-A<G)I960@870@9F%I<B!V86QU92P-"B!W:71H('5N<F5A;&EZ
M960@9V%I;G,@86YD(&QO<W-E<R!R97!O<G1E9"!I;B!S=&]C:VAO;&1E<G,F
M(W@R,#$Y.PT*(&5Q=6ET>2`H9&5F:6-I="D@87,@86-C=6UU;&%T960@;W1H
M97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I+@T*(%1H92!D:7-C;&]S
M960@9F%I<B!V86QU92!R96QA=&5D('1O(&]U<B!C87-H(&5Q=6EV86QE;G1S
M(&%N9`T*(&EN=F5S=&UE;G1S(&ES(&)A<V5D('!R:6UA<FEL>2!O;B!T:&4@
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M:&5R#0H@:6YF;W)M871I;VXN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
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M:&]D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF
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M(&%N9`T*(&9U;F1S+"!A;F0@8V]R<&]R871E(&)O;F1S(&%N9"!P;&%C97,@
M<F5S=')I8W1I;VYS(&]N(&UA='5R:71I97,-"B!A;F0@8V]N8V5N=')A=&EO
M;G,@8GD@='EP92!A;F0@:7-S=65R+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!296-E:79A8FQE(&%N9"!3:6=N:69I8V%N="!#=7-T;VUE<B!#
M;VYC96YT<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,3AP="<^#0H@/&(^/&D^06-C;W5N=',@4F5C96EV86)L92!A
M;F0@4VEG;FEF:6-A;G0@0W5S=&]M97(-"B!#;VYC96YT<F%T:6]N<SPO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3W5R(&-U<W1O
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M<B8C>$$P.S,Q+"`R,#$T+"!T:')E92!D:69F97)E;G0@8W5S=&]M97)S#0H@
M<F5P<F5S96YT960@-#`E+"`S,24L(&%N9"`Q-24L(')E<W!E8W1I=F5L>2P@
M;V8@;W5R(&%C8V]U;G1S#0H@<F5C96EV86)L92X@070@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,RP@=&AR964@9&EF9F5R96YT(&-U<W1O;65R<PT*(')E<')E
M<V5N=&5D(#,P)2P@,C@E+"!A;F0@,C@E+"!R97-P96-T:79E;'DL(&]F(&]U
M<B!A8V-O=6YT<PT*(')E8V5I=F%B;&4N/"]P/@T*(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT
M;W)Y(&%N9"!3:6=N:69I8V%N="!3=7!P;&EE<B!#;VYC96YT<F%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^
M#0H@/&(^/&D^26YV96YT;W)Y(&%N9"!3:6=N:69I8V%N="!3=7!P;&EE<B!#
M;VYC96YT<F%T:6]N<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@26YV96YT;W)Y(&ES(&=E;F5R86QL>2!M86YU9F%C='5R960@
M=7!O;B!R96-E:7!T(&]F(&9I<FT@<'5R8VAA<V4-"B!O<F1E<G,@9G)O;2!O
M=7(@8V]L;&%B;W)A=&EO;B!P87)T;F5R<RX@26YV96YT;W)Y(&EN8VQU9&5S
M(&1I<F5C=`T*(&UA=&5R:6%L<RP@9&ER96-T(&QA8F]R+"!A;F0@;6%N=69A
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M:65S(&ES(&5X<&5N<V5D('=H96X@<'5R8VAA<V5D+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
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M86YD(')E<W5L=',@;V8@;W!E<F%T:6]N<RX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG
M+4QI=F5D($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/DQO;F<M3&EV960-"B!!<W-E
M=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^4')O<&5R='DL('!L86YT#0H@86YD(&5Q=6EP;65N="!A
M<F4@<W1A=&5D(&%T(&-O<W0N($UA:F]R(&EM<')O=F5M96YT<R!A<F4-"B!C
M87!I=&%L:7IE9"P@=VAI;&4@;6%I;G1E;F%N8V4@86YD(')E<&%I<G,@87)E
M(&5X<&5N<V5D('=H96X-"B!I;F-U<G)E9"X@36%N=69A8W1U<FEN9RP@;&%B
M;W)A=&]R>2!A;F0@;W1H97(@97%U:7!M96YT(&%R90T*(&1E<')E8VEA=&5D
M('5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!G96YE<F%L;'D@;W9E
M<B!E<W1I;6%T960-"B!U<V5F=6P@;&EV97,@;V8@=&AR964@=&\@<V5V96X@
M>65A<G,N($QE87-E:&]L9"!I;7!R;W9E;65N=',@86YD#0H@8G5I;&1I;F=S
M(')E8V]R9&5D('5N9&5R(&-A<&ET86P@;&5A<V5S(&%R92!D97!R96-I871E
M9"!U<VEN9R!T:&4-"B!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H92!S
M:&]R=&5R(&]F('1H92!E<W1I;6%T960@=7-E9G5L(&QI9F4-"B!O<B!T:&4@
M<F5M86EN:6YG('1E<FT@;V8@=&AE(&QE87-E+CPO9F]N=#X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X
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M<&]R=&EN9R!U;FET(&%N9`T*(&5V86QU871E('1H92!G;V]D=VEL;"!F;W(@
M=&AE($-O;7!A;GD@87,@82!W:&]L92X@1V]O9'=I;&P@:&%S(&%N#0H@:6YD
M969I;FET92!U<V5F=6P@;&EF92!A;F0@:7,@;F]T(&%M;W)T:7IE9"P@8G5T
M(&EN<W1E860@=&5S=&5D(&9O<@T*(&EM<&%I<FUE;G0@86YN=6%L;'D@:6X@
M=&AE(&9O=7)T:"!Q=6%R=&5R(&]F(&5A8V@@>65A<B!U<VEN9R!A;@T*($]C
M=&]B97(F(WA!,#LQ(&UE87-U<F5M96YT(&1A=&4N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R
M<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
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M87)I;F<@=&AE(&%S<V5T)B-X,C`Q.3MS(&-A<G)Y:6YG('9A;'5E#0H@=VET
M:"!I=',@9F%I<B!V86QU92P@87,@;65A<W5R960@8GD@=&AE(&%N=&EC:7!A
M=&5D('5N9&ES8V]U;G1E9`T*(&YE="!C87-H(&9L;W=S(&]F('1H92!A<W-E
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5V96YU92!296-O9VYI=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E)E=F5N=64-"B!2
M96-O9VYI=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
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M<F%C="!R97-E87)C:`T*(&%N9"!D979E;&]P;65N="P@;6EL97-T;VYE('!A
M>6UE;G1S+"!M86YU9F%C='5R:6YG(&%N9"!S=7!P;'D-"B!P87EM96YT<RP@
M86YD(')O>6%L=&EE<RX@3W5R('!E<F9O<FUA;F-E(&]B;&EG871I;VYS('5N
M9&5R(&]U<@T*(&-O;&QA8F]R871I;VYS(&UA>2!I;F-L=61E(&QI8V5N<VEN
M9R!O=7(@:6YT96QL96-T=6%L('!R;W!E<G1Y+`T*(&UA;G5F86-T=7)I;F<@
M86YD('-U<'!L>2!O8FQI9V%T:6]N<RP@86YD(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N=`T*(&]B;&EG871I;VYS+B!);B!O<F1E<B!T;R!A8V-O=6YT(&9O
M<B!T:&4@;75L=&EP;&4M96QE;65N=`T*(&%R<F%N9V5M96YT<RP@=&AE($-O
M;7!A;GD@:61E;G1I9FEE<R!T:&4@9&5L:79E<F%B;&5S(&EN8VQU9&5D#0H@
M=VET:&EN('1H92!A<G)A;F=E;65N="!A;F0@979A;'5A=&5S('=H:6-H(&1E
M;&EV97)A8FQE<R!R97!R97-E;G0-"B!S97!A<F%T92!U;FET<R!O9B!A8V-O
M=6YT:6YG+B!!;F%L>7II;F<@=&AE(&%R<F%N9V5M96YT('1O(&ED96YT:69Y
M#0H@9&5L:79E<F%B;&5S(')E<75I<F5S('1H92!U<V4@;V8@:G5D9VUE;G0L
M(&%N9"!E86-H(&1E;&EV97)A8FQE(&UA>0T*(&)E(&%N(&]B;&EG871I;VX@
M=&\@9&5L:79E<B!S97)V:6-E<RP@82!R:6=H="!O<B!L:6-E;G-E('1O('5S
M92!A;@T*(&%S<V5T+"!O<B!A;F]T:&5R('!E<F9O<FUA;F-E(&]B;&EG871I
M;VXN(%)E=F5N=64@:7,@<F5C;V=N:7IE9`T*('-E<&%R871E;'D@9F]R(&5A
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M(')E87-O;F%B;'D-"B!A<W-U<F5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4
M+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%T('1H90T*(&EN8V5P=&EO;B!O
M9B!E86-H(&YE=R!M=6QT:7!L92UE;&5M96YT(&%R<F%N9V5M96YT(&]R('1H
M92!M871E<FEA;`T*(&UO9&EF:6-A=&EO;B!O9B!A;B!E>&ES=&EN9R!M=6QT
M:7!L92UE;&5M96YT(&%R<F%N9V5M96YT+"!W90T*(&%L;&]C871E(&%L;"!C
M;VYS:61E<F%T:6]N(')E8V5I=F5D('5N9&5R(&UU;'1I<&QE+65L96UE;G0-
M"B!A<G)A;F=E;65N=',@=&\@86QL('5N:71S(&]F(&%C8V]U;G1I;F<@8F%S
M960@;VX@=&AE(')E;&%T:79E#0H@<V5L;&EN9R!P<FEC92!M971H;V0L(&=E
M;F5R86QL>2!B87-E9"!O;B!O=7(@8F5S="!E<W1I;6%T92!O9@T*('-E;&QI
M;F<@<')I8V4@*$534"DN(%1H92!O8FIE8W1I=F4@;V8@15-0(&ES('1O(&1E
M=&5R;6EN92!T:&4@<')I8V4-"B!A="!W:&EC:"!W92!W;W5L9"!T<F%N<V%C
M="!A('-A;&4@:68@=&AE('!R;V1U8W0@;W(@<V5R=FEC92!W87,-"B!S;VQD
M(&]N(&$@<W1A;F0M86QO;F4@8F%S:7,N(%=E(&1E=&5R;6EN92!%4U`@9F]R
M('1H92!E;&5M96YT<R!I;@T*(&]U<B!C;VQL86)O<F%T:6]N(&%R<F%N9V5M
M96YT<R!B>2!C;VYS:61E<FEN9R!M=6QT:7!L92!F86-T;W)S#0H@:6YC;'5D
M:6YG+"!B=70@;F]T(&QI;6ET960@=&\L('1E8VAN:6-A;"!C;VUP;&5X:71Y
M(&]F('1H90T*('!E<F9O<FUA;F-E(&]B;&EG871I;VX@86YD('-I;6EL87)I
M='D@;V8@96QE;65N=',@=&\@=&AO<V4-"B!P97)F;W)M960@=6YD97(@<')E
M=FEO=7,@87)R86YG96UE;G1S+B!3:6YC92!W92!A<'!L>2!S:6=N:69I8V%N
M=`T*(&IU9&=M96YT(&EN(&%R<FEV:6YG(&%T('1H92!%4U!S+"!A;GD@;6%T
M97)I86P@8VAA;F=E(&EN(&]U<@T*(&5S=&EM871E<R!W;W5L9"!S:6=N:69I
M8V%N=&QY(&%F9F5C="!T:&4@86QL;V-A=&EO;B!O9B!T:&4@=&]T86P-"B!C
M;VYS:61E<F%T:6]N('1O('1H92!D:69F97)E;G0@96QE;65N=',@;V8@82!M
M=6QT:7!L92!E;&5M96YT#0H@87)R86YG96UE;G0N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X
M.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/CQF;VYT
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M<B!C=7-T;VUE<G,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQI/E)O
M>6%L='D-"B!R979E;G5E<SPO:3X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.
M1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D=E;F5R86QL>2P@=V4-"B!A<F4@96YT
M:71L960@=&\@<F]Y86QT:65S(&9R;VT@;W5R(&-O;&QA8F]R871I;VX@<&%R
M=&YE<G,@8F%S960@;VX-"B!T:&4@;F5T('-A;&5S(&]F('1H96ER(&%P<')O
M=F5D(&1R=6=S('1H870@87)E(&UA<FME=&5D(&%N9"!S;VQD(&EN#0H@;VYE
M(&]R(&UO<F4@8V]U;G1R:65S('=H97)E('=E(&AO;&0@<F]Y86QT>2!R:6=H
M=',N(%=E(')E8V]G;FEZ90T*(')O>6%L='D@<F5V96YU92!W:&5N('1H92!C
M87-H(&ES(')E8V5I=F5D(&]R('=H96X@=&AE(')O>6%L='D-"B!A;6]U;G0@
M=&\@8F4@<F5C96EV960@:7,@97-T:6UA8FQE(&%N9"!C;VQL96-T:6]N(&ES
M(')E87-O;F%B;'D-"B!A<W-U<F5D+B!7:71H(')E<W!E8W0@=&\@=&AE(&YO
M;BUC87-H(')O>6%L=&EE<R!R96QA=&5D('1O('-A;&4@;V8-"B!F=71U<F4@
M<F]Y86QT:65S(&1E<V-R:6)E9"!A="!.;W1E)B-X03`[-RP@<F5V96YU92!I
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M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQI/DQI8V5N<V4L(&-O;&QA8F]R871I
M;VX-"B!A;F0@;W1H97(\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@86UO=6YT(&]F#0H@=7!F<F]N="!F
M965S(&%N9"!O=&AE<B!P87EM96YT<R!R96-E:79E9"!B>2!U<R!I;B!L:6-E
M;G-E(&%N9`T*(&-O;&QA8F]R871I;VX@87)R86YG96UE;G1S('1H870@87)E
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M;"!D979E;&]P;65N=`T*(&%C=&EV:71I97,L(&%N9"!M86YU9F%C='5R:6YG
M(&%C=&EV:71I97,@9G)O;2!D979E;&]P;65N="!T:')O=6=H#0H@=&AE(&-O
M;6UE<F-I86QI>F%T:6]N(&]F('1H92!P<F]D=6-T+B!':79E;B!T:&4@=6YC
M97)T86EN=&EE<R!O9@T*('1H97-E(&-O;&QA8F]R871I;VX@87)R86YG96UE
M;G1S+"!S:6=N:69I8V%N="!J=61G;65N="!I<R!R97%U:7)E9`T*('1O(&1E
M=&5R;6EN92!T:&4@9'5R871I;VX@;V8@=&AE('!E<F9O<FUA;F-E('!E<FEO
M9"!A;F0@=&AI<PT*(&5S=&EM871E(&ES('!E<FEO9&EC86QL>2!R92UE=F%L
M=6%T960N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^0V]N=&EN9V5N=`T*(&-O;G-I9&5R871I;VX@<F5C96EV960@
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M;G-E(&%N9`T*(&-O;&QA8F]R871I;VX@86=R965M96YT<RX@02!M:6QE<W1O
M;F4@:7,@9&5F:6YE9"!A<R!A;B!E=F5N=`T*("AI*28C>$$P.W1H870@8V%N
M(&]N;'D@8F4@86-H:65V960@8F%S960@:6X@=VAO;&4@;W(@:6X@<&%R="!E
M:71H97(-"B!O;B!T:&4@96YT:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E(&]R
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M;`T*(&]F('1H92!O=&AE<B!D96QI=F5R86)L97,@86YD('!A>6UE;G1S('=I
M=&AI;B!T:&4-"B!A<G)A;F=E;65N="X\+V9O;G0^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
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M96UA:6YI;F<@8W)I=&5R:6$@=&\@8F4@8V]N<VED97)E9`T*('-U8G-T86YT
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z
M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].
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M(&%S<W5R960N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-
M"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@
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M(&%S<W5R960N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H:7!P:6YG(&%N9"!(
M86YD;&EN9R!#;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4VAI<'!I;F<@86YD($AA;F1L:6YG
M($-O<W1S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!792!R96-O9VYI>F4@8V]S=',@<F5L871E9"!T;R!S:&EP<&EN9R!A;F0@
M:&%N9&QI;F<@;V8@<')O9'5C="!T;PT*(&-U<W1O;65R<R!I;B!C;W-T(&]F
M(&=O;V1S('-O;&0N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y297-E87)C:"!A;F0-"B!$
M979E;&]P;65N="!%>'!E;G-E/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!4
M15A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9`T*(&1E
M=F5L;W!M96YT(&-O<W1S(&%R92!E>'!E;G-E9"!A<R!I;F-U<G)E9"!A;F0@
M:6YC;'5D92!S86QA<FEE<RP-"B!B96YE9FET<R!A;F0@;W1H97(@;W!E<F%T
M:6YG(&-O<W1S('-U8V@@87,@;W5T<VED92!S97)V:6-E<RP-"B!S=7!P;&EE
M<R!A;F0@86QL;V-A=&5D(&]V97)H96%D(&-O<W1S+B!792!P97)F;W)M(')E
M<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT(&9O<B!O=7(@<')O<')I971A<GD@
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M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)
M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@<W1Y;&4]
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M('1O(&)E(&-H86YG97,@:6X@97-T:6UA=&5S(&%N9`T*('=I;&P@8F4@<F5F
M;&5C=&5D(&EN(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!I
M;B!T:&4-"B!P97)I;V0@9FER<W0@:61E;G1I9FEE9"X@1'5R:6YG('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+`T*('=E(')E8V]R9&5D(&$@
M<F5D=6-T:6]N(')E;&%T960@=&\@<')I;W(@<&5R:6]D<R!O9B!A<'!R;WAI
M;6%T96QY#0H@)#0N-R!M:6QL:6]N('1O(&]U<B!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@97AP96YS97,@<')I;6%R:6QY#0H@<F5L871E9"!T;R!O=7(@
M0F5A8V]N(%!H87-E(#,@8VQI;FEC86P@=')I86P@9F]R(&5T:7)I;F]T96-A
M;@T*('!E9V]L+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y3=&]C:RU"87-E9`T*($-O;7!E
M;G-A=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY3=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;B!A
M<G)A;F=E;65N=',@:6YC;'5D92!S=&]C:R!O<'1I;VX@9W)A;G1S(&%N9`T*
M(')E<W1R:6-T960@<W1O8VL@=6YI="`H4E-5*2!A=V%R9',@=6YD97(@;W5R
M(&5Q=6ET>2!I;F-E;G1I=F4-"B!P;&%N<RP@87,@=V5L;"!A<R!S:&%R97,@
M:7-S=65D('5N9&5R(&]U<B!%;7!L;WEE92!3=&]C:R!0=7)C:&%S90T*(%!L
M86X@*$534%`I+"!T:')O=6=H('=H:6-H(&5M<&QO>65E<R!M87D@<'5R8VAA
M<V4@;W5R(&-O;6UO;B!S=&]C:PT*(&%T(&$@9&ES8V]U;G0@=&\@=&AE(&UA
M<FME="!P<FEC92X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY792!U<V4@=&AE#0H@0FQA8VLM4V-H;VQE<R!O<'1I
M;VX@<')I8VEN9R!M;V1E;"!F;W(@=&AE(')E<W!E8W1I=F4@9W)A;G0@=&\-
M"B!D971E<FUI;F4@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H92!O
M<'1I;VX@;VX@=&AE(&1A=&4@;V8-"B!G<F%N="`H9W)A;G0@9&%T92!F86ER
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M;VYS(&%N9`T*(&UE=&AO9&]L;V=I97,L(&%N9"!W:&EC:"!C;W5L9"!M871E
M<FEA;&QY(&EM<&%C="!O=7(@9F%I<B!V86QU90T*(&1E=&5R;6EN871I;VXN
M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@
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M('5N9&5R#0H@=&AE($534%`@:7,@<F5C;V=N:7IE9"!O=F5R('1H92!R97-P
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M(&-A<V@@9FQO=W,N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S(%!E
M<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z
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M(&5Q=6%L('1O('1H92!R97!O<G1E9`T*(&YE="!L;W-S+B!"87-I8R!A;F0@
M9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4@87)E('1H92!S86UE(&1U92!T
M;PT*(&]U<B!H:7-T;W)I8V%L(&YE="!L;W-S97,@86YD('1H92!R97%U:7)E
M;65N="!T;R!E>&-L=61E#0H@<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I
M=&EE<R!W:&EC:"!W;W5L9"!H879E(&%N(&%N=&DM9&EL=71I=F4-"B!E9F9E
M8W0@;VX@;F5T(&QO<W,@<&5R('-H87)E+B!$=7)I;F<@,C`Q-"P@,C`Q,R!A
M;F0@,C`Q,BP-"B!P;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S(&-O
M;G-I<W1E9"!O9B!C;VUM;VX@<VAA<F5S#0H@=6YD97)L>6EN9R!O=71S=&%N
M9&EN9R!S=&]C:R!O<'1I;VYS(&%N9"!T:&5R92!W97)E('=E:6=H=&5D#0H@
M879E<F%G92!O=71S=&%N9&EN9R!S=&]C:R!O<'1I;VYS(&]F(#(Q+CD@;6EL
M;&EO;BP@,C`N-R!M:6QL:6]N(&%N9`T*(#$X+C@@;6EL;&EO;B!D=7)I;F<@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9`T*
M(#(P,3(L(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q.'!T)SX-"B`\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M9&5T97)M:6YA=&EO;B!I<R!M861E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!792!U=&EL:7IE(&$@='=O+7-T97`@87!P<F]A8V@@=&\@
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M=&AE(&QA<F=E<W0@86UO=6YT('1H870@:7,@;6]R92!T:&%N#0H@-3`E(&QI
M:V5L>2!O9B!B96EN9R!R96%L:7IE9"!U<&]N('5L=&EM871E('-E='1L96UE
M;G0N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI
M/D-O;7!R96AE;G-I=F4@;&]S<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@0V]M<')E:&5N<VEV92!L;W-S(&ES('1H92!C:&%N
M9V4@:6X@<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U:71Y#0H@*&1E9FEC:70I
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M9&EA(&%N9`T*(%5+('-U8G-I9&EA<FEE<RP@86YD('5N<F5A;&EZ960@9V%I
M;G,@86YD(&QO<W-E<R!O;B!I;G9E<W1M96YT<R!I;@T*(&%V86EL86)L92UF
M;W(M<V%L92!S96-U<FET:65S+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N="!!8V-O
M=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E;G0@06-C;W5N
M=&EN9R!0<F]N;W5N8V5M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@26X@36%Y(#(P,30L('1H92!&:6YA;F-I86P@06-C
M;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*$9!4T(I(&ES<W5E9`T*(&=U:61A
M;F-E(&-O9&EF:65D(&EN($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A
M=&EO;B`H05-#*2`V,#8L#0H@/&D^4F5V96YU92!296-O9VYI=&EO;B`F(W@R
M,#$T.R!2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@-"B!#=7-T;VUE<G,\
M+VD^+"!W:&EC:"!A;65N9',@=&AE(&=U:61A;F-E(&EN(&9O<FUE<B!!4T,@
M-C`U+`T*(#QI/E)E=F5N=64@4F5C;V=N:71I;VXL/"]I/B!A;F0@:7,@969F
M96-T:79E(&9O<B!P=6)L:6,@8V]M<&%N:65S#0H@9F]R(&9I<V-A;"!Y96%R
M<R!B96=I;FYI;F<@869T97(@1&5C96UB97(F(WA!,#LQ-2P@,C`Q-BX@5V4@
M87)E#0H@8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&EM<&%C="!O9B!T:&4@
M<')O=FES:6]N<R!O9B!!4T,@-C`V+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!);B!!=6=U<W0@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%C
M8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T90T*($YO+B8C>$$P.S(P,30M,34L
M($1I<V-L;W-U<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;@T*($5N=&ET
M>28C>#(P,3D[<R!!8FEL:71Y('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N
M8V5R;B`H05-5#0H@,C`Q-"TQ-2DN($%352`R,#$T+3$U(')E<75I<F5S(&UA
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M9&]P=&EN9R!!4U4@,C`Q-"TQ-2!O;B!O=7(@8V]N<V]L:61A=&5D#0H@9FEN
M86YC:6%L('-T871E;65N=',@=VEL;"!B92!S:6=N:69I8V%N="X\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-A<V@@86YD($EN=F5S
M=&UE;G1S(&EN($UA<FME=&%B;&4@4V5C=7)I=&EE<R`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&
M86ER(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@26YV97-T
M;65N=',@:6X@36%R:V5T86)L92!396-U<FET:65S+"!);F-L=61I;F<@0V%S
M:"!%<75I=F%L96YT<R!A;F0@4F5S=')I8W1E9"!#87-H/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@0V%S:"!A;F0@:6YV97-T;65N=',@:6X@;6%R:V5T86)L92!S
M96-U<FET:65S+"!I;F-L=61I;F<@8V%S:`T*(&5Q=6EV86QE;G1S(&%N9"!R
M97-T<FEC=&5D(&-A<V@L(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I
M.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A
M;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0W,B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\8CY%<W1I
M;6%T960@1F%I<B!686QU92!A=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P
M.S,Q+#PO8CX\8G(@+SX-"B`\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\
M8G(@+SX-"B`\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$R+#,V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,SDL,#8W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3:&]R="UT97)M
M(&EN=F5S=&UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,C(U+#0U.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M.3<L.34Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR-2PP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C4L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
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M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M;W)T9F]L:6\@;V8@0V%S:"!A;F0@26YV97-T;65N=',@:6X@36%R:V5T86)L
M92!396-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.
M+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=7(@
M<&]R=&9O;&EO#0H@;V8@8V%S:"!A;F0@:6YV97-T;65N=',@:6X@;6%R:V5T
M86)L92!S96-U<FET:65S(&EN8VQU9&5S("AI;@T*('1H;W5S86YD<RDZ/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/
M3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@
M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A8FQE
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M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,B!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY&86ER)B-X03`[#0H@5F%L=64\+V(^
M/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DAI97)A<F-H>3PO8CX\+V9O
M;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^3&5V96P\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CX\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/D5S=&EM871E9"!&86ER(%9A;'5E#0H@870\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+#QB<B`O/@T*(#(P,30\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L/&)R("\^#0H@,C`Q,SPO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D-O<G!O<F%T92!N;W1E<R!A;F0-"B!B;VYD<SPO9F]N=#X\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ
M.#(L-30T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
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M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-O<G!O<F%T92!C;VUM97)C:6%L
M#0H@<&%P97(\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXR/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,BPY,34\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
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M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^079A:6QA8FQE+69O<BUS86QE#0H@:6YV97-T
M;65N=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/C(R-2PT-3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y-RPY-3D\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY-
M;VYE>2!M87)K970-"B!F=6YD<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,C8L-#4S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V%S:"P@:6YC
M;'5D:6YG(')E<W1R:6-T960-"B!C87-H/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^3B]!/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-BPQ
M,S8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
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M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@8V%S:"!A;F0@:6YV97-T;65N=',-
M"B!I;B!M87)K971A8FQE('-E8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
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M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,C8R+#`R-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T86)L
M93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q
M,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C
M.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#(V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV
M96YT;W)Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5N=&]R>2!$:7-C;&]S=7)E(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26YV96YT;W)Y(&-O
M;G-I<W1S(&]F('1H92!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@P)3X\
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X
M03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%)A=R!M871E<FEA;',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPR,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L
M.30W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!7;W)K+6EN+7!R;V-E
M<W,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#$X-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#$T-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1FEN:7-H
M960@9V]O9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#4V
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,U.3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($EN=F5N=&]R>3PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,BPY-3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#0U,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E
M7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T
M<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY0<F]P97)T>2P@<&QA;G0-"B!A;F0@97%U:7!M96YT(&-O;G-I
M<W1S(&]F('1H92!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:
M13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<Q)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0G5I;&1I;F<@86YD(&QE87-E
M:&]L9`T*(&EM<')O=F5M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
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M)R!S:7IE/3-$,CXW,BPR,C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW,2PS,#8\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,86)O<F%T;W)Y
M#0H@97%U:7!M96YT/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,C8L.3<U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-BPV,C$\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY-86YU9F%C='5R:6YG#0H@97%U:7!M96YT/"]F;VYT/CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C4L,C$R/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXR,RPV.3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY&=7)N:71U<F4L(&9I>'1U<F5S(&%N9`T*(&]T
M:&5R(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C,L,C,U/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/D1E<')E8VEA8FQE('!R;W!E<G1Y+"!P;&%N=`T*
M(&%N9"!E<75I<&UE;G0@870@8V]S=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C$T-RPX-C8\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T
M-"PX-C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY,97-S.B!A8V-U;75L871E9`T*(&1E<')E8VEA=&EO;CPO9F]N=#X\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Y,RPX,#<\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXH.#0L,30X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!R96-I86)L92!P
M<F]P97)T>2P@<&QA;G0-"B!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-"PP-3D\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/D-O;G-T<G5C=&EO;BUI;BUP<F]G<F5S<SPO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-BPR-C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4')O
M<&5R='DL('!L86YT(&%N9`T*(&5Q=6EP;65N="P@;F5T/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8V
M+#DW-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E
M,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E
M9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H
M965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY,96%S97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R
M92!-:6YI;75M(%!A>6UE;G1S(&9O<B!#87!I=&%L($QE87-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!&=71U<F4@;6EN:6UU;2!P87EM96YT<R!F;W(@;W5R
M(&-A<&ET86P@;&5A<V5S(&%T($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q-"!A
M<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#@E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^665A<G,@96YD:6YG($1E8V5M
M8F5R)B-X03`[,S$L/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XU+#4W,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@,C`Q-CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0L,C8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B`R,#$W/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3<U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!M:6YI;75M('!A>6UE;G1S(')E<75I
M<F5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L,#$U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,97-S.B!A;6]U;G0@
M<F5P<F5S96YT:6YG(&EN=&5R97-T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L
M,S8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@4')E<V5N="!V86QU92!O9B!F=71U<F4@;6EN:6UU;2!L
M96%S92!P87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L-C4Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,97-S
M.B!C=7)R96YT('!O<G1I;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-"PU,3(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!#87!I=&%L(&QE87-E(&]B;&EG871I;VXL(&QE<W,@8W5R<F5N
M="!P;W)T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,3,Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1G5T=7)E($UI;FEM=6T@3&5A<V4@4&%Y;65N
M=',@9F]R($]P97)A=&EN9R!,96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M3W5R(&9U='5R92!M:6YI;75M(&QE87-E('!A>6UE;G1S(&9O<B!O=7(@;W!E
M<F%T:6YG(&QE87-E<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30@87)E
M(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@X)3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/EEE87)S(&5N9&EN9R!$96-E;6)E
M<B8C>$$P.S,Q+#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,34\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"PW-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT
M+#@Y,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@,C`Q-SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L
M,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$X/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PQ.#<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,3D\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#,T-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@,C`R,#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C0U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@
M9G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,C4L-C8R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q
M,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U
M."]7;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY,:6%B:6QI='D@4F5L871E9"!T;R!386QE(&]F
M($9U='5R92!2;WEA;'1I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@3&EA8FEL:71Y(%)E;&%T960@=&\@4&]T96YT:6%L
M($9U='5R92!2;WEA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E1H92!F;VQL;W=I;F<-"B!T86)L92!S:&]W<R!T:&4@86-T:79I='D@=VET
M:&EN('1H92!L:6%B:6QI='D@86-C;W5N="!D=7)I;F<@=&AE#0H@>65A<B!E
M;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"!F;W(@=&AE('!E<FEO
M9"!F<F]M('1H90T*(&EN8V5P=&EO;B!O9B!T:&4@<F]Y86QT>2!T<F%N<V%C
M=&EO;B!O;B!&96)R=6%R>28C>$$P.S(T+"`R,#$R#0H@*&EN8V5P=&EO;BD@
M=&\@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"`H:6X@=&AO=7-A;F1S*3H\+V9O
M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].
M5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A
M;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@
M2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/EEE87(@96YD960\8G(@+SX-"B!$
M96-E;6)E<B8C>$$P.S,Q+#QB<B`O/@T*(#(P,30\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/E!E<FEO9`T*(&9R;VT\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/FEN8V5P=&EO;@T*('1O/&)R("\^#0H@1&5C96UB97(F(WA!,#LS,2P\8G(@
M+SX-"B`R,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^3&EA8FEL:71Y(')E;&%T960@=&\@<V%L
M90T*(&]F(&9U='5R92!R;WEA;'1I97,@)B-X,C`Q-#L@8F5G:6YN:6YG(&)A
M;&%N8V4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY0<F]C965D<R!F<F]M('-A;&4@;V8-"B!F=71U<F4@<F]Y
M86QT:65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3(T+#`P,#PO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E!A>6UE;G1S(&9R;VT@3F5K=&%R('1O#0H@4E!)/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#<L,#`P/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M*#$P+#`P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY.;VXM8V%S:"!#24U:24$\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B87-E;&EN93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U14
M3TTZ(#`N.&5X)SXF(WA!13L\+W-U<#X\+V9O;G0^#0H@86YD($U)4D-%4D$\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\<W5P('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B87-E;&EN
M93L@4$]3251)3TXZ(')E;&%T:79E.R!"3U143TTZ(#`N.&5X)SXF(WA!13L\
M+W-U<#X\+V9O;G0^#0H@<F]Y86QT>2!R979E;G5E/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(Q+#DS-SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B@U-"PW.#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^3F]N+6-A<V@@:6YT97)E<W0@97AP96YS
M90T*(')E8V]G;FEZ960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXR,"PX.#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
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M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,
M:6%B:6QI='D@<F5L871E9"!T;R!S86QE#0H@;V8@9G5T=7)E(')O>6%L=&EE
M<R`F(W@R,#$T.R!E;F1I;F<@8F%L86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ,C`L-#<Q/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q
M9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X
M,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T,S`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C
M:VAO;&1E<G,G($5Q=6ET>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6UM87)I>F%T:6]N(&]F($-O;6UO;B!3=&]C:R!3:&%R97,@9F]R($ES<W5A
M;F-E(%5N9&5R($5X:7-T:6YG($5Q=6ET>2!#;VUP96YS871I;VX@4&QA;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
M+"!W92!H860@,C0L.#`V+#4V-2!R97-E<G9E9"!S:&%R97,@;V8-"B!C;VUM
M;VX@<W1O8VLL(&%L;"!O9B!W:&EC:"!A<F4@<F5S97)V960@9F]R(&ES<W5A
M;F-E('5N9&5R(&]U<@T*(&5Q=6ET>2!C;VUP96YS871I;VX@<&QA;G,@87,@
M<W5M;6%R:7IE9"!I;B!T:&4@9F]L;&]W:6YG('1A8FQE#0H@*'-H87)E(&YU
M;6)E<B!I;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*
M(#QT<CX-"B`\=&0@=VED=&@],T0T."4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!724142#H@-#DN,7!T)SX-"B`\8CY0;&%N($-A=&5G;W)Y
M/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX-"B`\8CY.=6UB97(F(WA!,#MO9B8C>$$P.U-E8W5R
M:71I97,F(WA!,#MT;R8C>$$P.V)E/"]B/CQB<B`O/@T*(#QB/DES<W5E9"!5
M<&]N($5X97)C:7-E(&]F/"]B/CQB<B`O/@T*(#QB/D]U='-T86YD:6YG($]P
M=&EO;G,\+V(^/&)R("\^#0H@/&(^*&$I/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY796EG:'1E9"U!=F5R86=E/"]B/CQB
M<B`O/@T*(#QB/D5X97)C:7-E(%!R:6-E(&]F/"]B/CQB<B`O/@T*(#QB/D]U
M='-T86YD:6YG)B-X03`[3W!T:6]N<SPO8CX\8G(@+SX-"B`\8CXH8BD\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DYU
M;6)E<B8C>$$P.V]F)B-X03`[4V5C=7)I=&EE<R8C>$$P.U)E;6%I;FEN9SPO
M8CX\8G(@+SX-"B`\8CY!=F%I;&%B;&4@9F]R($ES<W5A;F-E(%5N9&5R/"]B
M/CQB<B`O/@T*(#QB/D5Q=6ET>2!#;VUP96YS871I;VX@4&QA;G,\+V(^/&)R
M("\^#0H@/&(^*$5X8VQU9&EN9R!396-U<FET:65S(%)E9FQE8W1E9#PO8CX\
M8G(@+SX-"B`\8CYI;B!#;VQU;6XH82DI/"]B/CQB<B`O/@T*(#QB/BAC*3PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17%U:71Y(&-O;7!E;G-A=&EO
M;B!P;&%N<R!A<'!R;W9E9"!B>2!S96-U<FET>2!H;VQD97)S*#$I/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L-C`Q/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ,"XV.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#@Q,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@17%U:71Y(&-O;7!E;G-A=&EO;B!P;&%N<R!N;W0@87!P<F]V960@
M8GD@<V5C=7)I='D@:&]L9&5R<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,L,SDT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY
M+C4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
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M1')I9VAT/C$P+C4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#$R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`R<'0[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!-05)'
M24XM5$]0.B`P<'0[($Q)3D4M2$5)1TA4.B`X<'0[(%=)1%1(.B`Q,"4G/@T*
M("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B@Q*3PO=&0^#0H@/'1D
M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^26YC;'5D97,@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:PT*(&%V86EL86)L92!F;W(@9G5T=7)E(&ES<W5A;F-E
M('5N9&5R(&]U<B!%4U!0(&%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q
M-"X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?
M-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O
M5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3&EC96YS92!A;F0@0V]L;&%B;W)A=&EO;B!!9W)E
M96UE;G1S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO
M;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&EC96YS92P@0V]L;&%B;W)A=&EO;B!A;F0@3W1H97(@4F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!A8V-O<F1A;F-E('=I=&@@;W5R
M(&-O;&QA8F]R871I;VX@86=R965M96YT<RP@=V4@<F5C;V=N:7IE9`T*(&QI
M8V5N<V4L(&-O;&QA8F]R871I;VX@86YD(&]T:&5R(')E=F5N=64@87,@9F]L
M;&]W<R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q
M,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$
M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$,SDE/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^#0H@/'1D('=I9'1H/3-$,S<E
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT
M97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\8CY087)T;F5R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$8V5N=&5R/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#%P
M=#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#!P="<@86QI9VX],T1C96YT97(^/&(^06=R965M
M96YT/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!!<W1R85IE;F5C82!!0CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/DU/5D%.5$E+/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^5$T\+W-U<#X@*$Y+5%(M,3$X
M*2!A;F0-"B!-3U9!3E1)2SQS=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[
M(%9%4E1)0T%,+4%,24=..B!T;W`G/E1-/"]S=7`^#0H@9FEX960M9&]S92!C
M;VUB:6YA=&EO;B!P<F]G<F%M("A.2U12+3$Q.2D\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#XQ
M,#4L,#`Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#XR-2PP,38\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A
M;&EG;CTS1')I9VAT/C4Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2;V-H
M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/E!%1T%365,\<W5P('-T
M>6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF
M(WA!13L\+W-U<#X@86YD#0H@34E20T5203QS=7`@<W1Y;&4],T0G1D].5"U3
M25I%.B`X-24[(%9%4E1)0T%,+4%,24=..B!T;W`G/B8C>$%%.SPO<W5P/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(L.#0U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+#,X,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XW+#$T-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F%X=&5R($AE86QT:&-A<F4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3Y"05@@.#4U("A(96UO<&AI
M;&EA*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L,C4X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-S`R/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C,X/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!!;6=E;BP@26YC+CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/DYE=6QA<W1A/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U
M)3L@5D525$E#04PM04Q)1TXZ('1O<"<^)B-X044[/"]S=7`^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU+#`S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XU+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0F%Y97(@2&5A;'1H8V%R92!,3$,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3Y"05DT,2TV-34Q("A!;6EK86-I;B!)
M;FAA;&4I/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<Q-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PR.3,\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-S$\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($%F9GEM87@L($EN8RX\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3Y/34].5%E3/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^)B-X044[/"]S=7`^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<L,30Y/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(L.#(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/=&AE<CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L
M-#8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,CDU
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.#@T/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3&EC96YS92P@8V]L;&%B;W)A=&EO;B!A;F0@;W1H97(@<F5V96YU93PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
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M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S`L,3(W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S
M=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R92UB87-E
M9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@=V%S(')E8V]G;FEZ960@87,@9F]L;&]W<R`H:6X-
M"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0W,R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%
M;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O<W0@;V8@9V]O9',@
M<V]L9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$V,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR.3<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L-#DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XW+#4R.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XW+#DQ,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XW+#`X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#,R.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#4P,3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#8R,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3<L,#$W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)L86-K+5-C:&]L
M97,@3W!T:6]N+5!R:6-I;F<@36]D96P@07-S=6UP=&EO;G,@57-E9"!T;R!#
M86QC=6QA=&4@1F%I<B!686QU92!O9B!%;7!L;WEE92!3=&]C:R!/<'1I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L97,@;&ES
M="!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;`T*(&%S
M<W5M<'1I;VYS('5S960@=&\@8V%L8W5L871E('1H92!F86ER('9A;'5E(&]F
M(&5M<&QO>65E(&%N9`T*(&1I<F5C=&]R('-T;V-K(&]P=&EO;G,N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4U)3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@16YD960\+V(^/&)R("\^#0H@/&(^
M1&5C96UB97(F(WA!,#LS,2PF(WA!,#LR,#$T/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY996%R($5N9&5D/"]B/CQB<B`O/@T*(#QB
M/D1E8V5M8F5R)B-X03`[,S$L)B-X03`[,C`Q,SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9#PO8CX\8G(@+SX-"B`\
M8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($%V97)A9V4@<FES:RUF<F5E(&EN=&5R97-T(')A=&4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C8\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C`N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,"XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&EV:61E;F0@>6EE;&0\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@079E
M<F%G92!V;VQA=&EL:71Y(&9A8W1O<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C4Q+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Q+C(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8R+C(\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!!=F5R86=E('=E:6=H=&5D(&%V97)A9V4@97AP96-T960@;&EF
M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,B8C>$$P.WEE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,B8C>$$P.WEE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,"8C>$$P.WEE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K($]P=&EO;B!!8W1I=FET>2!5;F1E<B!%<75I='D@26YC96YT
M:79E(%!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('1A8FQE(&)E;&]W
M('!R97-E;G1S(&$@<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I='D@
M=6YD97(-"B!O=7(@97%U:71Y(&EN8V5N=&EV92!P;&%N<R`H:6X@=&AO=7-A
M;F1S+"!E>&-E<'0@9F]R('!R:6-E('!E<@T*('-H87)E(&%N9"!C;VYT<F%C
M='5A;"!L:69E(&EN9F]R;6%T:6]N*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z
M(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$
M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C(E/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3G5M8F5R/"]B/CQB
M<B`O/@T*(#QB/F]F/"]B/CQB<B`O/@T*(#QB/E-H87)E<SPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960M/"]B
M/CQB<B`O/@T*(#QB/D%V97)A9V4\+V(^/&)R("\^#0H@/&(^17AE<F-I<V4\
M+V(^/&)R("\^#0H@/&(^4')I8V4\+V(^/&)R("\^#0H@/&(^<&5R(%-H87)E
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY7
M96EG:'1E9"T\+V(^/&)R("\^#0H@/&(^079E<F%G93PO8CX\8G(@+SX-"B`\
M8CY296UA:6YI;F<\+V(^/&)R("\^#0H@/&(^0V]N=')A8W1U86P\+V(^/&)R
M("\^#0H@/&(^3&EF928C>$$P.RAI;B8C>$$P.UEE87)S*3PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^06=G<F5G871E/"]B
M/CQB<B`O/@T*(#QB/DEN=')I;G-I8SPO8CX\8G(@+SX-"B`\8CY686QU92@Q
M*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W5T<W1A;F1I;F<@870@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(P+#8U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^.2XP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!/<'1I;VYS(&=R86YT960\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XW+#<Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,RXY-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/
M<'1I;VYS(&5X97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@T+#@U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2XT
M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/<'1I;VYS(&9O<F9E:71E9"8C>$$P.R9A;7`[(&-A;F-E;&5D
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L-3(Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2XX.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/=71S=&%N9&EN9R!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$L.3DU/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ,"XU,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+CDV/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,3(L-30Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%9E<W1E9"8C>$$P.V%N9"!E>'!E8W1E9"!T;R!V97-T(&%T($1E8V5M8F5R
M)B-X03`[,S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M;2!A;&EG;CTS1')I9VAT/C$P+C0Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
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M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X97)C:7-A8FQE
M(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@
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M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N.3`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,RXT-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#4L.#,Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`R<'0[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!-05)'24XM5$]0.B`P<'0[($Q)3D4M2$5)1TA4.B`X<'0[
M(%=)1%1(.B`Q,"4G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT
M<CX-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T
M/B@Q*3PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^06=G
M<F5G871E(&EN=')I;G-I8R!V86QU92!R97!R97-E;G1S#0H@=&AE(&1I9F9E
M<F5N8V4@8F5T=V5E;B!T:&4@97AE<F-I<V4@<')I8V4@;V8@=&AE(&]P=&EO
M;B!A;F0@=&AE#0H@8VQO<VEN9R!M87)K970@<')I8V4@;V8@;W5R(&-O;6UO
M;B!S=&]C:R!O;B!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,30N/"]T9#X-"B`\
M+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14I#04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^26YC;VUE(%1A>&5S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@0F5F;W)E("A"96YE9FET*2!0<F]V:7-I
M;VX@9F]R($EN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY,;W-S(&)E9F]R90T*("AB96YE9FET*2!P<F]V:7-I;VX@9F]R(&EN8V]M
M92!T87AE<R!I;F-L=61E<R!T:&4@9F]L;&]W:6YG#0H@8V]M<&]N96YT<R`H
M:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P
M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*
M(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-3DE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q
M,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R($5N9&5D#0H@1&5C
M96UB97(F(WA!,#LS,2P\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO
M='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1O;65S=&EC/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U-BPT,30\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$V,2PP
M-C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^*#$W-"PR-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^1F]R96EG;CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C$L.3@V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,BPX,#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/DQO<W,@8F5F;W)E("AB96YE9FET*0T*('!R;W9I<VEO;B!F
M;W(@:6YC;VUE('1A>&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B@U-"PT,C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$U.2PW-C@\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$W,2PT-#D\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@#0H@#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#XH0F5N969I="D@4')O=FES:6]N(&9O<B!);F-O;64@5&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!4:&4@*&)E;F5F:70I('!R;W9I<VEO;B!F;W(@:6YC
M;VUE('1A>&5S(&-O;G-I<W1S(&]F('1H92!F;VQL;W=I;F<-"B`H:6X@=&AO
M=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0X-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-S@E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@16YD960-
M"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#=7)R96YT.CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&961E<F%L/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
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M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!3=&%T93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!&;W)E:6=N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#0X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PX,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP
M,CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@5&]T86P@0W5R<F5N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T.#$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L.#,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C@Y,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9#H\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1F5D97)A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#(R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@T,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3=&%T93PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#0Y/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1F]R96EG;CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@S,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L
M($1E9F5R<F5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,Q/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XT,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#0X-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@*$)E;F5F:70I
M('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U
M,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#(T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`V
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>"!0<F]V:7-I;VX@4F5L871E9"!T;R!#;VYT:6YU
M:6YG($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN
M8V]M92!T87@-"B!P<F]V:7-I;VX@<F5L871E9"!T;R!C;VYT:6YU:6YG(&]P
M97)A=&EO;G,@9&EF9F5R<R!F<F]M('1H92!A;6]U;G0-"B!C;VUP=71E9"!B
M>2!A<'!L>6EN9R!T:&4@<W1A='5T;W)Y(&EN8V]M92!T87@@<F%T92!O9B`S
M-24@=&\@<')E=&%X#0H@;&]S<R!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I
M.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X
M.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/"$M+2!"96=I;B!4
M86)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,R4^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q
M+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR
M,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R
M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\(2TM($5N
M9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\
M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^52Y3+B!F961E<F%L('!R;W9I<VEO;@T*("AB96YE9FET
M*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY!="!S=&%T=71O<GD-"B!R871E/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q.2PP-3`\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#4U+#DQ
M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M:7IE/3-$,CXH-C`L,#`W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T871E('1A>&5S/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^-3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T.#PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#:&%N9V4@:6X@=F%L=6%T:6]N
M#0H@86QL;W=A;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,3$L.#,Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-2PP-#(\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
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M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
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M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPX,#@\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C8L,S(P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^4W1O8VLM8F%S960-"B!C;VUP96YS871I
M;VX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,C<Q/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,S8\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY&;W)E:6=N('1A>`T*(&EN8VQU<VEO;CPO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
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M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8L-3$P
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M1F]R96EG;B!T87@-"B!D:69F97)E;G1I86P\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,3<\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C`\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXH,C(W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&-R961I=',\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,BPY,S,\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXH-BPR-S,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-3DQ/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#0X-SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C$L,C@V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX-C0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/BA"96YE9FET*2!P<F]V:7-I;VX@9F]R#0H@:6YC
M;VUE('1A>&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B@U,3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,BPR-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($-O;7!O;F5N=',@
M;V8@1&5F97)R960@5&%X($%S<V5T<R!A;F0@3&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/&9O;G0@<VEZ93TS
M1#(^4VEG;FEF:6-A;G0@8V]M<&]N96YT<R!O9B!O=7(@9&5F97)R960@=&%X
M(&%S<V5T<PT*(&9O<B!F961E<F%L(&%N9"!S=&%T92!I;F-O;64@=&%X97,@
M87)E(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[
M($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R
M(&)O<F1E<CTS1#`^#0H@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0V.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P
M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@
M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@
M+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D1E9F5R<F5D('1A>`T*(&%S<V5T<SH\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^
M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DYE
M="!O<&5R871I;F<@;&]S<PT*(&-A<G)Y9F]R=V%R9',\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,Y
M,2PS.#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@;W1H97(-"B!C
M<F5D:71S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^-C8L-C8V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,2PW,#<\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E9"!R979E
M;G5E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,CDL-S4X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-2PU.#@\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY3=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;CPO9F]N=#X\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,C4L.38R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^4V%L92!O9B!F=71U<F4-"B!R;WEA;'1I97,\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,"PQ-3,\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C(X+#`U-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A<&ET86QI>F5D
M(')E<V5A<F-H#0H@97AP96YS97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ-"PW.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E)E<V5R=F5S(&%N9`T*(&%C8W)U86QS/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^."PR.#@\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
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M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E!R;W!E<G1Y+"!P;&%N="!A;F0-"B!E
M<75I<&UE;G0\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^."PU.#`\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L,C$X/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
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M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E
M9"!T87@@87-S971S(&)E9F]R90T*('9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU.34L.#8V
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXU.#8L,3DP/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5F%L=6%T:6]N(&%L;&]W86YC92!F
M;W(-"B!D969E<G)E9"!T87@@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#4Y-2PV.3`\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-3@V
M+#`T,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@9&5F97)R960@=&%X#0H@87-S
M971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,3<V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@9&5F97)R960@=&%X
M#0H@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/DYE="!D969E<G)E9"!T87@-"B!A<W-E=',\+V9O;G0^
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<V/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,34P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@5&%X($)E;F5F
M:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP
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M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X
M.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y
M;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\
M='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B/CPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0F5G:6YN:6YG#0H@8F%L86YC
M93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPS-C,\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M)R!S:7IE/3-$,CXQ-"PP-C<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY487@@<&]S:71I
M;VYS(')E;&%T960@=&\-"B!C=7)R96YT('EE87(\+V9O;G0^/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^061D:71I;VYS.CPO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT
M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&961E<F%L
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-3`R
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXT-S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/E-T871E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-BPQ-#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,S`R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^4F5D=6-T:6]N<SPO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
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M<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY487@@<&]S:71I;VYS(')E;&%T960@=&\-"B!P<FEO<B!Y96%R/"]F
M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D%D9&ET:6]N<SH\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^1F5D97)A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
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M,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3
M=&%T93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C4L,C4X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F]R96EG;CPO9F]N=#X\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
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M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E9'5C=&EO
M;G,@)B-X,C`Q-#L-"B!F;W)E:6=N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^*#<T,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
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M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3971T;&5M
M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY,87!S97,@:6X@<W1A='5T92!O9@T*(&QI;6ET871I;VYS
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\
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M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M*#$S-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D5N9&EN9R!B86QA
M;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
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M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T+#`V-SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(`T*(`T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F
M.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F
M930Q,60U."]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396=M96YT(%)E<&]R=&EN9R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY396=M96YT(%)E<&]R=&EN9R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@8GD@
M1V5O9W)A<&AI8R!!<F5A/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E=F5N=64@
M8GD@9V5O9W)A<&AI8R!A<F5A(&ES(&)A<V5D(&]N('1H92!L;V-A=&EO;G,@
M;V8@;W5R#0H@<&%R=&YE<G,N(%1H92!F;VQL;W=I;F<@=&%B;&4@<V5T<R!F
M;W)T:"!R979E;G5E(&)Y(&=E;V=R87!H:6,@87)E80T*("AI;B!T:&]U<V%N
M9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0W,24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E
M8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N:71E9"!3=&%T97,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,S(L-3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
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M9VAT/C,T+#4Y,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@175R;W!E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,38X+#$Y,SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#8L,S@V/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0V+#8P,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!R
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB
M7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T
M,3%D-3@O5V]R:W-H965T<R]3:&5E=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4V5L96-T960@475A<G1E<FQY($9I;F%N
M8VEA;"!$871A("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@26YF
M;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U87)T97)L>2!&:6YA;F-I
M86P@1&%T83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M('-H87)E(&EN9F]R;6%T:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-#0E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L
M:6=N/3-$8V5N=&5R/CQB/D9I<V-A;"!996%R(#(P,30\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&:7-C86P@665A<B`R,#$S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/E$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CY1,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M43,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB
M/E$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1,3PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^43(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1-#PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@4')O9'5C="!S86QE<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XU+#<Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PX,#(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,#DV/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XW+#0V,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3$L.#$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^."PP-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O
M=&%L(')E=F5N=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3DL-S<Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
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M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C,L,#`T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,RPX-C(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C8P+#DP.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S$L,30V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!#;W-T(&]F(&=O;V1S('-O;&0\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-RPY,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,3`X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#(R,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-BPR.3@\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$Q+#8V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PP,3$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#@W-SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^."PY-C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
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M/C,V+#<P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S0L,C`P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
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M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-3(L,C,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W!E<F%T:6YG(&EN8V]M92`H
M;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,V+#0P,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@R,BPY,38\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH-#4L,3`V/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#,R+#8P-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V+#4R-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
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M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.
M970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH
M-#8L,C`Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,R+#8S-SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C<P+#8P-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#0U+#8X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U-2PP-C,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH-#(L-S0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$V
M+#4T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T-RPV-3D\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S
M*2!P97(@<VAA<F4H,2D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#4^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A<VEC/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C,W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#`N,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C4U/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH,"XS-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@P+C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,S<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,"XQ-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C0Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&EL=71E9#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XS-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@P+C(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XU,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,S4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH,"XT.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C,W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#`N,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XT,3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#)P=#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[($U!4D=)3BU43U`Z(#!P=#L@3$E.12U(14E'2%0Z(#AP=#L@5TE$
M5$@Z(#$P)2<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H@/'1R/@T*
M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^*#$I
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y1=6%R=&5R
M;'D@;&]S<R!P97(@<VAA<F4@86UO=6YT<R!M87D-"B!N;W0@=&]T86P@=&\@
M=&AE('EE87(M=&\M9&%T92!L;W-S('!E<B!S:&%R92!D=64@=&\@<F]U;F1I
M;F<N/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A)04D^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!!9&1I=&EO;F%L
M($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^4VAA<F4@9&%T82!I
M;B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/E)E<&]R=&EN9U]5;FET/&)R/D-U<W1O;65R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^0W5S=&]M97(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,3$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3W)G86YI>F%T:6]N($%N9"!3=6UM87)Y($]F(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&EN=F5S
M=&UE;G1S(&EN(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-C(L.#(T+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8R+#`R-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN9&5B=&5D;F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34Q+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E;FEO<B!S96-U<F5D(&YO=&5S+"!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!M871U<FET>2!T97)M(&]F
M(&EN=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!T;R!B92!C
M;VYS:61E<F5D(&%S(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E1H<F5E(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I='D@=&5R;2!O
M9B!I;G9E<W1M96YT<R!C;VYS:61E<F5D(&%S('-H;W)T+71E<FT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DQE<W,@=&AA;B!O;F4@>65A<CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&-U<W1O;65R<R!A8V-O=6YT960@9F]R(&UA:F]R(&%C8V]U
M;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y097)C96YT86=E(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@8W5S=&]M
M97)S(&]N93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)C96YT86=E(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@8W5S
M=&]M97)S('1W;SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@
M8W5S=&]M97)S('1H<F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!R97!O<G1I;F<@=6YI="!E=F%L
M=6%T960@9F]R(&=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2961U8W1I;VX@;V8@<')I;W(@<&5R:6]D<R!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!P97)C96YT86=E(&]F(&%M
M;W5N="!R96%L:7IE9"!U<&]N('5L=&EM871E('-E='1L96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]R9V%N:7IA=&EO;B!!;F0@4W5M;6%R>2!/9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R
M86=E(&1I;'5T960@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M(&1I;'5T960@
M;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,2XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@
M06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="!E<W1I;6%T960@
M=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($%N9"!3=6UM87)Y($]F(%-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E
M<G1Y(&%N9"!E<75I<&UE;G0@97-T:6UA=&5D('5S969U;"!L:79E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,3(E(%-E;FEO<B!396-U
M<F5D($YO=&5S($1U92!*=6QY(#(P,3<@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@06YD
M(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5N:6]R('-E8W5R960@;F]T97,L(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;FEO<B!S
M96-U<F5D(&YO=&5S+"!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;FEO<B!S96-U<F5D(&YO
M=&5S+"!M871U<FET>2!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y*=6P@,34L#0H)"3(P,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y*=6P@,34L#0H)"3(P,3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P131!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
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M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;"X@,3$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I86P@26YS=')U;65N
M=',L($9I;F%N8VEA;"!!<W-E=',L($)A;&%N8V4@4VAE970@1W)O=7!I;F=S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPS-C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Y+#`V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L-#,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-2PS,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H;W)T+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(R-2PT-3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3<L.34Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D
M(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@86YD(&EN=F5S=&UE;G1S(&EN(&UA
M<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R-C(L.#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R-C(L,#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F
M,&4P9F4T,3%D-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,V(Q
M-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X+U=O<FMS:&5E=',O
M4VAE970S."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14]#04<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V%S:"!A;F0@26YV97-T;65N=',@:6X@36%R:V5T86)L92!396-U
M<FET:65S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5L+B`Q,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!);G9E<W1M96YT<R!I
M;B!-87)K971A8FQE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@;6%T
M=7)I='D@=&5R;2!F;W(@9&5B="!S96-U<FET:65S(&EN=F5S=&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E1W;R`@>65A<G,@;W(@;&5S
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!M871U<FET>2!T97)M(&9O<B!D96)T('-E
M8W5R:71I97,@:6YV97-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^3VYE('EE87(@;W(@;&5S<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,L('-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C$L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#0P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5V96P@,2!T;R!L979E;"`R('1R86YS9F5R<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#(@=&\@;&5V96P@,2!T
M<F%N<V9E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M971T97(@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$R)2!396YI;W(@4V5C=7)E9"!.;W1E
M<R!$=64@2G5L>2`R,#$W(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!A;F0@26YV97-T;65N=',@:6X@
M36%R:V5T86)L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A
M<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5N:6]R('-E8W5R960@;F]T97,L(&EN=&5R97-T(')A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5N:6]R
M('-E8W5R960@;F]T97,L(&UA='5R:71Y(&1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DIU;"`Q-2P-"@D),C`Q-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;"`Q-2P-"@D),C`Q
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q
M-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P
M93!F930Q,60U."]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$57
M4$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-A<V@@86YD($EN=F5S=&UE
M;G1S(&EN($UA<FME=&%B;&4@4V5C=7)I=&EE<R`M(%!O<G1F;VQI;R!O9B!#
M87-H(&%N9"!);G9E<W1M96YT<R!I;B!-87)K971A8FQE(%-E8W5R:71I97,@
M*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A
M;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR
M96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!I
M;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M,C4L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q.3<L.34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H+"!I;F-L=61I;F<@<F5S=')I8W1E9"!C
M87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPQ,S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPV
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!C87-H(&%N9"!I;G9E<W1M96YT<R!I;B!M87)K971A8FQE
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M,BPX,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-C(L,#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;W)P;W)A=&4@3F]T97,@86YD($)O;F1S(%M-96UB
M97)=('P@1F%I<B!686QU92!(:65R87)C:'D@3&5V96P@,B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C
M=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL
M86)L92UF;W(M<V%L92!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@R+#4T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S."PU,34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!#;VUM97)C
M:6%L(%!A<&5R(%M-96UB97)=('P@1F%I<B!686QU92!(:65R87)C:'D@3&5V
M96P@,B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@
M365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!I;G9E<W1M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L.3$U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DL-#0T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYE
M>2!-87)K970@1G5N9',@6TUE;6)E<ET@?"!&86ER(%9A;'5E($AI97)A<F-H
M>2!,979E;"`Q(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI
M=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"
M87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36]N97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+#(R.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8L-#4S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139%04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0Q/CQS=')O;F<^26YV96YT;W)Y("T@26YV96YT;W)Y("A$971A
M:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY);G9E;G1O<GD@1&ES8VQO<W5R92!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)A=R!M871E<FEA;',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,L.30W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y7;W)K+6EN+7!R;V-E<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;FES:&5D(&=O
M;V1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#4V-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$R+#DU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3,L-#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P150Q044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4')O
M<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@+2!0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA8FQE
M('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@870@8V]S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#<L.#8V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#0L.#8Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!A
M8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DS+#@P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X-"PQ-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%B;&4@<')O<&5R
M='DL('!L86YT(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-30L,#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L-S$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS=')U8W1I;VXM:6XM
M<')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#,P
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,C8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@<&QA;G0@86YD(&5Q=6EP;65N="P@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PS-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPY-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)U
M:6QD:6YG(&%N9"!,96%S96AO;&0@26UP<F]V96UE;G1S(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA8FQE
M('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@870@8V]S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S(L,C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L,S`V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y($5Q
M=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97!R96-I86)L92!P<F]P97)T>2!A;F0@97%U:7!M96YT(&%T
M(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#DW-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M+#8R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36%N=69A8W1U<FEN9R!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@
M4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%B;&4@<')O
M<&5R='D@86YD(&5Q=6EP;65N="!A="!C;W-T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-2PR,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,RPV.3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92P@1FEX='5R
M97,@86YD($]T:&5R($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I86)L92!P<F]P97)T>2!A
M;F0@97%U:7!M96YT(&%T(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C,L-#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R,RPR,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P
M93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V
M968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3
M:&5E=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%2D1!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="`M($%D9&ET:6]N
M86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CY);B!-:6QL:6]N
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L
M86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,RXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/8FQI9V%T:6]N(')E;&%T960@=&\@<'5R8VAA<V4@;V8@97%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]B
M;&EG871I;VX@<F5L871E9"!T;R!P=7)C:&%S92!O9B!E<75I<&UE;G0@;&EA
M8FEL:71Y('!A>6%B;&4@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&%N9"!A;F0@0G5I;&1I;F<@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T
M>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!C
M:&%R9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13%70D<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5N:6]R(%-E8W5R960@3F]T97,@
M+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;"X@,3$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EN92!O9B!#<F5D:70@1F%C:6QI
M='D@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E;FEO<B!S96-U<F5D(&YO=&5S+"!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<W5B;W)D:6YA
M=&5D(&YO=&5S(')E;6%I;FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<R+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUA='5R:71Y(&1A=&4@;V8@8V]N=F5R=&EB
M;&4@<W5B;W)D:6YA=&5D(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y397`@,C@L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!R97!U<F-H
M87-E(&]F(&YO=&5S(&]N('!R:6YC:7!A;"!A;6]U;G0@;V8@;F]T97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A
M9V4@;V8@<F5P=7)C:&%S92!O9B!N;W1E<R!O;B!P<FEN8VEP86P@86UO=6YT
M(&]F(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!3=6)O<F1I;F%T960@3F]T97,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6YE
M(&]F($-R961I="!&86-I;&ET>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T:7)E;65N="!O9B!C
M;VYV97)T:6)L92!S=6)O<F1I;F%T960@;F]T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0R+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$R)2!396YI;W(@4V5C=7)E
M9"!.;W1E<R!$=64@2G5L>2`R,#$W(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EN92!O9B!#<F5D:70@1F%C
M:6QI='D@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-E;FEO<B!S96-U<F5D(&YO=&5S+"!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M871U<FET>2!D871E(&]F('-E;FEO<B!S96-U<F5D(&YO=&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6P@,34L#0H)"3(P,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6P@,34L
M#0H)"3(P,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2G5L
M>2`Q+"`R,#$U('1H<F]U9V@@2G5N92`S,"P@,C`Q-R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI;F4@;V8@
M0W)E9&ET($9A8VEL:71Y(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M($-A<V@@4F5Q=6ER
M96UE;G0@*$IU;"`Q+"`R,#$U('1H<F]U9V@@2G5N92`S,"P@,C`Q-RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XQ,B4@4V5N:6]R(%-E8W5R960@3F]T97,@1'5E($IU;'D@,C`Q-R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQI;F4@;V8@0W)E9&ET($9A8VEL:71Y(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET
M>2!D871E(&]F('-E;FEO<B!S96-U<F5D(&YO=&5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y*=6P@,34L#0H)"3(P,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5N:6]R(%-E8W5R960@3F]T97,@8V%R<GEI;F<@86UO=6YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R-2PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y
M9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S+U-H965T-#0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4Q,T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E<R`M($%D
M9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CY);B!-
M:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`P.3QB<CYS<69T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQE87-E<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!C96EL:6YG(&]N(')E;G0@
M:6YC<F5A<V5S+"!A;FYU86QL>2P@8V%P:71A;"!L96%S93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;B!#87)L;W,@9F%C:6QI
M='D@8V%P:71A;"!L96%S97,L('1E<FUI;F%T:6]N(&1A=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D]C="`U+`T*"0DR,#$V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@
M;6EN:6UU;2!R96YT86P@<F5C96EP=',@=6YD97(@=&AE(%-A;B!#87)L;W,@
M9F%C:6QI='D@<W5B;&5A<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F]O:R!V86QU92!O9B!A<W-E=',L(&=R;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!B;V]K('9A
M;'5E(&]F(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W!E<F%T:6YG(%-U8FQE87-E('1E<FT@8V]M;65N8V5D('-T87)T
M(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%U9W5S="`R
M,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<&5R871I;F<@4W5B;&5A<V4@=&5R;2!C;VUM96YC960@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,30@;6]N=&AS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<&5R871I;F<@4W5B;&5A<V4@=&5R;2!C;VUM96YC960@96YD(&1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIA;G5A<GD@,S$L(#(P,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E;G0@97AP96YS92!F;W(@;W!E<F%T:6YG(&QE87-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(L
M($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY,96%S97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!S=6)L96%S
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(V+#(X-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?
M8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q
M,60U."]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V3T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DQE87-E<R`M($9U='5R92!-:6YI;75M
M(%!A>6UE;G1S(&9O<B!#87!I=&%L($QE87-E<R`H1&5T86EL*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3&5A<V5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U+#4W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PR-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&UI;FEM=6T@<&%Y;65N=',@<F5Q
M=6ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`Q-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5S<SH@86UO=6YT(')E<')E<V5N=&EN9R!I;G1E<F5S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<V5N="!V86QU92!O
M9B!F=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PV-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97-E;G0@=F%L=64@;V8@9G5T
M=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L-C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!C=7)R96YT('!O<G1I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-3$R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3,V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P
M:71A;"!L96%S92!O8FQI9V%T:6]N+"!L97-S(&-U<G)E;G0@<&]R=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#$S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PP-#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E
M9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P
M9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#0V+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3D9!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY,96%S97,@+2!&=71U<F4@36EN
M:6UU;2!,96%S92!087EM96YT<R!F;W(@3W!E<F%T:6YG($QE87-E<R`H1&5T
M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DQE87-E<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PW-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#DR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`S-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#(P/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!F=71U<F4@;6EN:6UU;2!L
M96%S92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-2PV-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?
M.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#0W+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%64)"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,:6%B:6QI='D@
M4F5L871E9"!T;R!386QE(&]F($9U='5R92!2;WEA;'1I97,@+2!!9&1I=&EO
M;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL;&EO
M;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y&96(N(#(T+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI='D@4F5L871E
M9"!T;R!386QE(&]F($9U='5R92!2;WEA;'1I97,@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L
M='D@86=R965M96YT(&-O;G1I;F=E;G0@<&%Y;65N="!D97-C<FEP=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^07,@82`@<F5S=6QT(&]F
M('=O<FQD=VED92!N970@<V%L97,@;V8@34E20T5202!F;W(@=&AE(#$R(&UO
M;G1H('!E<FEO9',@96YD960@;VX@($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R
M,#$R(&YO="!R96%C:&EN9R!C97)T86EN(&UI;FEM=6T@=&AR97-H;VQD<RX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%N;G5A;"!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!38V5N87)I;R!/;F4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,
M:6%B:6QI='D@4F5L871E9"!T;R!386QE(&]F($9U='5R92!2;WEA;'1I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!A>6UE;G0@;6%D92!F;W(@;6EL97-T;VYE(&YO="!A8VAI
M979E9"!Y96%R(&]N93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6QE<W1O;F4@4V-E;F%R:6\@5'=O(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA8FEL:71Y(%)E
M;&%T960@=&\@4V%L92!O9B!&=71U<F4@4F]Y86QT:65S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT(&UA9&4@9F]R(&UI;&5S=&]N92!N;W0@86-H:65V960@>65A<B!T
M=V\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E
M(&%N9"!386QE($%G<F5E;65N="!W:71H(%)022!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET>2!2
M96QA=&5D('1O(%-A;&4@;V8@1G5T=7)E(%)O>6%L=&EE<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!S86QE(&]F(')O>6%L='D@<FEG:'1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS86-T:6]N(&-O<W1S
M(')E;&%T960@=&\@<V%L92!O9B!P;W1E;G1I86P@9G5T=7)E(')O>6%L=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XT/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#24U:24$@
M86YD($U)4D-%4D$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI='D@4F5L871E9"!T;R!386QE(&]F
M($9U='5R92!2;WEA;'1I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H(')O>6%L=&EE
M<R!F<F]M(&YE="!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#(Q+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(R+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F
M930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X
M8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E
M=#0X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4T1!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
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M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,T($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]T:&5R($QI86)I;&ET:65S($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6%B:6QI='D@<F5L871E9"!T;R!S86QE(&]F(&9U='5R92!R;WEA;'1I97,M
M8F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3(X+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F(&9U='5R92!R
M;WEA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>6UE;G1S(&9R;VT@3F5K=&%R('1O(%)023PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@0TE-
M6DE!PJX@86YD($U)4D-%4D'"KG)O>6%L='D@<F5V96YU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C$L.3,W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R+#`U-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PW.3$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-30L
M-S@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N+6-A<V@@:6YT97)E<W0@97AP96YS92!R96-O9VYI>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PX.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPS,#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PP
M-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,2PR-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQI86)I;&ET>2!R96QA=&5D('1O('-A;&4@;V8@9G5T=7)E
M(')O>6%L=&EE<R`M(&5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$R,"PT-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R."PU,C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R,"PT-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB
M7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T
M,3%D-3@O5V]R:W-H965T<R]3:&5E=#0Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0C9!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3&]S<R!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA
M;'1Y(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RPT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@8V]M
M;6ET;65N=',@<F5L871E9"!T;R!C;VYT<F%C="!M86YU9F%C='5R:6YG+"!C
M;&EN:6-A;"!D979E;&]P;65N="!A;F0@8V5R=&%I;B!O=&AE<B!I=&5M<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L.3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YD
M96UN:69I8V%T:6]N($]B;&EG871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;W-S($-O;G1I;F=E;F-I
M97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN9&5M;FEF:6-A=&EO;B!/8FQI9V%T:6]N<RP@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M96-U<FET:65S(%)E;&%T960@0VQA:6US(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]S<R!#;VYT:6YG96YC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/8FQI9V%T:6]N<R!U;F1E<B!$:7)E8W1O<B!A;F0@
M3V9F:6-E<B!);F1E;6YI9FEC871I;VYS('!E<B!I;F-I9&5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM4V5C=7)I
M=&EE<R!296QA=&5D($-L86EM<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO<W,@0V]N=&EN9V5N8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3V)L:6=A=&EO;G,@=6YD97(@1&ER96-T;W(@86YD($]F9FEC
M97(@26YD96UN:69I8V%T:6]N<R!P97(@:6YC:61E;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUE<F=E<B!A;F0@06-Q=6ES
M:71I;VX@4F5L871E9"!#;&%I;7,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;W-S($-O;G1I;F=E;F-I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]B;&EG871I;VYS('5N9&5R($1I<F5C=&]R(&%N9"!/9F9I
M8V5R($EN9&5M;FEF:6-A=&EO;G,@<&5R(&EN8VED96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W
M7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K
M<VAE971S+U-H965T-3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$1T1)/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,C@L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!D97-I9VYA
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M('-A;&4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$Q-RPR,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T
M;V-K(%5N:71S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-87AI;75M(#0P,2AK*2!P97(@96UP;&]Y964L('!E<F-E;G1A
M9V4@;V8@86YN=6%L('-A;&%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUP96YS871I;VX@97AP96YS92!I;B!C;VYN96-T
M:6]N('=I=&@@-#`Q*&LI(')E=&ER96UE;G0@<&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E
M=F5R86YC92!P87EM96YT('!E<FEO9"!F;W(@97AE8W5T:79E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3(@;6]N=&AS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3979E<F%N8V4@
M<&%Y;65N="!P97)I;V0@9F]R(&5M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<V5V97)A;F-E('!A>6UE
M;G0@9F]R(&-H:65F(&5X96-U=&EV92!O9F9I8V5R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XR-"!M;VYT:',@8F%S92`@<V%L87)Y('!L=7,@
M86YN=6%L('1A<F=E="!I;F-E;G1I=F4@<&%Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R(%!E<F9O<FUA;F-E
M($EN8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%D9&ET:6]N86P@;F5W('-H87)E<R!A=F%I;&%B;&4@9F]R(&%W87)D(&=R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<&QA;B=S('-H87)E(&QI;6ET
M(')E9'5C=&EO;B!F;W(@979E<GD@;VYE(')E<W1R:6-T960@<W1O8VL@=6YI
M="!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUA>&EM=6T@=&5R;2!O9B!S=&]C:R!O<'1I;VYS('5N9&5R(&5Q=6ET>2!I
M;F-E;G1I=F4@<&QA;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C@@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/C(P,3(@4&5R9F]R;6%N8V4@26YC96YT:79E(%!L86X@6TUE
M;6)E<ET@?"!%;7!L;WEE92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y397)V:6-E('!E<FEO9"!F;W(@<W1O8VL@;W!T:6]N<R!G<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R(%!E
M<F9O<FUA;F-E($EN8V5N=&EV92!0;&%N(%M-96UB97)=('P@1&ER96-T;W(@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R=FEC92!P97)I;V0@
M9F]R('-T;V-K(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#`P($YO;BU/9F9I8V5R($5Q=6ET>2!)
M;F-E;G1I=F4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M87AI;75M('1E<FT@;V8@<W1O8VL@;W!T:6]N<R!U;F1E<B!E<75I='D@:6YC
M96YT:79E('!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XX
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@
M4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%W87)D<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K(%!U<F-H87-E
M(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F('!U<F-H87-E('!R
M:6-E(&]F('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%T8VAI;F<@-#`Q*&LI(&5M<&QO>65R(&-O;G1R:6)U=&EO;BP@;6%X:6UU
M;2!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-87AI;75M(%M-96UB97)=('P@,C`Q,B!097)F;W)M86YC92!);F-E;G1I
M=F4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@8V]M;6]N('-T;V-K('-H87)E<R!A=F%I;&%B;&4@9F]R('-T;V-K(&]P
M=&EO;G,@9W)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PS-#<L,30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y397)I97,@02!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S
M<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M9&5S:6=N871E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!3:&%R97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<W-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<W-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M9V%L+"!A8V-O=6YT:6YG(&9E97,L(&9I;&EN9R!F965S(&%N9"!O=&AE<B!O
M9F9E<FEN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YD97)W<FET:6YG(&-O;6UI<W-I;VX@86YD(&1I<V-O
M=6YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(')E<V5R=F5D(&9O<B!I<W-U86YC
M92!I;B!E<75I='D@8V]M<&5N<V%T:6]N('!L86YS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-"PX,#8L-38U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C$V968X8E]C.#$R7S1D,C=?.60V
M95]F,&4P9F4T,3%D-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X+U=O<FMS:&5E
M=',O4VAE970U,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-&044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@+2!3=6UM87)I>F%T:6]N
M(&]F($-O;6UO;B!3=&]C:R!3:&%R97,@9F]R($ES<W5A;F-E(%5N9&5R($5X
M:7-T:6YG($5Q=6ET>2!#;VUP96YS871I;VX@4&QA;G,@*$1E=&%I;"D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4V5C=7)I=&EE<R!T;R!B
M92!)<W-U960@57!O;B!%>&5R8VES92!O9B!/=71S=&%N9&EN9R!/<'1I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PY.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!396-U<FET:65S(%)E;6%I;FEN9R!!=F%I;&%B;&4@9F]R($ES<W5A
M;F-E(%5N9&5R($5Q=6ET>2!#;VUP96YS871I;VX@4&QA;G,@*$5X8VQU9&EN
M9R!396-U<FET:65S(%)E9FQE8W1E9"!I;B!#;VQU;6XI/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#@Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M079E<F%G92!%
M>&5R8VES92!0<FEC92!O9B!/=71S=&%N9&EN9R!/<'1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!#;VUP96YS
M871I;VX@4&QA;G,@07!P<F]V960@8GD@4V5C=7)I='D@2&]L9&5R<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4V5C
M=7)I=&EE<R!T;R!B92!)<W-U960@57!O;B!%>&5R8VES92!O9B!/=71S=&%N
M9&EN9R!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PV,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!396-U<FET:65S(%)E;6%I;FEN9R!!=F%I;&%B
M;&4@9F]R($ES<W5A;F-E(%5N9&5R($5Q=6ET>2!#;VUP96YS871I;VX@4&QA
M;G,@*$5X8VQU9&EN9R!396-U<FET:65S(%)E9FQE8W1E9"!I;B!#;VQU;6XI
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@Q,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960M079E<F%G92!%>&5R8VES92!0<FEC92!O9B!/=71S=&%N9&EN9R!/<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+C8X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<75I='D@0V]M<&5N<V%T:6]N(%!L86YS($YO="!!<'!R;W9E9"!B>2!396-U
M<FET>2!(;VQD97)S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R
M<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!396-U<FET:65S('1O(&)E($ES<W5E9"!5<&]N($5X
M97)C:7-E(&]F($]U='-T86YD:6YG($]P=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E($5X97)C
M:7-E(%!R:6-E(&]F($]U='-T86YD:6YG($]P=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.2XU,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?
M9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S-B
M,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE971S
M+U-H965T-3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!-4%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DQI8V5N<V4@86YD($-O;&QA8F]R871I;VX@06=R965M96YT<R`M
M($QI8V5N<V4L($-O;&QA8F]R871I;VX@86YD($]T:&5R(%)E=F5N=64@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R
M965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EC96YS92P@8V]L;&%B;W)A=&EO;B!A;F0@
M;W1H97(@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-3,L,C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`X,"PX-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,P+#$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-T<F%:96YE8V$@04(@6TUE
M;6)E<ET@?"!-3U9!3E1)2U1-("A.2U12+3$Q."D@86YD($U/5D%.5$E+5$T@
M9FEX960M9&]S92!C;VUB:6YA=&EO;B!P<F]G<F%M("A.2U12+3$Q.2D@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQI8V5N<V4L(&-O;&QA8F]R871I;VX@86YD(&]T:&5R(')E=F5N=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-2PP,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F]C:&4@6TUE;6)E<ET@?"!014=!4UE3(&%N9"!-25)#15)!(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3&EC96YS92!!;F0@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,:6-E;G-E+"!C;VQL86)O<F%T:6]N(&%N9"!O=&AE<B!R979E;G5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPX-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PS.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$T
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%X=&5R($AE86QT:&-A<F4@6TUE;6)E<ET@?"!"05@@.#4U("A(96UO
M<&AI;&EA*2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M
M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&EC96YS92P@8V]L;&%B;W)A=&EO;B!A;F0@;W1H
M97(@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L
M,C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PW,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#(S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UG96XL($EN8RX@6TUE;6)E<ET@?"!.975L87-T
M82!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&EC96YS92P@8V]L;&%B;W)A=&EO;B!A;F0@;W1H97(@<F5V
M96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`S
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"87EE<B!(96%L=&AC87)E($Q,0R!;365M8F5R72!\($)!630Q
M+38U-3$@*$%M:6MA8VEN($EN:&%L92D@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL
M86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4L(&-O;&QA
M8F]R871I;VX@86YD(&]T:&5R(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L-S$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34L,CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%F9GEM87@L($EN8RX@
M6TUE;6)E<ET@?"!/34].5%E3(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS92!!;F0@0V]L;&%B;W)A
M=&EO;B!!9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E+"!C;VQL86)O<F%T
M:6]N(&%N9"!O=&AE<B!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#$T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L.#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O
M;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92P@8V]L
M;&%B;W)A=&EO;B!A;F0@;W1H97(@<F5V96YU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-2PT-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,CDU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#@X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q
M,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U
M."]7;W)K<VAE971S+U-H965T-3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$5D--/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DQI8V5N<V4@86YD($-O;&QA8F]R871I;VX@
M06=R965M96YT<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P
M.3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`P-SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`Q-BP@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@4F5V96YU92!!<G)A;F=E;65N
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&]T96YT:6%L(&9U='5R92!A9&1I=&EO;F%L('!A>6UE
M;G1S(&9O<B!D979E;&]P;65N="!M:6QE<W1O;F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$S,"PS,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-3U9!3E1)2R!;365M
M8F5R72!\(%53(&%N9"!%52!#;VUM97)C:6%L($QA=6YC:"!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R
M<F5D(%)E=F5N=64@07)R86YG96UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1I;F=E;G0@
M<&%Y;65N=',@<F5C96EV86)L92!B87-E9"!O;B!D979E;&]P;65N="!E=F5N
M=',@<F5G=6QA=&]R>2!T;R!B92!P=7)S=65D(&%N9"!C;VUP;&5T960@<V]L
M96QY(&)Y(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DU/5D%.5$E+(%M-96UB97)=('P@56YI=&5D(%-T871E
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E9F5R<F5D(%)E=F5N=64@07)R86YG96UE;G0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G1I;F=E;G0@<&%Y;65N=',@<F5C96EV86)L92!B87-E9"!O;B!D979E
M;&]P;65N="!E=F5N=',@<F5G=6QA=&]R>2!T;R!B92!P=7)S=65D(&%N9"!C
M;VUP;&5T960@<V]L96QY(&)Y(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DU/5D%.5$E+(%M-96UB97)=('P@
M175R;W!E86X@56YI;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('!A>6UE;G1S(')E8V5I=F%B;&4@
M8F%S960@;VX@9&5V96QO<&UE;G0@979E;G1S(')E9W5L871O<GD@=&\@8F4@
M<'5R<W5E9"!A;F0@8V]M<&QE=&5D('-O;&5L>2!B>2!O=&AE<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O8VAE(%M-
M96UB97)=('P@3&EC96YS92!%>'1E;G-I;VX@3W!T:6]N(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R
M960@4F5V96YU92!!<G)A;F=E;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EV960@=7!F
M<F]N="!A;F0@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;V-H92!;365M8F5R72!\($U)
M4D-%4D$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO8V%T960@8V]N<VED97)A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M<VED97)A=&EO;B!R96-E:79E9"!F;W(@<')O9'5C="!D96QI=F5R960@:6X@
M,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F]C:&4@6TUE;6)E<ET@?"!-25)#15)!(%M-96UB97)=('P@4&5R9F]R
M;6%N8V4M8F%S960@36EL97-T;VYE(%!A>6UE;G1S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@
M4F5V96YU92!!<G)A;F=E;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EV960@=7!F<F]N
M="!A;F0@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;V-H92!;365M8F5R72!\($U)4D-%
M4D$@6TUE;6)E<ET@?"!5<&9R;VYT(%!A>6UE;G0@07)R86YG96UE;G0@:6X@
M,C`P-R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E9F5R<F5D(%)E=F5N=64@07)R86YG96UE;G0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E8V5I=F5D('5P9G)O;G0@86YD(&UI;&5S=&]N92!P87EM96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;V-H
M92!;365M8F5R72!\(%!%1T%365,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R
M<F%N9V5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O8VAE(%M-96UB
M97)=('P@4$5'05-94R!A;F0@34E20T5202!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D(%)E=F5N
M=64@07)R86YG96UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%Y97(@
M2&5A;'1H8V%R92!,3$,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0;W1E;G1I86P@9G5T=7)E(&%D9&ET:6]N86P@<&%Y
M;65N=',@9F]R(&1E=F5L;W!M96YT(&UI;&5S=&]N97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#@P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!A>6UE;G0@;6%D92!T;R!"87EE<B!F;W(@8V]S="!O9B!0:&%S92`S(&-L
M:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"87EE<B!(96%L=&AC87)E($Q,0R!;365M8F5R72!\(%!E
M<F9O<FUA;F-E+6)A<V5D($UI;&5S=&]N92!087EM96YT<R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R
M<F5D(%)E=F5N=64@07)R86YG96UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F5D('5P
M9G)O;G0@86YD(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5V96QO<&UE;G0@;6EL97-T
M;VYE(&%C:&EE=F5D(&EN(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A>65R($AE86QT:&-A<F4@3$Q#(%M-96UB
M97)=('P@57!F<F]N="!087EM96YT($%R<F%N9V5M96YT(&EN(#(P,#<@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M96YT(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E
M:79E9"!U<&9R;VYT(&%N9"!M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P:'1H;W1E8V@@
M0V]R<&]R871I;VX@6TUE;6)E<ET@?"!&;W9I<W1A(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@
M4F5V96YU92!!<G)A;F=E;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L(&9U='5R
M92!A9&1I=&EO;F%L('!A>6UE;G1S(&9O<B!D979E;&]P;65N="!M:6QE<W1O
M;F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8V5I=F5D('5P9G)O;G0@86YD(&UI;&5S=&]N92!P87EM96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-S4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L
M.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^07-T<F%:96YE8V$@04(@6TUE;6)E<ET@?"!-3U9!3E1)2U1-
M("A.2U12+3$Q."D@86YD($U/5D%.5$E+5$T@9FEX960M9&]S92!C;VUB:6YA
M=&EO;B!P<F]G<F%M("A.2U12+3$Q.2D@6TUE;6)E<ET@?"!5<&9R;VYT(%!A
M>6UE;G0@07)R86YG96UE;G0@:6X@,C`P-R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D(%)E=F5N
M=64@07)R86YG96UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F5D('5P9G)O;G0@86YD
M(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%S=')A6F5N96-A($%"(%M-96UB97)=('P@
M34]604Y424L@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-E:79E9"!U<&9R;VYT(&%N9"!M:6QE<W1O;F4@<&%Y;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G1I;F=E;G0@<&%Y;65N=',@<F5C96EV86)L92!B87-E9"!O;B!D979E
M;&]P;65N="!E=F5N=',@<F5G=6QA=&]R>2!T;R!B92!P=7)S=65D(&%N9"!C
M;VUP;&5T960@<V]L96QY(&)Y(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!R961U8W1I;VX@
M:6X@52Y3+B!R;WEA;'1Y(')A=&4@9F]R(')E<&%Y;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<&]S
M="!A<'!R;W9A;"!S='5D>2!C;W-T<R!T;R!R97!A>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('!O=&5N=&EA;"!R
M961U8W1I;VX@:6X@<F]Y86QT:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!<W1R85IE;F5C82!!0B!;365M8F5R72!\
M($U/5D%.5$E+(%M-96UB97)=('P@4')E+6%P<')O=F%L($-A<F1I;W9A<V-U
M;&%R(%-A9F5T>2!3='5D>2!.;W0@4F5Q=6ER960@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2
M979E;G5E($%R<F%N9V5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('!A>6UE
M;G1S(')E8V5I=F5D(&)A<V5D(&]N(&1E=F5L;W!M96YT(&5V96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-T<F%:
M96YE8V$@04(@6TUE;6)E<ET@?"!-;W9A;G1I:R!&:7AE9"UD;W-E($-O;6)I
M;F%T:6]N(%!R;V=R86T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('!A>6UE;G1S(')E8V5I=F%B;&4@
M8F%S960@;VX@9&5V96QO<&UE;G0@979E;G1S(')E9W5L871O<GD@=&\@8F4@
M<'5R<W5E9"!A;F0@8V]M<&QE=&5D('-O;&5L>2!B>2!O=&AE<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A>'1E<B!(
M96%L=&AC87)E(%M-96UB97)=('P@0D%8(#@U-2`H2&5M;W!H:6QI82D@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M96YT(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E
M;G1I86P@9G5T=7)E(&%D9&ET:6]N86P@<&%Y;65N=',@9F]R(&1E=F5L;W!M
M96YT(&UI;&5S=&]N97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E=F5L;W!M96YT(&UI;&5S=&]N97,@86-H
M:65V960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UG96XL($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E($%R<F%N9V5M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296-E:79E9"!U<&9R;VYT(&%N9"!M:6QE<W1O;F4@
M<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%F9GEM87@L($EN8RX@6TUE;6)E<ET@
M?"!/34].5%E3(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&5F97)R960@4F5V96YU92!!<G)A;F=E;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@<F5V96YU92!R96-O9VYI>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5F97)R960@4F5V96YU92!!<G)A;F=E;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT
M:6%L(&9U='5R92!A9&1I=&EO;F%L('!A>6UE;G1S(&9O<B!D979E;&]P;65N
M="!M:6QE<W1O;F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$979E;&]P;65N="!M:6QE<W1O;F5S(&%C:&EE=F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?
M8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q
M,60U."]7;W)K<VAE971S+U-H965T-30N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.4T%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;B`M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E("A$971A:6PI
M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@0V]M<&5N<V%T:6]N
M($-O<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPP,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W
M+#<P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,38L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;W-T(&]F($=O;V1S(%-O;&0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"P@0V]M<&5N<V%T:6]N($-O<W0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PQ-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#DV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@
M1&5V96QO<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@0V]M<&5N
M<V%T:6]N($-O<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D+"!#;VUP96YS871I;VX@0V]S="!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,S(X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#4P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPV,C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB
M7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T
M,3%D-3@O5V]R:W-H965T<R]3:&5E=#4U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0TY!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I
M;VX@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\
M8G(^26X@36EL;&EO;G,L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3$N.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C
M;V=N:7IE9"!O=F5R(&$@=V5I9VAT960M879E<F%G92!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A<G,@,2!M;VYT:"`V(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA
M=F5R86=E(&=R86YT+61A=&4@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@-"XY-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`S+CDR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!I;G1R:6YS
M:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!F86ER('9A
M;'5E(&]F(&]P=&EO;G,@=F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#X@,30N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B`Q-2XW/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14M*04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("T@0FQA8VLM4V-H;VQE
M<R!/<'1I;VXM4')I8VEN9R!-;V1E;"!!<W-U;7!T:6]N<R!5<V5D('1O($-A
M;&-U;&%T92!&86ER(%9A;'5E(&]F($5M<&QO>65E(%-T;V-K($]P=&EO;G,@
M*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E
M;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079E
M<F%G92!R:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N.3`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!=F5R86=E('9O;&%T:6QI='D@9F%C=&]R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,2XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2XR,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BXR,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V97)A9V4@
M=V5I9VAT960@879E<F%G92!E>'!E8W1E9"!L:69E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#(@;6]N=&AS(#$R(&1A>7,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE
M87)S(#(@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E2044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("T@4W1O8VL@3W!T
M:6]N($%C=&EV:71Y(%5N9&5R($5Q=6ET>2!);F-E;G1I=F4@4&QA;G,@*$1E
M=&%I;"D@*%-T;V-K($]P=&EO;G,@6TUE;6)E<ETL(%531"`D*3QB<CY);B!4
M:&]U<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VL@3W!T:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@4VAA<F5S+"!/=71S=&%N9&EN9RP@0F5G
M:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<RP@3W!T:6]N<R!G<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#<Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M(%-H87)E<RP@3W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0L.#4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<RP@3W!T:6]N
M<R!F;W)F96ET960@86YD(&-A;F-E;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q+#4R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,L($]U='-T86YD
M:6YG+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$L.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4VAA<F5S+"!697-T960@86YD($5X
M<&5C=&5D('1O(%9E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<RP@17AE<F-I<V%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#`P-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M079E
M<F%G92!%>&5R8VES92!0<FEC92!P97(@4VAA<F4L($]U='-T86YD:6YG+"!"
M96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y+C`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E($5X97)C:7-E(%!R:6-E('!E
M<B!3:&%R92P@3W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$S+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E($5X97)C:7-E
M(%!R:6-E('!E<B!3:&%R92P@3W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2XT,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M079E<F%G
M92!%>&5R8VES92!0<FEC92!P97(@4VAA<F4L($]P=&EO;G,@9F]R9F5I=&5D
M(&%N9"!#86YC96QE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,2XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960M079E<F%G92!%>&5R8VES92!0<FEC92!P97(@
M4VAA<F4L($]U='-T86YD:6YG+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"XU/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E
M($5X97)C:7-E(%!R:6-E('!E<B!3:&%R92P@5F5S=&5D(&%N9"!E>'!E8W1E
M9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P
M+C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"U!=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3:&%R
M92P@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@."XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A
M;"!,:69E+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^-"!Y96%R<R`Q,2!M;VYT:',@,38@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M079E
M<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF92P@5F5S=&5D(&%N9"!E
M>'!E8W1E9"!T;R!697-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XT('EE87)S(#$P(&UO;G1H<R`R,2!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E+"!%>&5R8VES86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<R`U(&UO;G1H<R`Q
M.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!/=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3(L-30Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!697-T960@86YD(&5X<&5C=&5D
M('1O(%9E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,2PP
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($5X97)C:7-A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@U+#@S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q
M,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U
M."]7;W)K<VAE971S+U-H965T-3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:1T%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<R`M($QO<W,@0F5F;W)E
M("A"96YE9FET*2!0<F]V:7-I;VX@9F]R($EN8V]M92!487AE<R`H1&5T86EL
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]M
M97-T:6,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-38L-#$T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,38Q+#`V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$W-"PR-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#DX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX,#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&)E9F]R
M92`H8F5N969I="D@<')O=FES:6]N(&9O<B!I;F-O;64@=&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-30L-#(X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,34Y+#<V."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$W,2PT-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15%)044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A
M>&5S("T@*$)E;F5F:70I(%!R;W9I<VEO;B!F;W(@26YC;VUE(%1A>&5S("A$
M971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@0W5R<F5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E9F5R<F5D.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!$969E<G)E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@W*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA"96YE
M9FET*2!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@U,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(T-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C$V968X8E]C.#$R
M7S1D,C=?.60V95]F,&4P9F4T,3%D-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X
M+U=O<FMS:&5E=',O4VAE970V,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13--04<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296%L($5S=&%T
M92!!8W%U:7)E9"!4:')O=6=H($9O<F5C;&]S=7)E(%5N9&5R($9O<G=A<F0@
M4'5R8VAA<V4@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A='5T;W)Y(&EN8V]M
M92!T87@@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-R96%S92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL-S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3$L.#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F%L=6%T:6]N(&%L;&]W86YC92!R96QA=&5D('1O('-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!A;F0@97AE<F-I<V5S('!R:6]R('1O('1H92!I;7!L
M96UE;G1A=&EO;B!O9B!!4T,@-3$U(&%N9"`W,3@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,U+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PV,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!5+E,N(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0R,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T,C(L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S(&AA=F4@;F]T
M(&)E96X@<')O=FED960@;VX@82!C=6UU;&%T:79E('1O=&%L/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DP,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87@@
M<F5S96%R8V@@8W)E9&ET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPY,S,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPR-S,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3DQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F5D97)A;"!O<G!H86X@
M9')U9R!C<F5D:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&961E<F%L(&]R<&AA;B!D<G5G(&-R961I=',L(&5X<&ER
M871I;VX@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^56YR96-O9VYI>F5D('1A>"!B96YE9FET<RP@<&5R:6]D(&UA>2!I;F-R
M96%S92!O<B!D96-R96%S92!D=64@=&\@=&%X(&5X86UI;F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.97AT('1W96QV92!M;VYT:',\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9E9&5R86P@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296%L($5S=&%T92!!8W%U:7)E9"!4:')O=6=H($9O
M<F5C;&]S=7)E(%5N9&5R($9O<G=A<F0@4'5R8VAA<V4@06=R965M96YT<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9"!F;W(@
M:6YC;VUE('1A>#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M,S$L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9"P@
M97AP:7)A=&EO;B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XR,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);F-O;64@=&%X(')E<V5A<F-H(&-R961I=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87@@
M<F5S96%R8V@@8W)E9&ET<RP@97AP:7)A=&EO;B!Y96%R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T92!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E86P@17-T
M871E($%C<75I<F5D(%1H<F]U9V@@1F]R96-L;W-U<F4@56YD97(@1F]R=V%R
M9"!0=7)C:&%S92!!9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG
M(&QO<W,@8V%R<GEF;W)W87)D(&9O<B!I;F-O;64@=&%X/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,#DL,C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y9F]R=V%R9"P@97AP:7)A=&EO;B!Y96%R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G1S(&EN8VQU9&5D
M(&EN('-T871E(&YE="!O<&5R871I;F<@;&]S<V5S(&YO="!-3%1./"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0L-C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE
M('1A>"!R97-E87)C:"!C<F5D:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(R+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F
M930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X
M8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E
M=#8Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4TE!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY);F-O;64@5&%X97,@+2!);F-O;64@5&%X(%!R;W9I<VEO;B!296QA=&5D
M('1O($-O;G1I;G5I;F<@3W!E<F%T:6]N<R`H1&5T86EL*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M52Y3+B!F961E<F%L('!R;W9I<VEO;B`H8F5N969I="D\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^070@<W1A='5T;W)Y(')A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3DL,#4P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M-34L.3$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-C`L,#`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1A=&4@=&%X97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('9A;'5A=&EO;B!A
M;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#@S
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4U+#`T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0W+#,T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@:6YT97)E<W0@97AP96YS92!O;B!L
M:6%B:6QI='D@<F5L871E9"!T;R!S86QE(&]F(&9U='5R92!R;WEA;'1I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,R
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#@S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R96EG;B!T87@@:6YC;'5S
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R
M96EG;B!T87@@9&EF9F5R96YT:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!C<F5D:71S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#DS,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#(W,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U.3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@W*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C@V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^*$)E;F5F:70I('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4Q,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,C0U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E
M9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R7S1D,C=?.60V95]F,&4P
M9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#8R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0DI!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY);F-O;64@5&%X97,@+2!3:6=N
M:69I8V%N="!#;VUP;VYE;G1S(&]F($1E9F5R<F5D(%1A>"!!<W-E=',@86YD
M($QI86)I;&ET:65S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E
M9"!T87@@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,C,L-S<V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.3$L
M,S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-E87)C:"!A;F0@;W1H97(@8W)E9&ET<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C8L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L-S`W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E
M;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PW-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PU
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C$L.30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L.38R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(&9U='5R92!R
M;WEA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#$U
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(X+#`U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%P:71A;&EZ960@<F5S96%R8V@@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#<Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#8X-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S97)V
M97,@86YD(&%C8W)U86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#(X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T+#8X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O<&5R='DL('!L86YT(&%N9"!E<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C8T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PU.#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@=&%X(&%S<V5T<R!B969O<F4@=F%L=6%T:6]N(&%L;&]W
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DU+#@V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X
M-BPQ.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4@9F]R(&1E9F5R<F5D('1A>"!A
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Y-2PV.3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-3@V+#`T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!D969E<G)E9"!T87@@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&1E9F5R<F5D
M('1A>"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@9&5F97)R960@=&%X(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED
M-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U."]7;W)K<VAE
M971S+U-H965T-C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5&14%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/DEN8V]M92!487AE<R`M(%5N<F5C;V=N:7IE9"!487@@0F5N
M969I=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@0V]N=&EN9V5N
M8WD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$V+#,V,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L,#8W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,RPU-S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M9'5C=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V5T=&QE;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&%P<V5S(&EN('-T871U=&4@;V8@;&EM:71A=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$S-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPU,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPS-C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PP
M-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9E9&5R86P@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y487@@<&]S:71I;VYS(')E;&%T960@=&\@8W5R<F5N="!Y96%R+"!!
M9&1I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&%X('!O<VET:6]N<R!R96QA=&5D('1O('!R:6]R('EE87(L($%D
M9&ET:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T871E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!#;VYT:6YG96YC>2!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&%X('!O<VET:6]N<R!R96QA=&5D('1O(&-U<G)E;G0@>65A<BP@061D:71I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&%X('!O<VET:6]N<R!R96QA=&5D('1O('!R:6]R('EE87(L($%D9&ET
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O
M<F5I9VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M87@@<&]S:71I;VYS(')E;&%T960@=&\@<')I;W(@>65A<BP@061D:71I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9'5C=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-S0R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,V(Q-F5F.&)?
M8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q
M,60U."]7;W)K<VAE971S+U-H965T-C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:2D)'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-E9VUE;G0@4F5P;W)T:6YG("T@061D
M:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V%L97,@
M26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<&5R871I;F<@8G5S
M:6YE<W,@<V5G;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F(&-O;7!O;F5N=',@=VET:&EN(&)U<VEN97-S('-E9VUE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y
M(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^(#<P+#,V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B`V-BPY-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N:71E9"!3=&%T97,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY386QE
M<R!);F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N
M="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPW,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-RPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!E<F-E;G1A9V4@;V8@;F5T(&)O;VL@=F%L=64@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);F1I82!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-A;&5S($EN9F]R;6%T:6]N
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`V+#<P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`W+#<P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N
M=&%G92!O9B!N970@8F]O:R!V86QU92!O9B!P<F]P97)T>2!A;F0@97%U:7!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E=F5N=64@6TUE;6)E<ET@?"!!<W1R85IE;F5C82!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-A;&5S
M($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(')E=F5N=64@9G)O
M;2!C;&EE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,BXP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E=F5N=64@6TUE;6)E<ET@?"!50T(@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY386QE<R!)
M;F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!R979E;G5E(&9R;VT@
M8VQI96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E(%M-96UB97)=('P@4F]C:&4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M86QE<R!);F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!R979E;G5E
M(&9R;VT@8VQI96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(%M-96UB97)=('P@0F%Y97(@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY386QE<R!);F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!R
M979E;G5E(&9R;VT@8VQI96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E(%M-96UB97)=('P@069F>6UA>"P@26YC
M+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-A;&5S($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E
M(')E=F5N=64@9G)O;2!C;&EE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F930Q,60U
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X8E]C.#$R
M7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E=#8U+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%1C1!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396=M
M96YT(%)E<&]R=&EN9R`M(%)E=F5N=64@8GD@1V5O9W)A<&AI8R!!<F5A("A$
M971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0X/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2
M979E;G5E(&)Y(&=E;V=R87!H:6,@87)E83PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+#4U,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,R+#@W,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C@L
M-3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q.2PW-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,Q+#$T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-C`L.3`Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,RPX-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S+#`P-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C`P+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,30X+#DR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#$L,3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!O<G1A8FQE($=E;V=R87!H
M:6-A;"!#;VUP;VYE;G1S(%M-96UB97)=('P@56YI=&5D(%-T871E<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E=F5N=64@8GD@9V5O9W)A<&AI8R!A<F5A/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#4Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#4S-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#4Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5P;W)T86)L92!'96]G<F%P:&EC86P@0V]M<&]N96YT<R!;365M8F5R72!\
M($5U<F]P96%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5V96YU92!B>2!G96]G<F%P:&EC(&%R96$\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C@L
M,3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,#8L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T-BPV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R-U\Y9#9E7V8P93!F
M930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C$V968X
M8E]C.#$R7S1D,C=?.60V95]F,&4P9F4T,3%D-3@O5V]R:W-H965T<R]3:&5E
M=#8V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-C9!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@+2!1=6%R=&5R
M;'D@1FEN86YC:6%L($1A=&$@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$.#XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC
M;VUE(%-T871E;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@<V%L97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPT-C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,#DV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#@P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-2PW.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#@L,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-"PV-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#,R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L.#$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-2PQ-3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0T+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S4L,SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.2PU-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S(L.#<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L-3$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-S<Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L
M,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C`L.3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S,L.#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,L,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#<P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T."PY,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PQ.3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M<W0@;V8@9V]O9',@<V]L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPR.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPY,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#DV,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@W-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-C8Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@L-3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S@L-3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`L-#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#0Y
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,T+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,V+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,X+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0X+#(T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#DQ-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#(S,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#8Q.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M-RPW,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.3`L,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30X+#8W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&EN8V]M92`H;&]S<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W+#0X."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PS,C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M,BPY,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,S8L-#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,U+#@Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#4R-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,BPV,#4I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#4L,3`V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#0X
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,C`L,3,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$T,2PR,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T-2PV.#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,"PV,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,R
M+#8S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#0V+#(P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#0W+#8U.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$V+#4T,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0R+#<T."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4U
M+#`V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#4S+#DQ-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$V,BPP,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-S$L.#4U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.
M970@:6YC;VUE("AL;W-S*2!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XS-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,C8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C,W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,"XT,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XT."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,C8I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P
M+C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XT,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@P+C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XT."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S-B,39E9CAB7V,X,3)?-&0R
M-U\Y9#9E7V8P93!F930Q,60U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
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M=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#DN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#4P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970U,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#4Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V,"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C$N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#8R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970V,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C0N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970V-BYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?
M3F5X=%!A<G1?,V(Q-F5F.&)?8S@Q,E\T9#(W7SED-F5?9C!E,&9E-#$Q9#4X
$+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1WBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Senior Secured Notes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 11, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, issued</a></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">$ 125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">$ 125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">$ 125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ConvertibleSubordinatedNotesRepaid', window );">Convertible subordinated notes remaining</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_ConvertibleSubordinatedNotesRepaid" onclick="toggleNextSibling(this);">172,400,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ConvertibleSubordinatedNotesRepaid</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ConvertibleSubordinatedNotesMaturityDate', window );">Maturity date of convertible subordinated notes</a></td>
        <td class="text">Sep. 28,  2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl', window );">Percentage of repurchase of notes on principal amount of notes</a></td>
        <td class="nump"><a title="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl" onclick="toggleNextSibling(this);">101.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets', window );">Percentage of repurchase of notes on principal amount of notes</a></td>
        <td class="nump"><a title="nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible Subordinated Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInstrumentExchangedAmount', window );">Retirement of convertible subordinated notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_DebtInstrumentExchangedAmount[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember]" onclick="toggleNextSibling(this);">42,500,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_DebtInstrumentExchangedAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleSubordinatedDebtMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">12% Senior Secured Notes Due July 2017 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of senior secured notes</a></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtIssuanceCosts[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">4,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtIssuanceCosts<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember', window );">July 1, 2015 through June 30, 2017 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MinimumRequiredCashBalance', window );">Minimum Cash Requirement (Jul 1, 2015 through June 30, 2017)</a></td>
        <td class="nump"><a title="nktr_MinimumRequiredCashBalance[us-gaap_DebtInstrumentAxis=nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_MinimumRequiredCashBalance<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_MinimumRequiredCashBalance[us-gaap_DebtInstrumentAxis=nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_MinimumRequiredCashBalance<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember', window );">12% Senior Secured Notes Due July 2017 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of senior secured notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Secured Notes carrying amount</a></td>
        <td class="nump"><a title="us-gaap_SeniorNotes[us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">$ 125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorNotes<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SeniorNotes[us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember]" onclick="toggleNextSibling(this);">$ 125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorNotes<br>/ us-gaap_DebtInstrumentAxis<br>= nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ConvertibleSubordinatedNotesMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible subordinated notes maturity date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ConvertibleSubordinatedNotesMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ConvertibleSubordinatedNotesRepaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible subordinated notes repaid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ConvertibleSubordinatedNotesRepaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInstrumentExchangedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Exchanged Amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DebtInstrumentExchangedAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumRequiredCashBalance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum Required Cash Balance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_MinimumRequiredCashBalance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_JulyFirstTwoThousandFifteenThroughJuneThirtyTwoThousandSeventeenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_TwelvePercentSeniorSecuredNotesDueJulyTwoThousandSeventeenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Summary of Liability Related to Potential Future Royalties</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The following
 table shows the activity within the liability account during the
 year ended December&#xA0;31, 2014 and for the period from the
 inception of the royalty transaction on February&#xA0;24, 2012
 (inception) to December&#xA0;31, 2014 (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year ended<br />
 December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Period
 from</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>inception
 to<br />
 December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Liability related to sale
 of future royalties &#x2014; beginning balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">128,520</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Proceeds from sale of
 future royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">124,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Payments from Nektar to
 RPI</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(10,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 royalty revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,937</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(54,783</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash interest expense
 recognized</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,888</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61,254</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Liability related to sale
 of future royalties &#x2014; ending balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liability related to sale of potential future royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future Minimum Payments for Capital Leases</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future minimum payments for our capital leases at December&#xA0;31,
 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">Years ending December&#xA0;31,</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,572</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,268</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total minimum payments required</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,015</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: amount representing interest</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,364</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Present value of future minimum lease payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,651</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: current portion</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capital lease obligation, less current portion</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments for Operating Leases</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our future minimum lease payments for our operating leases at
 December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">Years ending December&#xA0;31,</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total future minimum lease payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,662</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">0.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">0.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Average volatility factor</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" onclick="toggleNextSibling(this);">51.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" onclick="toggleNextSibling(this);">61.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" onclick="toggleNextSibling(this);">62.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average weighted average expected life</a></td>
        <td class="text">5 years 2 months 12 days<span></span></td>
        <td class="text">5 years 2 months 12 days<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average expected volatility rate of share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E13AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2009

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageCeilingOnRentIncrease', window );">Percentage ceiling on rent increases, annually, capital lease</a></td>
        <td class="nump"><a title="nktr_PercentageCeilingOnRentIncrease" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageCeilingOnRentIncrease</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CapitalLeasesTerminationDate', window );">San Carlos facility capital leases, termination date</a></td>
        <td class="text">Oct.  05,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumSubleaseRentals', window );">Future minimum rental receipts under the San Carlos facility subleases</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumSubleaseRentals" onclick="toggleNextSibling(this);">$ 4.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumSubleaseRentals</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsGross', window );">Book value of assets, gross</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasedAssetsGross" onclick="toggleNextSibling(this);">2.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasedAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeasedAssetsGross" onclick="toggleNextSibling(this);">2.3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasedAssetsGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet', window );">Net book value of assets</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" onclick="toggleNextSibling(this);">1.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" onclick="toggleNextSibling(this);">1.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SubleaseTermCommencedStartDate', window );">Operating Sublease term commenced start date</a></td>
        <td class="text">August 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SubleaseTermCommencedPeriod', window );">Operating Sublease term commenced period</a></td>
        <td class="text">114 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SubleaseTermCommencedEndDate', window );">Operating Sublease term commenced end date</a></td>
        <td class="text">January 31, 2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense for operating leases</a></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 3.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 2.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 2.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_PfizerMember', window );">Pfizer, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OperatingSublease', window );">Operating sublease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_OperatingSublease[dei_LegalEntityAxis=nktr_PfizerMember]" onclick="toggleNextSibling(this);">126,285</a><span style="display:none;white-space:normal;text-align:left;">nktr_OperatingSublease<br>/ dei_LegalEntityAxis<br>= nktr_PfizerMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CapitalLeasesTerminationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Capital leases termination date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CapitalLeasesTerminationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LeasesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OperatingSublease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating sublease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_OperatingSublease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageCeilingOnRentIncrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage ceiling on rent increase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageCeilingOnRentIncrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SubleaseTermCommencedEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sublease term commenced end date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SubleaseTermCommencedEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SubleaseTermCommencedPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sublease term commenced Period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SubleaseTermCommencedPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SubleaseTermCommencedStartDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sublease term commenced start date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SubleaseTermCommencedStartDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45014-112735<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total gross amount less the charge for the use of the long-lived depreciable assets subject to a lease meeting the criteria for capitalization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumSubleaseRentals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum payments receivable in the future under noncancelable subleases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumSubleaseRentals</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_PfizerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_PfizerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock', window );">Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014, we had 24,806,565 reserved shares of
 common stock, all of which are reserved for issuance under our
 equity compensation plans as summarized in the following table
 (share number in thousands):</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 49.1pt">
 <b>Plan Category</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Number&#xA0;of&#xA0;Securities&#xA0;to&#xA0;be</b><br />
 <b>Issued Upon Exercise of</b><br />
 <b>Outstanding Options</b><br />
 <b>(a)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-Average</b><br />
 <b>Exercise Price of</b><br />
 <b>Outstanding&#xA0;Options</b><br />
 <b>(b)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Number&#xA0;of&#xA0;Securities&#xA0;Remaining</b><br />
 <b>Available for Issuance Under</b><br />
 <b>Equity Compensation Plans</b><br />
 <b>(Excluding Securities Reflected</b><br />
 <b>in Column(a))</b><br />
 <b>(c)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity compensation plans approved by security holders(1)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,601</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity compensation plans not approved by security holders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,995</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Includes shares of common stock
 available for future issuance under our ESPP as of
 December&#xA0;31, 2014.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular Disclosure of shares of common stock for issuance under existing equity compensation plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SharesOfCommonStockForIssuanceUnderExistingEquityCompensationPlansTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In accordance with our collaboration agreements, we recognized
 license, collaboration and other revenue as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="39%"></td>
 <td valign="bottom" width="2%"></td>
 <td width="37%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>Partner</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Agreement</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 AstraZeneca AB</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">MOVANTIK<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> (NKTR-118) and
 MOVANTIK<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup>
 fixed-dose combination program (NKTR-119)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="top">$</td>
 <td valign="top" align="right">105,001</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="top">$</td>
 <td valign="top" align="right">25,016</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="top">$</td>
 <td valign="top" align="right">59</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Roche</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">PEGASYS<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> and
 MIRCERA<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,382</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Baxter Healthcare</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAX 855 (Hemophilia)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,258</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amgen, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Neulasta<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Bayer Healthcare LLC</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAY41-6551 (Amikacin Inhale)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,717</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,293</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,971</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Affymax, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">OMONTYS<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,829</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,295</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,884</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 License, collaboration and other revenue</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">153,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">80,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,127</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGDAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(21,937)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(22,055)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">(10,791)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">20,888</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">22,309</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">18,057</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">17,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">17,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">16,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">12,927</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">14,275</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">14,508</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash transactions</a></td>
        <td class="num"><a title="us-gaap_OtherNoncashIncomeExpense" onclick="toggleNextSibling(this);">(560)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNoncashIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNoncashIncomeExpense" onclick="toggleNextSibling(this);">664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNoncashIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNoncashIncomeExpense" onclick="toggleNextSibling(this);">2,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNoncashIncomeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(1,378)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">3,576</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(867)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">4,817</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(5,613)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(3,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">6,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">6,031</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(6,359)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">6,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(122)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(8,505)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">5,481</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(4,034)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">273</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">(1,915)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">1,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
        <td class="num"><a title="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" onclick="toggleNextSibling(this);">(9,197)</a><span style="display:none;white-space:normal;text-align:left;">nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses</span><span></span></td>
        <td class="num"><a title="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" onclick="toggleNextSibling(this);">(595)</a><span style="display:none;white-space:normal;text-align:left;">nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses</span><span></span></td>
        <td class="nump"><a title="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" onclick="toggleNextSibling(this);">5,547</a><span style="display:none;white-space:normal;text-align:left;">nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInterestPayableNet" onclick="toggleNextSibling(this);">(166)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInterestPayableNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInterestPayableNet" onclick="toggleNextSibling(this);">5,278</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInterestPayableNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(4,664)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(12,399)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(9,384)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInMilestonePaymentLiabilities', window );">Liability related to receipt of refundable milestone payment</a></td>
        <td class="num"><a title="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" onclick="toggleNextSibling(this);">(70,000)</a><span style="display:none;white-space:normal;text-align:left;">nktr_IncreaseDecreaseInMilestonePaymentLiabilities</span><span></span></td>
        <td class="nump"><a title="nktr_IncreaseDecreaseInMilestonePaymentLiabilities" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_IncreaseDecreaseInMilestonePaymentLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" onclick="toggleNextSibling(this);">(13,801)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" onclick="toggleNextSibling(this);">9,164</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" onclick="toggleNextSibling(this);">3,275</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(142,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(38,527)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(129,756)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">247,995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">319,181</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">307,887</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of investments</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" onclick="toggleNextSibling(this);">(297,251)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" onclick="toggleNextSibling(this);">(268,068)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" onclick="toggleNextSibling(this);">(164,662)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Sales of investments</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">21,661</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">2,887</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">5,378</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">(25,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(9,976)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(4,091)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(10,583)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(37,571)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">49,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">113,020</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" onclick="toggleNextSibling(this);">(3,536)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" onclick="toggleNextSibling(this);">(2,992)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" onclick="toggleNextSibling(this);">(2,437)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock, net of issuance costs</a></td>
        <td class="nump"><a title="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" onclick="toggleNextSibling(this);">116,536</a><span style="display:none;white-space:normal;text-align:left;">nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts', window );">(Repayment of) proceeds from sale of future royalties, net of $4.4 million of transaction costs in 2012</a></td>
        <td class="num"><a title="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" onclick="toggleNextSibling(this);">(7,000)</a><span style="display:none;white-space:normal;text-align:left;">nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts</span><span></span></td>
        <td class="num"><a title="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" onclick="toggleNextSibling(this);">(3,000)</a><span style="display:none;white-space:normal;text-align:left;">nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts</span><span></span></td>
        <td class="nump"><a title="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" onclick="toggleNextSibling(this);">119,588</a><span style="display:none;white-space:normal;text-align:left;">nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of senior secured notes, net of $4.5 million of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfSecuredDebt" onclick="toggleNextSibling(this);">77,940</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSubordinatedDebt', window );">Repayment of convertible subordinated notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfSubordinatedDebt" onclick="toggleNextSibling(this);">(172,407)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfSubordinatedDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" onclick="toggleNextSibling(this);">46,984</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" onclick="toggleNextSibling(this);">8,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" onclick="toggleNextSibling(this);">4,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">152,984</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">2,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">26,801</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">(109)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(26,702)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">13,630</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">10,125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">39,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">15,312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">12,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">39,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,445</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,590</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">9,620</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">964</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1,014</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1,021</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing', window );">Property and equipment acquired through capital leases and other financing</a></td>
        <td class="nump"><a title="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" onclick="toggleNextSibling(this);">5,231</a><span style="display:none;white-space:normal;text-align:left;">nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing</span><span></span></td>
        <td class="nump"><a title="nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Retirement of convertible subordinated notes in exchange for senior secured notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionOriginalDebtAmount1" onclick="toggleNextSibling(this);">$ 42,548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionOriginalDebtAmount1</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued clinical trial expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInMilestonePaymentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase(Decrease) in Milestone Payment Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_IncreaseDecreaseInMilestonePaymentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-cash interest expense related to sale of royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non cash royalty revenue related to sale future royalties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Issuance Of Common Stock Net Of Issuance Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Property And Equipment Acquired Through Capital Leases And Other Financing</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSubordinatedDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of long-term borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in case of liquidation of the entity's assets or underlying collateral.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfSubordinatedDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Stock-based compensation expense was recognized as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,161</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,297</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,496</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,910</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,328</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,501</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,621</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total stock-based compensation</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,017</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,199</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following tables list the Black-Scholes option-pricing model
 assumptions used to calculate the fair value of employee and
 director stock options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended</b><br />
 <b>December&#xA0;31,&#xA0;2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended</b><br />
 <b>December&#xA0;31,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended</b><br />
 <b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Average risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Average volatility factor</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Average weighted average expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.2&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.2&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.0&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under Equity Incentive Plans</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The table below presents a summary of stock option activity under
 our equity incentive plans (in thousands, except for price per
 share and contractual life information):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b><br />
 <b>of</b><br />
 <b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price</b><br />
 <b>per Share</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Remaining</b><br />
 <b>Contractual</b><br />
 <b>Life&#xA0;(in&#xA0;Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate</b><br />
 <b>Intrinsic</b><br />
 <b>Value(1)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,655</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9.06</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,713</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,852</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options forfeited&#xA0;&amp; canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,521</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,995</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">112,549</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested&#xA0;and expected to vest at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,338</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">111,071</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,007</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.47</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">85,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Aggregate intrinsic value represents
 the difference between the exercise price of the option and the
 closing market price of our common stock on December&#xA0;31,
 2014.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventory - Inventory (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterialsNetOfReserves" onclick="toggleNextSibling(this);">$ 2,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterialsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterialsNetOfReserves" onclick="toggleNextSibling(this);">$ 3,947</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterialsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcessNetOfReserves" onclick="toggleNextSibling(this);">5,187</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcessNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcessNetOfReserves" onclick="toggleNextSibling(this);">6,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcessNetOfReserves</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">5,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">3,359</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 12,952</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 13,452</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDVCM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Sep. 16, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
        <td class="nump"><a title="nktr_PotentialDevelopmentMilestones" onclick="toggleNextSibling(this);">$ 130,300,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialDevelopmentMilestones</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikMember', window );">MOVANTIK [Member] | US and EU Commercial Launch [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents[us-gaap_ProductOrServiceAxis=nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">140,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents<br>/ us-gaap_ProductOrServiceAxis<br>= nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikMember', window );">MOVANTIK [Member] | United States [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents[us-gaap_StatementGeographicalAxis=country_US;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents<br>/ us-gaap_StatementGeographicalAxis<br>= country_US<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikMember', window );">MOVANTIK [Member] | European Union [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents[us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">40,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents<br>/ us-gaap_StatementGeographicalAxis<br>= us-gaap_EuropeanUnionMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | License Extension Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[us-gaap_DeferredRevenueArrangementTypeAxis=nktr_LicenseOptionMember;dei_LegalEntityAxis=nktr_RocheMember]" onclick="toggleNextSibling(this);">31,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= nktr_LicenseOptionMember<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_MirceraMember]" onclick="toggleNextSibling(this);">10,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AllocatedConsideration', window );">Allocated consideration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_AllocatedConsideration[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_MirceraMember]" onclick="toggleNextSibling(this);">27,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_AllocatedConsideration<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ConsiderationReceivedForProductDelivered', window );">Consideration received for product delivered in 2013</a></td>
        <td class="nump"><a title="nktr_ConsiderationReceivedForProductDelivered[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_MirceraMember]" onclick="toggleNextSibling(this);">18,600,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ConsiderationReceivedForProductDelivered<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember;us-gaap_TypeOfArrangementAxis=nktr_MirceraMember]" onclick="toggleNextSibling(this);">22,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis<br>= nktr_PerformanceMilestonePaymentsMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember;dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_MirceraMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= us-gaap_UpFrontPaymentArrangementMember<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_PegasysMember]" onclick="toggleNextSibling(this);">5,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PegasysMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS and MIRCERA [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_RocheMember;us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember]" onclick="toggleNextSibling(this);">4,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_RocheMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_PegasysAndMirceraMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
        <td class="nump"><a title="nktr_PotentialDevelopmentMilestones[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember]" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialDevelopmentMilestones<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember]" onclick="toggleNextSibling(this);">20,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentForReimbursementOfCosts', window );">Payment made to Bayer for cost of Phase 3 clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PaymentForReimbursementOfCosts[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PaymentForReimbursementOfCosts<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember;us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember]" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember<br>/ us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis<br>= nktr_PerformanceMilestonePaymentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentMilestonePaymentReceived', window );">Development milestone achieved in 2013</a></td>
        <td class="nump"><a title="nktr_DevelopmentMilestonePaymentReceived[dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember;us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_DevelopmentMilestonePaymentReceived<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember<br>/ us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis<br>= nktr_PerformanceMilestonePaymentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember;dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember]" onclick="toggleNextSibling(this);">40,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= us-gaap_UpFrontPaymentArrangementMember<br>/ dei_LegalEntityAxis<br>= nktr_BayerHealthcareLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OphthotechCorporationMember', window );">Ophthotech Corporation [Member] | Fovista [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
        <td class="nump"><a title="nktr_PotentialDevelopmentMilestones[dei_LegalEntityAxis=nktr_OphthotechCorporationMember;us-gaap_TypeOfArrangementAxis=nktr_FovistaMember]" onclick="toggleNextSibling(this);">9,500,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialDevelopmentMilestones<br>/ dei_LegalEntityAxis<br>= nktr_OphthotechCorporationMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_FovistaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[dei_LegalEntityAxis=nktr_OphthotechCorporationMember;us-gaap_TypeOfArrangementAxis=nktr_FovistaMember]" onclick="toggleNextSibling(this);">19,750,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ dei_LegalEntityAxis<br>= nktr_OphthotechCorporationMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_FovistaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_OphthotechCorporationMember;us-gaap_TypeOfArrangementAxis=nktr_FovistaMember]" onclick="toggleNextSibling(this);">18,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_OphthotechCorporationMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_FovistaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember;dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember]" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= us-gaap_UpFrontPaymentArrangementMember<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIK [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">70,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">140,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired', window );">Potential reduction in U.S. royalty rate for repayment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPostApprovalStudyCostsToRepay', window );">Percentage of post approval study costs to repay</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PercentageOfPostApprovalStudyCostsToRepay[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">33.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPostApprovalStudyCostsToRepay<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies', window );">Maximum potential reduction in royalties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">35,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIK [Member] | Pre-approval Cardiovascular Safety Study Not Required [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents', window );">Contingent payments received based on development events</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_ProductOrServiceAxis=nktr_CardiovascularSafetyStudyNotRequiredMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikMember]" onclick="toggleNextSibling(this);">35,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_ProductOrServiceAxis<br>= nktr_CardiovascularSafetyStudyNotRequiredMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | Movantik Fixed-dose Combination Program [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
        <td class="nump"><a title="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents[dei_LegalEntityAxis=nktr_AstraZenecaAbMember;us-gaap_TypeOfArrangementAxis=nktr_MovantikFixedDoseCombinationProgramMember]" onclick="toggleNextSibling(this);">75,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents<br>/ dei_LegalEntityAxis<br>= nktr_AstraZenecaAbMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_MovantikFixedDoseCombinationProgramMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxterHealthcareMember', window );">Baxter Healthcare [Member] | BAX 855 (Hemophilia) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
        <td class="nump"><a title="nktr_PotentialDevelopmentMilestones[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialDevelopmentMilestones<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Development milestones achieved</a></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[dei_LegalEntityAxis=nktr_BaxterHealthcareMember;us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember]" onclick="toggleNextSibling(this);">8,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ dei_LegalEntityAxis<br>= nktr_BaxterHealthcareMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_HemophiliaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement[dei_LegalEntityAxis=nktr_AmgenIncMember]" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement<br>/ dei_LegalEntityAxis<br>= nktr_AmgenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[dei_LegalEntityAxis=nktr_AmgenIncMember]" onclick="toggleNextSibling(this);">29,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ dei_LegalEntityAxis<br>= nktr_AmgenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AffymaxIncMember', window );">Affymax, Inc. [Member] | OMONTYS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred revenue recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueRevenueRecognized[dei_LegalEntityAxis=nktr_AffymaxIncMember;us-gaap_TypeOfArrangementAxis=nktr_OmontysMember]" onclick="toggleNextSibling(this);">6,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueRevenueRecognized<br>/ dei_LegalEntityAxis<br>= nktr_AffymaxIncMember<br>/ us-gaap_TypeOfArrangementAxis<br>= nktr_OmontysMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
        <td class="nump"><a title="nktr_PotentialDevelopmentMilestones[dei_LegalEntityAxis=nktr_OtherPartnerMember]" onclick="toggleNextSibling(this);">53,800,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_PotentialDevelopmentMilestones<br>/ dei_LegalEntityAxis<br>= nktr_OtherPartnerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Development milestones achieved</a></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[dei_LegalEntityAxis=nktr_OtherPartnerMember]" onclick="toggleNextSibling(this);">$ 9,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ dei_LegalEntityAxis<br>= nktr_OtherPartnerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AllocatedConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocated Consideration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_AllocatedConsideration</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ConsiderationReceivedForProductDelivered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration received for product delivered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ConsiderationReceivedForProductDelivered</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent payments receivable based on development events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent payments received based on development events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentMilestonePaymentReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development milestone payment received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DevelopmentMilestonePaymentReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentForReimbursementOfCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment made to Bayer for cost of Phase 3 clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PaymentForReimbursementOfCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfPostApprovalStudyCostsToRepay">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of post approval study costs to repay.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfPostApprovalStudyCostsToRepay</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential development milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential royalty reduction on US sales to repay post-approval study if required</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront and Milestone Payments Received Under License Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AffymaxIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AffymaxIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxterHealthcareMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxterHealthcareMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OphthotechCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OphthotechCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_RocheMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_RocheMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MovantikMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001193125-15-063338-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-063338-xbrl.zip
M4$L#!!0````(`$4P6D9JT3FR[7@!`%FD#P`1`!P`;FMT<BTR,#$T,3(S,2YX
M;6Q55`D``S'][E0Q_>Y4=7@+``$$)0X```0Y`0``U%U9<]O(=GY/5?X#HX=4
M4I66T'NW:NQ;6&^YXK%5DN^2O+`@$I*0H0!=`+2M^^MS&EQ$@"`);A`\+_(0
M#;*_TV?O[G-^^]//Y\G@>Y3E<9I\N,"7UL4@2D;I.$X>/UQ,<Q3FHSB^&.1%
MF(S#29I$'RY>H_SB3Q__]5]^^S>$!K>W`R]-DF@RB5X'?Q]%DR@+BVCP*3%O
MC")X.)H^1TGQ7X/[,(_&@S09_-VY_3P@EW@P>"J*E^NKJQ\_?EQFV7CQ-9>C
M]/EJ@-#B)_XZF]WU8"`N";ED*X]NTVDROAZL?N1F45C`\,$8YG$](!;FR"*(
M\&^6=4W8-67_NSHZ?7G-XL>G8O`?H_^$P19'\`8=W%[>7JX`^_?!79KD,/KY
M)4Q>!_9D,K@U;^6#VRB/LN_1^'+^I3_OL\D`:)KD'RY6X)F/+]/L\0I^@E[%
M<^I<S$9>FZ>3+>,G<?*'(=]RO/F@,OX'+4=CK?55^70Q-,Y31K#<-IG9B.5W
MYW'3-\-0?/7WWS_?C9ZBYQ#5$0"G/(;AR_+-AS"_+]^;/X#W,4,61A0O7AE'
M;S]4SBB/1I>/Z?<K>-`P//FCR"H32Z(_BC`KF<6,QN1M+/QH\?H2Y8W3*9\T
M_("9P[BH3FF.G%_-'E:&QHU#Q6QHO!B:%R]9,TSSQ$P#5Z<Q`I8NLM?F=^8/
MS6NT]MHTRT!P-[TW?]H`._HY>FI^R3QI6H@P'N7-;Y2/&C#%R?<H+YK?F3UK
M0)3'HPV$BT<-OY%$CR#PXXV,KJ^R=!)=S8<MWYH^-[\Q+K(KPRE7,"+*XM'R
M!=`)N]])$U1[;UKCWNK4X.D%:(_!H-0?D^N\E++;Z&%0"O.U^=8/%WG\_#(Q
M(E=^%F8C@ZB=VBC?>,JBAP\71I#00F(N?^;C`[1*>X5U-8,%,GWM)T5<O((.
M?4Z3NR(=_7'W%&91_G5:E-8%+,Y@E"9%]+.X-?.,TLGPQL>6I!(A!-.UT'^#
M$K*&=]^\H34TBMTBQ!J"Q9HF\>R=O/S&B\$X&L7/X038]-.7X&(0`UO$XR$G
MC%B"#@-J!\J1!'D>Q8C9-D9:<!^Y%F6:.Z[T;3$D0W7Q$5-,%1:8_';5#L$,
M[5SI78-Q*(`'@-_<,'^RD_*/_X]I_#V<@$W,]\1++(EQ!>]<=P__<N>M@D9\
M#3,6TO$\["-,!$&,`&;%I4"^M)G/I:VDHX;FRS\2;I7__7;5%L8,M.&K:S<%
M<<Z*^'X2W4WOTPQH8L3M2UI$^6WT$L;C#C%[ME*V9=L(:^XAQIE`FFH?42YL
M2B4LO*UGF+$D;`ZZ)8SJ0GO1?6%<GJST=3X!0&"+XA;>N2O,BS=1-H('X6-T
M&/PA)E(3C'_"7T'9*CE>IEFTB^&M0)(@<"3"CA*(*4&15LQ!Q,66HSVA!;.'
M&'YY2"\^6I?PJV^+WQY:E21W41*GV><T>?P69<\EY4Z.O3TKM*>`X89U$6A`
ML\+U7U^,UPOB#\PRB4#O[8?4TI:F5HE4@<91/S$7EF9T5;']XZ%8A6BM(12@
M#;6K7.2[&`2<,0D"#KS/B>2^MJA-N+."4!#%Y\R^-ONZRKZ!S^-1,$G#8L\E
M9#`SJXWTKN-II:3I4`,803A02RIK54NO3+JJGPQ28-B;\-4P-(CS*(K!@7=,
M>/(U\:+OT21],8_\[P?H:&9I+&9,*R6EL)04IH9+)M:665K)A%Q9:BHD?-]!
M3.WZENVHP$6<,Z/3B84441;BMN<PUR8,?L"P5[GD=,G3!Q)BA8HWP/_P>CBY
MC<;3D8FV/B7!M`!-=)N^AA,@_OP[OZ5&6[[>I'EAO[QD*1B,NV(ZCO?6!2MD
M/3D9I:-],`@,4>8PQ#Q;(L=6!+DNE3;W-)<NGY&1K)'Q!)2HJ4WC5CREDS$$
MO<;$%J][4@H;MZZ5P:3K3H+F@:VP0B)0`6*!ZR/;M30"+B/$\8&AG5)+BJ$V
M-,`@>UHJC*NJ<@U!%>%?DBP:I8])_,]H_"W\Z41)]!#O+6?'P)2N[S#?8D@0
MRP6YH1[2MN*(^AX8`T)MJO60+U0E!3>I`G`#@"K*9D_)+MPPRUY!\/X:3J;[
M.@/'8/9`>4H;-(0KE8.8##SD.*!.B=(^QM0/&'-F3,X,:$[!_*Z";H5G545`
MK!%!T#E^\Y.]*(\?2S_J,-Q&^`6X:>`(@+V68F^_7UB46%R[R+85^(,VULBQ
MN(6$<`/"A*\<K@Q[TU+0<47.M\$YCP3/X1J_1R@A]%DEF@WE7*(1B#/=2Z#/
M`5ASI<X*F`_5$C#5BI<NWQZ8CPQ=UR%+"PSX5I8^`JV1:O@/V!ICQE0-Z_8@
M]@S+6\=Z^N7%0[ZP4/M9IW.@I>`$GQ6M46USM%Q+1E2WD,FY70ZZ=#G4Q4<F
M+;P?P--X',>@;.5Q,+.0QOA"U"3[X7$<@[F5QU$R+RNS3A`F'>IQG)J3NS.]
M=&EZ@;,1N)KO(KG=65ZZM+P&+T1Q%E56IY9W'?+Y+"]=6EZ3IL#@9.A.+>]N
MK*=?WKGE5=U;W@:TY[6\=&EY#5J!I61L+\AK.PF?\GRZ=WA$UY1T*P[F.O`8
M\S0"&P31D,\T4H[E(PM+P.)P1EQO2(:,FY443%>A;9CZ#GR'B^V908IV(#>*
MZMI(>UH\I9DQV/T"RB"RM:QZ>GO+]*LX&^+@_BXJ^,,K&'=,?>-ZWH39UVRV
MUU&Z'#=15KY\--85;31\B;)ANR1&6_#E3HX)"AI7>1.HW:O=4\:F1@6O\?5V
M`-O`_IJK3N7ZJK?#M7OA^VB;K)T2WF26CM^:W+JLI\%&Y'X;D8L!7XNG*/L<
MA_?Q)"[B*'?+HS_[;MQU`=`X%A97U9!GP_3KV^VS=898V,[SJ,@-*Y>G_NS)
M)/U1'CSL#J]%I&WY5"#/D19BU+60(WR%*'49^(S,[.8"7@SFB"MAL>J"ML#2
M#/XV^AXET^A+FHSZNL04("M"%6M$O`:@BM,>C:;/TXG15%[TDL%T2JK`OR=1
M29YD;#^G61'_L_S\)DM!G1:O-Y,P*>"9\;?+W<L.R>)[G@;X#&''A:@!$X6T
MXP`GN`0'-I%*<`9D`<97#+-J$NM4<+<I\D-20#OH\3./KY-X\N&BR*;1P7PB
ME@?%%A/_)3081`T:XL%JG+M+>;GA2UR$D\_FI,77^TG\6*YGWF<Y)N!<*8M5
MDQ<[<51A+TX.W82OX?TDZN^B@LX2&E>M4O/DJP"#,,Y*`9NI\<_F_`3^EI9_
MR;<L3'*0Q!QD>'H^V$VN(Q:^)EPIY"BJ$9-2(NT[)AEKDX!ZGN=+8O*P9%CU
MIO;!LS%X.H/&.8GC2-;24_5)KT.*B_(DA\E)+P[/C/8_R=*)/F5K^G3%O)0N
MEKG*D$5/49+'WZ-/R2A]CCZG>?XE*KX^@"O2PR4K$\98X4U6LPVL-9H8YLW[
MKI(PA`(:8UY'WC#Y^OGC(HR3:.R'60+\FE=\C(=X%/<0+--FG24E5%>/(>P&
M4UO=\3@V%BF<W(3Q^%,RMU<K<MY#\";H$XP*40T2=F-9XVQ0'^-?P8G"L-Z"
M,%IG[N;YGWC+H`-\'*PJ4EKO>:BF'@?WV3VDQIJ"CR&V1O*;',.5(6!:?XDE
M!1>14<:)W.3X-P+9[2Z2N7N%?PEW$>]T%S?AV9K0Z*VF(O3B(P'5O#6;T:BG
M3G,`Y1B(;0^@E$$`%F;?=.\#*"O\W[_%H[!X\$II9YIEM@K&?WZ9I*]1=!N5
M'L8O84G-%@@CO,J?.X&TRD[T%C0IS^13T28UL2N7_#X,W#9]3"OJMGG:-2]P
MD4`.TLQ+I_?%PW2R"!MFMSUZ'?:("N"]P)S_9%P7K`V<K>M'`0\X%>>FY?6]
M^>V4FRQ]S*(\_W,&<7'_<N/21`.BGIK9"*"*],]I.OX13R;]6TL,BRD%MZK`
M%O.MY^PWI/:_1#V44K.M)8265:NS#4--27T/XXD179#K.^#FNPBBA*YU,/9M
M2JD3((\'#)Q>;2$EX)=\V[8=3^/`TV0FD5A+73O%MQG!CEW+KD6PK:6QRHU*
MK'=L5#8(X(DOO!\#UL6^0X3+$'&9CQBS!+(#XP`S#BXODY:OYDKVT`OO&PE3
M1K[]6U=MH%*]?5'+N>_`M_A@EE_M'U!J7$((8;<CK:+8`1G^X<+_QS,[^Y!F
M/\)LG)OB/V$V>NH?"8"M!9:6W$Z"[:AVDV3QF?_S)4KRR"3?X6\XWZY>1(GE
M09SR5O'J`#?-N[1F+>G&C(QH07;2[5CH]<U1<\4ZS5Z#.(GSIVAL/(/9KL6\
MP%2GJM.1PM.60MPAX*I9-##W),$1<)3T6.!BR<3</Z4U6]@"R.9X<]R%65R_
M_ZT(]BUF!^#>`'\P+3FR.?@"VO>PXQ&7"Z6'96*$T/JYV0VSWV4@%A47S-Y4
M1?;Z)Q'81"&8UNX,[@&IYNZ5HWOHQK+&G.YLNIM9-G?"B0E*[YZBJ)@-=EY_
M#_\OS=Q)6.X[]H^1\?*D;#,C[\:T@[U7D_Z=ABQM69J9BY([O-LJB!V(^PF3
MM("YAFVIP7L9;9K]42.ES49G,YC;\,?O81%E,?Q^S\VJJ=6B6?W\T2X<S2<;
MWA)C,+BWB3X.EI606E"]!4';!$)O`;,]\PB-N,M(;2;$O06J+CYR+*NNP_J\
M-^+J\Z:WR<>K\IA@,[:-QYK[O6)EDD`J11K<H'9G\=>#HX6.,D>8S<$.F&+_
MK*6Q+$SL<G-;@=M@@_Z69G^4Z>M1E/?=")FD+I"CV0AM!K(C&_BIK/5:GJ+L
MM6BWJX+9B&:E!-+B&#]H](WI\)[NPA@#Q9B:[\/LAV:%`E^FS_=1]O7!G>9%
M^FR.?\RL>C0&$U=&%.MF_FAB+'YL9S4HWZ&6QR4P@ZF(*IA$CO9,?0K!M+`]
MYKETR$IW;$Z"0^"L4&,14;S.M^*_I<;*?WU8UI!;+1S79_>%`'O(A7@<`ZTB
M+#5-.X](S8F314)RKG%[:#S,]7$IYE?9]L:SC0RK=X$6<O=.MYM:TL+<%>'*
MVD**79B.D)D.R>%@[`:.$R`A;1^$!?2IC7T/!8%C8R>P;(SIK"!&67!5E4'K
MH0*S6L(4K$_5%M4/`X`G4@LE5DQ5_[;@S+$Z02PBWLAS),8:M6!P]<OZM[-L
MRC)(\+BJ)%B;^)D*+)[Y:KXN#_*TK:-XD'R``]9;<TE+^<='R?\;OA4BP72G
MR=B(P._Q!/@D3:)YN=E>'\4D>ND^+,C1"LF>KG6W^<N6CC4X"L*2F.[G5R_S
MFC/>B8H"G$_P0\N]VU.67]FCH+KDTI?205HIBAC'&JR?YYC2JCP@H-TI8\M;
MA=7B^IOGO\T1"K+T>28C[V?R6WI`)I^I++[-&]R(9H4$\TLP[B1.XE$X^6:2
MON_@`K>5ZO+@N+;X&^IM`,Y["&QH"ME95)4%[2RF3$TP@$O*@GZJ50^!`TWY
M@N7-CFG]QE[+<V+=$8-K100]HU\SOR;"-:M51FM+BQ6G;GG!Q(OST23-IX<6
MXUFAAR348BO,(257;8K('T@/:NA1NKN,T[7<VF:<#140UPZ5V%D6)H^1^0KG
M]6W(W(S:9BO^ZTMY#'Y%X?XM,EW,(O"EHRQ\C/R?43:*<S!$\:$55`PQ+8JI
M(2879$/IS`V5C\@:62G'EJL-';&M$`L(0QK6#$((0CS7%H'6;RT.]*4E:L45
MST^FLZW-+-MT\E5HY=E[H"2)SQER`]#T3,,/*8MZB#@,^YQ;CN<Y2[+#&[RA
MHO0IJ7#N`]*&7B"^);V,UC[()0)]3P.M`B0=GR#F<<_TD;"1XW-B@Z[U+6XO
M[0.7];-$+;V_MWX[$"VLOK(Z_E-RS#F;+=2H=QM:E]CV5##W!R^56D2&^^#J
MDA^8$N)\_%":2',Y0/X2[%`CQHG8@<SMHFD]=3@[=+'I4A:7Q524OA0HV//%
MBGC.&(0*K8_;ANF.)I)!%'3&^'GA/U%"^2]"$\:E)&?,*="Y*B5"D".WZSJC
M"<2,2AY69;P53187F4VB11Q'DS.D63OK8U/JC_?H8%,%VD$9?;XHHX]Y4Y6@
MLY<>;P!\WCKZ?%%'?P:XH5S.N>OHKT,^7QU]OJBCCYOK=)^[COYNK*=?WED=
M?<R[KZ/?@/:\=?3YHHY^B;:A_-$NR.6=@V5-MM?Y.:R37/`N&SER7E*!8=G"
MN6G4V)A[KDTMI'UE(7`)X%^*8(1MRB@8KB#P6%,-OE;`SM%3@)UQ1Q#/>@H`
M@7&M;$/'/07.#%*T`[E9;9G']_4L2KV(^5\2D(KRZV;)$^/1Y)4,U:W)NLP_
M,;[//,FR+:F%CZ;D0<D^B1VM3+=7-U`0*_H>LH4-),:8N$QR&R+'(9W=7[GD
M=?W_3I0Z5Q^(,S-GK_I`G!EKK_I`'"(J!W<$P#WL`W'>Q>YI'XB.5[UW?2#.
M+.'OU0=BZ[*>!MO[]H'H`B`X@YR+7K2!.`9NJ\,A>-8&0G.QJ[I*5VT@.EAA
MTP9""EV+8UNV@:C<3)X=EOD]3N+GZ?.BM3J(>PY_2S7V]>%+5-2>=T@00I@#
MX:N+?*488HZGD&:!1%2[W"',"P(A@""F`83@M2)71^/<EV[>-/J4?'O*HNA_
MHC#K(9G,_>7:Y<&]41U&E!]I3TEB*L\2H0ZBR1Q4+[JL'$.J=MMG1L@T5;42
M.'WMLK*#'B?H"H";NJR\5>W8RCS?P!A'X4.Q]W&48Y;9U1YF&L)_#O\'$B$L
MI"GA2%J*V%IA5U%GWNH;A*)6$F!O8"?N/M.%WV3.$C.+;2Q"W4GWF2Z`FJ;?
MF+Y_]YDNL/:P^TQKV,>4$\=]Z3[3P2*7W6?HIL3;6;O/=&)GNNX^T\62S=J5
MBXW>Q#MUG^D`NND^8TZ3-I9GZ;3[3!?K/.L^HP2UJO9FW^XS-]-L]!26A0'G
MHGL;/<,WP+MS-V2FNV;/]S]+TIX6ZP<3S=%3CUHN(DH2<*!M<Z@:2(-!5?N"
M4Z6QH<7\0D<MD[HOKH,<SD])D$ZSKF.P]AZG:2:`ZYU+]X9V0&S:O99H&9B:
M(\U<DOT#T^::3J?NW=2%ZC")6D48UK5K/^_4NZD+TV!Z-S&\ULBTD]Y-'>`S
MO9NHH+3*UIVU;NHB-6M<429K+4S;MFYJJ?)ZJ<*%J?$CQ$%I@T-M&GB%_;5I
M##0XK5W3VQ_:@:1YES1T>]J`E'"+'FCO-R6C3]SXK`M]:-+/#(O-'8_?M_%9
M1YF*4S4^:^4?]<_5H^4)"WS`QDR]*]HX-L5-[J?%6USU]2%(LRA^3.ZF]WD\
MCL/LY$F.[74-/)OZ+G"!ZYLS:%A19/L>1Q2\'%]0[;BVL\Q7T7ITU![2&5K@
M=9&>-)=O&)-TVT[N&5O@'0.Q;0L\/*O_)SDAM;5MT0.OO5'H?HNQO;DS:E[I
M@URC3?N,AU>DZ<(+!K9F%B=*;[)KYVT.V$6H9DKQ2E8%^)Z]`;O05L1L#.+-
M28E=O0$7R:ZW<1U:(I_;F`6$(L_W`\0X8T@QZ2`I'=!C'E8>#Y;B6F9>FO)T
M;U,_2%%UO[;MM11H:29K]>WW@W6&3I!=G"#K5R?(#@3YA)T@=WFIB[W63\EH
M,AV;[E#]/49FJO326COB8Q">OVMF%TK?')>E_T_>E36Y;23I_S+OY:C[>)D(
MG%Y%R)9"DF=CGARM;K;,W1:I8+-E:W[]9A8`$A>;``B`H-=AS^A@D\P/57EG
M?KH>G5R1-7.&7B?C29MK):NI:3/G\%JN0YLYAV1HM*FHM?)UI\T\1U&X^'LJ
MAA`OOGIC1]N;=HGTW9;$^<4>7,EK,HG.X:E0W^MNM6[-%\S()'J11]IEC3%;
M#)/H#,\524(X.\.O.3F3Z`R"HI)R1BV6270&")!)%/]Y'8(;8Q*=`3=D$F5.
MGCDZ-\`D>I'J[,(VDY775,UEOQ:3Z"4IFTX$C-G.Q/JZMVLSB<[A#>#LBC#F
MC"J9E$ET#L]>MA9)9V<2G>$@XR:&>N)Q.4RB<QQIZ8E?7C_0$S.)SB$F[R!F
M0[:BNO`1E/4:#T&;!?MUZS<?@\[S5_S3-FN-JUBX7[?[?Z]`M*+Z-N=%$,KI
M,#'$<09W/A0*KX0B/'"Q$6$BJ:.';+1B]7KP9!",QMDZ@T+T`^SN>IRM,S@P
M:-'KBO"*G*USM`)A9V1SN/)*G*USM/?VS-A,P]DZ@Z#(WV59RSJ&B3E;YW#-
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M\Y#0SF`'M+_]KK(8?Y$DM#-@@4XLU_(5*)9#0GL)')U(:(LE*8Q3:4H<`3=#
M0GL)0AUU"/4DM);7&%B70T([0U,"AKA(T%"%8"X2VHGW@BZ9A':.=AMZ^?UO
M):&=AHIU!F<9S*625/7DUIF(BO6BD:6.5*QL(!5KX3\?<UMEK8>+5;'&X[=K
M9_-^Y>2U7[(]CR;@U&@E8EQF$8&F#Z0F0:12T')A"CYR$DHK(3+`/AV;#P6,
M)%\)K$NI[RK:=JZ`8SB8S'<YE'W.Z0&8@R5X!A<568(I4^(5'W5FEN`YNK.I
MI[JS1Z&O0!(L%T`2G*W7L5P-),:=#XP92(+SWA`WD#!Y5)+@)A[SDP1G,]:,
M<]?(8TY.$GRPAMF2_-(C^!E^=J`?Y]%4/..C==GIROAI)=@.)7NGPV(FJ7#4
M$/@/?#S`C`1A2`'8,!`Q"VB0V.,UHP+\7CD&0>T9=,8E`_Y7UA6P\1G[>^^@
MXQ]=RA%\?";3<P07J0?.A*A6*.8"YQ:XL\\_D<FXLXO5+VV,.K=&GEUB[KF-
MBZ&S/:!FU(O10&$RD/]&-P">A/W)3?,4YKL`YW7BW^B1*:^T))O3I,SW*&_.
MR,MR)F`R%"8#^<UFOUMOGM?W%XQ+=KL*YP)I3E-&`T724'$BN07/UJ0!D9%(
MJ4B4#E0I@&000+JI(*]B,K>J"KY\V:V^W.U7-_AHL"+-X&NQF5W>$YB-D9\L
M$2>6C=L-/AP.MEY9X4;(678"96*&R#)ZAG/;.Y9V)K!2!P9WWD5$!CHB(6<)
MH0%R%'&DJ#59EH8>1EP'4$;>'IWI$5DA+1C".>A-.>H.]Y/B2V(W771EXY6G
M-%ZEPS\6(9R<O]"QA&-PZ9/!(RXO#@VZW!^6TP-KN[@+=*TZZBN/8;P+POZ?
MUE5G`A</M=647:G.VOYA_AGYOWJ[_KK>PT--X`K\>+=974"1>W%IH%.GK"@"
MJ)_4JWB>$7'J#40(AH!_T+?#XMB@_A#%E$B=38D)$_",8Q43T)0!"1/%`Z9<
M0E5PB"BUJ$^F=VR%>0]:#Z<LOF`#4?E'RJ]_L[ED:OL5-+Z][%:O6X_N*.!Z
M9Y\+["]7N>>O8&G:%^O5CMWE_IB]V\2X(GKKWR/Y/KPML@X+_MXY:O]BRDAM
M!H[C.)?*&#Z3I3$NO1&X%YLQDD8:KE6BJ0W9,=:EE);;BH;(?G7H.-=\/NB*
M5GTY%G+S*"%IM9Y."16@Z-O0034P1M)!/*__TY_8I3IHXE$FQ`+[A7W/")CL
M";LU\X/!%2][F$.&F^;#Q$CJ3N0,QL"D."=<2,5N!!.IC.$3=O6*W"#!>33J
M1C!1DEMCI\-$YIX=&#AN+\-D@G9_CP-\1:]#M-&]W7U-!:?*1=CN'$,`Q1S.
MA5*B=91RJ1,;*GO0'STF``[)@Y%X67)!F>\NU'I8DILYE0:66:)3L"(RC1*(
M%JDC06@Y#Q-C1!C\#L93XO]0KMI(*\_QLTPAL%-VV`GO*K#ZW1X$;F%O/"=S
M*8F=C\AEV:%\/!@'1;,.W")K<3$DADK.!\2V*@7I8A*'N!A:B9`XK2D)N6(1
M<[%):%QJ];=4*ZU:<_7=Q&S)0(Z3,NF,P@5G@J'JH]PWV3#.JNN+&K),?@GJ
MLHY_"9"P+KL$-7;A*UQY(^`23BHMJOY<VA;6Q7,B^^5R!R+E'_D&A%&V)O_N
M6X251T$RT\$%;+5K3,51("AQB:5PU0W\RG)&&-;CP+RG:2S;B+,["5:RZ24.
M#)^*C=?@%NRW.YR8?GQ<WZ]V;^"/OV[6\.OL9>_QC^[7#X/GW(X`"617[!!0
MTN989ZK3$!=S)8YC"2!6)-"&$QH$*A!"13Q,2PW`Y1C[(HF7@IR4&D[!9,@5
M3?GJ;P<<.-U*3@><R#U--@ER\V;&0-5B&EXP<,SGRXP=4O.CI\9P*<0;SXF`
MKRAX,#Z`S_]QCX[_,<TR'#/'F5?\6LC7\M-M&K_;I/HQ.\0K^WZZBG8%&H%7
M<!E[%T@Q;C`NLT"-X.X"%/P-`C^0^QD8"XXI_EXKTZGKJ065('5,.ESXH`R1
M-M8$?@\@2:-C*Z(XBBTJ<Y[MIZR!4I-K6J&5=+PDM`+#SSH(W>H;"<KB5!N2
M2A="S*\XL28%3<Q=)(RQ,6-^*R>O477.*J_CX)R.\I`C^%F>)@X<0&EPV$D2
M1QDGS@2&"LMTJ,QQC$Y?\R$[(Z@>1>@8#`*-N""4)H+@GQ$KDA0BWS#"(2^:
M4)F=;%^`JE<,YI0:9.2"EHXVIMK4(*FY#JFU2I#$I.!C8#^C32`(")A.),`1
M"18>3C:S]7VSK5)?P7,X>@K:'7$1VL#/#R/#8ZF6+H(HT#"%V]\<"1.:0'`D
M(YT8<!^8SDX#,@:ID1R'JR)GZ'S(B>)$W:+/9:G`R5*)R8"^/A?C*5,NC`A+
M'/KT,B2A3''1N3!6*2>E=,<H&WRNRUVNCZO->KO[=;N_8%3[E,C=CT5WP3VA
M6L.?*DE1NBOYVLT/*W"L=IFKE:^`OUA4K9D>J%,Q/@-52JB((.HP(B`A^DA1
M"`I5:2K#Y#A1P:NZX[1`90WQ\O7E"<*V[RM?,,EH8#[=_56L6,N6JUSRM+7*
MG6?7)8W>4GW7*948<_$$`E:9!@&QH6/$*AF))$JD-.&A^LZYKNB`;M*5&QU7
M^Y,D#MCY5[S#%0&!2$('D8[@O$/\*9,X(E9;1L#`4LMM$D3PR44L;ZCC942Z
MRG<.DC3GM8!;="1C;"P!N0F4<%\!E_HL2MU$OL99LE2J"5$JJK`,#?KPPS2V
M!UOX%^"YNV&-/1&8#2T5):DQH%TUYY@5,R10$(-2&L"KCGR]W-6W5,_BIQ=^
M.57@5@V+LV/JP"NS)&$&"5$H(V$<*V)DG+H(8F\GCIM,.*UOJ#[ME_MEQ*N'
MTJJ?4]O7>C8;8(L9@Q"4RVH4#O%8EZ:4)@0!%W!7P&-0#E,-VD!H(C3F&Z)(
MQVFB7:R.&?=\S]BQX-Y+S!)`GW9WF^>[^X((XWGT'9Q7!`K#]<H^MH'"EL]3
M\9+L+W]\6#UD#+#O-K\]X[L\?]I^6'V[^_$>WC_X]FVW_7[W]''_\O#CS6/A
MY?3$3L+5T+VBE_.=<B9TB0Z$)$*&DL@X,-@IQTD4"1.H&("-5,DOI[PX9R.(
M7T+SMV^/NZWOB?EE#3^[WVY6U4`H'QMYN[['A57!E]UJU6\A[D`$>^CGA`:A
M3>$T*HESD9P2B\.1*HA#&05<P@<<,@JF&OX-%?]42V8=<W_&\P=R4X?.MX@+
MT=:>^9J,C4[=@TXL&B[>/99Z-'I#`L(/W"$)GDH4,71?T@3"01TY8AG'Z%`G
M,4C/16+R,11FZC;\K"`MW0;XNM5#_+(#MP?P6V\?LHZ,7U=_^K_JJ\!SX2_M
M+>F&0ZYWG#$M30=G):N=@OQ"O7L\_#3BYX_-Z!B,?2"*?NWZ@7A%IK)V1=WQ
MYVZ-*TCQM*R?G_/))-QJAAOY;P(`<<@X%FKSK%ROY<A^N=OCN-R/&"Q_7_E/
M)8@&)G]XYLTR0Z@A3)W*?96_<5GUW^V\)4;-AR][]Y@;9;3#A<[H(2&592&G
M6Y?N<\BL:@D[R3+(K5\D`.P2#[X<O8,?BUO4"V?,1S\UI_86\!"X*]K8TJ[6
M`9(U<2F2Q@=&GLJ/+QL2"6H?M\\T(.DHU*Q>-G=%D.<R\P"*'7U$Z9BSDY0O
M0\83Q0!`>"/P)9U,21A*2D(1*?B,-`B*Q4GLP!TXHMM]!4CK$%(A_;94(=F,
MD!9[2M38B`9/3]M[/,D1F/+U@\_8;3<CXC5/Q?R0B3,5@-JEJQAS#U>ZW7U8
MK;]^?MD]KS([V--1%3XU!R+#+\9)S7'FN$D"11QW#O053T'LB!&G=,J5<$S&
M+"MPBA:S_II4L]ZG#!AY`.;2W@(YN+<@2^!E`U3C7*`Q'5V1Y^M,>V=9?1=[
M:C@8+O!>0ZN)M%I@$TU(>,1HZ&+MM/13WV*HIUMYW;#8[8Q$0Q@A.DN-7.7U
MC4X-46H\84<XDK_N_\!U$P_!UW[1VDF1#>VT:GR@R!Q%QJ%K7HG77A5J7B7@
M!\-=.8Q#(RJ58W8<(]&I8;#P2P2[/;]$:(48FCJ&=4=D:HOCSQIM#/B/HT@'
M+W\Y[(T/X()_;=U?]*\M5OL]+5`_Q>R!QU&K6NA13[RV9-TD(!I33E0<`*"A
MC>!0LI#0B,9*I<IJ1;.PG/ZD67TUVBPX5/%'7FL(=2`F_@[.TD/XX[=G+&0?
M"KG!_7[]/:.!]AU4+_!G^5]N^ZQQ.HEI]W`N=J`L`DY)9&Q())K^,%3(EXGE
M:O`/I0P16SBJ1%C%J\.BEPDZX:$M5F#&:_QBFX>EG55?(:@FAZ<6O\NZN.;'
M?>[S<4B=V6,97!WF85""V_Y>_9O_PGA\;J?;&.)->&@_K)__-P6%7FX67-*A
MS6JIU$UT:-O$KZ)=4\$5MHW2K"Y\VOK>I].?7GIM'C@)8;?B4$*IQK`ZY!$$
M4(9K$AC*(&2(P&<+TX!KGSW&]#$$:J+*,S],MBH^R=UN`Z_!Z;`"]I&!&+28
ML2,N#*?S?RKSL)R1I[U2]FD;W/M*_1@<2#-:6-S5HBW551Z4'E+568_RSK#5
M\_N[]4.O]4[S22T]MPBKDEPUOWJ;:-@-A]6&-L\B7#UN=ZO2^P!8<+]ZY.-&
M@$#+F"81''F;\A"[:BW<@#0AH0P#2B6W$*7EQ111B[&'2]B5!BSR0>R;#8#[
MVV:WRDB?_VO[A#KFY[OUYFVO;K(1T!(LP<6MCL1*)$3&'&R0$Q`Z:8B:M)(1
MTN)Y)Y_PVAVY3,HJ8FB4,B/V]+3]$W,<]?;3XCU[)S7Z8M32IZU8'#$G"941
M)S**''$B#HGE,8=_(V9C]7L^RU?O,>PK6*>F#&_"VYV`60]/IZ40&LS0[S@2
MQ2C2?],:X51O"6L(8?=87NC[>;M]>)Y;XW8TL[ZIT,K:NI.6+U^?!/YVZ-IX
MN]U\05\X7Q+S=@7(E$;8EVAGN,/N8E=UN7K(5`7CW?Z/U0Z/PF[U!YR&]??5
M46%CP_9CKX[S^<\_N!JDX#+O(U/##.\0IGB5_3_$_?@>Q^"_YWS"?*>!H:NI
M)1=UH]M!GG,8(`OC9K_=+=3-1-U'I&7FC.@E,;JZ%+XU^T-N9-&Z/N/963T/
MZ^<9P5Q:Z\(XB0.B0PJW(H#8UG&AB18B`N?,)`RKKMG@0<U:7B9E35L4!^AX
MH19I&-"U8K[Z6E4,S:]_(M+XL`*Q[M=/:Z\SX0_RV:]B%&QF?]+7SAEA6F.?
MBA%P'T1`DCB"3Y&)4BD#J>T__JFY:2B";@(UML35E>=5C$%'3UKCX];<BJHJ
M>$6*6I)[N]E6CT;>TK/(PVTP?^UTC67TI`P7!YR_K#=;+`47R:Q@\U!]EVSK
MV"^K_1_;AQ)S[R+!LWY1I#.UN&M&6&K.:*6M;HF0^1R?K,)5_=8M'N5MW2CM
M^>5:G,B.ERK'89$G'K<&2NLXJ\4+V3<^DW<\N2]WB?X@[K_$89G7DXXG16H_
MQ?>^S_-:![BCY&@1M&X_OPT!&O7=9?MROEP+QIW6-GU6OGC=QF4:&3.N2WQ<
M$MOSC'+U1.GQ6Y^+S()[/UQ1VE&R1#D=.BK*Z#/Q65.86ICV\#\ON>V$6_P`
M7BO8X[LGQ.G-IKS=MU$D]7..S^L]Q#R[[^O[598'0U?XR\:_2\]5;_.G-]#X
M&E/+[TT-R,4>8PR_>-ZO[Y=8H\C4":L7IRZ0LG9:B_[B]DSK@JV(:CUKG<1I
M7V9PP"I_5;C:K![7\_H.0:(X!QE)Q`S<MR20)$@22VP@XB`*&>=(1(*J2M*J
MHCHC1:U<_?BXNH?0LFBIQ(+_NTW[`L8E/GL!<5&MBM]'I$Y9%.^1E'37$G,H
M#L?!;,-B=1'GG,T>O.)CQHRJ\7DSX=P9D_WJ+I/FRY.OWYZV/U;%A-3;]=UG
M;#=<:E[9S\!9=@:#TT*U>Z-+#H"Q=<%*5<\=5KYX8YVNSQMB"TMI+]YR9;0X
MZ4$]KV1U6>YI,:H28]7=^TG_\77FW`P\%P<",ZDO3Y@H\`[$"UR/S3[SK^#5
M[[?/Z_DKBB9*0IE020"?B$@N8N("JXA(8AHZ+@*XZ5G;80F2<>2\`+N/J_W^
MR;?</?_W>O\'O!XK5AE[[>PZHR.$=CB$Y\1M]ZW\YD4XM6_!.WNZ(4<++(QT
MK7Y6%XFZUN_J/PY^2]X1TMH[\VZWU!XA+&]+T[6@-TCL6N6GU;_+[G?=!B[1
M>`OTX)"1I5H)ZB%5^WW+>])NZ*9AI4.KUJOVNC"=G/GZ6V!T$*\A9-AEFQ*6
MZ-RC=\O;NA-[2]<)HA/P!OMTA6/'3ZCP7O;;W8_*QRP1..PQ4<JQ1E@PGM@G
M$+WB->OJ.V,[%I>J'9K7;A9.G+Y[]#UJ'T$I+U$XN#'"JAK%7.U[U_5E1K8X
M<=]DR_9O%3"9<D'B)`&MJ*0D5IJ0&!."`Q=C/VF:I?_R%N6*7CQ^Z=/B@`$)
MOFYW^_5_YN\*[6C]L)`IN:EK_9,RU(3U7#V')AE\SGFA=_JXKFV9->ZCBB41
M(3-$!E809Z*0A(J+R+)0A-QF#U0VV#[."7*^\ZVHQ?Q`1VNA$P<LZWLY5U]I
M"M-IQ#-=;^Y`J]_BB*<PJ)-K/(B7B=EEH6&V_<X/-<-30$_A.P8T[9ESK#\O
M$SS=TE(^EL`U"YAE#RJ1WTWXUOG:M))-["))([)8;_P:FOUN_?FE@,@KJT/V
M8%:-*P(J8Z$44:%`TG8>$ZL"07![E.2ICCFRCI1VQE4BB_/"=/*:?]W"<?*K
M;$%7%7$LIMJ7Z!C+?_S36-I62>PNUV!4VJ\90KY$J)"KS#1RZI?+VJ%58O>R
M_)J#1%/N6".,."M-)UN>M1_>I"WG/F/H:C'(97*V6J$\YK\)^X,-1+;6`'Q&
MC%:9EQ!G=Q39EZB$:Q.Y<[2-BVGSURRRUPV'>;AV5+%&P%W^ZITL1GLZ?6ZY
MN]D&GF\Q/&L:3@E58[Q&70FO^H"KRI^N$;M:>.N4,D>D8A&1C%D2!/!9#OQJ
MIK2T*34GQG5:OWRWF;W\ZF>WXOY'B6(!WL__[BE+`AR:%HIQB/>8$H"_V&?>
M&X:)G[;8/(K^W/;IR;<_9U'D$JLD?O*>5\.]JX)4?5X_@S[:W3UA[N7AZWJS
M?M[O/,O4@JOEOA]*U3J"SLC1M6DUST,LT=G`?DO-SK:_U"0YG1O(MRB"&_)^
M=YC0]86HIZ?G=X\WMM:#XYX\QVJ=,:/(>QK";)GRC2$%"HE;:T[B=$ZH+IN9
M9A7<F20-@T225$:X<3<,21"KF(!Q5U8E`0M<OCV\V4+:9>7`H3*9U8ANR"_%
MH1/.Z\F0#L)T\N**^GV#.*ZY`V.)CAUVTBDJ>1??KH>H_8;WEQ[Z@ZUU3#?V
M!G65J;1SM$3:`$JWJ7!J:_HSQZ9&Q+5$B`06H`]5N]%$+2'7Q+N^M'3II\@V
M.*UZR72"R*HYFQ.!5PS7=_?\Z<_M!!O]FCO7=!(*&BL#ND5S(K4T)'1(\&JU
M=#J(91R)8F4JMRU$5:_+4!(\WT0;@2]_]WF[.W9Y+W@Z%SP-2ZWAQ\=^3HJ2
MP$W->N2PP!U"S76(F(0`:-?3)E`&KXO"3<ZJPLUZD8@#+L4?_\?>DS:W;23[
M/57^#WA:)V57D0Q`'`2LR@>>CM[:DLM6DLU^V0+)$8D-""`X)/']^M?=,SAY
MB*)(F9285"4B"<S1=_?T=(=L'X4NMV8+=2NVP%T\?O-7WD%MG;>NDQ^W==C#
M<W7U>3XAH5+C%5W/V>)I37U6GDMT7<=S\.@S=++8U6&J2QU3VBQ]G;9<MZ=G
MZ'#TC&%G/)MKJN*(Y6D=CM+K]<6;]>+F_1C$BI],IL6Z9!@<(.64I6$<(K5H
M!K;,**J5)V^SDLGNQ<X8*\$ZMX4H0/^>]PWG-U)G01)S97Y3+2;[M/J-_U&:
MAFF8+6P-KI1;KBPI%KPD\PX<XI:I6``Z4Z]K`VM0;QNR6>\H6DLVK%ZGU=9X
MCSV,=\NM:GVJ7>Q]1Z6L><F6O$-&1$B[!L_TBA=V_@A#Q-&%QU/'GP#QEJPJ
M*O9J4)K*^MZ=%Y>#1<;N:FU=-3IUE4#>M5IU2^\,ZJ#^.HK5;"I@'&5M#7=1
MF?V1@-D1.I:.7:DN33]BEYJL#O<NL*(;J[J.;%PK>B!WVHIFJO5N4^L"6S1!
MMFB]=KUI:-U!7VDW`6LB?[%AZ3O`T7;0>B[.^1W4"![1BZMB/HC&9\+8`^)K
M0SQAUM-"HNGW`==NN2OS=DJ376`BEQ<YHZ-!D+*DP=-SP&:WI:`(8IIJ(,3`
M"E'PLPK_4(=?0S6V,G/Z<LMHMP9:7;%:<EWK].5Z6^UB!["N,5"-_J!G"@U-
MN7V&6KD!O[Q:U#ZWBHE0^]MJ4VA&K:FK^@8[W>T!#.Y34W0+]FE8BKI)%[`M
M#V12E)JZK&S`%\^T:4"ZL1T=;W8*)2Q-I6FU#F;3JJD:YAZ/WE1!T2U+V40"
M5E.C*'F;APJQ=4D>*]FZ!0YN7;=4&;:N:[)!S(TMRHG989&/"O@,L&5;U[+J
M@VX3VY"UP=SMMMKUEMF4+<UH:I;9SYA:;C258N[4ZKT]*Q1,W6Q9^X>"*JA?
M;BBMPX.")FN:+.\?"IIH@@I0D`\0"M34</]0T(7XYP'@QT-AG[7A<?>&)F,K
M3,,TC$TLP^V+J6G_:>VN5OQ.*B86MV_IIKG7[>O_P80,GF+^J$***QI)\&L_
MNU>5`B#(%.M#(D^`A8*R0<9$6YBW;/MML=OOU5FD""TL=K!7\E'Q/_OI-'*H
MI1V_!WR_8ZE'GE%1.@MJ>V-1/+;\/<5CG=G_.38U=@7-$=I/@3+O_:UJIKR1
M;[L8'3"L?M=L@GELM*U^79--JVX99K]N6KU6>]"5V[+5RZ//3:48Q=]^R\^0
M-5"`CJ&!%[%%0]\ESL2@I_643KO>-?5.75/Z8#=HEHZ7Y@UP408="_UPA!;F
M5.M-2WUL8D$U"2X[6Q3_>^K-QAPLX+T;Q8;Q*@#*U+8BHH[9,U2K;]0'?1W,
M*6P=WVDWU;K9,CJM;LOL@LF6-8PWJB<8#VWU68EE:ZAL22SD=NG@>2J:]5A:
M>2Z0Z)K5-`O\HZJ&LIW%N1%(U#22UI*WR\MY!I!83;E9$"D;]UG?$B2:<,[Q
MUMJAPD1OX6EYD7,TR]HR4+4)3'3AI.JRJA\J2"P%N*<`$J,%(^P/)$:JIW59
M5&_80O.LJ+Z7)GB4J^]]`:LHW%V91@25;.AD.&IR2]\*5!O5'"0EC:4:Y')V
M]2YV_P1X[KSP91&BH*.W\Y0WJ^(HQ+9:N>"RF_T?)(V:LJ;O$:*J,"0-U7@M
M-/H<$,63JU9K;S2Z;]V2ZA+=;+7V:'*T4@'9M!ZM7O-8:?;8+2L<&_><:.3Z
M41*R:X!!Q_5'?ST:(%J:MU8-&\C]7KMGZ/6^C$E[:J=7-WOF`!S:5JL)$K"C
M]L!%0RWYDQN?CYW;GR;Q.:P:/P52%,]=]LO9Y_;7CQ>7]<[5]?75YP^2'-R?
M2^*[ZZLO'R3%#.[/\$5\ZP96GKXXN+J\K@_:GR\^_?E!NG9F+)(NV9WTU9_9
MWID4`7UA.#I]<XA_7/HQ^\F>!>?_N&_+YXJ<_RW^PLV>2P+RDNV-I1+X8>WM
M2<AX"5P<]>=A.O[/N+3L0U#8Z?_4Z]+],'1K0W\\E^KU;8!@X!?7_7]=UR\N
M>_W+ZP^2]N-98:#MX/('DZ;V+9,8Y4Z.82S'BWWIU@9N2U#$%+8NV=G&X2G,
M>,,,2#>%5/8C#()@&Q7)40I%[>H:,$M6NEH\-YMAX@)6?$U!7)CISHFGV7J"
MJ1W.[!%+8DQRI=>'#F!T-/5\UY_,<;#`]AP6-6`4JO4D`;_0M>723G+NB&K2
M':P^)!@XL0O./@`@I&1K!H.D^[MA#!Y-@IL0`9U>%ZU)L_2:2N&[,,TUK<$`
M$?;XS1^#GW'9Z</2C4]+E``UR8T]PBQF>B!*@L"=2_X-#.$GH12$?A`Z++;#
MN?2E_W'.+W[#:X`X@%V$+_T,8X7,F0V3,*+-X>CP?@I\&K@$_ZSR2$-JNR[,
M1G.-*A1?0`<":L*O5L/J1GA'@6Z%2L,Y7Z8=QO`KQYN?Q`@`!T3]#2`,U\-3
M2@%W`?,P;-60KFA"O,P%LP<LA"7/D+`(;_@Z#PE6I^84"-ARO)7[@[<93P:N
MP1\C%L0PJAV+Z1#R`%4LWB.0!(A?MOUL3[B"XKPX#JYZ@N4EI<AWQXWU@F!S
MD=?<"[M?`.F/1GXX1KS!2,1<"ULNX)N8(]?6*3<@75=>`<C[5/DJ%#K71@CC
M/99(>N<@&)$>(G@N>O_A"5"BS7Z[^'<_!5(1;+)0%#A0+MBKXU,UA'2.SM77
M7O]KO7OUZ5/[RS<8E?851.Q,`M)VH\#&#.A?SF3^.;#'X_3SG3..I[^<@0'^
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M3B\&X)DT:.Y)&*`_^EW9_94"73T!_?F!WCP@Q8;&.BCA15-]F27?60CLQ*$T
MG`#,?'`"_M'M]ON#P=GR]<?^<K4HI/*G_@"\/X7-*OY@';YZ8E2LC471_@TN
M]<B6VIT#D,1KQWSL[CY?_=Z^O+[XY\*TV]-IE&38^;W_]?JBV_Y4;W^Z^'CY
M0<*<)M?QV+GTY>K;Q?7%%7P7XA5DYQ:^RUS8ALFXBWK]F=8%(RY0^Y-<_'>7
M_[S^6E<4\SWZY##4ZP3#C7//QO6Q3R&DD3\;.AX/5`2A/PGMF93"R7I_@.+]
ML;M]^^CY4A$>XHW+)\ZNR'I-EI7'KV&);[#]*A8B^8?IL1X7:IN`6<4X8?;E
M85:WC@^KFT4>OI\]]=4?3=E+,Z.^]#^VO_WY[6`LAA00_?-UE@.>1WR^^-KM
M?VT?T\I?@%A[PL0[-4J:-5/3CT_&G5"\.8K-FFHV3RA^P2ANU13M",W/JJ%R
M^*&@CGT?,\P5^979;CP=V>&+,V0Z[7])IJY+[WYE,S^88BGGE^#['PBG*G*M
MJ9O'QZHG%&^.XEI+/JG;EXQAH]94CY"'#STNT)Y-F%>3+KS1`_F!QT>XERQQ
M[2BVMQGAY&0?N[S`N+]\?/+BA.''8%@]15%>.(:/D8>/T<6>L[#@7\,*/GWJ
MOC2#H-/^4U/JAJXKTKOVS/D+T^?!\IG:+CMYVSMC6JW64EK'Q[0G#&_N;.NU
MIJ6>4/R"4=RL6:TCS)HY>&_[YF8^L^]?IK]]]1D>/:[3^(,0&'OCFJ<N9)<"
MI7B%?2>B^[O+FF-@R0/1)GA4>H0Y72<,/\)>,)M'B.'C\]2IQLKA6@XG!MK>
MI]*,(SS?.J%XXV68X#6?XM4O&<-ZS32UX\/P@A8L3BKJF12JESQ=`907MDO5
M\NB1JQI<W#^E^^9++Y\NF>:QRG??<VX)XQ/L3K#;*^P./3HG*NO5%NM'P5I*
M%:1.!OA+N6NFZ&JM:1ZAZWI"[8/VMEPS6Z>DT!>(656N*<TC/&,^&=H/&A\J
M&!]C/QFZ[!DMGNTG/3!S\02]$_162)MRS:!"42#^*'Z[QNHNU3G]TN[U+BX_
M/GN)V';$:PXOK3LHX=%B;6W%6%Y3-BV9^^:'O&!NX,=88MEVI9N$RAR7:B`7
MRQ+GQ9+A_1B[6&-!8#L(0O_>P8K'[EQZJZAR0\5'75A`K5"1VI[Y"8T:^C-<
MZIO%>M+\MAM=$N=9>6,6C4)G"*L<PBKN&A)6RA4=S+`&+HZQO$0T%6_&<NHP
M-:X]VU1ER#<_\'-T_C*^]#H+\[P+P+W#8M[NG$#"NU$A3.Q(\FS7OV<3GY?V
M/E4RPI=75C(J0+(*QZRVD30.DTFE)+:H@(1URED4,"P!#@Q5HPV/)1BX6J$]
M9),$]NV'<PD]\YAS)9"U%"0AME-,Z[@'+D/ZCGP7.70XEPH%QIY2&;MLNJUH
M#H`#K9;K3Y.U<ME@W-*6=46A._S#X;)VH?Z:DT&G_.B'$O4?`<&_RWG9O[=1
M\+VO2:LIML3Y\'K*^[Q:_I'M/6?99:7'UH`AW[A5H8;M&.=!PMY/5PE0GM]8
M$)/]``,U9=FB0O*BRP3O,6$OMH[@RKG,%4A*A6^`B(!:;'@:38JRB"%22;`Y
MA=1.)DD4H[FB8JWZA#I!W$V=T137`5CP4%"5WI7N_-`=WSECWBS`3;"_,KX<
ML#!@<6*[:6.'>7W(;&P@6Q.=&H9\)V3TI9OB4W+S([!CWCPA*Y(/$&"N"[(W
MP58(H0]SQ'.D`2%[:]+,#O]B<4VP`U"G^TKUWTGWKZYBV"B1L!.11O>]R$%*
M1*O:!K*A;A=HP$:1/W+(`B4^>T1+%OK6B<A@6YR@:F.L;.N"?9(BZEV%K[Y.
ME")L0`2<2'HCD@YLAT2Z[55;[W`O]:W2U!N%)DZ9.YC)>N&F4;\6]+IN0"0#
M\?^=@(>*`OI&*"@B6O$6MBY)7-+.6><3F_K3K/2*96PXU%[_C+:NU1#LCVP`
MZK>3]<Z&#6IR0T[=7%KDVY9>^`8F7.)]EKW-UTEI)TY;SVD;^7_<X0,B@C$>
MY_"1H98%0>AUC*SLTYK=4TCL"GDR,VASME:,E*U1L/SF.0B+;S%P720-?)]#
MJ0?*$47#>.9X#D*'^^Z#7OL]CVBA;'JE!,I;GV$T(61V+*2ZY`>.[XSKCC=.
M1KSU>A0[@8#;U47W/8IR>YRX*.YB1X@[,FE&4U`1SJ@F>;Y7I^9DV)',\1K2
ME;=$+EL"?R2ZBVZ$YR<>SDW=P@`Y0$H7'P\&'QO<N4&O"8DR=ZN'(5*C!YY3
MJ@G["?H=H%F!<GWOO30%?ATRYJ7N$0I.<D(PJ-I.XJD?.A%'`W!Z:80N&'M.
M%!&&^H"@W6)VZO,FA5,;60J>L<<,]'?,4FN4H9)S[7N"V+OH/=H0X-"%U$>4
MJWA<+O!<?D/&.H\$_Z%CYWOK&1ST]AVC*]M%U6U+;]6B+D:J`X<>7#]R!5-+
M!0/191*K/6!II#W4G*HCK6C<3J%G<L/F:A3[\`@]4(E=+]LXFAABZXB6URE]
MV#T2=N)$4R)U?J:1&5(^^/033IEDHP$N"91O6T5S+,7P#"B2!T7!5JT$)0`]
MER#D9P(_JF3?Q"Q\U98)?IWJQ2!PG1$'-%*U/<(VC4#5-]3+\M:!1X6T`2HN
M,3:>^105<\ZJ"RP53\$W7HJZ&@F8E!=+@3GLDYC[#0@W"33\3,I9J7O^R;&'
MCNO$\[+!3;P9D,PKR(.%5J'Y2+US%$$\6M0%B8:9@318QW91C4G?IHR!8QUG
M6DP23H5ZC!858!%/"!$^3OQBQ-'V\,C$-$S]=^*$E=@D4)1HC"K9&$[TH[@^
M2U4S**\A]DBUA<?(`F?,9@[VPZ4FN5&<C$5C7(Q9OEJA@\U=,?9:-$K(7P?#
M`YD\M3@>LB11`O%`&,D@1)P("TLAVB3`V\3M7!G0(;0'K,L[S)(M\CKA+^3H
M;XUO#9#H%9/[#J0R^I=`^60:@LCG\9#XCF@?.TW9$P"N[W!W5$*I"H.HZH^(
M0QR9X9D^<@!O[^MXHX1.5BKZ6+PK10D(?62EHOCAS!(EP_^"7[S,Q+,GDY!-
M$,\C.P!B\.99?'75A$`](-S1/^:M=&^9>(A(!S<<\T".,%-3:J+8%U$1F72>
M#R/AB1(,EZ8X+!F12#,?$S:P&!Z2QF!;$F56``,$2PVC8Z#^9#*5[)(-BS_#
M0SLZU/U>NN</EE);Q9I/`W!KPF^E8!L=[(ADCR3P17C1":.X$/PFOC]RMG^*
M7GNKR!4`"FM+,'PJ+<L`Y`&K$@B+XH.BH%7$E,;EN%DR\K)QT2*;V?\%@[/L
M$M,J@,_">4/Z@P=N;3?RUT1OJZ'9\CY<._%@B<N2A<JI0<=,+'L.6:X/4E9"
ME'R0M5DIU42O:G@>Q2G)8X?Q\UNNQQ=,^2A?F>UY>*J;'2?#$$4#X)6B]G2,
MNYRL455'^]6CYGZRE_)N1ZN3E@K-@_8>`'VST/7G>6*NQYND,V##,+%#-,85
MRVJMR='!?!0ON;%'<1)2CBT9T$$``C7+WDF#\$07M54Y-_3KBFP;&"%-GX')
MP>6*P>-:D2M3T)@8NL/O0X?%?#=`=G.7LQBF"X>@?<%&B_)H3KX;MC);`43U
M$?:^$N?0A>BW`#F[QPU&A+T,S.@S>12W]P,"%X74LA@3S]SB[^/Q`+DG>+<(
MP5Z"H>OFP1P1P\ASNRL(6HZ>&_(\CA#B0NX`C6=!FMR!*+%-37+`(?/F->X/
MDJU`B3EU!!D8%.C%V9'#'3ZP$SW&_;B<K\H'&`*G+'<>UR"VBM9B<H2=.S.(
MQ[>JLB2KHK%1@@.,1*<UXS2S,3W,0&>TG,*O-Y3,6"Y9P)1JE`F60C8'NP^$
M8YY%=S-GM;`]1:\).QI0XOCC[)EL(#3SLE@;QM?`_P=A!.`?_55/`GASI<##
M8!M`N62T'R'9'J/O7M99V#!\F<Z*?=>M5]!73C$E5EK,"R7GL2C6D*,>$%PX
M2L2C+UQ.<F+",)9TA`T(47T(?5$$:DP;>PBLG.5\"IZA4PP<#T(-O'`GFN+C
MF,B%JBD"WO7&"%#!;AEK@:88T1@@&BGTFMD&J6#\C5!&ZV'AC.01JI?%Q94E
M"-_3VG0RE$?E3*N%9*QFL_`$QHRYP,?P<)W[?XN.(1)(P`]W)'LT=4`:IA.F
M%DX9J"&SQX#4**K1C;=Q:H_@BH3#0`2879(J7GY"P(R!*&X90!>FP`0?Y\:A
M(\Z_$QL=6X>[H<N4<"U5Y"E+A*S@05-^.OSXO[!<1!Z=/@G($NM0=`1/2A'$
M.=CPG!]D:YANA/)&O7EZ#0R/V<(HC>*NL0V.D)TH[6GN\TPT0)-#]]\*B"A(
MFUQ+"0!S$:<V<CV[PA)#3D"7DJW@TR(K4.R7QSD3#%@CS0HXH\JVT6;$Z/N3
M?-+G">/:0%QS?KR+,F-)3";)A$6^?V2C,>,@2U-\X(FY-':023P_EF9XUDKW
M^D*'0).>1I,=(RP/(M%\@FQV7`F+I_Z8R[K<#,\S#!+DU#+3Y_D&$08;4R,*
MV`9>0/ZEUU-QN>K=E(+*-KQB2"(7LB0:EG):)B^X)U`&'8@JU+DT&K-#=RX2
M&C@Y)@`38F-[1&%37%H^2`C^WX2&H6`J9DSP+0'44$N049@*`;SN@*^#XAW1
M)5"14!1E.\#0+@_($9Q`;/DC;HP1!\0DK5NYM*;`2T$,B4AKQ,_T"]$[?BC#
MF;Z\C@RQF]G!*ZW@]+RI<)55;K36Y3`OL7H+AS0E3/,#R12>@":\<L)IKT!B
MG&YI#"?*$7RD)F'ELL^=(-DQOT]#Y%)41P^KP74VW1%:^HN!L6-9.:)ST2(1
M."WDYMB`_CRCGU,"EQDH"19X'VT]Q6P84N;8_L&6Z02*UX)MQ6,90#HVVK6<
M=**IG[AXMSL;&RVD7)?._#'(T5$AF,3/J)V(!..)C)YWY?7462\HHN(=?7OH
MW[)*>ME=0:\(-58BFT6-PL#`%ZB.6'DJ?OY1(C*6G>/SDZM"PAH51!":HZB:
M\,@ZD^UE+9F2&(KVE#]*5L4FE1W6J*VRTH)QWFH-8T%K54XR$0H9SRS3:!0N
M7!?)6:/1R->LZ#1NBQ'O59"],WLV/4[9Y5G*JO;+JT]61#?CG_-FQCLYC/@>
MEX/U)4$<+S\56'Y1L9:&.H58>OA\HE3Z(X>S]*TMAEC\J>N'05KBY%WL3YBH
M3UBZNLY?>\_S?\4*LY,]%#'.Q.,/.S.Z[X$T&MH!:A'443D&I3:%844>6D*Q
M>K3<"C9*S$93#W/[YDM#(5Q$%".GRRZ<<7`*3R@_1L>T*`&\-S^("&GYMB<'
M*3XC8$4@=2B!83'F_^:'4O`L,Z\:Z=NK+JR"5,/419*7!83G=2AJ*ZZIHE@!
MDH`9KLN`P*F$EXPSB>0KS$%%+'#),0(C$LB5_&Z,3SE<;AZV&URA@=32*%KU
MM8?N+BZ]ETAA*\II:582;997ZBD*_IRB\3"*A[]6A+Z*@V6!PXB6?(=WWBGF
M5,FYB):.*-(N^+-`<,"LJ=;-,SA6)FF44S0R[N6F``^A4`I<Q6$".H//10Y.
M4U72ND=1*JGQ3`?!D3DK`/:L#E%ZX2CP(X<\S]@/ZI1RSE<@$DGY^=J7*>8!
MJE+@W)*CF_*+%)/E">M/6]US?3L3T0S@1$'>H$,IDS+UJRDN$8JR.P'I_-10
M!G9A8SJ[`MT,D&""JZ<@D>X=[H+3(4M`=M`MG:W:7.?^/WM7^MRVD>R_NTK_
M`YXWJ;*K``4`P2O9I(J7$K\XMLMV-I7]X@*)H80U"/#AD,S]ZU]WSPPN'I(H
M7J"0PY9(8(Z>GIZ>/GY-S6=QM3<!U]\-$]I8@`S":$,E\("#RQD[G,YRHJ4)
MHGF&+PE*'C&K=$Z<F3EO..N858)*H1K3R=C[4OD59L!MM2BV28/'`*,IS(1B
M2H45)<>T4WF-%DQ#_4O-4.A`A9Y1U8N2<13C-?26">=A7A%RBA8EV:\;T@8-
M6;R0(T$J*H2%L5&Q>Z#%P@G0_"5M3WD"+.F#&]QUE0QFX26ZH=&T:-AZU2M?
M\SI[K$*7H5/7#T4Z&[=_ZWQ#"\07CD<5Q?PNYV<7:JGMP?<YQ3`]_\<+KF!R
MHR2Y"?D;J%0Z+K<=1HD;,W%F%/7)Z\2F^)6\-?05O\$MCRO?\6ON2%J+=8-L
M1SQ'S]&OZ.DH1@V\=6>46[Q6!:7W7N<T0I1).9UP#?D*:F(V16%.+X7("`(+
M8^)]X1S0P*L/@;<`!0UF(SY\3>'C-&5,],RM7I':?!UDSCF9XM+;``Q!'EKY
M$:(EK]R=<!OQ#FFU"G15/F$WE'.*,RH.`7ZBO"YNP?X-;^FW<$8P5>EY]MB>
MV;S!*_'8:Z$)2"[,[IVH>:*^0:Z%)7^F\HKC`<4W-A?H290:P5<,5EQ4I/*$
M.O><<]D=M,*`R84B-PT96XK1X4A"?(3D:ELB&-V\%HH<DQLZI",O,N;D*#"R
M>>""B?23KR`_JBPKVT,O\^K;RT,X54:M(#64[YJK$C+7@7V00,%OX1!-0E]P
M""Y_RO[2BYKQNR1WR7#,YTN[-4<_R=[2(8O;'!0G$`"PAZ63ABF]U!Z-#G=T
MY"TA1JZXUDX9:A!HG<1%!HUHDGA"XJ2:+06;TKNW-HP*KSOHP@4]@LQ0/-]2
M)"CEUJTP#W+)BDP6F@^_*DJS$O</BJ_0&^D'Y'_SW5DRPP#L"2EN>#]S>9X5
M*+_3$OT>W#=L&33F9YZIK!TUKZ04??597#9H5;-R6E:!`\1==0,'K/4>K)G$
MB5\:/XM-E[,8;-QUJ&&2%!,'<Z8^F@2A`#=$?KDA2]TMG6Y,$KZ03#6V_:]A
M,H\G"U3]74QTA<<G"WZIF,BK!FK0S.9AH,&=C\_*&TI>ZO)D7]OU^%FQ[L0*
MTQW,!1%/%U`%>^$XZ%K%+37"B9B)/HIL((6XX'-G&)&JH@47N$6T?R$K6/"8
M.^@"]YC]%5[%:[7<<9G"D0IPKB5,)BR*!!GE'(D$=+=BZTX%F=J0H2[`%IP'
M_"0I"I#5@OK5&HGT6N[Q&6:_%X(,[F$8+E=AS8#4</N;,+)H/S3R0'E/&S(U
M5.4.XY5',4G$.QZJ%7"N(<`\?B]1''<*VA)I@8GK21.70I9]E,?B8F_'<D=+
MVG.F$#(9#]@3W]<[M_";W4OS'A-_T=+T0`-_AE=AZH^V[^_*8WT`H_ZB8$Z&
M0;U].[C7KO^W96BM9M-07O5F[E=@1;P@W-@>>UT="W]JY=+;PB5?BM&<!-HJ
M8[ZPZVK`A[-`QKV5#?A%JB)-E5?TZ>N\!1XU;M(9;,];:!BFQW4E&`$2$_59
M3MTTN:]DBRZ:GS<[&83@\-DX\8`2!&?.0T92^'.ADJ9K*LQ%EV)"*VSA,YZ<
M+,+D4B/8_6B-E)%,L7Q(OLQGC7(1QAN$<<[PF4-WGKIH$\,W13YT:D"5SM.<
M+V^*JC4+2\8PI<2SHH&IZ_/D#9PR'*R3K_:U)*&#L%CN.(G)`/<F,VR1;8^<
M^-P28)5BUE<'<6)>Z++,HM`EO2V=1<NA8A3UONK5`K0\Q>KHI.SR=E?:%W.(
M(JDADL=.4;!4!A^0QCO%`@V#SN?55D\X&@6G2$]P`5L)]E4R%E81F"`#%9S>
M!N8D:RY?P`+(`33Q:VC/-!\3VO%*.O=9`OJ,2Z`U/2"^)V(\"TF2\-W_)C#)
M7+P-Q=42:5+"`*_QX<K;>LC<V3@)H]1@C\9;F3N_<>HG?NH^O%2`+2+38+;"
MMU*XO"[+G'M<'BN<*!<OUKA1'N-$25TN.3?*HYTH9'DIR()MXN9HJZS+'X%[
M1V==`DE.*[EX\;`$$IE:@&I)IZ26<*?)VE"Z@P;2[<D$_GY^$]\$Z&#.^[TW
MJRLPA*O@UGVFQO`C96Y*+`)^0>5Q![9?UI-6+Z?R*OO\M:HX@K=7@-\U=-R3
M>JN8R9EKM9`\MBJ=<U4RY[+Y^.+%ZOB&$AIZZ6K/2+?)\5Y5.&Z-Z9.R0Y;"
M-GC(H"0GZ9JN!"T6<9'9@A13`],CM*@B+@5J"//G&GL^:!@$5"%S9RM*\/>^
M\H>]R`$[2N3//#^7;BB\4&D6#S-84K-[Q0WW#C3F,.9NZW!F*[U?!7TK2K0_
M906#]9*EI)"#"MB];#=S,?<Y>WPYG95.3"\C<C[+0.J7UH-1M1\1;-^Y[#Y`
M:4A5!CSY-R@-?Y"%:H7&<)\A8R-A*QJ)?X\>+)3>[F7*(ASP=871'E7,"Y$Y
MMT[$907%UNC%V=56W/O*.O`&7)]4VT5<5Q:G*C$T7\']3$9E.T:7T"+3W_F,
M/#QDJPE!TIM.%S/[VP/C-M[_`5T="(QD)Z:ZXR&#R,N_;JTVWST"%D2:&N1:
M\6B'5^+7U^4<;)&([\CGN60LJ9A%3WJQY,Z.-<V\=0UE6HZ)*K3Y7\W9->84
M0S,.>TUPZ/*VFW/F-521.B-I;U,MRZ_,0?ISM6;"DICTR@$BBOJ+-#@E"V*T
ME=O`2WS2)>'`%(HJMT9Z@0#=K!X9,T(Y'+M8FC-+>9X^#+@(T8KXT10_B-"1
M(5D2(PR93-#T=;.8LS!"+8ALJT@R>R+<ASG+HV_+D$NIFB`0Y)ACYDR9!OH(
MPS)3%#,>*E,[1L-9.N0WJ%2)A,UL?5.?GLQOV6)?OV-?8:5/W$;W%]<0N3.*
M:ZN9M9;[,*6!M)`ZO*RD99(,WU/+BR\O=1+AJWRU6]$&/9#VGR$*Y'5&J6CG
MXD-I+C.0=+A`W[4NV\48[9(FO")X.4O.S:)(UZO93\*9WKNK[3VZ(M8=_R?K
M*!MF3GE<`FYCW+0(6&KD+LB2R?,E>',E=U.G`X]BH;"":8+6=-N/ICP0BC>0
MF@7*>`$4C1%%JR]N:U`:<@!;;IC)Q]5H1K0KH@@5:>1UV7)4##TD\N0.:C&!
MJ'SQ3.WJ<+G(NV<P`&+)UT-:/XQ'..:R;,]L]W-O;3Y*.V<XY_(BOQ=G:R.T
M+UX\:'=9)RX_"W<[B0/RD"NYK?@)I?(1=&Z.7_..W<))MY:SE3\'_3*LW-I+
M9IXEFHV<FZ"8P'+Q8@L?2\G#0@KRHWTL10^+N)^N\+$4\E(*RFB*!H/D(T.'
MO[A4?@ONH*]05:XIDX&2.Q"6&KVDY%TK9?"D(6#9;3K-?DDS*BF8;W6];QZL
MA<H?$C,%<A#(26-1'@%5$OB&UG<J"")$7U3`[MAT#^7_T4>.>XL?_O.')-*N
M;7O^XR`;WBWK9>&W0S>:>$$$VOQG]BWN>\'DZR_0B/+/[,4T2+'G.P.)S3N!
M15CQ+H6AP2\?V?3GERSPOGP8&7J[T=8TS;`,7?M=UPW]RZ?/PR^-5O,+;@7#
M;!A?])>*Z_S\TG6^-$W+U%N-+P-K<&5V&P/-;`PZFM4?FEK':!C:L-TRC=ZH
MHU\U1E_PQ5]POF*ZQSQJWP%[9!N]DRNUG-IDK)^$F530DUBZ0-&'GLO_HVG*
MMW'HJ>/`62B:MN61O7,UXR.'9H>AC'BF8>54#J$(\PA',M!BC*-0^T5LL7`1
M"+AWQ'-:(9<H10KE$C\+I)A,90>L_0\86NL+]3;#S,&B*+)@`M=.+UZLOKNO
MDSD(.L4;$`F?F8N7PFBF&)O)=1$,,,#FKH/`B3!0TI'Q_ODR*^@!PQ#&K";$
M7&3UHWRSH[(-N7%I+<>)7%!*O+$B@(3PRLW+[G)8B@R.X.$N]R=RR0LZMLCA
M[_(U_"CM5<%R`/RR#1<,BLCF,`,9,$'>&.W*-:6C*CUI1%AP%BV>+NQXL4'Y
MY"83.@WXW10NI5&`2;>+S#)^TC>)#R)ZO2C**K?/11B5CW=)#H""H3>4T(EY
MY80N)\UZW*B'V0(!5BQQP]4Q_!>%$D<4CPTZ>AGA='V86BE&FG"7'A(2(O6/
M[%P1I=C*CIW6BAU60K0C99&\.7P6HE*`*^.SFB?-FV_9-2WF'W8,RU8]IKPB
M(P0\P4/Z\*?4U>WZMY@+0`OAV7>8`H;:=3AVXU023SS;G44H:.%I%"=2B`EH
M1)$_@$]B'"5/+>.Q<2F"-+^7$H:TFM.G587-YEZP2-F5,^F,4UI-V0?!=E.[
M28"V/+1R+N\N`7+V51BTLZK7GJ@8YC)>VQ"3A2A);`P]"I494P4HR2=]>I%5
M9TS+S&3U;0OR70&5-1+&P=7B5_E$I6^R<?';+J^VA@W'BL=RD$HBK=)V_I-$
M:8$S.F.I/W<V1SE`OM:(Q7`/(R+Z[#J`ZX18NO_`Y8X,#;REK!@JXGLD/.P4
M9^)@V"S.Q$->I_H;$?/4W)*X/AG(TK+D/)OC@J!^8V$.HPL@H3M@@E1(A7,N
ME;>NY!BDM^O?4%(`1;HG_CS$K`P$*V64K(2F[<2?VK<!8<V)0?($=DS)F,`J
M\"Q&?%\D)TT$WC`)K5#`/7%TO#FLBBLO0],\4A3,&0W`R-6"DA*%CF?^4^%,
MJ8[P1885$L#&F8H%<T3#XM0+[B*1!@MJ'-S9%R<MTZZ"D+G7N*,RG:MR@@WV
MNLS1<46N9VKUF/()BE(R+HM6H$R%^30I_C8+\3#&'!6/Y*&P.I%#FQB!N`"W
MN3`^H[)+\E%6HQPOTKZO42?TN6P35S'BG%)>IIO++B2U/@9Y@]DSN(UBGO!)
MNX0V75;(4NJ)4KU'91OSLLC23?BQ+AGY!(S"2?/C&]#!9WX>NNU]IBU7CC$S
M"W-!!T1YP55#*5K0R9,'ZI+F.PFDB*^+RUFN?I%;)%;A8D&E;66*0+D*N))/
M00Q(DJYO"80U]$:7F@67\W.&1SFU@JI#[GLLDY9+M16B-!<I0D<EO[.*Q(K4
MZ$NX'0+4+X\-3\=XSA9&^L?:X<*H`HJKS*B(MR%Y;.-AD0/6X+7JR`$]Q8`A
MJ?K@]N2'J=S5^9OW?2,0Y]=JVI:BD1`9*72OK]&]3T/&9#\:;6;_1AF4Z2T8
ME-5G$QMSU6GWIS7Q,D4$N\^HOFD$.``DD*W(+$)JA$=3B;OL\DV6FSMY$;_\
M;-*[YQK5YUU0TL!H@4BQ2BN^9F"S^9:#E6:#0GW6Z%ZD)5S6DW>FE41@Q!7>
M0<F!D\5#9H&0U1.0N4JT?%^MLSEE7JO4UE&$.DQ]YQ<EV++U0!H81["TL?.1
MN*GK2U8?PS>0QQUB0"ZH,]E'H^7"FHL3-=UY7(6_0?L7AG%XZ-LK3$:`-6`2
M+PAY2CS+9T'G-@W=@KBG)KUSY.(F4T].+D(BN\:\(C(*HY4LWI.=/!PN!51\
M/+9D5:'2#2ZK`20(3[5.Q%UDY7-NE*V)A"_((\5D580$-:H8?IGC9'[<B\J3
MW/XJ[*4NA7%%*4#&X,T?_WY3-2S7ZJ+09@Z[.RX+/GYXPZ'00S;'='<_SEDT
M[@A&1E8>I.B`7!!>IHZ!+FY+=PL<1BX(L'!1$%W2]G7Q0B:`\FT@I`->20M(
ML6E$+N(CV641.4^\64!V#SN*A'L2=U`:`,^3+3OI+-,OQ,WD_LG>,U7!!)LG
M6YRJ[6>S+>@?:<HI!Z[@QI@R&#3"66!<U@TK&#*GXJ*^<3H$7E%8HW2P9*-W
MF)!(W)K`=9JR@Y7TTB6M;(4>F!?4#ILS#NDI]&#N@E45W\;32)5(GP6MC;KG
M.F>5M!2N$U+.PAU5;>"T?B-*;DBS?AAE?/R)`3F)4I536PH!-1<O,N5$"GV\
MO@C<)N!,EVX3''/#8>.8_U*\Z\F`#">[C=RO/B1Y>@?\7L()/D\)SF/D4D]2
M(2DUB]27.$;2#E'61])'<PR>#QLI:O49%G2VR$J/K)2*T6TT^)@XALE)<_D0
M+J&3F`KF.,I[M,00TE!91:\<`Z.V@A(VYJO.UVL(7'"'DAO^XB9?C*EA!">#
M.,/B!@:,P&<N$GS>^)-<@J.,J.PO\"Y-[)UQ,7[A"))&F*H(W!'SRI,!)RY\
M*C!\TM^Y9X!1M$]JAJ:\.&[2SPX$48@836L3'G4SD28UO%5S]P$<4+SN-)>T
M]MR>H)%60!;+FV[99/$(@P6UDC-9T(E<%)8N!O=X/'+[)]C7(F8H$P6PY9*0
M;K9SN.U.W/PTZ#TB)?LVI_@8`8Z!&(N\YG:4(;]0]0T%#V)A'<R5?I+X]^B!
M0[-HE,PR<Y44&:G-G-H"NG/3`.(RP<,^B:*IT/YQ,"$'182VN-%+OL3O7BD8
M529Z8HYVJW+/"<TNRE8:91*28)'SF*@<W\K#L"YN:5F9$+[B>+ZC]1(F"ND"
M4)4<"B`I*JXXW;\SU*:NJ[JNXW9!<4<5@3@\"`NO62B0HV#Q(S?.I[1ESC)H
M1%_72'80E%[D00NB<VYU*[Z).1CKWTZIBFA76+$,V$*TPDU2!?;*QZWY?/'H
MV]2/)8/9[%BXWFA9.9@GK7G$<;K(D`0R93:G-7;<:)Z(:#2JI8:@86764G&_
M9IM,,DR*W,=C3'BBB70@T6')SR5N*9+#('@,&9^/FWV-/>WB1?%*O11%'K$R
M[Q3M=EO'R3TFW*T8*C>R0_2N11]8^`FT`/:!EF[WL7&ZT3#[HT%':YB=CF:U
MS;[6-9I]36\-^OK`Z':ONJV3BHU+3^MW<%:]12'R@>0&4:ER1W/?CMP)Q9VB
M/!2;-KJQN:4]`YTLULRZ8P@9QQS-%MLG]8!Q']`,HXNP$50<8]P&I+8Y60@\
M]V@BZ`]=IM!:>\4K`ER\6/XRM6#D[+$;@KCXD2(GI=BWMNM)/$@YNAB8^(;@
MR,DJ#@<J(M`$\HY'5\E<(XC<A)3B&$9>@@-(.\AH)O/X(U`W!03>!<^YAQ,"
MU!`*EI'OB=LO[S%-U">\P6\4KGZ1"]3U%KQ?7JDLE<0B-IH.&N[$P4,E=C7Y
M,"HJTRGCGN;E$5\JPFN4!9QE\68/Z%_$7C!'1BRG*R\5/5Y"(L\&1'L)FRA)
M$#+N;I>LA4)7,-?Z=Q'CU<@RO''\N=08?N$U.KF`<*>8A!&50O658NB=:&%%
M[-WF/;TLB>^1ID71^PDM#XG'WD_7!3JC.'\7^),U7W_&S`F15_89&7_W8KMO
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MR?\N3O<#=P(^:4Y[6K'E1;KGS#!*Y^>]="N>*'`B;.2,U/%?(E9!\SD)RJ6\
M;FZ<$*HWNV7FTY]PX[E-V#RXN+I?M0(=Z!IF$(`2](_!8#2ZNEHCP>)@OG+C
M;Z<DOQU=@4ILL%E)2=;@(]E-#P.U_\U\-K&57G^_^WO%NW^\_U?OW><WO^,3
M.8=]7J@UO_])*3OP)9T^_T$="8>\\NK=[Y\_:H;1>2UN<CMM_N(%+[^A.0%/
M61E+'`A9%4[VWWV]-]K)H7UW[U-RGU!1`WK'T)LJW/?N?W/5`;H;]6C_DS1A
MCD;KO.?8[.YQ?KN1>*<BWZC$^\'%6JX`^!9B9W6XD11I66S4SIH^O3O2"N%E
MJAVK^:!WC[VU=SGKCMKHF,]MUFW5L#:+\"=/^MSUNJ5RUP>7@;),[:NL@.[^
MU*)=;CE=-9N=Y[;E#+6M/SLYTU+-QIY7^KRT*5Y(-X-C/:0\R1?F?5::#U[:
M].>V-6'2C6>G[1U@I<]?[UDN('8$U>>>,F\GSH>6VC;:SVWS&4W5[#:>VZQ-
MM=O>;!$\$9%S*@*F@'1^<,FR&N7^M'6@>SAGBQ:6V1A?S4$5[FFHE=K9:$39
M;"<^PTF;:L?<\Z3/78/*T+8/*=BJP%R@(5BM9V<9ZH!:]`QO8IV.=7PY4BRL
M<\2=<X`^RA).!(E0J%(6(?)-1(BL6.3'BJN]=OAX)JSI5]/O</0[KTO9VP?&
MZF^GUASIN<V1(1NTE(9J=HZC^>]W9AU=[;2/XZ3:[\0:NFJ8>S:XU>K&XZ5O
M`Z2O$R1CCQU*WF_?XVD>F#4%:PJNDT$_4*Y:_H.E-,H]9D:N2\$<4?(LM(+`
M(S/VV?[VT8[91X8EI3"&!9O:4XZE-;2N.GUCH%UU1R/-ZG:'6K]K];3V8-!M
M]#MZ?S32GYX:OZ\:4D@M);:_7;S(L#3*-05</Z'DX`SQ&@&(4X1"`AN4&*X(
M+9Q(?"\$592)O(@DFF#=7P1>$)TJ(0>,41K-[P64,1\*3P@O9&@NY6=NEZN?
M/SC-,I7UQR=K/CW[LF,],/D2*_#TL6:H0IR,[E*G6(AG37IFJ_'X/,K6\9(9
MFV?<=5F?>Y!2Q?=V'BBQR)R%G?!`16U3FX]H?75J4'@]?J6K\._KW%5XB>8/
MR'7<'D=RC#\\.DMRUY3<W&;-#"N886VJV!-Y844:X6%7^]F3OYS46)/_H.0O
MIU@>4]:A*C.B0N8E16:5GM-?*C@8AT]UQ#[42KF]:OWGY:=+9<H<Q`'/5&L8
MQZLQ\]G4C5]OUF(/S+TG9$&M9W6*LWJ8LG*\_=:+LRLF](XWRRILL.TF^]VC
M^ULV7V_?^RNCJ^I-_?%C6`/QL=TH7I_.T7].:]MLJEVC6Z_M.:YM"Y%CVY59
MVR7GU\DK?01VB99-@5]_EH?/$SK>)3<;1^;C/:Q$O<XKAG%T1:->Z`,=3U:G
MLD?3J1U$@QOTI2(@,XPE2?'1T9N&R*KUX;3OP\E0.XWZA'H>BPU7)MTRZ\5^
M%HMMM=6&=>S[\1;+4;W+U+O`U["">E8AD9?]H,I`6=&I13Y<1=;:$L5L>(U%
MM[Z-[7U;P*XPZO/NN:QU1S^VJEZO]6'6NJ4VS`I>P$_]?O8)"Z1H5*WG@@=-
MPL%&U[3ZI-HS1YMP,ZN5]6>RUNU:)WDF*]UH56^EJW<GNPI"!D,0&0-4ZC<Z
M\4-K;ZO\U('LDOW%L#;#Z)P$U4Y5"M9L<E)4.U4V.8O#LJ4VC?I2M^?#D>?(
M\;*<IWP^G@5'OS*J$]94+_`V"WQT*U2]P'M>8+,Z6[AZ%[>/+&)V.+E1)B%S
MW+AVB.V?G]5NHU$9CJ[7>*N`:M5LUVM\WFO<[![;AGP^88D92FU]].PUD+8Z
MJE2]PMN$EZIFIX+^CGJMMQA&IV55;Z6KA%M8/@;SZ&HKX1M6,,<N$=UVT>>*
MQVLJUE0\22I6SYCRJB\@/'*8>=,@Y!YQ@6UWSC''QTY1-XX=OW6NZNUQ%]94
M35$KNE*Z3KW$C\B>T2MX;3E#9?9P^,0[Z?1D%;&:CL>>TA$ZW0"(S?^CCS?`
M8C\>K9KC7CO,_7$83!+"R%[,V<XPK(UFKVNV]9XVO.I?:=:@U]8Z_;:A=4;#
M9J,S,OK-49MC6&.K__RA/)!L>",_=N/%1W;M1G%H^_$[>[:[85XU>E<P+E,;
M#AN&9O5ZAM9M-4?:0&]8W69_T![U6C!,X^4O[T:_?^Y]5#[_-OK8^S#Z\_.;
MP2<^ZE7C*X_^+^9YO\-AXW]B=A3XS'D310D+#ST-Z^4O?[,H/^PU`\O&_SFT
M$5[ZTV(V#KQ#CQ>XX]WOGS_R`1=&4D1MO[+=\%^VE[!>%+$X^@/FDH3,>>_#
M!DC"$-[JVY$;[1ZIO6'HO6;+,K6!:0PU:S@TM:[5[VC-IM$:C#I#RVI;IXK4
M_CX)E7D0QE.X@0?04C!5*#<6B^6X_BV+8L+51\2'F1U^90*D'"GJ8@(LC]5V
M&&&IP_LUFOJV:.K-#=#H2ZJK>*=[/$CS<^ZZ!M#.:!X&=RF$\-[AA%&$9Q.#
M"9`\ISF-T]GEISH.E1^>(`-+W?_FLA"#F18'Z_$MNV7>AM[NW1*YY3ES1DR9
MK[4GYAM%L3LCP`=D0\YZ,'0[?L+Z/'U-SDT658#!]B7=UE:*R,F4NIQ`%9;H
MN"4'GAWF_2`(YP'5=/*#&!Z#^P4,8AS`-6/S)>.49%M%PT2.[1([Q5/FC!PG
M1L=4FU8%(X'J17[$(C<Z:M.HH`OTU...LX-I$LQF+)RXM@>CF-OS.ARY/IGJ
M==Z-;]]4NU447O5B;S&,9E>UJJB.5"F6XVC/U0&LA3Y7/%Y3L0X#_JEW:[L>
MFFNT:1!J"#U\\2+OC*V"9GFLY^JC=;V^;#95JUE!B/%ZM;>Y\W?;:K>*JWWJ
M=_X_`I\M1#`,]#Y-:BOT`;BY>GQ<K_,VZVRHIEE!H54O]C8*20OTD6/#G.SB
MKG_R-XJ!'=VH(E33]:\5K'H2NI.8H\3#E_4!MF=>?_=#KWJ,7J_T=E+-J")H
M>+W86PRCT59;1FVNOO^YVEQ]]H;6FHK[,%>?FBKY.8AM;V6.$!FI5V<)54&]
MK"W6IQ*N9+9,M6-6\%2M%_EQBZR;%=23:]7I)`[]2F7VG[#R5"DZ;HF0\-C,
M\&)>>0JF\`'TO<EB]_GCO5:K8?0;IC8:=GJ:I3?[6D=O=;2NJ5^UKSI7>K?9
M?GS^>%Q,H\X^6",82^GFG7F<7]&QW/XN_L!)HGQ.X<C<5#JD#SXPV_MIPVSA
MXVN2XO]BBCV9!`F<"],@+$"H*8GOL%");YB2E7N>L?@F<"Z5/\5W+FJT_$-5
M<=B4A2$6@[:_*3:Q$>F_\G5,A;=#!L_%+)RY/CQ)53B5`+/B9<V6"3PU9O$=
M8SYU/G5]V\>@825DF(6/MEEL%3O)/L&&<"S!=&W/\#OV/A.<K201OLA\>Q*+
M,6.4,C9"K]IW$?1OQ_025K^>B#K78X8Z/",<$>7N1@PS/WQX`UK)OQ.R6Q9&
M[%+YR$`@_)=01G"LJTA&-'78G`&-85V2.2+<\9K:S`Y]&'2D4I>Q.Y/$L&>T
MAM#BW8T[N1$C2&`T86R[_B4N=,@F00B/HDQ*^`ALSPON@+K`!=?P6!07!H24
MX$.B&3@)/`?]NB%<;<)P@7UC4PR_MGTY!J*9&RFS@,;@N5^9M\!/?<Q,$@0,
MB0P,..DO).`=3"U"2>7"E0GX,.L,6E@UW%S9<2+^,AE5)4@0%;"`$EAD\#O7
M\_`3&$S$L%N'\9]5-/[/.4R,MU#YI0W[F;/0#1PE2H#$DHOYT'#"ML,N#[:K
M#7/SMDYB%RD,RQW?!5H4L[EBSX$8-@R=EG,27/OT`+"/V!,9PT`;2,IY$+DX
MO>A2^4Q;,8Q0@82V7&(*QM>&<7;,O2`@&44O],EXD9(,.<>=TDMW#/5DVK8R
MH@M:=1W<2$1WQYW@KA1LE7+6,E_A][1&<@BTO&-L)4HBG!3N>=Q,Q"0)R*P0
M11K[9LM5++E_`B\1^Y2FPCD.B`B\&R&[H&"YYLL/A(6-#R)(Q8G9_H(3+$)8
M(4=2#(D:I+26)!MS/$M@6RYK[?`:]L*JW423A4::^O=R^D"W,>/#Y1N*SS#Q
M>)HV#""./8:FAV7.7-8!UIWBQ;,^PU)ZX]]"RT&X&("&@'!$!=RDG9W][?Z5
M90R:IM9N]`::98V&6K?;ZVI6;]#LC@8CHZ\W#WWV;SI44[(@!4!G`@$:<&Z?
M!BC!<+U>D40IXL!L)39(#!2A7S*E9+W.6(!^>20=GHX4TVX]$"EF#0Y,1W\\
M#HQU/#"6O7?]@/MVY[YU?<!M?']WL]4)[__0Z1_%F,?;(UZ0LKTV9SVGBS]N
M/O4:/`)Q@(B\`K;AB20__0F701#VSV/W"_"73XW%V>[8O-??`MU\M.\4U%M"
MN.Y%6QE7GF(-^FX[^ZZIFKJ^M5GV*9;+P\^UH7:M]G[GNAL>/Q6._BL(OVJN
MKXD+PL%Y^G%O+"]X4S4Z>U[PTYMT2S6L5A6X_'0E^17<\B.X)RK70>!4D>V;
MK>9S8_N&VA#),$=E^U-Q#&[RTV1*XH'":I[<X9YUZ6=/O_-26U(3UG:2>[]*
MJ&&JW:9Y%.F\YXDU5&O?$SLW"7PXW_S3>SQ-&7Q.%-P0_$`?;"@,L=F9L<X%
M\NG&#ED?O=B#8#9G?D3^H$\QO/)^3JZS'KH1W7BQ)^=(U^B/S,90U\RK9E>S
M6KV!UC>P5(")L/JMJRNK?_#`B$W.D<_D]D+GPYAYP9TR#UE$Z/FV$B6SF1V2
M4RM"`BK!G+M]!05Y1`*T$22APOXOP8]<'RUO[BU3YI[M1T6_BJJP;Q,VY[$-
M\]"=D`<7&HAPU<CSB<L00@>)[2F>.T77/CP\HU5\=FZ9KODTMTS+?+Q;IGD\
MMTS==>V,6O7NOOT"[Q)R17EYST`),I\^#Z;W/T/G3U1\[LS=*G]1R`ASM/NI
MT[MEH7W-[G]P]`V!*:,'//D!CY'['X-S1J&UJ9?FB4OSD<UL"AFZ_]%!=IC?
M__!;..TS<H'>D/WR-[/#Z/6S6KG>]77(KNWX`0OR!HCL^I$[N?]1"BA^9>R8
ME.=N.W^?Q%$,RBD%=\;*RMB%#&&_2F9U4U=;S<K9U;>TYG0O]3T[D>IDF,.,
MN6JVW<9F\<+M$LHUUF!D3N6$2%MM"]%7I8WUQ$D;C<MN+4W.8LS55U\>)E^8
MN%-53\*\LM3.]GZ8U]62+-U+JWK2M!8LST9-F0;AE+FHJ!2)C_\K$\P&\ZHH
M8@RU:1K/1,08QF5GSX%%5=RO51SSN84/G$\`4A6YJ1[SZ>S:T[YR[,9B:FVG
M)QSHF#0-M=L]CG7T@<]M&]>F7S:/DR%SH)6SCF6<V?.Z&5CXL@X)?[;A=%4\
MZ^HQ5TFG.!4-XE\L*I@8,#8P#^!S2Y@<558M&HW..1Y1^J6UM1FE&JK%D4PG
M^U8M#%5O[WGESOW:(Z+6*&:XNK+):*BZ?IP<X_WR>.>R>]:WGL;EOK$`CK-L
M3;73..BE9RE/95V:`645K(T!%(;%I;R#GY2W;]Z-M-]&;W[][;,(OO[KS?#S
M;RB0TL2,D\U*,'08Y,/R$/*B.`>^)-?88U/I?7F]<7WI_?)+:8BDXLH(2'PA
M031"F<4"317!(`M0EM(C+G)1!"B8S')!3$L"/)QX`4%3<ICX[&%,>YD$LQD\
M+/)C_-4R']I`J7_Y:+[;E!^U;:93*7.*72,:W4<)W#ET(YQN$NXA-:K?;%N]
MGJYK1L>ZTBS3LK1>QQIHHZ;>;;2Z>L>"UTX!,_9=$.="D8W&D@S!2>;DB2"B
MDE*1UFZ<RL830)4-YBSD6P6X%'8!@JVR*%(B,70.4SH-)DD$?2#[S^<>08IR
MV,Z836Y\T+JN%YC8%6-.%B%.NC,$]&02C9-RM7R^/5($441I]+%JEP]/>LJ,
M.>X$>[]<,3`YGC&;V`FB@,(>DX.]0#A9V,>(N*K<V-!KY,Y<SPX5A'4,9NZ$
MH\H&,!C8F;`_$$HV=*,8ON&HH1)-$H?KVX3A"B.%*3C)1&#4POB3*0:M8S]Y
M(,EX,9>0MD`E.&]8")\Z+I8E&W-D2HZ\R]L!V90`I1!VD/FW;ACX!/L(<X8V
M,-T-1`>(J1O8N01KBAW;UTBK:/42C1=$C<&-RZ9<V9PDE&GW?CH%B112KS<$
M?(H-T3LQLV?0I1O?('WA[7S+T$BZ_(P3-+X+:%SPF(^8K1]&ORX\#JF9XP#L
M:)YX(/CL<%%@CA/!6WV?A`3QZ\-A``2!@PKHY*#D!AGN`JVG83`#N>Y2IJ,$
MDP6&F=D3!D2=V-X%AQT>NT%NXJ[O)+C<R+L]^,'^-_.!457EST&?'O\83.C(
M2$\@Z+5I?J\J1@O^P"<,XWMY=H@1EM!M*3F2'SP+AKSM.]#(^KL$8ACSF=*D
M:`0T(.3XW""I][Z]8&%A=&8'!F8:.,3V]WR$NAPA3633&!\TPL8EM%,8(PZ.
M#Y0Z[$VGBQE'CTZ'U=!Q6(WO<S2[>/$`JMT[(GX6FR?"J)(LL+>O67`-2BO(
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M4QE/>&8=`_2S$]#$JW1DU]'O-05K"N[KX'YPH-A>G8B]3:&FJO)=JW&9"V&9
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MJTZ_;6K#(2*.]WJ&UFTU1]I`;UC=9G_0'O5:0(CVRU_>8E5;I3=!L(Z0&(Y&
M],\?U@RQ/'Z87>+'=LB?B@X]@];+7]X%^<&6QE-D]VP_K(N:S"UYM&[-]Q`/
MV;H:-`:&J>'?FM6TNEK7:K>T3M/HFY;5&>B][JE!Q9>"3$!@N1&O\]SW[,E7
M[=/D)L"/>1"MAK&R%#H;.(Q"JK+]HB013^6:V-X$(^5X$.$4ME9VY+#9W`L6
MC`EQZK@AF\1!6,"CCYX0RU/)D)6GPL(W-T".KPO>Z!XO;N2<NZX#).YQGV<1
M*]1]ZD1?A6Z\.J`E_>4(L1;5I]BA@S6J3[$ZVN-1EF*A+BNA&WW5IB&C;!X6
M8GIW*.'/*^5%OMS:E?K]OD>[B_GIEUNGXCWK^9U7B,?0O74=YCO*PF5>]=`>
M]<NM/?\58>)Z?L?;I*=_V-ZFQBD%4]V"L'([N'GNYVS+N-P:\;H:$S3W-,'S
M.FGEEKT3YF7%%A^D:$A8)K%Z^Q<6/VT"<_:B;7GA<+.HY_V4>>L'G?>C@15V
M["0H>B!&PHS]B86W[H2M;O]=X-\2ZAFU%%$(5?[[01#%[X+X;Q9_9)/@VG?_
M"WVST`V<JR`4'^%SQLX<%)U&L]OJC]I:US2&FM5O-+4._F'VNL-VHS^R]"XZ
MUHR7OWPP_S;^:`TS<AYVQD5JIY6#]PEF,>KI>L,`VG2&_8YF@9ZG=;N#EM;5
MKT:#P=!HZ/W!"8)9K,&R*!68SZQ7QX:N2,>%"Q>Y41Q)AWWFB7K>"<SMUM.\
M01V]3F"N73(%<WEKH[F\SAL^OENLSANN'2OW7!P_VG<*1I>%KNU5)HW65,U]
M)V6=S%P;:G??>(WG90KY*PB_:BX&%1$F5_5L'JK1.4[&R1$GW5(-:\_)I><N
MR:]<GZ/H70>!4T6V;[8J!Q;PU$DWU$:S+M3Q3+,[:_J=0G;LJ8COHFGMQ/)@
M#5/M;E]:]TD2=L\3:ZC6OB=V;A+XG!+U:@KN5@H_P(6VR>]2]-"\8_'`CFX^
MA`&&D3G]Q9\1<][X[PD+VO6O!7*YRZ)!X,,'"7PFOL3,D:<GE;E18)E&^\N?
MGX;YW#)M.;ELV&TUVSU3UP;M3E^SVE=#K=]OCC2STQT91F-T95E]3"[37_X"
MO9NZWH)5R6CRM)F6TO92[/<'>==ZGH2,?3\M^\_0LQ;MWBG6TX>F95@]S>IU
M#,UJZ4VM,]1;6K\U[+0[(ZO=-@_N%-OD72*T?(W#[$YRI*/@"C]BE)(9IK1#
M:&[N=HK0Z73QXAF[G9Z,F]NHW4XGTG7M;:EQ<T]N16K_5WG"-6YN[?#;9&=`
MG0Z#8\A*C-0_?%[&MG=UU6@=![#J&',UNY5S`FT]5VO?=;C/RU3XD46@:4QN
M"&S&8;?,"PANYN`;^:GNC[;:-(]3WO:HD^X:E0M>>/JD]<X)F%FK?'#_RGP6
MVAYM>MN9H;<W1@/0;?72.CIJX_GM^X[:U"NGOCQ]W[?V#3)Z;NZ5\W'0UO2K
MZ7=,^IV7UL_!LJ,UOHCM=(`]7^Q`ZS/.$CR[K;;UXR@P>YY82S6Z=4#:LW7F
MUQ2L*7AL"CZAV/V.`QZ*<16B"&\NH?@#*"V3Q>[C(^"=[K`]N-)ZH^9(LQK-
MKM8==+K:L--L&>:P-3#Z_<?'1WQ;R@+^ELK1*8R\((?7FD<B(!8Z9>2;J=_%
MQ1\$C<A&F9*)5LU-17;FJ<%>TU\>%A/QK1RU\6UMU,;V\RK6!8>F9&5P*DN-
M<-]V+LE?N7/CFU)9\.6BX-`*!4^,`QZTDU9E%M7D%UBH.O%BT8?/$/U[%O#*
M\[S.=YK*_*.2S.$QF!J^"SQ(02A3AN7GYQQF@$HZ$T-B=7MLFRS&%R_*-F-5
MF;D>`ZT2>I3OJJ7J]OA*E,SG!/Z>/43EZX.%[<54Z1RI-F<A]`MO3V#<8Q`L
M(A0K\8&$HAQU@0P13=WU)U[B,#$5[!*)C`A_GL=@%$!0";".R.WK1I?O4@QO
MC:4<&LD]>ZF\\14*2D&@87LR"1*@K2P5/H-5<><>TYC'Q+OYY5?I(10PM@\S
M<>`S=PH$H8\=YKD(Q$(8R&*6&!R`+"/PX'-M<?!X$,@)8</?W;@P\D(3:>US
M:"-BP$*(AXSA:I3O+D8.1+E4>K[M+?Y+",RE3F"*8I0+8NU"\_^7N*$8>Q(1
M[_TG<:XYH]#H[.*0</F@E3%"+^=(BIV(IV"<)(QQ1132-)&S)=/"<]B/C5%2
M=A2QF*/>^P&,8!T[9:7LW7S858XDP`JX>C38=$4<(E213D!CQI<!;E3NY"*M
M9"_;I<E,0I<2)+$4NC)C\8_X1DC=PPBC!%Z]9;!PV-4$=VI\8^-B%LC.OB$L
M@2K)LE!N;%BTR20)0^9P)D(8;"%QINXWK.D>PN/0]<SUD=A\"7#_8$%[&!C-
MWXX"_';!*9A`:Y<[DJZ&N1?QVHN%0(,-P0B;FS"\<;%\>*.\WPI4E'M29*RB
M,`@<6%U^H-/B^IS4A">^H2E5N<,QV%P;8/@#!X]P1%@EL@`CL<^EUSUR@$0'
MM+%B-RK\NAYP3@N91U9[XE?/P^_YP@-GW03`"M?<T`],G+Z'XG",8*?P/Q6#
MX)4GBN^_&GWZ\/J2\->#\7^016YI!\/'R"FT)3DSL8S=<!:Q$#5W3+D+$L]1
MX-``90G.#5N);-CD[E2\$#C)A!9!;&I1T0.C"'"8\'@,+*K9'AXGN*5`MO[%
M<OWB6*1@%71$P7C!JV@43\@"=<>+='7R*RN`Z2+.32!>X4M5&2<QW$]CD#(S
M*K81![#!\"BFLQG-)A[P2+S(SM;5DH:?+="(9X?B\7300$Y8KBCW<LHI(*-O
MW2")"C.X5#XAOR.1;3JL(E"[B7.)E:28Q9(>\)I[2T<;Q\P'HM%YMDCY7IG<
M8,/X,#]4)5]$8@5SC4-7]G0*[,!/@E3[E0@I,=J5Z%S.,S]-#U;.A5=#DE]R
MXLC:&?U7;H:G"*"B&6"-SHH-K;]Q/%C`Z3M1@4FU_<#W!FX&V#%12><]54U7
MC)J/F=:0Q,(,V!W8IJ#V\A.)2QI^#$6Q-O>2J*B."0U3*&3V=<CR6O+R)I=J
M,,F)&QLD%FQ<9.AOL*M</$\=XOP<0X,$A;Y`=4S5\4D""NP,6]G5R;>;RQ&_
M$Y&*O,ATBZHPQZ_R'))')3`'ZE*QQRMRI+I_;B%67W'D.4:J$2^B1!PG1)`K
MZAPAKSEA<AT)!0JU+3O\R@C/$)D*CQE^6.3N1W3*ABXIS*B5@8"]P0?Y\!9<
MY^3\E2J+N!CR:Z'PI9K@Q(YNA&;)CW_H*/TR3!?3GM$M`>@P9MFS\!X7Q:@;
M/U!;4_["K0%J]YR$-!>\?N!K-)*,RJ0X<-+3J4PJP#2!O<!R3SDL`GUUC"2+
ME?]G[TV;&T>.1='O':'_@-MW'*&.`&BL7,;G3`37F3ZG/:W;ZO:$WY<.D(0D
M>$"`QB*U_.M?9E854.`FBB)%D,*]/K9:`@J52^56N92[>K54R:TM6\X$8+YS
M,,+1PGWP$V_-*\J4.5]D%E#HA#0P-R1R,\>3R$!SIV3$JOSIW-Y!PJ)!G(A9
M6?_.@(-`H;HW^-^DOD"L@!!`[,YEV87,0I[AU*NB#/C$W!VU?$"XK"1<GXA,
M0..2<SZQGPA$8/"A`*:(0N0'`^RWC.@J/#\VJF>#Q9?+`&&BLS%`>?W36JL-
M;*4D0Y\_V13'*,<*8C12P=*)N:@I;'")YV&7>'25Z#X/9N3M5>6ML`/!C4'R
M:_CA1H-<-I-`)A'3_NFMM/"ET\6^F9OI[+.`#Y(`P8T/CD>T/OXB3IH<:RF%
MILC@O\&3EF#W/'Q?E8(G>?49,#`X'&1%EZ,I\B,LH%5"?/Y7IBJD=P'&.,IN
M[[AJ`-L<]/@$3%S_/R4KE9_VAO(K()%)APQV&:>N']+"Q([PZ\3;P%1JR8XH
M;.X\]($\N>0H@:PK[V69U@AS>D>N>TY`%AZ`OR*^B),T$=RINHO.J@QO&6W7
M>,5$29+)DSL?",K\<W0.DFR,/,2=W"*^6-8@(`O04T:+`@RZ1R'S.4)E7;*X
M"/]@KD#@0(R]`'^%?^4=(&G\(BI6M@#?TZ0842D1,0]/*O=@^:+GME%*Y49M
M0^F6=P8R!)B&*@`Q#G'/$'CI?RB4,(FU"4;+0O3P<_1-N95$@$<!V3<^LZ$4
MST>I2G8/\YQIFAU?T]2-SM^2\M&/Q9,\P,3A=A$1(#GP``"X*9PVC\>=\9CF
M%'UB?95@DH&ZB>*"7"PR)C&!=%(?A4\[A5/`S[P<W_&)(;R8$$&F$'^><`D$
M!4$GX4SE*A1VLX1CY@CSJ#IZU=,IA?,PF"S4T]A#N*=T8\$-+P;[$F5E<'@X
MI'0N\."[<;CA7%#<2EYRD5&91I'I*(02"TO3:@O+\%`*"'4T+3UF'=_37#P.
M3YEW%XB]<!!4;K7QF`[&46$5>L@%U51Z$M$N6[1%8(M'PI!=&=3,)BA%FO'M
MG`I%-'Q_8817$))XX;&=G"B<W]PEFK-2;PJ&Y8@@?0[2)YOSX[O`0K+>S'E`
M,G<8!EE\2RBL7&&GU.(/.2;V;G&2(K;+!;:>^:#SF15$3A@\A!']1^7.`\,=
MULW2NRB6='NAHY7`A:-]QQPY\MPD_8P[N0,^\("::/G=L3@2$)J#(4RR:(RB
M`?\E;4SLA>Z]8EI<V`",>_!$$W;PQ15;4KDHXA%*<7S=H"2-P.\AYJ00`V*Q
M0"L7(&-B2B&CN30"#<\&3_[P)IED&B3R'=93NN-C(9-4,NJ$<9#OBF%Q-=65
MF>>EW-.:<?SE%Q7,*Q4"BMV-%`(,A%N"ES%,-')]Z.*%$<@CVHIXD_Z2K[]^
M+TR!8OB;KR:=BV6?IS@7;)^R;(475`J=QQC*9;&'DKF;6Q`*%=TSWY1[P<MN
M!TFY!<*2'@71YM^P7/J$V>@K38PS$T&<\:7+YR")9%G$S#UN^\F""<42,U"X
M8LAE5,GP$/%TR>'AWVHH([PW0%)(7V"^9+*>R/0%L0V)XBQ@P30NX[YR>(`#
M@K??PDP$LA9N'6V_+"EE0$#\K0-$%?B:,NODL/=Q&\/AYM[#X17@T9*:7,&?
M"TRY3E=R.Q<9E@)$]U&0S82?6`XW4FPP%WE,C,M?01'%+H&*L*><"D%B!"_/
MT#HM6)=XG3[.\W7SYW'/A5;)=YP_+S:[D=6(.06S;<EJR\E33V8UK6LNPU\<
M@8`=_@"M`^JC+\+PW12,C7$&JNQK!*?>`Y^[+Z*TO<=?O>@V=N=P)KL`P/[3
MIZR>;;5:HZYFM$=-S1Z9(ZW;'_2T9GO0[':ZP^:PJ[_ZS`5S0W\9D<X`0N<V
MQPW&I%R4**7+8W%YEW!%2UPH;E!63-Y6$H_E`E&$>=UGR)][R],17MRFQJC;
MU%3DTW53E+I-3>4H4K>I602X;E-3MZG95.WV+:3,K>L4PY'+=FPU.YE8INKP
MHWQ"-=X[`FL#L-;)=6S?E;*VZG0J4,A^.N6JPPPS]E_]Y+ZT88'1;*M&QSHU
MMGXQV'I3M=H'[L)4/;#MIMH\]"2A<ZMW/9_^`#7^:OP=$W_G;L.SCA4\[+B;
M)7!8J\[4=;6EGV6'"KNM=@[=>>DHD+4-L,\J8(F?DLH^I_8`-09K#!X;@R]H
M4;'W:].%^]G5+2^*G+K>8_'(%;N/[CZX\73D^O$_,&^PFR39C*IRDR%/;A_X
M5-H\_8)9S2^?JC+/8D\>I[(\3<6RC8XYT$W-&70[FMUK][6.8?0TO:\/'&?D
MM)L.WN`:[W_1&[H\1^7@X*_`]OCISXV?\[FO7CPS]G<9OATJK?>_7#G_-/]N
MF(,%;!X$O'5)!3@$!_]O^._,AU./R1+=<'I]%\4IOH>C@Y*4<BB^XIG;?^Z`
MH7<-W7(,S3`Z?<TV34-KCT9]K=?J#H9-HV_T!F:51M,@LG@Z9(X:3(UD=7,\
M`V"2B?3-O$::JMS@?:]`M&B8`>*&*EKP"5894YYG\X;3!%K-%Z8)F,]/$V@=
M[Z[^X)^N;X;?-S?>&PYY+=%409&JD$Q57-;HO;Z?WQ\5-M_>;I$C,8Z5OTJ;
M>IO7^KOC:<_9`.<>6,NU/E6(2SI\)U_J"->IAJE:IS?M>]>[XXZJ-P\<9#RO
MNV,R^#4LP97MVE=G[I?>+IJFH]J'GN]>/;"-3DOM5&&L_2F+^"]E1^ST>-]1
M]4/?K+]-J,_M<N)\[G-K_%7A/KPJ$IS=?D^>$Z#;3<H?UGHUFZ;:-H^3U'IX
MR'2S`I,'3TE:G],U7HW!_4KL9UV$[GK5L_;J*)K-HQ"?_WSS,<3.-E_='WCI
M%"9>SPN]&S\]T)V1[C1'[5:OI[5'IJ'9]G"D]0;]GF;H[6YG:/1;NMFNTIT1
MEHE>CAE*/K`*8VP`0GTV?,*<DKH_O+Q!C6C36-267M3UHB^\"&H__R+(.MY%
MT#E_NK[]J.M%*T>1NEYT$>"Z7K2^$MMX)49M#M-E0^3@(<-C/5?O><_/G5KX
MR=IX($8>MJ8,7O4\K`J3;!><67AQ.5A3>`.H_?:ZPV-<-M28>H6+]TO#VOG:
M_<,YJM#-$H-Z+;R^_GSI;?.I,7,-<+4`/C.US^I&3NX87]IM<W=9?5K\K+:M
MXPP//RK0NEF!E*!3NFH[GXO]&G\U_HZ)O].WW+=)->$AL-U4_^NI^9W-N5W4
M_"NJ]./D^;X2@.U#M\2JE7=5A6>-OQI_IZ^\JZ*J!WS*X(X75?5S9_+<Z9ND
M![Q^>KFEL<,*IW.3\DHVGVWN')$[!?`N7P#?P6Z'JG)\7W`75!_>*G"W?=;N
MZ.7NX+W!B]T7W0F]%D6M<XP+7>[>Y*#*4!D[%TUMA*J.`575!Z_Q5^.OC@'M
M][I&1()JM?SZQK%^G$D7KV8=MU^0]U@KZ!,4D#7^:OR=OH*N;H;%9>_I>NF#
M*O)=4^`=XU73*@\+C:F:]G&Z!AX6KH/;(^>FN,^IAT:-P1J#Q\;@2_JX/+?O
MRKH&+J,LS6+O[W[HS[+9)\]-/#Y2(!E%<=^=^^`TTZ\/U?N_V;6=3J>G:]V6
MW=%LH^5H[8YE:D[7&'0&H[;N=+JOW<>%M4=9T\B%84R9,90I<XXN,DRB+%8F
M#&E*0%A3W'1U]P98";%2M_J7.[PTVR_K\-+>H</+F?3;QWXAB>*%-&=B?;^0
M`XIPN<W"BY7'F_-U0!@XN_DR+]"X.UK.CNJT#IRE<EZQ9R!N\]6)^^)XK6HV
M#UPQ]P8.=>ODZ`XFV/&I?DI^<1U0K*;493=^2X9ZC*,[JGX%:.BJ,`AJZ;LC
M_3]Y2?*SXLYPFB-0?1Y["3``VL<^NA9>4O&J/4.UFCNW@*ZO%&L)?/03>,6.
M'.X@\["A[4TY>$(QDEPR5_HTMM6F<Q(]4:HNCR>L8%J91S&.**TTT2]M]5!7
M>;4(KD7PZTRMD\+12C2&?=!`815^DR2O>AIWO:=5C4.7^9_;8:QOR5YTN77`
MZ>Y?_.3/4>QY'[D'4K7I[CI-=S>:!YKNO@K\16S[\SGX:-UP^IL;3@/XL1\E
MZ15(^LGC_J\?AT:WW^H/':W?,P$MMF5HG7:KHSFZ,^B/>CW;'+[Z&`FC+5W5
M!;PY-?[@XP\"033?2*!(01PQ`]K/!5'^WFXWB'L<?O&'!_[W)+H-_?\@MR<4
MA0EHQ'(:*8D,T9V`"+R%>1Q-LTD*S\`:DRP!@>3%-,@)U\`G;J-HFJ`9,&TL
M"YIER;`5;Y7Y\0\/%9$W[=Y[L7OK_9[AO=KG&V+YSUF:I"Y=N0'W^Q-8=^`'
M&8T/?/&13O`+B7RHM16G>JCK3?A)ZYG]@6:WS*;6;>F&IK?Z>L?HC;HF/&1\
M-\WWOQAFL]VR0%87^-@--H:?J>?_/(@F&1[W*R_VH^D0GGB1-%N`S7"Z';.E
M=[7!J#?2['ZWI;5[+4-K#P>.U1X:/6?80MC>_X*+:(:I6<9__77MOLIDQ2$X
M`-+"+)Q#29F19?6<MM'1$";-;O8&6M?J=S5SZ.`KK>ZH;SQ?ROQ8$AL_<BOD
M!G9>LF+6NHL)G,G\RG9)VB""5!I]#-N1,*72897F!;%?2`/3X72._-`-)[X;
MP+L?PR2-L\+/7R6F<-//E%D_%H70C[5":'>T_.&QJ3Q3+P;S%*'99JZ<\N"G
M.(5.B<"6!4P$\%B*?WL$W,`:Z1TH0F4&.[I+X!EFCS_<>:$"VGQRA^H4I>/8
M6QHXW2!\EG:P^-G8F[E@]X`<Y1_%OP!)Z",I"%E8(@H]Y=%S8Q6_#A^./4I@
MP>`H8,E/\.L9.`TXA4@&&'Y]DX53DLG,>XCF($!(P>-2\/>9^R>]-U/<>]</
M"#.8(,-?P(_GKZB4`S,)W"3Q;WP`V@6)OG(6<6-/7&*8!V$3F20`$JPU]1(P
MIDG/`5`Y*C1`A98`+>G,$/1N'!/HJ7*#1X@"9I@C1,3,PM@#L_P_\,`M4#6A
MUX(HP?RBV$/7S9L2$Z0@M.Y`&8*6+,KP.P@5<@\PWN74N_$GF%&-^YF`F,R8
M&HZ`6$`>L/!B#U@P\>\]D69]B5_Z@#R',ZRF?C*!7\`KQ49E9<Y2H,K\BOM=
M/#2),B8.G\>@W6(_@$,1$J?E`!7K$X?#PK#&G$2ZY@$"QG'T)^DM@!N^SJ70
MPYT_N2.<LO4C<3KQ2Q,O@35NX@CX$I8&E--AA.6G8%W$CPJI/+!=E:F;NBSK
M')%)"+_U0FRN$CS"$OEM@O+O+$H9&+`X\7CBSX#,("F`/NQPNI,4\<GV@4<$
M5KASX3=C#TX[?`#^.F7;BL:)%]_3>>';QITTT(*"37I@?T_AJ[0']-2FJ'`!
M:W!*971E"9E3^='C2]%>&3!$;Z();'E&!['RIXNY#)R90$D":4*P_J*2]"O+
MD>4CI^*O'SR2XOC`#`,?_R$$,)/3F_G9C"$)#DCLB;\@X^--4L+D&Y/D>$21
MU^"H!-F4G4)QN<3/3T/YLO;P<E"\"9BBC,OS2/D*82%!^:]L>BO4`PI3I*:&
M8AUDY@S.CQL_JHH/JX2/ZM(&V5EGNX.7+SV6-_JA00=<F-;2U]"^+DXL/Z?)
M'`Q3$";(1,B3^#-#X\Q+[Z)IQ=GI,Y=3*OTWEY`EXV:U#B)L`L8BKIZ!0Z9^
MJL3@V-)Q(MQX]Z05@6F\&S<+4F7\2+]/[WR0+7,W)K0"O5(%Q34J31^<9*1&
MDJ'X(M'14,J;W':+G"?O/%@9/GPCK#!X)DG]-&.*FKX.:'&9%P^,%/BP;P8@
M&2AWX!T(^/Z=`0^#L"3904:"^)PR)Z-9"4#LD;B3#064MOX/8CO2)1)3`<]$
M,Y\KQQ"Q\DBR"E#XK7'=4*:8/!HG!4K8KV\C<%9"^G`1S`1T@!WE/0I!YQ?&
M)C]C:+!PI$VB&$\(",YQA/*#/AZX$U*F;/X[LV1"R79"G-*[(>:E"F,'R?HX
M9VJ<"!@_P?7+/NE6CDC9=[F*T7A*'Z\"-TSA77QO3O[.@=R7=KO=<H;MGJ8;
M?5VS>QU'ZW7TH=;O.JUALVF8MNU4TWWY%(6WVB=4K["=+IVJD_,^!+E5Y%*R
MG9'=/$%T.J]D`9'YB.*[H?S=_1?*E!E:,)YLD?+L=%1'9"N1<4`6/\@(QLA@
MVX`ID0LZ5`U3\DM(OI$%/\4OA-D-&#9P/L);50%5A6<JBA\+\Z*\1U)TH%Y!
M$N%6F8E"B@2.$\8A-%2"7'D4QI:"YUV!<PEF8DID!)?D)@M`WMQ[?$@J^E$8
M1T*Q2QX-B$Z*ZY)P+6.!I,$X\P.,;"04EHI1+X)\\):3]P$%*S>-4FG5MFFS
M!!1*9OB9#W'-]U_L_H84=\QM7N&MD2SG+]$F*JY&?XVBZ8-/UE1N$R<,Y!\3
M]#4Y+&0?@XSWIV0CNR'G$+`;TL<<;2BH"Z^"O\KM:'?"TK:8_>2[8S]@BL3%
M\#*S;%RB;8+&%`[2G8U1OZ!IB_8SZ;7XU@W)%D,[*!3>!F(>`V^</3S\/K>L
M*<2($-*^\1<8!@>[BJQ'.!=1`":>0`.8]<AC=%+0U8(U/9GD7%,H`+XP/?$@
MCC.FLSP7;`K@%8^PA*O,\"RR(Q2&&1T(;F/<@!H&WQ`4LV`TSP4]B>PO['_<
MQ^=)&I4J`0S@53?)8J;UT8&H.(O]P5B`XA9>&2<8T$`)'Y`#Q1A%E5S*>5ET
M"O(68@G=.D&Z91,YC$)-A#CXXNB2@RCT2"C=$[-C6.,.+T/(@"_8SX_!O4:'
M<D)_F:)Y[)'91<$?YO0_$J%FS+$H,_S,?20^&0.M,R0\RBJ,U(*5A-[X'Q@J
M(MM(;`3\^1BD.LHLE",HEV"S!$I*X1WD3O(Y&8L6B,P]#[!H,`C@QD(ZTV;D
M8$)2[)M>$4$*-/ZDV`4>#\YH4V'^`@G\B3]G<C`4#A4)]1"L-K)Q;Z@,2L9$
M0_D8<GPEG@CZ,XKE`"!=N.V7:SCFC,!A*W1)EC"W$%?CFZ.L)%B%.=09G.6/
MZ#:M1([W`P=SJ\76</4',!!3=..C!T0JZ"'$1"'P"YP\VS;<UM`KFX?_CTF$
MX#$/OWXLG/S]&X>#87\PM%J.UAD-.YK=&G2T;LL::$ZW;QAFT[9;IO7:-VCZ
MB@NTWZ/4DZ2@O70'3QTKE6LO\"9(MQR-11A;&;@IJIC+;Z&;@5?D33]4[*+M
MJSPP7A$1:5:="&=T`MP$A@8</KY_H3XHH%0XBBSF])&";DHT!S6&"2/(]L6;
M4N0(/\&^@/K7@Z\7DF:.YF0LA0W<&87F_$0<1+Y@.1C%%"63R`D&W15W^J],
M.):AA[:%"\8F'#=N=7#;(7CD\>H5NU-0"/K,&J#X&YJWL>^!A"8?,<C`GN6N
M'8LX%OA!WQ`\>>8NXGMX+\D";])K3`#@T?+#S,M5->4A-)1!1G8J>ZTPD]&,
MCF*,77H,?^B',_^<?UY+(TTH>BZ>$W)1;SB%*)8>WI(5QK9)`I*K#Q!U:%R"
M%F$>\&.4H8&:@7&,3\0>B[ZR"*M8@)EICV0EB6^3<2-T&8^+X088@"P\2W@'
MC#:4/N<VH.XL03+=^U&6$"JEF'411BKX+P_HHC1G]"CBI:`&BQ@?PS9^DT4;
M2$^(G":*%0O^X(;@-2K,8HF)*RT/R"`]`J#ZS-0"5$]8>'=Y\RF5%\2H?#,/
MJ"=3`>-[:!B@6L.?&THW8,<*589<XTMV\IPVJ]"5[ZJ@[-NI`#9T_64EP+;]
M_!)@X]`EP/6GZT_7GS[I^OH#MD(IIU4*>5[D.:<\SWE]P;UA+\K,4CAT!)X6
MJ"IL$4!-)Q:,UKTGTF_QQFO#;.T7YIKGWIL;T?__C+-@LB>`--\"D'L^.E5G
MW/.0CO7IK$_G^0"YYS-Y[H665SQO'K.&=JRJ/493H5;G.&U&7P_"MGZ<X5ZO
M!6%3U3O':?+^^OS:4NVF?M;4-`RU;9PYB+IJF3OWV#@-$&VU>>AN;4<&L:WJ
M]H'Y]+R*PK_*5Q>G8B`8';75.G`+CB,SLME6'>/`,]^/+8XL4VT?G8ROR+/.
MH=O&')MG+577SUN%6I;:;IZW"FWJ:D<_SO325Z.BH1IV!48^G')DH;]4=W\J
MUD,+^'OG^5PGP=^.:N@'[M=[9`@[JFD>VQ]]O5"*V3EO:AJ&VFR>MVWDJ+IQ
MWA`::,V?MUQMJYU#!_K.*[KPQ4L\-\::S7"J3+U[+XA8N06O)CN9*PFKK5K6
M>0MAJZFVSOQ2PK)54W\K9@.PK-TY;V_<=M2F<=ZGTC%5TSHVRQZ8BI;:,<Z<
M4=NJ:=<35%YD2WP6117E;D2G8D%<@GZU=]>ONPR#?3703!-.\,[QM"J#UL9;
MX6/[;:_'HBW5;N\LIJI,QTL;8V)GR:*7EJDV]9WSI2H-6E-US/.$S'+4]N[6
M^8OG"9Q.".%W+SU1A6\WP=O<67=4FWM!Y%@[Q_JJ#%I+?XDP/36%CPYT>^<L
MDRK3\=)Q5+UYGJ#9IMK:W9NL-&@&:'S[3*G64IO.SGD5KZ#QJ^OZ+]D`18^$
M2^/U#8*C/5?O])`[/<B>B\(FI\9TO=.=GSLUI\[:*-!ICLBKR^U=-;?>.$]?
M!P`SSS(DIC><-^/"`7.>9X1,;YRICW/&XF3W:]R*`V8?)HYW^H[;9CW/YX35
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MAC@D$5]/LOD\\/DL0C<`5F53*.^]^`Z'H-`*U*>==Q3'MN3K0,!.Y=B%'*=]
MX$A'[`L_C3/8!\XOQO/(OI-ZD[L07*;;QX4%\(\TG90W+"^/:>.3@5">T8PC
M.%_POGL;>VRF4$,9;;D!,5TU#FDD;K&?TFY@E=O8G5$_>#Y.C75Y?PC9&#.:
MMP%8O<!F[?YLG,4):Y;.!UL6VW^L_F@7-H`)$3J9Q)D;)/F<G6*$!N,GWFL>
M9R7ZV-HUQ2;M;+:F&-'&F45,')&HR&8;%AWF<3Z*&#."S?AS:EZPX7E)-OX7
MM?B/E-"[C5*?Z*Z"Z@#:$IY14,8N>R3_&:G,]`-KHZ_0L`6:2S5W'QF1:,`)
MGY0*?YA&.*[JBOU5<!N;=".6Q6%Y./D3F_3S80'YZ:()"I,['!D@1N)P-KYX
MQP?#J/@P#DS`*41>&`,GBT?G`%8Q3A!'"P1BX"6B$P<4\3D#U%B_C'IIUBGL
M=.K3LW1HY5&I1%<Q]=U-DHC/TJ*A,6S^%Y!(R^9B^!B?QS2_HQ%<?%3RXL<3
M!4XB*,EB=I3$+],LSL<3B&%=&[Y1WO*Z#5^\*[:<QI[+AQ_>\:$TB]LKS<HD
M0P'I46)I@=:EU4(XQ&@\<.J(<1FP=9H0P04UFZLE/49K;D`+?P[Q67R1S4C(
M=RO6DMB$#[%@<.%4$,0GG]I0GG*DYEQ9DJ8@`33V`<(IGW.!!_\69W$MLI6H
M$A13K/AL-28H:2K&`S\<;"(WFY$]BV(4)C<XO06'[0K<`H/"(D@@HF<^P`Y6
MZ$[O:>C=7)P]W#7K;("LS=45_R2.TQA[;()0Q.9DX$EED[KX`(R2DBIKF%Q*
M+<_A0WS1E!1_6L#.^)1CB!X15'?%'"PQ=)GMF(VJPT%8-&Q%S)5CC^2PX%.Y
MD*0A4FQ.,@DCP2F)8-LQFV(K#67))PJ[*=\%4K>A_!8]X$@L$"-3)@=HVFCQ
M(LZR&GN4RU&L0>/%\5C1R&9\!"V!!_AE/D+<973%2=4TL5-L$9E2'CH"/)SP
M.5%P4DCLD?IDWP4\\-EQ:(23PBF-DZ')(6MIE],D_Z;X(IO6SB1PFM$)#_!%
MFM_+*"[`3A@@_$SP,23`C#$;-`CTFGK\'Q<T1I8.,Y*K$$R"XXNY\,78L8)V
MS#X2_,I/!)NULA6(C*Q<+MSX,;(`G^^+<Q\'63X:C$;-X2F8@I$\\69C.(R6
MH5*+>1J4)K0[,C#\B#U)D1FD:>%@+@'H`IV(MCF8/S\(%-(>/]F-E@(Z)L`7
MN=)\&HQ\`IQT3/C+/<\%/"I7)&FM1=F#9QD4((`8@75&4]+FH/Z#9X_NVL+5
M*OMFU]+L]B$-:\>!50,V;1UX;O^#NYJC[J#9-3I:9]0<:;:CC[2>8]C:J&.9
M3=MH#PUG\-J#N\"A>VIR5V<I"LL'=TD(+/[0^9O"L+G@J;W2H*XE6'(O\PI.
MID<N%FU\K4MY[(EB8E26FX$2CDD9&;JJZ_1_!2DHSD$G>`$P,IK0:,'AE"P:
M`NLQQ0ZV.<9BV*C/G_0&K&B0%`?"&2A!+-58\Z$''&<H366:>HE_RX9)7^-(
MKZ1XHPL+_4\6HJ"Y0F>`)A#B!A9W>KGT9O$(K$$/?6"R.0P])LO()$2Y<DV@
M765PYE&R?,'H8J+@Y#[EDOT#EL!_?F`&!<@JGX]%@\W)D^E(@`(>/H?*WU&$
M%'^R=/J;R2VH&S\@R8I*A8VR(D1Z.(D[E`U@CA*ENP@R64%$-2'`I8]Q24Y2
M%B=HJ$I(P];X`IP08K*O0+_*!F&3"8*>?^I*(:_78.:5(B0_=OUH-@.\5/O,
M`>7_QPTS<#4+<IAMKEA1K7)'#;4:SKH#A.?3F['G-W.:L%VF@X='*0XG.=`,
M!0GQO$^^1C8&A01_!]+BP>!'EH4W01]//&^%=E9^,HQ6P\RULWN#(^*F3,WG
M8Y+)G\49F2PP-)O!;LFG).7-1X"N6KS5<.!UOCA)!6%;\L"(B%"57],;S7Q'
MY`,'WBV&"3#.-*&/X49N//16X``5_R@"6<)38$Y&Z:23>2GP5!6>9@J.YA*#
M=<$./DJ:]:/.C\W@W72#P"'RWKD@=&RUK3=5I^F0R1??%U*'&%QF9)5F1`(7
M,6?"Y<X8O8-&77Y&6'R%C3KT&.(F,N)P4#"-IDRR&=J0?%9TNCQ8$Q:X9`HM
MS,CVE<?Z??CY><$V&=&K@F\ON+YY<A!1->;VM7>8VV<=<:S967_[\/.M5MVE
M+AZ4G9AX[?B1_#;4[C2,%?*4;+4^J)';*-[D+NPU4^1`HU-*[E-6EK/13?'S
MM0=:E.)2Q>_2J/AY[)41,8Z5ORZN_Y'9>]_F(#V'/[QXXE-$].D7/Q?FH?*9
MC7E]^J5+=W'F\F%R^X],P!S>/SQT'KRIUL71[[=;T".GP57L3YY-B0+<[4DR
M?A,D><F9^N+-7!]G,#^-S6X>'T6[Y:.P6[ZAW;(%\3?:@IO)./R!][QX&@L0
ME"\B@/CT`F#_]*,@FX5P1C]L\;W)GMGF]/-J-Q=$#M>;J^@#W;-KSX31[E'A
ML;"CU$H^ZXT5747;:G/W)@HGEN)I@,MZ['9VKTYA4VT;!VX[>6K%<[L>?LQ$
MVR0`3N[T6ZIU]!:6KW7X.PWGV-U7GT>MS?O8885EG!1A#KK9>:VM;B,OI$#,
M>M2^`K<MRAUNZU*X:"E3>!7DSY4'!_W@@?V!&G\U_EZ$OW-W+&@<W&YFPFN9
MBX;:.=)TV(,;_\YQ&CV_+4/_E!2W!7)L&F7CP'LMR;G[%U]?]1SMN9KJ.RK,
MNN[M%.K>/K(JGT3*%I$OV&$5MQ29YJFPRQ?KRO#ZZHH*?_"2?OT]__.KX(Z3
M7H$95\H52YHF2`%3F`][[U%DG79:Q22+ST"*)_:N7+('*"WM`4CF3J-Y*LIG
M,,.A%[GQE!+$_-ACE2?`$=UY[`<%16V6EL8J%-QR.)IE6B12<N9RRAO/;3(I
MYPTS+:8\E8TMY`:8G8.YO!L2F7AA0.PML&F9/Y&+,4^$\GRD]$'OAY]08A!;
MC`76+G$KIJZW>?`-7BZC3U7X$[H(SRW^G<K.^#/P^N]1J'V^N?$G\/65;WS`
M='%WM@Z(BW=%?9"2DVXA.<I1+98TJ83`-'*^Y,R=>DOGV'U`"M_&;JGZ2%[]
M]XA6H@?92K`(O0`D9F\`>42NH<!J"94L-VR)ZK`.HWL7WE\M=^1*+"F?D.^F
MA)"57Y:2+55*"YH@(H,`,Q6ICH-XX0'O2[$F#!,GJ;H!(<+:!K[UM6+,X!F0
M;I!$ZS&KS+-X'B7>:@R_FK@PS`WR`@OD^#8%+?,MYN6+[.3X.=,R)/N\AL)-
MJ5Y-5681_!4PJ2JQAP4/*B]H(8Q,A2A1,94.#P/5A'JS>1`]+N3B>:"E?$3H
M')Z*B)YQE-VR,BR&6I03@AEXN2K;'"OHN0-7A)5E$&_YP#[W_C3#S$9)+K*J
M"5Z0(0H<\MQDA'R,Y4A>@KO#0P!2Q*4ZE9LLIIV2/KU@M6I4Y.GQHD7&!@"R
M/Z=:NQR7LE!D]8F([XMW'.,BX5KP<\3NXU7^3Y2-WH35)2KD;Q$6\;.Q3Q4?
M/#%.!I/_BJV0A7Z:+S>.PBQAQ;F$("PWQ/PXP`$K$&3T$`5_[(-4PB%2GI'C
M)U1GDTMJF9*XAP(?22Y`J/0EC-C)HUP[IC)*0@`>HMWFE8C1;`XG5,[S3Q;S
M`1F5D"G@3VYRQT#DGV\4"DWB0OQ.F0UQ([R.#<MOLB!U!0G=Z;V?H$+$(B-8
MR\/SP($KGW).T@:FAZ,@3T7/@/Q\4<ZCA!&>0YVSLE"A@@E(&O)=TV9"T"S_
M!J:F*IVE9\NGJP!7O"G^6!Q-D89OB?1OJNAA-65`X\1/\X+NO%8HBA<^+`!B
MI3?R)E:)0?E<K5+2^/XJ-8T61U$D=8,G"RN3DK^5MXLH?-Z&"VS@-U#GY5^)
M0E;^5"'1/7-_^+-L)I)1X:`\92WQXCC&:Z@)@2"`@(0G^,\E9EW)UHQJ(/L-
M7;7LEFK8NG3RYP$>MD*O;]3CI;+G'?1XH<612W,]3EHXQ-/I)IA$_JL@H"IV
M1<LN%'R364`;"OS\1+.\8K8!_&!YZ?*.V`KY-J9LP_#&C>?3/V_`3,`O86V_
M*J_&>)ZM"4M<>C\FWIQU..`;AM]0U1\9URXK;\>*%E2$,26IWWD!JZVC.G0J
M`18987.>$:;@:2NL$][G(:^4<W^PA4`U`8F0,\:@W$C3)!\(%KQSIH)5DMZB
MZG05>V`A(LK@6Q2AXT7#%K">P`&E$MFU+(95*M<,^EPNHIZ;([T(F$?VME!2
M0%0L:Y#/-B/).LVI+IBSRR#`UDDG90Q;"$V2,JL3?<"2'F))X5B%DZ(L,QK.
M4OG2#6T'2V:9+.$=9JB*%,1+`>9R`0+G2"Q:)UT])6(P4P@Q\>7ZF\#EM%RK
MF;!BS8U.N<J$?A07'ET8X9JL=KAT<M,MW/M*B,8%4A;R8=F5M7#SIJD"(P1@
M["F`-A`"Y>/,O>,5OG&C)(GQ#>+//(*2\^):3EPG8BD+%%9@=*0&%+*C3.1G
M7R^Z#JTZ]L4F"F6&>@!Y"$XGP4S'APH>7#^&O\9_>FEA"[M"QF]MBXER\M_=
M9.K^6_DUB,94*WWM868A%KGA!Z)P!42OQT,;0T"?2:RL]-BK6V0C!056VYM4
MU\G=+`;:@E^7>]=,^2U:23$EM99DPCA+45Y@N(`_#6MP.T.\!CJ0_*6$BL*I
M2PKG)!'N67(_F7&">V(:F`X,L7N2NZ`L?/FS<NE++=F>BN!@``S^R@-@!.5R
M&"P_Z"COY##80GFF2>69L!QY!^486,G90W`68V!-]N[?8/\K`%@38$(3@?ZZ
M)0"E[</+"\+/Z*CL8VA:S#PNYLDR``J3X8V@&)V.O3XD1D%`R5BB$M>1-X[+
M]8ST*4/_&W>R`.I%L.$S[:<C9@70:&448%.M_^K@97:;):D$=5NE;PE_3\+B
MC'4W*%#`E#(ZHKB%V(/ML#^&[LQ[7JAO'0OHC*0+2Q"!GR,.]U-3=BBYI6^0
M6\M.,C^AI6AJ(<:D,"X7,4Q<+/K0RQYTX8Y2F$+RIR_>;?*H52G\P4,>RW&7
M%;$8$7&A.ETYZE+:3#DJMMH]%_V:\HC$JMC"2B9:@S()827`%P,/VX"^#!^:
M3XOHEL,I#W<1<RNX;LA)$4:2%XYDO0&.^C,%QWN3I25,'!Z;#H1"(>\PCUB2
M2<4,JJK8&4-!:-:0(.\F4.E[IH^%>"?5D(.E%AM=)XZ%P&:._R;PE4N\5OQ0
MBDHDS#.2+J),ZW+\@?$)GH&/O-F>\@5;`H']VH^F9%T:G7:SP6IJZ$%<FVXC
M5&=]9XNE*`H94&//"^7N&,RU$S<VC$_E;G/L>A2-`VR*F,>WB\,A_#PRU;%3
M&4J-1_G`H?)X`.L]N?/G>:P9%1,[&R)&CLQ>-+R@>GB,&+#V@M3]C>)@_@1#
M!=CN2Q3OHWCD7?APC3S`NXR"1DXS%@9E%CV>=>H?)CIE:?R?O)":,$!=SA)O
MYFMN&&(XGKJ<-3CMX7R*[TZ9I]EV_B(P&$0/+,+%^L)%%+#G3@[W7*AOT=05
MMU+H;!<=S7C\CS?)"MS2H\L/5D4ZV+IQ^><'X&6T/&A_E98+?X#&G0,K86A+
MX7N/B[W/F?$&O#M^7'4,6!O%G*&H%Z(/_H6G9'.AX]!=99S0U`5W^!A)"UDW
MKE*U!"<WFG$9"!\?E!_HP60"JY*-1TS(HS98Z,]K_)D269(DUSR6''NW6>#R
MUH=XUCFD!-X<8P;4^47J:39ST\D=ZX;!06(]%C$\=N<&-Z3(X+!(H3U0N]F<
M*5$W5WK8,\>B>U[6!#!_FC4D?7[41Q6Q?FHP([>?^TEO=$17#123/QD-24**
M/]#K^.B*/_%P'9AA&'P5[1L*XHCN=FNZZRRQ#U?D53F:?8K)*E0!"42-`N`/
MK-?%.[=*']+/X0JV8(X(_/<ZK2U\6U=A@#.-NPQZCW4)Y@J\_['/_1@X*"#@
MQ;]!C^(1*6+!P2/7JL+_DBXU4H)TP<$K.>9YG'1&_3"]"467<2G6]11["5)<
M=#GZY_",!(,=Y7R#?L(['+&[(3K&XEJPZ(0L(MOLH%)'Q66QQE4@M2AD)BN+
MY[.\!X9``HCK<CA3JM1YA!IL+KV!1R__1BD0EU^Z$>R$FHS:#;JB*6P4BP@>
M7>,744X\BGDG6=[P$WMXRAT_J76J9,05*$/S+"/S16IFZX?D"'-%*V[4!4YX
M8[LU6$&LXNV4.\F#/\77T%NG.CB^%29&4@0];X3%4XCRSJ5+:)>7KT;PNC!0
M!:3JE@S$V8>G1+CR18L@,4>+Q!X^&)J^B'!S-J&#N<@HTC4+VHE]%YP\Y=+%
M4W+CAT7'G/S$<X]<7I^`$`8_W7\IOT9@E7UA%VI?>$<QW.4ER8=U:U/[2^PN
M-T$C%5D<GWCP@GL4`6%ZAR\7)V@5OB3*J\L!Q/Z=[^&)'/[P)AE%$H1#_1!E
MP11CFQAA2(.\P2BE`E#.09++0G8=YZ%GC4^9MJ0E:9>L$2LU67\4MZ=DDP`=
M;]DLW#P9`!93^=5>"GJS1$K/*V02[P(,!UO:"!FUG#/(6,[PTAUH''A%W^2,
M&H]C8$`*[_(P,;M>4OD2Y8`E]<+SJ-O>/]`^N@+-3_U#F=>_\#N*_(6B[<`5
MB&4T80)P*)%<R0>.82+O:C2C9%E"=('F$A^LPS"*E@4</Q_#E%]0QO'S,7SQ
MKHQCWM-VV^/.#GM)EVY[W(G1Q?%^UKE_^8DKLCUR/8EQV*=(OXGP\'YSBP.&
MWK"&+;-%KW.F**1C=_'N59F"M<D$)2]ERY1OUIX^F(VRWKAX)R+S>41;71-6
MY#BG7,8RSI&@J_:+>^$-MHF*TIYX+)!=1>>-A3<R\D8-O-QD=^N>N:S5[M3S
M?^X*.W`4N+=[:Z5K.-V.V=*[VF#4&VEVO]O2VKV6H;6'`\=J#XV>,VQ]-[X;
M[W^Y`=QZ__77I:T4.^QC6T/X)4#A!O\$!VX83@=X*;JOS8ZL[@AV9VJ#@65H
M=K=K:)VF,]3ZNF5WG%Z_->PV8;/6^U]@95.S#+;==?LJ=CZ(P#`L/3*"WR2O
MC678."["=KUF3^7>RWV,4@0XJ`,8CS5GWG^[Y4YOU-%;/5WK]P<MV+T^U'K]
M]E!KV4U]V&\VS5&W5\V!.#T:/T!."6INP"8?AL'U=<#"HR4LDI3[EO!6I$/1
MG7RM'US5R3F?>2ZJ``T#O/D0$;H19"WDQ8R<M#1E9!XE+"G_0@P$88'D.9>@
M_"8$U1@;"\)#K`\@U()'#8.\4Z[-_:E/PW=^%JH>_)_8G7M@D$X2Y?(CR%SW
M`U($TZZ53QC&8C>7A2M9>N/;_ZK*IW3:4"[Y7[_]+_CE70K2@LD@-#[OF2IR
MJR4!G4CA;]%R./>\"D:H^`2:;>G+QBO(:<KHGC6N&X61,<7*+\P!ZDZPZ3VH
M0`QUR3WZ>>H>SNC`&(8')I,G4L9='(@T$8EQ'O@^"C6X#2>/N<6PZGMY@MW-
M#45*:5('$"DHFQ1BS9R5%O)U<J`E3@5&B%;#2-9?7M(`WRA&JD2;$,I7!N==
MVB+ETA&,.#4M;RG-3Q1Q%,Y_F&4L.U'TZ)W-8^\.C;![:@:,HR4N<8$/A:TA
MYUS(X`ISZ1)=RHF??A`W27ED`FQ$2I>_\[P4TP^_1I28Q`><\,W@EV5<RR,E
MZ&RPI"HB,3JSU*,[3$5P:`V.A,P`/KJ]C;U;/,ZW,0!&-O4"9TCGD>/QDB'Q
M0S%Z`5-T<H'#%ED,#C\C-,PJB0"R,E`5/^9?67G0W,WG=S&K\TFIC@]AY0*R
M"T7/\#Q<O"N/"_(HYB2UEYX7BO'RUV[WZH.80(+7&J%[*T+8(I98FMZ!,X>R
MF<A2H/SDXFRS@X9?FPFYC+8TD)P[V('OCOV`CYKA+;:9-2P,;=@@143S=V"-
MTEMI*1&/1^8V8TJ*)BSND(D'=FF"S^1#.HKL5)(Y^4PF=N=&4I2C<SUZA*C`
M:R2*&V=A/F*E2]FTN32;D&LS];%Y-][!>#CP(V##O$@&8]W3VB]1:2(E[=Q&
ME.B&-A%=DWB8&>E2?4%IB(ZJ%($-MK@TB:08RI1X09!?7W)R\HQJ5`:<!Z79
M<]*L,E4>[I3/4+EX)Y?\,'\U]#`2CO.&2,/DR9PX7@ZD?,S=6A^4OA]SYN1_
MYA)M\0'*T8RB*674,N$=WFJX[REG+34/^@*_37PJJ*'16M-U$Y]D>,2U]D4Q
M[XJR7A''@EL?%X>[\.;W^3BFZ-$-4CZQD)1!/H>JN'KB-4J<KG@&;L7O9Q$J
M--0W%\7L+A;S7CTT"3Q^O%F<<)C`7A-M^9G,X8F/"\>[$`F@+0*<Y);P!N88
M"26"E:;"E0/P+`FRV`9-2V1*#,UVE/8@8Q"V?V73V_RTCL%59V?;C>-'_#,Q
M1;)!G(AI1Y1&PY\6Q0"PURG>J((9X\;Y+$)>,P9XHJT.B]/%:B914R$]R$21
MPB/9?"K(R@<8<96W,(XJ9&',Q]63D(@U"T&].`TIO9-BH4N#CC;KL^58Q"8?
MLNQM?B1CY:O[XY##?8R!.>@-S!&H1\<";W/D:+UF7]?`!S4MNZV/>GJK4MYF
M><B/82ZUVV!3?ACR%,">EVSK0OX?35-^C.-`'4?31T73JN-=?L(QP6,/S3J,
MA//XX0>6'43A1:K^9C"G"+,PBY/R1`)^G1Z%9+9<KIA$L)MI)E]LF8LXT9\_
MEN#E[3+:]I9S!I#J/>\64/&5=O`;SI4M$7_-)`*G\_Q)!,WC#0-PSOC3BYV=
M-NZJ+(CHE!FK&MN43L*6#8(VK?F,U5=W)H]OQY>Z"O__@]3";GUS<D-?US#^
MN4+(*(M@C(XJPTW)0ILD[AXPN7G-FAF>,SS@A;R`VO:HU'[SZ+=J]!\3_6:%
M9!V:,B"7EPV9579.;\G(3>.7MA[=MI?H[I;P`&?DIO[D";?K=7ETX^K/A?"G
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M=(=`\<+W]QDXENL3*XBL$\B+J;FCYHYSO52R6D>F\(=G&:%[MB(/HN^NL>U(
ME;7=WH[D,5G7J"533>>:SC6=JY.S6S5%5)>2O)(59;?-HUM1M7`Z:`%)VSIV
M6EVMB%Z+UKIY["R[NH#D[)+V:RS66*P*%D^O@.1KE+J!PN_G:H/V\`;ML=VQ
MVJ`]N$%[@D9.3>L=MM'N6*='Z=J<K;8)46.QQF)5L%CUECX#[\8#PW5:YY75
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M(,^_N?'BA`&-"'1G41:FL`BL-\_PW?&CXL[GP2.^B4\DJ9MF:10_2KZ.`NMY
M.(C$<OZ"'YO''MM*@,,'W80/)TEP-$D]F&3GP21-JQY,4I%/U[,H"IS7@TEJ
M9EAFAGHPR;FBOQY,4@\F6>G9G.5@DF^-ZX9RPZI;"],:]I'/Z=MLQ58C5GBL
MYVJHJ@95U1/$NFGA8J)?7O'2O)<!>^P1!!U5=_3G[Z&^2ZL^;1U'[1C'K["J
M:7N(XA2P0_433@:KO-%'%>'GGL51D;S&8R<HG_V-?T7H?'1#HR;T*ZDG^]C]
M^G=735531/T[-[SU\#83]I*)RTH7;]/<<'+&GE%%>-G`;KVUAGH;Q`:72;>/
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M[U)/Z#87.B\0A@'O#X@_^/B#F+`(F_VA=)/$2Q/8EPN[_\3K[40UG9]#D*^P
MWMK=&JCF0?I<YU`Q^QS6$DV^;P)ODE*#ZM!+J2>U=W,#OTJPBI"UH0;8V:6I
M,G'C^!$,_0<WG@JTI-YL'L5N_)@G_$Q@X;&7/G@>:TE.;V$;;-8D&Q=V";'X
M/JP2%(A%+T*Y\4,WG/AN`-N#I5-\=9[%\RCQV&Z*AMN)DK$*$GQ/ZJLM'F\H
MUW`V_!M_XL*'L<PD"KV0`1=EL3(5>&$I2WQ;M`G>N1"_EU!7&]FU4=S86^C/
MC3@]TP[=K>;!.W1WGM^ANW6\-MD';PY>=T8N<)[WAFT>J#=LW1C[),A?-\8^
M5_0?MS'VF^O,/%AE]#QAL50CXG.LYTX9JJJGQ/P.;@>?K`-V/GH<L(>2HW$*
MG'F2L4C34ENM$XQ'UD3>_NM6QU"M]@G>*IS>K6B>8HXQ@P@S_5"2U>GFK\+G
MS:;:;-:R[(T0VU!;1^_C?88%G+EG$'OW7IC5;5(/?N/?45M.W4KL;1#;<E2G
M?8+$/CU+K.XN=CR)9JB=H_<QKR7:*Q';43O-8^<BGJ$==EWJX@O?K_OXOAI+
MZZKA'+NDM99?KT3LMJH[9^!'5M\BZ[MS/X5=_(><2Q8G@UWPAN:U6#LTIQNV
MVNJ<8!2X)O8NQ&ZIS:-70)^A688!_OC>$WF+[F029VY0"Z]#\W-;-4\Q;E+3
M>C=%U:RO*U]#FEW%F':1/JK*/,#L:";4O']G_GSF`9BU5#NX5#O%S@8UK7>B
MM=,^=O_&,S3(ZG9*KQ(E44VC-K_>"JT=ZQR&^YU^A?)9M3BIL;C_JMI3\#'D
M4@-173GV;B*ZU+H7DYGKN<RO)M^=CJ.VZSS)MT+M=E,U.K7CL7>Y]H]ET<4;
M8$V7)5XMU`[,YI<HU9I'Y_-S;8I5&2J#--/MTZ%R[914VYRNL?@VG9*O4>H&
MJUN_U*KZX*D)M>_Q1BCM'%M3UW'$LU,V-18/H;)/0D$'"^WW*JJEZS&ZE<):
M555\S28GA+7:*JBV/JNQ^#8=>6P=]<;<^.,V$ZJ]]W,G<.VT5T*QG%D[^!J/
MAU#1AVJK;QZD!?T7#Q#Z'W9I'MW`4HO]UT5^D)_`K^=>./7@,]D<1TM1&;SB
MN7'HA[>)JO@WBAL^JA?OJ!5\ZL^HNSR@HN@P_W#G8R<V>"T+)UZ<NG[84'K>
MQ,T23W1_#]S)G[B1&^5;X[I1(%Y\2+GSDS2*']6\/W[YN=7=X^_<>T\98_/[
MFRP('F'Y&_B],GY4W%4I3PWEZ]V:;"AL.1][V,4$W_ZITV@5WY[Y04`/4]7&
M3X[1:"__<9K%B!G<_2,`E2B(U:FRLN&U@F[:!>OICSUY5:S3G7N3U+_W@D?:
MY;H]!MG4HW$`\WD<_?!G;@IO*#]93J.YO"?`MM2H?\P&B2DN("A*L21X_>9H
M:VO_;,%^`_@R4"."99*B!4RI`0PMXOWPXHF/XP3FL1_%\`;AR)_-`P]K7^A)
MQADT:V`R0;9"5-YF_E1D>ZS_1GH'\#P`P+#&V.,]`&EG"G;7QV?<0)F[/@YD
M4":L-AI8%G@FIF/B31N;;=ACG^9OX13.1NR/LY1Z[.1'AA\M3/$#\:DDV3CQ
MISZ.AP!(/\);+AW*213"[[V8(66,!V#NQ?`9P#[P#KP<WGL)XHR.-1`@QJD$
M`9S%,,K%!KQ5/I&E&0W%0:0I=<CY6"_@12`)OLV)P#D0G#/3NR@I!`UN&>D/
MP,SPKU,?5PFG`"6F^E"+QP=@(U5Y\)2'*`NF2&T`^5\T4R-:N[F&TDV8$%S/
M[2J]K2Q#%$;I`E0$BJM,LED&)P#.*WP;&0JV_)/5Z"C2T4LRD(H"/MA&^'CQ
MCHD9XON`#J4(M3X60/E`KF*0QC3#3^1$9N*/=[KDS"]>%/S,)+F,[[UQ^"'&
MP*!K^3GO2OR)=25V0S86IL^FH?27FA2?TDB8;3@0V/K.A>-'NJ_<I+G4HOGB
M76EFRHI!+#3T158/J+0,U;!6Z2U5H;$O("(*38[2%/@)>Z\#YWD_YGZ,7`G+
MP%;;_$!M!PP['&RH"P"&)WD]:$L;5WYJZ9V&N;QIIB^XW5%^PS#M1C,_AM,(
M\(&G>.9Y;/3.#`X2G+H_&5[@`(7T=]AB.,4](./=N4EQ]+G2)?6Q=HY-0_F<
MQ1S.#1`F*W%+8@$QYX"P3'W)=%,2)"Y7C<MC<DJL@O<VFV8(D2Z0!*8;AAFL
M%H!%QY1P@K(&<<(T=!%1[O]M`FBZ]0@##Z$7)W?^O/CSX&_%:-)$;/8CSBT`
MS0OK?6$-+I5^-"58C$Z[R8"`3P>N0%NQ1L7U\1\>4PZ<'K"6Z+*2R^5E1K;U
MAK[B\!4'CLR7Q2.'3-&1"/[DA_"HFZ9T`-@'N#)C"S/FFL+S#64!%E"V<R`U
M:NLXNY6_\I/16F42/RTPS";9LPF346+%!5Y$CDG<F2=S(S,9)EF")I\[CNZ]
M2FNQ;V'L32+0V__)10,WN$]/7W&N8.9*1L)N62O!ZXG/O1)O3E8&"<%Y%/B3
M1W0MR3G@XA/^%P0"F)G$S6"^LQYKDB,!SN-:#.9N*+!:>L=-Q=(\Y++QQIY`
M0PD8"0/X]`TZ0[-\)AF#!N6-\O$&518R)<JJ%.0BG%ER]0F&?%^D`'(G%T!-
MR,&`_>$?V#0WL@F!U6,\L#/WD5G<@,-L`JX&GCA"*=G>=/9<<EY7.GSN+7P&
M<`:K<_N;"+'LRHN#2*8@^%8N'S3'_74FE-%W6-ZB<`N3.WH9L,P?3R1_GM,C
M!QC-S1OW/HH!28\*;"`-F(8D144Q!+)XP0?[5Y:D#.F$RS(&R6[)%V7;!R[)
M@A07`]U<O,_='5ABA86$CF4N7IC>4W+%!P^"]T"ZG@EK6![?Q"_`L\D=K)L&
M[F/U]<Z-'WBEN8(`#>`ZS-TG9!$5K.7`!^A#WU65;N".W1G\@.>.G$(Y-K,2
MFWSTWX*R85@%,1P#NZ.O"193ZN-)02LH"/(Y?["Y)/4GM#T6"@&/!XD-7V$Q
M@4+R(TO^<(%'729`_F"GL#@A60B*27ZF\&WQU#.NO@$]`<HKC[L@(*:N=^#/
M<93=WI%5^A+JEL/;R]3.B;L^_K@U]^@'-5HXPFB6(D7R4!J@^TF"F")8RY(X
ME\-G/GRQ;1]\^.*&<89+ESW\'>=XPQ?MXWWZX%#7@_\*G.>3YPR]'OSXENE?
M#WX\5_0?=_#CFT>_62%9]P;F;A($(8N*CMW@O/M='#F/J:E:S;J+^WG3V%;U
MY@EV.:YI_`P:6ZISBCFGE:^P*H4X2XDS/,Q%@:M34$_'>JZ&JFI0G5X!0Y<G
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MJL@\"RNJ?8HY#[5`J`7"6:7&*#+R+]Z)#KA55I)G(?TN6_:QQ5]UIWO74J]2
M6*O9I&:34_$<#Z(NKZGS)K77K+)BK,]#I;!6B\V:36HVJ=FD=CUED#YAKUCJ
MI(R-PK.4]T>66M+7*K8^%+7LK-GD_-GD>&RQSTB6<?3\G>TC66<X6?6L1G;7
M6*RQ6!4LGEZ<:LB&<M2M>`^J\,R6ZIC'OKPY>^NF;K=<T_C`-#[1=LMG:,.>
MV53[&H\U'JN$QTV#*:3)$^Q1_.T&\_6UY_%U`YR#=GNG^*GBX[C2V'.3**2)
MB/,H27R:'XD3NL6TP_5SU69N/AS<Q<%\.&:8_RQ-O`R]'ZF2/GC!/<XQ#M.[
MA$8M3R.<5GR!0[-3?^+/<:HCCG&4QXBS";[)QNENL`*.]UO\5$$_]LV&,LAB
MFA0'S^4S]VA"_*:9T#B#AJ;_X304&BTO[R\?#TKCWHOYH`_P6T7:[Z8Q=1?%
MP-`-P_[8?^A74_\>?_E??\T2[=9UYS]_I-&*7]T?`S^9!%&2Q=Y70$0OB"9_
M_@)O*?\EGOP4A;=?O7@V\,9I_@B.&TWA'U^\F_]^[T7!]ZNAH;>LEJ9IAFWH
MVO_JNJ%_O_XZ^&XUG>^(%L.TC._Z>\6?_O=[?_K=,6U3;UK?ASW':+5,2^O8
MO99F]YV.UC5;NM8=]?J.8=C-CC[\CB_^@G!P,!:/Q<R-;_U0`Z?O9Z,]3_^F
M\%^P\_^SCK]"#&G(U#\;Q;]OW)D?//Z\R/S2-\;X\^]1*O&&LR3\*/RJ7'LA
M-MVX]B893BS%E]@]RGBE\[=J]\TUFT=4:SZP7IC^;/]E)V`^A\K_9,%CL7>#
M\:M)!\M/D@SV_)-A.@T]'ZF,8T-O;V/O%L[9!345"?'0!8H[B[*0YI0F#.B$
M`QTBT,HE1P6AX`.=:S&5%<YM["VO-,U`%"SMT*$=MFBLLB*O2?SOQM*HW11D
M7T/_2_'R'(XW#OZ>*7/WD:0L0$,C4!-OYFML)GC`9)'BQC&=;MR""W^(2[N@
ML[RX-03><R=W)!=HA["4O$<V^9GC9?R(PV_].$DU:LV"<R@#WPOQBQLFC(J1
MZQ]#/'"A1_FB`I\X=SAVP\2EWQ(98P_1B_+I)]ML.#DA8;E5Q,-/P+H@"5,2
MX;"3*)[B^%%:@Q$327/MS5,2=\0QB#'O!Y^4SF>3LJ'6BQ^YH.GU9:S0O-6)
MY]^C*+OS^,A4%'3S.)IXWC01E%*5P$N0UHL3QB7(4%\42`!H$L37'YZ2)6Q]
MXEN^[DT<S>B;R.XT=IC/<%_:(0TY_N$G?-P\\0W(X=@#9EK8]4]&RVS8\H96
MH/KBW49D<U3#NS0@&;@98,V(2Z*0^(KCO^!`L\V.;V,KP0*&P<$DR^+A)-V`
M1L`D2^`[<)C@-_>@YT(:;TU3LA%Q^2\OWC'C@>Z?T2+`(QW[DY2=@;$?("(`
M_32CF\X-6XAF)./FQX##$'B%S?Z=N7]ZN24BU@(D`^TH?TQ5QEE:V!+Y=L5^
MY%'=;,(S'%WXRP1.*"CL&%A^AMR#YQ+9RP6*3K+`C57EIY+\Y-Q5\#4N_>_,
MC]G:-"X;V0@_SX9*N_)^W<F$V`?^SP\6!1!1GXDF,LDF`0@+L#'PO41>A8U]
M#@F7?7E(>(^%*)7K.P^%#*PQPO.Q^CMBOC#"\V\0D"G.*F:ASO_)0DD[6KH*
M*Z'85NGA7(&(D*@0/&C3E#>)L.`/J"<`2V#%TS!MEPWX]O!8TFQTL-8BFG<.
MPI4F?/.IR'Q?PL8$ZN+P;I0A-!&[3!Q5FLV<,PLLROO[K)7H\*&`U`F(](PV
M1SN"H[%J19(^'F<\_''F9S,F8N1OL:GLW@]@+F#N2<&]3,@R,8I\&D<!&]R>
M,.S>1<$4(5XEQQX`4'D4,L5KF!0C'L3MP[_F60Q?`?.;]`Z<-S#IXU1B7[8H
M+,"1D.(CXB60=9-"M<+"0`=8U-"-OQ3LS\4A2G(F$'%*N1?=J,H\0!Q.)C%:
M'XB5+)R[_K10[+`6KH$<R\2H^#(I19>W8U*5;([2GV.-#8I/@'^8V\!FT^=G
M#^5-!*O=H`<0H:;@CD!:'%6^PQ*"$K"8BP'S9<X`^T/7ET'>"##Y,4^!7`!\
M=$'?)3[;Y/F,7=2Z$<JQ*9Q)!%T<[IL@>B"`W>`Q`4&8)2@[/@$S!XH%P,^S
M-)&40R%PQ4(XW![H"6L`1<<>:`'&V8M&*PUOIX'?)3O',/]2<'+)1B<+!Z4>
M22T4TBA;0/?CD25;"_W6&]>/,;"0K2#$LGNUTFDJ^U77DSMOF@7>YYN!!YP(
MVP%OK$L&7S><?O*9W@//D&($^_>\1L/NP#:=@=9KZ8YFMRU#ZYGMIC8<]?O-
MMMGI.[W1.L]+"F3S[&S9`8]F<!A)='/<3SF`Y(,SF_:"RIR4&];EB<X!YJ*A
M*$''%)_D`A>T&1OB_M1,]FV")=6;Q-YJ'GP2>^?YD]A;QQN'OF%N_'Y^7X_#
M+G">#P1NUM/0WS+YZVGHYXK^XTY#?W/CN`>2J8/F+AD[=;/8,X6JZH4>OX-+
M&\W!PJ:+I""B:"HY2&!\/[CQM-*%'B^#_;B)+;9IJ:U3'#)=$_D933,[AFJU
MG=,C\NFEU7[Q$L^-)RQ('&$X#249*%J_VO7@>R/M,?F\V52;S5J6O1%B&VI+
M/X.4S*I)L-PSB/$")SOCTH"*,++945MUC^`W0FS+49WV"1+[]"RQZS2:_*G1
M31\E3\SF7IA0UX!:HAU:HAEJQSY!)J^)O0NQ';73/,$2MZK;8==N0'D5++,+
M\V*B1Y:"7<NO0[.TKAI.7='W1HC=5G7G#/S(ZEMD?7?NI[`+5C7"XF2P"TPG
M#)-:K!V<TPU;;75.,`I<$WL78K?49OL,Q%K5A!@&^.-[5GZ!%^>8(NL&M?`Z
M-#^W5?,4XR8UK7=35,WZNO(UI-E5C&D7Z2,F_&-.-!-J6'\PQTJ06JH=7JHU
M[=-C])K6.]'::>NG1^NJ&V2?,<FB%E2'CI*HIE&;7V^%UH[5.3U:GV&OJ[/J
MD5EC<1]8/#T?8[!<5:F,/1P>!WO!2E6ZE,>R[NCAO'N15D2^.QU';==YDF^%
MVNVF:G1JQV/O<NT?RZ(+:\5A(ROJR&NA=F`VOT2IUCPZGU=W4.:94!FDF6Z?
M#I5KIZ3:YG2-Q;?IE'R-4NS9LZH*NE;5!T]-J'V/-T)IY]B:NHXCGIVRJ;%X
M")5]$@HZ*+K-55E+UR,=*X6UJJKXFDU."&NU55!M?59C\6TZ\M@ZZHVY\4<>
MA59[[V=.X-IIKX1B.;/!8C4>M_EHF8]+$]8N-HS)VK%)^[I.[R.J.?^['_JS
M;/;%"\$5O^)#2491_%ET:OR$X]`.U?>]8_:<=M\>:%;3;&NVV1UI7;O7T4:C
MX<AJ&:9C]MM/3MQ:ZJV>EGNK%[]8(YB6YM:E:^?6?<YB,89EQC"G!#0O3LQS
MH4[RV&=>:G5)&%1<G.^R?F#!BO[R2]WE5PY<>`I\`J?<6C[-N7P]RY9:RS\3
MG2_O1-]L;]F)?DV?^7;[^7WF7[W9^PKLMI]"[M/:[9]B-B#RWOJ6YP>4VW(O
MZ1=KC)VL@"=Y]/U+G9[=!,R3/M(%C2MR=G-E7J!F?]K-`+75%C<D=[$=M]KO
M?LA=(>(V7YVXSSR]*ZC<[IBG0.5*'^K6R='=476K=0ITKQ"5VR=(9:-]$E2N
M].GNG"#=+=L^!;I7A\JF?G)4MIT*:.Y3",K]7YW^W^M=];SX@V_=46+9(QNC
M,;L=U\/Z3*:C-IOUH7S6&7F]\.[+O_B\8UF*_M(O-L1]7Q"R71<%_G]L3G'P
M.!)#3C^&-%,:BYX.%/7MM8<]N]<SM):CCS1[U!]I[:8ST/K6H-G3>\U1KVN\
M=M2WN2'HBT/%65@60VH\,.JQ6&]ZET_ZS4(WF_HX9/;?`JGPLC0\UDU=FA3,
MPL-`11P6C%-CBS?]`OGX"?8%6&7LP=>5.Q>K:KV0S7&.V7C;?.#]V,59MF["
M1EVS!2_>E9:D"=TTUQ8#TCC=??JO+$E9Y#KT)EZ2X(AT'#2,S1M##%GCL-F`
M#9I?N3L%QPG[84/I!@Q&G%HK!Z\OL/WCQ)NG.*]<2>XPT"VMM&&6\%F&MG$V
M\XMBV[;]_-BV<;P9JO6GZT_7GSZ!BZ,#7NR7#2TASPL/*'UR*JEAKQM+.L8?
M1GXR`16+=U_*BCFO>W>TMWCCM6%>'*YZ^&NV<^>YM9-P"<G_SS@+)GL"2/,M
M`+GGHU-UQCT/Z5B?SOITG@^0>SZ3YQ[[O8JC:38!K+N!MV.4]_6S99Q\-,/!
M`K_[.@X[0]C6#QS:/C*$357O-(\,X6O!VE+MYH&SNXY,3<-0V\:9@ZBKEGG@
M>_YC@VBKS=9YBYUVWA#KJ'>&IY.LP2Z'Y?'&)V`@&!VUU3+.FI'-MNKP4-6Y
M@FA8IMH^.AE?D6<=Y]C`'IAG+577SUN%6I;:/G12RK$M=UWMZ)VS!M$R5,,^
ML'=R[I&%?I2D.)+W-HJF"49UIJ=B/;2`OP^<R'WT\(*AM\\:PHYJFL?V1U\O
ME&)VSIN:AJ$VF^=M&SFJ;IPWA`9:\^<M5]MJY]"!OO.*+GSADZTIH7+JW7M!
M1+,4RW.N3\!FL-JJ99VW$+:::NO,+R4L6S7UMV(V`,O:G?/VQFU';1KG?2H=
M4S6M8[/L@:EHJ1WCS!FUK9KV@1GUW`,.>=D.5F9$,T^Y#*(D^7`J%L0EZ%=[
M=_VZ.&6E2MQ]:9IP@G>.IU49M#;>"A_;;WL]%FVI=GMG,55E.E[:&!,[2Q:]
MM$RUJ>^<+U5IT)JJ8YXG9):CMG>WSC>"=EXA!.QI?)H*WVZ"M[FS[J@V]X+(
MV;WE495!:^DO$::GIO#1@6[OG&5293I>.HZJ-\\3--M46[M[DY4&S0"-;Y\I
MU5IJT]DYK^(5-'YU7?\E&Z#HD'!IO+Y!<+3GZIT><J<'V7-1V.34F*YWNO-S
MI^;461L%>L]-_,FKR^U=-;?>.$]?!P`SSS(DIC><-^/"`7.>9X1,;YRICW/&
MXF3W:]R*`V8?)HYW^H[;9CT_\(,L]4XF,_R<C^;9:OIC%\G5FK[6]&]/G-2:
M_B6:?JF;\;I6KM2Y=6TW'=X0?:FWZ]^43Q]_'VJ_#3_^^MM7WG_NCX^#K[^A
M@L_;]2YLMVJ=7[=J]2J;-GG?UZ)M;.#=B(N%#QO)2N\OOI3W?%8PZ"QUY75G
M48:=@&<N=BX.HU1)J8P^C:C][Z/GQEH::5,W]19?G68>/A;#`@AVX]F<LJGO
M]3.:5+,^UU//_WD8IG[ZV/?"-,;GI]Z/__4>]];#>F1U1^U>R]0&`\O0[&[7
MT#I-9ZCU=<ON.+U^:]AM?C>^F^]_09[NZ,V6WOFOOZ[=5[D]]\!/)H#?+`;8
M^]$,2PH(U"]>`*B?8HEB<HUH[[F)-Q4MP/??J-LQ>T;/TD?:<.3HFMT<]+1.
MI]W16KU6<]1V>H;>L9_?J/O'XKG^D<<&=QPE&_`N6K]'J5><?L,0HH`&T\.^
MKE/`CD9(4V2\$O^-Q5+K!TK_'TU3?HSC0!U'TT=%TW8!MXF_6--H?'<4_.$I
M?I)D'BR2$)!C`M)]<.-IHMS$T8RZCGO_SH#W\,X)&,:_]Y1YX(:)JCS<^5C,
M@G,4HA@7N<D"$`]3+YG$_ICZDBMEY'8:')OL0Q,)FZ((!I9Y<!,E]B;1;0A[
MG3XUWG(MWC<BM]P0?`US/4,MO%S.M^TM&WPC/_6\6T`%"3'E-\^=EMEJ30OP
M9NOY+<"=XS5(/N=/+X8ZGC;Z@LT#R9=.PI;W*GL:<KZZTZ$T];B85[/^3M#0
MUW4[?*YX,\H2GIH=#T%IXF2#]<--U\CR/6!R\YHU,ZQ@AK6=+U_("ROZ?+\N
MM=\\^A<[L];H?U7T+W;_/::L0U,&Y/*R(;/*SNDMF<]I_-)@_[9I5[O;V*7.
M,&AHB]XP:^W65^;7C:L_%]J?GOV]Y;#3[E\W5(,WSGC6#E9%PW?>PP&(4)-8
M)K'9:=4D/F\2V[Q9\DF1>#LK_GB*2.X^`E^7^H^<KSIZP8?WR=$MU3';I\?1
M-:UWHG6']P:O:7W^M-;;YNG1>BG/JO).U*]>Z,5NP%67.\6YS4F*#3#NO5I[
M'9C+VZI5:Z\W0VM'KSWHMT'KEMHT3Y#6YS*E?F5$>`5[['-._3Z^N>+Q&HLU
M%BN)Q:K'9-B\&2GW!K8P64PQ.DO;]L@A1O#<C#J,?.XT;NFUWW+>-&ZJ1J=S
M>C0^0QO6`AT^C;)QX+VBX;#[1RMK?]5X/#9(E<3CIKP9*3&&/;IE.<U2ECG+
MA-Y[FGDW4:*;BS69EPHFY*F\9"0+I;SO4G;X!*L7V#(_.4:CH\S\(,`_Q*RZ
M`<M(LO#>2_#G9$V..<:.X]@-;STJ?:#4=4P[G_`%QMY"WCG/25>B>R]67'C]
MP4.MY4TU%W[CWGI8R^)'4TSP,1L&U;HDC<U6^_;4:.^OQ@%_\/&'7N`":JXG
M=U'@83I2-TFRV1R1PZ9/^/F>\_?V`,IARA>^WGF\,L`/;V$EXOM$"?PDI<JC
M$JQ*1%!J\]C'3'QE%DV]`&B<@Z]DS/\"/IBXP21#MJ)E;EP_1IF0>4AF;S8/
MHD?/8T,\?."7-(H9Q\'+[",O8H&W6)E@=9Y?F6!8QZL/,,QS_G:=C_Z*&;E8
MFP!;I>J$#7)W'"M_?8'`7/CHZAJ(_!\GFB-?,\(!&.$4L_5K1C@`(]1U`Z]Z
M-=#E#D;L)W]J-S$8G#XR&3@XL)<8;-/-)N8IQQ0K<C]N-(Z=A?R78\O)<R2K
MWCAVP+@FZQLG:]6OI0?^O3_U0+\^^MXY5ZM5AG6/G3!>2Z2:K#59SX^LIY?I
M+]R>^RAP4S_P4^PI=N-BD+W60P?F;*?V>,Z2KDVC<>PJI9JNAZ"K>4)TK;K/
M(Q2/N.%7^`T_["1/$0C\FSKL=G`M!$R=[X02*H[,XZ^6PUF3NR;W^9-;/WER
MGW(N'N9,%9IM^7*)KI84/U%8]EP44@K4M\9UHT!/&GMNDL6/+#P(RTRR^!Z7
M4+R;&]"4BLORKU+8"+6^BEW8ZDT4\VRY!)/R9EX(:^#''OST#O.N[KRRIL57
M\9=+K6D;RA^><@=0**&'B7ESUZ>.)CQJF:C`(;$RC4"7\Q4QJ6ON/A:/*#X#
M##;E)9Z'1$(_,TNSV/L;_B7V\$\J+I'1A_-W&=2X.;VA_Z6A?,8.N0G`"K!@
M!MA-`47AQ"YA=.KZP:-RYP-PL3_!;MFQ.V5I;%,W=7$9;+V+B((W"`6KT<I2
M$Z658`6>E+B$Y:UP#.\S+&^V=([-R",@L6@OCHF,'EZ7;TPQQ60&E=+V\#:;
M2"OH-L6E+E:D=Y:15:(@MLN.W4F:L;X$"N:>\CQ$+YXE)<R*O$`5DTH?O``3
M#W.2*1,WQ,P[ENC*6AQX/[QXXB<>,4/%*7&]MGQ-@<.5!8B5HIGT\/KJBCH\
M8Z-XQ'WL`P+Y<=R5F/O*MUR;@GNQ,=_R&%W+\0=*UKW.9C,7A#'PVS7/0OU,
MW*9T)RG(K/21]GMJB;TLAW7L!=$#2C04TY2RK20%O/+94EP.K9(!\\12XW)X
M?:%U>;F/N`JG;>+-N8:"`^G)PPU"QM3%62=)X!>3!,ZL#7G'/'2RK[.AN_:Z
MI-?F&?<"KR34!_]TG63\BBF%OV>D1]=+__TF$T8WK_8I&FB2;-)K1_?4SYNU
M_A`F\ZN1G$=J7^U[0VZ+O]H'K]`&>;6O@:T#"]$YJH]1?8P.]KTOWLSU0[`V
M7^V+_<)J?[5O?L(KHIPIP<\H_H%Y_<F'^HP=[8QU;V]C[U:DSK\&-WP$!O3#
MQ)^\VA?_@76J^*\DRQW/?PR_?/W8[W[2NI\^_OK[SQ3&"OS0^YMR]?GZX]>/
MG^%W5$8-#C).+.3^::/M,?]3C`N$)7,(CL7!;ZX.Y'.6)JE+XQ$5%VL_UD;%
MK&74U5?3>[V\,G6UZ3C/W\*Q+ZQ.B]C';2G4:>C'3H([(0H?Z[E3AFJ/F5#6
M030.[X=!]XM>7?YQ:(G34ENK='<M<LZ0UH;5.,79-N<IB,\3JH/6?!Q2X4AI
M#[72.;0@NK35MG/L[/$/E1=`)TWC3L.N[8J*2.7SA.I$7!GX\$T4WW@^NC-E
M[.+_\02\6NL<7NL8JG/TF2.UUCFLBV,TVL=NQ5&KG;.&Z@S;IY_5V)7]8_%H
MS]5[/J7PQ)%O8.W:@#ST#:RA=CKU#>Q9W\`:>L,Y=HN=LR=Q1<ZS75^'G/MI
M-DS5L4_0(3Q#)^/,9N*<HOE;[_DX;D;5G(I_T*2B`G-8R2R-(H(-83TYEOS7
MWL8QO0W+JD=(GK=]HC?L8]](G#V)*W*>[?IFXMQ/LV&H>NL$S_/IA45Y62R5
MUM1AT>,*-L-2=;V>9W[6HJW=Z-11T;=QG*V&71_F\S[,CMJV3M`6/43K2^I[
MM;YB7&\X\Y3E*2RUQ_J;\NGC[T/MM^''7W\#JZ:-O_GCX^#K;V#SZ$4CLO4A
MQSTWSS)T^.KJ=EF;0E#B=6G.;N#=O#S9[L/V#$;;V-^W\U)[;"S*2N#Q4QDU
M'?7R;F[4"=._N?%B+YQ@M[?TP?-"WJ:2=T!D'=EX-T76ZPT6P7@9=6$,HH3&
M.;OQGUY:/+S4/)/>6F^BKN@@N('QJ]C6]6)%^THJX=.F2`=IBG71W0X15:[V
M@U6F68P8S?LQ/KL;([9WA'5^:C8<755^LAL=A_WQ)ZO1,57L"HF!3O_>"QX;
M"C7[H^GO"ZS"IKV+_>6E(3OL#Y99WJ'RD^D4<^1IGT[Q;OYKU@#P)Z/16?''
M94B*CJ*EL>$2('Q&_:Y8YKQ?0&$X#5."`EC9V`"&TV@]!<=Z;XW]AWXU]>_Q
ME__UURS1;EUW_O/`3_`L9K'W^:8O]0#]@HTEO&D_2M*$F@SUL%'HE?LX0PGP
MU?N1]@(XG[_`PLI_B<6&;HR=8I(K+Q;O^)-N.!WX08;(PWZ,\.87[^:_WWM1
M\/UJ:.@MJZ5IFF$;NO:_NF[HWZ^_#KY;3><[(L\P+>,[R.DL]-E;?A+9IM'Z
M_NUZ\!W.PW<Z#\E[9>I-@'Y!0EU(_"D\./WNF+:I-ZWOUE#7F_"3UC/[`\UN
MF4VMV](-36_U]8[1&W5->,CX;AKO?]'TAFT6R'D"G@7@J8DRT.)C"!+,^^K^
M^`(8_.(!T!,_\`FKW73D@8YQ@^O43;,TBA]+#^\!07.@I(R.C[^/EA#2;!J=
MIF[T--,<6IK=ZQE:9]`TM*X][/9&G7:_T^Q\QV5_T1N6(Z'CY1"643:"L_8/
M/&H%%Q:LM3LR%L`=]D;&J-_K:W:[;VNVU6MI7;,[U-JC]JBI=^%OML[`Q2/"
M3\BS%41[?SUB?X]2J1F1N63O(:RXP;Z;W)%4^1BB=**3B2UY_TY*E4RD:V\"
M`BOU-_?:FR\8AS_&<:".E_JN'+F]K`#W`AO#E@">%0`G.<`JMH\-,LK_F^"K
MV%86!#N^Q*4Q=DX'RX-$$SP!XA9;QR;*#1B0T<-"O]DS:QC;:AZZ86QS0S/2
M)0^)O],^7NO4@W^Z;IU:X#QO&M8\4-.P86[0H9)1_L&=&#?=)`?W@+_GN",U
M"QRT;]Q*FYS^6K1NRZ\YCL41-8FV()%5H4/[!GK7Y78E&D7P><EPVFP"U8'E
MG6\"316\F.=OX=B!Y9K&S[@>ZJAZ\P0OB*J>DWE]%\6IAM-[RI[A^<JJBMQW
MFJ:CVLX)7H?5U-Y%175::N<4J7UZ.5I?RG&I6I`=6I`YJJ[763HUL:M,[#,L
M;*N[9]18/#%GXRNE/$Q$A$1R-\CY6'T5=;X*_+@>M=DTU;:Y(D^]ZK*\)O+S
MB*R;)]ANX`P5=EV)?FR0*HG'0Z07OU8*YA\>5^+P/[!0X/\[\Z>J<@>22_EW
MYM(4^*DW3B5USH;'+^2@X#/P?O$4)9,DV?A??)"]CQ=G^!V:ZQ[[R9\-Y6ND
MS/S0G\%^^"AS[\><\J"4:8;YE6!D*.[TWHL36.O.O\%=EE=*:"*Z#(*T!9H>
M/W-3\6],QWV(>.9B%"N!ER1DQ^",MQ3^3W$OBGQ41>2C\A5H>',4LLQ'\7I#
MZ28L4W)]#J1(?<14SB`0>;XR`N_<Q7G-Y5TO?I56?``L*)/`31+_QL?MH@V6
MY-'@BL]?_S6.$MQP%L8>L-E_`(!;H``#+8"_(?T0PC!"B^`V!"`G;DC-!3R@
M*\U_W(!SP!2BO*$,5J:L;GR9):WF&:O$8F#N(T>X?H`G6+N)8BUQ`Z_,<)01
MC%_[R30:+2F_U5R1B,N2BYV&#6N(7\DIK2I/TGH*.[@%"3_(Q>$C2SV/$LJ;
M]J-I4G%V6(CYP5H``.8ZZSEN_`20`>(IIEX3RMC+CZTW):B!$G.7Q(L[F419
MF!)[I7Z@_$\6/!;X9U1V^,AU9`P\+XDXF(;Y%U@I](&#B+3$+(!GV#Q*)5P+
MWV\UE&]S(EG@N0G/]:<],DAPRY2^O_+C0%PX[_=>B"3C90+EC_)/<I#QJ*1W
MP/OXH)O7*8S=`+M`BZWC82KA<<T]ML(7@J.`KR*_H&`$`80?IY'S-WXR`3D$
M.B`&["2`ZT>&!D0\R2#83E@FD2H+_(D7DTB%1:<^2R*_3#P\,)C@J3@?*LZ1
MJ.3F($QOP,^/&#^N\GO7>KT\_]*C/$JBWGEF4K;M0V=2.CMD4G:.ETEYSI^N
M,_@*G,?10YX>=O!4,4SC+``#`/XA1J:N20S;[X#6WWPPA>/)W>.K??&3!S;0
MAJ\]>20D\IPY(];9Q&<ABTZ`P>I<Y9I$=:YRA>[C^E$,/@IZ@LQ;9/5A8W"Y
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M@KAU?;B^E]%$/O[`BA+S/1E+7$BSB6BK]+SR_[((R^9HP!^5BKO4W`%`8-8@
M#MN)%7\*5J*/Y?9NDN`OL<V'[X[]@#5<V6PD/F<NT8$0L69(DX2(C^$\0\"P
M<0?K'+"(RPO>X(`F_(T3+[Y')E1YLP]EZL?>)`T>$3=^*/Z%'0<F=SBTZ-^$
M:5B$XQKQFO@S/W#CU5C]&W]%(@ZGB;P3;'C`:/8W?)_MWV?`K-@N/C,!X,9(
MXDD4Q]&8LJ"GROA1?HP/?IRZJ<MVFHV3U`4F<`,`$5LSW&0!)DQC9PK1'^)$
MF<-ZDCF^A1)J%I`+<"39'!LQ,"0"U"G#<Q@)-!*!L$$/FZ_)J2(U14%$1@RM
M\GS#PV/U0+TINGD;H8OR-#"$>P+\=AO%U#0&#@910S$00/:CJ>*OO1_S0+1.
M(8;W%.:;NN/HWFLH?WA*EL"_<AS/YW'DPED#1'+\9?F*Y5VLZ[GS9,>=BW=2
MSQT\:9YH<J.DL1LF-]B(1(Q;%7#A&WP;K!'3`IGO1.EZU6F*7+I5$ZD'#QM&
M*8&7@G2@OB2Q-_7Q=3<&--UZ>6.2&_<^HB=<)8#W@RB>LHXPO#?+/=`EBHN^
M1;#$3V;#+K[.&[O0E-#$XY],BF^R@\8;UHP?%[@1'LM%\`P;\FPZ5Q<;QG1N
MG)18'JH(V.VR[C\`SU4<A?#CA&'D"@R1R2/[[_W/66R9@Z%A&"-M:)HCS;:&
MNM9U6BW-:IFFU>YV[4%_\/PYBVFYY4OQBS4\M326,94Y<UR2TU\\+!%6"G0I
M97P5$II^&C_SV+QLZTU\?,TA^XA#'A^YX,#C/O)#-\02(QF8:U"H4S>>)F#>
MPO\HEZ/N=>^#XB=)1H;";>9/J7G2))JR#FIP(E:^WZ<')C3A4[GL7O<_*$V]
MJ7(,<%S"60)I@^-`0>W0D[*V4\0#-W$T@P59IS?6H@[6Z6<).`IPM`J<PSF_
M\]&V`5I,V=#I?,=XM*,8GE=@,[`7YZF]J)*VI>`DB&0QSI0,D#FX'/X$B[7F
M;NA3NRG\->\"Q83X&,NE<2*LXMZ@Y%D65MC7"L!MDOI@RAM$0PS,!%:-A_+8
M385B\.%+D[SW%2B7>S^A+E'P&P95L_%JW`8R?2.[=;-;H)#,<<!+G)56\\RW
M.0ZPOL!N5PW)4(8%-,12(<@0WF\AE\BL<^(XRD"RHEH>PF_2QX*1.G]+E"X9
M*8^HB)&/?"0U*'17^37"+<#O8#'BTV\7K&T"?/%#`Y#Z3?PK[RH&VCUTF<+`
M]3B)0.W>>=Q2]XB*P"^2B4H>:IKO4_%6[-(M=CDI=HDZ2KFE?4[X/LEFBQ@#
M3#ULI\8&44=1BC7M8/CG(I]@*&`J<S&<"60]UO01^!4XSIVR\=78`V\&=J,W
M)<:<8CLOULDL\.&L++`C>PMV*",,F[G1</:0W%F7^1HWN=P!U*1<[SZ`SL0F
M:9+]N<S(RSKNN8JKK/8^Q[=P;O]#(JJ?;Q(G$H?3*S:XGO[Y^2:7E=?YE@MF
MA*>OBVU+^\%O^X<83]SMV8.!WN]KHZ'A:+8#:K-GM`>:WAIV1DVSV1X.[)>/
M)S8/-9YX30@`-BA3A)C\.IN!+4V=&24<2](#7A)X7E"X:XW6/8TKWA=N<A4D
M`[_6C-B+TWJ8GK@T"1D6&?O1_,Z-9^[$RUB$AFG(1^7.<Z>\.2*S'*Y!$(YB
M/%K))$)]W`>3&G1HZ+O\/G`B:J+I^0$(N@?XCM"5RA2=F&A.^A7C&/X<Q%-(
M^F$:9SC%.9R2Y.'.,6P(.X.27+H:_OH8Y*R&4G9ZCY;"5)E'P2,:"G!>_Y51
MS\C4F]R%41#=/BK@`J9H2/!6N2@'(VK@R&)4V+9WAH*9B<BQ%WHW/K/K<4<L
MR#*'SWJ;3?LJN%?8SA'E(+J"W,_D""?EQT,(J'[OW'NOZ#0JMU:-0E)=)2\'
MD32EGJ.P(I(1'&N/^F_*F@]^YBM>+'9K%0M1)V$7]Y@%*3EY;*7%=8"/R.V7
M]3'O"(M;"+$Q*.I#NHB^H4'>9'-&H`1=UH>3YGKC3FZR-.,<2%`S?09[1YZ2
M7IC'/H@NGT)3<93=WHF>HK?`$HRCZ1L@O+PP`12IK(\D!;^$_`.29#?8WCAF
M.'1O8X^K3/PSUZ5H':*O[U('553YZ::XP<4[X0Y3@.(']2F#??YD-LU&N^@=
M&ZYKWIF'8I?FIP.7,PN\W(;VP4WDR>FT`ADM^$>@S^H6LJP_#VOI^Y/A&*6]
M$4-A!VUO&E)/Z:]HD$B_*7J)_F24>^*&13-8%OL$%,XQD$S^-L)@F`U]]6[R
M=K8E`Y[95RU5&8-QY_W@WT6H`N!_:BV=1\H>.>1(-!9?PYH\%H9AO*7$T:,;
ML+;AP-]@L=UD,0OH>LDD]L=,&%)+V);*.^C2*QA,B,`IN668+3Y)]A5O1)MX
M&`V<"OKN30:U#Z`3>V[B\U[ALD6FPK^(:@'K]5VRWHA?OB4<I:(/WWK/O*HJ
M]3.)+-EZ7FT[<SYG,;S\@7F4,"^6CAK*1]:LN1!0HLTQ%WB\'?+#'0BA1RUZ
M",E:1XGI3WT09%[R,^STS]2-\:C%[IRT>Z)<?@05ZWY`BMRC3/_D@]O@3;E.
M7?7&M_]5E4\I^!67_*_?_A==+>!0:E,OK`7>D#KAFD>6<$SRCC&D"?I^!D!S
M`V$B,T+UM>M6]&5V3A@58,)KWQK7DHL\1<41H[@`G,68E(_7/),[#&R2Z@*9
M1/]@_?]%/)@'?D$+@!(B60[&B0>:ED<@)N)VP%OY/9(J2!WR)UDX'(G$Y3HP
ME(?!;[%FSDH+7F\.M,2IP`C1:AAYY`6LPH2=_=C#BPX4I]$FA/*504](6USJ
M#\_B+_Q$L0[IDTDVRYA_S6ZRD#]C[PZ5-KG0\&]/N<0%/A160I*"PP=':8KQ
M*0E<ZB@.`OER"F;AQ$\_H'H1Z"*#D7<G3^X\+VW`2E^9K<1O[?AF\,LRKMWI
MO[)B,,*]QV4]D5@VG;BN78,C(3.`C_)NZ;=\YL`29TCGD>/QDB'Q`^`:N9#A
MKQ`X/#SVW`L.-;_?6-.]O^+'_"M%ZEB7?9^:V^--P!92'1]"1X/I;W`U\#SD
M]B/>>0)O>G.2M44T;5XHQLM?N]VK#ZOB5LQ/F;E_@L$L]",SQI,DF\V9C&67
M@L799@<-OS83<ADC/^PJD,Y0<1?(?(52O([9X[?D..3O7+PKO\6^1+X!/P]/
M8DJHAQ4[9.*!!7;Q&70.PH2,.''71C)'"!`V]J$A!R?7HT>("HSV4:PV$P%)
M7(`&D@AI!JL%B`[`98Q32N`S1#^T_TD&X\R)M5]J*)_1IA&>%$@(L(F8L\-#
MCT@).-7Y"G)Q%EM<1`@Q7IDW)DZ\(.`L,_$X.:>@3W&$RSCP.`^67)+<_5"E
M=?BT#&9OP3^0:5&&L:AOZ*5\(`=IF/P>&5T*D/+QHYK'$OV8,R?_,Y=HBP_@
MGV^C:$I&+1/>8&3COJ><M52F!QB_3<@S@2,28^!Y`B!34")%(N0L(<,CAN5<
MO!-_YMY@%B]:\0RE^`=NQ"^9\*I0!AK0#;\/V@.6Y&8L[E[0%<_`K?C]+$*%
MQD>VY(0EKW-,DS-D>F.D%9P`0"9!AIL&>PVU"%L?,4JJ:^EX2Z%L'MAE]@80
M+(E"(E@^\0-QZL>@@-"%GGB)N.`LMH&$YTH,S7:4]B!C$+9_9=/;_+12")S.
MMAO'C_AG8HID@SAY`'6+KR2X"_ZT2#6!O4[1S08SQL6CR(E%`">`)]KJL#A=
M=&[Q.PG2@TP4QL'TU6P^%62-O9L`A1^_C@&^(,Z6(T9@ILI65OX18LU"4(\]
ML1A3BG1[0]^D@'B,<Y@HGPFOU%ZBS\IIHVL<M(LJY8@M7:_RX4SLYO#TO+8^
M3Q,`'VB64'C!N_>C+`D>"_4$?\:110CE*I4&YV)>N#D8445')_:DN54LOL7.
M&PLB"";EK#R7O&4T&J[1>(P7L:M,(SI"DD[B=SHKMDU&0TIJC52J*FP[E%U@
M^5%^$0A[\3-[N!#(\GG&L,JV%G*E`Q2L%KK/(GO#8EH0$^T?926&ORAF`:"P
M&TF>S\<P2>-L<PY!57G^#V:F^:@H7'()MQKV0T8M&C:Q?PN8".2A<606@;&A
M@"),[XK)<Z0(P/T#J9OD,ZTHBB&-:FH0/DL[6/QL[.$@+&3=\M2X?$H3ZDP^
M04[%KS]0:A4;0I>2-L`4(,KW(NM$^AS\&ONX%!?Y<M2%#@8SO>&]63$>C=0E
M?P$_GK^BL@PU>6B=-+*NE$16;4_H8SGI#M::>NC'D;[%V_BE3F7Y!0%:"@1Z
M*J6I42`;B;EI'EY)Z*X1.1?OEMURW,]S7']RU>_RJW=T5HI\N@5;<9%?N351
M.C2)PNS%XAHA"LM.3K$^<3B+?C#QK^&0LG$<_<F&,1;.4IX@$WM\_4B<SL(-
M(/O)A:4!Y6R"HQ].,Q!/C[@2Y6JP+%R>?Q`SA.?F#O.IF`):2!A>D6&<)WCG
MZ=T1`E)$^.`#9-HSLVYE/C#9Q1C\GV-,`;TQ9B:2V\CLQA*ZLH1N#/.CQY>B
MO3)@A.DMV7R5/UU\Q"=CIJF/I,$LJ*@D_<IR9/G(4:+K@\<">PDZ(N`;_R>/
MZ`%99SZX`.QD@D_EB;\@XS.OF^0;D^1X1)'7Y(A:/HN4G9^&\F7MX>6@>.BT
M,2[/W<<5PD*"$OT-H1Z$]Z.A6`>9.<,+970[?9KBIRYM4"2LX^[@Y4ON!'Y@
M=TR3*"$/5/H:S;G,3RP_I\+"0R;BMCW/AIMYX)2_R,Q_I;O?"1DWRZ,0F2VS
M6@>)^]R(JV>>\XK#:^DXL1F*]]R-!W'K9D&*2>H4/K[S0;:`&\<F@Z*'BN*:
MZA<P;XPN)*AV`44'&ZI;;'+;+7*>O/,"RHXO+'#@OM1/LRW\8S)0:.`OAT_,
M_27949I4B]D$_@23\&<^B3O94"#W[X<W%;I$8BHYY(^KSMU'GNM/@4"%Q\,+
ME+!?WT;W7ARR,$E^$PCHF$F-Y@A0;FSR,T:-YQC2\I0+-A.%?3QP)UYI3F?"
M-(>PG7@4CA+4,$^3/8)D?9Q[/'T2"!A7VICG<;\$LT`]G[0,ATM./A)YIRQK
M,`?VY*QV.CPBAY:?B<+:6$CA022,_4C*@\G37N6RDR":N%*,HWR#@VL,LQ@L
M6W9RQ04?^J4%NL4%",;O2!^`TQCP,Y"%_!^`=,I[%._Q?`TP2*;9A.X'W(!K
M\B(2)S0;_F\*F.$9%LSU%=(;/P#&06X'20%02G%AV3#+N3!Y9!1LD3NZ=Z'D
M"D`H7=X\>'FV)MI`.*,["*('@A1_0=FA-UE0(&7,["@T=]!8(<N)JQ3FJ.<!
MH^67T1XJW11P/Y]?!3"@4OQ;$=G,68&,*1[&13#@K=L,#38,"0`K\8OB_/F2
M\PY2BO#!PY&Y#@>)'4U\X@U)(Q19-+B[(FY93B'*2S6X59!O>04#;9'[POQ*
M%HVG:(L`I+!:80.V_A=5L8R_,)EH.'_A%^G2J&F.B&?M@F6*6.J6N[!P%V:;
M[P)_>,XNJBQK/XKP/V<06<)>9W@C??H2MH#13TK'L4CK\C#B3!.Q@6ISLHEN
M?#!71(A#H:G`B;@J8I>W\I4,&DLAG5KI:R+SB95\%C).)<>`?D=+J,M)9@K:
M#YBHR?5Y0I&.J8=&%)6^T76"RZ+6FA^J_">,Z5/8O[21A!GL4W&S!R*/RJ_H
M?@;MZ#BOE2.!*A+3X??>CPG+XI(6>X@Q(QU<PN@A9-;3RMNEW`Y??2F""01Q
M]"^/=RS,$C#QY%TO>.OK97Z>_WA!V?[<3Y@N!*D.%L\W]Q[//UAB,'EQW#D7
M=0$)/^6)L!RIO$<^&U1E)_0F"C[W0>)EGD_+J4+A!?0+"ZTK&^4D-HO+.UY`
M,?-8E:9(?\DW088#J3WD"'J9-"?7\!_#8E2[2[>'#Q3DH2`-QA;0&V573^0J
M(J2/[%X3@XK(]1&J8;2=)RSPR8!J4"H;?(N"&&K97T([Z^*=P)M(#`K<1X]Y
M2.A7Q]F<58+$=#G%[O%4IB'RZA*B!O$Q,^[):F+!S<6L:2R%++W+<!;Q=%J$
M2_8S^%5WN9*#WRI@:K"(/]%C(LKCYO!C"C90W>,E*H)3QABO`6&@2KX:D&KJ
M\X0*1JT5.6Z5UH"?\-;Z$X:V8#M=\FA/3L-=H34?I\"IX"%2W)KR+."L<!$9
M\^@C:0`4^0WE[^Z_D%M9DKP<#9ZX<S]EH2#B$PK,4;3=%7?9F$?CQWF0H1"W
M%%N@Z/D4OR`I-%7AVI+;&CR\4]HC$T^@%YF%RL*#%,0!<8#MB32J*F"!&TF/
MHZXL$@=(EWAHAV,N0L(R6-#*@U.3X!%F>4\-Y1.<2H\"&V4LL$&DF1]@YD92
MI%&Q*WB.'B7`M\7I7[%I2CA8L6W:+`&%41%6!4W")4]\R'=_0T&SF,>;Q4V)
MW%>!-E'Q$-:O/$=$CD>SHE!N6^1UE*`\P)#RA=SD'$(5>CG:T"%<UPC!G?#*
MAZ4T*$RXX(F$1%LFR-!Y'F-LAY+M>"U+Q.I_>`PR%)%^Q'P6^B*NFY<;4G&K
MR((1B75]D3N+91&8R@N&C4`#"-N$54ABI!PDJ9]Z,LE%D2NU[V!A7SR(F-*.
M\2(T"4$C<.V"JQ0).6X89LPI9?KJ)L*$=877^N29H,C^(O:.^_@\2:-R+2SP
MJHL)8[0J:J"*L]@?'L\DX1Q23E):SDN2`RQET2G(6X@EO%(1I%L.3X=1J(GK
MQ>*.'46A1T+IGG43B.7\E(+]Y#P>:@TS82Q%!D8I-4=*I9,8?N8^BG(";+KR
M2+**YXWA31B&0%A<4FQD`ILE,REW)<H%L\2==-_#6+1`9![U'_.@4]XG@S93
M3B8NIQ2)"T(,O$KWAG@\.*--1>@9JX*P#"1E\I9?9I!01Q^CG"B??YQ,088O
M*CB0*)8#@'3A3DZNX9CO!H>MT"59PJYD<#6^.?(&894+GO,$7\,KBY7(\7Z`
MK\-3Y6AKB_[2!:M-`TP4`K_`2:4M)5Z<#WN1RO-/SE9BU70L&Y7B`>6+3;2R
MY58DQ+A/16')CUX5#N"._2.WB_DW)-^#<3$JM0@#D7!D?E:R.3S&10\K2X/C
M[:%[P\-Z[`(W]Y+6UP:J6&T%?(9?%.^J"X$&NJ`1GE'Q4"EFRP+%4DYIR=E@
M=I%(^Y?0P`24*(S)*^SR](T`4_$P0S<7PG1&5^^N?(_"?8V5$8$+N?J*N8D4
MOL&#Q^-SN::>`54P35OS`I&2+9-?+:GS/-;+Q,-"DBY3#5S6<0TLK<5,<FXV
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M1<@52"&\L7C>2E@49Y*'(5`8R.UK(M*ZA&K*&-NP%)HXB+*`W83A#WEN'%N,
MQ>=SK^X).4"B`]98<1K+Z0:LJ)3214MY_=S[4^5L9/$>Q58P$T-8!"PR6W[_
M<GA]Q5,?\CIWW`C\FN?`%19=SFX(1<I%#=A\#Q05$A5#<&(I7\//V]C@I1WE
MA+)#C?7"N`^Z^@_Q<4P[TMP`U0D/,O\A6Y*X%R%8.1YYG?)RP+R$73(I&75D
MRBJH!Z*8-2'GE13,$T*C-^`5CFFDLL8`>9.#`'B$94PQ5EPM:9AN85E0_/%\
MTY3-&R72RSFGB)3<$@0-Y1KY'9'LDK(J=_`38I8<T!C,#5)M+!8/2"-]]EB$
MWWB18)Y-)B6T$P7+03VI-HCSNU3'1MF_%^\6F)\G*Q?77CG@U'`MQ__*P_"V
M$N-]'E^3+[07;-ZJ6KI\UVS/2YD%);.7:20F:<2%DS8/LF2Y]4%AD$E=$,A*
MWG0K)ETP7[PK73$CY\O7S+$'WPJ353?BU7*.F$^4%_QSV^)4F.-7H8>$JL10
M+H;:`EYU(VQ_B1"K71RAQWC(`MUTEO;!1!"XMG09A+S&KHKR-J?,'>?Q.I:]
M)Q*^\[L9U+(QKSVBIIHL%8TW6F`V)^.OW%A$8H@_<X,OMP0I@.`GA?IG.>5<
M>>?$Y#TH6%Y[_JPOG/9QX&UKK2E_L#SW1#1$(1QAU`AW4F!9NNU<WXA"ZCP!
M*"RW<VJIDEM;MIP)P'SG*@M=/?B)M^85J3"SJ(\";<0,B=S,\20R4(Q41JRX
M8I+3D<D@%CU<\K`DZ\BW4`$_EV47OQN8N=.J!4C8#1)S=Q8:QW!92;@^$9F`
MQF7>?06O47@@`H,/TIU-'H7(#\88XV9(5^'YL2CJ!HLOEP'"1)>;#C%-LR;<
M4/3-WA#'*,<*Z(H&+!UQ-5#8X!+/PR[QZ+*+!FYWB7Y(\E9X91<S!LFO*1*!
M2F822_ZB$I-5%KYTNM@W<S,];YY$$B"XP3AFM#[^(DZ:'&LIA:9$`V*423Z+
M-JM2\"1/GU"+JMQR-$5^9#E31>H_1:I"SLW@/9=$-#N:@1['>V,IE5WR/1K*
MK_X]E\59J:^DZ(Z<>!N82BW9$87-G8<^6.W<@J,$LJZ\EV5:L\)V<MUS`K+P
M`/R5YP'&X#KRX$[57?1^W@)@R3'(3S11DF3RY`[SK<5=BELT[V*S`/+X8EF#
M4.EE0A9%C-4KI6K;DBY97(1_,%<@#U[>[-)/V'83JOP2?=\N\H9B$T^DX<E$
MS,.35$J#GMM&*25ED';+.Z/;.EZP$;(;%7C]TO]0*&$2:Q/J$L#JC04TW$HB
MP"/6!-YG-A2?$D!V#_.<5[0D+1W]6#S)`TP<;KS9S.M9HRRE3'86=Z;,54'1
M)]97"289J)LH+LC%(F,2$T@G]5'N','/O!S?\8DA>-=!,H7X\RRQ1G0?S3F`
MJU#8S1*.F2/,H^KH54]9&@H&DX5Z&GL(]S3C_0`+V)<H*X/C%PTO\G.!!]^-
MPPWG@N)6\I*+C)K7A>5TS/OT45CZ+F_G6BS#0RD@U-&T])AUS.Z91+EQB7<7
MB+UP$%1NM?&8#L91>6K=W$W2\I/\#EKJ/R`"6SP2=O%.0,UL@E*DF==)%*YA
MWH]G3V&$5RJ\V4Y.%,YO[A+).>8Y(DB?@_2A1-,5+"3KS9P')'.']WZ@^)90
M6.4V&G317.3+(5O/_"3A5A`Y8?`01O2I"6B`=;]9>A?%DFXO=+02N'"T[[RB
M:::DGW$G=\`''K_49NU7\"3*O4#19!RG/&]%VIC8RP7K1439;MP&2'BC0XX=
MUFYY:4OYC`46H93Z2<K22-QL4X@!L5B@E0L0*DO+93271E24@-'`']XDDTR#
M1+[#>DIW?"QD4JE)S%2^;[]XMX;J++VOG/>37U3P:FLNH/+^<%R`E9IQYFGI
M>&$D^M7D1>(LK9:OOWXO3(&Z^>`.^5PL^SS%N6#[E&4KO$`M8(KF:`OF;FY!
M*-2JDO>=9U[PLMM!4FZ!L*1',07FAC?P83;Z2A/CS$20R(4M+I^#)))ET874
MCB>5!1.*)6:@<,60RZB2X2'BZ9+#P[_54$8T"HAR2HL&4SQI92V1Z0MB&Q+%
M6<"":=R\\8T4'N"`X.VW,!/+21RX_;*DE`%AN28K`5$%OO@TGL/>QYU^7OF+
MU.0*_EQ@RG6ZDMNYR+`4(+J/@FPF_,1RN)%B@[G(8V)<_@HE2;-2^#SL*:="
MD!C!RS.T3@O6)5ZGC_..4OGSN.="J^0[SI\7F]W(:L2<@MGV?O5[B.R@ZSM_
MGFO]W^"_^%2>?I2<8$;U0CP9[T/*,5H9VCL.+:O,9X%+C&;EM61DN(N*=<Q-
M8\7JE:;G%RF[Y@+'.Q6VP9"E?)\<41=`DLT=1N!2/KN;Y+GLW"9EL34XQ-2'
M%]W3O*]\$1TMNC&Q-87Y#AXYBJ`B8^9"KB%!4R6/A.:U7[2"7`A:RGE:`.&&
M%XFPPALOQ8$-BW4D%,F28X.E0JJ095X+.Z+<!H!GOZ\U]Y@)L,T&1/I7'+IL
M3F!>S"SO!E:YC=T9,UE9N3[K[?X0LC)Y4BB`51*5_FR<Q0F3MKQQ2K']JL]/
MX\(FI@I=;)"(KER>2)&GB3)^$G6_Y0:*I2*X(F6!+!V)BBR!I"C?P4!H4K@W
M!37YC2`8[__B]U:A=QN!A\4<FGND+2_,YEF(/'R?UVVQW+$B0I.%5'LA*I-9
M$B\/0/!A;@WE*E>B<KO#?.04*U[#\!?/#)&=XT6-R]D88S?W/#R<3;#@`#/M
MO3`&3A:/BD$0N0M<&(Z(3DS"Y^.=*.A21KW42R>OAF*'5K[[8HTOA9PIRK#S
MZ17@),6IELU%@8UHAGKG)E(`?,GC+UU;E/EE(;*-\F;3-\I;7K?ABW?%EE,P
M47ASC3N>>+VXO5)RE$A&*;-TGJJRN!JF',V]?$P';V?)S+&+HBDH=U/RQVC-
M#6CAS]'%2/Y%%I?.=RO6DMB$1[!37B#X,93#K:5,_B)D4Y*F(`'RYJ.4+/C@
ME9RA-2U11:4&SR!C@I+%0#TI?L]-6;HTYTTN>888#VEP^X31,R_2@A6Z;-Y*
M.;F8&2E%+AB_L1,A6LJ2)X,]QFK2F-<ZBOOJITMUEVO-$%_4H-F7.@0S/LUO
M%=R\NK<(B`FCC.V8%V-B+))=[LNWU3DLE`DCA"052JSKYTK9HZQ+DM1U-.]8
MY8IL1Z1N0_DM>L"R#U4.1\LOXA7=V*/`?+$&>3IT2R]N\:@G!;H_HD6=R^B*
MG=`H*;BXA0HYSB]$S[&$UT)@K/V>9T+R[Y8BSDSAE#J6<^=\#>URFN3?S#L.
MYPD4+J5SPRH!336E/$D^WY:!G?"L#M&AF?IABOAVPE)B^3]8R@$=9B17(9B*
MP)>(A*UJ_<KL(\&OI;:O6X&89PZB7%CJ#;LX)G:AB;JR,.0E+R'$N!RZ!RQ:
MGWL38"Y%L=3`N3P1!M;XR6ZT\LDI3Q7$YV#DR5[2,>$O]SP7\*A<D:2U%F4/
MY5>G/H"(10Z4OST']1]4VF&YIO;./92PY'86#9Y/SE&Y+CI5\Y"_`&5Q3BYW
M2?!YA4\,!*NY*&.5QOVPARA-_O++];</"L[PFDKE&Z+[HD_=/MC]+A;%E5OV
M)'<N%A'P`9+%RT,PFJ)'SU-H\\H5[[L`:US!&I2_?/5!%1D!7-IY_"56*5)T
MVZ!LL]DLXLTB+RB/V<V;VXGK+[EE8O5M?-ZD%);I!2[0]WJ"5\&)H!M"0=G/
M$2BPW/R70I1$6-$W0$YA6%5)EE_/\1S\,+^89;8D6^R2_0_]NGCW`\]X6+LR
M8\J</%(GV"):B_1F[L8J:"_>+<!;JDZA0>H(`?9V"QZ%&T)7"%)'_HMWO/<Y
M7NR7RG!8EKAH32YGBE/+"[9IGB%_'^'-9B`7&9=GU],Q47FK1:I7XNT:\MXE
M@HW+!]'[@;=6"1H0=^Z]3PY.#\1I)@P-_M;%N])[?'0((!2='M`)"8WK*2=]
M%ZG;I>D%N&7LR345:[%MC_E7)4U)+D<F3<QC.)=;TV,>@]226LHSEYA!<(@J
M!I*)3GWE!`.\$"3/D;@J+^%`TA=EK"(4[%Z(-B'8P(/U\9!J,1=VP!WB,@WP
M&FB>M_K=DEG_7K09Y`7K\O2ZHL*X/(`"?=W<-*=(">NY2.9M,*'.M1N/Z;JY
M!,C?_5*),"**%P<0-Q96)C6"765>(B*(JT$XE=I^2*ZY8`LF59,E^)"N,H2,
MJ>2UECN7(TD*,"61=0I-7/_P9.\R3[H0&6(L'K`H86,F*9BC!.8WIF+D!IP\
M6I%"627'6&J0!'+_QO.9&T7"FK4L$*TD%&HEP3SA7%J1[$RPCX"HW!&F9%Y"
M4HQF@Z\6XW,1AL]%GQ8*X7&S@,"@K?(+C14A%OE234Y9>)!<%'P-E\F3.DN.
M-IU</EV[E`\X%KUNR(F0OXK87$B[+&YWA>(2YJX4#<E5G[1<0[E><_B*F2-L
MT-6$Q6%(9'!DH-!82'N32))O+O%_:-0^/5\FQT-#A-+SJU(V]:.8V[1\::!N
MX:2I<IHK%Q5P]/PDC45UF@"OQ(<W65B:@B4E9`OQ2E,,UN$,==:M)V:"\!SW
M_)?L.AYC(Q?O1#5(+BY"[M/PKMI%H7^E?8[?P?K\A(,6KH@KKM$V/CEO`Z<[
M3O*9$8PYF9E/B6Q"ATW+O/+@H3SRIII[S]J;AQFYOB7KD/D*>/6!I8,L'6^A
MM"!1\CZ+7/Z0YEWZHS!:MI)D*I?;^2",4KA%-@=X'WK*3<1&9<*UD,9MB$7`
M>B-,T:'S@PPWD'^@P!G^'UE7[LRC.:5D"B!W2V)>O"?N9.[RZ(PHX^;S2RG^
MC&F$3+O2=TFJ2),46)XL*6+6R2ND/AJ:>!B/>][):WG'>32CF/;&^ESJAJEN
M\7V1ZCAE\46)\O`R"<S@D97]%VQ0-G@Y"JB^)RY8"V4U9Z[U[\(W3:/1$=$1
MW+\4*V'6B]&6AM9.RZ&;Q0%X2GGN'5^!<%%J^5EIN?11=$W_ZOXXP9FK?WAR
MHP9R3LBJ31$:R6PO.@GR9N[*-_XW/Q$5UV1Z\N(/>'_MI+Q8JF2>RD5MPM5"
M`YQ/[&3*4AIJ*6Y2B)'A(\5OQCR6N7E&'^L]P%OAL("_%[K,8,3E>-HNO>H^
M2.4SLETYIG@P/^EY3%;>/@NZR^]@QE6<Y-W_<RML%<IXMQ31/Y)R<W@D&'.U
ML%F:*M\V$&#Y,.=\X@4)A3P"G-]]TJ@+80<679E=FD:0EC9T\4YLB2"@KHDI
M51J6^PZ1UQ;FQ7S<+L<(-(:H_3\I!1I\'W(^1:T?NXU@[:.Y(0MZPP=SA))K
MQ<>X4["X72G,2LA?1J,J4L'1V<7<7+(P2PPN>DVQK&\I*%Z60.I%WLF?F]5T
M[U1RM`C@?=;-'2XZAC&8_S#G/WV(-%`H<Q8'1V.?WUCPW%!RN5D\(&<E0K$8
MG2IB0SQR3VNQ+@FEQFWR*T0&N3'(^%'R6I&G>&4`TTZEX1=Y>Y"\B1<_HM0O
MF_/<,L>)\H=\"^*Z(LD2!,F;YKX7L@]/U7Z$`^P*^LHS)H$WHB!/6!:<""CT
M6-8W=681PPV1__`RG,94T@0.%JP#O1YA)5V!,8%I?M$%.^%9+^+>/2#[/EUU
MSABPCOX7`3Q9AZPP(Q\61()$>,M\+OI>*P0.,G%,GD%TP9JBGYR>704$4?W.
MDYI0;#]$6<0BY1GA4J_/^SR?LMSY+N+Y\&ZHB*X;"Z4L\KB.\6/9<F?F.%YS
MC,7,D.BB//J9]:_:8FYTPO[LD_*_D6Q_=7DJ3EX*M'HF<SY^6X1.5FM_'KVD
MZ>WTQV__6YKVKG(#=--P+13SY3EKRV-Y$".YR5[IDX53/V"E8OHO7B'%41BA
MJ#_-R7P?0^7O[J,T^L`KA@[*8XZO^5RO1.E%&$J\''6O>Q_$7=MM!EXOZT$U
MH;Y(S"E>^7Y?;IQTV;WN?U":>E-5)"RO:.:G%,?;_EO>B(L8O9\G85'Z3S\?
M.Y'30LUS&,#Q#:=,BH@]4]8`IEO$"FP&]N(\M1>U6%F4HS'3%H\M"\J!63:1
M!J!0!HJ?3"@#@;EV8^_6#TEYLRX#R\,@#(?\O&;>_Y5W\V116V[B<7=1Q*KR
M("4SX.@0,ZB:%;>S@!&[V2W0KLR+P&6"R59RTS>:QJO\'DEC9'`!#;`':PQ*
M$\:_E2JWV9AAD.S#%66G7;D7>E_<M5#7W%]I&#--GHB)@[\I_(L?&HKTK_SB
ML'3Y5++TR@U.Y7)/O#C!H2WY+I'F*_8I]5V?E';)1D9/^"Y9.WMAVT\+;^`F
MBE),I9!FL2=E*$K<33=IR)3LK`$GX_7;5-P3HT&:4K@,NV]%O`-LD!>0YFR*
M?A*]!7N4/\:#K4_.=!>W8.4^\D^P^%^G_CW^\[_^FB7:K>O.?_[,.BJ3+"JB
M=_"/;CB]D@;D?K[)A6(1URMX"YZ6II,4?'J%@[V`U;YZ/])>`$K_%]B)\E_B
MZZ(W.F8AI+#&4+3V+5;.WR3JPC^^>#?__=Z+@N]70T-O62U-TPS;T+7_U75#
M_W[]=?#=:CK?$9V&:1G?]?>*/_WO]_[TNV/:IMZTOG?LMMXU>WUM,.AT-7AU
MH'6L_A!6&;0ZIM,<MCOZ=WSQ%T09Q]@QM6^YEXPM%1Q)&H$I8MXN^4JT2U9R
MC&ZKC?^/IBD_QG&@CJ/IHZ)IU5'43S72YZ'./!4X[]JJ7)(G'F4)O)!\^'E/
M16'FNJ9F%QN+POB,7_:-WN<O@^$7K?_YTZ?NU36L2CG\\\1[KTR\($A`6```
M__U>9_^>XZTR__>#/TWO_OM]J_F7]PH8G[?A?[^?4`7_>V5,+57QJ07"]E#E
M*E]I![]A$4.)OFDL_V.:?\'X2\Z/?TVGY6?N^:?'40HV1[ZK]OI7]O7[=9]N
M'?K3?RWC*=ZXJ[(((&XVV"_+'%)BQR<@W6;-9ZQ>9D7![O'M^%)7X?]_P/)'
MA13#^R6<`[L"C\(OFHM,N*OL,\JR;^6$L$VR;`^XV[QF3?X5Y#</1'Y4;4>E
M]IM'OU6APX8J;`@Z?TF!K=)OO27[)8V5\2W@+`+5^'_[_>%P-'J_>O]I-)?_
MLF@2?!J.P*8QO-F"E:/!KUYH]/7X:!L60A)#<"[>E<;@/&'DORX#;US]N>#_
M].SO"<:G9I,O_'K+5$VS_?PMA-%#[,[_^SW[WY>:_?NG0DUCB<:&:NG-TZ/Q
M=F;'\037IWR"V(4THN=\)=4+/KQ/=C:;:J?EG!X[U\3>C=A-TS@]8B_*KNJ;
M87]?Z*Q>"[17XW%'-0WS]'B\)O8NQ+;49J=S>L2NNC$VRN*0ZE1P'/`/_$'4
M"BU,=JW%V>$YW'9.4&77Q-Z-V*9U@L;XDGTF?S1O@;C&2%L@X%:$7K?%+=Y=
M%*8\<$H7<"NCIBOXX[DR[M#?7/%XC<6]8_'TO)`!GUW.AZYL'B//FBO5"OW`
M,MZP6VJ[>8(!Q)K:.U';!FJ?H/U6=0_EDY<D/U/3K!DK8+V@\B42=WE;H%J.
M'8ZS+SN6VM9;1^;L#[7X.BB1V[9JV,>^T=R>R+4C4FT3NL9B[8@\X8BH6)95
M:^\#"W;'5G7G!`/G-;%WV$935UL\#^^DB%UU'P3K7=*8=7S5_%"CKO9><L;I
M=15A:*.I6GHMO=X&L9NJ>0X!E-H5J98176/Q;;HB"U6`/*WAK;@?1\Z=UE6K
M>>QHTMGK[>/2N(D)Q?;IT?@,];4%4A];(`3>*ZJ:W3]:68U]9GC<5!,G%;VQ
M1_&W&Q3U:_<XD<O;+MX5!6ZE\K9\=`8VPIC)F=CJIAE[RZV4<1*9W,E1:CY]
M4:ZH*]JK%Z\TE**FA4]-6Y,4GF]8=#[$+FLX/S"*4P58YVX9DF($R)IFT3<W
M\#+L85V00GR36D^RS[+6;6-`,>NQ$MZQT<"KOKT)D?S;<ONZ\OL%X!Q(A@_\
M4'?F_XD]"Y2/\'46+<9)@6P8DQ]/-9KY5TRC6\0IC5FDOCV\>^*WQG6#-ORK
MA\W,'XLVHEXQ(8]U;93&K^1ST!)OU;>\&*!;ZG9\P3KN2&05.)T((GA3:J".
MO8BB<8#M^OB0(/>1=T/EO2Y+D[SP">SD0N._8;LKVMG"HM@>^.*=/(^(9K+A
M"S^U&F;>(Q?[QK-N::P;4M'%C?`7WFHT(4-N9+8P8(AOG<\KRB>[8&?6LBV=
MCV^6VY[/ERWPXAT:6D;MG.2^:CB/*G`G]#X.:&6=\%76"[9H%,M;+%[@@%^?
M-VPO35O""34>;PU<_6Y._Y,%CWFC9C[;/>_I@W1`WN:MVHOC6(QA(UPQULZG
M<ER[H3**L1%/,HF$L&+B:>*QP1ELU`B-0<'A/H1O:A6$/?AY2[LQE\.)(N::
M`F%_PR[W]T`#H$PW<,?NS.63Y5S679:US^2]:9?VRWI4NF'1#(YU8B&FFLB]
MA=C&?&R\ADL@BG"XU>TM&QQVYY5Z?2(PL,)/1J-5J,7\,,R`56+6_X5ZV3->
MIX,M3<SP4FEPV(JA8,7"_$B:%6>O@90K<_&NF"U0B&PYFT;N<#P1<^;XL"<^
MYD]H8Q",8KS1J@[<2XCBK;C5O"LY\KJ;`+E6T4N%WUL-?<7O\77\6WOY;Q?O
MMFWNS?Y#OUKJ=/6<7E.L2]74\W\>1),,'QI1[[HKTA,C^%VRMW94AM/MF"V]
MJPU&O9%F][LMK=UK&5I[.'"L]M#H.</6=^.[_?Z7T3__ZZ\;][387,N/8O;7
M+]XD`/KG70>[^63!@9=,8I\U+]L71,.VW>PXK8'6LGN.9CN=CM;1AY;FM/M-
MW=)U?3#H/[_!5EKNOE3\8LUY6>K'E<JG;BQX1[2U+.%G?1?+[63`R_;:Q,?7
M2(P^;ZCLI]Z,!C#<^U&6@)[)IW-@4U@Q^G1%X[@+&NPIS;(:8\_T.$<`$^_`
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M#VX\I>J[_3<N&`V&=L_JM+11NV-HMM,WM';;<#2GW[?,H=5W+--Y<>,"_2"-
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MK,]"I;!659%Y%E94^Q1S'FJ!4`N$LTJ-463D7V#/HLHKR;.0?I<M^]CBK[H3
M66JI5RFLU6Q2L\FI>(X'49?77IH&'O98K%-)Z_-0B\V:36HVJ=FDFFQ2==?S
M$_:*310_A%?=-$L]);J!703^S(=_U]4:]:&H96?-)F^#38['%ON,9!E'S]^I
MQ\Z>RY2B&HLU%JN"Q=.+4PU#G+50M^(]K,(S6ZIC'OORYNRMF[K=<DWC`]/X
M1-LMGZ$->U)SNRIL?]5X/#9(E<3CCI/F7FMRW,*\NCLW]GINXDW[T6SNA0E%
MA3_/\;^[X?1CB%-#_'L/Y]\E5V#X3Q[W-GJNU>[VVVUSH'7ZCJ'9PU%3Z_:<
MEM9M]X?6R#$<<]!_\>@YH\VE\PNT1L!GGN`//OYPG0(B-4(;[$?&'-'6SP5^
M_MIZUV!K2)H'&:+'0!ES4"82*(H;QVYXRV[B%3]$[L/!=#A],"(&46[A`?@;
MFQ4<>TD:^Q/L3,$>RD(_52Z_7'_[H+C(APG\9NK%2I3%-%@X?<15&7_!^SAW
M.%$5-U$>O"#`_TV0.>'329+!HL7+P]D\B!X]3Z'-*U=9/+D#`&`-9%/E<GA]
M=?5!5=*[.,IN[Y2'.W]RIWC\I429N8_*G+]#ZP'4LRADNX9%W%1QE:F?3/"8
MX>S`],Z#E^(_O13;;4R\QIXHRD8$'F(N8I:(L8B]P`7Z@G")`GB#TPVA0-]U
M%DV]`+,0"43`]=S#V8D>(RQK,#+U4B]&X4+/`(W]&74?N7']&.5OAG=*]#>^
M./P'_S5UQ6T36^R2_0_]NGCW`S+/II494^;DR0DG^`%?17HWE*_PTRIH+]XM
MP!LC\R%CX;M^.,]2A.`.C-S@44FR\;\X$ES@NQDMD31@$5@?L'KOQC[*T_Q$
MJ,H8%@!&!5,U93=KU)M%)=;BFT:N@27N(QQ(&2#G1_=\\XA=@4%V3%3"B3M)
M,S>@'^=QA'NB$RK8N'P0O1]>//%A>V/OSKWWHSAI*#UOXF:<P\5;L(#\7L(&
M:`)"8_B<%_M`@PF<.]"I_HT_`7H!1J;^S8U',QUNXFAV0:,R$T;TV)T"K'PM
MMNTQ_RJL";*#KAX1L@*ML`##N81>!3ZE(/$!MP%\TH4O3E)Z46(&P2&J0A,[
M@>]=)IV*NY'.WY#JH!2C4&5<]0-A$J1G9Q_I!"B]]T&<N22X`I\-W80'X7]F
MGIMD<<[694:7L9E+#('-*-Z66?^>;UYY\(.`N!P$80@?`8$#J/$2QI\REA"_
M,P_0/XV"Z-8'[&9)/G?##289]@7:>$R30MJ79#WR=]^/)]DL23&:Q1#%:,BX
MD;=#`8Z$$^S2GX'4T0S^?._Z`>(/$4%<#<))Y5(79&@P1<F2!2GR@F`+)E63
M)?B0KC*$C*GDM20V\6=S8%LB20&F)+(8:)47UMX/I(,0V"61.H]B)E/+$C9F
MD@)^![K*!S8(&+F#1Y00/^8D+!#']\`("B,W%\MW<!XB$$<NR?T;ST^1U6,2
MUB$=!]#B+CK\(,M`Z,/+\(%<6I'L3$#$*8D7WX-44^9`C6A*!QT(0>902!%B
M8C^JD686!,#P&1YF:0<-922@2!@8M-5L'K%AO,`8DSO?NV='!%Z%-V&_,V1.
M9>:#_$VC$-GCH6!V>@V783/2V,8*Z.GD(G9=&:4@",;NF,ODFX6O(C;A-[)F
MS+^=*R[1CJLX<X7JDY9K*-=K#E_.`*B(A<C@QA)'!@H-)+0TPU@B2;ZYQ/^A
M@?1)[_)E<CPTE"'_BLO<!U)9N%Z,,AR/9I00IF\C)">0<*HRJ\YS82T"=PJP
M!!'-OQ:;9@?T%GR4F&LK=PI'ST<NXN)>@%?BPYLLG,AT<.=S<"Y(#`OQBD)I
M+<Y09Z$@88HWU"9N<E?\$K<!,&23.UB#=%P8Y>*"L4+LX>'"9?'-FR!Z2)X0
M%2M\MN=[3\S]FGK^ST/X4_K89_.2OM!N@''QP&3)_L9[6]U1N]<RM<'``A^K
MVS6T3M,9:GW=LCM.K]\:=IO@8SGO?_FGE_S77Y_:UX+SB,3Y2-;Y((OAH2MB
MM7^@!`-Q1W]Y`2CH/]!;?A+9IM'Z_NUZ\!YX<`+'+$C^^[UF+8%K=)Q1MVVT
MM>:H/=+L47^H=?MZ!_S*MFGVAJV6U>M^[^AZ$_]+-UKO?S&,IF,UX1\25;<!
MJXR)*_>1A-S7J#LAX[(KE"*(N6LW\*Z]"2R5^J^,CP$0N]4U=:W?:O<TNS4:
M:+T>D-]L=X:&80U'MMT#\IO6^U_,3LMTC!(BG@%5&1W`^&`9?'5_>,F5ZT]_
M!\>I@E#;]OM?.DV[!/+RSE=!]BE*DA$8PWUFLP&+%)JMYV%5E[0.KX1^50PT
M[8$^[/<'6GMD`@;@3&@]<S34>G:OJ^NVV79:)F#``/[OM)LK,+`+A&5,K>>5
M/MF`'T-`+H:ZW`#UV6^@;^`KO[I^B-]^56Q9QM#NC]H=;>!80\T>F'VMT[%&
M6KO9')E-Q^X[31U/R?M?M(Y30M;+@"PC[!_"-.D&H(S0T!EXX'C%%-7K@D>0
MBC59`/"`*'*64.0XQJ!O=&Q-M_NF9O?[':UC#7I:VQR8\)^^T1XX+%;7:>EZ
M"4?/A6M[';-:_598X9B`'[O9:=M;ZYO5("Z@"!@O^0*F&7B/OZ+Q]MKRUAH"
M@/`3R!@0.7;+;&K=EFYH>@M08?1&71,QA=+&Q*AN&?@5FR^#!R8(UT.?;SY%
MX>U7\.WZ[MQ/W>`3>.K>YW'@W[H\CE`]+6-VWO]B+9H8SX"IC(S/8"O'R`JQ
M=P?<`+9E(:\!<Y]OL%5PA0\`&!J:M:!QMH%I20O'B*:!Q_[W8TAK<!45WI)4
MJ20W&'`(++.S9'1L`<Y3*/@8PB%"W[Z:-J8!LD]S%G3#1BBVM2=^C8%1OG`5
MB[HU0<[Q$GSJ*HXFGC<])$:6E66[W>D-AH.NUNSI(W2Z0%F:5E-K6E8?++/6
MT#`[3%G">@L8>1F8"\)",%!QGBJI%]"P,IIVNVQ;K=C]&B_CBP=03?S`)XD)
MO^B#<>&G@"P>NWA=8]+NM"R`TF@VP9@<MBPX#E97&P[Z\!5[Z#@C`/E[&STN
MRUKM?#P%4!D/*T3G453!EF9T$^6`;>EE.V`#$&5H?X_"J,P9(K!51=9NH;YK
M=>PRH=?"\&)G\^]^"+(S??P(J,`+61:%DE89TL7KWRG&CK(V25ETMHK(:Q.G
M@+?Z4@=U5ZPL&*+1HQNDC]Q8K2+&3#(NRI9F:=,KC,G3.D\@/-J&O6P^;GFB
M.!HJR>X.:`1=;^FM!4^![?B)>",8``!^^HB19F1O9&@6IZ^@*6@"%3N=5G-S
ML'$M2*N9&,/XQ^/?+2$'=>`T]97LN[3_!;7GI=6VXDRR[ZV.429K:=^+ZHU)
M8PRT5I%8-CBK1LNVG07U4^SZ*9>L.Z$<(K#;)IY_3Y=;%82S`V!:K24E^R0L
M"_[9]%\95YMPA/-T`433QY#'-BB:-5Z,9GT1=\K7[$J9A;^^L*M.?(`B856.
M:IC(*+I1EMR'1LB+;<4!_(`)/U6\F2!ATK2-5;<S.P&YP*Q!$$WPKGYU?+7"
M&L19R6I;@5-&@0C"Y[CB3_%TXU>%O3MT3!-@U/I&"X[;L&MKW>&PK;6[UJ#;
M[QFFZ729H-*L\A7E$U"401Y26MGGF^$/EH;T!5#V&8YB<@?F!?X/FACW;O#J
M#M&6M+?0(3+TLH'_'*"VBI^002()KRI&3Y`3['9KF^C)(CA/Z6S!4<=P\[8-
MI6)4P6XN7UUO!N4IR$5:]1>6T/3)9WE158TGXU5"V]$7K;/MH5IMC5;9^[51
M^+>;G94&Z1J'ET4,018,BN2M"L,((LZPP;ZR%[S@#6"4(5Y3/2,8`F.HF"X9
MWI()P;*<F($%3U_E0S9?$S6M_K!G#W5;`_ST-=NT!EJGVW8T:SC0>QW3ZEH=
MO"\`AI=0LA\X7X`[J4_C'WYZ!\_C5566WD5'2'3:$H7MW5'X%+@+,?F5^I?A
M?U%&55&Z6JAAS69K,4K_#+!6FYL\5^B$K,[V>JMS,S!;65N+2Z#Y-A`5%[X;
M5-'Z0O/#V,KX>@JZK5"T!KW=E$^.I-34-(H?2Y^I(N(,1%R'3):G<;<;V&LP
M>L1CMJUQ@Q+',<S5J-ETLOI1`OX/)0]=1\'KAA*W!`Y.C-EV%JY[%_:]*"_G
MH)S\0V>T+2<O#)VN88],2QL,AR`5'=O6VG:KI[5:/="P`TST&[$`C;&4O"!O
M>CTXH$"Z,\PJ_\_KY^MMJ?Z:`)W9,5MKH5N`80%8/T:77-Q'(9WY-=SA#>]E
M@II=>S0<#&S-ZADMS>ZV+:W3ZO>TGF-:_;;1LWIFFQ&4C.X2Q$\!LG1'@9;!
M%:NMF_8>OR48F1GYH1MB_647JU18=NR*T%T5^<#""@''7,S8?!F@"U=Y/'4'
M;4Q,`L4$V<\W%,A+OF$)4%Y%`CRW.KY'Y2651%]S5;[KOB#>X?ZAR+05'T:>
MKG2-"IB?S5UN%M:`NJ`ZF5](57J`[$_1Q`U.PBC'&Y>R,MT&DB67!'MFX!&-
M_7$F^(JD7%%G]YJBVNKJ]L!R',WI629F4`VTMM.U-,.R.[8Y:@Y,W63`=Y8T
M[Q:P;&5M_Q[!$:2!1>-`7$53#+6*!K7]_I>691C;F--KX=H9*ZM%$Z*\BJC"
M])*VM<:\?@FP6UR"QUGUP\G`2F9K*1_S25BVLH!82ME)6D`FRV!T6L8V%M"6
M@*Y40CQ6<!+JQZ+[)W.5!EH'QDJ8J^"?;PFR32"O5+I;>^D)IG&Q9RJ9PX35
M&;"@T5G,32YO?2N-4;)$I(2$*NJ&)6OJF3"5$4(53/#4%V`--SB&RPMLVAKI
M1D>S':.OV088V]TN?`OHVC:<IMT>Z2WN\IH+AM3*S6]7@\5//CL4D\>O,?@H
M[H1'"^A?`8L=Y.:[R'"_8FT^NBDSWJA?6X0Y@6C.14%`2:WLEJ^*&?VH.CME
M!CHJCLKD^I7UIL"(3:DS184O03O@-NL=LWRU_00<V^8B7KF/54U$I$*@IN4L
MWF\_`<KZ>,K?W9073UW%><4EW5\%0?+YYL2:-`!V3+O562A!WPN\ZU&(SYT<
MIE`@@<8SUB+J*:BV:9+YJI!W6L-1KSNTM9'=MS3;[/6T[L`9:*#<G;8S[!K=
MCL7LTN7LP&UJR/,;37:W5`6[M&>:MM'LFP!R"Y1/;V!K[0[HHJ'9Z?<&@YX]
M&O*+B%4WLQOAV,J`$UT)%KL5),L-#:IHTR$K&&UK*[ON&:`^KQ"[ZDX_WCD:
M5EM?PM*V4#%TA'^F\<^?XULWY/=!K-=3WG-W;^V<;,MJ@M70T48="PQ;6^]K
M/<>QM<ZHWVW#'\V^W7IQR]SF`3KFRL@YN1ZY?WC49@R;XXW]:`[B=.9.O"RE
M+GK8E<P-'Y4[SYW^.W-C-$&IG]JU&RJC&"^$DDF$K=1`"_LW41SZ+C4H\^$L
MQO,HII9Q\/S`"[`?GM=0^/=XMS7L7HF?GOMSCUKR13?*-,YNL6GFE-KL\0YZ
M&;86_0]K^'DU_/4QX&U\J:NB.[W'XSM5YE$`=@%%<_^5W5+;/&]R%V*_Q4?L
MP9MBF[U$>?#3.]9S4&K<F5(3M3BZ9[WVQCQA2NPH81WLX+-H=U2\\>)GZ@''
MT@H1/POM[=P\@,7ZQ_&FL5.Y.:H2A;<1:S;HYT6CB"1J`$A-Z&*OU(]1;O+)
M5\2.B]*2Q4(-I9LH+N^=R1H=TDJ+ZP`?9=@G,,G&V+R3DH8"Z@Q`6PB]6W(3
MI#YWU,A5B8JX(VO2"FO<9-@.DCB0H+ZA&TWLV@?8DEZ8QR![8S]XS)LLX^K8
MZY><%&H\BM\`*8C>7WBKPI8#L+6B.&=*;.":W6";VYCAT+V-/=XK$O]\(VY3
ML<^L\!(3P$H*1V7BS<9>7+1AMPQ50;F)Y^P!-S_%CH)Q](/WQ51^,IMFHXWM
M&P/\/O8[1'RP@UB40?/.LMCKF;6$S4U"%;F<-2+]R70:>K[4@YO(O:]I!>H)
MB7\$^B#J#/,OL%3HP_&@%>&Y,$I%>].?#,<H[8T8:NJ-8;W02Q+6VUC^C6@^
MG,"[I<T`7.XMX!$/-FM\#"B<8V=&UC,*8##,AKYZ-\H4..I_LN"QP*OA($8!
MLRW6Y]C[P;^+4`7`_QKU+PY\T4.308Y$8WVS$["K62],QEM*3`D$@%#B;Q^8
M,8OI>@E6G8!KSX3A[[`?I84]?+'K)<LYP/ZR>5\<Z9/80)>:^HZ17IBE.17T
MW;JCXU,:7-+S5R#CX8SE+7P^W_"<B%?J-[+"4C:,_JC7&VG-5A<MPOY(ZQK#
M@38"E\'HC?0NF#PLRL<2=G0.[U:02)!+#X)3N>Q/C8C"7P2!6>2F.+NO?]6^
M;9H"YN654;,/4"7,L>2&SS=]Z@Y-=_/@<XJ+>4IZ&/).U:P5P5*R0WF(P]X,
MREZO8SFMD:'U=7N@V?J@I;7;`Q,SJ,&7:-K#8;_Y?(,R_9LBS\<I?K%&,R\:
M<>E:?;]9^`O1;]IJ6V^J3M,A%1_?H]YFPP26.LJ#"`;QD<MVUA67OX/FC,^)
M5,P?P):V;'Q!J2,MS2]@;6=GJ!S_P\00-;N-T'TBJ<@;95_2=I0P0TC88U&6
M@#)(/OS\/%.I/(AHV73*+:7U$TZXJEL:;-1^FFY\NDK_\Z=/W:MK>(?4_#SQ
MWBL3+PB2N8L:_+_?Z^S?<^PCSO_]X$_3N_]^#Z[77_))4YCWX\7OE3%V)8[Q
ML=+PI?+P%[Z`W?[+UA.6\H]:Z]_9U^_?YK>WF)?U)%MMGJ:U:B38XD'9B8G%
ML?J_3!/`<4K9K,N_*7]\''S]#>10IP&_E+](SBM-'>F#Q74;Q8\+/NVSIT!N
M.V^I/-YH[=[?+Z$/3B@<RQ#]H(5CMPC7[UE9SD8WQ<]%K+3X71H5/X^],B+&
ML?+7Q?59>IKR;0[2<R@F6,!'GGSQ<Y:BJT/S-UFW[>3IER[=#PNT>1XY3H2`
M.;Q_>-C%WYMJW7MPR6ZWH$=.@RN<5_)<2A3@;D^2\9L@R4O.U!=OQH9\/8W-
M_#J#[!9A7"ID76Y!?&;2E&XXR/+<@HSY:#)%NA@"VS2@P,?3"X#]TX^";!;"
M&?VPQ?<F>V:;;88\/FG$OG_IR.+=3.8G)QS#9X;KS=4YA?.FROA1Q#H>E;LH
M`)9)+HT/AU5A+S[<RP-*C;;:U(VMWETU670_.W_VNS_M"*S>:+9/#=:74MA4
MVX9Y6*#W(PZJ?_@Q9K9)`)S<Z;=4JV.?VH'8\?!W&LZ!C\%^07UB'SNLL(R3
M(LR!X:!7V^JYS(@N#-T?W-!=`?D^Y_&^^(,']@=J_-7XV^,LZ/-S++Y&J1OL
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M1'3!"EV16*E<8C;*TB/%`Q]8WN^7JX\*:V;C*5_C+$EAD4OXY0?,5U3<FQLJ
M'"!*\(PQY8JRHE4</(VGB+)4648-[%$,D\8/XMIB.O549:.8:=PXI<1B;WF1
M(_BHB!(FVC=R`O\]C2@.^([=V,<,4Y9PBO`]1'$P!2'G*:&74@)BHK*_\E3H
M&\"8\C]N6,:J(9`*4.%=<?Z'_L>__W\?N[M0T<@9/<ER_OK'\,O7C_WN)ZW[
MZ>.OO_],8[$QKQNX[//UQZ\?/\/O6!;EO8=J@G-<H^W]*&G;(6-O6'F)[Q'7
M3*K^[OV9NG%QM#I_2WA2KJ>6$W").+#8/'@L,G%A'6*(;_T>I[!R"3]_8'FK
M>'V;8^GO'[_TAU_>-II&#>6WZ.8&7@BU3ZYTB1M-@"\_@2+%MS<\`JH4IYY?
MIM&M1TFQ,:_(P=,!BI&>^D#YV?RL3(M\7Y&#/1<YJ,#(/QFF+:4'H_K%([+B
M(#6*O7037,6-4S:<W4_H$)&TH61SW,]"=K7=L,OYRU+.-DV6AR/(Q0%FZXYI
M##VV3V.@^:*Z6<R*Q^GVN`KL%1M*S$@!!/Z-)^;%;Q!B#:4;8#K=+<H>6`2E
MCTCRR\5-LBQO\-):"!%X[?2./9>P)W@2&==BRQE,B2_*'@3)>*'%VJ-X(:>&
M)VPWC+.05WA1`K(BXYY$(CFQ-3+EQ;M2687+BHS%D9%?42CCG[6'QSU@%V$P
MPJ><<1;.G!\6)Y*S%YPH^7P0P(%D\5R*\UG,@?W`:GR63T]&RB^E`@%VB&"!
M&4TRHU/TG#,DVPH5+]_Y*J?5HJ1@KM@=EK<@;+Q^YY$$,T_#+4H&!'&GC)$8
MW1X]-P9S"@FYWO=@I2E<C,ZI\;$L-$`^>G.)TW)31J8W_&>]48?DSU?Y@)RX
M83.7*S*'=R.9[+V:BS34GY]&_'+WMF-NF1>,1GW/NP54D%>F_.:YT[)MOR9S
MN&4\/W-X0[+QOGZ_[M.MU\[=W2H"QHZOK#W*'%)BQRVC:IO6?,;JJ]/YXMOQ
MI:["__\@W?OLD&2YNVXE1_6?N;2A7Q5I;BN/^\(S>/@W^;Q[P'--N_6T8PWO
M8;,H^3?082%Y\85?S;4"JKOH%+FF+&!0;@]!FRY)[55"O;<4L$GCE]Z+;GO1
MN;N5\JE<%\E,TH196F`@+)9$EF-@8P0?4W_!X@XP%K-9O;_R`=VX^G/Q]-.S
MO[=\7[C[UPVSK3JF_OP]K+IXW#T>6AG9>U`P=R#UDWE?+T;ZYG2Q$^")[4RW
MK02A=0A!>%7R@-<7A5=9Q%7FN-<'HGI"\GC,L%=%:*NZ7B%%N*OXVZME>!B!
M**ZV2""R^P<P#O&2Z^ICE:7@63#Z9:L"?/ZA%F8'I;&AGQ21JV["_1Z%&O5,
MJB_&7G7GX@:!WSC5NN'0<@-3QJW6R<B-FLB[$-FQU5;;.ADBGYZ!FZN+Q=P.
M%&GY2*):FAV8T4U=;;?;I^?1U<3>81M-0S4=^_2(?2YU."NO)U?PQSYK,O;Q
MS16/UU@\>#'H"S1V]2XK/=:-J[ZI/'"`5E?MEG%Z$KXF\AL@\AFJ\=>KK=S+
M1RNKR,\,CYL2F:1,)?;HEC6LVQ6:'2B=^DHJVV*9S!L*+%3,:?\[#DXH4J+S
M?UHLH=Z+F://IR;`LG/WD8J_?FI)R?'4_MXJ?J%BXO^<#9P('K$6`&.W4C7`
MBN(N_/5IAG9%'KEA*C/X[1U/*$]X%GH4KL_]M@AU/&$<&WG%GCNY0Q-LXL6I
M"P3"&7&S#!/3`7O8T8MUW`=DK5STXEW10WL:T9+%O(F9^R<RPF/>K#^OS"N7
M6FSFFY>4%!SK8'1+Q2@7[UCUQE(E`8VXP`"]PBN/BMS_O*P(B^A8!2(K]F*M
MQF=^BOB;PC&9I#A0(Z)3DJ38G!_(285E4ND)JW:\8+FGHFJ&'P31;MR/DU3A
MPVB0X'FQ*)6/B"J7BW>\!HK%XO*2EA45+PUED%=*4)T$9]&+367:"WQ*&R@B
M?\I/IM'HY.<>5OK)-!M&63(8>C$78U$T`+`ACS'FMR0YKDO"H;ZP>KV=G^@9
MS]D',2^?2WX<B:GXL07"P%%6V0@DYN^*:I\O^:22HG(KK]GR;FX$]RHXGM&7
M"K2DLJP+:1).0_D8*E3S0F.%/!RV@B.@J,*)E8#)=6TKOT_GCL%4*&-1$$9O
MI=C%29H0PSQ]Z>HQE_;PYE@J/1TSC8X8R1]9^!@3,J0_."I=:CR)):1C'"2U
M"@4R`KX21A)09'GM'MLI2&&<A(./+U3<Y>5V#\5>+][E=,C+]=QD=>'ITG96
MH;6A7&-"?E'QQ6K9<\2*TEF&7*DV3WR)*14V),(-"^Z`?X29](H2L^60+TI%
MMT;K+U0)S(P&'$:&-<DX^"E9*/HK!NC(E,SYFBLFB;]YX:3W`YM6`/+!M!-O
M\@,"!'))N\2"#``#(@"L#AI!);Z.@Y,81N'?J$((DM*2.`4('XU]`F'J`RIB
M&J4E%HW`K_;#TJH7[W*%!D@I%(/BTNC@9QT1XK*83WD30SGP(+B3-(KY>#70
M\\%4VB<B@F@F/H6GAY`GX%P^/XCNB[JT^+6+_&=1DI9'O*!YRRM#D;_X$&DX
MT\B7@NQ\R!9-ON)LC^\%0%^F&E1E@I,SD=K4!=^-6=7]!!Y514TNL]`8!UZ\
M8WUXR;(K*I[+9<UP7"(^$2MP'^'/8S]*X)N!&Q?O,XF#,B+`+NLH,&`]$`7`
M;L"CP*1823T%:0:B!@V[E+$Q.65DS0+HMRCMPAF-.L<!A@&8FFX&%BQU`?9G
M\RA!Z<&'FU%I=21&Q65)+AYI&F$!C3S.CO##+-,;-OH;1XC1+W$G-+S031:L
MY47EBXB?N5/$IO*M<=T`_R0`9*`HNOQV/?B`=,7*4^F[<S8M/!%;I#8/P2-1
MBIN%]3E\]9U+=)RP"?!(;L;L).N!FJRU"/L=Y]N(^-Z/)]D,C]G$*TGD@IW!
MW,@FA;JKQ>Z1Q6YIL-;#`K%<1BZAFH4K)]DJW!]ETR#Q$(?K4DK6V='+;10:
M2C\*22B2"WE3.XG'E`6@$=BY%S-2U3*=%U(?<TZ@D-<Z7LC->_!.LH3SW5BR
M6#FOH&>"LRO+=J',*R]P95_!:P7/$)LFI#QZ\D13'`#?15&(^I2T[4+/+92P
M/'`(OBEHST22PWZ(0X&9&;TXX+.PIZ5F0O0N&E6PGA#PL"P.UH/?,<V,CSRX
M,6[+9_;\!$@3NF+^*\X[G3&%SH2$U."%Q#^RT`1,?4!-_$A1*QR37&JTP7VP
MT&5C;;^R::Q_AM%#X$UOO=PU9MH(PV_4O`AMK,`GQU[,00:DXJ`$/Y&MBHT-
M5%3E+GH`QHU)SO"8.'G0%*IE?DT!$^V%-!HL,BY[ZQ@ZG[HS%RTI;A/E&"A;
MI)RQ18,U'`"+0$@^.X\14@F>A*L-S,[^0[\JMU'<N=>AU"^1S4/Z?),/5^]A
M0QOP**^]6^*DE\\+Y2O)LT(__CY:[IO8;CO]9MO1S%;?U.S>R-;:W9ZE.<U1
ML]>S6X-6QV!]$PT._U-[E]M"XASY9.`GDR!*`"?[;_O8&K:;;;-I:J/FJ*79
MCM76.BV]I5EV=S!L-ON#@?[JDSR-]HII>=CNL0@6-Y<N'WD#2$(8,=WXF>+W
MQ=-'E[:,/]#`^KX[]]%7DG:W:I#]*^USK5+Y`PPAW"'(J1L\_]AM!X14BG%X
MY6,XS="A`S"^1*X852^U.W1CX-&%@?6L39X+GBU#`%N>I/<M#]11VU06Z/%P
M@CR_+>%;P>@]C3>?Q(0[!0P.$%?67WBX"P,WW,RCY[EV]D,F_&FB.DCRS^"9
MERX;'+IE:(JKK=]!A91O(\P.O]K2F83%Q:>%]XK-[1AVREW'2$=Z<$+=PG5'
MB;T"5?)@=*;WXGE$03MPJ:?\&B9AQ7VEUT<Q#CA/)I$JH5I`T@71'107JC2.
M/<&[;-Q_85SC/J]I_"1MY<:=\'NID`UMYUE;XC(P)E^?C&O0!W-0M9D@6U*L
M+Z*6/]G26/)M^_*^!O,;YJ89P>LO.8O[:H98Z@X71TDB1;\Q@DIASMR09"@J
ML7Y"8]]_,ALM^<(*&:UA%5]<=ZG-&3W_P+T;9%X>WT;BTAY4NL:"7T_1=)KX
M(IR/7S8:YL)5F72)SH(\^1<K0I=1F14+[SQBW9\7$.RN&?7,+ZI9L#;A3>"2
ME:W0=@*90%CH%)YKA"V[G[UZ+_!F^V5#E-L[#%%^]7YD*[#[PEG"^,=_BNML
M=&K6ME$Z9!Z5W+#JQ1E<NV#QI&?0@#!P=LHB>TG:VXY#6QS5:55@ILGI#"]$
MV^[5B?O,T[M$95LU#SV7\PT<ZM;)T=UH'7C0U+DD6->#WJHM=6FLV[*A+D*2
MNQW,USJ$NBH,@EKZ[DC_3UZ2_"Q<XCQNC_:QN&VI-`M<&JK5W'D.\&)1?BV!
M*_'!MR6!K]B1*R)#"W$\%G\5DKG2I[&M-AVCEL<OE\?\DE+D-E6:Z)>VZNP^
MO;,6P;4(/OJAZY>NNB(IGYX2GE_S-.X8;;)5P^H<7_*>TF&L9ZDNCX-9._L1
M%UJ_W4/=,>F;+NCS5`QV14^;JN(-_>=0N?;FZ>)=@XXWE'IGQ6#'4-PR8P8S
MOZ:%=2ZO^<]\<N/5C?\?S#C"07(L)4HQS*9JMIWB*PE>26.97X39X/F-,=UU
M>\OY`"MOJ97+O_L)YD(I/1=SOT9\E0^K\@#8)37?*,$V]FX!HIG[)RME9,E\
MX<1C0V++QBUNB)43LL&-K#!E[A<3O:(,$X1O8L]C209\+!/\L9O=9N"LYK"(
MBVJL]\AWQ-(`_40Q#/OB':O$352:88L9RN3U\I4HCX#=WXKD!$S8QYRQI7F2
M[+K9U!O*WW'%X)$R*=D.J6S%2R9N0+4]JS,2!9GQ)O3>!9`R7J\$DB:ARK`\
M_P^+?+'L-*)"!8'[E:AGQ5G)/`H37TSD!51+E<,7[]C$/H*39U5BEH0W\6_\
M(H.L6)7523!$)1FRBU=:P\74.4SV=]F(8*)9SLWY%^C1^3SP)\@%"(?[PTOR
M(FF)X7)VJ\C-]N?E1(L%'A9WW`78^2WWQ::4BOJ6^]BWW,WZEKN^Y3Z^-W)*
MM]RVVG+TX_L=I^-JGN@M=[MS$KD,E3[4IW?+[:@Z[XY=<;I7B,KM$Z2RT3X)
M*E?Z='=.D.Z6O?/5Z=L\W7QRX"E1V78JH+E/*2Y<7]*<BM1EN4O'NR[?T6<R
M';79K`]E?5GSW,N:`X8U_Y#Z];&X==YO`?LW)&GL(O]JV!T`@]M^(C5BX!<4
M+!;?4$8\BBLU#WRR=:!:]`Z\>%?>`%UM8`7<BIBJ')#&O_/`,2PAAXY9'56Y
MH]9/5L-<KMZZP-:$C<Z*LBXJO#(;[2<JOI:CU(N%U.NJ@Z4*8A%N_^K%LSZ[
MFO"FPW`ZP!N$?141=\S!J*,/V]JPV1IH]M#1M4Z_V=;:S1;\MFWVF]W^=^.[
M^?X7?MVAB%L.#LFF7<K`3.Z\:8:UXL^N(<>#L?_J::/3Z=J#84]K]9LMS6[W
M+*T]LBW-:+<[HTZKW1[8.U1/OTXC"+S+8O<#[#:-Q^CO\+Z`6I,A&^(-'V]X
MQ?JD+#0P5:9Y@T]8`D_IDX>4V%_<SO`[-^HGQ];(&^/EY;2\PT:I0T.HC+QQ
M7+XY,]GYQ\ZVE_DJ'[!<>,-F5MV,[-:[HWQ-\F/QFF2;N^_2-<G+[STZYI;W
M'MB)NH=CXWDOZM\\=\I[46^^&6D9S[\9V7"9LJ_?5Z;T<"N;:-,H@R5VW-+D
MW--XA#(K"G9?.?5DT[W-`A.6-[E+WR'*R/AG+FWH5['R5[[YM?=4TC-X^`GD
M(KECWWBN:;>>=E<D]R]8.^H-=)`HMH>OYEH!U5UTBERS:8*`)+57"75IP$#A
MRNUS'F#UI@N-$?RP'C"T93!A]Z\;9EMUS&,/3:Z.[#THF#N0>N'[^R2]?.`J
MB*P=)6OUYFA?B>[DY"M1'S;JJ[,H`:LLXBISW.L#43TA>3QFV*LBM%5=KY`B
MW%7\57]2])7<IAD>^C-U8]8M[<O5QRI+P;-@],M6!?B\GG9_6!IC4X03(G+5
M3;A\MGW=-/Q5=[[0#[S6#8>6&Z:A=GBRYRG(C9K(NQ#9L=56VSH9(I^>@?O[
MNED%%^^D@8BU-#LPHYNZVFZW3\^CJXF]PS::AFHZ]ND1^UQR]%9>3Z[@CP.-
M_CY8^FR-Q4,D(;]`8U?OLI(7V=8WE0<.T.JJW3).3\+71'X#1#Y#-?YZV?9[
M^6AE%?E)X7%#6<+%NK%@^TKNEO+%/_*Q00./_>_'\.]^`(YT%'K\]DA\"K7Q
MRT>&^4EDFT;K^[?K@3PV3+.6$L<'G:;3ZIJZUF^U>YK=&@VT7L\9:F:[,S0,
M:SBR[=YWX[O1?O^+UF)5)")7_EE`2<BX\F+,X7-O`9-=EKV=?*'Q;HB^/DW$
M\^+DZT.T!TS,@3XR"LPE##2'/4L?."UM.&B:FMVT6UJO,T`,-.U.LSNP!WV+
MU0SH#4N,3ML>AI6`]SU`2WC[.?P"_Q9X?!5HN[VAW>IU=6UH#'3--FU=:^OM
MKC:PG('1[+:;G6Z+%0KH#=U:@G;EQN4Y<?X$`T-]S!`?1ZS%U6<<G_B%A;Q?
ME;>MH:XWX2>M9_8'P-MF4^NV=$/36WV]8_1&71,K)[[;[W\Q'`L8OF#MI\!8
MQ\W4<?J+!V+N/][TVSP*OP5LWONUEXK1DJ]!9=L8].U.JP-+6I9F=WMPJO7>
M2!OV.MUFSS`&ECD25';T53R]!202$O[A!ADAJ8ME'.@V%!(S!5'8PZ%??9S\
M'2;LN7`Z_`'?\Y.#RCMG"3..`Z@Q.K:FVS@EL=_O:!UKT-/:YL"$__2-]L!!
M>??^%\MIRM+N12!*J!IY4R]V@\_Q_,X-!W%VVX^]J9\FP[PE'*63[ZLPR&F.
M='N$XFS8`GA'W:[6[G4,K>W8?6O8']H@#=@9,'6SR6'=;H\24'R(:CX[M!]1
MNW7XB6N"@9=,8I^5T^P-M'9O.#!&/:UG&4W-MD9]K=OO6EK7&@W:36,T,$<V
M$]Q=G(TG#<=[B.)@^N!//1I0EH]0YI>*>4V08;)F>KPX2)3]`0AYCC:O'S.L
MO-2/!IK2A%2I)5U>R)O>P2[NHF":-#BNGX.Z'93H'785K)`:M5#D&,XSU2A"
ML6+H*AXWL#;@I3^H-*SJLU=!JI@+LU>?`&$+P?&ZXG,[<0)4-EHM67RNV[T$
MX-]QRC$8VUA[^?GF8W@/MB0E5H%AZ<9_>F2\7WL3?`B-[:@'"CI,X!C#4MVD
M[R9WPW]GP#H!96/M2\S`2[UFJ]O1])'E@!71!($ST-N:,["M5K/5TSMMG>E2
M=MA8_TT.]GYADB4NX'-&0N$*1R1W$_DHP:_"B3]W`Z;&/X:P#ORZ?X?33I'G
MPC2.@E<1"U:W:9M]\"]`/H,-U@6QT&G"3\VN;@Z,E@F_&/"IQ`U=6-=[`$Y"
M%2+Q&@=9H]+F0G44Q5^C_IWOW8".GF28UO&99LWN3_,V];8^,JR^UM>[H)Y&
M0]!,K8ZNZ4-[T#6M)NBK#E-/ILV9AG58186$I<GS($OX=%DE=>-;C\;/HN-Y
M3[T@.+*>!U[IO/U`G40(\\<9H=N+A[-Y$#UZ7I<^?$U;*=!_`)Y9)4^MKFZ#
M1^)H3L\",3,P!R!A0+4;EMVQS5%S`,:*L%^;>G[6G@_/-N)'/I#7=U&<XA.O
M+5Y`=>`4!9R;CE7'K!'!4T)FY<Y?*$18!*1+`UY?C1NVDB$&R1#]!3)$ADVN
M]O=O0Q].CTO6&2["QR5?18$_>=Q_-?^@WQ\TN\VAUNZ,@/VM[D#KMGN&UN\-
M1WJW[<#_5&,6.OY`[<F%\:84UAM9Q!+J%&'.P0)E-%(,KI)=SG&JKS!"J97Q
M/`8^C?T`I/.=&\_<B0=R9@("&H$=^U'J3>["*(ANL:GX!&P[-\2('IS:E-Z7
MFI2CA_&M<=TH8IFXQC"+H[G7P$]CJJ-`:UR@E=_+$;.!:P%*PP\"6!+?SD+^
M#T#ME*?G\/=X>OH\CJ;91#@]^$Y^"ZABH^8'+PCP?\'9]_A(:/3Z<=PZ4T]3
M^AYX*'S!21$CN:?.W""7)G?\U2GHI2":DS'N"@\G:2A_W'DAZUT""(7EJ;,W
M_.L>?3+JC8*5L:[PM.E7&/Y-;[*@0,KXD;X7WZ.GA8_P'M\3',<.[\-BH"RI
MY_?2RPWL#@->%AJE0,UIQ/TVFA!'M`O0NX^Q%Q."&<FL0"^#4PC?G-'4]=L,
MU`JF=?K`9'E']_SYXGJU\S?1Q4FY\^&OL2\:AR=)A!.R8:\3LHR5V$_^Q`_!
M0C0\'?>'>5?P"C8E41+I:/%7@BA)!*%QPP+8$B,TE.Z:R=2\=4U*9NS4O[GQ
MJ&=-#@8MPX>IP09L_2\J^+]_87UD#.<OBW/"&2)VV86U_2XLW(79YKN@'YZQ
MB^7K@X6[@"U%OZPM%FPQ5F$.%IFP1/;GFFQI8H)B;);=DJ?W*`$T3%CD;\I,
MJ(\\"?`+_.ISR,,71<+!:S@53EL'"W"@PY+@>]IF:Z1UA[V.UA]V3+W5'YI=
M0Q?FH='B,#\+#`G\@3<&`R%)XPPQQ8U,87(QQ.V-H#WPPBU]I&N=8;NOV;V6
MI?7:W2&8A2U3;P.T[:'%?<V'2.'-J$#PX40?#N86VY7#2.(F:U!(ZOP6YY5#
M"YVA,>KJ+6U@@/EK-YM@Y5G."`SA7G?0''8[MFYP3]'2+3FVL!F(\C4<B)!/
M("5['LAN[PHU#O;6`LYG?_N*(QL.U*.I#TQK&$!72Q]T-%OO.UJO;W6U4=\V
M.I9I.@#SBWLT-0_2H@E1IHP)9[#.Y1CTYHV??F`JFZ9:H/KU"85\[`7K8>:Q
M%DYR>Z=)'O$ZZYY';?O0/8^<3@6G0:S_M'/&GZ[;+:UHV6/HA^RW-,2[F(L-
MW7(JTAJG9H:#]F\Z>B.D-X]^JT;_,=%O5DC6O8$V8`.P<,&1G&RV5>N,Z=VK
M.9NJ;1R[\.E<2W:/3%NC::AZ\]@EC#5Q#T/<EJV:SND0M^HU7*,H]F`+YZMH
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MPZH2>4>BDL5/\JK"A+KI2<]0N0[_R*0$,?-D$02$_0,"3P_X6$@3W5#_`?R+
MJMQ2+0]N7J[B8,FS=!%T@04E<0SGA8\@#5QY.JG+*O)H`:F7$*]^^!A.?9>#
M\NU_E20;)S[\)F9E/U0Y%/-F'\L[@8_("/*I-N?>]0.4I1IL3Z,I0$E>QOQD
M6<539WMM^OT?'EK0WK2+]0NW7CFO_7.X/Q&W928^B.K/O!AS8Q[^4_LNE2O/
M_=0-V$QEE))^2(3>JP3?L@T0-BS0C:8&2^M.7F^\?G^E7'L\CE'\V`VG4A7-
M=3:?![X7OTXAI=-O#LW6P-$Z71VH:'9[6L=NVIK1;7;,;GO4<3KM:A52YFA;
M*I\4F#N5XLD"$A!Z1:4=K)'=@/#.8A`UV1QD"Y5CS:DQRXT?SY1Y%H-RH.[B
ME"\O%;1-Y(9,RAR,AI#$K_0M478P]6'=]$(J7U3Y[Q1:@HF]8C<T;1U.YQUF
MK9$.B<!P\5%[3+V4V)SU?G%QETFJ^:'*?XJRE(V/;Y2!!M,ZP\),W`4-K8X>
M@'P`)BT-XF)&+2#H:Z#A6,D:_M[[,<%:;U]:#)9X`(F1>B'8W`\A:B#4'4QH
M4SX=?8V7:,(V>7DAUJ8658.$4@RV_@L^AOA/0!C)NY;:Q2*^-Y5SLJG<J&,`
M5-X0?JH\8&6GH.!T61$<[%29&UCQ#X^*;Z?>'#OXP.91;0)X"3]2W&C`Q@$`
MELRB<<(F.8G:U-A]*#%4G-TFG'[W_H3I6ZFN5?EWYK(IY80_P&XQMSPD+,\\
M9`#<QH2HF&^"2G.IL!0)0R]3;2JOH/T8YKV%)BB(J8(6UG]$V!)@9E3(`"/?
M$T&*JZ`]$!*3S3`&/T&%C3R2`]5`^9+`M^`[6#[)*Y7)N*(Z9EB$XRWA6`W<
M1^2YF,T'B+,Y<A"KXD6.<I,(C@K58'+8":6<F0A05I7LT4.(4X`)#)8I[(G*
MV\KO,IRQ$EL&EQ*-P8EE\A`PF`539>S)!;+PB#^;NX"^*2#JS@>.IL<N>&VM
MF\.ON%,0`F`A>C=X(`6GC'E;'CSR(5B5^"20:NKS(;Z,6FA3,I,+#AS;SI.F
MT$OTY%95IZ(!R*N7G6*EGKEMW6F^2PFF;V$Q70*<]QZ[+DK82XO=)[\0G^$9
MXD85[PBS-ZA;_6ZO;^JV9@WM/FM%T3;U'MB&EFGT1O:P,QPRJ'^'SRGI@Q?<
M+W0#V@M`SV\"]B*[>/\MP`PLR[57=AW<"$.I<0G32W!FI)K/(2HA.)*PT6/T
MQNJ;MFU;;5UKC4PX%H.1K76`:30X#K9CZ5V[:SJ,0>Q2:ZQM@9$)SV>PCL`P
M^I@D&1XIZB4&[$;="'_WTL\WXB]],#<JV5760A%A-!VK*17S/A\TN3-<A*U<
M[G@Y-^_6N="]=Z%I;Q5;DEK@=QD=JU6@90?`-O8?AJ,6@W':#_P0]?]7U'U#
M9L15DE4,Y_TO6L?HM#;U']X$5"FR"#HW3GULO99A32YZL-[T]PC,#>&9[]7;
M'G3;[:[>[6I&QP&J.W93ZUB=H68YS:YEM>QNM]OY;G)OV]3T#D"?1TJVV^OR
M&1`-#C@"%GBETNR/Q#;U=KN]Q/];`K6B5^07;Q[%&/'[!MM.OD;#>VKHZOT:
M1=,'/PCPFH!,Q#UUCLR_]QT_^%2+JW8'4&.,6MJHJ3N:;9I]K6OV.QIHU&%S
MH'?:_:$PJ18:2#X+KK(*`2,U1;,3.PR2SNE.R,68?KV+H^SVKA3I@>>H`_*(
MV;_8V[1Z4L)NOO_%@:^4U,G+P)0;H8@%KKA_^SEW.\">91=+>^P,-W2ZACTR
M+6TP'(Y0:MA:VV[UM%:KU[.'`^Q4/&(-!*^L?XHF)UMMD<&4)=JMZ\Y_[H:I
M/_4#,K^+5I3#'Q1(F:(>QG!MEK(NV#=#-PZQ_1,8;M=WX`"R%FJ[0OW=,)OM
M9KOUPS#;AFDZ$G<DN'KRA-$U[%J#5MOH`#NTX>",.B.M"_Z)UC/`R&IV!KU6
MU_X._$!G!W0J-[SV"GL9G8+CK@)PXV2VRQO0?$N\FRSX]!*?#-'6`4X'M+6<
MCMU>ML7;X)+@@1DY#MCB=JNK=7J`EWZGU^WT>U:K@Y(6\0):IU4@Y%F[+P,^
M\&[`^U]H@AW'Z+-0"-Q/[_`:XMZ?9J"66:.A6.[6N#]D/"5AE@_;=ATG.;ZL
M$@^]&.XC\P_@K+D;_YC\7%E[X1\Z4<MMU`M,]AZ+1W@`H?O@QO2-]+&X;$E(
M@G\%;_DS-8!,?H4EL.7NRZ[S`6<MW3((9X9IF!M%U<H^EGV["[Y.3[-(5O4[
M+:WC]$"T=YH]HV.BQ3_(>4QBL-="S)[(<3"D.TVSLUD_K#`<VFW;'#JVUA_I
M0\"T@1==UD`S>[8Q=!R]-QCT6$RBU3+*YWJ_"%B!W/'3:X_7K/T/L(&QD]D4
M#>$)F<#XJ\]9BI?>V(MHX<;QBS=S?=1=?1Y@!EF$IH"Q/\(L2A`P9\V.86FC
M(=Z].<T!:.:NJ?4ZP/V=00M,&]X3_<K^IZ'_W30&"[BO!'Z>>2B2)Y@B'PDA
M^&)A'^+OU+3V`(=&4HC?05!_7SY$*WIX.X;>[\!GAT:W#3:6:6L=T]*U)O@I
M@WZW.>K0+2H8HIV&;3WC`.T568>47@O?I3^BUST"O^H?=.]6#4J-]![X#&U+
MZYL8HQZ!%=.S!UW-;-K]$5`/7$H^W:=)<U^.A*W]D@H\W!N/`J6GHFUP/()C
M&GO5-BNPL%^5\WS9:1Y;M^A,MQA_-YI[U"T[(&+/2F0%K<]'C>#A,!KMSA[U
MR#/QM=]SPY?&V,NIV&0LI.3\W>CL\=CL@(<]'YN-6NJ$3PSFBUN-3G./)V9[
M5"W0"&_H\'+.FPXHIXHM0-]*Z(\+IEW5534<!;OMF&55_6P@7RO0P=P>0;:O
M4>H&KV2B/A&FW=(P-<DP6HC1'@==^[51ESP9^MA'C`&&B3\Y&0+A%:6S&$1_
M#>2LR7H1UQPDBC[?T.';!QY;IME^5NY+I]5MV\UN"Q/$`7_=9E_KF<90T[M-
M$.)FU[*M5A';:[173<!;!8R<XK4KFMEA$$*;,,S[PO^3&LB_&%]6J^,8RR*V
M.VAVK(Z#'<Z=-HI8`W#2;&EF=]@<.NV^Z?3T_&[FJBWNL`X%YYY.M+AX[4Y9
M]I\;,,'?S=*[**8*BA<CU.XXNF,_/\`\TLV>":9"WQSJP(DZ6':HXAPXO+W6
MJ-DSND:.<,?:US%^&B-[XV*4V+G"W2\3"YPO"<:!8_2:0ZUK8]"^[0RU]J`W
MTIJC?J?9M'NM?J>W=R9>"^:>>)C^ZPLF%"<^CO2-,7F9?6T/S@?#)/[;LMHD
M3JV.:2R+AW:[W7<&30V<$A"9K<%0ZW3TIF;IO3X(T8%N]GNYR+PR_KD'3MT$
M]TFB%OZEZ\M,NQ5JQ>W=E?VZJ.7):R\[LK;51,8RVSA8%;%A$:,!\,V=$DR&
M>@NT]\C6,,5,LWL@/[M6OX692<V1U1R.!FV>1X`V:K-M=,J710*HUP,5:+];
M+LU6H)KBJMMT#'L#I"RO>7X31W3=FX]=X:S!4WF]Z;=PZL5\K'H^Z_@E:#$,
MH_T#;^<-]('-MF'AO_%T-%L[6<"FT3%;PZX#+G:GH]E#<Z2UK;ZA=9SFR'2L
MCF$/C%(&@)3"NRL"2G6.R[-K^!IBB1-%%QZ8,KJV@'4;:?P2?-B&T_F!21"&
M9>UTBCJMX:C7'=K:R.Y;FFWV>EIWX`RTEJ4[8"1TC6['RN%O6V9["UOKE8`&
MD=+<34IN!;30*X;1W.:*XW6`!FW9;.\F+[<"VA*I5,X.E"X5^7SQDS\+K_!%
M-H,#2@I`=VR]2:H#"&^2*ND8SZOL&-FMYJ`/YWS4-_&P@Y_;Z;>Z6JMMZAV[
M:6(Y=*XR](8AA2(WP?:J6&@[[5;G\%BP./?K#<>L'A;LI@-P'QX+#A=\P`O&
M+EB@2%VI2T#1WX4*0+ZZ/UZ"C::M&S\H];2Y3;QL62@8'6?4;1MM\`/;(\T>
M]<%![.L=K=MKFV9OV&I9O>[W#MCFW[%BP;3>_Z)9[69),FP#8QDK\-OBD7V`
MWW':6V1+O@!\YSM*0],&\-$F*".@!,XS[A%^]Q[H3_M``1Z#S9E\+X#>^(ZF
ML]%Y_TNGU7*VOT/(`7S.Y<K>%>?K8<@$K6%W[-8S;EFV,256+T#AY$.RT/Y/
MD8'R5#=:S)!^$D5E"+='RJNQT*$P9.K/P5"E>,AJ6KM9I]MB",NV.0]AQ>7_
M3]ZU]KAM9-F_LO!WVJQW5>`QP&?B73MM.,X`NU\,N5MM<U<M-20Y=L^OGWN+
MI!X4)94HL<3>#`),NJ.6=`YOW5?=AY,V&IX@>:()!8E+H]E%A2FZ^]_OU1"E
M3[-ULOS#J+A[.ZVZD-JK+-KS:A_+9G)\P=D7B+X)QJ2``G'<[L;IF:!FO\KV
MIN3S&S^12$.))5(ROMMEPG68Y#K-`J'C*.`FTH'6,82224*4$09"39LTH)^Y
M[07%I%Q`Q&:OR;[OO-D=O]4D'$WO?@>_>Z=YV#8W%0__*D8V;06.^'QT%G`3
MV@R3#IU2L+L9)6FR1%.(LV5DLH"'V@1&ZBS0)E51GH11:-*65JXS(6_P5F7G
MDLTA0]9)K_[\`NQ(SHGHD']KR4KD*4\)2%&B11QPDD$8QHW`9D&IF<QC8ZK\
M&\>!`V2C<?H8SM8<]L996N7LWH^7W_"4;;[@S/O/DB<NN*&;>4K&).E6V`#Z
MC*2Y5$'.#?`4"1IHE=,@I"9A2NF4D/4EM*[3E-W!>Y6GSCQUE">VRN=2H4\5
MJ!X7SO<B.32-HYC+,$C2')2U2F@0$8+=QYDVN1$)I1OZ:#O#[;R2WH.,&!K2
M#9U3IH#ZDQ%>I0'A`[GH)",X@*JXJR8HU1<"^6S^P4Z)6J;C"?QB?A$]8Q0+
M90=N6J:_P-_2/`.;I;D*.`MY8'"8@U&1"IDF,A:J-.T8I-A4T(H;5\!>Y48H
MG-6PYH8!6Z;CM8&+W-B4(7OQ1FP=I`&I%A`-RL(-U0(_;S6LGR`L49:Q7-,@
M!\<XX((E@4Y-"IK&R#A*52PH7:D6(P:J680AH&\W)$0J>(?^)$36%TM8]$"Z
M^C-[AG#54V06'^O1P.@M?H`P8EX5)8Y^?I@MBGK(7%?N="B%#1!XJ%R$9Y<K
ME60QST"_2&J'FK(T@$!"!"Q+P]A0%C%C2N&!8%_Q[=KE2Z!WXK.>SN.-3\E,
MMURV$Y_V<DO@=!&A70@]"?X9A"9V)/3RV5(*SJ3$[].9TKT$;,X`&B]ORHF,
MTZ]XUY",YO.G^]F\K!=]+$J5@05VEV.M>6NF4QDE,@EP7DW`LQ0TOM0DH`D+
M-=59E-1A2!GYU_7![E]]6XA6*P\P,IG>%I/"OA!^44V3JZ?.70"Q#KEPD9-=
M.RAD'O(<1P1FB@8\CZ)`QX8$6O"$94G&N5H75_*P&9TY@QSH`7,EKN,!JVL2
M1.AD`Y[)^:I(ZW*^Z@H%>%_=\7S9/\K'Z*Q/V@<W5J+G";?["2IQFPKWZ1"N
MF!6J_4NAE>K8WL)#S:G!3&N$XA&%0222)$B5UKG)"01GV=KA?BY9H%-YZ>AW
M*^1%8FL6EP/+^IPO&2F<'\'3-(@T+GJ@.:;DTSB@4414K#00D6_T3.A.L5C?
M^,^HX^1I:""4U4%&E`RX"4D0IZD(%$]SD^1"&;8.1<7I6:ZS"\M7'7G18O']
MH>P8:S2D_G.&NU!P//C'$V]O)-))C\XZ;IEDR8FA:4@#D48FX#'(CL'D8)B$
MJ1"YT%*$GUE9`B4IO4"!_<D\[-0.X0#-#^4@^[OXZ<\%MCZNC%^TFN>/7=C%
M]#O\[F8UQOP"G%YXV"/6F;YX$Q!JE-@I*SH#:8]26\\B2G$6W'AZ-S1AM;6;
MEVD)<X5_H5$+AS[NY(D*VS1WHY*]>/-!--MJ>D'6H[QBA68^'X_KH;M#D]>P
ME-=3)H6<"W^;[8;ZK?L@[4=L3(F!3RMNT</&0:.G.<)[*'2JP7,:M@QJE-IU
M@YIN^[S=L&WSTQR7>GDB.DW5<.2%H'G9&I-U!$]CCF?5`/1I5LT;CNJ5:?EL
MCO.JU_-F!VE=<0Z/Y%)NYPY.0+63D&I,:X?8<SDO4)&AN1XD!SB'7+1DG0XB
MV9.(&R^PC@F<DR$BY=Q>ZI/V]-KJJ[=!PZQ).2AYUYDJ5[%NO$]>[C+T2H&$
M$"=+X*CKG,:8(M%P\O,LB'D<A2&G6BA:>C]4AZ:%@2X(&Y5_>P])N=/E[13(
M_7.U@O&WV01UZZ^C8GIJI?_9;#&2\237)D@%RW`0,MA>P_)`2YE3*7@"WG89
MV!!X_7;YWEDH?9:7GLV24[4C!SOSV2:30)=R0ISJV]U+DX'A195JP6'_"]^J
MQ=&.8K>L8&;[8+5]^6:"\;$R-3?W[V;3KW9?\,:D_INME5^#4ZC4@#KA3#7R
MB,Z8^FV'\BW_$B^BS^U^VK6[]CW6<7VY`7>`PD#0E90AVS&O#GB.<5#OCQNH
M&TDP:R@;D[4/HG"UG+_.05(^5K8$C<CBG5U7C*^JETCUR,AN)E5K$Z=9&@4R
M#N%,1!"Z&LID(!E+P`=1&:&FC%H%;ZZA.`ME0U?4\M.M5=";6:`87G%"P^U3
MT?+U/=QL7\!MLK6$)"!2@MN4*0;'@45!EB;P*3P3(B>`6L/#-WN\[-,NL5M4
MYU4L@:._*/%I*T(:#O8!%/O=@<U%6-@0,42]QP0VN%`>[O<`FC`:^?K9=+9]
M%*J=5X,\S`K[FT/*MVNC]F(X.XY\7TQG<SO<L<S-1=.[[7<I9S^6M[-O-Y;7
M#Y$\79X-SL\./KO2LML85>Z=6^"5[KSX"D(ZP=^6^X[.R*;WF,$`$>14-"3P
M*)2&EMEJ%QJBL-AYM*HQD6GK6[=G(6_N;>M8UXV@9SM'KFH3FY5$PSLZ@*$E
M3'I>BE/BB"VC=T,C1]W99<*8+W!@`C4A#7>G?5#:3EIY[QZI(>H>*FU1>J-=
MV!U3NQ3?VGV7UQ)@1^AH^*EHW!WM17"A<2;>E&U86F8MMMOE#PPNJ2TO)LR'
M^+PX>_'&R,;SVOS2Q_(-NSNZAPC3@.J1ZDC281?*</OU?6?L,'R1I)&U]=N?
MW\'_3>%?%LOB=HCW2Z4NX<W^D3-0-J1U,IG=8BS9?GDP8!O2+FM.<-HWD*ZX
MJEY55;A[Q1YE@E+`&"1$Y5AQS(,HRW2@(Y9&28R[;J-2407@T#>"EH,P&C46
M]_?CV^7-??;SUEZR897*C=V5#1X&_A]Z&7^-)MZC7U>/'Z)?N6V.3H'DE!NT
M_LB&\AIB9M!:+.Z2&6RB.6:Q:W&Z1E3K>DN`;J1A>@?_82C'D%?+=NLU\>^*
MT1>LCAWJ50D.">0A.T;"?E3MKNB0PU]NNPIT,_&U]<6;`6];Q\J`,8)^(QR<
M4=$(@P_`.*-A^2+M:F=3X]:>AE6R75N3C[2E=7K//\;+Y:1<CX5+N^'U>`M;
M+K'PKC0<*=3=*3P&M]VW^F,)2@>D]AUX9Y-GY&BAA6DDV$^!Y'HKW?QS\%NJ
MVJ?6PJ>;^5`+O+!D2;G>4G="W;C/;'7ORO/=M(%#M-[,8`Z0T&TU?PJJ]O-6
MU1,^HY-FK[-DZTD[#,;)EV^^!08':0$1P[QL11NB;V^3I'0G'=4%GA-'>_B-
MEE77+RJ\[\O9_&GK8X;(7%DX%89.W'6#O8?1*YXS5^?9X$P$V<[,H9-5^4X5
M*\]"I]A>C$8UY1$8S7*9Q?+FWI::_@&&:(C/4^%:&=Y8']'XWDT;\0C^7M%W
M^?/N;6XF(L)SRK!/')Z:X#S07,6!4C$XK2G1J<C+E"=9=4RW?>G]<,!H1@^S
M^;+XE__B;D>+CY=^7(3-@H.]&!I@BSDFN>HK7GS.U3U^_[%LRZS#B.=9FO*`
MQ40%/-(L,"J)@UA0EF@2LYCJ\H'2YO;/HT".5[#6MT]/Z%P.M$,&;^H%53O)
M^Z-@G-JP\V(Z`D/V'-NP&>@M*G6CC/,\G(WB@*K.%8/6NOJCZD1<V+5:;^U:
MD>(O#.+:KPOPRGV8[,F6UI!+`6XU^UO1[K,P_K0YU=\)R4XX54R1(MPJ_.5[
M39'55IU&U)RM<ED4\I0)$8B848S#TT"+B`6XI(W37*8TI"7X'8WK@L4I4/A]
M!M*$(T8+T%5U[([7"T.,!?B+-Y+M5"Z<AJLS*^VG#"D?(E78M\KV1`;G8'4H
M#IE_'_Y%"]XZ<"..F/)=,$ZFO"RK?9:FG-KM("QL'++S@+;'GF6:XUF8'V9;
MHTUK[+D'1BOF(:06'"'#`=&-!;>'0>P&VPLL<"Q?,\C:/NS)HY0R0W?B[<VO
M[F0PVB\0?.-V,PW4%IRXF(9]J%S;L3;NEZ[1]N_(!_C?4A#7N:*[F+;9L&V\
MP-E'W&HXN48DK^&M\Y"8@`N2!!!:Z""*X+-`SC41DNL\5%4DW\S,M'YYMT;D
MBHQ22=P^?9I#]#&ZK9(@]J=)F1)9E:W4;5X?,$$"_V%9^K(8-'^:8>TP>K>S
MR<26OY<Q]1"OR7"S84-ZKLJ14^2,]W8#;IT#@ZN4X:%+3+R&LHW\5[!+\]$$
M4W!W#\6T6-BMHW\-N1<$T_E$-K:M'\'A6JU=I:.&^+C+1F!*CWOCFTCVRWFU
M%`N\T0_S5;>EO8.=3!8W]\]L"A/%2P&E]?X$46>\^RG$UST[ICB.9VWD9T\!
M=>D]Y&<#=]L[;L.3G>IIEP$RJTOY\@+M&84GV$S.&QK##4U#7SX\CHHY'IAR
M'LL[W+M3CMWX;3S!:H4_AVDJ<*H&:984.J%Q<M[KXIV:4WA!^3[8I5'Z*)/)
M[`>:X"&Z]+9TB;5V4Y\#];1I-$//@1EL/&U*D#LFIS++CV5F$6=I;A8>OAL]
M+E`5/SY.BEO4Q65A!OSJ7?%0+*^0'W,LML02KT810@_(-S=YU@8=_F9ZMVO-
M\N]@^\?E=6LQKN8FK>.*OMN\N[OXN!^.X/;Y]3#Q2V#M:>R^+[7.T=DC].15
MG>4P]I(]4/,>):![HS\.,JC'(!WY_IN;1F:V#VA[XD'5"/%IUBHH0WS0-J6L
MS,8.LP[`-FC9>WF13"!FQ-O1>;'*Z`Q2(Q#<K27XANB?AFE71AI=)`TN!RT>
M2`;1H5`[\N$(JE&M/ET6=SBB&!S"=;R3_;R=?+\#A]FVG3X\?B_-S\U]<\IQ
M.2FE*T\0WTLMM<(--F1[7V++%.N64C-P_94F!J0&##+/31Y$,M1!3$!8I$EC
M%7'<3U%6F^EF3O,BV"\T8[T<OK->W[VPFOP3>*`WY<3Q7^$M<`]361]^!N,J
M9(3A+C+\W4'&W_Z>[TIIPB/!9!PP2WEB5&!$#/&8D3$Q$*`9EI:4DZWN$U_$
M7.AQM+YW8^RY_8^X7GTU(/X23T7(?4MFG8>8YV$<$:Y9D%`.'FM.0:WR-`JH
MY$F>D8C"4RO3_.REN<3ZD6YL/9-M&@<>SO%M!;$,LU0H'L`[@(4+HS"(TX0'
M>4)RH\(H56:]87P`"S9Z.:'_!*.$10%50]YL.9IX.C+'-G^Y'12L,;/V]B)/
MYRRZ+JO>LI_C^6VQ&"^V/NPMEHY-%\7MLWE`&#$V"^%\<'/9<5N6,<XD,@8>
M,,&?&?P/?P8RNJW7SD(E(Y7S@("Z"7B<A4'$$H5>I<R9S/)45RX2!EU2-EAL
MG\C5)U(BPF[^LQ-26GDFC#='K;8CO6RJ'W%R(@S@E(8PUE_JOWZB2C;V-CA-
MC^\+-#QTV7%+O`MH6GOZX(P.!C333.H^+WDJB5:AIB>#3F:V6+S,'>%.(U!U
M^`OPUSH/\D3HPK`0H!.`SO%G>/#4'G8X=`?\IQ97EBN9)L:`PT0-7OI`N)&H
M*%``UG!)N=%9*>P<_2="-JNU]F/SRH+@H23]LU"KMO`E"X?'`I<"</?/@J@4
M7_B2LBXLE!=E]=W8IUD\3HO%XPQ.T<U]7`W'73ELF%DILP`W]^L;MG.Z]I$@
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MP8[D$)1T6`W><3E\[9A3HS:N,T^XM^Z?$DX%',N-;?$V9NF/$NNE8PN>KKJ&
M!DB)X(;J#2EA#-1)?Y2PRF67E.FA4F)H2#<.3AG-]$<)KX-Z4CF9PZ,$$^*2
M;AX<;DS'Y(X+)3:P`]=AM7)U@)08`H=G@Q():J]']2HK8R1.UB1'*M3J\HJ>
MQT<B4Z$4UCF2S'0+79S*\VBE8LKVU:,5>B?B/X/3#_!>\UX8U2$7/3+**M/N
M5O)X$OB!BJ@/0NV>8=.;B/:M!VN])[12/5I'94,=T'NZ&@K=L1SR_>@.6SW>
M%Y/Q8CF;CG^?+:/;;P6\_.Z_QZ/YS?04+A12P4*VJFO25"(51C`7=W(W'A$Z
MSE*2QT',B`PXRQ.(^B(61"Q/M21Y2O-U<1/;LHK.^$[FY-./V0F<H.(EO,D)
MY\!*M\RF$R>@XFEY(W(Z)X"O,4*_4?258KW8*=-@3+@A&&<6]O"49CF/PB`7
M@L/I2'1@J"0!XU&4:RHX0X[LD,WP)=<;4_/;41R&&H\6IVS+N`)0=12HQ7#)
MW=@.*(^H.$=LF&0@NM$^?'PU]ED;7KV!P\YH+DAC0.71]:ZGUQUX0X26&Y1P
M8_E>:TU!Q[2_-R@"'HX0\`>NR?T+C=WW!A`3T$(2W7A6SD/W.\\+]880*]:(
ME(W):(?&A5[(SG%_ZI]4=HZI:]@YKT#54:`]V;F#*"\AJO8*6JC&O"TO9LX#
M-C1S3/)&TJ$W,^<!D:VT5,JE=.XL,^<!"IHY+ILKYGV9.0\`P<PQS=BUS)P'
MA%C@:!KSWWNV<J2TX'AGY$7YRVM9.?]`KV'ECJ.\A*3*\LJ84>[5S/D"9\T<
ME:'HW<SY0H05XDQ+VJ.9\P7%FCFJ&F/]/)@Y7P#Q3I!2UNQ;\&#F?"&D>.M)
MO`9SI+3@WK0_K<P<E=<P<UZ!JJ-`>S)S!U%>0E*I#>9T(]SQ8N4\8.-V49,A
M_><L?2&RMXV"L+ZMG`<HHG1!&K?1OJR<!X`8S$D5-CT27U;.`T*T<B1TV'!D
MK_/^?+R?`P1;2%E=Y54W?*!K;L<XWLQNPZANA:.O\['M^CP!.,6;1+._R"=D
M92,+XT1V*/II&6=!<LE-8H)(V>8-9H(X"[/`9#R1F9*QQ@^J^S;H=B545T+\
M<XJ;$!L%`ZZU8[N<&4VR1$>X8RI.`IX"9SJ6.`4./%XJ9<*2>,59Q=AE*+N<
MLT5+/]+X\D%4Y6P1[MG9\@]4'05Z>6?K.,I+*$Q5=KI*Y=?;\@4.O2TI:/\I
M!5^`P-F2H0E-C\Z6+RC"+G&%GWP[6[X`X@4Q,Z1YF>_!V?*%$"^(J59>4^>T
M="2]:?]R`?I+P:YAY;SB5!:G\&[D#H*\A*#:VD90F]*_C?.`#3?IA*PQH*,W
M&^<!$-X.,U`K?5X/^\(BL("T>:?AR\9YP(<)!4YWQOWXLG$>$.)V1-I85^;#
MQ+%#0T`OJ_IU7>M+KA+)^02JC@+M*Y([8Z:K([80#4%CIXV?0*Y_;/9R6&C#
M/45R_2/"RV%"&M,_^HCD^H=B+X>5%.8ZD5S_`#&2TY1?H0;*%T**ZQBE?RO'
M_2E_7M=`'8AP>HSD?`)51X'V%<KU+:D<K5PY,\E[*-<_-FOE%-?:4RS7/R);
MZ2M$_Z%<_U"LE1-27R=?Z0&@K?3EYEKY2@\([7@0XW`Y7'UU^S$G?'7[Q_#G
MP%"Q?*I^@I]Q5O:RN"_&\_]8W'X;/XS_\>+;<OGXRZM7/W[\>+D8W[[\.OOK
M5?+VOUZ\0<5F0JE"\_K5^L_J-WZU]<ZO']?#ZNW/B^5H;J>CO\$O%<`W#2'2
M6?]V]<(Q/,WURVC`"+[UW<:+7K_:>//7KRI".K'#AL@.<V.']<Y.G<(8%#L\
M")63[(0FP#FA_<G.$-EA;NRPWMG95P+1-UM(R/BK+6)X_?/+?')7_#+^B0O'
MBN7[\<,7>/N[X@&G5\ZF_WAQ-RY^>3?^.IID]MM$/XO%BS>V<B)Z^#J>@O4L
M_^;UJ]:W>@,T5Y_5X5&%;L<\[/N8=ZX`>BZ/$K<&_\]X.KX=15^./,^C'U.;
MYGIC8CT0;SUU_]/3X[C\]/JU?S[F6(53C^!?O_127P8_\N9^XXTWT+^?_34"
M1OX/:X"J?\V+G^.[=(:31!Z^%%,[1^3#?/9U/GKH3]Q!W[B(.[ZL/W'?JO0;
ME-X&<\7=K)KL36]O5?L/BAWFQ@[KDYVMEK]!L8/4N,D.Z^UD;?7]#XH=YL8.
MZY&=PV."!F5&UZ'G%-,Z\$?P;XOB;ER.FXJ?UN:M-"]U7>D?M^/I")CZ]&/6
MH\\$,DP#>E51/SP'Z__7P[R9CGM\F,P^3';5DWEXP-N@GN9^#]<.@?L`'$['
M\QZ?%W73I+1'#^[([,)!/:_Z]*UVKT??E]]F\]6C6X42\%\7R^(VP243\Z>_
MZ0,LYZ,^RP>(:\QQ)/J[V>UH\I_?Y\7BKK#[F_]FC_+PD.!!/5K/V8+G$*`/
M6J3:1W$_%Y%RRR5>1)I^'W^?C.`!_CWE9,\4^V<B)Q]G\"5\",D'^/C%TV*]
MH^-O*BWM:R">B;3$HY_+\?RW\6BR_'8[FGL1G-_&#[/';\6D^+M*3/LNE6<B
M,=']_=/#Z*<G2W3S`&P_+?Z>@K)G#]$S$91X]/3O]JZUN6U;B?XB3_FFV.G<
M&3_JU!W']EAVOV88$I;02*0"DD[47W\7@![4PPD=F]*"W$X[M2B*$GD.@-W%
M[MGZS'(].0AAX%LO\TJ*M@_Y]TO^S.1_\.ITRK_$"0<+:AQ/VHQ'8>:3[OJ%
MBC]-,-UN!M8W]#8ZXZ%$3P4O5-[<UPI^E>R+EV?PLMB,<;S04*^O>*JVFR;C
M"<=A?59-*7N*H>XE:S*&]ZR,><;290)]7X%4+9%-!O(T2:II-8%STY=Z+/<.
MVWJ+<)38WHD<[KR<WTUBI;`D(58)Z/5MU>7)UW&6PCEG%8>+9Z.^H>E'KK6,
MQLG7<OV4RZ@3V4C-HO,\2^`3>J/\GA=?SN9G+$O&TUA\V=K]J17XW+!WR^G[
M&/^;B_.J*&'PB^*54<*.$LCU/2NPB4!O(]!C\OEN'(MI[YRQ!8E4S(Y(]#82
M-8XE=HY%GNU'P*(!L`@I:[3%N+(]95J"Y$]]#=E;.==/)*4S'R`-K?T0R<TJ
M034!]!3!(+)=UV`$/[",B7@"H_$TG?*,%VK&?V:+4M:^H6IYRO<+G4&DC#T7
M_I&O;=]".N/*M-I\PE.%[15`O1.IF>6BC#]/V`<FTWAF8Y[$DW4XX+V6ZQ7/
MZE^C?TJBLPM_?QP2D:P`ZUZ*`41:R794,@#2N[D)W`=)(3_`EE>T"B9^BT6Z
M&X'Z<SJ;Y'/&5,C_=M;']-0E=O*84=B!N5X*GI0L5>@]9KPL[H>//<,O&`2#
M4*;ZVX[C(\4/KI%*G28PWH8LJ00O.2O^_)Y,JI2EER*?RJFZ*M7T?ONTHWPT
MWW^![73S7HY@7%6%*!Z/7Q-XZ4VNT1O+!YM5RAX>-:HX,P4OJCCK!H!4<=8=
M*#TK1&H2_@S*RUPP/LKZ.12I8M#HBD',E`IEQ]R:40ROL7F-/S"O9F.8+$J6
MC,]S,<OU_N\AJ'69/_-VJP=1<X:J3-%4F2+FB1>%KE63PZ,JT_W+5.LE'Z@Y
M0I7(R"J1,;.%*I$Q5B(C9@P5F!I88(J93U1@:B9ZCKV(97I(<Z.N\VP$R\/T
M@GW>HXT\9!G/Q0WXNFTF+Z*$CFJ#NXDGU08;CR'5!G<%2*H-[AZV5$UJ3C4I
M8@*Y`W\0$H'>6@BXWOWL*8VH*-F0HF24)*)RTFXA2>6DQB-(Y:2=0M6V53*'
M%]G1@#9,=F6,>);PV80]B#@K8I5%NECW+UB1"#[3M2JZ\I!GHW,`;)2+^<8N
MKGC*8>T&XV+50F;1[:YW<P@5+YM7O&P4D:AXV83B99R44@6P7B37/DVI@:M6
M0LM")F+^0D&L6FT>ON4/X[PJXBQ]^,8F8->H`.J5<FW!S)&"?.^63L#+";M]
MNLI2_LS3:DDC]3N6%=7$HH&:F-S(L8E%KV#1JAR+"Y:4>=\*Z3:(U"OB=!1)
M-XQ\&ZGC_!,D;Z2+\\03)@C-E4Y&B%9[MXG&25]1(V4:<[$C91HC\0LBW]$S
MIH^M7FP%E,R=W<3N(\_XM.I;?>@**S_RD*YN^["*O_<1*U)\.J#B$SH&X%)\
MPO-X7-(.:H"7VPPO]Z!XD790-P`D[:#N0$G:04;B1]I!OU(OB48["#.E2`<&
MCPX,8IZ0Q@<ZC0_,;"&-#XP:'Y@9X_A!7<-.=RXSA3&-.X2]"U=NI_"TYVUF
MFR(F"HG!&"@&@YE/)`9C)'JD*-)-/$E1Q'@,25&D*T"2HDCWL"5%D5?;UD=3
M%,%,(,OS+(L(]#8"*7^PGP0B21IS)&DPTX@D:0R1I$%)(I*DZ1:2)$EC/((D
M2=,I5$DDQ#R1$*.(1"(A)HB$X*04U9$:CQW5D1J)']6[';+>#1T#<-6[H7D\
M5EBKV7!U/,OU[(#RG;8'YP5[8D*P=!$DJR7)[,ZXCS,8K%FYD&FLG=K>B+/"
M1I2"TUJDE"T9%6TSRO,C>T`M/9N22'WK-4^D[][V/&U%D@X_9TW4-FML!][<
M:KLE'2U<+&G6=@N\L&<F2@YNUK#ZG(M4UOVP5)[<XHH+,(8-EA1UVJ&1I`9J
MV)&SE#2`)5/BJ='[6U-E#]+H/6BDEP"GN5:+E'%7E.F'N?A&GZ@):&Z+H#F1
MGJ$=^(.:KN-KN@YS?`-S3)_F1,>AR'XWL<>4.81G2/S]9?YNM:B@*0]9EPJB
M=E-JVY9GHY7PTC?N'U/"J_YP]$HEU0@]RW)\I.ZG=#NOLJ(4U1:?M?HUC"J9
MOZ?=4!709ZGR1B\J]G<UF==$EH=RP):,M2MBM\#NV!`#VP94Q?5K?J-]X@P:
M^(WZM)81Q#6#X7DX$5C6&V$8<*GK6@4DP]1$AJG=<12=V$$#JNC3VJ**-'.]
M32$4L&*1R5@TTK&I1#*."ZF=)U-13T>"M;QAMC!8O&8&G=<*AM:6P4(AM%W,
M.)A',)PW#(OEL=:AZ*0ZF1D`D)HK8E1(HA4K/MKE#0([0+9/]U.75SJTEUP4
M9<VKO>1/TJ=]&(N\&HW_KC+V,.:B/(#C>US\*&1A&G+DJN%QU8[.@"`B!KR2
M`0<32CXR.2BA!DM"S5&)0-N/Q]O6.S+PI&M]?%WKXU*`Q*J1B%4?EP:P]'L#
MF@F:S03=`)[RX5'A$8:RHM]S[2@(MWUXG/B`2Y1627DKADP\\X1M&,EY*A5Y
M1#6JZX#D&1S4U?:RVW8*U\]8<3IB63(_G<T$^%\_T_XE5W^'.+X,@P=2#,S&
M293KO"C.X?9X)I'FK#B;W\1E)0"?]>'ZA/Z1B1$34D0F^5KQ@NLL0*5D>CZ)
M^;0C(UX!YWF!ZW0%N)L\6]=Z=Q4Q,)%=K*HKKT:L^W!);:T0:1K*:^!:;RJF
M;)K!5VO]K0]5#$M<R=Y9O^9(D%%G`X-`HD17G,!0#P+4Z%!C`7,`L]1P"D*D
MYMX*,+#:BN+V24UEVW$2(767[L2B,K!#LYTM-1%]SQF$2&>[.QGI$.7\;@*/
M0H8^8%@I?>*S^9;&REG%X9+92":#L;A@XWR27DUE1$3!VY$)4`'F^6'H(#7N
MF@-V'7^6F\ZYF*_.Z1!&LEDZUM3]1ABM.J=78$!(A^I4)O!]EW]U:2S!VN3:
M2(6)7H73QSBKGN($\(%)\#).^`1NI!-`+95ZO0%6:?8&4LM7-QU!P7%4PW<#
M=E<:ZQ;'V6-VH-RG3NV;U+78C:=$`TUT8L"/&-!%Q,U`06M9>Y$L-<2)PI:6
M]:+"8%4[H(L-=,CD2C4YXL],6CV=&"0+>&S;\9!&K?;!LPY@P=DZ@1L`*722
M`4O/YDJE6GK93'3#(=`XN=Y@,#!H&+V`TV,6KY'2.Y3SOSH'EA."/8HT=-6D
M]T*GH*`V&#@`"2+?T8!$*B.UO_9!X^^_EX;Z=CSE.Y]6G2A7"B++'2C?W;4\
MU2K-L97H8^@/D-6RK:*.,1?_Q).*G<U7?_X%UY2-"N?7LDWA5I1R>=)5-JO*
M0IUAOQ<[KK)G5I3R#O:$W?*,S3_&X@LK+ZLL[<3BNN0+_%]/()HO?C1PL&JX
MOP=?G#;YHJ:T9:&=+(N<,I%PF=LR>^\6SJA(XP1@32.-#:`GS3K+9L$;F<B_
MSC<TGC9'5XP[Y#V[E%;YSC1U#P@9I54:!!*E5>($AM(J4:-#:97F`$9IE8CA
MH;1*$P&CM$K\&%%:I2$X45HE=J`HK1(3"I1!=4P4:`L;%R"T8]F!'<LC\(5V
M+$W?L3P^:6C'TL`=RT/1!M..9>OW[-#VUYN)Z1P!)-K^P@D,;7^A1H>VOPP`
M#-,"W/H]V[0`OYF8]A%`H@48)S"T`*-&AQ9@<P"C_!.<\&"RCUJ_9^JMC5Z+
M8M$R^P`,T/+_ONNYH4V,^''^PTM=!\YCD7(@19'`*B:&\1,KY\.R2N<W>7G/
M8.V#>9*(V8R8X*CAFH[AGH,3UVKMGN%'1O*>:[V0`BORD.V_O3S8[I[X?^WM
M;`'?X-\6'[_M6*%-K6E>$;VQPA.[S8B5Q@/3%-#Z/?N6XR";]OP3RSEQ7C7N
MJHSK&RZDQDVQNILIBXM*L/_IPW_\MGRM+R$_M?5Y7N2>8X>?'H<7.Q=9O/<[
MO-?@2C-X=^<2\F"#SQ9?G\J=SU8PX\DW7G<7G^"A?=IZ*BE_!GS6SUY^[J::
M,I6%O#K<Y,XU+OL_KRY[P;)\*OO)[K_P/ES6U]S]\!^_U7[[WEL_KXH2O':Q
M\_BTN;1XM\$S'.II:O]U%F\VN,P]F^5"EE]^>H1#^Z^V><X+%]43*OSQ?U!+
M`P04````"`!%,%I&:(=H-:L9``#6E`$`%0`<`&YK='(M,C`Q-#$R,S%?8V%L
M+GAM;%54"0`#,?WN5#'][E1U>`L``00E#@``!#D!``#M76USX[B1_IZJ_`>=
M4W65JSK;8\]N[G9J)RG9'D]<9:\<V9/;NR\IFH1D9BC"`2G;VE]_#9`47T2`
M``D:@&:^['HHO/33`!J-[D;CY[^\KJ+),R))B../!R='[PXF*/9Q$,;+CP=?
M[@ZG=^=75P=_^?/O?_?SOQT>3N;SR06.8Q1%:#/YU4<1(EZ*)O?>*X[Q:C,Y
M]R)_'7DIM#:Y#N.O#UZ"_G-"_QM,X-.O9_/KR>G1R63RF*9/'XZ/7UY>C@@)
MBB:/?+PZGAP>%MW]/2/LP^1/1Z>G1S]4?IGC=1Q\F%0_G1.4=1P`21\FI^].
M?CQ\=WIX^N/]NW<?3G_X\/Z'_ZN6QD\;$BX?T\D?_?^`PN]^/(0:[R?SH_E1
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M2N@<:O[C+H791ON8+2[#&(8G]*);G(2TB_/(2Y)P$:)`D6[)1M\2P:U'D"K[
M%5I.'U$:^EZD'],5B+,5FD8I(C$,_#/J#V*W*>W4`C/2&*3>N?<4IL".WK0V
M&]).Z=TCC-LCC@+HY-._UK"XIG$P@W$D5%C"3RA.@$49S_KC4.O&+,J!:T2]
MK_%6S;F7/%Y&^"6YBH.0(#_M#VNWJ?&I'3@2[>WIX_9%F/@13M8$S<C2B\/?
MV(X$HWVW7JT\LH&Y$"YCD(Z^%Z=3WP=E)P6-[!9'H1^B9!H$3(9ZT8"M<0P2
M-#*&#@%0<Q4_HR2EHP)C<>.1KRCU'B)TA_PU`0)0(EL.5DVTIFHMK4!7U[,7
MT=)0%S2YE(1^B@+Z6V\^FJ/8`-OU3L%AO1J`?XM)NH"E@#-9(5-E=.;TH4DC
MZVAG<8K)9OM';\0M36DD]);@)T32S6U$)1N<#&!I/5$F<7_H#:1'5V\!5._B
M5>Q&(\`[%(>8L.F,@E]PJELLR;:O$=(U@A.U9ABB-K63?KE.X>^;,`Y7Z]6M
MMV'2YQ*3_!R2%1H(1:X/,]#@='CR%O"*4R@Z&1DH^U2A8O9$;7Z@EN@?RJZN
M=`(-O8<P@B/6'$7`Q.`>WX%V-5MD],SQQHOTJSF#.GU[\-N3P&[Y6Q"&<![P
MHD:5L5G3AR2=ZB%>K<),H8*-[ARS(Q&*]9_)E#O2N:NFV/]:-T/HW54EVQ\5
M4C:1\E,O*,S`;QRS8LP*0Z7/59*LJ;G]2PS5/KV&"1V#K#:UQZ`X896IVM-_
MWH]/F5:YX4/;B,W(*/(>,,F,!DN"F.$DR0O4?\UM6',$NOQ:U1*HN?.W9(;N
MO:-7=[H7T1EUY54G6?O73Z_TS_Z#W:>OT:&.(`8E^Q@=VEGD@7SQ01"A9/;$
MA`<)?9`J-SA`T13DS8I]3;XD=*\MW+SHT@O)W[UH#3OU)Z`#;U#60=;&0+'X
M9E2^S2+)>IOZ:?@,@CJ3W4QF7X$HCZD[2<-6,JQKK>8@ZJ6X]UY1<HV3Y`S!
M;$9G*$:+D%H_GD/JV*=[65EN@+U(O:]QH(X/T`@LO9*OL^%Q0&S_W/)N>W;(
M%.PU2)+\R#E$=@WH<AS@%4<.E0PXINK";'&!%H@0H,5[!=&)V$FC.%8-.<H-
M[WD<-GR)"?(Q$/0;ZSE?2%IP\IK6:NM<4C5OCIXPH>J^;DNG3.LCPLD5]+/-
M9X27Q'MZ#/TI09XV0+SVM4**$'7)_6WMD121:+.->;GP4J_]ZP!\/3K3XW=G
MAO![O&UZZS=/JIYDD&\)CL*@.(;=PM&51F)EI]J6RB4VZH06^9[OT6MZ%H%:
MH\@]BPC?MY$H/C@[(EL`8X_,]BQ2$CG"A!;W8A3C/75!ZYLH,GV-C7?KIBYI
MT#^DPDY,(M0\H!)=C8V6Z]$><WR5.K6)`YK'OT?78W/C&L?+>T16%^@AU3_P
M[:V/CHFY5,><T/P>C&'3/%6[^AD=)\=IRG.%CC#&O2FPEC>ZY\A`.L;FD\#3
M/*9P4.QV;"[LNF%IV3$9(-^C-=@UKPS5?L=?"5N_ZC.:$N+!A!Q;Z5/ITR+\
MFF>">L]C\Z)R.V)1]:;E0OP<)S!_:3@&\[<5(6OZY\=0.BSGD^9YI(>:\<_2
MN=]@7&N!H!.3"+5;"SJ[&GW_;+@:1M4:)/JR`*]N34&ZQ[&Q[SI6*OXQ_<,M
MV9T=J#4/NE*G.0?\,OW$->"M<0)JH#B@5_&SK[1[#5D$LHZ/&SV/28YD<@!&
M`A`!7*IU'-$$$)C4IT3>+\ORL/"2!Y;J89T<+CWOZ9A.E6,4I4GQA4V>PW<G
M><:'/^2?_Y'[5Q+86>FPG*\)8;>GLIY`Q4/1QX..PL<&Z9XC'X7/E)I?4"I'
M?6L5-0R[RY%^H3V0-2@M4))>.KXG,,QYJ&/2(*J[O"&N4H(J@1V=+.64-T3]
M>L6B![E7\&FL&8SZ;`'J!Q^34BM&D&YC/6Z],+B*\VM&E<!S'KCNBD;PL)`B
M'LW9C^;HZE@#M3)&J'SVPHC*LTM,J*6R<F]=3'EG/1-HJE?F9@]1N,P"[<10
M.BI9A.,7'/M]H%3JF4'#KJ<W\QJDYQXA&]#OF3^?BTBFKA%4I=P3`F@6,T%K
M$8&9A\6)UP.GL`5T=\Y_?GD3U!>7#W)[E+1FU%W/!)K/&`<O811QB-[^;(*V
MJQB.CBA)I4XBG,)FZ,Z#7T`CY%);*6*"QEJ,>"N)N['<QBBD`8`[?J9NLMNK
M&<8BGL6#I0+G'*KJP&ZG<E!31G#`7J$12J4U$[.('3YE#B`M!0W3V[G'MY<U
M1K7T@N65MH%R.::W5S!!_RW)%;U.];NMI!F*.6&._)U?6$6+C)RCQ3H.J!)T
M$T:@$>&X2,?"W_05*IK@<SU57M]3IVHK5B"MI'_K7,^2E<W@2KTP1L$GC\3`
MX*1B4X7C7>B'?$R=%4W@R;**%5&_S`'&`=!6T@C%LAJT2&>N.,.FI$ZZ1_RB
M0?ASQQ-6SSV>ESA.:)X4VMIAF*)547]!\&K'VEMTAGF&U@DF0#++?_]?[]X=
M3%X0S?'._@W_>B(P"H#EX\'IP62=`''X*;-[VXI.5A24L/]['V"+]]02[$_[
M`+8TOVR!G;S;!V`<W;]$>>(:RL8YH`I64BDIY^X^@5?6S4HVG.X1&R1<;B7P
M]_L$7!AW46+^88\PURV\)<8?]PACF[6I1/HG=Y"VG'JK.-M,/5N<IPY)Z@Z<
MK2>6$JA#LK@#J(2;O83MD"3FP%:Q^92X'9+&(MQ#_`$E,QP2VQUS7^!:+^'N
MC^P66;Q+O`Y9`V2=GIP-K(K:(6-`']1MI;;@W[LIWB2T[&8L1'F@=G,#%T"6
M"+0IT;NYCXL'G!=X7:+>FVDN$2Q?HG9SNQ8>)]L#G4K(;F[90I.9.*:WA.[F
M[BV`S@O;+"&[N77SEG7OV*.2(0[9^N7F`#?(I-3?''(#R&ELK>$=)5Z'QE@.
M[VXH>:F?[MW@RMP_*N$[9%63A*]ZT:SDA4-ZNQPO9$(]2OA]%'<+;^K6WY8U
M2N7N`]=&[M$D0`IU;R=W,&$XH2;-4F9N_"0L?17G6BZWF)';&BA&Q(N`C&FP
M@E-2DF;I=K8OM;22WE7+R!V)U9,7DFS"4I_$-=`39-ZFOZ(HN,3D"Q>/7%TS
M-S\*27\)@K/M=8#L68M*UOF;,&;"KC@#LCB?:BN9H+U!Z2.N1@#Q>/.&%)CC
M,-"=3]X\2[^0&[NE3=YF$J_59BE-MR9V']6J/^=5HT6NC@D>@OY43DT.!^ME
MM/"/>HV\Y+$Q-HWC;.7YQ%UN*K:@D^JLU4T^;.*7&06D*S5C9&Z`-E0\-9I-
M`/%*XY<W<G>C3HI@?K>5-';;1)7I'94,1=PC.`31R+4+F-P19L&F8ACB.F90
ML'7)FS3;GXW05A,=/`KKA8Q$R(,L2W("V)F$?XNGM:C1LSGO&%.W2#4.94[&
M<\D@[5C43MX4D,'=>4!T\K*`#'+)`Z63]P<,'"MKSHHVW<3)2'[#C!1H2TYZ
MMUN/8W7']AORVTEON20+6PP>'`_YH>5XNPX,;7$1+:OD=-\P]S(T<.*?]H$?
MLL=,)X.A!*?]NA9;'.J<O&(BB7)7N^/<A;1\6C>/X+5HU=:CI9,7`D4PFR=]
M)Z_ZM0'L;U!U\M(?EP7=GH1A%_Y,^<QO/9+"R3G)PU:,Y-WF7R!]I&^I7,4@
M,^@;U5Y$7ZC^*XX"$*V?O3`6&(L'-FI7[MJF*CR+"Q"M"&:D%V/Z]6(H5VDS
MR*@CD[6HQC[Z\S1Z.EI8!U,'I%M^H<S?W!,O3CR?">HX8/_*Q7;PSW5V2BV8
M?4N?P(`?TI2$#^N4SL-[3"\OP0D91%/$=*;L#"!RI!BCR:91D$C@KI:UW8R%
MLW,IUPQ)]77CI!ZI"%DQK-*I<Y+"S)9,.2&E,3BIG>MG5D^U@J/86WY([<L^
MPWL@YU0ARVQ3QPKV3ETM8!JXPF.EV:AA)5(MBG:F)_++"+_`,@Y"@OS4R-DM
M8HVCH'R8L/ITH3B81+*R/6\\W")8;]0K0^CMO0N4_9]WY%!IPLQK!#"[_=#+
M9=9T1>72;^R?'$BB&D9>)%@L8-[/%I]>?;9QS6$RS>)VQG,@*35A*.ZW-E6N
MXL:->'X$<$<]N]"46;24`56J:HD?;>U)Z34SQ1:L&8G&Q7N5D6A6M0-3X\JQ
M-*!F/3O0\!-#2`,3-&$'QD9*`-%+(A)5;<&49<U3&:AJG9&DFF*6=+4&[.`\
MT^.W[ECAVWJ2E6W$U4<0\%NP`V$]NZHTK$8U0[9]VO<MP<\A'/+.-E_@8',5
MYW=H82+Y:?B<6:M:XL+XSH`AC5K$ARQT33,?9!NUB`^E8-'(!]E&]]'G]?T.
M&Y=TZ^^P%<%N/N.S_'6JW?)&7L/)U)_D'D_]?ZU#@O@V=PX>E1:L0,A]K$`6
M(+\!+>L'FO<1"EC@]%62K&&7A*E>R<K"K/'%+RP2KVW]]&G&T'M,+72R24.3
MCSP('F7JJ&<1&FHE3K[$`2*PY&D&K6=$LV:V&H_IM.(N-EW-F^;-C9?F0N&6
MH*=\A3&[910ELX6Z%-+2MFFN9+O:(/"=36AZKRSG*W05![O]-U,X,_]AZ6?D
M"BTM[9JYRUM,M.PJ&\W7SLF7R!E$E19,([Q;/V`2P`$N%8IH816S@2P]G&2-
M8)Y!!R,G\T:.Q#3I4[63F?!'8IJT2<;)!'Y#F:;F774RKY\>4UW]YI+"%L9Y
MB,'R2"I]3.M_4G/R30?-C-.C/CKY6H3^=2MQ@';RA8EQ)=RN"LM):_S-B#3]
M)@PG<R?K\?WP&#K`[N%D:O41N*EBL>:D9G=S36N:@MU&)B>?TM//M&[//N<I
MOF]O>BGX6#CO^+G),T5/^+[=!]/'%1V7]?=@#0[DG'H2&I<R'.A?@[)W0)Q\
M$5D_NX37+IR\QJF?1X)P$$[FSF]&4JG=I.#D^_S.K7I,-B<YZ'<V<0*H.<E$
MO_-K]W(6)Z77=TZ)+K,XF6/UC:;7SATM)U_"U:RZJU[9<_+]W+?9%G>O7SF9
M:?(MF+5SN]#59,;C+D7A/3-7DQ>_L>;%X5D?GZTU"2M,)].X"!,_PLF:H!E9
M>G%^"*?^.#H%R&:VN`N7<;@`\N(T5^Q@*&YQ%/HP#N7+GU?Q`I-LTAB%D<?F
M5)*#P^+SR%?$DLQ4LB1)EH-)&:UI^I]&M`_4;1CQK4J7V'A^6#XS9%[/GH0C
M4Q`SA&Q@!/*'=%L1R=75$K+,+,NUH=^=&DT&\]_NT]*DH:>3*O1*)QOIK&9D
M4],YL/67[J6FM%,^F[%X)2',G$I:-Q:?NA?>,*>,Y1NWNRH'37JW`,4)9WJ@
M3!6[E`IE;4+?AKNK;G&VT=V"WS=]G3DJMOU?>B%AVU>Y$#CSHZ/27@EGJ6BH
M;W&7%ZUDIX((QIHY74O+H;<52K(+#^-F^X>)'6W;^25]%?$1!<4K++,%?2N2
M/`MR!G77-"6'&5VBW&"5(D9IG'LO-UZ*J/=!C>G\BD;Q_`\F7Z]B%@F;J`$2
MU#3\-.+N=&K*IJZA=&IW4P8N&G.G3J7*R$4RT\F#)C>DF!]K;.(4YOOKU3K*
M;A65T7+P=X1:PN94<]%H:][,VS<QJ%YK=H6/+<HE@57YF?!S:HEJ:#D?%DP$
M=8_+JS8"%2N_&:V[>H5254/Y3V2Q2%4Q=[I0'*#M\4IA$CJU9_5EBGY9ZN:[
M']HG4>,!2X="8E2GCG"K&1:I;IOZ8Y]A_0[%P,/\`OHO.+71^,\R6EA+5W;)
MZ094^-5Z55RNN\2DFH[#B).A1D`KE1<"7[],73,1#!*4B4,SE)JP%N-5?`]]
MHO]%'N&JY,KMV(SV!>O`6K1B)](B+C8+B:+!?L4OO6$+FK23![=`+?R?6>=G
M"U`:&K_WYD1GPX;S:"F(ZWH`C(I$=-*&."YOJK+%J4/;F[&GLM$XY4C4+W24
MN>?H(<X4QT0;(.<L:.4CE;U."=,(P-,L5R>FSPN5_('RNG1+)=,:1H4D>L^[
M#Y1*/=-HONM+;RJAVA8!)R_`MR[,.>N,DQ?`.8'-/E6D=GE?RIAUIT&"HGU'
MMK:11UKD:!/O2XJ-6(R3YH=\%IIY>C1D-UZ\)GKP;ANR&F^G':]/2W8C%MOR
MU-NQ&.W](QQHO`5H]L/05MHQJDPH;CRU?$N*DMU)6]7X_''>7O4F+'+=9O46
M3*KLM$Y:J=Z$1Z7VY63:O/%Y5-WAAIV/39WX\JP7&W'^4@LC$.0(WR::V"U_
MBX&*-/2B9JY6H[<]\6H5IMMTZRRWR1+%=F;#8(^'/.((YGU"`WW2C0LT9E,B
MC\:KO8.2/1YPB4GQG@![1^#3:\CR36>U=]\/,+L*?)IOBTV5")1KG"7`F2Y!
M`V"3*"]0_S4.6.J;(JF2U0`LG5$[27C;OQ9)5>VCUQ6^GD4>+$P?5C!*9D]9
M`&U(7PRYP0&*IK!05^QK0A-$W>/SG$BTO>4X6Q1Y$%D'61MF5ZU@!F7DY=FM
M-IG\87)G^YJ)>:&3Y0N^]UY10I/"GR&8/^@,Q6@1IBQA5P(]4RE:EC-S+[-(
M6T^?DVA+$Y917B'S`OX`6>]SS!5#6C1SIU"97A@VT%MC?0PH&G0$/ZCX3$\O
MG/$LC4:UE6PUWJ#T$0?\%`PF*#!\X>_-6=U([M=_K3MI:W./X5O1,LQP9W[3
MLV^KR\W&EP@8ZT5`1JYWYI3RPB`Z:AF)^<AIRN:**A)>+8-(MC-#!0BODD$<
M+,TH2(QK["O/L(ZZ)E`5B87SR:\V2I*5C>+*ED)/7.+*)G'U`V0CDMJBZ`=+
MJ@ESBK<LG$[*C02.28GO6E!8UR;LI)[9FP]=&X:3[MO^LX*KT#CIH944Q_57
MN>1V7"<]C0/X(;</.!E\.V26=.@OP\)KC9[95<2&!'Z'8A9ZS`,)!O1Y*]Z\
M$<$^_TN%N.V?6QO'UFO>^MR&^RJF"<KGR,>Q'T99OICS1R]>5IZ\@0+98W#4
MBY6MTRC"+]0MW06R?\,6\:.Y`\QA_EV$"\"016VH,:&S-8N0<R;KM#A:4(UA
MG:4]K:!1XT?//BSBTB^8"CR:.^<A*AXO96$-:HS@-V,YUO:W@,]QTBD#![5M
M$5?8,$V#?ZYE?'#=M2U"UGXF$&2`56O%(J3PX1SVI)`^JIL@4":;J??5Z]N%
M[@ZE:82*VW.=OG7))EQ1XS7O<$Y:T(:SBR\.G#2B#6>(DJ[LI(%M.(\$^M&^
M&P\T:5%.6B*'LXFS:3EI@1S.C>YCZ+Z;(A4T-XY1SO($ML-YL7L2*3GQDY/F
MR<J[K%0PXIC"FBUV-ERJE50>SM630+S11YYM(_R-O@.=3;7RG?&:+JU>WV0$
MP);`NK&[P^G/JZ4I>?M.)V5&ZR*WK^`!@)Z-C$,[C4QLO10F132_MA5S1O0>
M`:>P%717I`4_<WY7+2N0*)!O#<WEM5:8$.R9V`4F+QX)I*>2H`4[$`I,P)S"
M5M"]5:=J/.TPBJFV8@O2XEN^#=?NI<5!KG\ERA;N4;JRE&?%,TGT=0G?)VLO
MDE["<HU9@5O:]VFK<[-"5U5/[@11+6Q%#$^[XM$6LB&UV3AIR1W`BR[Q[J0A
M=P`_FD<>)XVTP^;#\$W023MN-].43W-.&FK[\D%H#7'22*MU&;7J14Z::/M.
MD&Z3S;#826O9T74F'&:3M05VNP%%B+_^H-J)RQJ&$OJ:QEWB=^EQ/9'523CF
MS4?D0,UV=]1E00O=_R<G?<;=O"OF2PSB'"]CNN/#AT(Q-/QVWI)N)7/T1!^V
MC)?V1;,W*<R379UM/B.\)-[38^A/"?(,TQ@A/T7!W]8>21&)Z&O8,&E#+[KP
M4J_]JP&"V=N(]WA+!@M'8G[.&5EZ<9Y)C;YEB:,P*`XP>5[]S#^Z:*E<\@%*
M5_R-H+;A-<M[=POMT<QW]T#[683]K]\T^.*#54S8IMDJ`5DZ7$)*[^F#M'9Q
MEB9@B6D,9$FOG8P5$6HA7[DOU-K.9Q7"+>3[-8Z7]XBL+M!#:B>#LU2_MD\#
M+I4VCCDG22\O]:ZE'.^+PL(1.>?G%[9]XN]F\J5E]X9J*R?+-B7O,YH20H/N
M7=@I%>BVD.LEE2PY]=;GDTL?ZOJI>(6*9/1VCL1`+!:.SM8P8_LB$!%J(5^;
M]AK;V2M!KX5<WK4I5>QU=C):CN0N7O]\3`EZ`"D#__A_4$L#!!0````(`$4P
M6D:$OQ0PW#0``.A>`P`5`!P`;FMT<BTR,#$T,3(S,5]D968N>&UL550)``,Q
M_>Y4,?WN5'5X"P`!!"4.```$.0$``.U]:W/CN)7H]ZW:_^#;6[6U6W7[Y9[)
MW4QE=DM^=9QR6U[9GDGR90HF(0EIBE!`TFW-K[\'("62(@&")"B`:G](QDWA
M<<X!<'#>^-/_O*R"DV?,(D+#G]]\?/?AS0D./>J3</'SF\?[MY/[\^OK-__S
MW__Z+W_Z/V_?GLQF)Q<T#'$0X,W)7ST<8(9B?/*`7FA(5YN3"SPG(8EAL),;
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MUX]__.,?WXM?BZT!#C_>-2^"]>/[],>T=41^BL2<-]03--5`YT3:@O_K[;;9
M6_[I[<?3MY\^OGN)_#?_S2?\$Z,!GN'YB8#XIWBSQC^_B<AJ'>`WV;<EP_.?
MWX1?8\;7Z8>/IVG_?[N@7K+"(1#&OPQC$F^NPSEE*P'UFQ,^[N/LN@1^B+_&
MB(FM%F?;]CUO]UXYU/N^@,Z@YV_W,>Q-/L=T?D5"6$R"@CL:B0-S'J`H(G."
M_99P:PYZ2`SN$,-MR=]BY'B)8^*AP#Q.U\#[5G@2Q)B%L/#/N#L2U:&,0PO$
MB$/@D>=H36(@1V=8]P<R#NG]$M9M20,?)KG\9P*':Q+Z4UA'QEDK_(3#"$B4
MTJP['NVFL8MESS/2?J[A3LTYBI97`?T678<^8=B+NZ-5'6IX:'NN1/UXYJA]
M02(OH%'"\)0M4$A^%S<2K/9]LEHAMH&]0!8A<$</A?'$\T`TBD%\NZ,!\0B.
M)KXO>"@*>ER-0X!@D#!\"0":Z_`91S%?%5B++XA]Q3%Z"O`]]A(&`.!(MQV<
MFB#A,C#OP$_7,PIX:^@+<E_,B!=CG__6F8[V(+9`=K-;L-^L%M"_HRR>PU&@
M*:_0Z3(X<;K`9)!T?+(PIFRS^Z,SQC5#&03TCM$U9O'F+N"<#30#.%IK3B3I
M#YT1Z3#5(1`U>WA;3F,0P7L<$LK$=L;^+8U-LR7=\0VB=(-!HS:,AFI,XZ!?
M)3'\_86$9)6L[M!&<)\KRC(])&W4$Q6].89%37PJS#U=<[L9W-;F,6R:RB2B
M!#V1`#2/&0Y`&O8?Z#T(':"^"WAF=(,"\[=_KTD/C_Q.0*ZVOP,>`6(R"O:Z
M#$V:+B"9E)KH:D52.0/X_SD5F@(.S:LJK2<R>=G$U/M:UL[-7C::XP^*4KJ1
M,F40Y$B@-PU%,V&<X-SG.HH2;K-^#*';Y0N)^!JDO;F9`H>1Z,RE@>[[?GC(
MC/(-#\;&8D<&`7JB+-6E%PP+>T*4-2C_FIEV9AA$W*2M@<SPY(<DANF[H]-T
MI@_1&?>'%3=9_=?+%_YG]\7N,M?@J`[`!C7G&!RULP`!?_&`$>%HNA;,@Q$/
MN,H7ZN-@`OQF);Y&CQ&_:\]1X"7\WKU"A/V"@@1NZDN`@VYP.D$Z1D^V>#`H
M#W-(TMDF7DR>@5&GO%OP[&M@Y2'WLABX2OI-;=1*PHWW#^@%1S<TBLXP[&9\
MAD,\)]PH\$RX=YS?97F['F:4]G,-@^KP"%I!RRSG:QQX&"1V?^YHM],=4@$[
M`4Z2J9Q]>%>/*8=!O.#?X)R!AEQ<F,XO\!PS!K"@%V"=6&@:6[6JCRK7?^9A
MR/`8,NQ1`.AW,7-VD(S@*1O:J`EPP<6\&5Y3QL5]TP9`G=$'1"<3T,\VGS%=
M,+1>$F_",#*&D&Q\HR@%F'NJ_C=!+,8LV.Q"02Y0C.J_]L"OPV1FW-'"/OQ`
M=T/OW,E1T<$*_"VB`?&W:M@=J*X\0"G5:FLZY[AQWZS*)?N`7^*S`,2:EM1S
M"/!C6XGMA]&NR`Z!H5=FIXOD0`ZPH=6S6,7Q@7MFS6T4G;F&QG?GO<UA,+^D
MRDEL8FAX036F&AI;J:-WR/5M-:E+%#"\_AVF'IH:-S1</&"VNL!/L?F%KQ]]
M<)R$2W7(#2V?P1INAK=JTSR#XREQFLI<H0.L<6<(G*6-Z3W2$XZAZ:3P-`_)
M'%I..S05JFY8WG9(`NC/Z`SNAD]&VWF'/PD[O^HSGC"&8$,.+?2UF=,A_`WO
MA/8S#TV+0M+`O.A-RYCX.8U@__)P#.%OVX:LF=\??>%PG$Z&]Y$9:(;7I3._
MP;#6`L4D-C$T;BUHG&KP^W//U3"HU*`QEP/XFI84M&<<&O>J8Z7@'S._W)K3
MN8&UX45O-6E&`<0\72)(4OZWQ01XKO^/@C8H"-Z<9`,7T=KU(F'\WB>K]UF;
M][S#@/#`5#P]EH9O?3Q'21"W@Z[:_3"PTA4B86=0T]Y#0BIF>+O"JR?,6H)9
MZCH@C$L8@GG)$WZ[HTP[2.L&R.#U=\5/;@"R$LQPU'#H\](.Z5<^E(&J%.F\
M[\L3#PB,9JD)-\$JIV5;A+%:&<(B,/NE'RR"TJYZ@X`)H((;K`1*P&O64%;+
M'\2IGJ/H21SM)'J[0&C]GE_C[W$01]LOXF)_^^%C5J3FW[+/OTT\.(LB&E8*
MUI>,^:63@T:.@Y_?M.__W@9VNWBE.T3\ZS#;$6J,E'WL8/&/)$MC?J`2\,1&
M>]J/\IUAV'/`-/`]9L_$PW>8$>K/TJ`TWD"XR*6$&'A:&[0LY,TH=T&UG0UH
M\^0=$2-YD4E+M1#7MQTEU+^=6H'[%L<IQ^+1XA)XRVUL0"ECLQP@@&XZ?T`O
M$N"UNMK`:89C6';L7R(6@B(?*8^FI+$-N-/4NVD2\S)VO%2)!.1J.RO0;N62
MO4,735Z(;+^K^UC%`B0V?`U_-H*>-[0*K[!)-,&:-K(#Y[[?30IKI:$U>'G*
M*_8O$L:#-X64D1ZU6_Q-_"3?&UJ=G<,K=U,4Y:TN2$I&<@AC(21V7,B]OJYA
M96(950/M\,WUVPDK8XZ8MYTOLP.U-6EEO>>,KIJDT.W,5"5@GU`&+(57[/UX
M^N'#FY,U8,E@L)_?G+XY22*`CZY3%60,^#6HGCFNGXX`5WTC0H[W#^/'6R:V
MYDC^:`G)JC.@#E$M@;"(L(0R.WP_?+".;VFQAD`7E%/["`OODQ+'BG1<1&Q?
M)MWB\^%#AE'J8_B)NU.Q__.;F`DK4?:1AC%^B2\#,<+/;Z+4#>OH8=8E2%7X
MS1?YH[.LJ@5VS0)6CK"[]Z\FPE6]/$?.W0NWUVI6%)\<8W>OVO[[5R9*Y]C;
MNH,/LM[-Z/]AY.@/[_W(:?7_1DXK/=MPCN]_C1S?/8M]CM@?[2!6&XJA1*]D
M%*P5T>J%U;82Z`C<W\X$,U0+]KL$C%TR#5(VWX9/'<#R29#P6)6\'OCE"R\Y
MC_TK.*Q\AR;;:@);#1^N$+&G)RN.F,QQ;F1L*Y$&_2`_V]0/H/`O#3FC.Q2\
M12NL=(,W=CLB7%I[]ZN!R?S+;YPSEA^"J#X4,7E&).!7[!5E/,&R\"+`'O1&
MAC2"%T_X+E;RWEZ9VX3P4C&N*@YMNMO851R^ZQ!H+&)`K\,8@QH3S^#"$[>>
M#T>;%Q]$"YFOM,4`]O'[@F)^`#87`)D6/J4.-N#G^R3>UAV`R13,N[:I"S`K
M^9.DL9&SNUT]?M!X5.R.-?!B103$8.Q/0&>G+.8MZHYORQ&&A;K^U90'>H:+
MT.SQR%98=9O!QA[[@E[X8P3*T*1R&RM0ID\FJ*$LM3&R@VX3/A9H*TD4@RK'
MHDST!Q&.LB_H'Y1E'Z(9]C"L8S44IOLX1C'899,]@NX$&_$2]EP"O/@SI?XW
M$@2\L.IJC0A+?1YR%-H-9`2'3BI9Q<!21*;GB/:PJ@NVZCN:$6QRZ60ZK^[E
MW;Z?AK70M^A]2&@?8)`^\*;]#PKQ-]H'7NAM'EJA]\\P"GB]V,<U#1^#F*RX
M7(OC./6V-L*L,X:->TE:ONLR2N'S'R,\3X(;4!IEXF:[,:S$,?,2%0J!.?_=
M&G3JT.I""^<A-&5'X,^>(^;Q!P,O\#,.:+JG^/,1/N%%F,Y!!B7U<JUV7SM1
M]45+!J^GM&?,B,\18QNXYU1I0&U'L1)K*1ZJVUHX1/*X+)BRIJ4]B,7\ROU>
M;6<MEC5]+4(-;:6=W0"W`]BS2Z[J1H.I]<`QO4@YQ^CF1,B=AM-:UV!>B>XH
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M>K@RBGYRP<NG<H]6PE4J.Z3BRG``(X5+2A>AL3@4:^)ABACM!?OF/-T]15<7
MHW*0=>X)U5/!K"1"9L;`1G.7;KOKD#,AX#95)T_9`FDQ^5,7%W?R/??<8SF(
MGQF-HJVX]!GV;\23R7'$6X'&YV'L2Y,7^PUJ+`M.9R4JPN-^WEN[00X*NS28
MN]T`]K/!7K/=S&6[*;(GB^.G]TDV35H!I&XGZ70;`+Y?,5DL814GSYC!$I8G
ME.0`M!S!QJ[8O;X^`:;''\1]QL''!RK^>_K`4!C-N?5>E43?:@A7<#S-`/S8
M'4?I$$9VWPV.8V[[GZ=&)GGEZJ;6+F1YOF:F.@VWI2K^WUO4>Z\8\D/$&W:6
M4$OQ;RWDQ&.-*NQ/2"WAR/E@0=-T:!;"G`\1[$424SJR\P&$1JC4(PK,40>G
M$;)T"Z5TU+$Y`$5DT9...BB-4*"=&NA\M-]@-)&KC<Y'^/6_BU4JJ?70/3W7
M9"<[Y@@<TYINQ/$G@AT@WVTL+D=#&6_.5:5M[[NZHRR>TX#0M`BK3A>W/%NM
MO59&O3I[ODJY]V:OX6MM2!5>E*TI`Q&2/Y\$-Q-_%1K!%55K_]'I8><-U@PD
MSF/RW=?P'JNJCP/V?UC]0E;A%XPXJ_&GX8S#RJOV0X-;&K+M/\]01*1.V6'F
M&"N55`\GFAO?*G7.-KL__TPPX_'!&Z$2*'P<FIVMXG4=KI.MXJ<\WZH>KF!P
MVAJ#4Q<PR$Z!N(6J&T7IV&DWQG>!I26O5D&2V$&6B[02Q!HZV<6CP8-;T]`^
MO.<@@"Q`I4FCD)7L0*/CD>%CZ61\H2'>I,K851+Z:C%2TOC0K_0-(CLJK(Q]
MQ*XC]*8>;!E4NKG++H"#$:CI6G/9)S`XD536%)<=`X<CC*&B2*XZ%P93HNN/
MH$.>!S=(HZN>6\^@TW34M#,WU%)"3\VROG_T/#H'HL=87#^==.E:JM0935P.
M@QF4`A^K%'#[67BYCBZ_-^HU2?N[7HL/F$)X+`==WPA0Q+_!;>-RV&@WQ+4\
M;BZ'AO9;;YEAI6V8IQ4G/T<YC"G;[/ZPF"TK+1PD_<%*(('G):LDX,&:%W@-
M(C(1&P3^#G!6=&&RXI5]THTCAUT2=F!J>"..]+.$!'ZJ#X@*L?R1XNO5FM'G
M]-*7.]0U>]IQK(MP4X_3[YI3<,%PE`9O2]WJ\AZ&TAW3I7X*Y*>@#L"6G0\&
MZRVN?8-'MZL5%UG"0E%8"H"Y(B_\+[617-'!3!(B>N(W*O#D'6WDQTW>V,XC
M@&$R1QX/Y0X75\CCAH9-PY.`\AY./<1TMFGPR.GT=`JCBNU0%Z$;JR$S+7B/
M5A>G<&C,)=7I:279TEMB/PGP="Z'4!&GI-W=JB+<@CEH%<9T*LI;ZHW59R"E
M\&?M#7'$'M1VI&LK$=HWF)FF@'E=:PQNY(%VB;@/Q^`A[K9'E-K<&/R_W=#6
M76YW:]RU$'YV^UW7'C$&*VL7_!4ZX1@LK"U1UE(G74ZG[XFWRB1AW4^H'7O0
M5B70XG)%2;NMR.R6<=N9VH]%"4NBGI6:&#%RY3;^A'E+X.C3IX`L4FD.;?BV
M2-]PJ5J\-'M:B1X6=?OY*S0\V(:_WP/[8,VUF.G\#!A7O*3I0VL/2Q3R@*LT
MCWTZSPO^W\B-T:9&MU(O"X'$'OK;:UQI$JQOZY29YM48Z+HQ<+2&M$$QLI2#
M4.74,A2J#5^-F4/%,1VU-=.V0=>)6*=7DZXK5AMCDN&H#1Q*$I75D%%;-=0&
MO)K+<-2V#+F56E?)LV[3&,Z4(U%\K+MN7JTXK:PX:3$G$=6+?5'3R1GSS3D-
MGX'(A%=:2IZ`FB1,_69/]6%#^OT,E>2IG2:MBR5_#Z%=W\$AG6&XAFM?1M#H
M9?_A"86EHJ;A``\Y7+X`_P\7V*\M^*_1P3X-7Q\G,?<XR1#PWZ*5VCXB;3YB
MV"T9=`0X492@T,/G-*I4A).W,\);_I($FRO"HOCA&WU8TB1"W$\VCS$.'Y:,
M)HOE7Y(0/RP)R!Z%)O>8YSI`(WDXK:&1K9C800S?5HG=^DJ;K+KJ/JY@H;*U
MR=N[\"S(ZQ,L+4YU]ESC#(.6P-*2!6<HX*RC[J0J6AN!9H9]O%JGT67$PY.H
M^(@P?`H]LD9!*IU<A^=<N9V?"Y$%_DO#&!2(.K!-#&L-/VZ8FLY3&Y8IY$IC
MNO@@CN0D-':S]^0-/Z3<L")T$)F/HJ:EY4=ZE)`Z`6'79X3ZG-.';SAXQME!
MJIHA+A+,999V4D[O,>TZKN2ZK?Q]B:*$;=TOH^><ZH>F$PXH#;MJDR*T,R:;
M$OKS(NSN&INUB=*?.^3DL!0@+W52:BDT)5N[7'<X8H=D:S+5"@EC\"NVQE3O
MB2%W'8S:".M87,?@8^RYPKK/:KG+^+L1H&R)L^Y;-+ZS=3PS8TCT,H>UC)>Y
MF^35>F<WZ^5C2/)JM^0J$]@84KO:86O$Q-;V3:7C)$O9,I?3Y(B$N9*E*,?0
MDO2F'3^C4$J:Q)FQ%9MMA:KR33\G2L4.]M:=`VMJ]*4[C0BD_+PZK'R8>=I/
M3^BV$L4F4J<=BEQ#:Q*C0$"5148KB[')FENI)5<`)LIDM/LEQG$*V-GF"_H'
M9><!BB)Y7:*6@UC'\RKAJ<B9D`I'/>!?9UPT"7063=W?T,.&A>FX>8NS(EXY
M1!9AJ&K?G=X1]MXMZ#.<<9*2&O[8IS!\^NTRC+D25^=QK_SL%#26XH[$.HGG
M'OB>N7Q9PUTMC0RI;6NF0I_8+A5IM527;Z_)\*MW@Q>`IEBCFK"3NA9&:#$%
MX1".3+C8GN<Z:E0;&9D[5XS.,4B;X8*_9,"5(H_)(&GJ8@:N.?E=]>AHZ7<C
M,^91^ADKJPF94C0T`T.VMIR-BFK0<)OYEZ$OX[W*]L-!!#N`T-I0;E7SX>"Y
M!ZDM;D6CO,?AA679/;&S7I3WOG5+1,6[J&+@.R0DQ^D(O8A:Y&CDLRY[#[4P
M5,N-+OL*F]#K(,B[["GL@FY9MW39#=AI,36T3Y==@EKGLT;*=-GAIW?)-$@#
M+GOUNB.X$PCM^[/4T88*G8IC6!6$[!MUE;;KEO@X$3_8Z'IH5GZVN%50MXY<
MT_'2T:=*SH9ZXXC+#M(66I&:JVR5NK8A`1;-\"49[`YM1!W3*[BUBW>[Q5=Y
M:J`4GPJ@[FYE^\!FKUIN9EA4C7Z@J4<\!7]&-RC@CW$YX_J8,,;C&`0ATS<W
M4?[E`?Z*D"ALK$XY:#N*#9.M%4Q;FZ=E[@2R^IT@F/`+`0V8(;E)3]+2TC-'
M_$P"87B);.*+,TK#QIJ%S?T<PJ8Q4[&YWU%A8VK'7T8Q67$..@G#A+/)/*)V
M&J9\=+-CMG4'H=T`9MPQ>LR_HJB4_#5MQS@DY%)K?JO^AI)T`UA-&N)[#P,/
M)G0:8CE75+0>!IJ';[0%-'EK,VZ?5#+Z@GS^H/INMEL:3[PEP<_8_QM&#$A0
MZQ/2[GQ`6(%`W6'EG<W`RJB'L1]=@<Z0[N\["B)C3%"PM]&E3^6U'<(,W%G5
M,Y`*1$F_!<.X6+F_!DQU#S.)WRD/WHV=7RW9LE[@R&-D'9-*F=;V_4U"/..I
M:PE.Q3\/1<OR=[ZT^U*8`OXNHYE)Z,VE59&PL<>Z9?NR#I6N0]F0?+BH,IT7
MY'B%)%K?UEYD8$<=)O>?-3"",20R]*6!3)6R[B'63#K7UJKV(F.;Q'W[9DBM
MB.=AT'?"R*RQ^;75MD(FCUQ.MN_Y.`C&!5G<N@U:$@;247',GV5JI;\=;?A(
M7S*V%O#=CS?I2Y+.4J+[L2J]=XN^FNU^),MAB"'T>/<#7_H2HYUJZWY0C"%Z
M=%*<W0^OZ4N=EJ9NZ^$X>L$074S*19E=HJ=;E](/@[V&FN-2BJI*854:7$J/
M+;?5[*WO!3V5=2@"=%%:70Z*N$]6*\0VTWFUO53,M(<4#_DA\7:M=N?5<RFZ
MXX(P[,6[Z!@NP&?WB3IEK;F?#<OM-2S9*B1SX@F"?DX0'(D8U[O]-#O9*70<
M1:7]<K:YY65TLFHBZ>>ZW+D.`SB!7T7T:<+GQD"ZHD'XE76_ZQO;AWLS\3P&
MXN0D/H=;9`,??T%!HH>&K*\#6*4;O:$VN+S'Z#$P%5_S!;,%9G!S3;Q_)B02
M]U5VW9X'B*SJP^!:=34")PA!HI`HX=>])H"-?<PD'._>$(L>X9)AZ:5).6&F
M<[AO,-N[>WC]I&O@$3ZN?WBFWX`V=O;6GYC+0C/,-RE_8"R-U$VK0Z6_QW@_
MV[7[.&;28-MN+,U=947-:B]5E`L$*7C42/2LP2C@A'=07IZX4=R2HWG4/J%N
M!-+0F5SV^G1#N@,C=]F_8^)H2.5GEWTY[1`W(<98=^;H5P54JG5*'JFX2*S?
M"ZUW0ZT"4GHCNL'.XK*_JB7*.F*@RPZH+N@V:U36/4R&,=;6=4>1M7D?4^_K
MD@8`:L3+4,<;9^S-DV^(^0W97>4VAHKM14O^G@CCY2<R#_L590_T?$GP_/(%
M=GM,GG%VG=4I=BU'L)*QQ8MH3.=B]=4I6M6&(X/74E&_(B!-)NOZMG8R^58K
MX.@<D"QC^WZ)&.?L$6;/V(=MG#K-MJ\SR#!J/8YE;!L>%=]O9QG:E)B3)%["
ME?*[U!*FZF$#@PL\QXR_`$!77/E%Z0V_<TK_2N(EB(ODF?B@*EVNU@'=8"9J
MXI.GI"9SQ]RXEJ@!9]TOPG$7(!$8.<,>782*E=7K:P6K3.-3'JB]1F9R?--U
M5>1M[K6P09TM",T\IZZE%8B%4,A/%@UYK*'J\JUO:\;#A%ZXX:BTX3';$BF-
M=;M'`6(;Z?OUW<>Q0?<,4.4>*;>QXK/)RJ9DPHO.Z^G*+H8+Z$[G6UND>'0D
MF[)N7S3VL4)=EEUL`H0[Q*8L?0!,&`\!9'&KR^BLU]E0+G-Q+C'P!8[(0KR8
M4$MN90?[M-84L!HZN8('/V.M<,@ZN`+_-(FC&($$%RY:(%'L90>3//]GR^6X
MS7<GDTMQ:>IG`YL9EZ85EIC\=VO0*>_*8@LS^?N[E]S$HCR&)%9L5*TN5BA7
M`]/L_E%-2V4?&UCDQ1(%1&<;85)1A=JI>EC!`#,>[%MF9`U/L\M[&(IH*=LP
MTW*$5W0G+M>6;]#H-3!T6P-K2_#R;F;@XY?0&2_4+#%+G&WR)ADPPIPM_@^@
M81Z)<`I>)NCSI+=ZI(::R\I)Z(6,>&4R(C&&X_$,\GN*U$?9&1ID+@?VSR_`
MHN%*.<3VD4\UJMV3&B_R=PJC:;S$[&&)PJGPTT6?N>,ZN@YKG]HX^/2CHNUM
MPF^EZ3SW+6HJ6$/..$H*9E@\(Q)P407N+;$OAB*?;#HG:1<IV93P$H<^-Y/?
MHI4Z9'Z0J0:\%?A,D?CIAJP(=S9?@I2SF8:XSD+48R`KZ\ZM5B+QO>`F56BB
M\O96H=\SCD<Z&-3VL8-%9JK%_D7"=K=]RAYN\3?QDQP=K<Y6ZK>1F*N`N7=0
M5;^MMJT34',/IXA!XH+"DJP?:/'1`UU\&D;Y;C`UE17U\(T^+&D2(9%]G87[
M;.4\[FT`99,S7+G'LN4(IJ%^^(:#9]P5XJ;>1J`54<;?&.A@+!+QY!&/V>5)
MU#S&C4>9UT&IT<MJ\DEMZ%OIK>9!9*$QA!_+(\'*;UDKK&D[-$\M1:1*LV^4
M06,E_%3VSB/.OM$F4),[;PQ9-QV1E?N)QY!ETXBTCL-Y#%DUO;;RUJ-K/6%F
M:$1+'K4QY(KHLW!-E6H,&2,MEKC1)SZ&?!%]?)7Q46.HD*W'CW7$\%$4"-9=
MV`Z!\M;+!1OE7D.Z`NQ73W>!4FIW9DZC$<MRP[M%<C*-6!+L8_G/"7`$$N+A
MG+LYV48L:NK%J>6HCEC`'#9D(B?1B&72@:.2<AJ-6)BM$>]4XLF(!5G-3(G<
M5CIBH;5'!E&._Q&(H@;R+W-Z'('8J9F!F>,\>AE2)V8V1W?$$J-V`'..[=@%
MO;:%*W+,W97[E-FGD@N[ZN:S)9!H^7HKB35%M$IY+6-PS]8DXA3QV<MJW6'T
MR=+MJEWO2R/!I&S<5T9]65_)P?&NQNI9?V%B*)P+!SC#\=/1X;@7D)+A^</1
MX2F)!\SP_=%ESCMD>'3^@%N+X+#\_G5733XTT;3B`/-;T5U]8VC":::GYJ1R
M5U<Y%*EJ:\OD!+*EWN@5'&\,\B\)^S4Q@-9%*CUIOR>>3A0/;XFI*O&AM'_K
M=3V7T%6^3*9*)5#*&$TQ[2Y10/4RV4`$<&//-_/YCKD*^<N->P7,<M9]E#CO
MC+![!>-RM/4LS(Z4S4W?FR._"\Q+(6VI`^F*LFTHD`B6NH3#P=V-.=<KN?2_
MHX*[$@I,UFM&G[&?"4<9L175_3H,,R3\CR'*ITY+9&_^W!&)YK',/(^TC:;9
M5?0N1M24MZ]DV];@9&!4RR5E.@OPF@5H>H[O9#*V#.2*_\)4ROI-Q\+)ILMO
M9`%%H+)UJ!!U@%F=W"U'E;IOD&9/^XCL1Z,(MBD6.MT!@E_NPG1X*(<P3V=?
M.+O(=LJOF"R6_)EP[C#<-4B[**OEV`+I-2%S)'9V,[=EL_?!P=?3S-V*DF3/
MOK0]XM10L[0_F`PPAD34`4AK0M480SKK0!S!JFPPANS:@SCV.EDNQI"R:Y-Z
M&G:3MGG`5DR$-W!8PHC3X9P&P-@H2XFX8#@E8=:@_&OHB\R4&7[&(5S%)C39
MR7R^6:&7Z]"3VYTJ;8SHT)/5`H?J><LM;.A9Q5T]$1YZE']Y@+\BY`FNJ"S&
MVW84,_0%V0+]'8?80Y,G!9%KFAF9_PS!.6%_QBB(EQYP`SD(DI:&H-@4A[X)
M%/M-VM84)%<T83SYCKQ<D6?,_P?_FJS(5^01V.A+%"BIU*)_][,28>_=@CX#
M4R3I,8$_]D\'?/I-45FK\K,1^OT9K^AZ20*"Y#2JM!F>#C=X@8(4VQK/2%T+
M(]30N$#J3:EM>Q\&VCI;>)N>)J$L352Z<.7PR?N8>>"(/B/80%^!#-L_K\@+
M]B^H>$C[B82IB,3H@J'Z9X&ZCV/&>X23`(%B*X=MKX616:<K&L8;A4NMW,#,
MG'SU[Q"+0US_SIFLE:'GC18HVG`IXPMA'FAH<A!D3<T\@$&]I>(R*_YLI70D
M3#"=%^0R56G/VK;V]*^.,FF>Z]B)F8RA'$U?RD@/SQBJT_1%OBI?C:$F35^L
M]^^E,527Z8MS.TUD#+5D^E)D3TYPN2Z,3/?:X5*K][OL2&C$J"1+N&S7;\1$
M9A-QV6C>O.'V#'DNV[`U5DAF+W*YOF3S&E7,O"Y7CFQ$IT['LE\:4ADLHK`5
M<;2J*+L7R-#1\+1;-5TKT!'&(1@BG<(T9;V46V,T4`=+X/9D5`Z.]<,Q%+8-
M!@KK>?*:V3XJ\THI>*NMX-YVX=WT[N;U3:_#.64K\?/8_;F!:"TJ)D4$5BE%
MJF[^^I:O7N57KW+C_*]>Y3(DYXCYA#ZCR$L"Q.[1',>;^SCQ-[<T%N6!&?;E
ML+7H;0;:XH&?80^3M!KV':-^XL47.(`/K/+@8[N^IB#E"7B\+EA6I3V=DM_7
M(JYI&EZ`Z!70M<AB?N8M)%"W'V=0#+!O`G[%*#8XZK9X8;VG5M;*`4A+P9Y<
M;%)EA>GU=0NKBDZCC=--QQB$H3%J2(+5Z.@>/LJL*:VN1XA3ZZ?^!L%J]Y^\
MYJ@.1M5N1FZ5`KO_0@(<Q33<EI/<7@QUUXA.MS''K)E9^<N$T35&X6,((HY2
M]J]K:61]KRCU^<,L+%E,_!4HR5R0SX*/MY-^P3[Q@#E'$Y`+O$T:T8X"N9C9
M?U!#N#T390A2N<%KU.)048MI)HF<('7-S,31-<5$#1`)-?[8/2-@'QC69H`L
MVG]XWLMT/L-KRKAR=8YBO*!,_4RQNL]18&'J:64K49_K9;RD,?:6YY2M,X.O
M`@)%\V.(0MT5&)]ALGI*6"1$:U[Y**JW,S3T.*K8V&SPQMG-SEEXS`-(NI6O
MA+5/T/B!PK%$FWIX=#N;@E4X14(/[RL+2J(U]C(#'1Q;N#]04*?3U.]M=0^S
M4,TPMX8"-[D.TS<&9W2#@GBS)46V4OO+2!I`[S&L8?S2>7?P3,/'Z!X!,240
M;*[G6TNV&L$>X]JX?>\8"3VR#G#!TY/I_!<X\A@1PG/-7:LP7?4;TPX5A/%_
MRK(7$)7(U32U"#._7#)0(J7,)&\_:N@M6=?*=C$A=FU9\1<,,IFO:V_K,-#W
MD%ESG\9??<9<M5LOB0?7GK(DE[3]J*&WM+MW=96+$"F8HKS]R+.R^IRPQ_6<
M@8(HA/\]07)KK!;54[9A/MNPGKKCV'DL&_1_7%]Q8+<E.W+:*FW13;WZ6S/%
M&^%LPQ'YM/T'Q^%3`8?L\V^/]WM@%GX8;X**+!_-X4<F^Z*\9ZT?PU-LEC,S
M'7ZJS11EJC@?[P'HL@4<K@9O*#FWBK)[>6"'RT=V^&6;`?.1/QTOHY-EHGZR
ME'6O7>.U55S;B/,Z.N/K>F;'\)CKA-2-YY'$SF10Z.CC>3JQ,_8][=;6'UL\
M!(7J;-H9XG]P)QVT0^RO'C<HT><(DT$[$D[+^^ARH8<^>'>WR;E<,*(/1;IE
MJ+A<:6((:JBR75PN5&&$1_3RE;M<[Z(7=?0C85RND6%F@_0(%K%?;\,X<:39
M9&,H?M=E(\ARML=0[Z[C+:&9?SJ&VG<==W>7"(@QE,7KLB&TTIG&4`&OTS70
M$*7K<AD\LQQ>N>-M"8=Z+TOKYZGJF^*<*4&E5VUF.!*,Y77I-HFP11HT!GSD
MIV",2D`]\O),M-RK[![#ZU@E\Z-[`JN)&HRG[FGLS44+52E".6;N:5,]2\Z>
MCG(+-A1J_>2>'-R]4.NG$;([14733^[=5?TJFGYZK6AZ*&%"*ZFU:$MLS%3+
M^:!](5JE2!A)*"H*EPVDM+\;M)2+PY+%#85#=\/(<Z]J_-EU&4,NH:K<`STQ
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M`=R<9KB0JECS,'-9H5HMP#*TZQL?.BA]H+NL)$8.LYF...#]$(LBV:OVX^+U
M]#:-.[B(;L-5,1)EQB32;NAPS6=!ZY(O8EVC2XPAM4$;3PT)8PS)"ZW755.7
ML)ZLH)WX-JB0I<$'NF42.V3&,/`ZF*%WJKXAYN_'T.V_0E5JXZS9XI:&SSB*
ML2_@C1YHC(+B[WRGW=+X;SAN+/PVW'Q'1;WT!(O@XEV@^<=#D[0>"*MTYD=>
M40"_N;U=Q5G"Q`M6YK--WF8;62J8A):RW'=\=Q3D4D9S/<B7_TS@3KH.X<Y/
M!&XB#.AAB<)TQ:-?Q(:_#M-]++;\%2+L%Q1('[FR!,RHZ+X#>Q)%R2K%CLM;
M'N!W09Z)#S?[#,0*TR36GG=4U&RR^!L8>%3TF&X7%N1E$N&H=&*NPY@1D)Z]
M0<YPFZG'2-//T##>8?4K)HLE%PB>08-:8/'C!1R?P5AD1RB<I+3T'LTE^M"_
M"U#(`];417"'F.J59JVG*KIYK!@O:_7%9NML7P+;-_=I63FM4,<)<V@'TY$A
M-:,4"5.FOW6J2'U7Y@2Q>G=5;]H>L8MJ&-H/:**R[]@Z.J)*+%=C\+8,Q#J&
MU[/'X-IQC+A=52+KGJ31DEI/HQ]#X2S'Z-O3#CJ&.EU#ZI:UMV+5S]"V8I=#
M+M&S`'E?08*%ME&*U!WC&3:++]3'0>%V>82.#_0<!3POJ<#V"L[HG##1&]?P
M+``W\6*X(>.-*&NY/2"\<AUYQGP;1*\>X5=?VZNO[=5+842FX>MYFRC.B/EY
M1DZM/4E[*QOR>VE@MT[C[-8H^]2,VU-KW&:8RSH\59Z"I(V\.$'!`V8K63")
M#4C&N)>O*)MCPJN^[O29@?9MW4QCI%A9U3Z(<W&4=)HF<12CT(>3<A!WMWR^
MD5-OT!NY.L_(J67A1M:=?8PWLAPWV3UX.M"-W`62,>[EU,K%ZXAD-O('RC\5
MT)\L%@PO4(P/PE>[PW.<U!^4'6M/?YRTM<"\>P(U1I[>&N5#*U\&`322\MYY
MCQ7-S`6-4LFW#S&CD]S#[;BZD=%,YJP<@L.:!6*4=*XQ;MB@=%LP1DEK9:S#
M0<C<`@(K%.9WP'44)=B_2(#M+U(X!4I1S04A37+L,-#W%USK0!#I:VCM:VCM
M=QU:.X"U]?L-J37M(/F.0V8[7,2O,;!&79FO<:[#6T*/(O+29BQQ,>YF#"^J
MNDE,;3OR&!YRM41BD[KW&-Z/=93,+<UV8WBGUE%*MS;<C>$17#?Y<U_WWQA>
MHG63\MH!J_;?N[5*XD/'R8SA854WR6W2A3V&EXG<7(5.X=JC>"+(23:NB*AU
M^:E?MXG:(]PN)_KWHN`<)!K&_EN9XTKDU7P_SDJ":UJ=^0&]X.B&1M$9GE.@
M"0YAUOB.T6?"?96@@Q7:64S'+4`Q!A@-E(B6!+R=)RN>.4V>\6<&R[:;<UN9
M_9QAF'H_B;)55QN!$1=XCAG,?X5]7FU]!UM693U;<TDPA&9G*W@!)%%,O//T
M)49EFG-]6RL)VO,YYNGM^9;F56!XN9W0(P%).6J<D9L7>$\`D$VIL2R5V\#(
M1@)'LRFF;+U$(7\L5'%PI&T'A01V+TE?+OT;',\V<.WU-`EE_0,0;2%N,XJ]
M%[Y@OTV2>"GN[L9'UBJ-W8!;XU&RFN8CAKWU6VJ&H>=:-6@F_%EA59$'>7NK
MT)<9,0<O/9/;`]N$36-_([SH%L?3->8\(EQPV?4<,;8!,4N4*FKD02UZ#PYM
M479M"VNI[W"07J6S1;<TANF"Q.=UGK82%S]_483KK\T^PQEZ#Q$%EQ%_?V;B
MI4^>/RP9319+``)G0KLHWY,!=9?`%@6M<+)@.%45*ZIV^?E$<\/;"4;FH(<^
M?Y@G^$O"2.03KZC'UI[UIEXV,`$J\W>9R%,28_\2,6[>C*9SO@YD$=XG3Q'Q
M"6($R^[P%@,8V9F/(=N5LX1-GVDH4>KEA'/!,.R3"YS^%_99!*HD7`[I[]/Y
M^9(;,^KVI)F!;:PA-S&EXG\0T&\H]/`^5TB!NPXG*ZX@25:R]3!&UK,ZZPSS
M^F;^`Y6\(<6MFEDD0=TZ]AO0A3<29=)S]86P.IG/>HAZFY<1^Z#J1`%P[7?S
MY.)Y$5>)T6,,/M4V:#;>G];=E]K9)XWJBWHKNYI6,I046$N-*NF.,%GD$!0U
M8GUT.4GD$$1L+TZYG`PR),5,"'`NIX8<8K?INF]<SODX!)W:**HNURD?_#SJ
M&\U<3G&Q2J9]2ZC+Z2MV"*5KVG0Y*^6@(FZS>\#ES)+!-UD7'ZG+"2*#$TP[
MF,7EU(Y#;:N:4(6<+-^AR*X;-^%R<LK@1#+D:&B;?6([_F[WYRY*<*?.I6::
M!.2`3""P^\Y(`>A[4`'(G'@(+@O0-&G(EW8ZKP@DW.1(T!-<PS%Q)>!1LL]L
MO($RSI"[3`74`;JVJ1LA.Z]A4C8"C2KL7R/8Z,9JZ,&XPZ6.*7"BGFW+HB3J
M6SL$^5:4X2II$O"M<@6"UGD"%V@89Z_3@51`(Y)>_*T0;3NX\W2YXW+<,%21
M#>T\3>YQ'*<^N.A7$B^A/4\TRSB_*H+(Y!P.46FK)`QRHMH.[CQ=C)RH=D,[
M1),9]A-QI94AOT'K"$_GD_4Z`.T&;NW4:0N?;LB*Q*@#B7K--/*0(0<B+0X<
M,.2@,7G@@*'C6-=ZI=:Z,5=:?E9+N?I^@W\ZDTFJ9K@<I6,:V]:"E,L!.::)
MTUIO<SGBYC`[1RIJNAQD<YA]HT$:]V)J#D.:9O76Y8`:TS3JI[!8CZAQ.[[;
MBD_J/I6<9GA-&<=TN$H<D_E\LT(O0*U:LV]]&R/91I,H9NCOL(4]I)BZTLC(
MW&=H@YE\UN+/-@P3L+\]S.N:\66>D>@KG'1ON4+LJ]+%T]CMB'"QE"%?!6NS
M`TSA-FSLY@0N(&OP#VB!90_O*;MTQR'"WKL%?7[OI2HV1^'3]A\<^D\%Z+//
MOUW?[L%8^,$&-;^@?U!VGD0QW#HL4NR%FH8VX.5UP:;S$C#*`REO/VKH6_,1
M6=4!45Y_.L]C7KA@2L*S)`*)+HKNM[:0ZFVCV]4HG+LXXA8`2OL8@2QG)=/Y
M':,P5[SA!>SBRW\F1`2?WN+X.I17:F@W@(U=6X**Y]X4`)-L7&47,_4EJ+?$
M<EFH^+.9QTY1P$/;=F)L1>,IO5,J;6PE9()#,\//.$PPT%\=*%';U@K4^<-A
M>VI%@;!GF^Q'50!+EY&L8)P"\!G3!4/K)6B_@?H]5VE[:X$Y^_`H!`IY>S-5
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M+9=KMW1"BGMO[<>):RG\C>;8TL:4$V&4@4>9,?)LDV,T81C9R(B'NR"B`?$%
MBQ#7J3K@HJZQI3"+/5":`E_JFX\8=E-.]LLPAA/S*_'Q'6S/.4Q%10DL'B$G
MZC^6+L>*V%5T670=RLI#1@D7#97>QE(3&S"6^</6B1'Q.-1+X$L,^%HNM#Q%
MXLU."2Z=AK*!<\HEN8Q2Y/>Y7JI<,<W.=O!**2Z%//O9KC,[/\&[2ZHL&Y]M
M=M=8=JU%>L[M[B._.KO'XNP>H]-9VPNKD)/VM&O)[6Y=J];VN?9$=2SNN"9!
MK(BK[K5DW29<[S#H*>35NQ-Z7!;'ZEXP2.=NPI]U:Z;&N>LCUI;/Y%:DLFZ]
M[F"KZRUJJ5GQ>"VY1@G3;-2T9^`=UJCIGG^N%5+U>KI]E]RK>;-JW@RP%V/_
M?Q/$@'L'FRL2HM`C@`:*4?W7@Y<FO:4QCA[H#HC="D53MD`A^5UPSA(;G83^
M'<,1=R7R?T[G-9US*D#K0I76B2<.)7"H.QC/(S`WP'X&6M/7[QCU[0>'2'"%
M".,OO.`<'2>72@FGN/U<HNIU"!<W?WHIA]9%HJK`=(ZFTO@-MVG<!FSG:'Y#
MP\4#9JL+_!2[2-P;4<7#[0T@A=&]U<Y*IV_R![X05TCNH`=<:"BX2F)`8$8W
M*(@=O=([X^#<:IS3U8K$XD]@&WEU$N+ZAA>OPBUI`*)[Q+E=O.%MCP1F![=)
M$*`GRL1;,1/&^*L4[M^*+:!VCN(YC&F\\/;=PXSCG-,(]M,2,2Q>1KQ#F]1"
MX^`J],3$N979E6=R>_.KP'2.IOO!6VZ35@-:YRA<M1`5PE9=)+(>P`UT_M-[
M#L\3,!;XQ_\'4$L#!!0````(`$4P6D8OP$6LIK(``-@T"0`5`!P`;FMT<BTR
M,#$T,3(S,5]L86(N>&UL550)``,Q_>Y4,?WN5'5X"P`!!"4.```$.0$``-1=
M:V_C.);]OL#^!VYF,:@&[,3O.)FN&;A2E9D`J4H0IWM[NK`H*!*=:$H6O92<
M2OK7+TE)MNR(%"\E49X&NN(XE.ZY1_=<OJF?__:R#-`SII%/PO='_>/>$<*A
M2SP_?'Q_],N\.YM?7%T=H2AV0L\)2(C?'X7D"/WMK__Y'S__5[>+[N[01Q*&
M.`CP*_K-Q0&F3HS1O?-"0K)\1=?.`PXB=.V'WQ^<"'<0_]=#)$2_?;B[1H/C
M/D)/<;PZ/SGY\>/',:5>=K=CERQ/4+>;6?HU`7F.)L>#P?$H]Y<[L@Z]<Y3_
MZH)B)V:ED<?0G*-!KS_N]@;=P?B^USL?C,Z'H]_SI<GJE?J/3S%ZY_[$"O?&
M77;%$-T=WQWGW/LSFI,P8J67*R=\1;,@0'?\J@C=X0C39^P=IS<-4G<18S>,
MWA_E/'QYH,$QH8\GS,SP)"MXE)0\?^%?[)3_,12E^V=G9R?BKYNBD5]4D-VV
M?_+;Y^NY^X273M</^:-SN8'(/X_$E]?$%>1HX$+2$ORW;E:LR[_J]@?=8?_X
M)?*.&`<(_4Q)@._P`O&?O]Q=2<V=G?`2)R%^9`_+$Q'#X/)[GS]1O"B^+J!T
MYS(.X8Q#Z$\XA#\5W2U^7;'XC?SE*L!')U5`WK-@Q/4B?7O+(K@!+\#5E);A
M-U8\1V$WC9K</?%+C$,/IP^*WY:X17Z(FRV<Z$'<<1UU'QUGQ>[<'YW@((ZR
M;[A:1MU>/WW\?TJ__C9S72;-F.626Q+XKH^CV4,44\>-,SC"G?='^A<D^`,>
MP82FI&2T(-][?^1[W\:#T:`W&7[K#TXGT^GX6_];'VSO6_"P>0Y:'+]]<!1'
M9$W=1-O,,L^H..S^,C_ZZ]8NR@RCKYGI__TYN9N6;P,+OL62R*S5P1G-(M"A
M;@FJM,2)2UAF6\7='?(7E"Q!$46@G"7>,Q"Y^&M2/]&M\^H\!/AB32D.2[0C
M*0S3S71P=CHHU\V>+2N:B5!JM(-2LWIR25PJE4M%E\RE$J%58MF^.&0A\U88
M"G:LB^(.N]A_YFB^X%A/&JI+@`*9#D[/-`129-&23+:F.X@9A\I%.%@NESH<
MK"(:FO,RQ#$B"^0$`?G!V[S\E]`/D!.CCZS8\@%3-.QW>&]@A%A_AG\8MB`W
M91@6B*Z,8PWIA=]C*@35'Z1RXM]P"W2-O0M6TG>=X)[Z3O#I987#"$=[#UZ[
M/$A(X\EH,!I^&[Z)LU)ST"#SB+M>,N)$SP<29QP!<E,(*.88$$Y!'&N)*77R
M;;:HW4EPJA#.9::1L(TRXQ#?WB:*VGTSRQ*JIV=!^OJJ(4#*;-:W'-"U[SSX
M@1^S-G%I9:LN#ZQIAZ->7UW3%INSHYV<76@-*QQ3UK#U.%9!.!:5HA\^!,B1
M3:6LE^N`#^9\Q"O6,O%%9<,^!YA_F(7>;$EH[/\AOK^E9(5I_'K+J(_9WS[]
MW]I?+97"JO7VT"YA;U2BPUK0-2[;#"7*P^R@#5#1,LQ#[:`,+/O$X79$D0UB
MW?ZGX&]T.`0JAEU+>;S&472.G!R;7@ZSW711KRA(LT^DC61T$S]ARF<M*'YB
MZ=Q_QE>A2Y;XFD01ZU'<+.Z=E_*@A-P%/-HT.=5++3H@[&40@0;MP$$)'O2.
M(_I)]+QY-Y3!TAZF8EPH6P5-<F'65M@00@0A[@XA`8/33D(`16RQ[J$<'Y*\
M/XL1#_,XVKT>)NG)=#(I&1_3,W]`8D9?$TB:\S,)!964;$9!10W+>3C1X*$]
M5>^%*TS/;YFVIV3/\WGSP0EN'=^["B^<E1\[`0.Y).$\)NYW60!I7PCM<0_/
ME),_I78;%NW&/N(`D!^B%$(')2"00*';#>?>*F1:N[<&^DR-<E?QB\O:WKQ-
ML7(H>G:"M=49(_V8(Z8<MJT\=;VI<PUPD<)P,NS!]6:E?MR56G<K-6!EF/@(
M5IFU"C`GL$\;@=TR@?W*!=9*C:<5:.4B:[5F^]<ZBGD/.+HG$GCS)X=BL2:0
MU\JL2A9=Z3O,^LZ1'^,YIL^^BV\Q]8EWAUWR&(J[B,<BC24[9H&UZNBT-U&J
MO%G432>*#7H4$Z2JHH43W609:-Z-#MHX@E)/4.(*ROFB6:D+LE7IYK#(-LA8
MHMI,:71S`*VF*$M"(^T\N<-*E/QY7T71&GO\7[Z^X8)$\?XT?9VW!":XT\&9
M<JUE!42'D[PX0)0@[*`,(Q(@-5.3H*EB:JJ))M.T@_S,<5?F>)LIIRRLH>E$
M@^UV4@5/7J'KBW5!VW')>W+A1$^WE#S['O8^O/["$N%5>+/B.S/\\''FQOZS
MF"LM6XS=H"E@#VDZGHQT4TM-2*VFG`UF,5^P.^K(_LRAHPP[>GA%[SA\EIA^
M0AL/T-8%^%)RP:]F3FJ)7Y-1S5V2Z89DOE"03TOP;_EGE_.[3BA%9,.HLP%]
MWE:*JUMVLM37P$.ML"IQL7A=.B\,1^%0C+(,*+$,^\/)="1=?;AGPM**P\0J
M3P)ZJPM3)V2K"RLZ`4QK6_"P`:+4"=DRPHI.F.2.Q&1'/`>;XS_JZ"8:C%00
M7B"$P_M-8<0D3W="=^>)*$N"1#CI#P>#,ZD("PU9DF)F&^T8UPKHU"N9*FOQ
M"JC-ZM[(Y%F+-R8BW;CDEKG4B$K5(B#:]-CK/610Q!#)A_TADG2=L:P5"+H8
M.'@P'@R4<XY:MFT)2#:$F2V=UQP)$#XK6MV-^/QO.M0(BSU2A46K:A0;E2X)
M_4C6#_%B';S=\U.RVM[D'E!M]J=%NU>,(#0OT63KUX)0E(%!A7OB8(OU!0=J
MK3;&@6'-N"7">;M;SK)VX2%*:B`7J.0(N\>/Y/G$PWXB8O9A7[OLJV\SUI3T
M>'/R,G`>]P)"^G?HP07CPMG"-[=O6$^9*<1MZ9Y+,"Z<>ZL,W40&I?AKCGGY
MXR<E#%3HM2T?<:@>+"DL`1PJ&9V=3:2]M!T#EGIGW"9DF$0X(.N057(`*JH4
M.'2(1#@@ZX-5<L!(6LQ@6\,CQ?%,2KFPU[0+8]_S@W7L/^,Y=M=4#)-^>G&#
MM8>]2^8*;X2NDY"_67QR:.B'C]$MIJ*9.EORRDW6UJCSWL"F8*\_4<[QU@&M
M8?7E(*(M1I2!1#S.4`XF7PF6`>4+4I+>7P<E8#6;CX(W1?.Q#=X,1/\_F)]W
MQDARGC%U'C$2H-GOT99(O$-D5F`SY;)B#$8<M,T6:*V*(0T^MW^7!/7AM?@&
MLQ=?NB*E>8O@/2I3Y;:SY@"WD^*^<M/ZNU>FRGUHAT..2>,%S-!A9B8M4=27
MKW2?6LM9[(NSQ!_)TO'WIZZ@E\'SR12<3[966TD*'<0!H*\)!$!RF(*3@[FG
M]2E<PUVK2B^(N5*Y%O-H3W.4,J*Q6#@R"[TO)'2VW]RS3Q%?-T/"2+V/QNPN
MP%&T\;"O5"0,1,,"S8$1!TPP.-T<'I0'!!1L0H1"L,T28:+?VMAH2L^&`4QJ
M8=V>VJ,(RQ>9[_P1NES\]$PYJR3NW;#DA`W===L<[Z1FO#&)G0"FC'M^"7*D
MT)N*]]UG352>6X[.LG7,A87`>S0GRIIDQX:-J(4O\A4N*.J`2BZ8I/CY_-/]
MW'H(*]?$2CFP'-(ED_Y%9:`'V$[[R@4W>1,VXAE\/BW'7Y:.32?<3;.RF]AK
M*SNKYM!E?+03V%HI6U(6.I-^-E">6U=DRFK`&YS\SUTJR^0573+91+\3_5;W
M3"CC12:#FG<M\)O]CD/L.K,'Q5R\O!AL0GYRVN^=2B?DWUJQ-"N_-8QF'S2G
MYA-79%/SU5V!RI,91)D/#\!9^L07V2Q]=5],&EH[S\3^;+TBXHD>,;6H4DN3
M510Y'4]/Y1L9]FU8U&,6S+!(3MPI5Z5U39JX42[(5N38HA;+E=CFL-.SXP=\
M5><EH7,GR(U^R]H\I1=`%SV?3I2',DGM-2R$S&YW06@W8I9SLQNZ:YFY:XKF
M8VVNF8CCK7]^^(S3C:HVFY3E`46@G!V`?"Z>^`#S5?@%Q[^$%#N!_P?V_D$"
M_L+'OSM^R+?]@N,"<E/PJ>,#Y;A;)4PM2I7U_@1`ON.<[_G?8D0I2,119H<`
M/&!V#_%:36V5"^9,5-X$<P:9@+.RWK+R+A!$/')2^"'MAY\G0*K0RB70)W,(
M^48]D*E['71P<S@PJ[SM#'B6)`;8."AWU4CFUC8CS9\(C;OLPN7A:50Q8@IA
M[@"4]G?*U'^7)@6>#2*>#G#$2]U2XF+LP6MVR$W!A_Z/E1,0E3"U*F`!$&4(
M13T>)14YYJ\$X#A1!E3[K0!CY59AJV35TZR/<HQ%K`X[B'P`BG>M9`%]``>0
M29(#@%A;,]T<?1-F#8_"5L<-->HT5+("S#63@6%GW@ADJ\DG/3R,0<Y.(^#-
MY6UG0]W1T$Q'"9^*=QFU1&B55QJEQ,6,N!4_\2KB>W_>/>`0+_SX)TYBKC?R
M;]0-J:8SK1Q7^:':2WH_'.K=,VNJC2I%98"3SKUA7[FX+6^BX73!32%N"[3_
M(_%`T>*HXH%)`T+'C::T51@01(,,\WFK#\X+8^D?3#SQD^O0XI?Y:)0$Q>UX
M.)STI3-8Q8;L3&,EMM'3QKCFFW<3AR1S6/4X!)-CZLC6*&PV*W5(,IM5CT,&
MZH1YU<3$5HD*B#9#523[FK_U=:`XD:&L+$RVO?%H(ET*(C-E2[BONX%Q?7VA
MJ=W$*ZEVZ_$*JMY];P+@*0ZI5U(!U^.5D83?/J@65%PB"P(@JJ*22\1;0:^C
MWFC4ZRGU:E^BH"A./5!ITYX<39"K]&=9<JUH3"6KFI5TR=R_"?'<?[GTGS'_
MG_TV6_K?'=</K\(GUI-42@U\/7`9Y6C4'RNTJ&W>DEAG_QSUNY/QN(_>92A0
M`N,GW=66PF.Y=AOS&"QNQ*$@9ATQ,(@C2?[AW^PY#UVE*3B09X'&.#!)$XI'
MWD;V@`N25"2V0OY9^V+8:19ZU]B)\!,)O*LE']]+METJ,@_H2EA[?328GDZE
M.4?+L*5LDV(1.W`W:%`>CF9C/G%9EG0:<1F8;C)79U)7@2W]Q&59CFG$99/L
M4OZ([2<9F/:(,:?6QIW35PD)6%ZR"45,#$I&5\N*0[=:#P>J4]MDUIH57/;*
MS<0LRC9%"<NZ6[*Y7_(QZKK\,E$5(=^3E_/RX^.<U+='F6\-#5R7AA&!D=6*
M7&X>`O]15%LEB\GT+@)*9S0IW`.A9].B@%#..G0)F?!13T;5?:SP<MY`.$KR
MCF8;;E>$0MX.*AZJ?/JZ)H^KS$9?XR@ZUW'/0NI0B$F20-2DM9U&OC#W33+)
MV^N@2]Y&IZI7`)>:;2V?;"'HKE?CGH)3BKFG-6:5#OLFB@PS2_*$+3K^C.D#
MJ3&AZOIN-^T4**\\\Q23VDKRB3XX`7^!P?P)XSAI7'UX_>S\B]"+@#4.OV"=
M3*1_$VCW8#I4+5:!8;"8HUBXIG"0P--).Q'\#9D"$Q*@.GR#C6Z/@E.A)]_Z
MJ3#<)/-0T-=H2;*`$)7H%\9J.V*^7,=KBC_[H;]<+V^=5S&X\''[OG)5T)1=
M"Y3N<%HXE`\R;5>Q"0J4PD`9#L2`:&I4^"P_^:<1GXU/!%JF?JXR/RE_#3W%
M-I>[PP)0)DP=*@]+C_K#!;JW@*ISJ'Q;`@3!P8B4UZ8O,;K_@8-G5H*$\9/N
M<)V@0[-RK9D.@ZJ51=[XT$2JV?V&L'=8DKT*[YE-_$_L4)VQ<=!]P#O/>[HC
M?UHP#D;!?!>(@(4$+NWMY#W=0<)&Z#!3\.FA*;@P,*$REO%X<%K^0>I0\MY=
MP#KNJ_9^`4$<EHI_$*"&^ZJ]X@U38:;@R0$J>#\@#?1;P.$!J?<J9`\+1_%5
MF+P9Y"K,_F(<.N6WA![0-)BHSO6L@N@@1,ZW<B8`48:0:S[[L_8[ICE+>E-=
MC=%4?2+,$6_*8IWG%2O*;/,%*WX*[*`2A$:8@[*%'OL'E#INDP?T*Q^/O%E\
MP?'>WXWC4/?&\&:^ZB5@U7$=2#))8:)?LX%B/G2\7TR_+Z!Z-YA]S@R:%AD?
MFX'S1<)<-F"7S(VM#(BI,C19.S'P<<OJQ+26?+53!"@%0Y[)`23B^?I!/*([
MOMHW@.=;R?7@UPN,1T9I=<]\J]DSPX)2,-JO)F"^FZ3'BKX;9,'+76U389C]
M<+&_8OW,=>AABN(GC.9.B"X<&I`(+1S7#_SX%44IW,-(`K*XU=*Z@GGSS0<[
MYNXQ92R+E0D?62MX+S:TR\,V&O2'D[%THX'*G)WM!3OK4"(4;S$@CX'0W%J0
M."G96E"GDU5R"\K91MPXQ#?)'H(Z?3,YUJ\@);@[3[3SYI':VD&@)24"Y+%*
M)J">3YZ=R%T'#IT["QR_SN.U]_J%Q'?IA+!\*Q+\:N"I'Z/A:5^>)72-V\H9
M>3PH$H!0Q!$A/T(AB3=3[,?0LS4$#])$TA0/T+2RXW\"!`DDB$%!&18CWZ6)
MIBG?S3IN76?%=_6P/%,+&\TD(+!F226V+?8\HJ=9Z/$?GQ@8]A1X)ZCDA4YZ
M%P$/V6(`U2/`*IM-JS1Z$COJQ(><>?C+GH27JMY$G5X:K:,V<[6Q#H)6I!$3
M!MO66,Q2`WWUPT<Q%@$+B.)KX7,NJC-[M4RW)+P.<F*4`4E&0?6G4`;?5#,H
M#3B]PM0GWJ<0.%FR\=[E'W!.B\QYS+XG"_2*'0KQ?-R&Y_/8H7&-OC_@1S\,
M^9,W8`"<?*LQ4"4'[_O>?N*5Y)WR_"LGL>4T?"LB]"IT*>\P?L3)3U"$J&\!
M/MSX3+W`11]!:[DY@8,R/.A=ADC_1&)&@FKFI3D2#.98^-S;.R]S$?F9VWZ8
M*/@@I5P2M*6*+F>[;6&3P'=?[_%+_(&9_0X+I>)K@3V:\?!,/1FM8;H]#0L<
MZ&OZDP-"`I%N3T=X#ZUL*WIO6-EVBMJ7(4]@F\._DR\N'9]NY]PO_=`)7=\)
M6$'6O5C;GT*%Q&ZYHN7<5QDK%:9R3%Z%GQWZ'<?\[/'MH>/7?HBO8KS<G^&L
M=A.88,_&HXEB?@6(P=8`:JK@'#!>\6RAH2TV])6C0P*>IHP33J2CJ`US8IC-
M&N5".JK:,!=5.A*U$-+,P*JILDD=O#>?U^[YKU7B9><&L)F@\7`@/_\=9/\@
M<YE`ICDADE!1,8T94=%H"H-34#%[&5'0?.:2\]!FTMJ5+C1AO:&Z<K*Z8P:I
M[\98M/P485!<$'@J]K0W4$Q#%]BQF&3XJ9!;XZ+UKWG>M/!*G4>J>660+RIZ
MHTX)U;PQ[I#Y8H4\'^*E6\]<B6<-BEPB!:)+4C71[H^BAM[^:YMR:40R:5O/
MS8"OL)CVSR8J\1MAL9@@WLQ^<HUM("*&,7GQ8[YZ`LX%IR0I<HD5D@SRC3UR
M%*G)"CFF+9?Z&6HJQ55+"J3.!V)UO/@R(#_XD6+L8P(K.6DX'=)CG]W8?Q;M
ML(]^Y`8D6E.LL2JFCML"1YE[P\*CN.M"92&?<'C)J83\MPW"9,0UPXBV(-$6
M)7P!CJ!+/2QMDRZ3E;KKU2H09V`[`8K<)^RM`S$>'9*P*RCT=RA<;"AT-L#/
M+0]3UZ(+TLQCJM9$VVWZ@9*@K&JKX9:PMZ:<G4Y'RH&B"HCL-=HZ^YV@HFF=
M\HI8[Y4C"66*QIM%RN`IMP6J%$TYBU15&8KR=X>BEMNAJ.W+SR&,O%W?T`HC
MIF?AN55Y::I)6T?Z)/4_C&K5S!P_8\J/TDSWJ3);]^3BR<>+3R^,Y9B_>F>Q
M\%W9GA.3.\`&_-A_/>FKMV``+';T-Z"R7?,BT=T3)("A#3*40M,;6$NX4-0.
MS7%AT/YND@-%VF^.`],L'VV(2#?$HP4CPA4LX`T+1,Y"4RG-0+ND,M,5$I:_
M_,-W6&K\[#.VJ:/8#*<L"6O%CJ:]H7S0L="0I40C;(OV5&I=\]U^B4>R-%*+
M1\!T\<83X)OZ$H]D2:$6CTS$?_7Y]ZN9:,Q\OKJ[^'0WL[_#3"T$HDV1O5$T
M?H+WS6(>$_?[1[)T_'#OF987!(YTG?;ZRO64;^PT+`9NCX^["(OH:V)3=QQ*
M.*,8AZKLC(D.]#UJ:JQ('BM$EYQ6%'`M6;^H51:F@\GT5+U%H,B472E<0Y?6
M)3[IR<'8IQH44>*8!56\#1Z),`IILJ<-$C"'"'5XXW)&6>OS40Q9;X=B2U?F
MP^\`UY'R!4[Z`!I65QX(RB'9F0@!K]!/_%=HKCG_#91XS;HG8823W0I;9"1$
MLT>*L?6U]P;122IS:U&^RZ6?3M6&W@419W3BT/6QM((KOP)ZEN/90/DB([G!
MIN6X,9Q&8\ZT[M&"W#>5]&KSS:32VW/0+7.P,8V5AQ0!DW8(&M)?4V!R#_#!
M&P/EJQ$@$%I47J55`8(#(SVVL@2@)B+LZU9S=M^4[L/2=GD+U^0FT$;NM'`F
MP@S#H<C;H*T[+9R,L$-#W0H_-"V7-'5-J;6J9A**7G-Z>N#\R6$/YPY'F#YC
M[Y+0Y'S1JRA:\WD41109W0=88T\GIV4M8Q",YF7-NFD"#U]GDIPIF4!"&28Q
MTY:>7YO!TJR[!1MJ:3?*AJ&Z&2510DF44$'S5/@I&+ZB@A\;P4_C),L5ZP(G
MG=X5NY_M/&`6VJ2F1]%&-BB<N"PM!UW`.QHHC^':-V-/K;#)O=03+27:F]I+
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M(BFISR]9MK-4;5LZDEPU-?[1"R*#$CI!!!L`9:N>?N(&$!01@=AQ`Y5S>E6G
M;0G`OL3^OKCMV''$E@;7F!UGQ=G+,)A4UWO6-$U,[*T+_(3SDKKH*I^3%?Z*
MJ^OE??)3'5%];P`1>7+2>2#40&!P<&X%(R$9_?*9E.6O1_S:4+)$5(DC=%%5
M1?JP$4?W*L(6,W#>>1^ORGI-Q69_UEL<6-QU049-CPNBWD@C8$\Y',YI"V!A
MH"^4#'H'6"6(+78I#^STB(QT=&<O<@ROL1.VJ8[N>+;-A1"8^*;8,W1?79JI
M.L_CV4R[7CP^\F&0(1;>BMBQ4BOS2F3:WJ;E'^]Q/G]B1[SU1WX,7P,O4/;,
M%O520\.J)1TQ\:B1#ST<Q`W5#8?]&FH%+$MK@_6RAA%'[-PX(.)>&K4N?J;J
M]&NSU\!'[B;ZO6F]U"$1Q^2;'\:;Z#>N_9KI'6]*6Z.A31%M6K2IG3@<VFYP
MP7Z0/&+C8.AX!8BRD].9?I-;+3$VPOCE/E*X(;BX=0!P.5AG<P%I(PT5^!GG
M&XQ8K*-YED8_4F006#I`*1SG,E6D@]$%EA+8-?(B2>NF((O-O/J`,_J#8F]W
MS>I=8+&9V?1476S&4'2L*61+&QIC0AV>Y+<6"J%%K9'9Y%):KYQ<AK$>S!PM
MJV_;5DM%4*,)Q&CE5#.,T78]M7%[L^Q.ML(;;U(*!"5Q\&_,3KRD<^4%5XX?
M>=8/E#4/@R>DG?59]++"`Z^1*8ZJP\;"W"9M=^W!)DM<F1L6KH_610^!^&E`
M?/0MWF@?!V=PGO5,(3NE#8`2V!H-MPN"DYAK,R#CHF%%NQ33ZZUA\&)XC:3!
M*^"EEZE^AU\M,2)V/%P4R0TU!%+\'83W29GR"C`W['R.'/Q3JXLTGZ?K#//?
M[2*.[=M_*WE)[H]EE:Z2*O*1/8-85&'O0#8=V'6:<\X%.1UB/E+7E[\7I-0-
MZGK>`.[F3\?GDQ[T*02&!U\MF,T>:M%'B`LWO@B=6J>'G"?K++NO6OJ[-'^W
MEO(C0Z@OG@C87S$!)`[95COSMO<O]U0#_=S([#UPEN>X9YJD%QL<4E(\VIV[
M/]#>C+X,FCX)6[70\FNK'<!L#0Z'-\/`(Y:N'!I[3*>^69?9>^"]A=.>CDPO
M=B#LB3B$S<BXJ6#HV9OJ$WJ]]L9%7D?8]2.OVY-.VP]2C*Q;78J51Y:@2(?E
M>'&=?\#/."-K]LN/S\H[51R^`\MH&YU,CD\TVQ)@-:)M4=11*0N?EW+AFN>"
M/C#E$`W2Q58]A+E^AMEPPB_J#8O@?K%FI5HEM-4)<:70=8Y::B&A%\0=ZJV,
MX.YP8RY@C-#''C<9P\\+2RM^P&B]*9HL>%;5(L/LN#2=A.+LA0U"2/5$%8RX
M*6)/#\13J_EG2;SPP9']7P$QY&QT,IZ"&5*MQ-#\2,/6F1VE3X#LZ,\GOKB1
M>L&5&:4K@,SHSQ5>>5$?&T.SFP&P^[C-S.\Q9U[/N*A2=HOZYH$4BS1GM1T^
MX(>JIXZ/X7O@!?R9OIQ"C]C@.*[%H[9\Q!2`%O[AIFIG7GY-M<-IM[U?2354
M92#3N".6KG0:5'2)X;[ZDE3L5K>7#_0G"IH&O0N;8LW.Q^?JNRH-14<;-C0A
M5[9#+N<AMY(*H07]H>%$2EBO'BH$L=X3L0B@U8H@I@G$:/6@((C1%A3SI=V@
M;/=OK@V`B",`&!Z)@VO#4,XM7B>I*LW4\"WP/.5$-T_I$7H0!%-P5<PG(2>Z
M28AG@[URBE`!8J<%F=C9Z3A2Z6Q5ML(:IS@'%&(FS+'O1Q?.*-;L$@W,JA#@
M8IXFV4VRQH7FPD&C-V!#DO.S\4S#%3J!L7A"ZH"V2B"N!6R@+RU5DH1/2Z$$
MX=5")3WXM-"*&JS,#,,*1D`B8-=%7"^0*K')TUUS577/6H'!.^#LB(GV.C>=
MR%BHXHL"6^'`]0%AHFY]P*.)3K`2XPFV+_&>Y(N!E@5,0HQ8>"\BLLKJ>OD[
M(8ORCF3JXHN=3P$3]69G$_TJVXZ0T'@I>3D=+@XQ>8;Y>-P('3Z<C+!"A+#D
MD5M2*BP)AH#NP"!&'HD<Y7=)UMMG*)X#'S::Z;/H7HF)$^M<(+Q0_$R?).=H
MBD/$;[$[#/FK8F4O^!7NB1K^[$:7CS_9K12:>P&['P/2_.E93QWX72GA8U^,
M$FIYACS/K=!527.SPJ(TVCU[!9$U3^'*']&\,0UK3`L8_9VQ0LQ\-%CL]][B
MIW\<V!%,)U/M/>@*:;$Q`;^%CQNF[Q9\&&;1.UQK`/+O`R)$?XM>O[L<EMXV
M*Y;4E3YC?LY!5"J\3WZRNWSH]YXN"[Q(%;E&L%=!Z#@YGXU'9\K%.#/)D5;E
M&F70(],&I:(V9Y7\Y'=!,8707&ADMH@OC5>MSX4Q'D@36Z.Y%G5!4JH'JA5!
M4A.(S:H5NS`V6S#(E;IQHRW9`7%'[)T8KR?>%*Q*[2?,DM`SJI1DN_<XQ\M4
MV2&;O05?BM">=-<+#8T[+AQ)Z1QO4C[Z16KPJ_EJA?;DNU\[+;`F1<?LEPT#
MBEBY"8BF$L]_>R3/_[;`J0`2_<MK_-`?-1JDY3S)_D&A_#%?="3UF#P*','.
MIITWI>@D18('%XN87$0%FR>I2)OV4>'3)IME#:!AGO%A%#O$W$O1^Q52X/0Q
MA_8K/6_!USZT2]QZH9&`(Z0[]2O<SOY^Q9.=-OV*$#U`O](74!W]BH&;8J.I
M&3E"P-3S$AQ+VN.P6IEQH-2:$3D@::);9_1JI?6JHU0C/ISZ0FH?30:N.A`P
MB<,:FS1_E&M6).]=GG3^('#X-S[6EP2SUF=X@!ZAK7YHJR!\+93[J+<SC.`C
M^T%GU(51]Q@V1KVI=V,S`K_+]B)??*8XA"Z%F+T+[6Q/3`:N>M%Q(,UUX*OZ
M7`NWSO?$9!CKUVH+D'(%XB/4,-#VP6CN,/M-#99!=9FL4S:@P4G)Q%VSL^B?
M2?YXCXO5YS1Y2#.>7M6UVFSQ.FQS8WQ\<JJ\,0D@/<X&!T\:E!HAKA*B.B&N
M%&):(:86:NEEMN(OO*#8Y0CH!1BUA+5>L=\1T'JK/8\%U0<O\CC5VZPQ2-R\
M%ZV?Y_KQHQ4EQ>%UD3ZF>9*QGUZLR":O5%V.\7O`_OWD]%PWCN\5&P.`C?PC
M5&O`LYF/D%#"]'Y#9JJZ4_=NJ@7:;G&5%IB7&.@]>\A*1^*?\R?Z/N:EZ4N<
MI_R/^::(>$`1'J'$TNE10?HA+><9*:DK>Z;>^H>AE;9/Q[K[Y[ME1<#@5BA\
M&LQMTN/.W28+L,$,"X@:3?00B)^BXN.*UTME5*6I1JI^$-A-'9^,==/0?3D1
M,+$5""HO*FS1X\'-%ELL&!D4$`>*2"&FOG&;-&Z_^U'VJ@O1!ZD&Z;TO@&)\
M<C89CY5'4+7R(DX%6R'2*`$9A4DK-1,_;U:Z(=K%.LW$SIMU@0>7,:=Z_3@B
M4`\.U!->Y;19<%G=4D?RM:[%]CXW([8W^0#XR-&I[FBJN?RH^#M"M2J(Z7(D
M5G<7\)L+N?FFG:U/\ZW66J3)A7G*DFC>(0RD[/%`P"O6'7/4(SJ3[3$\RJ##
M"'S*P8BI:P>B)DW%+_,7P(/VD>ZTHUI>9*J!U[.2MIG";N@B5J8K0\HVC&&H
M1S[9*<LV&)^H"G/!7.=K4O,E^9FN-JM:#"6GE'26XP*\!IS@G$U.E<=Z#*1&
MG.:DVXG`2JBRC:DU5\;PFE=AL]%TQXO-;I,>J<*6$(42$%.-YCY>3+4BQE=M
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MX(*EFQ?IPZ;=T^VUMZ?O@D^\S[JJT7M3*S3ZA'JHK1]J*8A^4`W15L4C5"N)
MVEH:'YN?=56Q'\Q9=HN#\R=VLF5R//KECU\1KMTQ;^EQU"Q[),K=SV!4X`L'
M)%##1*<:65\`=O02]C*X"Q[KI]@FLB,Q0UTNP\.93&YV/_S]FFTU&Y>V?_OM
M[K=632+C57_1OK$MM=H!B%\H!(BL#AHR=UM\KA%GSBVYQNAEZ`#EY,2(:[2R
M8W&-+*'@@6NXV08(]&KVFRBH`(RV+OP9.RTZ_NR`YQ=QTY.QKE!KC]!(4/,`
M,6ZGNL2"9SNM:RS4>@P`,0MLO2%06=19\/!%8/[>Z:BSSI8'A0X`J-Y*+7`O
M]?>6AUEKH=8N9K$%'X%LCOZ#*[=0ZWO+;O+=J#/B.I\"=J>3V<1D`"N%1$*E
ME&;84W(3^N%E:8++#+=0VQ$8.:^#H@,-'?X8*L);JUWO7^ZI$O?L6GNS]M2_
M"TX*U5Z59"0Z+D;:R\E'Z.$%,3W0=ZZ)^9DO[>U)0:QV@96MZ7$PUQ.0:B3V
M._8`\/DYS?%5A5?J?53C-^'8!/1478*'0R;ZSI1`7`L`*@'=F@][/6.RU^CH
M>-P/02,T=CKT`+#(.$)[OMGT13@2]64Y^N0."$311\!.1&NKD?NWUC<,>TR.
MCL*]Z#,"89<W#P2#/?G#YJ\"5U^FTY&NUJR)Y,A(A*44"P-MH1<QO1A@Y2!H
MTV49PUPX%.)DC3ZS0'CU,'1%9'QBDG.T*RLNCHYTI8U5)AGCR-(D#PLE1V@N
MZV6N2:'*?(J#H-<QI,9,A[N&0LE7:B8$*/O/`[$R.I^9;,;MB8L-EZUD0\1P
MPXP18V^8%]!DN"P/!SD=0:4&3[?GAL)/\\></.;I/['J9FG3U^!;V[I[%_ND
MQ@95/=S9:F"^M:V[AM&WG1XP1O_4V1@'6.HP4^-+Z[SH,-LIL6R73`+Y!!1^
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M:>?OVQ$65%2+/4)K^O-JM_4'&P$8XU8Y#("XUB-K?:)&W249OEY^VE2;`M^2
MER137X($?1M6=&9R<C8;&?.44GAD@FK!DJF$F$[H>HF$5JA1RZS4BO"!*3-Y
M\X$[)7FSW92,O-ENL_K!["1+M!1V%CH[HQ!0/Q*5S&/DQ^&F'[\7I.S+L^I^
M&+X("9IL<%D#S#&X7/,U19.C;&XV69Q@ZQK=/>`EH5AZ3K*-&-<D649^L*HN
M0TXW=B-*-\O8\]UPF&G=9O85]ZWK][P%1-'IV;G^1A:MT`'@1*4:7[U-30.`
MR<TT"U11*72.M(>L(>&CB"D=CM1N&PY0`!0Y00?4`0V&%S;R^5M#TQ<ZFE:9
M"8!1'.R(,]4'AAY3R!P23@Q/2NM>`1^%[ES+,9$X$'XLSC%WKM*$,-%E>7B+
MFB'.+&M#J@<^!W'JN%%(GH;.'S_3(>5E4A0O=&C\(RD6QA.A_B]`.Z>3,Y/<
M7`,%!L!<HPQBVJ`==8RO?C\S2>0-8+\%('D?W=B<,9OG?3;'`J=!9.JP:N;7
M`:'+;I4V#I+VP^#Z5T8'IG=E#8$])M>XN)71<6@WFRSPI+0A&FAV`D6+C]<N
M&0X*]"^7]-]IM0/3.LG!M(W-O@).+#@S.;]EJ,0`J&)_%QKM]F9'31:0<>[!
MF<E!KT">L+JN4J;]L)T_PJ(=S;E"@_9JAE&J0ZZY9P>%=/TSF:2T4SHW7\@,
MRO+N*2GP^Z3<K:W+RG,#`LV7*#@YF)36\JGI0`S2_$+J?;1;+YLAK-;]"''M
MWSTP]7<?`Q2WYZZ%L4ULUUKE0I/Y'](S\Y;X@0G)&WQZ6,MG"QT2M3'J+9YQ
M28VXF,^+39(93[]!'X,7V0;-Q(UT.1@"JG7CY%-K9UZ>&C1'#^(9RR%-8W.B
ML7DX\M"%+XP>>EP\'`$T.QK-AH9I'*G?A!_J!6V>[@L>`,?V.T'"W$D4>\^%
MO3E^9'<PP_#YM_V4!'F+U$'M%FG"4`=1O5.'P&-K![@_,CH>AB;^C(X-]UU;
MLB("K245DJX@S#)"EXU=+H#JV&S-MBH,@Z&N..J&C<);,9&2YFP8O;V'YH:Z
MEPVE3<[/F[\+W2*:'/<<HN\7'1Q63(6=*YX04^*(3V+AY^FYR=H1IW^3;8[-
MM:?K\K@<2G-VMU..Y_RG_#XL>?=3@:NT$!7,6))]7#P"PI,X>-HEAUYDZC]D
MN$[49Z*J=K9^5]*JW<LP#)Y/1S/-21]#V;$2Z!MUD/94ATQY-3O:(UV@3*`/
MY`(H#^V;SGFHVCW#`\GU%78KD^<#V6V5+;(UOOL0%THJ?M5DO&QZ*"B)BU_#
M4L]^JJ+-JR#:F9Q/SL=G+K1CD>,7G'2H3F:4(\UWH)P(F9R&A&,ZO9`V[Z=Q
MAK39ZJ#!/MDHVCOO-GTHPGF5^VGKUXBSDNT!1N5P>/\1Z-[<><^U-UL)<1`%
MN27VO.<R&GO=';KA]IP@ZDB_(Q9(OS<&B6>V5KUBU?W^:1K>BC?@T:[?ZE$*
MC!?\K.C%.L/-AG%;"U[^D=+N8C.'X42_C>/-:E?8\/V:EOR!\*,*-@6<-$YS
M&9H^XXSP'NA+FN&R(CF^25[8O^D$'*?/>TM2T-=`V)F-SJF*ZB%IK]18P]%&
M$;2J-4%KH0HK?<AU,1N&2I.5PU#O)D,Y8VMJHP&2*J!:!XBERKFN=TNM>**K
M99/Y4TI_L6"+;Q1#)_$&G.8P(W9^C-<QIQ0759,'SI?X^)'U%[G#K.HW3-\#
M=](C;2?=)S8P[+CXU@D(IL"1K,SP4N==&/?,(VW/[-M4FUP*:=@`(UKC^"*6
M+HL,,5)\P:L']6F&SH>`9_=.^(WR/1%5RXB!%%*@[T*:Z=D\;D(?*&Q-L.EY
M3.P(BH&]F-@+^"YW1(SN<IZ1<E/@ZV5[9^P69VPKFV%09"ORC$[9Y?7>`.SE
MHV#TZ.>'3CJ%1ENM&SM-OK-!*=7C/=6KO.-:1_@)VI.>26545UFA.J"_@K&!
M%TR0$,UT>&SSOJWR/?Y9O:<*_>$:K_JO`OGF[.Q$>]+>3:G#)ARF)N)ZFE(.
M]Y8'RO'C+>MS#>_W3GP<(H7TQ+D-A_3[?1`2Z3Y(T;H_K'S_LJ?_!3M,!B$5
MCU*`)#,>'VN3H/TJ&9-TE">HVAJSZY0[&`AQM>4=RPA.1MRK9F0T@%<MR.E]
MEE!RNIL_T?=+=+UF.KZ[*=(Y6^3X0A;4"Q=EN5GQ7Y3H&_-E1=!EDLTW#.CH
M4Y(6/'F=M\W'U3HC+Q@C3GKR>U%340.!3\%\GAO98>-`+IRS/>R\2JN7JWQ)
MBI50IWO.!7X/ELUR<DQG"\JM`P.QD?8.Y%LBCX'K@M*M,H:Y*\)8U:9!`&.!
M!%H;R=-4A)$M):#S0&FN:N<@@+DV4STGFX-L'T"P1BR]"1Q,E7C^VR-Y_K<%
M3L4XBO[E]?")_JA1XQ,EOR2[P45*%I_HSUZGYQH]"QS*G,].NS+BM:(BX4G(
M14(PXI(-1Q+<J'T$>37*!36&EGG&B5GX$("?HN#A'S@IS-"P]R00"[/IJ*M>
MD4907"0PL2`<<(-,<&!MD`<4Z*T*CH']H.E$0*>'`L>_0-W'?/&!3@8T;=CY
M'##V)V>=Q?.48B)%OJ1(*A1]4-SFIS)&'_=.QKA$O8%%`6.^.U2(H6\"Q_L]
M_;RFR=J_AD7W[/QLUC?*85^/%-1,E%DD"\7UD6RCN$L`J[0/&+4[+4_TYL=;
M\"0K7%;I_))L\JIXT2<BZ)X%)O,<3Z;:_/(N4:$#6X@4-1<VU1,IV(00EJ0@
M[-(L__FPRR+N/^$%+N@P98A4!6W4$(!OHH'B8U+D:?Y8TBZ$+\WUI"3T/0X<
MQ$RGVO+T*FEAT5%+93V_6#:'IP9PP]38\&6891W?5-PL_0NKXOLK6E,S2Z9%
M1*3TQA&!.6LPO+Q/RG1NV,H[ST(+TH]'NAVL3E&Q87*$N%C3^O/,(G.(6%ED
MLP>D,B$2$G:#1`.#/8<,BX$+.OM(LTVE+!-B^!8X?62F*UG=(W0@A/#M%:F"
M<>+'3%?&VK.=MKCAABV$3';X5=2)/X0.1A5M?0#K]N%@4(-!S`E:LS,ZEP5`
M:S!(@8`DK#('4CP`:<R(A!$`-@X)$S<D2^<O?8E(AF_!,:*;V_<(C8\5H0#Z
M+O\$Y_P(@\WAXVBPY?R&W\C26#T@HE1!ID&6QF/Q$+9<LA)>SUC<;G^?_+Q-
M*LP*8:7YABHKSQ:1O)2_8O6P\GF:I;H4FT!?!PX8CZ?GNGQC3\H%1G:M)!):
M\G4\I@S:U>:(@6#.UH#!"QC<31J<#^,F"S[X]MO=;V@IUP37!7E.2Y;P\LN#
MJ"'^:TQV\!SX)&A[#,PVKQ2LY++N7954&PKTEYV'05%J]67XM%17M]*#8H?"
M,$F%ZA7W1M'7+S4\9#[9U97`',![5B<=:F_(Y596DK:(LX,<`@"];&/=`)&9
MYGKY\>?\B>4D,T6N\\ND?*+3?/8'JWCUG&0L55D;>[!/0&M'G\RT<PJ`!C%(
M@F>Z2UT$1;#[6Z@>?#&(_Z6ED6FA:>:#/@8(XP,+J&\=@6M',*"7S!/SVA/\
M+UCOB:`T``S:/;S#W6V?P5\?G>C<I-<\`8+:]'AZ?*PLZ+,K($[^?7-B!+05
M+^U0)-R[V0%D!!?]%1GT;OK;H-G$B!`I\8J0)KV.B->!2A7DN<96U?K+35'0
M<%?QM>E[P*YR,CO6+E'WB8V#AG>%/`R\<^N"5,&P0^26:CI$WY9:X(9?O3/<
M=67F,48L_18=9G>X>$[G6'&N+N,PH7^[7F[KT8M44'[@^'.:XZL*KY1#V3!2
MH.MQL\X<_D!*A@6\R6%<[5G<H_U;$-%WICSBVALOWLTZCQ$<B$]MYM)#.#8P
M3_F&70>K!6C@P^+`KR1_QB4E;M[();\#Z/55D%])]0_<?XM-<'G0FV_.)[KK
MI(.I&VF"(/56UB_@97Z%\@+!91>$J?+H!=M<LL.\Z\B0,;QKP97B(JQ-7C1"
M=T9D_!:,J(L/P8$%93[7AGO['%@?#RWDC]AST;&@50)<X&6JJ_D8UX8W3J%'
M]9$W=A]ERR[CJC!37>W*PVX*JYMV&YXES[A`"?J!T\<GJOR[A/X[><0L`9*J
M]F?@7#UF8Q!Q;S/'9V=6W4=[FDSS)/@80.>M0!I!L<B(ES@"EKGEUAA0A;TU
M+LN_PJ0;^M@3#5Q^M=$0A\ITP=,%N&YG#8,*4?+*'!M=ST./E,VT5]DKQ47%
MB1`,A0LWS1`N+J;9EG6L*YP-CI+.,%)A1>6I0&?G1=VB2YQ719)=Y0O\\S_P
MRZL6[7T.FHTT&G4=LU2*"8P%47Y*RD1<**)239.#F#'=)^R]&&/390`L"G#J
M7A\JQ-`W8>.=K%8DYWCC0\'R>E.559(OTOQ1W9`&+\$K!G4=HS23&0<67`'1
M3\BZP25J*6%>2:CK=&480QT@8V%M.`29Q!NQ<6)8;(F=REN\9A=PY8\\X:ZK
M^);)X\!5ZM')J&O=I4]:'"0)T:B1+1)435/0N&E:!'DQS0$[`/O"848?303F
ML*`X^4!62?KZHD75KZ&W9HPZ*YZ^_GJ4N/\N9!G?8C'JK%[JJKI]7.OT#Q;'
MKUJ?Z!T0-$X_I1DN+I,*/Y)"/3/H?`H8M:-I#WOO"(D2O%PBJD4:AC"W0Q?"
M3G;81W*_,<'BN3L\B)%3@D;WS>8A2^>?,I*\3A;4/@--##P==R4&=HJ($M="
M'N("35/^F`VZJ':PP3ZF^PP)%M%=04$,W!$TFF_Q8\J.SN75UV3550M1]QBX
M)N*I?A5G5TJ4L-Z*1$RF<9'$4_T2CILE]L%M8$ZP^%;$"#'S2]`H_QO)-GF5
M%*++4$\M%<^!1R6=]S<JQ40)]$:FZ-1-"SIS6W21[FB+?:B;&!0LUE6!0@Q=
M$S3:_XZS[#]R\B._PTE)<KRX*LO-WOZ5\?-PEM>/7!3BHJ"`R7[W!Q..:NE(
MB#=G?OV8QI-U]KB`F1@,(7U!18!.<SB*)T2D"WQ#BFI)LI1<)D7QDN:/%RM6
MO_1+\E^DN-R4%5GAXK/BT(&/3X&0-#F>G4ZFRL-]=II$.@4H(Y%JAQKU4*T?
M$@H>(:XBJG6$GQ.0'E(=&XSC(3L:BN,9U8'$.)YQH#"_[@ERU-&1"8B_MG!@
MQO_>I&M>?U_F"%W3">@CQ_I-\L(NU;O'Q:HSA$!O@GAO1H><)^I#S4:"(]%<
MK<LVQVJK#9+J(*:/$6BEX2HZ"V(XD+V"&*QBJ2`&6Y!2R\3Z'&Q%T+KV`"N:
MT/@ED^<O7]!:>J-2>",(*<%02:P]'2\9CZI6O?358^M\"#IM.1YIRZKMR`@/
M,[:-!"QY)DS0I-<YF6#3FYO8$2J=KCLFB(D[W#I4GE319("SI-OR8LWJMN&%
MO#WTB60+ZDU-:1#[S\"F&*/1>**\U=-"BWC]+HVKG4-A:Z8:2J1N["AMB><;
M?BN(U-#P[D_A$DTG'-@E5E2Q<RJ&JX1JG=![>:I8:@7+V97NT'31@=UA3SLZ
MG["3UG5X_,7`+Z$Z:UN0$S\-X)WHON7)5K1T\%\LV<[X6R#*.YF<G9UI9Q<V
MJKQ]WI-^@?&>=[_X(K^M8IS^(%!7>09&@=X]XY4'V9')M\"%YA300XB@YH@\
MN6'*DIR206=ZG]&S\+/&VC-X7:*B(9G+A*8`<HOZ9CZ.%KDAL-^LH!,A5>#L
MS8<T3G(8+915NF(+)Q=YOF&'-Z@O<5F)*HRWY"7)JI>Z<M7KA$'[#\"F0F>3
MT],3Y;@`(C_28*!6"0F=4*V4*&%ZG2.I5U.TS2P943I"-1`(Z0@@9X1U@*J_
M#^D`FYIUPO:TMCU2?68'5!)73\;KGS<%6>,D_Y;WG@%6/PGNFV?:9<A]08%1
M)@4B+A%ZX)=;H^F7W:VQZ97-30K5)VO"A1B[)S(.#`#@%/GT#VTIU):$&"$/
M#76N?E^HQX_QP:*[+ZP'C.=/25K\+<DV^*(L<55>Y.VRJ5]P4FX*O*!]$)LH
M%FPC/E]\):P<F?@GNU:OMS9I$!G`,P3'DW/=E:M>50P+2:8JXKH>(:$MKTC?
MTA?5"K.2]8W*_*FVTOSZRM*B)*EPIAK?@SK3YI+QR!X-Q#5A8$8BM.N;8KM[
ME@00,/)WO@^N*#75U1GUIEXLAJMQQY8$RB,=\KYSO<QK54UU%4,'\Y,3>7EQ
MU@%STRXP///27G,-Q4F?\3/.1O>$_SF^+Y*\7-*H$`F09O%J]`G@^&E\-NW*
M+K;1(/;PZ`AQ-="(I:J)OXY1H].1S*0U'/IP/Q@SAU<_6)!#R_!,&E[52@R'
M?K/X5`/<V*N#8G@L%1S98[CO$T`,GYQJ5Q4@&@R%X?$6PR-K#',_P##LRP_6
M&!YO,3PZ&`SWQF</ADV\.A2&.\8-8J#0<S6Y[6?`*X13`)9[M8B^9-$]H9;S
MYWN9.P^\SUPXQ1C8WIUB`>[MP1ZRW-ZS>,4K*?-Q/$IS]"4I_L`5]XE,V*#C
MVN&@;Q[2:OB#?!^?`MZ_-'_]2XH+*OKIA3/5Q<^T=Y73Z&5P1OZ)+DW%3'8\
MD#>RT7<FV#QI_T27NA+&2L<%0Q-30^/2+.*ZT&CLR?@8_)"6\XPPEBA[SKR8
MO`+L7B?'G:5%321&6QMKR0:?CQ$&&D#-@X%NBUKF5H9&F2ZZNK#5X[I!$64\
MBM6]`RU<?6XV_>P2.0RHX"-0;B,,5C&'FP<_PM2&6P_(#F3L>)6O-_4:E39/
MQ.`-:,+42>?-T08"XPT-A>SMFBPTB^JD\W+I`":Z=5O;8:&)H:%AI8FP+E#I
MG3<HI,9@2(U=($6G)!.CB=>^P*$@-09"2I@(@Y2EB7XAI3<T(J1>1U@/I#J<
M%Q]2[;WB_2F@]OB-U3?`RYOGNBL`02I$&SNVE@)@1W:XM08(#&&M+TP.<)S'
M+A"[T`EUK/WQGT]X0;^:71?KIR3_4&P>+PN\2*O."FM]S\(.]8PGYQ/EH1Z5
MJ#CG=Z1T1+AXM*#RT5PH8%BI0!BG.*CCRS@@,4BCA%C$Y"(I&&*3XNR-+YML
MX*]NK5BG;7J100!N\@_FCS_7:<$A\`^<=)[SA[T)+60R'8.!OBLX+NP[$(*V
M^B"FD&F!#F8YD`7<+/?&"2X6`SG"S6*_C'&$\-;N%X7=,2E$@<`^0E'[U)E>
M;G&)V3CD(E]\8/,'PNN30:G&XBLPVJ&!.%763X(K$9>":L40U0RU5'-#IW")
MGH\"NL2.FT*Z0D]4`5UA05I7^9RL,*J2GZBH77(@I&6#9>+%U_$6*M(\R><I
M.PM=5L5&S,SJGXD<DO<);2]V&SG&U>\%V:S3_+%WJ]C39\%;7YUUX'UI%9@8
M:DU02[TCM/UQG:(I=41<2=1H"=^<YN[2K(=$=I?-B">LST(MJ/A"!PG36`Y#
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MR[IBF/1Y(5X?LRGRM-H4F/:$G]*?[&_=I9?-7P#W-^?:A#REO,`Q7\OEXZ):
M,KS;.=>FXGDSS@82M?"CK7G,UNOJ"1=H>W?+$)U3?Y`1J!>C0>IWG+/50ZI,
M>ZSYC#_^9$6&5651#-\"'F<^FYQU3>(,A89%F!3.8VY7/)+R#<\J<R/5(/-L
MI`72VI8F.SI$Q)1I@!$KSQT*NK1]%^A=:!+LZ$1W&LI(]-!X`V?%,INM@1>M
MH],8/D#?!@M"<S0.VN.1QR)9/Z7SBP(GY2U^QOD&EY^HW1]_T@;+DZR^D;!O
M\\GE4\"!Y_GQ6+?A9*-):`#7&B&N$JM?)91"+,10K59STZ7%MA)WB@[2X9UB
M@7"I![N;XG'KI(2J&!78#J%+_/DX'NP)6?Q(LTP5*Z]^#1RZ3B=C77I[_?7`
MD)-2#$>B7&<->BQUMNGS-(J'BO_7[4WTEMNO'/X%KPC%1Y9J%@]5SP`3MB;G
MXS/5^N%K$7&6$+=2#?.^A0V*5417&V!PVDH#[J\)&Q1KB:XV6,#K_<7_@\ZF
M4_3+5O:OT=<6E2%.#!P3K9>X6JV3M,`+D<=P3]ZS\\AK4N+%]?+]RQ=</9$%
M7W*Z?TKRNR3#HK[5]5*\R`#RF92JBC*>OP[LHV:3F>[DHR?EPF*R5K*N.E41
M],#/^'-%6<TE.JH2NLJEP8HE*#-UZYIR[*&MRHCI;-AA<@>J.\R!'&B3";DU
M?_Z4%(\Q5W9\8X`$;8#(Q,-4N%Y^)OGC9SI7EH;\!6>+3Z3XIER-!;T+)`TZ
MQ>I*>`:)CD$)/)@ILID2[[@6-44P/=XM2?%N8[Q&RXWN`[IGH]U@3"W/F.49
MMSSAND0'M6D$[D$6X$H@($L\_^V1/%,;>$8`P^-)_0\&Q9,6%.6/__/JZZMV
MW_\%=-?P;-:U>+/];F"$?/UP=6&Z!\A4W0]]>U6M$O47/6-NSV'<T<!$9;/]
M1%"</V`]S'M,^0C?%&Q#G<ZF:)2+W]TG/[$H7*XJY^3^(=B4\OQD,E%.*:WT
MB#/OE&<],JH;'2`RY="ZU@[1?Z*T.0R"38\D"U\HIJ91?`&$O3"1Z82$4JC1
M"E&UD'R`*X9$B59PA2SI%<5D-XI7;$HPMWSRRWN<XV5:_=KRSO*5=V)-DMV0
M37QY/=ZHM]&4+1A?DKQ*\TV:/UZOL4AYE1:TM/Y`_U)6Z5PU-G/_(G"$/#D_
MUV4M."@4A1Y^8:K]*O9DMMJAK7HU?[;Q<(1J'0U'U-Q)FA%U/"=9L(7.UE`#
M:@]A3+S[]Y!Y0:;^^@NP5Q\$LL+H;**[ZM1>GT,F!:FB(2=P%WGE!$L7V>?"
M'S8CO(Y@-T+H<.XA\\&7-.=G+^JKER_RQ>Y7Q)7P8E6P53W57S2Z:@"]#&9V
MZGD<8FO`85&44++>%&BI>?2*O3[^K(J$%(LT3XH7<=OC$;MFC8*SHGIF[/.U
M*TPOIF%M,GN+;5*1*LDL)E72Z;\\U),J];3[L,G3&;UN;.NCG2/3\UV55+SB
M7D_67,_3T!+)$VTE!H6P*!352(5GMG&K^L9&SE;9%U$Q-2THGM4AM(<]K:N&
MPLEG%N/L7*_Z#AJ#-Z![$:/."D8&`B-CIA8-NG%&F&<,'!?S?(#'P,8X".H,
M+#6*5'X;&DG:,L=&[T#+&I^-=><!M2('PQ.PEC$S$8RH:+6+[>R,BRIUP6)C
M[T5&%AV#-M4+>KLGU</`">SQ;*K+H>Z6%05$KXHY`/HC850?>ER-LH>-J65!
M\:*,GSV@Z!PU($(,NAWUX^"#0)VY)'W2AL`)K)_AAD&0$KN+,;<N&EKZ.A:]
MN^(C1BQ]\))%G],<\S6VOO;6O0/$SO3T7'?L52LR&H!:PM%W)EXL19K"B-MH
M`",?-KIA"6)H:$1I@ZP+5GWN&Q1;/+,#$``[S\/[H_YMAPYQP^")BP;T2/U)
M"QY,\P@CM7T1$;0;3CWHV?-8?.1LKQPT6KG6O@%?O=:>R5$+C(:?K6BK96SM
MB1E_YKEAR-C&T"C2!%87CO1^&Q))???1FKP"Q-+I9&34$W5('`1,\,MHN84@
M.,5,JHV<,`N*)#UX#B$)EKOM)DD77W%O][/W(#PYS6BEK9$3"Q^X1$SB$:(R
MS;/(C!;8K&VQO95Y3<4-G_/0&2U=:.CT3WP,R/I`,B>_KU&[GP:?BSXS0L.N
ML&A=1EWNJCFG8'Q:^<P(&&YF6:!C>^`"EANDLK$OO\K=1G@NE*V-H;E``9@N
M0E#[+#XKW)`LI5-%TS&EXG'XWJ[1>/*5M%C$<(2$8/1=_@D?3W(+#2C"T<(W
M.)9415`74#3>B8^46\S,9%54V#[RY1-U*K[*/^`E+@J\8/L!_'`UNP]79'!D
M&?G!+FOIBP'G#X,+#YST9U:XZ!46IQ^72SSG51M;7?EM4F&TJ_`1$BK3G@'5
M2HN=)E&]H-$;-8K7A4R,BQF<].=OQ'2DS8"Z\=%SXX^DEC\$/[BCH8M)O#3!
MT)PCSXEL?TN#_D-*X5#@O$J3#!:'IE\#C_E/^[,@P<H<"J74-W6\?JZM*Y!%
MN,/`+.+;80ZWEM`A-UJT1`_/&L:AW4\5$#\/S0^*"<9%)2^R9,EP&PKBEQUK
M8''G)@.^?M!U[TD0%0^#85!2H?IVV4;/U^^`">:LZ_Z5@_"B!>U<5*AL/%-0
MF</SC2,H^EG(O3&&YJ:O)%_@Q89BX"&K2Y7SBG&PJ.S]#)!A3J<C"X91:G$8
M),+/5FX5K-<YCT3=1B![<`^!V<.;ARP(@LI^-V?[!*D\X<>NH.8+O91?J7X/
M5,F*4@?.J.L6K-!EF5`OD25:;OA-/P5Y2;(J'69]!!KO_>1AU!:'R`]W3TF!
MWR<E7ER2%?N)F+R1LG?WPL>WX4QBM-?AHMJ!TPM7_-T#TQRU54=,=SCM&.VQ
MQ'2G!1?=563^AW3)O"7^,)G%`!1V=&/6!D-S$"?%B\5_;4P*5AB_#;[OX,1H
M;T0O_%"80E2*;BD&I`'N#3`-N'K#`NA<Y/"H5@9A/VYU3AL:F?P8WT6^8*?X
MLE9B!2PL^KX"O53O>&2486JFQ*$@ENO'[\CB&KZJY`("+W<0&+R^'&356S/;
M!TLA`$9K/Z1-7#DTM.D/+@N\2*OR%I>8ZO$$"Q?U^]`J3V.;I8!]\8<"9/8+
MH1J[($SH!@0P=PD8P.XNL4]K8'L1A92*YD(+B+&C241KSX6U.7YD"Q$P>V\-
MC(S+5QH@]C.5WHL'P%%WN*HR7DG`J!XF[!/P@8?%%FNG!H=$5EOMFGU6^(##
M8BO5BV,<]T_3?)YMRH-8&-!'JA&4]>Z,B69V<R+^@,6?5_G%G%\]4-XD+_J#
MG&;O07$['4WUN-6+#9[_R,6B7VH%?F5I0;4.2"IA"D5FJQ:*?FVUV4BL+5NK
M+0L'/<,((Y8^.P"045K`Z;,5SO9?A9:.GTYZZA'T2AX6;5L]3.O`<XNUPU=_
M)KN,7!L3BT;N$<J[3R5%AU]'X!DAL-N'3C?:[$LJ-GAQ2=]-Z6S^ODB33*ZN
MOUX&<_@""&;3V6@T/M7<80-0(,[E-5(#-)<JH(KI4.\/&UY7(\U67U<3T&Q+
MDJF5H>-P5/N@U@=QA>I=/+/9LG2!^FZ:@"ZPZ^EUS1[Q#AH;2!)GMPX[&&`J
M?I9I%ZENS=[X5?C6/'@P\$KR4(,!'K8M/<QWSWM*%7FWV`&6$7%H%6U](P"-
MYP9$7GVXX18_XWQC/@97O`?>QI[T;&/KQ0X"N.:8D%3">)-ZTK-)[==6FXN6
M:LL*M671H*:*,"W.-#X;$&0?5^N,O&!\*Y();;JY_D_`H=>S+VVLP2`HK-5!
M4A^+_F_:?7-B#!>X#$\'2Q"#AZ06JV;>'!"V]=T?<N%,6QC&^%7HJ+0W?:17
M\B#PK-6H%X0A)65.>S-"O-MLM9<L+3R$A6%-O&DQJ/?<H-BC'3A%"*2/['@'
MB#96X@N(MD;D0#!KY!N"2Y@(60&VL=%EZ;>6]S(PHO:#J0=*G6[RN;K[)<TH
M5DF.*5SY=07*@:3]!T"(.9F=')^?FZ_M:N1'NY><J[*+HD8M)/4"#R:E(XQ7
M>STZPHY'`CG`>*W7HP-L[A_O.M_%=YK6%3OB16&YR1?\1O95XYJUT'2X=6`3
M]*J7@0T]/F"?+Z_CRQ\ODW5:)5E_-6#@!\"EM<][<CT-Y0\R-&B405(;>/E@
M[@#(0-R7`ZQ+U)3,\D24[F'9Z=DVR/]]T.%$;VAJQQ8F?AT2N.Q02*.C*))C
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M8VDPD!F%&;%Q8$2`B9TBF3FH;/G.I\"Y"3UW;.X("8T9N<TGI1GG%C`3=/V.
MG0UN&RN[E:ZB0J`[+HB11Z('.;N*HZ?AVH^`CYV,]9FF6PF18IN),CY!,M8G
MC=HK[^&F%R%\@,#>"8>.J'[MCP%"FN_P7VX*5I.VM_6Z'@:OQDWU`Z$N6=$"
M7F:E2+'&*VU3_;C'ATEO+1=%&S*=4%!YQV6O7.8,7.2+N_11#)WRZFZS7F<I
M+BZ9'7E5\-%4J;_-Q-OW8*>D1J>C\Y%Z)]U>G5@;ZU)#ONU2;G5$I502S7>T
M-#Q%)=RBW%>/YQ8HT=3NH*JAEFZH5@[M:M=<)@.]149Z2+GQ'L]#5KS5CAH#
M-\7;?/>`?^*Y$2*.&:3"@)MY>]\`W_XTTR]1*@7&0K;+Q;S<.MU`PIMU3J@<
M_E[>_K`B8+<-B:/^.]3Z7P$B:3SMN6U4+7$(*,&O4>,&@L`T2!\W+&YZ[E(S
M<U%\Y'Q*\[1\PHO?"5F47W%UO62EOXIGS9ZV\9O@HQ@]\]E>P9'@=(1J%1#7
M@9^]8&F-M1[&YS!Z9KO>#;:ICU6;^LBD#X$Q@T#K@IJ9U^(C3G?,:?\1<%&Z
MJ=&H+L*QI08LY@>3N/8&@(AU`$G3L:BTUUW6ZZ`]_(;>0;M%Y?FH;A?$!^%M
M\N-+0F,B33)8K]?[(ARP^A/Z?7*CP9AJ@!H5;+L\;JX!PKV9:X%[9NBJ%CX$
M>OICK`M31BZ+C[2_D^*/J_RF('-<PJ#6_R8X6?)4OR_8*S@:V)@*+"E+*F$+
M-VZQ`=S\66R!-R;\79J_6POQ0R#.(-2Z(&?FMJB8D]=&?$K2@EVCB[<33DT,
M]+\$GLKU%+_0R0P/LN86%":=7T&-6TLDQK.WGNH6/FVT@-47DN,7VI$5?U#J
M8,?M8B/+(*J(C;\&P-,]%7GQ,]5U6=T/0G,;QR/]`9O7<F)A!3&!Z#L3:9S#
MR&PQP8>M+993.C.#@N-B+U(ZL=#EFX'B_Y(.+A])D?Z3[Z/UY/V:O@C>M#HU
MZU=4<J/U+>C[![)*TMQ\P^K4K#?Q99D3>O3F1<&.-JJ46.KSG'V&S%\WV<NG
MM"BK^Q_D_HELRB1??$J7%<;Y_5-!-H]/?]WD^/XI+:J7UB-WK)`:>Z@34`&^
M#$+<9#8;S::JK!D_BL7)G_E$0PE1A='H"-'&FZ)*:(B8BNCDF/_TM,E>-\N>
MD>Y19,\,XQX88S$=$5<24150K0.2>J+[MI>$JKL/-MK"CCA(SRFR:H;QG`4C
M<O>9152LS!K/;$&"-8D]U=(V(@6CKY>/_[U)UXP,U.S9^S",$*>GI^-C%2$J
M9<7AN*UXA&OYAD0FS%(0F3>S8-S4,J>1"V0989:"9;R995,@!VI;"*KHAP:!
MN"K:O.0S)9:+?/%^DV:+-'_43D6TS\)F'[/S\5@W^^@4%1HBM`MF_U\+!1XT
M%":IIQU>3+*"!\2N0/,-?>@0@)?B(8.=%Z:JW+*^(],?)=0^"][%G.E2=SI%
MA45&JZ8$$UZRVS=SZ"%#;I8&'3[,LMF@9);(,X;\7!9IC,VXL3%!HHTB`G!6
M7)"4/0G7W0_!,T.U'<:.C,`]!9<%3Z3F)O1`P-H$FY[!Q(Z0L;X?$Z^#O-,=
M#K,=_LW^#&>SAV'E1VG[T_&!:K:CDA5IMB,B82O?;*HC;5)-=7S99(5.ES1M
M:9=JKN/++FO(1IO4]"*`0'SBBMO/:8ZO*KSJ+""L>`2V(G%^?'I^HL=H(R$J
M,K\SL8C+-9RN"U.TT+0VQ:Z[M#1!BT)K$QRZRQX[P@%Q/[A)OS.`0\$2SW][
M),__ML"I&`72O[P>_-$?48F/=.295VGUTK&9KWD"6OWKI/-.B0X!H8/XD5TI
MR*6!]NZ%!?M![,$"JQ@V,L-S#.O"@?2ZPJ7;J)B/KI>7!5ZDU?6F*JLD9^L*
MW8S2]S3LE/QX.ITJZ\VKA<7J5[A\=+U$0@/44L'L,+>P3]G#^+(/BE-/=BF[
M'5]V6:&7"6>YJW,N/5[WTXL,`O)/O/6)WKJR[G5C)^QB>,W*1*RZL/""KUQS
M]2D;EX*N\$,V]^R5@0JZ]A1L';H@:TL^*\M0T7G5$\D6%&=L"ZEZZ6\_[6O`
M>&?79YC%>Z?4:"#@FQY"IB$>N&5&>/!BF0^0B!(V+57^E>]7T]'=+PN\3.=I
M]>LP.-)'7#>X>KUZ,(CK6_$&O@Y<"Y^>G>JJ))A*'P*)\%5S;JQFU3R0L3;#
MLZN+]U>?K^ZO/MZABZ\?T-W]]>5__.7Z\X>/MW?_BC[^[V]7]_]`OWSX^.GJ
M\NK^D&"I78:W\.\0,-47"U0_""T42"?T9M"+4B2P)0]<'Y!98M39V=8&M.W>
MYD+>\&-!38%`O7L&!(!YSZ1X`;POJZU]I987'Q@V.[;:TE?^C+,I)[N/DIC7
M1AD$DA8NGC=VZTORY`7-]^0NR?#U\M.FVA3XEKPD&9.MWT&R_`8,,.?3R;&R
M=B94A4AKA<T-A+?;&PB98FPE2JB&&MW@^SS2):J%Q,`NL:.5L*Y0K3T&=H73
MY90^_!%D[=(6U<2#UX,3VCVK3NP0*SOOP_)9IE3GL2.1<?$'26)<,\-L$>$)
M-_ZR\D10[H)[P(VVK#P0GK+4;AB0K79A"V2J/4?[9ZD;4E&`IDGV2C0D//J^
M`6.KL_'YV03*5BH58C-6Z^+G4@;JNE8-+47(%K5RAJE[PB%`TO+E$%?BNI>(
MO5ZB1J4][$+\L'_Y310_K'&1DL7'''@YCC8R7L<#>H<PWX!%#PG]RMPL85_Z
M93JD7^ZJI*@">N;=`WY,\[S'-3%IOI?S^JC>I`'BT7WWFJR/3\'(?S0;GZG3
M.NTT&6K4:D1]H*5@Z1Y/74'49>\(;@$.:CV[Q6E\VZ+`Z@DK:?"H67!?DX)%
MYZ&R8,=RO*^VB,>)7TGND1;WOP9+>!^?GIRKC^!;*W/8Y$CU!#&!])(G@K3W
M4AR.M/2.)YZT]TX<JLQP6;X5ONP@!UO*[&Z6>*RI/ZCG^C'@:/)D>NYM*2'V
M0;^@:PK",YYX,M9Q04N:A!\J%-[QQ)-1#QU"5DP/E0PU9Q=]N-Z%"N?L^/Y%
MOK@D62:*PU!(-_>=JT[7V[T,W.,YG\TTPT-#V;&HC:O#<PWG;850TFADR&/"
M;"6/!3(;REO"7'9GXXXB:*L)-.%%&JZDJ$"&6U&2L_5A2`D*1^+BW("DTY,I
M`WT;=G+N9'(R49=*,!;^UGA'VFW+.]%28$R@!\U\D;;;4D_<G!</#AB$?71)
M+C8.#L@_FL06R)NPX<YD>G)JSSM1DUF\C76$S;:<$R5MQ01ND&P58;(MU<3+
M4W&S>Q"&426F0'WJS"P[@JZK)US<LO*Y&QVG]+X#8Y/SZ60TZV$3I<@X/"*%
M(9P4.9W6+S8%VPQG*Z!B!UZL$O&?$4HT>9DNL`S"`L]Q^DQ?8N%!B8@PY=$Z
M856M61T]]I$B?7RJV*N;$A^AATV%Z&.(_,B/T!P759+F;`6!/8EYY8=_+5%*
M3<@?4QH.*"E+3&D,U4JNDA>F@WB-=JY4R(H4N/[$DKJ2_&"ZXDQ$U;^CS9IJ
MEU=HB?DV%\GY$)KJ7E*+YT]':)5FN*S8U];)B[S(9I7DFR5]3#B#GZ]DMY^_
M'+77@=F/,XE0]G5#MA4QH6=;;S%AQ[.[7,/EUTT`L5%/K]YLM"?6H]<])VU1
M$<2%VMJ`I-K//L3"A\Y$>KU67E'2]QBP&OCYZ*R/+MM2XHZTA&33"N#<%#W*
M74RQ`[:0"*WZS4W1@]G%%(>!T<>?%?V3DU2_90&!VQGZQ,Q%$0\*YK@NRO(I
MF?/U;M4:#^@=<-WO4WWQ"(W(T##)^5A"E@VJI5L<XA%&ZHX->C32"D!VE@8[
M26@29L3"?X.BJVL%P_AY\"'<,]W-QTIQ`R$*,%F7ML'`%&^*#C8P(H;VYN(@
ME\7##LD?[W&Q^H`?*E6:A]&S0,R<3B=:S'2)"HP7*O(=#<,58D+A&0;2)@U6
M?-AD@9,[G*=TMGZ'YQL:=.@KJ>)6=-!&#0'X)RHHJEJ3%^V%J;I'@9`X'X^T
MQ4TZ),5$Q)'%S:G<)#TB7$VRZ3A@=@7$A3)RB+F3!D.%N#?3L&EW'P8BX_C\
M1%OEI%/6$-@`WI3*S#)'AYU9WO`1_YK4GAC28&3?51%14I:7)&?+]CB?I[A\
M__(U81EL=,S7_+BK:K?]!\!#KZF^GS&5'QIA98E:$I'0`M8!<5MU$`MEJQ7L
MH`8'PQTX`HFK3X?#9^\Z7.\+P")VQZ?GVKN4E/*BXLVN@HXP#@"XJ"MO<`MC
M(4R_XF;DM.$0I%UKTSX,G2&-SO6+!EVRXJ,&M,#&;0(`)MKJ&LBP6#A1KZKU
M^FD@?+Q<S.?%)LDNJLND*%[H#_^69'N),%;O@BN'=]9Y`XF./.232A@7$.^L
MWA;40`MD7>4+O,K393J721X/6?K(_\I..`Y3=144=DK8&?AT*!2*(6C/DD7O
M&^`5O>.NRF0&`N/B[*B9:L`6,+A]QH!SL<_#=,K(R#CXZ@PM-:I4CHN&I2_)
M?Y'B<E-69$7;0;-VH7X06F/_7'O+Q;Z<L("I1<$6'[@1:GBX&V%5M[C7DD`8
MT,0&,75*Q(AO9:'6N[2=:7B`-Z#).B>CKKI`!@+#@F%'<&O;'9+9)JW3@<.;
M=18HV3617;6P7O$2YO%RW"!Q1<!^LT],_<(Z(Y:R@(O5]?(J?\9EQ5.W+V6"
M.EY<E'=/I*C8$Z]:U^$+P'36V=G9J2J=%:9`G$S76B?$]UW($J5;M9K<?[Q`
M28E*IAE_SC0AECM#D1`;UAE09I%.8*)8!8B6.FBK#[HH$=>(/P?Q@2*3-JP/
MK/@'%@U\MRY6XJTE?HFSLP.0UE7^)2G^P!5;+.(),GSF?4_>X[8VETGYQ#J!
MYR1C+X%"R$D"M)S8Y$1YY:E?!0^`%-,<K1K%4=EHSDX\/>!7*)E3]?G5;%)_
M0^84'H4R9Q2/>F36JQQM%49;C5DMGO?X%?$RM5%+;X@CH?0;Q9%6]/PS76U6
M-/Y"Q>?@7.Y&6[U<[]RR+GT!;SRVOE*D#QM&2#>X^+A:9^0%XXL\WR3979(E
MQ0O]\9QQUF/GL567[\!X?3(='2O/9MFH$8N]!4KF+=78R5:$I7(HX=JQ"FA4
M/?8KJ9\A.PN_*-DYO%^@'"S\T58)4>&H5@H)K9!0"VWU@KA#R;'AW>'`I)/C
MT2]__+H3'4>M@&#<NA,L\?C1`>3$D^\CKGIQ17O6N3J>`:_N=A;:Z101!Y.P
MQ2MA@&[QRL$`!Q0-LCS5%0[$P!<./3@N'G%QD2\NYG1P4*8,4+)ZX&66I*M2
M?5X:^"HHKF>CD^E$>;F<H>1(73-7AA<W::G3%)@4"L%`(:U7]<9AK`>"/9C5
MJDXWC-4V#"%,3^Q-#]*[`M%([/WJP#9UD9([VC4G14JN<ZPAF-ZGH35`IR?*
M<L=J89%HI*G?4BN`J`;&93Z992J^\&89D"(Z+8)Q@K1,Q0G>++.A`;AY07#?
M#Q("<I='=-__(`!T[ST-G-G36%&6O%,+&PS=5`/3N3FWS!3=UI8YHYM*!M9D
M$9:9HMO:,C_H[C,O"KKW0:)$=Z>[XLU_T[Q__MOU#/@$UGG7NE6GB-"(R&WF
MO]P`S?S7Q0"KP.^W(M3\MS,<B($O7/HL_LE;ME]0T"%O4CZ]%S?H=5-2W]/`
M/NOX]$1YG9M:6*P^2T1"K8#8KGH/N'I1VJ?LN7S99X=39[N4_98ONQS@RVV2
M*O!TJU_^NLG0Z`A1"$Q1]520S>,3^NN&=G`GQ_RGI[_&Z]1Z441`OG2!/W5C
MD>A&J1T/P$!^?GJBV7)J?S\6KKE(P\&GT%X)80?MH:CEHH`#3*&]$J@.VMM@
M\^KV\N/MQ0"#R*X8)GU>B#=4I(/6%[&'_6F3+[J7G,T>!@\>M=7&NF4%CG,F
M4^:0("X5/J#4EAGS8Y1-^,,L"S7(U,</@3C*H=\ASTE>I7]<Y(OZKY_2GWCQ
M@;!JN*N'-.><?E.0QR+IGD0Y?P>$E>GY:#29*GLQ"S4B=792';Y3T?R#*X>8
M=JBE'I+Z&=YQ(CRBZADC>`1*+'!/P*A'>D35VT;PB`TK7?_MXNO]U7_<?T&_
M?/V/^]MWH]'9KWQSI_6;)5/TW8)Y:=[RTEIZJ7[Q_-?X?;L+`1!/3>/.@T[D
M%XCQ3B>SF3H%^$!IS@NS"<M[F.U0Z,PK@PG+>QCL(&AKQWQ!35#S0_*1/0E%
M9IY^>G'DD%/EM9.[`N(2A3D3=%8Y]Z"_)=S!>.XL8.Y!?X>QQF"H[('>@&L`
M7Y,5OE[NG%C6%ICH?1Y:2.QLVM7C]8J+=58>5$Q"6*->`O!FC=.A^?BE(_J#
MA@"=%!D?MWA-"E;*XC*I\",I7@PPTO,..-WX5+=BIA49%BM,-,MM;X2C6CJT
M%`NWL0\]GFRT0)"EH4$QU1=D>[@R<%\\;.&*;2S10>9SNL"+]R_?2KRXRC_1
MP6<^IRI>S*OTF1^J$H5D-O1GUVMY?9RJ?(N?CP)[L=.1MNRYFTZ!X8LKL6E9
M:X<>7M`O3$&4YK^B1D>T5?((;=5$6ST-^TCNJ]F!^*HB59(!:8`ZC!]U7+<<
MMFS<E#3ZQ20#/T%/0C3#&Z&3U_>J>PW+O4O;H55TIKK:\7YT>RLT@[[7&IN7
MZ9GJ:M0/XSZ;(3SSWS(C/TIQ96H7Z?S[FV&=/4QX8Y^N)AF:A<2Y<<^#&N!'
MH8.:Z;D%ZQCJ-"C;-#KZ&]0P7X$'-8%\Y3*H^653.ZD]O$D;AQW2\`8:_OT$
M8]$@;X18[(8WEA^'IY)KUP"]Z/96"`<\O!'N`P]O`KO/P_"FBW0.8'ACBPEO
M['.(PQNI75MU.\8Q^!"0728GG=E"]GH,RB2-7BTF@5,&]PF8,CSZQ`,]D,83
M!T4/)@'<3P6&KCY`V+O/:H`?!=+!>';6=6+;CTX'1PU.LQKA*_"L)I"O7&8U
M<E+3R1D'21F.\QB+)HA))5?YG*PPNR%`'5G[SP"7+R83_8YI6T1XW`I9Z!<F
M[5=T48DJ6KRL8D7035+@O#)<:^"&:3MO>\-LMD6I=:FT+F/60<S0DHN#&79<
MP=2':#\*U`K/N'@@-NV@,B`<GW7`E!AXP3Y_D'ZR83=^QPB[I6=)BA])L?CX
M<YT*:OL'3CIS"^%OPTK=S$:C,V6I&W/A<7(26<1L!PWBKIF62FBK$V)*F16.
M$1Y09"Z&\P"<D0-9KLAY#&>Y)65OAT*,-.@P::O/$<);^U\4]H=(E[1`)W'R
M;Q@:^D0*P7KWR4]H+'2]"SWV?'H^MJ&@MNAX!*2)0T3_K(<65?+3^.`TL]^"
M@%SL]TL_S&XY8*2Z0,RV8!\7L_USSZLV/P3FZ82D">^H/.N9=3X):>57P@9;
MV6;!9H`?\!(7!5Y0T1=EB;LO?/#P.7AU467=%0=MXM#5Q8IL1%5\H0A;42CI
M-S#*]X(:ER@G%?KR^?ZK&6])WT!X*XQO_%`9DA@H$=4.U>JQ:QIJ!1FU(:$B
MQ$$0A@OC(`O2LXR<0=D/R`-:0H0WA`M';K*$.E=]P*S[">`!L^/CF6:4U180
M:RPE9)H>,./Z*]G&17\H@0A9T`-F7'\E&;CH;S6H,3`B#'([0YGT.B+B<N^/
MB_F<T1\EA)N"Y/2O<UX:J[PA63I_$?^]QS^K]U2#/Y3K:7:?`>X.G8^G^MTA
MF!:AH?,#;=5!N_H<(:$+^B[_9$HAKI7YU<C3KO6,6,ZPP.$M9E=/J)T2=6W4
M,F")'P\[=*`D9WM*5SEM`%Q6'W^N<5YB69O\GMPE&3M'1%Z2C.TK=?*OU1>`
M'?!T=*Z\J`"F0*0.FN3O^&9D*K5BJVQ,+53("O8583?#\#-F1:V;:7?.O:'J
MSH-Z`\A9)!=[V+4V2*K3U/&G7KB37FAT@CA!-28(Z@2;,8,R'JB+LC1Y$%<2
M=P3'<L/O@"]LO-.Q917!/78;6AK`S,ECGOX3+T"F3Z*:?BY,S_$C^\XAQ4:0
M@:@=Y1/G-G#NY\177V[Q,\XWKT5^XNXTZ>QL/@/K\2:CZ52]MPC7(EJW)W)P
M1$BRH.6Z[06O':L)I^@[OI!.L>S]I$I(ZM1T?O>R\[M>(J$8M`\4_M"3?$A_
MN'2$?1%BW?7)(-'S?Q"O>.D$+J^^_+]7%__W__7S`O\O42%/%+05/WGE-9!'
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M)&<[)W]/JZ<T?[\ITQR7Y1U^9"#J;&+8JS"J&(].S]3Y`V:2(S$&5X;-IN:-
M.N@'UP<]2(50*30R)!!AO(I`PA@/Y!%A]/42;=5`0@]4*X*D)A";56P2QF8;
M4@&T=C1J`0*1V'O5`]'(FJ6EW+G%+`V45S.5/RC9)G7ZS(Y^:4/!XCNPLRK'
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M'[+T413&XL(^I`7U,IU`YXOKY3*=X^**_GB5I_3OXK$;]J-YNE`,7+U\$,;;
MH_.SL7(`ZZ1/',INJ2B)N%:2)[Y)-=%K/1&=R;#]<:ZI(4,+5RD8.JJK8.3<
M=M&W71==Z%QTPW\H-(1X2,'*43UD0<@^(BD6J?HA"N*[91RH=$7RZD63?]'Y
M`'`'=3H[40Y1=[X?B;J$2-,M4*Z]BGU<M`>RB1`%3(T0VJN8P45[&Z1_N?YZ
M_X^[Z!D/W3%,^KP0+;OP>C?W2E-N4_,D-!EWU)D9I!$4.+SW$@8_`TI4<FO4
M*8(>K+$)][V$0$C536Z2.J?8ATGP;&)>-J9=U%M1HCA0<J,N_(FQ;^+C^C-.
M2ER*,P!?Z#QSM5G=)"_\>/B'C2K]'O@V.!E?FT%L*#P6)P@MCNJC5E(15&N"
M/A@>IY%V&\#*K]W6B?OR7,Q*&IPQK=!:*C($\@R#L0N-YBX]-(1>;HIB?^G`
M[2/0(MEGYUUS8#L=#@BV1^@K*W=R_P-GS_0).A1[,J[LS%QBT.D'<8G%>(#&
MX/3P(/LZ+.'([?#@H0&8W4CXC%E1V=Z1-?A#\(ZW*RG$7H\#`?,10S-;YV:*
M\6+,ICCF'G'&L8-'[+!\?GA8[HI..)X5GCQ`3-/6\8/IUQ^"3Z9U-U?!]3@X
M3--/P3#-/.(#T[8>L</TV4%B>B\ZK3#=Y<G#P_0]E>JGH][_$KRGUI48M%#D
MT&#--8/VU;I*@Q%\8@?LTT,$=D>$VB"[VY<'".T?Q`^P7WT'?-W43'>)+5B-
M@P/U#P*"-/>'#TA;^L,.T+.#!/3KR+2"<X<?#PW,]T^XP,FRVMLS=OX.$,SC
M\8F'D?=6C8,"\U8M0RAS;SA#V=X;5E`>'Q\>E#OB$@[E;C\ZY&K48N\V#WPC
MH'-/7_40[*369'0Z4:>GO981*6^C04\IY1H>Q!+&J%(X7(VQI8!:'L0&52*'
MJPU.N]NEQI`@Z1S*$"<F_G`!X%/U1"H\?[HDQ9J(_6]-ZE3_X\!*VN/Q>*H&
MI5):+'C6"J"6!J9EL;EI2HAZ,PT*UBZ3H!=@<-.4R/5FFA6&P?:%`70_4`C,
M80X@+QZ3//TG_^Y%OKC;K%9)\7*]O$L?12)F7K5*_;.R_BDN/Z<YOJKPJO-H
MD)\OP@;&Y^<G(V6!*S>%(K%)2T>>!UP*+?DAH:V>=5D`U@^MI:9FE"-=I**<
MJ"X"LE+;-2R37&K'CP&U7-.^7$-JB+XS'1%7TK#\GG"3BKZBNLF&X0+Z*@@5
M^N$*XKU](A/JO:KJCOO78,GKQ]/CT9E7(KV/5X$G.(E*]_@D42OW1"10KI]A
M]KWPCD_NM/).;-Y4N^A@*/.^LT:/GR:)MUC;4O>2Y"55:%'K?D,;M^:+Z^6G
M-$_R>9ID=^PN2[Y`U5.YV.NW@=6-9\?CKA,W7E6+QS!':$=)SL-M-1D9-XJB
MK:;P0LG<;YKEWR'\YL@]@9P7:G79*VA(P*9[&QSU(2WG&2DW!69LK"7AGELI
MAU(#?*OE63#FL[#B#9#DUBK^3O_8Q.)RS;-@K!JA35P'?TEK\$=Z!W]OA6Q=
M(.V+EQT;W\^,7'^IK^GCP,7)R61R8C*G=KR7UGW2;+J4R`TRF`5'O75X!\;U
M'<-@_A.V&<QAXU\BW)8^Q&Q3<S$PQ#OQQF+5$RXNRA)79<^)-N6#P/2<L]GH
M5#>>V9,3&!%,'A("Z8A#B#3,K>&F:(8!SJ;8`(#;,Q?R4,*EQ^R!U6%"3#TS
M1/!_I::9QO_^LW`(="V0:D7%1,%6JCD0NM8TO1IDC84A,=`1*MTPZ/9+7"2P
MTFP%?L)YF3YC42?A$RDP'84*D-*^JDCR,IG+T2S_5R;&MHO_VI05&UA]Q=7U
M\C[Y><-J>-)?5%61/FPJMB!Z3YB5)*^H(S->BD%<&*R+FJ%U@B)[=*(MH3"D
M23$89,>VW;(M1TA:B6HS4<M./J=L68JVIK+CX!6;9U)SCY`T&+4M9H62=VUN
M;J@W)3#>;OMWS+ZMAG.ZL);Z>"D;:%XW4-5J$%&I!CTF:8R!]4$X7LG9AQ`)
M@_<-#-6U#4#8=+T*SO+7GZ\UD#PX(6YYS3B97W^$-H#1]E.0'<M%N:M_`Y6[
MXM9JZO*$L!9>E$=MK:1,?J<N:^>JNYTC,V<G]@P(3N76@^*A3BZ]2=BXNF]S
MV^_7X9L\O8LB[LH=$.&I!W)"9?A.-W>A&S<&<*%7^I2$$O/N8-^P`!(-L$7B
M<M'G-'E(,U[TW&#M5/TT<.0S.AUI:Q!T"XN!_994Z%(J-ZH'O>Y&.:^G9EL5
M8H-0$S^O0:5WU&`@:6UN&O3%1B\"N]G)Y+AK3\Y<;F04M5,9P!TB-]8<4N[&
M6J/+RN)(6-/$G@9V>F<.AD"S70[M"^"".2>]6QV=\J+W5^!-#VZ:.;X&V/G(
M2/[XCKZ].I!^RV`WI-=A<;'#=$C*)S$P_?B3W5RCK,W<]SRX)LV)MB:-2EP,
MX$BYS?1.BC9=V!&F]:RV.]GFLA(N3,Q)_H[;6&U7<J-C1QM.KZ'3Y[#HR&EN
M5X7`1_\2%$/'Q[W;<4J9D8"TO8/6%DW,R)Y^R)N1%GU1O7G!M_@(-[M>SL#2
M4KY$.@"X>H*M`V']7G3(P60R;I*BRG&A*2&A?`I6SF5Z=GIZKLRXW!,2*=&2
MR34LX2(,4&58.AM@`V<I$%8-0AJB2J=T-L1Z^!B]YH,ZLHF1-^RAQSZ9)MDM
MEO<H7"]OR4N252]W289O"C+'>-%9R`'T(K1>P^A866_)2&X<S$I54*,+6^*7
MVB"F#JKU,:TNP.Q6X#J(W3"H![)W?S@<P&"7<7%S10._[.<K_J-*"K9A<WMS
M%8LA8&@CMBYTX1$NX1,I;G&Z>MA0YA42+TE9*0C$Y`U8UWY\>GQZJF8.G<!8
ME"&`LTH6?,_O??)"^QMVN^Z<*L'P=//$;K4Y07/ZP71.T585M`D-1P;"?B6#
M^+0?2AW";G8)\XYT=H:>RX<8J!@Q^#708O1@V[KQ6,0(<@3L3Q^\T4H<,^`,
MU=.P(G(GL].Q`5^\%A:7*QAFV@FCYG"1]O7R@:M]]ES@9%<O#;C:94$!LH9M
MP?M9MJW36D7C+!!C*<T4*_M`UWG,&>1?*"U2&5_2#)<5R?%74EW,GU+\C!>L
MR/-UWEGD"/PR;,@P&\W&RII&QK+C,@+3A\.GT0A1E5"M$Z]XCJA69GVJ\(">
M)/Q[P(XS0EBNIQ'_EKL.+-AX8M68GQ-6LDJ:_\+,)]WF!^08`#:)BW=#,]#]
M#V(?":V788.0R61VK"Q/:2S[`!F(:F76G0L/.#&0A0<",A#0<B<&LK`\-`-5
MW>8/QT!M;,(8Z)5WHVTEUFM.U\L/^*&Z*LM-0AW1-3$"O`%-83D_TR6-:01&
M@6+))M1,-*IE`Z80TCKU[J%'ZRS@=H?SE(*LQ',ZFU@PB-&I1%J;&6L>`0DM
M`G;=`%BZJ\C\#QB8U*]`LY=GAFC:EQ@/3ERV'9ZX?29X<K?/`E"?\6.2';6+
MNRXQ2WY;IEG]C]8V/5DN<<%^+O?IAP&;)O0ZT:9W;'2XW9.+^7]OT@)?/"=I
MQDXPT'Z6[3S<,5;CF6X]L0+X`AR,ND.4``4B8;,B2*J"&EW>T7'8NY+MNVW5
M,0?K5)>(%L(!3EMP].=LZ9R35)H_8W&2>`A<0H*R`Z9`CPZ'VIN"I?Q4+S<9
M*\.6+S[2GZY7Z@QJ^`?@>:&ZXS_F\N-#ME;E"'%ECGA7T^ACGCPZ`6'6W0'>
M(+MN'+#.>)%U:C_6V1\+Q/U!JL.PD8<=5JVHW\N7DG[X2TJ=7"3JY+B>1V%U
M_L_'Q^J[E122(JT_">&\"KL4;UB<7]BD6F/R8Q.0*/9M@>7/29M4JT=^;+)9
M*_KX^\7=/^XXR+]<W5Y^O+V(GE+7AP=B[B5G_/:BU@6KX_%XHMZ_:G\_*D(-
M42FTUZ,R)A9A^!/:Z_$7'74#(4V/+[^HH@Z@8?F(+S&?O5_GM_3?5_F\4%T$
M:O@*;.?XC+I)@SRMQ%A8K)5`<Z$%(CGBY[E3J8AA8IFP58E3K[9"D=O8**6C
MZQPQ^:A6`&*B$LQ>3;2!=W];EFQ>D6^2+*/C['FR3JLD0U%O(S7%&8&[U0=?
M7"]E.?'R%E,G/K/9]^6FK,B*MH<J_03\-FSW=W1^KAMKFPJ/3BAT4B<74TL:
MA;5*:%[KQ-(0#.\[%2[H)1??+K#FF>ME7>V_1%M54*.+<0**M+R7<WQ;[D8_
M)BT?GW",T;G//1#W!J>A>_H1%R+:>1\VE1B=C49C1RKBX@^/C"JFEN&<1+C!
MC8ZLW!".D+@Z$.O=*,G*^L"D5*E<,"`M[6(52$Q[3@Y/38KT./#;L'G6*8U(
MY7E=<^$'2$H_B.'T2[C`D9*"9\A!",DP04Y:[DA'<3+D8"U_:%34E2%GY5Y/
M-+1BXFYQDJ7_Q(MO:Y)_RZITE53X#E=5ACLV(IV^`:.D\_/)Q&RD9*#"(,3$
M]:+!*11#&ZH9VDC54-GH9LA/PA\F_!3`'TXL)?Q0*X281JA6"6UU@KC!A*P"
MN,&"LKZD>;K:K-#:*C8&83`(I#MY#.AY/VQV0\KJ8KTNR#.[\VZS>.'96?>$
MG\SN"Q:CEV&+3J?3DY'ZW*.I["&(:\T.TB92(U0RE40Z+$NW*)A6AHM.P@4&
ME.75!=9<Q<X.,]-K31!7121H\EH$3!N(Y08LY=5RYQ%5?\L/04AFX.QB(F/O
M>J*@=JI*DZ?R%5=7N;B(J3<:3#\`&TJ=3`T7G7KE1Z<C.GZHE1)Y7=N4+E[P
M_2J7%XN9C1Z$)TP8R;<G7$90_CU@PDR^/>#,3NRFBP="_D`4S1O<3GF+GNOF
M@-Q.GH+XVA-7R=3!FR*=8YG7WAL2FG=@C$3_.#;:D>L2.<B82.I!0XXJPGY2
M,E4,YV["7!/:\6"N$]/49G(%V$^X"A`K3:C%@Y7N8YWN%AV$/'2XZN2+'@<Z
M4<22%"MVNJ4YKEFGY.IR[$S?@M'$Y'QTKDO_Z1$:C2AJ/5H'EFM-#!E"6*IF
M",^6@CE"8R&P(*6P5,T2GBVUXXE:B7</%&4+J-&!^,(48L3*F0Z<L4S_J2LJ
MV_5[V%K*[/A\<J+D@=;G(R&>2X3%O;1!A7`'&X!8MM==A5D'W6W0R<4=L<S#
MW^*CL"N428\C')!%*AJ<:9)]P,\X(WQ6T$"Y>S7!Z`W@4971Z%R].:P5&`F/
MM0YHL55B6SW#-%%>V*E"J%<[@9AM[&L)WW9*9C-_:9X*Q%[-LX%U8^-2E'=+
M%HN410']R;HI#DL*11-'(P`S?!&P6SV0Q"U>;'A9N:M<E,B3E6BW1^KXNN?K
M1='],^*^/PM<K3S6#?K=M8K-28VF;*E.UBZL*SHWP\E[N;W0L0-A>N)<.JZ/
MO^(YSI;D(CNLCQ'C.<QF>SGY*;:7&^\5C??2?%LC,SH_>F"-/1+UTQ(^F%;(
M;?2YSK^5K+Z`2H.7J^4MYJ>9%_I0<_\N;&AW>GI\HEZ']:!6;+(M)$]L4<"2
M3>X0*^&QW<7D&YWO7FUTIDOZ2Z&UV8!*.*^7;^,YSYIPI=-N7SGMKG::BFFY
MTVXMG-;+N?&<YC16W2';;[_=_;8-0);(P\:K17TS0'P*]L`F^QSLIV7BU5RA
MW\(%E<X7R6^2XKJXJUBEC;^Q3<0;7-P])87JWC#8R\!:*\?GIUTWD<!D!Z:(
M6@>Q#73$[B!"-*:%(HAK@J@JB.MB6&.%VZTI8A;$;AN4-\:7PO@U-9YO/<<L
MI@*+0.+B1X>!T8XL_N$/N$P?<R:OD^A-7@">K)H<3R?*H8Q.7J0QRNMP*ID6
M)5HT>IB>G>*&JH8=/@UU(@O!"6@K'6*=:GS@TSH?E+#7AM$Z>2,`$:C?!NJ6
MN4;EQ:9Z(@7+&3;J&E0OP;KAT_.3B;;DF59FY.Y7B$=;^8:WM7,;3;M<5QL]
MXBK1&AJERU5&F;*KU?EO4'RQLJ4@;.V^`![>GAT#<27D#8,I(=MX"$MM@^')
MSC:/6$J5!D;$T:N(ZL'0OL\&Q<_UIBJK)%^D^2.@X3O>`O90L^XK*PV%#@.G
ME@*&?12W$H8I!RL]`HOH38V(KJY0ZX&8PH4#X8Q/38T"8.=)8,\T'G7.GS2"
M(F.(RSR"=4G<*%/X6!GE`S+_X_BWX^/CT78IY7^AT?$1_='^B.\(Y61_?G4D
M^S&V"M4"'DHJ.M.<\]0;=#(Z0BS<^*D`^I>3(T0_LL;S*GW&68PC3"8QJP3F
M7N-$!&.:S]-UAEM7U-WB9YQOV'1Q7J1KON*[O,5K4K`"_Y>T21Y)\7+Q,U76
MF??Q36"'.1J-NO;!O:@4F@JX:DFV<VNC5.X(M=3C]T+7"J):0_2=Z6B6U2?]
MI..,B'ZR8I=@S@K&!S[`0`(T44R.(<4-IO]=W.)YEI1ENDSG?"GU8O%?&W'G
M0$MW=6Q:?08\B3WONC3-5HNPY/%:A2-T0[)T3N-<_GF/?U;H/37^#T.&$/9K
M&2*H_1:D\%J/J-=7V`8E\>/2B"`6]]I_HN;7E^&P*ZM7*Y)WG20$OP>$Z>GH
M3-_A]X@-W:D+\8A%R_;B)\)N96<J`,[825-UB/1LJE6_W+:77YY#;9T+6V,=
MLH.''+'THLNV:8^8K[BZ7NKN4G/]#.P8SG@VFJD/`L"UB+7Q*L/QTP[\KG?A
MQ\_2TY]9W,LF_:+<D0WN%TLZ"NP/Y1YN<']8<%:;E=M,=<2K#K`+L6)?#.D,
M;>+'X0,/*N[$]9SLEDM0E]?Q'G!0<3;2WU_7)W:H0854@5_;:CBHX*9"!Q4.
MICH/*M*6O67'/:X-;/_'Y+<I.R:4R56`X>YW-8[2WG&(PO%#`Y4OU7[+%[BX
MREFE@O097^0+_N/W[!0U91QVT2?OO%FA$_6*H=_/@^<2Y_I]:S_:#<8.8D5]
MPU1%C:Y\J9S_2IYX;^O+RPY12'W\.<\V?+5=C!"NU\H)MLJO8(X)[E?W^4U[
M>UWZE24\5ZQT6LN)[%*^`R`<>QCU\Y)38PU"7U^22EX(>M/DZ;.+RBZ3+"NO
ME_!;=7U^&SI>F1D3E[5J,5EKJ^01:JG)J8HKRNC,QT6]W'%FS!3-<59'`6O=
M!KS`UVO\*QC'2R,,0C=,'4=6,?T$G#RZ*K7::!"3(^[DXJ(G&N@JV1K#!19H
M%V?S#@+HQB&IP#/$FWX66X7$YDQ;^S"QJAH"^&W@!1S'QZ<CDZ55O?#(*ZH[
M"_S;(^BR@D=S^-ST!@[N`X-E5+\^<%D]Y?S#ZB8VMN_4*S"N1"!,-U@Q]6NZ
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M:DV15!5)79%0EC_-U46-OD:`E3Y3CZ/C^@Q,6`/X2CW:CNLK.P;LN)<%);7#
M*NFPN718)AS&GB;<84N=PP*-TCTQ"0G13C%'+-N;:'94?RBK(IEKDK#,W@./
M\2?Z`Q@]8N,0PY&\F2G9X8?OM1+F@_^)_K2%9V,=D&UC<;A1CF'H$4M?#H^^
M]R_W5`?]M-KT37#U@1-]]8%>P0-B\`@Q)6!3<&ZP!0KM#?:-PUZK8R.Q(PA-
ML-CMT>'1^"$MYQDI-P5F)^KX@3IHL&@^`:Y?==JS"F:LP9"=Y58=]!U\3E$X
MP0*S'IS@&[R'@%===)H`M\>MPR/X8RDNI%Y\*_%RDWU.GW7)-_!OP#'<LTYG
MKL*@O6VC$!(:(:Z2.8A[EO3"><'?)!<W+M@(%V0J%\1&M39@36#=Y^CA<?TY
MS?%5A5=@,.^]"$/P['QZW'6OL+G<02>J3`O$U3#L<(6]%EBUMM?_7+7'Z-CH
MW(]`$TAV^G-X''[%X(6BUBO`7:[I;&PU0Z42!^TLJ7S#S2YNH07:+"STUA'R
M(W@0^V9Q["-LQ=7.OG73BO96CN(TXS,N'H@]84(LC4V4;:(PH<A7WAN>'$4U
M'NNE`\7KX&6]SMM(H=(')5#7\D;""1:`='2"!<=^)OGC.S;@7J"+LL2Q<_UA
MD6B"2HT+AT>H-38=4<FR6KH*B9C+'70:<<^.;UA4&>-66\#P_ZS9:4//!(:'
M"D"J05^FG.F;P(YQ,NDI^=<K^`#VNT"Y=,)D&_Q9FQQJQVN0'#OC0#0"9*=/
MW?/N]@35:WA+=D:?UQPN%3D>SM\!(7`R.SL[T549`ZL1.:&NJVML5L.7HM2&
M4!":(2)=TY-$%](UEGESP5W2DRL7TB4N"R;>_!(R)<X*\:^SX&Q;P('XJ/.?
MDI)7($DR?/%88,P$?^%%XCNCQ>@-&)E-3\?GZEOIM`(CT9;4@<<:/RF5U&H8
MWD<G3%21DE<3@?13F\82<?EYN$8\^BX4,"098:**9+R::$,G[29\9>>/M'I"
MMS=76H.#L(<9F`C8B?$F)U(E5BDQY046;C$;EZ7YXQ?ZW]5F=;$BF[P2O]^_
MZ-+Y.\"U@Y/CB;:$!U2-2.#<ZG.$&HV05`D)G5"CE.&*`O>%9D83VA<N*)XW
M2I6HP!E/):@(_7'.>T>T2O+-DOYE4U!UC]"<?CZ=)QE:X&><$9EI3YE@3OM=
M:I/,J$_9)F',>9%UU!-/[12=**X?LO0QT5U:H'P0"/7)V;&VWOF>G$A8W@HT
MQ"DWI!^G]H98`'$KK`V_=6TC66[WQ`;`4T?L=`"FVV'1$/&_-TE!/9^]R,,L
M27:5+TFQXAIMDP-[SI18?@5\PN14E[D#5"(LT!IE4*,-:JFSDT0+/WQRJLOH
M">P'"YQZ<T8@Q-J&+_'B],/`>M]&&NQE\!;W3%?`VTSVL("V2(7G5EOB..:&
MVAW.\)QUKET^^)!4R:%`5;NQ!G=G-&#>4F_KCHSM_1Z<\CK699`TGP]\Z143
M`SK@)117(\1:<9O;JGJT#Q3O^TU/>NR/&[6=:[2:)Z#'+2;:9.V6@"BQ"]NL
MY<KW1&^TI<=^"T)&\/Y:8H\7['<3;G&2?2PK.AM\=8;_$RFP'(;QRN?TWS^2
M8M&L9]8+F>5GQ=&$4)^'5?V;S";'ROJC'K6+LZG!%$9"X_TJ'2VE$=<:2;71
M=L.@41Q^-D*Z4K$?,J`K@=PTO`L5^RT#NM#J/LIH?@RQC1."F$C8AG0A^05>
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MI<]I\I!F71<2P5\$#EC/)B?':LHTD!N+%VM54*,+DLJ@EC:&`R=NM9+S`E@-
M)3;_UBI)*X"U-L<MI;27=@H(G93B=%T)KFI<LFI<(J\BB\=+$!P26P^[,(ST
M""6N?+%_C\&KZPOX-=3W19*7R9RA47G?O<_OPE9)CX]/SY1'4WRH%8N^I*9\
MP)$O4/?5(7L7AL@KX5M*`VZ%E\Y3TEQ\YT%9<#BG*=DROM,LR/27K>O(\E<Z
MH#.Y0:I]@_>D?8-WU7(DO\0;I3FBY#..Q[L>Z8<$:LIX^[7-#9S72U:DX!X7
MJW9=ZVTFHC(/`?X%8+KL>#36G:H'*!")8OC%CKSD`X7;:K>N?"O)UO1F2V'_
M)*H#SH4#<OS(AD_`>6'#%KL5XA'1FQYJK]DB0(FS=P=!\-WF@12+-&=M]@$_
MJ#)S35Z!GEZ9S+0Y&1J),4'9EHV8<-,#*=P\,PA:V^>"N78?S<Z:/..B2MG\
MIFQ;'&OA!11H"JSIW!@37*2HV'3K=TP>BV3]Q,[J7)+5FDZ\J)KZ3"?0R\`D
MJ/&9MLZ%F>S@T),ZH+82:*L%[!RG-%J3/!7$:*NL`2?+PZ$1$H_$Q;$NRPXE
MIN\]T7'TA^V1N(\_USA?I&P4?5E@^A?%T@+L71#FIN/9:'JB7CXP$QUKB4!H
MPV>Z+7U02R$D-3+"GC1>.?T/8SR4;\(8K9R^AS':BF_8W6]RAKTN4E*@-:9_
M+-@15.D4=J:T?<84,T7+F/LP0&P2!S]''"`HE2NQLILR>`=<1+=SW]5(9"14
M)EVH++%Q]=7.O=(@!EHAL!MF$.LTM66]FF=57%9E8$P>@0&(6+CO,'A#%->T
M"87=-Z$'[L8CW;%T`\'#,HF/BK+,!98PM'.!*]<8,NH02'P5C*9XW/>C[\F$
MNH:4R?.P/<>SD]F9)B="+2[R1.$5K9L5CY+6@68%<58>%#,!T'J#M`XT_(^X
MQ*`@@=B5HHP@HQ_+#U@EBBI4%2D[R'R9E$PM]@>K<O><9&QE0]T1&+T&',7/
M1F>ZJS#ZI`8'E93.LAY%X/&_M#0P'.YR.[7=K%<[[>!5&SNGPN-VJ6:A1>P<
M=C#0NJ@NDZ)X2?-'7C_2,A847P%/GZ<]0U^($L/C\`A=;HH",O^<]HQ[0]K_
MI\*G*B`!<-6X<SCT7N7/]$=\<^XK]9((+]-XT;X,Q.KY>`+":J?L^!!MJ7&$
MMHH8`I0;#0"H%Z/?-B[U,:>#8Z_SG":D4M9=1>9_?,O3JKS>5&5%0X3B73'1
M,'D%-BT=G4W.QYIIJ4YBM)EI'4E<"\350"T]S"9QPE+U%-6GI=8LX<%"]335
MIX5NE-`VD^C-##15-4(2@?MN@'YYJ]/MW;>>1!2#=X"+Q:/Q2)_PI1$Y"*Q^
MH>++7Z$9)]Q,DW[7@YG^L#5(<HE)C'7VNCVNBP@M5G`9+SXF!2M17%[,:;^U
MR40"VC*=I^KAKNF+X)K@8WV25Y_<T$@3\E&M`/JEI0*2.OQJ7/1[K$_N\FVL
M!=[:YBV$U*@8,XXS8NNXP=#6TX/I'@97/CS33R"[9,5&$JR?$C:9@R=:!]7!
M!\/T3MKXT:!ET/[H&><;?(OGY)'VCG3RU)SY_(*K)[+8?>"?RBLL[#\$/JDS
MTI7LA>L1&G5<'&HI=-0Z(RUT8M=:[#SV3^-K++@[=*`,[0X+P+:W$INST25*
MYD\I_4VGY<$P:QVUQ)>3!\2ZV373QN]!CQ><]^03]H@=`+C.R3_<9@A<X]\C
MW6'XH(@TN$(:Y+;8>%/O[^_^&GK!R\FIMK:V_'H4D)CNR7.=>Z,_QM[[/6%'
M1@LA$*+]S+_V3!7/VH<%IR(_8-]\AST,,G_JKO&M^C6P\AJ[KT^Y-[']>J1]
M"";0\"Y%H;EJK\%><R#PF2#@%8E"<]4>@KWF-GU<K_I!]@8ZHI;H[7=!$"L$
M\=)4PF4E&.EDD_Y-GIW_@,MYD:X[+B.S?A^&P=%L--5@T%Q\+)!RC;:7G_+[
M]H1.=6$GM-AJ98AGX04EGL-Y`0IX8?WVWM"M+DVEKY8V$..5E!#.>"O.@+5_
M/%:Q`"IQ]'&\0;104(XN5$.OSH>@&R'G(^UT=$=&'+#=@L:GW`#-Z-K)``?`
M##!.[8X'8N(,YQY7?O,B7[#$GJ1\VOTY*]ATF:[^F2;TB2\I=5V1:-C/X6NP
MD^<G,U;X0-\;6R@3MV^NUR[8F0RJXCNF(WK]2UZ,3>C)'Y2:FAW7%F[2=]<1
MW.3$)\'=H^_0([C'@JT:?S3UY43U.59CCE6@BW>(W1WXQ*O#[1F1%:8K6[?=
M?=9=<-3[,&QV<38Y.U/65E?*BD-77/SN+8Z?@1?@2/L41.3-/AC/^+-+P2#>
M[+*YC1)L7`AVZ$<)@?@JVCB>:R,)YW="%JP^I6*@JGL4O%E\K#OLUB4I!D*D
MR"/$A1ZQ`K#&V[W'NE-M/@RRJ=)?$%8<)EH_:10IQ-PM@Z"`ZM!SNWG/TT`L
MC&CO;(B%EK`H^T<<`>#[R(5%9F!PL,A^"_7?!X)"5ZPHT*#PRU"`T";H:9\%
MYQZ,NFH*:$5%[1DX(("5"YE-QG"(F#\NYI4#I.3I(T8-B0$3\N[F3WBQ8?6\
MV4&QUX<V\\7=$RDJ5A^X=8#LGE5-[,OB\?=A(-0FTW/=NJJ[7F%QR30ZVCO\
M_/JX)?K.=;+(".+NT:`VNGLL(-YU`)75W/^2%']@4:/T#L\W12K*]E_E\VS#
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MSK'9TDH?\W29SA.>SM<F4P-_#4(<=K'>21K6C3$`87Q<+O&<#8H:=KM-*G[>
M)9]3??F($L@:]I\$SZ'&9NL_<(WB\4>C6WN8P=1#N_JYS('&9NM`X=UDP20M
MKVR'&K?;BW%%7NF&K?E<KW$1_8(V+W'?22-NS3$$EZS6&7G!^`X7SW1J>O>4
M%/A]4N(%ZP'HB(EK?)%Q?-._72^WQU9O^(4?_"9);E)_K/J7!2XX?V:V@N-1
MU8BT))5&4FO$U7[WP/1&;<6/T%9U]N)6>22T%S?.2OHR+V5_9K9N,Z!S;89%
M`WDX//<%@&,W*89I[[?+EN;#LC#RP-OC)V;3/<_JOGGFM"H)<&(V>QS8US9$
MRJJNO7N_Y],!;A$)C["01'@H0T<ZB*]>_IXNL-RS>/_R)?DO4EQNRHJ.?8OR
M_8NXQI&.\^_PXW8GLS^V7;\,7L_2%F/WH%@\*JL3;!Y>$%<--;H=L9\UZJ%:
M/^`HC_O*B*!B^<IQ3.?58>'YRAD:W<SDH[$&X*!/&W8?XY<T3U>;%;\=79Y4
M+3]1Y5N7ID.7T5T_#-Z`,TPML-4K'@$)#9%4$7%EZC/A)=]PDFJ*7[DD2YDF
M"L1RF@43O?*6QD^#T(TS##K9QD=[#$TVM^R<5];26ZYDYH_N?&/W;?"@9Z8]
M#>-#M<%81ZBY"Z=&4V?BX:X#$T]8U[ES3P=3OW;9\!QD"8U^&K)OG0&8B.6&
MYA3E+_+2)2#9F+T.KL]O.(G22X]'&8T>S=U5]HS`C3=A!+_&6^W-204&P;)A
MY'7"U=QU#F?4&VDMU+]JU/X'8;4VCL^.)^JSZ5UR(IU+K[%RO=SM,<U`(>U2
MG4GW89<E]IWL49U%]V&/RTJ&D5%!SJ!KD4!,_>,%LS)AYT7F&MP3=I3K>GE#
M*AK]:9*)'O^VKNFA[3:#?!MV9]9D1"TU8`8GU>*02:,C*K9Y(.R$..N)U[6B
M:"F&I$W5%<-;H86C^JDFJJ,<V*EQ5ITT<T\04Y7]LE&VGO,TZB(Q>OD.';Y(
M]_4S6U3WV9#A9K5*BA<64OLNI/&F=MT`9.F'3SKXU5LK#3"QN2D(G795+S>T
M7:N+?,'.QO&K`<PVCLQ>!V]_GYJE+.JEAZ6/6O81XM)Y>FXC'[C%PPTVF<SX
M-=BNU(B=U<$G.H:1V#G1,7?K``C]WYNDH"V5O7Q*\R2?4SYI514"KD-8?`N\
MR'ENEKH"4"7>"D6C%&JTVBTY9;^`>6Z691+0+19P[_+'AZ3JK$88'.$VP=L)
M=TL?#X#]5HG`CS^IRGF2-1O$%U55I`\;/N#X1`J</N:79)/3'^+R_<OOF#P6
MR?HIG5\4.#%GB&`2P6.`SO)Z$12.GSG""UW6RF^S(=!6?3:6E@:@Q@*6++&U
M`3$C7-+@.LO^':"_'6K@[#ML$"(+A[%.N@O:8@.0HDR':=)C6N3]_D7^TFSV
M`OX2.,EDJJWY!E<D'CE)J:UTK)92/%&K?@(VU^$^,2&:8#YQ3%_SXIC@'`,/
M[4[NL&J$(3BA.[.W5>*"JML\(S>=+WXDQ<*0*?Q\'[S#>VJ6,>*H7D164:3Y
M[Q:^81AJ/5C?;\(5!M(-=Z$1W<1UH2L)!?5C>';R!*=NSO+7D@?#9/PHQS6_
M!Z:\8.==T^H%N/;C^F$X=YEEI]CJ-3QI'2&N)9)J'J%:49>TEE.SM)987K,]
M=B2=LG7)MWR!"[Y63/]Q1;DBY^?YV9+K,%ENSG@`D`^L789@':;@^Y?++"D-
MCPPIWP#7Q3[17:2J$1B1`'A$T]Z4"X>-0(2!1I!V-=!U3&%L97AL*H.K&W0Z
MSPV`IF]YT9PCO$]^RAI8Y<>?LO#JQ8JML90WN*B2-*<_N"<??R:K-.>/W^)J
M4^3E+<FR3Z1HQB7F/7T<\7"<F\UEPFH?CS3:=O#*++4E1ZBQ!4ECT-8:MM1;
MVR/*W`B+$#,)29NL!QBB&4S8Z+":P8+:E/X?A-$B8;*3'N,UI4-.85.@6F;1
M4#)/5Z7Z#FJC%V#9?R<S^C]E]I].7J3\X$:%)J=OSI4P3-H3]JF2]GS:!V3-
MK5UU[I@0#KN"0=JGRJKS:9_-2,O*R"`I<4;((5"_Q1MGB67G[>94DGT@*\I<
MJCZM[WEH3:MN%/6*"PNBMCST74@T+B35C1OO%EG`QMBL4#UX;_`0H*-BXZ39
MN^F[[JKG<2!*SJ<3[?J?0EKHGN;UWAWTUBMA5R]6G.VRZF%@QH5%C#J.]@&C
M]=9@>/F0EO.,E)NB?^IM_B9T%?WD>`Q`48?@V(#:J@`_%R'M-4>7!WM]`&U`
M=.E"30.T'L=%Q%R>DN(SH7-.7*R^D@J_OIS8X$GH2M3L^%2+J3U!H3'$!"(N
MZ8A=^#(7QVU-5W28.3K(.)MC!1%N4\DF#W2FDS.Q$'M&00UZQL4#\6'2$4K+
M<H,740E`C0-B[*7(`.\'M@N@QZ-C;:[P5D`\()M?**Q-N[57W1ZT=S+"N5@T
M3XKBA77L"5\EC![I/1%^$)&MOS=5]1QXV6&BO3+HM9AXL0Z]*95;8A3TT5;G
M1N/_B3K#_\,&H[]NLA=$H^!TD$M4E>'3C06KA3GEHCS[K'3(!_R@NC';[&%0
MO$\F9Z.3J7HQ7B$KUD+\3J0P!:`+"=(^Y6*\)_NL0.W!+N4BO">[W'LW`^/"
M++[WH81`?!6QMV-'0BYN"GEM#T^YZ.GW>M\`7V6C3X=6"PP-&WX<ZP(UHF4N
M#:Q?%/;I^D5O]EG!Q\+(8'UB?V@1L.-<^DDZHTRHVC*96-0._T2*NO[XZ[D/
M\"U8SWEZS"Y$4_:<?4)C=:%2#[266>EK4<Z?54'$M2YF&]O28F5?ZMMB*#O4
MEM;Y]_+B`JI"<P^"V7Q1&JKL7'T;:D43)NT:K[<UAABQ\F((SOA)NWR6&PTD
MC;W78$7Q1F>3L;HH7K_40Z"-1ADSWI`V@WG#VF:?Q-$H`3$5S!S6IGJG#JV]
M<;EC'VG]Y-'IR'BC]\Y3":IQIO9AX-KLV>E4F][?*2LPKA3'>0R7;+E%FE&Z
M%XLLX'-/6`'NDM_Y(XR;]Q@7:G2NCQ\"\95#_]IW"E!U")#_A^*UF*<E%@#^
MDOQD%:O_@9.BNU,.+`N$N=GH9'QRK.S)`ZD:J?MGJJ']Z$;)U@!V@J5L/5=W
M)@E/G!?_Q=*.NH=9"4O0"S/%;/`@W:P:/!R(FRV8$75<&-92'+V7AXKE<[N'
MBL5_:_WK`8NT`'$3(-Y5C5<.Q+L6+%V[@KZZ8J=$.%\C(HX&H@T_)(G%(<FT
M.22YCG1(,@Z9D8BM./`(R]286];D95K5%]4)HV!##$^RH/7^SB?:!+40J@XS
M/-PA05UEA2/)@HWVS2670G_3DH',L]!Q9F3/VJTC<U^TYG:['/A(+:CBIM0$
MQ5/O>-=CFPTU7/X;+EE688S1<J\HV++7]/PLU&!9J6G,L;+[8$Z:83^6DSX.
M,E+VYN-A!LJ^?!MDG.S-M_]GF&S!8GY&R49M>/B#9%$VYBHOJX(S87E=/>'B
M_BG)95&5W]F@H;S*A:&^ATR6XJ'5(D^/M5>21M+^X$?730VAQB#$+4(5-6E;
MC$E81>D!-NSFK1!@V!VX%2PXEJOUIL;;MCCT,01W:+\_`;^R?@0O:N/X5L.G
M)"W^EF0;9:FH094!;E--9^=!EC&<;/FS,+&P<<O$1XB9B+B-AIMNO'V&8&6?
M[6/!T1_I\&W%BT4LF<N>F5@V'JY'PL]<O3\%=QNA.@J3F[;YX?-ZH_9%66Y6
MPKJ//]=X3NW[D#ZG"YPO;FEX^8855"YPI'QR/-9>,A-:[8,GYBV_HI8IK/"8
M,`;5UB!FCN'(F'L]``>'\KH%W39N>4EQ]B9H%8PT'PQJTV)QR?*AWZH'B%7L
M$*TV\(,*!--CYW)K>'W?/B\R,XSIL'/A]?"\;+,TP-(8'S'Z@=/')^:71/X`
MUX[*TF5GOQ&2'\-B[#4Q!F^[MSE\O$W+/SX5&%_E-*[H0#G6\%$G%[[0&FWX
MV*7VFZ5)9@QBUJ#:',CXD;L]TOC1A]L=>+.@XM\MF:/2VE&%PE%O84"IQ5ZH
M`65?$[Y-^OR[[%%EI/R-9/1K_/+H2#QJI`"X2MDXR.HI6/\WRZRU5:AFD*U=
M$(KE#1&)8KTVA`/7/F\]M4SF-%[?*LN:(3,4W1HWY^'S[N<TQU<57BDK3GG[
M,+B`09A=ID:O`^<_])UIBKBJYD41PNS\6/O,)N<UN.,.C=_VD>*#MSK;[/#Y
MZ.N&E9JX7EXL%BE[)<GX<^7%IGHB!;N5P7=PFTL$3YU'VAMMPRE\X-1VA(0)
M;'-V:X1XOD1;,XSGRB/M+;F'XV>;D=O6/SG^(0[KE2AY3M*,WVK#S@2(<WH\
M-RGJA2T1$.>#"6'M^'8H4EI1A\(G4O"TJE`PZ!$'ON+J-,BZ8H^V;X@9:SK<
M@3HWPOCZJM,@:XB>76Q!BELGS<EJ1?TK4MX[R;'CP-2;(LD^V/ED2(,6'>#4
M5'T7:+ZXQ655I&R#B)<E^Y:G57F]J<HJR=G=7%Z/=8"EPLY2G1R/CD^]GZ4R
M5OJME""H<4NU1D5CD@3UAAF%R-8JPU)&PO>^SU@%\WWLXU;2$'3!4IZV/A<5
M#+DQJ&4-Q.6^CUX%<[E3G]2ZO:PBZ`&C*U[W'GU;TU9HRCW0!UL*UDX_^!-9
M<%IT/IQEU<J'/XR_KE,>>$"P_E:$D._A6I\<>,*4]@(!WVH>_(C]>IL8U:A>
MC^/-TZ.T-QL,[5,W.N2#RAWWO(7Q=R]L?`R\31KH+3+9JPVRIOX,)6_O&_=V
MTN&L%^2\*4SY-\J%>QOVVYI7S"ISD@QRV#1L$UA09RW^7;>[6#48T09_`DXU
M@FH8IC5MY<-/QN^U[1:OQ&7EER3GUR)LDBQ(EKZ[)N"26M/>/;:XAOQ9.+HQ
M$+4LA.3\\Z8)D/,?KVE\<'>W&S^GRV'9>R!P^S@WX*?]W]JH&I<[9VROJ&5I
M7J;S(%4%+$2#2UW/>H]=!=;\S1$U+MME`1IC0+4!N-^##Z*]^MVZO'?:>&BO
M%$!=T_A-'%NU0:/_(;-QF[X99OU$BB5.JTV!@Q7#ZI<$7X?0WL?L7]&W0Y,M
MY<&5K(1?)P?IV'/AV!P_LN(FKLNP]>[>4FC$SJOF"S1G%W%D;XH/=:#R2'\]
M+?=FV"YLU3^/M?U8%GO(':8W5L%/6:/O"'W%%4-V*T+-SPF$W&^*7IU/S7)O
MJ&!?^+)\?X+B>YTFO)K_\U]^H'UEL*I[;EK`#XR>1:/#7B/>,E_NK7'R1Q"S
M#UQE3S1++`[UWBPN2YMU?1/.K>\6S'O;@GMOEFG-X1N,BD&M_&:XNI6@%675
MLE<>O-QID&-<?>J^':9MF6"[+LF='(Y-O3G9Y@37XV/!I^ZO77/4ET9[H+S9
M#S"/#&G4<F^1"X,F>RKE@$]IG<%O)'50\XUR'B394_@TW$JCLT_%95,?<_>5
MQK:+/HHT]X<D8RN-$%=-#]U5=U525%Z=]1X_IGG>XZ_#[QW")<QJ6^XM]@8#
M),P"I8-7+?KKJH97_HWV)WX29GD31.EH?#:!9?<#2)IU[I>$9Z/T2_X]:]%;
MV?KV3]*-Q<Y1MFC^-Y.CK+9-E;4W#I0_ZJ`)L"N<G<QZ)U%Q#?FS=(O..<J\
M:<+E*$=HFM`YR@,N40T$;H\YRH[M_V8F,N(2H(M\T=1O)^Q'+?.;1=`H6P#.
M^@"7R6;CXY!;M-;FO!V>E]>>L52TYGZ)BO`?O^H$E,OIAFM*O*W"[31$:RN_
M.Q$M_^-7_G]#@W9WW'L<QGN)A#]1%Q!TPP,J'IZ2&#+MVE3[/R.?0_9.1#L,
M2=X#UL_0N/1/1='A=@ULFO=/1,`#[#'X40I^)GS8T?B?8T?"G,+];%?P9AN2
MV]].V0_%:/WYS]85Q%YY]Q<C;V9!'FQR[%HB_A6$C_U[NY.#L.__%UV+ZY*_
M:,YP2_[#-6?HG8`#6B(ZB/8)L6$0)GH&J-G-Z[/N5VK1KOY'E`BKU7U\.CZ9
M>J_5;:1PS#K=[_7<KJT9+8I#UZ<N6^98K=)+C_NNT!W$XQ:]Z.%YVG=A[B">
M]KOC$;?X5DQN<RZX#6Z]PUDD*U4V\?_<4SUIYWI#8^1KLL(?".L\;=<;'$1!
M+Q)SW'VPT#0L"W[\[PV[@E00VG<AT?".0^$,AV6B",ZP("ICCPRUEN,2[9`5
M&L?F>0-,I"JK%6)Y/H@2T/63TV.G\[->;1A^C:1TJOKG9:E=-$D(#HW1)&&7
MUNN!]4%6"`P#9R_T[-KR;X>X.PJ"#4'=EFK`<]?###WMK'A#]-U9C=#77BEO
MEH`$'KA9XE#X;H7#RP.L<!@*XSX9W2$4W@ZG:^OP1*%SN`;@K!BWBMO^#'A#
M)&Y00\PRU\6M#/=PC1&'N@^P;&,``/ND:;L6'YBAA>X7^>**MD]>I<^8K>R4
M-R1+YR\@;!A]"5[\!C[VU2HR#//5L.+#H$8MQ/5"0C'T7?YYCW]6Z#UUT1^&
MZ['"2U`J\^HE"TKB.QSO]K?A!B<<LSCN)0YC__I.#>!B^*\^IZNTHH/'CY2"
M7JYSS']HOLEH^"$0I"?C\93VNZ"-_!X]!KY'>TT?^]=2WI^=,07YG?>8J8A(
MCL5OS*[%EMX!;;I[]HZGO73!;.+77"\V&4=<,T15$[^!^`2T/>[9)S;LUNH(
M^L*EP(O-G/]R-W`Z+UN/."[S0`WZ?7!`,PV<S,M_6EYLJB=2I/_$BV_Y`A>M
M/7INR<X0[Y:-&EL[]W*,J!L5PO(AXZH$WW""U]N(8]%0`T!A'=J:1^&\8-.N
M5C*1H,VCU[,S;N9.NLQV>NQM-PI>A.,PVRO`[)@LVQG1M>\'S[B-S`"].;;Q
MX\%QZ%Q>+ZG^*ZHY4Y)V/U=EN6%KU%SSCS_3LJ+M+?)"]OJM>Z8PFZOQJ9IR
M;!)`!HB+3X[/QL=C[8#;HXIQQN)4YB9+"O0A+><9*3<%AV@I");^;<ZMD8,F
M-J9*I4&2<K$T"6&1\K,W0"O-ANO2M[KA^H"^M>BX2G2]1$)?V2^Q47NM,N(Z
MHUII)!.F.L;]7''T';J2(?VI&^H/Z$^;6<!FM4HH%PK?D%>^E2Y?VK@XZO`_
M!(>1"*T:=]+0+C6E&T=U/0?<2#J?GO7F<[7%Q*".WCIE*CMZRJ.ZV&%9R%06
M)'TO*F;60W>(33V%2=UMLB@ANBT%:F!8R(%L)P!>CRY5+HJ(Z72]9A6"\L5?
MJ!H9/^!55F+]5C7NLWL9FHM^.IIIT6\B.S0E"!WX?D>M!6)J'#EO=PC[=9/5
M$/9;K0&JG!`7<J!0)"Z.=)B/I8]YNDSG25Y=$KYA4O`>OM3CS>I=V(;%Z?'Q
M9*:</QF*CK1'L=4&S7?4,=Q^$+:JYC.!;`4R2\O&734:8H$RBC1;->T(9+;-
M4;KYG&Q8,LPMGN/TF4^R&+?L^&1#I[TK.H?853;:?`&*1>+@YGAC`0I$=NCE
M,^6,[*^;(BT7*=^Q^8)U!?7,W@*G`^MK8>B%!@8G$\Y#DHM';?GHN]#`M)?G
M=FIZ>;]V6B4P,&-U5H7JT0WCBEAY*RZH6"=WF25E>;WD<_\+.M?7M;CN>2B0
M)L?:;$R5N+`0XM)XS4&^1O2=232&#+.H!S(^++(`B[%9(3&C#9[7:.ES5'R<
M;->_2,[2$4VPHGL'CA?MHI-.9)2SS%N18-AHC^+Y-,S^7+*1=:'1HPVG+@3U
M^2P^BG['Y+%(UD]TJ)F9($CU/!`])_3_3-#S6EQ8Y+2EP4##[3$`C:L]%H`Q
M-"HT5I2!TX43G9OB8^1SFN,K^M=><.P]"-[(.#\W044C)\+\A9]"^<XD(B[2
M%!'<%@-$6-MB.T<Q,B@T&O8CI0L&G;Z)'__7R\ND?/J4D1_EQ4/)B[KUM:KF
M%>B9A_%H8H*)#HFQT,%VLJELQ(53BI7BC<\K,`L-D.+!0B?,0,P,C1]=?'4A
MJ<=W0V#J4YHG^3Q-LAM2IOQPA#&V>E\%7XVJOP_.0')$K#4ZH%H),.:$Q4:8
M\V:Q*_;`9H?'8'\<=F/1R*=#8/(JGY,56QED4[0"/^&\3)^Q_*DQ/"%?@2/5
ML#<T42)F!]G6`@DUK&!KV%6&,-^Y]X3[(#R&0<':#6>HKX=`-E^T?"+9@K:A
M6(4QQW/_N_`Q;5<M69#HB-AM*_&O=1*FS3"WJZQK4*-=$6MA>7C$&H1C-T[-
M_!H?G3QEM2\L=AX"IXB9K39R&='65+@T\RPOLP5&*Q/<EE+4=H3&PFY,=`7]
MGCLB1O=KL"F;3O4@L%<YF9SH=Z1>RPD=Z1W<>5%51?JPJ7BR3D7035+05C+L
M0;B!FOQH9P.])$A#C-$D1GLRQD=F-,2B64"+*E(E&<R6>_:*./K4A*(\YO3+
M`B_3>5K]&I6YE%@GIIX:D,%ZA\Q^Q\FGL\E(WV\/-3@V9C;X%)?;K.OH!QT;
MZW#T[X,"23\&/K"![VMUOI(*;X]O]AZG@+X/AYU^D<E0_``H9)JT#\*"LY^E
M]1``>K+>&8]"FT%!V!>'6DP:^#$N1-FQ2[SXL"GH6$A4L1-GL;[B'_Q7ZGP`
MR,OPN:P^1\!$=@1D(J$$$EHTU2KKTY%4%?&$Z4%";G</++W;;9/:V3IM?U2?
MPD^Y8A!+1[%-?<;%`P$34)+AUR4&ACA'"0/<:Q8"^?(P**B[@I1-P.B_!":G
M2>\2!$R1X9E*7</H*Q8;L]MZU,8(G^A3;(.[R;:&6TUE=>D05<600R.!GB@W
M981^YQ\(/>S?EX875M&F^Q!XUVO<.ZT`Z3%\V6Z'FW.,=\V8TWH6/<-X[5QX
M+>?7%0*71+]NV$$JOH56E\,8\AH;^Q`W9H8^5P]-#/R*1,N92_>[4/A/S[N*
M0X%$#S<:D'=T0J<MPFIP5^]FM4WGWCF0S\4`IZD7-F?%&MA/_L=L=#H\?A5A
MV0]9M7L/`J4^!O<&'P+B=WQ\IJVS`M9C<##[']D+)]G!_6T,[`\$]<[C>4.7
MQ^4#,7[HJ:*@>`X^&->GH+T2$^7(JBS["RN-($SIP9R+*;8+\\V0=Y"B"*HP
M>0T-E6<<BA=M'C),076/BQ5;#<546Y94\8%.(UZUD?'SL"*O)^>STY&R2)%&
M7*3"1%(#1"-KQ8=<7`>$\P5:4"T,RZT**U7EB3Q:">QX:^N8:-3(1E0X8M(A
MQJF*$'DTS@+=UVO,JO'0`45?2T:K,V0"(0+TGF<&$/VN<7/N/@XK4G9^=CPY
M`>%?2!L6_D('P]IDPD0(^.U,](-]P)*7M`R"?#O+@@!_K30T&NQ?`4>+^GW/
M>08]3S\$=?Q[;X"@/ST>S<Y/0=!O!`Z+_I*I`>C^I:40!K"VU`\)</'F0P!I
M((0(K`T,P@7;%AV4#_8!I:6$3A_&FP9OUNN,;ZTD67UB^RI?DF*5F!R1AKT-
M/GMYIITRFPD/C;VM$MO3^JBEA\VARS/M_#J,W5;W"[2,7^S<AC%GKE@R5Z1;
MU:(FK`)#DS@Y.!I>FRR]'F0JGP.GIHYUV6][8L*B;9M<:I/G/=;ELSE;8H$?
M8W,"840=),30,?'B/JTRS$X^+]+G=+'1UD[3/@NNFW:F.Q'1*2HP!IA(1K%;
MH=#2:6>Z`P]>3+(!`\BN4(C0A@X!>&DX9/P]K9YN<2;*5S^EZWOR,:_2ZN4#
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MC5^X5DBJA>X)XMERUTO4J(:$;JA1#N(6Q0IG)+?849%+S,1:#75E`.*O(1P8
M\0?.GO$-+M@=,'<X3TEQA^=4SH(=ERP_;/!?-]G+_0]R_T0V99(O[O`S?1+C
M[C0BK]^$<>3Q\7AZK.1(1Y4BD277$DDUD=`3247YV>,24541TQ5195&M+6K4
MA24W2:>IB#.RTX`,.I"S5'0:V5D6O#H:_\\>-U%^.(V93N:7+DB`IG!AUN;[
M7TE^O5RF<UR(1,0K?N-62G6D[:/C49LOP%+93L^G(V4J"TR!.!Q)WS^F89N_
MD^K4E1D:A?B-S88I;L)Z)?V%M!Y*=BW^HMH@K?4P7I->4/):2"]8L)A9``S`
M8E9@)<YN]L)0@C)MV<GP;6"2W?1X.C%@IA[AL49N+7S*D8D':$HG]!.49R<X
MD)-WX_MYR;/Q5IPT&K.1*-\T9R?9#H>,3+'9040`O\;;_J&"KI>M(]*ZC5'=
ML]"K<\Z/=?>`=HH*C#KZ`%L(:1\7EZ.#=TGK9ZWE!>!-;=QFS6:.#YMMEH?\
M&AYJ.T<;?`3@1OL._MO\X>8IH92D[L45C\`F$=/)\4QY'N:5A#C]\;?+]TA(
M-9P)"!,4':VC"3!<4V%2=>`P7IB@Z"X=3;"`*6N"V/V>*II)OQ<<4,9.M/XH
M4N8CEN::EB6CG(M\P:K-L2O$.QO$^"T8%L]GQR=J+/8*C03/EAZHI0BZ8(>X
MI"IF42_L50'7N[U`+/NV4X5N[W;:`+Y6@FTCSQLM>-^\D&I$VYP!P(M8.3':
MB)>JE9:B]B]>?$P*5CF[O%Y^(@5.'_.[S4.9+M*DV-^FMO\`M##\V:FN\)*Y
M_.!@W.J!:D5D'0:F"FKK8EJ4G-FN'B.'L]T"H/)&H"KYB4OTE-#):4XJ],`V
M0M8%>4X7U"T,KXA2^H8E#3VS2M-5$B,;Q"%8B:N[(T*YP'/RF*?_Q(O[Y.=[
MG.-E6JEQJWT:"-+)R4B7V:X0%AJ16Z&(2D6U6$/P<9O4M<L\V>1V:\,#Z(X#
M;I'ZU@:O%CE=W:`Q*Q@SZ.%`0&X:&O,?\+Q@9^/*6UQN,C9D^D2MO=P4K*J_
M.#9+GZ[O+P12A.7'@8PR/1WI"C;YT6T@`CI"M9ZHT1.Q>$124WGDG+_4*&L(
M<N$X,&^%\IQ+'<9;O-C,E;;'90+;J.\G#@?/'R;/W%"5BS`LT_-I(,><C[7G
MD7QH=G`,P_5TX1?A-$_\XNJU/S>[]$6[+;<8>/TPF>4.5Y4X3%RRPR?T>?J+
MBTWU1-C"D&:-(H`,^'BFJ]Y%$!4/CG1:"J,?5&,D5$8MG<U'-Z?>V,>;'UUH
MJ*7$H?*0,21L"0G2$$,STU4><&YE^7'XDJJNF+4?W08CH5K/`',K[CC=>NP0
MCK-)<J"VKVMY[?,O<^FC%YP41^ABL5"[)RXQV0*CGY$<6N<PJ<C+],OJT^":
M^C-=22(?FAT<"3E/O[C3/%&0)Z?Y)*`U]\\;H1_W^9EUN[@DE'1J(L35^M3#
MM%OZ'Y*S6V'%[Z^7ET\LDZP[3<#CAV%U$T=G9Z,S=5J*![UB9:ZT"*6B&'EH
M"$7LJJ"TYI5?%E+C7U'1Z%P_Q6J&<;7-:A4*]RFS7`9PGR<>KHFV8>/6!+7Q
MF7SF>HDNP3Y39LP,X#.KI)J^>%LE+]N8H\Q<1QU:;/A%T>PE_#-9I3F/]'@)
M.#ZYAH1JMJ$'B-LESIW^Y7.R+EE6\'J=I7-FP1WEJ4U%?_0Y7:6"LX#C11^2
MX*OW%CN$+HH.-IILE'X]G.1J\W3U1G$D-6<_;>ENOKIOLWL8Q:LNJVQ<$WZ!
M7;EU3Z9W3]PAIA<$]8\X?;64PP!T3?V15Q?YXDN:X;(B.98W#U*5YCA]Q@N>
M+/DYG>.\Q!>/!>9+@YT=K>.W8,/,F:XROZTJD4:60CN>+MOH5]_XR,K#"`T1
M5Q%)'5&CI-F8:*8KZQ_+/T#2C><7U5@QDE^LRM=)ZS<M+ZT:+ZVEFM$&?:Y@
M)QY='F]HM_[$E)4*MDYR:6_:,GP+6L!UHD_*T@L-C>1W(DB;:VQ;I_5@EW()
M.S6+;'[MM)FXK=6VTC$._7;42BO0J"-6OK2L(LD/5Q0O#'$G]3\8V$Y:8),_
M_D_JV]TFW_\%M.[^]+BK!-+VNX%1\?7J_N,'='=_<?_QSK1D/E-Y/_KM5;9:
MF4@K<>L&*R$4,90[&IRH;(_6![#['D6Y_"PC/UAJ]`>\Q$7!1_8798DKL?9P
ME5^L.HX$NGX&.#$?=Q]VM=4B+$`:;5"C#LMC$0KQ:3A7J;6C\TN]`O3K$1(:
M&E^OVGF"-I9?[,[T")MIG_+<."JI]8O8LUB'+O'C8/OI[K[4;0E&=H7EW@VN
M=%A:W\'>61O6RP>AU0^/3Y458IWTB3/[_=M^[.Y4_61JRJN4=RX-9O,=7*MJ
M6"U6^$HQ"8[J*V<BW*D:RR^%?;]WW30_;-RH"'&18CX<U446G.@EEN0^-]M`
M>:+LNJJOR.%/LN7<NTLT'4WY2Z>CLU@S;#_40GRW9+1QUM]Q^OA$%;QXQD7R
MB+]NV*CS>LEOVK[>5&65\&-W5/%TSD]N9^PHJ*(_=_L8<)HQ.1OKCC+8Z1*6
M<&J=D%0*":U8^,M+W5N:'2&N&P>$U,YP-L,]HQYUQ?&,!<\T[DFD>TKA%+)5
M"FT8RZ0Y)YI-)4Y.UEY:"$U1CBN4D;)D.[KB&Q&';8X8(#[;Z36+2#=\IK^C
M_Z;_HG]AO$W_\?\!4$L#!!0````(`$4P6D;&A*/0[E(``/@E!@`5`!P`;FMT
M<BTR,#$T,3(S,5]P<F4N>&UL550)``,Q_>Y4,?WN5'5X"P`!!"4.```$.0$`
M`.U]:Y/;.'KN]U3E/_1QJD[.J8KM<7LV)S.UFY3ZYNU-N]51MV>R^3+%)B$)
M:XK0@J1LS:\_`.^4`!``08&"]"$9;PL`7SP`7KQW_/$_OJ_"BPW`,431G]Y\
M>/?#FPL0^2B`T>)/;[X\OYT\7]_?O_F/?__'?_CC_WK[]F(VN[A!403"$&PO
M_ML'(<!>`BY>O.\H0JOMQ1,&,8@2+R'#73S`Z.NK%X-_N:#_/[@@?_KOJ]G#
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M*`_(SU"2(/""VX+^K[=EL[?T3V\_7+[]^.'=]SAX\^_T@W_$*`0S,+_(:/@Y
MV:[!G][$<+4.P9OB;TL,YG]Z$WU-,$7^QP^7>?]_ND%^NJ*[*`INHP0FV_MH
MCO`JH_K-!1WWR^R^17X$OB8>SC9/4FS%][3=>^%0[_L2.B,]?WLFNQW0;TSG
M=S`BRP.]\`G%D'[B.O3B&,XA"!3IEASTD#-X\C!0A5]AY&0)$NA[H?DYW1-^
MM@*3,`$X(@N_`?J3V!_*.+4$C"0B7._:6\.$P*%-Z^Y`QBE]7I)U6Z(P(!^Y
M_7M*#M<D"J9D'3%EEN0G$,4$HAPS_7FH?<;N+'N>$?5O#7=JKKUX>1>B;_%]
M%$`,_$1_6OM##4]MSY5@CV<.[1L8^R&*4PRF>.%%\/?L1B*K_9RN5A[>DKT`
M%Q'ACKX7)1/?)\).0D2R)Q1"'X)X$@09#_7"'E?C$"08!(8N`:'F/MJ`.*&K
M0M;BLX>_@L1[#<$S\%-,"`"Q;#MR:L*4RK6T`SU=&R^DK4E?(LDE&/H)".AO
MVCC:H]@"[&:W8+^O6IC^$\+)G!P%E/,*F2Z#@Z-#DT'HZ,>B!.%M]0_M&3.&
M,DCH$T9K@)/M4T@Y&]$,R-%:4Y"X/VA/1.-3AYBHV<.K^!F#$WP&$40XV\X@
M>$2):;8D.[[!*3T`HE$;GH9H3..DWZ4)^?=G&,%5NGKRMAGWN4.XT$/R1CVG
M(O>-8:>6_:GQ[>F:VL+(;6U^AEV?,CE1Z+W"D&@>,Q`2:3AX0<]$Z"#J>T;/
M#&V]T/SMW^NCAY]\)2#OMW\B/(*(R5ZXTV5H:'1(,BDUH=4*YG(&X?_7*-,4
M0&1>55'^D,G+)D'^U[9V;O:RD1Q_T"GE&ZE0!HD<2?!&4=8L,TY0[G,?QRFU
M0G^)2+?;[S"F:Y#WIF8*$,599RH-Z._[X2DSRC=\,C;(=F08>J\(Y[KT`H/,
MGA`7#=J_%J:=&2`B;JIJ(#/\\4."8?KNT/J<Z4-T13U<S4W&_NOM=_I/_<76
M^=;@4QV`#4I^8_"I784>X2\^840@GJXSYH&A3[C*9Q2`<$+XS2K[:_PEIG?M
MM1?Z*;UW[SR(?_'"E-S4MX0.M`7Y!_(Q>K+%@U%YF$.2?VWB)W!#&'7.NS.>
M?4]8>42]+`:NDGZ?-FHEH<;[%^\[B!]0'%\!LIO!%8C`'%*CP`92?S>]R^IV
M/<PHZM\:9JK#3]#*M,QROLZ!AYE$]<\*NTIWR`7LE'"20N7LP[MZ?'*8B3?\
M&Y0SH(B*"]/Y#9@#C`DMWG?".D&F:91J51]5KO^7AX'A2X2!CPA!OV=?+@Z2
MD7GRAC9J`EQ0,6\&U@A3<=^T`5!F]`&G4PCH5]M/`"VPMUY"?X*!9VQ"O/&-
M3BD$U%/U7ZF'$X##;14*<N,E'ONO/>:G\3$S[NC,/OR"JJ$K=W+<=+`2_A:C
M$`:E&M:,F&M$R=2=Z[E1WZS()?L"OB=7(1%K%-$;$>&NK43YAZ-=D6H"0Z],
MI8O41`ZPH<5?L3K'%^J9-;=19+XU]'PK[VU-@_DE%7[$Y@P-+ZC$IX:>+=?1
M.^3Z*GUT3`@87G^-3P^-Q@.*%B\`KV[`:V)^X=FC#SZGS*4ZY(;F?\':W`QO
MU:[O##Y/CM.4YPH=8(VU*1@M-J;W2$\ZAL9)X&D>DCDH?G9H%/;=L+3MD`#(
M?W$T<S=\,E2_._Q)J/RJ&S#!V",;<FBA3^6;(YJ_X9V@_N6AL6@D#<R;WK2"
MB5^CF.Q?&HZ1^=O*D#7S^Z,O'2/'R?`^,D/-\+ITX3<8UEH@^(C-&1JW%G1^
M:O#[<\?5,*C4(/&M$<S7M*0@_<6AY[[O6&GXQ\POM^3GQC%KPXNN]-$"@77#
M,_!`)MR"@G0!44!3U/._TN\;R*[/ODR^3:AI?2ZD]0<0;D-??"TK,A`#_]T"
M;=X'`+ZGJT'_D2W+VQ\^%"4&_HG\Z;<)^71`/W\7>HMR."(O@?!/;_9_?S\X
M/=<IICFB=^00>N%?@8=OH^"&K!J#-&Y3-2KW-RS]RV_ELDP8RS)YC1/LT6S>
M%E'R_8;'L20C1^<)8(B"._*WF`$DO^VAZ:2K*$=EW?)P-.;(\#<DN]WAZ'LA
MPPK(RGX>GII\UU^3#V+*50/P_3_!ED$6N]W!Z-N-?)^F":T+0S.%^<2*.AV,
M\ISM5?(*O=28!T;8_%#4WL$0X&MR#A99*BN'R':K0]'VE+Z&T+\+D;?+R=EM
M#D77#"P@O2BBY-%;L4XTL]FAJ/L%A2F15G"^:/R-M]ON4/3]"L+P/R/T+7H&
M7HPB$-"$%H"Y=/+:#T_O"_8HYWC>KEY1R*"O_7M%3U,.G>`V;1[VRX'(/_>$
MT';]J:+%^W56EN.MOX1A);_.,5JI2#0E%8AQYUP@'`"<%4;[\,,/;R[(!/(0
MS8=\KEP",^J(F!Z#K"7M"1$F%/SIS>6;BS0FDT/K/)+PN.#9D;IK?"[/^`@D
MKAJGCV><A-)SC=2/9Z0Z]*$:JS^<L6+<2S4^_WK&AR^EU3#]OS-,`D6PQNG?
MSCB)35XU5#^=H9*0\"N\B)AYQJO38E##=1;+!8IK`Z>S>,XUVC10.@OGLC;#
M!FAG.9UC=6M@-+1\_L?WNSZ^03U_LD6OBZ_!A`[\@6IT/UR\O:AZM_Z-YA?5
M6!?E8/]RT1A.VZPU]^+7#-TT?KOPO'5NVP)A$I=_V35R%7_^K4B-BI^\+?6H
M%O?1CL6KH[&^.:X_W3/@`[BAU#R"1(YZ9A<CCDGR!9R"X)JTI&5T7S!9Z:)*
MR:XQMKN])50I08V<[$Y(.>TM49^NLL(?W*+2M$P$6?7I_,7[SI^3TBA69EJE
M:3]Y,+B/BKJ`C0N--[GNCE;FDU4#X-&<_VB/+DY,`:>1/3H[SFJKC74JI4#=
M;6N%ZHT'0WI;W"%,4S@:=:[%>'?VLS&;9@71*9'D%GD%$O%4.CJ-:!Z/*/)U
MIM+H9V<V63GKW3KHR;6'\99H(UFB,W=&,GVMS(J?Z\.;BZ"'K1D4]Z)P"7:;
MV:"U+*Y35#P1GVA.XQ'0W7F"^>UM4%_6E2M2#:0EY^Y^-F;S":'@&PQW(Q[V
M?K9!VWV4`*+L)U*:*J>Q';J+N@9$8^!2VVAB@\96^2\FB?MENJQ12&N[[*40
M=I/-[C;&N72(QM+=+<]-?$)'PO'VR9!'OY]VPK$AJ>:-LU'N-925>9![W.!4
M&J/9V%69X4A&*6<TM$QOI_S%;FN-:FF&PVL]!LKE0&=WL$'_4^GHZ52-6"WM
M4,RI+L27RH1=C/#(&9BG44`%U,\P)-(JBLI74/@"F4)'&SBW'V[3M6FHCC**
MF38>(^L\SY*=[<PK\6`$@EL/1P3@N.$/(:HW]"%_3IT=;<PG?^.J++:5Y9UR
M)L!J:85B@?.Y0SJ5ZFIG3I(:VTAT-&6M3$8/.V"41]N/P@KIZ/#*N)H8(@^,
M+(-W-45$'BFQ<-4K-60#\"LZ?H1JPZJKZ1_R6'"435=S/50Y<=^L#D3=FT>`
M!,?<U@1$4H6H\+IT^4A)X*6L?-7(N7SF))"3"/*HL7(KUTH=*V'H90V36[E6
MRC"U_7XU+&ZE5BG#PC*-U^"XE4RE?K0XN'S429H:OR"@Z@AM0B5RW+F:[VD"
M-Z8YS-7$3Q.`240:]DH&/0H-5P=`%1>'J^FAO?'KXT9W-8G4Q*D61!VZFE-J
M`C:1X]K5+%/#TDK?S%*WQ3IAS/CATDV/#SA1ZQHW-TT7ADXF)["T1D]'FSBJ
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M:0S+Q7@(XE.<+4Z0W:-/`&<57#ESD^EI>49Y`=I)FBS)`?B]WJO\F>SU&,4,
MLGK?TM07K4=!.?^5,:DN]M.P%0^%9&<CB<[M;V4#WX`8+B+ZO1WZ)#K8QUKR
MN'9T&LL\A(=6T&$L]'<?W:Y>3J?Y'I'M15&2<3U)51=&V8O!]=15,_CM,WM7
M7SO3Q4WFDG<]\=7D7BLO9-=S8DUBQGZ\P[&'T?H")Z5#NYX^8P`\T97@JJ/#
M$&C[O,U5SX<AP#BO$@WM_;!G:LW=%I.0D$MD![BI+!CE.SN7U&,M>F<G'\&&
M*?8:Q60&M-Q'_(Q"OB&LW<J.`2S.8NPY#]1PFXV!U@[UF-O<2H7PPK54WJ]7
M7@Q]0MP-#--]ZY=L+RO5P4$$L!<2*B;!"D;9$ZOT>!8P<V;2U<M*3>[5VH,X
MYS8T%?:!T!/D\3%_!F%PA_`7[GSD^MJI-%ZZ>^_(393GSJ1D$TW7`.=AG5=@
MCG#A%G[QOH/X,XRR6Z`,ELVJ7#5'R5U\GP$1=)KUKWC8')`">PA75TT'&^*U
MMD<Y0;PX=E?D5,ZYI1QYK6W6_1=SF=U6AFI8^W2P:Q22KZ%\!V=1%D7\+\MS
MT=G'!H:/(*D/%0?!=ALC^-%D9"]>[JS-3F!P%0G,0E-Q!)-4YZ-NBV7;^>1.
M$+.`=*5AK.P-(H3G[#E:Y!M`?-+X[4=%?0=O[NYGI2YXFR3!:66UM%;)7'4+
M=72R5,T9$-V>%DV[(4<U1%G]2O$TQ'WLS"+C,KQ-4_ULA;86(^11V&YDQ2U+
M.'-<$)!IZ/P*\<RFMFDF-'1YCSFM;5#^*X"+);D1)QO""A;@,5V]`CR=9SIO
MP_`EIS1K#F;32MAEV6A;!G=L2ZZ[OU7`Z6#@KGNZ5:#JM..X[MY6`4O25.2Z
M=UN53[4MR_W\V.-/R>NP"[7BYWE7M>O%;10PXF\VURO9*(#$U!5=KU6C@(^$
M9<#UY$0%M`[J.^B7].C4+N7:Y5U/<U0YR6WK=;\,1J=V3Z=OV?7<106L="T-
M_9(;QP^AM`6=55R)H3*J"&8_Y2A%8)%527,')RWWEU[<I;,8RKH87(^\U`)-
M"B\WI:\.8SA/&:]M_:X7(U<`:-=IXWI)<0EH]&,$7"\L+@M>=UB-ZZ7$54Y@
MY=(]7-EP>Z'?3QY.(K)^1>&?W<#O/U!E6!3X7?;_YXMR!!OE./B/B2V]:`'N
M([+F7R(,O)#FCOP9A53Q^.3!2!#PT7-0&[Y=/LF[5H]I5$Z".8,IU@)&[RN6
MBE'L5FVJ*S8Q9RWJX6*$H<%H)09T9.L`N"A>3O&W+]B+8L*/Z840!=G_"O/K
M(?A;FELQ2["?$,Y^2!(,7].$[L,71%_%0%%"F%N8B=^Y_B<*AK)&TYA6H5VH
M3`FL5M>QSHFY+GGQJ(Z('5.C6RYS421VT7<]]J8B7_%":A2;TIWAO2#Y3JF4
M:.%ZQ)`5Z#6E&;V0I&,R]PVX&I9O<KT(J?/:*=S__2*JQF^F'!!@H3KA>BR6
MIKPAXW#6*29R%,][&L#,V'8^7/41>V:NS.G<+KD;<>LW[QK!?ORW?Q4;P9JC
M__-%4:37AOVGNS;U9T"]\#S+CG1_*]8M=JUR\8R$?>S,HI2#XA?$(2_;3Z]>
M##*>0.#/3L8,D(T5PX0(PG@#?5H_"*)@!GRTB+)1B@KW'"`&_JSEDK+"7;#?
MSDI=BHPO4&A11-;A!JV(;L*AF-WV;&<\)0O7;JE\X1;G-+9B?Y(L$3N2HK"Z
MU/YV:=>ZM\,BXLEWR#N?XCY69T'$/7!/_ME)>MW0LDVU^_4&OB55T-?JK%ZH
M9M!%?M[(#IW[3V!P:-UK>&3T6N,JA)"\4.!-B@EWRZ6\G.D]@F_93_PS*M5Y
M=/,J([C;\J[.)#DCC6C&F9"NN9`[?<<V*Q/+*!K(IIU(J#-PBEB6<J+KT6_2
MV'08#ER/?9/'2=Y\U"\TSB',>$J:Z\G%4FI(*W.*C6AM?'8T])NKZ$B_\:83
M.;#.A9/$PXDS^'0+-:[7')$$2U2=7^.*.XV]M*?J]'*''Y<34OOL\43ODWE&
M0W^G=4/G9L$-.>B&]Y*=S)L;0IQ5(X/<3/B4PXH;I**1U>G:_;!KP^R7TIE+
M'+?1R"/V-,6Q-CS:POWQP"/C,VGOJ+9;XF1TQ)8;AHD(6]LN`?KAC%#S+%:P
M'`"7(PEML_]RNHQ@5\O-]/_3UTFS`G5]0IMX0SKN3#XFMM]O:QPNT<;>4:<5
M$.Y"]"V^)X($!@T8JW3M2W&D*AWA(AO"^N&G*EGDPQ"TY.H71$E\PF@#"5I7
MVR]$O;N/JM*+$S^!FRP'J..<#/(I*_&B838X"-@&`W'!?,G.5F(W"?8TZ)W\
MA[*&C1=F\DQR[6&\)?"+@EGE^CHY*TOQ(6S:<ML*.5$8D*UU`_+_*DV/,X2M
M.5+62%/0LBIBM(`F90114+PGV60*-S#V0Q2GN"N1MO>P-K"X`:_)-2*DXIC6
MBL%P04@-Z5\G*_HV_`?.9+O[V9D-N9M]Z!59B804G,#?16$BHAY68L?G<W+=
M3^>WW_TLTW5&F/HT8A\I7DBYRA!67TP#,97Y^*^`,!I:HK?%M.ZCB>_334ZH
MV@H"*KO[C6LV1'H"9&/H3*C1U<A+8<PO8:(,7).^5*5]P=`+.0^LZHPPFI6@
M)#Y`[Q6&D/'^F5+7<<SIIM#/Q,\3=?<;QVQN5^L0;4%9D4YGI01#C&..93)^
MP:6$_+F[ZUCF1'81^9K*0C7[#,35/A-=-4Y0!`A@N5&3MY\T!A@'\I6>75AV
MNI]VE1U@)/.C%MC:F)"]7R,_-U;G,<Y+A]'Q1QC'#&?DY&#H$QY,I6+I:>UT
ML_ER+Y6*N70WFEC*)V69W1BJ,.M-#,ZL>@YZ?#AT/;9J9O`1X5*;30SN#]E!
MCP\'O?VA.OB(<%'W$&@,-.[Y]C\/LH.Z6(?@_*(ZE_31OZA>/EB1V]=;;R\P
M]PF_O0WJ"Q6-.KW]OZ<0`W[A0\Y\5$88Q0P)XR'<)-D^A5Y$GS&CIN?L^5C9
M"?(',')^R/`^`$'VJ%H99S"=-W(LL]A847"*]C!6UH=)9[9I0$"=-[QEZ>PW
MHMED89A?H@!@<N3)3H$;6G2-[1BGVXI[V$P-;QN;SUY2,(4G#-;%"<M\06$8
M3^?J7,C(V+91R6^U7I/O',(4C\I88)/[%=PQ>%EBE"Z6A67L@1HHXC(JL%("
M.1RKYZ!&YC8K]PR!,0KVL=T1.O),A;KR+)<A&QG73BVH\A#ECV*_`+QJ+L3T
M-80+H<BO,H+M&3ZGKP@'9$LEPNM'V,5R8&<5JB<?S[G?Q<H<TO4ZS"CRPI*B
M^VB.\"H/ANB8CF1OFP&J0T8A&GJO2BF&M5WD^F7\T?R'7`"-MR#=S!T?&O3J
M.Y+QJKU2TL]X2T6J]2SI?@99PL"DE^I^3`\3F(J+K5BS`<VE0OU'-PL,F,2\
MYA2=,;TUK&X6'U`/0VF_P2T3(NG^P]RF46P%8;G_)K=I^-B11GHU&TX9Q[WH
M[7[O=I\>-Q0%P;K^Q/<`FW$OY-OUM\#U,-1*#'"]-JKY*WH_]MOUNJFF,=S+
M>'"]B*K1\RP,B7>]VNJP(B,'RK,*N`]EWVB\&EV=JG/C?PO0;%1SN]"R@@>T
MAEE%<C\FY<<\T/J!3Q7:EV[*]@-A;2;(H0;?3:5@.(XB$?56@^NFFG`8=KT?
MSE'CZNIKS@??MAKAC?4JN*E_#+<&?9/8:N3=?!+:;/(2;_?W"&"M%\!-+6?`
M!5#)5JAA=M69<YB=WAV47"/M9HGNX7#N3@"OL3TQ;7((=B%(_:EP_JBB1YYQ
M-I$V76.OHT8>K42B&`?&>P+@@P;3/:XG``01[7KVT7J4>NNYJ62K8CA,4&.-
MLIO>.E645?P`-79N*LJ&3KGR-5;CZJ;;SA"NR@:+&E<WM5M57-6JI];H.?XR
ME"1Z:K6?:_1T%-'Q"Y)FT-NK"%[#IA%K>'PO-)H$K_6>TH\G\-R4)'C2F9PU
M>&ZZ$'5V7;_DBQI11U4:M23AMMS=K%%8`^6H5M('J/URZ#5<0RLB(WKDIL>;
M5;S2&;E1\@YAF:(1@M8VBRE-Y]27+O-`EJB'4V421GRW=.Z[P[U?-6Z@I+;Y
MX9+U#\P':V%BBA=>5"1RTT".=+7R\'8Z?X:+",X)*Z0YLUG"$GU8&H70I^:^
MZM6TQB5CY:4O0E8`PY2&H=1N2J)_ARG!A;HT:3Q*FN-'%',/1V0:5*G,(E;R
MA%0.+S`SMI6WO/I1?K5E#Y`_`CH$5L(OC@?!1V\%;M#*@[SG?#J[&:E:E15\
M:?F.=Q77*-CUX>?*Q0KLO]MC9$@C\\H2QQNAUF4^?AF&W?$Z@4IW6V]=2;_F
MQ6ELB^[[B!"0TK4N]2IJV\SNVH`<8AH(Z"UX95`5!K`_OR+8:WM#*).:3ZN#
M#?KI_B:0KBA9+^1C`C;-;#H&FH5<E=/8",\I5X\RB.F\P=*N411#(OV!8!(_
M+Q%.:`L6VU$<85BJ[Z//'OX*$LJFZPOH!5V!)C7BA]R&^(*-/?;9^PY7Z>HS
M6+T"S-E:[396J(11-Y6M-F8J=Z=T+*(CI7&"5D13*81\(JPA_-G[&\*=S[+I
MCV-T!C.PIJ6HHL67"-)(AENRYU+"BS\A%'R#84CHN%^M/8@9=9][#&1D#EK*
MUT/]\OS^9'J.:&]6+[P=UF,T,_5O*^ED.M_?R]6^GT9,ZA5Z'Y+:%S)('WKS
M_@>E^!OJ0R_I;9[:3,.?`2^$OX/@RQI%7\($KJA<"Y(D-\=WTBPSAJ5:U>SX
MV=LXIR_X$H-Y&CX055=0K%IA#"O5@&F8AD!@KG^W1IU0,FBV,%01.P8>]JDW
M_`9L0(CR]:(%30)(\T2OB7P'>56O)?O:J?O<M&[HOIVN.HH5MP>((*JL'H\H
MX9Y/5DM[%&??%^[V_79VW$K(_SK-S/=B:O?:62UA.KQ-N!5<W&E`K7TK;F;S
MRYJ06Z$T^UO+]:('8JMHY=+LHU.XOM-$!L#F[N(9W4X-'\'YV[^(>N7>C!@<
M@_:'ZI#V=DRY&IPP!-A*WC)77QTP#*Q0A.[UDL"HL_`&0E'%<=CK!8$SN&VO
MI=Y;`2<,IK)Q0*_X^LGQTT&<E7J5V\_8R[BW]:JYGR:V>BY45XN]#X&PBNO-
MU<+O%G'-7&ZN%H.WB6ON?'6U-OQ`,IJB0]+5JO%#WF2*H32NUI4?`F)YOZJK
M->8'8@N&,D!<+4<_^#4G%0/3KQR]B^BVPMU$3IK<F5,"^(-K/IH!$&S$])2P
M.>?:&@"V00,$RH6X/"\$=R&,L.J*43C'*;@A>WMG?\]UZS(2[1"D)A8[F05Z
M;Y6X@T8[&^1PSUE8R^PN7!F=!G?9=O<1O0JRNH6[3OV=2L8V$G:Y-:NO4XSW
M`['E^]D(,>P3HCI$8*JKB<AF5JLHUD2+(93^V+CZ6_Y.[I47TK(2STL`DD\8
MI6LJ.G6D`/<>=HQAUIIQU59O%E/KVZ=<GV,!44-"*W$5N!H.-22LW2>[5X#4
MB:%J.EY2QP*O4@1U]%+L>$H2<=D/V1!Q7)I*/WDPBFF-=1#35N4K+,IBJM2@
M(Y)AQ3)/1R=C4JO,CMHS@._*J6J#')1V;C:UV@#VR[&<R\V8*S<C*+O4'#^W
MDQ2?R<MOLW:23+<!Z/L5P,62K.)D`S!9PO8'.4GXBB-8T2$]B#.9/Y<C'JB/
M^,,+ROY[F55QG-,(,U&].J4AQC+'RX+`#_ISY`YA9/<]@(2*IM-Y[J"?IDF<
M>!$U@[%VFJ#U&,HLG4M#G1/,1Y&N;4%[DY-'6[J9@J3EJJ^IG\3<2E;KE#%<
M-78-@F&W'.2JD:L_G*94=5<-7N80[I%8Y6!,J1%(];(JG4P$'`!/7B*E1E3H
MB>"GIKDZG;PW&)Y\+=GIA+W^,I-(>W<Z$T_+4'SJ<<C:H.GN5O>C-<^UB0Y2
MFVAH<$;O_GU".)FC$*+\V1^9+N-R#BL[?HTZ%'<"./F.PYV&QFA0"GS@.)%[
M#G8.B13-"^$UPD0IND:K%=$PH1<^>6N`F09@F1Y60A)*DBBWK4^2T(@M[C,"
M-QI9_4:IK\_`HVPSF$8S2BO.GQ-]1!$N_^>5%T-N;,,PWSA6E%A1%.;'MXK.
MU;;ZYY\AP#1%>9NIF@)7H61GJ_.ZC]9I:8P0GF]1C[',X%)Y!I=CF$%Q"O(X
MR;V-(O3KJHUA8Y:-&[:BJQ9;.=/JZ&1W'AT!`HR&]NF])A?S@J@N><*D\)A(
M=+3R_@^*P#973^[2*!`+(YS&5@TFO21W@>&SSXWMNM5@$!%0SC/J;NW#@X';
M=76XZB,9'&"11<-51\GA0#64J:+C;%')5#E>^+F^&):,YJPGYB"(RNJ_SA:0
M.2S*9GB2^]XR-;,,$VHYI?MD!&05&P033Y89QM4@M4'1^["/GEL%#KLM*OP[
MG6W'</V4RMMR6J43Q%X<5Z/(]4"3<MZY&BG>;Y_Q+'.'B_JV%G5!`8L2A+?5
M/VP$2U0?Y[\/Q[#Q\GK8,E9G]-S!",9+$-!*RO$C2&BMY1A@_M.Y,CVMSHB0
MTD4Z;6*5QIGW[3,Y[)CP.S70^1VMSN=7A+_>1UG^2:PV(4%/VXRYXX3ORDQ=
M"WL*U[\.9**]<PKWOPYF(J[M:NY77\RR>^$$ZA)QGZ/@_F`EWM3WTU4:TKRP
M&T`P(:(_183\.P1%B>')BK[YD`O#?-K9]XNQX8W$*%ZE9#?G9L3L1<PE"H/[
MU1JC36[!X,<J2O:T$[.8Y:;Y%+^,?R_(SL[S4[D1B_P>A@JRY$O]&O)/`8M`
MQ<X'HW5?E%7J:B7&*L51]FP((>8.?J?_$D>."#J8*9/BO5(+`[D`*FSXQXW?
MV$H$CA>E<W*MI=3G<.?YU#^Q%8?A"'K8F`%W>UYM.X*Z9'J.:D9[+FK9"3U8
MC496X#U2748UA\XJ/3(]C7`A[H?*I\'FE/]EG@EA$HG6.%9*\?A$/4E#,)WS
M,18$L4MWMZF)*'`WJ??B3BF]4)Z/-LK,2$MWKGORU-`SKW/I15K^E.,;@04E
MP26$U23Z?F&4XP\YT]N=0GW2]2!)/<ADMYF;D8T*8E]U1F4M,:X;ZW6P$VC2
MKMOI%>&24N!=M]-K8B8R(+D:WM9;16R5XY#6O%S7,51U4*FKM:G;.1_J/@B"
M#W8"I\?GD!O-RR!-;9!CD&DU,6(2J_V2*?:71!:;OH9PD6N>WI;NJA>`5RPC
MF&1/*Q$QV2OT(,CS"E[0%<V?6Z,8!-/Y%;GZDR4*ILD2X)>E%]%<I+Q<WG1>
M/U__P'>@F1K=2O5T+PK(YB\%<*$;@]UV5*;ELP-C[`Z,L_'?FO%_GR_SEF"_
MX=E9<796C$T,UK/.&9,%3M88)82W+;2>K`5*;"!F,.*3M3OQ/3>RJHBK]J>>
M)CN.:.^J$_9LK3L>6]/96G>VUJE9Z_)JUEGV+@BRHM:C,=-=HVA#U@C28M'I
M*UD-&.6Q'*_LD%;Y?H8J\3(_DQ<&Y[\FJM9W<$IG@`C?S'=%)7K9?[958)%B
M-!S@&=3;[T2"BA8@8#Z7*='!/H;GIWW-/>T[!/V/WDILV>,VMT9['*=>Y(-K
M%.^54N>W,W(Z_Y*&VSN(X^3E&WI9HC3VJ%]]G@`0O2PQ2A?+OZ01>%E"<ODW
MFCP#FC9'&O&3)0R-;,49082:\NF=,BZCR_XM[C.668CLE/SV8WA.]_P$L,*I
M_@PC^E#I#!`Q'>=U#Z^\D+(.UDD5M#9"S0P$8+7.8X:A#R9Q?=U1701&/EQ[
M87Z_WT?7U,`RO\XN??)?%"5$!&>1;6)8:_.C!MWI/+?]FII<:\PQ/B7-.0F=
MW>P]%DT/*37N95(\S[_#:&GY>6LAI:.@4/<![C[GM*6[4[8K\J;R&QNAY>4;
M"#>@.-3[1H6;%%#Y24WBZCVF3>L47T_E/WK:E/1=MW]VZ3B5M\*41%\_TN:F
M-T,:T/Y'M8;2S<KS4OK2_IN`.Y=K+S_VJ!\MUL9)[HUG-UW:TF#)6!E=]VKW
MW%FRK[&[>1/H@=>VV;GJS=8[C3(>%->?8S&'&(_ON_G*BO)I[+8ZN)X>K+;5
M1,9!5]^6UT/*B.'R<(]=NPIIVU9:X^EFN*NF,K6K1'TX':V`&[7$LBDY'^:E
MA!#;R^;\ZT%J&(D/I/NO^XA<L:+-="JF6;';=Z>(35>(7LW`';542(/%\!;5
MX+BE9<NYI[J8TL$CP:U%X6;%>484>>NM(:V'1*DJ\KF$A8YYS:W4:6X0$Q=Z
MX/,2@"0G[&K[V?L;PM>AEU7?EYB1Q"#6YWF7TL(QA2),.'%(_SJC6S:4631Q
M?S,QR,W/42<)O2EH-3Y>A+2HO3[>,?#?+=#F?0!@#C7YQR["Y$^_W48)-5"Q
MXIWV?K82F45QR5[7I6MT^WT-HI@;!\=L:XUJ7LXWIY&9JMC9F'M:9W/#[389
M?H\]@`59CFPG,8(!62V,8#%=`TR.4K0HSSD+C?U&9DH#5,:1:T"N^&A!'QVE
MAA$?\RCIZF*&KCG\O7Z&C4%$\W<SL3M5\E+!XAB!K(*&9F@HUI:RU^Q%.G++
M!;=1P./)PO;#441V`$3,%!51\^'H>2;27**$4=W#AC#.N\\J&V9[]SMOCV1>
M0A48G(/IJLXONA[K#=+%METMV2"%CEBT=36LI0L:#3W%U:`6':C::K>K$2M:
MFTA"J7<U>D6*'S$$?%=C4Z3PZ!+B7`U`T0>GT@%<#9\0J-\4F7V)V6GQ3ZB+
MEGCLP>6LXUD.$_;I<M=Y*FTQ:'EUV&9*5T.(%&P&8@9<FCP.%^AGV?754@R>
MO&WV.L4=$>F:@I]M5UA=)BV^3C'=!!*^%48GV^ZB!DF/*/)UIM+H9WLV[+US
MD_+<(7)]1SLK^9W7.<1HYWA/,_L`^"OPL+K[DC?.F&?[#9F8:SG*.&=:YN3<
M1WZ8DDOC/BI_T9ZV8,AQ8O"4WZ99G<3I_!$D.[]K(]$Y\!F/UN^_71Z?`WQ4
MOA*].\M5/X%AO)HW@JO^`_.0-40&5ST)AD'KZU@8_Z.))H`2"2YZCH9C>AG6
M!(+=UWP_!\5I[$,)F<997X8>CBR#C9Y)S=T3RS$&'<[S,R;+8_:GAOFQ<J7:
M,T`.'S-KALX=J!2-<K*]1SPSL6%.<9`1S_,^NH,;H6U.8Z!QSQ>EV,Q\JX%&
M/=].XZO.2..>L=@`JS[.B&?[LB3:C#=/N-4JU<<9M[2CRK_/1BJ-<W,V4VFQ
MU[.A2N<6=C4<=@C4:EG-U:!8XZ@U;TA7(V>-@];7]J1BP[-G,H#>:U::8`9"
M:@AZ07DMIQR4&=IZ80)'E,@_P9A6[\K6:!(%CX2D^B\OY%\Q671J^A&6+U<=
MQ4S".%S]#CWRN<\0^V0'\I,S.2VM>+Q11$\*@87\*X9!=G)0U/EZ>G>_$<VF
M\R60[GY&=LAMG,`5/863*$KI4:MKODZC_"QNJP/+VCAJ`YA)1)=C(`_"3'75
M,0Y).3>/6:F_H4=C0K*:*`+//B`<"Z)I!/A<1-!Z&&J([J1`3=W:BFF!OMM=
MKB!9I?I&[#!,2W0TD\"?"R*?O0#<(5RA]XB2"1%^P`8$5`@F2\H"6[[S`6DE
M"ZY/*^ULAE:,?`""^(X(C?EY?4)$C$J@%^X<7%:!(*TAS-!=O&Q-I(+LJ?D%
M4;DSW/@E'L0]S#RLE-\IU=CU15DLZPV(?0PS89=%HU)_DQ3/Z`L0*<B%/]^+
ME^V_TZ7=E<($].N,9N:1FEI6S<J<[UQ%O'W)FHKN4#:X-Q6\IO.&%"^01-EM
M;6JHFCI,7;R@@Q6X7DR[+WX\1<SU.B'2NMQ.0<PNE<G55%)EK;%1P)TOJ+N:
M@6P0K88BX71BI:[N7-\$JL*LJYY`,W!J2U.N^@H-[5)Y5=95[^$A@<ST;%<=
MBF:`5%-;774S&L522Z%VU1=I!EE%=X"KD?+:QOJF&L.Q&+A=\J4O:!(*H[,/
MD?0"4//\NUMK1]WMH@JCXU5-I2R?S;.K;"0[A4<IY+;2<[I:>7@[G>^WYZJ`
M0SJD5:SXRF,,ZDH?DG+E@@<<VLG)H`\LEM)54=)KAP@AY8HCF*2Z+62+M[6`
M=*5ASNYZI@L<TSU*G\[-%,ARP;<4P]),QW9_RW0\L.N[G]?;%0E#QMZG849=
M9Z7PLOIYXY8U-*!4V6*N&DW[P"?'1?2LI,>4\:V!G=:-J&<F/0TDI26B7O;1
M#<"OR,&CK"'.]C.'YM?*;22]'ZVI8;0H+$Q*S;0R,OECRC,0T"@M>ZJ-84.L
MOH$8^$F5#T.=G@7_%#_`UMW/QFSNR<9<17`._6S;?$H][!$>Q@Z1ENQDI:8>
MBN/6;KG:/GJ46>1OUN=_9KVPIC'`*.:WYP+IFL^#@4?M#-+/2A'H:&R?[NW$
M]W'JA9/DVL-X2_Z8U6&2F@:O[PAFE6]T83:/J(>9S`B`%P`3GC_Q_Y[".+O1
M"C'@.O3@BIV<IM35E!$I>\PXDVDD">SL8^9)Q[J&TQ?"H'%^X2`*S'1.>#7`
M.WP[?J)_\F$`]@K6&!C0QKXNHWQK*6(&Z!8EN[;(59VL4$I=<_3WI!;)=G:[
M^CAF'AI4W5B2N\I*1*.&+-AZ-()S8;CNK%(79/BH[3#VDX..&2:B(,>[&OFI
M!Y@&<W7=7*D&H*0LZ6H\IQIH)D0:5P,ZY90JX6TJN%6<C>\R`-O#*04>26B)
M3;"Z3$FNA@0KPB4CZ;L:XZL#5;?"[6H0KPY:TF:4$WA4[CE!_M<E"LE$XUN"
M1K(=C:MD\LW#04<YH'8;,^64O'CY##9$Y8G\LL+U'<(OZ'H)P?SV.SEG"=R`
M0K9B61P41[!2L(@^`#V=9ZLOKE"TW]`VO5U6?79;.V6A5BO"F2DA12'YYR7A
M9(1#QP!O0$`V1>ZMO8_CE&X6@<-/;1S+LQ5ZQO;;6:8V!W.2)DO"I'_G&CQ%
M/:PX68O;B-!%;3'%;5O%8O\*DR41-^$&!D2#OEVM0[0%F-Z1&+ZFC,(IYL:U
MA`8YZT&3CJ?0R_)M9\!'BTBPLG)][3G2$18>J)U&9DK&Y>LJ*`.VT\(&.B4)
MW3R'U=(*Q;F()8[OV&EDCT[*`5!$TU9%(@*[K1F'I_>=VDQ;!Q/@<C'S],5G
M+_3PEOS9IX+R@EFW3&L<&[@7A`KW<KN-%1=B4<RV$+)*J2.K;<#S%HJZF(E"
MKU9N.B_-\$^82-C%)YFQYUU]K*!;JID9"4\>GN+GA"JGF>V;D)Q)'SR<Y3H;
MBOMO?BL;^`;$<!%Y^UYCB0[VL984!#LZC64>](PIS:'H,!;ZIVD2)QZ1-*.%
MPB2:O>S,I,Y4*+D<=2!4N@-W+EW];,QF1J5^@?VE_MT:=<*[LMG"3)E'0*0R
MZ"?%GOL2P42P4:6Z6$&.0=/L^8L82V$?&[-X]I<@2,/RMK[:9J8?4=2DJ(>5
M&0!,H]/;C$RX"J(>A@*LVI;+IRS^_PY5XC(SBT^BU\#4E6951?+J;F;HHY?0
M%1$C>>:3JVW=I"`F,V)G_X]0@WT8@YR\0M!GO;<U[+>LG(1>DYF!W),#R/'8
M$/D]G]0'WAD:Y%LCV#^_$!9-KI1#;!_^IXYJ]^3&B_N(7&UIKJ#2E*R7I1=-
M,P]=_(DZZ./[*)^HZ0VE^OFCPO8QI;?2=%Y[%"45K"&_>)0(%K/8>#"DH@JY
MM[)],11\O,^-$KM8R*8RWW`44'/^H[<2YV\,\JD!;P7ZI3C[Z0&N('4QWQ(I
M9SN-`,M"U&,@*^M.K599#<6&.U>@B?+;6Z5^QS@>R\R`V<?.+`I3+0AN4ES=
M]CE[>`3?LI_XTY'J;*7,/TRH"EA[,45E_IEM1T$U]<1F<4M44%C"]0NZC1*R
M<X1,3G44,\])?$,O2Y3&7E8PK`A\*64?:H$G"AAE0GQOH^((IJE^^0;"#="E
MN*NW$6JSX.]O&-*XLRR](([IBI(;B49[T:0#%I42O:P^R<"*`6L&U`XC'KB>
M!<0/_VIA*S).51!=NAE0*HPX:Z7\=+B07$^0T@2*[]=T/2&J$S`9YZKK"5"]
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M5`G-Y1D:5N!I"<_',SRB"/H2IA_/,(E$;O?+(@^9M56I*BKQ^;6LZ:9%]-"`
M2Z5QU(*<FV::H4&7K-91P^RFB>=0,#/+"=;@NFD5ZLRSY-UGIY(K(Y7*V=I&
M;).(ZS@)DRJ%LF-7'N/)(2>7V%E=R[NU6FN6=<:+P^IWZ^K6D`WM@!M1I?_G
M=+7R,/P]^V8K9C^/*+A#N(P;SJ*R;\F!IG$O-8-KQ<.Y^$:`J2K.Y2)D*%>P
ME8].T/C_#/+7A@`3=U0)[CFHF2K1[)TP6:\QVH"@$,N*32<H):TQS)#T?XF\
M^M/YNRK;/VM.HGLL,T^NEN&\U3,PS9#>]C'F'%_&G`R,:KDNH+;J(%E%L.?X
MHZRHPR-YSVELJN[0@^8K':9KJ!61Q419U"CS>8"OCG*W.%5_R2!FK[L3V0W3
MS-AFMM#Y#LCX917[2N,4,_],\1?*+HJ=\BN`BR79)!,:I5$UR+L(2Q[:(NE<
M0<0Y'<R,2,L)H^E[:;L.OG'Y1L+SZ:ZK:D@P3<A:9V^AO$3:/P-%009TO;+/
M`,MB0DUUO3Z06=A'(0`Z7Z[H(.YW+6N;ZS60;"(O82<\7&$E:XZ%!W+$HYBB
M>(U"PLH1SI=@@4&^`$6#]J]1D"5TS\`&1"E0\QUP[#Z3^7R[\K[?1S[?2KO7
MQHC%:;):@$C\W78+&U:)YIF89!$\7OV7%_*OF&AFE)<+WQ]1'<4,OE1M_!\0
M`=^;O`I`9C0S\OTKCYP3_&?@A<G2)[R$3P*GI2$JMLVA'T+!?N.V-47)'4HQ
MK7<!O]_!#:#_1_[79`6_>CXD&WWIA4*4%/KKGY48^.\6:/,^`#`_)N0?NZ>#
M_.DWEK>X('?O9R/X_1FLT)K<:=#C8[379G@<'L#""_/9,ORIK!9&T)"X0-B.
M!]7>AZ&6Y3E2Z6F2RM:'6A<NGSY^'S-ONJ*-1S;05P)#^<\[^!T$-XA^>O4*
MHUS`PFB!/?9+J/KCF/&U@C3TXD1P=G=:&/GJ=(6B9"MP0+<;V)`PIGCA144\
MR341`5`(@U+:>VJ(H=/Y'5F=R(=>6$77=84[F!G;S$K0,_'DX20"[(>Y>:T,
MO7.[\.(ME;T^0^P3;9M/`J^IF9<0D;\47/'-GZV\ED`^,)TWI%71&P_,ME:]
M5GJR>EW20XO)NEZ!M"^JW*/G>D'2OL#MR[NNER'MB]BNC.%Z0=&^>*EII*Z7
M#^V+YHZLZ6HI4)[N7^'`M#NYZO;K1*,E\;GJA>M$@6<+=-7%U7U(=HS?KGJ<
M)'8&SS[KZO,:W7MCSR7CZL,9G5"PK`:NOHPA,"93//:Q<C5B3].^76V:;C.N
MJY7&-6SMY=;:VWG.QC!J@M1A(W.V3)(F7,J'V/V(3:.6?GF,3R2^6VB[;L5J
MJ^KYAT-NO.%(];L]]]$<X57V\[$'((59ZZQR<@S)&N>38GV?W?(<!G4.@^K\
M_CD,JDW)M8<#B#9>[*>AAY^].4BVSTD:;!]1DCU=13@KGS:%WF:H;1[X&?`!
MS%^(>\(H2/WD!H3D#[AFOBU:9?N:HI36F2`GJ4P<RS]);_\LC'<:W1#])T3K
MK"[/AK;@4*T^SJ`S`($)^@6C6"EO40@1[-`B7JL14-K*J:!"ERCI7Z[ON&:U
M9UB0GM.#9M#<T#/JJ/4BT7%\\Q$FQ4MU'<&<JO_4KW3(S&>_FQ'^VV",GV$(
MX@1%Y6,&)0ME,5R9;L<<CFQFY6]3C-;`B[Y$1!@02LFLED;6]PZA@#X)C-/%
M)%C!"%*1M[`_E!_]#`+H$S863\@-ZF_S-"DOY`MD_0<U-+<-%$:7MAN<`](/
M'Y#.B555[&R2UCP-D[]XK&9FPKF[@E`'"#T]_A!R(V0?F-9N@BQ:=6CRYG0^
M`VN$J<IT[25@@3#[$I7K,_Z@?=XWU\MDB1+@+Z\17A?L1T"!H+D+X?+5$U8S
M`%>O*8XS+DRKUL1LK;NCAU-!_,7@G5\W^\W&LYP$TE*&RFQ?&<8OB!Q*;\NF
M1[:S*5HS%T'D@UV%0`A:9R\SU)%C2_BN%[+T%O;>%O<P2]4,4-L@X2;WT5V:
MI!C,T-8+DVT)1;%2N\L(.TCO,:SA^>7?K>B91E_B9X^`R:%@>S\O[;KB"?88
MU\;=^X1AY,-U"!I^CT*OOP&QC^$Z=P7OW;0"0TZ_,>V@D)G"I_@9X`V1MH63
M8S2U2#.]7`I28J'$Q&]O@_JV[2@36TI6]AD0F2:0M4EI#'0**73/8$$9ZB=`
M50JB^?ODVA#6[^2VMT)]&6_2I$=P*/GMCSQ]L<\._;*>8Z*@9,+GCB!3&D2S
MDE&ET:,T<K"VL_98-O#_LKZCQ);U@FILA?;.KE[]+68^2J,$;^E$/I;_@\[A
M8V,.Q9]_^_*\0V;CAV/.3N(E7WXX)U^RX-JQ)[O^S+7EU&E'G\$VA>JIO,=G
M"B^5K>?H<S^&LO8/_]3/4<,E*'+@Z#.#`Q8Y^'B^%%32S#^Z67Y$*?KL])*9
MM&$ZU72FWH#)A-DY_S"\-GH"`Y/SS\5K@];35^#\`_,]@&6Y'TJ\_G#&2YKW
M/9Q2(J="['BM(72XG5TMD-,',WU#NJN%=OJ@J9<@Y&J%GB&0%"4JN5K@QPA/
M[!44XFJ=H%[(RH>+N5I;R,S&[!&-Y6J=(DU@N8F/KA?0U=F`O-($KM?,U;R-
M)5.T7:^?JWDB=4+"7"^MJ[,1I?(G7:^BJW7==J0;N%I*U^Q-*CREIZ9T[*:\
MRUOP7:^NJ)->WT2O,\BOWG2GIH^Q@>-GG-;Q/&[Q-<VBV!_<DO]-E#Z^=(MO
M=]?[%:5AUJBXI5#WK*A_>7+'IJ.6_$>W5!+]6O(?3^Q:$11._^B6+-*O</I'
M]_CGN7"Z=*EF5B5AQ<@`5P%4*HS1=+9TYKO7M[6;B!E)9V[NQ(XE<'T'BA*C
M&1%,K&3D$X&(GX==>P@42L[6VJB;[E!YU`R4BZNYGELBN72R-P6SF5E:[RZW
M1#`E0(0E$>LMXZ9_I#/#OA4MS8?3=>XNS.4_/^<@?L[A.4'^URP6[1JMUD0=
MR#[%_NOM=_I/H/:6@YEZ`=2]-YUG@5[""@'[[:S4[JW@I8[)&L`9"/-(C3B)
MGY=D8[]2B$L%H..%]IZ#6JEDNUJ':`M`(3YDU.WMJB*`I9#Y2X\DT90@RB>U
MY]G<`<;T5VP@]0E$`!/N'@5-`6H#BB,GW/-R?6W,ZCXBK`=4]]A#L0*"6BNB
M'B.:@;!.C[B/F<I&Y%8@%^22"MV-4!)^J2-1>RO5@_PE"-*0L#(SIU?TLL`P
MW[*"&I-@WK39C:WZPXW<BRVQ=YA]Y+K(/-#%W%H9SEYU/7M)XLYKPM1QP;B^
M$:7NUR9>#$7`]0PN:8PD1`/7<[24]Y.DX.UZ3M:@\I@$OSN1VAL'@]GX!7_(
M5.V1&<,,/&AJ1OR??/-PL!NNO"/UM]N<C5\C-WX]HF@#8C*#;-WB%Y1X8?-W
M.K%'E/P5))U5EH?[GE/HY>PM2R"IDI@^'!I2-A%6<::L3_#*47=[NV8DS@W7
M\/A<;>LV94I"QBRE3$=]QQ^/N:@5J<4F^?;O*;F?[R/"/=-L;EF,X,O2B_(5
MCW_)-OQ]E._C;,O?>1#_XH7<]TDM$7-4N%=D3^(X7>6SHXJ(3^9W`S<P(!+.
MC-QWIB&6_NY1H=GE-S(P\%'A,2T7%F`?QB!NG9C[*,$PBJ$_R!E6^?0Q8OJ)
M-$RJ6?T*X&))!8(-P-X"9#_>D.,S&(O4I&*42'/OT5JSB8*GT(MHV*?XO8PA
M/F6U'BQ+_^NVN?<%UW4;])!>J=YBJ>O@&Y?@6P%?[0-S0N;%`<`T(8>Y7_#1
MG+2J;,[5LR6Y[H\]L@7AF*=<]W$.LTH'4,1==ZB.;&%T]2WG_;>C7"8Y4X/K
M53E'MC8]C;NN%P$=TD#!E"#V'2^'*P<Z,D_[5>CY7XD20]K&.21/F"8-+CZC
M`(2-N_@+Z?B"KKV0IFDV&'TCKJ*&-;;AJS][P<^^D('0?.V>U:O*K%X`7O$\
MX`-^\.AWXPS&7^\P`$2>`81?)H?:C<SO'CV:.T+\+XBP-!B2R^M0L(H)<,Q`
M/?PY<-VN-/)%Z;)6N&E&&OFB=/`XUVU)`ZW.0/+0X4Q&(]/"&JK3Q$\(_TBV
MV=M)I>&`/A<"-X"JN%94JW,8]#$I@.<`TW.`Z3DT3\E>3M?S,16<$?/?.7*T
M=@2KTN]`K8<#QS)V?OVHS$2=<YL!:L^F5191E-TIJ1<.8C_J0<DQ[N4[A.<`
MTF?#*E_90/N6]:5C1*SM`CY(1.U1XC1-DSCQHH"<E(/$>/._=^3H#7HC[W_G
MC);"=WZ[/':\+$@PLE\_(SO0UVWNVAXR&7]V/)GL<B#I4(>28]S->40.+:9<
MFB@1_5-C^I/%`H.%EX"#W/'Z]+B)_J"7G?3GW<36`OON2=0Q\G3E*1_:$&"0
M0",5.+7W6#,PK6'=$/+M0WQQE-SC6))!CP(S7E#V$!S6+!%'B3/#T&8#:54R
MCA)K83[(06!6H,`*PO0.N(_C%`0W*6'[BYS.;$HQXX+@5IG2&.B<,G^.Y.F.
MY#FGS(\BR_N<,G].F3_T$AB+(C&9N\@P[_0*:5[G]V3BX>2\'/W=O:Y',@^T
M"AIBH%Y4\D\YTE%F!`Y.$NLA0D+T@I+/BS&$Q[E?XGI^']Q&Y^48U"5S\NGJ
M-@L_-`-9#Y?4?EX(C3B(>GG^[2S;FEXDD^;+>J%^.I^CPRV1HM>D?KWYK+,?
M<)64?2[U.KF9I7S4MU)+QOZ@H>>?96R+H3GURKF9S3S.59-.BJJ7YUP13W%Y
M#AT[6R_5N4#>X9;*9$A<O8)G*\3A5E`KC;%>JK.=PHI$R"T/^D'#,G%>D,.G
M'-0+=K90="_80:*)JR6Y/%%SQ`&+MEX.;4FP5BXH?[OWQ?L.X@<4QU=@C@BB
M(`)SF#QAM($Q^?(=PHUV-NH#Y9^G%-Z134)O>!BEA&%-UP!GX!24-\@D*TZ8
M&ZSVYD[08Y\1;41[:M!+EHV(2+SH^1X#'LG\/\,H.W5E$4/"#MJCY-6O/H-D
MB<@O]%V'C*^8`TR;`GL($[IK[M!1NDK4P_Z+\<*9[+]?KLE<7*^).3R6%9MR
M/?YK>"CU.5Z_.I7T/8%C$G7&)^!<IYANGSM`EL$+"1E41XOB4A3C,."N7C:N
MD9*F_%2KSH37R^),JIVA,A%>I_'-@\58.N[]'@-:G/\SX2U4)7P@7U(]81U]
MK10C+3AT<?C5=JED9ZOSREF!YKS$G6W.2V]"1S03#8;29T2;"+38@M["2@WA
MD#IH8P92"]*)O06-H?_-W50H.F5,UQ6P0>#L$BM<?P%@F#W*U1Y<?_5Q$#BY
MG+#?.XTJ:K^EI/;^HDH33EF9NU=BQ`;@5S3V;3H0L'("5:_$AB/@`4/MV@Z-
MRO4TA(%@[<93*V%@_,Q5T9[=YV8[>UE4MIXLEFX&+FJY683'5V?/'9M+9!($
M,"?J/IHCO,H^JN8)X915O$Y7]$5?N`&?,(KCZILS,CFRJLMK@BG<\[HK=3W;
M7PW.JW!M7Z,T2O!6^+`3NZV5)ZGF<T`?-JNW-'U_;P9\%/DPA#G_*4T?5,I,
M"2';5F/.'$V,;*0\:?&)*5XOO>@&IPO!P>&V'902LGMA?MW\E1Q/%;IV>IJD
MLN051*NX`1L0HC5U>:M2K#**55OG)$V6V6TC>$F/TW@<=`M+OG*;6Z4]E[<6
M(/*WHH?A^.W/]OU>,V@S8PIP?B[+0]LUG\[^1OC1(T@*<3Q:T'B<:P_C+1&U
M:+1R-Q]2Z#TXM<UP&55:6WV'H_0N_UK\B*C"&:8!599*J8ORCS@&[*NSSW!&
MYC,#7G@;9X8P_^\II!]88I0NEM1^4YR[[/'6@JBGE&Q1+P:3!09Y8/P#YRE&
MX\/;*7O;,!'^)<4P#J#?C-IGGO6N7C9F0E"&A'W"US0!P:V':?):/)T79KKG
M]#6&`?0P!+Q[7&$`(SOS2T1V"%I$\/=LTQ=:2IP792#G`@.R3VY`_E^RSV*B
M3I+K+?]].K]>TM0-UIXT,["--:3).+D*$(;HFQ?Y8)<KY,3=1Y,559(X*ZD\
MC)'UW/]J4>SW!;&?D<YRQXJB*:QU[#?@*(Q&3/F9:2_:DUA=+U+<):NW+)1L
M*X+K:>\J$'5>9*YGF'?J3^)C=R+5K*50,B\XNE^C6M=/L+\.KC+^H=215OJM
M"<.MJ^[!0RR`N@3K:IC@D&B;D+==C20\Q"Y7C]QR*[SP$!BKV#/Z!1Z>)LZ*
M=EE7XSRL0KQKJ'>U!+8=D&6M]JX&@!Z"2RMXS5P-"!U\<^N$'KA:7GIPL*7C
MRUPM#'VH[<R(/.I5ROD,:7<(E:L5EP<'V)"O\G`EE<<0!%S]LZJ,4ADH6#'E
M-@JEL.V%+.K8ID1QB).IT<\!72-(V+8?BE9:3O=4F'U+H%J,FLK`(\)C-P.-
MGJ`;2,X<O28@885*('2.-J*9<S:K7DBZV6^,"*5'1"^SE'!@<A47LY@F2VY4
ME_(P(Y\KN^8M?7J[/P""L4>$2K9,D^!OJ4PMSN[>(YH9.[69&]NG.LJ(9FH]
M`'OHV3V#)`ES!42FQJ[D$#9C(0Q+U1+V1MT+T57GL[V5X#,F5QW.]K!64@A<
M]47;@U\@7[KJD!X7V"(!UU5_M;T5X(@JKOJL[0'=;==PU6-M=7,;<EC_E*,<
M92\?C?Q=T</CO*^1N^JI/B3&]HK-'$6PO;$E.%QD^!C\=\_D$H)SZ'M10N4K
M%-$#.YWO:1M4VX/>*X$K@:KO'7!R"?>^<>VM(=F6U/]:,NABTS-3!Y7ZVZSW
M4Q'8+L+%L0!U]3*2Q\GX"-EU?GX6GC`BAR79TECROZ<P"T&26H#.08:AG3Y3
M\NR%8#J_2^FK[S.T]<)D/PE:M?<H]DP6H22[5?+&HZ"[P2T>05=1*UZO4<Q$
M@?PQT2Q90)_9911SX$942Q\'P0CCF*'`4<EI/`JZ*T6JA6F'ZT9UE+',M/Q;
M(4KL)%N546+*?MA!/C52S.B:X@V@0N3$]W'JA=)'6&ZP4<Q;.D)GK"$X#;J:
MLG[G))J-'0ICLUAO6G2/LW(4I>Y,U_V@O<'KNM9<=V[V!G!7OW7='6EBQ_47
M+USW0\JBK&P<<-U]V`\XH37.=8?@`">;*02[[N3KMP6[C9*NYIN:$PAW8E4<
M=<#UQJDPL[KN5.N-DS#J3"FE\YA\Z+UARVS(_3(SG=Y<+7N#7@;E2>VG7>]*
MORJ9X]]:FJ\=L?$]+0\_)ZW91B;N<3X44X3JR1#-;#J.1S+.CWO8>-SC@5-7
M7Z[/6&9Q?J+D_%B!SF,%[(N'/0->ZZ.E_+?+,=%>UBVA[HPTI`>5&D:+!S;S
M$B:D]1.*LR?]%*>J.OCH<7FB@MTPJ/"&'CTFC;R07V&R).W)#^6]*WIQQ.0W
M1H1261%HD!.E.OCH<3%RHM2&'A$FLSRKC5#5HOS!6\=@.I^LUR'TJ<R4IS"3
M/SW`%4P\#8AZ?6D4&O[Y.96#/*?BJ,-DH.=4SON);05QM4"FDD[?KFC.41UZ
M&1W7V>U&]BM.3@,O9>'*]>`V4\`JZX%Z06_'Y(P9=L]R!5_7@^.&W;$2L*IX
MPDYQO^JJ^7IA<Z>(<#^U3R_&[A1Q_NVR9R1=+E_=1D>(U_GY0S,HL;?@^4U#
M";P._J:AM;"*9["@-^,,K!&FLY\$`<PINX_F"*^R+QLICC"9S[<K[SN!F^GW
M8[<QDEX_H8O_/X2S^I[@TWN-C'S[RML"S/]J\V<;UEVRYWVR_'D=D1F,OY(+
MR%^N//Q5&*70V6T<<]E69`EB13J[C6(N1#&@?_`6X(/L/)I=].<0`__=`FW>
M^[F9C$[A8_D_*/4?&]07?_[M_G&'QL8/-M#\[/T-X>LT3@BCQ[%@+S`:VJ#W
MT5L1T;E%C/`X\ML;X6&/*>5/TWE=3H?J43"Z2F,B5\1Q<8>P^)ML5Z-T5BFC
M"@1R^QBAK#Z*TWF9]O$4>E%2)7X\@N0^*I]VVR=3;0`;>[9%53.EA5]L1-C%
M".XSY"\!__9M_FSD>S0M+VX(3GNJ7_/K_,96HK0H-3.P`5$*"/[BV"QF6RM4
MDP4,4IH+N2O(-H"]VA8_BJ+^=$:R,N.<@$\`+;"W7D+?"X5W`[^]1>IK=4,<
MRLAM;BV.<1=+@3#!;V^$UWSQ7Y^6'MF8?/ZVV^2P4N"79XX42'ZP:1^0U7E:
MCG4V=W0]:5A6I6I"U0VOZT$M?'6CB9-`R'<=H$[]IDJ@9IAN7*]Q(`_.W@W@
M>BB4/#0MP=_UD!YY6%K62%??K=7@,GNF::>?G.W44NL'ZCLM*H?+/#T*H#I-
M9*Y&=<GC)6?B=K4RF3I.8L.:JS%7BN=/T<#J>H&Q'F8QL2JWJ_XY'WIA"$F6
M2EABYZR:9P@[@=VMA/#R#"$3PBXNZGXP4*>YG,+4M%BZ7K]."1#JR'<]9:C+
M)=%B13K'T75K7J=?I(4@?_N=8+1=X5&XVM9X3##P;%0R(K)>C$(89)//K@=Q
MS!2KL:5(J1U2NB+7V,V-^.1NHX3LNU]A`)[(`L_)AU!6>9NRE17EJ2TY4!@=
MH#N4C36X3:G*)0P9:#6Q06/[A)6^O*R8\BTYV9APAUH^%WNEM8:R,>><S]!;
MJ,EO:QN5<,4D.]N95XXXE_+B9[L1*?4)KMA\6PV\VE8707$QQ'(1*OHCGR-6
MSA$KPT>L.!PY(I"1=BQG'*G$=6V@2QYKHB1[/SGM9.HI,S;QU)-Q7#>&]Y'\
MVKNUE#I<=;H,(,.(F>+).1&,XBEA&'?VFC$,:3].?#:C"\SH;L4Y*`'"MH^X
M&MK0SZ#>XQB[+E*?#>P*!O80^`D(_BOU,*$XW-[!R(M\2$#P$H_]5SO6]CB9
MSC\A%,3/J%[W/6-UNY45VZZ'(W+DXB>`LR?[.NP?W.9CH/W*BZ$O27C>=@Q4
MW\`P30!OC_!:VZM57[$KJ3KU^ZVM9%S3Z#!*SD/V:!:3WG8;&U168;B=M+):
MVK'4Y^\L3J+@AESK(<IB\8KW`[GF>U&?L[^!G[>;W13\?&MF4YN"3=?=TI*A
MV;S<5=.@"8BJB\-U9:SCWN$E<M;'Q7653`&@T[%R*H"R)ZZ[;C-7VC#"*[Y7
MNN8&X%?D$%9,`<[U)'(%?';$<-=C<160X<L!ATOZ/;!5YQ$E('Y!E:VFPBF>
MXH47P=^S#[:<2H0'/36(F<X9G1M5(:/@&2XB.(<^3:WR,_LU`?F)C.=#\FU"
M^Q41W;_:L!#MD].A3@LZ6-%5#[U&'$7XT&38Y"?=>Z9U&1U\A9Q]IG8\K*K\
MPYEE:1CEO9A*L?0_-&UT0U1%L@@9:=LN/B/7UTB0.8V/PF!)Q&NXR00E,85R
M?:R'[DO"+.HR!F.]W#2Z>EE]:%9N"MSF1O;X?;0AYP?A;9OQ/:?TA0&`6XG)
M,ON_UWAV'!+?&MP1D[LF)22N:J8BMTK*PQA9O>:E)[$XHN9V2IE6+[',@!]Z
M<9QME^S6#OZ6Q@G%[P;$/H:9U,'!7GF8495ME=M?TMU'YWS*"=1Q014]+3JB
M9OF3(?+79G<_*ZZKPH\#`BJ>$&AS27A=B,?W&4\F\@K=7+%PO71&LC-CN%[3
MD*@H^+,7!63\!34MRRVB9&<SA8SK.U+YKI7N.WY5N?LV<]W_J&92$$OTKKLA
MU;!2ES)<]U(J[C4Y;=UU+Z8"(Y-GZJZ[-Q5`ZZ>)NEZL5I7ER2H;KOM$U7"3
M$/M==Y6J`28K9[M>,%EUFTGHRZZ7@U+=:!HJK.OUJ-4@[+2@NUZG6@TNOIG>
MU9K5&D);MXNL!NN4U0)];T.-W]`:PFA<^7<>Q+]X80IJM[S=$"$601T>=V$7
M&Q91,:CRDQB'55%F19KGKF/V)Q@O(T0DR_>U$MI2D957$/\,/$I9,(V(3I9B
M3%]&\&(HOW-EAQG+D3PVME+GE5/[X(Z-D%IRE@@G+P"OJ'DG-[7FV>2=3IC^
M`Q\3@S*!H^LN$FVF+\U+#N<X&<T]4)E=:U"MREH,>CK3F_D][,1W"1"5GL(X
MV)C$:K1U9M'43U#*$@%B3\@Z_C-67Y<59=>$I8.B%KR\<-'1_8C.GCPD)W@.
MN0ZQD=QZ7/HZSF5WOU'%.LK?B$I#V#RETBLGY9\]WYOJY]7>/7HBIU;[K+IX
M0D_[7#Z@:$&M$#?@-;%Z85("I*573F,;AXP-()ML=EN;1TF,>O/\<.9YBD<&
M>#&(>\N9G/AQ_NCM/=71V,91J+[><7KWV]D\`ERJ*Y^X8$G.VW\,8ENM*=^E
M"2'I,XS@*EUEE#YYV]P]AO"UMX:)%^834#0K:`]LUYC2(GM&]TG8H+LJJM,?
M$L6QS^S)"'LR>0!<=S;U`5+UY)R@V^D!>J\P)*3.0$C^%KP@6C!P.G\B/:*$
M-,T!G:&M%R;Z)8)X4I/VUUE2E?9@9[9F4.K27])3E,ITT=*1VGBIKQ7S5*9&
M)'F8'?M\1,T=47,+?H(G]AJM5C"/^Z')F"B+(`81#3@>B0]+BL*.+:TVAIU:
M2DKKT&.:XS#Y::UJ.U5=#;`3/-O/"9GY$H5DXC%U-"1;VG8DQSHGJ.LUDG8C
M.V^PRH+(L51(][=:IIZY&NW'ZJ1Q.!\U/CKVS)/#'SB>0$ZS`N/IG')L%&5(
MW2%\'\<I01%\(4N!;[_#F/+O_//-5,PL\5)",#?]C7$>QH'P/,$#>XU"LG\0
M-9]MP`1CCP@/(PK<4B&/)PO*CW!T]:4[N)B9L6VR`*/HM,5FA8UUY@LB?.Q=
MY4=T=JSX&WF+2#7%1Q3YG)]?R+]B0CVM!*2:3&;\BTYRGT&7Z`2Y5<V5,G&P
MDO(*^R>MF1/7)4Y*SZ'="#M9DE^;)'=%XO4;U`:WZKMT/8'@C&HU"M#(SFBR
MF]X8GUF**F;VA*(S8]DGF5W>JGG=7FWW%G/RS<.!"J,Q\16[`N/M:AVB+0#/
M`&^@#S@3"C-:,KFG*.7W.YE.5@$VVPCRXJ+I[]E%CTU^9IC**ZG%$R*Q;0C[
M4Y2JM0=VZQH;<)^Z'FXWK$QAA+VZ7E5[R/.@SWD.5XM[-))=57EP)#9N!CV=
MY0+X/:P^N:12DD/0Q?Y;IL+58):Q/!N.NT^7P>C&^GG=*S!'&#QAM($QF21U
M`98DR(0RZ@TTDE-V9'RB:?9<K5%$]PNMIU%0651HO@(1F$/52B/J(]I%X*9@
M!83*O'[6)`K*N,VN&-R^HUE6,N=S0*414"W3C#`/*J$35A+"C%4I3E]C2+L8
M?(EPI9$0:HL-&M]^]\,TH`7?5[2(+:TEG7B0EI5^0;??O16,LN8SD*0XBF<H
M#`F7RN1H-;P&_OP1W-]]+A'7E45%$:@75W==Z]/&4H=+NOZPDC:8BI>MZV\M
M:>,X]+5UN/>:1J,O/8,%_>\,K!&FH8HC,4KLDM6A:7";6Q&S)""5F\;8C!-=
MJ](ZM3(HG*"!0@*7,=3.*-[*NB/K?TM0P`3)ZS1."-_&\21),'Q-L\P^PDD!
M7$37E/%B<I==;3\!M,#>>@G]"0:>O%)@_HMC./R]&=?8C_F0.^8$V<-_I1XF
ME(?;ZK?[B.B&JUS@MGDE"RF3M@FJCF+C#$NN@<8$QW&-:ZYD\]C+0G0^P1QH
M[-WQIW..Z[M)O"9JQDN5L8[\E&L":/G0__$]G0@-8R#_X_\#4$L#!!0````(
M`$4P6D9V#BQE:1L``(4W`0`1`!P`;FMT<BTR,#$T,3(S,2YX<V155`D``S']
M[E0Q_>Y4=7@+``$$)0X```0Y`0``[#U=<]LXDN];M?^!YX>[3-7(LNQD=I.:
M[)9LQS/>LB.?Y,SL[<L61$(2+B2@`4''FE]_#?!#)$%"!"4GU!P?9B(3Z$8W
MN@DTNAO-'__^'/C.$^8A8?3]R>CT[,3!U&4>H<OW)Y]F@_'LZO;VY.]_^_.?
M?OR/P<"93IUK1BGV?;QQ_NEB'W,DL/.(GAEEP<:9N2L<H.^=.0JQYS#J_/-R
M>N><GXX<9R7$^MUP^.7+EU/.O13)J<N"H3,8I`/\$I/RSOGA]/S\]'6N9<HB
MZKUS\H^N.$8">CL>$/'..3\;O1F<G0_.WSR>G;T[?_WNXO6_\KW9>L/)<B6<
M5^YWT/GLS0`@+ISIZ?0TQ]5_.C-&0^@=K!'=.&/?=Z82*G2F.,3\"7NG"=)0
M,>O`#-+P_4F.OR\7IXPOAS#$:/C/^[MX4D[^_"<G[OON><Y]4H"03U*8BR&A
MH4#4Q3D0G]#/!@C9+.<\/X@&DI`U>OOV[5"UYGI'X6")T#KKOT#A7/5.&F"8
MT>O!V6AP,2I"B<T:AY5@JJ4:CGX6O$`:Q9\%XDH9),#HO-@=A!,%U>Q[@@_E
M2$/H-(!>F!,W#[H;3H.1?3R1@>5G^LTP;LSU=D$O!=\4NX?8/5VRIV'2*)FZ
MT&;!C3B'EZT.-&FMGD$/DVHP:*B&P,_NJAI$ME3#$/J$0U$-%;=5<T81<<-J
M,-4DH48:5$C<:AAHJ($0:UX#`BUE&-"P)18?48##-7)Q(P6$%2[`5-PP'ESC
M!8I\F(W?(N23!<'>B8.$X&0>"5SH$-%ME[])+#\B2IE0:Y7Z6SY9KPE=L.1/
M>"!?R'><^?@1M-*1/SY-;^MH%,F".Y3]AM?,C225B'H?J"!B<PN8>:#&.W&(
M]_[$V".C(:7"PPM"B:)V=#9R!DX*GO\)J)P8EY-#]N.PC*&,/(*=84+_IGZ[
MR'<C7P'>P=\)<-+#!+CFL!93T0)R2UD]7/(T%<9!9#0#8I4J318WA,+J3I#_
MP$)%R96/PC#1*"FM*0#\NR&`67@7(+$,D2/W0!HRG\C]TG,ND2]W&6>VPEB$
MO>3VDMP#@M5:K+`@,#768E30.V3YNKDLG5<%<K[K9;M;MK=@]@9X[`O,*7#P
MA*N%J'<S2^V-26I90^BPA3-92VL:P/IWL8&\0,,%A=/"%5H34??*E3N99?5#
M<UG)XP''*TQ#4`'GCH6]S!K(;+:"96G%?`]$\N&W"&R',?4FL$SQPGS&[UBU
M1.U0F.7]E^;RG@GF?DZ&_2\G'MAY!18?<8GHU]=#R[[!;FJ/;X<V_/50VM#O
MOO;:<87"U8W/OH2WU",<NZ):Z'HWLTS?6JSH@-I1N'MYM9!7@S>V&L8LP=%9
M&PGV;V!#B7YD`H>/+#N9;"=TPI>(DM\5+]LYAS]@E7W(\9D[UFR!KTGH^BR,
M.(;>,[*D<,AQ$15C5SG$"%T^`#Z7P-CX65SZL)KF5*9#1)EU4[E&,JSP1YX^
MY2"914&`^$;M&=L1G>V03CIFKZ+6*GJ#"/\%^1'>RL!2G\P8S,(_+PM?+3]2
MZ+?*,QHO2X0Z]XA_Q@+-?3B=8S?B@*`7=PMQRVFE@O'-=M;MI&U$8!;V15G8
M&:Y>D-:"?.!LC;G8//AR]:6>M)_7LJ6M8*T0F@7]NBSH%/?WCL(>N[U3_+WP
MK85_Q^CR$<M@R5S82;D:TBS.-V5QSC`EC,<+,1B0:K1>BO92Q"C$8=OWM1[:
M+,T?RM*,$?7RLY<?07/B$[&98E^>I![9#/EXLG@`"+!+D7\3"9CB*=L@7UB;
MZ>VQF^7_%TW^Z4!.,I(CF"/'D@9W/(B3C=*KB;6:7+$@(+$E"]LJG+CDD053
M>5YI^^Y;HC0KQ%\U&WR+7>W4!?R]`E@K0-[1&;LY9=^VLF^.S2SVM]JN7N&/
M[:7=XG7W?31G7,4UQYPC>'/VL<MM\!DE?GZFK_PNIB%.7O)L&$:=\9+C>/A>
M`ZPU8#O'DX4,H\`<*[Z2[?6*A?`6R\#+I4SP?$`;!66G%?N.8=84S2>GUH:!
MPN7DA^NUHX4'1L;2'M%S>P^,`8%9KIJ[+<8E4X_[G;W-SHZ7\M\I7C,N3:36
M>WH#/&;):KZU!*63X>S%:RW>_XX0%YC[FZPMEZ1I)^&&J,Q"UOQJ,^QC5Y[8
M,O1.AM^Y1@+U0N]\S"Y]T,G874:<63$U#^$>,3SG5?JKCS@?.)SW*.-GS12M
M"1ZS3FA^1JO0GO,J'J37@</&^"Q4H`$:LP9HGL8,8R_=KQ/XLY!V"[1FZ6MN
M16,0L->(%X@C68A_%PZSK#5?8HRN%^HW""[9"'W/,8Q*<5'A;K0(-/6Z\Q4"
M#A:Z8HO3K!O5#D8M&;Q7@:\0A;!0`GNL9C70_)%-(A*]6GRST(2%JAQF)+/Z
MZ$[/FC!%KS(O$Z^P.DWN1&,6MN;\S,<N>@&_:!##QDYHC,TL[HJDPU)`HY?Y
M2T<V+,1NA=`L><UQN#/*T6O"SN(FV]TXYYF788#8+S]9&.,!8\]31!>DFA1%
M>0G,9@71_(K[1!L&SI:$?`T6>1-5(-)?>VN@4]*S#Q+/^?5OZ=:KOW7J-^T'
M.[L?R>II$D">!9^0G^0Z3@&2$[D:R+:R"GX[0LP:JZ=86L5"+/M_[V1TQX`Y
MRA62+>UQ>Z_J!U?U1BOF?LC,*J>Y9&U5KE\6OY:N/(`]NX#]B,6WNYN`M-6D
M-D,9]>RUYN6UU;.,I.SV>?,8<:^+374Q"[UF/\HJ5-'#+'G-A[L-[Q9"O;V0
MF@JI-@9;VU`68@L,9B%K'EIS%'=GE+=7AKV5H9%I80EM5@+-S[I+"7K;85_I
MQU=LDQNVRNW22.Q-P<SRKL@SU2_\]F(^@)CC/(E&HC5U-8M3<Z4FV1F]``\E
MP#AYX1YH":(@C67=,)Y43(P[50NT&:A9P#57NN%'DE61H'=2_`[(VDE&R')U
M>J'O(73U*">^I`PI73:6_2X,9A70;W77J(!Z7E2$;*1>%>Q5H2:%JI0YU6R%
MWP>763TT!Z1=+E:_4WPU3<G")GK_NK2\EGK49B2SENEIH)9:EHO;5()F=%6D
M"_::V-@O65\]HIG;VA;>J#5O=`^BJ?Y$OQ8=XG2I)7,V.UTV!#/+NUGN9R_F
MEQ!SO,`FH7*5F!<PJKJI7#QI=]Z&822_@O")`MB'9Q+*=R^&SJ?42<>/MO.\
M_(!FU=*\E36J5:`JJ40/=,7=G9@R91JGM#F*.">E+L54R#%4!/;J:6,1J61?
MM8?D4GVWF;Y)AV)K4I]\BI\PC;!N^QP`IUG)-&]HHZ3EK-OWI3X22HWN),/W
M*G1`%6IX\&J%Q:PFFA.UH9KTV]Y!MCV5!)Y?GZN??GB6/[5EI`T*LSKH^:QU
MN>J&IF2H7AGV58;FYFY#4+/P]936>N'W[__+B/S21V!TNF`,XG"R5A8E)RX8
M<_?,P_X8#+U`/0T_A=(%<I7,',XJ(4P6'X*USS8X'B#&46T"?[7!S6JG.84-
M:J<H'"0D.C'^04*DHZAT<F0ZDD[ID<DH=22ICJ)5&M0IM8E)G=#;:_%!=K%X
M-L>N($]P"HG/3>I`<@M'%2KOYM6?SO;#:-8WS<N\:X]+],))!TZ/6?'I*AN[
M/UK9IWLEMZUP>,?"\!+#1H(O,07"9"K0$Y'?AY9G[VT_/1_,'H59/33W<.$&
MUT!]`,Z)QW%>)2-]YV1CQ0?RPJ6O7B%:*$1K-=A'^#]H7MZ2\'N!OYC`&QF[
M._N;Q5N1#%H0;V_5'E"@V<_L5<DB=W&L)`*C;?LA5(.H;3&9E<!87K3P9^XE
MSX7WMD/F/N/:ZT@K'<G=>Y.6%Z/2O3197.,%YASDBY[!G,<J@I>&6BM"R?LC
M-&M,Q2>!"AJ3O[VW'54>,-)QE3;%(RO/6F[L7G-::<XGRK'+8-Y_5U)-]F63
M:M1!F&5OOM`_</)8E913O+U<;?*(B]?Q&V81-P$R2[?!_?W>*CB\?),8TN7F
M)\R6'*U7Q!USC'9)N`[,+..*F_JZC-.HUGSC;)$[$GLO9QLYQS40]#H+L@!"
M]5-=Z"UPF#5`]S#NK-4P,)1QZ/7A!?+.QSY,-@4;>[1'!CH@&>W0!3W'=(\L
M=.=51K8S^O^@$/)_<YB"*5XXS^J)@$[O3T(2K'U\DCQ#W)7P!6WY<G'*^'(X
M>OOV[5#U&J[CZUE@`@]3M"D"#?IYSGT%?WYV=A%K66G^$JI2#"N.%^]/Z&?!
M!^=GH]>C\XO1OP'B]#GPTRZ""#G*U1:/(Q&%WSO(]T^&W>6\*,8&C`-`!>/7
M&9HCX=M'<^PW9!GZ5K!\)S$<";?EU[P!TP!2P72^XGX5[S\.T7I-P+!5?\-?
ME+*X=_P`6`<SR:$HP.$:N2;""0V%3$0[<4)WA0-TQUR%R``B_QJD<`/Y:#`Z
M'UR,3I]#+R'1AH+M3-M1D,+94K!`X5RABL*!5)5P**4Q.!L!@EH:U/AYR"5"
M:P4XQ+X(,UR#+2[[Z?`$'THL0\KH@$8!YL1M-BMYR(\QH)R6MW):1C_L0TD[
M*MJ1D!?R&_67)QIK10H@!WUCK0B9./?7`_G$5@T4VA"[ITOV-%2UI/A&8KUH
M0DX57/K'8(ND!2$1YYBZF\834PF8_;77I'B86).1PL@?>PV.G]V5]>@9D/JU
MU_A$%2VQ5H@<6/)[+W6@B+AJL1S9$+&%BG\.M@CL20B):TU`"B-_[#>X6'/[
MT5,@]:MF?#C;*O>&).#]R=AU>82]*]C@"!C`CQS.L4F"7N(LE3;$O\W=8B-(
MDD+>!8S"X8=O;@4.Y`GAQ$'S4'#DBO<G"^0K(T=U!..',.]1@<8;O$B;YLB7
MV_W[$Y=CC\!C2F2FJ;16!)?ITF$$.(F(Y%3\Q%FT3D<G,&H-HXO%)D#/M]2]
MQ\$<\SQS6E/,$.QOL+F\\UB`"*WB)R9&9\>+>.*2/`3AOB^%+O-=:$@\S'/>
MSIC\F@Y[2V7+Q@N*)5AB6BF44D.G1")'^Q>FV$7CN4YY56M'R3<1WT72+]&S
MP/QGC'RQ<A''&OUU';K%Q"9/XIVO:W]]E\XQ4DU[1\F]81&?4#PCSS?D"<O_
MX*]Q0#XC%PBC*^17J90-6*<8CH@O"VC*:+;T3,H[9+?!FK.G^**&SFI#@"XQ
M6?#P/F(>$*J07\.6F&/-W"V_5WKPI.4^>1!VN$?8$PJEUY'/T`*+S4Q$GOQ2
MR13_%A'8>S6YV0!U2W;-RC?>$:I$$A9XMH;-2UD6CZ7+SG.N:H*WX#J!^\H<
M>^+="B"Y&\W5G!MYKZJ"G.>QW/YBIPP/SP]DS4I"]2K+XR=$%.8;QF7=B)SP
MQ@G5)>Y;XNB8?A<%:,53:3[VPG0D>C/#3W!T`\1)9!%8>617*X(7'Y[AM997
M"":+!7%+"[\=8#,-^4H['0E^)PBD=T\X$*>?1>HZ=&H'8V`>X16&D_<3EKG_
MJB;_IO1=[9B=G5T+C(GT^3>44-ZA,,4N!L(]4*\'SKS(%=?8AP=@6A28;`IR
M%.Z)K&J+2./],4\2K;H1-*'7\/KY3!4-_?!47KM:@1_#@E7#&/;VF!43\'',
MR9,,Z$H[+)HSL,AEXD=<P/0>"6F8;<J'DL8@'3J@&&B>XC4B7D,&T\['X#V^
M8GPM"QVHLE%@WQ+D/Z!UA?-C5\=.[5U1H#);GC``A-MK%&!M8<3=U96:O\*;
MVQ3B&&1ZC><B[Q5("ZC<,;J4#@+M1H&:`BNH8YF&6QB&1VJ]?797\H.8WCB0
M0=T2XX9^+[>='VZ%+K)PCYYE)E^ZSCXH6FH9KNG=)8.Z2/"OF"Q7L-:.Y>E@
MB8N$3RBNY70W8+>8+EW=25Y.>>$B798J`IIV8$=@?6@,76,X;<#^(W&DI>[U
MKRY43\9NV&.<D1O.@LHBHJ:I,``=Q1S$@@0LM1]34%MY80H:P_Q!9N`C%I;\
M*XBCX#X[2=T3'X<"R$P.7>F9J\!Y@]Y'<6Z_9J[:RZ3,X+`I2X!D-[,J?*[-
MNG?(O9I6IM'.'^6&+ITWXJG]E7@X^US6%>)\(P..RHJ\1__+^%4$>@='IZJ8
M3VL,71)=]C6C"&P,.$%,YCY9QELMVDCD\AB19[HA0,%%D%#\[>RRFMJGX[6*
M)GN7&U6@-*EJJJMQ&^A.Z7HU`Y\HVK(0!^LV/]O-00,4G9H(``BDSV<,U,B[
MMP)SV%FF\&A"8V-JDY5)SW-O!Y>P#/S*\",,_^TT_P9+_[<_X6LX(5_S:*G[
M4>J[',7N6D<^')A(//K_P`&J`;]E@#SW2_GHFTLQ/0N"99"SCAKR:P7<)=X9
M\R3-(*BQ%Q!*Y/#*%@+[*)(V,:+WP(0+&VPXEC7M-_'*C'QM%3L`KBXM9S>R
MXHO08Y6EYUTB^6<<L/4*UDF=:KVI2X3'[N5MW;::FEV/L0FD!UQ;PG<M"@ND
M<NEIOL;QO[>T8=*^+>`QN'!UGLHGU6JWO27<<4Q%\G5:6$ES)89FT7KM$\RO
MF*H\F12@JD]+V`]-UUZ6?T2R]@,/Q>,7]KAB48BH=T,6`F/ZN`(4R]4_(HH?
M5X2+3:Z+S*&ALI.V1!X*89<6UKNX:CO(/#M;:GP;^G2*%97/NZW84*7AACY=
M4]^8U"K7A];2(9?&'19P.@LGB]BTG41"^C5E(GF!@?I.QQ`G;?A!LDK968-V
M2;C-B"\G*MN!?65^F^4IU[%@_H2=D?MZT&-^!>JXNE*7L<4>\Y)A^"-.ST=&
M]Y^A/)(_XB15;NCM<71NP]_YU1X]6F4!TZE]9.='K:IVSN9`Q\2KOELV`^CH
M/JE_C4S_O%F>3T/7HW"`)VS$'W[0CTY5K5TZ-*4I73)N.%GD+LNDV?O8&X>S
M%>.B%(JT!>Q2HE@M[347Z-@ESG-5NG349%):(HXG+2WRE(5R9]]\_E0"I$S>
MYV2N(!\P3_,-XB@=;,/PNC[$$3BTQ(59:@/>H;#>/>9+S.5E,Q>D%9+X@HNR
M/ZY\1`(]@-L8HE-K0^H6G<%T(QAD0O4L$U.G3C/S^(7M9B;7J5O,J,JCZ7UN
MN6Y<QGM;@9GZ3D>0KU9W%;##-P#OV1/,"?DL[RDF/V_(,_:NF;1S@GE29^"!
MR[+1@<Y9*_`N3D`;KH^4U5I^NDCT1RR2#Y'0I0R&JHRY!>-?$/=J,QAL@#J4
MN6`B.Q_U;<AI$>0(UL]*9FYB9L*/3``W?N1A[Y9JB>Z[IJ0IEJ.8I<A'55D<
MY89.O<:,RMT\381+PO8E#UB5+]H6\!ABWPE/21Y@XCPP1QKT&;&#/@K'!'"V
M/6F:3R>[NW9*^R-)TV2Q_7[2KT2L"+V,0IDX%B8?[<CSUQ0B+U@"+PF<V;[A
M!I92G>2PAV-75==51114=GOR(%=)H(II*_!]9R!;L0\X`=D&M%O"]5T[*=KL
MNS*?*!'A(_OPA/P(WKZ?&/.^P##2Z`C6B/`:=BWA.SD'VY4G7[KG-@PCN23F
M/MVKI;]73,@^R`H>2GFG(/QFFK^]UA$JFJ_A`.\*)AU(2?V>6W@<Q`E:<3:6
M?.02KZ@G>^(YAB#B!`@3&WU/*SWOT@:6+5*S"!"I3Q!LR=;;MHY/T$GT[71R
MO1(K)K"[2@M;5`4\C+TZ)02^1)3\GN:?SZ(@`.V&%62;]YCLCR`,E>M8D]&S
M+Z(.Q2I;L5*.7^Z#I),QS3Q#];FSQEY=2S50<=8'Q`6MJ%M3U=BE-U>21N2-
MFG6<K9V>6#?RM/;`F8NQEW]!&_8_AK/NMJS?%)-@'O$0QQQ=L5`4>39W/"YF
M'SD8:$`/P-8SJG<ZBF-ZPL`]\J2EF@6@/C)8)5<$/V%/NE&+15HL8/Y`<_#X
MA5G/@8(YCCG`2Q1N0D,-S-H>G5J<8R+KB.\FR6F2P14FOOP^/)W*](+DFE"!
MB1T].Y2CL*5ULM`=/9E3J+2P6``='Z^/*XY;<)N`'2&_Q073`JBKO*K"'E,<
MU^;ZM&;TDQ^7!IAA(6*P.HX;@7:4[P>P9]*;T*J6OS)P'IDR:6L8W@'354[S
M59;R)99NJ1::M(3;C^-#>E(*A">%7!XX<>'/F2B>*G=W[98@5:DD,(W*-VJK
M#(+=G3ME)2Q@X=`/R\7'G2(XO0%15<JK\![MZ'@<YG/*Q!3+XN(`>$OS<=M-
MJEO)"EA>'DGUE.R#[7#>\X/.3QKI3AB;T$^A=(34L;*Y7:09A)43M`^Z+JU=
M/$E?4<NJ*BEUC4.R5#6J\XR;^W4HAI1ZMF35RC0`ID+@@4P@!^)E:L\B;='\
M*FV@C\*KE&.L\1U.&Z#C6"X;,U0N"6H->21*L2X7ME69^C*?+2[M4/AH6%KI
M^X90(*5XN?T`N(YIRK1ZJ)]"O(C\.[*05]A^07Z$JRXNM@/O4*PLM<9EB`M>
M@^QZGFXA[NC8)9M1GH\_P!8D<$EC;QC'2<D,E4B09(!FO!EO;AX4:X=4`(P>
M'*SC/'4XDHW#XHF4P-N\1G[L>;B5:89R!U6E\N5.2@5G?F&6#H"M0Q95&W[B
M#44[Z>^/JE/SLHBH)Y$T*U?5L/\QY.KD0K"P&NJ61+F>@30Q#;&_PZ`[ALVV
MNGJD2M\&V0"3>EW1YB!'8;!6LZ-MMN9NW=IJP^0[ANHXI1(XJZLE[>S9H4/G
ME+DK_8YHX6FGA!![+S)#0_L<&9SM74[6\8`Y?FS`FEDL7VGS*=QS@+?D(Z.N
M=O]!+J'E+R[J[+="<A2+C7)@Y>K^5QFUACX=,E%G\.)YD=P,DZ]=EY+U:MH[
MF8>7H_7_NKNVI81A(/I)_H`O./+`C(.,6-ZUA#$S)74:%?7KS=DDDMYH"D6V
MOC`,W29[MC39W>RE;]&?MK*PPPW)+<(O-O5G1'D_2Z%D7A##8HT^50UNA0,T
MG-[*2IO>!4UDK%]?`Z.TT$006VSLZH2TL^Z[$<<!#:BY(H7:12U+P\2225'`
M/@>=:U-!)`[?!+Z.B<VB1GM(+2QB5QX%X6LE\9QMBO#-N'RWD--PKHRRC+CR
M\TGRP`S_1)"V6A4<T_%&RE],QLC..1HN07.8W3L)5F8HA:2T3,GC/81<(R<Z
MF]MH..='LP@H:8\NW<FM1`#XU&P?7_=*T(^=(NR\G]N_39>.7VM9C9^2EJ66
M[,9V#7CPH=EIPON\H]@Z^/&WL`/KL@91@([:3AONUU.UKC0;/TQ6U;$0)'EI
M_:J)8;L%=\'R5%PUQR:>EV89?HMY9@$APZ=6=;;W+YY]]`AC\.H_[D3V(=Q9
M5LERG1M<^O9=H.-$5&N*TX?B9.D'?,YSY3+5[?8SH^78V(+8>QK$T.]&IJ#M
MT^P)N/,F3F"3]'EA-(]M/<NI=H45V]"'=H5$]PJLP5)K9[R@I0B.GT,D$<1C
M6*8258@T-QK1-Q7WNA%*;(QI9O?5:C.E!_.1*\QHK_L8A9)<!AF/Z7Z>O&Z*
MG$*::F'MOG$R_3%\F6]_AA0*Z.@A1G&ZLJ(:-;!BLRS?8?C]K@[[HV[MJE_W
M5:@;G#@.1UE=7^GT16R?S-<?4$L!`AX#%`````@`13!:1FK1.;+M>`$`6:0/
M`!$`&````````0```*2!`````&YK='(M,C`Q-#$R,S$N>&UL550%``,Q_>Y4
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`13!:1FB':#6K&0``UI0!`!4`
M&````````0```*2!.'D!`&YK='(M,C`Q-#$R,S%?8V%L+GAM;%54!0`#,?WN
M5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`$4P6D:$OQ0PW#0``.A>`P`5
M`!@```````$```"D@3*3`0!N:W1R+3(P,30Q,C,Q7V1E9BYX;6Q55`4``S']
M[E1U>`L``00E#@``!#D!``!02P$"'@,4````"`!%,%I&+\!%K*:R``#8-`D`
M%0`8```````!````I(%=R`$`;FMT<BTR,#$T,3(S,5]L86(N>&UL550%``,Q
M_>Y4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`13!:1L:$H]#N4@``^"4&
M`!4`&````````0```*2!4GL"`&YK='(M,C`Q-#$R,S%?<')E+GAM;%54!0`#
M,?WN5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`$4P6D9V#BQE:1L``(4W
M`0`1`!@```````$```"D@8_.`@!N:W1R+3(P,30Q,C,Q+GAS9%54!0`#,?WN
F5'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``!#Z@(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQ3AG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 12,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 39,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">225,459</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">197,959</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance of nil at December 31, 2014 and 2013</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">3,607</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">2,229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">12,952</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">13,452</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">8,817</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">5,175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">288,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">257,882</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndInvestmentsNoncurrent" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">70,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">66,974</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">76,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">76,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">6,552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">8,170</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">441,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">434,527</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">2,703</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">9,115</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,749</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">14,254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">6,418</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">6,243</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
        <td class="nump"><a title="nktr_AccruedClinicalTrialExpenses" onclick="toggleNextSibling(this);">7,708</a><span style="display:none;white-space:normal;text-align:left;">nktr_AccruedClinicalTrialExpenses</span><span></span></td>
        <td class="nump"><a title="nktr_AccruedClinicalTrialExpenses" onclick="toggleNextSibling(this);">16,905</a><span style="display:none;white-space:normal;text-align:left;">nktr_AccruedClinicalTrialExpenses</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">6,917</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">6,917</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">4,512</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">3,536</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">24,473</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">23,664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent', window );">Liability related to the sale of future royalties, current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent" onclick="toggleNextSibling(this);">7,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,567</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">10,587</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">64,047</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">98,221</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes</a></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, less current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">4,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">8,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RefundableMilestonePaymentLiabilities', window );">Liability related to receipt of refundable milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="nktr_RefundableMilestonePaymentLiabilities" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_RefundableMilestonePaymentLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties, less current portion</a></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" onclick="toggleNextSibling(this);">120,471</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</span><span></span></td>
        <td class="nump"><a title="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" onclick="toggleNextSibling(this);">121,520</a><span style="display:none;white-space:normal;text-align:left;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, less current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">76,911</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">82,384</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">14,721</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">19,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">405,289</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">524,430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized, no shares designated, issued or outstanding at December 31, 2014 and 2013, respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 authorized; 131,216 shares and 116,494 shares issued and outstanding at December 31, 2014 and 2013, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">1,824,195</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">1,643,660</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(1,567)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(1,181)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(1,786,309)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(1,732,393)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">36,332</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(89,903)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 441,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 434,527</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued clinical trial expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liability Related To Sale Of Potential Future Royalties Current</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liability Related To Sale Of Potential Future Royalties Non Current</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RefundableMilestonePaymentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refundable Milestone Payment Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RefundableMilestonePaymentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Leases - Future Minimum Payments for Capital Leases (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 5,572</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">4,268</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum payments required</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">10,015</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
        <td class="num"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" onclick="toggleNextSibling(this);">(1,364)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" onclick="toggleNextSibling(this);">8,651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" onclick="toggleNextSibling(this);">8,651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
        <td class="num"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">(4,512)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="num"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">(3,536)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligation, less current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">$ 4,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">$ 8,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3YAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Shares [Member]</div>
        </th>
        <th class="th">
          <div>Capital in Excess of Par Value [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income/(Loss) [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 197,811</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 1,597,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ (1,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (1,398,525)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">114,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">4,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">774</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">16,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">16,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">47,018</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,617,744</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(357)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(1,570,380)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">115,259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">8,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">8,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,235</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">17,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">17,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(824)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(824)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2013</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(89,903)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,643,660</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(1,181)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(1,732,393)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">116,494</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs of $617</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">116,536</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">116,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,775</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">46,984</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">46,983</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,947</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">17,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">17,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(386)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(386)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 36,332</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 1,824,195</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ (1,567)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (1,786,309)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">131,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - (Benefit) Provision for Income Taxes (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
        <td class="num"><a title="us-gaap_CurrentForeignTaxExpenseBenefit" onclick="toggleNextSibling(this);">(482)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentForeignTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentForeignTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentForeignTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentForeignTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,029</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentForeignTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
        <td class="num"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(481)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,839</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">893</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">422</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(422)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">49</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(49)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
        <td class="num"><a title="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(31)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(65)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(16)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(31)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(487)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (512)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 2,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table sets forth certain unaudited quarterly
 financial data. In our opinion, the unaudited information set forth
 below has been prepared on the same basis as the audited
 information and includes all adjustments necessary to present
 fairly the information set forth herein. All data is in thousands
 except per share information.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="44%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fiscal Year 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fiscal Year 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Product sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,795</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,802</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,096</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,324</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,672</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,771</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,513</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">132,871</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">23,004</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,862</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">60,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">31,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,108</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,011</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,877</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,960</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38,338</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38,494</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">45,618</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">43,914</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,248</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(36,402</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(22,916</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">80,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(37,488</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(45,106</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,525</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(35,894</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(46,201</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,637</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">70,605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(45,683</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(55,063</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(42,748</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,543</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(47,659</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) per share(1)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.35</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.35</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Quarterly loss per share amounts may
 not total to the year-to-date loss per share due to rounding.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EF4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Reporting - Revenue by Geographic Area (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 19,551</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 132,871</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 28,513</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 19,771</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 31,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 60,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 33,862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 23,004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 200,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 148,921</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 81,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components [Member] | United States [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">32,514</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">42,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">34,591</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components [Member] | European [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember]" onclick="toggleNextSibling(this);">$ 168,193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= us-gaap_EuropeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember]" onclick="toggleNextSibling(this);">$ 106,386</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= us-gaap_EuropeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember;us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember]" onclick="toggleNextSibling(this);">$ 46,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ us-gaap_ConsolidationItemsAxis<br>= us-gaap_ReportableGeographicalComponentsMember<br>/ us-gaap_StatementGeographicalAxis<br>= us-gaap_EuropeMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_ReportableGeographicalComponentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Reporting<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note&#xA0;13&#xA0;&#x2014;&#xA0;Segment Reporting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel medicines. We operate in one segment because our business
 offerings have similar economics and other characteristics,
 including the nature of products and manufacturing processes, types
 of customers, distribution methods and regulatory environment. We
 are comprehensively managed as one business segment by our Chief
 Executive Officer and his management team. Within our one business
 segment we have two components, PEGylation technology and pulmonary
 technology.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our revenue is derived primarily from clients in the pharmaceutical
 and biotechnology industries. AstraZeneca, UCB and Roche
 represented 52%, 16%, and 11% of our revenue, respectively, for the
 year ended December&#xA0;31, 2014. Revenue from Roche, UCB,
 AstraZeneca and Bayer represented 28%, 21%, 17% and 10% of our
 revenue, respectively, for the year ended December&#xA0;31, 2013.
 Revenue from UCB, Roche and Affymax represented 30%, 23% and 11% of
 our revenue, respectively, for the year ended December&#xA0;31,
 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenue by geographic area is based on the locations of our
 partners. The following table sets forth revenue by geographic area
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">42,535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,591</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Europe</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">168,193</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">106,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200,707</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">148,921</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">81,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014, $63.3&#xA0;million, or approximately
 90%, of the net book value of our property and equipment was
 located in the United States and $7.1&#xA0;million, or
 approximately 10%, was located in India. At December&#xA0;31, 2013,
 $57.3&#xA0;million, or approximately 88%, of the net book value of
 our property and equipment was located in the United States and
 $7.7&#xA0;million, or approximately 12%, was located in India.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHIAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br>Share data in Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Reporting_Unit

</div>
          <div>Customer</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Customer</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 11, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">$ 262,824,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
        <td class="nump"><a title="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" onclick="toggleNextSibling(this);">$ 262,026,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtCapitalLeaseAndOtherLongTermLiabilities', window );">Indebtedness</a></td>
        <td class="nump"><a title="nktr_DebtCapitalLeaseAndOtherLongTermLiabilities" onclick="toggleNextSibling(this);">151,800,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_DebtCapitalLeaseAndOtherLongTermLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, issued</a></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents', window );">Maximum maturity term of investments in marketable securities to be considered as cash equivalents</a></td>
        <td class="text">Three months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MaturityTermOfInvestmentsConsideredAsShortTerm', window );">Maturity term of investments considered as short-term</a></td>
        <td class="text">Less than one year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfCustomersAccountedForMajorAccountsReceivable', window );">Number of customers accounted for major accounts receivable</a></td>
        <td class="nump"><a title="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfCustomersAccountedForMajorAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="nktr_NumberOfCustomersAccountedForMajorAccountsReceivable" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfCustomersAccountedForMajorAccountsReceivable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfAccountsReceivableCustomersOne', window );">Percentage of accounts receivable customers one</a></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersOne" onclick="toggleNextSibling(this);">40.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersOne</span><span></span></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersOne" onclick="toggleNextSibling(this);">30.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersOne</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfAccountsReceivableCustomersTwo', window );">Percentage of accounts receivable customers two</a></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersTwo" onclick="toggleNextSibling(this);">31.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersTwo</span><span></span></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersTwo" onclick="toggleNextSibling(this);">28.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfAccountsReceivableCustomersThree', window );">Percentage of accounts receivable customers three</a></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersThree" onclick="toggleNextSibling(this);">15.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersThree</span><span></span></td>
        <td class="nump"><a title="nktr_PercentageOfAccountsReceivableCustomersThree" onclick="toggleNextSibling(this);">28.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAccountsReceivableCustomersThree</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment', window );">Number of reporting unit evaluated for goodwill</a></td>
        <td class="nump"><a title="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ResearchAndDevelopmentExpenditureCredits', window );">Reduction of prior periods research and development expenses</a></td>
        <td class="nump"><a title="nktr_ResearchAndDevelopmentExpenditureCredits" onclick="toggleNextSibling(this);">4,700,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ResearchAndDevelopmentExpenditureCredits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfAmountRealizedUponUltimateSettlement', window );">Minimum percentage of amount realized upon ultimate settlement</a></td>
        <td class="nump"><a title="nktr_PercentageOfAmountRealizedUponUltimateSettlement" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfAmountRealizedUponUltimateSettlement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average diluted securities excluded from diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">21.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">20.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">18.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful lives</a></td>
        <td class="text">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful lives</a></td>
        <td class="text">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">12% Senior Secured Notes Due July 2017 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SeniorLongTermNotes[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeniorLongTermNotes<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Senior secured notes, maturity date</a></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">$ 25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtCapitalLeaseAndOtherLongTermLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Capital Lease And Other Long Term Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DebtCapitalLeaseAndOtherLongTermLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MaturityTermOfInvestmentsConsideredAsShortTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maturity term of investments considered as short term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_MaturityTermOfInvestmentsConsideredAsShortTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maturity term of investments in marketable securities to be considered as cash equivalents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfCustomersAccountedForMajorAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of customers accounted for major accounts receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NumberOfCustomersAccountedForMajorAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of reporting units to evaluate goodwill for impairment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfAccountsReceivableCustomersOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of accounts receivable customers one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfAccountsReceivableCustomersOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfAccountsReceivableCustomersThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of accounts receivable customers three.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfAccountsReceivableCustomersThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfAccountsReceivableCustomersTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of accounts receivable customers two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfAccountsReceivableCustomersTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfAmountRealizedUponUltimateSettlement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of amount realized upon ultimate settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfAmountRealizedUponUltimateSettlement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ResearchAndDevelopmentExpenditureCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research And Development Expenditure Credits</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ResearchAndDevelopmentExpenditureCredits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6539997&amp;loc=d3e1205-110223<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EABAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We are a
 biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our research
 and development activities have required significant ongoing
 investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At December&#xA0;31, 2014,
 we had approximately $262.8 million in cash and investments in
 marketable securities, of which $25.0 million was restricted in
 relation to our 12% senior secured notes, and $151.8 million in
 indebtedness. The indebtedness includes $125.0 million in aggregate
 principal amount of 12.0% senior secured notes due July&#xA0;15,
 2017, but excludes our long-term liability relating to the sale of
 future royalties. As is further described in Note 7, this royalty
 obligation liability will not be settled in cash.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation, Principles of Consolidation and Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of
 Presentation, Principles of Consolidation and Use of
 Estimates</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our
 consolidated financial statements include the financial position,
 results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited and
 Nektar Therapeutics UK, Ltd. (Nektar UK). All intercompany accounts
 and transactions have been eliminated in consolidation.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our
 consolidated financial statements are denominated in
 U.S.&#xA0;dollars. Accordingly, changes in exchange rates between
 the applicable foreign currency and the U.S.&#xA0;dollar will
 affect the translation of each foreign subsidiary&#x2019;s financial
 results into U.S.&#xA0;dollars for purposes of reporting our
 consolidated financial results. Translation gains and losses are
 included in accumulated other comprehensive income (loss) in the
 stockholders&#x2019; equity (deficit) section of the balance sheet.
 To date, such cumulative translation adjustments have not been
 significant to our consolidated financial position. Aggregate gross
 foreign currency transaction gains (losses) recorded in operations
 for the years ended December&#xA0;31, 2014, 2013, and 2012 were not
 significant.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles (GAAP) requires management
 to make estimates and assumptions that affect the reported amounts
 of assets and liabilities and disclosure of contingent assets and
 liabilities at the date of the consolidated financial statements
 and the reported amounts of revenue and expenses during the
 reporting period. Accounting estimates and assumptions are
 inherently uncertain. Actual results could differ materially from
 those estimates and assumptions. On an ongoing basis, we evaluate
 our estimates, including those related to estimated selling prices
 of deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. Estimates are
 assessed each period and updated to reflect current information and
 any changes in estimates will generally be reflected in the period
 first identified.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Reclassifications</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported total revenue, operating loss or net loss or
 total assets, liabilities or stockholders&#x2019; equity
 (deficit).</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Investments, and Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash, Cash
 Equivalents, and Investments, and Fair Value of Financial
 Instruments</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We consider all
 investments in marketable securities with an original maturity of
 three months or less when purchased to be cash equivalents.
 Investments in securities with remaining maturities of less than
 one year, or where our intent is to use the investments to fund
 current operations or to make them available for current
 operations, are classified as short-term investments.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Investments are
 designated as available-for-sale and are carried at fair value,
 with unrealized gains and losses reported in stockholders&#x2019;
 equity (deficit) as accumulated other comprehensive income (loss).
 The disclosed fair value related to our cash equivalents and
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Interest and
 dividends on securities classified as available-for-sale, as well
 as amortization of premiums and accretion of discounts to maturity,
 are included in interest income. Realized gains and losses and
 declines in value of available-for-sale securities judged to be
 other-than-temporary, if any, are included in other income
 (expense). The cost of securities sold is based on the specific
 identification method.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our cash, cash
 equivalents, and short-term investments are exposed to credit risk
 in the event of default by the third parties that hold or issue
 such assets. Our cash, cash equivalents, and short-term investments
 are held by financial institutions that management believes are of
 high credit quality and our investment policy limits investments to
 fixed income securities denominated and payable in U.S. dollars
 such as U.S. government obligations, money market instruments and
 funds, and corporate bonds and places restrictions on maturities
 and concentrations by type and issuer.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SignificantConcentrationsPolicyTextBlock', window );">Accounts Receivable and Significant Customer Concentrations</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable and Significant Customer
 Concentrations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as time and
 materials based billings from collaborative research and
 development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable. At December&#xA0;31, 2014, three different customers
 represented 40%, 31%, and 15%, respectively, of our accounts
 receivable. At December&#xA0;31, 2013, three different customers
 represented 30%, 28%, and 28%, respectively, of our accounts
 receivable.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock', window );">Inventory and Significant Supplier Concentrations</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Inventory and Significant Supplier Concentrations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Inventory is generally manufactured upon receipt of firm purchase
 orders from our collaboration partners. Inventory includes direct
 materials, direct labor, and manufacturing overhead and cost is
 determined on a first-in, first-out basis. Inventory is valued at
 the lower of cost or market and defective or excess inventory is
 written down to net realizable value based on historical experience
 or projected usage. Inventory related to our research and
 development activities is expensed when purchased.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Long-Lived
 Assets</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Property, plant
 and equipment are stated at cost. Major improvements are
 capitalized, while maintenance and repairs are expensed when
 incurred. Manufacturing, laboratory and other equipment are
 depreciated using the straight-line method generally over estimated
 useful lives of three to seven years. Leasehold improvements and
 buildings recorded under capital leases are depreciated using the
 straight-line method over the shorter of the estimated useful life
 or the remaining term of the lease.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Goodwill
 represents the excess of the price paid for another entity over the
 fair value of the assets acquired and liabilities assumed in a
 business combination. We are organized in one reporting unit and
 evaluate the goodwill for the Company as a whole. Goodwill has an
 indefinite useful life and is not amortized, but instead tested for
 impairment annually in the fourth quarter of each year using an
 October&#xA0;1 measurement date.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We assess the
 impairment of long-lived assets, primarily property, plant and
 equipment and goodwill included in other non-current assets,
 whenever events or changes in business circumstances indicate that
 the carrying amounts of the assets may not be fully recoverable.
 When such events occur, we determine whether there has been an
 impairment in value by comparing the asset&#x2019;s carrying value
 with its fair value, as measured by the anticipated undiscounted
 net cash flows of the asset. In the case of goodwill impairment,
 market capitalization is generally used as the measure of fair
 value. If an impairment in value exists, the asset is written down
 to its estimated fair value.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue
 Recognition</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our revenue is
 derived from our arrangements with pharmaceutical and biotechnology
 collaboration partners and may result from one or more of the
 following: upfront and license fees, payments for contract research
 and development, milestone payments, manufacturing and supply
 payments, and royalties. Our performance obligations under our
 collaborations may include licensing our intellectual property,
 manufacturing and supply obligations, and research and development
 obligations. In order to account for the multiple-element
 arrangements, the Company identifies the deliverables included
 within the arrangement and evaluates which deliverables represent
 separate units of accounting. Analyzing the arrangement to identify
 deliverables requires the use of judgment, and each deliverable may
 be an obligation to deliver services, a right or license to use an
 asset, or another performance obligation. Revenue is recognized
 separately for each identified unit of accounting when the basic
 revenue recognition criteria are met: there is persuasive evidence
 that an arrangement exists, delivery has occurred, the price is
 fixed or determinable, and collection is reasonably
 assured.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">At the
 inception of each new multiple-element arrangement or the material
 modification of an existing multiple-element arrangement, we
 allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Product
 sales</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Product sales
 are primarily derived from fixed price and cost-plus manufacturing
 and supply agreements with our collaboration partners. We have not
 experienced any significant returns from our customers.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Royalty
 revenues</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Generally, we
 are entitled to royalties from our collaboration partners based on
 the net sales of their approved drugs that are marketed and sold in
 one or more countries where we hold royalty rights. We recognize
 royalty revenue when the cash is received or when the royalty
 amount to be received is estimable and collection is reasonably
 assured. With respect to the non-cash royalties related to sale of
 future royalties described at Note&#xA0;7, revenue is recognized
 when estimable, otherwise, revenue is recognized during the period
 in which the related royalty report is received, which generally
 occurs in the quarter after the applicable product sales are
 made.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>License, collaboration
 and other</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The amount of
 upfront fees and other payments received by us in license and
 collaboration arrangements that are allocated to continuing
 performance obligations, such as manufacturing and supply
 obligations, are deferred and generally recognized ratably over our
 expected performance period under each respective arrangement. We
 make our best estimate of the period over which we expect to
 fulfill our performance obligations, which may include technology
 transfer assistance, research activities, clinical development
 activities, and manufacturing activities from development through
 the commercialization of the product. Given the uncertainties of
 these collaboration arrangements, significant judgment is required
 to determine the duration of the performance period and this
 estimate is periodically re-evaluated.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Contingent
 consideration received from the achievement of a substantive
 milestone is recognized in its entirety in the period in which the
 milestone is achieved, which we believe is consistent with the
 substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&#xA0;that can only be achieved based in whole or in part either
 on the entity&#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&#x2019;s performance,
 (ii)&#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the
 arrangement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with our partners provide for payments to
 us upon the achievement of development milestones, such as the
 completion of clinical trials or regulatory submissions, approvals
 by health authorities, and commercial launches of drugs. Given the
 challenges inherent in developing and obtaining regulatory approval
 for drug products and in achieving commercial launches, there was
 substantial uncertainty whether any such milestones would be
 achieved at the time of execution of these licensing and
 collaboration agreements. In addition, we evaluated whether the
 development milestones meet the remaining criteria to be considered
 substantive. As a result of our analysis, we consider our remaining
 development milestones under all of our license and collaboration
 agreements to be substantive and, accordingly, we expect to
 recognize as revenue future payments received from such milestones
 only if and as each milestone is achieved.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with certain partners also provide for
 contingent payments to us based solely upon the performance of the
 respective partner. For such contingent amounts we expect to
 recognize the payments as revenue when earned under the applicable
 contract, which is generally upon completion of performance by the
 respective partner, provided that collection is reasonably
 assured.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with our partners also provide for
 payments to us upon the achievement of specified sales volumes of
 approved drugs. We consider these payments to be similar to royalty
 payments and we will recognize such sales-based payments upon
 achievement of such sales volumes, provided that collection is
 reasonably assured.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Shipping and Handling Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We recognize costs related to shipping and handling of product to
 customers in cost of goods sold.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and
 Development Expense</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Research and
 development costs are expensed as incurred and include salaries,
 benefits and other operating costs such as outside services,
 supplies and allocated overhead costs. We perform research and
 development for our proprietary drug candidates and technology
 development and for certain third parties under collaboration
 agreements. For our proprietary drug candidates and our internal
 technology development programs, we invest our own funds without
 reimbursement from a third party.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We record
 accruals for the estimated costs of our clinical trial activities
 performed by third parties. The financial terms of these agreements
 are subject to negotiation, vary from contract to contract and may
 result in uneven payment flows to our vendors. Payments under the
 contracts depend on factors such as the achievement of certain
 events, successful enrollment of patients, and completion of
 portions of the clinical trial or similar conditions. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period first identified. During the year ended December 31, 2014,
 we recorded a reduction related to prior periods of approximately
 $4.7 million to our research and development expenses primarily
 related to our Beacon Phase 3 clinical trial for etirinotecan
 pegol.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based
 Compensation</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation arrangements include stock option grants and
 restricted stock unit (RSU) awards under our equity incentive
 plans, as well as shares issued under our Employee Stock Purchase
 Plan (ESPP), through which employees may purchase our common stock
 at a discount to the market price.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We use the
 Black-Scholes option pricing model for the respective grant to
 determine the estimated fair value of the option on the date of
 grant (grant date fair value) and the estimated fair value of
 common stock purchased under the ESPP. The Black-Scholes option
 pricing model requires the input of highly subjective assumptions.
 These variables include, but are not limited to, our stock price
 volatility over the term of the awards, and actual and projected
 employee stock option exercise behaviors. Because our employee
 stock options have characteristics significantly different from
 those of traded options, and because changes in the subjective
 input assumptions can materially affect the fair value estimate, in
 management&#x2019;s opinion, the existing models may not provide a
 reliable single measure of the fair value of our employee stock
 options or common stock purchased under the ESPP. Management will
 continue to assess the assumptions and methodologies used to
 calculate the estimated fair value of stock-based compensation.
 Circumstances may change and additional data may become available
 over time, which could result in changes to these assumptions and
 methodologies, and which could materially impact our fair value
 determination.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We expense the
 value of the portion of the option or award that is ultimately
 expected to vest based on the historical forfeiture rate on a
 straight line basis over the requisite service periods in our
 Consolidated Statements of Operations. For awards that vest upon
 the achievement of performance milestones, we estimate the vesting
 period based on our evaluation of the probability of achievement of
 each respective milestone and the related estimated date of
 achievement. Stock-based compensation expense for purchases under
 the ESPP is recognized over the respective six-month purchase
 period. Expense amounts are recorded in cost of goods sold,
 research and development expense, and general and administrative
 expense based on the function of the applicable employee.
 Stock-based compensation charges are non-cash charges and as such
 have no impact on our reported cash flows.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Net Loss Per
 Share</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss
 per share is calculated based on the weighted-average number of
 common shares outstanding during the periods presented. For all
 periods presented in the Consolidated Statements of Operations, the
 net loss available to common stockholders is equal to the reported
 net loss. Basic and diluted net loss per share are the same due to
 our historical net losses and the requirement to exclude
 potentially dilutive securities which would have an anti-dilutive
 effect on net loss per share. During 2014, 2013 and 2012,
 potentially dilutive securities consisted of common shares
 underlying outstanding stock options and there were weighted
 average outstanding stock options of 21.9 million, 20.7 million and
 18.8 million during the years ended December 31, 2014, 2013 and
 2012, respectively.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We account for income taxes under the liability method. Under this
 method, deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax reporting bases
 of assets and liabilities and are measured using enacted tax rates
 and laws that are expected to be in effect when the differences are
 expected to reverse. Realization of deferred tax assets is
 dependent upon future earnings, the timing and amount of which are
 uncertain. We record a valuation allowance against deferred tax
 assets to reduce their carrying value to an amount that is more
 likely than not to be realized. When we establish or reduce the
 valuation allowance related to the deferred tax assets, our
 provision for income taxes will increase or decrease, respectively,
 in the period such determination is made.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We utilize a two-step approach to recognize and measure uncertain
 tax positions. The first step is to evaluate the tax position for
 recognition by determining if the weight of available evidence
 indicates that it is more likely than not that the position will be
 sustained upon tax authority examination, including resolution of
 related appeals or litigation processes, if any. The second step is
 to measure the tax benefit as the largest amount that is more than
 50% likely of being realized upon ultimate settlement.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ComprehensiveLossPolicyTextBlock', window );">Comprehensive loss</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Comprehensive loss</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive loss is the change in stockholders&#x2019; equity
 (deficit) from transactions and other events and circumstances
 other than those resulting from investments by stockholders and
 distributions to stockholders. Our other comprehensive income
 (loss) is comprised of net loss, gains and losses from the foreign
 currency translation of the assets and liabilities of our India and
 UK subsidiaries, and unrealized gains and losses on investments in
 available-for-sale securities.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC) 606,
 <i>Revenue Recognition &#x2014; Revenue from Contracts with
 Customers</i>, which amends the guidance in former ASC 605,
 <i>Revenue Recognition,</i> and is effective for public companies
 for fiscal years beginning after December&#xA0;15, 2016. We are
 currently evaluating the impact of the provisions of ASC 606.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August 2014, the FASB issued Accounting Standards Update
 No.&#xA0;2014-15, Disclosure of Uncertainties about an
 Entity&#x2019;s Ability to Continue as a Going Concern (ASU
 2014-15). ASU 2014-15 requires management to evaluate whether there
 is substantial doubt about an entity&#x2019;s ability to continue as
 a going concern and to provide related footnote disclosures. ASU
 2014-15 is effective in 2016 with early adoption permitted. We do
 not believe the impact of adopting ASU 2014-15 on our consolidated
 financial statements will be significant.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ComprehensiveLossPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Comprehensive loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ComprehensiveLossPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Inventory and significant supplier concentrations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Organization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SignificantConcentrationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Significant concentrations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SignificantConcentrationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408196&amp;loc=d3e61069-111654<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Handling Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6514758<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915142&amp;loc=d3e60635-111653<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408413&amp;loc=d3e221937-122793<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Shipping Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525344<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" onclick="toggleNextSibling(this);">$ 617</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated</a></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated</span><span></span></td>
        <td class="nump"><a title="nktr_PreferredStockShareDesignated" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">nktr_PreferredStockShareDesignated</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">131,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">116,494</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">131,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">116,494</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock, shares designated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;8&#xA0;&#x2014;
 Commitments and Contingencies</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Royalty
 Expense</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have third
 party licenses that require us to pay royalties based on our sales
 of certain products and/or on our recognition of royalty revenue
 under certain of our collaboration agreements. Royalty expense,
 which is reflected in cost of goods sold in our Consolidated
 Statements of Operations, was approximately $3.4&#xA0;million,
 $4.1&#xA0;million, and $2.9&#xA0;million for the years ended
 December&#xA0;31, 2014, 2013, and 2012, respectively. The overall
 maximum amount of these obligations is based upon sales of the
 applicable products by our collaboration partners and cannot be
 reasonably estimated.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Purchase
 Commitments</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In the normal
 course of business, we enter into various firm purchase commitments
 related to contract manufacturing, clinical development and certain
 other items. As of December&#xA0;31, 2014, these commitments were
 approximately $16.9&#xA0;million, all of which are expected to be
 paid in 2015.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Legal
 Matters</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">From time to
 time, we are involved in lawsuits, arbitrations, claims,
 investigations and proceedings, consisting of intellectual
 property, commercial, employment and other matters, which arise in
 the ordinary course of business. We make provisions for liabilities
 when it is both probable that a liability has been incurred and the
 amount of the loss can be reasonably estimated. Such provisions are
 reviewed at least quarterly and adjusted to reflect the impact of
 settlement negotiations, judicial and administrative rulings,
 advice of legal counsel, and other information and events
 pertaining to a particular case. Litigation is inherently
 unpredictable. If any unfavorable ruling were to occur in any
 specific period, there exists the possibility of a material adverse
 impact on the results of operations of that period or on our cash
 flows and liquidity.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Foreign
 Operations</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We operate in a
 number of foreign countries. As a result, we are subject to
 numerous local laws and regulations that can result in claims made
 by foreign government agencies or other third parties that are
 often difficult to predict even after the application of good faith
 compliance efforts.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Indemnification
 Obligations</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">During the
 course of our normal operating activities, we have agreed to
 certain contingent indemnification obligations as further described
 below. The term of our indemnification obligations is generally
 perpetual. There is generally no limitation on the potential amount
 of future payments we could be required to make under these
 indemnification obligations. To date, we have not incurred
 significant costs to defend lawsuits or settle claims based on our
 indemnification obligations. If any of our indemnification
 obligations is triggered, we may incur substantial liabilities.
 Because the aggregate amount of any potential indemnification
 obligation is not a stated amount, the overall maximum amount of
 any such obligations cannot be reasonably estimated. No liabilities
 have been recorded for these obligations on our Consolidated
 Balance Sheets as of December&#xA0;31, 2014 or 2013.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Indemnifications in
 Connection with Commercial Agreements</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As part of our
 collaboration agreements with our partners related to the license,
 development, manufacture and supply of drugs based on our
 proprietary technologies and drug candidates, we generally agree to
 defend, indemnify and hold harmless our partners from and against
 third party liabilities arising out of the agreement, including
 product liability (with respect to our activities) and infringement
 of intellectual property to the extent the intellectual property is
 developed by us and licensed to our partners.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As part of the
 sale of our royalty interest in the CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 products, we and RPI made representations and warranties and
 entered into certain covenants and ancillary agreements which are
 supported by indemnity obligations. Additionally, as part of our
 pulmonary asset sale to Novartis in 2008, we and Novartis made
 representations and warranties and entered into certain covenants
 and ancillary agreements which are supported by an indemnity
 obligation. In the event it is determined that we breached certain
 of the representations and warranties or covenants and agreements
 made by us in any such agreements, we could incur substantial
 indemnification liabilities depending on the timing, nature, and
 amount of any such claims.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Indemnification of
 Underwriters and Initial Purchasers of our
 Securities</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In connection
 with our sale of equity and senior secured debt securities, we have
 agreed to defend, indemnify and hold harmless our underwriters or
 initial purchasers, as applicable, as well as certain related
 parties from and against certain liabilities, including liabilities
 under the Securities Act of 1933, as amended.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Director and Officer
 Indemnifications</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As permitted
 under Delaware law, and as set forth in our Certificate of
 Incorporation and our Bylaws, we indemnify our directors, executive
 officers, other officers, employees, and other agents for certain
 events or occurrences that may arise while in such capacity. The
 maximum potential amount of future payments we could be required to
 make under this indemnification is unlimited; however, we have
 insurance policies that may limit our exposure and may enable us to
 recover a portion of any future amounts paid. Assuming the
 applicability of coverage, the willingness of the insurer to assume
 coverage, and subject to certain retention, loss limits and other
 policy provisions, we believe any obligations under this
 indemnification would not be material, other than an initial
 $1,500,000 per incident for merger and acquisition related claims,
 $1,000,000 per incident for securities related claims and $500,000
 per incident for non-securities related claims retention deductible
 per our insurance policy. However, no assurances can be given that
 the covering insurers will not attempt to dispute the validity,
 applicability, or amount of coverage without expensive litigation
 against these insurers, in which case we may incur substantial
 liabilities as a result of these indemnification
 obligations.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 20, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">NKTR<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">NEKTAR THERAPEUTICS<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000906709<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Large Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">131,381,612</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 1,625,943,780</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note&#xA0;9&#xA0;&#x2014; Stockholders&#x2019; Equity</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Preferred Stock</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We have authorized 10,000,000&#xA0;shares of Preferred Stock with
 each share having a par value of $0.0001. In 2011,
 3,100,000&#xA0;shares were previously designated Series&#xA0;A
 Junior Participating Preferred Stock (Series&#xA0;A Preferred
 Stock) in connection with our Share Purchase Rights Plan (Rights
 Plan) that expired on June&#xA0;1, 2011. On March&#xA0;30, 2012, we
 filed a certificate of elimination of the Series A Preferred Stock.
 As of December&#xA0;31, 2014 and 2013, no preferred shares are
 designated, issued or outstanding.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Common Stock</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On January&#xA0;28, 2014, we completed the issuance and sale of
 9,775,000 shares of our common stock in a public offering with
 total proceeds of approximately $117.2 million after deducting the
 underwriting commissions and discounts of approximately $7.5
 million. In addition, we incurred approximately $0.6 million in
 legal and accounting fees, filing fees, and other costs in
 connection with this offering.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Equity Compensation Plans</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014, we had 24,806,565 reserved shares of
 common stock, all of which are reserved for issuance under our
 equity compensation plans as summarized in the following table
 (share number in thousands):</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 49.1pt">
 <b>Plan Category</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Number&#xA0;of&#xA0;Securities&#xA0;to&#xA0;be</b><br />
 <b>Issued Upon Exercise of</b><br />
 <b>Outstanding Options</b><br />
 <b>(a)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-Average</b><br />
 <b>Exercise Price of</b><br />
 <b>Outstanding&#xA0;Options</b><br />
 <b>(b)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Number&#xA0;of&#xA0;Securities&#xA0;Remaining</b><br />
 <b>Available for Issuance Under</b><br />
 <b>Equity Compensation Plans</b><br />
 <b>(Excluding Securities Reflected</b><br />
 <b>in Column(a))</b><br />
 <b>(c)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity compensation plans approved by security holders(1)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,601</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity compensation plans not approved by security holders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,995</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Includes shares of common stock
 available for future issuance under our ESPP as of
 December&#xA0;31, 2014.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>2012 Performance Incentive Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Our 2012 Performance Incentive Plan (2012 Plan) was adopted by the
 Board of Directors on April&#xA0;4, 2012 and was approved by our
 stockholders on June&#xA0;28, 2012. On the date of approval, any
 shares of our common stock that were available for issuance under
 all other previously existing stock plans (the 2008 Equity
 Incentive Plan, the 2000 Equity Incentive Plan, and the 2000
 Non-Officer Equity Incentive Plan) became available for issuance
 under the 2012 Plan. In addition, 5,300,000 new shares were made
 available for award grants under the 2012 Plan. No new awards were
 granted under any of the previous stock plans after June&#xA0;28,
 2012. Any shares of common stock subject to outstanding awards
 under the previous stock plans that expire, are cancelled, or
 otherwise terminate at any time after December&#xA0;31, 2011 are
 also available for award grant purposes under the 2012 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The purpose of the 2012 Plan and our other incentive plans is to
 attract, motivate, retain, and reward directors, officers,
 employees, and other eligible persons through the grant of awards
 and incentives for high levels of individual performance and
 increasing the value of our business, as well as to further align
 the interests of award recipients and our stockholders. The 2012
 Plan authorizes stock options, stock appreciation rights,
 restricted stock, performance stock, stock units, stock bonuses,
 dividend equivalents, other similar rights to purchase or acquire
 shares, and other forms of awards granted or denominated in our
 common stock or units of the company&#x2019;s common stock, as well
 as cash bonus awards. Directors, officers, or employees, and
 certain consultants and advisors may receive awards under the 2012
 Plan. Pursuant to the 2012 Plan, we granted or issued incentive
 stock options to officers and non-qualified stock options to
 employees, officers, and non-employee directors. In 2013 and 2014,
 the requisite service period for stock options granted to our
 employees under the 2012 Plan as well as all other previously
 existing stock plans was generally four years; the requisite
 service period for stock options granted to our directors was
 generally one year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The maximum number of shares of our common stock that may be issued
 or transferred pursuant to awards under the 2012 Plan is 10,347,140
 shares, plus any shares subject to outstanding awards under the
 previous stock plans that expire, are cancelled, or otherwise
 terminate for any reason. Generally, shares that are subject to or
 underlie awards which expire or for any reason are cancelled or
 terminated, are forfeited, fail to vest, or for any other reason
 (except for shares exchanged by a participant or withheld to pay
 the exercise price of an award granted and related tax withholding
 obligations) are not paid or delivered under the 2012 Plan will
 again be available for subsequent awards under the 2012 Plan.
 Shares issued in respect of any award, other than a stock option or
 stock appreciation right, granted under the 2012 Plan will be
 counted against the plan&#x2019;s share limit as 1.5&#xA0;shares for
 every one share actually issued in connection with the award. We
 did not grant any RSU awards during the years ended
 December&#xA0;31, 2014, 2013 or 2012 and no RSUs are outstanding at
 December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The 2012 Plan will terminate on April&#xA0;3, 2022, unless earlier
 terminated by the Board of Directors. The maximum term of a stock
 option or stock appreciation right under the 2012 Plan is eight
 years from the date of grant. The per share exercise price of an
 option generally may not be less than the fair market value of a
 share of the company&#x2019;s common stock on the Nasdaq Global
 Select Market on the date of grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Other Equity Incentive Plans</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In addition to the 2012 Plan, we have other equity incentive plans
 under which options granted remain outstanding but no new options
 may be granted either as a result of the approval of the 2012 Plan
 or plan expiration. These plans include: (i)&#xA0;the 2008 Equity
 Incentive Plan (2008 Plan) which was adopted by the Board of
 Directors on March&#xA0;20, 2008 and approved by our stockholders
 on June&#xA0;6, 2008; (ii)&#xA0;the 2000 Equity Incentive Plan
 (2000 Plan) which was adopted by the Board of Directors on
 April&#xA0;19, 2000 by amending and restating our 1994 Equity
 Incentive Plan, and which expired on February&#xA0;9, 2010; and
 (iii)&#xA0;the 1998 Non-Officer Equity Incentive Plan which was
 adopted by our Board of Directors on August&#xA0;18, 1998, and
 which was amended and restated in its entirety and renamed the 2000
 Non-Officer Equity Incentive Plan on June&#xA0;6, 2000 (2000
 Non-Officer Plan).</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Pursuant to the 2008 Plan and the 2000 Plan, we previously granted
 or issued incentive stock options to employees and officers and
 non-qualified stock options, rights to acquire restricted stock,
 restricted stock units, and stock bonuses to employees, officers,
 non-employee directors, and consultants. Pursuant to the 2000
 Non-Officer Plan, we previously granted or issued non-qualified
 stock options, rights to acquire restricted stock and stock bonuses
 to employees and consultants who are neither officers nor directors
 of Nektar. The maximum term of a stock option under all of these
 plans is eight years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Employee Stock Purchase Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In February 1994<b>,</b> our Board of Directors adopted the
 Employee Stock Purchase Plan (ESPP) pursuant to section&#xA0;423(b)
 of the Internal Revenue Code of 1986. Under the ESPP,
 2,500,000&#xA0;shares of our common stock have been authorized for
 issuance. The terms of the ESPP provide eligible employees with the
 opportunity to acquire an ownership interest in Nektar through
 participation in a program of periodic payroll deductions for the
 purchase of our common stock. Employees may elect to enroll or
 re-enroll in the ESPP on a semi-annual basis. Stock is purchased at
 85% of the lower of the closing price on the first day of the
 enrollment period or the last day of the enrollment period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>401(k) Retirement Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We sponsor a 401(k) retirement plan whereby eligible employees may
 elect to contribute up to the lesser of 60% of their annual
 compensation or the statutorily prescribed annual limit allowable
 under Internal Revenue Service regulations. The 401(k) plan permits
 us to make matching contributions on behalf of all participants, up
 to a maximum of $3,000 per participant. For the years ended
 December&#xA0;31, 2014, 2013, and 2012, we recognized $0.9 million,
 $1.0&#xA0;million, and $0.9&#xA0;million, respectively, of
 compensation expense in connection with our 401(k) retirement
 plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Change in Control Severance Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On December&#xA0;6, 2006, our Board of Directors approved a Change
 of Control Severance Benefit Plan (CIC Plan). This CIC Plan has
 subsequently been amended a number of times by our Board of
 Directors with the most recent amendment occurring on April&#xA0;5,
 2011. The CIC Plan is designed to make certain benefits available
 to our eligible employees in the event of a change of control of
 Nektar and, following such change of control, an employee&#x2019;s
 employment with us or a successor company is terminated in certain
 specified circumstances. We adopted the CIC Plan to support the
 continuity of the business in the context of a change of control
 transaction. The CIC Plan was not adopted in contemplation of any
 specific change of control transaction.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Under the CIC Plan, in the event of a change of control of Nektar
 and a subsequent termination of employment initiated by us or a
 successor company other than for Cause (as defined in the CIC Plan)
 or initiated by the employee for a Good Reason Resignation (as
 defined in the CIC Plan) in each case within twelve months
 following a change of control transaction, (i)&#xA0;the Chief
 Executive Officer would be entitled to receive cash severance pay
 equal to 24&#xA0;months base salary plus annual target incentive
 pay, the extension of employee benefits over this severance period
 and the full acceleration of unvested outstanding equity awards,
 and (ii)&#xA0;our Senior Vice Presidents and Vice Presidents
 (including Principal Fellows) would each be entitled to receive
 cash severance pay equal to twelve months base salary plus annual
 target incentive pay, the extension of employee benefits over this
 severance period and the full acceleration of unvested outstanding
 equity awards. In the event of a change of control of Nektar and a
 subsequent termination of employment initiated by the Company or a
 successor company other than for Cause within twelve months
 following a change of control transaction, all other employees
 would each be entitled to receive cash severance pay equal to
 6&#xA0;months base salary plus a pro-rata portion of annual target
 incentive pay, the extension of employee benefits over this
 severance period and the full acceleration of each such
 employee&#x2019;s unvested outstanding equity awards. Under the CIC
 Plan, as amended, non-employee directors would also be entitled to
 full acceleration of vesting of all outstanding stock awards in the
 event of a change of control transaction.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenue:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 25,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 44,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 35,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">329</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">1,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">4,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
        <td class="nump"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">21,937</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">22,055</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
        <td class="nump"><a title="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" onclick="toggleNextSibling(this);">10,791</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">153,289</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">80,872</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
        <td class="nump"><a title="nktr_LicenseCollaborationOtherRevenue" onclick="toggleNextSibling(this);">30,127</a><span style="display:none;white-space:normal;text-align:left;">nktr_LicenseCollaborationOtherRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">200,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">148,921</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">81,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">28,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">38,509</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">30,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">147,734</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">190,010</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">148,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">40,925</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">40,532</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">41,614</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">1,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">217,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">269,051</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">222,392</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(16,485)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(120,130)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(141,201)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(17,869)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(18,453)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(15,489)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
        <td class="num"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">(20,888)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">(22,309)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
        <td class="num"><a title="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" onclick="toggleNextSibling(this);">(18,057)</a><span style="display:none;white-space:normal;text-align:left;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income (expense), net</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">814</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">1,124</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">3,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expense, net</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(37,943)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(39,638)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(30,248)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before (benefit) provision for income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">(54,428)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">(159,768)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">(171,449)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(512)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">2,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.42)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.50)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing basic and diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">126,873</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">115,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">114,820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-cash interest expense related to sale of royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non cash royalty revenue related to sale future royalties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 958<br><br><br><br> -SubTopic 225<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28367520&amp;loc=d3e92212-112881<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Impairment<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note&#xA0;3&#xA0;&#x2014; Inventory</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Inventory consists of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,947</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Work-in-process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Inventory</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;2&#xA0;&#x2014;
 Cash and Investments in Marketable Securities</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Cash and
 investments in marketable securities, including cash equivalents
 and restricted cash, are as follows (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Estimated Fair Value
 at</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash
 equivalents</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,365</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39,067</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term
 investments</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">225,459</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">197,959</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted cash</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total cash and investments
 in marketable securities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,824</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,026</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We invest in
 liquid, high quality debt securities. Our investments in debt
 securities are subject to interest rate risk. To minimize the
 exposure due to an adverse shift in interest rates, we invest in
 securities with maturities of two years or less and maintain a
 weighted average maturity of one year or less. As of
 December&#xA0;31, 2014 and 2013, all of our investments had
 contractual maturities of one year or less and were classified as
 short-term.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Gross
 unrealized gains and losses were not significant at either
 December&#xA0;31, 2014 or 2013. During the years ended
 December&#xA0;31, 2014, 2013 and 2012, we sold available-for-sale
 securities totaling $21.7 million, $2.9&#xA0;million and $5.4
 million respectively, and realized gains and losses were not
 significant in any of those periods.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Restricted cash
 of $25.0 million is required to be maintained in a separate account
 until July&#xA0;1, 2015 under the terms of our 12% senior secured
 notes due July 2017. Upon release of this restriction on
 July&#xA0;1, 2015, a covenant of the senior secured notes requires
 that the aggregate balance of our unrestricted cash and cash
 equivalents at the end of any two consecutive fiscal quarters may
 not be less than $25.0 million, subject to certain conditions (see
 Note 5).</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our portfolio
 of cash and investments in marketable securities includes (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="56%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;
 Value</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Hierarchy</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Level</b></font></td>
 <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Estimated Fair Value
 at</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,<br />
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Corporate notes and
 bonds</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">182,544</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">138,515</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Corporate commercial
 paper</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42,915</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59,444</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Available-for-sale
 investments</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">225,459</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">197,959</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market
 funds</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,229</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,453</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash, including restricted
 cash</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">N/A</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,136</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37,614</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total cash and investments
 in marketable securities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,824</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">262,026</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 2px; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; MARGIN-TOP: 0px; LINE-HEIGHT: 8px; WIDTH: 10%">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;1&#xA0;&#x2014;</i> Quoted prices in active
 markets for identical assets or liabilities.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;2&#xA0;&#x2014;</i> Inputs other than Level&#xA0;1
 that are observable, either directly or indirectly, such as quoted
 prices for similar assets or liabilities; quoted prices in markets
 that are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;3&#xA0;&#x2014;</i> Unobservable inputs that are
 supported by little or no market activity and that are significant
 to the fair value of the assets or liabilities.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">All of our
 investments are categorized as Level 1 or Level 2, as explained in
 the table above. We use a market approach to value our Level 2
 investments. During the years ended December&#xA0;31, 2014, 2013
 and 2012, there were no transfers between Level 1 and Level 2 of
 the fair value hierarchy.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">At
 December&#xA0;31, 2014 and 2013, we had letter of credit
 arrangements in favor of a landlord and certain vendors totaling
 $2.4&#xA0;million. These letters of credit are secured by
 investments of similar amounts.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Note&#xA0;14&#xA0;&#x2014; Selected Quarterly Financial Data
 (Unaudited)</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table sets forth certain unaudited quarterly
 financial data. In our opinion, the unaudited information set forth
 below has been prepared on the same basis as the audited
 information and includes all adjustments necessary to present
 fairly the information set forth herein. We have experienced
 fluctuations in our quarterly results and expect these fluctuations
 to continue in the future. Due to these and other factors, we
 believe that quarter-to-quarter comparisons of our operating
 results will not be meaningful, and you should not rely on our
 results for any one quarter as an indication of our future
 performance. Certain items previously reported in specific
 financial statement captions have been reclassified to conform to
 the current period presentation. Such reclassifications have not
 materially impacted previously reported total revenues, operating
 loss or net loss. All data is in thousands except per share
 information.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="44%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fiscal Year 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fiscal Year 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Product sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,795</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,802</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,096</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,324</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,672</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,771</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,513</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">132,871</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">23,004</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,862</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">60,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">31,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,108</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,011</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,877</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,960</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38,338</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38,494</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">45,618</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">43,914</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,248</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(36,402</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(22,916</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">80,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(37,488</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(45,106</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,525</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(35,894</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(46,201</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,637</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">70,605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(45,683</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(55,063</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(42,748</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,543</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(47,659</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) per share(1)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.35</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.35</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt; WIDTH: 10%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Quarterly loss per share amounts may
 not total to the year-to-date loss per share due to rounding.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;10&#xA0;&#x2014; License and Collaboration
 Agreements</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have entered
 into various collaboration agreements including license agreements
 and collaborative research, development and commercialization
 agreements with various pharmaceutical and biotechnology companies.
 Under these collaboration arrangements, we are entitled to receive
 license fees, upfront payments, milestone payments, royalties,
 sales milestones, and payments for the manufacture and supply of
 our proprietary PEGylation materials and/or reimbursement for
 research and development activities. All of our collaboration
 agreements are generally cancelable by our partners without
 significant financial penalty. Our costs of performing these
 services are generally included in research and development
 expense, except that costs for product sales to our collaboration
 partners are included in cost of goods sold.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In accordance
 with our collaboration agreements, we recognized license,
 collaboration and other revenue as follows (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="40%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="39%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom" nowrap="nowrap">
 <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 26pt">
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Partner</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center">
 <p style="MARGIN-BOTTOM: 1px; MARGIN-TOP: 0px" align="center">
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Agreement</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">AstraZeneca AB</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">(NKTR-118) and
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination program (NKTR-119)</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">105,001</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,016</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Roche</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,845</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,382</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,146</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Baxter
 Healthcare</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">BAX 855 (Hemophilia)</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,258</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,702</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,238</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amgen, Inc.</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">Neulasta<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,035</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bayer Healthcare
 LLC</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">BAY41-6551 (Amikacin Inhale)</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,717</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,293</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,971</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Affymax, Inc.</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">OMONTYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,149</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,829</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,468</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,295</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,884</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">License, collaboration and
 other revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">153,289</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">80,872</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30,127</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As of
 December&#xA0;31, 2014, our collaboration agreements with partners
 included potential future payments for development milestones
 totaling approximately $130.3 million, including amounts from our
 agreements with Baxter and Bayer described below. In addition, we
 are entitled to receive the contingent payments described below
 related to the MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">(previously
 referred to as naloxegol and NKTR-118) and
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination (previously referred to as NKTR-119) drug development
 programs, respectively, based on development and regulatory events
 to be pursued and completed solely by AstraZeneca.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 0px">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>AstraZeneca AB</i></b><i>: MOVANTIK<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 (naloxegol oxalate), previously referred to as naloxegol and
 NKTR-118, and MOVANTIK<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 fixed-dose combination program, previously referred to as
 NKTR-119</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In September
 2009, we entered into a license agreement with AstraZeneca AB
 (AstraZeneca), as amended by AstraZeneca and us in August 2013,
 under which we granted AstraZeneca a worldwide, exclusive,
 perpetual, royalty-bearing, and sublicensable license under our
 patents and other intellectual property to develop, market, and
 sell MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">and
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination program. AstraZeneca is responsible for all costs
 associated with research, development and commercialization and is
 responsible for all drug development and commercialization
 decisions for MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">and the
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination program. AstraZeneca paid us an upfront payment of
 $125.0&#xA0;million, which we received in the fourth quarter of
 2009 and which was fully recognized as of December&#xA0;31, 2010.
 As of December&#xA0;31, 2014, we are entitled to receive up to an
 additional $140.0 million and $75.0 million of contingent payments
 related to MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">and the
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination program, respectively, based on development events to
 be pursued and completed solely by AstraZeneca, as described
 below.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">On
 September&#xA0;16, 2014, the United States Food and Drug
 Administration (FDA) approved MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">for the
 treatment of opioid-induced constipation (OIC) in adult patients
 with chronic, non-cancer pain. On December&#xA0;9, 2014,
 AstraZeneca announced that MOVENTIG<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 (the naloxegol brand name in the European Union) has been granted
 Marketing Authorisation by the European Commission (EC) for the
 treatment of opioid-induced constipation (OIC) in adult patients
 who have had an inadequate response to laxative(s). As a result of
 the FDA&#x2019;s approval, on September&#xA0;16, 2014, we were
 entitled to a $35.0 million non-refundable payment from
 AstraZeneca, which was fully recognized as revenue in September
 2014 and was received in October 2014. In addition, the FDA&#x2019;s
 approval of MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">extinguished
 our contingent obligation to repay the $70.0 million payment made
 to us by AstraZeneca in November 2013 after the
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">New Drug
 Application was accepted for review by the FDA. As a result, in
 September 2014, we fully recognized this $70.0 million payment,
 which was previously recorded in the line item &#x201C;Liability
 related to receipt of refundable milestone payment&#x201D; on our
 Consolidated Balance Sheet at December 31, 2013.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As part of its
 approval of MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font><font style="FONT-FAMILY: Times New Roman" size="2">, the FDA required AstraZeneca to perform a
 post-marketing, observational epidemiological study comparing
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">to other
 treatments of OIC in patients with chronic, non-cancer pain. As a
 result, the royalty rate payable to us from net sales of
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">in the U.S. by
 AstraZeneca will be reduced by up to two percentage points to fund
 33% of the external costs incurred by AstraZeneca to fund such post
 approval study subject to a $35.0 million aggregate cap. Any costs
 incurred by AstraZeneca can only be recovered by the reduction of
 the royalty paid to us. In no case can amounts be recovered by the
 reduction of a contingent payment due from AstraZeneca to us or
 through a payment from us to AstraZeneca.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We will be
 entitled to up to an additional $140.0 million of contingent
 payments upon the first commercial sale of
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font><font style="FONT-FAMILY: Times New Roman" size="2">, $100.0 million of which will be payable upon the first
 commercial sale in the U.S. and $40.0 million of which will be
 payable upon the first commercial sale in one major European Union
 country. We are also entitled to receive up to $75.0 million of
 commercial launch contingent payments related to the
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination program, based on development events to be pursued and
 completed solely by AstraZeneca. In addition, we are entitled to
 royalties and sales milestone payments based on annual worldwide
 net sales of MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">and
 MOVANTIK</font><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">TM</sup></font>
 <font style="FONT-FAMILY: Times New Roman" size="2">fixed-dose
 combination products.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Roche</i></b><i>: PEGASYS<sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup>
 and MIRCERA<sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></i></font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In February
 1997, we entered into a license, manufacturing and supply agreement
 with Roche, under which we granted Roche a worldwide, exclusive
 license to certain intellectual property related to our proprietary
 PEGylation materials used in the manufacture and commercialization
 of PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.
 As a result of Roche exercising a license extension option in
 December 2009, Roche has the right to manufacture all of its
 requirements for our proprietary PEGylation materials for
 PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and we perform additional manufacturing, if any, only on an
 as-requested basis. In connection with Roche&#x2019;s exercise of
 the license extension option in December 2009, we received a
 payment of $31.0&#xA0;million. As of December&#xA0;31, 2014, we
 have deferred revenue of approximately $5.1 million related to this
 agreement, which we expect to recognize through December 2015, the
 period through which we are required to provide back-up
 manufacturing and supply services related to PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In February
 2012, we entered into a toll-manufacturing agreement with Roche
 under which we will manufacture the proprietary PEGylation material
 used by Roche to produce MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.
 Roche entered into the toll-manufacturing agreement with the
 objective of establishing us as a secondary back-up supply source
 on a non-exclusive basis. Under the terms of our toll-manufacturing
 agreement, Roche paid us an upfront payment of $5.0 million and an
 additional $22.0 million in performance-based milestone payments
 upon our achievement of certain manufacturing readiness, validation
 and production milestones, including the delivery of specified
 quantities of PEGylation materials, all of which were completed as
 of January 2013. Roche will also pay us additional consideration
 for any future orders of the PEGylation materials for
 MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 beyond the initial quantities manufactured through January
 2013.&#xA0;Roche has the right to terminate the toll-manufacturing
 agreement due to an uncured material default by us.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We analyzed the
 milestone payments under the agreement and determined that they did
 not meet the criteria for revenue recognition under the milestone
 method as a result of our continuing manufacturing obligations. We
 have identified our back-up manufacturing obligation through
 December 2016 and the delivery of PEGylation materials specified in
 the agreement in 2012 and early 2013 as the units of accounting in
 the arrangement. We made our best estimate of the selling prices
 for these deliverables and have allocated the total $27.0 million
 consideration to these items based on the relative selling price
 method. As of December&#xA0;31, 2014, we have deferred revenue of
 approximately $10.7&#xA0;million, which we expect to recognize
 through December 2016, the estimated end of our obligations under
 this agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In August 2013,
 we agreed to deliver additional quantities of PEGylation materials
 used by Roche to produce PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>,
 all of which were delivered in the last quarter of 2013, for total
 consideration of $18.6 million. We determined that these
 incremental activities should be considered a material modification
 of the existing PEGASYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 -related arrangements described above. As a result, we allocated
 the $18.6 million consideration to each of these arrangements and
 determined the amounts to be recognized or deferred based on the
 estimated selling prices of the undelivered obligations. As of
 December&#xA0;31, 2014, we have deferred revenue of approximately
 $4.6&#xA0;million related to these activities, which we expect to
 recognize through December 2016, the estimated end of our
 obligations under the modified arrangements.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Baxter
 Healthcare</i></b><i>: BAX 855/Hemophilia</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In September
 2005, we entered into an exclusive research, development, license
 and manufacturing and supply agreement with Baxter Healthcare SA
 and Baxter Healthcare Corporation (together referred to as Baxter)
 to develop products designed to improve therapies for Hemophilia A
 patients using our PEGylation technology. Under the terms of the
 agreement, we are entitled to research and development funding and
 are responsible for supplying Baxter with its requirements for our
 proprietary materials. Baxter is responsible for all clinical
 development, regulatory, and commercialization expenses. The
 agreement is terminable by the parties under customary
 conditions.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Under the terms
 of this agreement, as of December&#xA0;31, 2014, we are entitled to
 up to $20.0 million of development milestones related to Hemophilia
 A upon achievement of certain development objectives, as well as
 sales milestones upon achievement of annual sales targets and
 royalties based on annual worldwide net sales of products resulting
 from this agreement. This Hemophilia A program includes BAX 855. In
 August 2014, Baxter announced positive top-line results from its
 Phase 3 pivotal clinical trial of BAX 855 which met the primary
 endpoint for the control and prevention of bleeding, routine
 prophylaxis and perioperative management for patients who were 12
 years or older. As a result of this Phase 3 clinical trial meeting
 its primary endpoint, we achieved development milestones totaling
 $8.0 million. Given our significant efforts in the development of
 this product, we consider these milestones to be substantive and we
 recognized the milestones in their entirety in the year ended
 December&#xA0;31, 2014. As of December&#xA0;31, 2014, we do not
 have significant deferred revenue related to this
 agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Amgen,
 Inc.</i></b><i>: Neulasta</i><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 </font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In October
 2010, we amended and restated an existing supply and license
 agreement by entering into a supply, dedicated suite and
 manufacturing guarantee agreement (the amended and restated
 agreement) and a license agreement with Amgen Inc. and Amgen
 Manufacturing, Limited (together referred to as Amgen). Under the
 terms of the amended and restated agreement, we guarantee the
 manufacture and supply of our proprietary PEGylation materials
 (Polymer Materials) to Amgen in an existing manufacturing suite to
 be used exclusively for the manufacture of Polymer Materials for
 Amgen (the Manufacturing Suite) in our manufacturing facility in
 Huntsville, Alabama (the Facility). This supply arrangement is on a
 non-exclusive basis (other than the use of the Manufacturing Suite
 and certain equipment) whereby we are free to manufacture and
 supply the Polymer Materials to any other third party and Amgen is
 free to procure the Polymer Materials from any other third party.
 Under the terms of the amended and restated agreement, we received
 a $50.0 million payment in the fourth quarter of 2010 in return for
 our guaranteeing the supply of certain quantities of Polymer
 Materials to Amgen including without limitation the Additional
 Rights described below and manufacturing fees that are calculated
 based on fixed and variable components applicable to the Polymer
 Materials ordered by Amgen and delivered by us. Amgen has no
 minimum purchase commitments. If quantities of the Polymer
 Materials ordered by Amgen exceed specified quantities, significant
 additional payments become payable to us in return for our
 guaranteeing the supply of additional quantities of the Polymer
 Materials.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The term of the
 amended and restated agreement ends on October&#xA0;29, 2020. In
 the event we become subject to a bankruptcy or insolvency
 proceeding, we cease to own or control the Facility, we fail to
 manufacture and supply or certain other events, Amgen or its
 designated third party will have the right to elect, among certain
 other options, to take title to the dedicated equipment and access
 the Facility to operate the Manufacturing Suite solely for the
 purpose of manufacturing the Polymer Materials (the Additional
 Rights). Amgen may terminate the amended and restated agreement for
 convenience or due to an uncured material default by us. Our
 research facility in Huntsville, Alabama that we propose to sell is
 a different building and location from that of the Facility
 described here.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As of
 December&#xA0;31, 2014, we have deferred revenue of approximately
 $29.2&#xA0;million related to this agreement, which we expect to
 recognize through October 2020, the estimated end of our
 obligations under this agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Bayer Healthcare
 LLC</i></b><i>: BAY41-6551 (Amikacin Inhale)</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In August 2007,
 we entered into a co-development, license and co-promotion
 agreement with Bayer Healthcare LLC (Bayer) to develop a
 specially-formulated inhaled Amikacin. We are responsible for
 development and manufacturing and supply of the nebulizer device
 included in the Amikacin product. Bayer is responsible for most
 future clinical development and commercialization costs, all
 activities to support worldwide regulatory filings, approvals and
 related activities, further development of Amikacin Inhale and
 final product packaging and distribution. In the years prior to
 2014, we received an upfront payment of $40.0&#xA0;million in 2007
 and milestone payments of $30.0&#xA0;million, including a $10.0
 million development milestone which was achieved in 2013 as a
 result of the start of the Phase 3 clinical trial by Bayer in the
 treatment of intubated and mechanically ventilated patients with
 Gram-negative pneumonia in April 2013. In addition, in June 2013,
 we paid $10.0 million to Bayer for the reimbursement of its costs
 of the Phase 3 clinical trial.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In addition, we
 are entitled to receive a total of up to $50.0 million for
 development milestones upon achievement of certain development
 objectives, as well as sales milestones upon achievement of annual
 sales targets and royalties based on annual worldwide net sales of
 Amikacin Inhale. As of December&#xA0;31, 2014, we have deferred
 revenue of approximately $20.8 million related to this agreement,
 which we expect to recognize through February 2028, the estimated
 end of our obligations under this agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Ophthotech Corporation</i></b><i>:
 Fovista</i><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 </font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We are a party
 to an agreement with Ophthotech Corporation (Ophthotech), dated
 September&#xA0;30, 2006, under which Ophthotech received a
 worldwide, exclusive license to certain of our proprietary
 PEGylation technology to develop, manufacture and sell
 Fovista<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.
 Under the terms of our agreement, we are the exclusive supplier of
 all of Ophthotech&#x2019;s clinical and commercial requirements for
 our proprietary PEGylation reagent used in Fovista<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.
 On May&#xA0;19, 2014, Ophthotech entered into a Licensing and
 Commercialization Agreement with Novartis Pharma AG for
 Fovista<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.
 Under our agreement with Ophthotech, we received a $19.75 million
 payment in connection with this licensing agreement in June 2014.
 As of December&#xA0;31, 2014, we have deferred revenue of
 approximately $18.9 million related to this agreement, which we
 expect to recognize through March 2028, the estimated end of our
 obligations under our agreement with Ophthotech.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In addition, we
 are entitled to up to $9.5 million in additional payments based
 upon Ophthotech&#x2019;s potential achievement of certain regulatory
 and sales milestones. We are also entitled to royalties on net
 sales of Fovista<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 that vary based on sales levels.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 18px">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Affymax,
 Inc.</i></b><i>: OMONTYS<sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></i></font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In April 2004,
 we entered into a license, manufacturing and supply agreement with
 Affymax, Inc. (Affymax) under which we provided Affymax with a
 worldwide, non-exclusive license under certain of our proprietary
 PEGylation technology to develop, manufacture and commercialize
 OMONTYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 (peginesatide). On February&#xA0;23, 2013, Affymax and Takeda
 Pharmaceutical Company Limited announced a voluntary recall of all
 lots of OMONTYS<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>&#xA0;drug
 product as a result of new post-marketing reports regarding serious
 hypersensitivity reactions, including anaphylaxis, which can be
 life-threatening or fatal.&#xA0;In July 2013, Affymax terminated
 the license, manufacturing and supply agreement with
 Nektar.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have
 received milestone and related payments under our agreement with
 Affymax and, as a result of the termination of our agreement with
 Affymax and our related performance obligations, we recognized the
 remaining $6.7 million of deferred revenue from this agreement in
 the year ended December&#xA0;31, 2013.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Other</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">During the year
 ended December&#xA0;31, 2014, two of our collaboration partners
 achieved the successful transfer of our commercial manufacturing
 process in connection with the PEGylation materials used in their
 products. In connection with our assistance with these
 manufacturing technology transfers, we received a total of $9.0
 million of milestone payments. We concluded that these payments are
 substantive milestones and recognized them in their entirety in the
 year ended December&#xA0;31, 2014.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In addition, as
 of December&#xA0;31, 2014, we have a number of collaboration
 agreements, including our collaboration partner UCB, under which we
 are entitled to up to a total of $53.8 million of development
 milestones upon achievement of certain development objectives, as
 well as sales milestones upon achievement of annual sales targets
 and royalties based on net sales of commercialized products, if
 any. However, given the current phase of development of the
 potential products under these collaboration agreements, we cannot
 estimate the probability or timing of achieving these
 milestones.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesDisclosureTextBlock', window );">Leases</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note&#xA0;6&#xA0;&#x2014; Leases</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Capital Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We lease office space at 201 Industrial Road in San&#xA0;Carlos,
 California under a capital lease arrangement. Under the terms of
 the lease, rent increases up to 3% annually and the lease
 termination date is October&#xA0;5, 2016. As of November&#xA0;29,
 2010, we ceased use of this space as a result of the relocation of
 our San&#xA0;Carlos operations and corporate headquarters to
 San&#xA0;Francisco, California. As of April 2013, we have subleased
 all of the San Carlos facility and our future minimum rental
 receipts under these subleases total $4.8 million as of
 December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2014 and 2013, the gross amount of assets
 recorded under capital leases was $2.7 million and
 2.3&#xA0;million, respectively, and the recorded value of these
 assets, net of depreciation, was $1.2 million and $1.0 million,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future minimum payments for our capital leases at December&#xA0;31,
 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">Years ending December&#xA0;31,</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,572</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,268</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total minimum payments required</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,015</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: amount representing interest</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,364</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Present value of future minimum lease payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,651</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: current portion</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capital lease obligation, less current portion</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Operating Lease</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On September&#xA0;30, 2009, we entered into an operating sublease
 (Sublease) with Pfizer, Inc. for a 126,285&#xA0;square foot
 facility located in San&#xA0;Francisco, California (Mission Bay
 Facility). Under the terms of the Sublease, we began making
 non-cancelable lease payments in 2014, after the expiration of our
 free rent period on August&#xA0;1, 2014. The Sublease term is 114
 months, commencing in August 2010 and terminating on
 January&#xA0;31, 2020. Monthly base rent will escalate over the
 term of the sublease at various intervals. In addition, throughout
 the term of the Sublease, we are responsible for paying certain
 costs and expenses specified in the Sublease, including insurance
 costs and a pro rata share of operating expenses and applicable
 taxes for the Mission Bay Facility.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our future minimum lease payments for our operating leases at
 December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">Years ending December&#xA0;31,</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total future minimum lease payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,662</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We recognize rent expense on a straight-line basis over the lease
 period. For the years ended December&#xA0;31, 2014, 2013, and 2012,
 rent expense for all our operating leases, including our Mission
 Bay Facility, was approximately $3.2&#xA0;million,
 $2.9&#xA0;million, and $2.8&#xA0;million, respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Leases Disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LeasesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3MAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems', window );"><strong>Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">$ 9,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">$ 51,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises', window );">Valuation allowance related to stock-based compensation and exercises prior to the implementation of ASC 515 and 718</a></td>
        <td class="nump"><a title="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" onclick="toggleNextSibling(this);">35,600,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises</span><span></span></td>
        <td class="nump"><a title="nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises" onclick="toggleNextSibling(this);">35,600,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred U.S. income taxes</a></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">422,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(422,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Income taxes have not been provided on a cumulative total</a></td>
        <td class="nump"><a title="us-gaap_UndistributedEarningsOfForeignSubsidiaries" onclick="toggleNextSibling(this);">3,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">2,933,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">6,273,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">591,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FederalOrphanDrugCredits', window );">Federal orphan drug credits</a></td>
        <td class="nump"><a title="nktr_FederalOrphanDrugCredits" onclick="toggleNextSibling(this);">17,700,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_FederalOrphanDrugCredits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FederalOrphanDrugCreditsExpirationYear', window );">Federal orphan drug credits, expiration year</a></td>
        <td class="text">2026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange', window );">Unrecognized tax benefits, period may increase or decrease due to tax examination</a></td>
        <td class="text">Next twelve months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems', window );"><strong>Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
        <td class="nump"><a title="nktr_NetOperatingLossCarryforwardForIncomeTax[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">1,131,800,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_NetOperatingLossCarryforwardForIncomeTax<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardExpirationYear', window );">Net operating loss carryforward, expiration year</a></td>
        <td class="text">2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">40,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FederalResearchAndDevelopmentCreditsExpirationYear', window );">Income tax research credits, expiration year</a></td>
        <td class="text">2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems', window );"><strong>Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
        <td class="nump"><a title="nktr_NetOperatingLossCarryforwardForIncomeTax[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">709,200,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_NetOperatingLossCarryforwardForIncomeTax<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardExpirationYear', window );">Net operating loss carryforward, expiration year</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets', window );">Amounts included in state net operating losses not MLTN</a></td>
        <td class="nump"><a title="nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">124,600,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CumulativeGrossIncomeTaxResearchCredits', window );">Income tax research credits</a></td>
        <td class="nump"><a title="nktr_CumulativeGrossIncomeTaxResearchCredits[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">$ 22,600,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_CumulativeGrossIncomeTaxResearchCredits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CumulativeGrossIncomeTaxResearchCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative gross income tax research credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CumulativeGrossIncomeTaxResearchCredits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FederalOrphanDrugCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal orphan drug credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_FederalOrphanDrugCredits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FederalOrphanDrugCreditsExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal Orphan Drug Credits Expiration Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_FederalOrphanDrugCreditsExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FederalResearchAndDevelopmentCreditsExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal Research And Development Credits Expiration Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_FederalResearchAndDevelopmentCreditsExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetOperatingLossCarryforwardExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Operating Loss Carryforward Expiration Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NetOperatingLossCarryforwardExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetOperatingLossCarryforwardForIncomeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net operating loss carryforward for income tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NetOperatingLossCarryforwardForIncomeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts included in state net operating losses not MLTN.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NetOperatingLossCarryForwardsNotIncludedInDeferredTaxAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_RealEstateAcquiredThroughForeclosureUnderForwardPurchaseAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized tax benefits, period increase (decrease) reasonable period of change</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Valuation allowance related to stock-based compensation and exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ValuationAllowanceRelatedToStockBasedCompensationAndExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 995<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6503627&amp;loc=d3e59836-110443<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28200-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;4&#xA0;&#x2014;
 Property, Plant and Equipment</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Property, plant
 and equipment consists of the following (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Building and leasehold
 improvements</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72,228</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,306</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Laboratory
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,975</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,621</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Manufacturing
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,212</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,699</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Furniture, fixtures and
 other equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,451</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,235</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciable property, plant
 and equipment at cost</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">147,866</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">144,861</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: accumulated
 depreciation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(93,807</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(84,148</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciable property, plant
 and equipment, net</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54,059</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,713</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Construction-in-progress</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,309</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,261</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property, plant and
 equipment, net</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">70,368</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">66,974</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Building and
 leasehold improvements include our manufacturing, research and
 development and administrative facilities and the related
 improvements to these facilities. Laboratory and manufacturing
 equipment include assets that support both our manufacturing and
 research and development efforts. Construction-in-progress includes
 assets being built to enhance our manufacturing and research and
 development efforts, including manufacturing equipment supporting
 our Amikacin Inhale program at third-party contract manufacturing
 locations in the U.S. and Germany. Under the terms of our
 arrangement with these contract manufacturers, during the period
 the equipment is being constructed, we are obligated to pay for
 their costs incurred to date. As of December 31, 2014, we have
 recorded a total of $7.2 million in other current and other
 long-term liabilities related to our obligation to purchase this
 equipment, which is recorded in property, plant and equipment.
 After the assets are placed into service, this liability will be
 paid over approximately three years.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In July 2012,
 we consolidated our U.S.-based research activities into our
 existing San Francisco facility and ceased use of and plan to sell
 one of our buildings located in Huntsville, Alabama that was
 dedicated to research activities. The announcement of this
 consolidation plan in March 2012 triggered the recognition of a
 $1.7&#xA0;million impairment charge relating to these assets in the
 year ended December&#xA0;31, 2012.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Depreciation
 expense, including depreciation of assets acquired through capital
 leases, for the years ended December&#xA0;31, 2014, 2013, and 2012
 was $11.7&#xA0;million, $13.0&#xA0;million, and $13.8&#xA0;million,
 respectively.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Senior Secured Notes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Senior Secured Notes</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note&#xA0;5&#xA0;&#x2014; Senior Secured Notes</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On July&#xA0;11, 2012, we issued $125.0 million in aggregate
 principal amount of senior secured notes (Senior Notes) with the
 entire principal amount due on July&#xA0;15, 2017. The Senior Notes
 bear interest at 12.0%&#xA0;per annum payable in cash semi-annually
 in arrears on January&#xA0;15 and July&#xA0;15 of each year. The
 Senior Notes are secured by a first-priority lien on substantially
 all of our assets. In connection with this transaction, we retired
 $42.5 million of principal amount of our convertible subordinated
 notes due September 2012 in exchange for the same principal amount
 of Senior Notes and received the remaining proceeds in cash, less
 approximately $4.5 million in transaction costs. We used the
 proceeds from the issuance of the Senior Notes and our existing
 cash to repay the remaining $172.4 million in principal amount of
 our convertible subordinated notes in full at maturity on
 September&#xA0;28, 2012.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Senior Notes contain customary covenants, including covenants
 that limit or restrict our ability to incur liens, incur
 indebtedness, and make certain restricted payments, but do not
 contain covenants related to future financial performance. In
 particular, $25.0 million of the proceeds is required to be
 maintained in a restricted account until July&#xA0;1, 2015 and is
 classified as restricted cash on our Consolidated Balance Sheets.
 From July&#xA0;1, 2015 through the quarter ending June&#xA0;30,
 2017, the aggregate balance of our unrestricted cash and cash
 equivalents at the end of any two consecutive fiscal quarters may
 not be less than $25.0 million, subject to certain conditions. The
 Senior Notes are callable by us at any time, subject to certain
 prepayment premiums and conditions. If we experience certain change
 of control events, the holders of the Senior Notes will have the
 right to require us to purchase all or a portion of the Senior
 Notes at a purchase price in cash equal to 101% of the principal
 amount thereof, plus accrued and unpaid interest to the date of
 purchase. In addition, upon certain asset sales, we may be required
 to offer to use the net proceeds thereof to purchase some of the
 Senior Notes at 100% of the principal amount thereof, plus accrued
 and unpaid interest to the date of purchase.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2014, based on a discounted cash flow
 analysis using Level 3 inputs including financial discount rates,
 we believe the $125.0 million carrying amount of our 12% Senior
 Secured Notes due July 2017 is consistent with its fair value.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 7 &#x2014; Liability
 Related to Sale of Future Royalties</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">On
 February&#xA0;24, 2012, we entered into a Purchase and Sale
 Agreement (the Purchase and Sale Agreement) with RPI Finance Trust
 (RPI), an affiliate of Royalty Pharma, pursuant to which we sold,
 and RPI purchased, our right to receive royalty payments (the
 Royalty Entitlement) arising from the worldwide net sales, from and
 after January&#xA0;1, 2012, of (a)&#xA0;CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>,
 under Nektar&#x2019;s license, manufacturing and supply agreement
 with UCB Pharma (UCB), and (b)&#xA0;MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>,
 under Nektar&#x2019;s license, manufacturing and supply agreement
 with F. Hoffmann-La&#xA0;Roche Ltd and Hoffmann-La&#xA0;Roche Inc.
 (together referred to as Roche). We received aggregate cash
 proceeds of $124.0 million for the Royalty Entitlement.&#xA0;As
 part of this sale, we incurred approximately $4.4 million in
 transaction costs, which will be amortized to interest expense over
 the estimated life of the Purchase and Sale Agreement. Although we
 sold all of our rights to receive royalties from the
 CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 products, as a result of our ongoing manufacturing and supply
 obligations related to the generation of these royalties, we will
 continue to account for these royalties as revenue and recorded the
 $124.0 million in proceeds from this transaction as a liability
 (Royalty Obligation) that will be amortized using the interest
 method over the estimated life of the Purchase and Sale
 Agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The following
 table shows the activity within the liability account during the
 year ended December&#xA0;31, 2014 and for the period from the
 inception of the royalty transaction on February&#xA0;24, 2012
 (inception) to December&#xA0;31, 2014 (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year ended<br />
 December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Period
 from</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>inception
 to<br />
 December&#xA0;31,<br />
 2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Liability related to sale
 of future royalties &#x2014; beginning balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">128,520</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Proceeds from sale of
 future royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">124,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Payments from Nektar to
 RPI</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(10,000</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 royalty revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,937</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(54,783</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash interest expense
 recognized</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,888</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61,254</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Liability related to sale
 of future royalties &#x2014; ending balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the
 Purchase and Sale Agreement, in March 2014 and March 2013, we were
 required to pay RPI $7.0 million and $3.0 million, respectively, as
 a result of worldwide net sales of MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 for the 12 month periods ended on December&#xA0;31, 2013 and 2012
 not reaching certain minimum thresholds. As of December&#xA0;31,
 2014, we do not expect to make any further payments related to the
 Purchase and Sale Agreement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As a result of
 this liability accounting, even though the royalties from UCB and
 Roche are remitted directly to RPI starting with royalties arising
 from product sales in the first quarter of 2012, we will continue
 to recognize revenue for these royalties. During the years ended
 December&#xA0;31, 2014, 2013 and 2012, we recognized $21.9 million,
 $22.1 million and $10.8 million, respectively, in non-cash
 royalties from net sales of CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>.</font></p>
 <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As royalties
 are remitted to RPI from Roche and UCB, the balance of the Royalty
 Obligation will be effectively repaid over the life of the
 agreement. In order to determine the amortization of the Royalty
 Obligation, we are required to estimate the total amount of future
 royalty payments to be received by RPI and payments we are required
 to make to RPI as noted above over the life of the agreement. The
 sum of these amounts less the $124.0 million proceeds we received
 will be recorded as interest expense over the life of the Royalty
 Obligation. Since inception, our estimate of this total interest
 expense resulted in an effective annual interest rate of
 approximately 17%. We periodically assess the estimated royalty
 payments to RPI from UCB and Roche and to the extent such payments
 are greater or less than our initial estimates, or the timing of
 such payments is materially different than our original estimates,
 we will prospectively adjust the amortization of the Royalty
 Obligation. There are a number of factors that could materially
 affect the amount and timing of royalty payments from
 CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>,
 most of which are not within our control. Such factors include, but
 are not limited to, changing standards of care, the introduction of
 competing products, manufacturing or other delays, biosimilar
 competition, intellectual property matters, adverse events that
 result in governmental health authority imposed restrictions on the
 use of the drug products, significant changes in foreign exchange
 rates as the royalties remitted to RPI are made in U.S. dollars
 (USD) while significant portions of the underlying sales of
 CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 are made in currencies other than USD, and other events or
 circumstances that could result in reduced royalty payments from
 CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>,
 all of which would result in a reduction of non-cash royalty
 revenues and the non-cash interest expense over the life of the
 Royalty Obligation. Conversely, if sales of CIMZIA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 and MIRCERA<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>
 are more than expected, the non-cash royalty revenues and the
 non-cash interest expense recorded by us would be greater over the
 term of the Royalty Obligation.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In addition,
 the Purchase and Sale Agreement grants RPI the right to receive
 certain reports and other information relating to the Royalty
 Entitlement and contains other representations and warranties,
 covenants and indemnification obligations that are customary for a
 transaction of this nature. To our knowledge, we are currently in
 compliance with these provisions of the Purchase and Sale
 Agreement, however, if we were to breach our obligations, we could
 be required to pay damages to RPI that are not limited to the
 purchase price we received in the sale transaction.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liability related to sale of potential future royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZJBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Reporting - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfOperatingBusinessSegment', window );">Number of operating business segment</a></td>
        <td class="nump"><a title="nktr_NumberOfOperatingBusinessSegment" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfOperatingBusinessSegment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfComponentsWithinBusinessSegment', window );">Number of components within business segment</a></td>
        <td class="nump"><a title="nktr_NumberOfComponentsWithinBusinessSegment" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfComponentsWithinBusinessSegment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);"> 70,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);"> 66,974</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">63,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">57,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPropertyPlantEquipmentNetInAssets', window );">Percentage of net book value of property and equipment</a></td>
        <td class="nump"><a title="nktr_PercentageOfPropertyPlantEquipmentNetInAssets[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">90.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPropertyPlantEquipmentNetInAssets<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="nump"><a title="nktr_PercentageOfPropertyPlantEquipmentNetInAssets[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">88.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPropertyPlantEquipmentNetInAssets<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IN', window );">India [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet[us-gaap_StatementGeographicalAxis=country_IN]" onclick="toggleNextSibling(this);"> 6,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet<br>/ us-gaap_StatementGeographicalAxis<br>= country_IN</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet[us-gaap_StatementGeographicalAxis=country_IN]" onclick="toggleNextSibling(this);"> 7,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet<br>/ us-gaap_StatementGeographicalAxis<br>= country_IN</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPropertyPlantEquipmentNetInAssets', window );">Percentage of net book value of property and equipment</a></td>
        <td class="nump"><a title="nktr_PercentageOfPropertyPlantEquipmentNetInAssets[us-gaap_StatementGeographicalAxis=country_IN]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPropertyPlantEquipmentNetInAssets<br>/ us-gaap_StatementGeographicalAxis<br>= country_IN</span><span></span></td>
        <td class="nump"><a title="nktr_PercentageOfPropertyPlantEquipmentNetInAssets[us-gaap_StatementGeographicalAxis=country_IN]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">nktr_PercentageOfPropertyPlantEquipmentNetInAssets<br>/ us-gaap_StatementGeographicalAxis<br>= country_IN</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | AstraZeneca [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from clients</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_AstraZenecaMember]" onclick="toggleNextSibling(this);">52.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_AstraZenecaMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_AstraZenecaMember]" onclick="toggleNextSibling(this);">17.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_AstraZenecaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | UCB [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from clients</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_UcbPharmaMember]" onclick="toggleNextSibling(this);">16.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_UcbPharmaMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_UcbPharmaMember]" onclick="toggleNextSibling(this);">21.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_UcbPharmaMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_UcbPharmaMember]" onclick="toggleNextSibling(this);">30.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_UcbPharmaMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Roche [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from clients</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_RocheMember]" onclick="toggleNextSibling(this);">11.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_RocheMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_RocheMember]" onclick="toggleNextSibling(this);">28.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_RocheMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_RocheMember]" onclick="toggleNextSibling(this);">23.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_RocheMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Bayer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from clients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_BayerMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_BayerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Affymax, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesInformationLineItems', window );"><strong>Sales Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from clients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_MajorCustomersAxis=nktr_AffymaxIncMember]" onclick="toggleNextSibling(this);">11.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_MajorCustomersAxis<br>= nktr_AffymaxIncMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfComponentsWithinBusinessSegment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of components within business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NumberOfComponentsWithinBusinessSegment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfOperatingBusinessSegment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NumberOfOperatingBusinessSegment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfPropertyPlantEquipmentNetInAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage Of Property Plant Equipment Net In Assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_PercentageOfPropertyPlantEquipmentNetInAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_SalesInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IN">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IN</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E66AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data - Quarterly Financial Data (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 7,460</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 6,096</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 5,802</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 5,795</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 8,040</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 14,672</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 10,324</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 11,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 25,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 44,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 35,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">19,551</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">132,871</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">28,513</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">19,771</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">31,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">60,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">33,862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">23,004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">200,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">148,921</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">81,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">6,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">9,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">5,108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">7,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">8,960</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">12,877</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">5,011</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">11,661</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">28,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">38,509</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">30,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">38,494</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">34,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">36,702</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">38,338</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">48,248</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">43,914</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">52,230</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">45,618</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">147,734</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">190,010</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">148,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(37,488)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">80,321</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(22,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(36,402)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(35,894)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(6,525)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(32,605)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(45,106)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(16,485)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(120,130)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(141,201)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (45,683)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 70,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (32,637)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (46,201)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (47,659)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (16,543)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (42,748)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (55,063)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.35)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ 0.55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.26)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.37)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.41)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.37)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.48)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.35)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ 0.53</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.26)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.37)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.41)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.37)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.48)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 16,363</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 14,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 13,576</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses in statute of limitations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" onclick="toggleNextSibling(this);">(137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">27,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">16,363</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">14,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Tax positions related to current year, Additions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">477</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">289</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to prior year, Additions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">636</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Tax positions related to current year, Additions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">6,141</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">302</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to prior year, Additions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">5,258</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to prior year, Additions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember]" onclick="toggleNextSibling(this);">802</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_ForeignCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
        <td class="num"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember]" onclick="toggleNextSibling(this);">$ (742)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_ForeignCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Revenue by Geographic Area</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenue by geographic area is based on the locations of our
 partners. The following table sets forth revenue by geographic area
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">42,535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,591</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Europe</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">168,193</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">106,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200,707</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">148,921</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">81,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Stockholders' Equity - Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding', window );">Number of Securities to be Issued Upon Exercise of Outstanding Options</a></td>
        <td class="nump"><a title="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" onclick="toggleNextSibling(this);">21,995</a><span style="display:none;white-space:normal;text-align:left;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans', window );">Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column)</a></td>
        <td class="nump"><a title="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" onclick="toggleNextSibling(this);">2,812</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-Average Exercise Price of Outstanding Options</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" onclick="toggleNextSibling(this);">$ 10.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember', window );">Equity Compensation Plans Approved by Security Holders [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding', window );">Number of Securities to be Issued Upon Exercise of Outstanding Options</a></td>
        <td class="nump"><a title="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding[us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember]" onclick="toggleNextSibling(this);">18,601</a><span style="display:none;white-space:normal;text-align:left;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding<br>/ us-gaap_AwardTypeAxis<br>= nktr_EquityCompensationPlansApprovedByShareholdersMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans', window );">Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column)</a></td>
        <td class="nump"><a title="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans[us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember]" onclick="toggleNextSibling(this);">2,812</a><span style="display:none;white-space:normal;text-align:left;">nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans<br>/ us-gaap_AwardTypeAxis<br>= nktr_EquityCompensationPlansApprovedByShareholdersMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-Average Exercise Price of Outstanding Options</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember]" onclick="toggleNextSibling(this);">$ 10.68</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_AwardTypeAxis<br>= nktr_EquityCompensationPlansApprovedByShareholdersMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember', window );">Equity Compensation Plans Not Approved by Security Holders [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding', window );">Number of Securities to be Issued Upon Exercise of Outstanding Options</a></td>
        <td class="nump"><a title="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding[us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember]" onclick="toggleNextSibling(this);">3,394</a><span style="display:none;white-space:normal;text-align:left;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding<br>/ us-gaap_AwardTypeAxis<br>= nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-Average Exercise Price of Outstanding Options</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember]" onclick="toggleNextSibling(this);">$ 9.52</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_AwardTypeAxis<br>= nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities remaining available for issuance under equity compensation plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansApprovedByShareholdersMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_EquityCompensationPlansUnapprovedBySecurityHoldersMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;12&#xA0;&#x2014; Income Taxes</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Loss before
 (benefit) provision for income taxes includes the following
 components (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Domestic</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(56,414</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(161,068</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(174,258</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,986</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,300</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,809</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Loss before (benefit)
 provision for income taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(54,428</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(159,768</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(171,449</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Provision for Income
 Taxes</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The (benefit)
 provision for income taxes consists of the following (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(137</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(482</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,838</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,029</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total Current</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(481</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,839</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">893</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">422</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(422</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">49</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(49</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(31</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(65</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(16</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total Deferred</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(31</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">406</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(487</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Benefit) provision for
 income taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(512</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">406</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The foreign
 benefit provision in the year ended December&#xA0;31, 2014 is due
 to the reduction in taxes related to a favorable determination
 received from India proceedings.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Income tax
 provision related to continuing operations differs from the amount
 computed by applying the statutory income tax rate of 35% to pretax
 loss as follows (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. federal provision
 (benefit)</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">At statutory
 rate</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19,050</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(55,919</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(60,007</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(48</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Change in valuation
 allowance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,831</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">55,042</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">47,349</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-cash interest expense
 on liability related to sale of future royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,311</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,808</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,320</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,832</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">271</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">236</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign tax
 inclusion</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,510</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign tax
 differential</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(17</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(20</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(227</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research credits</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,933</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,273</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(591</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(487</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,286</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">864</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Benefit) provision for
 income taxes</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(512</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">406</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Deferred Tax Assets
 and Liabilities</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Deferred income
 taxes reflect the net tax effects of loss and credit carryforwards
 and temporary differences between the carrying amount of assets and
 liabilities for financial reporting purposes and the amounts used
 for income tax purposes. Significant components of our deferred tax
 assets for federal and state income taxes are as follows (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax
 assets:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net operating loss
 carryforwards</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">423,776</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">391,385</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and other
 credits</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">66,666</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61,707</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">29,758</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,588</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,948</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,962</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Sale of future
 royalties</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,153</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,057</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capitalized research
 expenses</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,795</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,687</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reserves and
 accruals</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,288</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,685</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property, plant and
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,264</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,580</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,218</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,539</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets before
 valuation allowance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595,866</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">586,190</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Valuation allowance for
 deferred tax assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(595,690</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(586,040</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax
 assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">176</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">150</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax
 liabilities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net deferred tax
 assets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">176</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">150</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Realization of
 our deferred tax assets is dependent upon future earnings, if any,
 the timing and amount of which are uncertain. Because of our lack
 of U.S.&#xA0;earnings history, the net U.S.&#xA0;deferred tax
 assets have been fully offset by a valuation allowance. The
 valuation allowance increased by $9.7&#xA0;million and
 $51.8&#xA0;million during the years ended December&#xA0;31, 2014
 and 2013, respectively. The valuation allowance includes
 approximately $35.6&#xA0;million of income tax benefit at both
 December&#xA0;31, 2014 and December&#xA0;31, 2013 related to
 stock-based compensation and exercises prior to the implementation
 of the accounting guidance for stock-based compensation that will
 be credited to additional paid in capital when realized.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Undistributed
 earnings of our foreign subsidiary in India are considered to be
 permanently reinvested and accordingly, no deferred
 U.S.&#xA0;income taxes have been provided thereon. Upon
 distribution of those earnings in the form of dividends or
 otherwise, we would be subject to U.S.&#xA0;income tax. As of
 December&#xA0;31, 2014, U.S. income taxes have not been provided on
 a cumulative total of $3.9 million of such earnings. Any
 incremental tax liability would be insignificant due to foreign tax
 credits that would be realized upon distribution.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Net Operating Loss
 and Tax Credit Carryforwards</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As of
 December&#xA0;31, 2014, we had a net operating loss carryforward
 for federal income tax purposes of approximately
 $1,131.8&#xA0;million, portions of which will begin to expire in
 2018. As of December&#xA0;31, 2014, we had a total state net
 operating loss carryforward of approximately $709.2&#xA0;million,
 of which approximately $124.6 million does not meet the more likely
 than not standard and has not been included in our deferred tax
 assets. Our state operating loss carryforwards will begin to expire
 in 2015. Utilization of some of the federal and state net operating
 loss and credit carryforwards are subject to annual limitations due
 to the &#x201C;change in ownership&#x201D; provisions of the Internal
 Revenue Code of 1986 and similar state provisions.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have federal
 research credits of approximately $40.0&#xA0;million, which will
 begin to expire in 2019 and state research credits of approximately
 $22.6 million which have no expiration date. We have federal orphan
 drug credits of $17.7&#xA0;million which will begin to expire in
 2026. These tax credits are subject to the same limitations
 discussed above.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Unrecognized tax
 benefits</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have
 incurred net operating losses since inception. Our policy is to
 include interest and penalties related to unrecognized tax
 benefits, if any, within the provision for income taxes in the
 consolidated statements of operations. If we are eventually able to
 recognize our uncertain positions, our effective tax rate may be
 reduced. We currently have a full valuation allowance against our
 U.S. net deferred tax asset which would impact the timing of the
 effective tax rate benefit should any of these uncertain tax
 positions be favorably settled in the future. Any adjustments to
 our uncertain tax positions would result in an adjustment of our
 net operating loss or tax credit carry forwards rather than
 resulting in a cash outlay.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We file income
 tax returns in the U.S., California, Alabama, and India. Because of
 net operating losses and research credit carryovers, substantially
 all of our domestic tax years remain open and subject to
 examination. We are currently under examination in India for the
 fiscal years ending 2009 through 2014.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We have the
 following activity relating to unrecognized tax benefits (in
 thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Beginning
 balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,363</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,067</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,576</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax positions related to
 current year</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">502</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">477</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">289</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,141</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">381</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">302</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax positions related to
 prior year</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions:</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">636</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,258</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">802</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions &#x2014;
 foreign</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(742</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Settlements</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Lapses in statute of
 limitations</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(137</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Ending balance</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,522</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,363</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,067</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Although it is
 reasonably possible that certain unrecognized tax benefits may
 increase or decrease within the next twelve months, we do not
 anticipate any significant changes to unrecognized tax benefits
 over the next twelve&#xA0;months. During the years ended
 December&#xA0;31, 2014, 2013 and 2012, no significant interest or
 penalties were recognized relating to unrecognized tax
 benefits.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Inventory consists of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,947</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Work-in-process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Inventory</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EB6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostRoyaltyExpense', window );">Royalty expense</a></td>
        <td class="nump"><a title="us-gaap_DirectOperatingCostRoyaltyExpense" onclick="toggleNextSibling(this);">$ 3,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DirectOperatingCostRoyaltyExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_DirectOperatingCostRoyaltyExpense" onclick="toggleNextSibling(this);">$ 4,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DirectOperatingCostRoyaltyExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_DirectOperatingCostRoyaltyExpense" onclick="toggleNextSibling(this);">$ 2,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DirectOperatingCostRoyaltyExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
        <td class="nump"><a title="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" onclick="toggleNextSibling(this);">16,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Indemnification Obligations, liabilities</a></td>
        <td class="nump"><a title="us-gaap_LossContingencyAccrualAtCarryingValue[us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LossContingencyAccrualAtCarryingValue<br>/ us-gaap_LossContingenciesByNatureOfContingencyAxis<br>= us-gaap_IndemnificationGuaranteeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LossContingencyAccrualAtCarryingValue[us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LossContingencyAccrualAtCarryingValue<br>/ us-gaap_LossContingenciesByNatureOfContingencyAxis<br>= us-gaap_IndemnificationGuaranteeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember', window );">Securities Related Claims [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
        <td class="nump"><a title="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident[us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident<br>/ us-gaap_LossContingenciesByNatureOfContingencyAxis<br>= nktr_SecuritiesRelatedClaimsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember', window );">Non-Securities Related Claims [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
        <td class="nump"><a title="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident[us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident<br>/ us-gaap_LossContingenciesByNatureOfContingencyAxis<br>= nktr_NonSecuritiesRelatedClaimsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember', window );">Merger and Acquisition Related Claims [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
        <td class="nump"><a title="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident[us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember]" onclick="toggleNextSibling(this);">$ 1,500,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident<br>/ us-gaap_LossContingenciesByNatureOfContingencyAxis<br>= nktr_MergerAndAcquisitionRelatedClaimsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Obligations under Director and Officer Indemnifications per incident.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostRoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DirectOperatingCostRoyaltyExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of loss contingency liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ET1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property, Plant and Equipment - Property, Plant and Equipment (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property and equipment at cost</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 147,866</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 144,861</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(93,807)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(84,148)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentNet', window );">Depreciable property, plant and equipment, net</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">54,059</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">60,713</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-progress</a></td>
        <td class="nump"><a title="us-gaap_ConstructionInProgressGross" onclick="toggleNextSibling(this);">16,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConstructionInProgressGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConstructionInProgressGross" onclick="toggleNextSibling(this);">6,261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConstructionInProgressGross</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property plant and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">70,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">66,974</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and Leasehold Improvements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property and equipment at cost</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">72,228</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= nktr_BuildingAndLeaseholdImprovementsMember</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">71,306</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= nktr_BuildingAndLeaseholdImprovementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property and equipment at cost</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">26,975</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= nktr_LaboratoryEquipmentMember</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">26,621</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= nktr_LaboratoryEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property and equipment at cost</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember]" onclick="toggleNextSibling(this);">25,212</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ManufacturingFacilityMember</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember]" onclick="toggleNextSibling(this);">23,699</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ManufacturingFacilityMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, Fixtures and Other Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property and equipment at cost</a></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">$ 23,451</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
        <td class="nump"><a title="nktr_DepreciablePropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">$ 23,235</a><span style="display:none;white-space:normal;text-align:left;">nktr_DepreciablePropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Depreciable Property, plant and equipment, Gross.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Depreciable Property, plant and equipment, Net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (53,916)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (162,013)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (171,855)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Net unrealized (loss) gain on available-for-sale investments</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" onclick="toggleNextSibling(this);">(95)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" onclick="toggleNextSibling(this);">(268)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" onclick="toggleNextSibling(this);">1,206</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss', window );">Income tax provision (benefit) on unrealized gain on available-for-sale investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" onclick="toggleNextSibling(this);">470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss" onclick="toggleNextSibling(this);">(470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Net foreign currency translation (loss) gain</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">(291)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">(1,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(386)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(824)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (54,302)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (162,837)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (171,109)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the pretax change in net unrealized holding gain (loss) on available-for-sale securities that has been included in accumulated other comprehensive income, a separate component of shareholders' equity, during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the tax effects occurring during the period which are related to the net unrealized gain (loss) resulting from changes in the fair [carrying] value during the period of available-for-sale securities. Such tax affects would have been charged or credited directly to other comprehensive income or to related components of shareholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e39076-109324<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;1&#xA0;&#x2014;
 Organization and Summary of Significant Accounting
 Policies</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We are a
 biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our research
 and development activities have required significant ongoing
 investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At December&#xA0;31, 2014,
 we had approximately $262.8 million in cash and investments in
 marketable securities, of which $25.0 million was restricted in
 relation to our 12% senior secured notes, and $151.8 million in
 indebtedness. The indebtedness includes $125.0 million in aggregate
 principal amount of 12.0% senior secured notes due July&#xA0;15,
 2017, but excludes our long-term liability relating to the sale of
 future royalties. As is further described in Note 7, this royalty
 obligation liability will not be settled in cash.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of
 Presentation, Principles of Consolidation and Use of
 Estimates</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our
 consolidated financial statements include the financial position,
 results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited and
 Nektar Therapeutics UK, Ltd. (Nektar UK). All intercompany accounts
 and transactions have been eliminated in consolidation.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our
 consolidated financial statements are denominated in
 U.S.&#xA0;dollars. Accordingly, changes in exchange rates between
 the applicable foreign currency and the U.S.&#xA0;dollar will
 affect the translation of each foreign subsidiary&#x2019;s financial
 results into U.S.&#xA0;dollars for purposes of reporting our
 consolidated financial results. Translation gains and losses are
 included in accumulated other comprehensive income (loss) in the
 stockholders&#x2019; equity (deficit) section of the balance sheet.
 To date, such cumulative translation adjustments have not been
 significant to our consolidated financial position. Aggregate gross
 foreign currency transaction gains (losses) recorded in operations
 for the years ended December&#xA0;31, 2014, 2013, and 2012 were not
 significant.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles (GAAP) requires management
 to make estimates and assumptions that affect the reported amounts
 of assets and liabilities and disclosure of contingent assets and
 liabilities at the date of the consolidated financial statements
 and the reported amounts of revenue and expenses during the
 reporting period. Accounting estimates and assumptions are
 inherently uncertain. Actual results could differ materially from
 those estimates and assumptions. On an ongoing basis, we evaluate
 our estimates, including those related to estimated selling prices
 of deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. Estimates are
 assessed each period and updated to reflect current information and
 any changes in estimates will generally be reflected in the period
 first identified.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reclassifications</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Certain items
 previously reported in specific financial statement captions have
 been reclassified to conform to the current period presentation.
 Such reclassifications do not materially impact previously reported
 total revenue, operating loss or net loss or total assets,
 liabilities or stockholders&#x2019; equity (deficit).</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash, Cash
 Equivalents, and Investments, and Fair Value of Financial
 Instruments</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We consider all
 investments in marketable securities with an original maturity of
 three months or less when purchased to be cash equivalents.
 Investments in securities with remaining maturities of less than
 one year, or where our intent is to use the investments to fund
 current operations or to make them available for current
 operations, are classified as short-term investments.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Investments are
 designated as available-for-sale and are carried at fair value,
 with unrealized gains and losses reported in stockholders&#x2019;
 equity (deficit) as accumulated other comprehensive income (loss).
 The disclosed fair value related to our cash equivalents and
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Interest and
 dividends on securities classified as available-for-sale, as well
 as amortization of premiums and accretion of discounts to maturity,
 are included in interest income. Realized gains and losses and
 declines in value of available-for-sale securities judged to be
 other-than-temporary, if any, are included in other income
 (expense). The cost of securities sold is based on the specific
 identification method.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our cash, cash
 equivalents, and short-term investments are exposed to credit risk
 in the event of default by the third parties that hold or issue
 such assets. Our cash, cash equivalents, and short-term investments
 are held by financial institutions that management believes are of
 high credit quality and our investment policy limits investments to
 fixed income securities denominated and payable in U.S. dollars
 such as U.S. government obligations, money market instruments and
 funds, and corporate bonds and places restrictions on maturities
 and concentrations by type and issuer.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Accounts Receivable
 and Significant Customer Concentrations</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our customers
 are primarily pharmaceutical and biotechnology companies that are
 located in the U.S.&#xA0;and Europe. Our accounts receivable
 balance contains billed and unbilled trade receivables from product
 sales and royalties, as well as time and materials based billings
 from collaborative research and development agreements. When
 appropriate, we provide for an allowance for doubtful accounts by
 reserving for specifically identified doubtful accounts. We
 generally do not require collateral from our customers. We perform
 a regular review of our customers&#x2019; payment histories and
 associated credit risk. We have not experienced significant credit
 losses from our accounts receivable. At December&#xA0;31, 2014,
 three different customers represented 40%, 31%, and 15%,
 respectively, of our accounts receivable. At December&#xA0;31,
 2013, three different customers represented 30%, 28%, and 28%,
 respectively, of our accounts receivable.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Inventory and
 Significant Supplier Concentrations</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Inventory is
 generally manufactured upon receipt of firm purchase orders from
 our collaboration partners. Inventory includes direct materials,
 direct labor, and manufacturing overhead and cost is determined on
 a first-in, first-out basis. Inventory is valued at the lower of
 cost or market and defective or excess inventory is written down to
 net realizable value based on historical experience or projected
 usage. Inventory related to our research and development activities
 is expensed when purchased.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We are
 dependent on our suppliers and contract manufacturers to provide
 raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Long-Lived
 Assets</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Property, plant
 and equipment are stated at cost. Major improvements are
 capitalized, while maintenance and repairs are expensed when
 incurred. Manufacturing, laboratory and other equipment are
 depreciated using the straight-line method generally over estimated
 useful lives of three to seven years. Leasehold improvements and
 buildings recorded under capital leases are depreciated using the
 straight-line method over the shorter of the estimated useful life
 or the remaining term of the lease.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Goodwill
 represents the excess of the price paid for another entity over the
 fair value of the assets acquired and liabilities assumed in a
 business combination. We are organized in one reporting unit and
 evaluate the goodwill for the Company as a whole. Goodwill has an
 indefinite useful life and is not amortized, but instead tested for
 impairment annually in the fourth quarter of each year using an
 October&#xA0;1 measurement date.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We assess the
 impairment of long-lived assets, primarily property, plant and
 equipment and goodwill included in other non-current assets,
 whenever events or changes in business circumstances indicate that
 the carrying amounts of the assets may not be fully recoverable.
 When such events occur, we determine whether there has been an
 impairment in value by comparing the asset&#x2019;s carrying value
 with its fair value, as measured by the anticipated undiscounted
 net cash flows of the asset. In the case of goodwill impairment,
 market capitalization is generally used as the measure of fair
 value. If an impairment in value exists, the asset is written down
 to its estimated fair value.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue
 Recognition</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our revenue is
 derived from our arrangements with pharmaceutical and biotechnology
 collaboration partners and may result from one or more of the
 following: upfront and license fees, payments for contract research
 and development, milestone payments, manufacturing and supply
 payments, and royalties. Our performance obligations under our
 collaborations may include licensing our intellectual property,
 manufacturing and supply obligations, and research and development
 obligations. In order to account for the multiple-element
 arrangements, the Company identifies the deliverables included
 within the arrangement and evaluates which deliverables represent
 separate units of accounting. Analyzing the arrangement to identify
 deliverables requires the use of judgment, and each deliverable may
 be an obligation to deliver services, a right or license to use an
 asset, or another performance obligation. Revenue is recognized
 separately for each identified unit of accounting when the basic
 revenue recognition criteria are met: there is persuasive evidence
 that an arrangement exists, delivery has occurred, the price is
 fixed or determinable, and collection is reasonably
 assured.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">At the
 inception of each new multiple-element arrangement or the material
 modification of an existing multiple-element arrangement, we
 allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Product
 sales</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Product sales
 are primarily derived from fixed price and cost-plus manufacturing
 and supply agreements with our collaboration partners. We have not
 experienced any significant returns from our customers.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Royalty
 revenues</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Generally, we
 are entitled to royalties from our collaboration partners based on
 the net sales of their approved drugs that are marketed and sold in
 one or more countries where we hold royalty rights. We recognize
 royalty revenue when the cash is received or when the royalty
 amount to be received is estimable and collection is reasonably
 assured. With respect to the non-cash royalties related to sale of
 future royalties described at Note&#xA0;7, revenue is recognized
 when estimable, otherwise, revenue is recognized during the period
 in which the related royalty report is received, which generally
 occurs in the quarter after the applicable product sales are
 made.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>License, collaboration
 and other</i></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The amount of
 upfront fees and other payments received by us in license and
 collaboration arrangements that are allocated to continuing
 performance obligations, such as manufacturing and supply
 obligations, are deferred and generally recognized ratably over our
 expected performance period under each respective arrangement. We
 make our best estimate of the period over which we expect to
 fulfill our performance obligations, which may include technology
 transfer assistance, research activities, clinical development
 activities, and manufacturing activities from development through
 the commercialization of the product. Given the uncertainties of
 these collaboration arrangements, significant judgment is required
 to determine the duration of the performance period and this
 estimate is periodically re-evaluated.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Contingent
 consideration received from the achievement of a substantive
 milestone is recognized in its entirety in the period in which the
 milestone is achieved, which we believe is consistent with the
 substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&#xA0;that can only be achieved based in whole or in part either
 on the entity&#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&#x2019;s performance,
 (ii)&#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the
 arrangement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with our partners provide for payments to
 us upon the achievement of development milestones, such as the
 completion of clinical trials or regulatory submissions, approvals
 by health authorities, and commercial launches of drugs. Given the
 challenges inherent in developing and obtaining regulatory approval
 for drug products and in achieving commercial launches, there was
 substantial uncertainty whether any such milestones would be
 achieved at the time of execution of these licensing and
 collaboration agreements. In addition, we evaluated whether the
 development milestones meet the remaining criteria to be considered
 substantive. As a result of our analysis, we consider our remaining
 development milestones under all of our license and collaboration
 agreements to be substantive and, accordingly, we expect to
 recognize as revenue future payments received from such milestones
 only if and as each milestone is achieved.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with certain partners also provide for
 contingent payments to us based solely upon the performance of the
 respective partner. For such contingent amounts we expect to
 recognize the payments as revenue when earned under the applicable
 contract, which is generally upon completion of performance by the
 respective partner, provided that collection is reasonably
 assured.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Our license and
 collaboration agreements with our partners also provide for
 payments to us upon the achievement of specified sales volumes of
 approved drugs. We consider these payments to be similar to royalty
 payments and we will recognize such sales-based payments upon
 achievement of such sales volumes, provided that collection is
 reasonably assured.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Shipping and Handling
 Costs</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We recognize
 costs related to shipping and handling of product to customers in
 cost of goods sold.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and
 Development Expense</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Research and
 development costs are expensed as incurred and include salaries,
 benefits and other operating costs such as outside services,
 supplies and allocated overhead costs. We perform research and
 development for our proprietary drug candidates and technology
 development and for certain third parties under collaboration
 agreements. For our proprietary drug candidates and our internal
 technology development programs, we invest our own funds without
 reimbursement from a third party.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We record
 accruals for the estimated costs of our clinical trial activities
 performed by third parties. The financial terms of these agreements
 are subject to negotiation, vary from contract to contract and may
 result in uneven payment flows to our vendors. Payments under the
 contracts depend on factors such as the achievement of certain
 events, successful enrollment of patients, and completion of
 portions of the clinical trial or similar conditions. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period first identified. During the year ended December 31, 2014,
 we recorded a reduction related to prior periods of approximately
 $4.7 million to our research and development expenses primarily
 related to our Beacon Phase 3 clinical trial for etirinotecan
 pegol.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based
 Compensation</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation arrangements include stock option grants and
 restricted stock unit (RSU) awards under our equity incentive
 plans, as well as shares issued under our Employee Stock Purchase
 Plan (ESPP), through which employees may purchase our common stock
 at a discount to the market price.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We use the
 Black-Scholes option pricing model for the respective grant to
 determine the estimated fair value of the option on the date of
 grant (grant date fair value) and the estimated fair value of
 common stock purchased under the ESPP. The Black-Scholes option
 pricing model requires the input of highly subjective assumptions.
 These variables include, but are not limited to, our stock price
 volatility over the term of the awards, and actual and projected
 employee stock option exercise behaviors. Because our employee
 stock options have characteristics significantly different from
 those of traded options, and because changes in the subjective
 input assumptions can materially affect the fair value estimate, in
 management&#x2019;s opinion, the existing models may not provide a
 reliable single measure of the fair value of our employee stock
 options or common stock purchased under the ESPP. Management will
 continue to assess the assumptions and methodologies used to
 calculate the estimated fair value of stock-based compensation.
 Circumstances may change and additional data may become available
 over time, which could result in changes to these assumptions and
 methodologies, and which could materially impact our fair value
 determination.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We expense the
 value of the portion of the option or award that is ultimately
 expected to vest based on the historical forfeiture rate on a
 straight line basis over the requisite service periods in our
 Consolidated Statements of Operations. For awards that vest upon
 the achievement of performance milestones, we estimate the vesting
 period based on our evaluation of the probability of achievement of
 each respective milestone and the related estimated date of
 achievement. Stock-based compensation expense for purchases under
 the ESPP is recognized over the respective six-month purchase
 period. Expense amounts are recorded in cost of goods sold,
 research and development expense, and general and administrative
 expense based on the function of the applicable employee.
 Stock-based compensation charges are non-cash charges and as such
 have no impact on our reported cash flows.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Net Loss Per
 Share</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss
 per share is calculated based on the weighted-average number of
 common shares outstanding during the periods presented. For all
 periods presented in the Consolidated Statements of Operations, the
 net loss available to common stockholders is equal to the reported
 net loss. Basic and diluted net loss per share are the same due to
 our historical net losses and the requirement to exclude
 potentially dilutive securities which would have an anti-dilutive
 effect on net loss per share. During 2014, 2013 and 2012,
 potentially dilutive securities consisted of common shares
 underlying outstanding stock options and there were weighted
 average outstanding stock options of 21.9 million, 20.7 million and
 18.8 million during the years ended December 31, 2014, 2013 and
 2012, respectively.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Income
 Taxes</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We account for
 income taxes under the liability method. Under this method,
 deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax reporting bases
 of assets and liabilities and are measured using enacted tax rates
 and laws that are expected to be in effect when the differences are
 expected to reverse. Realization of deferred tax assets is
 dependent upon future earnings, the timing and amount of which are
 uncertain. We record a valuation allowance against deferred tax
 assets to reduce their carrying value to an amount that is more
 likely than not to be realized. When we establish or reduce the
 valuation allowance related to the deferred tax assets, our
 provision for income taxes will increase or decrease, respectively,
 in the period such determination is made.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We utilize a
 two-step approach to recognize and measure uncertain tax positions.
 The first step is to evaluate the tax position for recognition by
 determining if the weight of available evidence indicates that it
 is more likely than not that the position will be sustained upon
 tax authority examination, including resolution of related appeals
 or litigation processes, if any. The second step is to measure the
 tax benefit as the largest amount that is more than 50% likely of
 being realized upon ultimate settlement.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Comprehensive
 loss</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Comprehensive
 loss is the change in stockholders&#x2019; equity (deficit) from
 transactions and other events and circumstances other than those
 resulting from investments by stockholders and distributions to
 stockholders. Our other comprehensive income (loss) is comprised of
 net loss, gains and losses from the foreign currency translation of
 the assets and liabilities of our India and UK subsidiaries, and
 unrealized gains and losses on investments in available-for-sale
 securities.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Recent Accounting
 Pronouncements</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In May 2014,
 the Financial Accounting Standards Board (FASB) issued guidance
 codified in Accounting Standards Codification (ASC) 606, <i>Revenue
 Recognition &#x2014; Revenue from Contracts with Customers</i>,
 which amends the guidance in former ASC 605, <i>Revenue
 Recognition,</i> and is effective for public companies for fiscal
 years beginning after December&#xA0;15, 2016. We are currently
 evaluating the impact of the provisions of ASC 606.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">In August 2014,
 the FASB issued Accounting Standards Update No.&#xA0;2014-15,
 Disclosure of Uncertainties about an Entity&#x2019;s Ability to
 Continue as a Going Concern (ASU 2014-15). ASU 2014-15 requires
 management to evaluate whether there is substantial doubt about an
 entity&#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective in
 2016 with early adoption permitted. We do not believe the impact of
 adopting ASU 2014-15 on our consolidated financial statements will
 be significant.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Loss Before (Benefit) Provision for Income Taxes (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (56,414)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (161,068)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (174,258)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
        <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">1,986</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">1,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">2,809</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before (benefit) provision for income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (54,428)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (159,768)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (171,449)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Property, plant
 and equipment consists of the following (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Building and leasehold
 improvements</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72,228</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,306</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Laboratory
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,975</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,621</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Manufacturing
 equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,212</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,699</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Furniture, fixtures and
 other equipment</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,451</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,235</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciable property, plant
 and equipment at cost</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">147,866</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">144,861</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: accumulated
 depreciation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(93,807</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(84,148</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciable property, plant
 and equipment, net</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54,059</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,713</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Construction-in-progress</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,309</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,261</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property, plant and
 equipment, net</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">70,368</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">66,974</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>197</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventory</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Senior Secured Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock</Role>
      <ShortName>Senior Secured Notes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock</Role>
      <ShortName>Leases</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock</Role>
      <ShortName>Segment Reporting</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables</Role>
      <ShortName>Leases (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlockTables</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Inventory - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory</Role>
      <ShortName>Inventory - Inventory (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment - Property, Plant and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Senior Secured Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureSeniorSecuredNotesAdditionalInformation</Role>
      <ShortName>Senior Secured Notes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLeasesAdditionalInformation</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Leases - Future Minimum Payments for Capital Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumPaymentsForCapitalLeases</Role>
      <ShortName>Leases - Future Minimum Payments for Capital Leases (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsForOperatingLeases</Role>
      <ShortName>Leases - Future Minimum Lease Payments for Operating Leases (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Liability Related to Sale of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesSummaryOfLiabilityRelatedToPotentialFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Stockholders' Equity - Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockholdersEquitySummarizationOfCommonStockSharesForIssuanceUnderExistingEquityCompensationPlans</Role>
      <ShortName>Stockholders' Equity - Summarization of Common Stock Shares for Issuance Under Existing Equity Compensation Plans (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedToCalculateFairValueOfEmployeeStockOptions</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityUnderEquityIncentivePlans</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Income Taxes - Loss Before (Benefit) Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesLossBeforeBenefitProvisionForIncomeTaxes</Role>
      <ShortName>Income Taxes - Loss Before (Benefit) Provision for Income Taxes (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Income Taxes - (Benefit) Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesBenefitProvisionForIncomeTaxes</Role>
      <ShortName>Income Taxes - (Benefit) Provision for Income Taxes (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionRelatedToContinuingOperations</Role>
      <ShortName>Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureIncomeTaxesUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Segment Reporting - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation</Role>
      <ShortName>Segment Reporting - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureSegmentReportingRevenueByGeographicArea</Role>
      <ShortName>Segment Reporting - Revenue by Geographic Area (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Selected Quarterly Financial Data - Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data - Quarterly Financial Data (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element nktr_PreferredStockShareDesignated had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement had a mix of decimals attribute values: -5 -4.</Log>
    <Log type="Info">Element us-gaap_CommonStockSharesAuthorized had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_IncomeTaxReconciliationTaxCreditsResearch had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_PropertyPlantAndEquipmentNet had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RestrictedCashAndCashEquivalents had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_SeniorLongTermNotes had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '1/1/2013 - 3/31/2013' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '10/1/2013 - 12/31/2013' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 1040 days and at least 39 values. Shorter duration columns must have at least one fourth (9) as many values. Column '10/1/2014 - 12/31/2014' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">'Monetary' elements on report '137 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '139 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '144 - Disclosure - Senior Secured Notes - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '150 - Disclosure - Commitments and Contingencies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Shares' elements on report '151 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '151 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '154 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '161 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '34 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 109 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">	Process Flow-Through: Removing column '34 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">Process Flow-Through: 110 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</Log>
  </Logs>
  <InputFiles>
    <File>nktr-20141231.xml</File>
    <File>nktr-20141231.xsd</File>
    <File>nktr-20141231_cal.xml</File>
    <File>nktr-20141231_def.xml</File>
    <File>nktr-20141231_lab.xml</File>
    <File>nktr-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 11, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInstrumentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
        <td class="text">Two  years or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInstrumentWeightedAverageMaturityPeriodOne', window );">Weighted average maturity term for debt securities investment</a></td>
        <td class="text">One year or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds', window );">Available-for-sale securities, sold</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" onclick="toggleNextSibling(this);">$ 21,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" onclick="toggleNextSibling(this);">$ 2,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" onclick="toggleNextSibling(this);">$ 5,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Level 1 to level 2 transfers</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Level 2 to level 1 transfers</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LettersOfCreditOutstanding', window );">Letter of credit</a></td>
        <td class="nump"><a title="nktr_LettersOfCreditOutstanding" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_LettersOfCreditOutstanding</span><span></span></td>
        <td class="nump"><a title="nktr_LettersOfCreditOutstanding" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">nktr_LettersOfCreditOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">12% Senior Secured Notes Due July 2017 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">$ 25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_SeniorNotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Senior secured notes, maturity date</a></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 15,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInstrumentMaximumMaturityPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument maximum maturity period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DebtInstrumentMaximumMaturityPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInstrumentWeightedAverageMaturityPeriodOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Weighted Average Maturity Period One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_DebtInstrumentWeightedAverageMaturityPeriodOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LettersOfCreditOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Letters Of Credit Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">nktr_LettersOfCreditOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>nktr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;11 &#x2014;
 Stock-Based Compensation</b></font></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">We issue
 stock-based awards from our equity incentive plans, which are more
 fully described in Note&#xA0;9. Stock-based compensation expense
 was recognized as follows (in thousands):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended
 December&#xA0;31,</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of goods
 sold</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,161</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,297</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,496</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and
 development</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,528</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,910</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,082</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and
 administrative</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,328</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,501</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,621</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total stock-based
 compensation</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,017</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,708</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,199</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">As of
 December&#xA0;31, 2014, total unrecognized compensation costs of
 $51.9 million related to unvested stock-based compensation
 arrangements are expected to be recognized as expense over a
 weighted-average period of 2.1 years.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Black-Scholes
 Assumptions</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The following
 tables list the Black-Scholes option-pricing model assumptions used
 to calculate the fair value of employee and director stock
 options.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="39%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year
 Ended</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2014</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year
 Ended</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year
 Ended</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Average risk-free interest
 rate</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dividend yield</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Average volatility
 factor</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">51.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">62.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Average weighted average
 expected life</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.2&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.2&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.0&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The average
 risk-free interest rate is based on the U.S.&#xA0;treasury yield
 curve in effect at the time of grant for periods commensurate with
 the expected life of the stock-based award. We have never paid
 dividends, nor do we expect to pay dividends in the foreseeable
 future; therefore, we used a dividend yield of 0.0%. Our estimate
 of expected volatility is based on the daily historical trading
 data of our common stock at the time of grant over a historical
 period commensurate with the expected life of the stock-based
 award.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">For the years
 ended December&#xA0;31, 2014, 2013, and 2012, we estimated the
 weighted-average expected life based on the contractual and vesting
 terms of the stock options, as well as historic cancellation and
 exercise data.</font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">Stock-based
 compensation resulting from our ESPP was not material in the years
 ended December&#xA0;31, 2014, 2013, and 2012.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Summary of Stock
 Option Activity</i></b></font></p>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The table below
 presents a summary of stock option activity under our equity
 incentive plans (in thousands, except for price per share and
 contractual life information):</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <!-- Begin Table Head -->
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>of</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Average</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Price</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>per
 Share</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Average</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Remaining</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Contractual</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Life&#xA0;(in&#xA0;Years)</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Intrinsic</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Value<sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">(1)</sup></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at
 December&#xA0;31, 2013</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,655</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.06</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,713</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13.96</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options
 exercised</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,852</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.43</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options
 forfeited&#xA0;&amp; canceled</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,521</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.89</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at
 December&#xA0;31, 2014</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,995</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.96</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">112,549</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested&#xA0;and expected to
 vest at December&#xA0;31, 2014</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,338</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.41</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.89</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">111,071</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at
 December&#xA0;31, 2014</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,007</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.90</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.47</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">85,839</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 2px; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; MARGIN-TOP: 0px; LINE-HEIGHT: 8px; WIDTH: 10%">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Aggregate intrinsic value
 represents the difference between the exercise price of the option
 and the closing market price of our common stock on
 December&#xA0;31, 2014.</font></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2">The
 weighted-average grant-date fair value per share of options granted
 during the years ended December&#xA0;31, 2014, 2013, and 2012 was
 $6.50, $4.95, and $3.92, respectively. The total intrinsic value of
 options exercised during the years ended December&#xA0;31, 2014,
 2013, and 2012 was $25.9 million, $4.5&#xA0;million, and
 $1.9&#xA0;million, respectively. The estimated fair value of
 options vested during the years ended December&#xA0;31, 2014, 2013,
 and 2012 was $15.2 million, $14.1&#xA0;million, and
 $15.7&#xA0;million, respectively.</font></p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
